ID,tags,text,tokens,ner_tags
NCT02564744,"34:68:cancer,72:104:cancer",Participants with a diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),"['Participants' 'with' 'a' 'diagnosis' 'of' 'chronic' 'lymphocytic'
 'leukemia' '(' 'CLL' ')' 'or' 'small' 'lymphocytic' 'lymphoma' '(' 'SLL'
 ')']",[0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 3. 3. 3. 3. 0. 0.]
NCT01754857,"26:60:cancer,61:93:cancer",Histologically confirmed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL),"['Histologically' 'confirmed' 'chronic' 'lymphocytic' 'leukemia' '(' 'CLL'
 ')' '/small' 'lymphocytic' 'lymphoma' '(' 'SLL' ')']",[0. 0. 3. 3. 3. 3. 0. 0. 3. 3. 3. 3. 0. 0.]
NCT02498951,"7:16:chronic_disease,22:56:chronic_disease",Known infection with human immunodeficiency virus (HIV),"['Known' 'infection' 'with' 'human' 'immunodeficiency' 'virus' '(' 'HIV'
 ')']",[0. 2. 0. 2. 2. 2. 2. 0. 0.]
NCT02037048,"21:30:chronic_disease,36:70:chronic_disease",Patients with known infection with human immunodeficiency virus (HIV) will not be eligible,"['Patients' 'with' 'known' 'infection' 'with' 'human' 'immunodeficiency'
 'virus' '(' 'HIV' ')' 'will' 'not' 'be' 'eligible']",[0. 0. 0. 2. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02004275,"15:49:chronic_disease,50:59:chronic_disease",Patients with human immunodeficiency virus (HIV) infection are eligible,"['Patients' 'with' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')'
 'infection' 'are' 'eligible']",[0. 0. 2. 2. 2. 2. 0. 0. 2. 0. 0.]
NCT03175978,21:30:chronic_disease,Active uncontrolled infection or severe systemic infection (enrollment is possible after control of infection),"['Active' 'uncontrolled' 'infection' 'or' 'severe' 'systemic' 'infection'
 '(' 'enrollment' 'is' 'possible' 'after' 'control' 'of' 'infection' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03016130,17:26:chronic_disease,Untreated major infection at presentation,['Untreated' 'major' 'infection' 'at' 'presentation'],[0. 0. 2. 0. 0.]
NCT03009110,14:23:chronic_disease,Pre-existing infection around incision site,['Pre-existing' 'infection' 'around' 'incision' 'site'],[0. 2. 0. 0. 0.]
NCT02978638,18:27:chronic_disease,Active untreated infection,['Active' 'untreated' 'infection'],[0. 0. 2.]
NCT02737202,9:18:chronic_disease,Current infection,['Current' 'infection'],[0. 2.]
NCT02641093,1:10:chronic_disease,infection,['infection'],[2.]
NCT02594111,1:10:chronic_disease,infection (major confounder with increased inflammatory markers),"['infection' '(' 'major' 'confounder' 'with' 'increased' 'inflammatory'
 'markers' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02579967,62:71:chronic_disease,"Life-threatening, organ-threatening, or severely disfiguring infection","['Life-threatening' ',' 'organ-threatening' ',' 'or' 'severely'
 'disfiguring' 'infection']",[0. 0. 0. 0. 0. 0. 0. 2.]
NCT02543866,",24:33:chronic_disease",A history at least one infection due to ESC-R Enterobacteriaceae,"['A' 'history' 'at' 'least' 'one' 'infection' 'due' 'to' 'ESC-R'
 'Enterobacteriaceae']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT02540330,21:30:chronic_disease,Presence of serious infection,['Presence' 'of' 'serious' 'infection'],[0. 0. 0. 2.]
NCT02532595,8:17:chronic_disease,Recent infection,['Recent' 'infection'],[0. 2.]
NCT02520011,30:39:chronic_disease,"Have an active, uncontrolled infection","['Have' 'an' 'active' ',' 'uncontrolled' 'infection']",[0. 0. 0. 0. 0. 2.]
NCT02518594,",112:121:chronic_disease",Rupture of membranes due to likelihood of pregnancy loss and preterm delivery as well as the risk of ascending infection which could be increased with pessary placement,"['Rupture' 'of' 'membranes' 'due' 'to' 'likelihood' 'of' 'pregnancy'
 'loss' 'and' 'preterm' 'delivery' 'as' 'well' 'as' 'the' 'risk' 'of'
 'ascending' 'infection' 'which' 'could' 'be' 'increased' 'with' 'pessary'
 'placement']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02515110,57:66:chronic_disease,"Unresolved post-surgical complications (eg, significant infection) with healing difficulties","['Unresolved' 'post-surgical' 'complications' '(' 'eg' ',' 'significant'
 'infection' ')' 'with' 'healing' 'difficulties']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT02514083,",,89:98:chronic_disease",Fevers of greater than 100.5 F for greater than or equal to 2 weeks without evidence of infection,"['Fevers' 'of' 'greater' 'than' '100.5' 'F' 'for' 'greater' 'than' 'or'
 'equal' 'to' '2' 'weeks' 'without' 'evidence' 'of' 'infection']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02514083,",58:67:chronic_disease",Night sweats for more than one month without evidence of infection,"['Night' 'sweats' 'for' 'more' 'than' 'one' 'month' 'without' 'evidence'
 'of' 'infection']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02490631,9:18:chronic_disease,Current infection,['Current' 'infection'],[0. 2.]
NCT02479698,89:98:chronic_disease,Persisting fever without other signs or symptoms will not be interpreted as progressing infection,"['Persisting' 'fever' 'without' 'other' 'signs' 'or' 'symptoms' 'will'
 'not' 'be' 'interpreted' 'as' 'progressing' 'infection']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02477423,49:58:chronic_disease,Infant must be considered to have a low risk of infection,"['Infant' 'must' 'be' 'considered' 'to' 'have' 'a' 'low' 'risk' 'of'
 'infection']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02469662,61:70:chronic_disease,Patient has a currently active or history of repeated local infection at the surgical site,"['Patient' 'has' 'a' 'currently' 'active' 'or' 'history' 'of' 'repeated'
 'local' 'infection' 'at' 'the' 'surgical' 'site']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT02446236,49:58:chronic_disease,Patients may be eligible upon resolution of the infection,"['Patients' 'may' 'be' 'eligible' 'upon' 'resolution' 'of' 'the'
 'infection']",[0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02417701,84:93:chronic_disease,"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02370693,22:31:chronic_disease,No evidence of acute infection,['No' 'evidence' 'of' 'acute' 'infection'],[0. 0. 0. 0. 2.]
NCT02346526,5:14:chronic_disease,Any infection ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 Grade 2,"['Any' 'infection' '≥' 'National' 'Cancer' 'Institute' 'Common'
 'Terminology' 'Criteria' 'for' 'Adverse' 'Events' '(' 'NCI-CTCAE' ')'
 'version' '4.03' 'Grade' '2']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02332863,9:18:chronic_disease,Current infection,['Current' 'infection'],[0. 2.]
NCT02323581,27:36:chronic_disease,Serious systemic or groin infection,['Serious' 'systemic' 'or' 'groin' 'infection'],[0. 0. 0. 0. 2.]
NCT02307565,30:39:chronic_disease,Currently have an illness or infection,['Currently' 'have' 'an' 'illness' 'or' 'infection'],[0. 0. 0. 0. 0. 2.]
NCT02271711,23:32:chronic_disease,Evidence of untreated infection,['Evidence' 'of' 'untreated' 'infection'],[0. 0. 0. 2.]
NCT02135588,27:36:chronic_disease,Active clinically serious infection > CTCAE (version 4.03) Grade 2,"['Active' 'clinically' 'serious' 'infection' '>' 'CTCAE' '(' 'version'
 '4.03' ')' 'Grade' '2']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02108860,20:29:chronic_disease,Evidence of active infection (includes chronic infection),"['Evidence' 'of' 'active' 'infection' '(' 'includes' 'chronic' 'infection'
 ')']",[0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02101736,35:44:chronic_disease,Patients who have an uncontrolled infection,['Patients' 'who' 'have' 'an' 'uncontrolled' 'infection'],[0. 0. 0. 0. 0. 2.]
NCT02075671,13:22:chronic_disease,Scarring or infection in the area being treated,['Scarring' 'or' 'infection' 'in' 'the' 'area' 'being' 'treated'],[0. 0. 2. 0. 0. 0. 0. 0.]
NCT02072148,44:53:chronic_disease,Active clinically significant uncontrolled infection,['Active' 'clinically' 'significant' 'uncontrolled' 'infection'],[0. 0. 0. 0. 2.]
NCT02050347,21:30:chronic_disease,Severe intercurrent infection,['Severe' 'intercurrent' 'infection'],[0. 0. 2.]
NCT01940757,"21:30:chronic_disease,",History of previous infection with hookworm or residence for more than 6 months in a hookworm-endemic area,"['History' 'of' 'previous' 'infection' 'with' 'hookworm' 'or' 'residence'
 'for' 'more' 'than' '6' 'months' 'in' 'a' 'hookworm-endemic' 'area']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01873131,13:22:chronic_disease,Scarring or infection of the area to be treated,['Scarring' 'or' 'infection' 'of' 'the' 'area' 'to' 'be' 'treated'],[0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT01614197,",,,77:86:chronic_disease",Fever above 38.2 within 48 hours of study enrollment with clinical signs of infection,"['Fever' 'above' '38.2' 'within' '48' 'hours' 'of' 'study' 'enrollment'
 'with' 'clinical' 'signs' 'of' 'infection']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT01554371,40:49:chronic_disease,Severe/uncontrolled concurrent illness/infection,['Severe/uncontrolled' 'concurrent' 'illness/infection'],[0. 0. 2.]
NCT01505062,"25:34:chronic_disease,",Intercurrent illness or infection 28 days prior to SAR421869 administration,"['Intercurrent' 'illness' 'or' 'infection' '28' 'days' 'prior' 'to'
 'SAR421869' 'administration']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT01313533,34:43:chronic_disease,Subject has clinical evidence of infection that the Investigator deems significant to the completion of the procedure or that could compromise the subject's safety,"['Subject' 'has' 'clinical' 'evidence' 'of' 'infection' 'that' 'the'
 'Investigator' 'deems' 'significant' 'to' 'the' 'completion' 'of' 'the'
 'procedure' 'or' 'that' 'could' 'compromise' 'the' 'subject' ""'s""
 'safety']","[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT01189786,26:35:chronic_disease,"Severe life, threatening infection","['Severe' 'life' ',' 'threatening' 'infection']",[0. 0. 0. 0. 2.]
NCT01059786,30:39:chronic_disease,Presence of active untreated infection,['Presence' 'of' 'active' 'untreated' 'infection'],[0. 0. 0. 0. 2.]
NCT00967785,43:52:chronic_disease,Absence of a documented history of severe infection,['Absence' 'of' 'a' 'documented' 'history' 'of' 'severe' 'infection'],[0. 0. 0. 0. 0. 0. 0. 2.]
NCT00906984,21:30:chronic_disease,Active uncontrolled infection,['Active' 'uncontrolled' 'infection'],[0. 0. 2.]
NCT00720785,19:28:chronic_disease,Ongoing or active infection,['Ongoing' 'or' 'active' 'infection'],[0. 0. 0. 2.]
NCT00670358,19:28:chronic_disease,Ongoing or active infection,['Ongoing' 'or' 'active' 'infection'],[0. 0. 0. 2.]
NCT02543866,"32:42:allergy_name,47:66:allergy_name",Allergy or hypersensitivity to omeprazole and polyethylene glycol,"['Allergy' 'or' 'hypersensitivity' 'to' 'omeprazole' 'and' 'polyethylene'
 'glycol']",[0. 0. 0. 0. 4. 0. 4. 4.]
NCT02193191,"45:64:chronic_disease,111:135:treatment","Patients must have confirmed and measurable Sickle Cell Disease, defined by SS or Sβ thalassemia confirmed by hemoglobin fractionation","['Patients' 'must' 'have' 'confirmed' 'and' 'measurable' 'Sickle' 'Cell'
 'Disease' ',' 'defined' 'by' 'SS' 'or' 'Sβ' 'thalassemia' 'confirmed'
 'by' 'hemoglobin' 'fractionation']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02675959,56:75:chronic_disease,Patients must demonstrate one or more of the following Sickle Cell Disease Complications (or patients in Cohort 2 can meet other high risk criteria instead),"['Patients' 'must' 'demonstrate' 'one' 'or' 'more' 'of' 'the' 'following'
 'Sickle' 'Cell' 'Disease' 'Complications' '(' 'or' 'patients' 'in'
 'Cohort' '2' 'can' 'meet' 'other' 'high' 'risk' 'criteria' 'instead' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02562040,1:20:chronic_disease,Sickle Cell Disease,['Sickle' 'Cell' 'Disease'],[2. 2. 2.]
NCT01461837,",56:75:chronic_disease",Patients must demonstrate one or more of the following Sickle Cell Disease Complications,"['Patients' 'must' 'demonstrate' 'one' 'or' 'more' 'of' 'the' 'following'
 'Sickle' 'Cell' 'Disease' 'Complications']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0.]
NCT02574728,"31:62:treatment,66:76:treatment",Currently receiving receiving potent CYP3A4 (enzyme) inducers or inhibitors,"['Currently' 'receiving' 'receiving' 'potent' 'CYP3A4' '(' 'enzyme' ')'
 'inducers' 'or' 'inhibitors']",[0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 1.]
NCT02374333,"19:36:treatment,165:180:treatment","Concurrent use of systemic steroids at the time of cell infusion or cell collection, or a condition, in the treating physician's opinion, that is likely to require steroid therapy during collection or after infusion","['Concurrent' 'use' 'of' 'systemic' 'steroids' 'at' 'the' 'time' 'of'
 'cell' 'infusion' 'or' 'cell' 'collection' ',' 'or' 'a' 'condition' ','
 'in' 'the' 'treating' 'physician' ""'s"" 'opinion' ',' 'that' 'is' 'likely'
 'to' 'require' 'steroid' 'therapy' 'during' 'collection' 'or' 'after'
 'infusion']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]"
NCT02264236,27:44:treatment,Subjects who have been on systemic steroids will require a 6-week washout period,"['Subjects' 'who' 'have' 'been' 'on' 'systemic' 'steroids' 'will'
 'require' 'a' '6-week' 'washout' 'period']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT01994382,"16:33:treatment,,",Current use of systemic steroids >20 mg QD prednisone (or equivalent),"['Current' 'use' 'of' 'systemic' 'steroids' '>' '20' 'mg' 'QD'
 'prednisone' '(' 'or' 'equivalent' ')']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01474889,70:87:treatment,Receiving treatment for a medical condition requiring chronic use of systemic steroids,"['Receiving' 'treatment' 'for' 'a' 'medical' 'condition' 'requiring'
 'chronic' 'use' 'of' 'systemic' 'steroids']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02429830,"1:5:chronic_disease,30:41:treatment,","GERD symptoms, in absence of PPI therapy (minimum 7 days)","['GERD' 'symptoms' ',' 'in' 'absence' 'of' 'PPI' 'therapy' '(' 'minimum'
 '7' 'days' ')']",[2. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02561988,"14:21:chronic_disease,50:73:treatment",History of a seizure disorder or requirement for anti-seizure medication,"['History' 'of' 'a' 'seizure' 'disorder' 'or' 'requirement' 'for'
 'anti-seizure' 'medication']",[0. 0. 0. 2. 0. 0. 0. 0. 1. 1.]
NCT03176784,12:19:chronic_disease,history of seizure within the last year,['history' 'of' 'seizure' 'within' 'the' 'last' 'year'],[0. 0. 2. 0. 0. 0. 0.]
NCT03093272,32:39:chronic_disease,Medications known to lower the seizure threshold must be discontinued,"['Medications' 'known' 'to' 'lower' 'the' 'seizure' 'threshold' 'must'
 'be' 'discontinued']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT02769000,12:19:chronic_disease,History of seizure activity,['History' 'of' 'seizure' 'activity'],[0. 0. 2. 0.]
NCT02480114,12:19:chronic_disease,History of seizure disorder,['History' 'of' 'seizure' 'disorder'],[0. 0. 2. 0.]
NCT02452008,21:28:chronic_disease,Have a history of a seizure,['Have' 'a' 'history' 'of' 'a' 'seizure'],[0. 0. 0. 0. 0. 2.]
NCT02366754,"23:30:chronic_disease,",Have had a documented seizure within 3 months of study screening,"['Have' 'had' 'a' 'documented' 'seizure' 'within' '3' 'months' 'of'
 'study' 'screening']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02316574,44:51:chronic_disease,"History of severe alcohol withdrawal (e.g. seizure, delirium tremens, multiple detoxifications or ER visits for alcohol withdrawal)","['History' 'of' 'severe' 'alcohol' 'withdrawal' '(' 'e.g' '.' 'seizure'
 ',' 'delirium' 'tremens' ',' 'multiple' 'detoxifications' 'or' 'ER'
 'visits' 'for' 'alcohol' 'withdrawal' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02254863,",108:115:chronic_disease","Three or more of the early clinical markers: problems sleeping, increased activity, behavior difficulties, seizure-like activity, chewing behavior, inappropriate bladder training, inappropriate bowel training","['Three' 'or' 'more' 'of' 'the' 'early' 'clinical' 'markers' ':'
 'problems' 'sleeping' ',' 'increased' 'activity' ',' 'behavior'
 'difficulties' ',' 'seizure-like' 'activity' ',' 'chewing' 'behavior' ','
 'inappropriate' 'bladder' 'training' ',' 'inappropriate' 'bowel'
 'training']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT01964261,12:19:chronic_disease,History of seizure,['History' 'of' 'seizure'],[0. 0. 2.]
NCT01961557,16:23:chronic_disease,A history of a seizure in the past year,['A' 'history' 'of' 'a' 'seizure' 'in' 'the' 'past' 'year'],[0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT01915095,81:88:chronic_disease,"Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold (see appendix 2)","['Receiving' 'drugs' 'acting' 'primarily' 'on' 'the' 'central' 'nervous'
 'system' ',' 'which' 'lower' 'the' 'seizure' 'threshold' '(' 'see'
 'appendix' '2' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT01882153,",41:48:chronic_disease","medically unstable (e.g., more than one seizure a month)","['medically' 'unstable' '(' 'e.g.' ',' 'more' 'than' 'one' 'seizure' 'a'
 'month' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0.]
NCT01434316,"21:28:chronic_disease,",Patients with prior seizure history who have experienced a seizure within the three months prior to enrollment,"['Patients' 'with' 'prior' 'seizure' 'history' 'who' 'have' 'experienced'
 'a' 'seizure' 'within' 'the' 'three' 'months' 'prior' 'to' 'enrollment']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00739362,42:49:chronic_disease,Personal or first-degree relative with a seizure history,['Personal' 'or' 'first-degree' 'relative' 'with' 'a' 'seizure' 'history'],[0. 0. 0. 0. 0. 0. 2. 0.]
NCT02515110,"27:47:treatment,51:62:treatment",History of ipsilateral or contralateral breast or thoracic RT for any condition,"['History' 'of' 'ipsilateral' 'or' 'contralateral' 'breast' 'or'
 'thoracic' 'RT' 'for' 'any' 'condition']",[0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0.]
NCT01953588,"30:50:cancer,",Mammogram for the unaffected contralateral breast is required within 12 months prior to registration,"['Mammogram' 'for' 'the' 'unaffected' 'contralateral' 'breast' 'is'
 'required' 'within' '12' 'months' 'prior' 'to' 'registration']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02478255,"30:41:treatment,",Patient scheduled to undergo thoracic RT at Duke University to a dose of at least 20 Gy,"['Patient' 'scheduled' 'to' 'undergo' 'thoracic' 'RT' 'at' 'Duke'
 'University' 'to' 'a' 'dose' 'of' 'at' 'least' '20' 'Gy']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02323880,"1:33:treatment,,61:90:treatment",Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent,"['Biologic' '(' 'anti-neoplastic' 'agent' ')' ':' 'At' 'least' '7' 'days'
 'after' 'the' 'last' 'dose' 'of' 'a' 'biologic' 'agent']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1.]
NCT01994538,"1:10:treatment,29:58:treatment","Treatment initiated with an empiric antimicrobial regimen that is underdosed, based on current guidelines and reviews","['Treatment' 'initiated' 'with' 'an' 'empiric' 'antimicrobial' 'regimen'
 'that' 'is' 'underdosed' ',' 'based' 'on' 'current' 'guidelines' 'and'
 'reviews']",[1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02574910,1:10:treatment,Treatment with growth hormone at enrollment or during the course of the study,"['Treatment' 'with' 'growth' 'hormone' 'at' 'enrollment' 'or' 'during'
 'the' 'course' 'of' 'the' 'study']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02477839,",105:114:treatment","device settings must be kept stable for >=2 weeks prior to Visit 1 and kept stable during the Baseline, Treatment, and Transition Periods","['device' 'settings' 'must' 'be' 'kept' 'stable' 'for' '>' '=2' 'weeks'
 'prior' 'to' 'Visit' '1' 'and' 'kept' 'stable' 'during' 'the' 'Baseline'
 ',' 'Treatment' ',' 'and' 'Transition' 'Periods']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0.]"
NCT02453373,"1:10:treatment,",Treatment must be initiated within 8 hours from known time of symptom onset,"['Treatment' 'must' 'be' 'initiated' 'within' '8' 'hours' 'from' 'known'
 'time' 'of' 'symptom' 'onset']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02414139,11:20:treatment,Cohort 5: Treatment-naïve patients with cMET dysregulation,"['Cohort' '5' ':' 'Treatment-naïve' 'patients' 'with' 'cMET'
 'dysregulation']",[0. 0. 0. 1. 0. 0. 0. 0.]
NCT02346526,1:10:treatment,Treatment should be completed for spinal cord compression,['Treatment' 'should' 'be' 'completed' 'for' 'spinal' 'cord' 'compression'],[1. 0. 0. 0. 0. 0. 0. 0.]
NCT02336217,1:10:treatment,Treatment by Marshall Internal Medicine Department,['Treatment' 'by' 'Marshall' 'Internal' 'Medicine' 'Department'],[1. 0. 0. 0. 0. 0.]
NCT02130687,"1:10:treatment,",Treatment with any investigational drug in the 1 month preceding the study,"['Treatment' 'with' 'any' 'investigational' 'drug' 'in' 'the' '1' 'month'
 'preceding' 'the' 'study']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01584076,"1:10:treatment,",Treatment with topical atropine within the past 4 weeks,['Treatment' 'with' 'topical' 'atropine' 'within' 'the' 'past' '4' 'weeks'],[1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00147056,",70:79:treatment,,",Size of the targeted portion of the tumor (i.e. prescribed Region Of Treatment) is less than 2.5 cm in diameter or 8 cm3 in volume,"['Size' 'of' 'the' 'targeted' 'portion' 'of' 'the' 'tumor' '(' 'i.e' '.'
 'prescribed' 'Region' 'Of' 'Treatment' ')' 'is' 'less' 'than' '2.5' 'cm'
 'in' 'diameter' 'or' '8' 'cm3' 'in' 'volume']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT03058146,"14:20:cancer,,53:77:cancer",treatment of cancer in the past 2 years (other than non-melanoma skin cancer),"['treatment' 'of' 'cancer' 'in' 'the' 'past' '2' 'years' '(' 'other'
 'than' 'non-melanoma' 'skin' 'cancer' ')']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0.]
NCT02945969,"12:18:cancer,30:54:cancer,",History of cancer other than non-melanoma skin cancer within two years prior to enrollment based on patient self-report,"['History' 'of' 'cancer' 'other' 'than' 'non-melanoma' 'skin' 'cancer'
 'within' 'two' 'years' 'prior' 'to' 'enrollment' 'based' 'on' 'patient'
 'self-report']",[0. 0. 3. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02695433,"13:19:cancer,31:55:cancer,",Have or had cancer other than non-melanoma skin cancer in past 5 years,"['Have' 'or' 'had' 'cancer' 'other' 'than' 'non-melanoma' 'skin' 'cancer'
 'in' 'past' '5' 'years']",[0. 0. 0. 3. 0. 0. 3. 3. 3. 0. 0. 0. 0.]
NCT02359864,"30:36:cancer,44:68:cancer",The patient has a history of cancer except non-melanoma skin cancer,"['The' 'patient' 'has' 'a' 'history' 'of' 'cancer' 'except' 'non-melanoma'
 'skin' 'cancer']",[0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 3.]
NCT01365169,"16:22:cancer,35:59:cancer","History of any cancer, other than non-melanoma skin cancer (Arm 4)","['History' 'of' 'any' 'cancer' ',' 'other' 'than' 'non-melanoma' 'skin'
 'cancer' '(' 'Arm' '4' ')']",[0. 0. 0. 3. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0.]
NCT03187951,11:17:cancer,Recurrent cancer following prior resection,['Recurrent' 'cancer' 'following' 'prior' 'resection'],[0. 3. 0. 0. 0.]
NCT03181750,109:115:cancer,Meeting medium to high risk for death at 1 year using the CARING criteria (although excluding patients with cancer diagnosis),"['Meeting' 'medium' 'to' 'high' 'risk' 'for' 'death' 'at' '1' 'year'
 'using' 'the' 'CARING' 'criteria' '(' 'although' 'excluding' 'patients'
 'with' 'cancer' 'diagnosis' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0.]
NCT03174379,8:14:cancer,active cancer,['active' 'cancer'],[0. 3.]
NCT03146663,"48:54:cancer,",Patients who have a history of another type of cancer diagnosed within the past 5 years,"['Patients' 'who' 'have' 'a' 'history' 'of' 'another' 'type' 'of' 'cancer'
 'diagnosed' 'within' 'the' 'past' '5' 'years']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0.]
NCT03135171,",,,89:95:cancer",Eastern Cooperative Oncology Group Performance Status of 0 or 1 (An attempt to quantify cancer patients' general well-being and activities of daily life,"['Eastern' 'Cooperative' 'Oncology' 'Group' 'Performance' 'Status' 'of'
 '0' 'or' '1' '(' 'An' 'attempt' 'to' 'quantify' 'cancer' 'patients' ""'""
 'general' 'well-being' 'and' 'activities' 'of' 'daily' 'life']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT03108820,35:41:cancer,have a self-reported diagnosis of cancer with short life expectancy,"['have' 'a' 'self-reported' 'diagnosis' 'of' 'cancer' 'with' 'short'
 'life' 'expectancy']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0.]
NCT03087903,"20:26:cancer,",History of another cancer is exclusionary unless it is believed to be likely cured or is unlikely to be fatal in the next 3 years,"['History' 'of' 'another' 'cancer' 'is' 'exclusionary' 'unless' 'it' 'is'
 'believed' 'to' 'be' 'likely' 'cured' 'or' 'is' 'unlikely' 'to' 'be'
 'fatal' 'in' 'the' 'next' '3' 'years']","[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT03070535,27:33:cancer,"Remote history of treated cancer is ok, as long as current cognition and digestion are not affected","['Remote' 'history' 'of' 'treated' 'cancer' 'is' 'ok' ',' 'as' 'long' 'as'
 'current' 'cognition' 'and' 'digestion' 'are' 'not' 'affected']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03059888,26:32:cancer,Subject has a history of cancer in the last 5 years,['Subject' 'has' 'a' 'history' 'of' 'cancer' 'in' 'the' 'last' '5' 'years'],[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT03058029,"12:18:cancer,",History of cancer within the past five(5) years,['History' 'of' 'cancer' 'within' 'the' 'past' 'five' '(' '5' ')' 'years'],[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03043742,"13:19:cancer,","Untreatable cancer, current or within preceding 5 years","['Untreatable' 'cancer' ',' 'current' 'or' 'within' 'preceding' '5'
 'years']",[0. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT03042689,",,,,137:143:cancer",Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN (≤ 5 x ULN for subjects with liver involvement of their cancer),"['Alanine' 'aminotransferase' '(' 'ALT' ')' 'and' 'aspartate'
 'aminotransferase' '(' 'AST' ')' '≤' '2.5' 'x' 'ULN' '(' '≤' '5' 'x'
 'ULN' 'for' 'subjects' 'with' 'liver' 'involvement' 'of' 'their' 'cancer'
 ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 3. 0.]"
NCT03042689,",,,104:110:cancer",Alkaline phosphatase limit ≤ 2.5 x ULN (≤ 5 x ULN for subjects with liver or bone involvement of their cancer),"['Alkaline' 'phosphatase' 'limit' '≤' '2.5' 'x' 'ULN' '(' '≤' '5' 'x'
 'ULN' 'for' 'subjects' 'with' 'liver' 'or' 'bone' 'involvement' 'of'
 'their' 'cancer' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0.]
NCT03042689,"22:28:cancer,",Subjects surviving a cancer that was curatively treated and without evidence of disease for more than 3 years before registration are allowed,"['Subjects' 'surviving' 'a' 'cancer' 'that' 'was' 'curatively' 'treated'
 'and' 'without' 'evidence' 'of' 'disease' 'for' 'more' 'than' '3' 'years'
 'before' 'registration' 'are' 'allowed']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03040726,14:20:cancer,Diagnosis of cancer,['Diagnosis' 'of' 'cancer'],[0. 0. 3.]
NCT03037385,11:17:cancer,Patient's cancer has a known primary driver alteration other than RET,"['Patient' ""'s"" 'cancer' 'has' 'a' 'known' 'primary' 'driver' 'alteration'
 'other' 'than' 'RET']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03035773,11:17:cancer,"Had their cancer care primarily managed by either JHMI or PRMC, with JHMI or PRMC primarily responsible for the patients' survivorship care","['Had' 'their' 'cancer' 'care' 'primarily' 'managed' 'by' 'either' 'JHMI'
 'or' 'PRMC' ',' 'with' 'JHMI' 'or' 'PRMC' 'primarily' 'responsible' 'for'
 'the' 'patients' ""'"" 'survivorship' 'care']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03030859,16:22:cancer,No evidence of cancer (NED),['No' 'evidence' 'of' 'cancer' '(' 'NED' ')'],[0. 0. 0. 3. 0. 0. 0.]
NCT03030859,18:24:cancer,any other active cancer,['any' 'other' 'active' 'cancer'],[0. 0. 0. 3.]
NCT03029442,22:28:cancer,Current diagnosis of cancer or history of cancer,['Current' 'diagnosis' 'of' 'cancer' 'or' 'history' 'of' 'cancer'],[0. 0. 0. 3. 0. 0. 0. 0.]
NCT03006913,32:38:cancer,don't have a family history of cancer,"['do' ""n't"" 'have' 'a' 'family' 'history' 'of' 'cancer']",[0. 0. 0. 0. 0. 0. 0. 3.]
NCT02986152,26:32:cancer,Have been diagnosed with cancer or are/were a caregiver to someone with cancer,"['Have' 'been' 'diagnosed' 'with' 'cancer' 'or' 'are/were' 'a' 'caregiver'
 'to' 'someone' 'with' 'cancer']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02963831,33:39:cancer,Previously treated for advanced cancer with no additional therapy options available known to prolong survival,"['Previously' 'treated' 'for' 'advanced' 'cancer' 'with' 'no' 'additional'
 'therapy' 'options' 'available' 'known' 'to' 'prolong' 'survival']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02939755,58:64:cancer,a spouse or cohabitating intimate partner of an advanced cancer patient being evaluated at the UPMC's LCC,"['a' 'spouse' 'or' 'cohabitating' 'intimate' 'partner' 'of' 'an'
 'advanced' 'cancer' 'patient' 'being' 'evaluated' 'at' 'the' 'UPMC' ""'s""
 'LCC']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02937272,67:73:cancer,The participant must have histological or cytological evidence of cancer,"['The' 'participant' 'must' 'have' 'histological' 'or' 'cytological'
 'evidence' 'of' 'cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02932748,30:36:cancer,"Serious medical risk such as cancer, recent cardiac event","['Serious' 'medical' 'risk' 'such' 'as' 'cancer' ',' 'recent' 'cardiac'
 'event']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0.]
NCT02916472,26:32:cancer,histologically confirmed cancer,['histologically' 'confirmed' 'cancer'],[0. 0. 3.]
NCT02914171,16:22:cancer,history of any cancer,['history' 'of' 'any' 'cancer'],[0. 0. 0. 3.]
NCT02911831,57:63:cancer,Patients currently undergoing treatment for any type of cancer,"['Patients' 'currently' 'undergoing' 'treatment' 'for' 'any' 'type' 'of'
 'cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02911792,12:18:cancer,History of cancer,['History' 'of' 'cancer'],[0. 0. 3.]
NCT02881242,",50:56:cancer",Hospitalization within 30 days of enrollment for cancer related events,"['Hospitalization' 'within' '30' 'days' 'of' 'enrollment' 'for' 'cancer'
 'related' 'events']",[0. 0. 0. 0. 0. 0. 0. 3. 0. 0.]
NCT02869789,110:116:cancer,Physically able to carry out light housework or office work through to being fully active as you were before cancer,"['Physically' 'able' 'to' 'carry' 'out' 'light' 'housework' 'or' 'office'
 'work' 'through' 'to' 'being' 'fully' 'active' 'as' 'you' 'were' 'before'
 'cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02865135,"7:13:cancer,",Other cancer in the past 5 years,['Other' 'cancer' 'in' 'the' 'past' '5' 'years'],[0. 3. 0. 0. 0. 0. 0.]
NCT02836574,"12:18:cancer,",history of cancer within the past 3 years,['history' 'of' 'cancer' 'within' 'the' 'past' '3' 'years'],[0. 0. 3. 0. 0. 0. 0. 0.]
NCT02826577,20:26:cancer,Medical history of cancer,['Medical' 'history' 'of' 'cancer'],[0. 0. 0. 3.]
NCT02802787,",22:28:cancer",Women diagnosed with cancer,['Women' 'diagnosed' 'with' 'cancer'],[0. 0. 0. 3.]
NCT02793921,20:26:cancer,Prior diagnoses of cancer,['Prior' 'diagnoses' 'of' 'cancer'],[0. 0. 0. 3.]
NCT02791646,",52:58:cancer",current or past (<6 months) engagement in PCST for cancer,"['current' 'or' 'past' '(' '<' '6' 'months' ')' 'engagement' 'in' 'PCST'
 'for' 'cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02786251,"9:15:cancer,",Current cancer or cancer that has been in remission for < 5 years,"['Current' 'cancer' 'or' 'cancer' 'that' 'has' 'been' 'in' 'remission'
 'for' '<' '5' 'years']",[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02753283,",106:112:cancer",We will suggest that participants stop long-term calcitonin as it has been discontinued in Europe due to cancer concerns,"['We' 'will' 'suggest' 'that' 'participants' 'stop' 'long-term'
 'calcitonin' 'as' 'it' 'has' 'been' 'discontinued' 'in' 'Europe' 'due'
 'to' 'cancer' 'concerns']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0.]
NCT02746458,22:28:cancer,Current diagnosis of cancer,['Current' 'diagnosis' 'of' 'cancer'],[0. 0. 0. 3.]
NCT02724930,14:20:cancer,Diagnosis of cancer,['Diagnosis' 'of' 'cancer'],[0. 0. 3.]
NCT02663622,",,,40:46:cancer,",Karnofsky >70% (an attempt to quantify cancer patients' general well-being and activities of daily life. The score ranges from 0 to 100 where 100 is perfect health and 0 is death.),"['Karnofsky' '>' '70' '%' '(' 'an' 'attempt' 'to' 'quantify' 'cancer'
 'patients' ""'"" 'general' 'well-being' 'and' 'activities' 'of' 'daily'
 'life' '.' 'The' 'score' 'ranges' 'from' '0' 'to' '100' 'where' '100'
 'is' 'perfect' 'health' 'and' '0' 'is' 'death' '.' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02657993,6:12:cancer,Past cancer,['Past' 'cancer'],[0. 3.]
NCT02656550,"28:34:cancer,",Subject who has history of cancer in last five years,['Subject' 'who' 'has' 'history' 'of' 'cancer' 'in' 'last' 'five' 'years'],[0. 0. 0. 0. 0. 3. 0. 0. 0. 0.]
NCT02639065,"7:13:cancer,",other cancer for which the subject has been disease-free for at least 3 years,"['other' 'cancer' 'for' 'which' 'the' 'subject' 'has' 'been'
 'disease-free' 'for' 'at' 'least' '3' 'years']",[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02607033,8:14:cancer,Active cancer,['Active' 'cancer'],[0. 3.]
NCT02584647,78:84:cancer,Disease site/type with pathologic confirmation of diagnosis at participating cancer site,"['Disease' 'site/type' 'with' 'pathologic' 'confirmation' 'of' 'diagnosis'
 'at' 'participating' 'cancer' 'site']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0.]
NCT02584244,17:23:cancer,Subjects at any cancer stage will be enrolled,['Subjects' 'at' 'any' 'cancer' 'stage' 'will' 'be' 'enrolled'],[0. 0. 0. 3. 0. 0. 0. 0.]
NCT02580981,23:29:cancer,Not willing to obtain cancer care at the University of New Mexico,"['Not' 'willing' 'to' 'obtain' 'cancer' 'care' 'at' 'the' 'University'
 'of' 'New' 'Mexico']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02578641,24:30:cancer,Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study,"['Previous' 'or' 'concurrent' 'cancer' 'that' 'is' 'distinct' 'in'
 'primary' 'site' 'or' 'histology' 'from' 'the' 'cancer' 'being'
 'evaluated' 'in' 'this' 'study']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02578641,"5:11:cancer,",any cancer curatively treated >3 years prior to study entry,"['any' 'cancer' 'curatively' 'treated' '>' '3' 'years' 'prior' 'to'
 'study' 'entry']",[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02576444,13:19:cancer,Progressive cancer at the time of study entry,['Progressive' 'cancer' 'at' 'the' 'time' 'of' 'study' 'entry'],[0. 3. 0. 0. 0. 0. 0. 0.]
NCT02568267,27:33:cancer,History of other previous cancer that would interfere with the determination of safety or efficacy,"['History' 'of' 'other' 'previous' 'cancer' 'that' 'would' 'interfere'
 'with' 'the' 'determination' 'of' 'safety' 'or' 'efficacy']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02563574,30:36:cancer,Unstable medical conditions (cancer),['Unstable' 'medical' 'conditions' '(' 'cancer' ')'],[0. 0. 0. 0. 3. 0.]
NCT02535832,8:14:cancer,Active cancer,['Active' 'cancer'],[0. 3.]
NCT02505165,32:38:cancer,The child is being treated for cancer and returning to the medical center (CCHMC or OUHSC),"['The' 'child' 'is' 'being' 'treated' 'for' 'cancer' 'and' 'returning'
 'to' 'the' 'medical' 'center' '(' 'CCHMC' 'or' 'OUHSC' ')']",[0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02502006,"12:18:cancer,",History of cancer within the last 5 years,['History' 'of' 'cancer' 'within' 'the' 'last' '5' 'years'],[0. 0. 3. 0. 0. 0. 0. 0.]
NCT02494869,64:70:cancer,Clinical breast exam interpreted as benign (not suspicious for cancer) at MSK,"['Clinical' 'breast' 'exam' 'interpreted' 'as' 'benign' '(' 'not'
 'suspicious' 'for' 'cancer' ')' 'at' 'MSK']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0.]
NCT02494869,10:16:cancer,Invasive cancer diagnosis,['Invasive' 'cancer' 'diagnosis'],[0. 3. 0.]
NCT02474368,37:43:cancer,Participants must have a pathologic cancer diagnosis,['Participants' 'must' 'have' 'a' 'pathologic' 'cancer' 'diagnosis'],[0. 0. 0. 0. 0. 3. 0.]
NCT02467478,"12:18:cancer,",History of cancer within the past 5 years,['History' 'of' 'cancer' 'within' 'the' 'past' '5' 'years'],[0. 0. 3. 0. 0. 0. 0. 0.]
NCT02465541,26:32:cancer,Prior diagnosis of other cancer,['Prior' 'diagnosis' 'of' 'other' 'cancer'],[0. 0. 0. 0. 3.]
NCT02460835,",,122:128:cancer,,",Zubrod performance status of less than or equal to 2 (Zubrod performance status is a measure that attempts to quantify a cancer patients' general well-being. Scores run from 0 to 5 where 0 denotes normal activity and 5 denotes death),"['Zubrod' 'performance' 'status' 'of' 'less' 'than' 'or' 'equal' 'to' '2'
 '(' 'Zubrod' 'performance' 'status' 'is' 'a' 'measure' 'that' 'attempts'
 'to' 'quantify' 'a' 'cancer' 'patients' ""'"" 'general' 'well-being' '.'
 'Scores' 'run' 'from' '0' 'to' '5' 'where' '0' 'denotes' 'normal'
 'activity' 'and' '5' 'denotes' 'death' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02459769,62:68:cancer,"For caregivers, be currently undergoing active treatment for cancer","['For' 'caregivers' ',' 'be' 'currently' 'undergoing' 'active' 'treatment'
 'for' 'cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02459769,25:31:cancer,Have had a diagnosis of cancer,['Have' 'had' 'a' 'diagnosis' 'of' 'cancer'],[0. 0. 0. 0. 0. 3.]
NCT02459769,1:7:cancer,cancer survivors,['cancer' 'survivors'],[3. 0.]
NCT02459119,"22:28:cancer,",Subjects surviving a cancer that was curatively treated and without evidence of disease for more than 3 years before randomization,"['Subjects' 'surviving' 'a' 'cancer' 'that' 'was' 'curatively' 'treated'
 'and' 'without' 'evidence' 'of' 'disease' 'for' 'more' 'than' '3' 'years'
 'before' 'randomization']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02436070,9:15:cancer,Current cancer diagnosis,['Current' 'cancer' 'diagnosis'],[0. 3. 0.]
NCT02413047,"5:11:cancer,",Any cancer within the past 5 years,['Any' 'cancer' 'within' 'the' 'past' '5' 'years'],[0. 3. 0. 0. 0. 0. 0.]
NCT02408406,28:34:cancer,Malignant diagnosis in any cancer type at any stage,['Malignant' 'diagnosis' 'in' 'any' 'cancer' 'type' 'at' 'any' 'stage'],[0. 0. 0. 0. 3. 0. 0. 0. 0.]
NCT02406885,"12:18:cancer,",History of cancer (within the last year),['History' 'of' 'cancer' '(' 'within' 'the' 'last' 'year' ')'],[0. 0. 3. 0. 0. 0. 0. 0. 0.]
NCT02406599,49:55:cancer,Multi-centric disease (histologically diagnosed cancer in two different quadrants of the breast),"['Multi-centric' 'disease' '(' 'histologically' 'diagnosed' 'cancer' 'in'
 'two' 'different' 'quadrants' 'of' 'the' 'breast' ')']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02389465,22:28:cancer,Current diagnosis of cancer,['Current' 'diagnosis' 'of' 'cancer'],[0. 0. 0. 3.]
NCT02367196,"16:22:cancer,,","Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks prior to starting CC-90002, whichever is shorter","['Prior' 'systemic' 'cancer-directed' 'treatments' 'or' 'investigational'
 'modalities' '≤' '5' 'half' 'lives' 'or' '4' 'weeks' 'prior' 'to'
 'starting' 'CC-90002' ',' 'whichever' 'is' 'shorter']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02366611,49:55:cancer,Patients are actively being treated for another cancer at the time of enrollment,"['Patients' 'are' 'actively' 'being' 'treated' 'for' 'another' 'cancer'
 'at' 'the' 'time' 'of' 'enrollment']",[0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT02360579,16:22:cancer,Patients whose cancer requires immediate attention or who would otherwise suffer a disadvantage by participating in this trial,"['Patients' 'whose' 'cancer' 'requires' 'immediate' 'attention' 'or' 'who'
 'would' 'otherwise' 'suffer' 'a' 'disadvantage' 'by' 'participating' 'in'
 'this' 'trial']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02356861,48:54:cancer,Presence of a life-threatening disease such as cancer,['Presence' 'of' 'a' 'life-threatening' 'disease' 'such' 'as' 'cancer'],[0. 0. 0. 0. 0. 0. 0. 3.]
NCT02347995,8:14:cancer,active cancer,['active' 'cancer'],[0. 3.]
NCT02339948,"20:26:cancer,,","2002 AJCC clinical cancer stage as determined by either urologist or radiation oncologist must be T1c - T2b, N0, M0","['2002' 'AJCC' 'clinical' 'cancer' 'stage' 'as' 'determined' 'by' 'either'
 'urologist' 'or' 'radiation' 'oncologist' 'must' 'be' 'T1c' '-' 'T2b' ','
 'N0' ',' 'M0']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02332928,45:51:cancer,Fatigue brought on by conditions other than cancer,['Fatigue' 'brought' 'on' 'by' 'conditions' 'other' 'than' 'cancer'],[0. 0. 0. 0. 0. 0. 0. 3.]
NCT02312245,97:103:cancer,Willing to agree to periodic contact with a member of the study team during the period that the cancer has not recurred and/or has not become platinum resistant,"['Willing' 'to' 'agree' 'to' 'periodic' 'contact' 'with' 'a' 'member' 'of'
 'the' 'study' 'team' 'during' 'the' 'period' 'that' 'the' 'cancer' 'has'
 'not' 'recurred' 'and/or' 'has' 'not' 'become' 'platinum' 'resistant']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02258438,1:7:cancer,cancer,['cancer'],[3.]
NCT02219711,14:20:cancer,Other active cancer,['Other' 'active' 'cancer'],[0. 0. 3.]
NCT02217345,12:18:cancer,History of cancer,['History' 'of' 'cancer'],[0. 0. 3.]
NCT02178709,"5:11:cancer,",Any cancer curatively treated >3 years prior to entry with no clinical evidence of recurrence,"['Any' 'cancer' 'curatively' 'treated' '>' '3' 'years' 'prior' 'to'
 'entry' 'with' 'no' 'clinical' 'evidence' 'of' 'recurrence']",[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02169830,15:21:cancer,Patients with cancer,['Patients' 'with' 'cancer'],[0. 0. 3.]
NCT02161380,"34:40:cancer,",Patients with a prior history of cancer will need documentation from their cancer specialist that the cancer was cured at least 5 years before study entry,"['Patients' 'with' 'a' 'prior' 'history' 'of' 'cancer' 'will' 'need'
 'documentation' 'from' 'their' 'cancer' 'specialist' 'that' 'the'
 'cancer' 'was' 'cured' 'at' 'least' '5' 'years' 'before' 'study' 'entry']","[0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02139436,1:7:cancer,cancer,['cancer'],[3.]
NCT02138214,33:39:cancer,Failure to confirm diagnosis of cancer in participant,['Failure' 'to' 'confirm' 'diagnosis' 'of' 'cancer' 'in' 'participant'],[0. 0. 0. 0. 0. 3. 0. 0.]
NCT02129348,38:44:cancer,past history of successfully treated cancer,['past' 'history' 'of' 'successfully' 'treated' 'cancer'],[0. 0. 0. 0. 0. 3.]
NCT02081404,13:19:cancer,Presence of cancer or mass lesion in the esophagus or stomach,"['Presence' 'of' 'cancer' 'or' 'mass' 'lesion' 'in' 'the' 'esophagus' 'or'
 'stomach']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02081404,"21:27:cancer,,",recent diagnosis of cancer with a life-expectancy < 5 years,"['recent' 'diagnosis' 'of' 'cancer' 'with' 'a' 'life-expectancy' '<' '5'
 'years']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0.]
NCT02048722,",,,98:104:cancer",Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer),"['Alkaline' 'phosphatase' 'limit' '=' '<' '2.5' 'x' 'ULN' '(' '=' '<' '5'
 'x' 'ULN' 'for' 'subjects' 'with' 'liver' 'involvement' 'of' 'their'
 'cancer' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0.]
NCT02013492,32:38:cancer,the first 10 patients may have cancer of any histology,"['the' 'first' '10' 'patients' 'may' 'have' 'cancer' 'of' 'any'
 'histology']",[0. 0. 0. 0. 0. 0. 3. 0. 0. 0.]
NCT01983475,22:28:cancer,Current diagnosis of cancer,['Current' 'diagnosis' 'of' 'cancer'],[0. 0. 0. 3.]
NCT01983475,12:18:cancer,history of cancer,['history' 'of' 'cancer'],[0. 0. 3.]
NCT01918644,"14:20:cancer,",any invasive cancer in the last 5 years,['any' 'invasive' 'cancer' 'in' 'the' 'last' '5' 'years'],[0. 0. 3. 0. 0. 0. 0. 0.]
NCT01851369,"11:17:cancer,",Any other cancer from which the patient has been disease-free for three years,"['Any' 'other' 'cancer' 'from' 'which' 'the' 'patient' 'has' 'been'
 'disease-free' 'for' 'three' 'years']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01836354,"25:31:cancer,","Patients with end stage cancer, or other medical conditions resulting in mortality less than 1 year","['Patients' 'with' 'end' 'stage' 'cancer' ',' 'or' 'other' 'medical'
 'conditions' 'resulting' 'in' 'mortality' 'less' 'than' '1' 'year']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01804465,11:17:cancer,Any other cancer from which the patient has been disease-free for 5 years,"['Any' 'other' 'cancer' 'from' 'which' 'the' 'patient' 'has' 'been'
 'disease-free' 'for' '5' 'years']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01684904,"4:10:cancer,",he cancer may involve the stomach up to 5 cm,['he' 'cancer' 'may' 'involve' 'the' 'stomach' 'up' 'to' '5' 'cm'],[0. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01684397,"33:39:cancer,",Subjects diagnosed with another cancer in the past 3 years,"['Subjects' 'diagnosed' 'with' 'another' 'cancer' 'in' 'the' 'past' '3'
 'years']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT01365169,110:116:cancer,"During clinician's pre-surgical evaluation, presents with high risk for non-therapeutic resection related to cancer diagnosis (PCS study)","['During' 'clinician' ""'s"" 'pre-surgical' 'evaluation' ',' 'presents'
 'with' 'high' 'risk' 'for' 'non-therapeutic' 'resection' 'related' 'to'
 'cancer' 'diagnosis' '(' 'PCS' 'study' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT01306019,83:89:cancer,previously diagnosed known genotype of the subject conferring a predisposition to cancer (no DNA or other testing for cancer predisposition genes will be performed as part of the screen for this protocol),"['previously' 'diagnosed' 'known' 'genotype' 'of' 'the' 'subject'
 'conferring' 'a' 'predisposition' 'to' 'cancer' '(' 'no' 'DNA' 'or'
 'other' 'testing' 'for' 'cancer' 'predisposition' 'genes' 'will' 'be'
 'performed' 'as' 'part' 'of' 'the' 'screen' 'for' 'this' 'protocol' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01239095,15:21:cancer,Patients with cancer judged to be stage 4 are not eligible,"['Patients' 'with' 'cancer' 'judged' 'to' 'be' 'stage' '4' 'are' 'not'
 'eligible']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01238120,29:35:cancer,Have a primary diagnosis of cancer,['Have' 'a' 'primary' 'diagnosis' 'of' 'cancer'],[0. 0. 0. 0. 0. 3.]
NCT00906984,5:11:cancer,The cancer must be unresectable,['The' 'cancer' 'must' 'be' 'unresectable'],[0. 3. 0. 0. 0.]
NCT00819208,143:149:cancer,"Able (i.e., sufficiently fluent) and willing to effectively communicate with the physical activity consultant affiliated with the originating cancer center","['Able' '(' 'i.e.' ',' 'sufficiently' 'fluent' ')' 'and' 'willing' 'to'
 'effectively' 'communicate' 'with' 'the' 'physical' 'activity'
 'consultant' 'affiliated' 'with' 'the' 'originating' 'cancer' 'center']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0.]
NCT00579514,70:76:cancer,Patients of Ashkenazi Jewish ancestry with a histologic diagnosis of cancer of any type,"['Patients' 'of' 'Ashkenazi' 'Jewish' 'ancestry' 'with' 'a' 'histologic'
 'diagnosis' 'of' 'cancer' 'of' 'any' 'type']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0.]
NCT02807272,1:25:cancer,non-melanoma skin cancer,['non-melanoma' 'skin' 'cancer'],[3. 3. 3.]
NCT02579096,1:25:cancer,non-melanoma skin cancer,['non-melanoma' 'skin' 'cancer'],[3. 3. 3.]
NCT02501954,1:25:cancer,non-melanoma skin cancer,['non-melanoma' 'skin' 'cancer'],[3. 3. 3.]
NCT02493530,1:25:cancer,non-melanoma skin cancer,['non-melanoma' 'skin' 'cancer'],[3. 3. 3.]
NCT02273375,20:44:cancer,adequately treated non-melanoma skin cancer,['adequately' 'treated' 'non-melanoma' 'skin' 'cancer'],[0. 0. 3. 3. 3.]
NCT02268253,1:25:cancer,non-melanoma skin cancer,['non-melanoma' 'skin' 'cancer'],[3. 3. 3.]
NCT02257424,48:72:cancer,Subjects with a history of completely resected non-melanoma skin cancer,"['Subjects' 'with' 'a' 'history' 'of' 'completely' 'resected'
 'non-melanoma' 'skin' 'cancer']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT02237183,1:25:cancer,non-melanoma skin cancer,['non-melanoma' 'skin' 'cancer'],[3. 3. 3.]
NCT02176161,20:44:cancer,adequately treated non-melanoma skin cancer,['adequately' 'treated' 'non-melanoma' 'skin' 'cancer'],[0. 0. 3. 3. 3.]
NCT02152995,48:72:cancer,patients with a history of completely resected non-melanoma skin cancer,"['patients' 'with' 'a' 'history' 'of' 'completely' 'resected'
 'non-melanoma' 'skin' 'cancer']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT01676259,20:44:cancer,adequately treated non-melanoma skin cancer,['adequately' 'treated' 'non-melanoma' 'skin' 'cancer'],[0. 0. 3. 3. 3.]
NCT02515110,"27:29:chronic_disease,33:43:chronic_disease",Clinical nodal staging of N2 or N3 disease,['Clinical' 'nodal' 'staging' 'of' 'N2' 'or' 'N3' 'disease'],[0. 0. 0. 0. 2. 0. 2. 2.]
NCT02582957,"44:62:treatment,77:81:chronic_disease",Treating physicians being unwilling to use low VT ventilation strategy when ARDS is diagnosed as low VT ventilation is now considered standard of care for patients with ARDS,"['Treating' 'physicians' 'being' 'unwilling' 'to' 'use' 'low' 'VT'
 'ventilation' 'strategy' 'when' 'ARDS' 'is' 'diagnosed' 'as' 'low' 'VT'
 'ventilation' 'is' 'now' 'considered' 'standard' 'of' 'care' 'for'
 'patients' 'with' 'ARDS']","[0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02334865,"14:30:treatment,34:65:treatment",Patients had prior autologous or allogeneic stem cell transplant,"['Patients' 'had' 'prior' 'autologous' 'or' 'allogeneic' 'stem' 'cell'
 'transplant']",[0. 0. 1. 1. 0. 1. 1. 1. 1.]
NCT02939183,24:55:treatment,Previously received an allogeneic stem cell transplant,['Previously' 'received' 'an' 'allogeneic' 'stem' 'cell' 'transplant'],[0. 0. 0. 1. 1. 1. 1.]
NCT02845596,7:38:treatment,Prior allogeneic stem cell transplant,['Prior' 'allogeneic' 'stem' 'cell' 'transplant'],[0. 1. 1. 1. 1.]
NCT02670044,16:47:treatment,Ineligible for allogeneic stem cell transplant,['Ineligible' 'for' 'allogeneic' 'stem' 'cell' 'transplant'],[0. 0. 1. 1. 1. 1.]
NCT02576444,33:64:treatment,Patients must not have received allogeneic stem cell transplant,"['Patients' 'must' 'not' 'have' 'received' 'allogeneic' 'stem' 'cell'
 'transplant']",[0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02367196,"7:38:treatment,",Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 6 months prior to starting CC-90002,"['Prior' 'allogeneic' 'stem' 'cell' 'transplant' 'with' 'either'
 'standard' 'or' 'reduced' 'intensity' 'conditioning' '≤' '6' 'months'
 'prior' 'to' 'starting' 'CC-90002']",[0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02309580,"29:60:treatment,",Patients who have undergone allogeneic stem cell transplant > 12 months,"['Patients' 'who' 'have' 'undergone' 'allogeneic' 'stem' 'cell'
 'transplant' '>' '12' 'months']",[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0.]
NCT02035137,18:49:treatment,They have had an allogeneic stem cell transplant (received stem cell from someone else),"['They' 'have' 'had' 'an' 'allogeneic' 'stem' 'cell' 'transplant' '('
 'received' 'stem' 'cell' 'from' 'someone' 'else' ')']",[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01966367,92:123:treatment,Requirement for CD34+ stem cell selection for a second infusion of stem cells following an allogeneic stem cell transplant from a related or unrelated adult donor,"['Requirement' 'for' 'CD34+' 'stem' 'cell' 'selection' 'for' 'a' 'second'
 'infusion' 'of' 'stem' 'cells' 'following' 'an' 'allogeneic' 'stem'
 'cell' 'transplant' 'from' 'a' 'related' 'or' 'unrelated' 'adult' 'donor']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01877382,"8:29:treatment,,58:78:treatment",Had an autologous transplant within 3 months of starting study drug treatment,"['Had' 'an' 'autologous' 'transplant' 'within' '3' 'months' 'of'
 'starting' 'study' 'drug' 'treatment']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT01660607,15:36:treatment,Candidate for autologous transplant,['Candidate' 'for' 'autologous' 'transplant'],[0. 0. 1. 1.]
NCT02923921,",80:110:chronic_disease,112:135:chronic_disease","Clinically significant bleeding within two weeks prior to randomization (e.g., gastrointestinal (GI) bleeding, intracranial hemorrhage)","['Clinically' 'significant' 'bleeding' 'within' 'two' 'weeks' 'prior' 'to'
 'randomization' '(' 'e.g.' ',' 'gastrointestinal' '(' 'GI' ')' 'bleeding'
 ',' 'intracranial' 'hemorrhage' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 2. 2. 0.]
NCT03042767,9:39:chronic_disease,Current gastrointestinal (GI) bleeding,['Current' 'gastrointestinal' '(' 'GI' ')' 'bleeding'],[0. 2. 2. 2. 0. 0.]
NCT03063892,12:35:chronic_disease,History of intracranial hemorrhage,['History' 'of' 'intracranial' 'hemorrhage'],[0. 0. 2. 2.]
NCT02342444,13:36:chronic_disease,Presence of intracranial hemorrhage,['Presence' 'of' 'intracranial' 'hemorrhage'],[0. 0. 2. 2.]
NCT02169739,10:33:chronic_disease,Previous intracranial hemorrhage,['Previous' 'intracranial' 'hemorrhage'],[0. 2. 2.]
NCT02092324,1:24:chronic_disease,intracranial hemorrhage,['intracranial' 'hemorrhage'],[2. 2.]
NCT02053909,12:35:chronic_disease,History of intracranial hemorrhage,['History' 'of' 'intracranial' 'hemorrhage'],[0. 0. 2. 2.]
NCT01967823,15:38:chronic_disease,No history of intracranial hemorrhage,['No' 'history' 'of' 'intracranial' 'hemorrhage'],[0. 0. 0. 2. 2.]
NCT02512926,"31:41:cancer,45:59:cancer",Patients may not have primary CNS tumors or CNS metastases,"['Patients' 'may' 'not' 'have' 'primary' 'CNS' 'tumors' 'or' 'CNS'
 'metastases']",[0. 0. 0. 0. 0. 3. 3. 0. 0. 0.]
NCT02304458,"15:25:cancer,35:49:cancer",Patients with CNS tumors or known CNS metastases,['Patients' 'with' 'CNS' 'tumors' 'or' 'known' 'CNS' 'metastases'],[0. 0. 3. 3. 0. 0. 0. 0.]
NCT03178552,24:38:cancer,"Symptomatic, untreated CNS metastases","['Symptomatic' ',' 'untreated' 'CNS' 'metastases']",[0. 0. 0. 3. 3.]
NCT03069469,14:28:cancer,Known active CNS metastases,['Known' 'active' 'CNS' 'metastases'],[0. 0. 3. 3.]
NCT02310464,57:71:cancer,"Subjects with known or clinically manifest, symptomatic CNS metastases in Dose Escalation Phase","['Subjects' 'with' 'known' 'or' 'clinically' 'manifest' ',' 'symptomatic'
 'CNS' 'metastases' 'in' 'Dose' 'Escalation' 'Phase']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0.]
NCT02304458,28:42:cancer,patients with a history of CNS metastases that have been previously treated may enroll if sequential imaging shows not evidence for active disease,"['patients' 'with' 'a' 'history' 'of' 'CNS' 'metastases' 'that' 'have'
 'been' 'previously' 'treated' 'may' 'enroll' 'if' 'sequential' 'imaging'
 'shows' 'not' 'evidence' 'for' 'active' 'disease']",[0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02057133,11:25:cancer,Untreated CNS metastases,['Untreated' 'CNS' 'metastases'],[0. 3. 3.]
NCT01976585,7:21:cancer,Known CNS metastases,['Known' 'CNS' 'metastases'],[0. 3. 3.]
NCT01968109,14:28:cancer,Uncontrolled CNS metastases,['Uncontrolled' 'CNS' 'metastases'],[0. 3. 3.]
NCT01697371,1:15:cancer,CNS metastases,['CNS' 'metastases'],[3. 3.]
NCT01453088,14:28:cancer,Uncontrolled CNS metastases,['Uncontrolled' 'CNS' 'metastases'],[0. 3. 3.]
NCT01366612,14:28:cancer,Uncontrolled CNS metastases,['Uncontrolled' 'CNS' 'metastases'],[0. 3. 3.]
NCT00412594,13:27:cancer,Presence of CNS metastases,['Presence' 'of' 'CNS' 'metastases'],[0. 0. 3. 3.]
NCT02013154,",23:29:cancer,115:127:cancer",Must have one or more tumors measurable on radiographic imaging as defined by the Response Evaluation Criteria in Solid Tumors (RECIST). Patients with evaluable but not measurable disease per RECIST criteria may be enrolled with the approval of the medical monitor,"['Must' 'have' 'one' 'or' 'more' 'tumors' 'measurable' 'on' 'radiographic'
 'imaging' 'as' 'defined' 'by' 'the' 'Response' 'Evaluation' 'Criteria'
 'in' 'Solid' 'Tumors' '(' 'RECIST' ')' '.' 'Patients' 'with' 'evaluable'
 'but' 'not' 'measurable' 'disease' 'per' 'RECIST' 'criteria' 'may' 'be'
 'enrolled' 'with' 'the' 'approval' 'of' 'the' 'medical' 'monitor']","[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03109041,34:40:cancer,Recurrent or previously resected tumors,['Recurrent' 'or' 'previously' 'resected' 'tumors'],[0. 0. 0. 0. 3.]
NCT02519322,12:18:cancer,"resectable tumors are defined as having no significant vascular, neural or bony involvement","['resectable' 'tumors' 'are' 'defined' 'as' 'having' 'no' 'significant'
 'vascular' ',' 'neural' 'or' 'bony' 'involvement']",[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02490631,15:21:cancer,Patients with tumors,['Patients' 'with' 'tumors'],[0. 0. 3.]
NCT02451423,30:36:cancer,Presence of PD-L1 antigen on tumors is NOT required for study entry,"['Presence' 'of' 'PD-L1' 'antigen' 'on' 'tumors' 'is' 'NOT' 'required'
 'for' 'study' 'entry']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0.]
NCT02451215,",,59:65:cancer",Tumor volume less than 10 cm3 is mandatory for high grade tumors,"['Tumor' 'volume' 'less' 'than' '10' 'cm3' 'is' 'mandatory' 'for' 'high'
 'grade' 'tumors']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02442297,"20:26:cancer,,,,",HER2 expression in tumors on IHC should be greater than or equal to grade 1 and greater than or equal to 1+ intensity score,"['HER2' 'expression' 'in' 'tumors' 'on' 'IHC' 'should' 'be' 'greater'
 'than' 'or' 'equal' 'to' 'grade' '1' 'and' 'greater' 'than' 'or' 'equal'
 'to' '1+' 'intensity' 'score']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02373644,1:7:cancer,tumors,['tumors'],[3.]
NCT02324608,"131:137:cancer,","Patients must have untreated or relapsed SCCS that is considered to be aggressive and locally advanced by the following criteria: tumors 2 cm or more, tumors invading deep tissues such as muscle, cartilage or bone; tumors showing perineural invasion, and/or tumors metastatic to loco-regional lymph nodes; patients may have had prior surgical interventions or been treated with investigational agents with residual or recurrent disease","['Patients' 'must' 'have' 'untreated' 'or' 'relapsed' 'SCCS' 'that' 'is'
 'considered' 'to' 'be' 'aggressive' 'and' 'locally' 'advanced' 'by' 'the'
 'following' 'criteria' ':' 'tumors' '2' 'cm' 'or' 'more' ',' 'tumors'
 'invading' 'deep' 'tissues' 'such' 'as' 'muscle' ',' 'cartilage' 'or'
 'bone' ';' 'tumors' 'showing' 'perineural' 'invasion' ',' 'and/or'
 'tumors' 'metastatic' 'to' 'loco-regional' 'lymph' 'nodes' ';' 'patients'
 'may' 'have' 'had' 'prior' 'surgical' 'interventions' 'or' 'been'
 'treated' 'with' 'investigational' 'agents' 'with' 'residual' 'or'
 'recurrent' 'disease']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02312245,23:29:cancer,Prior consent to have tumors used for unspecified future research,"['Prior' 'consent' 'to' 'have' 'tumors' 'used' 'for' 'unspecified'
 'future' 'research']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT02271711,40:46:cancer,patient must have presented with these tumors in the posterior fossa (PF) or relapsed in the PF,"['patient' 'must' 'have' 'presented' 'with' 'these' 'tumors' 'in' 'the'
 'posterior' 'fossa' '(' 'PF' ')' 'or' 'relapsed' 'in' 'the' 'PF']",[0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02213497,23:29:cancer,Patients with primary tumors located at or above the carina,"['Patients' 'with' 'primary' 'tumors' 'located' 'at' 'or' 'above' 'the'
 'carina']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0.]
NCT02176967,30:36:cancer,Patients with MYCN amplified tumors,['Patients' 'with' 'MYCN' 'amplified' 'tumors'],[0. 0. 0. 0. 3.]
NCT02124902,19:25:cancer,Patients with PR+ tumors are allowed,['Patients' 'with' 'PR+' 'tumors' 'are' 'allowed'],[0. 0. 0. 3. 0. 0.]
NCT02124772,25:31:cancer,Measurable or evaluable tumors,['Measurable' 'or' 'evaluable' 'tumors'],[0. 0. 0. 3.]
NCT02085941,19:25:cancer,"Participants with tumors involving the optic chiasm, brain, or spinal cord","['Participants' 'with' 'tumors' 'involving' 'the' 'optic' 'chiasm' ','
 'brain' ',' 'or' 'spinal' 'cord']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02085941,1:7:cancer,"tumors that encase any major blood vessel (carotid, jugular, vertebral)","['tumors' 'that' 'encase' 'any' 'major' 'blood' 'vessel' '(' 'carotid' ','
 'jugular' ',' 'vertebral' ')']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02079181,18:24:cancer,"Have one or more tumors visualized by conventional PET-CT, CT or magnetic resonance imaging (MRI) prior to the PET FMAU study","['Have' 'one' 'or' 'more' 'tumors' 'visualized' 'by' 'conventional'
 'PET-CT' ',' 'CT' 'or' 'magnetic' 'resonance' 'imaging' '(' 'MRI' ')'
 'prior' 'to' 'the' 'PET' 'FMAU' 'study']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01734512,35:41:cancer,Patients with primary spinal cord tumors,['Patients' 'with' 'primary' 'spinal' 'cord' 'tumors'],[0. 0. 0. 0. 0. 3.]
NCT01591356,49:55:cancer,this may be one of the lesions mentioned above; tumors within a previously irradiated field will be designated as 'non-target' lesions,"['this' 'may' 'be' 'one' 'of' 'the' 'lesions' 'mentioned' 'above' ';'
 'tumors' 'within' 'a' 'previously' 'irradiated' 'field' 'will' 'be'
 'designated' 'as' ""'non-target"" ""'"" 'lesions']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01351103,15:21:cancer,patients with tumors of any histological origin with documented genetic alterations upstream in the Wnt signaling pathway (e.g. RNF43 or RSPO fusion) are eligible with prior agreement with Novartis,"['patients' 'with' 'tumors' 'of' 'any' 'histological' 'origin' 'with'
 'documented' 'genetic' 'alterations' 'upstream' 'in' 'the' 'Wnt'
 'signaling' 'pathway' '(' 'e.g' '.' 'RNF43' 'or' 'RSPO' 'fusion' ')'
 'are' 'eligible' 'with' 'prior' 'agreement' 'with' 'Novartis']","[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01351103,1:7:cancer,tumors of any histological origin with documented genetic alterations upstream in the Wnt signaling pathway are eligible with prior agreement with Novartis,"['tumors' 'of' 'any' 'histological' 'origin' 'with' 'documented' 'genetic'
 'alterations' 'upstream' 'in' 'the' 'Wnt' 'signaling' 'pathway' 'are'
 'eligible' 'with' 'prior' 'agreement' 'with' 'Novartis']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01037790,5:11:cancer,All tumors must test positive for Rb expression,['All' 'tumors' 'must' 'test' 'positive' 'for' 'Rb' 'expression'],[0. 3. 0. 0. 0. 0. 0. 0.]
NCT03123783,"29:40:chronic_disease,55:70:treatment",History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis,"['History' 'of' '(' 'non-infectious' ')' 'pneumonitis' 'that' 'required'
 'corticosteroids' 'or' 'current' 'pneumonitis']",[0. 0. 0. 0. 0. 2. 0. 0. 1. 0. 0. 0.]
NCT02530463,12:23:chronic_disease,History of pneumonitis,['History' 'of' 'pneumonitis'],[0. 0. 2.]
NCT02112565,42:53:chronic_disease,Patients with a history of noninfectious pneumonitis will be excluded during the dose-escalation phase of the trial,"['Patients' 'with' 'a' 'history' 'of' 'noninfectious' 'pneumonitis' 'will'
 'be' 'excluded' 'during' 'the' 'dose-escalation' 'phase' 'of' 'the'
 'trial']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02441140,"4:22:chronic_disease,36:64:cancer",No measurable disease or suspected Stage I or II ovarian cancer on preoperative imaging,"['No' 'measurable' 'disease' 'or' 'suspected' 'Stage' 'I' 'or' 'II'
 'ovarian' 'cancer' 'on' 'preoperative' 'imaging']",[0. 2. 2. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0.]
NCT03153410,20:38:chronic_disease,Patients must have measurable disease,['Patients' 'must' 'have' 'measurable' 'disease'],[0. 0. 0. 2. 2.]
NCT02562716,20:38:chronic_disease,Patients must have measurable disease in the pancreas,['Patients' 'must' 'have' 'measurable' 'disease' 'in' 'the' 'pancreas'],[0. 0. 0. 2. 2. 0. 0. 0.]
NCT02542657,20:38:chronic_disease,Patients must have measurable disease according to International Myeloma Working Group (IMWG) criteria,"['Patients' 'must' 'have' 'measurable' 'disease' 'according' 'to'
 'International' 'Myeloma' 'Working' 'Group' '(' 'IMWG' ')' 'criteria']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02487095,20:38:chronic_disease,"Patients must have measurable disease, per RECIST 1.1. Subjects with evaluable, but not measurable disease will be eligible for Phase 1","['Patients' 'must' 'have' 'measurable' 'disease' ',' 'per' 'RECIST' '1.1'
 '.' 'Subjects' 'with' 'evaluable' ',' 'but' 'not' 'measurable' 'disease'
 'will' 'be' 'eligible' 'for' 'Phase' '1']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02452268,14:32:chronic_disease,"Evaluable or measurable disease, defined as by Response Evaluation Criteria in Solid Tumors (RECIST)","['Evaluable' 'or' 'measurable' 'disease' ',' 'defined' 'as' 'by'
 'Response' 'Evaluation' 'Criteria' 'in' 'Solid' 'Tumors' '(' 'RECIST' ')']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02452008,6:24:chronic_disease,Have measurable disease,['Have' 'measurable' 'disease'],[0. 2. 2.]
NCT02437370,6:24:chronic_disease,Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,"['Have' 'measurable' 'disease' 'based' 'on' 'Response' 'Evaluation'
 'Criteria' 'in' 'Solid' 'Tumors' '(' 'RECIST' ')' '1.1']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02419495,11:29:chronic_disease,must have measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1),"['must' 'have' 'measurable' 'disease' '(' 'Response' 'Evaluation'
 'Criteria' 'in' 'Solid' 'Tumors' '[' 'RECIST' ']' '1.1' ')']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02401347,5:23:chronic_disease,Non-measurable disease only,['Non-measurable' 'disease' 'only'],[2. 2. 0.]
NCT02383927,13:31:chronic_disease,Subject has measurable disease according to RECIST v1.1,['Subject' 'has' 'measurable' 'disease' 'according' 'to' 'RECIST' 'v1.1'],[0. 0. 2. 2. 0. 0. 0. 0.]
NCT02343042,20:38:chronic_disease,Patients must have measurable disease,['Patients' 'must' 'have' 'measurable' 'disease'],[0. 0. 0. 2. 2.]
NCT02128906,20:38:chronic_disease,Patients must have measurable disease according to RECIST 1.1,"['Patients' 'must' 'have' 'measurable' 'disease' 'according' 'to' 'RECIST'
 '1.1']",[0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT01876511,6:24:chronic_disease,Have measurable disease,['Have' 'measurable' 'disease'],[0. 2. 2.]
NCT00914823,"18:29:treatment,34:61:treatment",seasonal allergy medications and hormone replacement therapy,"['seasonal' 'allergy' 'medications' 'and' 'hormone' 'replacement'
 'therapy']",[0. 0. 1. 0. 1. 1. 1.]
NCT03179163,",42:69:treatment",Women are post-menopausal and not taking hormone replacement therapy,"['Women' 'are' 'post-menopausal' 'and' 'not' 'taking' 'hormone'
 'replacement' 'therapy']",[0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02582905,",25:52:treatment",Oral contraceptives and hormone replacement therapy,['Oral' 'contraceptives' 'and' 'hormone' 'replacement' 'therapy'],[0. 0. 0. 1. 1. 1.]
NCT02467478,",34:61:treatment",post-menopausal women who are on hormone replacement therapy,"['post-menopausal' 'women' 'who' 'are' 'on' 'hormone' 'replacement'
 'therapy']",[0. 0. 0. 0. 0. 1. 1. 1.]
NCT02322203,",,51:78:treatment,",Female subjects taking hormonal contraceptives or hormone replacement therapy may be included in this study only if they have been on a stable dose for at least 3 months,"['Female' 'subjects' 'taking' 'hormonal' 'contraceptives' 'or' 'hormone'
 'replacement' 'therapy' 'may' 'be' 'included' 'in' 'this' 'study' 'only'
 'if' 'they' 'have' 'been' 'on' 'a' 'stable' 'dose' 'for' 'at' 'least' '3'
 'months']","[0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02172651,",10:37:treatment,,",women on hormone replacement therapy with documented serum follicle stimulating hormone level >35 mIU/mL),"['women' 'on' 'hormone' 'replacement' 'therapy' 'with' 'documented'
 'serum' 'follicle' 'stimulating' 'hormone' 'level' '>' '35' 'mIU/mL' ')']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01883258,",29:56:treatment",postmenopausal women taking hormone replacement therapy,['postmenopausal' 'women' 'taking' 'hormone' 'replacement' 'therapy'],[0. 0. 0. 1. 1. 1.]
NCT01591356,17:44:treatment,continuation of hormone replacement therapy is permitted,['continuation' 'of' 'hormone' 'replacement' 'therapy' 'is' 'permitted'],[0. 0. 1. 1. 1. 0. 0.]
NCT01538966,116:143:treatment,"The patient has had appropriate dynamic testing of the pituitary axis and, if applicable, is receiving appropriate hormone replacement therapy","['The' 'patient' 'has' 'had' 'appropriate' 'dynamic' 'testing' 'of' 'the'
 'pituitary' 'axis' 'and' ',' 'if' 'applicable' ',' 'is' 'receiving'
 'appropriate' 'hormone' 'replacement' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02982226,18:29:treatment,has receive such medications during the screening period,['has' 'receive' 'such' 'medications' 'during' 'the' 'screening' 'period'],[0. 0. 0. 1. 0. 0. 0. 0.]
NCT02819440,"8:19:treatment,",Use of medications that strongly alter CYP3A4 activity,['Use' 'of' 'medications' 'that' 'strongly' 'alter' 'CYP3A4' 'activity'],[0. 0. 1. 0. 0. 0. 0. 0.]
NCT02549937,15:26:treatment,Currently use medications known to cause QT prolongation or Torsades de Pointes,"['Currently' 'use' 'medications' 'known' 'to' 'cause' 'QT' 'prolongation'
 'or' 'Torsades' 'de' 'Pointes']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02547818,18:29:treatment,Currently taking medications that could lead to difficulty complying with the protocol,"['Currently' 'taking' 'medications' 'that' 'could' 'lead' 'to'
 'difficulty' 'complying' 'with' 'the' 'protocol']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02547818,"24:35:treatment,",Stability of permitted medications for 4 weeks prior to study start,"['Stability' 'of' 'permitted' 'medications' 'for' '4' 'weeks' 'prior' 'to'
 'study' 'start']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02543944,54:65:allergy_name,report having had a severe adverse reaction to study medications,"['report' 'having' 'had' 'a' 'severe' 'adverse' 'reaction' 'to' 'study'
 'medications']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 4.]
NCT02536794,"31:42:treatment,",patients must be off any such medications by the time of registration for at least 2 weeks,"['patients' 'must' 'be' 'off' 'any' 'such' 'medications' 'by' 'the' 'time'
 'of' 'registration' 'for' 'at' 'least' '2' 'weeks']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02535169,"8:19:treatment,,,",use of medications that adversely affect glucose metabolism (such as glucocorticoid-containing medications or atypical antipsychotics),"['use' 'of' 'medications' 'that' 'adversely' 'affect' 'glucose'
 'metabolism' '(' 'such' 'as' 'glucocorticoid-containing' 'medications'
 'or' 'atypical' 'antipsychotics' ')']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02519322,36:47:treatment,Any of the following procedures or medications,['Any' 'of' 'the' 'following' 'procedures' 'or' 'medications'],[0. 0. 0. 0. 0. 0. 1.]
NCT02514070,25:36:treatment,Subjects initiating new medications or patients on multiple medications may also be excluded according to investigator discretion,"['Subjects' 'initiating' 'new' 'medications' 'or' 'patients' 'on'
 'multiple' 'medications' 'may' 'also' 'be' 'excluded' 'according' 'to'
 'investigator' 'discretion']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02508311,74:85:treatment,Use or are suspected of using over-the counter supplements or prescribed medications with anabolic characteristics (promotes improvements to muscle mass and strength),"['Use' 'or' 'are' 'suspected' 'of' 'using' 'over-the' 'counter'
 'supplements' 'or' 'prescribed' 'medications' 'with' 'anabolic'
 'characteristics' '(' 'promotes' 'improvements' 'to' 'muscle' 'mass'
 'and' 'strength' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02498301,",94:105:treatment",Subject is currently taking or plans to take during deployment at least one of the following medications,"['Subject' 'is' 'currently' 'taking' 'or' 'plans' 'to' 'take' 'during'
 'deployment' 'at' 'least' 'one' 'of' 'the' 'following' 'medications']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02495168,32:43:treatment,"Able to continue the following medications without a significant adjustment of dosage, formulation, dosing interval for the duration of the study","['Able' 'to' 'continue' 'the' 'following' 'medications' 'without' 'a'
 'significant' 'adjustment' 'of' 'dosage' ',' 'formulation' ',' 'dosing'
 'interval' 'for' 'the' 'duration' 'of' 'the' 'study']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02487082,158:169:treatment,Drugs that induce or inhibit cytochrome P450 2D6 and cytochrome P450 3A4 (enzymes important for drug metabolism) will be allowed because any effects of such medications are likely to be lost in individual variability due to genetic polymorphisms,"['Drugs' 'that' 'induce' 'or' 'inhibit' 'cytochrome' 'P450' '2D6' 'and'
 'cytochrome' 'P450' '3A4' '(' 'enzymes' 'important' 'for' 'drug'
 'metabolism' ')' 'will' 'be' 'allowed' 'because' 'any' 'effects' 'of'
 'such' 'medications' 'are' 'likely' 'to' 'be' 'lost' 'in' 'individual'
 'variability' 'due' 'to' 'genetic' 'polymorphisms']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02484300,12:23:treatment,Use of any medications that may affect sleep or breathing,"['Use' 'of' 'any' 'medications' 'that' 'may' 'affect' 'sleep' 'or'
 'breathing']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02481310,55:66:treatment,"Patients who have a known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent","['Patients' 'who' 'have' 'a' 'known' 'allergy' 'to' 'any' 'of' 'the'
 'study' 'medications' ',' 'their' 'analogues' ',' 'or' 'excipients' 'in'
 'the' 'various' 'formulations' 'of' 'any' 'agent']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02481245,22:33:treatment,Agrees not to change medications during the study,['Agrees' 'not' 'to' 'change' 'medications' 'during' 'the' 'study'],[0. 0. 0. 0. 1. 0. 0. 0.]
NCT02473250,51:62:treatment,History of clinical deterioration when any of the medications that the patient is taking at presentation have been discontinued in the past with the exception of any medications that will be continued during the research protocol,"['History' 'of' 'clinical' 'deterioration' 'when' 'any' 'of' 'the'
 'medications' 'that' 'the' 'patient' 'is' 'taking' 'at' 'presentation'
 'have' 'been' 'discontinued' 'in' 'the' 'past' 'with' 'the' 'exception'
 'of' 'any' 'medications' 'that' 'will' 'be' 'continued' 'during' 'the'
 'research' 'protocol']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02413047,28:39:treatment,Previous noncompliant with medications,['Previous' 'noncompliant' 'with' 'medications'],[0. 0. 0. 1.]
NCT02411318,18:29:treatment,Currently taking medications that are not recommended to be taken in conjunction with alcohol,"['Currently' 'taking' 'medications' 'that' 'are' 'not' 'recommended' 'to'
 'be' 'taken' 'in' 'conjunction' 'with' 'alcohol']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02410954,"8:19:treatment,",Use of medications known to affect Central Nervous System (CNS) function within 5 half-lives screening,"['Use' 'of' 'medications' 'known' 'to' 'affect' 'Central' 'Nervous'
 'System' '(' 'CNS' ')' 'function' 'within' '5' 'half-lives' 'screening']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02401347,19:30:treatment,Able to take oral medications,['Able' 'to' 'take' 'oral' 'medications'],[0. 0. 0. 0. 1.]
NCT02371720,"47:58:treatment,",Patients receiving automatic home delivery of medications since medication possession ratio is reflective of the patient initiation the refill when they have exhausted the home supply of HU,"['Patients' 'receiving' 'automatic' 'home' 'delivery' 'of' 'medications'
 'since' 'medication' 'possession' 'ratio' 'is' 'reflective' 'of' 'the'
 'patient' 'initiation' 'the' 'refill' 'when' 'they' 'have' 'exhausted'
 'the' 'home' 'supply' 'of' 'HU']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02354703,"8:19:treatment,,","Taking medications (within the last 7 days prior to the Baseline Visit) that have the potential to prolong the QT interval, as judged by a study physician, or may require such medications during the course of the study","['Taking' 'medications' '(' 'within' 'the' 'last' '7' 'days' 'prior' 'to'
 'the' 'Baseline' 'Visit' ')' 'that' 'have' 'the' 'potential' 'to'
 'prolong' 'the' 'QT' 'interval' ',' 'as' 'judged' 'by' 'a' 'study'
 'physician' ',' 'or' 'may' 'require' 'such' 'medications' 'during' 'the'
 'course' 'of' 'the' 'study']","[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02265874,"16:27:treatment,",Doses of these medications must be stable for at least 1 month before study entry,"['Doses' 'of' 'these' 'medications' 'must' 'be' 'stable' 'for' 'at'
 'least' '1' 'month' 'before' 'study' 'entry']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02252432,57:68:allergy_name,"Intolerance, allergy, or contraindication to use of any medications used in this study","['Intolerance' ',' 'allergy' ',' 'or' 'contraindication' 'to' 'use' 'of'
 'any' 'medications' 'used' 'in' 'this' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0.]
NCT02233868,18:29:treatment,chronically used medications are exclusionary from the study,"['chronically' 'used' 'medications' 'are' 'exclusionary' 'from' 'the'
 'study']",[0. 0. 1. 0. 0. 0. 0. 0.]
NCT02213575,"135:146:treatment,","unwilling to discontinue vitamin or supplements, including probiotics, potentially affecting gut microbiota (vitamins/supplements and medications that possibly affect the gut microbiota should be discontinued for at least 2wks prior to stool collection)","['unwilling' 'to' 'discontinue' 'vitamin' 'or' 'supplements' ','
 'including' 'probiotics' ',' 'potentially' 'affecting' 'gut' 'microbiota'
 '(' 'vitamins/supplements' 'and' 'medications' 'that' 'possibly' 'affect'
 'the' 'gut' 'microbiota' 'should' 'be' 'discontinued' 'for' 'at' 'least'
 '2wks' 'prior' 'to' 'stool' 'collection' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02203513,",85:96:treatment",Patients must be at least 1 week from the last dose of complementary or alternative medications,"['Patients' 'must' 'be' 'at' 'least' '1' 'week' 'from' 'the' 'last' 'dose'
 'of' 'complementary' 'or' 'alternative' 'medications']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02201992,11:22:treatment,"No use of medications, herbals, or foods that are known potent cytochrome P450, subfamily 3A, polypeptide 4 (CYP3A4) inhibitors or inducers, included but not limited to those outlined","['No' 'use' 'of' 'medications' ',' 'herbals' ',' 'or' 'foods' 'that' 'are'
 'known' 'potent' 'cytochrome' 'P450' ',' 'subfamily' '3A' ','
 'polypeptide' '4' '(' 'CYP3A4' ')' 'inhibitors' 'or' 'inducers' ','
 'included' 'but' 'not' 'limited' 'to' 'those' 'outlined']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02192359,15:26:treatment,Use of herbal medications,['Use' 'of' 'herbal' 'medications'],[0. 0. 0. 1.]
NCT02165449,24:35:treatment,"Psychotic reactions to medications, alcohol or illicit substances in the past","['Psychotic' 'reactions' 'to' 'medications' ',' 'alcohol' 'or' 'illicit'
 'substances' 'in' 'the' 'past']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02159027,44:55:treatment,Anticipated need for specific prescription medications,['Anticipated' 'need' 'for' 'specific' 'prescription' 'medications'],[0. 0. 0. 0. 0. 1.]
NCT02143726,13:24:treatment,Concomitant medications,['Concomitant' 'medications'],[0. 1.]
NCT02059239,106:117:treatment,History of allergic reactions attributed to compounds of similar chemical or biologic composition to any medications listed in the protocol,"['History' 'of' 'allergic' 'reactions' 'attributed' 'to' 'compounds' 'of'
 'similar' 'chemical' 'or' 'biologic' 'composition' 'to' 'any'
 'medications' 'listed' 'in' 'the' 'protocol']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02056873,36:47:treatment,Must be willing to keep TS related medications stable and unchanged throughout the trial,"['Must' 'be' 'willing' 'to' 'keep' 'TS' 'related' 'medications' 'stable'
 'and' 'unchanged' 'throughout' 'the' 'trial']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02047721,"1:12:treatment,,","medications affecting weight, Energy Intake (EI) or Energy Expenditure (EE) in the last 6 months","['medications' 'affecting' 'weight' ',' 'Energy' 'Intake' '(' 'EI' ')'
 'or' 'Energy' 'Expenditure' '(' 'EE' ')' 'in' 'the' 'last' '6' 'months']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02001142,8:19:treatment,taking medications know to affect lipid and/or glucose metabolism,"['taking' 'medications' 'know' 'to' 'affect' 'lipid' 'and/or' 'glucose'
 'metabolism']",[0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01943851,",,,,127:138:treatment","In addition, male subjects whose partners are or become pregnant must continue to use condoms for 7 days after stopping study medications","['In' 'addition' ',' 'male' 'subjects' 'whose' 'partners' 'are' 'or'
 'become' 'pregnant' 'must' 'continue' 'to' 'use' 'condoms' 'for' '7'
 'days' 'after' 'stopping' 'study' 'medications']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01943851,"33:44:treatment,",This includes excluding current medications known or suspected to be associated QT prolongation,"['This' 'includes' 'excluding' 'current' 'medications' 'known' 'or'
 'suspected' 'to' 'be' 'associated' 'QT' 'prolongation']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01896921,69:80:treatment,Subject requires or is anticipated to require any of the prohibited medications noted in the protocol,"['Subject' 'requires' 'or' 'is' 'anticipated' 'to' 'require' 'any' 'of'
 'the' 'prohibited' 'medications' 'noted' 'in' 'the' 'protocol']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT01684397,45:56:treatment,Unable to discontinue the use of prohibited medications,['Unable' 'to' 'discontinue' 'the' 'use' 'of' 'prohibited' 'medications'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT01620216,"24:35:treatment,",Discontinuation of any medications known to contribute significantly to the risk of QT prolongation,"['Discontinuation' 'of' 'any' 'medications' 'known' 'to' 'contribute'
 'significantly' 'to' 'the' 'risk' 'of' 'QT' 'prolongation']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01532687,54:65:treatment,Unable or unwilling to discontinue use of prohibited medications,"['Unable' 'or' 'unwilling' 'to' 'discontinue' 'use' 'of' 'prohibited'
 'medications']",[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01500551,53:64:treatment,The subject has discontinued disallowed concomitant medications for the required time prior to the first dose of study drug,"['The' 'subject' 'has' 'discontinued' 'disallowed' 'concomitant'
 'medications' 'for' 'the' 'required' 'time' 'prior' 'to' 'the' 'first'
 'dose' 'of' 'study' 'drug']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01438073,"4:15:treatment,",no medications known to affect reproductive endocrine function for at least 2 months except for medications used to treat the subject's reproductive condition,"['no' 'medications' 'known' 'to' 'affect' 'reproductive' 'endocrine'
 'function' 'for' 'at' 'least' '2' 'months' 'except' 'for' 'medications'
 'used' 'to' 'treat' 'the' 'subject' ""'s"" 'reproductive' 'condition']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01200940,7:18:treatment,Other medications may be permitted at the discretion of the investigators,"['Other' 'medications' 'may' 'be' 'permitted' 'at' 'the' 'discretion' 'of'
 'the' 'investigators']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00914823,1:12:treatment,medications used to treat the subject's reproductive condition,"['medications' 'used' 'to' 'treat' 'the' 'subject' ""'s"" 'reproductive'
 'condition']",[1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00914823,"17:28:treatment,",no prescription medications for at least 2 months,['no' 'prescription' 'medications' 'for' 'at' 'least' '2' 'months'],[0. 0. 1. 0. 0. 0. 0. 0.]
NCT00914823,"17:28:treatment,",no prescription medications known to affect reproductive endocrine function for at least 2 months,"['no' 'prescription' 'medications' 'known' 'to' 'affect' 'reproductive'
 'endocrine' 'function' 'for' 'at' 'least' '2' 'months']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02772562,"14:20:cancer,31:47:treatment,",Diagnosis of cancer requiring systemic therapy in the past 5 years,"['Diagnosis' 'of' 'cancer' 'requiring' 'systemic' 'therapy' 'in' 'the'
 'past' '5' 'years']",[0. 0. 3. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT03137771,",103:119:treatment",Patients must be registered within 35 days of administration of the last dose of first-line/induction systemic therapy,"['Patients' 'must' 'be' 'registered' 'within' '35' 'days' 'of'
 'administration' 'of' 'the' 'last' 'dose' 'of' 'first-line/induction'
 'systemic' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02990481,72:88:treatment,"Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy","['Active' ',' 'uncontrolled' 'bacterial' ',' 'viral' ',' 'or' 'fungal'
 'infections' ',' 'requiring' 'systemic' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02807272,",32:48:treatment",At least 1 week since the last systemic therapy regimen prior to Cycle 1 Day 1,"['At' 'least' '1' 'week' 'since' 'the' 'last' 'systemic' 'therapy'
 'regimen' 'prior' 'to' 'Cycle' '1' 'Day' '1']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02417701,",55:71:treatment",Patients must have completed at least 1 prior line of systemic therapy,"['Patients' 'must' 'have' 'completed' 'at' 'least' '1' 'prior' 'line' 'of'
 'systemic' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02309580,",41:57:treatment",Relapse or progression after at least 1 systemic therapy,"['Relapse' 'or' 'progression' 'after' 'at' 'least' '1' 'systemic'
 'therapy']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01670877,56:72:treatment,There is no limitation on the number of prior lines of systemic therapy,"['There' 'is' 'no' 'limitation' 'on' 'the' 'number' 'of' 'prior' 'lines'
 'of' 'systemic' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02341287,",,,144:160:treatment,168:178:treatment","Have difficulty initiating sleep for at least two-weeks, including a sleep latency of at least 30-minutes, three days per week (as measured by wrist actigraphy and/or sleep logs)","['Have' 'difficulty' 'initiating' 'sleep' 'for' 'at' 'least' 'two-weeks'
 ',' 'including' 'a' 'sleep' 'latency' 'of' 'at' 'least' '30-minutes' ','
 'three' 'days' 'per' 'week' '(' 'as' 'measured' 'by' 'wrist' 'actigraphy'
 'and/or' 'sleep' 'logs' ')']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 0. 0. 0. 0.]"
NCT02965638,"1:13:chronic_disease,17:31:chronic_disease",Fetal mitral or aortic atresia,['Fetal' 'mitral' 'or' 'aortic' 'atresia'],[2. 2. 0. 2. 2.]
NCT03157713,"1:7:chronic_disease,",stroke in the past 6 mo,['stroke' 'in' 'the' 'past' '6' 'mo'],[2. 0. 0. 0. 0. 0.]
NCT03152409,12:18:chronic_disease,History of stroke,['History' 'of' 'stroke'],[0. 0. 2.]
NCT03123731,1:7:chronic_disease,stroke,['stroke'],[2.]
NCT03120728,12:18:chronic_disease,history of stroke,['history' 'of' 'stroke'],[0. 0. 2.]
NCT03113825,"7:13:chronic_disease,",Hx of stroke within 1 year,['Hx' 'of' 'stroke' 'within' '1' 'year'],[0. 0. 2. 0. 0. 0.]
NCT03108950,16:22:chronic_disease,Diagnosed with stroke,['Diagnosed' 'with' 'stroke'],[0. 0. 2.]
NCT03105700,12:18:chronic_disease,History of stroke,['History' 'of' 'stroke'],[0. 0. 2.]
NCT03096288,1:7:chronic_disease,stroke,['stroke'],[2.]
NCT03056287,",47:53:chronic_disease",Unable to ambulate at least 150 feet prior to stroke,['Unable' 'to' 'ambulate' 'at' 'least' '150' 'feet' 'prior' 'to' 'stroke'],[0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT03028012,1:7:chronic_disease,stroke,['stroke'],[2.]
NCT03023449,",43:49:chronic_disease",Study can be initiated within 72 hours of stroke symptom onset,"['Study' 'can' 'be' 'initiated' 'within' '72' 'hours' 'of' 'stroke'
 'symptom' 'onset']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0.]
NCT02964039,17:23:chronic_disease,Experience of a stroke 6 months prior to participation,['Experience' 'of' 'a' 'stroke' '6' 'months' 'prior' 'to' 'participation'],[0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02926378,",,,,165:171:chronic_disease",Participants must have experienced a left Cerebrovascular Accident (CVA) at least one year prior to study participation and the injury timeframe is 1-10 years post stroke,"['Participants' 'must' 'have' 'experienced' 'a' 'left' 'Cerebrovascular'
 'Accident' '(' 'CVA' ')' 'at' 'least' 'one' 'year' 'prior' 'to' 'study'
 'participation' 'and' 'the' 'injury' 'timeframe' 'is' '1-10' 'years'
 'post' 'stroke']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 2.]"
NCT02918175,17:23:chronic_disease,"Impairment from stroke, injury or other medical disorder that precludes participation in the intervention","['Impairment' 'from' 'stroke' ',' 'injury' 'or' 'other' 'medical'
 'disorder' 'that' 'precludes' 'participation' 'in' 'the' 'intervention']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02907983,1:7:chronic_disease,stroke,['stroke'],[2.]
NCT02806570,"12:18:chronic_disease,",History of stroke within the prior 3 months,['History' 'of' 'stroke' 'within' 'the' 'prior' '3' 'months'],[0. 0. 2. 0. 0. 0. 0. 0.]
NCT02769000,56:62:chronic_disease,Clinically or radiographically significant evidence of stroke,"['Clinically' 'or' 'radiographically' 'significant' 'evidence' 'of'
 'stroke']",[0. 0. 0. 0. 0. 0. 2.]
NCT02737930,51:57:chronic_disease,Current use of a medication likely to impair post-stroke recovery,"['Current' 'use' 'of' 'a' 'medication' 'likely' 'to' 'impair'
 'post-stroke' 'recovery']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT02680574,"1:7:chronic_disease,",stroke within 12 weeks prior to or during Screening,['stroke' 'within' '12' 'weeks' 'prior' 'to' 'or' 'during' 'Screening'],[2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02667392,14:20:chronic_disease,Diagnosis of stroke,['Diagnosis' 'of' 'stroke'],[0. 0. 2.]
NCT02637947,"26:32:chronic_disease,",subject has a history of stroke within 1 month prior to enrollment,"['subject' 'has' 'a' 'history' 'of' 'stroke' 'within' '1' 'month' 'prior'
 'to' 'enrollment']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02596776,10:16:chronic_disease,previous stroke,['previous' 'stroke'],[0. 2.]
NCT02588664,",,54:60:chronic_disease",Must be 18 years of age and older at the time of the stroke,"['Must' 'be' '18' 'years' 'of' 'age' 'and' 'older' 'at' 'the' 'time' 'of'
 'the' 'stroke']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02577406,1:7:chronic_disease,stroke,['stroke'],[2.]
NCT02570256,"15:21:chronic_disease,",Chronic stage stroke recovery (8+ months post),['Chronic' 'stage' 'stroke' 'recovery' '(' '8+' 'months' 'post' ')'],[0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02570256,40:46:chronic_disease,healthy individuals with no history of stroke or neural injury,"['healthy' 'individuals' 'with' 'no' 'history' 'of' 'stroke' 'or' 'neural'
 'injury']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 0.]
NCT02565407,",25:31:chronic_disease",at least 3 months after stroke,['at' 'least' '3' 'months' 'after' 'stroke'],[0. 0. 0. 0. 0. 2.]
NCT02551679,7:13:chronic_disease,Major stroke,['Major' 'stroke'],[0. 2.]
NCT02533882,16:22:chronic_disease,Diagnosed with stroke,['Diagnosed' 'with' 'stroke'],[0. 0. 2.]
NCT02521818,12:18:chronic_disease,history of stroke,['history' 'of' 'stroke'],[0. 0. 2.]
NCT02471833,12:18:chronic_disease,History of stroke,['History' 'of' 'stroke'],[0. 0. 2.]
NCT02465034,31:37:chronic_disease,Individuals with a first time stroke that affects the corona radiata and/or internal capsule,"['Individuals' 'with' 'a' 'first' 'time' 'stroke' 'that' 'affects' 'the'
 'corona' 'radiata' 'and/or' 'internal' 'capsule']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02457832,12:18:chronic_disease,History of stroke,['History' 'of' 'stroke'],[0. 0. 2.]
NCT02453373,",,42:48:chronic_disease",Patients receiving IV tPA > 3 hours from stroke onset,['Patients' 'receiving' 'IV' 'tPA' '>' '3' 'hours' 'from' 'stroke' 'onset'],[0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT02451683,27:33:chronic_disease,History of head injury or stroke,['History' 'of' 'head' 'injury' 'or' 'stroke'],[0. 0. 0. 0. 0. 2.]
NCT02445768,",24:30:chronic_disease",at least 6 months post-stroke,['at' 'least' '6' 'months' 'post-stroke'],[0. 0. 0. 0. 2.]
NCT02445768,27:33:chronic_disease,having ever experienced a stroke,['having' 'ever' 'experienced' 'a' 'stroke'],[0. 0. 0. 0. 2.]
NCT02366871,8:14:chronic_disease,recent stroke,['recent' 'stroke'],[0. 2.]
NCT02359253,"7:13:chronic_disease,,",Had a stroke 1-12 months prior to enrollment,['Had' 'a' 'stroke' '1-12' 'months' 'prior' 'to' 'enrollment'],[0. 0. 2. 0. 0. 0. 0. 0.]
NCT02355912,1:7:chronic_disease,stroke,['stroke'],[2.]
NCT02332291,1:7:chronic_disease,stroke,['stroke'],[2.]
NCT02301546,18:24:chronic_disease,History of major stroke,['History' 'of' 'major' 'stroke'],[0. 0. 0. 2.]
NCT02299414,7:13:chronic_disease,Prior stroke,['Prior' 'stroke'],[0. 2.]
NCT02189889,"12:18:chronic_disease,",history of stroke within the last 6 months,['history' 'of' 'stroke' 'within' 'the' 'last' '6' 'months'],[0. 0. 2. 0. 0. 0. 0. 0.]
NCT02186418,144:150:chronic_disease,"weaning transfusions is necessary, so that a selective pressure on gene-modified red blood cells is evident, and this will place subjects with stroke risk at risk for a recurrent stroke","['weaning' 'transfusions' 'is' 'necessary' ',' 'so' 'that' 'a' 'selective'
 'pressure' 'on' 'gene-modified' 'red' 'blood' 'cells' 'is' 'evident' ','
 'and' 'this' 'will' 'place' 'subjects' 'with' 'stroke' 'risk' 'at' 'risk'
 'for' 'a' 'recurrent' 'stroke']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02169739,"11:17:chronic_disease,,",Disabling stroke (Rankin Scale ≥4),['Disabling' 'stroke' '(' 'Rankin' 'Scale' '≥4' ')'],[0. 2. 0. 0. 0. 0. 0.]
NCT02165007,1:7:chronic_disease,stroke,['stroke'],[2.]
NCT02033941,35:41:chronic_disease,History of clinically significant stroke,['History' 'of' 'clinically' 'significant' 'stroke'],[0. 0. 0. 0. 2.]
NCT02008136,8:14:chronic_disease,recent stroke,['recent' 'stroke'],[0. 2.]
NCT01954966,12:18:chronic_disease,history of stroke or other medical conditions that the physician investigator deems as contraindicated for the patient to be in the study,"['history' 'of' 'stroke' 'or' 'other' 'medical' 'conditions' 'that' 'the'
 'physician' 'investigator' 'deems' 'as' 'contraindicated' 'for' 'the'
 'patient' 'to' 'be' 'in' 'the' 'study']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01948739,32:38:chronic_disease,No previous clinically defined stroke,['No' 'previous' 'clinically' 'defined' 'stroke'],[0. 0. 0. 0. 2.]
NCT01807897,7:13:chronic_disease,"Prior stroke with functional impairment or other severe, uncontrolled medical problems that may impair ability to participate in the study exams, based on medical history and review of medical records","['Prior' 'stroke' 'with' 'functional' 'impairment' 'or' 'other' 'severe'
 ',' 'uncontrolled' 'medical' 'problems' 'that' 'may' 'impair' 'ability'
 'to' 'participate' 'in' 'the' 'study' 'exams' ',' 'based' 'on' 'medical'
 'history' 'and' 'review' 'of' 'medical' 'records']","[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01801072,18:24:chronic_disease,History of prior stroke,['History' 'of' 'prior' 'stroke'],[0. 0. 0. 2.]
NCT01686373,",45:51:chronic_disease",Patients must be greater than 6-months post-stroke,['Patients' 'must' 'be' 'greater' 'than' '6-months' 'post-stroke'],[0. 0. 0. 0. 0. 0. 2.]
NCT01600131,56:62:chronic_disease,All caregivers of Veterans with a primary diagnosis of stroke,"['All' 'caregivers' 'of' 'Veterans' 'with' 'a' 'primary' 'diagnosis' 'of'
 'stroke']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT01600131,"75:81:chronic_disease,,",provide the majority of care for a Veteran who has a primary diagnosis of stroke (ICD9 codes for stroke: 430-438),"['provide' 'the' 'majority' 'of' 'care' 'for' 'a' 'Veteran' 'who' 'has'
 'a' 'primary' 'diagnosis' 'of' 'stroke' '(' 'ICD9' 'codes' 'for' 'stroke'
 ':' '430-438' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00903266,31:37:chronic_disease,active participation in other stroke recovery trials testing experimental interventions,"['active' 'participation' 'in' 'other' 'stroke' 'recovery' 'trials'
 'testing' 'experimental' 'interventions']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT00903266,",13:19:chronic_disease",more than 1 stroke,['more' 'than' '1' 'stroke'],[0. 0. 0. 2.]
NCT00903266,24:30:chronic_disease,right-handed (prior to stroke),['right-handed' '(' 'prior' 'to' 'stroke' ')'],[0. 0. 0. 0. 2. 0.]
NCT00678145,1:7:chronic_disease,stroke,['stroke'],[2.]
NCT00065676,1:7:chronic_disease,stroke,['stroke'],[2.]
NCT03126110,21:39:cancer,Locally advanced or metastatic disease,['Locally' 'advanced' 'or' 'metastatic' 'disease'],[0. 0. 0. 3. 3.]
NCT03096418,24:42:cancer,Patients must not have metastatic disease on staging work-up with CBC and liver function studies,"['Patients' 'must' 'not' 'have' 'metastatic' 'disease' 'on' 'staging'
 'work-up' 'with' 'CBC' 'and' 'liver' 'function' 'studies']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03085095,36:54:cancer,Newly diagnosed androgen-sensitive metastatic disease,['Newly' 'diagnosed' 'androgen-sensitive' 'metastatic' 'disease'],[0. 0. 0. 3. 3.]
NCT03042897,15:33:cancer,Patients with metastatic disease,['Patients' 'with' 'metastatic' 'disease'],[0. 0. 3. 3.]
NCT02997709,15:33:cancer,Patients with metastatic disease are encouraged to participate,"['Patients' 'with' 'metastatic' 'disease' 'are' 'encouraged' 'to'
 'participate']",[0. 0. 3. 3. 0. 0. 0. 0.]
NCT02977468,42:60:cancer,"Clinically node negative, no evidence of metastatic disease","['Clinically' 'node' 'negative' ',' 'no' 'evidence' 'of' 'metastatic'
 'disease']",[0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02885649,16:34:cancer,"No evidence of metastatic disease on baseline imaging (chest x-ray [CXR] or chest CT, abdominal CT or MRI)","['No' 'evidence' 'of' 'metastatic' 'disease' 'on' 'baseline' 'imaging' '('
 'chest' 'x-ray' '[' 'CXR' ']' 'or' 'chest' 'CT' ',' 'abdominal' 'CT' 'or'
 'MRI' ')']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02876302,43:61:cancer,Extensive nodal involvement is defined as metastatic disease involving any nodal region outside of the involved breast,"['Extensive' 'nodal' 'involvement' 'is' 'defined' 'as' 'metastatic'
 'disease' 'involving' 'any' 'nodal' 'region' 'outside' 'of' 'the'
 'involved' 'breast']",[0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02876302,23:41:cancer,Patients with minimal metastatic disease involvement in bone or viscera are allowed,"['Patients' 'with' 'minimal' 'metastatic' 'disease' 'involvement' 'in'
 'bone' 'or' 'viscera' 'are' 'allowed']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02843945,23:41:cancer,Patient does not have metastatic disease,['Patient' 'does' 'not' 'have' 'metastatic' 'disease'],[0. 0. 0. 0. 3. 3.]
NCT02680535,1:19:chronic_disease,metastatic disease,['metastatic' 'disease'],[2. 2.]
NCT02641093,11:29:cancer,Confirmed metastatic disease,['Confirmed' 'metastatic' 'disease'],[0. 3. 3.]
NCT02578732,15:33:cancer,Patients with metastatic disease,['Patients' 'with' 'metastatic' 'disease'],[0. 0. 3. 3.]
NCT02562716,16:34:cancer,No evidence of metastatic disease,['No' 'evidence' 'of' 'metastatic' 'disease'],[0. 0. 0. 3. 3.]
NCT02544880,9:27:chronic_disease,Distant metastatic disease,['Distant' 'metastatic' 'disease'],[0. 2. 2.]
NCT02515110,53:71:chronic_disease,Known definitive clinical or radiologic evidence of metastatic disease,"['Known' 'definitive' 'clinical' 'or' 'radiologic' 'evidence' 'of'
 'metastatic' 'disease']",[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02502708,15:33:cancer,Patients with metastatic disease are eligible for enrollment,"['Patients' 'with' 'metastatic' 'disease' 'are' 'eligible' 'for'
 'enrollment']",[0. 0. 3. 3. 0. 0. 0. 0.]
NCT02488967,"47:65:cancer,",Definitive clinical or radiologic evidence of metastatic disease; required imaging studies must have been performed within 90 days prior to randomization,"['Definitive' 'clinical' 'or' 'radiologic' 'evidence' 'of' 'metastatic'
 'disease' ';' 'required' 'imaging' 'studies' 'must' 'have' 'been'
 'performed' 'within' '90' 'days' 'prior' 'to' 'randomization']",[0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02479230,32:50:cancer,Patients must have evidence of metastatic disease measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria or non-measurable lytic or mixed (lytic + blastic) bone lesions in the absence of measurable disease,"['Patients' 'must' 'have' 'evidence' 'of' 'metastatic' 'disease'
 'measurable' 'by' 'Response' 'Evaluation' 'Criteria' 'in' 'Solid'
 'Tumors' '(' 'RECIST' ')' 'criteria' 'or' 'non-measurable' 'lytic' 'or'
 'mixed' '(' 'lytic' '+' 'blastic' ')' 'bone' 'lesions' 'in' 'the'
 'absence' 'of' 'measurable' 'disease']","[0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02474368,25:43:cancer,Cohort 2 (patients with metastatic disease with targetable lesions within the head and neck),"['Cohort' '2' '(' 'patients' 'with' 'metastatic' 'disease' 'with'
 'targetable' 'lesions' 'within' 'the' 'head' 'and' 'neck' ')']",[0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02473536,15:33:cancer,Any number of metastatic disease is allowed in the Pilot phase of the trial,"['Any' 'number' 'of' 'metastatic' 'disease' 'is' 'allowed' 'in' 'the'
 'Pilot' 'phase' 'of' 'the' 'trial']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02466009,12:30:chronic_disease,Measurable metastatic disease,['Measurable' 'metastatic' 'disease'],[0. 2. 2.]
NCT02456857,13:31:cancer,Presence of metastatic disease,['Presence' 'of' 'metastatic' 'disease'],[0. 0. 3. 3.]
NCT02427581,7:25:cancer,Known metastatic disease,['Known' 'metastatic' 'disease'],[0. 3. 3.]
NCT02423863,"52:70:cancer,",Radiologically or visually measurable recurrent or metastatic disease that is measurable and at least 10mm in longest dimension,"['Radiologically' 'or' 'visually' 'measurable' 'recurrent' 'or'
 'metastatic' 'disease' 'that' 'is' 'measurable' 'and' 'at' 'least' '10mm'
 'in' 'longest' 'dimension']",[0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02353819,13:31:cancer,Evidence of metastatic disease by imaging study,['Evidence' 'of' 'metastatic' 'disease' 'by' 'imaging' 'study'],[0. 0. 3. 3. 0. 0. 0.]
NCT02349867,13:31:cancer,Evidence of metastatic disease,['Evidence' 'of' 'metastatic' 'disease'],[0. 0. 3. 3.]
NCT02324582,37:55:cancer,Currently has active or progressive metastatic disease,['Currently' 'has' 'active' 'or' 'progressive' 'metastatic' 'disease'],[0. 0. 0. 0. 0. 3. 3.]
NCT02315196,47:65:cancer,Definitive clinical or radiologic evidence of metastatic disease,"['Definitive' 'clinical' 'or' 'radiologic' 'evidence' 'of' 'metastatic'
 'disease']",[0. 0. 0. 0. 0. 0. 3. 3.]
NCT02286843,15:33:chronic_disease,biopsy proven metastatic disease,['biopsy' 'proven' 'metastatic' 'disease'],[0. 0. 2. 2.]
NCT02213289,12:30:cancer,Measurable metastatic disease,['Measurable' 'metastatic' 'disease'],[0. 3. 3.]
NCT02204098,7:25:chronic_disease,Known metastatic disease,['Known' 'metastatic' 'disease'],[0. 2. 2.]
NCT02201992,82:100:chronic_disease,if clinically indicated additional imaging studies must be performed to rule out metastatic disease,"['if' 'clinically' 'indicated' 'additional' 'imaging' 'studies' 'must'
 'be' 'performed' 'to' 'rule' 'out' 'metastatic' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02153229,23:41:cancer,Patients with distant metastatic disease or otherwise not confined to the ipsilateral hemithorax,"['Patients' 'with' 'distant' 'metastatic' 'disease' 'or' 'otherwise' 'not'
 'confined' 'to' 'the' 'ipsilateral' 'hemithorax']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02141919,25:43:cancer,No clinical evidence of metastatic disease,['No' 'clinical' 'evidence' 'of' 'metastatic' 'disease'],[0. 0. 0. 0. 3. 3.]
NCT02101034,25:43:cancer,Incurable is defined as metastatic disease or a local or regional recurrence in a previously irradiated site that is unresectable (or patient declines resection),"['Incurable' 'is' 'defined' 'as' 'metastatic' 'disease' 'or' 'a' 'local'
 'or' 'regional' 'recurrence' 'in' 'a' 'previously' 'irradiated' 'site'
 'that' 'is' 'unresectable' '(' 'or' 'patient' 'declines' 'resection' ')']","[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02072148,",160:178:cancer","Advanced Stage III,IV (N2C, N3) or surgically unresectable disease or disease that cannot be fully resected, obvious radiologic ECS, supraclavicular or matted metastatic disease, >3 cervical nodes. (These patients will be placed on the Quarterback trial due to advanced state of disease and poor prognostic features)","['Advanced' 'Stage' 'III' ',' 'IV' '(' 'N2C' ',' 'N3' ')' 'or'
 'surgically' 'unresectable' 'disease' 'or' 'disease' 'that' 'can' 'not'
 'be' 'fully' 'resected' ',' 'obvious' 'radiologic' 'ECS' ','
 'supraclavicular' 'or' 'matted' 'metastatic' 'disease' ',' '>' '3'
 'cervical' 'nodes' '.' '(' 'These' 'patients' 'will' 'be' 'placed' 'on'
 'the' 'Quarterback' 'trial' 'due' 'to' 'advanced' 'state' 'of' 'disease'
 'and' 'poor' 'prognostic' 'features' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02035085,13:31:cancer,Evidence of metastatic disease,['Evidence' 'of' 'metastatic' 'disease'],[0. 0. 3. 3.]
NCT02035085,16:34:cancer,No evidence of metastatic disease,['No' 'evidence' 'of' 'metastatic' 'disease'],[0. 0. 0. 3. 3.]
NCT01903330,36:54:cancer,"History, presence, or suspicion of metastatic disease","['History' ',' 'presence' ',' 'or' 'suspicion' 'of' 'metastatic' 'disease']",[0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT01872975,47:65:cancer,Definitive clinical or radiologic evidence of metastatic disease,"['Definitive' 'clinical' 'or' 'radiologic' 'evidence' 'of' 'metastatic'
 'disease']",[0. 0. 0. 0. 0. 0. 3. 3.]
NCT01795313,34:52:cancer,"may have non-bulky, asymptomatic metastatic disease","['may' 'have' 'non-bulky' ',' 'asymptomatic' 'metastatic' 'disease']",[0. 0. 0. 0. 0. 3. 3.]
NCT01783535,13:31:cancer,Presence of metastatic disease or gross (residual) orbital involvement,"['Presence' 'of' 'metastatic' 'disease' 'or' 'gross' '(' 'residual' ')'
 'orbital' 'involvement']",[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT01730118,",,,,,,,,271:289:cancer","Chemistry parameters: Creatinine less than 1.5 mg/dL, SGOT and SGPT less than or equal to 3X the upper limits of normal and total bilirubin less than or equal to 1.5 mg/dl, Alk PO4 less than or equal to 3X the upper limits of normal (except for patients with documented metastatic disease to bone and/or liver)","['Chemistry' 'parameters' ':' 'Creatinine' 'less' 'than' '1.5' 'mg/dL' ','
 'SGOT' 'and' 'SGPT' 'less' 'than' 'or' 'equal' 'to' '3X' 'the' 'upper'
 'limits' 'of' 'normal' 'and' 'total' 'bilirubin' 'less' 'than' 'or'
 'equal' 'to' '1.5' 'mg/dl' ',' 'Alk' 'PO4' 'less' 'than' 'or' 'equal'
 'to' '3X' 'the' 'upper' 'limits' 'of' 'normal' '(' 'except' 'for'
 'patients' 'with' 'documented' 'metastatic' 'disease' 'to' 'bone'
 'and/or' 'liver' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0.]"
NCT01730118,",,,,,,,220:238:cancer","Chemistry parameters: Creatinine less than mg/dL, SGOT and SGPT less than or equal to 3X ULN, total bilirubin less than or equal to 1.5X ULN and Alk PO4 less than or equal to 3X ULN (except for patients with documented metastatic disease to bone and/or liver)","['Chemistry' 'parameters' ':' 'Creatinine' 'less' 'than' 'mg/dL' ','
 'SGOT' 'and' 'SGPT' 'less' 'than' 'or' 'equal' 'to' '3X' 'ULN' ','
 'total' 'bilirubin' 'less' 'than' 'or' 'equal' 'to' '1.5X' 'ULN' 'and'
 'Alk' 'PO4' 'less' 'than' 'or' 'equal' 'to' '3X' 'ULN' '(' 'except' 'for'
 'patients' 'with' 'documented' 'metastatic' 'disease' 'to' 'bone'
 'and/or' 'liver' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0.
 0. 0. 0.]"
NCT01676259,13:31:chronic_disease,Evidence of metastatic disease,['Evidence' 'of' 'metastatic' 'disease'],[0. 0. 2. 2.]
NCT01562626,60:78:cancer,Patients must have measurable or evaluable advanced and/or metastatic disease by RECIST 1.1,"['Patients' 'must' 'have' 'measurable' 'or' 'evaluable' 'advanced'
 'and/or' 'metastatic' 'disease' 'by' 'RECIST' '1.1']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0.]
NCT01238120,16:34:cancer,Have confirmed metastatic disease to the central nervous system,"['Have' 'confirmed' 'metastatic' 'disease' 'to' 'the' 'central' 'nervous'
 'system']",[0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT01130077,13:31:cancer,"Presence of metastatic disease for patients in Stratum A, B, D and E","['Presence' 'of' 'metastatic' 'disease' 'for' 'patients' 'in' 'Stratum'
 'A' ',' 'B' ',' 'D' 'and' 'E']",[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00715611,16:34:cancer,No evidence of metastatic disease,['No' 'evidence' 'of' 'metastatic' 'disease'],[0. 0. 0. 3. 3.]
NCT02584647,38:60:treatment,Patients who are receiving any other investigational agents concurrently,"['Patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents' 'concurrently']",[0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT02584309,25:47:treatment,Currently receiving any investigational agents,['Currently' 'receiving' 'any' 'investigational' 'agents'],[0. 0. 0. 1. 1.]
NCT02573493,21:43:treatment,Receiving any other investigational agents,['Receiving' 'any' 'other' 'investigational' 'agents'],[0. 0. 0. 1. 1.]
NCT02567422,38:60:treatment,Patients who are receiving any other investigational agents,"['Patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02536794,"42:64:treatment,",Patients may not have received any other investigational agents within 4 weeks prior to registration,"['Patients' 'may' 'not' 'have' 'received' 'any' 'other' 'investigational'
 'agents' 'within' '4' 'weeks' 'prior' 'to' 'registration']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02535312,38:60:treatment,Patients who are receiving any other investigational agents,"['Patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02520791,38:60:treatment,Patients who are receiving any other investigational agents,"['Patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02503709,38:60:treatment,Patients who are receiving any other investigational agents,"['Patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02498613,"45:67:treatment,",Patients should not have received any other investigational agents within the past 4 weeks,"['Patients' 'should' 'not' 'have' 'received' 'any' 'other'
 'investigational' 'agents' 'within' 'the' 'past' '4' 'weeks']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02496663,38:60:treatment,Patients who are receiving any other investigational agents,"['Patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02487095,38:60:treatment,Subjects who are receiving any other investigational agents,"['Subjects' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02474173,"38:60:treatment,,",Patients who are receiving any other investigational agents within 4 weeks or 5 half-lives (whichever is shorter) prior to the first dose of the study regimen,"['Patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents' 'within' '4' 'weeks' 'or' '5' 'half-lives' '(' 'whichever' 'is'
 'shorter' ')' 'prior' 'to' 'the' 'first' 'dose' 'of' 'the' 'study'
 'regimen']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02464878,"12:34:treatment,",Use of any investigational agents within 4 weeks of enrollment,"['Use' 'of' 'any' 'investigational' 'agents' 'within' '4' 'weeks' 'of'
 'enrollment']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02417701,38:60:treatment,Patients who are receiving any other investigational agents,"['Patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02369458,31:53:treatment,Currently receiving any other investigational agents,['Currently' 'receiving' 'any' 'other' 'investigational' 'agents'],[0. 0. 0. 0. 1. 1.]
NCT02346253,23:45:treatment,Past history of other investigational agents,['Past' 'history' 'of' 'other' 'investigational' 'agents'],[0. 0. 0. 0. 1. 1.]
NCT02339922,"51:73:treatment,","Participation in other clinical trials with other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trial","['Participation' 'in' 'other' 'clinical' 'trials' 'with' 'other'
 'investigational' 'agents' 'not' 'included' 'in' 'this' 'trial' ','
 'within' '21' 'days' 'of' 'the' 'start' 'of' 'this' 'trial' 'and'
 'throughout' 'the' 'duration' 'of' 'this' 'trial']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02273362,"21:43:treatment,",Receiving any other investigational agents =< 6 months prior to registration,"['Receiving' 'any' 'other' 'investigational' 'agents' '=' '<' '6' 'months'
 'prior' 'to' 'registration']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02217709,41:63:treatment,Patients may not be receiving any other investigational agents,"['Patients' 'may' 'not' 'be' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02203513,38:60:treatment,Patients who are receiving any other investigational agents,"['Patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02201992,41:63:treatment,Patients may not be receiving any other investigational agents while on study,"['Patients' 'may' 'not' 'be' 'receiving' 'any' 'other' 'investigational'
 'agents' 'while' 'on' 'study']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT02133196,38:60:treatment,Patients who are receiving any other investigational agents,"['Patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02128906,57:79:treatment,Patients may not be receiving any other anti-neoplastic investigational agents,"['Patients' 'may' 'not' 'be' 'receiving' 'any' 'other' 'anti-neoplastic'
 'investigational' 'agents']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02124902,31:53:treatment,Currently receiving any other investigational agents,['Currently' 'receiving' 'any' 'other' 'investigational' 'agents'],[0. 0. 0. 0. 1. 1.]
NCT02122185,38:60:treatment,Patients who are receiving any other investigational agents,"['Patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02122185,38:60:treatment,patients who are receiving any other investigational agents,"['patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02122172,41:63:treatment,Patients may not be receiving any other investigational agents,"['Patients' 'may' 'not' 'be' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02111850,38:60:treatment,Patients who are receiving any other investigational agents,"['Patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02101034,31:53:treatment,Currently receiving any other investigational agents,['Currently' 'receiving' 'any' 'other' 'investigational' 'agents'],[0. 0. 0. 0. 1. 1.]
NCT02076906,36:58:treatment,Patients currently receiving other investigational agents,['Patients' 'currently' 'receiving' 'other' 'investigational' 'agents'],[0. 0. 0. 0. 1. 1.]
NCT02073097,38:60:treatment,Patients who are receiving any other investigational agents,"['Patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT01993719,34:56:treatment,Patients who are receiving other investigational agents,['Patients' 'who' 'are' 'receiving' 'other' 'investigational' 'agents'],[0. 0. 0. 0. 0. 1. 1.]
NCT01989546,38:60:treatment,Patients who are receiving any other investigational agents,"['Patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT01967823,38:60:treatment,Patients who are receiving any other investigational agents,"['Patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT01947140,10:32:treatment,No other investigational agents are allowed,['No' 'other' 'investigational' 'agents' 'are' 'allowed'],[0. 0. 1. 1. 0. 0.]
NCT01869114,"37:59:treatment,",Patients must not have received any investigational agents within 21days of study entry,"['Patients' 'must' 'not' 'have' 'received' 'any' 'investigational'
 'agents' 'within' '21days' 'of' 'study' 'entry']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01851369,47:69:treatment,Patients who are actively receiving any other investigational agents,"['Patients' 'who' 'are' 'actively' 'receiving' 'any' 'other'
 'investigational' 'agents']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01849146,21:43:treatment,receiving any other investigational agents are ineligible,['receiving' 'any' 'other' 'investigational' 'agents' 'are' 'ineligible'],[0. 0. 0. 1. 1. 0. 0.]
NCT01827384,38:60:treatment,Patients who are receiving any other investigational agents,"['Patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT01720836,41:63:treatment,Subjects may not be receiving any other investigational agents,"['Subjects' 'may' 'not' 'be' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01614990,7:29:treatment,other investigational agents (a wash-out period of five times the half life of drugs that prolong QT will be allowed with approval of prescriber),"['other' 'investigational' 'agents' '(' 'a' 'wash-out' 'period' 'of'
 'five' 'times' 'the' 'half' 'life' 'of' 'drugs' 'that' 'prolong' 'QT'
 'will' 'be' 'allowed' 'with' 'approval' 'of' 'prescriber' ')']","[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01572480,38:60:treatment,Patients who are receiving any other investigational agents,"['Patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT01494662,52:74:treatment,Participants who are currently receiving any other investigational agents,"['Participants' 'who' 'are' 'currently' 'receiving' 'any' 'other'
 'investigational' 'agents']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01174121,38:60:treatment,Patients who are receiving any other investigational agents,"['Patients' 'who' 'are' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT01054196,41:63:treatment,Patients may not be receiving any other investigational agents,"['Patients' 'may' 'not' 'be' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT00703105,41:63:treatment,Patients may not be receiving any other investigational agents,"['Patients' 'may' 'not' 'be' 'receiving' 'any' 'other' 'investigational'
 'agents']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT03113825,"30:43:chronic_disease,",Hx of coronary events and/or heart failure within 1 year,"['Hx' 'of' 'coronary' 'events' 'and/or' 'heart' 'failure' 'within' '1'
 'year']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0.]
NCT03112720,15:28:chronic_disease,Subjects with heart failure,['Subjects' 'with' 'heart' 'failure'],[0. 0. 2. 2.]
NCT03089281,"20:33:chronic_disease,,,,,,,",Moderate to severe heart failure (NYHA Class III-IV) with EF ≤ 35% and QRS duration ≥ 120 ms,"['Moderate' 'to' 'severe' 'heart' 'failure' '(' 'NYHA' 'Class' 'III-IV'
 ')' 'with' 'EF' '≤' '35' '%' 'and' 'QRS' 'duration' '≥' '120' 'ms']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03073343,"7:20:chronic_disease,,,","Known heart failure of New York Heart Association class 2, 3, or 4","['Known' 'heart' 'failure' 'of' 'New' 'York' 'Heart' 'Association' 'class'
 '2' ',' '3' ',' 'or' '4']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03073070,1:14:chronic_disease,heart failure,['heart' 'failure'],[2. 2.]
NCT03060772,12:25:chronic_disease,History of heart failure,['History' 'of' 'heart' 'failure'],[0. 0. 2. 2.]
NCT03059355,1:14:chronic_disease,heart failure patients,['heart' 'failure' 'patients'],[2. 2. 0.]
NCT03058146,1:14:chronic_disease,heart failure,['heart' 'failure'],[2. 2.]
NCT03037931,"39:52:chronic_disease,,,",Either documented hospitalization for heart failure within 12 months of enrollment or elavated N-terminal-pro-brain natriuretic peptide (NT-proBNP) within 90 days of randomization,"['Either' 'documented' 'hospitalization' 'for' 'heart' 'failure' 'within'
 '12' 'months' 'of' 'enrollment' 'or' 'elavated' 'N-terminal-pro-brain'
 'natriuretic' 'peptide' '(' 'NT-proBNP' ')' 'within' '90' 'days' 'of'
 'randomization']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02762825,"39:52:chronic_disease,",Any patient recently hospitalized for heart failure will have to wait at least 2 weeks before starting CR,"['Any' 'patient' 'recently' 'hospitalized' 'for' 'heart' 'failure' 'will'
 'have' 'to' 'wait' 'at' 'least' '2' 'weeks' 'before' 'starting' 'CR']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02582827,",,17:30:chronic_disease,",Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification,"['Class' 'III' 'or' 'IV' 'heart' 'failure' 'as' 'defined' 'by' 'the' 'New'
 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'functional' 'classification']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02544880,"54:67:chronic_disease,",New York Heart Association (NYHA) Class 2 or greater heart failure in the last 3 months,"['New' 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'Class' '2' 'or'
 'greater' 'heart' 'failure' 'in' 'the' 'last' '3' 'months']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02538198,",,51:64:chronic_disease",New York Heart Association (NYHA) Class III or IV heart failure,"['New' 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'Class' 'III' 'or' 'IV'
 'heart' 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02513797,",56:69:chronic_disease",Currently exhibits New York Heart Association Class IV heart failure symptoms,"['Currently' 'exhibits' 'New' 'York' 'Heart' 'Association' 'Class' 'IV'
 'heart' 'failure' 'symptoms']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.]
NCT02513797,29:42:chronic_disease,Documented history of right heart failure specifically when right ventricle exceeds the left ventricular size,"['Documented' 'history' 'of' 'right' 'heart' 'failure' 'specifically'
 'when' 'right' 'ventricle' 'exceeds' 'the' 'left' 'ventricular' 'size']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02503722,",,,51:64:chronic_disease",New York Heart Association (NYHA) class III or IV heart failure,"['New' 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'class' 'III' 'or' 'IV'
 'heart' 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02484404,",,26:39:chronic_disease",NYHA Class II or greater heart failure,['NYHA' 'Class' 'II' 'or' 'greater' 'heart' 'failure'],[0. 0. 0. 0. 0. 2. 2.]
NCT02476409,"18:31:chronic_disease,",Prior history of heart failure with this diagnosis for at least 1 month with preserved or reduced left ventricular ejection fraction,"['Prior' 'history' 'of' 'heart' 'failure' 'with' 'this' 'diagnosis' 'for'
 'at' 'least' '1' 'month' 'with' 'preserved' 'or' 'reduced' 'left'
 'ventricular' 'ejection' 'fraction']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02441101,"39:52:chronic_disease,,",Any other known conditions other than heart failure that could limit survival to < 6 months,"['Any' 'other' 'known' 'conditions' 'other' 'than' 'heart' 'failure'
 'that' 'could' 'limit' 'survival' 'to' '<' '6' 'months']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02441101,20:33:chronic_disease,Inotrope dependent heart failure condition,['Inotrope' 'dependent' 'heart' 'failure' 'condition'],[0. 0. 2. 2. 0.]
NCT02417701,",,17:30:chronic_disease",class III or IV heart failure,['class' 'III' 'or' 'IV' 'heart' 'failure'],[0. 0. 0. 0. 2. 2.]
NCT02393885,",15:28:chronic_disease",NYHA Class IV heart failure,['NYHA' 'Class' 'IV' 'heart' 'failure'],[0. 0. 0. 2. 2.]
NCT02277548,",,,44:57:chronic_disease",New York Heart Association class III or IV heart failure,"['New' 'York' 'Heart' 'Association' 'class' 'III' 'or' 'IV' 'heart'
 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02251431,",,,44:57:chronic_disease",New York Heart Association Class III or IV heart failure,"['New' 'York' 'Heart' 'Association' 'Class' 'III' 'or' 'IV' 'heart'
 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02178566,14:27:chronic_disease,uncontrolled heart failure,['uncontrolled' 'heart' 'failure'],[0. 2. 2.]
NCT02177695,",,14:27:chronic_disease,,",Class III/IV heart failure or known left ventricular ejection fraction (LVEF) < 50%,"['Class' 'III/IV' 'heart' 'failure' 'or' 'known' 'left' 'ventricular'
 'ejection' 'fraction' '(' 'LVEF' ')' '<' '50' '%']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02133885,28:41:chronic_disease,Current of past history of heart failure,['Current' 'of' 'past' 'history' 'of' 'heart' 'failure'],[0. 0. 0. 0. 0. 2. 2.]
NCT02121158,",,,23:36:chronic_disease",NYHA Class II and III heart failure,['NYHA' 'Class' 'II' 'and' 'III' 'heart' 'failure'],[0. 0. 0. 0. 0. 2. 2.]
NCT02121158,23:36:chronic_disease,NYHA class II and III heart failure,['NYHA' 'class' 'II' 'and' 'III' 'heart' 'failure'],[0. 0. 0. 0. 0. 2. 2.]
NCT02025465,",55:68:chronic_disease",A low ejection fraction is not always associated with heart failure,"['A' 'low' 'ejection' 'fraction' 'is' 'not' 'always' 'associated' 'with'
 'heart' 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02025465,",,58:71:chronic_disease","Known ejection fraction <45%, regardless of a history of heart failure","['Known' 'ejection' 'fraction' '<' '45' '%' ',' 'regardless' 'of' 'a'
 'history' 'of' 'heart' 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02025465,"18:31:chronic_disease,,",Known history of heart failure with an ejection fraction <50%,"['Known' 'history' 'of' 'heart' 'failure' 'with' 'an' 'ejection'
 'fraction' '<' '50' '%']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT01990495,",,,140:153:chronic_disease","Subjects will be required to be in the peak VO2 range of 10 to 20 ml/kg/min, equivalent to moderate functional impairment in patients with heart failure","['Subjects' 'will' 'be' 'required' 'to' 'be' 'in' 'the' 'peak' 'VO2'
 'range' 'of' '10' 'to' '20' 'ml/kg/min' ',' 'equivalent' 'to' 'moderate'
 'functional' 'impairment' 'in' 'patients' 'with' 'heart' 'failure']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 2. 2.]"
NCT01990209,",,,51:64:chronic_disease",New York Heart Association (NYHA) Class III or IV heart failure,"['New' 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'Class' 'III' 'or' 'IV'
 'heart' 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01841333,",,,44:57:chronic_disease",New York Heart Association Class III or IV heart failure,"['New' 'York' 'Heart' 'Association' 'Class' 'III' 'or' 'IV' 'heart'
 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01754857,",,,38:51:chronic_disease",New York Heart Association class 3-4 heart failure,['New' 'York' 'Heart' 'Association' 'class' '3-4' 'heart' 'failure'],[0. 0. 0. 0. 0. 0. 2. 2.]
NCT01696734,12:25:chronic_disease,history of heart failure,['history' 'of' 'heart' 'failure'],[0. 0. 2. 2.]
NCT01627821,"33:46:chronic_disease,","Clinical conditions, other than heart failure, which could limit survival to less than three years","['Clinical' 'conditions' ',' 'other' 'than' 'heart' 'failure' ',' 'which'
 'could' 'limit' 'survival' 'to' 'less' 'than' 'three' 'years']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01626079,",54:67:chronic_disease,,,,,,,,,,",The subject has had at least one hospitalization for heart failure in the 12 months prior to subject registration and/or a corrected brain natriuretic peptide (BNP) ≥300 pg/ml or corrected n-Terminal pro- brain natriuretic peptide NT-proBNP ≥1500 pg/ml measured within 90 days prior to subject registration (corrected refers to a 4% reduction in the BNP or NT-proBNP cutoff for every increase of 1 kg/m2 in BMI above a reference BMI of 20 kg/m2),"['The' 'subject' 'has' 'had' 'at' 'least' 'one' 'hospitalization' 'for'
 'heart' 'failure' 'in' 'the' '12' 'months' 'prior' 'to' 'subject'
 'registration' 'and/or' 'a' 'corrected' 'brain' 'natriuretic' 'peptide'
 '(' 'BNP' ')' '≥300' 'pg/ml' 'or' 'corrected' 'n-Terminal' 'pro-' 'brain'
 'natriuretic' 'peptide' 'NT-proBNP' '≥1500' 'pg/ml' 'measured' 'within'
 '90' 'days' 'prior' 'to' 'subject' 'registration' '(' 'corrected'
 'refers' 'to' 'a' '4' '%' 'reduction' 'in' 'the' 'BNP' 'or' 'NT-proBNP'
 'cutoff' 'for' 'every' 'increase' 'of' '1' 'kg/m2' 'in' 'BMI' 'above' 'a'
 'reference' 'BMI' 'of' '20' 'kg/m2' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01505569,",,61:74:chronic_disease",Cardiac: ejection fraction ≥ 45% or no clinical evidence of heart failure,"['Cardiac' ':' 'ejection' 'fraction' '≥' '45' '%' 'or' 'no' 'clinical'
 'evidence' 'of' 'heart' 'failure']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01187368,"34:47:chronic_disease,",Presence of condition other than heart failure that would limit survival to less than 3 years,"['Presence' 'of' 'condition' 'other' 'than' 'heart' 'failure' 'that'
 'would' 'limit' 'survival' 'to' 'less' 'than' '3' 'years']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00737893,1:14:chronic_disease,heart failure,['heart' 'failure'],[2. 2.]
NCT00065676,1:14:chronic_disease,heart failure,['heart' 'failure'],[2. 2.]
NCT03109431,13:26:chronic_disease,Established HIV infection (not acutely infected),['Established' 'HIV' 'infection' '(' 'not' 'acutely' 'infected' ')'],[0. 2. 2. 0. 0. 0. 0. 0.]
NCT03109431,33:46:chronic_disease,RNA test will determine whether HIV infection is acute or established,"['RNA' 'test' 'will' 'determine' 'whether' 'HIV' 'infection' 'is' 'acute'
 'or' 'established']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT03078907,1:14:chronic_disease,HIV infection,['HIV' 'infection'],[2. 2.]
NCT03073343,7:20:chronic_disease,Known HIV infection,['Known' 'HIV' 'infection'],[0. 2. 2.]
NCT03033888,1:14:chronic_disease,HIV infection,['HIV' 'infection'],[2. 2.]
NCT03008408,32:45:chronic_disease,Patient has a known history of HIV infection (testing not mandatory),"['Patient' 'has' 'a' 'known' 'history' 'of' 'HIV' 'infection' '('
 'testing' 'not' 'mandatory' ')']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02898597,14:27:chronic_disease,Diagnosis of HIV infection,['Diagnosis' 'of' 'HIV' 'infection'],[0. 0. 2. 2.]
NCT02876510,1:14:chronic_disease,HIV infection,['HIV' 'infection'],[2. 2.]
NCT02819440,7:20:chronic_disease,Known HIV infection,['Known' 'HIV' 'infection'],[0. 2. 2.]
NCT02811679,21:34:chronic_disease,Subjects with known HIV infection,['Subjects' 'with' 'known' 'HIV' 'infection'],[0. 0. 0. 2. 2.]
NCT02776059,7:20:chronic_disease,Known HIV infection,['Known' 'HIV' 'infection'],[0. 2. 2.]
NCT02693145,"74:87:chronic_disease,",Residents within the health department jurisdiction with newly diagnosed HIV infection who have not linked to medical care within 90 days,"['Residents' 'within' 'the' 'health' 'department' 'jurisdiction' 'with'
 'newly' 'diagnosed' 'HIV' 'infection' 'who' 'have' 'not' 'linked' 'to'
 'medical' 'care' 'within' '90' 'days']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02663934,23:36:chronic_disease,documented history of HIV infection,['documented' 'history' 'of' 'HIV' 'infection'],[0. 0. 0. 2. 2.]
NCT02582775,12:25:chronic_disease,History of HIV infection,['History' 'of' 'HIV' 'infection'],[0. 0. 2. 2.]
NCT02570542,1:14:chronic_disease,HIV infection,['HIV' 'infection'],[2. 2.]
NCT02555189,32:45:chronic_disease,Patient has a known history of HIV infection (testing not mandatory),"['Patient' 'has' 'a' 'known' 'history' 'of' 'HIV' 'infection' '('
 'testing' 'not' 'mandatory' ')']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02532621,66:79:chronic_disease,"Subject currently has a known or suspected bacterial, fungal, or HIV infection","['Subject' 'currently' 'has' 'a' 'known' 'or' 'suspected' 'bacterial' ','
 'fungal' ',' 'or' 'HIV' 'infection']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02516696,19:32:chronic_disease,Subject has known HIV infection,['Subject' 'has' 'known' 'HIV' 'infection'],[0. 0. 0. 2. 2.]
NCT02514083,1:14:chronic_disease,HIV infection,['HIV' 'infection'],[2. 2.]
NCT02512497,1:14:chronic_disease,HIV infection,['HIV' 'infection'],[2. 2.]
NCT02469857,"7:20:chronic_disease,,,",Known HIV infection with CD4 count < 200 cells/mm3 or < 14% of all lymphocytes,"['Known' 'HIV' 'infection' 'with' 'CD4' 'count' '<' '200' 'cells/mm3' 'or'
 '<' '14' '%' 'of' 'all' 'lymphocytes']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02466750,18:31:chronic_disease,Have a confirmed HIV infection (antibody positivity),['Have' 'a' 'confirmed' 'HIV' 'infection' '(' 'antibody' 'positivity' ')'],[0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02408861,47:60:chronic_disease,"the referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection","['the' 'referring' 'physician' ""'s"" 'written' 'record' 'that' 'HIV'
 'infection' 'was' 'documented' ',' 'with' 'supporting' 'information' 'on'
 'the' 'participant' ""'s"" 'relevant' 'medical' 'history' 'and/or'
 'current' 'management' 'of' 'HIV' 'infection']","[0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02367196,7:20:chronic_disease,Known HIV infection,['Known' 'HIV' 'infection'],[0. 2. 2.]
NCT02291848,22:35:chronic_disease,Patients with active HIV infection at time of procurement (can be pending at the time of blood draw),"['Patients' 'with' 'active' 'HIV' 'infection' 'at' 'time' 'of'
 'procurement' '(' 'can' 'be' 'pending' 'at' 'the' 'time' 'of' 'blood'
 'draw' ')']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02256631,18:31:chronic_disease,Documentation of HIV infection,['Documentation' 'of' 'HIV' 'infection'],[0. 0. 2. 2.]
NCT02256631,43:56:chronic_disease,"Mother with documented* 2-class resistant HIV infection, which may include historical documentation of lack of response","['Mother' 'with' 'documented' '*' '2-class' 'resistant' 'HIV' 'infection'
 ',' 'which' 'may' 'include' 'historical' 'documentation' 'of' 'lack' 'of'
 'response']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02140255,49:62:chronic_disease,"Any clinically significant diseases (other than HIV infection) or clinically significant findings during review of medical history or physical examination prior to entry that, in the investigator's opinion, would interfere with study participation or interpretation","['Any' 'clinically' 'significant' 'diseases' '(' 'other' 'than' 'HIV'
 'infection' ')' 'or' 'clinically' 'significant' 'findings' 'during'
 'review' 'of' 'medical' 'history' 'or' 'physical' 'examination' 'prior'
 'to' 'entry' 'that' ',' 'in' 'the' 'investigator' ""'s"" 'opinion' ','
 'would' 'interfere' 'with' 'study' 'participation' 'or' 'interpretation']","[0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02140255,20:33:chronic_disease,Confirmed in utero HIV infection,['Confirmed' 'in' 'utero' 'HIV' 'infection'],[0. 0. 0. 2. 2.]
NCT01940757,32:45:chronic_disease,Positive confirmatory test for HIV infection,['Positive' 'confirmatory' 'test' 'for' 'HIV' 'infection'],[0. 0. 0. 0. 2. 2.]
NCT01861106,1:14:chronic_disease,HIV infection,['HIV' 'infection'],[2. 2.]
NCT01841333,7:20:chronic_disease,Known HIV infection,['Known' 'HIV' 'infection'],[0. 2. 2.]
NCT01822522,19:32:chronic_disease,participants with HIV infection will be eligible provided they meet the criteria,"['participants' 'with' 'HIV' 'infection' 'will' 'be' 'eligible' 'provided'
 'they' 'meet' 'the' 'criteria']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01333046,22:35:chronic_disease,Patients with active HIV infection at time of procurement (can be pending at the time of blood draw),"['Patients' 'with' 'active' 'HIV' 'infection' 'at' 'time' 'of'
 'procurement' '(' 'can' 'be' 'pending' 'at' 'the' 'time' 'of' 'blood'
 'draw' ')']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00085982,7:20:chronic_disease,Known HIV infection,['Known' 'HIV' 'infection'],[0. 2. 2.]
NCT00001651,12:25:chronic_disease,"Documented HIV infection (ELISA/Western blot positive or, for acute seroconverters, PCR positive)","['Documented' 'HIV' 'infection' '(' 'ELISA/Western' 'blot' 'positive' 'or'
 ',' 'for' 'acute' 'seroconverters' ',' 'PCR' 'positive' ')']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00001651,70:83:chronic_disease,"Willingness to allow stored samples to be used for future studies of HIV infection and/or immunological function, and willingness to have HLA typing performed. (For previously enrolled patients, patients would be requested, but not required, to provide permission to use stored samples in the future, and to permit HLA testing","['Willingness' 'to' 'allow' 'stored' 'samples' 'to' 'be' 'used' 'for'
 'future' 'studies' 'of' 'HIV' 'infection' 'and/or' 'immunological'
 'function' ',' 'and' 'willingness' 'to' 'have' 'HLA' 'typing' 'performed'
 '.' '(' 'For' 'previously' 'enrolled' 'patients' ',' 'patients' 'would'
 'be' 'requested' ',' 'but' 'not' 'required' ',' 'to' 'provide'
 'permission' 'to' 'use' 'stored' 'samples' 'in' 'the' 'future' ',' 'and'
 'to' 'permit' 'HLA' 'testing']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03066596,28:34:chronic_disease,Persistent or uncontrolled asthma as per clinic assessment,"['Persistent' 'or' 'uncontrolled' 'asthma' 'as' 'per' 'clinic'
 'assessment']",[0. 0. 0. 2. 0. 0. 0. 0.]
NCT03066596,",35:41:chronic_disease","in past month, > 2 days/week with asthma symptoms","['in' 'past' 'month' ',' '>' '2' 'days/week' 'with' 'asthma' 'symptoms']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT03028350,32:38:chronic_disease,History of physician-diagnosed asthma,['History' 'of' 'physician-diagnosed' 'asthma'],[0. 0. 0. 2.]
NCT03028350,8:14:chronic_disease,Stable asthma,['Stable' 'asthma'],[0. 2.]
NCT03028350,"50:56:chronic_disease,",no hospitalizations or emergency room visits for asthma at least three months prior to starting treatment,"['no' 'hospitalizations' 'or' 'emergency' 'room' 'visits' 'for' 'asthma'
 'at' 'least' 'three' 'months' 'prior' 'to' 'starting' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03002389,23:29:chronic_disease,previous diagnosis of asthma,['previous' 'diagnosis' 'of' 'asthma'],[0. 0. 0. 2.]
NCT02995733,"34:40:chronic_disease,",Clinical history consistent with asthma for > 1 year,['Clinical' 'history' 'consistent' 'with' 'asthma' 'for' '>' '1' 'year'],[0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT02953431,27:33:chronic_disease,No physician diagnosis of asthma,['No' 'physician' 'diagnosis' 'of' 'asthma'],[0. 0. 0. 0. 2.]
NCT02752165,26:32:chronic_disease,Participation in another asthma study at the time of enrollment,"['Participation' 'in' 'another' 'asthma' 'study' 'at' 'the' 'time' 'of'
 'enrollment']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02752165,31:37:chronic_disease,"Persistent or poor control of asthma, defined by NHLBI guidelines","['Persistent' 'or' 'poor' 'control' 'of' 'asthma' ',' 'defined' 'by'
 'NHLBI' 'guidelines']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02752165,30:36:chronic_disease,Prior physician diagnosis of asthma,['Prior' 'physician' 'diagnosis' 'of' 'asthma'],[0. 0. 0. 0. 2.]
NCT02752165,127:133:chronic_disease,a sibling participating in this or another study Other significant medical conditions that could interfere with assessment of asthma-related measures,"['a' 'sibling' 'participating' 'in' 'this' 'or' 'another' 'study' 'Other'
 'significant' 'medical' 'conditions' 'that' 'could' 'interfere' 'with'
 'assessment' 'of' 'asthma-related' 'measures']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT02740543,5:11:chronic_disease,Has asthma according to Phase I diagnostic criteria,['Has' 'asthma' 'according' 'to' 'Phase' 'I' 'diagnostic' 'criteria'],[0. 2. 0. 0. 0. 0. 0. 0.]
NCT02740543,"86:92:chronic_disease,,","Patients will be recruited from the NYUBAR and will have no respiratory symptoms, no asthma diagnosis, no WTC dust exposure, no current tobacco use, ≤ 5 p-y history of tobacco use, and normal spirometry with no bronchodilator response and negative methacholine challenge in past 6 months","['Patients' 'will' 'be' 'recruited' 'from' 'the' 'NYUBAR' 'and' 'will'
 'have' 'no' 'respiratory' 'symptoms' ',' 'no' 'asthma' 'diagnosis' ','
 'no' 'WTC' 'dust' 'exposure' ',' 'no' 'current' 'tobacco' 'use' ',' '≤'
 '5' 'p-y' 'history' 'of' 'tobacco' 'use' ',' 'and' 'normal' 'spirometry'
 'with' 'no' 'bronchodilator' 'response' 'and' 'negative' 'methacholine'
 'challenge' 'in' 'past' '6' 'months']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02740543,75:81:chronic_disease,"Patients will be recruited from the NYUBAR or advertisement and will have asthma as defined by NIH guidelines, persistent symptoms, absence of WTC dust exposure","['Patients' 'will' 'be' 'recruited' 'from' 'the' 'NYUBAR' 'or'
 'advertisement' 'and' 'will' 'have' 'asthma' 'as' 'defined' 'by' 'NIH'
 'guidelines' ',' 'persistent' 'symptoms' ',' 'absence' 'of' 'WTC' 'dust'
 'exposure']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02682147,14:20:chronic_disease,Diagnosis of asthma,['Diagnosis' 'of' 'asthma'],[0. 0. 2.]
NCT02624765,1:7:chronic_disease,asthma,['asthma'],[2.]
NCT02580604,25:31:chronic_disease,Diagnosis or history of asthma,['Diagnosis' 'or' 'history' 'of' 'asthma'],[0. 0. 0. 0. 2.]
NCT02570984,60:66:chronic_disease,first degree relative with history or current diagnosis of asthma or allergy,"['first' 'degree' 'relative' 'with' 'history' 'or' 'current' 'diagnosis'
 'of' 'asthma' 'or' 'allergy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0.]
NCT02554786,"14:20:chronic_disease,","diagnosis of asthma, for a period of at least 1 year prior to Visit 1 (Screening)","['diagnosis' 'of' 'asthma' ',' 'for' 'a' 'period' 'of' 'at' 'least' '1'
 'year' 'prior' 'to' 'Visit' '1' '(' 'Screening' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02547818,22:28:chronic_disease,Uncontrolled chronic asthma,['Uncontrolled' 'chronic' 'asthma'],[0. 0. 2.]
NCT02508311,12:18:chronic_disease,History of asthma,['History' 'of' 'asthma'],[0. 0. 2.]
NCT02495168,16:22:chronic_disease,Diagnosed with asthma as defined by the NAEPP 3,['Diagnosed' 'with' 'asthma' 'as' 'defined' 'by' 'the' 'NAEPP' '3'],[0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02494869,14:20:chronic_disease,Uncontrolled asthma,['Uncontrolled' 'asthma'],[0. 2.]
NCT02472834,13:19:chronic_disease,Presence of asthma,['Presence' 'of' 'asthma'],[0. 0. 2.]
NCT02458482,",215:221:chronic_disease",Patients will be evaluated using the Acute Asthma Intensity Research Score (AAIRS) which has been validated at Vanderbilt University Medical Center and is currently the standard of care when triaging patients with asthma,"['Patients' 'will' 'be' 'evaluated' 'using' 'the' 'Acute' 'Asthma'
 'Intensity' 'Research' 'Score' '(' 'AAIRS' ')' 'which' 'has' 'been'
 'validated' 'at' 'Vanderbilt' 'University' 'Medical' 'Center' 'and' 'is'
 'currently' 'the' 'standard' 'of' 'care' 'when' 'triaging' 'patients'
 'with' 'asthma']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]"
NCT02436070,21:27:chronic_disease,Previous history of asthma as represented in the medical record or by parental report,"['Previous' 'history' 'of' 'asthma' 'as' 'represented' 'in' 'the'
 'medical' 'record' 'or' 'by' 'parental' 'report']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02433977,44:50:chronic_disease,History of ICU admission/intubation due to asthma in the past year,"['History' 'of' 'ICU' 'admission/intubation' 'due' 'to' 'asthma' 'in'
 'the' 'past' 'year']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT02401074,68:74:chronic_disease,Diagnosis of well-controlled airway allergy with mild-intermittent asthma (a stable clinical condition with good asthma control) and demonstrating an allergen-specific airway response to inhaled allergen provocation,"['Diagnosis' 'of' 'well-controlled' 'airway' 'allergy' 'with'
 'mild-intermittent' 'asthma' '(' 'a' 'stable' 'clinical' 'condition'
 'with' 'good' 'asthma' 'control' ')' 'and' 'demonstrating' 'an'
 'allergen-specific' 'airway' 'response' 'to' 'inhaled' 'allergen'
 'provocation']","[0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02291302,17:23:chronic_disease,grades K-8 with asthma attending sampling/intervention schools,"['grades' 'K-8' 'with' 'asthma' 'attending' 'sampling/intervention'
 'schools']",[0. 0. 0. 2. 0. 0. 0.]
NCT02148796,21:27:chronic_disease,Parental history of asthma,['Parental' 'history' 'of' 'asthma'],[0. 0. 0. 2.]
NCT02148796,54:60:chronic_disease,Participants may not have a physician's diagnosis of asthma,"['Participants' 'may' 'not' 'have' 'a' 'physician' ""'s"" 'diagnosis' 'of'
 'asthma']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02148796,"21:27:chronic_disease,,",Physician-diagnosed asthma in a blood sibling aged 4 years or more,"['Physician-diagnosed' 'asthma' 'in' 'a' 'blood' 'sibling' 'aged' '4'
 'years' 'or' 'more']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02025465,30:36:chronic_disease,history of being treated for asthma,['history' 'of' 'being' 'treated' 'for' 'asthma'],[0. 0. 0. 0. 0. 2.]
NCT03112902,14:34:chronic_disease,diagnosis of cognitive impairment,['diagnosis' 'of' 'cognitive' 'impairment'],[0. 0. 2. 2.]
NCT03105700,"13:33:chronic_disease,,",Significant cognitive impairment measured by the Montreal Cognitive Assessment (MOCA) <23,"['Significant' 'cognitive' 'impairment' 'measured' 'by' 'the' 'Montreal'
 'Cognitive' 'Assessment' '(' 'MOCA' ')' '<' '23']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03029884,"13:33:chronic_disease,,",Significant cognitive impairment or Dementia (MoCA < 25),"['Significant' 'cognitive' 'impairment' 'or' 'Dementia' '(' 'MoCA' '<'
 '25' ')']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02991534,15:35:chronic_disease,Patients with cognitive impairment precluding informed consent,"['Patients' 'with' 'cognitive' 'impairment' 'precluding' 'informed'
 'consent']",[0. 0. 2. 2. 0. 0. 0.]
NCT02951455,"7:27:chronic_disease,",Gross cognitive impairment as measured by the Mini Mental State Exam,"['Gross' 'cognitive' 'impairment' 'as' 'measured' 'by' 'the' 'Mini'
 'Mental' 'State' 'Exam']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02926378,10:30:chronic_disease,Evidence cognitive impairment that would negatively impact capacity to understand and participate in this study,"['Evidence' 'cognitive' 'impairment' 'that' 'would' 'negatively' 'impact'
 'capacity' 'to' 'understand' 'and' 'participate' 'in' 'this' 'study']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02791646,1:21:chronic_disease,cognitive impairment,['cognitive' 'impairment'],[2. 2.]
NCT02719327,6:26:chronic_disease,mild cognitive impairment on screening evaluation,['mild' 'cognitive' 'impairment' 'on' 'screening' 'evaluation'],[0. 2. 2. 0. 0. 0.]
NCT02712229,1:21:chronic_disease,"cognitive impairment or inability to consent to treatment, as determined by the patient's oncologist","['cognitive' 'impairment' 'or' 'inability' 'to' 'consent' 'to' 'treatment'
 ',' 'as' 'determined' 'by' 'the' 'patient' ""'s"" 'oncologist']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02685358,7:27:chronic_disease,gross cognitive impairment,['gross' 'cognitive' 'impairment'],[0. 2. 2.]
NCT02667119,13:33:chronic_disease,significant cognitive impairment,['significant' 'cognitive' 'impairment'],[0. 2. 2.]
NCT02585232,21:41:chronic_disease,Experiencing severe cognitive impairment that would impair their ability to communicate during an interview,"['Experiencing' 'severe' 'cognitive' 'impairment' 'that' 'would' 'impair'
 'their' 'ability' 'to' 'communicate' 'during' 'an' 'interview']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02521818,52:72:chronic_disease,availability of cohabitating study partner without cognitive impairment,"['availability' 'of' 'cohabitating' 'study' 'partner' 'without'
 'cognitive' 'impairment']",[0. 0. 0. 0. 0. 0. 2. 2.]
NCT02506192,52:72:chronic_disease,"other diagnosis that produces symptoms of fatigue, cognitive impairment, or pain will be excluded based on the Kansas GWI Case definition","['other' 'diagnosis' 'that' 'produces' 'symptoms' 'of' 'fatigue' ','
 'cognitive' 'impairment' ',' 'or' 'pain' 'will' 'be' 'excluded' 'based'
 'on' 'the' 'Kansas' 'GWI' 'Case' 'definition']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02497300,1:21:chronic_disease,cognitive impairment prohibiting consent,['cognitive' 'impairment' 'prohibiting' 'consent'],[2. 2. 0. 0.]
NCT02466126,1:21:chronic_disease,cognitive impairment,['cognitive' 'impairment'],[2. 2.]
NCT02454517,35:55:chronic_disease,Doctor of medicine (MD) confirmed cognitive impairment,"['Doctor' 'of' 'medicine' '(' 'MD' ')' 'confirmed' 'cognitive'
 'impairment']",[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02442102,",48:68:chronic_disease",Unable to understand or speak English due to a cognitive impairment,"['Unable' 'to' 'understand' 'or' 'speak' 'English' 'due' 'to' 'a'
 'cognitive' 'impairment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02435667,13:33:chronic_disease,Significant cognitive impairment,['Significant' 'cognitive' 'impairment'],[0. 2. 2.]
NCT02340650,37:57:chronic_disease,Patient with sufficient evidence of cognitive impairment that limits the subject's ability to understand the protocol,"['Patient' 'with' 'sufficient' 'evidence' 'of' 'cognitive' 'impairment'
 'that' 'limits' 'the' 'subject' ""'s"" 'ability' 'to' 'understand' 'the'
 'protocol']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02316574,13:33:chronic_disease,Significant cognitive impairment,['Significant' 'cognitive' 'impairment'],[0. 2. 2.]
NCT02269124,13:33:chronic_disease,Significant cognitive impairment,['Significant' 'cognitive' 'impairment'],[0. 2. 2.]
NCT02159027,78:98:chronic_disease,Ability and willingness to provide written informed consent Mild to moderate cognitive impairment with global neuropsychological (NP) test (NPZglobal),"['Ability' 'and' 'willingness' 'to' 'provide' 'written' 'informed'
 'consent' 'Mild' 'to' 'moderate' 'cognitive' 'impairment' 'with' 'global'
 'neuropsychological' '(' 'NP' ')' 'test' '(' 'NPZglobal' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02157025,57:77:chronic_disease,Inability to understand study or communicate responses (cognitive impairment),"['Inability' 'to' 'understand' 'study' 'or' 'communicate' 'responses' '('
 'cognitive' 'impairment' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.]
NCT02153229,37:57:chronic_disease,Patients unwilling or unable due to cognitive impairment to sign informed consent,"['Patients' 'unwilling' 'or' 'unable' 'due' 'to' 'cognitive' 'impairment'
 'to' 'sign' 'informed' 'consent']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT01974609,27:47:chronic_disease,those with a diagnosis of cognitive impairment,['those' 'with' 'a' 'diagnosis' 'of' 'cognitive' 'impairment'],[0. 0. 0. 0. 0. 2. 2.]
NCT01878617,"16:36:chronic_disease,,,",No significant cognitive impairment operationalized as either an IQ < 70 for children with St. Jude SJMB12 study baseline testing or based on clinician judgment baseline IQ missing,"['No' 'significant' 'cognitive' 'impairment' 'operationalized' 'as'
 'either' 'an' 'IQ' '<' '70' 'for' 'children' 'with' 'St.' 'Jude' 'SJMB12'
 'study' 'baseline' 'testing' 'or' 'based' 'on' 'clinician' 'judgment'
 'baseline' 'IQ' 'missing']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01829958,",,45:65:chronic_disease","Patients scoring ≥ 11 on the BOMC (implying cognitive impairment) will be excluded since their ability to reliably complete the questionnaire will be in doubt Subjects meeting the following criteria will be excluded from enrollment in the pre-phase arm of the study, but may be included in the GA only arm","['Patients' 'scoring' '≥' '11' 'on' 'the' 'BOMC' '(' 'implying'
 'cognitive' 'impairment' ')' 'will' 'be' 'excluded' 'since' 'their'
 'ability' 'to' 'reliably' 'complete' 'the' 'questionnaire' 'will' 'be'
 'in' 'doubt' 'Subjects' 'meeting' 'the' 'following' 'criteria' 'will'
 'be' 'excluded' 'from' 'enrollment' 'in' 'the' 'pre-phase' 'arm' 'of'
 'the' 'study' ',' 'but' 'may' 'be' 'included' 'in' 'the' 'GA' 'only'
 'arm']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01175044,88:108:chronic_disease,Inability to provide informed consent or to comply with study assessments (e.g. due to cognitive impairment or geographic distance),"['Inability' 'to' 'provide' 'informed' 'consent' 'or' 'to' 'comply' 'with'
 'study' 'assessments' '(' 'e.g' '.' 'due' 'to' 'cognitive' 'impairment'
 'or' 'geographic' 'distance' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT03144245,24:39:chronic_disease,Clinically significant cardiac disease,['Clinically' 'significant' 'cardiac' 'disease'],[0. 0. 2. 2.]
NCT03140488,38:53:chronic_disease,Patients with history of significant cardiac disease,['Patients' 'with' 'history' 'of' 'significant' 'cardiac' 'disease'],[0. 0. 0. 0. 0. 2. 2.]
NCT03114319,24:39:chronic_disease,Clinically significant cardiac disease,['Clinically' 'significant' 'cardiac' 'disease'],[0. 0. 2. 2.]
NCT03042689,34:49:chronic_disease,Active or clinically significant cardiac disease,['Active' 'or' 'clinically' 'significant' 'cardiac' 'disease'],[0. 0. 0. 0. 2. 2.]
NCT02994940,",,,,259:274:chronic_disease","Patients who meet UCDCH criteria for PICU admission: on home oxygen pre-operatively, exhibit airway obstruction when awake (stertor above larynx, stridor at larynx), sleep study with apnea hypoxia index greater than 25 or sleep oxygen saturation nadir <80%, cardiac disease, difficult intubation","['Patients' 'who' 'meet' 'UCDCH' 'criteria' 'for' 'PICU' 'admission' ':'
 'on' 'home' 'oxygen' 'pre-operatively' ',' 'exhibit' 'airway'
 'obstruction' 'when' 'awake' '(' 'stertor' 'above' 'larynx' ',' 'stridor'
 'at' 'larynx' ')' ',' 'sleep' 'study' 'with' 'apnea' 'hypoxia' 'index'
 'greater' 'than' '25' 'or' 'sleep' 'oxygen' 'saturation' 'nadir' '<' '80'
 '%' ',' 'cardiac' 'disease' ',' 'difficult' 'intubation']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 0. 0. 0.]"
NCT02990481,1:16:chronic_disease,cardiac disease,['cardiac' 'disease'],[2. 2.]
NCT02852239,33:48:chronic_disease,History or current diagnosis of cardiac disease indicating significant risk such as uncontrolled,"['History' 'or' 'current' 'diagnosis' 'of' 'cardiac' 'disease'
 'indicating' 'significant' 'risk' 'such' 'as' 'uncontrolled']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02774421,1:16:chronic_disease,cardiac disease risk factors,['cardiac' 'disease' 'risk' 'factors'],[2. 2. 0. 0.]
NCT02774421,13:28:chronic_disease,significant cardiac disease,['significant' 'cardiac' 'disease'],[0. 2. 2.]
NCT02665338,10:25:chronic_disease,Unstable cardiac disease,['Unstable' 'cardiac' 'disease'],[0. 2. 2.]
NCT02488967,8:23:chronic_disease,Active cardiac disease,['Active' 'cardiac' 'disease'],[0. 2. 2.]
NCT02488967,12:27:chronic_disease,History of cardiac disease,['History' 'of' 'cardiac' 'disease'],[0. 0. 2. 2.]
NCT02466009,34:49:chronic_disease,Active or clinically significant cardiac disease,['Active' 'or' 'clinically' 'significant' 'cardiac' 'disease'],[0. 0. 0. 0. 2. 2.]
NCT02464878,20:35:chronic_disease,Severe co-existing cardiac disease,['Severe' 'co-existing' 'cardiac' 'disease'],[0. 0. 2. 2.]
NCT02435069,1:16:chronic_disease,cardiac disease,['cardiac' 'disease'],[2. 2.]
NCT02433626,51:66:chronic_disease,History of clinically significant or uncontrolled cardiac disease,"['History' 'of' 'clinically' 'significant' 'or' 'uncontrolled' 'cardiac'
 'disease']",[0. 0. 0. 0. 0. 0. 2. 2.]
NCT02387216,24:39:chronic_disease,Clinically significant cardiac disease,['Clinically' 'significant' 'cardiac' 'disease'],[0. 0. 2. 2.]
NCT02367196,53:68:chronic_disease,Impaired cardiac function or clinically significant cardiac disease,"['Impaired' 'cardiac' 'function' 'or' 'clinically' 'significant' 'cardiac'
 'disease']",[0. 2. 2. 0. 0. 0. 0. 0.]
NCT02252588,10:25:chronic_disease,Unstable cardiac disease,['Unstable' 'cardiac' 'disease'],[0. 2. 2.]
NCT02048722,34:49:chronic_disease,Active or clinically significant cardiac disease,['Active' 'or' 'clinically' 'significant' 'cardiac' 'disease'],[0. 0. 0. 0. 2. 2.]
NCT01676259,1:16:chronic_disease,cardiac disease,['cardiac' 'disease'],[2. 2.]
NCT01474889,20:35:chronic_disease,Severe co-existing cardiac disease,['Severe' 'co-existing' 'cardiac' 'disease'],[0. 0. 2. 2.]
NCT00788164,27:42:chronic_disease,No evidence or history of cardiac disease,['No' 'evidence' 'or' 'history' 'of' 'cardiac' 'disease'],[0. 0. 0. 0. 0. 2. 2.]
NCT00467987,33:48:chronic_disease,"Any other life-threatening, non-cardiac disease","['Any' 'other' 'life-threatening' ',' 'non-cardiac' 'disease']",[0. 0. 0. 0. 2. 2.]
NCT00432094,51:66:chronic_disease,Patients must be free of symptoms of uncontrolled cardiac disease,"['Patients' 'must' 'be' 'free' 'of' 'symptoms' 'of' 'uncontrolled'
 'cardiac' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT03099070,97:113:chronic_disease,Any condition that would preclude the safe experience of a benign laboratory stressor including seizure disorder,"['Any' 'condition' 'that' 'would' 'preclude' 'the' 'safe' 'experience'
 'of' 'a' 'benign' 'laboratory' 'stressor' 'including' 'seizure'
 'disorder']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT03017937,11:27:chronic_disease,Any known seizure disorder,['Any' 'known' 'seizure' 'disorder'],[0. 0. 2. 2.]
NCT02924194,28:44:chronic_disease,Subjects with a history of seizure disorder,['Subjects' 'with' 'a' 'history' 'of' 'seizure' 'disorder'],[0. 0. 0. 0. 0. 2. 2.]
NCT02882802,35:51:chronic_disease,"Participants also must not have a seizure disorder and must not be taking any medications that would affect cognition or behavior on the aggression task, including pain medication","['Participants' 'also' 'must' 'not' 'have' 'a' 'seizure' 'disorder' 'and'
 'must' 'not' 'be' 'taking' 'any' 'medications' 'that' 'would' 'affect'
 'cognition' 'or' 'behavior' 'on' 'the' 'aggression' 'task' ','
 'including' 'pain' 'medication']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02864147,35:51:chronic_disease,Patients who have an uncontrolled seizure disorder,['Patients' 'who' 'have' 'an' 'uncontrolled' 'seizure' 'disorder'],[0. 0. 0. 0. 0. 2. 2.]
NCT02859142,1:17:chronic_disease,seizure disorder,['seizure' 'disorder'],[2. 2.]
NCT02833792,12:28:chronic_disease,History of seizure disorder,['History' 'of' 'seizure' 'disorder'],[0. 0. 2. 2.]
NCT02768727,12:28:chronic_disease,History of seizure disorder,['History' 'of' 'seizure' 'disorder'],[0. 0. 2. 2.]
NCT02737930,12:28:chronic_disease,History of seizure disorder,['History' 'of' 'seizure' 'disorder'],[0. 0. 2. 2.]
NCT02676193,67:83:chronic_disease,Marked organic impairment or unstable medical problems (such as a seizure disorder),"['Marked' 'organic' 'impairment' 'or' 'unstable' 'medical' 'problems' '('
 'such' 'as' 'a' 'seizure' 'disorder' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.]
NCT02629120,14:30:chronic_disease,Uncontrolled seizure disorder,['Uncontrolled' 'seizure' 'disorder'],[0. 2. 2.]
NCT02562430,16:32:chronic_disease,any history of seizure disorder,['any' 'history' 'of' 'seizure' 'disorder'],[0. 0. 0. 2. 2.]
NCT02442102,8:24:chronic_disease,Active seizure disorder,['Active' 'seizure' 'disorder'],[0. 2. 2.]
NCT02414269,18:34:chronic_disease,Prior history of seizure disorder,['Prior' 'history' 'of' 'seizure' 'disorder'],[0. 0. 0. 2. 2.]
NCT02404155,14:30:chronic_disease,Uncontrolled seizure disorder,['Uncontrolled' 'seizure' 'disorder'],[0. 2. 2.]
NCT02234934,14:30:chronic_disease,Uncontrolled seizure disorder,['Uncontrolled' 'seizure' 'disorder'],[0. 2. 2.]
NCT02202369,21:37:chronic_disease,Patients who have a seizure disorder,['Patients' 'who' 'have' 'a' 'seizure' 'disorder'],[0. 0. 0. 0. 2. 2.]
NCT02159027,14:30:chronic_disease,Uncontrolled seizure disorder,['Uncontrolled' 'seizure' 'disorder'],[0. 2. 2.]
NCT02101853,28:44:chronic_disease,Patients with uncontrolled seizure disorder,['Patients' 'with' 'uncontrolled' 'seizure' 'disorder'],[0. 0. 0. 2. 2.]
NCT01967238,12:28:chronic_disease,History of seizure disorder for Flumist group participants only,"['History' 'of' 'seizure' 'disorder' 'for' 'Flumist' 'group'
 'participants' 'only']",[0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT01964404,14:30:chronic_disease,History of a seizure disorder,['History' 'of' 'a' 'seizure' 'disorder'],[0. 0. 0. 2. 2.]
NCT01912612,12:28:chronic_disease,History of seizure disorder,['History' 'of' 'seizure' 'disorder'],[0. 0. 2. 2.]
NCT01625923,12:28:chronic_disease,History of seizure disorder,['History' 'of' 'seizure' 'disorder'],[0. 0. 2. 2.]
NCT01618357,12:28:chronic_disease,History of seizure disorder,['History' 'of' 'seizure' 'disorder'],[0. 0. 2. 2.]
NCT03104699,1:16:chronic_disease,unstable angina,['unstable' 'angina'],[2. 2.]
NCT03096288,11:26:chronic_disease,stable or unstable angina,['stable' 'or' 'unstable' 'angina'],[0. 0. 2. 2.]
NCT03078907,1:16:chronic_disease,unstable angina,['unstable' 'angina'],[2. 2.]
NCT03072238,8:23:chronic_disease,severe unstable angina,['severe' 'unstable' 'angina'],[0. 2. 2.]
NCT03043742,",,50:65:chronic_disease",Increased Troponin T (> 3X ULN) in patients with unstable angina at time of intervention,"['Increased' 'Troponin' 'T' '(' '>' '3X' 'ULN' ')' 'in' 'patients' 'with'
 'unstable' 'angina' 'at' 'time' 'of' 'intervention']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT03037983,1:16:chronic_disease,unstable angina,['unstable' 'angina'],[2. 2.]
NCT02945293,1:16:chronic_disease,unstable angina,['unstable' 'angina'],[2. 2.]
NCT02925923,15:30:chronic_disease,Patients with unstable angina,['Patients' 'with' 'unstable' 'angina'],[0. 0. 2. 2.]
NCT02703220,9:24:chronic_disease,Current unstable angina,['Current' 'unstable' 'angina'],[0. 2. 2.]
NCT02637947,13:28:chronic_disease,subject has unstable angina,['subject' 'has' 'unstable' 'angina'],[0. 0. 2. 2.]
NCT02583893,1:16:chronic_disease,unstable angina,['unstable' 'angina'],[2. 2.]
NCT02513797,"23:38:chronic_disease,",Documented history of unstable angina within 3 months prior to the planned study intervention,"['Documented' 'history' 'of' 'unstable' 'angina' 'within' '3' 'months'
 'prior' 'to' 'the' 'planned' 'study' 'intervention']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02497300,1:16:chronic_disease,unstable angina,['unstable' 'angina'],[2. 2.]
NCT02353728,"12:27:chronic_disease,",History of unstable angina within 1 year of study entry,"['History' 'of' 'unstable' 'angina' 'within' '1' 'year' 'of' 'study'
 'entry']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02353728,1:16:chronic_disease,unstable angina,['unstable' 'angina'],[2. 2.]
NCT02347995,1:16:chronic_disease,unstable angina,['unstable' 'angina'],[2. 2.]
NCT02321501,"1:16:chronic_disease,",unstable angina within 6 months prior to screening,['unstable' 'angina' 'within' '6' 'months' 'prior' 'to' 'screening'],[2. 2. 0. 0. 0. 0. 0. 0.]
NCT02178566,1:16:chronic_disease,unstable angina,['unstable' 'angina'],[2. 2.]
NCT02106598,1:16:chronic_disease,unstable angina,['unstable' 'angina'],[2. 2.]
NCT02006069,"1:16:chronic_disease,",unstable angina within 40 days prior the enrollment,['unstable' 'angina' 'within' '40' 'days' 'prior' 'the' 'enrollment'],[2. 2. 0. 0. 0. 0. 0. 0.]
NCT01568177,1:16:chronic_disease,unstable angina,['unstable' 'angina'],[2. 2.]
NCT01562626,1:16:chronic_disease,unstable angina (anginal symptoms at rest),['unstable' 'angina' '(' 'anginal' 'symptoms' 'at' 'rest' ')'],[2. 2. 0. 0. 0. 0. 0. 0.]
NCT00432094,1:16:chronic_disease,unstable angina,['unstable' 'angina'],[2. 2.]
NCT03143894,1:9:chronic_disease,Dementia as assessed by a MMSE score on initial screening,"['Dementia' 'as' 'assessed' 'by' 'a' 'MMSE' 'score' 'on' 'initial'
 'screening']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03136029,30:38:chronic_disease,These include a diagnosis of Dementia,['These' 'include' 'a' 'diagnosis' 'of' 'Dementia'],[0. 0. 0. 0. 0. 2.]
NCT03104205,1:9:chronic_disease,Dementia,['Dementia'],[2.]
NCT02992275,"1:9:chronic_disease,,",Dementia (on medical record review or mini-mental status exam score <24),"['Dementia' '(' 'on' 'medical' 'record' 'review' 'or' 'mini-mental'
 'status' 'exam' 'score' '<' '24' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02924194,1:9:chronic_disease,Dementia per DSM-V criteria,['Dementia' 'per' 'DSM-V' 'criteria'],[2. 0. 0. 0.]
NCT02875301,1:9:chronic_disease,Dementia,['Dementia'],[2.]
NCT02838797,"1:9:chronic_disease,,",Dementia (Mini Mental Status Exam < 25),['Dementia' '(' 'Mini' 'Mental' 'Status' 'Exam' '<' '25' ')'],[2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02828618,1:9:chronic_disease,Dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent,"['Dementia' 'or' 'significantly' 'altered' 'mental' 'status' 'that'
 'would' 'prohibit' 'the' 'understanding' 'and' 'giving' 'of' 'informed'
 'consent']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02719327,1:9:chronic_disease,Dementia,['Dementia'],[2.]
NCT02665338,1:9:chronic_disease,Dementia,['Dementia'],[2.]
NCT02544503,1:9:chronic_disease,Dementia,['Dementia'],[2.]
NCT02522494,1:9:chronic_disease,Dementia,['Dementia'],[2.]
NCT02497300,1:9:chronic_disease,Dementia,['Dementia'],[2.]
NCT02471833,1:9:chronic_disease,Dementia,['Dementia'],[2.]
NCT02437110,1:9:chronic_disease,Dementia,['Dementia'],[2.]
NCT02436408,1:9:chronic_disease,Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol,"['Dementia' 'or' 'significantly' 'altered' 'mental' 'status' 'that'
 'would' 'prohibit' 'the' 'understanding' 'or' 'rendering' 'of' 'informed'
 'consent' 'and' 'compliance' 'with' 'the' 'requirements' 'of' 'this'
 'protocol']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02415556,"1:9:chronic_disease,,",Dementia (Mini Mental State Examination [MMSE] scores ≤20),"['Dementia' '(' 'Mini' 'Mental' 'State' 'Examination' '[' 'MMSE' ']'
 'scores' '≤20' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02311361,1:9:chronic_disease,Dementia or significantly altered mental status that would prohibit the understanding or rendering of Information and Consent and compliance with the requirements of the protocol,"['Dementia' 'or' 'significantly' 'altered' 'mental' 'status' 'that'
 'would' 'prohibit' 'the' 'understanding' 'or' 'rendering' 'of'
 'Information' 'and' 'Consent' 'and' 'compliance' 'with' 'the'
 'requirements' 'of' 'the' 'protocol']","[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02159560,1:9:chronic_disease,Dementia,['Dementia'],[2.]
NCT02106052,"1:9:chronic_disease,,,,",Dementia based on a definition validated in people with MS using the MACFIMS (> 2 SD below the mean on at least one memory test and > 2 SD below the mean on at least one neuropsychological test in another domain),"['Dementia' 'based' 'on' 'a' 'definition' 'validated' 'in' 'people' 'with'
 'MS' 'using' 'the' 'MACFIMS' '(' '>' '2' 'SD' 'below' 'the' 'mean' 'on'
 'at' 'least' 'one' 'memory' 'test' 'and' '>' '2' 'SD' 'below' 'the'
 'mean' 'on' 'at' 'least' 'one' 'neuropsychological' 'test' 'in' 'another'
 'domain' ')']","[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01581580,1:9:chronic_disease,Dementia as evidenced by formal neuropsychological evaluation,"['Dementia' 'as' 'evidenced' 'by' 'formal' 'neuropsychological'
 'evaluation']",[2. 0. 0. 0. 0. 0. 0.]
NCT01539109,1:9:chronic_disease,Dementia,['Dementia'],[2.]
NCT03145298,13:19:chronic_disease,Significant anemia or a falling Hb,['Significant' 'anemia' 'or' 'a' 'falling' 'Hb'],[0. 2. 0. 0. 0. 0.]
NCT03130777,"1:7:chronic_disease,,",anemia (Hgb < 7 g/dL),['anemia' '(' 'Hgb' '<' '7' 'g/dL' ')'],[2. 0. 0. 0. 0. 0. 0.]
NCT03073070,1:7:chronic_disease,anemia,['anemia'],[2.]
NCT02925923,"1:7:chronic_disease,,",anemia with HCT<30%,['anemia' 'with' 'HCT' '<' '30' '%'],[2. 0. 0. 0. 0. 0.]
NCT02823665,"13:19:chronic_disease,,",significant anemia (hemoglobin <11g/dL),['significant' 'anemia' '(' 'hemoglobin' '<' '11g/dL' ')'],[0. 2. 0. 0. 0. 0. 0.]
NCT02690116,26:32:chronic_disease,Currently diagnosed with anemia (fatigue-related factor),"['Currently' 'diagnosed' 'with' 'anemia' '(' 'fatigue-related' 'factor'
 ')']",[0. 0. 0. 2. 0. 0. 0. 0.]
NCT02589977,1:7:chronic_disease,anemia,['anemia'],[2.]
NCT02574910,"13:19:chronic_disease,,",Significant anemia (hemoglobin < 12 g/dl),['Significant' 'anemia' '(' 'hemoglobin' '<' '12' 'g/dl' ')'],[0. 2. 0. 0. 0. 0. 0. 0.]
NCT02473354,5:11:chronic_disease,has anemia [measured by venous blood gas sample],['has' 'anemia' '[' 'measured' 'by' 'venous' 'blood' 'gas' 'sample' ']'],[0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02411773,"8:14:chronic_disease,,",Severe anemia with hemoglobin (Hbg) level < 10 g/dL,"['Severe' 'anemia' 'with' 'hemoglobin' '(' 'Hbg' ')' 'level' '<' '10'
 'g/dL']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02404012,"20:26:chronic_disease,,","Subject has severe anemia, with a hemoglobin > 7.0 g/dL","['Subject' 'has' 'severe' 'anemia' ',' 'with' 'a' 'hemoglobin' '>' '7.0'
 'g/dL']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02341300,",,,,70:76:chronic_disease,,,,",Pregnant women of any age in their first trimester of pregnancy with anemia defined as a Hemoglobin less than 11 and/or a hematocrit less than 33,"['Pregnant' 'women' 'of' 'any' 'age' 'in' 'their' 'first' 'trimester' 'of'
 'pregnancy' 'with' 'anemia' 'defined' 'as' 'a' 'Hemoglobin' 'less' 'than'
 '11' 'and/or' 'a' 'hematocrit' 'less' 'than' '33']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02226341,"19:25:chronic_disease,,",Moderately severe anemia (Hgb < 8 mg/dL),['Moderately' 'severe' 'anemia' '(' 'Hgb' '<' '8' 'mg/dL' ')'],[0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02189889,29:35:chronic_disease,diagnosed with preoperative anemia,['diagnosed' 'with' 'preoperative' 'anemia'],[0. 0. 0. 2.]
NCT02145351,"8:14:chronic_disease,,",Severe anemia (Hemoglobin <10 g/dL),['Severe' 'anemia' '(' 'Hemoglobin' '<' '10' 'g/dL' ')'],[0. 2. 0. 0. 0. 0. 0. 0.]
NCT01947673,"8:14:chronic_disease,,",severe anemia with hgb level <8 g/dL,['severe' 'anemia' 'with' 'hgb' 'level' '<' '8' 'g/dL'],[0. 2. 0. 0. 0. 0. 0. 0.]
NCT01803451,13:19:chronic_disease,significant anemia,['significant' 'anemia'],[0. 2.]
NCT01573429,"21:27:chronic_disease,,,,,",Clinically relevant anemia as defined as hemoglobin concentration <13g/dL for males and hemoglobin concentration <11g/dL for females,"['Clinically' 'relevant' 'anemia' 'as' 'defined' 'as' 'hemoglobin'
 'concentration' '<' '13g/dL' 'for' 'males' 'and' 'hemoglobin'
 'concentration' '<' '11g/dL' 'for' 'females']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01572480,12:18:chronic_disease,Absence of anemia,['Absence' 'of' 'anemia'],[0. 0. 2.]
NCT01326715,40:46:chronic_disease,Clinically significant iron-deficiency anemia,['Clinically' 'significant' 'iron-deficiency' 'anemia'],[0. 0. 0. 2.]
NCT00065676,1:7:chronic_disease,anemia,['anemia'],[2.]
NCT03175159,21:38:chronic_disease,"Discovery of active suicidal ideation at the time of interview (participants will be referred immediately for treatment, but may join the study once resolved)","['Discovery' 'of' 'active' 'suicidal' 'ideation' 'at' 'the' 'time' 'of'
 'interview' '(' 'participants' 'will' 'be' 'referred' 'immediately' 'for'
 'treatment' ',' 'but' 'may' 'join' 'the' 'study' 'once' 'resolved' ')']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT03060902,12:29:chronic_disease,mother has suicidal ideation + an active plan,['mother' 'has' 'suicidal' 'ideation' '+' 'an' 'active' 'plan'],[0. 0. 2. 2. 0. 0. 0. 0.]
NCT03034863,44:61:chronic_disease,evidence of current (within the past week) suicidal ideation,"['evidence' 'of' 'current' '(' 'within' 'the' 'past' 'week' ')' 'suicidal'
 'ideation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT03004170,8:25:chronic_disease,Active suicidal ideation as determined by the Patient Health Questionnaire 9-item Depression Module,"['Active' 'suicidal' 'ideation' 'as' 'determined' 'by' 'the' 'Patient'
 'Health' 'Questionnaire' '9-item' 'Depression' 'Module']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02927847,1:18:chronic_disease,suicidal ideation with plan or intent,['suicidal' 'ideation' 'with' 'plan' 'or' 'intent'],[2. 2. 0. 0. 0. 0.]
NCT02914483,8:25:chronic_disease,Active suicidal ideation (PHQ-9 item #9 or otherwise reported during screening),"['Active' 'suicidal' 'ideation' '(' 'PHQ-9' 'item' '#' '9' 'or'
 'otherwise' 'reported' 'during' 'screening' ')']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02909387,"9:26:chronic_disease,",Reports suicidal ideation within the past month,['Reports' 'suicidal' 'ideation' 'within' 'the' 'past' 'month'],[0. 2. 2. 0. 0. 0. 0.]
NCT02859142,"9:26:chronic_disease,",Current suicidal ideation (past 6 months),['Current' 'suicidal' 'ideation' '(' 'past' '6' 'months' ')'],[0. 2. 2. 0. 0. 0. 0. 0.]
NCT02727972,21:38:chronic_disease,"active, significant suicidal ideation","['active' ',' 'significant' 'suicidal' 'ideation']",[0. 0. 0. 2. 2.]
NCT02587312,33:50:chronic_disease,Participants who report current suicidal ideation on the MINI suicide subscale questions 4 & 5,"['Participants' 'who' 'report' 'current' 'suicidal' 'ideation' 'on' 'the'
 'MINI' 'suicide' 'subscale' 'questions' '4' '&' '5']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02582905,",,,,141:158:chronic_disease","High risk for suicide defined as > 1 attempt in past 12 months that required medical attention, any attempt in the past 3 months or current suicidal ideation with plan and intent such that outpatient care is precluded","['High' 'risk' 'for' 'suicide' 'defined' 'as' '>' '1' 'attempt' 'in'
 'past' '12' 'months' 'that' 'required' 'medical' 'attention' ',' 'any'
 'attempt' 'in' 'the' 'past' '3' 'months' 'or' 'current' 'suicidal'
 'ideation' 'with' 'plan' 'and' 'intent' 'such' 'that' 'outpatient' 'care'
 'is' 'precluded']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02513225,",48:65:chronic_disease,",At least one episode of binge substance use or suicidal ideation recorded in the Apache community-based surveillance system in the past 90 days,"['At' 'least' 'one' 'episode' 'of' 'binge' 'substance' 'use' 'or'
 'suicidal' 'ideation' 'recorded' 'in' 'the' 'Apache' 'community-based'
 'surveillance' 'system' 'in' 'the' 'past' '90' 'days']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02452203,30:47:chronic_disease,Participant endorses current suicidal ideation with intent or plan,"['Participant' 'endorses' 'current' 'suicidal' 'ideation' 'with' 'intent'
 'or' 'plan']",[0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02421315,8:25:chronic_disease,Active suicidal ideation,['Active' 'suicidal' 'ideation'],[0. 2. 2.]
NCT02391402,20:37:chronic_disease,Clients who report suicidal ideation without imminent risk will be admitted into the study,"['Clients' 'who' 'report' 'suicidal' 'ideation' 'without' 'imminent'
 'risk' 'will' 'be' 'admitted' 'into' 'the' 'study']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02283333,23:40:chronic_disease,Individuals with both suicidal ideation and clear intent,['Individuals' 'with' 'both' 'suicidal' 'ideation' 'and' 'clear' 'intent'],[0. 0. 0. 2. 2. 0. 0. 0.]
NCT02270619,18:35:chronic_disease,prior or current suicidal ideation assessed by the Columbia Suicide Severity Rating Scale (C-SSRS),"['prior' 'or' 'current' 'suicidal' 'ideation' 'assessed' 'by' 'the'
 'Columbia' 'Suicide' 'Severity' 'Rating' 'Scale' '(' 'C-SSRS' ')']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02101554,",53:70:chronic_disease",Columbia-Suicide Severity Rating Scale (C-SSRS) for suicidal ideation and behavior in past year,"['Columbia-Suicide' 'Severity' 'Rating' 'Scale' '(' 'C-SSRS' ')' 'for'
 'suicidal' 'ideation' 'and' 'behavior' 'in' 'past' 'year']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02061553,",,,123:140:chronic_disease","At least mild depression and/ or anxiety as evidenced by a score of >5 on PHQ-9 and/ or GAD-7, but without endorsement of suicidal ideation","['At' 'least' 'mild' 'depression' 'and/' 'or' 'anxiety' 'as' 'evidenced'
 'by' 'a' 'score' 'of' '>' '5' 'on' 'PHQ-9' 'and/' 'or' 'GAD-7' ',' 'but'
 'without' 'endorsement' 'of' 'suicidal' 'ideation']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 2. 2.]"
NCT02061553,8:25:chronic_disease,active suicidal ideation,['active' 'suicidal' 'ideation'],[0. 2. 2.]
NCT02538198,",,,248:260:treatment","must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide","['must' 'either' 'commit' 'to' 'continued' 'abstinence' 'from'
 'heterosexual' 'intercourse' 'or' 'begin' 'TWO' 'acceptable' 'methods'
 'of' 'birth' 'control' ',' 'one' 'highly' 'effective' 'method' 'and'
 'one' 'additional' 'effective' 'method' 'AT' 'THE' 'SAME' 'TIME' ',' 'at'
 'least' '28' 'days' 'before' 'she' 'starts' 'taking' 'lenalidomide']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02538198,",,,,,159:171:treatment,",must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days and again within24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days as required by Revlimid REMS®),"['must' 'have' 'a' 'negative' 'serum' 'or' 'urine' 'pregnancy' 'test'
 'with' 'a' 'sensitivity' 'of' 'at' 'least' '50' 'mIU/mL' 'within' '10'
 '-' '14' 'days' 'and' 'again' 'within24' 'hours' 'prior' 'to'
 'prescribing' 'lenalidomide' 'for' 'Cycle' '1' '(' 'prescriptions' 'must'
 'be' 'filled' 'within' '7' 'days' 'as' 'required' 'by' 'Revlimid' 'REMS®'
 ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02538198,71:83:treatment,no dosing or adverse event data are currently available on the use of lenalidomide in patients,"['no' 'dosing' 'or' 'adverse' 'event' 'data' 'are' 'currently' 'available'
 'on' 'the' 'use' 'of' 'lenalidomide' 'in' 'patients']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT02538198,"107:119:treatment,","there is a potential risk for adverse events to nursing infants secondary to treatment of the mother with lenalidomide, lactating females must agree not to breast feed while taking lenalidomide","['there' 'is' 'a' 'potential' 'risk' 'for' 'adverse' 'events' 'to'
 'nursing' 'infants' 'secondary' 'to' 'treatment' 'of' 'the' 'mother'
 'with' 'lenalidomide' ',' 'lactating' 'females' 'must' 'agree' 'not' 'to'
 'breast' 'feed' 'while' 'taking' 'lenalidomide']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02446457,"17:29:treatment,",enrolled in the lenalidomide cohort must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategy (REMS) program,"['enrolled' 'in' 'the' 'lenalidomide' 'cohort' 'must' 'adhere' 'to' 'the'
 'scheduled' 'pregnancy' 'testing' 'as' 'required' 'in' 'the' 'Revlimid'
 'Risk' 'Evaluation' 'and' 'Mitigation' 'Strategy' '(' 'REMS' ')'
 'program']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02446457,17:29:treatment,enrolled in the lenalidomide containing cohort (cohort 2) must be registered into the mandatory Revlimid REMS program,"['enrolled' 'in' 'the' 'lenalidomide' 'containing' 'cohort' '(' 'cohort'
 '2' ')' 'must' 'be' 'registered' 'into' 'the' 'mandatory' 'Revlimid'
 'REMS' 'program']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02389517,"28:40:treatment,,",Patients must be receiving lenalidomide 10 mg or 15 mg and be able to tolerate dose escalation to 25 mg daily,"['Patients' 'must' 'be' 'receiving' 'lenalidomide' '10' 'mg' 'or' '15'
 'mg' 'and' 'be' 'able' 'to' 'tolerate' 'dose' 'escalation' 'to' '25' 'mg'
 'daily']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02389517,"29:41:treatment,,",Patients must have received lenalidomide maintenance for 3 months (+1 month window for a maximum of 4 months lenalidomide prior to enrollment),"['Patients' 'must' 'have' 'received' 'lenalidomide' 'maintenance' 'for'
 '3' 'months' '(' '+1' 'month' 'window' 'for' 'a' 'maximum' 'of' '4'
 'months' 'lenalidomide' 'prior' 'to' 'enrollment' ')']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02334865,",62:74:treatment",lactating females must agree not to breast feed while taking lenalidomide,"['lactating' 'females' 'must' 'agree' 'not' 'to' 'breast' 'feed' 'while'
 'taking' 'lenalidomide']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02253316,",,,267:279:treatment","This is defined as either committing to continued abstinence from heterosexual intercourse or beginning TWO acceptable methods of contraception (one highly effective method and one additional effective method AT THE SAME TIME) at least 28 days prior to the start of lenalidomide, for the duration of study participation, and for 28 days following the last dose of lenalidomide","['This' 'is' 'defined' 'as' 'either' 'committing' 'to' 'continued'
 'abstinence' 'from' 'heterosexual' 'intercourse' 'or' 'beginning' 'TWO'
 'acceptable' 'methods' 'of' 'contraception' '(' 'one' 'highly'
 'effective' 'method' 'and' 'one' 'additional' 'effective' 'method' 'AT'
 'THE' 'SAME' 'TIME' ')' 'at' 'least' '28' 'days' 'prior' 'to' 'the'
 'start' 'of' 'lenalidomide' ',' 'for' 'the' 'duration' 'of' 'study'
 'participation' ',' 'and' 'for' '28' 'days' 'following' 'the' 'last'
 'dose' 'of' 'lenalidomide']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01919619,",62:74:treatment",lactating females must agree not to breast-feed while taking lenalidomide,"['lactating' 'females' 'must' 'agree' 'not' 'to' 'breast-feed' 'while'
 'taking' 'lenalidomide']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01754857,",43:55:treatment",at least 28 days before she starts taking lenalidomide,['at' 'least' '28' 'days' 'before' 'she' 'starts' 'taking' 'lenalidomide'],[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01754857,",62:74:treatment",lactating females must agree not to breast-feed while taking lenalidomide,"['lactating' 'females' 'must' 'agree' 'not' 'to' 'breast-feed' 'while'
 'taking' 'lenalidomide']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01619761,",,,,283:295:treatment","Woman with child bearing potential must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks before she starts taking lenalidomide","['Woman' 'with' 'child' 'bearing' 'potential' 'must' 'either' 'commit'
 'to' 'continued' 'abstinence' 'from' 'heterosexual' 'intercourse' 'or'
 'begin' 'TWO' 'acceptable' 'methods' 'of' 'birth' 'control' ',' 'one'
 'highly' 'effective' 'method' 'and' 'one' 'additional' 'effective'
 'method' 'AT' 'THE' 'SAME' 'TIME' ',' 'at' 'least' '4' 'weeks' 'before'
 'she' 'starts' 'taking' 'lenalidomide']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT01433965,",,,,,,201:213:treatment,",Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days and again within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days as required by RevAssist),"['Females' 'of' 'childbearing' 'potential' '(' 'FCBP' ')' 'must' 'have'
 'a' 'negative' 'serum' 'or' 'urine' 'pregnancy' 'test' 'with' 'a'
 'sensitivity' 'of' 'at' 'least' '50' 'mIU/mL' 'within' '10' '-' '14'
 'days' 'and' 'again' 'within' '24' 'hours' 'prior' 'to' 'prescribing'
 'lenalidomide' 'for' 'Cycle' '1' '(' 'prescriptions' 'must' 'be' 'filled'
 'within' '7' 'days' 'as' 'required' 'by' 'RevAssist' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01433965,",62:74:treatment",Lactating females must agree not to breast feed while taking lenalidomide,"['Lactating' 'females' 'must' 'agree' 'not' 'to' 'breast' 'feed' 'while'
 'taking' 'lenalidomide']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01433965,25:37:treatment,Not able to swallow the lenalidomide capsule as a whole,"['Not' 'able' 'to' 'swallow' 'the' 'lenalidomide' 'capsule' 'as' 'a'
 'whole']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT01433965,",,,248:260:treatment","must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide","['must' 'either' 'commit' 'to' 'continued' 'abstinence' 'from'
 'heterosexual' 'intercourse' 'or' 'begin' 'TWO' 'acceptable' 'methods'
 'of' 'birth' 'control' ',' 'one' 'highly' 'effective' 'method' 'and'
 'one' 'additional' 'effective' 'method' 'AT' 'THE' 'SAME' 'TIME' ',' 'at'
 'least' '28' 'days' 'before' 'she' 'starts' 'taking' 'lenalidomide']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT01054196,",,,,,,201:213:treatment,",Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days and again within 24 hours prior to prescribing lenalidomide (prescriptions must be filled within 7 days),"['Females' 'of' 'childbearing' 'potential' '(' 'FCBP' ')' 'must' 'have'
 'a' 'negative' 'serum' 'or' 'urine' 'pregnancy' 'test' 'with' 'a'
 'sensitivity' 'of' 'at' 'least' '50' 'mIU/mL' 'within' '10' '-' '14'
 'days' 'and' 'again' 'within' '24' 'hours' 'prior' 'to' 'prescribing'
 'lenalidomide' '(' 'prescriptions' 'must' 'be' 'filled' 'within' '7'
 'days' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01054196,",43:55:treatment",at least 28 days before she starts taking lenalidomide,['at' 'least' '28' 'days' 'before' 'she' 'starts' 'taking' 'lenalidomide'],[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03158519,1:14:chronic_disease,schizophrenia,['schizophrenia'],[2.]
NCT03149783,1:14:chronic_disease,schizophrenia,['schizophrenia'],[2.]
NCT03105700,1:14:chronic_disease,schizophrenia,['schizophrenia'],[2.]
NCT03053908,1:14:chronic_disease,schizophrenia,['schizophrenia'],[2.]
NCT03018704,1:14:chronic_disease,schizophrenia,['schizophrenia'],[2.]
NCT02945293,14:27:chronic_disease,Diagnosis of schizophrenia,['Diagnosis' 'of' 'schizophrenia'],[0. 0. 2.]
NCT02922569,1:14:chronic_disease,schizophrenia,['schizophrenia'],[2.]
NCT02901041,1:14:chronic_disease,schizophrenia,['schizophrenia'],[2.]
NCT02826577,1:14:chronic_disease,schizophrenia,['schizophrenia'],[2.]
NCT02724930,1:14:chronic_disease,schizophrenia,['schizophrenia'],[2.]
NCT02481245,1:14:chronic_disease,schizophrenia,['schizophrenia'],[2.]
NCT02473250,10:23:chronic_disease,lifetime schizophrenia,['lifetime' 'schizophrenia'],[0. 2.]
NCT02404155,63:76:chronic_disease,treatment would likely alter the presentation or treatment of schizophrenia or significantly increase the risks associated with the proposed protocol,"['treatment' 'would' 'likely' 'alter' 'the' 'presentation' 'or'
 'treatment' 'of' 'schizophrenia' 'or' 'significantly' 'increase' 'the'
 'risks' 'associated' 'with' 'the' 'proposed' 'protocol']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02361554,28:41:chronic_disease,"Subject has a diagnosis of schizophrenia as determined by a review of medical records, discussion with referring psychiatrist as well as the Structured Clinical Interview for DSM-IV (SCID-IV)","['Subject' 'has' 'a' 'diagnosis' 'of' 'schizophrenia' 'as' 'determined'
 'by' 'a' 'review' 'of' 'medical' 'records' ',' 'discussion' 'with'
 'referring' 'psychiatrist' 'as' 'well' 'as' 'the' 'Structured' 'Clinical'
 'Interview' 'for' 'DSM-IV' '(' 'SCID-IV' ')']","[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02261519,15:28:chronic_disease,The subject's schizophrenia condition is clinically stable with residual symptoms,"['The' 'subject' ""'s"" 'schizophrenia' 'condition' 'is' 'clinically'
 'stable' 'with' 'residual' 'symptoms']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02118610,21:34:chronic_disease,DSM-IV diagnosis of schizophrenia,['DSM-IV' 'diagnosis' 'of' 'schizophrenia'],[0. 0. 0. 2.]
NCT01964404,14:27:chronic_disease,Diagnosis of schizophrenia,['Diagnosis' 'of' 'schizophrenia'],[0. 0. 2.]
NCT01850355,22:35:chronic_disease,Current diagnosis of schizophrenia,['Current' 'diagnosis' 'of' 'schizophrenia'],[0. 0. 0. 2.]
NCT02882802,",43:47:chronic_disease",participants with sub-syndromal levels of PTSD will also be allowed to participate,"['participants' 'with' 'sub-syndromal' 'levels' 'of' 'PTSD' 'will' 'also'
 'be' 'allowed' 'to' 'participate']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02856412,"19:23:chronic_disease,",Meet criteria for PTSD of at least 3 months duration,['Meet' 'criteria' 'for' 'PTSD' 'of' 'at' 'least' '3' 'months' 'duration'],[0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02856412,"23:27:chronic_disease,,",have some symptoms of PTSD with a current CAPS score of 23 or higher,"['have' 'some' 'symptoms' 'of' 'PTSD' 'with' 'a' 'current' 'CAPS' 'score'
 'of' '23' 'or' 'higher']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02774642,47:51:chronic_disease,"Veterans who are engaged in treatment for non-PTSD symptoms (e.g., 12-step programs) will be eligible","['Veterans' 'who' 'are' 'engaged' 'in' 'treatment' 'for' 'non-PTSD'
 'symptoms' '(' 'e.g.' ',' '12-step' 'programs' ')' 'will' 'be' 'eligible']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02727972,31:35:chronic_disease,Clinical diagnosis of current PTSD as per DSM-IV,['Clinical' 'diagnosis' 'of' 'current' 'PTSD' 'as' 'per' 'DSM-IV'],[0. 0. 0. 0. 2. 0. 0. 0.]
NCT02655692,14:18:chronic_disease,diagnosis of PTSD,['diagnosis' 'of' 'PTSD'],[0. 0. 2.]
NCT02553161,1:5:chronic_disease,PTSD,['PTSD'],[2.]
NCT02500602,52:56:chronic_disease,"Meet DSM-5 criteria for current (i.e., last month) PTSD","['Meet' 'DSM-5' 'criteria' 'for' 'current' '(' 'i.e.' ',' 'last' 'month'
 ')' 'PTSD']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02479906,"33:37:chronic_disease,,",Subjects with at least moderate PTSD with a CAPS-5 score ≥ 25 at both Screening and Baseline visits,"['Subjects' 'with' 'at' 'least' 'moderate' 'PTSD' 'with' 'a' 'CAPS-5'
 'score' '≥' '25' 'at' 'both' 'Screening' 'and' 'Baseline' 'visits']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02397889,",81:85:chronic_disease",Participants must fulfill DSM-5 criteria for current civilian or combat-related PTSD,"['Participants' 'must' 'fulfill' 'DSM-5' 'criteria' 'for' 'current'
 'civilian' 'or' 'combat-related' 'PTSD']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02391402,14:18:chronic_disease,Diagnosis of PTSD based on the Clinician Administered PTSD Scale,"['Diagnosis' 'of' 'PTSD' 'based' 'on' 'the' 'Clinician' 'Administered'
 'PTSD' 'Scale']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02377089,"27:31:chronic_disease,,",with significant residual PTSD symptoms as evidenced by a CAPS score >50,"['with' 'significant' 'residual' 'PTSD' 'symptoms' 'as' 'evidenced' 'by'
 'a' 'CAPS' 'score' '>' '50']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02356861,36:40:chronic_disease,Must meet screening criteria for a PTSD diagnosis,['Must' 'meet' 'screening' 'criteria' 'for' 'a' 'PTSD' 'diagnosis'],[0. 0. 0. 0. 0. 0. 2. 0.]
NCT02308202,29:33:chronic_disease,Meet DSM-IV TR criteria for PTSD,['Meet' 'DSM-IV' 'TR' 'criteria' 'for' 'PTSD'],[0. 0. 0. 0. 0. 2.]
NCT02308202,87:91:chronic_disease,We anticipate that participants will be on a wide range of medications prescribed for PTSD,"['We' 'anticipate' 'that' 'participants' 'will' 'be' 'on' 'a' 'wide'
 'range' 'of' 'medications' 'prescribed' 'for' 'PTSD']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT01627301,63:67:chronic_disease,Prehypertensive and Normotensive OEF/OIF/OND veterans without PTSD (controls),"['Prehypertensive' 'and' 'Normotensive' 'OEF/OIF/OND' 'veterans' 'without'
 'PTSD' '(' 'controls' ')']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 0.]
NCT01627301,138:142:chronic_disease,Prehypertensive and Normotensive Operation Enduring Freedom (OEF)/ Operation Iraqi Freedom (OIF)/ Operation New Dawn (OND) veterans with PTSD,"['Prehypertensive' 'and' 'Normotensive' 'Operation' 'Enduring' 'Freedom'
 '(' 'OEF' ')' '/' 'Operation' 'Iraqi' 'Freedom' '(' 'OIF' ')' '/'
 'Operation' 'New' 'Dawn' '(' 'OND' ')' 'veterans' 'with' 'PTSD']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 2.]"
NCT00875342,16:20:chronic_disease,Diagnosed with PTSD,['Diagnosed' 'with' 'PTSD'],[0. 0. 2.]
NCT03145181,25:41:cancer,Documented diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria,"['Documented' 'diagnosis' 'of' 'multiple' 'myeloma' 'according' 'to'
 'International' 'Myeloma' 'Working' 'Group' '(' 'IMWG' ')' 'diagnostic'
 'criteria']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03145181,12:28:cancer,Measurable multiple myeloma that is relapsed or refractory to established therapies with known clinical benefit in relapsed/refractory multiple myeloma,"['Measurable' 'multiple' 'myeloma' 'that' 'is' 'relapsed' 'or'
 'refractory' 'to' 'established' 'therapies' 'with' 'known' 'clinical'
 'benefit' 'in' 'relapsed/refractory' 'multiple' 'myeloma']",[0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03145181,53:69:cancer,exhibits clinical signs of meningeal involvement of multiple myeloma,"['exhibits' 'clinical' 'signs' 'of' 'meningeal' 'involvement' 'of'
 'multiple' 'myeloma']",[0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT03143985,44:60:cancer,Patient has been previously diagnosed with multiple myeloma based on standard criteria,"['Patient' 'has' 'been' 'previously' 'diagnosed' 'with' 'multiple'
 'myeloma' 'based' 'on' 'standard' 'criteria']",[0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0.]
NCT02519452,70:86:cancer,Participant is exhibiting clinical signs of meningeal involvement of multiple myeloma,"['Participant' 'is' 'exhibiting' 'clinical' 'signs' 'of' 'meningeal'
 'involvement' 'of' 'multiple' 'myeloma']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02516696,38:54:cancer,Subject has histologically confirmed multiple myeloma that has never before been treated,"['Subject' 'has' 'histologically' 'confirmed' 'multiple' 'myeloma' 'that'
 'has' 'never' 'before' 'been' 'treated']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0.]
NCT02516696,41:57:cancer,Subject has previously been treated for multiple myeloma,['Subject' 'has' 'previously' 'been' 'treated' 'for' 'multiple' 'myeloma'],[0. 0. 0. 0. 0. 0. 3. 3.]
NCT02278315,43:59:cancer,Histologically or cytologically confirmed multiple myeloma,['Histologically' 'or' 'cytologically' 'confirmed' 'multiple' 'myeloma'],[0. 0. 0. 0. 3. 3.]
NCT02253316,51:67:cancer,Histologically confirmed diagnosis of symptomatic multiple myeloma,"['Histologically' 'confirmed' 'diagnosis' 'of' 'symptomatic' 'multiple'
 'myeloma']",[0. 0. 0. 0. 0. 3. 3.]
NCT02253316,1:17:cancer,multiple myeloma,['multiple' 'myeloma'],[3. 3.]
NCT02101944,",,,,,199:215:cancer",Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%) is required for eligibility; those patients with lower performance status based solely on bone pain secondary to multiple myeloma,"['Eastern' 'Cooperative' 'Oncology' 'Group' '(' 'ECOG' ')' 'performance'
 'status' '=' '<' '2' '(' 'Karnofsky' '>' '=' '60' '%' ')' 'is' 'required'
 'for' 'eligibility' ';' 'those' 'patients' 'with' 'lower' 'performance'
 'status' 'based' 'solely' 'on' 'bone' 'pain' 'secondary' 'to' 'multiple'
 'myeloma']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]"
NCT02046395,12:28:cancer,History of multiple myeloma,['History' 'of' 'multiple' 'myeloma'],[0. 0. 3. 3.]
NCT02004275,20:36:cancer,"Primary refractory multiple myeloma, where primary refractory multiple myeloma is defined as disease that is nonresponsive","['Primary' 'refractory' 'multiple' 'myeloma' ',' 'where' 'primary'
 'refractory' 'multiple' 'myeloma' 'is' 'defined' 'as' 'disease' 'that'
 'is' 'nonresponsive']",[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01464034,54:70:cancer,Cytopathologically or histologically confirmed dx of multiple myeloma,"['Cytopathologically' 'or' 'histologically' 'confirmed' 'dx' 'of'
 'multiple' 'myeloma']",[0. 0. 0. 0. 0. 0. 3. 3.]
NCT01453088,22:38:cancer,Diagnosis other than multiple myeloma,['Diagnosis' 'other' 'than' 'multiple' 'myeloma'],[0. 0. 0. 3. 3.]
NCT01415882,"23:39:cancer,",Measurable disease of multiple myeloma as defined by at least ONE of the following,"['Measurable' 'disease' 'of' 'multiple' 'myeloma' 'as' 'defined' 'by' 'at'
 'least' 'ONE' 'of' 'the' 'following']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01241708,22:38:cancer,Diagnosis other than multiple myeloma,['Diagnosis' 'other' 'than' 'multiple' 'myeloma'],[0. 0. 0. 3. 3.]
NCT02516969,13:31:cancer,Evidence of distant metastases on any staging or imaging modality,"['Evidence' 'of' 'distant' 'metastases' 'on' 'any' 'staging' 'or'
 'imaging' 'modality']",[0. 0. 3. 3. 0. 0. 0. 0. 0. 0.]
NCT02516969,16:34:cancer,No evidence of distant metastases,['No' 'evidence' 'of' 'distant' 'metastases'],[0. 0. 0. 3. 3.]
NCT02468024,16:34:cancer,No evidence of distant metastases,['No' 'evidence' 'of' 'distant' 'metastases'],[0. 0. 0. 3. 3.]
NCT02451982,4:22:cancer,No distant metastases,['No' 'distant' 'metastases'],[0. 3. 3.]
NCT02177292,38:56:cancer,Clinical or pathological evidence of distant metastases (M1),"['Clinical' 'or' 'pathological' 'evidence' 'of' 'distant' 'metastases' '('
 'M1' ')']",[0. 0. 0. 0. 0. 3. 3. 0. 0. 0.]
NCT02163317,13:31:cancer,Evidence of distant metastases,['Evidence' 'of' 'distant' 'metastases'],[0. 0. 3. 3.]
NCT02158234,13:31:cancer,Evidence of distant metastases,['Evidence' 'of' 'distant' 'metastases'],[0. 0. 3. 3.]
NCT02138214,16:34:cancer,No evidence of distant metastases,['No' 'evidence' 'of' 'distant' 'metastases'],[0. 0. 0. 3. 3.]
NCT02041936,"13:31:cancer,",Evidence of distant metastases of stage IV,['Evidence' 'of' 'distant' 'metastases' 'of' 'stage' 'IV'],[0. 0. 3. 3. 0. 0. 0.]
NCT02040610,13:31:cancer,Evidence of distant metastases,['Evidence' 'of' 'distant' 'metastases'],[0. 0. 3. 3.]
NCT02031250,24:42:cancer,Documented evidence of distant metastases,['Documented' 'evidence' 'of' 'distant' 'metastases'],[0. 0. 0. 3. 3.]
NCT01993810,52:70:cancer,"Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup","['Appropriate' 'stage' 'for' 'protocol' 'entry' ',' 'including' 'no'
 'distant' 'metastases' ',' 'based' 'upon' 'the' 'following' 'minimum'
 'diagnostic' 'workup']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01950351,13:31:cancer,Evidence of distant metastases,['Evidence' 'of' 'distant' 'metastases'],[0. 0. 3. 3.]
NCT01436968,36:54:cancer,Regional lymph node involvement or distant metastases,['Regional' 'lymph' 'node' 'involvement' 'or' 'distant' 'metastases'],[0. 0. 0. 0. 0. 3. 3.]
NCT01220583,26:44:cancer,patients must be free of distant metastases based upon the following minimum diagnostic workup,"['patients' 'must' 'be' 'free' 'of' 'distant' 'metastases' 'based' 'upon'
 'the' 'following' 'minimum' 'diagnostic' 'workup']",[0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT00924027,1:19:cancer,distant metastases,['distant' 'metastases'],[3. 3.]
NCT00909909,4:22:cancer,No distant metastases,['No' 'distant' 'metastases'],[0. 3. 3.]
NCT03060473,"13:26:chronic_disease,,",Significant renal disease defined as serum creatinine known to be >2.0 mg/dl,"['Significant' 'renal' 'disease' 'defined' 'as' 'serum' 'creatinine'
 'known' 'to' 'be' '>' '2.0' 'mg/dl']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03043742,11:24:chronic_disease,End stage renal disease,['End' 'stage' 'renal' 'disease'],[0. 0. 2. 2.]
NCT03016351,"13:26:chronic_disease,,",Presence of renal disease with a creatinine > 1.5mg/dL,['Presence' 'of' 'renal' 'disease' 'with' 'a' 'creatinine' '>' '1.5mg/dL'],[0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02966665,"13:26:chronic_disease,,",Significant renal disease (Glomerular Filtration Rate < 50 mL/min/1.73m2),"['Significant' 'renal' 'disease' '(' 'Glomerular' 'Filtration' 'Rate' '<'
 '50' 'mL/min/1.73m2' ')']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02926248,15:28:chronic_disease,Patients with renal disease,['Patients' 'with' 'renal' 'disease'],[0. 0. 2. 2.]
NCT02852239,"8:21:chronic_disease,",Stable renal disease without evidence of renal progression in the past 28 days prior to dosing,"['Stable' 'renal' 'disease' 'without' 'evidence' 'of' 'renal'
 'progression' 'in' 'the' 'past' '28' 'days' 'prior' 'to' 'dosing']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02833207,26:39:chronic_disease,Self-reported history of renal disease,['Self-reported' 'history' 'of' 'renal' 'disease'],[0. 0. 0. 2. 2.]
NCT02819440,",,89:102:chronic_disease",Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2 by the modified diet in renal disease (MDRD) equation,"['Estimated' 'glomerular' 'filtration' 'rate' '(' 'eGFR' ')' '<' '60'
 'ml/min/1.73' 'm2' 'by' 'the' 'modified' 'diet' 'in' 'renal' 'disease'
 '(' 'MDRD' ')' 'equation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02366871,"13:26:chronic_disease,,",Significant renal disease as defined by creatinine clearance less than 30 mL/min,"['Significant' 'renal' 'disease' 'as' 'defined' 'by' 'creatinine'
 'clearance' 'less' 'than' '30' 'mL/min']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02245841,1:14:chronic_disease,renal disease,['renal' 'disease'],[2. 2.]
NCT02207439,31:44:chronic_disease,Subjects with moderate-severe renal disease,['Subjects' 'with' 'moderate-severe' 'renal' 'disease'],[0. 0. 0. 2. 2.]
NCT02202369,"15:28:chronic_disease,,",Patients with renal disease (documented glomerular filtration rate < 60mL/min/1.73m2),"['Patients' 'with' 'renal' 'disease' '(' 'documented' 'glomerular'
 'filtration' 'rate' '<' '60mL/min/1.73m2' ')']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02139436,1:14:chronic_disease,renal disease,['renal' 'disease'],[2. 2.]
NCT01940757,"24:37:chronic_disease,,,","Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the upper reference limit, or more than trace protein or blood on urine dipstick testing)","['Laboratory' 'evidence' 'of' 'renal' 'disease' '(' 'serum' 'creatinine'
 'greater' 'than' '1.25-times' 'the' 'upper' 'reference' 'limit' ',' 'or'
 'more' 'than' 'trace' 'protein' 'or' 'blood' 'on' 'urine' 'dipstick'
 'testing' ')']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01568177,5:18:chronic_disease,Any renal disease,['Any' 'renal' 'disease'],[0. 2. 2.]
NCT00875342,42:55:chronic_disease,"Significant health impairment, including renal disease","['Significant' 'health' 'impairment' ',' 'including' 'renal' 'disease']",[0. 0. 0. 0. 0. 2. 2.]
NCT03137498,14:22:treatment,Currently on dialysis,['Currently' 'on' 'dialysis'],[0. 0. 1.]
NCT03089281,21:29:treatment,currently requiring dialysis,['currently' 'requiring' 'dialysis'],[0. 0. 1.]
NCT03088033,"21:29:treatment,,",Currently requiring dialysis; or estimated-GFR <25ml/min/1.73 m2 by CKD-Epi equation,"['Currently' 'requiring' 'dialysis' ';' 'or' 'estimated-GFR' '<'
 '25ml/min/1.73' 'm2' 'by' 'CKD-Epi' 'equation']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03078491,4:12:treatment,on dialysis (since impact of fluid shift on sensor lag not clearly understood),"['on' 'dialysis' '(' 'since' 'impact' 'of' 'fluid' 'shift' 'on' 'sensor'
 'lag' 'not' 'clearly' 'understood' ')']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03060473,4:12:treatment,on dialysis,['on' 'dialysis'],[0. 1.]
NCT02764359,"13:21:treatment,,",Patients on dialysis or with unstable renal function (a change of >0.5 mg/dL in SCr concentration in patients with a SCr of <2 mg/dL or a 20% change in SCr in patients with a SCr of ≥2 mg/dL),"['Patients' 'on' 'dialysis' 'or' 'with' 'unstable' 'renal' 'function' '('
 'a' 'change' 'of' '>' '0.5' 'mg/dL' 'in' 'SCr' 'concentration' 'in'
 'patients' 'with' 'a' 'SCr' 'of' '<' '2' 'mg/dL' 'or' 'a' '20' '%'
 'change' 'in' 'SCr' 'in' 'patients' 'with' 'a' 'SCr' 'of' '≥2' 'mg/dL'
 ')']","[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02593526,"21:29:treatment,",Has been undergoing dialysis for more than 12 weeks,['Has' 'been' 'undergoing' 'dialysis' 'for' 'more' 'than' '12' 'weeks'],[0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02578901,13:21:treatment,Subjects on dialysis,['Subjects' 'on' 'dialysis'],[0. 0. 1.]
NCT02554903,12:20:treatment,undergoing dialysis,['undergoing' 'dialysis'],[0. 1.]
NCT02489539,20:28:treatment,patient undergoing dialysis,['patient' 'undergoing' 'dialysis'],[0. 0. 1.]
NCT02208362,31:39:treatment,Research participant requires dialysis,['Research' 'participant' 'requires' 'dialysis'],[0. 0. 0. 1.]
NCT02128802,21:29:treatment,Non-compliance with dialysis regimen,['Non-compliance' 'with' 'dialysis' 'regimen'],[0. 0. 1. 0.]
NCT02124902,4:12:treatment,On dialysis,['On' 'dialysis'],[0. 1.]
NCT01895777,17:25:treatment,requirement for dialysis,['requirement' 'for' 'dialysis'],[0. 0. 1.]
NCT01758042,"27:35:treatment,,",Participants should be on dialysis or have an estimated or measured CrCl < 35 ml/min,"['Participants' 'should' 'be' 'on' 'dialysis' 'or' 'have' 'an' 'estimated'
 'or' 'measured' 'CrCl' '<' '35' 'ml/min']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03028012,1:18:chronic_disease,Diabetes mellitus,['Diabetes' 'mellitus'],[2. 2.]
NCT03006770,"1:18:chronic_disease,,",Diabetes mellitus with HbA1c >10%,['Diabetes' 'mellitus' 'with' 'HbA1c' '>' '10' '%'],[2. 2. 0. 0. 0. 0. 0.]
NCT02957149,1:18:chronic_disease,Diabetes mellitus diagnosis,['Diabetes' 'mellitus' 'diagnosis'],[2. 2. 0.]
NCT02950337,1:18:chronic_disease,Diabetes mellitus with end organ damage,['Diabetes' 'mellitus' 'with' 'end' 'organ' 'damage'],[2. 2. 0. 0. 0. 0.]
NCT02903511,1:18:chronic_disease,Diabetes mellitus,['Diabetes' 'mellitus'],[2. 2.]
NCT02740595,1:18:chronic_disease,Diabetes mellitus,['Diabetes' 'mellitus'],[2. 2.]
NCT02734888,1:18:chronic_disease,Diabetes mellitus,['Diabetes' 'mellitus'],[2. 2.]
NCT02563678,1:18:chronic_disease,Diabetes mellitus,['Diabetes' 'mellitus'],[2. 2.]
NCT02437110,1:18:chronic_disease,Diabetes mellitus,['Diabetes' 'mellitus'],[2. 2.]
NCT02312596,"1:18:chronic_disease,,",Diabetes mellitus (type I or II) that is adequately controlled,"['Diabetes' 'mellitus' '(' 'type' 'I' 'or' 'II' ')' 'that' 'is'
 'adequately' 'controlled']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02217345,1:18:chronic_disease,Diabetes mellitus,['Diabetes' 'mellitus'],[2. 2.]
NCT01996449,1:18:chronic_disease,Diabetes mellitus,['Diabetes' 'mellitus'],[2. 2.]
NCT01950234,"1:18:chronic_disease,,,,","Diabetes mellitus, defined as pre-existing diagnosis, fasting blood glucose > 125 mg/dl, or glycosylated hemoglobin >/= 6.5%","['Diabetes' 'mellitus' ',' 'defined' 'as' 'pre-existing' 'diagnosis' ','
 'fasting' 'blood' 'glucose' '>' '125' 'mg/dl' ',' 'or' 'glycosylated'
 'hemoglobin' '>' '/=' '6.5' '%']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01547429,1:18:chronic_disease,Diabetes mellitus,['Diabetes' 'mellitus'],[2. 2.]
NCT00977977,1:18:chronic_disease,Diabetes mellitus,['Diabetes' 'mellitus'],[2. 2.]
NCT02731326,77:80:treatment,"Ability to successfully use the AliveCor™ Heart Monitor, capture a baseline ECG, and transmit on the day of enrollment","['Ability' 'to' 'successfully' 'use' 'the' 'AliveCor™' 'Heart' 'Monitor'
 ',' 'capture' 'a' 'baseline' 'ECG' ',' 'and' 'transmit' 'on' 'the' 'day'
 'of' 'enrollment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02585973,27:30:treatment,"Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant","['Prior' 'to' 'study' 'entry' ',' 'any' 'ECG' 'abnormality' 'at'
 'Screening' 'has' 'to' 'be' 'documented' 'by' 'the' 'investigator' 'as'
 'not' 'medically' 'relevant']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02585973,",,45:48:treatment",≤470 msec for females required on screening ECG,['≤470' 'msec' 'for' 'females' 'required' 'on' 'screening' 'ECG'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT02555189,",,63:66:treatment,","On screening, inability to determine the QTcF interval on the ECG (i.e.: unreadable or not interpretable) or QTcF >450 msec (using Fridericia's correction). All as determined by screening ECG (mean of triplicate ECGs","['On' 'screening' ',' 'inability' 'to' 'determine' 'the' 'QTcF' 'interval'
 'on' 'the' 'ECG' '(' 'i.e' '.' ':' 'unreadable' 'or' 'not'
 'interpretable' ')' 'or' 'QTcF' '>' '450' 'msec' '(' 'using' 'Fridericia'
 ""'s"" 'correction' ')' '.' 'All' 'as' 'determined' 'by' 'screening' 'ECG'
 '(' 'mean' 'of' 'triplicate' 'ECGs']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02353728,41:44:treatment,Inability to monitor the QT interval on ECG,['Inability' 'to' 'monitor' 'the' 'QT' 'interval' 'on' 'ECG'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT02278367,"18:21:treatment,,,",Have a screening ECG with QTc > 450 msec if male,['Have' 'a' 'screening' 'ECG' 'with' 'QTc' '>' '450' 'msec' 'if' 'male'],[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02239913,35:38:treatment,"Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians deem clinically significant","['Abnormal' 'screening' 'outcome' '(' 'e.g.' ',' 'ECG' ',' 'blood'
 'chemistry' 'result' ')' 'that' 'study' 'physicians' 'deem' 'clinically'
 'significant']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02129348,70:73:treatment,"unstable cardiac disease based on history, physical examination, and ECG","['unstable' 'cardiac' 'disease' 'based' 'on' 'history' ',' 'physical'
 'examination' ',' 'and' 'ECG']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01943851,24:27:treatment,Clinically significant ECG assessments should be reviewed by the site cardiologist prior to study entry,"['Clinically' 'significant' 'ECG' 'assessments' 'should' 'be' 'reviewed'
 'by' 'the' 'site' 'cardiologist' 'prior' 'to' 'study' 'entry']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01943851,1:4:treatment,ECG findings or assessments,['ECG' 'findings' 'or' 'assessments'],[1. 0. 0. 0.]
NCT01877382,",,42:45:treatment",> 470 ms for females based on triplicate ECG,['>' '470' 'ms' 'for' 'females' 'based' 'on' 'triplicate' 'ECG'],[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01817751,",27:30:treatment",baseline QTc on screening ECG meets exclusion criteria on screening assessment,"['baseline' 'QTc' 'on' 'screening' 'ECG' 'meets' 'exclusion' 'criteria'
 'on' 'screening' 'assessment']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01366612,27:30:treatment,"Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant","['Prior' 'to' 'study' 'entry' ',' 'any' 'ECG' 'abnormality' 'at'
 'screening' 'has' 'to' 'be' 'documented' 'by' 'the' 'investigator' 'as'
 'not' 'medically' 'relevant']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00713492,22:25:treatment,"Abnormal findings on ECG, unless cleared for participation by cardiologist or Licensed Independent Practitioner (LIP)","['Abnormal' 'findings' 'on' 'ECG' ',' 'unless' 'cleared' 'for'
 'participation' 'by' 'cardiologist' 'or' 'Licensed' 'Independent'
 'Practitioner' '(' 'LIP' ')']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03157713,"6:13:chronic_disease,,,,","With obesity, based on BMI of 30 to 40 kg/m2 during a prior visit in the past 6 months","['With' 'obesity' ',' 'based' 'on' 'BMI' 'of' '30' 'to' '40' 'kg/m2'
 'during' 'a' 'prior' 'visit' 'in' 'the' 'past' '6' 'months']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03082157,"24:31:chronic_disease,","Participant in another obesity, eating or physical activity program or study -Psychiatric hospitalization in the past 12 months","['Participant' 'in' 'another' 'obesity' ',' 'eating' 'or' 'physical'
 'activity' 'program' 'or' 'study' '-Psychiatric' 'hospitalization' 'in'
 'the' 'past' '12' 'months']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03045341,",,,29:36:chronic_disease",BMI 27-30 with a controlled obesity-related co-morbidity,['BMI' '27-30' 'with' 'a' 'controlled' 'obesity-related' 'co-morbidity'],[0. 0. 0. 0. 0. 2. 0.]
NCT03013543,226:233:chronic_disease,"Bi-allelic, homozygous or compound heterozygous (a different gene mutation on each allele) genetic status for either the POMC, PCSK1, or LEPR genes, with the loss-of-function (LOF) variant for each allele conferring a severe obesity phenotype","['Bi-allelic' ',' 'homozygous' 'or' 'compound' 'heterozygous' '(' 'a'
 'different' 'gene' 'mutation' 'on' 'each' 'allele' ')' 'genetic' 'status'
 'for' 'either' 'the' 'POMC' ',' 'PCSK1' ',' 'or' 'LEPR' 'genes' ','
 'with' 'the' 'loss-of-function' '(' 'LOF' ')' 'variant' 'for' 'each'
 'allele' 'conferring' 'a' 'severe' 'obesity' 'phenotype']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]"
NCT02881515,"1:8:chronic_disease,,",obesity (BMI > 30 kg/m2),['obesity' '(' 'BMI' '>' '30' 'kg/m2' ')'],[2. 0. 0. 0. 0. 0. 0.]
NCT02620449,"9:16:chronic_disease,,",extreme obesity (BMI ≥ 35 kg/m2),['extreme' 'obesity' '(' 'BMI' '≥' '35' 'kg/m2' ')'],[0. 2. 0. 0. 0. 0. 0. 0.]
NCT02527200,",,,,182:189:chronic_disease",BMI (body mass index) corresponding to equal or above 30 kg/m^2 for adults by international cut-off points1 and equal or above the 95th percentile for age and sex (for diagnosis of obesity),"['BMI' '(' 'body' 'mass' 'index' ')' 'corresponding' 'to' 'equal' 'or'
 'above' '30' 'kg/m^2' 'for' 'adults' 'by' 'international' 'cut-off'
 'points1' 'and' 'equal' 'or' 'above' 'the' '95th' 'percentile' 'for'
 'age' 'and' 'sex' '(' 'for' 'diagnosis' 'of' 'obesity' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]"
NCT02429830,",43:50:chronic_disease,",Laparoscopic sleeve gastrectomy (LSG) for obesity >12 months prior to proposed device implantation date,"['Laparoscopic' 'sleeve' 'gastrectomy' '(' 'LSG' ')' 'for' 'obesity' '>'
 '12' 'months' 'prior' 'to' 'proposed' 'device' 'implantation' 'date']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02270619,",,32:39:chronic_disease",BMI > 35 due to the effects of obesity on cytokine activity and risk for sleep disordered breathing,"['BMI' '>' '35' 'due' 'to' 'the' 'effects' 'of' 'obesity' 'on' 'cytokine'
 'activity' 'and' 'risk' 'for' 'sleep' 'disordered' 'breathing']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02251431,8:15:chronic_disease,Morbid obesity or body girth that prohibits the ability to undergo echocardiography or MRI scanning with high-quality image results,"['Morbid' 'obesity' 'or' 'body' 'girth' 'that' 'prohibits' 'the' 'ability'
 'to' 'undergo' 'echocardiography' 'or' 'MRI' 'scanning' 'with'
 'high-quality' 'image' 'results']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02148003,"8:15:chronic_disease,,",morbid obesity (BMI > 35kg/m2),['morbid' 'obesity' '(' 'BMI' '>' '35kg/m2' ')'],[0. 2. 0. 0. 0. 0. 0.]
NCT02008136,11:18:chronic_disease,Excessive obesity,['Excessive' 'obesity'],[0. 2.]
NCT01967849,",,,,,,,221:228:chronic_disease","Lean (not overweight or obese) will be defined as a body mass index (BMI) (kg/m2) less than the 85th percentile specific for age and gender, overweight will be defined as a BMI between the 85th and 95th percentiles, and obesity will be defined as a BMI greater than the 95th percentile","['Lean' '(' 'not' 'overweight' 'or' 'obese' ')' 'will' 'be' 'defined' 'as'
 'a' 'body' 'mass' 'index' '(' 'BMI' ')' '(' 'kg/m2' ')' 'less' 'than'
 'the' '85th' 'percentile' 'specific' 'for' 'age' 'and' 'gender' ','
 'overweight' 'will' 'be' 'defined' 'as' 'a' 'BMI' 'between' 'the' '85th'
 'and' '95th' 'percentiles' ',' 'and' 'obesity' 'will' 'be' 'defined' 'as'
 'a' 'BMI' 'greater' 'than' 'the' '95th' 'percentile']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03088709,1:12:chronic_disease,Hepatitis C,['Hepatitis' 'C'],[2. 2.]
NCT03061201,"12:23:chronic_disease,","History of Hepatitis C, unless viral assays in two samples, collected at least 6 months apart, are negative","['History' 'of' 'Hepatitis' 'C' ',' 'unless' 'viral' 'assays' 'in' 'two'
 'samples' ',' 'collected' 'at' 'least' '6' 'months' 'apart' ',' 'are'
 'negative']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03048448,1:12:chronic_disease,Hepatitis C test result,['Hepatitis' 'C' 'test' 'result'],[2. 2. 0. 0.]
NCT02983240,1:12:chronic_disease,Hepatitis C,['Hepatitis' 'C'],[2. 2.]
NCT02710396,"1:12:chronic_disease,","Hepatitis C (e.g., HCV RNA [qualitative] is detected)","['Hepatitis' 'C' '(' 'e.g.' ',' 'HCV' 'RNA' '[' 'qualitative' ']' 'is'
 'detected' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02641093,1:12:chronic_disease,Hepatitis C,['Hepatitis' 'C'],[2. 2.]
NCT02635360,1:12:chronic_disease,Hepatitis C,['Hepatitis' 'C'],[2. 2.]
NCT02508038,1:12:chronic_disease,Hepatitis C antibody (Anti-HCV),['Hepatitis' 'C' 'antibody' '(' 'Anti-HCV' ')'],[2. 2. 0. 0. 0. 0.]
NCT02374021,1:12:chronic_disease,Hepatitis C Virus,['Hepatitis' 'C' 'Virus'],[2. 2. 0.]
NCT02324582,1:12:chronic_disease,"Hepatitis C (e.g., HCV RNA [qualitative] is detected)","['Hepatitis' 'C' '(' 'e.g.' ',' 'HCV' 'RNA' '[' 'qualitative' ']' 'is'
 'detected' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02091999,"36:47:chronic_disease,,",Subjects who have been treated for Hepatitis C infection can be included if they have documented sustained virologic response of ≥ 12 weeks,"['Subjects' 'who' 'have' 'been' 'treated' 'for' 'Hepatitis' 'C'
 'infection' 'can' 'be' 'included' 'if' 'they' 'have' 'documented'
 'sustained' 'virologic' 'response' 'of' '≥' '12' 'weeks']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02072148,1:12:chronic_disease,Hepatitis C by history,['Hepatitis' 'C' 'by' 'history'],[2. 2. 0. 0.]
NCT01481974,1:12:chronic_disease,Hepatitis C positive donor liver,['Hepatitis' 'C' 'positive' 'donor' 'liver'],[2. 2. 0. 0. 0.]
NCT03035890,14:34:chronic_disease,Uncontrolled intercurrent illness,['Uncontrolled' 'intercurrent' 'illness'],[0. 2. 2.]
NCT03006302,1:21:chronic_disease,intercurrent illness,['intercurrent' 'illness'],[2. 2.]
NCT02905578,15:35:chronic_disease,"Uncontrolled, intercurrent illness","['Uncontrolled' ',' 'intercurrent' 'illness']",[0. 0. 2. 2.]
NCT02648282,54:74:chronic_disease,"Conditions, including alcohol or drug dependence, or intercurrent illness that would affect the patient's ability to comply with study visits and procedures","['Conditions' ',' 'including' 'alcohol' 'or' 'drug' 'dependence' ',' 'or'
 'intercurrent' 'illness' 'that' 'would' 'affect' 'the' 'patient' ""'s""
 'ability' 'to' 'comply' 'with' 'study' 'visits' 'and' 'procedures']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02552953,14:34:chronic_disease,Uncontrolled intercurrent illness,['Uncontrolled' 'intercurrent' 'illness'],[0. 2. 2.]
NCT02536794,35:55:chronic_disease,Patients who have an uncontrolled intercurrent illness,['Patients' 'who' 'have' 'an' 'uncontrolled' 'intercurrent' 'illness'],[0. 0. 0. 0. 0. 2. 2.]
NCT02451982,54:74:chronic_disease,"Conditions, including alcohol or drug dependence, or intercurrent illness that would affect the patient's ability to comply with study visits and procedures","['Conditions' ',' 'including' 'alcohol' 'or' 'drug' 'dependence' ',' 'or'
 'intercurrent' 'illness' 'that' 'would' 'affect' 'the' 'patient' ""'s""
 'ability' 'to' 'comply' 'with' 'study' 'visits' 'and' 'procedures']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02213289,17:37:chronic_disease,No uncontrolled intercurrent illness or infection,['No' 'uncontrolled' 'intercurrent' 'illness' 'or' 'infection'],[0. 0. 2. 2. 0. 0.]
NCT02159703,14:34:chronic_disease,Uncontrolled intercurrent illness,['Uncontrolled' 'intercurrent' 'illness'],[0. 2. 2.]
NCT01871727,9:29:chronic_disease,Serious intercurrent illness,['Serious' 'intercurrent' 'illness'],[0. 2. 2.]
NCT01515527,14:34:chronic_disease,Uncontrolled intercurrent illness,['Uncontrolled' 'intercurrent' 'illness'],[0. 2. 2.]
NCT01367444,"13:33:chronic_disease,",Significant intercurrent illness or infection during the 28 days prior to enrolment,"['Significant' 'intercurrent' 'illness' 'or' 'infection' 'during' 'the'
 '28' 'days' 'prior' 'to' 'enrolment']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01228448,14:34:chronic_disease,"Uncontrolled intercurrent illness that, in the opinion of the investigator, would limit the participant's compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'that' ',' 'in' 'the' 'opinion'
 'of' 'the' 'investigator' ',' 'would' 'limit' 'the' 'participant' ""'s""
 'compliance' 'with' 'study' 'requirements']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03171168,"11:27:treatment,",No recent physical therapy (no more recent than 6 months) on the affected limb,"['No' 'recent' 'physical' 'therapy' '(' 'no' 'more' 'recent' 'than' '6'
 'months' ')' 'on' 'the' 'affected' 'limb']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03135145,14:30:treatment,referred for physical therapy for mobility/gait training to regain functional walking and ambulation,"['referred' 'for' 'physical' 'therapy' 'for' 'mobility/gait' 'training'
 'to' 'regain' 'functional' 'walking' 'and' 'ambulation']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03072381,37:53:treatment,self-reported failure of supervised physical therapy,['self-reported' 'failure' 'of' 'supervised' 'physical' 'therapy'],[0. 0. 0. 0. 1. 1.]
NCT02905370,23:39:treatment,Referred to home care physical therapy following acute medical deconditioning,"['Referred' 'to' 'home' 'care' 'physical' 'therapy' 'following' 'acute'
 'medical' 'deconditioning']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02890485,14:30:treatment,Referred for physical therapy,['Referred' 'for' 'physical' 'therapy'],[0. 0. 1. 1.]
NCT02759211,26:42:treatment,Current participation in physical therapy,['Current' 'participation' 'in' 'physical' 'therapy'],[0. 0. 0. 1. 1.]
NCT02746458,84:100:treatment,Use of blood flow restriction (BFR) at any time between treatment and the start of physical therapy for the study,"['Use' 'of' 'blood' 'flow' 'restriction' '(' 'BFR' ')' 'at' 'any' 'time'
 'between' 'treatment' 'and' 'the' 'start' 'of' 'physical' 'therapy' 'for'
 'the' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT02667392,11:27:treatment,Receiving physical therapy services for mobility and/or gait,"['Receiving' 'physical' 'therapy' 'services' 'for' 'mobility' 'and/or'
 'gait']",[0. 1. 1. 0. 0. 0. 0. 0.]
NCT02383979,29:45:treatment,inability to cooperate with physical therapy,['inability' 'to' 'cooperate' 'with' 'physical' 'therapy'],[0. 0. 0. 0. 1. 1.]
NCT02323945,23:39:treatment,Undergoing concurrent physical therapy,['Undergoing' 'concurrent' 'physical' 'therapy'],[0. 0. 1. 1.]
NCT02274116,12:28:treatment,concurrent physical therapy,['concurrent' 'physical' 'therapy'],[0. 1. 1.]
NCT01420887,36:52:treatment,Not possible to have postoperative physical therapy appointment,"['Not' 'possible' 'to' 'have' 'postoperative' 'physical' 'therapy'
 'appointment']",[0. 0. 0. 0. 0. 1. 1. 0.]
NCT03092609,4:18:chronic_disease,No Claustrophobia,['No' 'Claustrophobia'],[0. 2.]
NCT02826343,1:15:chronic_disease,"Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning","['Claustrophobia' ',' 'inner' 'ear' 'implants' ',' 'aneurysm' 'or' 'other'
 'surgical' 'clips' ',' 'metal' 'foreign' 'bodies' 'in' 'eye' ','
 'pacemaker' 'or' 'other' 'contraindication' 'to' 'MR' 'scanning']","[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02721303,1:15:chronic_disease,Claustrophobia,['Claustrophobia'],[2.]
NCT02719327,"1:15:chronic_disease,",Claustrophobia requiring sedation for MRI,['Claustrophobia' 'requiring' 'sedation' 'for' 'MRI'],[2. 0. 0. 0. 0.]
NCT02531880,1:15:chronic_disease,Claustrophobia to a degree that the subject would feel uncomfortable in the MRI machine,"['Claustrophobia' 'to' 'a' 'degree' 'that' 'the' 'subject' 'would' 'feel'
 'uncomfortable' 'in' 'the' 'MRI' 'machine']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02489591,1:15:chronic_disease,Claustrophobia,['Claustrophobia'],[2.]
NCT02067975,1:15:chronic_disease,Claustrophobia,['Claustrophobia'],[2.]
NCT01986205,1:15:chronic_disease,Claustrophobia precluding chamber or hood tolerance,['Claustrophobia' 'precluding' 'chamber' 'or' 'hood' 'tolerance'],[2. 0. 0. 0. 0. 0.]
NCT01738009,1:15:chronic_disease,Claustrophobia,['Claustrophobia'],[2.]
NCT01614990,1:15:chronic_disease,Claustrophobia (this would make lying in the scanner very uncomfortable),"['Claustrophobia' '(' 'this' 'would' 'make' 'lying' 'in' 'the' 'scanner'
 'very' 'uncomfortable' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01608438,1:15:chronic_disease,Claustrophobia precluding MRI,['Claustrophobia' 'precluding' 'MRI'],[2. 0. 0.]
NCT01604512,1:15:chronic_disease,Claustrophobia,['Claustrophobia'],[2.]
NCT02905578,19:34:treatment,Side effects from prior therapies that are still deemed moderate to severe by a physician,"['Side' 'effects' 'from' 'prior' 'therapies' 'that' 'are' 'still' 'deemed'
 'moderate' 'to' 'severe' 'by' 'a' 'physician']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02594384,40:55:treatment,Not recovered from toxicity due to all prior therapies,['Not' 'recovered' 'from' 'toxicity' 'due' 'to' 'all' 'prior' 'therapies'],[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02577406,80:95:treatment,"Subject has persistent, clinically significant non-hematologic toxicities from prior therapies","['Subject' 'has' 'persistent' ',' 'clinically' 'significant'
 'non-hematologic' 'toxicities' 'from' 'prior' 'therapies']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02503722,15:30:treatment,Any number of prior therapies are allowed,['Any' 'number' 'of' 'prior' 'therapies' 'are' 'allowed'],[0. 0. 0. 1. 1. 0. 0.]
NCT02496663,15:30:treatment,Any number of prior therapies is allowed,['Any' 'number' 'of' 'prior' 'therapies' 'is' 'allowed'],[0. 0. 0. 1. 1. 0. 0.]
NCT02203513,36:51:treatment,There is no limit on the number of prior therapies,['There' 'is' 'no' 'limit' 'on' 'the' 'number' 'of' 'prior' 'therapies'],[0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02132598,",,87:102:treatment",The subject has not recovered to baseline or CTCAE ≤ Grade 1 from toxicity due to all prior therapies,"['The' 'subject' 'has' 'not' 'recovered' 'to' 'baseline' 'or' 'CTCAE' '≤'
 'Grade' '1' 'from' 'toxicity' 'due' 'to' 'all' 'prior' 'therapies']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02048722,",9:24:treatment",up to 4 prior therapies are allowed,['up' 'to' '4' 'prior' 'therapies' 'are' 'allowed'],[0. 0. 0. 1. 1. 0. 0.]
NCT01947140,34:49:treatment,No upper limit for the number of prior therapies,['No' 'upper' 'limit' 'for' 'the' 'number' 'of' 'prior' 'therapies'],[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01896999,30:45:treatment,no upper limit for number of prior therapies,['no' 'upper' 'limit' 'for' 'number' 'of' 'prior' 'therapies'],[0. 0. 0. 0. 0. 0. 1. 1.]
NCT01822522,",,141:156:treatment",The participant has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies,"['The' 'participant' 'has' 'not' 'recovered' 'to' 'baseline' 'or' 'Common'
 'Terminology' 'Criteria' 'for' 'Adverse' 'Events' '(' 'CTCAE' ')' '=' '<'
 'grade' '1' 'from' 'toxicity' 'due' 'to' 'all' 'prior' 'therapies']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1.]"
NCT01241708,32:47:treatment,Recovery from complications of prior therapies,['Recovery' 'from' 'complications' 'of' 'prior' 'therapies'],[0. 0. 0. 0. 1. 1.]
NCT03181867,41:62:chronic_disease,Subjects with any coexisting medical or psychiatric condition that is likely to interfere with study procedures and/or results,"['Subjects' 'with' 'any' 'coexisting' 'medical' 'or' 'psychiatric'
 'condition' 'that' 'is' 'likely' 'to' 'interfere' 'with' 'study'
 'procedures' 'and/or' 'results']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03138512,52:73:chronic_disease,"Any severe or serious, acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation","['Any' 'severe' 'or' 'serious' ',' 'acute' 'or' 'chronic' 'medical' 'or'
 'psychiatric' 'condition' ',' 'or' 'laboratory' 'abnormality' 'that'
 'may' 'increase' 'the' 'risk' 'associated' 'with' 'study' 'participation']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT03104699,5:26:chronic_disease,Any psychiatric condition that would prohibit understanding or rendering of informed consent,"['Any' 'psychiatric' 'condition' 'that' 'would' 'prohibit' 'understanding'
 'or' 'rendering' 'of' 'informed' 'consent']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02979860,1:22:chronic_disease,psychiatric condition that may impact sleep/weight status,['psychiatric' 'condition' 'that' 'may' 'impact' 'sleep/weight' 'status'],[2. 2. 0. 0. 0. 0. 0.]
NCT02872935,23:44:chronic_disease,Any other physical or psychiatric condition that may impair their ability to cooperate with study data collection,"['Any' 'other' 'physical' 'or' 'psychiatric' 'condition' 'that' 'may'
 'impair' 'their' 'ability' 'to' 'cooperate' 'with' 'study' 'data'
 'collection']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02707692,14:35:chronic_disease,Uncontrolled psychiatric condition,['Uncontrolled' 'psychiatric' 'condition'],[0. 2. 2.]
NCT02576444,46:67:chronic_disease,Any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results,"['Any' 'other' 'severe' 'acute' 'or' 'chronic' 'medical' 'or'
 'psychiatric' 'condition' 'or' 'laboratory' 'abnormality' 'that' 'may'
 'increase' 'the' 'risk' 'associated' 'with' 'study' 'participation' 'or'
 'may' 'interfere' 'with' 'the' 'interpretation' 'of' 'study' 'results']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02245997,41:62:chronic_disease,"Patients with any concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study","['Patients' 'with' 'any' 'concurrent' 'medical' 'or' 'psychiatric'
 'condition' 'or' 'disease' 'which' ',' 'in' 'the' 'investigator' ""'s""
 'judgment' ',' 'would' 'make' 'them' 'inappropriate' 'candidates' 'for'
 'entry' 'into' 'this' 'study']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02243813,7:28:chronic_disease,Has a psychiatric condition judged to be incompatible with establishment of rapport or safe exposure to psilocybin,"['Has' 'a' 'psychiatric' 'condition' 'judged' 'to' 'be' 'incompatible'
 'with' 'establishment' 'of' 'rapport' 'or' 'safe' 'exposure' 'to'
 'psilocybin']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02025426,23:44:chronic_disease,Any other physical or psychiatric condition which may impair their ability to cooperate with study data collection,"['Any' 'other' 'physical' 'or' 'psychiatric' 'condition' 'which' 'may'
 'impair' 'their' 'ability' 'to' 'cooperate' 'with' 'study' 'data'
 'collection']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01886794,62:83:chronic_disease,History of prior noncompliance or the presence or history of psychiatric condition that would in the opinion of the investigator make it difficult for the subject to comply with study procedures or follow instructions,"['History' 'of' 'prior' 'noncompliance' 'or' 'the' 'presence' 'or'
 'history' 'of' 'psychiatric' 'condition' 'that' 'would' 'in' 'the'
 'opinion' 'of' 'the' 'investigator' 'make' 'it' 'difficult' 'for' 'the'
 'subject' 'to' 'comply' 'with' 'study' 'procedures' 'or' 'follow'
 'instructions']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03108950,1:14:chronic_disease,Renal failure,['Renal' 'failure'],[2. 2.]
NCT03003390,1:14:chronic_disease,Renal failure,['Renal' 'failure'],[2. 2.]
NCT02981082,1:14:chronic_disease,Renal failure,['Renal' 'failure'],[2. 2.]
NCT02943590,1:14:chronic_disease,Renal failure,['Renal' 'failure'],[2. 2.]
NCT02919436,1:14:chronic_disease,Renal failure,['Renal' 'failure'],[2. 2.]
NCT02776059,1:14:chronic_disease,Renal failure,['Renal' 'failure'],[2. 2.]
NCT02679560,1:14:chronic_disease,Renal failure requiring dialysis,['Renal' 'failure' 'requiring' 'dialysis'],[2. 2. 0. 0.]
NCT02564796,1:14:chronic_disease,Renal failure,['Renal' 'failure'],[2. 2.]
NCT02551679,1:14:chronic_disease,Renal failure,['Renal' 'failure'],[2. 2.]
NCT02533882,1:14:chronic_disease,Renal failure,['Renal' 'failure'],[2. 2.]
NCT00967785,"1:14:chronic_disease,,",Renal failure (calculated creatinine clearance [CrCl] <15 mL/min or requiring dialysis),"['Renal' 'failure' '(' 'calculated' 'creatinine' 'clearance' '[' 'CrCl'
 ']' '<' '15' 'mL/min' 'or' 'requiring' 'dialysis' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03016871,1:24:treatment,Prior radiation therapy is allowed,['Prior' 'radiation' 'therapy' 'is' 'allowed'],[1. 1. 1. 0. 0.]
NCT02504489,1:24:treatment,Prior radiation therapy is not exclusionary,['Prior' 'radiation' 'therapy' 'is' 'not' 'exclusionary'],[1. 1. 1. 0. 0. 0.]
NCT02344355,1:24:treatment,Prior radiation therapy to the head or neck resulting in overlap of RT fields,"['Prior' 'radiation' 'therapy' 'to' 'the' 'head' 'or' 'neck' 'resulting'
 'in' 'overlap' 'of' 'RT' 'fields']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02159703,1:24:treatment,Prior radiation therapy to the head and neck,['Prior' 'radiation' 'therapy' 'to' 'the' 'head' 'and' 'neck'],[1. 1. 1. 0. 0. 0. 0. 0.]
NCT02143726,"1:24:treatment,",Prior radiation therapy to the non-index lesions is allowed if ≥ 28 days prior to registration on this protocol,"['Prior' 'radiation' 'therapy' 'to' 'the' 'non-index' 'lesions' 'is'
 'allowed' 'if' '≥' '28' 'days' 'prior' 'to' 'registration' 'on' 'this'
 'protocol']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02094794,1:24:treatment,Prior radiation therapy that would exclude the use of TMLI,"['Prior' 'radiation' 'therapy' 'that' 'would' 'exclude' 'the' 'use' 'of'
 'TMLI']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01804465,"1:24:treatment,",Prior radiation therapy must be completed ≥ 4 weeks prior to enrollment and the patient must have recovered from all toxicity,"['Prior' 'radiation' 'therapy' 'must' 'be' 'completed' '≥' '4' 'weeks'
 'prior' 'to' 'enrollment' 'and' 'the' 'patient' 'must' 'have' 'recovered'
 'from' 'all' 'toxicity']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01766297,1:24:treatment,Prior radiation therapy to the ipsilateral breast or thorax,"['Prior' 'radiation' 'therapy' 'to' 'the' 'ipsilateral' 'breast' 'or'
 'thorax']",[1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT01737502,1:24:treatment,Prior radiation therapy,['Prior' 'radiation' 'therapy'],[1. 1. 1.]
NCT01434316,1:24:treatment,Prior radiation therapy,['Prior' 'radiation' 'therapy'],[1. 1. 1.]
NCT00967577,"1:24:treatment,",Prior radiation therapy encompassing >25% of skeleton,['Prior' 'radiation' 'therapy' 'encompassing' '>' '25' '%' 'of' 'skeleton'],[1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02852057,1:7:chronic_disease,Asthma,['Asthma'],[2.]
NCT02696980,"1:7:chronic_disease,,",Asthma diagnosis when ≥ 18 years of age,['Asthma' 'diagnosis' 'when' '≥' '18' 'years' 'of' 'age'],[2. 0. 0. 0. 0. 0. 0. 0.]
NCT02507011,1:7:chronic_disease,Asthma,['Asthma'],[2.]
NCT02493257,1:7:chronic_disease,Asthma,['Asthma'],[2.]
NCT02487082,1:7:chronic_disease,Asthma,['Asthma'],[2.]
NCT02433977,"1:7:chronic_disease,,",Asthma diagnosed at age 9 or later,['Asthma' 'diagnosed' 'at' 'age' '9' 'or' 'later'],[2. 0. 0. 0. 0. 0. 0.]
NCT02433977,"1:7:chronic_disease,",Asthma-related ER visit within the previous 4 weeks,['Asthma-related' 'ER' 'visit' 'within' 'the' 'previous' '4' 'weeks'],[2. 0. 0. 0. 0. 0. 0. 0.]
NCT02433977,"1:7:chronic_disease,",Asthma-related hospitalization within the last 2 months,['Asthma-related' 'hospitalization' 'within' 'the' 'last' '2' 'months'],[2. 0. 0. 0. 0. 0. 0.]
NCT02193373,1:7:chronic_disease,Asthma,['Asthma'],[2.]
NCT02025465,1:7:chronic_disease,Asthma,['Asthma'],[2.]
NCT01536522,"1:7:chronic_disease,,,",Asthma diagnosed by a medical specialist and/or history of positive methacholine rest and/or reversibility of >10% of FEV1,"['Asthma' 'diagnosed' 'by' 'a' 'medical' 'specialist' 'and/or' 'history'
 'of' 'positive' 'methacholine' 'rest' 'and/or' 'reversibility' 'of' '>'
 '10' '%' 'of' 'FEV1']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02585973,20:36:treatment,Ability to swallow oral medications,['Ability' 'to' 'swallow' 'oral' 'medications'],[0. 0. 0. 1. 1.]
NCT02516696,36:52:treatment,Subject is unable to reliably take oral medications,['Subject' 'is' 'unable' 'to' 'reliably' 'take' 'oral' 'medications'],[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02466009,36:52:treatment,Must be able to swallow and retain oral medications,['Must' 'be' 'able' 'to' 'swallow' 'and' 'retain' 'oral' 'medications'],[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02433626,23:39:treatment,Inability to tolerate oral medications,['Inability' 'to' 'tolerate' 'oral' 'medications'],[0. 0. 0. 1. 1.]
NCT02417701,20:36:treatment,Ability to swallow oral medications,['Ability' 'to' 'swallow' 'oral' 'medications'],[0. 0. 0. 1. 1.]
NCT02321501,17:33:treatment,Able to swallow oral medications,['Able' 'to' 'swallow' 'oral' 'medications'],[0. 0. 0. 1. 1.]
NCT02122172,19:35:treatment,Inability to take oral medications,['Inability' 'to' 'take' 'oral' 'medications'],[0. 0. 0. 1. 1.]
NCT01972919,20:36:treatment,Ability to swallow oral medications,['Ability' 'to' 'swallow' 'oral' 'medications'],[0. 0. 0. 1. 1.]
NCT01835626,78:94:treatment,Patients with any condition that may impair the ability to swallow or absorb oral medications/investigational product,"['Patients' 'with' 'any' 'condition' 'that' 'may' 'impair' 'the' 'ability'
 'to' 'swallow' 'or' 'absorb' 'oral' 'medications/investigational'
 'product']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT01618357,30:46:treatment,Unable to swallow and retain oral medications,['Unable' 'to' 'swallow' 'and' 'retain' 'oral' 'medications'],[0. 0. 0. 0. 0. 1. 1.]
NCT01595529,34:50:treatment,A child that is not able to take oral medications,['A' 'child' 'that' 'is' 'not' 'able' 'to' 'take' 'oral' 'medications'],[0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT03181126,19:41:chronic_disease,Participants with malabsorption syndrome or any other condition that precludes enteral administration,"['Participants' 'with' 'malabsorption' 'syndrome' 'or' 'any' 'other'
 'condition' 'that' 'precludes' 'enteral' 'administration']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02876302,24:46:chronic_disease,Clinically significant malabsorption syndrome,['Clinically' 'significant' 'malabsorption' 'syndrome'],[0. 0. 2. 2.]
NCT02574910,16:38:chronic_disease,A history of a malabsorption syndrome,['A' 'history' 'of' 'a' 'malabsorption' 'syndrome'],[0. 0. 0. 0. 2. 2.]
NCT02419560,13:35:chronic_disease,Subject has malabsorption syndrome or other condition which may affect an enteral route of administration,"['Subject' 'has' 'malabsorption' 'syndrome' 'or' 'other' 'condition'
 'which' 'may' 'affect' 'an' 'enteral' 'route' 'of' 'administration']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02394535,1:23:chronic_disease,malabsorption syndrome,['malabsorption' 'syndrome'],[2. 2.]
NCT02187848,15:37:chronic_disease,Patients with malabsorption syndrome,['Patients' 'with' 'malabsorption' 'syndrome'],[0. 0. 2. 2.]
NCT02101736,1:23:chronic_disease,malabsorption syndrome,['malabsorption' 'syndrome'],[2. 2.]
NCT01972919,14:36:chronic_disease,Uncontrolled malabsorption syndrome significantly affecting gastrointestinal function,"['Uncontrolled' 'malabsorption' 'syndrome' 'significantly' 'affecting'
 'gastrointestinal' 'function']",[0. 2. 2. 0. 0. 0. 0.]
NCT01835626,1:23:chronic_disease,malabsorption syndrome,['malabsorption' 'syndrome'],[2. 2.]
NCT01639508,1:23:chronic_disease,malabsorption syndrome,['malabsorption' 'syndrome'],[2. 2.]
NCT03158519,1:8:chronic_disease,dyspnea requiring oxygen,['dyspnea' 'requiring' 'oxygen'],[2. 0. 0.]
NCT02833805,",92:99:chronic_disease,,",For patients < 8 years old or unable to undergo pulmonary function testing: no evidence of dyspnea at rest; no need for supplemental oxygen; oxygen saturation > 92% on room air,"['For' 'patients' '<' '8' 'years' 'old' 'or' 'unable' 'to' 'undergo'
 'pulmonary' 'function' 'testing' ':' 'no' 'evidence' 'of' 'dyspnea' 'at'
 'rest' ';' 'no' 'need' 'for' 'supplemental' 'oxygen' ';' 'oxygen'
 'saturation' '>' '92' '%' 'on' 'room' 'air']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02688647,41:48:chronic_disease,"Acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements (eg, pulmonary function tests)","['Acute' 'or' 'chronic' 'impairment' '(' 'other' 'than' 'dyspnea' ')'
 'limiting' 'the' 'ability' 'to' 'comply' 'with' 'study' 'requirements'
 '(' 'eg' ',' 'pulmonary' 'function' 'tests' ')']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02508038,16:23:chronic_disease,No evidence of dyspnea at rest,['No' 'evidence' 'of' 'dyspnea' 'at' 'rest'],[0. 0. 0. 2. 0. 0.]
NCT02389309,"59:66:chronic_disease,,","Adequate pulmonary function as defined as: no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination","['Adequate' 'pulmonary' 'function' 'as' 'defined' 'as' ':' 'no' 'evidence'
 'of' 'dyspnea' 'at' 'rest' ',' 'no' 'exercise' 'intolerance' ',' 'and'
 'a' 'pulse' 'oximetry' '>' '94' '%' 'if' 'there' 'is' 'clinical'
 'indication' 'for' 'determination']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02145351,38:45:chronic_disease,Other clinically important causes of dyspnea,['Other' 'clinically' 'important' 'causes' 'of' 'dyspnea'],[0. 0. 0. 0. 0. 2.]
NCT02076906,15:22:chronic_disease,Defined as no dyspnea at rest,['Defined' 'as' 'no' 'dyspnea' 'at' 'rest'],[0. 0. 0. 2. 0. 0.]
NCT01966367,"108:115:chronic_disease,,","Adequate pulmonary function by pulmonary function test. For children who are uncooperative, no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry >94% on room air","['Adequate' 'pulmonary' 'function' 'by' 'pulmonary' 'function' 'test' '.'
 'For' 'children' 'who' 'are' 'uncooperative' ',' 'no' 'evidence' 'of'
 'dyspnea' 'at' 'rest' ',' 'no' 'exercise' 'intolerance' ',' 'and' 'a'
 'pulse' 'oximetry' '>' '94' '%' 'on' 'room' 'air']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01896999,"35:42:chronic_disease,,",Patients must have no evidence of dyspnea at rest and a pulse oximetry > 92% while breathing room air,"['Patients' 'must' 'have' 'no' 'evidence' 'of' 'dyspnea' 'at' 'rest' 'and'
 'a' 'pulse' 'oximetry' '>' '92' '%' 'while' 'breathing' 'room' 'air']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01614197,16:23:chronic_disease,No evidence of dyspnea at rest and no exercise intolerance,"['No' 'evidence' 'of' 'dyspnea' 'at' 'rest' 'and' 'no' 'exercise'
 'intolerance']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT03112720,29:38:allergy_name,Subjects with an allergy to lidocaine,['Subjects' 'with' 'an' 'allergy' 'to' 'lidocaine'],[0. 0. 0. 0. 0. 4.]
NCT03051516,33:42:allergy_name,Known allergy or intolerance to lidocaine,['Known' 'allergy' 'or' 'intolerance' 'to' 'lidocaine'],[0. 0. 0. 0. 0. 4.]
NCT02924441,44:53:allergy_name,Must not have a contraindication for using lidocaine: e.g no history of allergic reactions to lidocaine,"['Must' 'not' 'have' 'a' 'contraindication' 'for' 'using' 'lidocaine' ':'
 'e.g' 'no' 'history' 'of' 'allergic' 'reactions' 'to' 'lidocaine']",[0. 0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02833207,16:25:treatment,Sensitivity to lidocaine,['Sensitivity' 'to' 'lidocaine'],[0. 0. 1.]
NCT02832115,41:50:allergy_name,Hypersensitivity or contraindication to lidocaine,['Hypersensitivity' 'or' 'contraindication' 'to' 'lidocaine'],[0. 0. 0. 0. 4.]
NCT02638454,12:21:allergy_name,Allergy to lidocaine,['Allergy' 'to' 'lidocaine'],[0. 0. 4.]
NCT02485639,18:27:allergy_name,known allergy to lidocaine,['known' 'allergy' 'to' 'lidocaine'],[0. 0. 0. 4.]
NCT02233868,40:49:allergy_name,"Have a history of allergic reaction to lidocaine (self-report, medical history)","['Have' 'a' 'history' 'of' 'allergic' 'reaction' 'to' 'lidocaine' '('
 'self-report' ',' 'medical' 'history' ')']",[0. 0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0.]
NCT01901562,25:34:allergy_name,Have a known allergy to lidocaine,['Have' 'a' 'known' 'allergy' 'to' 'lidocaine'],[0. 0. 0. 0. 0. 4.]
NCT01434316,34:43:allergy_name,Subjects with a known allergy to lidocaine,['Subjects' 'with' 'a' 'known' 'allergy' 'to' 'lidocaine'],[0. 0. 0. 0. 0. 0. 4.]
NCT03057548,44:68:chronic_disease,Patients with any corrected or uncorrected congenital heart disease,"['Patients' 'with' 'any' 'corrected' 'or' 'uncorrected' 'congenital'
 'heart' 'disease']",[0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02946892,6:30:chronic_disease,with congenital heart disease that has been palliated with a Fontan circulation,"['with' 'congenital' 'heart' 'disease' 'that' 'has' 'been' 'palliated'
 'with' 'a' 'Fontan' 'circulation']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02816736,9:33:chronic_disease,Complex congenital heart disease,['Complex' 'congenital' 'heart' 'disease'],[0. 2. 2. 2.]
NCT02589977,1:25:chronic_disease,congenital heart disease,['congenital' 'heart' 'disease'],[2. 2. 2.]
NCT02477839,43:67:chronic_disease,Subject has a hemodynamically significant congenital heart disease,"['Subject' 'has' 'a' 'hemodynamically' 'significant' 'congenital' 'heart'
 'disease']",[0. 0. 0. 0. 0. 2. 2. 2.]
NCT02476409,9:33:chronic_disease,Complex congenital heart disease,['Complex' 'congenital' 'heart' 'disease'],[0. 2. 2. 2.]
NCT02249039,28:52:chronic_disease,Postoperative from complex congenital heart disease,['Postoperative' 'from' 'complex' 'congenital' 'heart' 'disease'],[0. 0. 0. 2. 2. 2.]
NCT02145351,9:33:chronic_disease,Complex congenital heart disease,['Complex' 'congenital' 'heart' 'disease'],[0. 2. 2. 2.]
NCT01883076,49:73:chronic_disease,Child with the following complications of their congenital heart disease,"['Child' 'with' 'the' 'following' 'complications' 'of' 'their'
 'congenital' 'heart' 'disease']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT01878617,14:38:chronic_disease,Must have no congenital heart disease,['Must' 'have' 'no' 'congenital' 'heart' 'disease'],[0. 0. 0. 2. 2. 2.]
NCT03001830,"25:30:chronic_disease,,",Serological evidence of HIV-1 who have CD4 counts ≤ 200/mm3,"['Serological' 'evidence' 'of' 'HIV-1' 'who' 'have' 'CD4' 'counts' '≤'
 '200/mm3']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02881320,"11:16:chronic_disease,,,,,,",Cohort 1: HIV-1 infected adolescents (12 to < 18 years of age and screening weight ≥ 35 kg) who are virologically suppressed for ≥ 6 months prior to screening,"['Cohort' '1' ':' 'HIV-1' 'infected' 'adolescents' '(' '12' 'to' '<' '18'
 'years' 'of' 'age' 'and' 'screening' 'weight' '≥' '35' 'kg' ')' 'who'
 'are' 'virologically' 'suppressed' 'for' '≥' '6' 'months' 'prior' 'to'
 'screening']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02881320,"11:16:chronic_disease,,,,,,",Cohort 2: HIV-1 infected children (6 to < 12 years of age and screening weight ≥ 25 kg) who are virologically suppressed for ≥ 6 months prior to screening,"['Cohort' '2' ':' 'HIV-1' 'infected' 'children' '(' '6' 'to' '<' '12'
 'years' 'of' 'age' 'and' 'screening' 'weight' '≥' '25' 'kg' ')' 'who'
 'are' 'virologically' 'suppressed' 'for' '≥' '6' 'months' 'prior' 'to'
 'screening']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02881320,"11:16:chronic_disease,,,,,,,",Cohort 3: HIV-1 infected children (≥ 2 years of age and screening weight of ≥ 14 to < 25 kg) who are virologically suppressed for ≥ 6 months prior to screening,"['Cohort' '3' ':' 'HIV-1' 'infected' 'children' '(' '≥' '2' 'years' 'of'
 'age' 'and' 'screening' 'weight' 'of' '≥' '14' 'to' '<' '25' 'kg' ')'
 'who' 'are' 'virologically' 'suppressed' 'for' '≥' '6' 'months' 'prior'
 'to' 'screening']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02610374,29:34:chronic_disease,Documentation of a negative HIV-1 antibody test,['Documentation' 'of' 'a' 'negative' 'HIV-1' 'antibody' 'test'],[0. 0. 0. 0. 2. 0. 0.]
NCT02471430,"23:28:chronic_disease,,,",Documented suppressed HIV-1 RNA (plasma HIV-1 RNA values <50 copies/ml),"['Documented' 'suppressed' 'HIV-1' 'RNA' '(' 'plasma' 'HIV-1' 'RNA'
 'values' '<' '50' 'copies/ml' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02471430,1:6:chronic_disease,HIV-1 infection prior to entry,['HIV-1' 'infection' 'prior' 'to' 'entry'],[2. 0. 0. 0. 0.]
NCT02285114,1:6:chronic_disease,HIV-1 infected,['HIV-1' 'infected'],[2. 0.]
NCT02256631,"12:17:chronic_disease,",Born to an HIV-1-infected woman who meets all maternal inclusion/exclusion criteria listed above,"['Born' 'to' 'an' 'HIV-1-infected' 'woman' 'who' 'meets' 'all' 'maternal'
 'inclusion/exclusion' 'criteria' 'listed' 'above']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02191098,1:6:chronic_disease,HIV-1 infected adults,['HIV-1' 'infected' 'adults'],[2. 0. 0.]
NCT03182075,22:25:chronic_disease,primary diagnosis of OCD,['primary' 'diagnosis' 'of' 'OCD'],[0. 0. 0. 2.]
NCT03182075,24:27:chronic_disease,sufficient severity of OCD symptoms,['sufficient' 'severity' 'of' 'OCD' 'symptoms'],[0. 0. 0. 2. 0.]
NCT02624596,22:25:chronic_disease,Primary diagnosis of OCD,['Primary' 'diagnosis' 'of' 'OCD'],[0. 0. 0. 2.]
NCT02624596,24:27:chronic_disease,Sufficient severity of OCD symptoms,['Sufficient' 'severity' 'of' 'OCD' 'symptoms'],[0. 0. 0. 2. 0.]
NCT02437773,",8:11:chronic_disease,",Age of OCD onset after 15 years old,['Age' 'of' 'OCD' 'onset' 'after' '15' 'years' 'old'],[0. 0. 2. 0. 0. 0. 0. 0.]
NCT02437773,25:28:chronic_disease,subjects diagnosed with OCD,['subjects' 'diagnosed' 'with' 'OCD'],[0. 0. 0. 2.]
NCT02421315,77:80:chronic_disease,Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Diagnosis of OCD as the principal problem,"['Diagnostic' 'and' 'Statistical' 'Manual' 'of' 'Mental' 'Disorders' '('
 'DSM-IV' ')' 'Diagnosis' 'of' 'OCD' 'as' 'the' 'principal' 'problem']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT02206945,"30:33:chronic_disease,,","Primary Diagnosis of Current OCD, based on Diagnostic and Statistical Manual (DSM-IV) criteria, a Y-BOCS (Yale-Brown Obsessive-Compulsive Scale) score >=16","['Primary' 'Diagnosis' 'of' 'Current' 'OCD' ',' 'based' 'on' 'Diagnostic'
 'and' 'Statistical' 'Manual' '(' 'DSM-IV' ')' 'criteria' ',' 'a' 'Y-BOCS'
 '(' 'Yale-Brown' 'Obsessive-Compulsive' 'Scale' ')' 'score' '>' '=16']","[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02206945,11:14:chronic_disease,Principle OCD symptoms- Primary symptoms must be either Cleaning/Contamination or Checking; other symptoms okay,"['Principle' 'OCD' 'symptoms-' 'Primary' 'symptoms' 'must' 'be' 'either'
 'Cleaning/Contamination' 'or' 'Checking' ';' 'other' 'symptoms' 'okay']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03143985,20:32:treatment,Patients requiring hemodialysis,['Patients' 'requiring' 'hemodialysis'],[0. 0. 1.]
NCT02965508,",102:114:treatment","Patients must live in Manhattan, have access to a telephone 24 hours a day, 7 days a week, not be on hemodialysis, agree to open the door and allow access to the members of the team","['Patients' 'must' 'live' 'in' 'Manhattan' ',' 'have' 'access' 'to' 'a'
 'telephone' '24' 'hours' 'a' 'day' ',' '7' 'days' 'a' 'week' ',' 'not'
 'be' 'on' 'hemodialysis' ',' 'agree' 'to' 'open' 'the' 'door' 'and'
 'allow' 'access' 'to' 'the' 'members' 'of' 'the' 'team']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02570854,"11:23:treatment,",Receiving hemodialysis at least 2 times per week,['Receiving' 'hemodialysis' 'at' 'least' '2' 'times' 'per' 'week'],[0. 1. 0. 0. 0. 0. 0. 0.]
NCT02532621,"46:58:treatment,",has a reasonable expectation of remaining on hemodialysis for at least 6 months,"['has' 'a' 'reasonable' 'expectation' 'of' 'remaining' 'on' 'hemodialysis'
 'for' 'at' 'least' '6' 'months']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02522871,16:28:treatment,Chronic use of hemodialysis,['Chronic' 'use' 'of' 'hemodialysis'],[0. 0. 0. 1.]
NCT02468778,15:27:treatment,Subject is on hemodialysis,['Subject' 'is' 'on' 'hemodialysis'],[0. 0. 0. 1.]
NCT02433210,"11:23:treatment,",Stable on hemodialysis for more than 3 months,['Stable' 'on' 'hemodialysis' 'for' 'more' 'than' '3' 'months'],[0. 0. 1. 0. 0. 0. 0. 0.]
NCT02378428,21:33:treatment,Patients who are on hemodialysis,['Patients' 'who' 'are' 'on' 'hemodialysis'],[0. 0. 0. 0. 1.]
NCT02278198,1:13:treatment,hemodialysis,['hemodialysis'],[1.]
NCT03126370,1:12:chronic_disease,Hepatitis B infection,['Hepatitis' 'B' 'infection'],[2. 2. 0.]
NCT02641093,1:12:chronic_disease,Hepatitis B,['Hepatitis' 'B'],[2. 2.]
NCT02635360,1:12:chronic_disease,Hepatitis B,['Hepatitis' 'B'],[2. 2.]
NCT02587962,8:19:chronic_disease,Active Hepatitis B (HBsAg reactive,['Active' 'Hepatitis' 'B' '(' 'HBsAg' 'reactive'],[0. 2. 2. 0. 0. 0.]
NCT02570854,12:23:chronic_disease,A positive Hepatitis B surface antigen test result,['A' 'positive' 'Hepatitis' 'B' 'surface' 'antigen' 'test' 'result'],[0. 0. 2. 2. 0. 0. 0. 0.]
NCT02520427,14:25:chronic_disease,Positive for Hepatitis B,['Positive' 'for' 'Hepatitis' 'B'],[0. 0. 2. 2.]
NCT02508038,1:12:chronic_disease,Hepatitis B surface antigen (HBsAg),['Hepatitis' 'B' 'surface' 'antigen' '(' 'HBsAg' ')'],[2. 2. 0. 0. 0. 0. 0.]
NCT01880567,16:27:chronic_disease,positive serum Hepatitis B antibody,['positive' 'serum' 'Hepatitis' 'B' 'antibody'],[0. 0. 2. 2. 0.]
NCT01306019,19:30:chronic_disease,Documented active Hepatitis B infection,['Documented' 'active' 'Hepatitis' 'B' 'infection'],[0. 0. 2. 2. 0.]
NCT03116685,1:4:chronic_disease,CKD-EPI formula will be used for adults,['CKD-EPI' 'formula' 'will' 'be' 'used' 'for' 'adults'],[2. 0. 0. 0. 0. 0. 0.]
NCT02945969,",,,339:342:chronic_disease,,","The investigators chose an upper eGFR limit slightly higher than the Kidney Disease Outcomes Quality Initiative (KDOQI) definition of moderately reduced glomerular filtration rate (GFR) to be more inclusive of patients with mild reduction in GFR but significant proteinuria. The lower eGFR limit was set to exclude patients with advanced CKD, where the potential effects of dietary sodium reduction on proteinuria may not be apparent or greatly alter CKD progression. The eGFR to define eligibility will be calculated using calibrated serum creatinine values and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) estimating equation","['The' 'investigators' 'chose' 'an' 'upper' 'eGFR' 'limit' 'slightly'
 'higher' 'than' 'the' 'Kidney' 'Disease' 'Outcomes' 'Quality'
 'Initiative' '(' 'KDOQI' ')' 'definition' 'of' 'moderately' 'reduced'
 'glomerular' 'filtration' 'rate' '(' 'GFR' ')' 'to' 'be' 'more'
 'inclusive' 'of' 'patients' 'with' 'mild' 'reduction' 'in' 'GFR' 'but'
 'significant' 'proteinuria' '.' 'The' 'lower' 'eGFR' 'limit' 'was' 'set'
 'to' 'exclude' 'patients' 'with' 'advanced' 'CKD' ',' 'where' 'the'
 'potential' 'effects' 'of' 'dietary' 'sodium' 'reduction' 'on'
 'proteinuria' 'may' 'not' 'be' 'apparent' 'or' 'greatly' 'alter' 'CKD'
 'progression' '.' 'The' 'eGFR' 'to' 'define' 'eligibility' 'will' 'be'
 'calculated' 'using' 'calibrated' 'serum' 'creatinine' 'values' 'and'
 'the' 'Chronic' 'Kidney' 'Disease' 'Epidemiology' 'Collaboration' '('
 'CKD-EPI' ')' 'estimating' 'equation']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02836574,123:126:chronic_disease,"The subject should have adequate, historical clinical data to provide a reasonable estimate of the rate of progression of CKD","['The' 'subject' 'should' 'have' 'adequate' ',' 'historical' 'clinical'
 'data' 'to' 'provide' 'a' 'reasonable' 'estimate' 'of' 'the' 'rate' 'of'
 'progression' 'of' 'CKD']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02820350,96:99:chronic_disease,Patients who have never seen a pediatric nephrologist will be assumed not to have pre-existing CKD,"['Patients' 'who' 'have' 'never' 'seen' 'a' 'pediatric' 'nephrologist'
 'will' 'be' 'assumed' 'not' 'to' 'have' 'pre-existing' 'CKD']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02587936,"1:4:chronic_disease,",CKD Inclusion Criteria (present at least ≥ 3 months apart),"['CKD' 'Inclusion' 'Criteria' '(' 'present' 'at' 'least' '≥' '3' 'months'
 'apart' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02497300,"1:4:chronic_disease,,,,,",CKD (eGFR 25-60 mL/min/1.73m2) with urine albumin-to-creatinine ratio > 30 mg/g,"['CKD' '(' 'eGFR' '25-60' 'mL/min/1.73m2' ')' 'with' 'urine'
 'albumin-to-creatinine' 'ratio' '>' '30' 'mg/g']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02497300,"1:4:chronic_disease,,,,",CKD (eGFR > 60 mL/min/1.73m2) with urine albumin-to-creatinine ratio ≥ 300 mg/g,"['CKD' '(' 'eGFR' '>' '60' 'mL/min/1.73m2' ')' 'with' 'urine'
 'albumin-to-creatinine' 'ratio' '≥' '300' 'mg/g']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02411773,"8:11:chronic_disease,,",Severe CKD (estimated glomerular filtration rate (eGFR) < 15 cc/minute),"['Severe' 'CKD' '(' 'estimated' 'glomerular' 'filtration' 'rate' '('
 'eGFR' ')' '<' '15' 'cc/minute' ')']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01530958,15:18:chronic_disease,Patients with CKD,['Patients' 'with' 'CKD'],[0. 0. 2.]
NCT03076021,"1:8:chronic_disease,,","Obesity, BMI ≥ 30 kg/m2","['Obesity' ',' 'BMI' '≥' '30' 'kg/m2']",[2. 0. 0. 0. 0. 0.]
NCT03061903,"1:8:chronic_disease,,",Obesity (Body Mass Index (BMI) > 30),['Obesity' '(' 'Body' 'Mass' 'Index' '(' 'BMI' ')' '>' '30' ')'],[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02866279,"1:8:chronic_disease,,",Obesity (pre-pregnancy BMI >35),['Obesity' '(' 'pre-pregnancy' 'BMI' '>' '35' ')'],[2. 0. 0. 0. 0. 0. 0.]
NCT02819440,"1:8:chronic_disease,,",Obesity (BMI ≥ 30 kg/m2),['Obesity' '(' 'BMI' '≥' '30' 'kg/m2' ')'],[2. 0. 0. 0. 0. 0. 0.]
NCT02706249,"1:8:chronic_disease,,",Obesity (BMI ≥ 30),['Obesity' '(' 'BMI' '≥' '30' ')'],[2. 0. 0. 0. 0. 0.]
NCT02548351,"1:8:chronic_disease,,",Obesity (BMI ≥30 kg/m2),['Obesity' '(' 'BMI' '≥30' 'kg/m2' ')'],[2. 0. 0. 0. 0. 0.]
NCT02473250,"1:8:chronic_disease,,",Obesity with weight >350 lbs,['Obesity' 'with' 'weight' '>' '350' 'lbs'],[2. 0. 0. 0. 0. 0.]
NCT01614990,"1:8:chronic_disease,,",Obesity (body weight >140 Kg),['Obesity' '(' 'body' 'weight' '>' '140' 'Kg' ')'],[2. 0. 0. 0. 0. 0. 0. 0.]
NCT01026532,"1:8:chronic_disease,,",Obesity as defined by a Body Mass Index (BMI) >30,"['Obesity' 'as' 'defined' 'by' 'a' 'Body' 'Mass' 'Index' '(' 'BMI' ')' '>'
 '30']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03029884,1:13:chronic_disease,Coagulopathy,['Coagulopathy'],[2.]
NCT03003390,1:13:chronic_disease,Coagulopathy,['Coagulopathy'],[2.]
NCT02983903,"1:13:chronic_disease,,,,,","Coagulopathy (platelet count < 50,000, INR > 1.5) detected on blood testing done within 3 weeks of the procedural visit","['Coagulopathy' '(' 'platelet' 'count' '<' '50,000' ',' 'INR' '>' '1.5'
 ')' 'detected' 'on' 'blood' 'testing' 'done' 'within' '3' 'weeks' 'of'
 'the' 'procedural' 'visit']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02937402,"1:13:chronic_disease,,",Coagulopathy with international normalized ratio (INR) > 2.0 or,"['Coagulopathy' 'with' 'international' 'normalized' 'ratio' '(' 'INR' ')'
 '>' '2.0' 'or']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02937402,"1:13:treatment,,",Coagulopathy with platelets (Plt) < 10 k,['Coagulopathy' 'with' 'platelets' '(' 'Plt' ')' '<' '10' 'k'],[1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02679560,"1:13:chronic_disease,,",Coagulopathy with INR >1.5,['Coagulopathy' 'with' 'INR' '>' '1.5'],[2. 0. 0. 0. 0.]
NCT02473276,1:13:chronic_disease,Coagulopathy,['Coagulopathy'],[2.]
NCT01419561,"1:13:chronic_disease,,",Coagulopathy (PT or PTT >1.5 times upper limit of normal),"['Coagulopathy' '(' 'PT' 'or' 'PTT' '>' '1.5' 'times' 'upper' 'limit' 'of'
 'normal' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01187368,1:13:chronic_disease,Coagulopathy,['Coagulopathy'],[2.]
NCT02947347,1:19:chronic_disease,Measurable disease,['Measurable' 'disease'],[2. 2.]
NCT02939183,"1:19:chronic_disease,",Measurable disease (assessed within 28 days prior to day 1),"['Measurable' 'disease' '(' 'assessed' 'within' '28' 'days' 'prior' 'to'
 'day' '1' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02595996,1:19:chronic_disease,Measurable disease,['Measurable' 'disease'],[2. 2.]
NCT02592707,1:19:chronic_disease,Measurable disease based on RECIST v1.1,['Measurable' 'disease' 'based' 'on' 'RECIST' 'v1.1'],[2. 2. 0. 0. 0. 0.]
NCT02476786,1:19:chronic_disease,Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) by ultrasound or mammogram,"['Measurable' 'disease' 'defined' 'as' 'lesions' 'that' 'can' 'be'
 'accurately' 'measured' 'in' 'at' 'least' 'one' 'dimension' '(' 'longest'
 'diameter' 'to' 'be' 'recorded' ')' 'by' 'ultrasound' 'or' 'mammogram']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02451553,1:19:chronic_disease,Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1,"['Measurable' 'disease' 'according' 'to' 'Response' 'Evaluation'
 'Criteria' 'in' 'Solid' 'Tumors' '(' 'RECIST' ')' 'version' '(' 'v' ')'
 '1.1']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02250157,1:19:chronic_disease,Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria,"['Measurable' 'disease' 'as' 'per' 'Response' 'Evaluation' 'Criteria' 'in'
 'Solid' 'Tumors' '(' 'RECIST' ')' 'Version' '1.1' 'criteria']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02091141,1:19:chronic_disease,Measurable disease by RECIST v1.1,['Measurable' 'disease' 'by' 'RECIST' 'v1.1'],[2. 2. 0. 0. 0.]
NCT01464034,1:19:cancer,Measurable disease,['Measurable' 'disease'],[3. 3.]
NCT02901067,"1:17:chronic_disease,,","Thrombocytopenia (platelet count < 50,000)","['Thrombocytopenia' '(' 'platelet' 'count' '<' '50,000' ')']",[2. 0. 0. 0. 0. 0. 0.]
NCT02474927,1:17:chronic_disease,Thrombocytopenia,['Thrombocytopenia'],[2.]
NCT02343549,"1:17:chronic_disease,,",Thrombocytopenia (platelet count < 100 x 103 ),['Thrombocytopenia' '(' 'platelet' 'count' '<' '100' 'x' '103' ')'],[2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02335905,"1:17:chronic_disease,","Thrombocytopenia (less than 50,000 platelets/mm^3)","['Thrombocytopenia' '(' 'less' 'than' '50,000' 'platelets/mm^3' ')']",[2. 0. 0. 0. 0. 0. 0.]
NCT02234934,"1:17:chronic_disease,,","Thrombocytopenia (platelet count < 150,000/mm3)","['Thrombocytopenia' '(' 'platelet' 'count' '<' '150,000/mm3' ')']",[2. 0. 0. 0. 0. 0. 0.]
NCT02226341,"1:17:chronic_disease,,","Thrombocytopenia (platelets < 50,000/mm3)","['Thrombocytopenia' '(' 'platelets' '<' '50,000/mm3' ')']",[2. 0. 0. 0. 0. 0.]
NCT02074436,"1:17:cancer,,",Thrombocytopenia with untransfused platelet counts < 20 x 10⁹/L in the out-patient or in the in-patient setting,"['Thrombocytopenia' 'with' 'untransfused' 'platelet' 'counts' '<' '20' 'x'
 '10⁹/L' 'in' 'the' 'out-patient' 'or' 'in' 'the' 'in-patient' 'setting']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01419561,"1:17:chronic_disease,,","Thrombocytopenia (platelets<100,000 cells/microL)","['Thrombocytopenia' '(' 'platelets' '<' '100,000' 'cells/microL' ')']",[2. 0. 0. 0. 0. 0. 0.]
NCT01059786,"1:17:chronic_disease,,","Thrombocytopenia (Plt less than 100,000/microl)","['Thrombocytopenia' '(' 'Plt' 'less' 'than' '100,000/microl' ')']",[2. 0. 0. 0. 0. 0. 0.]
NCT02706249,8:28:chronic_disease,Active peptic ulcer disease,['Active' 'peptic' 'ulcer' 'disease'],[0. 2. 2. 2.]
NCT02509546,8:28:chronic_disease,Active peptic ulcer disease,['Active' 'peptic' 'ulcer' 'disease'],[0. 2. 2. 2.]
NCT02464878,8:28:chronic_disease,Active peptic ulcer disease,['Active' 'peptic' 'ulcer' 'disease'],[0. 2. 2. 2.]
NCT02132598,8:28:chronic_disease,Active peptic ulcer disease,['Active' 'peptic' 'ulcer' 'disease'],[0. 2. 2. 2.]
NCT02078102,"49:69:chronic_disease,",Patients must not have nor had active or recent peptic ulcer disease within the past 6 months,"['Patients' 'must' 'not' 'have' 'nor' 'had' 'active' 'or' 'recent'
 'peptic' 'ulcer' 'disease' 'within' 'the' 'past' '6' 'months']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT01974609,22:42:chronic_disease,patients with active peptic ulcer disease (history of severe heartburn),"['patients' 'with' 'active' 'peptic' 'ulcer' 'disease' '(' 'history' 'of'
 'severe' 'heartburn' ')']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT01639508,8:28:chronic_disease,active peptic ulcer disease,['active' 'peptic' 'ulcer' 'disease'],[0. 2. 2. 2.]
NCT01553214,21:41:chronic_disease,"Active, symptomatic peptic ulcer disease","['Active' ',' 'symptomatic' 'peptic' 'ulcer' 'disease']",[0. 0. 0. 2. 2. 2.]
NCT01238120,"19:39:chronic_disease,",have a history of peptic ulcer disease within the last 12 months,"['have' 'a' 'history' 'of' 'peptic' 'ulcer' 'disease' 'within' 'the'
 'last' '12' 'months']",[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02473354,18:37:chronic_disease,has a history of sickle cell disease [self-reported],"['has' 'a' 'history' 'of' 'sickle' 'cell' 'disease' '[' 'self-reported'
 ']']",[0. 0. 0. 0. 2. 2. 2. 0. 0. 0.]
NCT02312596,1:20:chronic_disease,sickle cell disease,['sickle' 'cell' 'disease'],[2. 2. 2.]
NCT02312518,1:20:chronic_disease,sickle cell disease,['sickle' 'cell' 'disease'],[2. 2. 2.]
NCT02186418,24:43:chronic_disease,"Confirmed diagnosis of sickle cell disease genotype Hb- S/beta-thalassemia or Hb-S/ beta + thalassemia disease or HbS/Hb-S, confirmed by beta-globin gene analysis and a hemoglobin separation method","['Confirmed' 'diagnosis' 'of' 'sickle' 'cell' 'disease' 'genotype' 'Hb-'
 'S/beta-thalassemia' 'or' 'Hb-S/' 'beta' '+' 'thalassemia' 'disease' 'or'
 'HbS/Hb-S' ',' 'confirmed' 'by' 'beta-globin' 'gene' 'analysis' 'and' 'a'
 'hemoglobin' 'separation' 'method']","[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02186418,18:37:chronic_disease,Most adults with sickle cell disease will have compromised PFTs,"['Most' 'adults' 'with' 'sickle' 'cell' 'disease' 'will' 'have'
 'compromised' 'PFTs']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0.]
NCT02186418,8:27:chronic_disease,Severe sickle cell disease,['Severe' 'sickle' 'cell' 'disease'],[0. 2. 2. 2.]
NCT02165007,22:41:chronic_disease,Patients with severe sickle cell disease,['Patients' 'with' 'severe' 'sickle' 'cell' 'disease'],[0. 0. 0. 2. 2. 2.]
NCT01891812,15:34:chronic_disease,Patients with sickle cell disease,['Patients' 'with' 'sickle' 'cell' 'disease'],[0. 0. 2. 2. 2.]
NCT01754298,14:33:chronic_disease,Diagnosis of sickle cell disease,['Diagnosis' 'of' 'sickle' 'cell' 'disease'],[0. 0. 2. 2. 2.]
NCT03144921,8:22:chronic_disease,severe mental illness,['severe' 'mental' 'illness'],[0. 2. 2.]
NCT03084640,48:62:chronic_disease,"Any concurrent uncontrolled illness, including mental illness or substance abuse, which in the opinion of the Investigator","['Any' 'concurrent' 'uncontrolled' 'illness' ',' 'including' 'mental'
 'illness' 'or' 'substance' 'abuse' ',' 'which' 'in' 'the' 'opinion' 'of'
 'the' 'Investigator']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03026816,24:38:chronic_disease,Clinically significant mental illness,['Clinically' 'significant' 'mental' 'illness'],[0. 0. 2. 2.]
NCT02826577,10:24:chronic_disease,Unstable mental illness,['Unstable' 'mental' 'illness'],[0. 2. 2.]
NCT02799095,68:82:chronic_disease,"Subjects with any other concurrent uncontrolled illness, including mental illness or substance abuse, which may interfere with the ability of the subject to cooperate and participate in the study","['Subjects' 'with' 'any' 'other' 'concurrent' 'uncontrolled' 'illness' ','
 'including' 'mental' 'illness' 'or' 'substance' 'abuse' ',' 'which' 'may'
 'interfere' 'with' 'the' 'ability' 'of' 'the' 'subject' 'to' 'cooperate'
 'and' 'participate' 'in' 'the' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02680535,1:15:chronic_disease,mental illness,['mental' 'illness'],[2. 2.]
NCT02437773,31:45:chronic_disease,No history of past or current mental illness,['No' 'history' 'of' 'past' 'or' 'current' 'mental' 'illness'],[0. 0. 0. 0. 0. 0. 2. 2.]
NCT02155946,22:36:chronic_disease,No history of severe mental illness,['No' 'history' 'of' 'severe' 'mental' 'illness'],[0. 0. 0. 0. 2. 2.]
NCT03133013,16:41:chronic_disease,diagnosed with Major Depressive Disorder by a psychiatric specialist of this research according to MINI screening and DSM-5 criteria,"['diagnosed' 'with' 'Major' 'Depressive' 'Disorder' 'by' 'a' 'psychiatric'
 'specialist' 'of' 'this' 'research' 'according' 'to' 'MINI' 'screening'
 'and' 'DSM-5' 'criteria']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03038620,"12:37:chronic_disease,",History of Major Depressive Disorder within the last 2 years,"['History' 'of' 'Major' 'Depressive' 'Disorder' 'within' 'the' 'last' '2'
 'years']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02734602,37:62:chronic_disease,"Meet DSM-IV diagnostic criteria for Major Depressive Disorder, and for a current depressive episode","['Meet' 'DSM-IV' 'diagnostic' 'criteria' 'for' 'Major' 'Depressive'
 'Disorder' ',' 'and' 'for' 'a' 'current' 'depressive' 'episode']",[0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02674529,56:81:chronic_disease,Currently experiencing a depressive episode as part of Major Depressive Disorder,"['Currently' 'experiencing' 'a' 'depressive' 'episode' 'as' 'part' 'of'
 'Major' 'Depressive' 'Disorder']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02389465,21:46:chronic_disease,DSM-IV criteria for Major Depressive Disorder,['DSM-IV' 'criteria' 'for' 'Major' 'Depressive' 'Disorder'],[0. 0. 0. 2. 2. 2.]
NCT02357849,22:47:chronic_disease,"current diagnosis of Major Depressive Disorder, single episode or recurrent, severe without psychotic features","['current' 'diagnosis' 'of' 'Major' 'Depressive' 'Disorder' ',' 'single'
 'episode' 'or' 'recurrent' ',' 'severe' 'without' 'psychotic' 'features']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02301260,24:49:chronic_disease,a current diagnosis of Major Depressive Disorder,['a' 'current' 'diagnosis' 'of' 'Major' 'Depressive' 'Disorder'],[0. 0. 0. 0. 2. 2. 2.]
NCT02133898,"14:39:chronic_disease,",Diagnosis of Major Depressive Disorder based on Structured Clinical Interview for DSM-IV (SCID),"['Diagnosis' 'of' 'Major' 'Depressive' 'Disorder' 'based' 'on'
 'Structured' 'Clinical' 'Interview' 'for' 'DSM-IV' '(' 'SCID' ')']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03122639,"1:4:chronic_disease,,",OSA is defined as apnea-hypopnea index (AHI) ≥5 events/hour of sleep,"['OSA' 'is' 'defined' 'as' 'apnea-hypopnea' 'index' '(' 'AHI' ')' '≥5'
 'events/hour' 'of' 'sleep']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03109210,"21:24:chronic_disease,,",have a diagnosis of OSA with an AHI > 5 on a diagnostic polysomnogram,"['have' 'a' 'diagnosis' 'of' 'OSA' 'with' 'an' 'AHI' '>' '5' 'on' 'a'
 'diagnostic' 'polysomnogram']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02962557,"11:14:chronic_disease,,,",Suspected OSA will be defined as a patient with a screening questionnaire (STOP-Bang) score of 5-8 (A score consistent with a high risk of OSA),"['Suspected' 'OSA' 'will' 'be' 'defined' 'as' 'a' 'patient' 'with' 'a'
 'screening' 'questionnaire' '(' 'STOP-Bang' ')' 'score' 'of' '5-8' '('
 'A' 'score' 'consistent' 'with' 'a' 'high' 'risk' 'of' 'OSA' ')']","[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02781701,"44:47:chronic_disease,,,",At home confirmation of moderate to severe OSA (AHI 15-60),"['At' 'home' 'confirmation' 'of' 'moderate' 'to' 'severe' 'OSA' '(' 'AHI'
 '15-60' ')']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT02413970,34:37:chronic_disease,Likely suffer moderate-to-severe OSA based on history and physical,"['Likely' 'suffer' 'moderate-to-severe' 'OSA' 'based' 'on' 'history' 'and'
 'physical']",[0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02413970,"34:37:chronic_disease,,",have an established diagnosis of OSA (AHI >= 15) based on a prior sleep study,"['have' 'an' 'established' 'diagnosis' 'of' 'OSA' '(' 'AHI' '>' '=' '15'
 ')' 'based' 'on' 'a' 'prior' 'sleep' 'study']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02202811,"20:23:chronic_disease,,",Moderate to severe OSA (AHI)>15,['Moderate' 'to' 'severe' 'OSA' '(' 'AHI' ')' '>' '15'],[0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT01738009,34:37:chronic_disease,Normal subjects or patients with OSA,['Normal' 'subjects' 'or' 'patients' 'with' 'OSA'],[0. 0. 0. 0. 0. 2.]
NCT03076021,7:21:chronic_disease,Known kidney disease,['Known' 'kidney' 'disease'],[0. 2. 2.]
NCT03034564,13:27:chronic_disease,Significant kidney disease history,['Significant' 'kidney' 'disease' 'history'],[0. 2. 2. 0.]
NCT02982772,1:15:chronic_disease,kidney disease,['kidney' 'disease'],[2. 2.]
NCT02914483,26:40:chronic_disease,chronic elevation due to kidney disease,['chronic' 'elevation' 'due' 'to' 'kidney' 'disease'],[0. 0. 0. 0. 2. 2.]
NCT02881515,12:26:chronic_disease,history of kidney disease,['history' 'of' 'kidney' 'disease'],[0. 0. 2. 2.]
NCT02682147,1:15:chronic_disease,kidney disease,['kidney' 'disease'],[2. 2.]
NCT02462161,1:15:chronic_disease,kidney disease,['kidney' 'disease'],[2. 2.]
NCT02411773,",,35:49:chronic_disease","Veterans 18-75 years old, without kidney disease, as study controls","['Veterans' '18-75' 'years' 'old' ',' 'without' 'kidney' 'disease' ','
 'as' 'study' 'controls']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT03066648,11:14:chronic_disease,High risk MDS,['High' 'risk' 'MDS'],[0. 0. 2.]
NCT02649790,"25:28:chronic_disease,,,",Documented diagnosis of MDS with 5-19% myeloblasts,['Documented' 'diagnosis' 'of' 'MDS' 'with' '5-19' '%' 'myeloblasts'],[0. 0. 0. 2. 0. 0. 0. 0.]
NCT02649790,",33:36:cancer",IPSS low or intermediate-1 risk MDS,['IPSS' 'low' 'or' 'intermediate-1' 'risk' 'MDS'],[0. 0. 0. 0. 0. 3.]
NCT02530463,"15:18:cancer,",Patients with MDS (up to 20% blasts) of any risk as defined as,"['Patients' 'with' 'MDS' '(' 'up' 'to' '20' '%' 'blasts' ')' 'of' 'any'
 'risk' 'as' 'defined' 'as']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02131597,"13:16:cancer,,,,",higher risk MDS (International Prognostic Scoring System [IPSS] int-2 or high; or >= 10% blasts as defined by World Health Organization [WHO]),"['higher' 'risk' 'MDS' '(' 'International' 'Prognostic' 'Scoring' 'System'
 '[' 'IPSS' ']' 'int-2' 'or' 'high' ';' 'or' '>' '=' '10' '%' 'blasts'
 'as' 'defined' 'by' 'World' 'Health' 'Organization' '[' 'WHO' ']' ')']","[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT01861106,",68:71:chronic_disease,,","Clinical history of at least one life-threatening infection and/or MDS with International Prognostic Scoring System (IPSS) category of Intermediate-1, Intermediate-2 or High","['Clinical' 'history' 'of' 'at' 'least' 'one' 'life-threatening'
 'infection' 'and/or' 'MDS' 'with' 'International' 'Prognostic' 'Scoring'
 'System' '(' 'IPSS' ')' 'category' 'of' 'Intermediate-1' ','
 'Intermediate-2' 'or' 'High']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT01861106,"31:34:cancer,,",The majority of patients with MDS will have less than 5% blasts,"['The' 'majority' 'of' 'patients' 'with' 'MDS' 'will' 'have' 'less' 'than'
 '5' '%' 'blasts']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT01349101,15:18:cancer,patients with MDS,['patients' 'with' 'MDS'],[0. 0. 3.]
NCT03028831,1:19:chronic_disease,bleeding disorders,['bleeding' 'disorders'],[2. 2.]
NCT02914171,18:36:chronic_disease,Individuals with bleeding disorders,['Individuals' 'with' 'bleeding' 'disorders'],[0. 0. 2. 2.]
NCT02703272,41:59:chronic_disease,Participants with inherited or acquired bleeding disorders,['Participants' 'with' 'inherited' 'or' 'acquired' 'bleeding' 'disorders'],[0. 0. 0. 0. 0. 2. 2.]
NCT02553941,"7:25:chronic_disease,,","Known bleeding disorders, active bleeding disorders or clinical signs of bleeding (grade >= 2)","['Known' 'bleeding' 'disorders' ',' 'active' 'bleeding' 'disorders' 'or'
 'clinical' 'signs' 'of' 'bleeding' '(' 'grade' '>' '=' '2' ')']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02514083,7:25:chronic_disease,Known bleeding disorders,['Known' 'bleeding' 'disorders'],[0. 2. 2.]
NCT02366871,21:39:chronic_disease,Known or documented bleeding disorders,['Known' 'or' 'documented' 'bleeding' 'disorders'],[0. 0. 0. 2. 2.]
NCT02203552,7:25:chronic_disease,Known bleeding disorders,['Known' 'bleeding' 'disorders'],[0. 2. 2.]
NCT01695967,1:19:chronic_disease,bleeding disorders,['bleeding' 'disorders'],[2. 2.]
NCT02987491,",,,,54:59:chronic_disease,,",Normal weight (body mass index [BMI] 18-26 kg/m2) or obese (BMI 30-46 kg/m2),"['Normal' 'weight' '(' 'body' 'mass' 'index' '[' 'BMI' ']' '18-26' 'kg/m2'
 ')' 'or' 'obese' '(' 'BMI' '30-46' 'kg/m2' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02577549,"32:37:chronic_disease,,","Not sufficiently overweight or obese, BMI < 27 kg/m2","['Not' 'sufficiently' 'overweight' 'or' 'obese' ',' 'BMI' '<' '27' 'kg/m2']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02465541,",15:20:chronic_disease,",Overweight or obese (> 25 kg/m^2),['Overweight' 'or' 'obese' '(' '>' '25' 'kg/m^2' ')'],[0. 0. 2. 0. 0. 0. 0. 0.]
NCT02425566,1:6:chronic_disease,obese,['obese'],[2.]
NCT02424929,19:24:chronic_disease,Patients that are obese or that have severe potential airway issues,"['Patients' 'that' 'are' 'obese' 'or' 'that' 'have' 'severe' 'potential'
 'airway' 'issues']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02392897,"24:29:chronic_disease,","Normal, overweight and obese males and females","['Normal' ',' 'overweight' 'and' 'obese' 'males' 'and' 'females']",[0. 0. 0. 0. 2. 0. 0. 0.]
NCT02347527,12:17:chronic_disease,Overweight/obese adults,['Overweight/obese' 'adults'],[2. 0.]
NCT01421797,12:17:chronic_disease,Normal and obese,['Normal' 'and' 'obese'],[0. 0. 2.]
NCT02764801,26:45:chronic_disease,with clinically unstable cardiac arrhythmias,['with' 'clinically' 'unstable' 'cardiac' 'arrhythmias'],[0. 0. 0. 2. 2.]
NCT02496208,24:43:chronic_disease,Clinically-significant cardiac arrhythmias,['Clinically-significant' 'cardiac' 'arrhythmias'],[0. 2. 2.]
NCT02208362,70:89:chronic_disease,Research participant requires pressor support and/or has symptomatic cardiac arrhythmias,"['Research' 'participant' 'requires' 'pressor' 'support' 'and/or' 'has'
 'symptomatic' 'cardiac' 'arrhythmias']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02101736,24:43:chronic_disease,clinically-significant cardiac arrhythmias,['clinically-significant' 'cardiac' 'arrhythmias'],[0. 2. 2.]
NCT01978509,16:35:chronic_disease,Risk of severe cardiac arrhythmias,['Risk' 'of' 'severe' 'cardiac' 'arrhythmias'],[0. 0. 0. 2. 2.]
NCT01841333,"8:27:chronic_disease,",Active cardiac arrhythmias with rapid ventricular response (defined as heart rate greater than 100 beats/minute),"['Active' 'cardiac' 'arrhythmias' 'with' 'rapid' 'ventricular' 'response'
 '(' 'defined' 'as' 'heart' 'rate' 'greater' 'than' '100' 'beats/minute'
 ')']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01822522,24:43:chronic_disease,Clinically-significant cardiac arrhythmias,['Clinically-significant' 'cardiac' 'arrhythmias'],[0. 2. 2.]
NCT01639508,24:43:chronic_disease,clinically-significant cardiac arrhythmias,['clinically-significant' 'cardiac' 'arrhythmias'],[0. 2. 2.]
NCT02573493,"18:37:cancer,",History of prior invasive malignancy diagnosed within 3 years prior to study enrollment,"['History' 'of' 'prior' 'invasive' 'malignancy' 'diagnosed' 'within' '3'
 'years' 'prior' 'to' 'study' 'enrollment']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02465268,"7:26:cancer,",Prior invasive malignancy unless disease free for ≥ 3 years,"['Prior' 'invasive' 'malignancy' 'unless' 'disease' 'free' 'for' '≥' '3'
 'years']",[0. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02237183,"47:66:cancer,",Participants must not have a current or prior invasive malignancy within the past 6 months,"['Participants' 'must' 'not' 'have' 'a' 'current' 'or' 'prior' 'invasive'
 'malignancy' 'within' 'the' 'past' '6' 'months']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT02122185,"19:38:cancer,,,",Concurrent active invasive malignancy or one previously diagnosed with a greater than 30% chance of recurrence in the next two years,"['Concurrent' 'active' 'invasive' 'malignancy' 'or' 'one' 'previously'
 'diagnosed' 'with' 'a' 'greater' 'than' '30' '%' 'chance' 'of'
 'recurrence' 'in' 'the' 'next' 'two' 'years']",[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02110992,7:26:cancer,Prior invasive malignancy,['Prior' 'invasive' 'malignancy'],[0. 3. 3.]
NCT02080221,"10:29:cancer,",No prior invasive malignancy within the prior two years,['No' 'prior' 'invasive' 'malignancy' 'within' 'the' 'prior' 'two' 'years'],[0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT01890590,"18:37:cancer,",Prior history of invasive malignancy within the last 2 years,"['Prior' 'history' 'of' 'invasive' 'malignancy' 'within' 'the' 'last' '2'
 'years']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT01659203,"24:43:cancer,",History of a different invasive malignancy within the past 3 years,"['History' 'of' 'a' 'different' 'invasive' 'malignancy' 'within' 'the'
 'past' '3' 'years']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT02416674,35:50:treatment,Strong motivation to proceed with transplantation,['Strong' 'motivation' 'to' 'proceed' 'with' 'transplantation'],[0. 0. 0. 0. 0. 1.]
NCT02327403,",17:32:treatment",≥6 months after transplantation,['≥6' 'months' 'after' 'transplantation'],[0. 0. 0. 1.]
NCT01459107,116:131:treatment,Functionless or minimally functional hand desiring removal of functionless / minimally functional hand followed by transplantation,"['Functionless' 'or' 'minimally' 'functional' 'hand' 'desiring' 'removal'
 'of' 'functionless' '/' 'minimally' 'functional' 'hand' 'followed' 'by'
 'transplantation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01453088,",,26:41:treatment",Age ≥60 years at time of transplantation,['Age' '≥60' 'years' 'at' 'time' 'of' 'transplantation'],[0. 0. 0. 0. 0. 0. 1.]
NCT01366612,45:60:treatment,Any stage of disease will be considered for transplantation,"['Any' 'stage' 'of' 'disease' 'will' 'be' 'considered' 'for'
 'transplantation']",[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01241708,",,,29:44:treatment",Age: 18-75 years at time of transplantation,['Age' ':' '18-75' 'years' 'at' 'time' 'of' 'transplantation'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT01054196,82:97:treatment,Patients must have an adequate number of CD34+ stem cells collected to allow for transplantation,"['Patients' 'must' 'have' 'an' 'adequate' 'number' 'of' 'CD34+' 'stem'
 'cells' 'collected' 'to' 'allow' 'for' 'transplantation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT00711373,68:83:treatment,severe concomitant diseases which would exclude the recipient from transplantation,"['severe' 'concomitant' 'diseases' 'which' 'would' 'exclude' 'the'
 'recipient' 'from' 'transplantation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03176979,",12:22:allergy_name",Women with gadolinium contrast allergy,['Women' 'with' 'gadolinium' 'contrast' 'allergy'],[0. 0. 4. 0. 0.]
NCT02844465,12:22:allergy_name,Allergy to gadolinium,['Allergy' 'to' 'gadolinium'],[0. 0. 4.]
NCT02776891,16:26:treatment,intolerance to gadolinium,['intolerance' 'to' 'gadolinium'],[0. 0. 1.]
NCT02531880,12:22:allergy_name,Allergy to gadolinium,['Allergy' 'to' 'gadolinium'],[0. 0. 4.]
NCT02251431,27:37:allergy_name,Allergy or intolerance to gadolinium,['Allergy' 'or' 'intolerance' 'to' 'gadolinium'],[0. 0. 0. 0. 4.]
NCT02124902,28:38:allergy_name,Prior allergic reaction to gadolinium-based MR contrast agents,"['Prior' 'allergic' 'reaction' 'to' 'gadolinium-based' 'MR' 'contrast'
 'agents']",[0. 0. 0. 0. 4. 0. 0. 0.]
NCT01644591,50:60:allergy_name,Patients are excluded if there is any history of gadolinium allergy,"['Patients' 'are' 'excluded' 'if' 'there' 'is' 'any' 'history' 'of'
 'gadolinium' 'allergy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0.]
NCT03159754,17:29:treatment,Patients taking theophylline,['Patients' 'taking' 'theophylline'],[0. 0. 1.]
NCT02498301,1:13:treatment,theophylline,['theophylline'],[1.]
NCT02495168,40:52:treatment,Once-a-day controlled-release forms of theophylline: 36 hours,"['Once-a-day' 'controlled-release' 'forms' 'of' 'theophylline' ':' '36'
 'hours']",[0. 0. 0. 0. 1. 0. 0. 0.]
NCT02495168,23:35:treatment,Short-acting forms of theophylline: 12 hours,['Short-acting' 'forms' 'of' 'theophylline' ':' '12' 'hours'],[0. 0. 0. 1. 0. 0. 0.]
NCT02495168,41:53:treatment,Twice-a-day controlled-release forms of theophylline: 24 hours,"['Twice-a-day' 'controlled-release' 'forms' 'of' 'theophylline' ':' '24'
 'hours']",[0. 0. 0. 0. 1. 0. 0. 0.]
NCT02479451,33:45:treatment,Patients currently treated with theophylline for clinical indication,"['Patients' 'currently' 'treated' 'with' 'theophylline' 'for' 'clinical'
 'indication']",[0. 0. 0. 0. 1. 0. 0. 0.]
NCT02479451,28:40:allergy_name,Prior allergic reaction to theophylline,['Prior' 'allergic' 'reaction' 'to' 'theophylline'],[0. 0. 0. 0. 4.]
NCT03153410,15:30:chronic_disease,Patients with thyroid disease,['Patients' 'with' 'thyroid' 'disease'],[0. 0. 2. 2.]
NCT03073070,14:29:chronic_disease,uncontrolled thyroid disease,['uncontrolled' 'thyroid' 'disease'],[0. 2. 2.]
NCT03035799,"14:29:chronic_disease,",Uncontrolled thyroid disease as indicated by an abnormal thyroid stimulating hormone (TSH) level,"['Uncontrolled' 'thyroid' 'disease' 'as' 'indicated' 'by' 'an' 'abnormal'
 'thyroid' 'stimulating' 'hormone' '(' 'TSH' ')' 'level']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03007745,1:16:chronic_disease,thyroid disease,['thyroid' 'disease'],[2. 2.]
NCT02272556,11:26:chronic_disease,Untreated thyroid disease,['Untreated' 'thyroid' 'disease'],[0. 2. 2.]
NCT02169037,40:55:chronic_disease,"AF secondary to electrolyte imbalance, thyroid disease","['AF' 'secondary' 'to' 'electrolyte' 'imbalance' ',' 'thyroid' 'disease']",[0. 0. 0. 0. 0. 0. 2. 2.]
NCT01614990,11:26:chronic_disease,untreated thyroid disease,['untreated' 'thyroid' 'disease'],[0. 2. 2.]
NCT03133013,1:19:chronic_disease,multiple sclerosis,['multiple' 'sclerosis'],[2. 2.]
NCT03058796,1:19:chronic_disease,multiple sclerosis,['multiple' 'sclerosis'],[2. 2.]
NCT03016351,1:19:chronic_disease,multiple sclerosis,['multiple' 'sclerosis'],[2. 2.]
NCT02862938,26:44:chronic_disease,Patient has a history of multiple sclerosis,['Patient' 'has' 'a' 'history' 'of' 'multiple' 'sclerosis'],[0. 0. 0. 0. 0. 2. 2.]
NCT02694666,15:33:chronic_disease,Self-reported multiple sclerosis and confirmed by the physician,"['Self-reported' 'multiple' 'sclerosis' 'and' 'confirmed' 'by' 'the'
 'physician']",[0. 2. 2. 0. 0. 0. 0. 0.]
NCT02329652,1:19:chronic_disease,multiple sclerosis,['multiple' 'sclerosis'],[2. 2.]
NCT01326715,14:32:chronic_disease,Diagnosis of multiple sclerosis according to the current McDonald Criteria,"['Diagnosis' 'of' 'multiple' 'sclerosis' 'according' 'to' 'the' 'current'
 'McDonald' 'Criteria']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT03114891,12:15:allergy_name,Additional TMS contraindications,['Additional' 'TMS' 'contraindications'],[0. 4. 0.]
NCT03037983,38:41:allergy_name,History of prior adverse reaction to TMS,['History' 'of' 'prior' 'adverse' 'reaction' 'to' 'TMS'],[0. 0. 0. 0. 0. 0. 4.]
NCT02565199,24:27:allergy_name,Has a contradiction to TMS,['Has' 'a' 'contradiction' 'to' 'TMS'],[0. 0. 0. 0. 4.]
NCT02565199,",27:30:treatment",MEP cannot be evoked with TMS in the ECU muscle,['MEP' 'can' 'not' 'be' 'evoked' 'with' 'TMS' 'in' 'the' 'ECU' 'muscle'],[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02565199,49:52:treatment,The subjects must be comfortable when receiving TMS of all strengths,"['The' 'subjects' 'must' 'be' 'comfortable' 'when' 'receiving' 'TMS' 'of'
 'all' 'strengths']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02544503,21:24:treatment,Contraindication to TMS,['Contraindication' 'to' 'TMS'],[0. 0. 1.]
NCT02479906,41:44:treatment,Subject has had previous treatment with TMS,['Subject' 'has' 'had' 'previous' 'treatment' 'with' 'TMS'],[0. 0. 0. 0. 0. 0. 1.]
NCT03096288,1:24:chronic_disease,Hemodynamic instability,['Hemodynamic' 'instability'],[2. 2.]
NCT02973139,1:24:chronic_disease,Hemodynamic instability,['Hemodynamic' 'instability'],[2. 2.]
NCT02836899,"1:24:chronic_disease,,",Hemodynamic instability as defined by a systolic blood pressure <90 mmHg,"['Hemodynamic' 'instability' 'as' 'defined' 'by' 'a' 'systolic' 'blood'
 'pressure' '<' '90' 'mmHg']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02749968,"1:24:chronic_disease,,,,",Hemodynamic instability (defined as new intravenous vasopressor or inotrope requirement or mean arterial pressure < 55 mmHg),"['Hemodynamic' 'instability' '(' 'defined' 'as' 'new' 'intravenous'
 'vasopressor' 'or' 'inotrope' 'requirement' 'or' 'mean' 'arterial'
 'pressure' '<' '55' 'mmHg' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02741180,1:24:chronic_disease,Hemodynamic instability,['Hemodynamic' 'instability'],[2. 2.]
NCT02464904,"1:24:chronic_disease,,,,","Hemodynamic instability with systolic blood pressure <90 mmHg or heart rate > 120 beats/min, unless deemed to be stable with these values by the surgical or interventional pulmonary attending physicians","['Hemodynamic' 'instability' 'with' 'systolic' 'blood' 'pressure' '<' '90'
 'mmHg' 'or' 'heart' 'rate' '>' '120' 'beats/min' ',' 'unless' 'deemed'
 'to' 'be' 'stable' 'with' 'these' 'values' 'by' 'the' 'surgical' 'or'
 'interventional' 'pulmonary' 'attending' 'physicians']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT00871260,1:24:chronic_disease,Hemodynamic instability,['Hemodynamic' 'instability'],[2. 2.]
NCT03089853,",36:51:treatment",can be enrolled within 36 hours of hospitalization,['can' 'be' 'enrolled' 'within' '36' 'hours' 'of' 'hospitalization'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT03078907,"5:20:treatment,",Any hospitalization during the last 30 days prior to screening,"['Any' 'hospitalization' 'during' 'the' 'last' '30' 'days' 'prior' 'to'
 'screening']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02531295,"8:23:treatment,",Recent hospitalization in the last 90 days,['Recent' 'hospitalization' 'in' 'the' 'last' '90' 'days'],[0. 1. 0. 0. 0. 0. 0.]
NCT02494141,"12:27:treatment,",History of hospitalization within the last 3 months,['History' 'of' 'hospitalization' 'within' 'the' 'last' '3' 'months'],[0. 0. 1. 0. 0. 0. 0. 0.]
NCT02408406,67:82:treatment,Current outpatient status (participation will be suspended during hospitalization),"['Current' 'outpatient' 'status' '(' 'participation' 'will' 'be'
 'suspended' 'during' 'hospitalization' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02341300,",98:113:treatment,",Women with severe chronic illness and high likelihood of preterm birth and/or expected long-term hospitalizations during pregnancy,"['Women' 'with' 'severe' 'chronic' 'illness' 'and' 'high' 'likelihood'
 'of' 'preterm' 'birth' 'and/or' 'expected' 'long-term' 'hospitalizations'
 'during' 'pregnancy']",[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT01705119,37:52:treatment,patient was not ambulatory prior to hospitalization,['patient' 'was' 'not' 'ambulatory' 'prior' 'to' 'hospitalization'],[0. 0. 0. 0. 0. 0. 1.]
NCT03069469,44:58:chronic_disease,History or presence of clinically relevant cardiovascular abnormalities,"['History' 'or' 'presence' 'of' 'clinically' 'relevant' 'cardiovascular'
 'abnormalities']",[0. 0. 0. 0. 0. 0. 2. 0.]
NCT02469857,",,123:137:chronic_disease","(in any one or combination of the 5 major components of SOFA score with one organ component having a score of at least 2: cardiovascular, respiratory, renal, coagulation, CNS), measured as close as possible to the first debridement","['(' 'in' 'any' 'one' 'or' 'combination' 'of' 'the' '5' 'major'
 'components' 'of' 'SOFA' 'score' 'with' 'one' 'organ' 'component'
 'having' 'a' 'score' 'of' 'at' 'least' '2' ':' 'cardiovascular' ','
 'respiratory' ',' 'renal' ',' 'coagulation' ',' 'CNS' ')' ',' 'measured'
 'as' 'close' 'as' 'possible' 'to' 'the' 'first' 'debridement']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02397889,1:15:chronic_disease,cardiovascular,['cardiovascular'],[2.]
NCT02343042,18:32:chronic_disease,"Active, unstable cardiovascular function","['Active' ',' 'unstable' 'cardiovascular' 'function']",[0. 0. 0. 2. 0.]
NCT02215096,24:38:chronic_disease,History or evidence of cardiovascular risk,['History' 'or' 'evidence' 'of' 'cardiovascular' 'risk'],[0. 0. 0. 0. 2. 0.]
NCT02070549,24:38:chronic_disease,History or evidence of cardiovascular risk,['History' 'or' 'evidence' 'of' 'cardiovascular' 'risk'],[0. 0. 0. 0. 2. 0.]
NCT01532687,45:59:chronic_disease,History of any one or more of the following cardiovascular conditions,"['History' 'of' 'any' 'one' 'or' 'more' 'of' 'the' 'following'
 'cardiovascular' 'conditions']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT03043807,"1:16:treatment,",hormone therapy was recently initiated (<90 days duration)),"['hormone' 'therapy' 'was' 'recently' 'initiated' '(' '<' '90' 'days'
 'duration' ')' ')']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02907983,10:25:treatment,for whom hormone therapy is contraindicated,['for' 'whom' 'hormone' 'therapy' 'is' 'contraindicated'],[0. 0. 1. 1. 0. 0.]
NCT01886794,"8:23:treatment,,",Use of hormone therapy in postmenopausal women in the last 90 days,"['Use' 'of' 'hormone' 'therapy' 'in' 'postmenopausal' 'women' 'in' 'the'
 'last' '90' 'days']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01570998,1:16:treatment,hormone therapy,['hormone' 'therapy'],[1. 1.]
NCT01438073,42:57:treatment,able to undergo appropriate washout from hormone therapy,['able' 'to' 'undergo' 'appropriate' 'washout' 'from' 'hormone' 'therapy'],[0. 0. 0. 0. 0. 0. 1. 1.]
NCT00914823,42:57:treatment,able to undergo appropriate washout from hormone therapy,['able' 'to' 'undergo' 'appropriate' 'washout' 'from' 'hormone' 'therapy'],[0. 0. 0. 0. 0. 0. 1. 1.]
NCT00914823,30:45:treatment,able to undergo washout from hormone therapy,['able' 'to' 'undergo' 'washout' 'from' 'hormone' 'therapy'],[0. 0. 0. 0. 0. 1. 1.]
NCT03018704,34:57:treatment,"current regular treatment with a psychotropic medication, including medications that, when combined with alcohol, present a risk of overdose","['current' 'regular' 'treatment' 'with' 'a' 'psychotropic' 'medication'
 ',' 'including' 'medications' 'that' ',' 'when' 'combined' 'with'
 'alcohol' ',' 'present' 'a' 'risk' 'of' 'overdose']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02707887,"12:35:treatment,",The use of psychotropic medication for < 3 months,['The' 'use' 'of' 'psychotropic' 'medication' 'for' '<' '3' 'months'],[0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02483910,4:27:treatment,"On psychotropic medication, but regimen is not stable (Once stabilized, eligibility could be reconsidered.)","['On' 'psychotropic' 'medication' ',' 'but' 'regimen' 'is' 'not' 'stable'
 '(' 'Once' 'stabilized' ',' 'eligibility' 'could' 'be' 'reconsidered' '.'
 ')']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02283333,"25:48:treatment,",Veterans starting a new psychotropic medication at baseline will be asked to wait 4 weeks for medication stabilization before starting the study,"['Veterans' 'starting' 'a' 'new' 'psychotropic' 'medication' 'at'
 'baseline' 'will' 'be' 'asked' 'to' 'wait' '4' 'weeks' 'for' 'medication'
 'stabilization' 'before' 'starting' 'the' 'study']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02046330,"29:52:treatment,",On a stable drug regimen of psychotropic medication for at least 6 weeks at the time of entry into the study,"['On' 'a' 'stable' 'drug' 'regimen' 'of' 'psychotropic' 'medication' 'for'
 'at' 'least' '6' 'weeks' 'at' 'the' 'time' 'of' 'entry' 'into' 'the'
 'study']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01986075,28:51:treatment,Currently being prescribed psychotropic medication by another physician,"['Currently' 'being' 'prescribed' 'psychotropic' 'medication' 'by'
 'another' 'physician']",[0. 0. 0. 1. 1. 0. 0. 0.]
NCT01964404,12:35:treatment,Taking any psychotropic medication,['Taking' 'any' 'psychotropic' 'medication'],[0. 0. 1. 1.]
NCT02947945,1:11:chronic_disease,"Neuropathy, mono or poly (motor deficit or nerve conduction abnormality)","['Neuropathy' ',' 'mono' 'or' 'poly' '(' 'motor' 'deficit' 'or' 'nerve'
 'conduction' 'abnormality' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02828618,"22:32:chronic_disease,,",Neurologic function: Neuropathy (sensory and motor) less than or equal to CTCAE Grade 1,"['Neurologic' 'function' ':' 'Neuropathy' '(' 'sensory' 'and' 'motor' ')'
 'less' 'than' 'or' 'equal' 'to' 'CTCAE' 'Grade' '1']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02366819,"1:11:chronic_disease,","Neuropathy, grade 2 or greater by NCI-CTCAE, v 4.0","['Neuropathy' ',' 'grade' '2' 'or' 'greater' 'by' 'NCI-CTCAE' ',' 'v'
 '4.0']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02269293,"22:32:chronic_disease,",Neurologic function: Neuropathy (sensory and motor) less than or equal to Grade 1,"['Neurologic' 'function' ':' 'Neuropathy' '(' 'sensory' 'and' 'motor' ')'
 'less' 'than' 'or' 'equal' 'to' 'Grade' '1']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01690468,"1:11:chronic_disease,,",Neuropathy (sensory and motor) less than or equal to grade 1 per Common Toxicity Criteria (CTC) version 4,"['Neuropathy' '(' 'sensory' 'and' 'motor' ')' 'less' 'than' 'or' 'equal'
 'to' 'grade' '1' 'per' 'Common' 'Toxicity' 'Criteria' '(' 'CTC' ')'
 'version' '4']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01591356,1:11:chronic_disease,Neuropathy (sensory and motor) =< to CTCAE grade 1,"['Neuropathy' '(' 'sensory' 'and' 'motor' ')' '=' '<' 'to' 'CTCAE' 'grade'
 '1']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01419561,1:11:chronic_disease,Neuropathy with or without pain,['Neuropathy' 'with' 'or' 'without' 'pain'],[2. 0. 0. 0. 0.]
NCT02931110,"19:21:chronic_disease,,,,,,","For subjects with MM, measurable disease with serum monoclonal immunoglobulin protein (M-protein) ≥1 g/dL, or urine M-protein protein ≥200 mg/24 hours, or involved serum free light chain (SFLC) ≥10 mg/dL","['For' 'subjects' 'with' 'MM' ',' 'measurable' 'disease' 'with' 'serum'
 'monoclonal' 'immunoglobulin' 'protein' '(' 'M-protein' ')' '≥1' 'g/dL'
 ',' 'or' 'urine' 'M-protein' 'protein' '≥200' 'mg/24' 'hours' ',' 'or'
 'involved' 'serum' 'free' 'light' 'chain' '(' 'SFLC' ')' '≥10' 'mg/dL']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02343042,95:97:cancer,"Histologically confirmed diagnosis, measurable disease and evidence of disease progression of MM","['Histologically' 'confirmed' 'diagnosis' ',' 'measurable' 'disease' 'and'
 'evidence' 'of' 'disease' 'progression' 'of' 'MM']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02343042,13:15:cancer,"Symptomatic MM, based on IMWG guidelines","['Symptomatic' 'MM' ',' 'based' 'on' 'IMWG' 'guidelines']",[0. 3. 0. 0. 0. 0. 0.]
NCT02253316,13:15:cancer,Evidence of MM disease progression any time prior to enrollment,"['Evidence' 'of' 'MM' 'disease' 'progression' 'any' 'time' 'prior' 'to'
 'enrollment']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02253316,42:44:cancer,Progression from smoldering/asymptomatic MM to symptomatic MM,"['Progression' 'from' 'smoldering/asymptomatic' 'MM' 'to' 'symptomatic'
 'MM']",[0. 0. 0. 3. 0. 0. 0.]
NCT01572480,30:32:cancer,Patients with a diagnosis of MM as defined by the 2014 IMWH diagnostic criteria,"['Patients' 'with' 'a' 'diagnosis' 'of' 'MM' 'as' 'defined' 'by' 'the'
 '2014' 'IMWH' 'diagnostic' 'criteria']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00734877,43:45:cancer,Patients must have newly diagnosed active MM requiring treatment,"['Patients' 'must' 'have' 'newly' 'diagnosed' 'active' 'MM' 'requiring'
 'treatment']",[0. 0. 0. 0. 0. 0. 3. 0. 0.]
NCT02770547,1:22:chronic_disease,Peripheral neuropathy,['Peripheral' 'neuropathy'],[2. 2.]
NCT02457832,1:22:chronic_disease,Peripheral neuropathy,['Peripheral' 'neuropathy'],[2. 2.]
NCT02365766,"1:22:chronic_disease,,",Peripheral neuropathy of Grade 2-4,['Peripheral' 'neuropathy' 'of' 'Grade' '2-4'],[2. 2. 0. 0. 0.]
NCT02287558,1:22:chronic_disease,"Peripheral neuropathy, as determined from neurologic consultation","['Peripheral' 'neuropathy' ',' 'as' 'determined' 'from' 'neurologic'
 'consultation']",[2. 2. 0. 0. 0. 0. 0. 0.]
NCT02177695,"1:22:chronic_disease,",Peripheral neuropathy >/= Grade 2,['Peripheral' 'neuropathy' '>' '/=' 'Grade' '2'],[2. 2. 0. 0. 0. 0.]
NCT02064296,1:22:chronic_disease,Peripheral neuropathy of know cause that interferes with activities of daily living,"['Peripheral' 'neuropathy' 'of' 'know' 'cause' 'that' 'interferes' 'with'
 'activities' 'of' 'daily' 'living']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01959698,"1:22:chronic_disease,",Peripheral neuropathy of grade 2 or greater severity as defined by the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,"['Peripheral' 'neuropathy' 'of' 'grade' '2' 'or' 'greater' 'severity' 'as'
 'defined' 'by' 'the' 'National' 'Cancer' 'Institute' ""'s"" '(' 'NCI' ')'
 'Common' 'Terminology' 'Criteria' 'for' 'Adverse' 'Events' '(' 'CTCAE'
 ')' 'version' '4.0']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02682407,1:12:chronic_disease,hepatitis C infection,['hepatitis' 'C' 'infection'],[2. 2. 0.]
NCT02578641,18:29:chronic_disease,Known history of hepatitis C,['Known' 'history' 'of' 'hepatitis' 'C'],[0. 0. 0. 2. 2.]
NCT02412540,1:12:chronic_disease,hepatitis C,['hepatitis' 'C'],[2. 2.]
NCT02004275,14:25:chronic_disease,Known active hepatitis C based on,['Known' 'active' 'hepatitis' 'C' 'based' 'on'],[0. 0. 2. 2. 0. 0.]
NCT01919619,1:12:chronic_disease,hepatitis C infection,['hepatitis' 'C' 'infection'],[2. 2. 0.]
NCT01865162,1:12:chronic_disease,hepatitis C,['hepatitis' 'C'],[2. 2.]
NCT01823198,28:39:chronic_disease,"Patients with a history of hepatitis C, but have a negative viral load, are eligible","['Patients' 'with' 'a' 'history' 'of' 'hepatitis' 'C' ',' 'but' 'have' 'a'
 'negative' 'viral' 'load' ',' 'are' 'eligible']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02615353,"1:16:chronic_disease,,,,",Type 2 diabetes: Fasting glucose ≥126 mg/dl or 2-hour glucose ≥200 mg/dl,"['Type' '2' 'diabetes' ':' 'Fasting' 'glucose' '≥126' 'mg/dl' 'or'
 '2-hour' 'glucose' '≥200' 'mg/dl']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02587936,1:16:chronic_disease,Type 2 diabetes included in problem list,['Type' '2' 'diabetes' 'included' 'in' 'problem' 'list'],[2. 2. 2. 0. 0. 0. 0.]
NCT02548351,1:16:chronic_disease,Type 2 diabetes diagnosed per 2013 American Diabetes Association criteria,"['Type' '2' 'diabetes' 'diagnosed' 'per' '2013' 'American' 'Diabetes'
 'Association' 'criteria']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02356848,",24:39:chronic_disease",Adults (21 years) with Type 2 diabetes,['Adults' '(' '21' 'years' ')' 'with' 'Type' '2' 'diabetes'],[0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02157974,1:16:chronic_disease,Type 2 diabetes,['Type' '2' 'diabetes'],[2. 2. 2.]
NCT00862433,",,,100:115:chronic_disease",Overweight (BMI greater than or equal to 27) with mild to moderate non-insulin dependent diabetes (Type 2 diabetes),"['Overweight' '(' 'BMI' 'greater' 'than' 'or' 'equal' 'to' '27' ')' 'with'
 'mild' 'to' 'moderate' 'non-insulin' 'dependent' 'diabetes' '(' 'Type'
 '2' 'diabetes' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0.]
NCT00739362,1:16:chronic_disease,Type 2 diabetes (according to the World Health Organization diagnostic criteria),"['Type' '2' 'diabetes' '(' 'according' 'to' 'the' 'World' 'Health'
 'Organization' 'diagnostic' 'criteria' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02536794,1:23:cancer,leptomeningeal disease,['leptomeningeal' 'disease'],[3. 3.]
NCT02439450,7:29:cancer,Known leptomeningeal disease,['Known' 'leptomeningeal' 'disease'],[0. 3. 3.]
NCT02091141,12:34:cancer,History of leptomeningeal disease,['History' 'of' 'leptomeningeal' 'disease'],[0. 0. 3. 3.]
NCT01903330,21:43:chronic_disease,Presence of diffuse leptomeningeal disease,['Presence' 'of' 'diffuse' 'leptomeningeal' 'disease'],[0. 0. 0. 2. 2.]
NCT01894061,15:37:cancer,Patients with leptomeningeal disease,['Patients' 'with' 'leptomeningeal' 'disease'],[0. 0. 3. 3.]
NCT01891318,34:56:cancer,Imaging or cytologic evidence of leptomeningeal disease,['Imaging' 'or' 'cytologic' 'evidence' 'of' 'leptomeningeal' 'disease'],[0. 0. 0. 0. 0. 3. 3.]
NCT01644591,89:111:cancer,Patients are excluded if there is radiographic or cerebrospinal fluid (CSF) evidence of leptomeningeal disease,"['Patients' 'are' 'excluded' 'if' 'there' 'is' 'radiographic' 'or'
 'cerebrospinal' 'fluid' '(' 'CSF' ')' 'evidence' 'of' 'leptomeningeal'
 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT03162731,1:24:cancer,squamous cell carcinoma of the skin,['squamous' 'cell' 'carcinoma' 'of' 'the' 'skin'],[3. 3. 3. 0. 0. 0.]
NCT03059355,1:24:cancer,squamous cell carcinoma,['squamous' 'cell' 'carcinoma'],[3. 3. 3.]
NCT02582775,13:36:cancer,Evidence of squamous cell carcinoma,['Evidence' 'of' 'squamous' 'cell' 'carcinoma'],[0. 0. 3. 3. 3.]
NCT02158234,48:71:cancer,"Recurrence of previously pathologically proven squamous cell carcinoma of the head and neck, including original primary sites in the paranasal sinuses, nasal cavity, nasopharynx, oropharynx, oral cavity, larynx, hypopharynx, salivary glands, and/or involvement of cervical lymph nodes","['Recurrence' 'of' 'previously' 'pathologically' 'proven' 'squamous'
 'cell' 'carcinoma' 'of' 'the' 'head' 'and' 'neck' ',' 'including'
 'original' 'primary' 'sites' 'in' 'the' 'paranasal' 'sinuses' ',' 'nasal'
 'cavity' ',' 'nasopharynx' ',' 'oropharynx' ',' 'oral' 'cavity' ','
 'larynx' ',' 'hypopharynx' ',' 'salivary' 'glands' ',' 'and/or'
 'involvement' 'of' 'cervical' 'lymph' 'nodes']","[0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02106598,13:36:cancer,oral cavity squamous cell carcinoma,['oral' 'cavity' 'squamous' 'cell' 'carcinoma'],[0. 0. 3. 3. 3.]
NCT02101034,56:79:cancer,Histologically or cytologically confirmed diagnosis of squamous cell carcinoma of the head and neck,"['Histologically' 'or' 'cytologically' 'confirmed' 'diagnosis' 'of'
 'squamous' 'cell' 'carcinoma' 'of' 'the' 'head' 'and' 'neck']",[0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0.]
NCT03151083,"16:24:chronic_disease,","Diagnosed with insomnia lasting 3 months by the PACT provider, as evidenced by referral by the provider for access to the SHUTiTM program","['Diagnosed' 'with' 'insomnia' 'lasting' '3' 'months' 'by' 'the' 'PACT'
 'provider' ',' 'as' 'evidenced' 'by' 'referral' 'by' 'the' 'provider'
 'for' 'access' 'to' 'the' 'SHUTiTM' 'program']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03151083,",67:75:chronic_disease",Willing to participate in an internet-based self-help program for insomnia after the access to and requirements of the program are explained to them,"['Willing' 'to' 'participate' 'in' 'an' 'internet-based' 'self-help'
 'program' 'for' 'insomnia' 'after' 'the' 'access' 'to' 'and'
 'requirements' 'of' 'the' 'program' 'are' 'explained' 'to' 'them']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03112902,1:9:chronic_disease,insomnia,['insomnia'],[2.]
NCT03109210,",,67:75:chronic_disease",Insomnia Severity Index (ISI) score > 10 indicating at least mild insomnia,"['Insomnia' 'Severity' 'Index' '(' 'ISI' ')' 'score' '>' '10' 'indicating'
 'at' 'least' 'mild' 'insomnia']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02774642,30:38:chronic_disease,Meet diagnostic criteria for insomnia,['Meet' 'diagnostic' 'criteria' 'for' 'insomnia'],[0. 0. 0. 0. 2.]
NCT02535923,"27:35:chronic_disease,,",Self-reported symptoms of insomnia via an Insomnia Severity Index (ISI) score of 15 or greater,"['Self-reported' 'symptoms' 'of' 'insomnia' 'via' 'an' 'Insomnia'
 'Severity' 'Index' '(' 'ISI' ')' 'score' 'of' '15' 'or' 'greater']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03133793,",,,57:59:chronic_disease",New York Heart Association (NYHA) Classification II-III HF,"['New' 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'Classification'
 'II-III' 'HF']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02589977,21:23:chronic_disease,acute decompensated HF,['acute' 'decompensated' 'HF'],[0. 0. 2.]
NCT02589977,34:36:chronic_disease,physician-confirmed diagnosis of HF,['physician-confirmed' 'diagnosis' 'of' 'HF'],[0. 0. 0. 2.]
NCT02519283,18:20:chronic_disease,Prior history of HF,['Prior' 'history' 'of' 'HF'],[0. 0. 0. 2.]
NCT02145351,35:37:chronic_disease,Hospitalization for decompensated HF,['Hospitalization' 'for' 'decompensated' 'HF'],[0. 0. 0. 2.]
NCT02145351,"32:34:chronic_disease,,,",Previous clinical diagnosis of HF with current NYHA Class II-III symptoms,"['Previous' 'clinical' 'diagnosis' 'of' 'HF' 'with' 'current' 'NYHA'
 'Class' 'II-III' 'symptoms']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT03104205,1:18:chronic_disease,Suicidal ideation,['Suicidal' 'ideation'],[2. 2.]
NCT02910648,1:18:chronic_disease,Suicidal ideation in past year,['Suicidal' 'ideation' 'in' 'past' 'year'],[2. 2. 0. 0. 0.]
NCT02250664,1:18:chronic_disease,Suicidal ideation in the past month,['Suicidal' 'ideation' 'in' 'the' 'past' 'month'],[2. 2. 0. 0. 0. 0.]
NCT02250534,1:18:chronic_disease,Suicidal ideation in the past month,['Suicidal' 'ideation' 'in' 'the' 'past' 'month'],[2. 2. 0. 0. 0. 0.]
NCT02133898,1:18:chronic_disease,Suicidal ideation,['Suicidal' 'ideation'],[2. 2.]
NCT01964261,1:18:chronic_disease,Suicidal ideation,['Suicidal' 'ideation'],[2. 2.]
NCT03072381,18:27:allergy_name,known allergy to Lidocaine,['known' 'allergy' 'to' 'Lidocaine'],[0. 0. 0. 4.]
NCT03016351,1:10:allergy_name,Lidocaine allergy,['Lidocaine' 'allergy'],[4. 0.]
NCT02987491,1:10:allergy_name,Lidocaine allergy,['Lidocaine' 'allergy'],[4. 0.]
NCT02803359,12:21:allergy_name,Allergy to Lidocaine,['Allergy' 'to' 'Lidocaine'],[0. 0. 4.]
NCT02340650,13:22:allergy_name,Person with Lidocaine sensitivity,['Person' 'with' 'Lidocaine' 'sensitivity'],[0. 0. 4. 0.]
NCT01842399,45:54:allergy_name,Allergy or intolerance to local anesthetic- Lidocaine,['Allergy' 'or' 'intolerance' 'to' 'local' 'anesthetic-' 'Lidocaine'],[0. 0. 0. 0. 0. 0. 4.]
NCT03039036,1:27:chronic_disease,hepatitis B or C infection,['hepatitis' 'B' 'or' 'C' 'infection'],[2. 2. 2. 2. 2.]
NCT02953509,25:51:chronic_disease,Known active or chronic hepatitis B or C infection,['Known' 'active' 'or' 'chronic' 'hepatitis' 'B' 'or' 'C' 'infection'],[0. 0. 0. 0. 2. 2. 2. 2. 2.]
NCT02907918,7:33:chronic_disease,Known hepatitis B or C infection,['Known' 'hepatitis' 'B' 'or' 'C' 'infection'],[0. 2. 2. 2. 2. 2.]
NCT02833805,8:34:chronic_disease,Active hepatitis B or C infection determined by serology and/or nucleic acid testing (NAT),"['Active' 'hepatitis' 'B' 'or' 'C' 'infection' 'determined' 'by'
 'serology' 'and/or' 'nucleic' 'acid' 'testing' '(' 'NAT' ')']",[0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02776761,27:53:chronic_disease,Any confirmed evidence of hepatitis B or C infection,['Any' 'confirmed' 'evidence' 'of' 'hepatitis' 'B' 'or' 'C' 'infection'],[0. 0. 0. 0. 2. 2. 2. 2. 2.]
NCT01572480,8:34:chronic_disease,Active hepatitis B or C infection,['Active' 'hepatitis' 'B' 'or' 'C' 'infection'],[0. 2. 2. 2. 2. 2.]
NCT03009110,1:18:chronic_disease,Bleeding disorder,['Bleeding' 'disorder'],[2. 2.]
NCT02940288,1:18:chronic_disease,Bleeding disorder,['Bleeding' 'disorder'],[2. 2.]
NCT02622295,1:18:chronic_disease,Bleeding disorder,['Bleeding' 'disorder'],[2. 2.]
NCT02490943,1:18:chronic_disease,Bleeding disorder,['Bleeding' 'disorder'],[2. 2.]
NCT02414607,1:18:chronic_disease,Bleeding disorder,['Bleeding' 'disorder'],[2. 2.]
NCT02254863,1:18:chronic_disease,Bleeding disorder,['Bleeding' 'disorder'],[2. 2.]
NCT02985801,12:37:cancer,Underlying pancreatic adenocarcinoma,['Underlying' 'pancreatic' 'adenocarcinoma'],[0. 3. 3.]
NCT02843945,18:43:cancer,locally advanced pancreatic adenocarcinoma,['locally' 'advanced' 'pancreatic' 'adenocarcinoma'],[0. 0. 3. 3.]
NCT02562716,59:84:cancer,Patients must have histologically or cytologically proven pancreatic adenocarcinoma,"['Patients' 'must' 'have' 'histologically' 'or' 'cytologically' 'proven'
 'pancreatic' 'adenocarcinoma']",[0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02311361,54:79:cancer,Patients must have histopathological confirmation of pancreatic adenocarcinoma prior to entering this study by the Laboratory of Pathology of the NCI to entering this study by the Laboratory of Pathology of the NCI prior to entering this study,"['Patients' 'must' 'have' 'histopathological' 'confirmation' 'of'
 'pancreatic' 'adenocarcinoma' 'prior' 'to' 'entering' 'this' 'study' 'by'
 'the' 'Laboratory' 'of' 'Pathology' 'of' 'the' 'NCI' 'to' 'entering'
 'this' 'study' 'by' 'the' 'Laboratory' 'of' 'Pathology' 'of' 'the' 'NCI'
 'prior' 'to' 'entering' 'this' 'study']","[0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02128100,43:68:cancer,Pathologic or clinical diagnosis of a new pancreatic adenocarcinoma,"['Pathologic' 'or' 'clinical' 'diagnosis' 'of' 'a' 'new' 'pancreatic'
 'adenocarcinoma']",[0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02047474,42:67:cancer,Pathologic or cytologic documentation of pancreatic adenocarcinoma,"['Pathologic' 'or' 'cytologic' 'documentation' 'of' 'pancreatic'
 'adenocarcinoma']",[0. 0. 0. 0. 0. 3. 3.]
NCT02943915,60:72:chronic_disease,"History of long bone fractures since the SCI, secondary to osteoporosis","['History' 'of' 'long' 'bone' 'fractures' 'since' 'the' 'SCI' ','
 'secondary' 'to' 'osteoporosis']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02589600,",13:25:chronic_disease,",Men because osteoporosis is less common in men,['Men' 'because' 'osteoporosis' 'is' 'less' 'common' 'in' 'men'],[0. 0. 2. 0. 0. 0. 0. 0.]
NCT02589600,"1:13:chronic_disease,,","osteoporosis by axial bone density (spine, hip or forearm bone mineral density (BMD) T-score ≤ -2.5 SD)","['osteoporosis' 'by' 'axial' 'bone' 'density' '(' 'spine' ',' 'hip' 'or'
 'forearm' 'bone' 'mineral' 'density' '(' 'BMD' ')' 'T-score' '≤' '-2.5'
 'SD' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02446886,34:46:chronic_disease,Patients with a known history of osteoporosis or bone density values in the osteoporosis range at screening,"['Patients' 'with' 'a' 'known' 'history' 'of' 'osteoporosis' 'or' 'bone'
 'density' 'values' 'in' 'the' 'osteoporosis' 'range' 'at' 'screening']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02373644,8:20:chronic_disease,severe osteoporosis,['severe' 'osteoporosis'],[0. 2.]
NCT02245841,15:27:chronic_disease,Patients with osteoporosis,['Patients' 'with' 'osteoporosis'],[0. 0. 2.]
NCT02878044,32:46:cancer,Clinical diagnosis of low risk thyroid cancer,['Clinical' 'diagnosis' 'of' 'low' 'risk' 'thyroid' 'cancer'],[0. 0. 0. 0. 0. 3. 3.]
NCT02747888,15:29:cancer,Families with thyroid cancer and a known genetic syndrome,"['Families' 'with' 'thyroid' 'cancer' 'and' 'a' 'known' 'genetic'
 'syndrome']",[0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT02747888,70:84:cancer,Individual adult patient with current or previous known or suspected thyroid cancer or nodule(s) if they come from a family with a high suspicion of hereditary cancer,"['Individual' 'adult' 'patient' 'with' 'current' 'or' 'previous' 'known'
 'or' 'suspected' 'thyroid' 'cancer' 'or' 'nodule' '(' 's' ')' 'if' 'they'
 'come' 'from' 'a' 'family' 'with' 'a' 'high' 'suspicion' 'of'
 'hereditary' 'cancer']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02564978,30:44:cancer,Participant has a history of thyroid cancer,['Participant' 'has' 'a' 'history' 'of' 'thyroid' 'cancer'],[0. 0. 0. 0. 0. 3. 3.]
NCT02393690,"49:63:cancer,",It is pathologically proven to be involved with thyroid cancer (by cytology or pathology) and it measures >= 1 cm in the long axis,"['It' 'is' 'pathologically' 'proven' 'to' 'be' 'involved' 'with' 'thyroid'
 'cancer' '(' 'by' 'cytology' 'or' 'pathology' ')' 'and' 'it' 'measures'
 '>' '=' '1' 'cm' 'in' 'the' 'long' 'axis']","[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02278198,17:31:cancer,nown metastatic thyroid cancer,['nown' 'metastatic' 'thyroid' 'cancer'],[0. 0. 3. 3.]
NCT02833805,28:53:treatment,Previous administration of immunosuppressive therapy for SAA,"['Previous' 'administration' 'of' 'immunosuppressive' 'therapy' 'for'
 'SAA']",[0. 0. 0. 1. 1. 0. 0.]
NCT02384954,31:56:treatment,No disease requiring systemic immunosuppressive therapy,['No' 'disease' 'requiring' 'systemic' 'immunosuppressive' 'therapy'],[0. 0. 0. 0. 1. 1.]
NCT02324582,"19:44:treatment,",any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment,"['any' 'other' 'form' 'of' 'immunosuppressive' 'therapy' 'within' '7'
 'days' 'prior' 'to' 'the' 'first' 'dose' 'of' 'trial' 'treatment']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02268253,11:36:treatment,receiving immunosuppressive therapy,['receiving' 'immunosuppressive' 'therapy'],[0. 1. 1.]
NCT02266745,1:26:treatment,immunosuppressive therapy,['immunosuppressive' 'therapy'],[1. 1.]
NCT01087294,26:51:treatment,A trial of withdrawal of immunosuppressive therapy,['A' 'trial' 'of' 'withdrawal' 'of' 'immunosuppressive' 'therapy'],[0. 0. 0. 0. 0. 1. 1.]
NCT02746458,14:32:chronic_disease,Diagnosis of sickle cell anemia,['Diagnosis' 'of' 'sickle' 'cell' 'anemia'],[0. 0. 2. 2. 2.]
NCT02286154,14:32:chronic_disease,Diagnosis of sickle cell anemia,['Diagnosis' 'of' 'sickle' 'cell' 'anemia'],[0. 0. 2. 2. 2.]
NCT02056470,1:19:chronic_disease,sickle cell anemia,['sickle' 'cell' 'anemia'],[2. 2. 2.]
NCT01966367,",,55:73:chronic_disease,",Patient must be < or = 40 years of age. Patients with sickle cell anemia must be at least 2 years of age,"['Patient' 'must' 'be' '<' 'or' '=' '40' 'years' 'of' 'age' '.' 'Patients'
 'with' 'sickle' 'cell' 'anemia' 'must' 'be' 'at' 'least' '2' 'years' 'of'
 'age']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01966367,63:81:chronic_disease,The following additional exclusion criteria for patients with sickle cell anemia the following exclusion criteria also apply,"['The' 'following' 'additional' 'exclusion' 'criteria' 'for' 'patients'
 'with' 'sickle' 'cell' 'anemia' 'the' 'following' 'exclusion' 'criteria'
 'also' 'apply']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT00737893,30:48:chronic_disease,The patient has a history of sickle cell anemia,['The' 'patient' 'has' 'a' 'history' 'of' 'sickle' 'cell' 'anemia'],[0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02624258,1:19:chronic_disease,refractory disease who are unresponsive to,['refractory' 'disease' 'who' 'are' 'unresponsive' 'to'],[2. 2. 0. 0. 0. 0.]
NCT02530034,29:47:cancer,Patients must have relapsed/refractory disease,['Patients' 'must' 'have' 'relapsed/refractory' 'disease'],[0. 0. 0. 3. 3.]
NCT02519452,13:31:cancer,Relapsed or refractory disease,['Relapsed' 'or' 'refractory' 'disease'],[0. 0. 3. 3.]
NCT02394028,14:32:chronic_disease,"Intolerance, refractory disease","['Intolerance' ',' 'refractory' 'disease']",[0. 0. 2. 2.]
NCT01614197,83:101:chronic_disease,Second or greater relapse B-cell patients are eligible at time of relapse or with refractory disease,"['Second' 'or' 'greater' 'relapse' 'B-cell' 'patients' 'are' 'eligible'
 'at' 'time' 'of' 'relapse' 'or' 'with' 'refractory' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01349101,15:33:chronic_disease,Patients with refractory disease,['Patients' 'with' 'refractory' 'disease'],[0. 0. 2. 2.]
NCT02535312,31:40:treatment,Arm A dose level 4 (75 mg/m^2 cisplatin),['Arm' 'A' 'dose' 'level' '4' '(' '75' 'mg/m^2' 'cisplatin' ')'],[0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02535312,36:45:treatment,for whom the current dose level of cisplatin in combination with pemetrexed is appropriate,"['for' 'whom' 'the' 'current' 'dose' 'level' 'of' 'cisplatin' 'in'
 'combination' 'with' 'pemetrexed' 'is' 'appropriate']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02466971,",,43:52:treatment",Creatinine =< 1.5 mg/dL to receive weekly cisplatin,['Creatinine' '=' '<' '1.5' 'mg/dL' 'to' 'receive' 'weekly' 'cisplatin'],[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02365766,"5:14:treatment,,,",The cisplatin dose will be split over two days for values between 50-59 mL/min,"['The' 'cisplatin' 'dose' 'will' 'be' 'split' 'over' 'two' 'days' 'for'
 'values' 'between' '50-59' 'mL/min']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02158234,26:35:treatment,Medically fit to receive cisplatin,['Medically' 'fit' 'to' 'receive' 'cisplatin'],[0. 0. 0. 0. 1.]
NCT02094625,"9:18:treatment,,",Planned cisplatin dose to be infused over ≤6 hours for ≤2 days per cycle,"['Planned' 'cisplatin' 'dose' 'to' 'be' 'infused' 'over' '≤6' 'hours'
 'for' '≤2' 'days' 'per' 'cycle']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02512718,"14:28:chronic_disease,,",Pathological hyperlipidemia (2 consecutive fasting triglyceride levels > 500 mg/dL),"['Pathological' 'hyperlipidemia' '(' '2' 'consecutive' 'fasting'
 'triglyceride' 'levels' '>' '500' 'mg/dL' ')']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02512718,"14:28:chronic_disease,,",pathological hyperlipidemia (2 consecutive fasting triglyceride levels > 500 mg/dL),"['pathological' 'hyperlipidemia' '(' '2' 'consecutive' 'fasting'
 'triglyceride' 'levels' '>' '500' 'mg/dL' ')']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02393742,1:15:chronic_disease,hyperlipidemia,['hyperlipidemia'],[2.]
NCT02302235,25:39:chronic_disease,History of uncontrolled hyperlipidemia,['History' 'of' 'uncontrolled' 'hyperlipidemia'],[0. 0. 0. 2.]
NCT01627301,1:15:chronic_disease,hyperlipidemia,['hyperlipidemia'],[2.]
NCT01625923,12:26:chronic_disease,History of hyperlipidemia,['History' 'of' 'hyperlipidemia'],[0. 0. 2.]
NCT02210650,15:31:chronic_disease,Patients with systemic disease,['Patients' 'with' 'systemic' 'disease'],[0. 0. 2. 2.]
NCT01947673,13:29:chronic_disease,any serious systemic disease that might influence survival,"['any' 'serious' 'systemic' 'disease' 'that' 'might' 'influence'
 'survival']",[0. 0. 2. 2. 0. 0. 0. 0.]
NCT01772329,"42:58:chronic_disease,,",any co-morbidity which results in severe systemic disease limiting function {as defined by the American Society of Anesthesiology (ASA) physical status classification > 3},"['any' 'co-morbidity' 'which' 'results' 'in' 'severe' 'systemic' 'disease'
 'limiting' 'function' '{' 'as' 'defined' 'by' 'the' 'American' 'Society'
 'of' 'Anesthesiology' '(' 'ASA' ')' 'physical' 'status' 'classification'
 '>' '3' '}']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01627301,13:29:chronic_disease,any serious systemic disease,['any' 'serious' 'systemic' 'disease'],[0. 0. 2. 2.]
NCT00338377,40:56:chronic_disease,Many patients present with concomitant systemic disease outside of the central nervous system,"['Many' 'patients' 'present' 'with' 'concomitant' 'systemic' 'disease'
 'outside' 'of' 'the' 'central' 'nervous' 'system']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT00147056,24:40:chronic_disease,Known life-threatening systemic disease,['Known' 'life-threatening' 'systemic' 'disease'],[0. 0. 2. 2.]
NCT03175159,37:41:treatment,Self reports being 100% adherent to PrEP,['Self' 'reports' 'being' '100' '%' 'adherent' 'to' 'PrEP'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT03148171,",23:27:treatment,",Have had fewer than 3 PrEP clinical visits in the past 12 months,"['Have' 'had' 'fewer' 'than' '3' 'PrEP' 'clinical' 'visits' 'in' 'the'
 'past' '12' 'months']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT03132415,11:15:chronic_disease,Not be on PrEP at time of enrollment,['Not' 'be' 'on' 'PrEP' 'at' 'time' 'of' 'enrollment'],[0. 0. 0. 2. 0. 0. 0. 0.]
NCT03078153,"17:21:treatment,",Actively taking PrEP or having taken PrEP within 30 days of enrollment,"['Actively' 'taking' 'PrEP' 'or' 'having' 'taken' 'PrEP' 'within' '30'
 'days' 'of' 'enrollment']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03078153,"15:19:treatment,",Not a current PrEP user and have not taken PrEP in the last 30 days,"['Not' 'a' 'current' 'PrEP' 'user' 'and' 'have' 'not' 'taken' 'PrEP' 'in'
 'the' 'last' '30' 'days']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03166371,1:15:chronic_disease,encephalopathy,['encephalopathy'],[2.]
NCT02811263,20:34:chronic_disease,Sentinel event and encephalopathy occurred only after birth,"['Sentinel' 'event' 'and' 'encephalopathy' 'occurred' 'only' 'after'
 'birth']",[0. 0. 0. 2. 0. 0. 0. 0.]
NCT02621944,"32:46:chronic_disease,,,",All infants must have signs of encephalopathy within 6 hours of age using the modified Sarnat scoring system,"['All' 'infants' 'must' 'have' 'signs' 'of' 'encephalopathy' 'within' '6'
 'hours' 'of' 'age' 'using' 'the' 'modified' 'Sarnat' 'scoring' 'system']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02146924,54:68:chronic_disease,Research participants without clinically significant encephalopathy/new focal deficits,"['Research' 'participants' 'without' 'clinically' 'significant'
 'encephalopathy/new' 'focal' 'deficits']",[0. 0. 0. 0. 0. 2. 0. 0.]
NCT01903330,",,,,,92:106:chronic_disease","blood pressure of > 150 mmHg systolic and > 100 mmHg diastolic, or history of hypertensive encephalopathy","['blood' 'pressure' 'of' '>' '150' 'mmHg' 'systolic' 'and' '>' '100'
 'mmHg' 'diastolic' ',' 'or' 'history' 'of' 'hypertensive'
 'encephalopathy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT03153982,",,,,,,,304:315:treatment","Women (patients or partners of male patients) of childbearing potential (WOCBP) must practice acceptable methods of birth control to prevent pregnancy. All WOCBP must have a negative pregnancy test within 4 weeks prior to registration, and this must be repeated within 72 hours prior to first receiving ruxolitinib","['Women' '(' 'patients' 'or' 'partners' 'of' 'male' 'patients' ')' 'of'
 'childbearing' 'potential' '(' 'WOCBP' ')' 'must' 'practice' 'acceptable'
 'methods' 'of' 'birth' 'control' 'to' 'prevent' 'pregnancy' '.' 'All'
 'WOCBP' 'must' 'have' 'a' 'negative' 'pregnancy' 'test' 'within' '4'
 'weeks' 'prior' 'to' 'registration' ',' 'and' 'this' 'must' 'be'
 'repeated' 'within' '72' 'hours' 'prior' 'to' 'first' 'receiving'
 'ruxolitinib']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1.]"
NCT02876302,79:90:treatment,Because no dosing or adverse event data are currently available on the use of ruxolitinib in participants,"['Because' 'no' 'dosing' 'or' 'adverse' 'event' 'data' 'are' 'currently'
 'available' 'on' 'the' 'use' 'of' 'ruxolitinib' 'in' 'participants']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT02876302,16:27:treatment,The effects of ruxolitinib on the developing human fetus are unknown,"['The' 'effects' 'of' 'ruxolitinib' 'on' 'the' 'developing' 'human'
 'fetus' 'are' 'unknown']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02493530,81:92:treatment,"Patients with these diagnoses may be eligible, provided they are able to obtain ruxolitinib from commercial supply","['Patients' 'with' 'these' 'diagnoses' 'may' 'be' 'eligible' ','
 'provided' 'they' 'are' 'able' 'to' 'obtain' 'ruxolitinib' 'from'
 'commercial' 'supply']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02098161,76:87:allergy_name,"Patients who are not candidates for, intolerant, or relapsed/refractory to ruxolitinib","['Patients' 'who' 'are' 'not' 'candidates' 'for' ',' 'intolerant' ',' 'or'
 'relapsed/refractory' 'to' 'ruxolitinib']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4.]
NCT03135522,12:24:chronic_disease,History of lung disease,['History' 'of' 'lung' 'disease'],[0. 0. 2. 2.]
NCT02995590,15:27:chronic_disease,No history of lung disease,['No' 'history' 'of' 'lung' 'disease'],[0. 0. 0. 2. 2.]
NCT02128802,13:25:chronic_disease,Significant lung disease,['Significant' 'lung' 'disease'],[0. 2. 2.]
NCT02013492,"27:39:chronic_disease,,,,","Patients with significant lung disease, an ejection fraction less than 40%, or a resting heart rate less than 60/min will not be enrolled","['Patients' 'with' 'significant' 'lung' 'disease' ',' 'an' 'ejection'
 'fraction' 'less' 'than' '40' '%' ',' 'or' 'a' 'resting' 'heart' 'rate'
 'less' 'than' '60/min' 'will' 'not' 'be' 'enrolled']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01445821,"11:23:chronic_disease,,",End-stage lung disease characterized by TLC<45% of predicted value,"['End-stage' 'lung' 'disease' 'characterized' 'by' 'TLC' '<' '45' '%' 'of'
 'predicted' 'value']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03121352,",50:59:treatment",Subjects must have received no more than 2 prior therapies for this disease,"['Subjects' 'must' 'have' 'received' 'no' 'more' 'than' '2' 'prior'
 'therapies' 'for' 'this' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02703272,26:35:treatment,has taken any disallowed therapies as noted in Section 8.2,"['has' 'taken' 'any' 'disallowed' 'therapies' 'as' 'noted' 'in' 'Section'
 '8.2']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02013492,52:61:treatment,Patients may have had any number of prior systemic therapies,"['Patients' 'may' 'have' 'had' 'any' 'number' 'of' 'prior' 'systemic'
 'therapies']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01495637,87:96:treatment,DNR status or care team/family is considering plans for withdrawal of life-sustaining therapies,"['DNR' 'status' 'or' 'care' 'team/family' 'is' 'considering' 'plans' 'for'
 'withdrawal' 'of' 'life-sustaining' 'therapies']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT00338377,"57:66:treatment,","Patients who have been previously treated with other IT therapies are eligible, as long as there is at least a 2 week wash out period","['Patients' 'who' 'have' 'been' 'previously' 'treated' 'with' 'other' 'IT'
 'therapies' 'are' 'eligible' ',' 'as' 'long' 'as' 'there' 'is' 'at'
 'least' 'a' '2' 'week' 'wash' 'out' 'period']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT03104725,"1:3:chronic_disease,",PD diagnosed within the past 5 years,['PD' 'diagnosed' 'within' 'the' 'past' '5' 'years'],[2. 0. 0. 0. 0. 0. 0.]
NCT02231073,12:14:chronic_disease,Idiopathic PD subjects: Same as above and deep brain stimulation electrodes,"['Idiopathic' 'PD' 'subjects' ':' 'Same' 'as' 'above' 'and' 'deep' 'brain'
 'stimulation' 'electrodes']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01742182,"1:3:chronic_disease,,,",PD Hoehn and Yahr stage 2-4,['PD' 'Hoehn' 'and' 'Yahr' 'stage' '2-4'],[2. 0. 0. 0. 0. 0.]
NCT01581580,31:33:chronic_disease,"Patients with tremor-dominant PD with Scans Without Evidence of Dopaminergic Effect (SWEDD) will be excluded based on clinical and historic information, including DaT functional imaging obtained during routine clinical evaluation of PD as needed","['Patients' 'with' 'tremor-dominant' 'PD' 'with' 'Scans' 'Without'
 'Evidence' 'of' 'Dopaminergic' 'Effect' '(' 'SWEDD' ')' 'will' 'be'
 'excluded' 'based' 'on' 'clinical' 'and' 'historic' 'information' ','
 'including' 'DaT' 'functional' 'imaging' 'obtained' 'during' 'routine'
 'clinical' 'evaluation' 'of' 'PD' 'as' 'needed']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01341080,",,83:85:chronic_disease,,",Subjects will have to be at least stage 2 on the Hoehn and Yahr staging system of PD and have a history of at least 1 fall or near fall in the last 6 months,"['Subjects' 'will' 'have' 'to' 'be' 'at' 'least' 'stage' '2' 'on' 'the'
 'Hoehn' 'and' 'Yahr' 'staging' 'system' 'of' 'PD' 'and' 'have' 'a'
 'history' 'of' 'at' 'least' '1' 'fall' 'or' 'near' 'fall' 'in' 'the'
 'last' '6' 'months']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03080142,22:45:treatment,Patients on systemic anticoagulation therapy,['Patients' 'on' 'systemic' 'anticoagulation' 'therapy'],[0. 0. 0. 1. 1.]
NCT02278315,",,52:75:treatment","Platelet count < 150,000/uL with ongoing full-dose anticoagulation therapy","['Platelet' 'count' '<' '150,000/uL' 'with' 'ongoing' 'full-dose'
 'anticoagulation' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02053363,9:32:treatment,Current anticoagulation therapy that cannot be interrupted,"['Current' 'anticoagulation' 'therapy' 'that' 'can' 'not' 'be'
 'interrupted']",[0. 1. 1. 0. 0. 0. 0. 0.]
NCT01187368,15:38:treatment,Intolerant of anticoagulation therapy,['Intolerant' 'of' 'anticoagulation' 'therapy'],[0. 0. 1. 1.]
NCT00737893,19:42:treatment,The patient is on anticoagulation therapy,['The' 'patient' 'is' 'on' 'anticoagulation' 'therapy'],[0. 0. 0. 0. 1. 1.]
NCT03071393,18:39:chronic_disease,severe recurrent autonomic dysreflexia,['severe' 'recurrent' 'autonomic' 'dysreflexia'],[0. 0. 2. 2.]
NCT02943915,14:35:chronic_disease,Uncontrolled autonomic dysreflexia,['Uncontrolled' 'autonomic' 'dysreflexia'],[0. 2. 2.]
NCT02329652,39:60:chronic_disease,subjects should not have a history of autonomic dysreflexia,"['subjects' 'should' 'not' 'have' 'a' 'history' 'of' 'autonomic'
 'dysreflexia']",[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02274116,11:32:chronic_disease,recurrent autonomic dysreflexia,['recurrent' 'autonomic' 'dysreflexia'],[0. 2. 2.]
NCT02115685,15:36:chronic_disease,an episode of autonomic dysreflexia in the past year,['an' 'episode' 'of' 'autonomic' 'dysreflexia' 'in' 'the' 'past' 'year'],[0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT03060096,1:26:cancer,non-melanoma skin cancers,['non-melanoma' 'skin' 'cancers'],[3. 3. 3.]
NCT02585973,1:26:cancer,non-melanoma skin cancers,['non-melanoma' 'skin' 'cancers'],[3. 3. 3.]
NCT02583893,1:26:cancer,non-melanoma skin cancers,['non-melanoma' 'skin' 'cancers'],[3. 3. 3.]
NCT02541903,21:46:cancer,effectively treated non-melanoma skin cancers,['effectively' 'treated' 'non-melanoma' 'skin' 'cancers'],[0. 0. 3. 3. 3.]
NCT02217345,1:26:cancer,non-melanoma skin cancers,['non-melanoma' 'skin' 'cancers'],[3. 3. 3.]
NCT03053908,22:38:chronic_disease,life-long history of major depression,['life-long' 'history' 'of' 'major' 'depression'],[0. 0. 0. 2. 2.]
NCT02837510,"28:44:chronic_disease,",subjects with a history of major depression but in remission for past 6 months are eligible,"['subjects' 'with' 'a' 'history' 'of' 'major' 'depression' 'but' 'in'
 'remission' 'for' 'past' '6' 'months' 'are' 'eligible']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02620579,1:17:chronic_disease,major depression,['major' 'depression'],[2. 2.]
NCT02347995,11:27:chronic_disease,untreated major depression by clinical interview,['untreated' 'major' 'depression' 'by' 'clinical' 'interview'],[0. 2. 2. 0. 0. 0.]
NCT02243813,",157:173:chronic_disease",Current or past history within the last 5 years of meeting DSM-5 criteria for alcohol or substance use disorder (excluding caffeine and nicotine) or severe major depression,"['Current' 'or' 'past' 'history' 'within' 'the' 'last' '5' 'years' 'of'
 'meeting' 'DSM-5' 'criteria' 'for' 'alcohol' 'or' 'substance' 'use'
 'disorder' '(' 'excluding' 'caffeine' 'and' 'nicotine' ')' 'or' 'severe'
 'major' 'depression']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 2. 2.]"
NCT03008408,12:26:chronic_disease,Documented cardiomyopathy,['Documented' 'cardiomyopathy'],[0. 2.]
NCT02624765,1:15:chronic_disease,cardiomyopathy,['cardiomyopathy'],[2.]
NCT02488967,12:26:chronic_disease,Documented cardiomyopathy,['Documented' 'cardiomyopathy'],[0. 2.]
NCT02152254,18:32:chronic_disease,prior or current cardiomyopathy,['prior' 'or' 'current' 'cardiomyopathy'],[0. 0. 0. 2.]
NCT01696734,1:15:chronic_disease,cardiomyopathy,['cardiomyopathy'],[2.]
NCT03004287,22:42:cancer,Diagnosis of primary plasma cell leukemia,['Diagnosis' 'of' 'primary' 'plasma' 'cell' 'leukemia'],[0. 0. 0. 3. 3. 3.]
NCT02343042,8:28:cancer,Active plasma cell leukemia,['Active' 'plasma' 'cell' 'leukemia'],[0. 3. 3. 3.]
NCT02334865,36:56:cancer,Patients with a known diagnosis of plasma cell leukemia,['Patients' 'with' 'a' 'known' 'diagnosis' 'of' 'plasma' 'cell' 'leukemia'],[0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT02004275,22:42:cancer,Primary or secondary plasma cell leukemia,['Primary' 'or' 'secondary' 'plasma' 'cell' 'leukemia'],[0. 0. 0. 3. 3. 3.]
NCT01464034,22:42:cancer,Current diagnosis of plasma cell leukemia,['Current' 'diagnosis' 'of' 'plasma' 'cell' 'leukemia'],[0. 0. 0. 3. 3. 3.]
NCT02977299,"17:31:treatment,,,","currently on an antidepressant of adequate dose (as defined by the MGH ATRQ) and duration (at least 8 weeks), with the antidepressant dose being stable over the past four weeks, and with documented (in the MGH ATRQ) non-response (less than 50% improvement) to the current antidepressant","['currently' 'on' 'an' 'antidepressant' 'of' 'adequate' 'dose' '(' 'as'
 'defined' 'by' 'the' 'MGH' 'ATRQ' ')' 'and' 'duration' '(' 'at' 'least'
 '8' 'weeks' ')' ',' 'with' 'the' 'antidepressant' 'dose' 'being' 'stable'
 'over' 'the' 'past' 'four' 'weeks' ',' 'and' 'with' 'documented' '(' 'in'
 'the' 'MGH' 'ATRQ' ')' 'non-response' '(' 'less' 'than' '50' '%'
 'improvement' ')' 'to' 'the' 'current' 'antidepressant']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02960763,",46:60:treatment",Failure to respond adequately to two or more antidepressant treatment trials of recommended dose and length,"['Failure' 'to' 'respond' 'adequately' 'to' 'two' 'or' 'more'
 'antidepressant' 'treatment' 'trials' 'of' 'recommended' 'dose' 'and'
 'length']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02669030,14:28:treatment,Currently on antidepressant,['Currently' 'on' 'antidepressant'],[0. 0. 1.]
NCT02562430,27:41:treatment,Only one failed one prior antidepressant in the current episode,"['Only' 'one' 'failed' 'one' 'prior' 'antidepressant' 'in' 'the' 'current'
 'episode']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02553161,23:37:treatment,a history of previous antidepressant exposure,['a' 'history' 'of' 'previous' 'antidepressant' 'exposure'],[0. 0. 0. 0. 1. 0.]
NCT02931110,1:16:chronic_disease,lymphadenopathy,['lymphadenopathy'],[2.]
NCT02514083,42:57:chronic_disease,Massive nodes or clusters or progressive lymphadenopathy,['Massive' 'nodes' 'or' 'clusters' 'or' 'progressive' 'lymphadenopathy'],[0. 0. 0. 0. 0. 0. 2.]
NCT02227199,27:42:chronic_disease,patients with evidence of lymphadenopathy in the neck must have a dedicated CT of neck,"['patients' 'with' 'evidence' 'of' 'lymphadenopathy' 'in' 'the' 'neck'
 'must' 'have' 'a' 'dedicated' 'CT' 'of' 'neck']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01750567,"16:31:chronic_disease,",ny increase in lymphadenopathy over best response that has persisted for more than 3 months,"['ny' 'increase' 'in' 'lymphadenopathy' 'over' 'best' 'response' 'that'
 'has' 'persisted' 'for' 'more' 'than' '3' 'months']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01419561,"12:27:chronic_disease,,",Pathologic lymphadenopathy (at least five discrete nodes each >1cm in their longest dimension),"['Pathologic' 'lymphadenopathy' '(' 'at' 'least' 'five' 'discrete' 'nodes'
 'each' '>' '1cm' 'in' 'their' 'longest' 'dimension' ')']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02913430,",,31:46:cancer",ALP ≤ 5X ULN in patients with bone metastases,['ALP' '≤' '5X' 'ULN' 'in' 'patients' 'with' 'bone' 'metastases'],[0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02699697,"26:41:cancer,",Radiographic evidence of bone metastases within 8 weeks of study,"['Radiographic' 'evidence' 'of' 'bone' 'metastases' 'within' '8' 'weeks'
 'of' 'study']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT02479230,",,,83:98:cancer",Alkaline phosphatase < 2.5 upper limit of normal (ULN) (< 10 x ULN in presence of bone metastases),"['Alkaline' 'phosphatase' '<' '2.5' 'upper' 'limit' 'of' 'normal' '('
 'ULN' ')' '(' '<' '10' 'x' 'ULN' 'in' 'presence' 'of' 'bone' 'metastases'
 ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0.]
NCT02408861,45:60:cancer,Repeat imaging demonstrates no new sites of bone metastases,"['Repeat' 'imaging' 'demonstrates' 'no' 'new' 'sites' 'of' 'bone'
 'metastases']",[0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02101034,",,56:71:cancer,",Alkaline phosphatase ≤ 2.5 x IULN for patients without bone metastases and ≤ 5.0 x IULN for patients with bone metastases,"['Alkaline' 'phosphatase' '≤' '2.5' 'x' 'IULN' 'for' 'patients' 'without'
 'bone' 'metastases' 'and' '≤' '5.0' 'x' 'IULN' 'for' 'patients' 'with'
 'bone' 'metastases']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02856412,1:17:chronic_disease,systemic illness affecting central nervous system (CNS) function,"['systemic' 'illness' 'affecting' 'central' 'nervous' 'system' '(' 'CNS'
 ')' 'function']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02634957,12:28:chronic_disease,History of systemic illness that could affect wound healing,"['History' 'of' 'systemic' 'illness' 'that' 'could' 'affect' 'wound'
 'healing']",[0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02076906,34:50:chronic_disease,Clinically significant unrelated systemic illness,['Clinically' 'significant' 'unrelated' 'systemic' 'illness'],[0. 0. 0. 2. 2.]
NCT01996449,7:23:chronic_disease,other systemic illness,['other' 'systemic' 'illness'],[0. 2. 2.]
NCT00670358,13:29:chronic_disease,"No comorbid systemic illness or other severe concurrent disease that, in the judgment of the investigator, would preclude study entry or significantly interfere with the proper assessment of safety and toxicity of the prescribed study regimen","['No' 'comorbid' 'systemic' 'illness' 'or' 'other' 'severe' 'concurrent'
 'disease' 'that' ',' 'in' 'the' 'judgment' 'of' 'the' 'investigator' ','
 'would' 'preclude' 'study' 'entry' 'or' 'significantly' 'interfere'
 'with' 'the' 'proper' 'assessment' 'of' 'safety' 'and' 'toxicity' 'of'
 'the' 'prescribed' 'study' 'regimen']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02816697,1:12:chronic_disease,Hypotension,['Hypotension'],[2.]
NCT02806570,"26:37:chronic_disease,,",Hemodynamic instability: Hypotension (systolic pressure <90 millimeter Mercury (mmHg)) or requirement for inotropic support or mechanical hemodynamic support,"['Hemodynamic' 'instability' ':' 'Hypotension' '(' 'systolic' 'pressure'
 '<' '90' 'millimeter' 'Mercury' '(' 'mmHg' ')' ')' 'or' 'requirement'
 'for' 'inotropic' 'support' 'or' 'mechanical' 'hemodynamic' 'support']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02507011,"1:12:chronic_disease,,",Hypotension defined as systolic blood pressure < 100 mmHg at the time of enrollment,"['Hypotension' 'defined' 'as' 'systolic' 'blood' 'pressure' '<' '100'
 'mmHg' 'at' 'the' 'time' 'of' 'enrollment']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02497300,"1:12:chronic_disease,,",Hypotension (office BP < 110/70 mm Hg),['Hypotension' '(' 'office' 'BP' '<' '110/70' 'mm' 'Hg' ')'],[2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02192398,"1:12:chronic_disease,,,,,,,",Hypotension (SBP < 90 mmHg and DBP < 60 mmHg for female or SBP < 100 mmHg and DBP < 60 mmHg for male; measured while in a sitting position) will be reviewed by a study physician,"['Hypotension' '(' 'SBP' '<' '90' 'mmHg' 'and' 'DBP' '<' '60' 'mmHg' 'for'
 'female' 'or' 'SBP' '<' '100' 'mmHg' 'and' 'DBP' '<' '60' 'mmHg' 'for'
 'male' ';' 'measured' 'while' 'in' 'a' 'sitting' 'position' ')' 'will'
 'be' 'reviewed' 'by' 'a' 'study' 'physician']","[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02762006,",,76:99:treatment",Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from an electrocardiogram (ECG) using Fridericia's Correction (QTcF),"['Mean' 'QT' 'interval' 'corrected' 'for' 'heart' 'rate' '(' 'QTc' ')'
 '≥470' 'ms' 'calculated' 'from' 'an' 'electrocardiogram' '(' 'ECG' ')'
 'using' 'Fridericia' ""'s"" 'Correction' '(' 'QTcF' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02525861,"80:103:treatment,","The participant has clinically significant abnormalities detected on a 12-lead electrocardiogram (ECG) performed at the time of screening. (Past records obtained within 26 weeks prior to screening may be used, if available.)","['The' 'participant' 'has' 'clinically' 'significant' 'abnormalities'
 'detected' 'on' 'a' '12-lead' 'electrocardiogram' '(' 'ECG' ')'
 'performed' 'at' 'the' 'time' 'of' 'screening' '.' '(' 'Past' 'records'
 'obtained' 'within' '26' 'weeks' 'prior' 'to' 'screening' 'may' 'be'
 'used' ',' 'if' 'available' '.' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02503722,87:110:treatment,"Any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiogram (ECG)","['Any' 'clinically' 'important' 'abnormalities' 'in' 'rhythm' ','
 'conduction' 'or' 'morphology' 'of' 'resting' 'electrocardiogram' '('
 'ECG' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]
NCT02402660,39:62:treatment,Has a clinically significant abnormal electrocardiogram (ECG),"['Has' 'a' 'clinically' 'significant' 'abnormal' 'electrocardiogram' '('
 'ECG' ')']",[0. 0. 0. 0. 0. 1. 1. 0. 0.]
NCT00540761,"30:53:treatment,,,",defined as chest pain or new electrocardiogram (ECG) changes in the 12 hours prior to study entry and/or rising creatine kinase (CK) and CK-MB serum enzymes,"['defined' 'as' 'chest' 'pain' 'or' 'new' 'electrocardiogram' '(' 'ECG'
 ')' 'changes' 'in' 'the' '12' 'hours' 'prior' 'to' 'study' 'entry'
 'and/or' 'rising' 'creatine' 'kinase' '(' 'CK' ')' 'and' 'CK-MB' 'serum'
 'enzymes']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02703220,1:16:treatment,antidepressants,['antidepressants'],[1.]
NCT02556606,",80:95:treatment","Participants have not responded to two or more adequate trials of FDA-approved antidepressants, determined by Antidepressant Treatment Response Questionnaire (ATRQ) criteria","['Participants' 'have' 'not' 'responded' 'to' 'two' 'or' 'more' 'adequate'
 'trials' 'of' 'FDA-approved' 'antidepressants' ',' 'determined' 'by'
 'Antidepressant' 'Treatment' 'Response' 'Questionnaire' '(' 'ATRQ' ')'
 'criteria']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02466685,1:16:treatment,antidepressants,['antidepressants'],[1.]
NCT02233868,1:16:treatment,antidepressants,['antidepressants'],[1.]
NCT02046330,",93:108:treatment,",Adequate trials (equal or >6 weeks at the maximum recommended or tolerated dose) of primary antidepressants from at least 3 different classes,"['Adequate' 'trials' '(' 'equal' 'or' '>' '6' 'weeks' 'at' 'the' 'maximum'
 'recommended' 'or' 'tolerated' 'dose' ')' 'of' 'primary'
 'antidepressants' 'from' 'at' 'least' '3' 'different' 'classes']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0.]"
NCT02665338,1:14:chronic_disease,Schizophrenia,['Schizophrenia'],[2.]
NCT02243813,90:103:chronic_disease,Current or past history of meeting Diagnostic and Statistics Manual (DSM)-5 criteria for Schizophrenia,"['Current' 'or' 'past' 'history' 'of' 'meeting' 'Diagnostic' 'and'
 'Statistics' 'Manual' '(' 'DSM' ')' '-5' 'criteria' 'for' 'Schizophrenia']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02133898,1:14:chronic_disease,Schizophrenia,['Schizophrenia'],[2.]
NCT02128802,1:14:chronic_disease,Schizophrenia,['Schizophrenia'],[2.]
NCT02021578,1:14:chronic_disease,Schizophrenia (parent or child),['Schizophrenia' '(' 'parent' 'or' 'child' ')'],[2. 0. 0. 0. 0. 0.]
NCT02592551,",56:75:treatment",Any unresolved toxicity (>CTCAE grade 2) from previous anti-cancer therapy,"['Any' 'unresolved' 'toxicity' '(' '>' 'CTCAE' 'grade' '2' ')' 'from'
 'previous' 'anti-cancer' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02576444,40:59:treatment,Concurrent administration of any other anti-cancer therapy,['Concurrent' 'administration' 'of' 'any' 'other' 'anti-cancer' 'therapy'],[0. 0. 0. 0. 0. 1. 1.]
NCT02401347,"5:24:treatment,",Any anti-cancer therapy within the past 21 days of the first day of treatment,"['Any' 'anti-cancer' 'therapy' 'within' 'the' 'past' '21' 'days' 'of'
 'the' 'first' 'day' 'of' 'treatment']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02393690,",100:119:treatment",Unresolved toxicity > Common Terminology Criteria for Adverse Events (CTCAE) grade 2 from previous anti-cancer therapy,"['Unresolved' 'toxicity' '>' 'Common' 'Terminology' 'Criteria' 'for'
 'Adverse' 'Events' '(' 'CTCAE' ')' 'grade' '2' 'from' 'previous'
 'anti-cancer' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02199236,24:43:treatment,Patients on concurrent anti-cancer therapy other than that allowed in the study,"['Patients' 'on' 'concurrent' 'anti-cancer' 'therapy' 'other' 'than'
 'that' 'allowed' 'in' 'the' 'study']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02570321,42:62:chronic_disease,Participants who are decisionally and/or cognitively impaired,"['Participants' 'who' 'are' 'decisionally' 'and/or' 'cognitively'
 'impaired']",[0. 0. 0. 0. 0. 2. 2.]
NCT02352480,18:38:chronic_disease,Subjects who are cognitively impaired,['Subjects' 'who' 'are' 'cognitively' 'impaired'],[0. 0. 0. 2. 2.]
NCT02352467,18:38:chronic_disease,Subjects who are cognitively impaired,['Subjects' 'who' 'are' 'cognitively' 'impaired'],[0. 0. 0. 2. 2.]
NCT02352454,18:38:chronic_disease,Subjects who are cognitively impaired,['Subjects' 'who' 'are' 'cognitively' 'impaired'],[0. 0. 0. 2. 2.]
NCT02312518,18:38:chronic_disease,Subjects who are cognitively impaired and do not have a healthcare proxy,"['Subjects' 'who' 'are' 'cognitively' 'impaired' 'and' 'do' 'not' 'have'
 'a' 'healthcare' 'proxy']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02551679,1:19:chronic_disease,Bleeding diathesis,['Bleeding' 'diathesis'],[2. 2.]
NCT02548104,1:19:chronic_disease,Bleeding diathesis,['Bleeding' 'diathesis'],[2. 2.]
NCT02535832,1:19:chronic_disease,Bleeding diathesis,['Bleeding' 'diathesis'],[2. 2.]
NCT02389465,1:19:chronic_disease,Bleeding diathesis,['Bleeding' 'diathesis'],[2. 2.]
NCT02056288,1:19:chronic_disease,Bleeding diathesis,['Bleeding' 'diathesis'],[2. 2.]
NCT02519322,80:83:treatment,"following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method","['following' 'confirmation' 'of' 'their' 'post-menopausal' 'status' ','
 'they' 'can' 'resume' 'use' 'of' 'HRT' 'during' 'the' 'study' 'without'
 'use' 'of' 'a' 'contraceptive' 'method']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02519322,49:52:treatment,this interval depends on the type and dosage of HRT,['this' 'interval' 'depends' 'on' 'the' 'type' 'and' 'dosage' 'of' 'HRT'],[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02056873,42:45:treatment,"(Subjects not required to participate in HRT but it will be highly encouraged, and must be completed prior to start of this study's protocol","['(' 'Subjects' 'not' 'required' 'to' 'participate' 'in' 'HRT' 'but' 'it'
 'will' 'be' 'highly' 'encouraged' ',' 'and' 'must' 'be' 'completed'
 'prior' 'to' 'start' 'of' 'this' 'study' ""'s"" 'protocol']","[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01943851,"80:83:treatment,","Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method","['Following' 'confirmation' 'of' 'their' 'post-menopausal' 'status' ','
 'they' 'can' 'resume' 'use' 'of' 'HRT' 'during' 'the' 'study' 'without'
 'use' 'of' 'a' 'contraceptive' 'method']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01943851,34:37:treatment,"Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment","['Otherwise' ',' 'they' 'must' 'discontinue' 'HRT' 'to' 'allow'
 'confirmation' 'of' 'post-menopausal' 'status' 'prior' 'to' 'study'
 'enrolment']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02496585,14:42:chronic_disease,History of a gastrointestinal perforation,['History' 'of' 'a' 'gastrointestinal' 'perforation'],[0. 0. 0. 2. 2.]
NCT02120222,"1:29:chronic_disease,",gastrointestinal perforation within 28 days prior to beginning study treatment,"['gastrointestinal' 'perforation' 'within' '28' 'days' 'prior' 'to'
 'beginning' 'study' 'treatment']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02101736,1:29:chronic_disease,gastrointestinal perforation,['gastrointestinal' 'perforation'],[2. 2.]
NCT02007239,11:39:chronic_disease,Suspected gastrointestinal perforation,['Suspected' 'gastrointestinal' 'perforation'],[0. 2. 2.]
NCT01639508,1:29:chronic_disease,gastrointestinal perforation,['gastrointestinal' 'perforation'],[2. 2.]
NCT02462161,1:38:chronic_disease,chronic obstructive pulmonary disease,['chronic' 'obstructive' 'pulmonary' 'disease'],[2. 2. 2. 2.]
NCT02332928,1:38:chronic_disease,chronic obstructive pulmonary disease requiring oxygen replacement,"['chronic' 'obstructive' 'pulmonary' 'disease' 'requiring' 'oxygen'
 'replacement']",[2. 2. 2. 2. 0. 0. 0.]
NCT02329652,1:38:chronic_disease,chronic obstructive pulmonary disease,['chronic' 'obstructive' 'pulmonary' 'disease'],[2. 2. 2. 2.]
NCT02081404,18:55:chronic_disease,oxygen dependent chronic obstructive pulmonary disease,['oxygen' 'dependent' 'chronic' 'obstructive' 'pulmonary' 'disease'],[0. 0. 2. 2. 2. 2.]
NCT01341080,20:57:chronic_disease,Moderate or severe chronic obstructive pulmonary disease,['Moderate' 'or' 'severe' 'chronic' 'obstructive' 'pulmonary' 'disease'],[0. 0. 0. 2. 2. 2. 2.]
NCT02421315,35:54:chronic_disease,DSM-IV current diagnosis of major depressive disorder,['DSM-IV' 'current' 'diagnosis' 'of' 'major' 'depressive' 'disorder'],[0. 0. 0. 0. 0. 2. 2.]
NCT02214667,1:20:chronic_disease,depressive disorder,['depressive' 'disorder'],[2. 2.]
NCT02106052,15:34:chronic_disease,Current major depressive disorder,['Current' 'major' 'depressive' 'disorder'],[0. 0. 2. 2.]
NCT02021578,24:43:chronic_disease,Current diagnosis of a depressive disorder (child),['Current' 'diagnosis' 'of' 'a' 'depressive' 'disorder' '(' 'child' ')'],[0. 0. 0. 0. 2. 2. 0. 0. 0.]
NCT02021578,39:58:chronic_disease,Parent with a current or history of a depressive disorder within child's lif,"['Parent' 'with' 'a' 'current' 'or' 'history' 'of' 'a' 'depressive'
 'disorder' 'within' 'child' ""'s"" 'lif']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02362308,13:35:treatment,status-post surgical sterilization,['status-post' 'surgical' 'sterilization'],[0. 1. 1.]
NCT02341209,",93:115:treatment,,",WOCBP includes any female who has experienced menarche and who has not undergone successful surgical sterilization or is not postmenopausal (defined as amenorrhea ≥ 12 consecutive months without an alternative medical cause),"['WOCBP' 'includes' 'any' 'female' 'who' 'has' 'experienced' 'menarche'
 'and' 'who' 'has' 'not' 'undergone' 'successful' 'surgical'
 'sterilization' 'or' 'is' 'not' 'postmenopausal' '(' 'defined' 'as'
 'amenorrhea' '≥' '12' 'consecutive' 'months' 'without' 'an' 'alternative'
 'medical' 'cause' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01904136,",,,125:147:treatment",Positive pregnancy test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization,"['Positive' 'pregnancy' 'test' 'in' 'a' 'woman' 'with' 'child' 'bearing'
 'potential' 'defined' 'as' 'not' 'post-menopausal' 'for' '12' 'months'
 'or' 'no' 'previous' 'surgical' 'sterilization']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01823198,",,,,136:158:treatment",Pregnancy: positive pregnancy test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization,"['Pregnancy' ':' 'positive' 'pregnancy' 'test' 'in' 'a' 'woman' 'with'
 'child' 'bearing' 'potential' 'defined' 'as' 'not' 'post-menopausal'
 'for' '12' 'months' 'or' 'no' 'previous' 'surgical' 'sterilization']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01701986,",,166:188:treatment",Pregnancy (positive beta human chorionic gonadotropin [HCG] test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization) or currently breast-feeding,"['Pregnancy' '(' 'positive' 'beta' 'human' 'chorionic' 'gonadotropin' '['
 'HCG' ']' 'test' 'in' 'a' 'woman' 'with' 'child' 'bearing' 'potential'
 'defined' 'as' 'not' 'post-menopausal' 'for' '12' 'months' 'or' 'no'
 'previous' 'surgical' 'sterilization' ')' 'or' 'currently'
 'breast-feeding']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]"
NCT02343549,"15:26:treatment,,",Able to start bevacizumab at least 2 weeks but no more than 4 weeks from date of biopsy,"['Able' 'to' 'start' 'bevacizumab' 'at' 'least' '2' 'weeks' 'but' 'no'
 'more' 'than' '4' 'weeks' 'from' 'date' 'of' 'biopsy']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02343549,44:55:allergy_name,Known hypersensitivity to any component of bevacizumab,['Known' 'hypersensitivity' 'to' 'any' 'component' 'of' 'bevacizumab'],[0. 0. 0. 0. 0. 0. 4.]
NCT02343549,39:50:allergy_name,Subjects meeting any of the following bevacizumab-specific contraindications,"['Subjects' 'meeting' 'any' 'of' 'the' 'following' 'bevacizumab-specific'
 'contraindications']",[0. 0. 0. 0. 0. 0. 4. 0.]
NCT01903330,64:75:allergy_name,Known contraindication or hypersensitivity to any component of bevacizumab,"['Known' 'contraindication' 'or' 'hypersensitivity' 'to' 'any' 'component'
 'of' 'bevacizumab']",[0. 0. 0. 0. 0. 0. 0. 0. 4.]
NCT01894061,16:27:treatment,The effects of bevacizumab on developing fetus or nursing infant are not known,"['The' 'effects' 'of' 'bevacizumab' 'on' 'developing' 'fetus' 'or'
 'nursing' 'infant' 'are' 'not' 'known']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03182907,41:44:chronic_disease,At screening has suspected or confirmed CDI,['At' 'screening' 'has' 'suspected' 'or' 'confirmed' 'CDI'],[0. 0. 0. 0. 0. 0. 2.]
NCT02667418,"18:21:chronic_disease,",second recurrent CDI episode occurring within 3 months of the first recurrent episode,"['second' 'recurrent' 'CDI' 'episode' 'occurring' 'within' '3' 'months'
 'of' 'the' 'first' 'recurrent' 'episode']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01905709,",33:36:chronic_disease",At least two episodes of severe CDI resulting in hospitalization and associated with significant morbidity,"['At' 'least' 'two' 'episodes' 'of' 'severe' 'CDI' 'resulting' 'in'
 'hospitalization' 'and' 'associated' 'with' 'significant' 'morbidity']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01905709,36:39:chronic_disease,Subject has recurrent or relapsing CDI,['Subject' 'has' 'recurrent' 'or' 'relapsing' 'CDI'],[0. 0. 0. 0. 0. 2.]
NCT03169543,1:15:chronic_disease,"Claustrophobic, or intolerant of the scanner environment","['Claustrophobic' ',' 'or' 'intolerant' 'of' 'the' 'scanner' 'environment']",[2. 0. 0. 0. 0. 0. 0. 0.]
NCT02315950,1:15:chronic_disease,Claustrophobic,['Claustrophobic'],[2.]
NCT02095808,1:15:chronic_disease,Claustrophobic,['Claustrophobic'],[2.]
NCT02035085,1:15:chronic_disease,Claustrophobic,['Claustrophobic'],[2.]
NCT03152409,12:20:chronic_disease,History of GI bleed,['History' 'of' 'GI' 'bleed'],[0. 0. 2. 2.]
NCT03100461,9:17:chronic_disease,current GI bleed,['current' 'GI' 'bleed'],[0. 2. 2.]
NCT02272998,"1:9:chronic_disease,",GI bleed within 30 days prior to registration on study,"['GI' 'bleed' 'within' '30' 'days' 'prior' 'to' 'registration' 'on'
 'study']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01918683,"8:16:chronic_disease,",Active GI bleed within 2 weeks of study enrollment,['Active' 'GI' 'bleed' 'within' '2' 'weeks' 'of' 'study' 'enrollment'],[0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT03146663,57:84:treatment,Disease that progressed while receiving initial line of platinum-based chemotherapy,"['Disease' 'that' 'progressed' 'while' 'receiving' 'initial' 'line' 'of'
 'platinum-based' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT03146663,"28:55:treatment,",Time from the last line of platinum-based chemotherapy of less than 6 months,"['Time' 'from' 'the' 'last' 'line' 'of' 'platinum-based' 'chemotherapy'
 'of' 'less' 'than' '6' 'months']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02203513,",133:160:treatment",Patients should have recurrent platinum-resistant - defined as disease recurrence by imaging within 6 months of the last receipt of platinum-based chemotherapy,"['Patients' 'should' 'have' 'recurrent' 'platinum-resistant' '-' 'defined'
 'as' 'disease' 'recurrence' 'by' 'imaging' 'within' '6' 'months' 'of'
 'the' 'last' 'receipt' 'of' 'platinum-based' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01941316,",66:93:treatment",Patients who progressed during or within one month of completing platinum-based chemotherapy,"['Patients' 'who' 'progressed' 'during' 'or' 'within' 'one' 'month' 'of'
 'completing' 'platinum-based' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT03141359,",,54:67:chronic_disease","Centrally located primary tumor < 2 cm from involved nodal disease which would result in significant overlap of radiation dose. Centrally located is defined as within or touching the zone of the proximal bronchial tree, which is a volume 2 cm in all directions around the proximal bronchial tree (carina, right and left main bronchi, right and left upper lobe bronchi, intermedius bronchus, right middle lobe bronchus, lingular bronchus right and left lower lobe bronchi)","['Centrally' 'located' 'primary' 'tumor' '<' '2' 'cm' 'from' 'involved'
 'nodal' 'disease' 'which' 'would' 'result' 'in' 'significant' 'overlap'
 'of' 'radiation' 'dose' '.' 'Centrally' 'located' 'is' 'defined' 'as'
 'within' 'or' 'touching' 'the' 'zone' 'of' 'the' 'proximal' 'bronchial'
 'tree' ',' 'which' 'is' 'a' 'volume' '2' 'cm' 'in' 'all' 'directions'
 'around' 'the' 'proximal' 'bronchial' 'tree' '(' 'carina' ',' 'right'
 'and' 'left' 'main' 'bronchi' ',' 'right' 'and' 'left' 'upper' 'lobe'
 'bronchi' ',' 'intermedius' 'bronchus' ',' 'right' 'middle' 'lobe'
 'bronchus' ',' 'lingular' 'bronchus' 'right' 'and' 'left' 'lower' 'lobe'
 'bronchi' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02977468,23:36:chronic_disease,Pathologically proven nodal disease at diagnosis is not allowed,"['Pathologically' 'proven' 'nodal' 'disease' 'at' 'diagnosis' 'is' 'not'
 'allowed']",[0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02541565,17:30:cancer,Have measurable nodal disease,['Have' 'measurable' 'nodal' 'disease'],[0. 0. 3. 3.]
NCT02353819,4:17:cancer,No nodal disease,['No' 'nodal' 'disease'],[0. 3. 3.]
NCT03131960,12:30:chronic_disease,History of hemorrhagic stroke,['History' 'of' 'hemorrhagic' 'stroke'],[0. 0. 2. 2.]
NCT02576301,16:34:chronic_disease,Any history of hemorrhagic stroke,['Any' 'history' 'of' 'hemorrhagic' 'stroke'],[0. 0. 0. 2. 2.]
NCT02169739,1:19:chronic_disease,hemorrhagic stroke,['hemorrhagic' 'stroke'],[2. 2.]
NCT02140554,10:28:chronic_disease,overt or hemorrhagic stroke,['overt' 'or' 'hemorrhagic' 'stroke'],[0. 0. 2. 2.]
NCT03125902,7:43:chronic_disease,Known central nervous system (CNS) disease,['Known' 'central' 'nervous' 'system' '(' 'CNS' ')' 'disease'],[0. 2. 2. 2. 2. 2. 0. 0.]
NCT02530034,28:64:chronic_disease,Patients with known active central nervous system (CNS) disease,"['Patients' 'with' 'known' 'active' 'central' 'nervous' 'system' '(' 'CNS'
 ')' 'disease']",[0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0.]
NCT01701986,21:57:chronic_disease,Patient with active central nervous system (CNS) disease,"['Patient' 'with' 'active' 'central' 'nervous' 'system' '(' 'CNS' ')'
 'disease']",[0. 0. 0. 2. 2. 2. 2. 2. 0. 0.]
NCT00075387,35:71:chronic_disease,Subjects with rapidly progressing central nervous system (CNS) disease with associated neurological deterioration,"['Subjects' 'with' 'rapidly' 'progressing' 'central' 'nervous' 'system'
 '(' 'CNS' ')' 'disease' 'with' 'associated' 'neurological'
 'deterioration']",[0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT03119467,"20:34:treatment,",Patients receiving cancer therapy within 3 weeks prior to Cycle1 Day1 (C1D1),"['Patients' 'receiving' 'cancer' 'therapy' 'within' '3' 'weeks' 'prior'
 'to' 'Cycle1' 'Day1' '(' 'C1D1' ')']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02538198,61:75:treatment,"has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months)","['has' 'not' 'been' 'naturally' 'postmenopausal' '(' 'amenorrhea'
 'following' 'cancer' 'therapy' 'does' 'not' 'rule' 'out' 'childbearing'
 'potential' ')' 'for' 'at' 'least' '24' 'consecutive' 'months' '(' 'i.e.'
 ',' 'has' 'had' 'menses' 'at' 'any' 'time' 'during' 'the' 'preceding'
 '24' 'consecutive' 'months' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01858168,65:79:treatment,Persistent clinically significant toxicities caused by previous cancer therapy,"['Persistent' 'clinically' 'significant' 'toxicities' 'caused' 'by'
 'previous' 'cancer' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01625234,30:44:treatment,Patients currently receiving cancer therapy,['Patients' 'currently' 'receiving' 'cancer' 'therapy'],[0. 0. 0. 1. 1.]
NCT03108950,8:23:chronic_disease,Active pressure ulcers,['Active' 'pressure' 'ulcers'],[0. 2. 2.]
NCT02978638,21:36:chronic_disease,"Active or recurrent pressure ulcers, particularly in sacral, ischial or trochanteric areas","['Active' 'or' 'recurrent' 'pressure' 'ulcers' ',' 'particularly' 'in'
 'sacral' ',' 'ischial' 'or' 'trochanteric' 'areas']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02533882,8:23:chronic_disease,Active pressure ulcers,['Active' 'pressure' 'ulcers'],[0. 2. 2.]
NCT02139436,",28:43:chronic_disease",current grade 2 or greater pressure ulcers at relevant contact sites,"['current' 'grade' '2' 'or' 'greater' 'pressure' 'ulcers' 'at' 'relevant'
 'contact' 'sites']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT03085485,",59:76:chronic_disease",Clinically stable in the last 4 weeks with no evidence of COPD exacerbation,"['Clinically' 'stable' 'in' 'the' 'last' '4' 'weeks' 'with' 'no'
 'evidence' 'of' 'COPD' 'exacerbation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02178566,21:38:chronic_disease,Hospitalization for COPD exacerbation,['Hospitalization' 'for' 'COPD' 'exacerbation'],[0. 0. 2. 2.]
NCT02178566,24:41:chronic_disease,Use of antibiotics for COPD exacerbation,['Use' 'of' 'antibiotics' 'for' 'COPD' 'exacerbation'],[0. 0. 0. 0. 2. 2.]
NCT01742338,40:57:chronic_disease,re-admitted to the hospital with a new COPD exacerbation,"['re-admitted' 'to' 'the' 'hospital' 'with' 'a' 'new' 'COPD'
 'exacerbation']",[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT03073785,5:14:cancer,All malignant disease must be able to be encompassed within a single irradiation field,"['All' 'malignant' 'disease' 'must' 'be' 'able' 'to' 'be' 'encompassed'
 'within' 'a' 'single' 'irradiation' 'field']",[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02406599,",25:34:cancer","Women with non-palpable malignant lesions, requiring image guided localization","['Women' 'with' 'non-palpable' 'malignant' 'lesions' ',' 'requiring'
 'image' 'guided' 'localization']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0.]
NCT02186418,25:34:cancer,Patients with an active malignant disease,['Patients' 'with' 'an' 'active' 'malignant' 'disease'],[0. 0. 0. 0. 3. 0.]
NCT02105545,20:29:cancer,Any patient with a malignant diagnosis at the time of diagnosis or relapse,"['Any' 'patient' 'with' 'a' 'malignant' 'diagnosis' 'at' 'the' 'time' 'of'
 'diagnosis' 'or' 'relapse']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03063892,1:27:chronic_disease,Myocardial infarction (MI) and/or stents within the past year,"['Myocardial' 'infarction' '(' 'MI' ')' 'and/or' 'stents' 'within' 'the'
 'past' 'year']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02343042,"1:27:chronic_disease,",Myocardial infarction (MI) within 3 months prior to C1D1,"['Myocardial' 'infarction' '(' 'MI' ')' 'within' '3' 'months' 'prior' 'to'
 'C1D1']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01684397,1:27:chronic_disease,Myocardial infarction (MI),['Myocardial' 'infarction' '(' 'MI' ')'],[2. 2. 2. 0. 0.]
NCT01620216,1:27:chronic_disease,Myocardial infarction (MI),['Myocardial' 'infarction' '(' 'MI' ')'],[2. 2. 2. 0. 0.]
NCT03058029,1:9:chronic_disease,Diabetic subjects,['Diabetic' 'subjects'],[2. 0.]
NCT02490631,1:9:chronic_disease,Diabetic,['Diabetic'],[2.]
NCT02313428,1:9:chronic_disease,Diabetic,['Diabetic'],[2.]
NCT00085982,"1:9:chronic_disease,,",Diabetic symptoms with a random plasma glucose >= 200 mg/dL,"['Diabetic' 'symptoms' 'with' 'a' 'random' 'plasma' 'glucose' '>' '='
 '200' 'mg/dL']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03040726,"1:24:chronic_disease,,",Severe renal impairment (calculated creatinine clearance =< 29 cc/min),"['Severe' 'renal' 'impairment' '(' 'calculated' 'creatinine' 'clearance'
 '=' '<' '29' 'cc/min' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03012815,"1:24:chronic_disease,,",Severe renal impairment (estimated CrCl < 30),['Severe' 'renal' 'impairment' '(' 'estimated' 'CrCl' '<' '30' ')'],[2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02950233,"1:24:chronic_disease,,",Severe renal impairment (creatinine clearance based GFR of <30ml/min),"['Severe' 'renal' 'impairment' '(' 'creatinine' 'clearance' 'based' 'GFR'
 'of' '<' '30ml/min' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01585402,"1:24:chronic_disease,,",Severe renal impairment (estimated creatinine clearance/eGFR of < 30ml/min calculated using CKD-EPI equation,"['Severe' 'renal' 'impairment' '(' 'estimated' 'creatinine'
 'clearance/eGFR' 'of' '<' '30ml/min' 'calculated' 'using' 'CKD-EPI'
 'equation']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03033498,29:42:chronic_disease,has a diagnosis of definite idiopathic PD,['has' 'a' 'diagnosis' 'of' 'definite' 'idiopathic' 'PD'],[0. 0. 0. 0. 0. 2. 2.]
NCT01742182,14:27:chronic_disease,Diagnosis of idiopathic PD as defined by the United Kingdom PD Society Brain Bank Criteria,"['Diagnosis' 'of' 'idiopathic' 'PD' 'as' 'defined' 'by' 'the' 'United'
 'Kingdom' 'PD' 'Society' 'Brain' 'Bank' 'Criteria']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01581580,30:43:chronic_disease,Have a clinical diagnosis of idiopathic PD,['Have' 'a' 'clinical' 'diagnosis' 'of' 'idiopathic' 'PD'],[0. 0. 0. 0. 0. 2. 2.]
NCT01581580,18:31:chronic_disease,The diagnosis of idiopathic PD will be based on the UK Brain Bank Criteria,"['The' 'diagnosis' 'of' 'idiopathic' 'PD' 'will' 'be' 'based' 'on' 'the'
 'UK' 'Brain' 'Bank' 'Criteria']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03012815,"16:26:treatment,",Already taking gabapentin more than 300 mg three times a day,"['Already' 'taking' 'gabapentin' 'more' 'than' '300' 'mg' 'three' 'times'
 'a' 'day']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03012815,40:50:treatment,Patients receiving therapeutic dose of gabapentin (rather than continuation of home dose) prior to enrollment,"['Patients' 'receiving' 'therapeutic' 'dose' 'of' 'gabapentin' '('
 'rather' 'than' 'continuation' 'of' 'home' 'dose' ')' 'prior' 'to'
 'enrollment']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02480114,14:24:treatment,Currently on gabapentin,['Currently' 'on' 'gabapentin'],[0. 0. 1.]
NCT02480114,24:34:treatment,Prior non-tolerance of gabapentin,['Prior' 'non-tolerance' 'of' 'gabapentin'],[0. 0. 0. 1.]
NCT02996227,1:16:chronic_disease,"Hepatic disease, e.g. twice the normal levels of liver enzymes","['Hepatic' 'disease' ',' 'e.g' '.' 'twice' 'the' 'normal' 'levels' 'of'
 'liver' 'enzymes']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02755116,1:16:chronic_disease,Hepatic disease,['Hepatic' 'disease'],[2. 2.]
NCT01895777,1:16:chronic_disease,Hepatic disease,['Hepatic' 'disease'],[2. 2.]
NCT01184547,1:16:chronic_disease,Hepatic disease,['Hepatic' 'disease'],[2. 2.]
NCT02971202,1:20:chronic_disease,severe hypoglycemia,['severe' 'hypoglycemia'],[2. 2.]
NCT02415556,12:31:chronic_disease,History of severe hypoglycemia,['History' 'of' 'severe' 'hypoglycemia'],[0. 0. 2. 2.]
NCT02251431,12:31:chronic_disease,History of severe hypoglycemia,['History' 'of' 'severe' 'hypoglycemia'],[0. 0. 2. 2.]
NCT01474889,"16:35:chronic_disease,",No episodes of severe hypoglycemia in the past 3 years,"['No' 'episodes' 'of' 'severe' 'hypoglycemia' 'in' 'the' 'past' '3'
 'years']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02945800,1:37:chronic_disease,symptomatic congestive heart failure,['symptomatic' 'congestive' 'heart' 'failure'],[2. 2. 2. 2.]
NCT02857218,1:37:chronic_disease,symptomatic congestive heart failure,['symptomatic' 'congestive' 'heart' 'failure'],[2. 2. 2. 2.]
NCT02843568,1:37:chronic_disease,symptomatic congestive heart failure,['symptomatic' 'congestive' 'heart' 'failure'],[2. 2. 2. 2.]
NCT02159703,1:37:chronic_disease,symptomatic congestive heart failure,['symptomatic' 'congestive' 'heart' 'failure'],[2. 2. 2. 2.]
NCT02931110,",10:21:chronic_disease",Grade ≥2 bradycardia,['Grade' '≥2' 'bradycardia'],[0. 0. 2.]
NCT02925923,19:30:chronic_disease,increased risk of bradycardia,['increased' 'risk' 'of' 'bradycardia'],[0. 0. 0. 2.]
NCT02329652,8:19:chronic_disease,severe bradycardia,['severe' 'bradycardia'],[0. 2.]
NCT01696734,24:35:chronic_disease,clinically significant bradycardia,['clinically' 'significant' 'bradycardia'],[0. 0. 2.]
NCT02923921,26:37:treatment,who were intolerant of a gemcitabine containing regimen,['who' 'were' 'intolerant' 'of' 'a' 'gemcitabine' 'containing' 'regimen'],[0. 0. 0. 0. 0. 1. 0. 0.]
NCT02533674,27:38:allergy_name,Known hypersensitivity to gemcitabine or any component of the formulation,"['Known' 'hypersensitivity' 'to' 'gemcitabine' 'or' 'any' 'component' 'of'
 'the' 'formulation']",[0. 0. 0. 4. 0. 0. 0. 0. 0. 0.]
NCT02533674,43:54:treatment,Patients who have previously discontinued gemcitabine-containing regimens due to gemcitabine-related toxicity,"['Patients' 'who' 'have' 'previously' 'discontinued'
 'gemcitabine-containing' 'regimens' 'due' 'to' 'gemcitabine-related'
 'toxicity']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02437370,43:54:treatment,Patients with a known hypersensitivity to gemcitabine (Arm B only),"['Patients' 'with' 'a' 'known' 'hypersensitivity' 'to' 'gemcitabine' '('
 'Arm' 'B' 'only' ')']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02918864,8:24:chronic_disease,simple febrile seizures,['simple' 'febrile' 'seizures'],[0. 2. 2.]
NCT02477839,25:41:chronic_disease,Subject has experienced febrile seizures exclusively,['Subject' 'has' 'experienced' 'febrile' 'seizures' 'exclusively'],[0. 0. 0. 2. 2. 0.]
NCT02477839,19:35:chronic_disease,The occurrence of febrile seizures in addition to partial-onset seizures,"['The' 'occurrence' 'of' 'febrile' 'seizures' 'in' 'addition' 'to'
 'partial-onset' 'seizures']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02418195,16:32:chronic_disease,only childhood febrile seizures,['only' 'childhood' 'febrile' 'seizures'],[0. 0. 2. 2.]
NCT02905188,"1:14:chronic_disease,,",Heart failure of Class III-IV and / or C-D per NYHA Criteria,"['Heart' 'failure' 'of' 'Class' 'III-IV' 'and' '/' 'or' 'C-D' 'per' 'NYHA'
 'Criteria']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02508038,1:14:chronic_disease,Heart failure,['Heart' 'failure'],[2. 2.]
NCT02471833,1:14:chronic_disease,Heart failure,['Heart' 'failure'],[2. 2.]
NCT02095808,1:14:chronic_disease,Heart failure,['Heart' 'failure'],[2. 2.]
NCT02881242,"1:20:chronic_disease,",Uncontrolled angina within 3 months,['Uncontrolled' 'angina' 'within' '3' 'months'],[2. 2. 0. 0. 0.]
NCT02519322,"1:20:chronic_disease,",Uncontrolled angina within the 3 months prior to consent,"['Uncontrolled' 'angina' 'within' 'the' '3' 'months' 'prior' 'to'
 'consent']",[2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02203695,"1:20:chronic_disease,",Uncontrolled angina within 3 months of Screening visit,['Uncontrolled' 'angina' 'within' '3' 'months' 'of' 'Screening' 'visit'],[2. 2. 0. 0. 0. 0. 0. 0.]
NCT01620216,1:20:chronic_disease,Uncontrolled angina at time of consent OR,['Uncontrolled' 'angina' 'at' 'time' 'of' 'consent' 'OR'],[2. 2. 0. 0. 0. 0. 0.]
NCT02871349,7:18:chronic_disease,Major head trauma,['Major' 'head' 'trauma'],[0. 2. 2.]
NCT02479906,"38:49:chronic_disease,",Subject has a history of significant head trauma with loss of consciousness for longer than 5 minutes,"['Subject' 'has' 'a' 'history' 'of' 'significant' 'head' 'trauma' 'with'
 'loss' 'of' 'consciousness' 'for' 'longer' 'than' '5' 'minutes']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02469389,1:12:chronic_disease,head trauma with loss of consciousness,['head' 'trauma' 'with' 'loss' 'of' 'consciousness'],[2. 2. 0. 0. 0. 0.]
NCT01782599,14:25:chronic_disease,a history of head trauma,['a' 'history' 'of' 'head' 'trauma'],[0. 0. 0. 2. 2.]
NCT02860000,40:62:cancer,"History of primary, operable ER+/HER2− invasive breast cancer","['History' 'of' 'primary' ',' 'operable' 'ER+/HER2−' 'invasive' 'breast'
 'cancer']",[0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT02476786,68:90:cancer,"Newly diagnosed histologically or cytologically confirmed operable invasive breast cancer defined as cT1 or T2, N0-1, and M0","['Newly' 'diagnosed' 'histologically' 'or' 'cytologically' 'confirmed'
 'operable' 'invasive' 'breast' 'cancer' 'defined' 'as' 'cT1' 'or' 'T2'
 ',' 'N0-1' ',' 'and' 'M0']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02427581,39:61:cancer,Histologically confirmed diagnosis of invasive breast cancer,"['Histologically' 'confirmed' 'diagnosis' 'of' 'invasive' 'breast'
 'cancer']",[0. 0. 0. 0. 3. 3. 3.]
NCT02422641,43:65:cancer,Histologically or cytologically confirmed invasive breast cancer,"['Histologically' 'or' 'cytologically' 'confirmed' 'invasive' 'breast'
 'cancer']",[0. 0. 0. 0. 3. 3. 3.]
NCT02851914,1:11:chronic_disease,Depression diagnosis by mental health provider,['Depression' 'diagnosis' 'by' 'mental' 'health' 'provider'],[2. 0. 0. 0. 0. 0.]
NCT02726906,1:11:chronic_disease,Depression,['Depression'],[2.]
NCT02473250,"1:11:chronic_disease,,",Depression of sufficient severity to score at least 16 on the first 17 items of the Hamilton Depression Rating Scale,"['Depression' 'of' 'sufficient' 'severity' 'to' 'score' 'at' 'least' '16'
 'on' 'the' 'first' '17' 'items' 'of' 'the' 'Hamilton' 'Depression'
 'Rating' 'Scale']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01581580,"1:11:chronic_disease,,",Depression or evidenced by self-report on the Beck Depression Inventory-2 (score above 20),"['Depression' 'or' 'evidenced' 'by' 'self-report' 'on' 'the' 'Beck'
 'Depression' 'Inventory-2' '(' 'score' 'above' '20' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02822001,",54:70:treatment",Patients weighing ≥ 80 pounds who are not -intubated prior to surgery,"['Patients' 'weighing' '≥' '80' 'pounds' 'who' 'are' 'not' '-intubated'
 'prior' 'to' 'surgery']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02565966,",,13:29:treatment",3 - 4 weeks prior to surgery,['3' '-' '4' 'weeks' 'prior' 'to' 'surgery'],[0. 0. 0. 0. 1. 1. 1.]
NCT02565966,",,,17:33:treatment",diet 3 -4 weeks prior to surgery,['diet' '3' '-4' 'weeks' 'prior' 'to' 'surgery'],[0. 0. 0. 0. 1. 1. 1.]
NCT02561104,101:117:treatment,Study doctor will assess patient findings and determine how long RGP lens wear must be discontinued prior to surgery,"['Study' 'doctor' 'will' 'assess' 'patient' 'findings' 'and' 'determine'
 'how' 'long' 'RGP' 'lens' 'wear' 'must' 'be' 'discontinued' 'prior' 'to'
 'surgery']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02780401,",,177:198:treatment",Left ventricular ejection fraction (LVEF) results must be >= lower limit of normal (LLN) for institution performing based on results from the multi-gated acquisition (MUGA) or echocardiogram (ECHO) done at baseline,"['Left' 'ventricular' 'ejection' 'fraction' '(' 'LVEF' ')' 'results'
 'must' 'be' '>' '=' 'lower' 'limit' 'of' 'normal' '(' 'LLN' ')' 'for'
 'institution' 'performing' 'based' 'on' 'results' 'from' 'the'
 'multi-gated' 'acquisition' '(' 'MUGA' ')' 'or' 'echocardiogram' '('
 'ECHO' ')' 'done' 'at' 'baseline']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]"
NCT02465060,15:36:treatment,documented by echocardiogram (ECHO) (as clinically indicated),"['documented' 'by' 'echocardiogram' '(' 'ECHO' ')' '(' 'as' 'clinically'
 'indicated' ')']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01989585,",84:105:treatment",Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO),"['Left' 'ventricular' 'ejection' 'fraction' '>' '=' 'institutional'
 'lower' 'limit' 'of' 'normal' '(' 'LLN' ')' 'by' 'echocardiogram' '('
 'ECHO' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]
NCT00720785,",,53:74:treatment",Left ventricular ejection fraction less than 40% by echocardiogram (ECHO),"['Left' 'ventricular' 'ejection' 'fraction' 'less' 'than' '40' '%' 'by'
 'echocardiogram' '(' 'ECHO' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]
NCT02740595,1:16:chronic_disease,Cardiac disease,['Cardiac' 'disease'],[2. 2.]
NCT02734888,1:16:chronic_disease,Cardiac disease,['Cardiac' 'disease'],[2. 2.]
NCT02323581,1:16:chronic_disease,Cardiac disease,['Cardiac' 'disease'],[2. 2.]
NCT02025426,"8:23:chronic_disease,",Severe Cardiac disease in pregnancy with marked functional limitations (NYHA Class III and IV),"['Severe' 'Cardiac' 'disease' 'in' 'pregnancy' 'with' 'marked'
 'functional' 'limitations' '(' 'NYHA' 'Class' 'III' 'and' 'IV' ')']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02669173,1:23:treatment,cytotoxic chemotherapy,['cytotoxic' 'chemotherapy'],[1. 1.]
NCT02346526,"21:43:treatment,",No intention to use cytotoxic chemotherapy within the next 6 months,"['No' 'intention' 'to' 'use' 'cytotoxic' 'chemotherapy' 'within' 'the'
 'next' '6' 'months']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02232516,",,83:105:treatment",with a cumulative illness rating scale (CIRS) score >= 6 OR deemed ineligible for cytotoxic chemotherapy by the treating investigator,"['with' 'a' 'cumulative' 'illness' 'rating' 'scale' '(' 'CIRS' ')' 'score'
 '>' '=' '6' 'OR' 'deemed' 'ineligible' 'for' 'cytotoxic' 'chemotherapy'
 'by' 'the' 'treating' 'investigator']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02048722,"8:30:treatment,",Use of cytotoxic chemotherapy within 21 days of registration,"['Use' 'of' 'cytotoxic' 'chemotherapy' 'within' '21' 'days' 'of'
 'registration']",[0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02617589,24:27:cancer,Recurrent or secondary GBM,['Recurrent' 'or' 'secondary' 'GBM'],[0. 0. 0. 3.]
NCT02359097,"27:30:cancer,","for presumed diagnosis of GBM, histological confirmation of GBM must be completed within 12 weeks of enrollment","['for' 'presumed' 'diagnosis' 'of' 'GBM' ',' 'histological' 'confirmation'
 'of' 'GBM' 'must' 'be' 'completed' 'within' '12' 'weeks' 'of'
 'enrollment']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02343549,26:29:cancer,Pathological evidence of GBM using WHO classification criteria,"['Pathological' 'evidence' 'of' 'GBM' 'using' 'WHO' 'classification'
 'criteria']",[0. 0. 0. 3. 0. 0. 0. 0.]
NCT01865162,"56:59:cancer,,",Measurable contrast-enhancing progressive or recurrent GBM by MRI imaging ≤ two weeks before screening,"['Measurable' 'contrast-enhancing' 'progressive' 'or' 'recurrent' 'GBM'
 'by' 'MRI' 'imaging' '≤' 'two' 'weeks' 'before' 'screening']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02587403,"21:51:treatment,",Participation in an investigational drug or device study that would impact the safety or scientific integrity of this study (in the opinion of the Investigator and with the approval of the Sponsor) within the past 6 weeks prior to enrollment into this trial,"['Participation' 'in' 'an' 'investigational' 'drug' 'or' 'device' 'study'
 'that' 'would' 'impact' 'the' 'safety' 'or' 'scientific' 'integrity' 'of'
 'this' 'study' '(' 'in' 'the' 'opinion' 'of' 'the' 'Investigator' 'and'
 'with' 'the' 'approval' 'of' 'the' 'Sponsor' ')' 'within' 'the' 'past'
 '6' 'weeks' 'prior' 'to' 'enrollment' 'into' 'this' 'trial']","[0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02366611,11:41:treatment,Use of an investigational drug or device,['Use' 'of' 'an' 'investigational' 'drug' 'or' 'device'],[0. 0. 0. 1. 1. 1. 1.]
NCT02169830,"21:51:treatment,",Patient has used an investigational drug or device in the the 3 months prior to screening,"['Patient' 'has' 'used' 'an' 'investigational' 'drug' 'or' 'device' 'in'
 'the' 'the' '3' 'months' 'prior' 'to' 'screening']",[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01464164,"24:54:treatment,",Treatment with another investigational drug or device <56 days pre-study entry,"['Treatment' 'with' 'another' 'investigational' 'drug' 'or' 'device' '<'
 '56' 'days' 'pre-study' 'entry']",[0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02573493,",,14:28:cancer",Arm 1: T2-T4 primary tumors,['Arm' '1' ':' 'T2-T4' 'primary' 'tumors'],[0. 0. 0. 0. 3. 3.]
NCT02573493,",,16:30:cancer",Arm 3: T2T1-T4 primary tumors,['Arm' '3' ':' 'T2T1-T4' 'primary' 'tumors'],[0. 0. 0. 0. 3. 3.]
NCT02573493,",,7:21:cancer",T2-T4 primary tumors,['T2-T4' 'primary' 'tumors'],[0. 3. 3.]
NCT02427841,46:60:cancer,"Subjects with locally advanced, unresectable primary tumors","['Subjects' 'with' 'locally' 'advanced' ',' 'unresectable' 'primary'
 'tumors']",[0. 0. 0. 0. 0. 0. 3. 3.]
NCT02562040,1:19:chronic_disease,Bleeding disorders,['Bleeding' 'disorders'],[2. 2.]
NCT02558010,1:19:chronic_disease,Bleeding disorders,['Bleeding' 'disorders'],[2. 2.]
NCT02226159,1:19:chronic_disease,Bleeding disorders or other medical contraindications to the injection procedure,"['Bleeding' 'disorders' 'or' 'other' 'medical' 'contraindications' 'to'
 'the' 'injection' 'procedure']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01850758,1:19:chronic_disease,Bleeding disorders,['Bleeding' 'disorders'],[2. 2.]
NCT02551679,8:23:chronic_disease,Severe aortic stenosis,['Severe' 'aortic' 'stenosis'],[0. 2. 2.]
NCT02468778,"24:39:chronic_disease,,",Documented presence of aortic stenosis (orifice area of 1.5cm2 or less),"['Documented' 'presence' 'of' 'aortic' 'stenosis' '(' 'orifice' 'area'
 'of' '1.5cm2' 'or' 'less' ')']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02000115,"17:32:chronic_disease,,,","has symptomatic aortic stenosis as demonstrated by NYHA Functional Classification of II, III, or IV","['has' 'symptomatic' 'aortic' 'stenosis' 'as' 'demonstrated' 'by' 'NYHA'
 'Functional' 'Classification' 'of' 'II' ',' 'III' ',' 'or' 'IV']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01791543,8:23:chronic_disease,Severe aortic stenosis,['Severe' 'aortic' 'stenosis'],[0. 2. 2.]
NCT02506192,27:37:treatment,Known hypersensitivity to Prednisone,['Known' 'hypersensitivity' 'to' 'Prednisone'],[0. 0. 0. 1.]
NCT02474199,"1:11:treatment,",Prednisone: maximum dose of 5mg daily,['Prednisone' ':' 'maximum' 'dose' 'of' '5mg' 'daily'],[1. 0. 0. 0. 0. 0. 0.]
NCT02043548,1:11:treatment,Prednisone Tapering: Prednisone should be held constant without tapering or escalation (unless there is a serious adverse event or disease flare) until the subject has achieved the DOI,"['Prednisone' 'Tapering' ':' 'Prednisone' 'should' 'be' 'held' 'constant'
 'without' 'tapering' 'or' 'escalation' '(' 'unless' 'there' 'is' 'a'
 'serious' 'adverse' 'event' 'or' 'disease' 'flare' ')' 'until' 'the'
 'subject' 'has' 'achieved' 'the' 'DOI']","[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT01940094,"1:11:treatment,,",Prednisone dose at time of enrollment of ≥ 5 mg/day and ≤ 20 mg/day,"['Prednisone' 'dose' 'at' 'time' 'of' 'enrollment' 'of' '≥' '5' 'mg/day'
 'and' '≤' '20' 'mg/day']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02496208,1:25:chronic_disease,Cardiovascular disorders,['Cardiovascular' 'disorders'],[2. 2.]
NCT02132598,1:25:chronic_disease,Cardiovascular disorders,['Cardiovascular' 'disorders'],[2. 2.]
NCT02101736,1:25:chronic_disease,Cardiovascular disorders,['Cardiovascular' 'disorders'],[2. 2.]
NCT01822522,1:25:chronic_disease,Cardiovascular disorders,['Cardiovascular' 'disorders'],[2. 2.]
NCT02474927,25:36:treatment,Previous intolerance to carfilzomib,['Previous' 'intolerance' 'to' 'carfilzomib'],[0. 0. 0. 1.]
NCT02073097,",118:129:treatment",breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with carfilzomib,"['breastfeeding' 'women' 'are' 'excluded' 'from' 'this' 'study' ';'
 'breastfeeding' 'should' 'be' 'discontinued' 'if' 'the' 'mother' 'is'
 'treated' 'with' 'carfilzomib']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01572480,16:27:treatment,The effects of carfilzomib on a developing human fetus are unknown,"['The' 'effects' 'of' 'carfilzomib' 'on' 'a' 'developing' 'human' 'fetus'
 'are' 'unknown']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01464034,44:55:treatment,Pts who have received prior treatment with carfilzomib (Phase II only),"['Pts' 'who' 'have' 'received' 'prior' 'treatment' 'with' 'carfilzomib'
 '(' 'Phase' 'II' 'only' ')']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02442323,40:49:cancer,undifferentiated/poorly differentiated carcinoma,['undifferentiated/poorly' 'differentiated' 'carcinoma'],[0. 0. 3.]
NCT02419495,73:82:cancer,"For the Arm B (paclitaxel) expansion cohort, patients must have ovarian carcinoma","['For' 'the' 'Arm' 'B' '(' 'paclitaxel' ')' 'expansion' 'cohort' ','
 'patients' 'must' 'have' 'ovarian' 'carcinoma']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02128906,23:32:cancer,"poorly differentiated carcinoma of the oropharynx, larynx","['poorly' 'differentiated' 'carcinoma' 'of' 'the' 'oropharynx' ','
 'larynx']",[0. 0. 3. 0. 0. 0. 0. 0.]
NCT00906984,37:46:cancer,Confirmed diagnosis of intrahepatic carcinoma,['Confirmed' 'diagnosis' 'of' 'intrahepatic' 'carcinoma'],[0. 0. 0. 0. 3.]
NCT02378428,106:123:treatment,"The presence of mixed response (MR), or no response (NR) following the completion of A3973 or equivalent induction therapy","['The' 'presence' 'of' 'mixed' 'response' '(' 'MR' ')' ',' 'or' 'no'
 'response' '(' 'NR' ')' 'following' 'the' 'completion' 'of' 'A3973' 'or'
 'equivalent' 'induction' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02378428,",,78:95:treatment",the presence of a partial response (PR) with high Curie score (>2) following induction therapy,"['the' 'presence' 'of' 'a' 'partial' 'response' '(' 'PR' ')' 'with' 'high'
 'Curie' 'score' '(' '>' '2' ')' 'following' 'induction' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02003222,83:100:treatment,"Patient should be human leukocyte antigen (HLA) typed (A, B, C, DR and DQ) during induction therapy phase or a written explanation for not undergoing HLA typing on the flow sheet","['Patient' 'should' 'be' 'human' 'leukocyte' 'antigen' '(' 'HLA' ')'
 'typed' '(' 'A' ',' 'B' ',' 'C' ',' 'DR' 'and' 'DQ' ')' 'during'
 'induction' 'therapy' 'phase' 'or' 'a' 'written' 'explanation' 'for'
 'not' 'undergoing' 'HLA' 'typing' 'on' 'the' 'flow' 'sheet']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01515527,",,58:75:treatment",Patients aged < 60 years who are unsuitable for standard induction therapy may be eligible after discussion with PI,"['Patients' 'aged' '<' '60' 'years' 'who' 'are' 'unsuitable' 'for'
 'standard' 'induction' 'therapy' 'may' 'be' 'eligible' 'after'
 'discussion' 'with' 'PI']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02354547,",42:56:treatment",At least 7 days after the last dose of a biologic agent,"['At' 'least' '7' 'days' 'after' 'the' 'last' 'dose' 'of' 'a' 'biologic'
 'agent']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02101736,",38:52:treatment",At least 14 days since completion of biologic agent,['At' 'least' '14' 'days' 'since' 'completion' 'of' 'biologic' 'agent'],[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02030028,"28:42:treatment,",Have received at least are biologic agent for at least 6 months,"['Have' 'received' 'at' 'least' 'are' 'biologic' 'agent' 'for' 'at'
 'least' '6' 'months']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02007239,"38:52:treatment,",Previous administration of any other biologic agent targeted at cytokine blockade within 5 days of enrollment,"['Previous' 'administration' 'of' 'any' 'other' 'biologic' 'agent'
 'targeted' 'at' 'cytokine' 'blockade' 'within' '5' 'days' 'of'
 'enrollment']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02324608,102:111:allergy_name,History of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab or other agents used in the study,"['History' 'of' 'allergic' 'reactions' 'attributed' 'to' 'compounds' 'of'
 'similar' 'chemical' 'or' 'biologic' 'composition' 'to' 'cetuximab' 'or'
 'other' 'agents' 'used' 'in' 'the' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0.]
NCT02159495,104:113:allergy_name,History of allergic reactions attributed to compounds of similar chemical or biological composition to cetuximab,"['History' 'of' 'allergic' 'reactions' 'attributed' 'to' 'compounds' 'of'
 'similar' 'chemical' 'or' 'biological' 'composition' 'to' 'cetuximab']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4.]
NCT02128906,1:10:treatment,cetuximab may be harmful to the fetus or the nursing infant,"['cetuximab' 'may' 'be' 'harmful' 'to' 'the' 'fetus' 'or' 'the' 'nursing'
 'infant']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01874860,",33:42:treatment",Receipt of at least one dose of cetuximab during the study time period,"['Receipt' 'of' 'at' 'least' 'one' 'dose' 'of' 'cetuximab' 'during' 'the'
 'study' 'time' 'period']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02262832,17:28:treatment,"Availability of metreleptin to the patient either as an approved drug, or through local compassionate use or expanded access programs","['Availability' 'of' 'metreleptin' 'to' 'the' 'patient' 'either' 'as' 'an'
 'approved' 'drug' ',' 'or' 'through' 'local' 'compassionate' 'use' 'or'
 'expanded' 'access' 'programs']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02262806,17:28:treatment,"Availability of metreleptin to the patient either as an approved drug, or through local compassionate use or expanded access programs","['Availability' 'of' 'metreleptin' 'to' 'the' 'patient' 'either' 'as' 'an'
 'approved' 'drug' ',' 'or' 'through' 'local' 'compassionate' 'use' 'or'
 'expanded' 'access' 'programs']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02262806,38:49:treatment,Previously or currently treated with metreleptin under NIH study 02-DK-0022 and/or NIH study 13-DK-0057,"['Previously' 'or' 'currently' 'treated' 'with' 'metreleptin' 'under'
 'NIH' 'study' '02-DK-0022' 'and/or' 'NIH' 'study' '13-DK-0057']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02262806,15:26:treatment,Withdrawal of metreleptin led to marked worsening of metabolic parameters,"['Withdrawal' 'of' 'metreleptin' 'led' 'to' 'marked' 'worsening' 'of'
 'metabolic' 'parameters']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02167009,29:47:treatment,Is considered high risk for surgical treatment,['Is' 'considered' 'high' 'risk' 'for' 'surgical' 'treatment'],[0. 0. 0. 0. 0. 1. 1.]
NCT02167009,9:27:treatment,Refuses surgical treatment,['Refuses' 'surgical' 'treatment'],[0. 1. 1.]
NCT02021279,46:64:treatment,Subject is to planning to undergo concurrent surgical treatment of prolapse using mesh other than the MatriStem Pelvic Floor Matrix,"['Subject' 'is' 'to' 'planning' 'to' 'undergo' 'concurrent' 'surgical'
 'treatment' 'of' 'prolapse' 'using' 'mesh' 'other' 'than' 'the'
 'MatriStem' 'Pelvic' 'Floor' 'Matrix']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01714596,"41:59:treatment,",patients with more than one instance of surgical treatment of infection and approximately 6 week course of antibiotics,"['patients' 'with' 'more' 'than' 'one' 'instance' 'of' 'surgical'
 'treatment' 'of' 'infection' 'and' 'approximately' '6' 'week' 'course'
 'of' 'antibiotics']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02114229,",,,82:106:chronic_disease",Performance status defined by Karnofsky or Lansky > 30 (except for patients with posterior fossa syndrome),"['Performance' 'status' 'defined' 'by' 'Karnofsky' 'or' 'Lansky' '>' '30'
 '(' 'except' 'for' 'patients' 'with' 'posterior' 'fossa' 'syndrome' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0.]
NCT02114229,",,,82:106:chronic_disease",Performance status defined by Karnofsky or Lansky > 60 (except for patients with posterior fossa syndrome),"['Performance' 'status' 'defined' 'by' 'Karnofsky' 'or' 'Lansky' '>' '60'
 '(' 'except' 'for' 'patients' 'with' 'posterior' 'fossa' 'syndrome' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0.]
NCT01878617,12:36:chronic_disease,except for posterior fossa syndrome,['except' 'for' 'posterior' 'fossa' 'syndrome'],[0. 0. 2. 2. 2.]
NCT01503086,82:106:chronic_disease,"motor, visual, or auditory handicap that prevents computer use (e.g., unresolved posterior fossa syndrome) are not eligible to participate in this trial","['motor' ',' 'visual' ',' 'or' 'auditory' 'handicap' 'that' 'prevents'
 'computer' 'use' '(' 'e.g.' ',' 'unresolved' 'posterior' 'fossa'
 'syndrome' ')' 'are' 'not' 'eligible' 'to' 'participate' 'in' 'this'
 'trial']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01835626,108:118:treatment,Agreement not to donate blood or blood products during the study and for 7 months after discontinuation of vismodegib,"['Agreement' 'not' 'to' 'donate' 'blood' 'or' 'blood' 'products' 'during'
 'the' 'study' 'and' 'for' '7' 'months' 'after' 'discontinuation' 'of'
 'vismodegib']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01835626,",,,100:110:treatment",Verify the pregnancy status of females of reproductive potential within 7 days prior to initiating vismodegib,"['Verify' 'the' 'pregnancy' 'status' 'of' 'females' 'of' 'reproductive'
 'potential' 'within' '7' 'days' 'prior' 'to' 'initiating' 'vismodegib']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01835626,",89:99:treatment",agreement not to donate sperm during the study and for 3 months after the final dose of vismodegib,"['agreement' 'not' 'to' 'donate' 'sperm' 'during' 'the' 'study' 'and'
 'for' '3' 'months' 'after' 'the' 'final' 'dose' 'of' 'vismodegib']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01835626,",90:100:treatment",agreement not to donate sperm during the study and for 7 months after discontinuation of vismodegib,"['agreement' 'not' 'to' 'donate' 'sperm' 'during' 'the' 'study' 'and'
 'for' '7' 'months' 'after' 'discontinuation' 'of' 'vismodegib']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03184389,48:76:treatment,Will not use non-cigarette tobacco products or nicotine replacement therapy during the study period,"['Will' 'not' 'use' 'non-cigarette' 'tobacco' 'products' 'or' 'nicotine'
 'replacement' 'therapy' 'during' 'the' 'study' 'period']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0.]
NCT02927847,35:63:treatment,presence of contraindications for nicotine replacement therapy,"['presence' 'of' 'contraindications' 'for' 'nicotine' 'replacement'
 'therapy']",[0. 0. 0. 0. 1. 1. 1.]
NCT02067975,16:44:treatment,Current use of nicotine replacement therapy or other nicotine products,"['Current' 'use' 'of' 'nicotine' 'replacement' 'therapy' 'or' 'other'
 'nicotine' 'products']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0.]
NCT03181048,1:17:treatment,Previous surgery about the hip,['Previous' 'surgery' 'about' 'the' 'hip'],[1. 1. 0. 0. 0.]
NCT02532595,1:17:treatment,Previous surgery to the foot/ankle,['Previous' 'surgery' 'to' 'the' 'foot/ankle'],[1. 1. 0. 0. 0.]
NCT02132130,1:17:treatment,Previous surgery in the study ear,['Previous' 'surgery' 'in' 'the' 'study' 'ear'],[1. 1. 0. 0. 0. 0.]
NCT03179163,10:18:treatment,taking a diuretic,['taking' 'a' 'diuretic'],[0. 0. 1.]
NCT02546583,",37:45:treatment",At least 6 hours since last dose of diuretic,['At' 'least' '6' 'hours' 'since' 'last' 'dose' 'of' 'diuretic'],[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02133885,"24:32:treatment,,,",one of which must be a diuretic (with no changes for a minimum of two weeks prior to screening) that is expected to be maintained without changes for at least 6-9 months,"['one' 'of' 'which' 'must' 'be' 'a' 'diuretic' '(' 'with' 'no' 'changes'
 'for' 'a' 'minimum' 'of' 'two' 'weeks' 'prior' 'to' 'screening' ')'
 'that' 'is' 'expected' 'to' 'be' 'maintained' 'without' 'changes' 'for'
 'at' 'least' '6-9' 'months']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03170453,36:56:chronic_disease,"Presence of significant social and cognitive disability, based on the Cognitive Style and Social Cognition Eligibility Interview (Hogarty et al., 2004)","['Presence' 'of' 'significant' 'social' 'and' 'cognitive' 'disability' ','
 'based' 'on' 'the' 'Cognitive' 'Style' 'and' 'Social' 'Cognition'
 'Eligibility' 'Interview' '(' 'Hogarty' 'et' 'al.' ',' '2004' ')']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02927639,13:33:chronic_disease,Significant cognitive disability,['Significant' 'cognitive' 'disability'],[0. 2. 2.]
NCT01983228,",58:78:chronic_disease",must be able to communicate effectively by telephone (no cognitive disability),"['must' 'be' 'able' 'to' 'communicate' 'effectively' 'by' 'telephone' '('
 'no' 'cognitive' 'disability' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.]
NCT03164538,1:4:chronic_disease,T2D,['T2D'],[2.]
NCT03036254,14:17:chronic_disease,Diagnosis of T2D,['Diagnosis' 'of' 'T2D'],[0. 0. 2.]
NCT02519543,23:26:chronic_disease,alcohol dependence or T2D,['alcohol' 'dependence' 'or' 'T2D'],[0. 0. 0. 2.]
NCT03153319,"12:15:chronic_disease,",History of HCT less than 2 years prior to enrollment,['History' 'of' 'HCT' 'less' 'than' '2' 'years' 'prior' 'to' 'enrollment'],[0. 0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02509546,"21:24:treatment,",Expected to undergo HCT within 120 days of enrollment,['Expected' 'to' 'undergo' 'HCT' 'within' '120' 'days' 'of' 'enrollment'],[0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02100891,"89:92:treatment,","Donors unable or unwilling to undergo marrow harvest or PBSC collection for the initial HCT, storage of autologous blood prior to marrow harvest (if applicable), or apheresis one week after marrow harvest","['Donors' 'unable' 'or' 'unwilling' 'to' 'undergo' 'marrow' 'harvest' 'or'
 'PBSC' 'collection' 'for' 'the' 'initial' 'HCT' ',' 'storage' 'of'
 'autologous' 'blood' 'prior' 'to' 'marrow' 'harvest' '(' 'if'
 'applicable' ')' ',' 'or' 'apheresis' 'one' 'week' 'after' 'marrow'
 'harvest']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03145181,"26:46:treatment,",Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less,"['Toxicities' 'from' 'previous' 'anticancer' 'therapies' 'should' 'have'
 'resolved' 'to' 'baseline' 'levels' 'or' 'to' 'Grade' '1' 'or' 'less']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02257424,30:50:treatment,Any number and type of prior anticancer therapies,['Any' 'number' 'and' 'type' 'of' 'prior' 'anticancer' 'therapies'],[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02187848,47:67:treatment,non-resolution of toxicities induced by these anticancer therapies,"['non-resolution' 'of' 'toxicities' 'induced' 'by' 'these' 'anticancer'
 'therapies']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT03137121,48:65:cancer,Have histologically or cytologically-confirmed malignant disease in an advanced incurable stage,"['Have' 'histologically' 'or' 'cytologically-confirmed' 'malignant'
 'disease' 'in' 'an' 'advanced' 'incurable' 'stage']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT02338999,34:51:cancer,Current or previous diagnosis of malignant disease,['Current' 'or' 'previous' 'diagnosis' 'of' 'malignant' 'disease'],[0. 0. 0. 0. 0. 3. 3.]
NCT01570998,"21:38:cancer,",Previous history of malignant disease does not preclude entry if the expectation of relapse-free survival at 10 years or greater,"['Previous' 'history' 'of' 'malignant' 'disease' 'does' 'not' 'preclude'
 'entry' 'if' 'the' 'expectation' 'of' 'relapse-free' 'survival' 'at' '10'
 'years' 'or' 'greater']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03131635,14:38:chronic_disease,"Diagnosis of Autism Spectrum Disorder based on Autism Diagnostic Interview Revised (ADI-R), Autism Diagnostic Observation Schedule (ADOS-2), DSM-5, and expert clinical opinion","['Diagnosis' 'of' 'Autism' 'Spectrum' 'Disorder' 'based' 'on' 'Autism'
 'Diagnostic' 'Interview' 'Revised' '(' 'ADI-R' ')' ',' 'Autism'
 'Diagnostic' 'Observation' 'Schedule' '(' 'ADOS-2' ')' ',' 'DSM-5' ','
 'and' 'expert' 'clinical' 'opinion']","[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT03020927,31:55:chronic_disease,have a community diagnosis of Autism Spectrum Disorder (as reported by parent),"['have' 'a' 'community' 'diagnosis' 'of' 'Autism' 'Spectrum' 'Disorder'
 '(' 'as' 'reported' 'by' 'parent' ')']",[0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT01970345,25:49:chronic_disease,Meet DSM-5 criteria for Autism Spectrum Disorder confirmed by the Autism Diagnostic Interview-Revised (ADI-R),"['Meet' 'DSM-5' 'criteria' 'for' 'Autism' 'Spectrum' 'Disorder'
 'confirmed' 'by' 'the' 'Autism' 'Diagnostic' 'Interview-Revised' '('
 'ADI-R' ')']",[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03114501,",38:40:treatment,",going to receive at least 4 weeks of RT with at least 20 fractions,"['going' 'to' 'receive' 'at' 'least' '4' 'weeks' 'of' 'RT' 'with' 'at'
 'least' '20' 'fractions']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02533674,"23:25:treatment,,",Patients who have had RT in more than 35% of the bone marrow,"['Patients' 'who' 'have' 'had' 'RT' 'in' 'more' 'than' '35' '%' 'of' 'the'
 'bone' 'marrow']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02332928,29:31:treatment,Patients to be treated with RT for curative intent,['Patients' 'to' 'be' 'treated' 'with' 'RT' 'for' 'curative' 'intent'],[0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT03109041,"11:26:cancer,",Any other invasive cancer in the past 5 years,['Any' 'other' 'invasive' 'cancer' 'in' 'the' 'past' '5' 'years'],[0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT02494869,13:28:cancer,Any current invasive cancer diagnosis,['Any' 'current' 'invasive' 'cancer' 'diagnosis'],[0. 0. 3. 3. 0.]
NCT02033616,"24:39:cancer,",Diagnosis of any other invasive cancer or other disease process which is considered to be life-threatening within the next five years,"['Diagnosis' 'of' 'any' 'other' 'invasive' 'cancer' 'or' 'other' 'disease'
 'process' 'which' 'is' 'considered' 'to' 'be' 'life-threatening' 'within'
 'the' 'next' 'five' 'years']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03104699,1:9:treatment,"Steroids with no or minimal systemic effect (topical, inhalation)","['Steroids' 'with' 'no' 'or' 'minimal' 'systemic' 'effect' '(' 'topical'
 ',' 'inhalation' ')']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02848417,1:9:treatment,Steroids,['Steroids'],[1.]
NCT02393157,1:9:treatment,Steroids,['Steroids'],[1.]
NCT03096288,1:26:chronic_disease,transient ischemic attack,['transient' 'ischemic' 'attack'],[2. 2. 2.]
NCT02885649,"37:62:chronic_disease,",History of loss of consciousness or transient ischemic attack within twelve (12) months of enrollment,"['History' 'of' 'loss' 'of' 'consciousness' 'or' 'transient' 'ischemic'
 'attack' 'within' 'twelve' '(' '12' ')' 'months' 'of' 'enrollment']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02844738,"16:41:chronic_disease,",Diagnosis of a transient ischemic attack in the 6 months prior to screening,"['Diagnosis' 'of' 'a' 'transient' 'ischemic' 'attack' 'in' 'the' '6'
 'months' 'prior' 'to' 'screening']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT03087799,30:33:chronic_disease,Meet diagnostic criteria for IBS,['Meet' 'diagnostic' 'criteria' 'for' 'IBS'],[0. 0. 0. 0. 2.]
NCT03087799,"23:26:chronic_disease,",Stable medication for IBS for at least 1 month,['Stable' 'medication' 'for' 'IBS' 'for' 'at' 'least' '1' 'month'],[0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02079857,14:17:chronic_disease,Diagnosis of IBS based on ROME III criteria,['Diagnosis' 'of' 'IBS' 'based' 'on' 'ROME' 'III' 'criteria'],[0. 0. 2. 0. 0. 0. 0. 0.]
NCT03070535,54:72:treatment,Acid reflux is allowed if participant is on a stable medication regimen,"['Acid' 'reflux' 'is' 'allowed' 'if' 'participant' 'is' 'on' 'a' 'stable'
 'medication' 'regimen']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02472834,90:108:treatment,"Willing and able to adhere to all study-related procedures, including adherence to study medication regimen","['Willing' 'and' 'able' 'to' 'adhere' 'to' 'all' 'study-related'
 'procedures' ',' 'including' 'adherence' 'to' 'study' 'medication'
 'regimen']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02133872,11:29:treatment,On stable medication regimen,['On' 'stable' 'medication' 'regimen'],[0. 0. 1. 1.]
NCT03060473,1:20:chronic_disease,placental abruption,['placental' 'abruption'],[2. 2.]
NCT02742454,67:86:chronic_disease,Medical emergency necessitating emergency delivery (e.g. complete placental abruption),"['Medical' 'emergency' 'necessitating' 'emergency' 'delivery' '(' 'e.g'
 '.' 'complete' 'placental' 'abruption' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.]
NCT02438371,11:30:chronic_disease,suspected placental abruption,['suspected' 'placental' 'abruption'],[0. 2. 2.]
NCT03057548,1:18:chronic_disease,Mental impairment precluding the patient from providing informed consent or completing appropriate follow-up,"['Mental' 'impairment' 'precluding' 'the' 'patient' 'from' 'providing'
 'informed' 'consent' 'or' 'completing' 'appropriate' 'follow-up']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02494869,1:18:chronic_disease,Mental impairment leading to inability to cooperate,['Mental' 'impairment' 'leading' 'to' 'inability' 'to' 'cooperate'],[2. 2. 0. 0. 0. 0. 0.]
NCT02166905,1:18:chronic_disease,Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study,"['Mental' 'impairment' 'that' 'may' 'compromise' 'the' 'ability' 'to'
 'give' 'informed' 'consent' 'and' 'comply' 'with' 'the' 'requirements'
 'of' 'the' 'study']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03051282,27:37:chronic_disease,Subject with a history of angioedema,['Subject' 'with' 'a' 'history' 'of' 'angioedema'],[0. 0. 0. 0. 0. 2.]
NCT02277548,12:22:chronic_disease,History of angioedema,['History' 'of' 'angioedema'],[0. 0. 2.]
NCT01568177,7:17:chronic_disease,known angioedema,['known' 'angioedema'],[0. 2.]
NCT03038620,",,47:67:chronic_disease",triglycerides > 150 mg/dL or on treatment for hypertriglyceridemia,"['triglycerides' '>' '150' 'mg/dL' 'or' 'on' 'treatment' 'for'
 'hypertriglyceridemia']",[0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02272998,19:39:chronic_disease,Have uncontrolled hypertriglyceridemia,['Have' 'uncontrolled' 'hypertriglyceridemia'],[0. 0. 2.]
NCT01620216,14:34:chronic_disease,Uncontrolled hypertriglyceridemia,['Uncontrolled' 'hypertriglyceridemia'],[0. 2.]
NCT03029806,9:14:treatment,Chronic NSAID use,['Chronic' 'NSAID' 'use'],[0. 1. 0.]
NCT02358681,"15:20:treatment,",Receipt of an NSAID within six hours of study drug administration,"['Receipt' 'of' 'an' 'NSAID' 'within' 'six' 'hours' 'of' 'study' 'drug'
 'administration']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01238120,"43:48:treatment,,,",Currently taking a consistent dosage of a NSAID at least 3 days a week for the last 3 months that is over 400mg daily,"['Currently' 'taking' 'a' 'consistent' 'dosage' 'of' 'a' 'NSAID' 'at'
 'least' '3' 'days' 'a' 'week' 'for' 'the' 'last' '3' 'months' 'that' 'is'
 'over' '400mg' 'daily']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03017937,17:38:chronic_disease,Known increased intracranial pressure,['Known' 'increased' 'intracranial' 'pressure'],[0. 0. 2. 2.]
NCT01777035,10:31:cancer,Elevated intracranial pressure,['Elevated' 'intracranial' 'pressure'],[0. 3. 3.]
NCT01705119,22:43:chronic_disease,Evidence of elevated intracranial pressure,['Evidence' 'of' 'elevated' 'intracranial' 'pressure'],[0. 0. 0. 2. 2.]
NCT03015805,1:33:chronic_disease,Pervasive developmental disorder,['Pervasive' 'developmental' 'disorder'],[2. 2. 2.]
NCT02877875,1:33:chronic_disease,Pervasive developmental disorder,['Pervasive' 'developmental' 'disorder'],[2. 2. 2.]
NCT02418195,1:33:chronic_disease,Pervasive developmental disorder,['Pervasive' 'developmental' 'disorder'],[2. 2. 2.]
NCT03005574,1:17:chronic_disease,medical disorder with known effects on cognitive functioning,"['medical' 'disorder' 'with' 'known' 'effects' 'on' 'cognitive'
 'functioning']",[2. 2. 0. 0. 0. 0. 0. 0.]
NCT02891850,17:33:chronic_disease,"Patients with a medical disorder, condition, or history","['Patients' 'with' 'a' 'medical' 'disorder' ',' 'condition' ',' 'or'
 'history']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02500147,30:46:chronic_disease,Past or present history of a medical disorder or medication known to affect body composition,"['Past' 'or' 'present' 'history' 'of' 'a' 'medical' 'disorder' 'or'
 'medication' 'known' 'to' 'affect' 'body' 'composition']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02981173,1:26:chronic_disease,Axis I psychotic disorder in first degree relative,['Axis' 'I' 'psychotic' 'disorder' 'in' 'first' 'degree' 'relative'],[2. 2. 2. 2. 0. 0. 0. 0.]
NCT02404194,21:46:chronic_disease,Lifetime history of Axis I psychotic disorder,['Lifetime' 'history' 'of' 'Axis' 'I' 'psychotic' 'disorder'],[0. 0. 0. 2. 2. 2. 2.]
NCT02155699,25:50:chronic_disease,meeting criteria for an Axis I psychotic disorder,['meeting' 'criteria' 'for' 'an' 'Axis' 'I' 'psychotic' 'disorder'],[0. 0. 0. 0. 2. 2. 2. 2.]
NCT02953860,1:11:cancer,Metastatic,['Metastatic'],[3.]
NCT02080221,1:11:cancer,Metastatic advanced disease,['Metastatic' 'advanced' 'disease'],[3. 0. 0.]
NCT01568255,1:11:cancer,Metastatic malignancy,['Metastatic' 'malignancy'],[3. 0.]
NCT02943590,20:32:treatment,Concomitant use of cyclosporine,['Concomitant' 'use' 'of' 'cyclosporine'],[0. 0. 0. 1.]
NCT02594111,1:13:treatment,cyclosporine,['cyclosporine'],[1.]
NCT02245841,1:13:treatment,cyclosporine,['cyclosporine'],[1.]
NCT02931110,1:9:treatment,apixaban,['apixaban'],[1.]
NCT02406885,41:49:allergy_name,History of hypersensitivity reaction to apixaban,['History' 'of' 'hypersensitivity' 'reaction' 'to' 'apixaban'],[0. 0. 0. 0. 0. 4.]
NCT02366871,121:129:treatment,WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) apixaban plus 5 half-lives of study drug apixaban (2.5 days) plus 30 days (duration of ovulatory cycle) for a total of 32.5 days post-treatment completion,"['WOCBP' 'must' 'agree' 'to' 'follow' 'instructions' 'for' 'method' '('
 's' ')' 'of' 'contraception' 'for' 'the' 'duration' 'of' 'treatment'
 'with' 'study' 'drug' '(' 's' ')' 'apixaban' 'plus' '5' 'half-lives' 'of'
 'study' 'drug' 'apixaban' '(' '2.5' 'days' ')' 'plus' '30' 'days' '('
 'duration' 'of' 'ovulatory' 'cycle' ')' 'for' 'a' 'total' 'of' '32.5'
 'days' 'post-treatment' 'completion']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02925923,19:22:chronic_disease,troponin negative ACS,['troponin' 'negative' 'ACS'],[0. 0. 2.]
NCT02519283,13:16:chronic_disease,Evidence of ACS based on ischemia on ECG or Troponin elevation,"['Evidence' 'of' 'ACS' 'based' 'on' 'ischemia' 'on' 'ECG' 'or' 'Troponin'
 'elevation']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02469519,26:29:chronic_disease,Received first course of ACS at or prior to 31w6d gestation,"['Received' 'first' 'course' 'of' 'ACS' 'at' 'or' 'prior' 'to' '31w6d'
 'gestation']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02918981,14:18:allergy_name,Allergies to milk consumption,['Allergies' 'to' 'milk' 'consumption'],[0. 0. 4. 0.]
NCT02778867,32:36:allergy_name,Have history of anaphylaxis to milk,['Have' 'history' 'of' 'anaphylaxis' 'to' 'milk'],[0. 0. 0. 0. 0. 4.]
NCT01536522,5:9:allergy_name,Any milk allergies,['Any' 'milk' 'allergies'],[0. 4. 0.]
NCT02912572,45:53:allergy_name,"History of allergic reactions attributed to avelumab or any component in its formulations, or compounds of similar chemical or biologic composition to avelumab","['History' 'of' 'allergic' 'reactions' 'attributed' 'to' 'avelumab' 'or'
 'any' 'component' 'in' 'its' 'formulations' ',' 'or' 'compounds' 'of'
 'similar' 'chemical' 'or' 'biologic' 'composition' 'to' 'avelumab']",[0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02912572,",62:70:treatment,",Participant must not be pregnant or breastfeeding given that avelumab is an agent with unknown effects in pregnancy and breastfeeding and the potential for teratogenesis,"['Participant' 'must' 'not' 'be' 'pregnant' 'or' 'breastfeeding' 'given'
 'that' 'avelumab' 'is' 'an' 'agent' 'with' 'unknown' 'effects' 'in'
 'pregnancy' 'and' 'breastfeeding' 'and' 'the' 'potential' 'for'
 'teratogenesis']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02912572,16:24:treatment,The effects of avelumab on the developing human fetus are unknown,"['The' 'effects' 'of' 'avelumab' 'on' 'the' 'developing' 'human' 'fetus'
 'are' 'unknown']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02905370,1:10:chronic_disease,Pneumonia,['Pneumonia'],[2.]
NCT02652247,1:10:chronic_disease,Pneumonia diagnosis at the time of ICU admission,['Pneumonia' 'diagnosis' 'at' 'the' 'time' 'of' 'ICU' 'admission'],[2. 0. 0. 0. 0. 0. 0. 0.]
NCT02449980,1:10:chronic_disease,Pneumonia,['Pneumonia'],[2.]
NCT02898597,18:30:chronic_disease,Having an active skin disease,['Having' 'an' 'active' 'skin' 'disease'],[0. 0. 0. 2. 2.]
NCT02369770,8:20:chronic_disease,active skin disease with open wounds present below knee of treated limb,"['active' 'skin' 'disease' 'with' 'open' 'wounds' 'present' 'below' 'knee'
 'of' 'treated' 'limb']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02359864,16:28:chronic_disease,Dermatological skin disease of the scalp,['Dermatological' 'skin' 'disease' 'of' 'the' 'scalp'],[0. 2. 2. 0. 0. 0.]
NCT02875301,7:24:chronic_disease,other cardiac condition in the past year,['other' 'cardiac' 'condition' 'in' 'the' 'past' 'year'],[0. 2. 2. 0. 0. 0. 0.]
NCT02454010,"9:26:chronic_disease,",Serious cardiac condition within the last 6 months,['Serious' 'cardiac' 'condition' 'within' 'the' 'last' '6' 'months'],[0. 2. 2. 0. 0. 0. 0. 0.]
NCT02446236,11:28:chronic_disease,"Any other cardiac condition that, in the opinion of the treatment physician, would make this protocol unreasonably hazardous for the patient","['Any' 'other' 'cardiac' 'condition' 'that' ',' 'in' 'the' 'opinion' 'of'
 'the' 'treatment' 'physician' ',' 'would' 'make' 'this' 'protocol'
 'unreasonably' 'hazardous' 'for' 'the' 'patient']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02865135,1:10:chronic_disease,mucositis,['mucositis'],[2.]
NCT02727062,44:53:chronic_disease,Physical exam demonstrating no preexisting mucositis,['Physical' 'exam' 'demonstrating' 'no' 'preexisting' 'mucositis'],[0. 0. 0. 0. 0. 2.]
NCT02422641,8:17:chronic_disease,Active mucositis,['Active' 'mucositis'],[0. 2.]
NCT02851472,",24:39:chronic_disease",Hypotensive for age or active bleeding,['Hypotensive' 'for' 'age' 'or' 'active' 'bleeding'],[0. 0. 0. 0. 2. 2.]
NCT02575404,4:19:chronic_disease,No active bleeding,['No' 'active' 'bleeding'],[0. 2. 2.]
NCT01925573,4:19:chronic_disease,"No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)","['No' 'active' 'bleeding' 'or' 'pathological' 'condition' 'that' 'carries'
 'a' 'high' 'risk' 'of' 'bleeding' '(' 'e.g.' ',' 'tumor' 'involving'
 'major' 'vessels' 'or' 'known' 'varices' ')']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02836574,"21:35:chronic_disease,,","individuals who are morbidly obese (defined as BMI greater than 45 kg/m2), have excessive fat surrounding the kidney, or who are otherwise at excessive risk for serious complications","['individuals' 'who' 'are' 'morbidly' 'obese' '(' 'defined' 'as' 'BMI'
 'greater' 'than' '45' 'kg/m2' ')' ',' 'have' 'excessive' 'fat'
 'surrounding' 'the' 'kidney' ',' 'or' 'who' 'are' 'otherwise' 'at'
 'excessive' 'risk' 'for' 'serious' 'complications']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02501733,19:33:chronic_disease,Patients that are morbidly obese,['Patients' 'that' 'are' 'morbidly' 'obese'],[0. 0. 0. 2. 2.]
NCT02452203,"16:30:chronic_disease,,",Participant is morbidly obese (BMI > 40),['Participant' 'is' 'morbidly' 'obese' '(' 'BMI' '>' '40' ')'],[0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02826343,1:17:treatment,Liver transplant,['Liver' 'transplant'],[1. 1.]
NCT02762266,1:17:treatment,Liver transplant,['Liver' 'transplant'],[1. 1.]
NCT02522871,",,35:51:treatment",Registered male or female primary Liver transplant candidate,"['Registered' 'male' 'or' 'female' 'primary' 'Liver' 'transplant'
 'candidate']",[0. 0. 0. 0. 0. 1. 1. 0.]
NCT02819141,1:13:chronic_disease,Acute stroke,['Acute' 'stroke'],[2. 2.]
NCT02409810,1:13:chronic_disease,Acute stroke,['Acute' 'stroke'],[2. 2.]
NCT02145260,1:13:chronic_disease,Acute stroke,['Acute' 'stroke'],[2. 2.]
NCT02806570,8:30:chronic_disease,Active bacterial endocarditis,['Active' 'bacterial' 'endocarditis'],[0. 2. 2.]
NCT02000115,"8:30:chronic_disease,",Active bacterial endocarditis within 6 months prior to the index procedure,"['Active' 'bacterial' 'endocarditis' 'within' '6' 'months' 'prior' 'to'
 'the' 'index' 'procedure']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01562626,18:40:chronic_disease,prior history of bacterial endocarditis,['prior' 'history' 'of' 'bacterial' 'endocarditis'],[0. 0. 0. 2. 2.]
NCT02783157,1:8:chronic_disease,Hepatic,['Hepatic'],[2.]
NCT01804634,1:8:chronic_disease,Hepatic,['Hepatic'],[2.]
NCT01505569,"1:8:chronic_disease,,,,,,","Hepatic: AST or ALT ≤ 2.5 x upper limits of normal (ULN), if hepatic involvement < 5 x ULN; bilirubin ≤ 2.0 x upper limits of normal (ULN)","['Hepatic' ':' 'AST' 'or' 'ALT' '≤' '2.5' 'x' 'upper' 'limits' 'of'
 'normal' '(' 'ULN' ')' ',' 'if' 'hepatic' 'involvement' '<' '5' 'x' 'ULN'
 ';' 'bilirubin' '≤' '2.0' 'x' 'upper' 'limits' 'of' 'normal' '(' 'ULN'
 ')']","[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02750319,18:20:chronic_disease,History of prior AF,['History' 'of' 'prior' 'AF'],[0. 0. 0. 2.]
NCT02347111,"1:3:chronic_disease,",AF symptoms present at least once per month,['AF' 'symptoms' 'present' 'at' 'least' 'once' 'per' 'month'],[2. 0. 0. 0. 0. 0. 0. 0.]
NCT02169037,11:13:chronic_disease,sustained AF during the procedure,['sustained' 'AF' 'during' 'the' 'procedure'],[0. 2. 0. 0. 0.]
NCT02734771,19:32:treatment,Prior exposure to anthracycline,['Prior' 'exposure' 'to' 'anthracycline'],[0. 0. 0. 1.]
NCT02666378,25:38:treatment,Patients should receive anthracycline as part of the recommended treatment,"['Patients' 'should' 'receive' 'anthracycline' 'as' 'part' 'of' 'the'
 'recommended' 'treatment']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02456857,",34:47:treatment",Received at least one dose of an anthracycline-based NACT,"['Received' 'at' 'least' 'one' 'dose' 'of' 'an' 'anthracycline-based'
 'NACT']",[0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02710396,"11:36:treatment,,","Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier","['Has' 'had' 'a' 'prior' 'monoclonal' 'antibody' 'within' '4' 'weeks'
 'prior' 'to' 'study' 'Day' '1' 'or' 'who' 'has' 'not' 'recovered' '('
 'i.e.' ',' '≤' 'Grade' '1' 'or' 'at' 'baseline' ')' 'from' 'adverse'
 'events' 'due' 'to' 'agents' 'administered' 'more' 'than' '4' 'weeks'
 'earlier']","[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02446457,"11:36:treatment,,,","Has had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events (AEs) due to agents administered more than 4 weeks earlier","['Has' 'had' 'a' 'prior' 'monoclonal' 'antibody' 'within' '4' 'weeks'
 'prior' 'to' 'study' 'day' '1' 'or' 'who' 'has' 'not' 'recovered' '('
 'i.e.' ',' '=' '<' 'grade' '1' 'or' 'at' 'baseline' ')' 'from' 'adverse'
 'events' '(' 'AEs' ')' 'due' 'to' 'agents' 'administered' 'more' 'than'
 '4' 'weeks' 'earlier']","[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02437370,"11:36:treatment,,,","Has had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier","['Has' 'had' 'a' 'prior' 'monoclonal' 'antibody' 'within' '4' 'weeks'
 'prior' 'to' 'study' 'day' '1' 'or' 'who' 'has' 'not' 'recovered' '('
 'i.e.' ',' '=' '<' 'grade' '1' 'or' 'at' 'baseline' ')' 'from' 'adverse'
 'events' 'due' 'to' 'agents' 'administered' 'more' 'than' '4' 'weeks'
 'earlier']","[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02682407,19:35:treatment,Have a history of renal transplant,['Have' 'a' 'history' 'of' 'renal' 'transplant'],[0. 0. 0. 0. 1. 1.]
NCT02213068,14:30:treatment,Recipient of renal transplant from living or deceased donor,"['Recipient' 'of' 'renal' 'transplant' 'from' 'living' 'or' 'deceased'
 'donor']",[0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02128802,10:26:treatment,Previous renal transplant,['Previous' 'renal' 'transplant'],[0. 1. 1.]
NCT02670044,15:43:cancer,Patients with acute promyelocytic leukemia (French-American-British [FAB] class M3 AML),"['Patients' 'with' 'acute' 'promyelocytic' 'leukemia' '('
 'French-American-British' '[' 'FAB' ']' 'class' 'M3' 'AML' ')']",[0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02509546,14:42:cancer,Diagnosis of acute promyelocytic leukemia,['Diagnosis' 'of' 'acute' 'promyelocytic' 'leukemia'],[0. 0. 3. 3. 3.]
NCT02319369,20:48:cancer,Has a diagnosis of acute promyelocytic leukemia,['Has' 'a' 'diagnosis' 'of' 'acute' 'promyelocytic' 'leukemia'],[0. 0. 0. 0. 3. 3. 3.]
NCT02635360,1:19:cancer,Distant metastases,['Distant' 'metastases'],[3. 3.]
NCT02207439,1:19:cancer,Distant metastases,['Distant' 'metastases'],[3. 3.]
NCT01688388,1:19:cancer,Distant metastases,['Distant' 'metastases'],[3. 3.]
NCT02594501,1:18:chronic_disease,Cardiogenic shock,['Cardiogenic' 'shock'],[2. 2.]
NCT02468778,"1:18:chronic_disease,,,,,",Cardiogenic shock (SBP <90 mmHg for >1 hour with either cool clammy skin OR oliguria OR altered sensorium AND cardiac index <2.2 L/min/m2),"['Cardiogenic' 'shock' '(' 'SBP' '<' '90' 'mmHg' 'for' '>' '1' 'hour'
 'with' 'either' 'cool' 'clammy' 'skin' 'OR' 'oliguria' 'OR' 'altered'
 'sensorium' 'AND' 'cardiac' 'index' '<' '2.2' 'L/min/m2' ')']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02100722,1:18:chronic_disease,Cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support,"['Cardiogenic' 'shock' 'and/or' 'need' 'for' 'mechanical/pharmacologic'
 'hemodynamic' 'support']",[2. 2. 0. 0. 0. 0. 0. 0.]
NCT02583893,53:75:cancer,Patients must have histologic evidence of high risk acute myeloid leukemia,"['Patients' 'must' 'have' 'histologic' 'evidence' 'of' 'high' 'risk'
 'acute' 'myeloid' 'leukemia']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT02162420,"1:23:cancer,",acute myeloid leukemia with >30% blasts,['acute' 'myeloid' 'leukemia' 'with' '>' '30' '%' 'blasts'],[3. 3. 3. 0. 0. 0. 0. 0.]
NCT01660607,11:33:cancer,High risk acute myeloid leukemia in CR1,['High' 'risk' 'acute' 'myeloid' 'leukemia' 'in' 'CR1'],[0. 0. 3. 3. 3. 0. 0.]
NCT02570672,1:18:cancer,"Active malignancy, non-skin","['Active' 'malignancy' ',' 'non-skin']",[3. 3. 0. 0.]
NCT01293214,1:18:cancer,Active malignancy,['Active' 'malignancy'],[3. 3.]
NCT01140087,1:18:cancer,Active malignancy,['Active' 'malignancy'],[3. 3.]
NCT02553941,"28:53:treatment,,","Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4.03), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria","['Unresolved' 'toxicities' 'from' 'prior' 'anti-cancer' 'therapy' ','
 'defined' 'as' 'having' 'not' 'resolved' 'to' 'Common' 'Terminology'
 'Criteria' 'for' 'Adverse' 'Event' '(' 'CTCAE' ',' 'version' '4.03' ')'
 ',' 'grade' '=' '<' '1' ',' 'or' 'to' 'the' 'levels' 'dictated' 'in'
 'the' 'inclusion/exclusion' 'criteria']","[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02390752,85:110:treatment,Patients must have fully recovered (to Grade 1) from the acute toxic effects of all prior anti-cancer therapy,"['Patients' 'must' 'have' 'fully' 'recovered' '(' 'to' 'Grade' '1' ')'
 'from' 'the' 'acute' 'toxic' 'effects' 'of' 'all' 'prior' 'anti-cancer'
 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT01532687,27:52:treatment,Any ongoing toxicity from prior anti-cancer therapy,['Any' 'ongoing' 'toxicity' 'from' 'prior' 'anti-cancer' 'therapy'],[0. 0. 0. 0. 1. 1. 1.]
NCT02544503,8:20:chronic_disease,Normal neurological examination,['Normal' 'neurological' 'examination'],[0. 2. 0.]
NCT02428205,7:19:chronic_disease,Other neurological diagnosis,['Other' 'neurological' 'diagnosis'],[0. 2. 0.]
NCT01923662,",52:64:chronic_disease",Time post injury greater than six months to assure neurological and emotional stability,"['Time' 'post' 'injury' 'greater' 'than' 'six' 'months' 'to' 'assure'
 'neurological' 'and' 'emotional' 'stability']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0.]
NCT02535832,16:18:chronic_disease,Diagnosed with RA by a Rheumatologist and according to American College of Rheumatology 2010 criteria,"['Diagnosed' 'with' 'RA' 'by' 'a' 'Rheumatologist' 'and' 'according' 'to'
 'American' 'College' 'of' 'Rheumatology' '2010' 'criteria']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02373644,1:3:chronic_disease,RA,['RA'],[2.]
NCT02030028,1:3:chronic_disease,RA diagnosis by American College of Rheumatology criteria,['RA' 'diagnosis' 'by' 'American' 'College' 'of' 'Rheumatology' 'criteria'],[2. 0. 0. 0. 0. 0. 0. 0.]
NCT02530034,1:29:cancer,acute myeloid leukemia (AML) by WHO classification,['acute' 'myeloid' 'leukemia' '(' 'AML' ')' 'by' 'WHO' 'classification'],[3. 3. 3. 3. 0. 0. 0. 0. 0.]
NCT01823198,19:47:cancer,Treatment related acute myeloid leukemia (AML),['Treatment' 'related' 'acute' 'myeloid' 'leukemia' '(' 'AML' ')'],[0. 0. 3. 3. 3. 3. 0. 0.]
NCT00719888,52:80:cancer,Very high risk pediatric/young adult patients with acute myeloid leukemia (AML),"['Very' 'high' 'risk' 'pediatric/young' 'adult' 'patients' 'with' 'acute'
 'myeloid' 'leukemia' '(' 'AML' ')']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0.]
NCT02522494,14:38:chronic_disease,Diagnosis of type 2 diabetes mellitus,['Diagnosis' 'of' 'type' '2' 'diabetes' 'mellitus'],[0. 0. 2. 2. 2. 2.]
NCT01967849,19:43:chronic_disease,family history of type 2 diabetes mellitus,['family' 'history' 'of' 'type' '2' 'diabetes' 'mellitus'],[0. 0. 0. 2. 2. 2. 2.]
NCT01666665,14:38:chronic_disease,Pre Existing type 2 diabetes mellitus and receiving treatment,"['Pre' 'Existing' 'type' '2' 'diabetes' 'mellitus' 'and' 'receiving'
 'treatment']",[0. 0. 2. 2. 2. 2. 0. 0. 0.]
NCT02515513,30:48:treatment,do not meet the criteria for surgical resection,['do' 'not' 'meet' 'the' 'criteria' 'for' 'surgical' 'resection'],[0. 0. 0. 0. 0. 0. 1. 1.]
NCT01893307,10:28:treatment,Previous surgical resection,['Previous' 'surgical' 'resection'],[0. 1. 1.]
NCT01835626,10:28:treatment,"Complete surgical resection is not possible or is deemed excessively morbid (e.g. invasion into cranial nerves or skull base, proximity to brain, spinal canal, or orbit)","['Complete' 'surgical' 'resection' 'is' 'not' 'possible' 'or' 'is'
 'deemed' 'excessively' 'morbid' '(' 'e.g' '.' 'invasion' 'into' 'cranial'
 'nerves' 'or' 'skull' 'base' ',' 'proximity' 'to' 'brain' ',' 'spinal'
 'canal' ',' 'or' 'orbit' ')']","[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02512497,",,158:166:treatment",Hematopoetic Transplant Co-Morbidity Index (HCT-CI) >4 unless deemed clinically insignificant by primary investigator for patients receiving Time-Sequential Busulfan (total exposure 20000 umol-min,"['Hematopoetic' 'Transplant' 'Co-Morbidity' 'Index' '(' 'HCT-CI' ')' '>'
 '4' 'unless' 'deemed' 'clinically' 'insignificant' 'by' 'primary'
 'investigator' 'for' 'patients' 'receiving' 'Time-Sequential' 'Busulfan'
 '(' 'total' 'exposure' '20000' 'umol-min']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 0. 0.]"
NCT02338232,1:9:treatment,Busulfan 130 mg/m2 iv daily x 2 (reduced intensity) or 4 days,"['Busulfan' '130' 'mg/m2' 'iv' 'daily' 'x' '2' '(' 'reduced' 'intensity'
 ')' 'or' '4' 'days']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01951885,"1:9:treatment,,","Busulfan dose may be adjusted according to pharmacokinetics targeting a daily AUC of 5000 μmol-min/L, per institution standard of practice","['Busulfan' 'dose' 'may' 'be' 'adjusted' 'according' 'to'
 'pharmacokinetics' 'targeting' 'a' 'daily' 'AUC' 'of' '5000' 'μmol-min/L'
 ',' 'per' 'institution' 'standard' 'of' 'practice']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02500381,"16:36:treatment,",Stable dose of oral corticosteroids for at least 24 weeks,"['Stable' 'dose' 'of' 'oral' 'corticosteroids' 'for' 'at' 'least' '24'
 'weeks']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01787682,26:46:treatment,Current use of long-term oral corticosteroids (CHF only),"['Current' 'use' 'of' 'long-term' 'oral' 'corticosteroids' '(' 'CHF'
 'only' ')']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT01787682,"24:44:treatment,",Use of short course of oral corticosteroids within 4 weeks preceding first study day,"['Use' 'of' 'short' 'course' 'of' 'oral' 'corticosteroids' 'within' '4'
 'weeks' 'preceding' 'first' 'study' 'day']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02485639,14:37:chronic_disease,a history of Guillain-Barre syndrome,['a' 'history' 'of' 'Guillain-Barre' 'syndrome'],[0. 0. 0. 2. 2.]
NCT02418195,1:24:chronic_disease,Guillain-Barre syndrome (if active),['Guillain-Barre' 'syndrome' '(' 'if' 'active' ')'],[2. 2. 0. 0. 0. 0.]
NCT01967238,12:35:chronic_disease,History of Guillain-Barre syndrome,['History' 'of' 'Guillain-Barre' 'syndrome'],[0. 0. 2. 2.]
NCT02477839,31:40:treatment,Subject has been treated with felbamate,['Subject' 'has' 'been' 'treated' 'with' 'felbamate'],[0. 0. 0. 0. 0. 1.]
NCT02477839,"23:32:treatment,",Subjects treated with felbamate for <12 months,['Subjects' 'treated' 'with' 'felbamate' 'for' '<' '12' 'months'],[0. 0. 0. 1. 0. 0. 0. 0.]
NCT02477839,"23:32:treatment,",Subjects treated with felbamate for >=12 months prior to Visit 1,"['Subjects' 'treated' 'with' 'felbamate' 'for' '>' '=12' 'months' 'prior'
 'to' 'Visit' '1']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02470897,1:12:chronic_disease,Scleroderma,['Scleroderma'],[2.]
NCT02429830,16:27:chronic_disease,Diagnosed with Scleroderma,['Diagnosed' 'with' 'Scleroderma'],[0. 0. 2.]
NCT02418195,1:12:chronic_disease,Scleroderma,['Scleroderma'],[2.]
NCT02453373,5:29:chronic_disease,Any intracerebral hemorrhage,['Any' 'intracerebral' 'hemorrhage'],[0. 2. 2.]
NCT02329327,19:43:chronic_disease,A patient with an intracerebral hemorrhage,['A' 'patient' 'with' 'an' 'intracerebral' 'hemorrhage'],[0. 0. 0. 0. 2. 2.]
NCT02174016,1:25:chronic_disease,intracerebral hemorrhage,['intracerebral' 'hemorrhage'],[2. 2.]
NCT02448173,"11:29:treatment,",Following curative resection patients must have a CEA within normal limits,"['Following' 'curative' 'resection' 'patients' 'must' 'have' 'a' 'CEA'
 'within' 'normal' 'limits']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02311361,64:82:treatment,Patients must have disease that is not amenable to potentially curative resection,"['Patients' 'must' 'have' 'disease' 'that' 'is' 'not' 'amenable' 'to'
 'potentially' 'curative' 'resection']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01684904,71:89:treatment,Surgical consultation to confirm that patient will be able to undergo curative resection after completion of PCT prior to registration,"['Surgical' 'consultation' 'to' 'confirm' 'that' 'patient' 'will' 'be'
 'able' 'to' 'undergo' 'curative' 'resection' 'after' 'completion' 'of'
 'PCT' 'prior' 'to' 'registration']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02431897,12:37:chronic_disease,History of connective tissue disease,['History' 'of' 'connective' 'tissue' 'disease'],[0. 0. 2. 2. 2.]
NCT02159703,1:26:chronic_disease,connective tissue disease,['connective' 'tissue' 'disease'],[2. 2. 2.]
NCT01886794,12:37:chronic_disease,History of connective tissue disease,['History' 'of' 'connective' 'tissue' 'disease'],[0. 0. 2. 2. 2.]
NCT02412540,"1:13:treatment,",Liver biopsy for clinical indication to evaluate for NASH within 1 year of enrollment,"['Liver' 'biopsy' 'for' 'clinical' 'indication' 'to' 'evaluate' 'for'
 'NASH' 'within' '1' 'year' 'of' 'enrollment']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01465100,1:13:treatment,"Liver biopsy shows significant fibrosis, defined by the Ishak Stage 5","['Liver' 'biopsy' 'shows' 'significant' 'fibrosis' ',' 'defined' 'by'
 'the' 'Ishak' 'Stage' '5']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01461837,1:13:treatment,Liver biopsy is optional to assess for iron overload in chronically transfused patients,"['Liver' 'biopsy' 'is' 'optional' 'to' 'assess' 'for' 'iron' 'overload'
 'in' 'chronically' 'transfused' 'patients']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02403128,11:25:chronic_disease,Any other ocular disease responsible for decrease in vision,"['Any' 'other' 'ocular' 'disease' 'responsible' 'for' 'decrease' 'in'
 'vision']",[0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02403128,13:27:chronic_disease,Concomitant ocular disease that can cause increase in foveal thickness,"['Concomitant' 'ocular' 'disease' 'that' 'can' 'cause' 'increase' 'in'
 'foveal' 'thickness']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT01280669,17:31:chronic_disease,Any significant ocular disease that could compromise the visual outcome in the study eye,"['Any' 'significant' 'ocular' 'disease' 'that' 'could' 'compromise' 'the'
 'visual' 'outcome' 'in' 'the' 'study' 'eye']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02393794,1:28:chronic_disease,Congenital long QT syndrome,['Congenital' 'long' 'QT' 'syndrome'],[2. 2. 2. 2.]
NCT01908777,1:28:chronic_disease,Congenital long QT syndrome,['Congenital' 'long' 'QT' 'syndrome'],[2. 2. 2. 2.]
NCT01582191,1:28:chronic_disease,Congenital long QT syndrome,['Congenital' 'long' 'QT' 'syndrome'],[2. 2. 2. 2.]
NCT02382549,1:35:treatment,Allergy desensitization injections,['Allergy' 'desensitization' 'injections'],[1. 1. 1.]
NCT02358187,1:35:treatment,Allergy desensitization injections,['Allergy' 'desensitization' 'injections'],[1. 1. 1.]
NCT01130077,1:35:treatment,Allergy desensitization injections,['Allergy' 'desensitization' 'injections'],[1. 1. 1.]
NCT02366871,12:30:treatment,undergoing surgical debulking,['undergoing' 'surgical' 'debulking'],[0. 1. 1.]
NCT01061515,73:91:treatment,Intraperitoneal ports may be placed during or at any time separate from surgical debulking,"['Intraperitoneal' 'ports' 'may' 'be' 'placed' 'during' 'or' 'at' 'any'
 'time' 'separate' 'from' 'surgical' 'debulking']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01061515,",72:90:treatment","Provided the patient has been allowed at least 4 weeks to recover from surgical debulking, no additional recovery time is required for port placement","['Provided' 'the' 'patient' 'has' 'been' 'allowed' 'at' 'least' '4'
 'weeks' 'to' 'recover' 'from' 'surgical' 'debulking' ',' 'no'
 'additional' 'recovery' 'time' 'is' 'required' 'for' 'port' 'placement']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02343549,"12:29:chronic_disease,,","History of abdominal fistula, gastrointestinal perforation within 6 months prior to study enrollment","['History' 'of' 'abdominal' 'fistula' ',' 'gastrointestinal' 'perforation'
 'within' '6' 'months' 'prior' 'to' 'study' 'enrollment']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02120222,12:29:chronic_disease,history of abdominal fistula,['history' 'of' 'abdominal' 'fistula'],[0. 0. 2. 2.]
NCT01639508,12:29:chronic_disease,history of abdominal fistula,['history' 'of' 'abdominal' 'fistula'],[0. 0. 2. 2.]
NCT02324582,1:28:treatment,Prior systemic chemotherapy,['Prior' 'systemic' 'chemotherapy'],[1. 1. 1.]
NCT01261728,1:28:treatment,Prior systemic chemotherapy,['Prior' 'systemic' 'chemotherapy'],[1. 1. 1.]
NCT00969111,1:28:treatment,Prior systemic chemotherapy for any reason,['Prior' 'systemic' 'chemotherapy' 'for' 'any' 'reason'],[1. 1. 1. 0. 0. 0.]
NCT02314377,",,,,,,226:245:treatment,","Patients must not have proteinuria at screening as demonstrated by either 1) urine protein: creatinine (UPC) ratio > 1.0 at screening, OR 2) urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible)","['Patients' 'must' 'not' 'have' 'proteinuria' 'at' 'screening' 'as'
 'demonstrated' 'by' 'either' '1' ')' 'urine' 'protein' ':' 'creatinine'
 '(' 'UPC' ')' 'ratio' '>' '1.0' 'at' 'screening' ',' 'OR' '2' ')' 'urine'
 'dipstick' 'for' 'proteinuria' '≥' '2+' '(' 'patients' 'discovered' 'to'
 'have' '≥2+' 'proteinuria' 'on' 'dipstick' 'urinalysis' 'at' 'baseline'
 'should' 'undergo' 'a' '24' 'hour' 'urine' 'collection' 'and' 'must'
 'demonstrate' '≤' '1g' 'of' 'protein' 'in' '24' 'hours' 'to' 'be'
 'eligible' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02138617,",,,48:67:treatment,,,",patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours,"['patients' 'discovered' 'to' 'have' '≥2+' 'proteinuria' 'on' 'dipstick'
 'urinalysis' 'at' 'baseline' 'should' 'undergo' 'a' '24' 'hour' 'urine'
 'collection' 'and' 'must' 'demonstrate' '≤' '1g' 'of' 'protein' 'in' '24'
 'hours']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02020707,",,,50:69:treatment,,",patients discovered to have >= 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate =< 1 g of protein in 24 hours to be eligible,"['patients' 'discovered' 'to' 'have' '>' '=' '2+' 'proteinuria' 'on'
 'dipstick' 'urinalysis' 'at' 'baseline' 'should' 'undergo' 'a' '24'
 'hour' 'urine' 'collection' 'and' 'must' 'demonstrate' '=' '<' '1' 'g'
 'of' 'protein' 'in' '24' 'hours' 'to' 'be' 'eligible']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02301611,1:17:treatment,biologic therapy as clinically indicated,['biologic' 'therapy' 'as' 'clinically' 'indicated'],[1. 1. 0. 0. 0.]
NCT02120222,219:235:treatment,"If patient did not receive such agents, rationale for not treating the patients with the 629 agent must be cleared with the study PI (ie no V600e/k BRAF mutation or patient with autoimmunity, thus 630 not eligible for biologic therapy)","['If' 'patient' 'did' 'not' 'receive' 'such' 'agents' ',' 'rationale'
 'for' 'not' 'treating' 'the' 'patients' 'with' 'the' '629' 'agent' 'must'
 'be' 'cleared' 'with' 'the' 'study' 'PI' '(' 'ie' 'no' 'V600e/k' 'BRAF'
 'mutation' 'or' 'patient' 'with' 'autoimmunity' ',' 'thus' '630' 'not'
 'eligible' 'for' 'biologic' 'therapy' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]"
NCT00107289,",48:64:treatment",At least 2 weeks should have elapsed since any biologic therapy,"['At' 'least' '2' 'weeks' 'should' 'have' 'elapsed' 'since' 'any'
 'biologic' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02277613,41:67:treatment,Anticipated need for additional planned coronary revascularization procedure(s),"['Anticipated' 'need' 'for' 'additional' 'planned' 'coronary'
 'revascularization' 'procedure' '(' 's' ')']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02121158,68:94:treatment,Clinical symptoms or findings that would make them a candidate for coronary revascularization,"['Clinical' 'symptoms' 'or' 'findings' 'that' 'would' 'make' 'them' 'a'
 'candidate' 'for' 'coronary' 'revascularization']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT00673842,26:52:treatment,the specified time after coronary revascularization,['the' 'specified' 'time' 'after' 'coronary' 'revascularization'],[0. 0. 0. 0. 1. 1.]
NCT02236000,"1:14:cancer,",Breast cancer must be determined by local testing to be human epidermal growth factor receptor 2 (HER2)-positive prior to study entry using American Society of Clinical Oncology (ASCO) - College of American Pathologists (CAP) HER2 test guidelines,"['Breast' 'cancer' 'must' 'be' 'determined' 'by' 'local' 'testing' 'to'
 'be' 'human' 'epidermal' 'growth' 'factor' 'receptor' '2' '(' 'HER2' ')'
 '-positive' 'prior' 'to' 'study' 'entry' 'using' 'American' 'Society'
 'of' 'Clinical' 'Oncology' '(' 'ASCO' ')' '-' 'College' 'of' 'American'
 'Pathologists' '(' 'CAP' ')' 'HER2' 'test' 'guidelines']","[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01980823,"1:14:cancer,",Breast cancer is uncommon in patients less than this age,"['Breast' 'cancer' 'is' 'uncommon' 'in' 'patients' 'less' 'than' 'this'
 'age']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00948285,1:14:cancer,Breast cancer patients identified as conservation candidates by their surgeons,"['Breast' 'cancer' 'patients' 'identified' 'as' 'conservation'
 'candidates' 'by' 'their' 'surgeons']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02204098,",28:31:treatment,","no menses for <1 year with FSH and estradiol levels in postmenopausal range, according to institutional standards","['no' 'menses' 'for' '<' '1' 'year' 'with' 'FSH' 'and' 'estradiol'
 'levels' 'in' 'postmenopausal' 'range' ',' 'according' 'to'
 'institutional' 'standards']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01842399,"10:13:treatment,","If their FSH test is more than 20, they will be considered menopausal","['If' 'their' 'FSH' 'test' 'is' 'more' 'than' '20' ',' 'they' 'will' 'be'
 'considered' 'menopausal']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01842399,",,109:112:treatment",Women over 55 years old who haven't had a period for a year will be considered menopausal and do not need a FSH test,"['Women' 'over' '55' 'years' 'old' 'who' 'have' ""n't"" 'had' 'a' 'period'
 'for' 'a' 'year' 'will' 'be' 'considered' 'menopausal' 'and' 'do' 'not'
 'need' 'a' 'FSH' 'test']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0.]"
NCT02159495,1:20:chronic_disease,Infectious diseases: no clinical evidence of uncontrolled active infectious process,"['Infectious' 'diseases' ':' 'no' 'clinical' 'evidence' 'of'
 'uncontrolled' 'active' 'infectious' 'process']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02146924,1:20:chronic_disease,Infectious diseases criteria: no clinical evidence of uncontrolled active infectious process,"['Infectious' 'diseases' 'criteria' ':' 'no' 'clinical' 'evidence' 'of'
 'uncontrolled' 'active' 'infectious' 'process']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02146924,1:20:chronic_disease,Infectious diseases: no clinical evidence of uncontrolled active infectious process,"['Infectious' 'diseases' ':' 'no' 'clinical' 'evidence' 'of'
 'uncontrolled' 'active' 'infectious' 'process']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02122081,11:42:treatment,Receiving supplementary continuous oxygen,['Receiving' 'supplementary' 'continuous' 'oxygen'],[0. 1. 1. 1.]
NCT02100891,",,,,59:90:treatment","Pulmonary: DLCO <40% TLC <40%, FEV1 <40% and/or receiving supplementary continuous oxygen","['Pulmonary' ':' 'DLCO' '<' '40' '%' 'TLC' '<' '40' '%' ',' 'FEV1' '<'
 '40' '%' 'and/or' 'receiving' 'supplementary' 'continuous' 'oxygen']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT01366612,",,,,55:86:treatment","FVC, FEV1, or DLCO <50% of predicted and/or receiving supplementary continuous oxygen","['FVC' ',' 'FEV1' ',' 'or' 'DLCO' '<' '50' '%' 'of' 'predicted' 'and/or'
 'receiving' 'supplementary' 'continuous' 'oxygen']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02072356,1:30:chronic_disease,Active uncontrolled infection,['Active' 'uncontrolled' 'infection'],[2. 2. 2.]
NCT01618357,1:30:chronic_disease,Active uncontrolled infection,['Active' 'uncontrolled' 'infection'],[2. 2. 2.]
NCT00716066,1:30:chronic_disease,Active uncontrolled infection,['Active' 'uncontrolled' 'infection'],[2. 2. 2.]
NCT01966367,10:24:chronic_disease,Adequate renal function as determined by the institutional normal range,"['Adequate' 'renal' 'function' 'as' 'determined' 'by' 'the'
 'institutional' 'normal' 'range']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT01853163,29:43:chronic_disease,patient has stable impaired renal function,['patient' 'has' 'stable' 'impaired' 'renal' 'function'],[0. 0. 0. 0. 2. 2.]
NCT01835626,10:24:chronic_disease,Adequate renal function,['Adequate' 'renal' 'function'],[0. 2. 2.]
NCT01877382,",29:43:treatment",within 3 weeks before study drug treatment,['within' '3' 'weeks' 'before' 'study' 'drug' 'treatment'],[0. 0. 0. 0. 0. 1. 1.]
NCT01620216,",59:73:treatment",a result is available within 2 weeks of starting on study drug treatment,"['a' 'result' 'is' 'available' 'within' '2' 'weeks' 'of' 'starting' 'on'
 'study' 'drug' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT00902720,1:15:treatment,drug treatment,['drug' 'treatment'],[1. 1.]
NCT01811368,15:44:chronic_disease,Uncorrectable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time,"['Uncorrectable' 'hepatic' 'synthetic' 'dysfunction' 'evidenced' 'by'
 'prolongation' 'of' 'the' 'prothrombin' 'time']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT01453088,"13:42:chronic_disease,,,,",Evidence of hepatic synthetic dysfunction or total bilirubin > 2x or AST > 3x ULN,"['Evidence' 'of' 'hepatic' 'synthetic' 'dysfunction' 'or' 'total'
 'bilirubin' '>' '2x' 'or' 'AST' '>' '3x' 'ULN']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01366612,"13:42:chronic_disease,,,,","Evidence of hepatic synthetic dysfunction, or total bilirubin >2x or AST >3x UL","['Evidence' 'of' 'hepatic' 'synthetic' 'dysfunction' ',' 'or' 'total'
 'bilirubin' '>' '2x' 'or' 'AST' '>' '3x' 'UL']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01453088,1:18:chronic_disease,Organ dysfunction,['Organ' 'dysfunction'],[2. 2.]
NCT01366612,1:18:chronic_disease,Organ dysfunction,['Organ' 'dysfunction'],[2. 2.]
NCT00472329,1:18:chronic_disease,Organ dysfunction felt to be due to the conditioning for the first transplant,"['Organ' 'dysfunction' 'felt' 'to' 'be' 'due' 'to' 'the' 'conditioning'
 'for' 'the' 'first' 'transplant']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03188042,"21:36:chronic_disease,,",Medically diagnosed memory disorder or Telephone Interview for Cognitive Status-modified (TICS-m) score ≤ 27,"['Medically' 'diagnosed' 'memory' 'disorder' 'or' 'Telephone' 'Interview'
 'for' 'Cognitive' 'Status-modified' '(' 'TICS-m' ')' 'score' '≤' '27']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02751866,",13:28:chronic_disease",age-related memory disorder,['age-related' 'memory' 'disorder'],[0. 2. 2.]
NCT03186937,55:82:chronic_disease,Patients not able to swallow oral medications or with gastrointestinal conditions that may impact absorption of oral medications,"['Patients' 'not' 'able' 'to' 'swallow' 'oral' 'medications' 'or' 'with'
 'gastrointestinal' 'conditions' 'that' 'may' 'impact' 'absorption' 'of'
 'oral' 'medications']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02120222,7:34:chronic_disease,other gastrointestinal conditions with increased risk of perforation,"['other' 'gastrointestinal' 'conditions' 'with' 'increased' 'risk' 'of'
 'perforation']",[0. 2. 2. 0. 0. 0. 0. 0.]
NCT03181867,20:54:treatment,Subjects receiving androgen deprivation therapy (ADT),['Subjects' 'receiving' 'androgen' 'deprivation' 'therapy' '(' 'ADT' ')'],[0. 0. 1. 1. 1. 1. 0. 0.]
NCT02663908,24:58:treatment,Indication to initiate androgen deprivation therapy (ADT),"['Indication' 'to' 'initiate' 'androgen' 'deprivation' 'therapy' '(' 'ADT'
 ')']",[0. 0. 0. 1. 1. 1. 1. 0. 0.]
NCT03179397,1:9:chronic_disease,Aniridia,['Aniridia'],[2.]
NCT02332369,1:9:chronic_disease,Aniridia,['Aniridia'],[2.]
NCT03176784,23:37:allergy_name,had a reaction to the nicotine patch that prevented them from continuing to use it,"['had' 'a' 'reaction' 'to' 'the' 'nicotine' 'patch' 'that' 'prevented'
 'them' 'from' 'continuing' 'to' 'use' 'it']",[0. 0. 0. 0. 0. 4. 4. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02157610,22:36:treatment,Contraindication for nicotine patch use,['Contraindication' 'for' 'nicotine' 'patch' 'use'],[0. 0. 1. 1. 0.]
NCT03171168,31:47:chronic_disease,Patients suffering from acute septic arthritis,['Patients' 'suffering' 'from' 'acute' 'septic' 'arthritis'],[0. 0. 0. 0. 2. 2.]
NCT01420887,18:34:chronic_disease,Current or prior septic arthritis,['Current' 'or' 'prior' 'septic' 'arthritis'],[0. 0. 0. 2. 2.]
NCT03170401,9:36:chronic_disease,massive gastrointestinal hemorrhage,['massive' 'gastrointestinal' 'hemorrhage'],[0. 2. 2.]
NCT02053909,12:39:chronic_disease,History of gastrointestinal hemorrhage,['History' 'of' 'gastrointestinal' 'hemorrhage'],[0. 0. 2. 2.]
NCT03162731,",13:24:chronic_disease",men who are azoospermic do not require contraception,['men' 'who' 'are' 'azoospermic' 'do' 'not' 'require' 'contraception'],[0. 0. 0. 2. 0. 0. 0. 0.]
NCT03016871,",,109:120:chronic_disease","women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception","['women' 'who' 'are' 'not' 'of' 'childbearing' 'potential' '(' 'i.e.' ','
 'who' 'are' 'postmenopausal' 'or' 'surgically' 'sterile' ')' 'as' 'well'
 'as' 'azoospermic' 'men' 'do' 'not' 'require' 'contraception']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0.
 0. 0.]"
NCT03155724,1:28:chronic_disease,Chronic atrial fibrillation,['Chronic' 'atrial' 'fibrillation'],[2. 2. 2.]
NCT00291525,1:28:chronic_disease,Chronic atrial fibrillation,['Chronic' 'atrial' 'fibrillation'],[2. 2. 2.]
NCT03153319,8:33:chronic_disease,Active graft versus host disease,['Active' 'graft' 'versus' 'host' 'disease'],[0. 2. 2. 2. 2.]
NCT01943851,35:60:chronic_disease,"there are no signs or symptoms of graft versus host disease, other than Grade 1 skin involvement","['there' 'are' 'no' 'signs' 'or' 'symptoms' 'of' 'graft' 'versus' 'host'
 'disease' ',' 'other' 'than' 'Grade' '1' 'skin' 'involvement']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT03148795,1:26:chronic_disease,Gastrointestinal disorder affecting absorption,['Gastrointestinal' 'disorder' 'affecting' 'absorption'],[2. 2. 0. 0.]
NCT03093272,1:26:chronic_disease,Gastrointestinal disorder affecting absorption,['Gastrointestinal' 'disorder' 'affecting' 'absorption'],[2. 2. 0. 0.]
NCT03145298,1:23:treatment,prior organ transplant,['prior' 'organ' 'transplant'],[1. 1. 1.]
NCT01220583,4:26:treatment,No prior organ transplant,['No' 'prior' 'organ' 'transplant'],[0. 1. 1. 1.]
NCT03143985,1:24:treatment,inhaled corticosteroids are permitted,['inhaled' 'corticosteroids' 'are' 'permitted'],[1. 1. 0. 0.]
NCT02203695,1:24:treatment,inhaled corticosteroids,['inhaled' 'corticosteroids'],[1. 1.]
NCT03136029,",24:57:treatment",Women currently taking hormone replacement therapy (HRT),"['Women' 'currently' 'taking' 'hormone' 'replacement' 'therapy' '(' 'HRT'
 ')']",[0. 0. 0. 1. 1. 1. 1. 0. 0.]
NCT01532687,20:53:treatment,Subjects not using hormone replacement therapy (HRT) must have experienced total cessation of menses,"['Subjects' 'not' 'using' 'hormone' 'replacement' 'therapy' '(' 'HRT' ')'
 'must' 'have' 'experienced' 'total' 'cessation' 'of' 'menses']",[0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03135522,1:12:chronic_disease,Sarcoidosis,['Sarcoidosis'],[2.]
NCT02981082,1:12:chronic_disease,Sarcoidosis,['Sarcoidosis'],[2.]
NCT03133793,8:42:treatment,Recent percutaneous coronary intervention,['Recent' 'percutaneous' 'coronary' 'intervention'],[0. 1. 1. 1.]
NCT01275716,12:46:treatment,Undergoing percutaneous coronary intervention for any clinical indication,"['Undergoing' 'percutaneous' 'coronary' 'intervention' 'for' 'any'
 'clinical' 'indication']",[0. 1. 1. 1. 0. 0. 0. 0.]
NCT03130543,15:19:allergy_name,Patients with food allergies such that they cannot be on a milk or rice based diet,"['Patients' 'with' 'food' 'allergies' 'such' 'that' 'they' 'can' 'not'
 'be' 'on' 'a' 'milk' 'or' 'rice' 'based' 'diet']",[0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02589353,18:22:allergy_name,has a history of food allergy,['has' 'a' 'history' 'of' 'food' 'allergy'],[0. 0. 0. 0. 4. 0.]
NCT03125902,10:33:chronic_disease,Negative hepatitis C virus (HCV) antibody test at screening,"['Negative' 'hepatitis' 'C' 'virus' '(' 'HCV' ')' 'antibody' 'test' 'at'
 'screening']",[0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02120222,"26:49:chronic_disease,",known to be positive for hepatitis C virus (HCV) ribonucleic acid (RNA),"['known' 'to' 'be' 'positive' 'for' 'hepatitis' 'C' 'virus' '(' 'HCV' ')'
 'ribonucleic' 'acid' '(' 'RNA' ')']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT03119363,",,,71:75:treatment",Who are currently over age 18 and were at least age 16 at the time of ASCT,"['Who' 'are' 'currently' 'over' 'age' '18' 'and' 'were' 'at' 'least' 'age'
 '16' 'at' 'the' 'time' 'of' 'ASCT']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02362997,87:91:treatment,Participants who entered clinical remission with one of those agents and proceeded to ASCT without intervening relapse may be eligible after discussion with the Study Chair,"['Participants' 'who' 'entered' 'clinical' 'remission' 'with' 'one' 'of'
 'those' 'agents' 'and' 'proceeded' 'to' 'ASCT' 'without' 'intervening'
 'relapse' 'may' 'be' 'eligible' 'after' 'discussion' 'with' 'the' 'Study'
 'Chair']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT03115463,22:55:chronic_disease,Prenatally diagnosed cyanotic congenital heart disease,['Prenatally' 'diagnosed' 'cyanotic' 'congenital' 'heart' 'disease'],[0. 0. 2. 2. 2. 2.]
NCT02861950,1:34:chronic_disease,cyanotic congenital heart disease,['cyanotic' 'congenital' 'heart' 'disease'],[2. 2. 2. 2.]
NCT03112863,"21:33:treatment,",Those who have used isotretinoin in the last 6 months,['Those' 'who' 'have' 'used' 'isotretinoin' 'in' 'the' 'last' '6' 'months'],[0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT03076021,56:68:treatment,Patients with severe acne that are expected to receive isotretinoin for therapeutic reasons,"['Patients' 'with' 'severe' 'acne' 'that' 'are' 'expected' 'to' 'receive'
 'isotretinoin' 'for' 'therapeutic' 'reasons']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT03112590,31:53:chronic_disease,"Known current or a history of hepatitis B or C virus, including chronic and dormant states, unless disease has been treated and confirmed cleared","['Known' 'current' 'or' 'a' 'history' 'of' 'hepatitis' 'B' 'or' 'C'
 'virus' ',' 'including' 'chronic' 'and' 'dormant' 'states' ',' 'unless'
 'disease' 'has' 'been' 'treated' 'and' 'confirmed' 'cleared']","[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02481310,39:61:chronic_disease,Patients who have a clinically active hepatitis B or C virus infection,"['Patients' 'who' 'have' 'a' 'clinically' 'active' 'hepatitis' 'B' 'or'
 'C' 'virus' 'infection']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 0.]
NCT03106220,"1:18:chronic_disease,",variceal bleeding in the previous 1 month,['variceal' 'bleeding' 'in' 'the' 'previous' '1' 'month'],[2. 2. 0. 0. 0. 0. 0.]
NCT01360606,14:31:chronic_disease,A history of variceal bleeding where the varices have not been eradicated or decompressed by shunt placement,"['A' 'history' 'of' 'variceal' 'bleeding' 'where' 'the' 'varices' 'have'
 'not' 'been' 'eradicated' 'or' 'decompressed' 'by' 'shunt' 'placement']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03101566,"27:51:treatment,",Must not have undergone a major surgical procedure < 4 weeks prior to registration,"['Must' 'not' 'have' 'undergone' 'a' 'major' 'surgical' 'procedure' '<'
 '4' 'weeks' 'prior' 'to' 'registration']",[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02530034,"27:51:treatment,",Patients who have had any major surgical procedure within 14 days of day 1,"['Patients' 'who' 'have' 'had' 'any' 'major' 'surgical' 'procedure'
 'within' '14' 'days' 'of' 'day' '1']",[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT03096288,1:9:treatment,edoxaban,['edoxaban'],[1.]
NCT03088072,21:29:allergy_name,Hypersensitivity to edoxaban,['Hypersensitivity' 'to' 'edoxaban'],[0. 0. 4.]
NCT03090607,8:26:treatment,Had an ablation procedure in the lower esophageal sphincter area,"['Had' 'an' 'ablation' 'procedure' 'in' 'the' 'lower' 'esophageal'
 'sphincter' 'area']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT00584649,"74:92:treatment,","Any medical condition significantly increasing the risk of extending the ablation procedure or of X ray exposure, including pregnancy","['Any' 'medical' 'condition' 'significantly' 'increasing' 'the' 'risk'
 'of' 'extending' 'the' 'ablation' 'procedure' 'or' 'of' 'X' 'ray'
 'exposure' ',' 'including' 'pregnancy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03088592,49:60:treatment,Medically cleared for undergoing anesthesia and DBS surgery,"['Medically' 'cleared' 'for' 'undergoing' 'anesthesia' 'and' 'DBS'
 'surgery']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02056873,65:76:treatment,Those who improve significantly will be excluded from receiving DBS surgery),"['Those' 'who' 'improve' 'significantly' 'will' 'be' 'excluded' 'from'
 'receiving' 'DBS' 'surgery' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT03086369,9:33:cancer,Current hematologic malignancies,['Current' 'hematologic' 'malignancies'],[0. 3. 3.]
NCT02091141,19:43:cancer,Participants with hematologic malignancies,['Participants' 'with' 'hematologic' 'malignancies'],[0. 0. 3. 3.]
NCT03085485,62:68:treatment,Subjects taking moderate or strong inhibitors or inducers of CYP3A4,"['Subjects' 'taking' 'moderate' 'or' 'strong' 'inhibitors' 'or' 'inducers'
 'of' 'CYP3A4']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02857270,83:89:treatment,Currently using concomitant medications that are strong inhibitors or inducers of CYP3A4,"['Currently' 'using' 'concomitant' 'medications' 'that' 'are' 'strong'
 'inhibitors' 'or' 'inducers' 'of' 'CYP3A4']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03085004,1:6:chronic_disease,Cysts with the following high risk features,['Cysts' 'with' 'the' 'following' 'high' 'risk' 'features'],[2. 0. 0. 0. 0. 0. 0.]
NCT02634957,1:6:chronic_disease,Cysts,['Cysts'],[2.]
NCT03078504,1:20:chronic_disease,unstable arrhythmia,['unstable' 'arrhythmia'],[2. 2.]
NCT02990481,1:20:chronic_disease,unstable arrhythmia,['unstable' 'arrhythmia'],[2. 2.]
NCT03074877,27:44:chronic_disease,Having moderate to severe mental disability (based on medical records),"['Having' 'moderate' 'to' 'severe' 'mental' 'disability' '(' 'based' 'on'
 'medical' 'records' ')']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT01568918,17:34:chronic_disease,Patients with a mental disability,['Patients' 'with' 'a' 'mental' 'disability'],[0. 0. 0. 2. 2.]
NCT03071393,1:19:chronic_disease,Spinal cord injury affecting segments between C4-T12,['Spinal' 'cord' 'injury' 'affecting' 'segments' 'between' 'C4-T12'],[2. 2. 2. 0. 0. 0. 0.]
NCT01715571,1:19:chronic_disease,Spinal cord injury,['Spinal' 'cord' 'injury'],[2. 2. 2.]
NCT03069716,12:34:chronic_disease,Functional class IV heart failure,['Functional' 'class' 'IV' 'heart' 'failure'],[0. 2. 2. 2. 2.]
NCT02121158,",28:50:chronic_disease",New York Heart Association class IV heart failure,['New' 'York' 'Heart' 'Association' 'class' 'IV' 'heart' 'failure'],[0. 0. 0. 0. 2. 2. 2. 2.]
NCT03060772,12:26:cancer,History of bladder cancer,['History' 'of' 'bladder' 'cancer'],[0. 0. 3. 3.]
NCT02177695,23:37:cancer,Histologically proven bladder cancer,['Histologically' 'proven' 'bladder' 'cancer'],[0. 0. 3. 3.]
NCT03059355,1:35:chronic_disease,Proliferative diabetic retinopathy,['Proliferative' 'diabetic' 'retinopathy'],[2. 2. 2.]
NCT02911792,1:35:chronic_disease,Proliferative diabetic retinopathy,['Proliferative' 'diabetic' 'retinopathy'],[2. 2. 2.]
NCT03058029,"1:18:treatment,",Blood transfusion within three (3) months prior to Screening Visit,"['Blood' 'transfusion' 'within' 'three' '(' '3' ')' 'months' 'prior' 'to'
 'Screening' 'Visit']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02570854,"1:18:treatment,",Blood transfusion administered within 4 weeks prior to baseline,"['Blood' 'transfusion' 'administered' 'within' '4' 'weeks' 'prior' 'to'
 'baseline']",[1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT03058029,",103:122:treatment,",Thyroid hormones or preparations within one (1) month prior to Screening Visit [except stable dose of replacement therapy for at least two(2) months],"['Thyroid' 'hormones' 'or' 'preparations' 'within' 'one' '(' '1' ')'
 'month' 'prior' 'to' 'Screening' 'Visit' '[' 'except' 'stable' 'dose'
 'of' 'replacement' 'therapy' 'for' 'at' 'least' 'two' '(' '2' ')'
 'months' ']']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02271711,1:20:treatment,replacement therapy,['replacement' 'therapy'],[1. 1.]
NCT03054519,"1:13:treatment,",gene therapy study so long as at least six months have passed since the final intervention administration,"['gene' 'therapy' 'study' 'so' 'long' 'as' 'at' 'least' 'six' 'months'
 'have' 'passed' 'since' 'the' 'final' 'intervention' 'administration']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02140554,18:30:treatment,Prior receipt of gene therapy,['Prior' 'receipt' 'of' 'gene' 'therapy'],[0. 0. 0. 1. 1.]
NCT03045341,1:22:chronic_disease,"Binge eating disorder (full criteria as described in the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 5th edition)","['Binge' 'eating' 'disorder' '(' 'full' 'criteria' 'as' 'described' 'in'
 'the' 'American' 'Psychiatric' 'Association' 'Diagnostic' 'and'
 'Statistical' 'Manual' 'of' 'Mental' 'Disorders' ',' '5th' 'edition' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02932748,1:22:chronic_disease,Binge eating disorder,['Binge' 'eating' 'disorder'],[2. 2. 2.]
NCT03043794,10:20:treatment,Planning mastectomy,['Planning' 'mastectomy'],[0. 1.]
NCT02511301,10:20:treatment,Previous mastectomy,['Previous' 'mastectomy'],[0. 1.]
NCT03042689,1:31:chronic_disease,Active coronary artery disease,['Active' 'coronary' 'artery' 'disease'],[2. 2. 2. 2.]
NCT02048722,1:31:chronic_disease,Active coronary artery disease,['Active' 'coronary' 'artery' 'disease'],[2. 2. 2. 2.]
NCT03038269,1:16:chronic_disease,Visual problems (uncorrected by glasses/contact lenses),['Visual' 'problems' '(' 'uncorrected' 'by' 'glasses/contact' 'lenses' ')'],[2. 2. 0. 0. 0. 0. 0. 0.]
NCT02637349,1:16:chronic_disease,Visual problems preventing them from reading the assessment and reports,"['Visual' 'problems' 'preventing' 'them' 'from' 'reading' 'the'
 'assessment' 'and' 'reports']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03036254,",35:39:treatment",Chest pathology incompatible with HBOT,['Chest' 'pathology' 'incompatible' 'with' 'HBOT'],[0. 0. 0. 0. 1.]
NCT03036254,33:37:treatment,Subjects with an indication for HBOT,['Subjects' 'with' 'an' 'indication' 'for' 'HBOT'],[0. 0. 0. 0. 0. 1.]
NCT03034564,1:10:treatment,modafinil,['modafinil'],[1.]
NCT02131467,1:10:treatment,modafinil,['modafinil'],[1.]
NCT03027388,74:84:treatment,Patients must be in adequate general medical health to safely tolerate a craniotomy,"['Patients' 'must' 'be' 'in' 'adequate' 'general' 'medical' 'health' 'to'
 'safely' 'tolerate' 'a' 'craniotomy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03027388,31:41:treatment,Patients unwilling to undergo craniotomy,['Patients' 'unwilling' 'to' 'undergo' 'craniotomy'],[0. 0. 0. 0. 1.]
NCT03019367,1:14:chronic_disease,Cord prolapse,['Cord' 'prolapse'],[2. 2.]
NCT02478684,1:14:chronic_disease,Cord prolapse,['Cord' 'prolapse'],[2. 2.]
NCT03012815,12:22:treatment,Prescribed pregabalin,['Prescribed' 'pregabalin'],[0. 1.]
NCT01511640,43:53:treatment,medical history that would contraindicate pregabalin administration,"['medical' 'history' 'that' 'would' 'contraindicate' 'pregabalin'
 'administration']",[0. 0. 0. 0. 0. 1. 0.]
NCT03008616,1:22:chronic_disease,Chronic renal disease,['Chronic' 'renal' 'disease'],[2. 2. 2.]
NCT00904046,1:22:chronic_disease,Chronic renal disease,['Chronic' 'renal' 'disease'],[2. 2. 2.]
NCT03007030,1:39:chronic_disease,Serious medical or psychiatric illness likely to interfere with participation in this clinical study,"['Serious' 'medical' 'or' 'psychiatric' 'illness' 'likely' 'to'
 'interfere' 'with' 'participation' 'in' 'this' 'clinical' 'study']",[2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02734771,1:39:chronic_disease,Serious medical or psychiatric illness likely to interfere with participation in this clinical study,"['Serious' 'medical' 'or' 'psychiatric' 'illness' 'likely' 'to'
 'interfere' 'with' 'participation' 'in' 'this' 'clinical' 'study']",[2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03005418,56:76:treatment,Known medical condition which would preclude long term antiplatelet therapy after resolution of acute injuries,"['Known' 'medical' 'condition' 'which' 'would' 'preclude' 'long' 'term'
 'antiplatelet' 'therapy' 'after' 'resolution' 'of' 'acute' 'injuries']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02100722,"24:44:treatment,",Inability to take dual antiplatelet therapy for six months,"['Inability' 'to' 'take' 'dual' 'antiplatelet' 'therapy' 'for' 'six'
 'months']",[0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT02994940,21:36:chronic_disease,Patients with known G6PD deficiency,['Patients' 'with' 'known' 'G6PD' 'deficiency'],[0. 0. 0. 2. 2.]
NCT02466971,51:66:chronic_disease,Patients with self-reported or known diagnosis of G6PD deficiency,"['Patients' 'with' 'self-reported' 'or' 'known' 'diagnosis' 'of' 'G6PD'
 'deficiency']",[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02993406,1:32:chronic_disease,transient ischemic attack (TIA),['transient' 'ischemic' 'attack' '(' 'TIA' ')'],[2. 2. 2. 2. 0. 0.]
NCT02169739,33:64:chronic_disease,other prior cortical or retinal transient ischemic attack (TIA),"['other' 'prior' 'cortical' 'or' 'retinal' 'transient' 'ischemic' 'attack'
 '(' 'TIA' ')']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02990377,26:32:treatment,DSM-V moderate or severe opiate (heroin or OA),['DSM-V' 'moderate' 'or' 'severe' 'opiate' '(' 'heroin' 'or' 'OA' ')'],[0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT01625923,9:15:treatment,Regular opiate use,['Regular' 'opiate' 'use'],[0. 1. 0.]
NCT02985801,8:29:chronic_disease,Common bile duct obstruction resulting in obstructive jaundice,"['Common' 'bile' 'duct' 'obstruction' 'resulting' 'in' 'obstructive'
 'jaundice']",[0. 2. 2. 2. 0. 0. 0. 0.]
NCT02285101,",,,41:62:chronic_disease,,,,,,,,,,,","total bilirubin >2.0 mg/dL, evidence of bile duct obstruction, serum albumin <2.5 g/dL, serum ALT or AST >2.5 x upper limit of normal, serum creatinine ≥1.5 mg/dL, ANC ≥1.5 x 109/L, platelets <100 x 109/L, or INR >2.0","['total' 'bilirubin' '>' '2.0' 'mg/dL' ',' 'evidence' 'of' 'bile' 'duct'
 'obstruction' ',' 'serum' 'albumin' '<' '2.5' 'g/dL' ',' 'serum' 'ALT'
 'or' 'AST' '>' '2.5' 'x' 'upper' 'limit' 'of' 'normal' ',' 'serum'
 'creatinine' '≥1.5' 'mg/dL' ',' 'ANC' '≥1.5' 'x' '109/L' ',' 'platelets'
 '<' '100' 'x' '109/L' ',' 'or' 'INR' '>' '2.0']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02978885,",,,,,,132:147:treatment",forced expiratory volume 1 (FEV1)/forced vital capacity (FVC) <0.70 and FEV1 50-79% normal) undergoing Whipple procedures or other major surgeries,"['forced' 'expiratory' 'volume' '1' '(' 'FEV1' ')' '/forced' 'vital'
 'capacity' '(' 'FVC' ')' '<' '0.70' 'and' 'FEV1' '50-79' '%' 'normal' ')'
 'undergoing' 'Whipple' 'procedures' 'or' 'other' 'major' 'surgeries']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1.]"
NCT01686659,45:60:treatment,Adult patients undergoing one of the listed major surgeries associated with possibility of significant blood loss,"['Adult' 'patients' 'undergoing' 'one' 'of' 'the' 'listed' 'major'
 'surgeries' 'associated' 'with' 'possibility' 'of' 'significant' 'blood'
 'loss']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02974257,"1:15:chronic_disease,,","Cardiac arrest occurring while admitted to the hospital, with sustained (>20 minutes) return of spontaneous circulation (ROSC)","['Cardiac' 'arrest' 'occurring' 'while' 'admitted' 'to' 'the' 'hospital'
 ',' 'with' 'sustained' '(' '>' '20' 'minutes' ')' 'return' 'of'
 'spontaneous' 'circulation' '(' 'ROSC' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02934555,1:15:chronic_disease,Cardiac arrest defined by cessation of pulse requiring chest compressions,"['Cardiac' 'arrest' 'defined' 'by' 'cessation' 'of' 'pulse' 'requiring'
 'chest' 'compressions']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02967315,33:56:chronic_disease,Patients that present with free pulmonary insufficiency,['Patients' 'that' 'present' 'with' 'free' 'pulmonary' 'insufficiency'],[0. 0. 0. 0. 0. 2. 2.]
NCT02072356,13:36:chronic_disease,Evidence of pulmonary insufficiency,['Evidence' 'of' 'pulmonary' 'insufficiency'],[0. 0. 2. 2.]
NCT02955394,31:65:cancer,Current or previously treated brain or leptomeningeal metastases,"['Current' 'or' 'previously' 'treated' 'brain' 'or' 'leptomeningeal'
 'metastases']",[0. 0. 0. 0. 3. 3. 3. 3.]
NCT02581215,40:74:cancer,Documented and/or symptomatic or known brain or leptomeningeal metastases,"['Documented' 'and/or' 'symptomatic' 'or' 'known' 'brain' 'or'
 'leptomeningeal' 'metastases']",[0. 0. 0. 0. 0. 3. 3. 3. 3.]
NCT02947945,1:15:chronic_disease,Cardiomyopathy (established by echocardiography or MRI),['Cardiomyopathy' '(' 'established' 'by' 'echocardiography' 'or' 'MRI' ')'],[2. 0. 0. 0. 0. 0. 0. 0.]
NCT02496208,1:15:chronic_disease,Cardiomyopathy,['Cardiomyopathy'],[2.]
NCT02944825,",,115:128:chronic_disease",We anticipated enrolling a study population of approximately 60% men and 40% women based on a higher incidence of kidney stones among men in NHANES data,"['We' 'anticipated' 'enrolling' 'a' 'study' 'population' 'of'
 'approximately' '60' '%' 'men' 'and' '40' '%' 'women' 'based' 'on' 'a'
 'higher' 'incidence' 'of' 'kidney' 'stones' 'among' 'men' 'in' 'NHANES'
 'data']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.
 0. 0. 0. 0.]"
NCT01968590,"12:25:chronic_disease,",history of kidney stones in last 5 years,['history' 'of' 'kidney' 'stones' 'in' 'last' '5' 'years'],[0. 0. 2. 2. 0. 0. 0. 0.]
NCT02937402,50:82:chronic_disease,Inability to perform informed consent due to any medical or psychiatric condition,"['Inability' 'to' 'perform' 'informed' 'consent' 'due' 'to' 'any'
 'medical' 'or' 'psychiatric' 'condition']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2.]
NCT02834403,"5:37:chronic_disease,",Any medical or psychiatric condition that would prevent informed consent or limit expected survival to less than 4 weeks,"['Any' 'medical' 'or' 'psychiatric' 'condition' 'that' 'would' 'prevent'
 'informed' 'consent' 'or' 'limit' 'expected' 'survival' 'to' 'less'
 'than' '4' 'weeks']",[0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02932280,15:52:cancer,Patients with primary central nervous system tumors,['Patients' 'with' 'primary' 'central' 'nervous' 'system' 'tumors'],[0. 0. 3. 3. 3. 3. 3.]
NCT02354547,1:38:cancer,primary central nervous system tumors,['primary' 'central' 'nervous' 'system' 'tumors'],[3. 3. 3. 3. 3.]
NCT02930018,"1:11:treatment,",Study drug intended to be administered within 60 minutes of the baseline/qualifying NCCT,"['Study' 'drug' 'intended' 'to' 'be' 'administered' 'within' '60'
 'minutes' 'of' 'the' 'baseline/qualifying' 'NCCT']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02474667,"1:11:treatment,",Study drug can be administered starting within 30 hours after restoration of blood flow to the engrafted kidney,"['Study' 'drug' 'can' 'be' 'administered' 'starting' 'within' '30' 'hours'
 'after' 'restoration' 'of' 'blood' 'flow' 'to' 'the' 'engrafted' 'kidney']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02925923,1:11:treatment,Dabigatran,['Dabigatran'],[1.]
NCT02329327,1:11:treatment,Dabigatran,['Dabigatran'],[1.]
NCT02924441,1:15:treatment,breast surgery,['breast' 'surgery'],[1. 1.]
NCT02540330,1:15:treatment,breast surgery which interrupts communication of the ductal systems with the nipple,"['breast' 'surgery' 'which' 'interrupts' 'communication' 'of' 'the'
 'ductal' 'systems' 'with' 'the' 'nipple']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02920086,1:20:chronic_disease,respiratory failure episode within the preceding year; forced expiratory volume in 1 sec <0.5 L,"['respiratory' 'failure' 'episode' 'within' 'the' 'preceding' 'year' ';'
 'forced' 'expiratory' 'volume' 'in' '1' 'sec' '<' '0.5' 'L']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02469857,16:35:chronic_disease,a patient with respiratory failure such that an SaO2 of 80% cannot be achieved,"['a' 'patient' 'with' 'respiratory' 'failure' 'such' 'that' 'an' 'SaO2'
 'of' '80' '%' 'can' 'not' 'be' 'achieved']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02913495,23:45:allergy_name,A contraindication to progesterone treatment,['A' 'contraindication' 'to' 'progesterone' 'treatment'],[0. 0. 0. 4. 4.]
NCT02518594,"19:41:treatment,,",Planned or actual progesterone treatment of any type or form after 14 weeks 6 days during the current pregnancy,"['Planned' 'or' 'actual' 'progesterone' 'treatment' 'of' 'any' 'type' 'or'
 'form' 'after' '14' 'weeks' '6' 'days' 'during' 'the' 'current'
 'pregnancy']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02912572,20:39:cancer,"POLE-mutated, i.e. endometrial cancers known to harbor mutations in the exonuclease domain (amino acid residues 268-471) of polymerase e (POLE) as determined by targeted sequencing or other next generation sequencing assay","['POLE-mutated' ',' 'i.e' '.' 'endometrial' 'cancers' 'known' 'to'
 'harbor' 'mutations' 'in' 'the' 'exonuclease' 'domain' '(' 'amino' 'acid'
 'residues' '268-471' ')' 'of' 'polymerase' 'e' '(' 'POLE' ')' 'as'
 'determined' 'by' 'targeted' 'sequencing' 'or' 'other' 'next'
 'generation' 'sequencing' 'assay']","[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02912572,41:60:cancer,first cohort (MSI/POLE cohort) includes endometrial cancers,"['first' 'cohort' '(' 'MSI/POLE' 'cohort' ')' 'includes' 'endometrial'
 'cancers']",[0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02911116,"24:40:treatment,",Participant received a live vaccination within the past six weeks,"['Participant' 'received' 'a' 'live' 'vaccination' 'within' 'the' 'past'
 'six' 'weeks']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02108860,"3:19:treatment,",A live vaccination fewer than 3 months before enrollment,"['A' 'live' 'vaccination' 'fewer' 'than' '3' 'months' 'before'
 'enrollment']",[0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02905591,1:52:chronic_disease,Glucose-6-phosphate dehydrogenase (G6PD) deficiency,['Glucose-6-phosphate' 'dehydrogenase' '(' 'G6PD' ')' 'deficiency'],[2. 2. 2. 2. 0. 0.]
NCT02905578,1:52:chronic_disease,Glucose-6-phosphate dehydrogenase (G6PD) deficiency,['Glucose-6-phosphate' 'dehydrogenase' '(' 'G6PD' ')' 'deficiency'],[2. 2. 2. 2. 0. 0.]
NCT02905188,1:23:chronic_disease,Hepatic encephalopathy,['Hepatic' 'encephalopathy'],[2. 2.]
NCT01811368,1:23:chronic_disease,Hepatic encephalopathy,['Hepatic' 'encephalopathy'],[2. 2.]
NCT02900794,1:23:chronic_disease,Chronic rhinosinusitis as described by the guidelines published in the 2015 Clinical practice guideline (update),"['Chronic' 'rhinosinusitis' 'as' 'described' 'by' 'the' 'guidelines'
 'published' 'in' 'the' '2015' 'Clinical' 'practice' 'guideline' '('
 'update' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02493257,1:23:chronic_disease,Chronic rhinosinusitis,['Chronic' 'rhinosinusitis'],[2. 2.]
NCT02890485,12:24:treatment,History of knee surgery,['History' 'of' 'knee' 'surgery'],[0. 0. 1. 1.]
NCT02219581,30:42:treatment,Patients undergoing revision knee surgery,['Patients' 'undergoing' 'revision' 'knee' 'surgery'],[0. 0. 0. 1. 1.]
NCT02876510,1:29:chronic_disease,gastrointestinal obstruction,['gastrointestinal' 'obstruction'],[2. 2.]
NCT02099591,22:50:chronic_disease,Signs or symptoms of gastrointestinal obstruction,['Signs' 'or' 'symptoms' 'of' 'gastrointestinal' 'obstruction'],[0. 0. 0. 0. 2. 2.]
NCT02871726,26:43:treatment,Scheduled for an initial diagnostic biopsy,['Scheduled' 'for' 'an' 'initial' 'diagnostic' 'biopsy'],[0. 0. 0. 0. 1. 1.]
NCT01925378,",92:109:treatment","have a satisfactory (readable, good quality) colposcopic evaluation at least 14 days after diagnostic biopsy","['have' 'a' 'satisfactory' '(' 'readable' ',' 'good' 'quality' ')'
 'colposcopic' 'evaluation' 'at' 'least' '14' 'days' 'after' 'diagnostic'
 'biopsy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02864160,1:20:chronic_disease,diabetic neuropathy,['diabetic' 'neuropathy'],[2. 2.]
NCT00065676,8:27:chronic_disease,severe diabetic neuropathy,['severe' 'diabetic' 'neuropathy'],[0. 2. 2.]
NCT02861417,22:36:treatment,Patients must have a haploidentical related donor or a fully matched related or unrelated donor,"['Patients' 'must' 'have' 'a' 'haploidentical' 'related' 'donor' 'or' 'a'
 'fully' 'matched' 'related' 'or' 'unrelated' 'donor']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01758042,14:28:treatment,Existence of haploidentical first degree relative who passes standard donor evaluations for bone marrow and kidney donation,"['Existence' 'of' 'haploidentical' 'first' 'degree' 'relative' 'who'
 'passes' 'standard' 'donor' 'evaluations' 'for' 'bone' 'marrow' 'and'
 'kidney' 'donation']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02857218,27:40:chronic_disease,Subjects with evidence of iron overload,['Subjects' 'with' 'evidence' 'of' 'iron' 'overload'],[0. 0. 0. 0. 2. 2.]
NCT02516670,16:29:chronic_disease,Has history of iron overload,['Has' 'history' 'of' 'iron' 'overload'],[0. 0. 0. 2. 2.]
NCT02851303,41:54:treatment,"Primary substance exposure in-utero was buprenorphine, or was not opioids","['Primary' 'substance' 'exposure' 'in-utero' 'was' 'buprenorphine' ','
 'or' 'was' 'not' 'opioids']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02187198,33:46:allergy_name,known allergy or intolerance to buprenorphine,['known' 'allergy' 'or' 'intolerance' 'to' 'buprenorphine'],[0. 0. 0. 0. 0. 4.]
NCT02844751,29:43:chronic_disease,Patients with indication of Osteoarthritis,['Patients' 'with' 'indication' 'of' 'Osteoarthritis'],[0. 0. 0. 0. 2.]
NCT02844738,29:43:chronic_disease,Patients with indication of Osteoarthritis,['Patients' 'with' 'indication' 'of' 'Osteoarthritis'],[0. 0. 0. 0. 2.]
NCT02830360,7:28:chronic_disease,Prior Myocardial Infarction,['Prior' 'Myocardial' 'Infarction'],[0. 2. 2.]
NCT02006069,1:22:chronic_disease,Myocardial Infarction,['Myocardial' 'Infarction'],[2. 2.]
NCT02826681,9:25:treatment,Planned elective surgery during the study year,['Planned' 'elective' 'surgery' 'during' 'the' 'study' 'year'],[0. 1. 1. 0. 0. 0. 0.]
NCT02431897,19:35:treatment,Medically fit for elective surgery,['Medically' 'fit' 'for' 'elective' 'surgery'],[0. 0. 0. 1. 1.]
NCT02819141,"1:19:treatment,",General anesthesia within 12 hours prior to enrollment,['General' 'anesthesia' 'within' '12' 'hours' 'prior' 'to' 'enrollment'],[1. 1. 0. 0. 0. 0. 0. 0.]
NCT02548104,1:19:treatment,General anesthesia,['General' 'anesthesia'],[1. 1.]
NCT02811939,51:63:allergy_name,Individuals with a documented reaction/allergy to Pregnenolone,"['Individuals' 'with' 'a' 'documented' 'reaction/allergy' 'to'
 'Pregnenolone']",[0. 0. 0. 0. 0. 0. 4.]
NCT02576912,51:63:allergy_name,Individuals with a documented reaction/allergy to Pregnenolone,"['Individuals' 'with' 'a' 'documented' 'reaction/allergy' 'to'
 'Pregnenolone']",[0. 0. 0. 0. 0. 0. 4.]
NCT02807272,14:18:cancer,Diagnosis of CMML as defined by the World Health Organization (WHO) criteria,"['Diagnosis' 'of' 'CMML' 'as' 'defined' 'by' 'the' 'World' 'Health'
 'Organization' '(' 'WHO' ')' 'criteria']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02566304,16:20:cancer,"A diagnosis of CMML, unless in morphologic CR","['A' 'diagnosis' 'of' 'CMML' ',' 'unless' 'in' 'morphologic' 'CR']",[0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT02796209,",74:102:treatment",Previous history (within 14 days prior to enrollment) and current use of monoamine oxidase inhibitors,"['Previous' 'history' '(' 'within' '14' 'days' 'prior' 'to' 'enrollment'
 ')' 'and' 'current' 'use' 'of' 'monoamine' 'oxidase' 'inhibitors']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02784535,16:44:treatment,current use of monoamine oxidase inhibitors,['current' 'use' 'of' 'monoamine' 'oxidase' 'inhibitors'],[0. 0. 0. 1. 1. 1.]
NCT02792036,31:49:chronic_disease,Participants must not have an invasive infection at time of protocol entry,"['Participants' 'must' 'not' 'have' 'an' 'invasive' 'infection' 'at'
 'time' 'of' 'protocol' 'entry']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT01783535,31:49:chronic_disease,Participants must not have an invasive infection at time of protocol entry,"['Participants' 'must' 'not' 'have' 'an' 'invasive' 'infection' 'at'
 'time' 'of' 'protocol' 'entry']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02778282,7:30:chronic_disease,other organic mental disorder,['other' 'organic' 'mental' 'disorder'],[0. 2. 2. 2.]
NCT00875342,9:32:chronic_disease,Current organic mental disorder,['Current' 'organic' 'mental' 'disorder'],[0. 2. 2. 2.]
NCT02770326,12:53:treatment,History of hematopoietic stem cell transplant (HSCT),['History' 'of' 'hematopoietic' 'stem' 'cell' 'transplant' '(' 'HSCT' ')'],[0. 0. 1. 1. 1. 1. 1. 0. 0.]
NCT01685411,",,,58:99:treatment",<45 years of age who are at least 6 months after initial hematopoietic stem cell transplant (HSCT),"['<' '45' 'years' 'of' 'age' 'who' 'are' 'at' 'least' '6' 'months' 'after'
 'initial' 'hematopoietic' 'stem' 'cell' 'transplant' '(' 'HSCT' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0.]
NCT02762032,5:28:chronic_disease,Any dermatological disorder that may interfere with the accurate evaluation of the subject's skin,"['Any' 'dermatological' 'disorder' 'that' 'may' 'interfere' 'with' 'the'
 'accurate' 'evaluation' 'of' 'the' 'subject' ""'s"" 'skin']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02341287,14:37:chronic_disease,History of a dermatological disorder,['History' 'of' 'a' 'dermatological' 'disorder'],[0. 0. 0. 2. 2.]
NCT02746458,22:30:chronic_disease,Current diagnosis of acidosis,['Current' 'diagnosis' 'of' 'acidosis'],[0. 0. 0. 2.]
NCT02174016,"8:16:chronic_disease,,",Severe acidosis (serum bicarbonate ≤ 17 mEq/L) resistant to correction,"['Severe' 'acidosis' '(' 'serum' 'bicarbonate' '≤' '17' 'mEq/L' ')'
 'resistant' 'to' 'correction']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02742454,18:30:chronic_disease,Suspected severe fetal anemia,['Suspected' 'severe' 'fetal' 'anemia'],[0. 0. 2. 2.]
NCT02122328,",,114:126:chronic_disease",Recipient twin with a middle cerebral artery peak systolic velocity > 1.5 multiples of the median (indicative of fetal anemia),"['Recipient' 'twin' 'with' 'a' 'middle' 'cerebral' 'artery' 'peak'
 'systolic' 'velocity' '>' '1.5' 'multiples' 'of' 'the' 'median' '('
 'indicative' 'of' 'fetal' 'anemia' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.]
NCT02740543,",,48:60:treatment",≥ 20% (PC20) after inhalation of < 16 mg/ml of methacholine),"['≥' '20' '%' '(' 'PC20' ')' 'after' 'inhalation' 'of' '<' '16' 'mg/ml'
 'of' 'methacholine' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT01026532,",,,118:130:treatment,,,,,,","Women of child-bearing potential (WCBP) must have a negative urine pregnancy test (urine HCG) within 48 hours of the methacholine challenge at Visit 2, within 48 hours of the inhaled allergen challenge at V3 and on the day of the segmental allergen challenge on Visit 5. WCBP must agree to use a reliable method of birth control for the duration of the study (reliable methods of birth control can include abstinence, barrier methods, oral contraceptives, injection contraceptives or skin absorption contraceptives)","['Women' 'of' 'child-bearing' 'potential' '(' 'WCBP' ')' 'must' 'have' 'a'
 'negative' 'urine' 'pregnancy' 'test' '(' 'urine' 'HCG' ')' 'within' '48'
 'hours' 'of' 'the' 'methacholine' 'challenge' 'at' 'Visit' '2' ','
 'within' '48' 'hours' 'of' 'the' 'inhaled' 'allergen' 'challenge' 'at'
 'V3' 'and' 'on' 'the' 'day' 'of' 'the' 'segmental' 'allergen' 'challenge'
 'on' 'Visit' '5' '.' 'WCBP' 'must' 'agree' 'to' 'use' 'a' 'reliable'
 'method' 'of' 'birth' 'control' 'for' 'the' 'duration' 'of' 'the' 'study'
 '(' 'reliable' 'methods' 'of' 'birth' 'control' 'can' 'include'
 'abstinence' ',' 'barrier' 'methods' ',' 'oral' 'contraceptives' ','
 'injection' 'contraceptives' 'or' 'skin' 'absorption' 'contraceptives'
 ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02734602,1:27:chronic_disease,neurodegenerative disorder,['neurodegenerative' 'disorder'],[2. 2.]
NCT02465034,14:40:chronic_disease,History of a neurodegenerative disorder,['History' 'of' 'a' 'neurodegenerative' 'disorder'],[0. 0. 0. 2. 2.]
NCT02724540,16:30:allergy_name,intolerance to contrast media,['intolerance' 'to' 'contrast' 'media'],[0. 0. 4. 4.]
NCT02169037,24:38:allergy_name,untreatable allergy to contrast media,['untreatable' 'allergy' 'to' 'contrast' 'media'],[0. 0. 0. 4. 4.]
NCT02719327,27:31:allergy_name,Known hypersensitivity to fish,['Known' 'hypersensitivity' 'to' 'fish'],[0. 0. 0. 4.]
NCT02176902,24:28:allergy_name,Patient has allergy to fish,['Patient' 'has' 'allergy' 'to' 'fish'],[0. 0. 0. 0. 4.]
NCT02710331,1:17:chronic_disease,Hearing deficits,['Hearing' 'deficits'],[2. 2.]
NCT02407808,1:17:chronic_disease,Hearing deficits,['Hearing' 'deficits'],[2. 2.]
NCT02706249,20:58:chronic_disease,Known diagnosis of disseminated intravascular coagulation,['Known' 'diagnosis' 'of' 'disseminated' 'intravascular' 'coagulation'],[0. 0. 0. 2. 2. 2.]
NCT02520011,31:69:chronic_disease,Have evidence of uncontrolled disseminated intravascular coagulation,"['Have' 'evidence' 'of' 'uncontrolled' 'disseminated' 'intravascular'
 'coagulation']",[0. 0. 0. 0. 2. 2. 2.]
NCT02703090,1:19:chronic_disease,Neurologic disease,['Neurologic' 'disease'],[2. 2.]
NCT02495389,1:19:chronic_disease,Neurologic disease known to affect the lower urinary tract,"['Neurologic' 'disease' 'known' 'to' 'affect' 'the' 'lower' 'urinary'
 'tract']",[2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02688647,"1:27:chronic_disease,,",Severe concomitant illness limiting life expectancy (< 1 year),"['Severe' 'concomitant' 'illness' 'limiting' 'life' 'expectancy' '(' '<'
 '1' 'year' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02578641,1:27:chronic_disease,Severe concomitant illness,['Severe' 'concomitant' 'illness'],[2. 2. 2.]
NCT02680574,1:26:chronic_disease,peripheral artery disease (aortic or lower extremity),['peripheral' 'artery' 'disease' '(' 'aortic' 'or' 'lower' 'extremity' ')'],[2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02393742,"20:45:chronic_disease,,",Moderate or severe peripheral artery disease (ankle-brachial index <0.7)(183),"['Moderate' 'or' 'severe' 'peripheral' 'artery' 'disease' '('
 'ankle-brachial' 'index' '<' '0.7' ')' '(' '183' ')']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02679560,12:32:chronic_disease,Concern or compartment syndrome,['Concern' 'or' 'compartment' 'syndrome'],[0. 0. 2. 2.]
NCT02015390,22:42:chronic_disease,Patients with active compartment syndrome,['Patients' 'with' 'active' 'compartment' 'syndrome'],[0. 0. 0. 2. 2.]
NCT02667418,11:26:chronic_disease,incipient toxic megacolon,['incipient' 'toxic' 'megacolon'],[0. 2. 2.]
NCT02463305,24:39:chronic_disease,Evidence or history of toxic megacolon,['Evidence' 'or' 'history' 'of' 'toxic' 'megacolon'],[0. 0. 0. 0. 2. 2.]
NCT02665338,1:32:chronic_disease,increased intracranial pressure,['increased' 'intracranial' 'pressure'],[2. 2. 2.]
NCT02479906,44:75:chronic_disease,Any condition likely to be associated with increased intracranial pressure,"['Any' 'condition' 'likely' 'to' 'be' 'associated' 'with' 'increased'
 'intracranial' 'pressure']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02655614,126:135:treatment,"For participants participating in a designated drug-drug interaction (DDI) cohort in the MAD stage of the study, who require midazolam/caffeine administration: known allergy, religious prohibition, or other condition limiting midazolam or caffeine administration","['For' 'participants' 'participating' 'in' 'a' 'designated' 'drug-drug'
 'interaction' '(' 'DDI' ')' 'cohort' 'in' 'the' 'MAD' 'stage' 'of' 'the'
 'study' ',' 'who' 'require' 'midazolam/caffeine' 'administration' ':'
 'known' 'allergy' ',' 'religious' 'prohibition' ',' 'or' 'other'
 'condition' 'limiting' 'midazolam' 'or' 'caffeine' 'administration']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02556606,41:50:allergy_name,Past intolerance or hypersensitivity to midazolam,['Past' 'intolerance' 'or' 'hypersensitivity' 'to' 'midazolam'],[0. 0. 0. 0. 0. 4.]
NCT02642939,"13:35:chronic_disease,,,",significant ischemic heart disease; mean QTc interval > 480 msec on at least two separate electrocardiograms (ECGs) prior to study start,"['significant' 'ischemic' 'heart' 'disease' ';' 'mean' 'QTc' 'interval'
 '>' '480' 'msec' 'on' 'at' 'least' 'two' 'separate' 'electrocardiograms'
 '(' 'ECGs' ')' 'prior' 'to' 'study' 'start']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02037048,1:23:chronic_disease,ischemic heart disease are not eligible,['ischemic' 'heart' 'disease' 'are' 'not' 'eligible'],[2. 2. 2. 0. 0. 0.]
NCT02639065,4:24:cancer,in situ cervical cancer,['in' 'situ' 'cervical' 'cancer'],[0. 3. 3. 3.]
NCT02128230,4:24:cancer,in situ cervical cancer,['in' 'situ' 'cervical' 'cancer'],[0. 3. 3. 3.]
NCT02632422,1:29:chronic_disease,severe autonomic dysreflexia,['severe' 'autonomic' 'dysreflexia'],[2. 2. 2.]
NCT02329652,1:29:chronic_disease,severe autonomic dysreflexia,['severe' 'autonomic' 'dysreflexia'],[2. 2. 2.]
NCT02624765,8:12:chronic_disease,severe IUGR,['severe' 'IUGR'],[0. 2.]
NCT02299414,11:15:chronic_disease,Suspected IUGR,['Suspected' 'IUGR'],[0. 2.]
NCT02620449,"1:14:chronic_disease,,,,,",severe anemia (hemoglobin < 8 g/dl for women and < 9 g/dl for men),"['severe' 'anemia' '(' 'hemoglobin' '<' '8' 'g/dl' 'for' 'women' 'and' '<'
 '9' 'g/dl' 'for' 'men' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02339233,"1:14:chronic_disease,,",severe anemia (Hgb<8 g/dL),['severe' 'anemia' '(' 'Hgb' '<' '8' 'g/dL' ')'],[2. 2. 0. 0. 0. 0. 0. 0.]
NCT02607514,8:23:chronic_disease,Active suicidal intent within the past year (yes on item 4 or 5 on the Columbia-Suicide Severity Rating Scale),"['Active' 'suicidal' 'intent' 'within' 'the' 'past' 'year' '(' 'yes' 'on'
 'item' '4' 'or' '5' 'on' 'the' 'Columbia-Suicide' 'Severity' 'Rating'
 'Scale' ')']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00285935,20:35:chronic_disease,"No current, active suicidal intent","['No' 'current' ',' 'active' 'suicidal' 'intent']",[0. 0. 0. 0. 2. 2.]
NCT02593526,",,,164:180:treatment",Expected geographic unavailability at a participating HD unit for >2 consecutive weeks or >4 weeks total during the next 6 months (excluding unavailability due to hospitalizations),"['Expected' 'geographic' 'unavailability' 'at' 'a' 'participating' 'HD'
 'unit' 'for' '>' '2' 'consecutive' 'weeks' 'or' '>' '4' 'weeks' 'total'
 'during' 'the' 'next' '6' 'months' '(' 'excluding' 'unavailability' 'due'
 'to' 'hospitalizations' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0.]"
NCT02495168,1:17:treatment,hospitalizations within the past year or during the Run-in Period,"['hospitalizations' 'within' 'the' 'past' 'year' 'or' 'during' 'the'
 'Run-in' 'Period']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02593110,9:19:chronic_disease,current foot ulcer,['current' 'foot' 'ulcer'],[0. 2. 2.]
NCT02356848,25:35:chronic_disease,Patients with an active foot ulcer,['Patients' 'with' 'an' 'active' 'foot' 'ulcer'],[0. 0. 0. 0. 2. 2.]
NCT02589977,1:20:chronic_disease,pericardial disease,['pericardial' 'disease'],[2. 2.]
NCT02004275,27:46:chronic_disease,No clinically significant pericardial disease,['No' 'clinically' 'significant' 'pericardial' 'disease'],[0. 0. 0. 2. 2.]
NCT02587936,8:27:treatment,Use of hypoglycemic agents,['Use' 'of' 'hypoglycemic' 'agents'],[0. 0. 1. 1.]
NCT00065676,"28:47:treatment,,",Subjects will be taken off hypoglycemic agents for 3 to 7 days prior to each part of the study,"['Subjects' 'will' 'be' 'taken' 'off' 'hypoglycemic' 'agents' 'for' '3'
 'to' '7' 'days' 'prior' 'to' 'each' 'part' 'of' 'the' 'study']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02584309,1:36:treatment,Prior treatment with anthracyclines,['Prior' 'treatment' 'with' 'anthracyclines'],[1. 1. 1. 1.]
NCT02498613,1:36:treatment,Prior treatment with anthracyclines,['Prior' 'treatment' 'with' 'anthracyclines'],[1. 1. 1. 1.]
NCT02580604,",,,,,,194:219:treatment",Serum calcium <8.5 or >10.3 mg/dL Serum 25(OH)D <20 ng/mL; volunteers with abnormal serum 25(OH)D values may be re-considered for participation in the study if serum 25(OH)D is >20 ng/mL after vitamin D supplementation,"['Serum' 'calcium' '<' '8.5' 'or' '>' '10.3' 'mg/dL' 'Serum' '25' '(' 'OH'
 ')' 'D' '<' '20' 'ng/mL' ';' 'volunteers' 'with' 'abnormal' 'serum' '25'
 '(' 'OH' ')' 'D' 'values' 'may' 'be' 're-considered' 'for'
 'participation' 'in' 'the' 'study' 'if' 'serum' '25' '(' 'OH' ')' 'D'
 'is' '>' '20' 'ng/mL' 'after' 'vitamin' 'D' 'supplementation']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1. 1.]"
NCT01968590,"1:26:treatment,,",vitamin D supplementation in the last 3 months equal to or greater than 600IU per day,"['vitamin' 'D' 'supplementation' 'in' 'the' 'last' '3' 'months' 'equal'
 'to' 'or' 'greater' 'than' '600IU' 'per' 'day']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02576301,1:29:cancer,Acute promyelocytic leukemia,['Acute' 'promyelocytic' 'leukemia'],[3. 3. 3.]
NCT02074436,1:29:cancer,Acute promyelocytic leukemia,['Acute' 'promyelocytic' 'leukemia'],[3. 3. 3.]
NCT02574728,1:40:cancer,diffuse intrinsic pontine glioma (DIPG),['diffuse' 'intrinsic' 'pontine' 'glioma' '(' 'DIPG' ')'],[3. 3. 3. 3. 3. 0. 0.]
NCT02502708,78:117:cancer,Patients with a radiographic diagnosis or histologically proven diagnosis of diffuse intrinsic pontine glioma (DIPG),"['Patients' 'with' 'a' 'radiographic' 'diagnosis' 'or' 'histologically'
 'proven' 'diagnosis' 'of' 'diffuse' 'intrinsic' 'pontine' 'glioma' '('
 'DIPG' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 0. 0.]
NCT02573597,1:14:chronic_disease,Pre-eclampsia,['Pre-eclampsia'],[2.]
NCT02025426,1:14:chronic_disease,"Pre-eclampsia (mild, or severe)","['Pre-eclampsia' '(' 'mild' ',' 'or' 'severe' ')']",[2. 0. 0. 0. 0. 0. 0.]
NCT02572323,54:65:allergy_name,Known allergy/sensitivity or any hypersensitivity to tesamorelin,"['Known' 'allergy/sensitivity' 'or' 'any' 'hypersensitivity' 'to'
 'tesamorelin']",[0. 0. 0. 0. 0. 0. 4.]
NCT02572323,"8:19:treatment,",Use of tesamorelin in the last 6 months,['Use' 'of' 'tesamorelin' 'in' 'the' 'last' '6' 'months'],[0. 0. 1. 0. 0. 0. 0. 0.]
NCT02570854,"14:34:chronic_disease,,,,,","Uncontrolled renal osteodystrophy defined asthe coexistence of all of the following at screening (1) intact PTH ≥ 750 pg/mL, (2) serum phosphate above the upper limit of the lab normal range, and (3) calcium x phosphate product > 75 mg2/dL2 (6.05 mmol2/L2)","['Uncontrolled' 'renal' 'osteodystrophy' 'defined' 'asthe' 'coexistence'
 'of' 'all' 'of' 'the' 'following' 'at' 'screening' '(' '1' ')' 'intact'
 'PTH' '≥' '750' 'pg/mL' ',' '(' '2' ')' 'serum' 'phosphate' 'above' 'the'
 'upper' 'limit' 'of' 'the' 'lab' 'normal' 'range' ',' 'and' '(' '3' ')'
 'calcium' 'x' 'phosphate' 'product' '>' '75' 'mg2/dL2' '(' '6.05'
 'mmol2/L2' ')']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02056470,1:21:chronic_disease,renal osteodystrophy,['renal' 'osteodystrophy'],[2. 2.]
NCT02566395,1:21:cancer,Non-Hodgkin lymphoma,['Non-Hodgkin' 'lymphoma'],[3. 3.]
NCT02338232,1:21:cancer,Non-Hodgkin lymphoma,['Non-Hodgkin' 'lymphoma'],[3. 3.]
NCT02565446,1:17:treatment,cochlear implant,['cochlear' 'implant'],[1. 1.]
NCT02132130,28:44:treatment,Patients with a history of cochlear implant in the study ear,"['Patients' 'with' 'a' 'history' 'of' 'cochlear' 'implant' 'in' 'the'
 'study' 'ear']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02563678,"16:33:treatment,",presenting for hyperbaric oxygen for acute carbon monoxide poisoning (up to 3 sessions),"['presenting' 'for' 'hyperbaric' 'oxygen' 'for' 'acute' 'carbon'
 'monoxide' 'poisoning' '(' 'up' 'to' '3' 'sessions' ')']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01986205,22:39:treatment,Contraindications to hyperbaric oxygen,['Contraindications' 'to' 'hyperbaric' 'oxygen'],[0. 0. 1. 1.]
NCT02562430,"20:29:treatment,",Concomitant use of trazodone (up to 200 mg daily),['Concomitant' 'use' 'of' 'trazodone' '(' 'up' 'to' '200' 'mg' 'daily' ')'],[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02266329,45:54:treatment,Potential participants who have been taking trazodone will undergo a 2-week washout period before beginning the preliminary screening period,"['Potential' 'participants' 'who' 'have' 'been' 'taking' 'trazodone'
 'will' 'undergo' 'a' '2-week' 'washout' 'period' 'before' 'beginning'
 'the' 'preliminary' 'screening' 'period']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02561104,14:30:treatment,Referred for cataract surgery at Parkland Memorial Hospital,"['Referred' 'for' 'cataract' 'surgery' 'at' 'Parkland' 'Memorial'
 'Hospital']",[0. 0. 1. 1. 0. 0. 0. 0.]
NCT01988246,",,71:87:treatment",Central subfield macular thickness ≤ 320 μm in the study eye prior to cataract surgery as determined by SD-OCT and confirmed by the reading center,"['Central' 'subfield' 'macular' 'thickness' '≤' '320' 'μm' 'in' 'the'
 'study' 'eye' 'prior' 'to' 'cataract' 'surgery' 'as' 'determined' 'by'
 'SD-OCT' 'and' 'confirmed' 'by' 'the' 'reading' 'center']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02554786,",,,,105:120:treatment","Pre-bronchodilator ≥ 50% FEV1 of < 85 % of the predicted normal value for the patient after withholding bronchodilators at both Visit 101 and 102, according to ATS/ERS criteria","['Pre-bronchodilator' '≥' '50' '%' 'FEV1' 'of' '<' '85' '%' 'of' 'the'
 'predicted' 'normal' 'value' 'for' 'the' 'patient' 'after' 'withholding'
 'bronchodilators' 'at' 'both' 'Visit' '101' 'and' '102' ',' 'according'
 'to' 'ATS/ERS' 'criteria']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT01799538,23:38:treatment,Inability to withhold bronchodilators for 24 hours,['Inability' 'to' 'withhold' 'bronchodilators' 'for' '24' 'hours'],[0. 0. 0. 1. 0. 0. 0.]
NCT02553447,31:64:treatment,Simultaneous participation in other therapeutic clinical trials will be allowed,"['Simultaneous' 'participation' 'in' 'other' 'therapeutic' 'clinical'
 'trials' 'will' 'be' 'allowed']",[0. 0. 0. 1. 1. 1. 1. 0. 0. 0.]
NCT02524275,31:64:treatment,Simultaneous participation in other therapeutic clinical trials will not be allowed,"['Simultaneous' 'participation' 'in' 'other' 'therapeutic' 'clinical'
 'trials' 'will' 'not' 'be' 'allowed']",[0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0.]
NCT02547818,8:35:chronic_disease,Severe renal or hepatic impairment,['Severe' 'renal' 'or' 'hepatic' 'impairment'],[0. 2. 2. 2. 2.]
NCT01850355,12:39:chronic_disease,History of renal or hepatic impairment,['History' 'of' 'renal' 'or' 'hepatic' 'impairment'],[0. 0. 2. 2. 2. 2.]
NCT02543983,13:25:treatment,Agree to be hospitalized,['Agree' 'to' 'be' 'hospitalized'],[0. 0. 0. 1.]
NCT02516670,122:134:treatment,Patients who require frequent (several times a day) monitoring of their blood glucose or patients who have recently been hospitalized for glucose control,"['Patients' 'who' 'require' 'frequent' '(' 'several' 'times' 'a' 'day' ')'
 'monitoring' 'of' 'their' 'blood' 'glucose' 'or' 'patients' 'who' 'have'
 'recently' 'been' 'hospitalized' 'for' 'glucose' 'control']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0.]"
NCT02542956,45:71:treatment,Participating in another study involving an investigational medication,"['Participating' 'in' 'another' 'study' 'involving' 'an' 'investigational'
 'medication']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT00980538,",,,,,275:301:treatment","Girls, who are sexually active and able to become pregnant, not using safe and effective birth control methods, or not willing to continue practicing these birth control methods, during the trial and until 30 days after the end of the trial (or after the last intake of the investigational medication)","['Girls' ',' 'who' 'are' 'sexually' 'active' 'and' 'able' 'to' 'become'
 'pregnant' ',' 'not' 'using' 'safe' 'and' 'effective' 'birth' 'control'
 'methods' ',' 'or' 'not' 'willing' 'to' 'continue' 'practicing' 'these'
 'birth' 'control' 'methods' ',' 'during' 'the' 'trial' 'and' 'until' '30'
 'days' 'after' 'the' 'end' 'of' 'the' 'trial' '(' 'or' 'after' 'the'
 'last' 'intake' 'of' 'the' 'investigational' 'medication' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 0.]"
NCT02541903,1:25:cancer,ductal carcinoma in situ,['ductal' 'carcinoma' 'in' 'situ'],[3. 3. 3. 3.]
NCT01918644,23:47:cancer,appropriately treated ductal carcinoma in situ,['appropriately' 'treated' 'ductal' 'carcinoma' 'in' 'situ'],[0. 0. 3. 3. 3. 3.]
NCT02536170,26:51:chronic_disease,Established diagnosis of sickle cell disease (SCD); all genotypes,"['Established' 'diagnosis' 'of' 'sickle' 'cell' 'disease' '(' 'SCD' ')'
 ';' 'all' 'genotypes']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02140554,14:39:chronic_disease,"Diagnosis of sickle cell disease (SCD), with either βS/βS or βS/β0 or βS/β+ genotype","['Diagnosis' 'of' 'sickle' 'cell' 'disease' '(' 'SCD' ')' ',' 'with'
 'either' 'βS/βS' 'or' 'βS/β0' 'or' 'βS/β+' 'genotype']",[0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02534168,22:32:treatment,Pre-operative use of analgesics,['Pre-operative' 'use' 'of' 'analgesics'],[0. 0. 0. 1.]
NCT02358681,"60:70:treatment,",Frequent use of drugs for headache (i.e. regular intake of analgesics for acute headaches on more than 10 days per month),"['Frequent' 'use' 'of' 'drugs' 'for' 'headache' '(' 'i.e' '.' 'regular'
 'intake' 'of' 'analgesics' 'for' 'acute' 'headaches' 'on' 'more' 'than'
 '10' 'days' 'per' 'month' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02531932,",,,125:135:treatment",Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of Everolimus,"['Women' 'of' 'childbearing' 'potential' 'must' 'have' 'a' 'negative'
 'urine' 'or' 'serum' 'pregnancy' 'test' 'within' '7' 'days' 'prior' 'to'
 'administration' 'of' 'Everolimus']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02327403,1:11:treatment,Everolimus,['Everolimus'],[1.]
NCT02526212,21:24:treatment,Currently receiving BMT at Montefiore community health center (CHC),"['Currently' 'receiving' 'BMT' 'at' 'Montefiore' 'community' 'health'
 'center' '(' 'CHC' ')']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02526212,"10:13:treatment,",Received BMT for 12 or more weeks,['Received' 'BMT' 'for' '12' 'or' 'more' 'weeks'],[0. 1. 0. 0. 0. 0. 0.]
NCT02522468,1:25:cancer,Locally advanced disease,['Locally' 'advanced' 'disease'],[3. 3. 3.]
NCT01835626,1:25:cancer,Locally advanced disease is considered to include involved lymph nodes of the neck,"['Locally' 'advanced' 'disease' 'is' 'considered' 'to' 'include'
 'involved' 'lymph' 'nodes' 'of' 'the' 'neck']",[3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02519322,26:37:chronic_disease,"Subjects with history of myocarditis, regardless of etiology","['Subjects' 'with' 'history' 'of' 'myocarditis' ',' 'regardless' 'of'
 'etiology']",[0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT01568177,1:12:chronic_disease,myocarditis,['myocarditis'],[2.]
NCT02516670,6:29:chronic_disease,Have end stage renal disease,['Have' 'end' 'stage' 'renal' 'disease'],[0. 2. 2. 2. 2.]
NCT02293096,1:24:chronic_disease,end stage renal disease,['end' 'stage' 'renal' 'disease'],[2. 2. 2. 2.]
NCT02512497,1:30:treatment,Prior whole brain irradiation,['Prior' 'whole' 'brain' 'irradiation'],[1. 1. 1. 1.]
NCT01701986,1:30:treatment,Prior whole brain irradiation,['Prior' 'whole' 'brain' 'irradiation'],[1. 1. 1. 1.]
NCT02508311,1:16:chronic_disease,Hyperthyroidism,['Hyperthyroidism'],[2.]
NCT01983475,1:16:chronic_disease,Hyperthyroidism,['Hyperthyroidism'],[2.]
NCT02504866,3:30:treatment,A ventriculo-peritoneal shunt,['A' 'ventriculo-peritoneal' 'shunt'],[0. 1. 1.]
NCT02355002,1:28:treatment,ventriculo-peritoneal shunt,['ventriculo-peritoneal' 'shunt'],[1. 1.]
NCT02503722,1:24:chronic_disease,malabsorption syndromes,['malabsorption' 'syndromes'],[2. 2.]
NCT01675154,9:32:chronic_disease,Chronic malabsorption syndromes,['Chronic' 'malabsorption' 'syndromes'],[0. 2. 2.]
NCT02501954,15:29:cancer,Patients with carcinosarcoma,['Patients' 'with' 'carcinosarcoma'],[0. 0. 3.]
NCT01600040,1:15:cancer,carcinosarcoma,['carcinosarcoma'],[3.]
NCT02501473,"15:71:treatment,",Has undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years,"['Has' 'undergone' 'prior' 'allogeneic' 'hematopoietic' 'stem' 'cell'
 'transplantation' 'within' 'the' 'last' '5' 'years']",[0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02332668,"1:57:treatment,",prior allogeneic hematopoietic stem cell transplantation within the last 5 years,"['prior' 'allogeneic' 'hematopoietic' 'stem' 'cell' 'transplantation'
 'within' 'the' 'last' '5' 'years']",[1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02498535,"17:43:treatment,",Ongoing chronic inhaled antibiotic therapy for at least 3 months prior to (screening or baseline),"['Ongoing' 'chronic' 'inhaled' 'antibiotic' 'therapy' 'for' 'at' 'least'
 '3' 'months' 'prior' 'to' '(' 'screening' 'or' 'baseline' ')']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02498535,22:48:treatment,Willing to be off of inhaled antibiotic therapy from Day 1 to Day 15,"['Willing' 'to' 'be' 'off' 'of' 'inhaled' 'antibiotic' 'therapy' 'from'
 'Day' '1' 'to' 'Day' '15']",[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02496585,22:43:chronic_disease,Diagnosis of diffuse radiation pneumonitis,['Diagnosis' 'of' 'diffuse' 'radiation' 'pneumonitis'],[0. 0. 0. 2. 2.]
NCT02496585,",44:65:chronic_disease",Newly diagnosed clinical grade 2 or higher radiation pneumonitis according to CTCAE version 4.0 criteria,"['Newly' 'diagnosed' 'clinical' 'grade' '2' 'or' 'higher' 'radiation'
 'pneumonitis' 'according' 'to' 'CTCAE' 'version' '4.0' 'criteria']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02495415,29:61:chronic_disease,Patients with an identified familial hyperlipidemia disorder,"['Patients' 'with' 'an' 'identified' 'familial' 'hyperlipidemia'
 'disorder']",[0. 0. 0. 0. 2. 2. 2.]
NCT01553071,29:61:chronic_disease,Patients with an identified familial hyperlipidemia disorder,"['Patients' 'with' 'an' 'identified' 'familial' 'hyperlipidemia'
 'disorder']",[0. 0. 0. 0. 2. 2. 2.]
NCT02494258,50:66:treatment,any investigational agent after the last dose of oral azacitidine administered as part of the parent oral azacitidine study,"['any' 'investigational' 'agent' 'after' 'the' 'last' 'dose' 'of' 'oral'
 'azacitidine' 'administered' 'as' 'part' 'of' 'the' 'parent' 'oral'
 'azacitidine' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02494258,10:26:treatment,received oral azacitidine,['received' 'oral' 'azacitidine'],[0. 1. 1.]
NCT02490943,"4:19:chronic_disease,",No MS exacerbation for 60 days prior to screening,['No' 'MS' 'exacerbation' 'for' '60' 'days' 'prior' 'to' 'screening'],[0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02427997,"9:24:chronic_disease,","have no MS exacerbation within the preceding 4 weeks, as determined by interview and medical notes review","['have' 'no' 'MS' 'exacerbation' 'within' 'the' 'preceding' '4' 'weeks'
 ',' 'as' 'determined' 'by' 'interview' 'and' 'medical' 'notes' 'review']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02489019,24:46:treatment,Patients scheduled for cardiovascular surgery,['Patients' 'scheduled' 'for' 'cardiovascular' 'surgery'],[0. 0. 0. 1. 1.]
NCT02436070,10:32:treatment,Previous cardiovascular surgery,['Previous' 'cardiovascular' 'surgery'],[0. 1. 1.]
NCT02487095,103:114:treatment,History of allergic reactions attributed to compounds of similar chemical or biologic composition to (study agent) or other agents used in study,"['History' 'of' 'allergic' 'reactions' 'attributed' 'to' 'compounds' 'of'
 'similar' 'chemical' 'or' 'biologic' 'composition' 'to' '(' 'study'
 'agent' ')' 'or' 'other' 'agents' 'used' 'in' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02273362,",,,,112:123:treatment",Willingness to use adequate contraception to avoid pregnancy or impregnation until 2 weeks after discontinuing study agent,"['Willingness' 'to' 'use' 'adequate' 'contraception' 'to' 'avoid'
 'pregnancy' 'or' 'impregnation' 'until' '2' 'weeks' 'after'
 'discontinuing' 'study' 'agent']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02484404,",19:60:treatment",with at least one prior line of platinum-based chemotherapy,"['with' 'at' 'least' 'one' 'prior' 'line' 'of' 'platinum-based'
 'chemotherapy']",[0. 0. 0. 0. 1. 1. 1. 1. 1.]
NCT02484404,",19:60:treatment",with at least one prior line of platinum-based chemotherapy are eligible,"['with' 'at' 'least' 'one' 'prior' 'line' 'of' 'platinum-based'
 'chemotherapy' 'are' 'eligible']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0.]
NCT02479906,12:36:chronic_disease,History of cerebrovascular accident,['History' 'of' 'cerebrovascular' 'accident'],[0. 0. 2. 2.]
NCT02469857,"8:32:chronic_disease,",Recent cerebrovascular accident in the last 3 months,['Recent' 'cerebrovascular' 'accident' 'in' 'the' 'last' '3' 'months'],[0. 2. 2. 0. 0. 0. 0. 0.]
NCT02476409,61:70:allergy_name,History of adverse reaction or clinical contraindication to tolvaptan,"['History' 'of' 'adverse' 'reaction' 'or' 'clinical' 'contraindication'
 'to' 'tolvaptan']",[0. 0. 0. 0. 0. 0. 0. 0. 4.]
NCT02476409,32:41:allergy_name,History of hypersensitivity to tolvaptan,['History' 'of' 'hypersensitivity' 'to' 'tolvaptan'],[0. 0. 0. 0. 4.]
NCT02473250,"1:4:treatment,",ECT within the past 6 months,['ECT' 'within' 'the' 'past' '6' 'months'],[1. 0. 0. 0. 0. 0.]
NCT02046330,33:36:treatment,Refusal of an adequate trial of ECT,['Refusal' 'of' 'an' 'adequate' 'trial' 'of' 'ECT'],[0. 0. 0. 0. 0. 0. 1.]
NCT02471430,10:45:chronic_disease,Negative Hepatitis B surface antigen (HBsAg) or Negative HBV DNA PCR,"['Negative' 'Hepatitis' 'B' 'surface' 'antigen' '(' 'HBsAg' ')' 'or'
 'Negative' 'HBV' 'DNA' 'PCR']",[0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02320292,1:36:chronic_disease,Hepatitis B surface antigen (HBsAg) positive,['Hepatitis' 'B' 'surface' 'antigen' '(' 'HBsAg' ')' 'positive'],[2. 2. 2. 2. 2. 0. 0. 0.]
NCT02466685,"31:56:treatment,",change in mood stabilizing or antidepressant medication or dose within 2 months prior to screening,"['change' 'in' 'mood' 'stabilizing' 'or' 'antidepressant' 'medication'
 'or' 'dose' 'within' '2' 'months' 'prior' 'to' 'screening']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02133898,"4:29:treatment,",No antidepressant medication in past 3 months,['No' 'antidepressant' 'medication' 'in' 'past' '3' 'months'],[0. 1. 1. 0. 0. 0. 0.]
NCT02464969,1:33:chronic_disease,Uncontrolled severe hypertension at the time of randomization,"['Uncontrolled' 'severe' 'hypertension' 'at' 'the' 'time' 'of'
 'randomization']",[2. 2. 2. 0. 0. 0. 0. 0.]
NCT02369653,1:33:chronic_disease,Uncontrolled severe hypertension at enrollment,['Uncontrolled' 'severe' 'hypertension' 'at' 'enrollment'],[2. 2. 2. 0. 0.]
NCT02460900,51:62:allergy_name,Previous allergic reaction or hypersensitivity to Varenicline (by participant report ever in lifetime),"['Previous' 'allergic' 'reaction' 'or' 'hypersensitivity' 'to'
 'Varenicline' '(' 'by' 'participant' 'report' 'ever' 'in' 'lifetime' ')']",[0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02460900,"15:26:treatment,",Recent use of Varenicline (by participant report in the past 3 months),"['Recent' 'use' 'of' 'Varenicline' '(' 'by' 'participant' 'report' 'in'
 'the' 'past' '3' 'months' ')']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02457845,63:85:treatment,Radiation: Patients must have received their last fraction of craniospinal radiation,"['Radiation' ':' 'Patients' 'must' 'have' 'received' 'their' 'last'
 'fraction' 'of' 'craniospinal' 'radiation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01130077,42:64:treatment,Patients in Stratum F must have received craniospinal radiation,"['Patients' 'in' 'Stratum' 'F' 'must' 'have' 'received' 'craniospinal'
 'radiation']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02451488,",72:78:treatment",All WOCBP must have a negative pregnancy test prior to first receiving GM-CSF,"['All' 'WOCBP' 'must' 'have' 'a' 'negative' 'pregnancy' 'test' 'prior'
 'to' 'first' 'receiving' 'GM-CSF']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02033616,27:33:allergy_name,Known hypersensitivity to GM-CSF,['Known' 'hypersensitivity' 'to' 'GM-CSF'],[0. 0. 0. 4.]
NCT02442297,",,,,202:220:treatment",Available autologous transduced T lymphocytes with greater than or equal to 15% expression of HER2 CAR determined by flow-cytometry and killing of HER2-positive targets greater than or equal to 20% in cytotoxicity assay,"['Available' 'autologous' 'transduced' 'T' 'lymphocytes' 'with' 'greater'
 'than' 'or' 'equal' 'to' '15' '%' 'expression' 'of' 'HER2' 'CAR'
 'determined' 'by' 'flow-cytometry' 'and' 'killing' 'of' 'HER2-positive'
 'targets' 'greater' 'than' 'or' 'equal' 'to' '20' '%' 'in' 'cytotoxicity'
 'assay']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT01953900,",,65:83:treatment",killing of GD2-positive targets greater than or equal to 20% in cytotoxicity assay,"['killing' 'of' 'GD2-positive' 'targets' 'greater' 'than' 'or' 'equal'
 'to' '20' '%' 'in' 'cytotoxicity' 'assay']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02442297,"1:13:treatment,",Temozolomide will be allowed up to 48 hours preinfusion,['Temozolomide' 'will' 'be' 'allowed' 'up' 'to' '48' 'hours' 'preinfusion'],[1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02340156,73:85:allergy_name,Have a history of hypersensitivity reaction to any of the components of Temozolomide,"['Have' 'a' 'history' 'of' 'hypersensitivity' 'reaction' 'to' 'any' 'of'
 'the' 'components' 'of' 'Temozolomide']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4.]
NCT02436070,1:15:chronic_disease,Bronchiectasis,['Bronchiectasis'],[2.]
NCT02434809,1:15:chronic_disease,Bronchiectasis in the region of the intended implantation,['Bronchiectasis' 'in' 'the' 'region' 'of' 'the' 'intended' 'implantation'],[2. 0. 0. 0. 0. 0. 0. 0.]
NCT02429934,"22:40:chronic_disease,",Subjects with active glomerulonephritis (>3 g protein/24h and/or active urine sediment),"['Subjects' 'with' 'active' 'glomerulonephritis' '(' '>' '3' 'g'
 'protein/24h' 'and/or' 'active' 'urine' 'sediment' ')']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02418195,12:30:chronic_disease,Autoimmune glomerulonephritis,['Autoimmune' 'glomerulonephritis'],[0. 2.]
NCT02426047,14:36:chronic_disease,Metabolic or mitochondrial disorder,['Metabolic' 'or' 'mitochondrial' 'disorder'],[0. 0. 2. 2.]
NCT01817751,7:29:chronic_disease,Known mitochondrial disorder caused by mutations in mitochondrial DNA polymerase γ,"['Known' 'mitochondrial' 'disorder' 'caused' 'by' 'mutations' 'in'
 'mitochondrial' 'DNA' 'polymerase' 'γ']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02421380,15:28:chronic_disease,patients with brain lesions,['patients' 'with' 'brain' 'lesions'],[0. 0. 2. 2.]
NCT02339376,21:34:cancer,Rapidly progressive brain lesions,['Rapidly' 'progressive' 'brain' 'lesions'],[0. 0. 3. 3.]
NCT02416206,14:30:cancer,Diagnosis of Multiple Myeloma,['Diagnosis' 'of' 'Multiple' 'Myeloma'],[0. 0. 3. 3.]
NCT01947140,1:17:cancer,Multiple Myeloma patients specified in the protocol,['Multiple' 'Myeloma' 'patients' 'specified' 'in' 'the' 'protocol'],[3. 3. 0. 0. 0. 0. 0.]
NCT02413970,54:58:treatment,"Subjects who have been prescribed, but refuse to try CPAP would be considered intolerant","['Subjects' 'who' 'have' 'been' 'prescribed' ',' 'but' 'refuse' 'to' 'try'
 'CPAP' 'would' 'be' 'considered' 'intolerant']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02261857,23:27:treatment,Inability to tolerate CPAP attributed to poor fit by a sleep clinician,"['Inability' 'to' 'tolerate' 'CPAP' 'attributed' 'to' 'poor' 'fit' 'by'
 'a' 'sleep' 'clinician']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02405078,"1:9:treatment,,,,",CT scans showing involvement of 1 or more clearly demarcated lesions with a long axis > 1.5 cm and short axis >= 1.0 cm,"['CT' 'scans' 'showing' 'involvement' 'of' '1' 'or' 'more' 'clearly'
 'demarcated' 'lesions' 'with' 'a' 'long' 'axis' '>' '1.5' 'cm' 'and'
 'short' 'axis' '>' '=' '1.0' 'cm']","[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT00975520,39:47:treatment,Inability to localise surgical bed on CT scans and/or surgical margins (cm) not known,"['Inability' 'to' 'localise' 'surgical' 'bed' 'on' 'CT' 'scans' 'and/or'
 'surgical' 'margins' '(' 'cm' ')' 'not' 'known']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02401347,14:31:chronic_disease,Known active hepatitis C virus,['Known' 'active' 'hepatitis' 'C' 'virus'],[0. 0. 2. 2. 2.]
NCT01676259,1:18:chronic_disease,hepatitis C virus,['hepatitis' 'C' 'virus'],[2. 2. 2.]
NCT02397083,42:54:allergy_name,Known intolerance or hypersensitivity to progesterone or its excipients,"['Known' 'intolerance' 'or' 'hypersensitivity' 'to' 'progesterone' 'or'
 'its' 'excipients']",[0. 0. 0. 0. 0. 4. 0. 0. 0.]
NCT02133573,"17:29:treatment,",Maternal use of progesterone within 30 days of enrollment,"['Maternal' 'use' 'of' 'progesterone' 'within' '30' 'days' 'of'
 'enrollment']",[0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02389517,84:87:cancer,available deoxyribonucleic acid (DNA) sample will be used for calibration step for MRD evaluation by gene sequencing,"['available' 'deoxyribonucleic' 'acid' '(' 'DNA' ')' 'sample' 'will' 'be'
 'used' 'for' 'calibration' 'step' 'for' 'MRD' 'evaluation' 'by' 'gene'
 'sequencing']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0.]
NCT02003222,1:4:chronic_disease,MRD results will be reported to the submitting institution,"['MRD' 'results' 'will' 'be' 'reported' 'to' 'the' 'submitting'
 'institution']",[2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02379520,"69:83:treatment,,",Currently receiving any investigational agents or have received any tumor vaccines or T cell antibodies within previous 4 weeks,"['Currently' 'receiving' 'any' 'investigational' 'agents' 'or' 'have'
 'received' 'any' 'tumor' 'vaccines' 'or' 'T' 'cell' 'antibodies' 'within'
 'previous' '4' 'weeks']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02354547,1:15:treatment,tumor vaccines,['tumor' 'vaccines'],[1. 1.]
NCT02373241,1:13:chronic_disease,Hyperkalemia,['Hyperkalemia'],[2.]
NCT02169089,"1:13:chronic_disease,,",Hyperkalemia defined as serum K+≥ 5.1 meq/L at visit 0 (screening),"['Hyperkalemia' 'defined' 'as' 'serum' 'K+≥' '5.1' 'meq/L' 'at' 'visit'
 '0' '(' 'screening' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02369406,",,28:41:chronic_disease,",30-365 days after birth if HIV-infection diagnosed within 96 hours after birth,"['30-365' 'days' 'after' 'birth' 'if' 'HIV-infection' 'diagnosed' 'within'
 '96' 'hours' 'after' 'birth']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02369406,"1:14:chronic_disease,",HIV-infection documented within 42 days after birth,['HIV-infection' 'documented' 'within' '42' 'days' 'after' 'birth'],[2. 0. 0. 0. 0. 0. 0.]
NCT02366754,1:23:chronic_disease,Traumatic Brain Injury etiology,['Traumatic' 'Brain' 'Injury' 'etiology'],[2. 2. 2. 0.]
NCT02249039,1:23:chronic_disease,Traumatic Brain Injury,['Traumatic' 'Brain' 'Injury'],[2. 2. 2.]
NCT02362308,1:18:chronic_disease,"Mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study","['Mental' 'conditions' 'rendering' 'the' 'subject' 'unable' 'to'
 'understand' 'the' 'nature' ',' 'scope' 'and' 'possible' 'consequences'
 'of' 'the' 'study']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02130687,1:18:chronic_disease,"Mental conditions rendering the subject unable to understand the nature, scope, or possible consequences of the study","['Mental' 'conditions' 'rendering' 'the' 'subject' 'unable' 'to'
 'understand' 'the' 'nature' ',' 'scope' ',' 'or' 'possible'
 'consequences' 'of' 'the' 'study']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02354703,114:125:treatment,"As of Screen Visit, the subject is sharing a household with a subject randomized to any investigational trial of ondansetron","['As' 'of' 'Screen' 'Visit' ',' 'the' 'subject' 'is' 'sharing' 'a'
 'household' 'with' 'a' 'subject' 'randomized' 'to' 'any'
 'investigational' 'trial' 'of' 'ondansetron']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02354703,60:71:allergy_name,History of severe or life-threatening adverse reactions to ondansetron,"['History' 'of' 'severe' 'or' 'life-threatening' 'adverse' 'reactions'
 'to' 'ondansetron']",[0. 0. 0. 0. 0. 0. 0. 0. 4.]
NCT02353728,43:46:cancer,Documented diagnosis of Ph+ Chronic phase CML,['Documented' 'diagnosis' 'of' 'Ph+' 'Chronic' 'phase' 'CML'],[0. 0. 0. 0. 0. 0. 3.]
NCT00368355,1:4:cancer,CML,['CML'],[3.]
NCT02352454,8:22:chronic_disease,Proven venous disease,['Proven' 'venous' 'disease'],[0. 2. 2.]
NCT02312518,35:49:chronic_disease,Medicare/Medicaid eligible Proven venous disease,['Medicare/Medicaid' 'eligible' 'Proven' 'venous' 'disease'],[0. 0. 0. 2. 2.]
NCT02347111,1:25:chronic_disease,structural heart disease,['structural' 'heart' 'disease'],[2. 2. 2.]
NCT02169037,1:25:chronic_disease,structural heart disease of clinical significance,['structural' 'heart' 'disease' 'of' 'clinical' 'significance'],[2. 2. 2. 0. 0. 0.]
NCT02343042,46:55:treatment,"Prior exposure to a SINE compound, including selinexor","['Prior' 'exposure' 'to' 'a' 'SINE' 'compound' ',' 'including' 'selinexor']",[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02323880,51:60:treatment,Patients must not have received prior exposure to selinexor,"['Patients' 'must' 'not' 'have' 'received' 'prior' 'exposure' 'to'
 'selinexor']",[0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02340650,17:32:chronic_disease,Patients having acute infection,['Patients' 'having' 'acute' 'infection'],[0. 0. 2. 2.]
NCT01239160,14:29:chronic_disease,Diagnosis of acute infection,['Diagnosis' 'of' 'acute' 'infection'],[0. 0. 2. 2.]
NCT02338999,",47:56:treatment",Postmenopausal women who have not undergone a DEXA scan over the last year will undergo a DEXA scan at screening,"['Postmenopausal' 'women' 'who' 'have' 'not' 'undergone' 'a' 'DEXA' 'scan'
 'over' 'the' 'last' 'year' 'will' 'undergo' 'a' 'DEXA' 'scan' 'at'
 'screening']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02338999,",43:52:treatment,,",Postmenopausal women who have undergone a DEXA scan during the last year and have a T score better than -2.5 will be included without repeating the DEXA scan prior to enrollment,"['Postmenopausal' 'women' 'who' 'have' 'undergone' 'a' 'DEXA' 'scan'
 'during' 'the' 'last' 'year' 'and' 'have' 'a' 'T' 'score' 'better' 'than'
 '-2.5' 'will' 'be' 'included' 'without' 'repeating' 'the' 'DEXA' 'scan'
 'prior' 'to' 'enrollment']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02332187,"18:26:treatment,,,,",Use of high dose pressors (more than 15 mcg/min of norepinephrine or more than 15 mg/kg/min of dopamine),"['Use' 'of' 'high' 'dose' 'pressors' '(' 'more' 'than' '15' 'mcg/min' 'of'
 'norepinephrine' 'or' 'more' 'than' '15' 'mg/kg/min' 'of' 'dopamine' ')']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02145260,8:16:treatment,Use of pressors,['Use' 'of' 'pressors'],[0. 0. 1.]
NCT02323880,",,,106:128:treatment","Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1","['Antibodies' ':' '>' '=' '21' 'days' 'must' 'have' 'elapsed' 'from'
 'infusion' 'of' 'last' 'dose' 'of' 'antibody' ',' 'and' 'toxicity'
 'related' 'to' 'prior' 'antibody' 'therapy' 'must' 'be' 'recovered' 'to'
 'grade' '=' '<' '1']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02304458,",,,106:128:treatment,","Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1","['Antibodies' ':' '>' '=' '21' 'days' 'must' 'have' 'elapsed' 'from'
 'infusion' 'of' 'last' 'dose' 'of' 'antibody' ',' 'and' 'toxicity'
 'related' 'to' 'prior' 'antibody' 'therapy' 'must' 'be' 'recovered' 'to'
 'grade' '=' '<' '1']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02323126,"1:13:cancer,",Tumor tissue for determination and/or confirmation of genetic pre-requisites (i.e. EGFR T790M positivity post progression on EGFR TKI for Group 1; cMet status for Group 2) must be provided for analysis,"['Tumor' 'tissue' 'for' 'determination' 'and/or' 'confirmation' 'of'
 'genetic' 'pre-requisites' '(' 'i.e' '.' 'EGFR' 'T790M' 'positivity'
 'post' 'progression' 'on' 'EGFR' 'TKI' 'for' 'Group' '1' ';' 'cMet'
 'status' 'for' 'Group' '2' ')' 'must' 'be' 'provided' 'for' 'analysis']","[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT00887146,1:13:cancer,Tumor tissue must show co-deletion of chromosomes 1p and 19q; for eligibility,"['Tumor' 'tissue' 'must' 'show' 'co-deletion' 'of' 'chromosomes' '1p'
 'and' '19q' ';' 'for' 'eligibility']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02317991,26:40:treatment,anticipation of need for major surgical procedure during the course of the study,"['anticipation' 'of' 'need' 'for' 'major' 'surgical' 'procedure' 'during'
 'the' 'course' 'of' 'the' 'study']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01903330,26:40:treatment,Anticipation of need for major surgical procedure during the course of the study,"['Anticipation' 'of' 'need' 'for' 'major' 'surgical' 'procedure' 'during'
 'the' 'course' 'of' 'the' 'study']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02312596,1:11:chronic_disease,vasculitis,['vasculitis'],[2.]
NCT02312518,1:11:chronic_disease,vasculitis,['vasculitis'],[2.]
NCT02308904,",32:51:treatment,",History of at least 5 years of chronic transfusion (defined as ≥ 8 transfusions/year),"['History' 'of' 'at' 'least' '5' 'years' 'of' 'chronic' 'transfusion' '('
 'defined' 'as' '≥' '8' 'transfusions/year' ')']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02140554,",,53:72:treatment",abnormal transcranial Doppler [≥200 cm/sec] needing chronic transfusion,"['abnormal' 'transcranial' 'Doppler' '[' '≥200' 'cm/sec' ']' 'needing'
 'chronic' 'transfusion']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02302235,12:33:cancer,History of non-glioma malignancy,['History' 'of' 'non-glioma' 'malignancy'],[0. 0. 3. 3.]
NCT01865162,12:33:cancer,History of non-glioma malignancy,['History' 'of' 'non-glioma' 'malignancy'],[0. 0. 3. 3.]
NCT02287558,"1:22:chronic_disease,,,,","Hepatic insufficiency, bilirubin > 2.0 or transaminases > 3.0 x normal","['Hepatic' 'insufficiency' ',' 'bilirubin' '>' '2.0' 'or' 'transaminases'
 '>' '3.0' 'x' 'normal']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01970345,1:22:chronic_disease,Hepatic insufficiency,['Hepatic' 'insufficiency'],[2. 2.]
NCT02271100,22:41:allergy_name,Contraindications to neuraxial analgesia,['Contraindications' 'to' 'neuraxial' 'analgesia'],[0. 0. 4. 4.]
NCT02121184,21:40:allergy_name,Contraindication to neuraxial analgesia,['Contraindication' 'to' 'neuraxial' 'analgesia'],[0. 0. 4. 4.]
NCT02266745,41:61:treatment,"Evaluable disease, either measurable on physical examination","['Evaluable' 'disease' ',' 'either' 'measurable' 'on' 'physical'
 'examination']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT01220583,"9:29:treatment,",History/physical examination within 8 weeks prior to registration,"['History/physical' 'examination' 'within' '8' 'weeks' 'prior' 'to'
 'registration']",[1. 1. 0. 0. 0. 0. 0. 0.]
NCT02262806,1:21:chronic_disease,Psychiatric disorder impeding competence or compliance,['Psychiatric' 'disorder' 'impeding' 'competence' 'or' 'compliance'],[2. 2. 0. 0. 0. 0.]
NCT00085982,1:21:chronic_disease,Psychiatric disorder impeding competence or compliance,['Psychiatric' 'disorder' 'impeding' 'competence' 'or' 'compliance'],[2. 2. 0. 0. 0. 0.]
NCT02252588,13:26:chronic_disease,Presence of chronic cough and sputum will be defined by responses to the first two questions on the SGRQ. Subjects w,"['Presence' 'of' 'chronic' 'cough' 'and' 'sputum' 'will' 'be' 'defined'
 'by' 'responses' 'to' 'the' 'first' 'two' 'questions' 'on' 'the' 'SGRQ'
 '.' 'Subjects' 'w']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02252588,32:45:chronic_disease,Presence or high likelihood of chronic cough and sputum production,"['Presence' 'or' 'high' 'likelihood' 'of' 'chronic' 'cough' 'and' 'sputum'
 'production']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0.]
NCT02250664,18:44:treatment,Currently taking anticonvulsant medications,['Currently' 'taking' 'anticonvulsant' 'medications'],[0. 0. 1. 1.]
NCT02250534,18:44:treatment,Currently taking anticonvulsant medications,['Currently' 'taking' 'anticonvulsant' 'medications'],[0. 0. 1. 1.]
NCT02234934,10:33:treatment,Abnormal electrocardiogram (EKG) indicating cardiac pathology,"['Abnormal' 'electrocardiogram' '(' 'EKG' ')' 'indicating' 'cardiac'
 'pathology']",[0. 1. 1. 0. 0. 0. 0. 0.]
NCT01409161,",48:71:treatment,",Fridericia corrected QT (QTcF) interval on the electrocardiogram (EKG) greater than 480 milliseconds,"['Fridericia' 'corrected' 'QT' '(' 'QTcF' ')' 'interval' 'on' 'the'
 'electrocardiogram' '(' 'EKG' ')' 'greater' 'than' '480' 'milliseconds']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02233868,7:23:chronic_disease,"Major medical problems that can permanently impact brain function (e.g., CNS, cardiovascular, metabolic, autoimmune, endocrine) as determined by history and clinical exam","['Major' 'medical' 'problems' 'that' 'can' 'permanently' 'impact' 'brain'
 'function' '(' 'e.g.' ',' 'CNS' ',' 'cardiovascular' ',' 'metabolic' ','
 'autoimmune' ',' 'endocrine' ')' 'as' 'determined' 'by' 'history' 'and'
 'clinical' 'exam']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02230189,29:45:chronic_disease,"Presence of past or current medical problems/other factors that may pose additional risks from participation or influence study results, as determined per study investigator","['Presence' 'of' 'past' 'or' 'current' 'medical' 'problems/other'
 'factors' 'that' 'may' 'pose' 'additional' 'risks' 'from' 'participation'
 'or' 'influence' 'study' 'results' ',' 'as' 'determined' 'per' 'study'
 'investigator']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02232516,1:33:cancer,Enteropathy-type T-cell lymphoma,['Enteropathy-type' 'T-cell' 'lymphoma'],[3. 3. 3.]
NCT01787409,1:33:cancer,Enteropathy-type T-cell lymphoma,['Enteropathy-type' 'T-cell' 'lymphoma'],[3. 3. 3.]
NCT02219711,28:50:cancer,Metastatic or unresectable solid tumor malignancy,['Metastatic' 'or' 'unresectable' 'solid' 'tumor' 'malignancy'],[0. 0. 0. 3. 3. 3.]
NCT01625234,65:87:cancer,Histologically or cytologically confirmed diagnosis of advanced solid tumor malignancy,"['Histologically' 'or' 'cytologically' 'confirmed' 'diagnosis' 'of'
 'advanced' 'solid' 'tumor' 'malignancy']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT02206945,1:22:chronic_disease,severe claustrophobia,['severe' 'claustrophobia'],[2. 2.]
NCT00285935,"25:46:chronic_disease,,","No MRI exclusions (e.g. severe claustrophobia, metal implants, pacemakers, BMI >38)","['No' 'MRI' 'exclusions' '(' 'e.g' '.' 'severe' 'claustrophobia' ','
 'metal' 'implants' ',' 'pacemakers' ',' 'BMI' '>' '38' ')']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02194387,",20:32:treatment",Less than 3 months post-surgery,['Less' 'than' '3' 'months' 'post-surgery'],[0. 0. 0. 0. 1.]
NCT01101451,",53:65:treatment,",Patients should not be randomized less than 3 weeks post-surgery but will not be acceptable for randomization more than 8 weeks post-surgery,"['Patients' 'should' 'not' 'be' 'randomized' 'less' 'than' '3' 'weeks'
 'post-surgery' 'but' 'will' 'not' 'be' 'acceptable' 'for' 'randomization'
 'more' 'than' '8' 'weeks' 'post-surgery']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02189798,"18:44:chronic_disease,,,,,,,,","Up to a moderate sensorineural hearing loss in the low-to-mid frequencies (pure tone average ≤65 dB for 125, 250, 500, and 1000 Hz) and a severe-to-profound sensorineural hearing loss in the high frequencies (pure tone average ≥ 70 dB HL for 2,000, 3000, 4,000, and 8,000 Hz) in the contralateral (non-implanted) ear","['Up' 'to' 'a' 'moderate' 'sensorineural' 'hearing' 'loss' 'in' 'the'
 'low-to-mid' 'frequencies' '(' 'pure' 'tone' 'average' '≤65' 'dB' 'for'
 '125' ',' '250' ',' '500' ',' 'and' '1000' 'Hz' ')' 'and' 'a'
 'severe-to-profound' 'sensorineural' 'hearing' 'loss' 'in' 'the' 'high'
 'frequencies' '(' 'pure' 'tone' 'average' '≥' '70' 'dB' 'HL' 'for'
 '2,000' ',' '3000' ',' '4,000' ',' 'and' '8,000' 'Hz' ')' 'in' 'the'
 'contralateral' '(' 'non-implanted' ')' 'ear']","[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02189798,"18:44:chronic_disease,,,","Up to a moderate sensorineural hearing loss in the low-to-mid frequencies (pure tone average ≤65 dB for 125, 250, 500, and 1000 Hz) and a severe-to-profound sensorineural hearing loss in the high frequencies (pure tone average ≥ 70 dB HL for 2,000, 3000, 4,000, and 8,000 Hz) in the ear to be implanted","['Up' 'to' 'a' 'moderate' 'sensorineural' 'hearing' 'loss' 'in' 'the'
 'low-to-mid' 'frequencies' '(' 'pure' 'tone' 'average' '≤65' 'dB' 'for'
 '125' ',' '250' ',' '500' ',' 'and' '1000' 'Hz' ')' 'and' 'a'
 'severe-to-profound' 'sensorineural' 'hearing' 'loss' 'in' 'the' 'high'
 'frequencies' '(' 'pure' 'tone' 'average' '≥' '70' 'dB' 'HL' 'for'
 '2,000' ',' '3000' ',' '4,000' ',' 'and' '8,000' 'Hz' ')' 'in' 'the'
 'ear' 'to' 'be' 'implanted']","[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02181257,",144:147:chronic_disease,",Frequent laboratory based spirometry defined as having had regular FEV1 measurements during the preceding six months prior to diagnosis of new BOS with no time interval between FEV1 measurements that exceeds 8 weeks,"['Frequent' 'laboratory' 'based' 'spirometry' 'defined' 'as' 'having'
 'had' 'regular' 'FEV1' 'measurements' 'during' 'the' 'preceding' 'six'
 'months' 'prior' 'to' 'diagnosis' 'of' 'new' 'BOS' 'with' 'no' 'time'
 'interval' 'between' 'FEV1' 'measurements' 'that' 'exceeds' '8' 'weeks']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02181257,",60:63:chronic_disease",History of close FEV1 monitoring prior to diagnosis of new BOS defined as having had either of the two monitoring approaches,"['History' 'of' 'close' 'FEV1' 'monitoring' 'prior' 'to' 'diagnosis' 'of'
 'new' 'BOS' 'defined' 'as' 'having' 'had' 'either' 'of' 'the' 'two'
 'monitoring' 'approaches']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02172950,",,,61:84:chronic_disease,,",Males 0 to <18 years of who have been diagnosed with severe congenital hemophilia A (FVIII activity levels < 1%),"['Males' '0' 'to' '<' '18' 'years' 'of' 'who' 'have' 'been' 'diagnosed'
 'with' 'severe' 'congenital' 'hemophilia' 'A' '(' 'FVIII' 'activity'
 'levels' '<' '1' '%' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02172950,",,,,62:85:chronic_disease,,,,","Males 0 to <65 years age who have been diagnosed with severe congenital hemophilia A (FVIII activity levels < 1%), who have at least 50 EDs to any FVIII product, and who are not currently enrolled in a CSL-sponsored clinical study with rVIII-SingleChain","['Males' '0' 'to' '<' '65' 'years' 'age' 'who' 'have' 'been' 'diagnosed'
 'with' 'severe' 'congenital' 'hemophilia' 'A' '(' 'FVIII' 'activity'
 'levels' '<' '1' '%' ')' ',' 'who' 'have' 'at' 'least' '50' 'EDs' 'to'
 'any' 'FVIII' 'product' ',' 'and' 'who' 'are' 'not' 'currently'
 'enrolled' 'in' 'a' 'CSL-sponsored' 'clinical' 'study' 'with'
 'rVIII-SingleChain']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02167009,12:30:treatment,History of pelvic irradiation,['History' 'of' 'pelvic' 'irradiation'],[0. 0. 1. 1.]
NCT01868386,11:29:treatment,had prior pelvic irradiation,['had' 'prior' 'pelvic' 'irradiation'],[0. 0. 1. 1.]
NCT02152995,",,69:82:treatment",patients with controlled atrial fibrillation for > 30 days prior to randomization,"['patients' 'with' 'controlled' 'atrial' 'fibrillation' 'for' '>' '30'
 'days' 'prior' 'to' 'randomization']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01872975,",,61:74:treatment,",Pregnancy testing must be performed within 2 weeks prior to randomization according to institutional standards for women of childbearing potential,"['Pregnancy' 'testing' 'must' 'be' 'performed' 'within' '2' 'weeks'
 'prior' 'to' 'randomization' 'according' 'to' 'institutional' 'standards'
 'for' 'women' 'of' 'childbearing' 'potential']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02148003,"21:24:treatment,",History of previous RFA at the same level(s) in the previous 12 months,"['History' 'of' 'previous' 'RFA' 'at' 'the' 'same' 'level' '(' 's' ')'
 'in' 'the' 'previous' '12' 'months']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02148003,"27:30:treatment,,",Patients who will undergo RFA of 3‐4 lumbar facet medial branches on one side only,"['Patients' 'who' 'will' 'undergo' 'RFA' 'of' '3‐4' 'lumbar' 'facet'
 'medial' 'branches' 'on' 'one' 'side' 'only']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02143726,1:25:chronic_disease,Cerebrovascular accident,['Cerebrovascular' 'accident'],[2. 2.]
NCT01626079,"1:25:chronic_disease,",Cerebrovascular accident within 30 days prior to subject registration,"['Cerebrovascular' 'accident' 'within' '30' 'days' 'prior' 'to' 'subject'
 'registration']",[2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02133196,77:99:treatment,Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities,"['Patients' 'who' 'have' 'decreased' 'immune' 'competence' 'may' 'be'
 'less' 'responsive' 'to' 'the' 'experimental' 'treatment' 'and' 'more'
 'susceptible' 'to' 'its' 'toxicities']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT01967823,76:98:treatment,Patients who have decreased immunecompetence may be less responsive to the experimental treatment and more susceptible to its toxicities,"['Patients' 'who' 'have' 'decreased' 'immunecompetence' 'may' 'be' 'less'
 'responsive' 'to' 'the' 'experimental' 'treatment' 'and' 'more'
 'susceptible' 'to' 'its' 'toxicities']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02130687,",,49:61:treatment",2-hour plasma glucose ≥200 mg/dL following 75gr oral glucose load,"['2-hour' 'plasma' 'glucose' '≥200' 'mg/dL' 'following' '75gr' 'oral'
 'glucose' 'load']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT00085982,",,,85:97:treatment",2 hour plasma glucose >= 200 mg/dL following a 75 gram (1.75g/kg if less than 40kg) oral glucose load,"['2' 'hour' 'plasma' 'glucose' '>' '=' '200' 'mg/dL' 'following' 'a' '75'
 'gram' '(' '1.75g/kg' 'if' 'less' 'than' '40kg' ')' 'oral' 'glucose'
 'load']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT02128230,74:93:treatment,Patients must be either untreated or have not had more than one cycle of systemic MM therapy,"['Patients' 'must' 'be' 'either' 'untreated' 'or' 'have' 'not' 'had'
 'more' 'than' 'one' 'cycle' 'of' 'systemic' 'MM' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT00734877,",74:93:treatment",Patients must be either untreated or have not had more than one cycle of systemic MM therapy,"['Patients' 'must' 'be' 'either' 'untreated' 'or' 'have' 'not' 'had'
 'more' 'than' 'one' 'cycle' 'of' 'systemic' 'MM' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02124772,35:63:chronic_disease,History of or current evidence of retinal vein occlusion (RVO),"['History' 'of' 'or' 'current' 'evidence' 'of' 'retinal' 'vein'
 'occlusion' '(' 'RVO' ')']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02070549,37:65:chronic_disease,History or current evidence/risk of retinal vein occlusion (RVO),"['History' 'or' 'current' 'evidence/risk' 'of' 'retinal' 'vein'
 'occlusion' '(' 'RVO' ')']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02111850,1:18:cancer,Metastatic cancer diagnosis will be confirmed by the Laboratory of Pathology at the NCI,"['Metastatic' 'cancer' 'diagnosis' 'will' 'be' 'confirmed' 'by' 'the'
 'Laboratory' 'of' 'Pathology' 'at' 'the' 'NCI']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02019641,"1:18:cancer,",Metastatic cancer with a life expectancy of less than one year,"['Metastatic' 'cancer' 'with' 'a' 'life' 'expectancy' 'of' 'less' 'than'
 'one' 'year']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02101944,",13:31:chronic_disease,",> 200 mg of monoclonal protein in the urine on screening 24-hour electrophoresis,"['>' '200' 'mg' 'of' 'monoclonal' 'protein' 'in' 'the' 'urine' 'on'
 'screening' '24-hour' 'electrophoresis']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT01415882,",14:32:chronic_disease,",>= 200 mg of monoclonal protein in the urine on 24 hour electrophoresis,"['>' '=' '200' 'mg' 'of' 'monoclonal' 'protein' 'in' 'the' 'urine' 'on'
 '24' 'hour' 'electrophoresis']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02089607,1:19:chronic_disease,Saccular aneurysms deemed at significant risk for rupture based upon physician interpretation,"['Saccular' 'aneurysms' 'deemed' 'at' 'significant' 'risk' 'for' 'rupture'
 'based' 'upon' 'physician' 'interpretation']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01937949,1:19:chronic_disease,Saccular aneurysms deemed at significant risk for rupture based upon physician interpretation,"['Saccular' 'aneurysms' 'deemed' 'at' 'significant' 'risk' 'for' 'rupture'
 'based' 'upon' 'physician' 'interpretation']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02081404,1:25:chronic_disease,Eosinophilic esophagitis,['Eosinophilic' 'esophagitis'],[2. 2.]
NCT01942018,1:25:chronic_disease,Eosinophilic esophagitis,['Eosinophilic' 'esophagitis'],[2. 2.]
NCT02058095,40:55:treatment,Current or anticipated future need for nitrate therapy,['Current' 'or' 'anticipated' 'future' 'need' 'for' 'nitrate' 'therapy'],[0. 0. 0. 0. 0. 0. 1. 1.]
NCT01970176,40:55:treatment,Current or anticipated future need for nitrate therapy,['Current' 'or' 'anticipated' 'future' 'need' 'for' 'nitrate' 'therapy'],[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02048722,14:25:treatment,Prior use of regorafenib,['Prior' 'use' 'of' 'regorafenib'],[0. 0. 0. 1.]
NCT02048371,51:62:allergy_name,"Known or suspected allergy or hypersensitivity to regorafenib, or excipients of the formulations given during the course of this trial","['Known' 'or' 'suspected' 'allergy' 'or' 'hypersensitivity' 'to'
 'regorafenib' ',' 'or' 'excipients' 'of' 'the' 'formulations' 'given'
 'during' 'the' 'course' 'of' 'this' 'trial']",[0. 0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02036853,31:44:treatment,Concomitant administration of valproic acid,['Concomitant' 'administration' 'of' 'valproic' 'acid'],[0. 0. 0. 1. 1.]
NCT01817751,59:72:treatment,Any condition that would prohibit patient from initiating valproic acid,"['Any' 'condition' 'that' 'would' 'prohibit' 'patient' 'from' 'initiating'
 'valproic' 'acid']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02021604,41:43:chronic_disease,Patients who do not have a diagnosis of HI,['Patients' 'who' 'do' 'not' 'have' 'a' 'diagnosis' 'of' 'HI'],[0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02021604,15:17:chronic_disease,Patients with HI attending the Cook Children's Congenital Hyperinsulinism Center and being treated by an Endocrinologist which may be the PI or a partner of this clinician,"['Patients' 'with' 'HI' 'attending' 'the' 'Cook' 'Children' ""'s""
 'Congenital' 'Hyperinsulinism' 'Center' 'and' 'being' 'treated' 'by' 'an'
 'Endocrinologist' 'which' 'may' 'be' 'the' 'PI' 'or' 'a' 'partner' 'of'
 'this' 'clinician']","[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02013778,"8:21:chronic_disease,",Active GI hemorrhage within 2 weeks of study enrollment,['Active' 'GI' 'hemorrhage' 'within' '2' 'weeks' 'of' 'study' 'enrollment'],[0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT01696734,"1:14:chronic_disease,",GI hemorrhage or obstruction experienced within the previous 6 weeks,"['GI' 'hemorrhage' 'or' 'obstruction' 'experienced' 'within' 'the'
 'previous' '6' 'weeks']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01996865,33:48:allergy_name,Known sensitivity or allergy to murine products,['Known' 'sensitivity' 'or' 'allergy' 'to' 'murine' 'products'],[0. 0. 0. 0. 0. 4. 4.]
NCT01959698,30:45:allergy_name,No known hypersensitivity to murine products,['No' 'known' 'hypersensitivity' 'to' 'murine' 'products'],[0. 0. 0. 0. 4. 4.]
NCT01969643,38:49:allergy_name,Combination Arm: hypersensitivity to trastuzumab,['Combination' 'Arm' ':' 'hypersensitivity' 'to' 'trastuzumab'],[0. 0. 0. 0. 0. 4.]
NCT01494662,14:25:treatment,Washout from trastuzumab,['Washout' 'from' 'trastuzumab'],[0. 0. 1.]
NCT01964261,1:24:chronic_disease,Intellectual impairment,['Intellectual' 'impairment'],[2. 2.]
NCT01581580,"1:24:chronic_disease,,",Intellectual impairment as determined by a score of less than 70 on the estimated General Ability Index (GAI),"['Intellectual' 'impairment' 'as' 'determined' 'by' 'a' 'score' 'of'
 'less' 'than' '70' 'on' 'the' 'estimated' 'General' 'Ability' 'Index' '('
 'GAI' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01954173,30:40:treatment,Patients treated with simple cystectomy with macroscopically negative margins are eligible for this study,"['Patients' 'treated' 'with' 'simple' 'cystectomy' 'with'
 'macroscopically' 'negative' 'margins' 'are' 'eligible' 'for' 'this'
 'study']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01730118,21:31:treatment,Status-post primary cystectomy with curative intent,['Status-post' 'primary' 'cystectomy' 'with' 'curative' 'intent'],[0. 0. 1. 0. 0. 0.]
NCT01928576,24:48:cancer,Patients with advanced malignant hepatic tumors,['Patients' 'with' 'advanced' 'malignant' 'hepatic' 'tumors'],[0. 0. 0. 3. 3. 3.]
NCT01333046,24:48:cancer,Patients with advanced malignant hepatic tumors,['Patients' 'with' 'advanced' 'malignant' 'hepatic' 'tumors'],[0. 0. 0. 3. 3. 3.]
NCT01897259,27:39:chronic_disease,conservative treatment of tennis elbow is recommended as standard of care treatment,"['conservative' 'treatment' 'of' 'tennis' 'elbow' 'is' 'recommended' 'as'
 'standard' 'of' 'care' 'treatment']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT01897259,",133:145:chronic_disease","treatment by a health care profession (MD, physicians assistnat, therapist, or nurse practitioner) within the previous 6 months for tennis elbow","['treatment' 'by' 'a' 'health' 'care' 'profession' '(' 'MD' ','
 'physicians' 'assistnat' ',' 'therapist' ',' 'or' 'nurse' 'practitioner'
 ')' 'within' 'the' 'previous' '6' 'months' 'for' 'tennis' 'elbow']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 2.]"
NCT01878617,",,,,214:233:cancer","Age greater than or equal to 3 years and less than 22 years of age at the time of diagnosis (may enroll on Strata W, S or N), OR (2) age is greater than or equal to 22 years and less than 40 years AND patient has SHH medulloblastoma (must enroll on Stratum S)","['Age' 'greater' 'than' 'or' 'equal' 'to' '3' 'years' 'and' 'less' 'than'
 '22' 'years' 'of' 'age' 'at' 'the' 'time' 'of' 'diagnosis' '(' 'may'
 'enroll' 'on' 'Strata' 'W' ',' 'S' 'or' 'N' ')' ',' 'OR' '(' '2' ')'
 'age' 'is' 'greater' 'than' 'or' 'equal' 'to' '22' 'years' 'and' 'less'
 'than' '40' 'years' 'AND' 'patient' 'has' 'SHH' 'medulloblastoma' '('
 'must' 'enroll' 'on' 'Stratum' 'S' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.]"
NCT01878617,",,,,141:160:cancer",≥5 years at the time of remediation intervention consent or age is greater than or equal to 22 years and less than 40 years and patient has SHH medulloblastoma,"['≥5' 'years' 'at' 'the' 'time' 'of' 'remediation' 'intervention'
 'consent' 'or' 'age' 'is' 'greater' 'than' 'or' 'equal' 'to' '22' 'years'
 'and' 'less' 'than' '40' 'years' 'and' 'patient' 'has' 'SHH'
 'medulloblastoma']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 3. 3.]"
NCT01865162,16:44:treatment,≥ weeks from a non-nitrosourea chemotherapy (all [a-c] in order to allow recovery from the potential of severe toxicity related to these treatments),"['≥' 'weeks' 'from' 'a' 'non-nitrosourea' 'chemotherapy' '(' 'all' '['
 'a-c' ']' 'in' 'order' 'to' 'allow' 'recovery' 'from' 'the' 'potential'
 'of' 'severe' 'toxicity' 'related' 'to' 'these' 'treatments' ')']","[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01849146,",16:44:treatment",3 weeks from a non-nitrosourea chemotherapy,['3' 'weeks' 'from' 'a' 'non-nitrosourea' 'chemotherapy'],[0. 0. 0. 0. 1. 1.]
NCT01823198,1:31:cancer,Chronic myeloid leukemia (CML),['Chronic' 'myeloid' 'leukemia' '(' 'CML' ')'],[3. 3. 3. 3. 0. 0.]
NCT01619761,1:31:cancer,Chronic myeloid leukemia (CML) second chronic phase or accelerated phase,"['Chronic' 'myeloid' 'leukemia' '(' 'CML' ')' 'second' 'chronic' 'phase'
 'or' 'accelerated' 'phase']",[3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01804634,5:8:chronic_disease,"For CMV seronegative recipients, a CMV seronegative donor","['For' 'CMV' 'seronegative' 'recipients' ',' 'a' 'CMV' 'seronegative'
 'donor']",[0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT00919503,290:293:chronic_disease,DONOR: Unrelated Umbilical Cord Blood: Any cord blood units that have not passed donor screening for infectious disease markers as recommended by NMDP will not be used unless a waiver is signed by the clinical attending allowing use of cord blood unit; cord blood units are presumed to be CMV negative regardless of serologic testing due to passive transmission of maternal CMV antibodies,"['DONOR' ':' 'Unrelated' 'Umbilical' 'Cord' 'Blood' ':' 'Any' 'cord'
 'blood' 'units' 'that' 'have' 'not' 'passed' 'donor' 'screening' 'for'
 'infectious' 'disease' 'markers' 'as' 'recommended' 'by' 'NMDP' 'will'
 'not' 'be' 'used' 'unless' 'a' 'waiver' 'is' 'signed' 'by' 'the'
 'clinical' 'attending' 'allowing' 'use' 'of' 'cord' 'blood' 'unit' ';'
 'cord' 'blood' 'units' 'are' 'presumed' 'to' 'be' 'CMV' 'negative'
 'regardless' 'of' 'serologic' 'testing' 'due' 'to' 'passive'
 'transmission' 'of' 'maternal' 'CMV' 'antibodies']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01789333,15:24:chronic_disease,Patients with nystagmus or any other condition that is severe enough to prevent steady gaze during the treatment,"['Patients' 'with' 'nystagmus' 'or' 'any' 'other' 'condition' 'that' 'is'
 'severe' 'enough' 'to' 'prevent' 'steady' 'gaze' 'during' 'the'
 'treatment']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01115283,37:46:chronic_disease,"any ocular pathological conditions, nystagmus","['any' 'ocular' 'pathological' 'conditions' ',' 'nystagmus']",[0. 0. 0. 0. 0. 2.]
NCT01754857,27:38:allergy_name,Known hypersensitivity to thalidomide,['Known' 'hypersensitivity' 'to' 'thalidomide'],[0. 0. 0. 4.]
NCT01433965,27:38:allergy_name,Known hypersensitivity to thalidomide,['Known' 'hypersensitivity' 'to' 'thalidomide'],[0. 0. 0. 4.]
NCT01696734,18:29:allergy_name,Known allergy to domperidone,['Known' 'allergy' 'to' 'domperidone'],[0. 0. 0. 4.]
NCT01696734,",,84:95:treatment,",have a negative urine pregnancy test within 30 days of the first administration of domperidone and must either commit to continued abstinence from heterosexual intercourse or use an effective method of birth control during the course of the study),"['have' 'a' 'negative' 'urine' 'pregnancy' 'test' 'within' '30' 'days'
 'of' 'the' 'first' 'administration' 'of' 'domperidone' 'and' 'must'
 'either' 'commit' 'to' 'continued' 'abstinence' 'from' 'heterosexual'
 'intercourse' 'or' 'use' 'an' 'effective' 'method' 'of' 'birth' 'control'
 'during' 'the' 'course' 'of' 'the' 'study' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01659203,16:24:cancer,Other types of sarcomas,['Other' 'types' 'of' 'sarcomas'],[0. 0. 0. 3.]
NCT01449149,27:35:cancer,other soft tissue or bony sarcomas,['other' 'soft' 'tissue' 'or' 'bony' 'sarcomas'],[0. 0. 0. 0. 0. 3.]
NCT01625923,12:30:chronic_disease,History of hyperprolactinemia,['History' 'of' 'hyperprolactinemia'],[0. 0. 2.]
NCT00914823,",,20:38:chronic_disease",Men and women with hyperprolactinemia,['Men' 'and' 'women' 'with' 'hyperprolactinemia'],[0. 0. 0. 0. 2.]
NCT01568177,"7:26:chronic_disease,,",Prior non-cardiac illness with an estimated life expectancy < 4 years,"['Prior' 'non-cardiac' 'illness' 'with' 'an' 'estimated' 'life'
 'expectancy' '<' '4' 'years']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00573027,"7:26:chronic_disease,,",Prior non-cardiac illness with an estimated life expectancy <4 years,"['Prior' 'non-cardiac' 'illness' 'with' 'an' 'estimated' 'life'
 'expectancy' '<' '4' 'years']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01524536,43:55:chronic_disease,signs and/or symptoms attributable to the eosinophilia,['signs' 'and/or' 'symptoms' 'attributable' 'to' 'the' 'eosinophilia'],[0. 0. 0. 0. 0. 0. 2.]
NCT00044304,31:43:chronic_disease,no secondary etiology for the eosinophilia despite careful clinical evaluation,"['no' 'secondary' 'etiology' 'for' 'the' 'eosinophilia' 'despite'
 'careful' 'clinical' 'evaluation']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT01494662,53:83:chronic_disease,"In cohort 3, eligible patients must have measurable Central Nervous System disease","['In' 'cohort' '3' ',' 'eligible' 'patients' 'must' 'have' 'measurable'
 'Central' 'Nervous' 'System' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2.]
NCT01494662,53:83:chronic_disease,"In cohort 4, eligible patients must have measurable Central Nervous System disease","['In' 'cohort' '4' ',' 'eligible' 'patients' 'must' 'have' 'measurable'
 'Central' 'Nervous' 'System' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2.]
NCT01389024,",,51:68:treatment",Room air oxygen saturation <90% on the day of the MRI with sedation,"['Room' 'air' 'oxygen' 'saturation' '<' '90' '%' 'on' 'the' 'day' 'of'
 'the' 'MRI' 'with' 'sedation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT01389024,",,107:124:treatment",Room air oxygen saturation greater than or equal to 5% below the participant's baseline on the day of the MRI with sedation,"['Room' 'air' 'oxygen' 'saturation' 'greater' 'than' 'or' 'equal' 'to' '5'
 '%' 'below' 'the' 'participant' ""'s"" 'baseline' 'on' 'the' 'day' 'of'
 'the' 'MRI' 'with' 'sedation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT01042522,"1:31:chronic_disease,,",Neuropathy (sensory and motor) less than or equal to CTCAE grade 1,"['Neuropathy' '(' 'sensory' 'and' 'motor' ')' 'less' 'than' 'or' 'equal'
 'to' 'CTCAE' 'grade' '1']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00492778,"1:31:chronic_disease,,",Neuropathy (sensory and motor) =< CTCAE v 3.0 grade 1,"['Neuropathy' '(' 'sensory' 'and' 'motor' ')' '=' '<' 'CTCAE' 'v' '3.0'
 'grade' '1']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00501826,"13:15:chronic_disease,",patients in CR after =< 2 courses are also eligible,"['patients' 'in' 'CR' 'after' '=' '<' '2' 'courses' 'are' 'also'
 'eligible']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00357565,",20:22:treatment",>1 cycle to obtain CR,['>' '1' 'cycle' 'to' 'obtain' 'CR'],[0. 0. 0. 0. 0. 1.]
NCT00004317,14:38:chronic_disease,Asymptomatic congenital toxoplasmosis,['Asymptomatic' 'congenital' 'toxoplasmosis'],[0. 2. 2.]
NCT00004317,"14:38:chronic_disease,,",Infants with congenital toxoplasmosis Toxoplasma gondii confirmed prior to age 2.5 months,"['Infants' 'with' 'congenital' 'toxoplasmosis' 'Toxoplasma' 'gondii'
 'confirmed' 'prior' 'to' 'age' '2.5' 'months']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03188042,"1:21:chronic_disease,",Visual field defects present for at least 6 months,['Visual' 'field' 'defects' 'present' 'for' 'at' 'least' '6' 'months'],[2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT03187379,1:38:treatment,laparoscopic roux-en-y gastric bypass,['laparoscopic' 'roux-en-y' 'gastric' 'bypass'],[1. 1. 1. 1.]
NCT03187379,8:31:treatment,use of EEA stapler anastomosis,['use' 'of' 'EEA' 'stapler' 'anastomosis'],[0. 0. 1. 1. 1.]
NCT03186872,1:30:chronic_disease,Personality pathology or PTSD (captured from DSM-V cross cutting symptoms inventory already being used as part of routine care screening in this clinic),"['Personality' 'pathology' 'or' 'PTSD' '(' 'captured' 'from' 'DSM-V'
 'cross' 'cutting' 'symptoms' 'inventory' 'already' 'being' 'used' 'as'
 'part' 'of' 'routine' 'care' 'screening' 'in' 'this' 'clinic' ')']","[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT03185130,1:10:chronic_disease,Meningeal signs are present,['Meningeal' 'signs' 'are' 'present'],[2. 0. 0. 0.]
NCT03183102,12:40:chronic_disease,History of venous thromboembolic events,['History' 'of' 'venous' 'thromboembolic' 'events'],[0. 0. 2. 2. 2.]
NCT03182907,"17:44:treatment,",Has received an investigational study agent within the previous 30 days,"['Has' 'received' 'an' 'investigational' 'study' 'agent' 'within' 'the'
 'previous' '30' 'days']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT03182075,1:34:chronic_disease,psychiatric or medical conditions that make participation unsafe,"['psychiatric' 'or' 'medical' 'conditions' 'that' 'make' 'participation'
 'unsafe']",[2. 2. 2. 2. 0. 0. 0. 0.]
NCT03181516,1:12:treatment,Amoxicillin,['Amoxicillin'],[1.]
NCT03181516,1:10:treatment,Cefoxitin,['Cefoxitin'],[1.]
NCT03181516,1:13:treatment,Erythromycin,['Erythromycin'],[1.]
NCT03181516,1:13:allergy_name,Milk-protein allergy,['Milk-protein' 'allergy'],[4. 0.]
NCT03181516,1:21:treatment,Velosef (cephradine),['Velosef' '(' 'cephradine' ')'],[1. 1. 0. 0.]
NCT03181126,"1:16:treatment,",Steroid therapy for anti-neoplastic intent within 5 days,['Steroid' 'therapy' 'for' 'anti-neoplastic' 'intent' 'within' '5' 'days'],[1. 1. 0. 0. 0. 0. 0. 0.]
NCT03180086,",25:56:treatment",women with a history of breast enlargement or reduction,['women' 'with' 'a' 'history' 'of' 'breast' 'enlargement' 'or' 'reduction'],[0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT03179397,1:24:chronic_disease,Iris Neovascularization,['Iris' 'Neovascularization'],[2. 2.]
NCT03179397,10:28:treatment,Previous refractive surgery,['Previous' 'refractive' 'surgery'],[0. 1. 1.]
NCT03179163,22:72:allergy_name,contraindication for all three pharmacotherapy drugs used in this study,"['contraindication' 'for' 'all' 'three' 'pharmacotherapy' 'drugs' 'used'
 'in' 'this' 'study']",[0. 0. 4. 4. 4. 4. 4. 4. 4. 4.]
NCT03176784,7:29:treatment,using Chantix or varenicline and not willing to stop for duration of the study,"['using' 'Chantix' 'or' 'varenicline' 'and' 'not' 'willing' 'to' 'stop'
 'for' 'duration' 'of' 'the' 'study']",[0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03175978,"1:35:treatment,",prior use of systemic methotrexate > 1 month prior to study entry is allowed,"['prior' 'use' 'of' 'systemic' 'methotrexate' '>' '1' 'month' 'prior' 'to'
 'study' 'entry' 'is' 'allowed']",[1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03171493,26:41:cancer,History of or concurrent non-invasive UC involving a portion of urinary tract outside of the bladder,"['History' 'of' 'or' 'concurrent' 'non-invasive' 'UC' 'involving' 'a'
 'portion' 'of' 'urinary' 'tract' 'outside' 'of' 'the' 'bladder']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03171168,"20:45:treatment,",Patient started on lipid lowering medication in last 3 months,"['Patient' 'started' 'on' 'lipid' 'lowering' 'medication' 'in' 'last' '3'
 'months']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0.]
NCT03170518,"1:20:chronic_disease,",Severe hypoglycemia within 6 months prior to Day 1,['Severe' 'hypoglycemia' 'within' '6' 'months' 'prior' 'to' 'Day' '1'],[2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT03170453,1:31:chronic_disease,disruptive or violent behavior,['disruptive' 'or' 'violent' 'behavior'],[2. 2. 2. 2.]
NCT03170375,1:31:chronic_disease,severely uncontrolled diabetes,['severely' 'uncontrolled' 'diabetes'],[2. 2. 2.]
NCT03169881,1:30:chronic_disease,Congenital thrombotic disease,['Congenital' 'thrombotic' 'disease'],[2. 2. 2.]
NCT03168776,26:70:treatment,Current participation in another investigational drug or device study,"['Current' 'participation' 'in' 'another' 'investigational' 'drug' 'or'
 'device' 'study']",[0. 0. 0. 1. 1. 1. 1. 1. 1.]
NCT03168776,22:64:treatment,contraindications to anti-platelet and/or anticoagulant therapy,"['contraindications' 'to' 'anti-platelet' 'and/or' 'anticoagulant'
 'therapy']",[0. 0. 1. 1. 1. 1.]
NCT03168347,40:59:treatment,Currently or previously managed with a biologic medication,"['Currently' 'or' 'previously' 'managed' 'with' 'a' 'biologic'
 'medication']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT03166371,"1:22:chronic_disease,,,,,,",Acute hepatic failure during current hospitalization with total serum bilirubin > 3.5 mg/dL or transaminase values [alanine transaminase (ALT) and/or aspartate transaminase (AST) values > 3-fold the upper limit of normal range],"['Acute' 'hepatic' 'failure' 'during' 'current' 'hospitalization' 'with'
 'total' 'serum' 'bilirubin' '>' '3.5' 'mg/dL' 'or' 'transaminase'
 'values' '[' 'alanine' 'transaminase' '(' 'ALT' ')' 'and/or' 'aspartate'
 'transaminase' '(' 'AST' ')' 'values' '>' '3-fold' 'the' 'upper' 'limit'
 'of' 'normal' 'range' ']']","[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03163901,14:53:chronic_disease,Diagnosis of mild to moderate traumatic brain injury,['Diagnosis' 'of' 'mild' 'to' 'moderate' 'traumatic' 'brain' 'injury'],[0. 0. 2. 2. 2. 2. 2. 2.]
NCT03160547,1:11:chronic_disease,Sarcopenia,['Sarcopenia'],[2.]
NCT03159936,"1:23:treatment,",Topical corticosteroid within the past 2 weeks,['Topical' 'corticosteroid' 'within' 'the' 'past' '2' 'weeks'],[1. 1. 0. 0. 0. 0. 0.]
NCT03159754,16:26:treatment,Patient taking tizanidine,['Patient' 'taking' 'tizanidine'],[0. 0. 1.]
NCT03158974,1:16:treatment,Cytotoxic drugs,['Cytotoxic' 'drugs'],[1. 1.]
NCT03158974,1:35:treatment,Oral or parenteral corticosteroids,['Oral' 'or' 'parenteral' 'corticosteroids'],[1. 1. 1. 1.]
NCT03157492,",45:47:treatment",Greater than three years post-activation of CI,['Greater' 'than' 'three' 'years' 'post-activation' 'of' 'CI'],[0. 0. 0. 0. 0. 0. 1.]
NCT03154580,1:17:chronic_disease,Major depression that is not substance-induced),['Major' 'depression' 'that' 'is' 'not' 'substance-induced' ')'],[2. 2. 0. 0. 0. 0. 0.]
NCT03154476,1:25:chronic_disease,Severe renal dysfunction,['Severe' 'renal' 'dysfunction'],[2. 2. 2.]
NCT03153969,"1:17:chronic_disease,",Cervical lesions must provide for a minimum of 1mm thickness of restorative material while maintaining natural tooth contour,"['Cervical' 'lesions' 'must' 'provide' 'for' 'a' 'minimum' 'of' '1mm'
 'thickness' 'of' 'restorative' 'material' 'while' 'maintaining' 'natural'
 'tooth' 'contour']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03153969,12:32:chronic_disease,Teeth with periapical pathology,['Teeth' 'with' 'periapical' 'pathology'],[0. 0. 2. 2.]
NCT03153319,1:22:chronic_disease,Hepatitis B infection (active or chronic carrier),['Hepatitis' 'B' 'infection' '(' 'active' 'or' 'chronic' 'carrier' ')'],[2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT03152409,10:30:chronic_disease,Comorbid autoimmune condition,['Comorbid' 'autoimmune' 'condition'],[0. 2. 2.]
NCT03152058,"1:26:chronic_disease,",Type 1 or Type 2 diabetes antedating pregnancy,['Type' '1' 'or' 'Type' '2' 'diabetes' 'antedating' 'pregnancy'],[2. 2. 2. 2. 2. 2. 0. 0.]
NCT03151330,"27:45:treatment,",The subject has a planned cerclage placement for the current pregnancy,"['The' 'subject' 'has' 'a' 'planned' 'cerclage' 'placement' 'for' 'the'
 'current' 'pregnancy']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT03150004,70:117:treatment,"In first or subsequent relapse or refractory status, with or without prior hematopoietic stem cell transplant (HSCT)","['In' 'first' 'or' 'subsequent' 'relapse' 'or' 'refractory' 'status' ','
 'with' 'or' 'without' 'prior' 'hematopoietic' 'stem' 'cell' 'transplant'
 '(' 'HSCT' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0.]
NCT03149783,7:30:treatment,other sodium channel blockers,['other' 'sodium' 'channel' 'blockers'],[0. 1. 1. 1.]
NCT03149549,21:58:treatment,Currently receiving anticoagulation therapy with warfarin,['Currently' 'receiving' 'anticoagulation' 'therapy' 'with' 'warfarin'],[0. 0. 1. 1. 1. 1.]
NCT03148795,36:50:chronic_disease,Patients must have measurable soft tissue disease per RECIST 1.1,"['Patients' 'must' 'have' 'measurable' 'soft' 'tissue' 'disease' 'per'
 'RECIST' '1.1']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0.]
NCT03148379,72:101:treatment,retained hardware in the knee that requires removal or interferes with Total Knee Arthroplasty (TKA) procedure,"['retained' 'hardware' 'in' 'the' 'knee' 'that' 'requires' 'removal' 'or'
 'interferes' 'with' 'Total' 'Knee' 'Arthroplasty' '(' 'TKA' ')'
 'procedure']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0.]
NCT03146663,",23:61:treatment",Received fewer than 3 prior chemotherapy-containing regimens,"['Received' 'fewer' 'than' '3' 'prior' 'chemotherapy-containing'
 'regimens']",[0. 0. 0. 0. 1. 1. 1.]
NCT03145298,"25:47:treatment,,",The subjects must be on PAH-specific therapies for at least 4 months and on a stable dose for at least 4 weeks prior to enrollment into study,"['The' 'subjects' 'must' 'be' 'on' 'PAH-specific' 'therapies' 'for' 'at'
 'least' '4' 'months' 'and' 'on' 'a' 'stable' 'dose' 'for' 'at' 'least'
 '4' 'weeks' 'prior' 'to' 'enrollment' 'into' 'study']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT03144921,47:59:chronic_disease,Exhibit changes in memory as specified on the AD8 dementia screening tool,"['Exhibit' 'changes' 'in' 'memory' 'as' 'specified' 'on' 'the' 'AD8'
 'dementia' 'screening' 'tool']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0.]
NCT03144206,10:42:treatment,Plan for post operative radiation therapy,['Plan' 'for' 'post' 'operative' 'radiation' 'therapy'],[0. 0. 1. 1. 1. 1.]
NCT03143153,11:28:cancer,"Must have esophageal cancer that cannot be operated on, or treated with definitive chemoradiation with curative intent, that is advanced, reoccurring or has spread out","['Must' 'have' 'esophageal' 'cancer' 'that' 'can' 'not' 'be' 'operated'
 'on' ',' 'or' 'treated' 'with' 'definitive' 'chemoradiation' 'with'
 'curative' 'intent' ',' 'that' 'is' 'advanced' ',' 'reoccurring' 'or'
 'has' 'spread' 'out']","[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT03140527,"1:24:chronic_disease,,,","Abnormal liver function as defined by aspartate aminotransferase (AST), alanine aminotransferase (ALT) or bilirubin > upper limit of the normal range","['Abnormal' 'liver' 'function' 'as' 'defined' 'by' 'aspartate'
 'aminotransferase' '(' 'AST' ')' ',' 'alanine' 'aminotransferase' '('
 'ALT' ')' 'or' 'bilirubin' '>' 'upper' 'limit' 'of' 'the' 'normal'
 'range']","[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT03139227,"20:68:treatment,",Chronic use of any herbal or dietary supplement containing apigenin within the 3 months prior to entry on the study,"['Chronic' 'use' 'of' 'any' 'herbal' 'or' 'dietary' 'supplement'
 'containing' 'apigenin' 'within' 'the' '3' 'months' 'prior' 'to' 'entry'
 'on' 'the' 'study']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03138733,"1:39:chronic_disease,,","Staphylococcus aureus bacteremia (SAB), based on at least one positive blood culture obtained within the 72 h prior to randomization","['Staphylococcus' 'aureus' 'bacteremia' '(' 'SAB' ')' ',' 'based' 'on'
 'at' 'least' 'one' 'positive' 'blood' 'culture' 'obtained' 'within' 'the'
 '72' 'h' 'prior' 'to' 'randomization']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03137771,1:21:cancer,Cutaneous metastasis of NSCLC,['Cutaneous' 'metastasis' 'of' 'NSCLC'],[3. 3. 0. 0.]
NCT03137459,1:25:chronic_disease,"Severe visual impairment, defined as being unable to read large-print materials","['Severe' 'visual' 'impairment' ',' 'defined' 'as' 'being' 'unable' 'to'
 'read' 'large-print' 'materials']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03137173,"12:44:treatment,",Use of any systemic antibacterial treatment within 14 days,"['Use' 'of' 'any' 'systemic' 'antibacterial' 'treatment' 'within' '14'
 'days']",[0. 0. 0. 1. 1. 1. 0. 0. 0.]
NCT03136029,1:28:chronic_disease,Peripheral Vascular Disease,['Peripheral' 'Vascular' 'Disease'],[2. 2. 2.]
NCT03135990,9:45:chronic_disease,Current substance use disorder or dependence as primary diagnosis,"['Current' 'substance' 'use' 'disorder' 'or' 'dependence' 'as' 'primary'
 'diagnosis']",[0. 2. 2. 2. 2. 2. 0. 0. 0.]
NCT03134274,6:21:chronic_disease,Have impaired vision that prevents them from reading instructions,"['Have' 'impaired' 'vision' 'that' 'prevents' 'them' 'from' 'reading'
 'instructions']",[0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT03133793,1:28:chronic_disease,Severe cognitive impairment,['Severe' 'cognitive' 'impairment'],[2. 2. 2.]
NCT03132636,1:33:treatment,Immunosuppressive corticosteroid doses,['Immunosuppressive' 'corticosteroid' 'doses'],[1. 1. 0.]
NCT03131960,13:25:chronic_disease,Significant sensory loss,['Significant' 'sensory' 'loss'],[0. 2. 2.]
NCT03130907,15:30:chronic_disease,Patients with solitary kidney,['Patients' 'with' 'solitary' 'kidney'],[0. 0. 2. 2.]
NCT03129880,16:41:chronic_disease,Diagnosed with benign vocal fold lesions and/or hyper-function,"['Diagnosed' 'with' 'benign' 'vocal' 'fold' 'lesions' 'and/or'
 'hyper-function']",[0. 0. 2. 2. 2. 2. 0. 0.]
NCT03129542,1:23:chronic_disease,ischemic bowel disease,['ischemic' 'bowel' 'disease'],[2. 2. 2.]
NCT03128008,39:73:cancer,Histologic/cytologic documentation of non-small cell lung cancer (NSCLC),"['Histologic/cytologic' 'documentation' 'of' 'non-small' 'cell' 'lung'
 'cancer' '(' 'NSCLC' ')']",[0. 0. 0. 3. 3. 3. 3. 3. 0. 0.]
NCT03127722,36:65:treatment,Subjects who have had an attempted prior sterilization procedure,"['Subjects' 'who' 'have' 'had' 'an' 'attempted' 'prior' 'sterilization'
 'procedure']",[0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT03125902,"34:57:chronic_disease,",previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for at least 2 weeks prior to randomization,"['previously' 'diagnosed' 'and' 'treated' 'spinal' 'cord' 'compression'
 'without' 'evidence' 'that' 'disease' 'has' 'been' 'clinically' 'stable'
 'for' 'at' 'least' '2' 'weeks' 'prior' 'to' 'randomization']",[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03125226,1:17:treatment,Prior cystectomy,['Prior' 'cystectomy'],[1. 1.]
NCT03123068,1:19:chronic_disease,Infectious disease within the last month,['Infectious' 'disease' 'within' 'the' 'last' 'month'],[2. 2. 0. 0. 0. 0.]
NCT03122912,12:19:chronic_disease,History of keloids,['History' 'of' 'keloids'],[0. 0. 2.]
NCT03122145,24:30:allergy_name,Anyone with allergy to barium,['Anyone' 'with' 'allergy' 'to' 'barium'],[0. 0. 0. 0. 4.]
NCT03121586,1:11:treatment,Lurasidone,['Lurasidone'],[1.]
NCT03121352,35:56:treatment,Patients who have participated in MK-3475 Merck studies,['Patients' 'who' 'have' 'participated' 'in' 'MK-3475' 'Merck' 'studies'],[0. 0. 0. 0. 0. 1. 1. 1.]
NCT03120728,",55:68:treatment,,,,,,","Use of a non-hormonal form of contraception, such as: sterilization (tubal ligation, Essure), copper IUD (intrauterine device), barrier methods or abstinence","['Use' 'of' 'a' 'non-hormonal' 'form' 'of' 'contraception' ',' 'such' 'as'
 ':' 'sterilization' '(' 'tubal' 'ligation' ',' 'Essure' ')' ',' 'copper'
 'IUD' '(' 'intrauterine' 'device' ')' ',' 'barrier' 'methods' 'or'
 'abstinence']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT03120728,12:37:chronic_disease,history of peripartum cardiomyopathy,['history' 'of' 'peripartum' 'cardiomyopathy'],[0. 0. 2. 2.]
NCT03120585,56:76:treatment,Those neonates who are intubated for administration of exogenous surfactant but who are immediately extubated to non-invasive respiratory support after surfactant administration will remain eligible for study inclusion,"['Those' 'neonates' 'who' 'are' 'intubated' 'for' 'administration' 'of'
 'exogenous' 'surfactant' 'but' 'who' 'are' 'immediately' 'extubated' 'to'
 'non-invasive' 'respiratory' 'support' 'after' 'surfactant'
 'administration' 'will' 'remain' 'eligible' 'for' 'study' 'inclusion']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT03119363,"1:17:cancer,",Secondary cancer diagnosis (prior or current) within the past 5 years,"['Secondary' 'cancer' 'diagnosis' '(' 'prior' 'or' 'current' ')' 'within'
 'the' 'past' '5' 'years']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03117751,",34:60:cancer",LLy participants must have < 25% tumor cells in bone marrow and peripheral blood by morphology and flow cytometry,"['LLy' 'participants' 'must' 'have' '<' '25' '%' 'tumor' 'cells' 'in'
 'bone' 'marrow' 'and' 'peripheral' 'blood' 'by' 'morphology' 'and' 'flow'
 'cytometry']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03116997,7:20:chronic_disease,Known liver Disease,['Known' 'liver' 'Disease'],[0. 2. 2.]
NCT03116464,1:20:chronic_disease,Caregiver psychosis,['Caregiver' 'psychosis'],[2. 2.]
NCT03115359,1:29:treatment,Cognitive Behavioral Therapy training,['Cognitive' 'Behavioral' 'Therapy' 'training'],[1. 1. 1. 0.]
NCT03114501,26:29:cancer,Diagnosed with a primary HNC,['Diagnosed' 'with' 'a' 'primary' 'HNC'],[0. 0. 0. 0. 3.]
NCT03114020,"1:43:chronic_disease,",Upper or lower respiratory tract infection within 2 weeks prior to screening and baseline (day1),"['Upper' 'or' 'lower' 'respiratory' 'tract' 'infection' 'within' '2'
 'weeks' 'prior' 'to' 'screening' 'and' 'baseline' '(' 'day1' ')']",[2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03113825,"10:39:treatment,",Received systemic investigational drug within 6 weeks prior to AVB-620 administration or has received AVB-620 previously,"['Received' 'systemic' 'investigational' 'drug' 'within' '6' 'weeks'
 'prior' 'to' 'AVB-620' 'administration' 'or' 'has' 'received' 'AVB-620'
 'previously']",[0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03113760,33:54:treatment,Patients with genetic diagnosis of NLRC4-MAS mutation,['Patients' 'with' 'genetic' 'diagnosis' 'of' 'NLRC4-MAS' 'mutation'],[0. 0. 0. 0. 1. 1. 1.]
NCT03113695,",,,,,166:175:treatment",Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test within 10 - 14 days prior to and again within 24 hours prior to starting REVLIMID®,"['Females' 'of' 'childbearing' 'potential' '(' 'FCBP' ')' 'must' 'have'
 'a' 'negative' 'serum' 'or' 'urine' 'pregnancy' 'test' 'within' '10' '-'
 '14' 'days' 'prior' 'to' 'and' 'again' 'within' '24' 'hours' 'prior' 'to'
 'starting' 'REVLIMID®']","[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
 1. 1. 1. 1. 1. 1. 1. 1.]"
NCT03113695,1:31:chronic_disease,fungal infections of nail beds,['fungal' 'infections' 'of' 'nail' 'beds'],[2. 2. 2. 2. 2.]
NCT03112902,1:49:chronic_disease,rapid eye movement (REM)-sleep behavior disorder,['rapid' 'eye' 'movement' '(' 'REM' ')' '-sleep' 'behavior' 'disorder'],[2. 2. 2. 2. 2. 2. 0. 0. 0.]
NCT03112824,1:7:treatment,SSRI's,"['SSRI' ""'s""]",[1. 1.]
NCT03112720,37:52:treatment,Subjects already being treated with lidocaine patch or other vehicle for chronic pain,"['Subjects' 'already' 'being' 'treated' 'with' 'lidocaine' 'patch' 'or'
 'other' 'vehicle' 'for' 'chronic' 'pain']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT03112603,1:13:chronic_disease,Severe cGvHD,['Severe' 'cGvHD'],[2. 2.]
NCT03111121,1:18:treatment,Microlaryngoscopy,['Microlaryngoscopy'],[1.]
NCT03109210,"11:29:treatment,",change in thyroid medication dosage or received a new prescription for thyroid medication 3 months before the screening visit,"['change' 'in' 'thyroid' 'medication' 'dosage' 'or' 'received' 'a' 'new'
 'prescription' 'for' 'thyroid' 'medication' '3' 'months' 'before' 'the'
 'screening' 'visit']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03108820,9:21:chronic_disease,have an acute stroke upon admission,['have' 'an' 'acute' 'stroke' 'upon' 'admission'],[0. 0. 2. 2. 0. 0.]
NCT03107546,1:74:treatment,Previous surgery on the web that requires a subsequent syndactyly release,"['Previous' 'surgery' 'on' 'the' 'web' 'that' 'requires' 'a' 'subsequent'
 'syndactyly' 'release']",[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT03106740,13:27:treatment,on a stable pain treatment,['on' 'a' 'stable' 'pain' 'treatment'],[0. 0. 0. 1. 1.]
NCT03105362,8:21:treatment,Stable GI medication regime,['Stable' 'GI' 'medication' 'regime'],[0. 1. 1. 0.]
NCT03105362,1:30:chronic_disease,microvillus inclusion disease,['microvillus' 'inclusion' 'disease'],[2. 2. 2.]
NCT03104699,1:56:cancer,Efficacy Expansion Cohort (Second-Line Cervical Cancer),['Efficacy' 'Expansion' 'Cohort' '(' 'Second-Line' 'Cervical' 'Cancer' ')'],[3. 3. 3. 3. 3. 3. 0. 0.]
NCT03104699,"1:34:chronic_disease,",cerebral vascular accident/stroke (<6 months before enrollment),"['cerebral' 'vascular' 'accident/stroke' '(' '<' '6' 'months' 'before'
 'enrollment' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT03104699,1:35:cancer,minimal deviation/adenoma malignum,['minimal' 'deviation/adenoma' 'malignum'],[3. 3. 3.]
NCT03104517,12:56:cancer,"History of cancer in pelvic organs, ureters, or kidneys","['History' 'of' 'cancer' 'in' 'pelvic' 'organs' ',' 'ureters' ',' 'or'
 'kidneys']",[0. 0. 3. 3. 3. 3. 3. 3. 3. 0. 0.]
NCT03103646,40:50:treatment,Subject has previously been dosed with Lu AF35700,['Subject' 'has' 'previously' 'been' 'dosed' 'with' 'Lu' 'AF35700'],[0. 0. 0. 0. 0. 0. 1. 1.]
NCT03101956,"1:13:treatment,",Knee surgery on the affected knee within the last 6 months,"['Knee' 'surgery' 'on' 'the' 'affected' 'knee' 'within' 'the' 'last' '6'
 'months']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03101956,1:13:chronic_disease,Osteoporosis or recent fracture of the hip or spinal joints,"['Osteoporosis' 'or' 'recent' 'fracture' 'of' 'the' 'hip' 'or' 'spinal'
 'joints']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03100539,"26:41:treatment,",Any massage professional massage therapy within the last 6 months,"['Any' 'massage' 'professional' 'massage' 'therapy' 'within' 'the' 'last'
 '6' 'months']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT03100461,"1:12:treatment,",Colonoscopy within 10 years,['Colonoscopy' 'within' '10' 'years'],[1. 0. 0. 0.]
NCT03100370,26:49:treatment,No planned alteration in upper-extremity therapy or medication for muscle tone during the course of the study,"['No' 'planned' 'alteration' 'in' 'upper-extremity' 'therapy' 'or'
 'medication' 'for' 'muscle' 'tone' 'during' 'the' 'course' 'of' 'the'
 'study']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03098082,1:27:chronic_disease,Stage 3 or 4 renal disease and/or oliguria,['Stage' '3' 'or' '4' 'renal' 'disease' 'and/or' 'oliguria'],[2. 2. 2. 2. 2. 2. 0. 0.]
NCT03096886,1:39:treatment,Centrally acting antiadrenergic agents,['Centrally' 'acting' 'antiadrenergic' 'agents'],[1. 1. 1. 1.]
NCT03096366,1:110:treatment,Anterior cruciate ligament (ACL) reconstruction with concomitant meniscus or cartilage restoration procedures,"['Anterior' 'cruciate' 'ligament' '(' 'ACL' ')' 'reconstruction' 'with'
 'concomitant' 'meniscus' 'or' 'cartilage' 'restoration' 'procedures']",[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0.]
NCT03096288,"4:82:treatment,","On therapy with clopidogrel (75mg od), with or without low-dose aspirin (81mg od), as per standard-of-care for at least 30 days","['On' 'therapy' 'with' 'clopidogrel' '(' '75mg' 'od' ')' ',' 'with' 'or'
 'without' 'low-dose' 'aspirin' '(' '81mg' 'od' ')' ',' 'as' 'per'
 'standard-of-care' 'for' 'at' 'least' '30' 'days']","[0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT03096288,1:22:treatment,vitamin K antagonists,['vitamin' 'K' 'antagonists'],[1. 1. 1.]
NCT03093272,1:37:cancer,Castration-resistant prostate cancer,['Castration-resistant' 'prostate' 'cancer'],[3. 3. 3.]
NCT03092011,70:73:chronic_disease,Babies being started on medication to control withdrawal symptoms of NAS,"['Babies' 'being' 'started' 'on' 'medication' 'to' 'control' 'withdrawal'
 'symptoms' 'of' 'NAS']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT03090672,12:43:chronic_disease,History of severe traumatic brain injuries,['History' 'of' 'severe' 'traumatic' 'brain' 'injuries'],[0. 0. 2. 2. 2. 2.]
NCT03090607,21:84:chronic_disease,History of or known esophageal stricture or gross esophageal anatomic abnormalities,"['History' 'of' 'or' 'known' 'esophageal' 'stricture' 'or' 'gross'
 'esophageal' 'anatomic' 'abnormalities']",[0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 2.]
NCT03089905,38:67:chronic_disease,Existing diagnosis of behavioural or neurodevelopmental disability,"['Existing' 'diagnosis' 'of' 'behavioural' 'or' 'neurodevelopmental'
 'disability']",[0. 0. 0. 0. 0. 2. 2.]
NCT03089515,7:27:chronic_disease,Known prostate hyperplasia,['Known' 'prostate' 'hyperplasia'],[0. 2. 2.]
NCT03089515,1:25:chronic_disease,bladder-neck obstruction,['bladder-neck' 'obstruction'],[2. 2.]
NCT03088072,20:35:chronic_disease,Moderate or severe mitral stenosis,['Moderate' 'or' 'severe' 'mitral' 'stenosis'],[0. 0. 0. 2. 2.]
NCT03088033,1:32:treatment,treatment with intravenous (IV),['treatment' 'with' 'intravenous' '(' 'IV' ')'],[1. 1. 1. 1. 0. 0.]
NCT03086369,40:68:cancer,Have received first line treatment for metastatic pancreatic cancer,"['Have' 'received' 'first' 'line' 'treatment' 'for' 'metastatic'
 'pancreatic' 'cancer']",[0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT03085485,12:28:chronic_disease,Element of CFTR Dysfunction,['Element' 'of' 'CFTR' 'Dysfunction'],[0. 0. 2. 2.]
NCT03085433,",26:45:chronic_disease",Male partner with severe oligoasthenospermia,['Male' 'partner' 'with' 'severe' 'oligoasthenospermia'],[0. 0. 0. 0. 2.]
NCT03085095,1:20:cancer,Metastases to brain per prior clinical evaluation,['Metastases' 'to' 'brain' 'per' 'prior' 'clinical' 'evaluation'],[3. 3. 3. 0. 0. 0. 0.]
NCT03084640,44:89:cancer,Histopathologically confirmed diagnosis of metastatic or unresectable malignant melanoma,"['Histopathologically' 'confirmed' 'diagnosis' 'of' 'metastatic' 'or'
 'unresectable' 'malignant' 'melanoma']",[0. 0. 0. 0. 3. 3. 3. 3. 3.]
NCT03084640,34:57:treatment,"who have previously received any anti-PD-1/PD-L1 therapy, alone or in combination","['who' 'have' 'previously' 'received' 'any' 'anti-PD-1/PD-L1' 'therapy'
 ',' 'alone' 'or' 'in' 'combination']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT03081390,39:58:treatment,"Chronic use of medications, including oral contraceptives","['Chronic' 'use' 'of' 'medications' ',' 'including' 'oral'
 'contraceptives']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT03080142,33:51:treatment,Patients scheduled for elective colorectal surgery with Dr. Linda Farkas,"['Patients' 'scheduled' 'for' 'elective' 'colorectal' 'surgery' 'with'
 'Dr.' 'Linda' 'Farkas']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT03079297,6:31:chronic_disease,Have Maple Syrup Urine Disease,['Have' 'Maple' 'Syrup' 'Urine' 'Disease'],[0. 2. 2. 2. 2.]
NCT03078907,"20:59:treatment,",Participation in a cardio-pulmonary rehabilitation program based on exercise training within 8 weeks prior to screening,"['Participation' 'in' 'a' 'cardio-pulmonary' 'rehabilitation' 'program'
 'based' 'on' 'exercise' 'training' 'within' '8' 'weeks' 'prior' 'to'
 'screening']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03078530,15:38:chronic_disease,Veterans with psychological disorders will not be excluded but will be identified for sub-group analysis,"['Veterans' 'with' 'psychological' 'disorders' 'will' 'not' 'be'
 'excluded' 'but' 'will' 'be' 'identified' 'for' 'sub-group' 'analysis']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03078023,",,40:68:treatment",Esophageal minimal diameter < 13 mm on structured barium esophagram,"['Esophageal' 'minimal' 'diameter' '<' '13' 'mm' 'on' 'structured'
 'barium' 'esophagram']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT03077243,1:15:chronic_disease,Systemic lupus,['Systemic' 'lupus'],[2. 2.]
NCT03076658,22:35:treatment,without a history of spine surgery,['without' 'a' 'history' 'of' 'spine' 'surgery'],[0. 0. 0. 0. 1. 1.]
NCT03075306,92:99:chronic_disease,"Serious health condition precluding participation in weight management intervention (e.g., bulimia)","['Serious' 'health' 'condition' 'precluding' 'participation' 'in' 'weight'
 'management' 'intervention' '(' 'e.g.' ',' 'bulimia' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT03074240,",,39:62:treatment",Patients ≥ 18 years of age undergoing umbilical hernia repair,"['Patients' '≥' '18' 'years' 'of' 'age' 'undergoing' 'umbilical' 'hernia'
 'repair']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT03073785,62:70:cancer,Patients with inoperable conditions with resectable disease (T1-2NoMo),"['Patients' 'with' 'inoperable' 'conditions' 'with' 'resectable' 'disease'
 '(' 'T1-2NoMo' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 0.]
NCT03073343,",,52:74:treatment",2-hour plasma glucose level of > 200mg/dL during a glucose tolerance test,"['2-hour' 'plasma' 'glucose' 'level' 'of' '>' '200mg/dL' 'during' 'a'
 'glucose' 'tolerance' 'test']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT03073070,12:39:chronic_disease,history of gastrointestinal blood loss,['history' 'of' 'gastrointestinal' 'blood' 'loss'],[0. 0. 2. 2. 2.]
NCT03072238,12:36:chronic_disease,History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias,"['History' 'of' 'ventricular' 'dysrhythmias' 'or' 'risk' 'factors' 'for'
 'ventricular' 'dysrhythmias']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT03072238,12:31:chronic_disease,measurable soft tissue disease by computed tomography (CT),"['measurable' 'soft' 'tissue' 'disease' 'by' 'computed' 'tomography' '('
 'CT' ')']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT03071393,8:35:chronic_disease,"severe musculoskeletal impairments, open wounds, or skin lesions that would limit participation in functional assessments","['severe' 'musculoskeletal' 'impairments' ',' 'open' 'wounds' ',' 'or'
 'skin' 'lesions' 'that' 'would' 'limit' 'participation' 'in' 'functional'
 'assessments']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03070899,13:38:chronic_disease,Undiagnosed abnormal uterine bleeding,['Undiagnosed' 'abnormal' 'uterine' 'bleeding'],[0. 2. 2. 2.]
NCT03070145,1:19:chronic_disease,Moderate arthritis that does not preclude physical activity is not a reason for ineligibility,"['Moderate' 'arthritis' 'that' 'does' 'not' 'preclude' 'physical'
 'activity' 'is' 'not' 'a' 'reason' 'for' 'ineligibility']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03069469,1:51:cancer,Diffuse-type Tenosynovial Giant Cell Tumor (DTGCT) patients,"['Diffuse-type' 'Tenosynovial' 'Giant' 'Cell' 'Tumor' '(' 'DTGCT' ')'
 'patients']",[3. 3. 3. 3. 3. 3. 0. 0. 0.]
NCT03068780,1:20:chronic_disease,junctional EB (JEB),['junctional' 'EB' '(' 'JEB' ')'],[2. 2. 2. 0. 0.]
NCT03067818,1:31:chronic_disease,Brainstem or cerebellar stroke,['Brainstem' 'or' 'cerebellar' 'stroke'],[2. 2. 2. 2.]
NCT03065972,26:47:chronic_disease,Diagnosed with End-stage Renal Disease stage 4,['Diagnosed' 'with' 'End-stage' 'Renal' 'Disease' 'stage' '4'],[0. 0. 0. 2. 2. 2. 2.]
NCT03065465,"7:24:chronic_disease,,",Acute hypovolemic shock that is unresponsive to transfusion of 5 or more units of red blood cells (RBC's),"['Acute' 'hypovolemic' 'shock' 'that' 'is' 'unresponsive' 'to'
 'transfusion' 'of' '5' 'or' 'more' 'units' 'of' 'red' 'blood' 'cells' '('
 'RBC' ""'s"" ')']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03065465,1:18:chronic_disease,anastomotic ulcer,['anastomotic' 'ulcer'],[2. 2.]
NCT03062462,14:52:chronic_disease,Diagnosed as respiratory or circulatory instability,['Diagnosed' 'as' 'respiratory' 'or' 'circulatory' 'instability'],[0. 0. 2. 2. 2. 2.]
NCT03062111,1:19:chronic_disease,Neurogenic bladder,['Neurogenic' 'bladder'],[2. 2.]
NCT03061201,"1:20:chronic_disease,,",Severe hemophilia A (past evidence of circulating FVIII activity of < 1% normal),"['Severe' 'hemophilia' 'A' '(' 'past' 'evidence' 'of' 'circulating'
 'FVIII' 'activity' 'of' '<' '1' '%' 'normal' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03060772,12:34:chronic_disease,History of cirrhosis of the liver,['History' 'of' 'cirrhosis' 'of' 'the' 'liver'],[0. 0. 2. 2. 2. 2.]
NCT03060473,61:71:allergy_name,Contraindication to any of the antibiotics used (allergy to macrolides),"['Contraindication' 'to' 'any' 'of' 'the' 'antibiotics' 'used' '('
 'allergy' 'to' 'macrolides' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0.]
NCT03059888,48:60:treatment,History of inadequate response to conventional MG treatment,"['History' 'of' 'inadequate' 'response' 'to' 'conventional' 'MG'
 'treatment']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT03059407,39:54:chronic_disease,or concern for immune system function/infectious risk that could be worsened by animal exposure,"['or' 'concern' 'for' 'immune' 'system' 'function/infectious' 'risk'
 'that' 'could' 'be' 'worsened' 'by' 'animal' 'exposure']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT03059030,22:33:treatment,"Contraindications to angiography and selective visceral catheterization such as bleeding, diathesis or coagulopathy that is not correctable by usual therapy or hemostatic agents (e.g. closure device)","['Contraindications' 'to' 'angiography' 'and' 'selective' 'visceral'
 'catheterization' 'such' 'as' 'bleeding' ',' 'diathesis' 'or'
 'coagulopathy' 'that' 'is' 'not' 'correctable' 'by' 'usual' 'therapy'
 'or' 'hemostatic' 'agents' '(' 'e.g' '.' 'closure' 'device' ')']","[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT03059004,13:27:chronic_disease,Evidence of osteoarthritic changes on imaging,['Evidence' 'of' 'osteoarthritic' 'changes' 'on' 'imaging'],[0. 0. 2. 0. 0. 0.]
NCT03058952,1:32:chronic_disease,antisocial personality disorder,['antisocial' 'personality' 'disorder'],[2. 2. 2.]
NCT03058783,"1:20:cancer,",carcinoma of cervix effectively treated more than 5 years ago,"['carcinoma' 'of' 'cervix' 'effectively' 'treated' 'more' 'than' '5'
 'years' 'ago']",[3. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT03058029,12:41:treatment,History of abdominal radiation treatment,['History' 'of' 'abdominal' 'radiation' 'treatment'],[0. 0. 1. 1. 1.]
NCT03057730,47:68:treatment,Healthy subjects with no contraindications to root coverage surgery,"['Healthy' 'subjects' 'with' 'no' 'contraindications' 'to' 'root'
 'coverage' 'surgery']",[0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT03056287,1:17:chronic_disease,Severe arthritis or other problems that limit passive range of motion,"['Severe' 'arthritis' 'or' 'other' 'problems' 'that' 'limit' 'passive'
 'range' 'of' 'motion']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03055377,",60:81:chronic_disease",Must meet current (within last 30 days) DSM-5 criteria for cannabis use disorder,"['Must' 'meet' 'current' '(' 'within' 'last' '30' 'days' ')' 'DSM-5'
 'criteria' 'for' 'cannabis' 'use' 'disorder']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT03054155,33:49:treatment,Patients unable to tolerate the laser treatments,['Patients' 'unable' 'to' 'tolerate' 'the' 'laser' 'treatments'],[0. 0. 0. 0. 0. 1. 1.]
NCT03053908,10:32:chronic_disease,Subjects hypomotility disorders of the gastrointestinal tract including but not limited to Ileus,"['Subjects' 'hypomotility' 'disorders' 'of' 'the' 'gastrointestinal'
 'tract' 'including' 'but' 'not' 'limited' 'to' 'Ileus']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03053453,1:38:treatment,Contralateral Total Knee Arthroplasty,['Contralateral' 'Total' 'Knee' 'Arthroplasty'],[1. 1. 1. 1.]
NCT03053453,10:33:treatment,Revision Total Knee Arthroplasty,['Revision' 'Total' 'Knee' 'Arthroplasty'],[0. 1. 1. 1.]
NCT03053037,54:74:treatment,Confirmed restorability with crown restoration after root canal treatment or adequate existing full cuspal coverage restoration,"['Confirmed' 'restorability' 'with' 'crown' 'restoration' 'after' 'root'
 'canal' 'treatment' 'or' 'adequate' 'existing' 'full' 'cuspal' 'coverage'
 'restoration']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT03051347,42:56:chronic_disease,Any child with a potentially disfiguring skin condition or change in appearance related to disease/intervention will be considered eligible,"['Any' 'child' 'with' 'a' 'potentially' 'disfiguring' 'skin' 'condition'
 'or' 'change' 'in' 'appearance' 'related' 'to' 'disease/intervention'
 'will' 'be' 'considered' 'eligible']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03051282,"45:52:treatment,",habitual consumption of large quantities of ethanol (>3 drinks/day),"['habitual' 'consumption' 'of' 'large' 'quantities' 'of' 'ethanol' '(' '>'
 '3' 'drinks/day' ')']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT03049189,9:28:treatment,Planned alternative therapy (for the period of study participation),"['Planned' 'alternative' 'therapy' '(' 'for' 'the' 'period' 'of' 'study'
 'participation' ')']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03049189,1:47:chronic_disease,Somatostatin receptor positive (SSTR+) disease,['Somatostatin' 'receptor' 'positive' '(' 'SSTR+' ')' 'disease'],[2. 2. 2. 2. 2. 0. 0.]
NCT03048448,"1:24:chronic_disease,,,",Mild hepatic impairment (Group 4): Child-Pugh Class A (5-6 points),"['Mild' 'hepatic' 'impairment' '(' 'Group' '4' ')' ':' 'Child-Pugh'
 'Class' 'A' '(' '5-6' 'points' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03045341,18:45:treatment,Currently taking anti-depressant medications,['Currently' 'taking' 'anti-depressant' 'medications'],[0. 0. 1. 1.]
NCT03043794,46:66:treatment,Planning breast conserving surgery including sentinel node biopsy,"['Planning' 'breast' 'conserving' 'surgery' 'including' 'sentinel' 'node'
 'biopsy']",[0. 0. 0. 0. 0. 1. 1. 1.]
NCT03042897,20:36:treatment,"Must agree to take progestin agents (i.e., oral agents or MIRENA intrauterine device [IUD] which are accepted treatments for low grade uterine malignancies to control their disease while the intervention is ongoing)","['Must' 'agree' 'to' 'take' 'progestin' 'agents' '(' 'i.e.' ',' 'oral'
 'agents' 'or' 'MIRENA' 'intrauterine' 'device' '[' 'IUD' ']' 'which'
 'are' 'accepted' 'treatments' 'for' 'low' 'grade' 'uterine'
 'malignancies' 'to' 'control' 'their' 'disease' 'while' 'the'
 'intervention' 'is' 'ongoing' ')']","[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03042689,1:26:cancer,superficial bladder tumor,['superficial' 'bladder' 'tumor'],[3. 3. 3.]
NCT03041844,"8:30:chronic_disease,,,,",Severe vascular insufficiency (ankle-brachial index lower than 0.75 or toe-brachial index below 0.5),"['Severe' 'vascular' 'insufficiency' '(' 'ankle-brachial' 'index' 'lower'
 'than' '0.75' 'or' 'toe-brachial' 'index' 'below' '0.5' ')']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03040778,12:28:cancer,Absence of tumor in the jaw at the time of recruitment,"['Absence' 'of' 'tumor' 'in' 'the' 'jaw' 'at' 'the' 'time' 'of'
 'recruitment']",[0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0.]
NCT03040778,21:57:chronic_disease,Patients with known hemorrhagic and coagulation disorder,['Patients' 'with' 'known' 'hemorrhagic' 'and' 'coagulation' 'disorder'],[0. 0. 0. 2. 2. 2. 2.]
NCT03040778,1:29:chronic_disease,extensive retinal hemorrhage,['extensive' 'retinal' 'hemorrhage'],[2. 2. 2.]
NCT03038867,"12:32:treatment,",use of any hormonal medications on a daily or intermittent basis during the preceding 3 months,"['use' 'of' 'any' 'hormonal' 'medications' 'on' 'a' 'daily' 'or'
 'intermittent' 'basis' 'during' 'the' 'preceding' '3' 'months']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03038620,40:78:allergy_name,Known or suspected hypersensitivity to trial product(s) or related product(s),"['Known' 'or' 'suspected' 'hypersensitivity' 'to' 'trial' 'product' '('
 's' ')' 'or' 'related' 'product' '(' 's' ')']",[0. 0. 0. 0. 0. 4. 4. 4. 4. 4. 0. 0. 0. 0. 0. 0.]
NCT03038269,"1:24:treatment,","Botulinum toxin therapy in either upper extremity during last 2 months, or planned during study period","['Botulinum' 'toxin' 'therapy' 'in' 'either' 'upper' 'extremity' 'during'
 'last' '2' 'months' ',' 'or' 'planned' 'during' 'study' 'period']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03038269,"1:19:treatment,",Orthopedic surgery in affected arm within 2 years,['Orthopedic' 'surgery' 'in' 'affected' 'arm' 'within' '2' 'years'],[1. 1. 0. 0. 0. 0. 0. 0.]
NCT03037983,33:37:treatment,Patients with prior exposure to rTMS,['Patients' 'with' 'prior' 'exposure' 'to' 'rTMS'],[0. 0. 0. 0. 0. 1.]
NCT03037879,10:28:chronic_disease,Level of Spinal Cord Injury between C1 and T12,['Level' 'of' 'Spinal' 'Cord' 'Injury' 'between' 'C1' 'and' 'T12'],[0. 0. 2. 2. 2. 0. 0. 0. 0.]
NCT03037385,58:78:cancer,"have a pathologically documented, definitively diagnosed advanced solid tumor with an oncogenic RET mutation previously treated with SOC appropriate for the tumor type and not eligible for any of the other groups","['have' 'a' 'pathologically' 'documented' ',' 'definitively' 'diagnosed'
 'advanced' 'solid' 'tumor' 'with' 'an' 'oncogenic' 'RET' 'mutation'
 'previously' 'treated' 'with' 'SOC' 'appropriate' 'for' 'the' 'tumor'
 'type' 'and' 'not' 'eligible' 'for' 'any' 'of' 'the' 'other' 'groups']","[0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03036280,"38:55:chronic_disease,",has been hospitalized or treated for suicidal behavior in the past 5 years,"['has' 'been' 'hospitalized' 'or' 'treated' 'for' 'suicidal' 'behavior'
 'in' 'the' 'past' '5' 'years']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT03036098,44:57:treatment,Patients with disease that is suitable for local therapy administered,"['Patients' 'with' 'disease' 'that' 'is' 'suitable' 'for' 'local'
 'therapy' 'administered']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT03034564,4:23:chronic_disease,No supine hypertension (high blood pressure while laying down) judged to be of clinical significance by the investigator,"['No' 'supine' 'hypertension' '(' 'high' 'blood' 'pressure' 'while'
 'laying' 'down' ')' 'judged' 'to' 'be' 'of' 'clinical' 'significance'
 'by' 'the' 'investigator']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03034564,1:17:chronic_disease,light headedness,['light' 'headedness'],[2. 2.]
NCT03033498,",,60:74:treatment,",Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to initial study drug administration,"['Donation' 'or' 'loss' 'of' '550' 'mL' 'or' 'more' 'blood' 'volume' '('
 'including' 'plasmapheresis' ')' 'or' 'receipt' 'of' 'a' 'transfusion'
 'of' 'any' 'blood' 'product' 'within' '8' 'weeks' 'prior' 'to' 'initial'
 'study' 'drug' 'administration']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03033212,1:22:chronic_disease,degenerative kyphosis,['degenerative' 'kyphosis'],[2. 2.]
NCT03033212,1:28:chronic_disease,intervertebral disc disease,['intervertebral' 'disc' 'disease'],[2. 2. 2.]
NCT03032432,13:52:chronic_disease,Evidence of symptomatic glenohumeral osteoarthritis,['Evidence' 'of' 'symptomatic' 'glenohumeral' 'osteoarthritis'],[0. 0. 2. 2. 2.]
NCT03030859,1:27:chronic_disease,cardiac or pulmonary edema,['cardiac' 'or' 'pulmonary' 'edema'],[2. 2. 2. 2.]
NCT03029884,179:182:treatment,"Patients may be excluded from enrollment due to a condition that, in the judgment of the PI, significantly increases risk or reduces significantly the likelihood of benefit from DBS","['Patients' 'may' 'be' 'excluded' 'from' 'enrollment' 'due' 'to' 'a'
 'condition' 'that' ',' 'in' 'the' 'judgment' 'of' 'the' 'PI' ','
 'significantly' 'increases' 'risk' 'or' 'reduces' 'significantly' 'the'
 'likelihood' 'of' 'benefit' 'from' 'DBS']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1.]"
NCT03029806,"1:13:treatment,",Decongestant use in the past 2 weeks,['Decongestant' 'use' 'in' 'the' 'past' '2' 'weeks'],[1. 0. 0. 0. 0. 0. 0.]
NCT03028831,1:20:treatment,previous GI surgery resulting in disturbed gut function due to of loss of bowel or altered anatomy,"['previous' 'GI' 'surgery' 'resulting' 'in' 'disturbed' 'gut' 'function'
 'due' 'to' 'of' 'loss' 'of' 'bowel' 'or' 'altered' 'anatomy']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03028012,1:28:chronic_disease,Gastrointestinal ulceration,['Gastrointestinal' 'ulceration'],[2. 2.]
NCT03027388,"16:21:treatment,,,,,,,,,","The effects of LB100 on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately","['The' 'effects' 'of' 'LB100' 'on' 'the' 'developing' 'human' 'fetus'
 'are' 'unknown' '.' 'For' 'this' 'reason' ',' 'women' 'of'
 'child-bearing' 'potential' 'and' 'men' 'must' 'agree' 'to' 'use'
 'adequate' 'contraception' '(' 'hormonal' 'or' 'barrier' 'method' 'of'
 'birth' 'control' ';' 'abstinence' ')' 'prior' 'to' 'study' 'entry' 'and'
 'for' 'the' 'duration' 'of' 'study' 'participation' '.' 'Should' 'a'
 'woman' 'become' 'pregnant' 'or' 'suspect' 'she' 'is' 'pregnant' 'while'
 'she' 'or' 'her' 'partner' 'is' 'participating' 'in' 'this' 'study' ','
 'she' 'should' 'inform' 'her' 'treating' 'physician' 'immediately']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT03023930,18:21:chronic_disease,ED patients with OUD,['ED' 'patients' 'with' 'OUD'],[0. 0. 0. 2.]
NCT03023059,7:25:chronic_disease,Known retinal hemorrhage,['Known' 'retinal' 'hemorrhage'],[0. 2. 2.]
NCT03022292,1:39:chronic_disease,Prior retinal pigment epithelial (RPE) tear in study eye,"['Prior' 'retinal' 'pigment' 'epithelial' '(' 'RPE' ')' 'tear' 'in'
 'study' 'eye']",[2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT03021538,37:41:treatment,Patients bridged to transplant with ECMO,['Patients' 'bridged' 'to' 'transplant' 'with' 'ECMO'],[0. 0. 0. 0. 0. 1.]
NCT03019367,1:17:chronic_disease,Bleeding Accreta,['Bleeding' 'Accreta'],[2. 2.]
NCT03018704,35:51:chronic_disease,"a current, clinically significant physical disease or abnormality","['a' 'current' ',' 'clinically' 'significant' 'physical' 'disease' 'or'
 'abnormality']",[0. 0. 0. 0. 0. 2. 2. 0. 0.]
NCT03018704,1:34:chronic_disease,imminent suicide or violence risk,['imminent' 'suicide' 'or' 'violence' 'risk'],[2. 2. 2. 2. 2.]
NCT03017937,"8:32:chronic_disease,",Recent penetrating brain trauma (within 6 months),['Recent' 'penetrating' 'brain' 'trauma' '(' 'within' '6' 'months' ')'],[0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT03017118,1:45:treatment,Radiographic evidence of Eaton stage 1 and 2 only,['Radiographic' 'evidence' 'of' 'Eaton' 'stage' '1' 'and' '2' 'only'],[1. 1. 1. 1. 1. 1. 1. 1. 0.]
NCT03016130,1:30:treatment,Allogeneic or autologous HSCT for any indication,['Allogeneic' 'or' 'autologous' 'HSCT' 'for' 'any' 'indication'],[1. 1. 1. 1. 0. 0. 0.]
NCT03015805,1:26:chronic_disease,Active psychotic disorder,['Active' 'psychotic' 'disorder'],[2. 2. 2.]
NCT03014687,1:17:chronic_disease,Active sinusitis,['Active' 'sinusitis'],[2. 2.]
NCT03013543,1:17:chronic_disease,Alström Syndrome,['Alström' 'Syndrome'],[2. 2.]
NCT03013543,26:46:treatment,Inability to comply with QD injection regimen,['Inability' 'to' 'comply' 'with' 'QD' 'injection' 'regimen'],[0. 0. 0. 0. 1. 1. 1.]
NCT03013543,1:29:chronic_disease,Smith-Magenis Syndrome (SMS),['Smith-Magenis' 'Syndrome' '(' 'SMS' ')'],[2. 2. 2. 0. 0.]
NCT03011801,"1:26:treatment,",Corticosteroid medication use during this pregnancy,['Corticosteroid' 'medication' 'use' 'during' 'this' 'pregnancy'],[1. 1. 0. 0. 0. 0.]
NCT03011567,",,57:75:treatment","Low platelet count (recorded measurement <50,000 during hospital admission)","['Low' 'platelet' 'count' '(' 'recorded' 'measurement' '<' '50,000'
 'during' 'hospital' 'admission' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT03010852,"1:15:treatment,",Oxygen therapy within the previous 30 days,['Oxygen' 'therapy' 'within' 'the' 'previous' '30' 'days'],[1. 1. 0. 0. 0. 0. 0.]
NCT03008616,1:23:chronic_disease,Active hepatic disease,['Active' 'hepatic' 'disease'],[2. 2. 2.]
NCT03008616,1:35:chronic_disease,antiphospholipid antibody syndrome,['antiphospholipid' 'antibody' 'syndrome'],[2. 2. 2.]
NCT03008070,78:117:allergy_name,Have a known hypersensitivity to any of the ingredients or excipients of the Investigational medicinal product (IMP),"['Have' 'a' 'known' 'hypersensitivity' 'to' 'any' 'of' 'the' 'ingredients'
 'or' 'excipients' 'of' 'the' 'Investigational' 'medicinal' 'product' '('
 'IMP' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 4. 4. 4. 0. 0.]
NCT03007745,1:24:chronic_disease,Cheyne-Stokes breathing,['Cheyne-Stokes' 'breathing'],[2. 2.]
NCT03007030,1:14:cancer,Positive CD30+ immunohistochemical expression,['Positive' 'CD30+' 'immunohistochemical' 'expression'],[3. 3. 0. 0.]
NCT03006770,"1:20:treatment,",Concomitant therapy with a statin and an anti-platelet agent for at least 2 weeks prior to randomization,"['Concomitant' 'therapy' 'with' 'a' 'statin' 'and' 'an' 'anti-platelet'
 'agent' 'for' 'at' 'least' '2' 'weeks' 'prior' 'to' 'randomization']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03006770,1:31:treatment,endovascular revascularization,['endovascular' 'revascularization'],[1. 1.]
NCT03006302,12:29:chronic_disease,History of Seratonin Syndome,['History' 'of' 'Seratonin' 'Syndome'],[0. 0. 2. 2.]
NCT03005782,1:31:treatment,Prior treatment with any LAG-3 targeting biologic or small molecule,"['Prior' 'treatment' 'with' 'any' 'LAG-3' 'targeting' 'biologic' 'or'
 'small' 'molecule']",[1. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT03004807,"14:35:chronic_disease,,",Uncontrolled stage II hypertension (blood pressure above 159/99 mm Hg),"['Uncontrolled' 'stage' 'II' 'hypertension' '(' 'blood' 'pressure' 'above'
 '159/99' 'mm' 'Hg' ')']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03003780,19:50:chronic_disease,Clinical signs of unstable cardiovascular disease,['Clinical' 'signs' 'of' 'unstable' 'cardiovascular' 'disease'],[0. 0. 0. 2. 2. 2.]
NCT03003689,1:33:chronic_disease,uncontrolled systemic conditions,['uncontrolled' 'systemic' 'conditions'],[2. 2. 2.]
NCT03002389,1:27:chronic_disease,pulmonary vascular disease,['pulmonary' 'vascular' 'disease'],[2. 2. 2.]
NCT03001830,8:26:chronic_disease,severe bleeding phenotype,['severe' 'bleeding' 'phenotype'],[0. 2. 2.]
NCT03000439,19:81:treatment,Subjects who have previously failed treatment with more than two biologic DMARDs,"['Subjects' 'who' 'have' 'previously' 'failed' 'treatment' 'with' 'more'
 'than' 'two' 'biologic' 'DMARDs']",[0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT02998021,1:16:chronic_disease,upper limb pain that interferes with the ability to propel or transfer,"['upper' 'limb' 'pain' 'that' 'interferes' 'with' 'the' 'ability' 'to'
 'propel' 'or' 'transfer']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02995733,22:33:allergy_name,Known allergy to the ICS inhaler used in the study,['Known' 'allergy' 'to' 'the' 'ICS' 'inhaler' 'used' 'in' 'the' 'study'],[0. 0. 0. 0. 4. 4. 0. 0. 0. 0.]
NCT02993900,1:36:cancer,Carcinoma of the vulva: Stage I-IVA or recurrence,['Carcinoma' 'of' 'the' 'vulva' ':' 'Stage' 'I-IVA' 'or' 'recurrence'],[3. 3. 3. 3. 3. 3. 0. 0. 0.]
NCT02992275,",,66:84:chronic_disease,","Poorly controlled hypertension (>160/100); or patient report of: symptomatic angina at rest or during exercise, syncope without known resolution of cause, or a significant coronary event (such as a MI) in the past six months","['Poorly' 'controlled' 'hypertension' '(' '>' '160/100' ')' ';' 'or'
 'patient' 'report' 'of' ':' 'symptomatic' 'angina' 'at' 'rest' 'or'
 'during' 'exercise' ',' 'syncope' 'without' 'known' 'resolution' 'of'
 'cause' ',' 'or' 'a' 'significant' 'coronary' 'event' '(' 'such' 'as' 'a'
 'MI' ')' 'in' 'the' 'past' 'six' 'months']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02991677,1:27:chronic_disease,Musculoskeletal conditions which preclude participation in an exercise training program,"['Musculoskeletal' 'conditions' 'which' 'preclude' 'participation' 'in'
 'an' 'exercise' 'training' 'program']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02991651,1:34:cancer,non-melanoma cutaneous malignancy,['non-melanoma' 'cutaneous' 'malignancy'],[3. 3. 3.]
NCT02991144,"18:96:treatment,",Participation in another investigational medicine study (including another gene transfer trial) within 3 months of Screening,"['Participation' 'in' 'another' 'investigational' 'medicine' 'study' '('
 'including' 'another' 'gene' 'transfer' 'trial' ')' 'within' '3' 'months'
 'of' 'Screening']",[0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02990481,1:29:cancer,Symptomatic brain metastases,['Symptomatic' 'brain' 'metastases'],[3. 3. 3.]
NCT02990377,32:52:treatment,Presenting for pain related to acute cancer therapy,['Presenting' 'for' 'pain' 'related' 'to' 'acute' 'cancer' 'therapy'],[0. 0. 0. 0. 0. 1. 1. 1.]
NCT02989597,1:21:chronic_disease,Severe heart disease,['Severe' 'heart' 'disease'],[2. 2. 2.]
NCT02988895,14:24:chronic_disease,Diagnosis of active CNV,['Diagnosis' 'of' 'active' 'CNV'],[0. 0. 2. 2.]
NCT02987491,"1:21:chronic_disease,,",Hypercholesterolemia (fasting LDL>140mg/dl),['Hypercholesterolemia' '(' 'fasting' 'LDL' '>' '140mg/dl' ')'],[2. 0. 0. 0. 0. 0. 0.]
NCT02986087,1:24:chronic_disease,Placental abnormalities known at time of enrollment,['Placental' 'abnormalities' 'known' 'at' 'time' 'of' 'enrollment'],[2. 2. 0. 0. 0. 0. 0.]
NCT02983903,1:20:treatment,Supplemental oxygen utilization at baseline,['Supplemental' 'oxygen' 'utilization' 'at' 'baseline'],[1. 1. 0. 0. 0.]
NCT02983240,1:20:chronic_disease,Severe preeclampsia,['Severe' 'preeclampsia'],[2. 2.]
NCT02982564,"16:41:treatment,,",Have completed adjuvant curative therapy at least two months to 5 years prior to recruitment,"['Have' 'completed' 'adjuvant' 'curative' 'therapy' 'at' 'least' 'two'
 'months' 'to' '5' 'years' 'prior' 'to' 'recruitment']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02982226,1:16:chronic_disease,Fat Pad Atrophy,['Fat' 'Pad' 'Atrophy'],[2. 2. 2.]
NCT02981173,1:33:treatment,"lysergic acid diethylamide (LSD), or related compounds","['lysergic' 'acid' 'diethylamide' '(' 'LSD' ')' ',' 'or' 'related'
 'compounds']",[1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02981082,1:30:chronic_disease,Pulmonary venous hypertension,['Pulmonary' 'venous' 'hypertension'],[2. 2. 2.]
NCT02979366,",61:76:treatment",already enrolled in the study who has received at least one S64315 infusion,"['already' 'enrolled' 'in' 'the' 'study' 'who' 'has' 'received' 'at'
 'least' 'one' 'S64315' 'infusion']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02978443,38:88:treatment,Patients must be eligible to receive nivolumab in combination with ipilimumab treatment per institutional guidelines,"['Patients' 'must' 'be' 'eligible' 'to' 'receive' 'nivolumab' 'in'
 'combination' 'with' 'ipilimumab' 'treatment' 'per' 'institutional'
 'guidelines']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0.]
NCT02975869,16:51:cancer,A diagnosis of acute promyelocytic leukemia (APML),['A' 'diagnosis' 'of' 'acute' 'promyelocytic' 'leukemia' '(' 'APML' ')'],[0. 0. 0. 3. 3. 3. 3. 0. 0.]
NCT02974686,4:61:treatment,On standard immunosuppression with tacrolimus and prednisone,"['On' 'standard' 'immunosuppression' 'with' 'tacrolimus' 'and'
 'prednisone']",[0. 1. 1. 1. 1. 1. 1.]
NCT02973425,"60:76:treatment,,",The Food and Drug Administration (FDA) advises caution for nicotine lozenge use among women who are pregnant,"['The' 'Food' 'and' 'Drug' 'Administration' '(' 'FDA' ')' 'advises'
 'caution' 'for' 'nicotine' 'lozenge' 'use' 'among' 'women' 'who' 'are'
 'pregnant']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02971137,1:17:chronic_disease,Terminal Illness,['Terminal' 'Illness'],[2. 2.]
NCT02969187,10:33:treatment,Previous major abdominal surgery (possible adhesions and longer operation),"['Previous' 'major' 'abdominal' 'surgery' '(' 'possible' 'adhesions' 'and'
 'longer' 'operation' ')']",[0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02969187,1:29:treatment,laparoscopic cholecystectomy,['laparoscopic' 'cholecystectomy'],[1. 1.]
NCT02968602,"1:25:chronic_disease,",Severe liver dysfunction (LFT 3X upper limit of normal),"['Severe' 'liver' 'dysfunction' '(' 'LFT' '3X' 'upper' 'limit' 'of'
 'normal' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02966665,12:51:treatment,History of percutaneous coronary revascularization,['History' 'of' 'percutaneous' 'coronary' 'revascularization'],[0. 0. 1. 1. 1.]
NCT02965638,12:28:chronic_disease,Persistent fetal arrhythmia,['Persistent' 'fetal' 'arrhythmia'],[0. 2. 2.]
NCT02964741,35:56:chronic_disease,Presence of any other systemic or chronic pain disorder,['Presence' 'of' 'any' 'other' 'systemic' 'or' 'chronic' 'pain' 'disorder'],[0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02964182,1:8:treatment,Chantix,['Chantix'],[1.]
NCT02962895,1:29:chronic_disease,Secondary Sjogren's syndrome,"['Secondary' 'Sjogren' ""'s"" 'syndrome']",[2. 2. 2. 0.]
NCT02960763,9:40:chronic_disease,Current Major Depressive Disorder (MDD),['Current' 'Major' 'Depressive' 'Disorder' '(' 'MDD' ')'],[0. 2. 2. 2. 2. 0. 0.]
NCT02960113,22:55:treatment,Subjects who receive spinal and/or epidural anesthesia,['Subjects' 'who' 'receive' 'spinal' 'and/or' 'epidural' 'anesthesia'],[0. 0. 0. 1. 1. 1. 1.]
NCT02959671,1:42:chronic_disease,Mental/emotional/developmental disability,['Mental/emotional/developmental' 'disability'],[2. 2.]
NCT02956486,"12:48:chronic_disease,",History of transient ischemic attacks or stroke within 12 months of Screening,"['History' 'of' 'transient' 'ischemic' 'attacks' 'or' 'stroke' 'within'
 '12' 'months' 'of' 'Screening']",[0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02955537,1:37:chronic_disease,Stage IV or V chronic kidney disease,['Stage' 'IV' 'or' 'V' 'chronic' 'kidney' 'disease'],[2. 2. 2. 2. 2. 2. 2.]
NCT02954185,1:24:chronic_disease,Neurological conditions,['Neurological' 'conditions'],[2. 2.]
NCT02953860,1:18:treatment,Vaginal estrogens are allowed if necessary for patient comfort,"['Vaginal' 'estrogens' 'are' 'allowed' 'if' 'necessary' 'for' 'patient'
 'comfort']",[1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02953509,"1:18:cancer,",Second malignancy within the last 3 years,['Second' 'malignancy' 'within' 'the' 'last' '3' 'years'],[3. 3. 0. 0. 0. 0. 0.]
NCT02953392,26:51:chronic_disease,Subjects presenting with maxillary sinus pathology,['Subjects' 'presenting' 'with' 'maxillary' 'sinus' 'pathology'],[0. 0. 0. 2. 2. 2.]
NCT02952365,40:53:treatment,Subjects who have previously undergone LASIK surgery,['Subjects' 'who' 'have' 'previously' 'undergone' 'LASIK' 'surgery'],[0. 0. 0. 0. 0. 1. 1.]
NCT02950337,1:22:chronic_disease,Chronic heart disease,['Chronic' 'heart' 'disease'],[2. 2. 2.]
NCT02950337,1:46:chronic_disease,severely symptomatic congestive heart failure,['severely' 'symptomatic' 'congestive' 'heart' 'failure'],[2. 2. 2. 2. 2.]
NCT02947945,1:17:chronic_disease,Palpable purpura,['Palpable' 'purpura'],[2. 2.]
NCT02947373,20:34:treatment,Patients receiving active therapy on an investigational trial at the time of enrollment should consult with the study chair regarding potential interactions with other study agents,"['Patients' 'receiving' 'active' 'therapy' 'on' 'an' 'investigational'
 'trial' 'at' 'the' 'time' 'of' 'enrollment' 'should' 'consult' 'with'
 'the' 'study' 'chair' 'regarding' 'potential' 'interactions' 'with'
 'other' 'study' 'agents']","[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02946892,"12:25:treatment,",The use of beta blockers within 2 months of randomization,"['The' 'use' 'of' 'beta' 'blockers' 'within' '2' 'months' 'of'
 'randomization']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02946892,1:22:chronic_disease,primary aldosteronism,['primary' 'aldosteronism'],[2. 2.]
NCT02946658,20:43:chronic_disease,Prior Diagnosis of moderate to severe COPD,['Prior' 'Diagnosis' 'of' 'moderate' 'to' 'severe' 'COPD'],[0. 0. 0. 2. 2. 2. 2.]
NCT02945800,1:21:treatment,Stem Cell Transplant or Rescue: No evidence of active graft vs. host disease and 2 months must have elapsed from the start of protocol therapy since transplant,"['Stem' 'Cell' 'Transplant' 'or' 'Rescue' ':' 'No' 'evidence' 'of'
 'active' 'graft' 'vs.' 'host' 'disease' 'and' '2' 'months' 'must' 'have'
 'elapsed' 'from' 'the' 'start' 'of' 'protocol' 'therapy' 'since'
 'transplant']","[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02944825,22:56:treatment,Patients who perform clean intermittent catheterization,['Patients' 'who' 'perform' 'clean' 'intermittent' 'catheterization'],[0. 0. 0. 1. 1. 1.]
NCT02944825,1:19:treatment,ureteroscopy [URS],['ureteroscopy' '[' 'URS' ']'],[1. 1. 0. 0.]
NCT02943915,"1:11:chronic_disease,,","Spasticity that prevents joint motion (severe stiffness or rigidity,) where both legs have a Modified Ashworth Score (MAS) score of 3 or higher for half or more of their proximal lower extremity muscles; proximal muscles include hip flexors/extensors/adductors and knee flexors/extensors","['Spasticity' 'that' 'prevents' 'joint' 'motion' '(' 'severe' 'stiffness'
 'or' 'rigidity' ',' ')' 'where' 'both' 'legs' 'have' 'a' 'Modified'
 'Ashworth' 'Score' '(' 'MAS' ')' 'score' 'of' '3' 'or' 'higher' 'for'
 'half' 'or' 'more' 'of' 'their' 'proximal' 'lower' 'extremity' 'muscles'
 ';' 'proximal' 'muscles' 'include' 'hip' 'flexors/extensors/adductors'
 'and' 'knee' 'flexors/extensors']","[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02943590,35:38:cancer,All patients with newly diagnosed NHL,['All' 'patients' 'with' 'newly' 'diagnosed' 'NHL'],[0. 0. 0. 0. 0. 3.]
NCT02943408,7:57:chronic_disease,other specified or unspecified depressive disorder (311),"['other' 'specified' 'or' 'unspecified' 'depressive' 'disorder' '(' '311'
 ')']",[0. 2. 2. 2. 2. 2. 2. 0. 0.]
NCT02942095,1:33:cancer,Pancreatic ductal adenocarcinoma patient with KRAS point mutation at codon G12 or G13,"['Pancreatic' 'ductal' 'adenocarcinoma' 'patient' 'with' 'KRAS' 'point'
 'mutation' 'at' 'codon' 'G12' 'or' 'G13']",[3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02940288,1:26:treatment,Prosthetic cardiac valves,['Prosthetic' 'cardiac' 'valves'],[1. 1. 1.]
NCT02939183,34:78:treatment,Currently receiving treatment in another investigational device or drug study,"['Currently' 'receiving' 'treatment' 'in' 'another' 'investigational'
 'device' 'or' 'drug' 'study']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 1.]
NCT02937350,1:15:treatment,Gastric bypass,['Gastric' 'bypass'],[1. 1.]
NCT02933034,"19:27:chronic_disease,",have a history of torsades or prolonged QT/QTc interval,['have' 'a' 'history' 'of' 'torsades' 'or' 'prolonged' 'QT/QTc' 'interval'],[0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT02932410,1:16:chronic_disease,schistosomiasis,['schistosomiasis'],[2.]
NCT02932280,1:13:cancer,Solid tumors must have a lesion evaluable by RECIST criteria version 1.1,"['Solid' 'tumors' 'must' 'have' 'a' 'lesion' 'evaluable' 'by' 'RECIST'
 'criteria' 'version' '1.1']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02931110,1:29:chronic_disease,extranodal organ involvement,['extranodal' 'organ' 'involvement'],[2. 2. 2.]
NCT02931110,1:13:chronic_disease,organomegaly,['organomegaly'],[2.]
NCT02930018,139:151:treatment,Intent to use any endovascular device other than a stent retriever or clot aspiration device or intra-arterial medications as the initial thrombectomy approach,"['Intent' 'to' 'use' 'any' 'endovascular' 'device' 'other' 'than' 'a'
 'stent' 'retriever' 'or' 'clot' 'aspiration' 'device' 'or'
 'intra-arterial' 'medications' 'as' 'the' 'initial' 'thrombectomy'
 'approach']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02929069,9:39:chronic_disease,Current suicidal or homicidal ideation,['Current' 'suicidal' 'or' 'homicidal' 'ideation'],[0. 2. 2. 2. 2.]
NCT02928991,1:24:chronic_disease,Diamond-Blackfan Anemia,['Diamond-Blackfan' 'Anemia'],[2. 2.]
NCT02928991,1:30:chronic_disease,Severe Congenital Neutropenia,['Severe' 'Congenital' 'Neutropenia'],[2. 2. 2.]
NCT02928991,25:34:chronic_disease,negative evaluation for dysplasia,['negative' 'evaluation' 'for' 'dysplasia'],[0. 0. 0. 2.]
NCT02927301,"5:34:treatment,",Any prior therapy for lung cancer within 3 years,['Any' 'prior' 'therapy' 'for' 'lung' 'cancer' 'within' '3' 'years'],[0. 1. 1. 1. 1. 1. 0. 0. 0.]
NCT02926729,20:32:cancer,Patients that have complex DCIS,['Patients' 'that' 'have' 'complex' 'DCIS'],[0. 0. 0. 3. 3.]
NCT02926378,1:25:treatment,Magnetic dental implants - loss of magnetic hold to keep the implant in place,"['Magnetic' 'dental' 'implants' '-' 'loss' 'of' 'magnetic' 'hold' 'to'
 'keep' 'the' 'implant' 'in' 'place']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02926248,",41:60:treatment",Patients with less than 10 degrees of a flexion contracture,"['Patients' 'with' 'less' 'than' '10' 'degrees' 'of' 'a' 'flexion'
 'contracture']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02925923,1:9:treatment,Edoxaban,['Edoxaban'],[1.]
NCT02925923,"1:7:chronic_disease,,",NSTEMI as evidenced by elevation of troponin levels (Troponin > 0.034 ng/ml),"['NSTEMI' 'as' 'evidenced' 'by' 'elevation' 'of' 'troponin' 'levels' '('
 'Troponin' '>' '0.034' 'ng/ml' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02925923,1:14:treatment,Telithormycin,['Telithormycin'],[1.]
NCT02924402,22:54:allergy_name,Known intolerance to CD20 monoclonal antibody therapy,['Known' 'intolerance' 'to' 'CD20' 'monoclonal' 'antibody' 'therapy'],[0. 0. 0. 4. 4. 4. 4.]
NCT02924363,1:28:treatment,Ferromagnetic aneurysm clip,['Ferromagnetic' 'aneurysm' 'clip'],[1. 1. 1.]
NCT02924194,24:45:chronic_disease,currently uncontrolled visual hallucinations,['currently' 'uncontrolled' 'visual' 'hallucinations'],[0. 0. 2. 2.]
NCT02923011,33:72:allergy_name,Known intolerance or allergy to MR contrast agent (gadolinium chelates),"['Known' 'intolerance' 'or' 'allergy' 'to' 'MR' 'contrast' 'agent' '('
 'gadolinium' 'chelates' ')']",[0. 0. 0. 0. 0. 4. 4. 4. 4. 4. 0. 0.]
NCT02922881,8:17:treatment,Use of biologics in present or in the past,['Use' 'of' 'biologics' 'in' 'present' 'or' 'in' 'the' 'past'],[0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02921022,"30:47:treatment,,",Patients with current use of megestrol acetate (use with 10 days of Day 1),"['Patients' 'with' 'current' 'use' 'of' 'megestrol' 'acetate' '(' 'use'
 'with' '10' 'days' 'of' 'Day' '1' ')']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02920710,18:48:chronic_disease,Diagnosis of any underlying neurologic disorder that would potentially confound interpretation of the study results,"['Diagnosis' 'of' 'any' 'underlying' 'neurologic' 'disorder' 'that'
 'would' 'potentially' 'confound' 'interpretation' 'of' 'the' 'study'
 'results']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02919436,12:19:allergy_name,Allergy to lactose,['Allergy' 'to' 'lactose'],[0. 0. 4.]
NCT02918981,1:34:treatment,non-steroidal anti-inflammatories,['non-steroidal' 'anti-inflammatories'],[1. 1.]
NCT02916472,11:28:treatment,completed primary treatment,['completed' 'primary' 'treatment'],[0. 1. 1.]
NCT02914834,1:29:treatment,concomitant physical therapy,['concomitant' 'physical' 'therapy'],[1. 1. 1.]
NCT02914483,1:19:chronic_disease,anginal equivalent symptoms at rest,['anginal' 'equivalent' 'symptoms' 'at' 'rest'],[2. 2. 0. 0. 0.]
NCT02914171,26:37:treatment,Individuals with current IV inotrope requirements,['Individuals' 'with' 'current' 'IV' 'inotrope' 'requirements'],[0. 0. 0. 1. 1. 0.]
NCT02914171,11:34:chronic_disease,extensive extra-cardiac syndromes,['extensive' 'extra-cardiac' 'syndromes'],[0. 2. 2.]
NCT02913430,"1:17:cancer,","Brain metastasis is allowed if previously treated, stable and off steroids for a minimum of 56 days","['Brain' 'metastasis' 'is' 'allowed' 'if' 'previously' 'treated' ','
 'stable' 'and' 'off' 'steroids' 'for' 'a' 'minimum' 'of' '56' 'days']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02913430,33:84:treatment,There is no minimum duration of AI in the metastatic setting or neoadjuvant setting,"['There' 'is' 'no' 'minimum' 'duration' 'of' 'AI' 'in' 'the' 'metastatic'
 'setting' 'or' 'neoadjuvant' 'setting']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT02913404,76:102:treatment,Subjects will be of generally good health and will have decided to undergo ACL reconstruction surgery and agreed to participate in the study (following informed consent procedures),"['Subjects' 'will' 'be' 'of' 'generally' 'good' 'health' 'and' 'will'
 'have' 'decided' 'to' 'undergo' 'ACL' 'reconstruction' 'surgery' 'and'
 'agreed' 'to' 'participate' 'in' 'the' 'study' '(' 'following' 'informed'
 'consent' 'procedures' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02912572,1:27:chronic_disease,Grade 2 sensory neuropathy,['Grade' '2' 'sensory' 'neuropathy'],[2. 2. 2. 2.]
NCT02911792,1:124:treatment,"Ingestion of medications known to interfere with the renin-angiotensin system or renal function, including diuretic therapy","['Ingestion' 'of' 'medications' 'known' 'to' 'interfere' 'with' 'the'
 'renin-angiotensin' 'system' 'or' 'renal' 'function' ',' 'including'
 'diuretic' 'therapy']",[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0.]
NCT02911467,37:54:chronic_disease,A history of clinically significant EKG abnormalities,['A' 'history' 'of' 'clinically' 'significant' 'EKG' 'abnormalities'],[0. 0. 0. 0. 0. 2. 2.]
NCT02911467,31:58:chronic_disease,Patients with rate-controlled atrial fibrillation/flutter,['Patients' 'with' 'rate-controlled' 'atrial' 'fibrillation/flutter'],[0. 0. 0. 2. 2.]
NCT02911467,",,70:90:treatment",willing to use adequate contraception for one month after undergoing HP pyruvate infusion,"['willing' 'to' 'use' 'adequate' 'contraception' 'for' 'one' 'month'
 'after' 'undergoing' 'HP' 'pyruvate' 'infusion']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02910700,15:40:cancer,Patients with melanoma brain metastases are allowed,['Patients' 'with' 'melanoma' 'brain' 'metastases' 'are' 'allowed'],[0. 0. 3. 3. 3. 0. 0.]
NCT02910648,31:52:chronic_disease,Below the clinical cutoff for Restless Leg Syndrome,['Below' 'the' 'clinical' 'cutoff' 'for' 'Restless' 'Leg' 'Syndrome'],[0. 0. 0. 0. 0. 2. 2. 2.]
NCT02908906,29:61:treatment,Treatment with any local or systemic anti-neoplastic therapy,"['Treatment' 'with' 'any' 'local' 'or' 'systemic' 'anti-neoplastic'
 'therapy']",[0. 0. 0. 0. 0. 1. 1. 1.]
NCT02908841,1:34:treatment,Preoperative prophylactic heparin is not an exclusion criterion,"['Preoperative' 'prophylactic' 'heparin' 'is' 'not' 'an' 'exclusion'
 'criterion']",[1. 1. 1. 0. 0. 0. 0. 0.]
NCT02908841,1:43:treatment,robotic assisted laparoscopic hysterectomy,['robotic' 'assisted' 'laparoscopic' 'hysterectomy'],[1. 1. 1. 1.]
NCT02907983,12:22:chronic_disease,history of neurologic deficit to the brachial plexus,['history' 'of' 'neurologic' 'deficit' 'to' 'the' 'brachial' 'plexus'],[0. 0. 2. 0. 0. 0. 0. 0.]
NCT02907983,1:47:treatment,serotonin selective reuptake inhibitors (SSRI) (2 weeks),"['serotonin' 'selective' 'reuptake' 'inhibitors' '(' 'SSRI' ')' '(' '2'
 'weeks' ')']",[1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02905929,8:27:treatment,Use of insulin medications,['Use' 'of' 'insulin' 'medications'],[0. 0. 1. 1.]
NCT02905591,1:13:treatment,amphetamines,['amphetamines'],[1.]
NCT02905578,1:36:chronic_disease,Metastatic or node positive disease,['Metastatic' 'or' 'node' 'positive' 'disease'],[2. 2. 2. 2. 2.]
NCT02905370,1:48:chronic_disease,Deep vein thrombosis/pulmonary embolus (DVT/PE),['Deep' 'vein' 'thrombosis/pulmonary' 'embolus' '(' 'DVT/PE' ')'],[2. 2. 2. 2. 2. 0. 0.]
NCT02905370,1:14:chronic_disease,Heart Disease,['Heart' 'Disease'],[2. 2.]
NCT02905370,1:22:treatment,Post-op bowel surgery,['Post-op' 'bowel' 'surgery'],[1. 1. 1.]
NCT02903446,12:27:chronic_disease,History of Addison disease,['History' 'of' 'Addison' 'disease'],[0. 0. 2. 2.]
NCT02903446,7:20:chronic_disease,Other bone diseases which affect bone metabolism,['Other' 'bone' 'diseases' 'which' 'affect' 'bone' 'metabolism'],[0. 2. 2. 0. 0. 0. 0.]
NCT02902952,"1:31:chronic_disease,,",Autism Spectrum Disorder (ASD) Diagnosis 6-12 years old,"['Autism' 'Spectrum' 'Disorder' '(' 'ASD' ')' 'Diagnosis' '6-12' 'years'
 'old']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02901314,1:21:chronic_disease,cognitive conditions that limit ability to understand,['cognitive' 'conditions' 'that' 'limit' 'ability' 'to' 'understand'],[2. 2. 0. 0. 0. 0. 0.]
NCT02901067,"1:11:chronic_disease,,",Severe TBI; defined as AIS Head >3,['Severe' 'TBI' ';' 'defined' 'as' 'AIS' 'Head' '>' '3'],[2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02901041,1:12:treatment,anxiolytics,['anxiolytics'],[1.]
NCT02900794,",,22:44:chronic_disease",age 18 or older with chronic rhinosinusitis as described by the guidelines published in the 2015 Clinical practice guideline (update),"['age' '18' 'or' 'older' 'with' 'chronic' 'rhinosinusitis' 'as'
 'described' 'by' 'the' 'guidelines' 'published' 'in' 'the' '2015'
 'Clinical' 'practice' 'guideline' '(' 'update' ')']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02896751,"11:23:treatment,",On stable NIV settings for a minimum of 2 months,['On' 'stable' 'NIV' 'settings' 'for' 'a' 'minimum' 'of' '2' 'months'],[0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02895945,25:52:chronic_disease,Participant has another active coagulation disorder,['Participant' 'has' 'another' 'active' 'coagulation' 'disorder'],[0. 0. 0. 2. 2. 2.]
NCT02895945,1:13:chronic_disease,hemophilia A,['hemophilia' 'A'],[2. 2.]
NCT02891850,10:60:chronic_disease,Relevant obstructive and restrictive or other lung diseases,"['Relevant' 'obstructive' 'and' 'restrictive' 'or' 'other' 'lung'
 'diseases']",[0. 2. 2. 2. 2. 2. 2. 2.]
NCT02891447,43:73:allergy_name,"Subjects with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity","['Subjects' 'with' 'a' 'known' 'hypersensitivity' 'to' 'protocol'
 'systemic' 'chemotherapy' 'that' 'was' 'life-threatening' ',' 'required'
 'hospitalization' 'or' 'prolongation' 'of' 'existing' 'hospitalization'
 ',' 'or' 'resulted' 'in' 'persistent' 'or' 'significant' 'disability'
 'or' 'incapacity']","[0. 0. 0. 0. 0. 0. 4. 4. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02886572,"3:29:treatment,,",A contrast-enhanced MRI scan showing = or > 4 brain metastases,"['A' 'contrast-enhanced' 'MRI' 'scan' 'showing' '=' 'or' '>' '4' 'brain'
 'metastases']",[0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02885649,1:33:chronic_disease,Retroperitoneal/hilar adenopathy concerning for locally advanced disease,"['Retroperitoneal/hilar' 'adenopathy' 'concerning' 'for' 'locally'
 'advanced' 'disease']",[2. 2. 0. 0. 0. 0. 0.]
NCT02881320,"1:121:treatment,",Stable antiretroviral regimen of 2 nucleoside reverse transcriptase inhibitors (NRTIs) in combination with a third agent for a minimum of 6 months prior to the screening visit,"['Stable' 'antiretroviral' 'regimen' 'of' '2' 'nucleoside' 'reverse'
 'transcriptase' 'inhibitors' '(' 'NRTIs' ')' 'in' 'combination' 'with'
 'a' 'third' 'agent' 'for' 'a' 'minimum' 'of' '6' 'months' 'prior' 'to'
 'the' 'screening' 'visit']","[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02879136,46:67:chronic_disease,Presence of signs and symptoms suggestive of atypical parkinsonism,"['Presence' 'of' 'signs' 'and' 'symptoms' 'suggestive' 'of' 'atypical'
 'parkinsonism']",[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02877134,1:35:treatment,Oral 5-aminosalicylic acid (5-ASA) compounds,['Oral' '5-aminosalicylic' 'acid' '(' '5-ASA' ')' 'compounds'],[1. 1. 1. 1. 0. 0. 0.]
NCT02876302,1:26:treatment,Enlargement of the breast,['Enlargement' 'of' 'the' 'breast'],[1. 1. 1. 1.]
NCT02875405,1:34:chronic_disease,mitral or tricuspid valve disease,['mitral' 'or' 'tricuspid' 'valve' 'disease'],[2. 2. 2. 2. 2.]
NCT02875301,1:16:chronic_disease,Type I Diabetes,['Type' 'I' 'Diabetes'],[2. 2. 2.]
NCT02875301,7:27:chronic_disease,other cardiovascular event,['other' 'cardiovascular' 'event'],[0. 2. 2.]
NCT02872935,"1:11:treatment,",Antiemetic drug use in the 24 hours prior to cesarean delivery,"['Antiemetic' 'drug' 'use' 'in' 'the' '24' 'hours' 'prior' 'to' 'cesarean'
 'delivery']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02871349,1:17:chronic_disease,Bradyarrhythmias,['Bradyarrhythmias'],[2.]
NCT02867124,33:39:allergy_name,History of allergic reaction to XR-NTX,['History' 'of' 'allergic' 'reaction' 'to' 'XR-NTX'],[0. 0. 0. 0. 0. 4.]
NCT02865135,1:38:chronic_disease,Active uncontrolled serious infection,['Active' 'uncontrolled' 'serious' 'infection'],[2. 2. 2. 2.]
NCT02864147,27:70:treatment,Known hypersensitivity or prior intravaginal treatment with Imiquimod,"['Known' 'hypersensitivity' 'or' 'prior' 'intravaginal' 'treatment' 'with'
 'Imiquimod']",[0. 0. 0. 1. 1. 1. 1. 1.]
NCT02864147,1:31:chronic_disease,renal or hepatic insufficiency,['renal' 'or' 'hepatic' 'insufficiency'],[2. 2. 2. 2.]
NCT02863809,1:18:treatment,Cornea transplant,['Cornea' 'transplant'],[1. 1.]
NCT02863809,48:62:treatment,No or minimal tear production with evidence of keratinization of the bulbar conjunctiva,"['No' 'or' 'minimal' 'tear' 'production' 'with' 'evidence' 'of'
 'keratinization' 'of' 'the' 'bulbar' 'conjunctiva']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02862938,"5:24:treatment,",Any intraocular surgery of the study eye within 12 weeks prior to the screening visit,"['Any' 'intraocular' 'surgery' 'of' 'the' 'study' 'eye' 'within' '12'
 'weeks' 'prior' 'to' 'the' 'screening' 'visit']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02862938,"37:53:treatment,",Participant is likely to be offered glaucoma surgery within 6 months of screening,"['Participant' 'is' 'likely' 'to' 'be' 'offered' 'glaucoma' 'surgery'
 'within' '6' 'months' 'of' 'screening']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02861950,28:45:chronic_disease,abnormal caudal anatomy or spinal dysraphism,['abnormal' 'caudal' 'anatomy' 'or' 'spinal' 'dysraphism'],[0. 0. 0. 0. 2. 2.]
NCT02860702,19:49:treatment,Infants requiring cardio-pulmonary resuscitation prior to surgical repair,"['Infants' 'requiring' 'cardio-pulmonary' 'resuscitation' 'prior' 'to'
 'surgical' 'repair']",[0. 0. 1. 1. 0. 0. 0. 0.]
NCT02859142,8:28:chronic_disease,recent major cardiovascular event,['recent' 'major' 'cardiovascular' 'event'],[0. 2. 2. 0.]
NCT02857218,45:72:cancer,"Pathologically confirmed, locally advanced, malignancy of the esophagus","['Pathologically' 'confirmed' ',' 'locally' 'advanced' ',' 'malignancy'
 'of' 'the' 'esophagus']",[0. 0. 0. 0. 0. 0. 3. 3. 3. 3.]
NCT02857218,1:18:chronic_disease,severely agitated,['severely' 'agitated'],[2. 2.]
NCT02855554,1:38:chronic_disease,Hypertrophic cardiomyopathy (group 2),['Hypertrophic' 'cardiomyopathy' '(' 'group' '2' ')'],[2. 2. 2. 2. 0. 0.]
NCT02852538,1:22:chronic_disease,intellectual disorder,['intellectual' 'disorder'],[2. 2.]
NCT02851758,7:29:chronic_disease,Known mitochondria disorders,['Known' 'mitochondria' 'disorders'],[0. 2. 2.]
NCT02851290,1:18:chronic_disease,Genetic syndromes,['Genetic' 'syndromes'],[2. 2.]
NCT02849639,1:30:chronic_disease,Blockage of the urinary tract,['Blockage' 'of' 'the' 'urinary' 'tract'],[2. 2. 2. 2. 2.]
NCT02848417,1:19:treatment,Immunosuppressives,['Immunosuppressives'],[1.]
NCT02848417,15:31:chronic_disease,Veterans with Gulf War Illness,['Veterans' 'with' 'Gulf' 'War' 'Illness'],[0. 0. 2. 2. 2.]
NCT02847689,1:42:chronic_disease,Cystic periventricular leukomalacia (PVL),['Cystic' 'periventricular' 'leukomalacia' '(' 'PVL' ')'],[2. 2. 2. 2. 0. 0.]
NCT02847689,1:34:chronic_disease,Major sensori-neural hearing loss,['Major' 'sensori-neural' 'hearing' 'loss'],[2. 2. 2. 2.]
NCT02846532,34:65:treatment,Satisfactory initial post-Fontan transthoracic echocardiographic Screening,"['Satisfactory' 'initial' 'post-Fontan' 'transthoracic'
 'echocardiographic' 'Screening']",[0. 0. 0. 1. 1. 0.]
NCT02845596,1:48:chronic_disease,Inherited bone marrow failure syndromes (IBMFS),['Inherited' 'bone' 'marrow' 'failure' 'syndromes' '(' 'IBMFS' ')'],[2. 2. 2. 2. 2. 2. 0. 0.]
NCT02844751,"1:18:cancer,",Neoplastic cancer within 5 years prior to screening,['Neoplastic' 'cancer' 'within' '5' 'years' 'prior' 'to' 'screening'],[3. 3. 0. 0. 0. 0. 0. 0.]
NCT02843945,"1:6:treatment,",3DCRT (up to 56 Gy),['3DCRT' '(' 'up' 'to' '56' 'Gy' ')'],[1. 0. 0. 0. 0. 0. 0.]
NCT02843568,1:28:treatment,Prior thoracic radiotherapy,['Prior' 'thoracic' 'radiotherapy'],[1. 1. 1.]
NCT02842658,1:28:chronic_disease,Uncompensated heart failure,['Uncompensated' 'heart' 'failure'],[2. 2. 2.]
NCT02841540,30:65:treatment,Participant is candidate for hematopoietic stem cell transplants at the time of enrollment,"['Participant' 'is' 'candidate' 'for' 'hematopoietic' 'stem' 'cell'
 'transplants' 'at' 'the' 'time' 'of' 'enrollment']",[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02839759,"14:35:treatment,",Prior use of hearing amplification within the past 10 years,"['Prior' 'use' 'of' 'hearing' 'amplification' 'within' 'the' 'past' '10'
 'years']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02837510,1:27:treatment,Anti-psychotic medications,['Anti-psychotic' 'medications'],[1. 1.]
NCT02837497,14:36:treatment,AND Received CPR in the ICU setting,['AND' 'Received' 'CPR' 'in' 'the' 'ICU' 'setting'],[0. 0. 1. 1. 1. 1. 1.]
NCT02836899,1:25:treatment,Emergent cardiac surgery,['Emergent' 'cardiac' 'surgery'],[1. 1. 1.]
NCT02836574,19:39:chronic_disease,history of severe systemic reaction(s),['history' 'of' 'severe' 'systemic' 'reaction' '(' 's' ')'],[0. 0. 0. 2. 2. 0. 0. 0.]
NCT02834403,19:41:treatment,Concurrent use of potent CYP3A4 inducers,['Concurrent' 'use' 'of' 'potent' 'CYP3A4' 'inducers'],[0. 0. 0. 1. 1. 1.]
NCT02834403,1:27:chronic_disease,Severe renal insufficiency,['Severe' 'renal' 'insufficiency'],[2. 2. 2.]
NCT02833792,1:32:treatment,Prior treatment with stem cells,['Prior' 'treatment' 'with' 'stem' 'cells'],[1. 1. 1. 1. 1.]
NCT02832115,24:38:treatment,Likely need for use of nitroglycerine for non-study indication,"['Likely' 'need' 'for' 'use' 'of' 'nitroglycerine' 'for' 'non-study'
 'indication']",[0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02832115,7:17:treatment,known LIMA graft,['known' 'LIMA' 'graft'],[0. 1. 1.]
NCT02830074,"6:19:chronic_disease,",with chronic SCI/D (>3 months post injury),['with' 'chronic' 'SCI/D' '(' '>' '3' 'months' 'post' 'injury' ')'],[0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02829268,"10:36:treatment,",received blood product transfusions within 90 days prior to screening,"['received' 'blood' 'product' 'transfusions' 'within' '90' 'days' 'prior'
 'to' 'screening']",[0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02828592,10:22:chronic_disease,markedly hypocellular,['markedly' 'hypocellular'],[0. 2.]
NCT02826681,"13:29:treatment,",Subjects on sleep medication must be on a stable dose for at least 6 months prior screening,"['Subjects' 'on' 'sleep' 'medication' 'must' 'be' 'on' 'a' 'stable' 'dose'
 'for' 'at' 'least' '6' 'months' 'prior' 'screening']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02826577,12:32:chronic_disease,History of heart irregularities,['History' 'of' 'heart' 'irregularities'],[0. 0. 2. 2.]
NCT02824276,15:34:treatment,candidate for oral opioid therapy as assessed at the BWH Pain Management Center,"['candidate' 'for' 'oral' 'opioid' 'therapy' 'as' 'assessed' 'at' 'the'
 'BWH' 'Pain' 'Management' 'Center']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02823665,1:25:chronic_disease,type 2 diabetes mellitis,['type' '2' 'diabetes' 'mellitis'],[2. 2. 2. 2.]
NCT02822378,1:10:treatment,denosumab at any time,['denosumab' 'at' 'any' 'time'],[1. 0. 0. 0.]
NCT02822378,"1:9:treatment,",tibolone within the past 3 months,['tibolone' 'within' 'the' 'past' '3' 'months'],[1. 0. 0. 0. 0. 0.]
NCT02819843,67:83:chronic_disease,"Previously infected, with evidence of immunity and no evidence of active hepatitis","['Previously' 'infected' ',' 'with' 'evidence' 'of' 'immunity' 'and' 'no'
 'evidence' 'of' 'active' 'hepatitis']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02819635,1:19:treatment,biologic therapies in the opinion of the investigator,['biologic' 'therapies' 'in' 'the' 'opinion' 'of' 'the' 'investigator'],[1. 1. 0. 0. 0. 0. 0. 0.]
NCT02819141,34:89:treatment,currently receiving a continuous intravenous infusion of a sedative/opioid medication(s),"['currently' 'receiving' 'a' 'continuous' 'intravenous' 'infusion' 'of'
 'a' 'sedative/opioid' 'medication' '(' 's' ')']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0.]
NCT02816736,22:47:treatment,patients who require chronic inotropic therapy,['patients' 'who' 'require' 'chronic' 'inotropic' 'therapy'],[0. 0. 0. 1. 1. 1.]
NCT02815917,"8:35:treatment,","Use of dopaminergic CNS stimulants (prescription, over-the counter or recreational drugs) within 30 days of screening intake visit, as assessed by review of health history form and concomitant medication review at screening intake visit (from medical record and/or self-reported) that are deemed by a physician investigator to have a potential influence on the binding of [18F]FTP","['Use' 'of' 'dopaminergic' 'CNS' 'stimulants' '(' 'prescription' ','
 'over-the' 'counter' 'or' 'recreational' 'drugs' ')' 'within' '30' 'days'
 'of' 'screening' 'intake' 'visit' ',' 'as' 'assessed' 'by' 'review' 'of'
 'health' 'history' 'form' 'and' 'concomitant' 'medication' 'review' 'at'
 'screening' 'intake' 'visit' '(' 'from' 'medical' 'record' 'and/or'
 'self-reported' ')' 'that' 'are' 'deemed' 'by' 'a' 'physician'
 'investigator' 'to' 'have' 'a' 'potential' 'influence' 'on' 'the'
 'binding' 'of' '[' '18F' ']' 'FTP']","[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02811263,"11:59:chronic_disease,,",Receiving active or passive whole body cooling/hypothermia since < 6 hours of age,"['Receiving' 'active' 'or' 'passive' 'whole' 'body' 'cooling/hypothermia'
 'since' '<' '6' 'hours' 'of' 'age']",[0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02808442,1:17:cancer,Burkitt leukemia,['Burkitt' 'leukemia'],[3. 3.]
NCT02807883,15:24:cancer,Patients with B-lineage,['Patients' 'with' 'B-lineage'],[0. 0. 3.]
NCT02807272,25:38:chronic_disease,Modification of Diet in Renal Disease formulas,['Modification' 'of' 'Diet' 'in' 'Renal' 'Disease' 'formulas'],[0. 0. 0. 0. 2. 2. 0.]
NCT02805504,21:37:treatment,Patients undergoing urologic surgery,['Patients' 'undergoing' 'urologic' 'surgery'],[0. 0. 1. 1.]
NCT02804230,"34:59:chronic_disease,",Patients with a known history of psychogenic non-epileptic spells in the last three years,"['Patients' 'with' 'a' 'known' 'history' 'of' 'psychogenic'
 'non-epileptic' 'spells' 'in' 'the' 'last' 'three' 'years']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02803359,29:65:treatment,Healthy Subjects undergoing thyroid or other open neck surgeries,"['Healthy' 'Subjects' 'undergoing' 'thyroid' 'or' 'other' 'open' 'neck'
 'surgeries']",[0. 0. 0. 1. 1. 1. 1. 1. 1.]
NCT02803359,1:33:chronic_disease,Laryngopharyngeal Reflux Disease,['Laryngopharyngeal' 'Reflux' 'Disease'],[2. 2. 2.]
NCT02803164,105:129:chronic_disease,Subject is scheduled to undergo surgical intervention(s) as part of the standard care for management of intra-thoracic infection,"['Subject' 'is' 'scheduled' 'to' 'undergo' 'surgical' 'intervention' '('
 's' ')' 'as' 'part' 'of' 'the' 'standard' 'care' 'for' 'management' 'of'
 'intra-thoracic' 'infection']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02801539,31:42:treatment,Able to complete a home-based RMT regimen,['Able' 'to' 'complete' 'a' 'home-based' 'RMT' 'regimen'],[0. 0. 0. 0. 0. 1. 1.]
NCT02801136,7:28:chronic_disease,Other serious mental health diagnoses,['Other' 'serious' 'mental' 'health' 'diagnoses'],[0. 2. 2. 2. 0.]
NCT02798458,14:40:allergy_name,Allergies to components of the SmartBar,['Allergies' 'to' 'components' 'of' 'the' 'SmartBar'],[0. 0. 4. 4. 4. 4.]
NCT02798458,21:28:chronic_disease,Previous history of bezoars,['Previous' 'history' 'of' 'bezoars'],[0. 0. 0. 2.]
NCT02796391,1:30:treatment,"Clozapine (Clozaril, FazaClo)","['Clozapine' '(' 'Clozaril' ',' 'FazaClo' ')']",[1. 1. 1. 0. 0. 0.]
NCT02796391,1:23:treatment,Irinotecan (Camptosar),['Irinotecan' '(' 'Camptosar' ')'],[1. 1. 0. 0.]
NCT02796391,22:41:chronic_disease,significant unstable medical/psychiatric or substance use disorders,"['significant' 'unstable' 'medical/psychiatric' 'or' 'substance' 'use'
 'disorders']",[0. 0. 2. 0. 0. 0. 0.]
NCT02796209,1:35:chronic_disease,Neurogenic Orthostatic Hypotension,['Neurogenic' 'Orthostatic' 'Hypotension'],[2. 2. 2.]
NCT02796209,1:12:treatment,delavirdine,['delavirdine'],[1.]
NCT02793921,36:49:cancer,"Diagnosed with Stage 0, 1, 2 or 3a Breast Cancer","['Diagnosed' 'with' 'Stage' '0' ',' '1' ',' '2' 'or' '3a' 'Breast'
 'Cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02793921,1:17:treatment,wound dehiscence,['wound' 'dehiscence'],[1. 1.]
NCT02792257,13:20:chronic_disease,Presence of Agit-AD as defined by the provisional criteria from the International Psychogeriatric Association (IPA),"['Presence' 'of' 'Agit-AD' 'as' 'defined' 'by' 'the' 'provisional'
 'criteria' 'from' 'the' 'International' 'Psychogeriatric' 'Association'
 '(' 'IPA' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02789111,1:31:chronic_disease,Chronic kidney disease stage 5,['Chronic' 'kidney' 'disease' 'stage' '5'],[2. 2. 2. 2. 2.]
NCT02783716,",84:103:treatment",Patients who are unwilling or unable to return for follow up visits 3 months after device implantation,"['Patients' 'who' 'are' 'unwilling' 'or' 'unable' 'to' 'return' 'for'
 'follow' 'up' 'visits' '3' 'months' 'after' 'device' 'implantation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02780401,1:23:chronic_disease,Dilated cardiomyopathy,['Dilated' 'cardiomyopathy'],[2. 2.]
NCT02779556,1:22:chronic_disease,cognitive impairments,['cognitive' 'impairments'],[2. 2.]
NCT02778867,28:53:chronic_disease,Have been diagnosed with a GI malabsorption disorder,['Have' 'been' 'diagnosed' 'with' 'a' 'GI' 'malabsorption' 'disorder'],[0. 0. 0. 0. 0. 2. 2. 2.]
NCT02778867,1:18:allergy_name,IgE-mediated food allergy,['IgE-mediated' 'food' 'allergy'],[4. 4. 0.]
NCT02778529,1:26:chronic_disease,Cervical SCI (C-5 to C-7),['Cervical' 'SCI' '(' 'C-5' 'to' 'C-7' ')'],[2. 2. 2. 2. 2. 0. 0.]
NCT02778282,1:33:chronic_disease,Substantial cognitive impairment,['Substantial' 'cognitive' 'impairment'],[2. 2. 2.]
NCT02776761,8:23:chronic_disease,single febrile seizure as a child,['single' 'febrile' 'seizure' 'as' 'a' 'child'],[0. 2. 2. 0. 0. 0.]
NCT02775162,12:40:treatment,undergoing simultaneous transplantation of more than one organ,"['undergoing' 'simultaneous' 'transplantation' 'of' 'more' 'than' 'one'
 'organ']",[0. 1. 1. 0. 0. 0. 0. 0.]
NCT02774421,1:14:cancer,subependymoma,['subependymoma'],[3.]
NCT02772562,1:23:cancer,pN1 lymph node disease,['pN1' 'lymph' 'node' 'disease'],[3. 3. 3. 3.]
NCT02772302,1:26:chronic_disease,Minimally conscious state,['Minimally' 'conscious' 'state'],[2. 2. 2.]
NCT02771626,16:45:treatment,Intolerance to prior anti-PD-1/PD-L1 therapy,['Intolerance' 'to' 'prior' 'anti-PD-1/PD-L1' 'therapy'],[0. 0. 1. 1. 1.]
NCT02770547,1:32:treatment,Implanted cardiac defibrillator,['Implanted' 'cardiac' 'defibrillator'],[1. 1. 1.]
NCT02770326,1:22:chronic_disease,Gastrointestinal (GI) contraindications,['Gastrointestinal' '(' 'GI' ')' 'contraindications'],[2. 2. 0. 0. 0.]
NCT02770326,1:24:chronic_disease,Small bowel obstruction,['Small' 'bowel' 'obstruction'],[2. 2. 2.]
NCT02769611,"1:26:treatment,",Resynchronization therapy initiated less than 90 days prior to enrollment,"['Resynchronization' 'therapy' 'initiated' 'less' 'than' '90' 'days'
 'prior' 'to' 'enrollment']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02768727,23:49:chronic_disease,Current or history of neuropsychiatric disorders,['Current' 'or' 'history' 'of' 'neuropsychiatric' 'disorders'],[0. 0. 0. 0. 2. 2.]
NCT02766998,32:77:chronic_disease,all pre-natal diagnoses of any single ventricle circulation physiology (SVP),"['all' 'pre-natal' 'diagnoses' 'of' 'any' 'single' 'ventricle'
 'circulation' 'physiology' '(' 'SVP' ')']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0.]
NCT02765633,"26:58:treatment,,",Participation in another investigational therapeutic drug or investigational therapeutic device trial within 30 days of starting study,"['Participation' 'in' 'another' 'investigational' 'therapeutic' 'drug'
 'or' 'investigational' 'therapeutic' 'device' 'trial' 'within' '30'
 'days' 'of' 'starting' 'study']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02764801,25:48:treatment,who have received prior radioembolization (Y90) of the lesion of interest,"['who' 'have' 'received' 'prior' 'radioembolization' '(' 'Y90' ')' 'of'
 'the' 'lesion' 'of' 'interest']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02763917,13:41:chronic_disease,Significant pulmonary or cardiac disease,['Significant' 'pulmonary' 'or' 'cardiac' 'disease'],[0. 2. 2. 2. 2.]
NCT02762825,"34:51:treatment,,",Referred by physician to CR with echocardiographic evidence of HFpEF defined as an ejection fraction ≥ 50 %,"['Referred' 'by' 'physician' 'to' 'CR' 'with' 'echocardiographic'
 'evidence' 'of' 'HFpEF' 'defined' 'as' 'an' 'ejection' 'fraction' '≥'
 '50' '%']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02762773,15:63:chronic_disease,Patients with pre-gestational or gestational diabetes mellitus,"['Patients' 'with' 'pre-gestational' 'or' 'gestational' 'diabetes'
 'mellitus']",[0. 0. 2. 2. 2. 2. 2.]
NCT02762266,1:24:cancer,Extrahepatic metastases,['Extrahepatic' 'metastases'],[3. 3.]
NCT02762266,"1:22:cancer,",Unifocal liver tumors not to exceed 7.5 cm in greatest axial dimension,"['Unifocal' 'liver' 'tumors' 'not' 'to' 'exceed' '7.5' 'cm' 'in'
 'greatest' 'axial' 'dimension']",[3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02762032,1:20:treatment,Immunosuppressant's,"['Immunosuppressant' ""'s""]",[1. 1.]
NCT02760498,69:88:allergy_name,Allergic reactions or acute hypersensitivity reaction attributed to antibody treatments,"['Allergic' 'reactions' 'or' 'acute' 'hypersensitivity' 'reaction'
 'attributed' 'to' 'antibody' 'treatments']",[0. 0. 0. 0. 0. 0. 0. 0. 4. 4.]
NCT02759575,1:60:treatment,Prior radiation therapy to the larynx area or involved neck,"['Prior' 'radiation' 'therapy' 'to' 'the' 'larynx' 'area' 'or' 'involved'
 'neck']",[1. 1. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT02758847,1:15:chronic_disease,Acute thrombus in the target limb,['Acute' 'thrombus' 'in' 'the' 'target' 'limb'],[2. 2. 0. 0. 0. 0.]
NCT02755896,1:28:cancer,"Stage 1 (pT1) breast cancer, excised with negative margins","['Stage' '1' '(' 'pT1' ')' 'breast' 'cancer' ',' 'excised' 'with'
 'negative' 'margins']",[3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02755116,30:48:treatment,Patient scheduled to undergo ambulatory surgery under general anesthesia,"['Patient' 'scheduled' 'to' 'undergo' 'ambulatory' 'surgery' 'under'
 'general' 'anesthesia']",[0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT02752191,25:28:chronic_disease,with known or suspected CHD with inconclusive echocardiographic exams,"['with' 'known' 'or' 'suspected' 'CHD' 'with' 'inconclusive'
 'echocardiographic' 'exams']",[0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT02750319,8:25:chronic_disease,not in cardiogenic shock,['not' 'in' 'cardiogenic' 'shock'],[0. 0. 2. 2.]
NCT02748070,22:46:treatment,scheduled to undergo endoscopic sinus surgery,['scheduled' 'to' 'undergo' 'endoscopic' 'sinus' 'surgery'],[0. 0. 0. 1. 1. 1.]
NCT02747238,10:26:treatment,Previous spinal surgeries,['Previous' 'spinal' 'surgeries'],[0. 1. 1.]
NCT02746458,12:24:cancer,History of lymphotomies,['History' 'of' 'lymphotomies'],[0. 0. 3.]
NCT02746458,1:30:chronic_disease,severe traumatic brain injury,['severe' 'traumatic' 'brain' 'injury'],[2. 2. 2. 2.]
NCT02744677,15:34:chronic_disease,History of or active endocarditis,['History' 'of' 'or' 'active' 'endocarditis'],[0. 0. 0. 2. 2.]
NCT02744430,27:61:treatment,Patients already taking a beta-adrenergic agonist medication,"['Patients' 'already' 'taking' 'a' 'beta-adrenergic' 'agonist'
 'medication']",[0. 0. 0. 0. 1. 1. 1.]
NCT02744391,"55:75:chronic_disease,",Diagnosis of substance abuse or dependence (excluding Tobacco Use Disorder) within the past 12 months,"['Diagnosis' 'of' 'substance' 'abuse' 'or' 'dependence' '(' 'excluding'
 'Tobacco' 'Use' 'Disorder' ')' 'within' 'the' 'past' '12' 'months']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02743728,1:20:chronic_disease,Metabolic Disorders,['Metabolic' 'Disorders'],[2. 2.]
NCT02743494,16:43:cancer,Diagnosed with Stage IV resectable disease,['Diagnosed' 'with' 'Stage' 'IV' 'resectable' 'disease'],[0. 0. 3. 3. 3. 3.]
NCT02741791,1:8:chronic_disease,Suicide risk,['Suicide' 'risk'],[2. 0.]
NCT02740543,"1:23:treatment,",Inhaled corticosteroid use in previous 1 month or more will be allowed,"['Inhaled' 'corticosteroid' 'use' 'in' 'previous' '1' 'month' 'or' 'more'
 'will' 'be' 'allowed']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02740361,52:56:treatment,willingness to engage in self-administration of an iCBT intervention for 3 months and complete follow-up,"['willingness' 'to' 'engage' 'in' 'self-administration' 'of' 'an' 'iCBT'
 'intervention' 'for' '3' 'months' 'and' 'complete' 'follow-up']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02737930,1:21:chronic_disease,Premorbid depression,['Premorbid' 'depression'],[2. 2.]
NCT02734771,1:19:cancer,Composite lymphoma containing both indolent and large cell features will be included,"['Composite' 'lymphoma' 'containing' 'both' 'indolent' 'and' 'large'
 'cell' 'features' 'will' 'be' 'included']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02734134,15:30:chronic_disease,Patients with systemic sepsis who require emergent surgery,"['Patients' 'with' 'systemic' 'sepsis' 'who' 'require' 'emergent'
 'surgery']",[0. 0. 2. 2. 0. 0. 0. 0.]
NCT02730481,"10:13:treatment,,","Received IPs within 14 days or 5 half-lives of the first study dosing day, whichever is longer","['Received' 'IPs' 'within' '14' 'days' 'or' '5' 'half-lives' 'of' 'the'
 'first' 'study' 'dosing' 'day' ',' 'whichever' 'is' 'longer']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02727062,1:17:cancer,Laryngeal cancer,['Laryngeal' 'cancer'],[3. 3.]
NCT02726347,21:46:treatment,subjects who are on immune suppressive agents,['subjects' 'who' 'are' 'on' 'immune' 'suppressive' 'agents'],[0. 0. 0. 0. 1. 1. 1.]
NCT02725177,",28:75:treatment",Recent (less than 4 weeks) intra-ocular or intra-orbital steroid injection,"['Recent' '(' 'less' 'than' '4' 'weeks' ')' 'intra-ocular' 'or'
 'intra-orbital' 'steroid' 'injection']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1.]
NCT02724540,"12:31:cancer,,",Measurable metastasis to liver with at least one dimension ≥ 1.0 cm,"['Measurable' 'metastasis' 'to' 'liver' 'with' 'at' 'least' 'one'
 'dimension' '≥' '1.0' 'cm']",[0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02724540,1:10:treatment,sedatives,['sedatives'],[1.]
NCT02723994,1:54:treatment,CRLF2 rearrangement with JAK1 or JAK2 mutation (JAK+),"['CRLF2' 'rearrangement' 'with' 'JAK1' 'or' 'JAK2' 'mutation' '(' 'JAK+'
 ')']",[1. 1. 1. 1. 1. 1. 1. 1. 0. 0.]
NCT02723994,1:27:chronic_disease,Trisomy 21 (Down syndrome),['Trisomy' '21' '(' 'Down' 'syndrome' ')'],[2. 2. 2. 2. 0. 0.]
NCT02721303,12:29:treatment,Use of any weight loss drugs,['Use' 'of' 'any' 'weight' 'loss' 'drugs'],[0. 0. 0. 1. 1. 1.]
NCT02718001,25:57:chronic_disease,"Clinically significant, symptomatic mitral regurgitation","['Clinically' 'significant' ',' 'symptomatic' 'mitral' 'regurgitation']",[0. 0. 0. 2. 2. 2.]
NCT02712736,22:54:chronic_disease,Patients with active inflammatory bowel disease (IBD) flares,"['Patients' 'with' 'active' 'inflammatory' 'bowel' 'disease' '(' 'IBD' ')'
 'flares']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0.]
NCT02710396,24:57:chronic_disease,Has a known history of active TB (Bacillus Tuberculosis),"['Has' 'a' 'known' 'history' 'of' 'active' 'TB' '(' 'Bacillus'
 'Tuberculosis' ')']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02709655,17:48:chronic_disease,"The patient has Major depressive disorder (MDD), diagnosed according to DSM-5™","['The' 'patient' 'has' 'Major' 'depressive' 'disorder' '(' 'MDD' ')' ','
 'diagnosed' 'according' 'to' 'DSM-5™']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02707471,",31:34:chronic_disease",within 12 months of beginning AET,['within' '12' 'months' 'of' 'beginning' 'AET'],[0. 0. 0. 0. 0. 2.]
NCT02703272,16:66:chronic_disease,A diagnosis of post-transplant lymphoproliferative disease (PTLD),"['A' 'diagnosis' 'of' 'post-transplant' 'lymphoproliferative' 'disease'
 '(' 'PTLD' ')']",[0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02703220,7:56:treatment,other central nervous system (CNS) altering medications,"['other' 'central' 'nervous' 'system' '(' 'CNS' ')' 'altering'
 'medications']",[0. 1. 1. 1. 1. 1. 1. 0. 0.]
NCT02700451,",,22:42:treatment",Require 1 or 2 level lumbar spinal fusion through posterior or lateral approach,"['Require' '1' 'or' '2' 'level' 'lumbar' 'spinal' 'fusion' 'through'
 'posterior' 'or' 'lateral' 'approach']",[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02698722,1:17:chronic_disease,Stage 4 or 5 CKD,['Stage' '4' 'or' '5' 'CKD'],[2. 2. 2. 2. 2.]
NCT02695043,29:55:chronic_disease,Trauma related intracranial neuroimaging abnormalities,['Trauma' 'related' 'intracranial' 'neuroimaging' 'abnormalities'],[0. 0. 0. 2. 2.]
NCT02693990,16:40:treatment,The effects of proton radiation therapy on the developing human fetus are known to be teratogenic,"['The' 'effects' 'of' 'proton' 'radiation' 'therapy' 'on' 'the'
 'developing' 'human' 'fetus' 'are' 'known' 'to' 'be' 'teratogenic']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02690116,1:15:chronic_disease,Hypothyroidism (fatigue-related factor),['Hypothyroidism' '(' 'fatigue-related' 'factor' ')'],[2. 0. 0. 0. 0.]
NCT02688647,"16:47:treatment,",Treatment with endothelin receptor antagonists within 4 weeks before study entry,"['Treatment' 'with' 'endothelin' 'receptor' 'antagonists' 'within' '4'
 'weeks' 'before' 'study' 'entry']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02688309,"20:66:treatment,",Previous use of an anti-Vascular Endothelial Growth Factor (VEGF) drug within 1 month of study entry,"['Previous' 'use' 'of' 'an' 'anti-Vascular' 'Endothelial' 'Growth'
 'Factor' '(' 'VEGF' ')' 'drug' 'within' '1' 'month' 'of' 'study' 'entry']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02687906,10:23:chronic_disease,Signs of severe sepsis,['Signs' 'of' 'severe' 'sepsis'],[0. 0. 2. 2.]
NCT02686528,20:45:chronic_disease,Index diagnosis of noninflammatory arthritis,['Index' 'diagnosis' 'of' 'noninflammatory' 'arthritis'],[0. 0. 0. 2. 2.]
NCT02685605,1:21:chronic_disease,Supratentorial T1-Gd enhancing lesion(s) amenable to total resection,"['Supratentorial' 'T1-Gd' 'enhancing' 'lesion' '(' 's' ')' 'amenable' 'to'
 'total' 'resection']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02682147,38:48:allergy_name,Prior history of hypersensitivity to Sildenafil,['Prior' 'history' 'of' 'hypersensitivity' 'to' 'Sildenafil'],[0. 0. 0. 0. 0. 4.]
NCT02680574,1:51:treatment,surgical or percutaneous intervention for coronary,['surgical' 'or' 'percutaneous' 'intervention' 'for' 'coronary'],[1. 1. 1. 1. 1. 1.]
NCT02680535,"1:37:chronic_disease,,,,,,,,,","acute or chronic hepatic dysfunction as evidenced by clinically significant abnormalities in albumin, total protein, or prothrombin time, or evidence of hepatic injury with clinically important (> grade 1) changes in AST, ALT, ALP, bilirubin, or GGT values","['acute' 'or' 'chronic' 'hepatic' 'dysfunction' 'as' 'evidenced' 'by'
 'clinically' 'significant' 'abnormalities' 'in' 'albumin' ',' 'total'
 'protein' ',' 'or' 'prothrombin' 'time' ',' 'or' 'evidence' 'of'
 'hepatic' 'injury' 'with' 'clinically' 'important' '(' '>' 'grade' '1'
 ')' 'changes' 'in' 'AST' ',' 'ALT' ',' 'ALP' ',' 'bilirubin' ',' 'or'
 'GGT' 'values']","[2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02680145,9:27:chronic_disease,Have an isolated rectocele,['Have' 'an' 'isolated' 'rectocele'],[0. 0. 2. 2.]
NCT02678351,9:49:treatment,Planned prostatectomy with lymph node dissection,['Planned' 'prostatectomy' 'with' 'lymph' 'node' 'dissection'],[0. 1. 1. 1. 1. 1.]
NCT02674529,43:70:treatment,Have a medical condition that contradicts treatment with escitalopram,"['Have' 'a' 'medical' 'condition' 'that' 'contradicts' 'treatment' 'with'
 'escitalopram']",[0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02672098,21:36:chronic_disease,Patients with known acute hepatitis,['Patients' 'with' 'known' 'acute' 'hepatitis'],[0. 0. 0. 2. 2.]
NCT02670837,14:52:chronic_disease,Diagnosis of Dystrophic Epidermolysis Bullosa (DEB),['Diagnosis' 'of' 'Dystrophic' 'Epidermolysis' 'Bullosa' '(' 'DEB' ')'],[0. 0. 2. 2. 2. 2. 0. 0.]
NCT02670837,26:60:treatment,Skin Graft Donor (either hematopoietic cell transplantation donor for the EB patient [Arm A] or EB patient herself/himself [Arm B]),"['Skin' 'Graft' 'Donor' '(' 'either' 'hematopoietic' 'cell'
 'transplantation' 'donor' 'for' 'the' 'EB' 'patient' '[' 'Arm' 'A' ']'
 'or' 'EB' 'patient' 'herself/himself' '[' 'Arm' 'B' ']' ')']","[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02669173,"39:61:chronic_disease,",Electrocardiogram without evidence of acute cardiac ischemia within 14 days prior study registration,"['Electrocardiogram' 'without' 'evidence' 'of' 'acute' 'cardiac'
 'ischemia' 'within' '14' 'days' 'prior' 'study' 'registration']",[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02667418,",86:97:chronic_disease,",Current episode represents the first recurrent episode of CDI within 3 months of the primary CDI episode in a patient who has not had CDI in the 3 months prior to the primary episode,"['Current' 'episode' 'represents' 'the' 'first' 'recurrent' 'episode' 'of'
 'CDI' 'within' '3' 'months' 'of' 'the' 'primary' 'CDI' 'episode' 'in' 'a'
 'patient' 'who' 'has' 'not' 'had' 'CDI' 'in' 'the' '3' 'months' 'prior'
 'to' 'the' 'primary' 'episode']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02667418,1:11:treatment,vancomycin,['vancomycin'],[1.]
NCT02665962,22:40:cancer,Newly diagnosed with Endometrial Cancer,['Newly' 'diagnosed' 'with' 'Endometrial' 'Cancer'],[0. 0. 0. 3. 3.]
NCT02665338,1:17:chronic_disease,Major Depression,['Major' 'Depression'],[2. 2.]
NCT02664909,21:49:treatment,Patients undergoing hip hemiarthroplasty surgery for a displaced femoral neck fracture,"['Patients' 'undergoing' 'hip' 'hemiarthroplasty' 'surgery' 'for' 'a'
 'displaced' 'femoral' 'neck' 'fracture']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02664168,48:86:treatment,Skin integrity issues that preclude the use of Negative Pressure Wound Therapy (NPWT),"['Skin' 'integrity' 'issues' 'that' 'preclude' 'the' 'use' 'of' 'Negative'
 'Pressure' 'Wound' 'Therapy' '(' 'NPWT' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0.]
NCT02663908,"1:29:chronic_disease,",Acute cardiovascular disease in the previous 30 days,['Acute' 'cardiovascular' 'disease' 'in' 'the' 'previous' '30' 'days'],[2. 2. 2. 0. 0. 0. 0. 0.]
NCT02663596,76:86:allergy_name,History of any moderate or severe hypersensitivity or allergic reaction to vancomcyin (a history of mild rash followed by uneventful re-exposure and/or red man syndrome is not a contraindication),"['History' 'of' 'any' 'moderate' 'or' 'severe' 'hypersensitivity' 'or'
 'allergic' 'reaction' 'to' 'vancomcyin' '(' 'a' 'history' 'of' 'mild'
 'rash' 'followed' 'by' 'uneventful' 're-exposure' 'and/or' 'red' 'man'
 'syndrome' 'is' 'not' 'a' 'contraindication' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02660528,"1:32:chronic_disease,",Active drug or alcohol disorder in the last three months,"['Active' 'drug' 'or' 'alcohol' 'disorder' 'in' 'the' 'last' 'three'
 'months']",[2. 2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02660528,1:10:chronic_disease,hypomania,['hypomania'],[2.]
NCT02657993,"1:22:treatment,",Bone fracture/surgery of an extremity during the preceding 6 months,"['Bone' 'fracture/surgery' 'of' 'an' 'extremity' 'during' 'the'
 'preceding' '6' 'months']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02656550,14:45:chronic_disease,Subject with Diabetes Mellitus Type I and II by medical history,"['Subject' 'with' 'Diabetes' 'Mellitus' 'Type' 'I' 'and' 'II' 'by'
 'medical' 'history']",[0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0.]
NCT02655614,"18:27:treatment,,,","Currently taking edaravone unless after completion of at least the second 14-day drug-treatment period, as long as Day 1 occurs during a drug-free period at least 24 hours after the last edaravone dose and at least 5 days prior to the first dose of the next cycle","['Currently' 'taking' 'edaravone' 'unless' 'after' 'completion' 'of' 'at'
 'least' 'the' 'second' '14-day' 'drug-treatment' 'period' ',' 'as' 'long'
 'as' 'Day' '1' 'occurs' 'during' 'a' 'drug-free' 'period' 'at' 'least'
 '24' 'hours' 'after' 'the' 'last' 'edaravone' 'dose' 'and' 'at' 'least'
 '5' 'days' 'prior' 'to' 'the' 'first' 'dose' 'of' 'the' 'next' 'cycle']","[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02650206,1:11:chronic_disease,Gallstones,['Gallstones'],[2.]
NCT02650206,31:55:cancer,Personal or family history of medullary thyroid cancer,['Personal' 'or' 'family' 'history' 'of' 'medullary' 'thyroid' 'cancer'],[0. 0. 0. 0. 0. 3. 3. 3.]
NCT02646930,13:62:treatment,Patients on monoclonal antibody preparations directed to TNFα,"['Patients' 'on' 'monoclonal' 'antibody' 'preparations' 'directed' 'to'
 'TNFα']",[0. 0. 1. 1. 1. 1. 1. 1.]
NCT02646787,60:85:treatment,Any face/head/neck injuries that interfere with the use of Virtual Reality equipment,"['Any' 'face/head/neck' 'injuries' 'that' 'interfere' 'with' 'the' 'use'
 'of' 'Virtual' 'Reality' 'equipment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02645539,1:29:chronic_disease,Severe end-organ dysfunction or failure,['Severe' 'end-organ' 'dysfunction' 'or' 'failure'],[2. 2. 2. 0. 0.]
NCT02641093,1:15:cancer,Nasopharyngeal,['Nasopharyngeal'],[3.]
NCT02640950,"17:34:chronic_disease,",The patient has attempted suicide within the past 12 months prior to Screening,"['The' 'patient' 'has' 'attempted' 'suicide' 'within' 'the' 'past' '12'
 'months' 'prior' 'to' 'Screening']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02640638,1:24:chronic_disease,Pregestational diabetes,['Pregestational' 'diabetes'],[2. 2.]
NCT02639390,19:54:treatment,Receiving oral or injected antispasticity medications during study treatment,"['Receiving' 'oral' 'or' 'injected' 'antispasticity' 'medications'
 'during' 'study' 'treatment']",[0. 0. 0. 1. 1. 1. 0. 0. 0.]
NCT02639065,1:24:chronic_disease,Ventricular arrhythmias requiring medication(s),['Ventricular' 'arrhythmias' 'requiring' 'medication' '(' 's' ')'],[2. 2. 0. 0. 0. 0. 0.]
NCT02638454,",,,,,,158:176:chronic_disease,,","10 subjects with Normal Muscle Mass and 10 subjects with Low Muscle Mass as determined by DXA scan (70-85 years of age cohort) Low Muscle Mass is defined as Class I Sarcopenia, Skeletal Muscle Index within 1 to 2 standard deviations from the sex-specific mean of young adults","['10' 'subjects' 'with' 'Normal' 'Muscle' 'Mass' 'and' '10' 'subjects'
 'with' 'Low' 'Muscle' 'Mass' 'as' 'determined' 'by' 'DXA' 'scan' '('
 '70-85' 'years' 'of' 'age' 'cohort' ')' 'Low' 'Muscle' 'Mass' 'is'
 'defined' 'as' 'Class' 'I' 'Sarcopenia' ',' 'Skeletal' 'Muscle' 'Index'
 'within' '1' 'to' '2' 'standard' 'deviations' 'from' 'the' 'sex-specific'
 'mean' 'of' 'young' 'adults']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02638454,13:28:chronic_disease,Significant immune disorder,['Significant' 'immune' 'disorder'],[0. 2. 2.]
NCT02636530,"1:21:treatment,",anti-resorptive drug use in the last 2 years,['anti-resorptive' 'drug' 'use' 'in' 'the' 'last' '2' 'years'],[1. 1. 0. 0. 0. 0. 0. 0.]
NCT02635919,21:42:treatment,Recently prescribed varenicline (Chantix) with the intention to quit smoking in the next 3 months,"['Recently' 'prescribed' 'varenicline' '(' 'Chantix' ')' 'with' 'the'
 'intention' 'to' 'quit' 'smoking' 'in' 'the' 'next' '3' 'months']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02634957,15:55:chronic_disease,Patients with benign mid membranous vocal fold lesions,['Patients' 'with' 'benign' 'mid' 'membranous' 'vocal' 'fold' 'lesions'],[0. 0. 2. 2. 2. 2. 2. 2.]
NCT02634957,1:28:chronic_disease,Sub-epithelial fibrous mass,['Sub-epithelial' 'fibrous' 'mass'],[2. 2. 2.]
NCT02632721,1:34:cancer,"Acute promyelocytic leukemia (APL, French-American-British (FAB) subtype M3), according to WHO classification","['Acute' 'promyelocytic' 'leukemia' '(' 'APL' ','
 'French-American-British' '(' 'FAB' ')' 'subtype' 'M3' ')' ','
 'according' 'to' 'WHO' 'classification']",[3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02632422,1:24:chronic_disease,pulmonary complications,['pulmonary' 'complications'],[2. 2.]
NCT02629731,14:30:chronic_disease,diagnosis of ankle OA or PTTD [non-control subjects only],"['diagnosis' 'of' 'ankle' 'OA' 'or' 'PTTD' '[' 'non-control' 'subjects'
 'only' ']']",[0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02628535,28:49:treatment,"Patients with prior immune checkpoint inhibitors must have related toxicities reduced to Grade 0, 1, or baseline","['Patients' 'with' 'prior' 'immune' 'checkpoint' 'inhibitors' 'must'
 'have' 'related' 'toxicities' 'reduced' 'to' 'Grade' '0' ',' '1' ',' 'or'
 'baseline']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02624765,5:30:chronic_disease,Any maternal-fetal conditions associated with high odds of premature delivery or death,"['Any' 'maternal-fetal' 'conditions' 'associated' 'with' 'high' 'odds'
 'of' 'premature' 'delivery' 'or' 'death']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02624765,1:4:chronic_disease,SVT with fetal hydrops (irrespective of duration),['SVT' 'with' 'fetal' 'hydrops' '(' 'irrespective' 'of' 'duration' ')'],[2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02624765,1:20:chronic_disease,sick sinus syndrome,['sick' 'sinus' 'syndrome'],[2. 2. 2.]
NCT02624518,1:23:treatment,Post-radiation therapy,['Post-radiation' 'therapy'],[1. 1.]
NCT02624258,",29:41:treatment,,",Are more than 6 months from transplant 6) Karnofsky performance status ≥ 50 at screening,"['Are' 'more' 'than' '6' 'months' 'from' 'transplant' '6' ')' 'Karnofsky'
 'performance' 'status' '≥' '50' 'at' 'screening']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02624258,",,81:98:chronic_disease,",Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygenation > 94% on room air,"['Must' 'have' 'a' 'minimum' 'level' 'of' 'pulmonary' 'reserve' 'defined'
 'as' '≤' 'Grade' '1' 'dyspnea' 'and' 'pulse' 'oxygenation' '>' '94' '%'
 'on' 'room' 'air']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02622295,1:30:treatment,Anti-osteoporosis medications,['Anti-osteoporosis' 'medications'],[1. 1.]
NCT02622295,1:16:chronic_disease,Pressure ulcers,['Pressure' 'ulcers'],[2. 2.]
NCT02620761,25:37:treatment,No previous exposure to indomethacin,['No' 'previous' 'exposure' 'to' 'indomethacin'],[0. 0. 0. 0. 1.]
NCT02620579,21:44:treatment,previous history of upper-extremity surgery,['previous' 'history' 'of' 'upper-extremity' 'surgery'],[0. 0. 0. 1. 1.]
NCT02615873,24:32:treatment,Has a good response to Levodopa in the opinion of the investigator,"['Has' 'a' 'good' 'response' 'to' 'Levodopa' 'in' 'the' 'opinion' 'of'
 'the' 'investigator']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02615249,"1:58:treatment,",Treatment with ultraviolet (UV) light (including tanning) during the 3 weeks prior to inclusion in this study,"['Treatment' 'with' 'ultraviolet' '(' 'UV' ')' 'light' '(' 'including'
 'tanning' ')' 'during' 'the' '3' 'weeks' 'prior' 'to' 'inclusion' 'in'
 'this' 'study']",[1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02613936,",21:49:chronic_disease",less than 1 week of post-traumatic amnesia (PTA),['less' 'than' '1' 'week' 'of' 'post-traumatic' 'amnesia' '(' 'PTA' ')'],[0. 0. 0. 0. 0. 2. 2. 2. 0. 0.]
NCT02611063,1:24:chronic_disease,Active hemolytic anemia,['Active' 'hemolytic' 'anemia'],[2. 2. 2.]
NCT02608840,10:41:chronic_disease,unstable medical or psychiatric disorder,['unstable' 'medical' 'or' 'psychiatric' 'disorder'],[0. 2. 2. 2. 2.]
NCT02607748,17:33:chronic_disease,Patients in the asymptomatic CAD group,['Patients' 'in' 'the' 'asymptomatic' 'CAD' 'group'],[0. 0. 0. 2. 2. 0.]
NCT02606396,20:43:chronic_disease,Prior diagnosis of oropharyngeal dysphagia,['Prior' 'diagnosis' 'of' 'oropharyngeal' 'dysphagia'],[0. 0. 0. 2. 2.]
NCT02606045,45:49:chronic_disease,Willingness to comply with randomization to rVWF or TA study arms,"['Willingness' 'to' 'comply' 'with' 'randomization' 'to' 'rVWF' 'or' 'TA'
 'study' 'arms']",[0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT02603757,"27:52:treatment,","Patients taking high-dose Vitamin D supplementation (50,000 IU weekly) prior to enrollment","['Patients' 'taking' 'high-dose' 'Vitamin' 'D' 'supplementation' '('
 '50,000' 'IU' 'weekly' ')' 'prior' 'to' 'enrollment']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02600273,"1:19:chronic_disease,,",Acute intoxication as measured by breath alcohol level (BAL) > 0,"['Acute' 'intoxication' 'as' 'measured' 'by' 'breath' 'alcohol' 'level'
 '(' 'BAL' ')' '>' '0']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02599922,13:32:chronic_disease,Evidence of degenerative myopia regardless of the refractive error in the study eye,"['Evidence' 'of' 'degenerative' 'myopia' 'regardless' 'of' 'the'
 'refractive' 'error' 'in' 'the' 'study' 'eye']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02597985,1:21:chronic_disease,Advanced Parkinson's,"['Advanced' 'Parkinson' ""'s""]",[2. 2. 0.]
NCT02595866,1:25:chronic_disease,Active tuberculosis (TB),['Active' 'tuberculosis' '(' 'TB' ')'],[2. 2. 2. 0. 0.]
NCT02595372,1:22:treatment,Esomeprazole (Nexium),['Esomeprazole' '(' 'Nexium' ')'],[1. 1. 0. 0.]
NCT02595372,7:28:chronic_disease,Prior osteoporotic fracture,['Prior' 'osteoporotic' 'fracture'],[0. 2. 2.]
NCT02594384,1:27:cancer,mantle cell lymphoma (MCL),['mantle' 'cell' 'lymphoma' '(' 'MCL' ')'],[3. 3. 3. 3. 0. 0.]
NCT02594111,8:32:treatment,Use of anti-inflammatory agents,['Use' 'of' 'anti-inflammatory' 'agents'],[0. 0. 1. 1.]
NCT02594111,1:10:treatment,ritonavir,['ritonavir'],[1.]
NCT02593526,6:28:treatment,Post kidney transplantation,['Post' 'kidney' 'transplantation'],[0. 1. 1.]
NCT02593123,1:22:cancer,Multiple myeloma (MM),['Multiple' 'myeloma' '(' 'MM' ')'],[3. 3. 3. 0. 0.]
NCT02593123,1:59:treatment,Previous therapy with rabbit anti-thymocyte globulin (ATG),"['Previous' 'therapy' 'with' 'rabbit' 'anti-thymocyte' 'globulin' '('
 'ATG' ')']",[1. 1. 1. 1. 1. 1. 1. 0. 0.]
NCT02593123,9:44:treatment,revious myeloablative autologous transplant is permitted but not required,"['revious' 'myeloablative' 'autologous' 'transplant' 'is' 'permitted'
 'but' 'not' 'required']",[0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02593110,18:38:treatment,Currently taking aliskiren (Tekturna),['Currently' 'taking' 'aliskiren' '(' 'Tekturna' ')'],[0. 0. 1. 1. 0. 0.]
NCT02593110,"1:19:treatment,",orthopedic surgery during the past 3 months,['orthopedic' 'surgery' 'during' 'the' 'past' '3' 'months'],[1. 1. 0. 0. 0. 0. 0.]
NCT02592707,65:89:treatment,Documentation of progressive disease based on RECIST v1.1 under prior anti-tumor therapy within 6 months of entry in the study (although the progression might have occurred more than 6 months before study entry),"['Documentation' 'of' 'progressive' 'disease' 'based' 'on' 'RECIST' 'v1.1'
 'under' 'prior' 'anti-tumor' 'therapy' 'within' '6' 'months' 'of' 'entry'
 'in' 'the' 'study' '(' 'although' 'the' 'progression' 'might' 'have'
 'occurred' 'more' 'than' '6' 'months' 'before' 'study' 'entry' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02592551,1:17:chronic_disease,N3 nodal disease,['N3' 'nodal' 'disease'],[2. 2. 2.]
NCT02592551,23:26:cancer,Surgically resectable MPM with no disease extension beyond the ipsilateral hemithorax,"['Surgically' 'resectable' 'MPM' 'with' 'no' 'disease' 'extension'
 'beyond' 'the' 'ipsilateral' 'hemithorax']",[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02591147,39:49:treatment,"The approximal lesion detected in the radiograph has advanced dentine lesion (RB4, RC5, or RC6)","['The' 'approximal' 'lesion' 'detected' 'in' 'the' 'radiograph' 'has'
 'advanced' 'dentine' 'lesion' '(' 'RB4' ',' 'RC5' ',' 'or' 'RC6' ')']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02589977,1:15:chronic_disease,symptomatic HF,['symptomatic' 'HF'],[2. 2.]
NCT02589938,21:36:cancer,have a diagnosis of head/neck cance,['have' 'a' 'diagnosis' 'of' 'head/neck' 'cance'],[0. 0. 0. 0. 3. 3.]
NCT02589353,69:91:chronic_disease,"has a history of taste or smell loss or other oral disorders (e.g., burning mouth syndrome)","['has' 'a' 'history' 'of' 'taste' 'or' 'smell' 'loss' 'or' 'other' 'oral'
 'disorders' '(' 'e.g.' ',' 'burning' 'mouth' 'syndrome' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0.]
NCT02589340,16:26:chronic_disease,Mild to Severe dyskinesia,['Mild' 'to' 'Severe' 'dyskinesia'],[0. 0. 0. 2.]
NCT02588612,",,,,89:114:chronic_disease",Corrected QT interval (QTc) >450 milliseconds (msec) or QTc >480 msec for subjects with Bundle Branch Block (BBB),"['Corrected' 'QT' 'interval' '(' 'QTc' ')' '>' '450' 'milliseconds' '('
 'msec' ')' 'or' 'QTc' '>' '480' 'msec' 'for' 'subjects' 'with' 'Bundle'
 'Branch' 'Block' '(' 'BBB' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2.
 0. 0.]"
NCT02588326,"1:16:chronic_disease,",Acute sinusitis within the last six weeks prior to enrollment,"['Acute' 'sinusitis' 'within' 'the' 'last' 'six' 'weeks' 'prior' 'to'
 'enrollment']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02588326,1:15:chronic_disease,ear infections,['ear' 'infections'],[2. 2.]
NCT02588027,47:58:treatment,Patients with rotator cuff tears that require open repair,"['Patients' 'with' 'rotator' 'cuff' 'tears' 'that' 'require' 'open'
 'repair']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02587403,1:24:chronic_disease,Enterocutaneous fistula,['Enterocutaneous' 'fistula'],[2. 2.]
NCT02585973,1:20:chronic_disease,HPV/p16 (+) disease,['HPV/p16' '(' '+' ')' 'disease'],[2. 2. 2. 0. 0.]
NCT02585791,19:51:chronic_disease,Other concomitant inflammatory pulmonary disorders,['Other' 'concomitant' 'inflammatory' 'pulmonary' 'disorders'],[0. 0. 2. 2. 2.]
NCT02584933,",,,,,211:230:treatment","Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 3 months afer stopping ceritinib treatment","['Women' 'of' 'child-bearing' 'potential' ',' 'defined' 'as' 'all' 'women'
 'physiologically' 'capable' 'of' 'becoming' 'pregnant' ',' 'unless'
 'they' 'are' 'using' 'highly' 'effective' 'methods' 'of' 'contraception'
 'during' 'dosing' 'and' 'for' '3' 'months' 'afer' 'stopping' 'ceritinib'
 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02584647,77:103:treatment,these patients are at increased risk of lethal infections when treated with marrow suppressive therapy,"['these' 'patients' 'are' 'at' 'increased' 'risk' 'of' 'lethal'
 'infections' 'when' 'treated' 'with' 'marrow' 'suppressive' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02584309,1:13:cancer,Fibrosarcoma,['Fibrosarcoma'],[3.]
NCT02584309,1:40:cancer,Malignant peripheral nerve sheath tumor,['Malignant' 'peripheral' 'nerve' 'sheath' 'tumor'],[3. 3. 3. 3. 3.]
NCT02584309,"1:23:chronic_disease,,",Systolic heart failure defined as left ventricular ejection fraction ≤ 45%,"['Systolic' 'heart' 'failure' 'defined' 'as' 'left' 'ventricular'
 'ejection' 'fraction' '≤' '45' '%']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02584270,36:55:cancer,Patients with a new diagnosis of a T1/T2 tongue cancer,"['Patients' 'with' 'a' 'new' 'diagnosis' 'of' 'a' 'T1/T2' 'tongue'
 'cancer']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT02584244,",82:101:chronic_disease",total bilirubin within normal institutional limits (except in cases of malignant biliary obstruction),"['total' 'bilirubin' 'within' 'normal' 'institutional' 'limits' '('
 'except' 'in' 'cases' 'of' 'malignant' 'biliary' 'obstruction' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.]
NCT02583893,1:28:treatment,"Telithromycin (e.g., Ketek)","['Telithromycin' '(' 'e.g.' ',' 'Ketek' ')']",[1. 1. 1. 0. 0. 0.]
NCT02582957,1:15:chronic_disease,Lung contusion,['Lung' 'contusion'],[2. 2.]
NCT02582827,12:31:chronic_disease,History of vascular neuropathy,['History' 'of' 'vascular' 'neuropathy'],[0. 0. 2. 2.]
NCT02582775,16:19:chronic_disease,beta 3 laminin JEB mutants,['beta' '3' 'laminin' 'JEB' 'mutants'],[0. 0. 0. 2. 0.]
NCT02581982,25:73:cancer,Patients diagnosed with platinum-refractory metastatic urothelial cancer that is measureable based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1,"['Patients' 'diagnosed' 'with' 'platinum-refractory' 'metastatic'
 'urothelial' 'cancer' 'that' 'is' 'measureable' 'based' 'on' 'Response'
 'Evaluation' 'Criteria' 'in' 'Solid' 'Tumors' '(' 'RECIST' ')' 'criteria'
 '1.1']",[0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02581384,"1:7:cancer,",Lesion larger than 3 cm in diameter,['Lesion' 'larger' 'than' '3' 'cm' 'in' 'diameter'],[3. 0. 0. 0. 0. 0. 0.]
NCT02581215,20:42:chronic_disease,Acute or sub-acute intestinal obstruction,['Acute' 'or' 'sub-acute' 'intestinal' 'obstruction'],[0. 0. 0. 2. 2.]
NCT02580604,12:37:chronic_disease,History of type 1 or type 2 diabetes,['History' 'of' 'type' '1' 'or' 'type' '2' 'diabetes'],[0. 0. 2. 2. 2. 2. 2. 2.]
NCT02579967,19:41:chronic_disease,Infection with an opportunistic organism,['Infection' 'with' 'an' 'opportunistic' 'organism'],[0. 0. 0. 2. 2.]
NCT02579265,1:33:chronic_disease,Cyanotic congenital heart defect,['Cyanotic' 'congenital' 'heart' 'defect'],[2. 2. 2. 2.]
NCT02579265,1:15:chronic_disease,Meconium ileus,['Meconium' 'ileus'],[2. 2.]
NCT02579265,1:35:chronic_disease,spontaneous intestinal perforation,['spontaneous' 'intestinal' 'perforation'],[2. 2. 2.]
NCT02579174,37:52:treatment,"Medical contraindication to undergo preoperative CT, or inability to tolerate preoperative CT","['Medical' 'contraindication' 'to' 'undergo' 'preoperative' 'CT' ',' 'or'
 'inability' 'to' 'tolerate' 'preoperative' 'CT']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02579096,"70:94:treatment,",Previous history of failure to reach target uric acid levels despite therapy with allopurinol at dose > 300 mg/day,"['Previous' 'history' 'of' 'failure' 'to' 'reach' 'target' 'uric' 'acid'
 'levels' 'despite' 'therapy' 'with' 'allopurinol' 'at' 'dose' '>' '300'
 'mg/day']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02579044,58:107:allergy_name,Subjects who have known or suspected hypersensitivity to any of the excipients included in the formulation should not be treated,"['Subjects' 'who' 'have' 'known' 'or' 'suspected' 'hypersensitivity' 'to'
 'any' 'of' 'the' 'excipients' 'included' 'in' 'the' 'formulation'
 'should' 'not' 'be' 'treated']",[0. 0. 0. 0. 0. 0. 0. 0. 4. 4. 4. 4. 4. 4. 4. 4. 0. 0. 0. 0.]
NCT02578901,15:18:chronic_disease,Patients with DIC according to the patient's physician,"['Patients' 'with' 'DIC' 'according' 'to' 'the' 'patient' ""'s"" 'physician']",[0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02578641,1:34:cancer,Central nervous system metastasis,['Central' 'nervous' 'system' 'metastasis'],[3. 3. 3. 3.]
NCT02578641,1:31:chronic_disease,Severe intercurrent infections,['Severe' 'intercurrent' 'infections'],[2. 2. 2.]
NCT02578641,1:44:cancer,"superficial bladder tumors [Ta, Tis and T1]","['superficial' 'bladder' 'tumors' '[' 'Ta' ',' 'Tis' 'and' 'T1' ']']",[3. 3. 3. 3. 3. 3. 3. 0. 0. 0.]
NCT02577731,32:53:chronic_disease,Patients with any pre-existing hematological disease,['Patients' 'with' 'any' 'pre-existing' 'hematological' 'disease'],[0. 0. 0. 0. 2. 2.]
NCT02577549,12:21:chronic_disease,Not having knee pain,['Not' 'having' 'knee' 'pain'],[0. 0. 2. 2.]
NCT02577406,71:100:allergy_name,Subject has known or suspected to have hypersensitivity to any of the components of study treatment,"['Subject' 'has' 'known' 'or' 'suspected' 'to' 'have' 'hypersensitivity'
 'to' 'any' 'of' 'the' 'components' 'of' 'study' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 4. 4. 4.]
NCT02577406,1:30:chronic_disease,acute coronary syndrome (ACS),['acute' 'coronary' 'syndrome' '(' 'ACS' ')'],[2. 2. 2. 2. 0. 0.]
NCT02576444,48:62:cancer,"Patients with known germline BRCA mutations in breast cancers will be excluded from the study, however testing is not required for inclusion in the study","['Patients' 'with' 'known' 'germline' 'BRCA' 'mutations' 'in' 'breast'
 'cancers' 'will' 'be' 'excluded' 'from' 'the' 'study' ',' 'however'
 'testing' 'is' 'not' 'required' 'for' 'inclusion' 'in' 'the' 'study']","[0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02576431,47:89:treatment,Prior progression while receiving approved or investigational tyrosine kinase inhibitors targeting TRK,"['Prior' 'progression' 'while' 'receiving' 'approved' 'or'
 'investigational' 'tyrosine' 'kinase' 'inhibitors' 'targeting' 'TRK']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0.]
NCT02574910,54:73:allergy_name,"Known allergies, hypersensitivity, or intolerance to abiraterone acetate or its excipients (refer to United States Prescribing Information)","['Known' 'allergies' ',' 'hypersensitivity' ',' 'or' 'intolerance' 'to'
 'abiraterone' 'acetate' 'or' 'its' 'excipients' '(' 'refer' 'to' 'United'
 'States' 'Prescribing' 'Information' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 4. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02574728,19:32:cancer,participants with pineal tumors and elevations of serum or cerebrospinal fluid (CSF) alpha-fetoprotein (AFP) or beta-human chorionic gonadotropin (beta-HCG),"['participants' 'with' 'pineal' 'tumors' 'and' 'elevations' 'of' 'serum'
 'or' 'cerebrospinal' 'fluid' '(' 'CSF' ')' 'alpha-fetoprotein' '(' 'AFP'
 ')' 'or' 'beta-human' 'chorionic' 'gonadotropin' '(' 'beta-HCG' ')']","[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02574650,10:47:treatment,Previous tricuspid valve repair or replacement,['Previous' 'tricuspid' 'valve' 'repair' 'or' 'replacement'],[0. 1. 1. 1. 1. 1.]
NCT02574455,"21:39:cancer,",patients with other prior malignancies must have had at least a 3-year disease-free interval,"['patients' 'with' 'other' 'prior' 'malignancies' 'must' 'have' 'had' 'at'
 'least' 'a' '3-year' 'disease-free' 'interval']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02573883,16:41:treatment,Treatment with systemic immunomodulators,['Treatment' 'with' 'systemic' 'immunomodulators'],[0. 0. 1. 1.]
NCT02573597,",35:59:treatment",Narcotics within 3 hours prior to labor epidural placement,"['Narcotics' 'within' '3' 'hours' 'prior' 'to' 'labor' 'epidural'
 'placement']",[0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02573376,9:22:chronic_disease,Chronic HCV infection as documented by quantifiable HCV RNA,"['Chronic' 'HCV' 'infection' 'as' 'documented' 'by' 'quantifiable' 'HCV'
 'RNA']",[0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02570984,12:28:chronic_disease,History of hypoxic seizures during a wheezing episode,['History' 'of' 'hypoxic' 'seizures' 'during' 'a' 'wheezing' 'episode'],[0. 0. 2. 2. 0. 0. 0. 0.]
NCT02570984,1:27:chronic_disease,major congenital anomalies,['major' 'congenital' 'anomalies'],[2. 2. 2.]
NCT02570854,15:38:chronic_disease,Patients with Hepatitis C Virus (HCV) infection may be included if all other liver function eligibility criteria are met,"['Patients' 'with' 'Hepatitis' 'C' 'Virus' '(' 'HCV' ')' 'infection' 'may'
 'be' 'included' 'if' 'all' 'other' 'liver' 'function' 'eligibility'
 'criteria' 'are' 'met']",[0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02570321,14:31:chronic_disease,Impending or frank perforation at recruitment,['Impending' 'or' 'frank' 'perforation' 'at' 'recruitment'],[0. 0. 2. 2. 0. 0.]
NCT02570256,1:18:chronic_disease,bilateral paresis,['bilateral' 'paresis'],[2. 2.]
NCT02568267,",56:81:treatment",At least 4 weeks must have elapsed since completion of antibody-directed therapy,"['At' 'least' '4' 'weeks' 'must' 'have' 'elapsed' 'since' 'completion'
 'of' 'antibody-directed' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02568267,1:25:treatment,Prior anticancer therapy,['Prior' 'anticancer' 'therapy'],[1. 1. 1.]
NCT02567448,"20:31:treatment,",detached retina or eye surgery in the past three months,"['detached' 'retina' 'or' 'eye' 'surgery' 'in' 'the' 'past' 'three'
 'months']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02567422,",,136:147:treatment",Pregnant women are excluded from this study because M6620 (VX-970) as a DNA-damage response (DDR) inhibitor may have the potential for teratogenic or abortifacient effects,"['Pregnant' 'women' 'are' 'excluded' 'from' 'this' 'study' 'because'
 'M6620' '(' 'VX-970' ')' 'as' 'a' 'DNA-damage' 'response' '(' 'DDR' ')'
 'inhibitor' 'may' 'have' 'the' 'potential' 'for' 'teratogenic' 'or'
 'abortifacient' 'effects']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 0. 0.]"
NCT02567266,20:52:chronic_disease,Adolescents with a current substance abuse disorder as determined using the ADIS-5-C/P,"['Adolescents' 'with' 'a' 'current' 'substance' 'abuse' 'disorder' 'as'
 'determined' 'using' 'the' 'ADIS-5-C/P']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02566395,1:26:cancer,Acue myelogenous leukemia,['Acue' 'myelogenous' 'leukemia'],[3. 3. 3.]
NCT02565901,25:52:treatment,Agree to participate in biopsy of metastatic lesion during the study at day 21,"['Agree' 'to' 'participate' 'in' 'biopsy' 'of' 'metastatic' 'lesion'
 'during' 'the' 'study' 'at' 'day' '21']",[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02565901,7:35:cancer,Known parenchymal brain metastasis,['Known' 'parenchymal' 'brain' 'metastasis'],[0. 3. 3. 3.]
NCT02565901,1:14:cancer,squamous cell histology,['squamous' 'cell' 'histology'],[3. 3. 0.]
NCT02565498,13:35:chronic_disease,Presence of regional nodal disease or unequivocal distant metastases,"['Presence' 'of' 'regional' 'nodal' 'disease' 'or' 'unequivocal' 'distant'
 'metastases']",[0. 0. 2. 2. 2. 0. 0. 0. 0.]
NCT02565407,19:34:treatment,Regular intake of benzodiazepines,['Regular' 'intake' 'of' 'benzodiazepines'],[0. 0. 0. 1.]
NCT02564978,12:33:treatment,History of vitreoretinal surgery,['History' 'of' 'vitreoretinal' 'surgery'],[0. 0. 1. 1.]
NCT02564978,1:18:chronic_disease,Pathologic myopia,['Pathologic' 'myopia'],[2. 2.]
NCT02564978,",,111:122:treatment",The total area of GA lesions combined should be less than 7.0 MPS disc areas (DA) (17.78 mm(2)) as evident on FAF imaging,"['The' 'total' 'area' 'of' 'GA' 'lesions' 'combined' 'should' 'be' 'less'
 'than' '7.0' 'MPS' 'disc' 'areas' '(' 'DA' ')' '(' '17.78' 'mm' '(' '2'
 ')' ')' 'as' 'evident' 'on' 'FAF' 'imaging']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1.]"
NCT02564796,15:38:chronic_disease,Newborns with acyanotic heart disease,['Newborns' 'with' 'acyanotic' 'heart' 'disease'],[0. 0. 2. 2. 2.]
NCT02564744,"51:75:chronic_disease,","For Part 2 and Part 3 of the study, patients with primary refractory DLBCL (defined as progression of disease within 24 weeks after first line of treatment)","['For' 'Part' '2' 'and' 'Part' '3' 'of' 'the' 'study' ',' 'patients'
 'with' 'primary' 'refractory' 'DLBCL' '(' 'defined' 'as' 'progression'
 'of' 'disease' 'within' '24' 'weeks' 'after' 'first' 'line' 'of'
 'treatment' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02564198,8:25:chronic_disease,Active non-healing wound or bone fracture,['Active' 'non-healing' 'wound' 'or' 'bone' 'fracture'],[0. 2. 2. 0. 0. 0.]
NCT02563678,23:49:treatment,Medical clearance for hyperbaric oxygen exposure,['Medical' 'clearance' 'for' 'hyperbaric' 'oxygen' 'exposure'],[0. 0. 0. 1. 1. 1.]
NCT02563574,9:38:chronic_disease,Current major psychiatric disturbance,['Current' 'major' 'psychiatric' 'disturbance'],[0. 2. 2. 2.]
NCT02562755,12:25:chronic_disease,History of severe eczema (as determined by the Investigator) requiring medical treatment,"['History' 'of' 'severe' 'eczema' '(' 'as' 'determined' 'by' 'the'
 'Investigator' ')' 'requiring' 'medical' 'treatment']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02562430,5:38:treatment,Any investigational psychotropic drug within the last year,"['Any' 'investigational' 'psychotropic' 'drug' 'within' 'the' 'last'
 'year']",[0. 1. 1. 1. 0. 0. 0. 0.]
NCT02562430,1:29:treatment,Monoamine oxidase inhibitors,['Monoamine' 'oxidase' 'inhibitors'],[1. 1. 1.]
NCT02562235,1:19:chronic_disease,Hereditable (HPAH),['Hereditable' '(' 'HPAH' ')'],[2. 2. 0. 0.]
NCT02562235,"1:32:chronic_disease,,","Pulmonary arterial hypertension confirmed by a RHC at any time prior to start of study, with mean pulmonary artery pressure (PAPmean) ≥25 mmHg at rest","['Pulmonary' 'arterial' 'hypertension' 'confirmed' 'by' 'a' 'RHC' 'at'
 'any' 'time' 'prior' 'to' 'start' 'of' 'study' ',' 'with' 'mean'
 'pulmonary' 'artery' 'pressure' '(' 'PAPmean' ')' '≥25' 'mmHg' 'at'
 'rest']","[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02562040,"1:15:chronic_disease,,",Severe obesity (body mass index (BMI) z-score ≥3),"['Severe' 'obesity' '(' 'body' 'mass' 'index' '(' 'BMI' ')' 'z-score' '≥3'
 ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02561988,1:13:chronic_disease,Eosinophilia and known positivity for the FIP1L1-PGDFRA fusion,"['Eosinophilia' 'and' 'known' 'positivity' 'for' 'the' 'FIP1L1-PGDFRA'
 'fusion']",[2. 0. 0. 0. 0. 0. 0. 0.]
NCT02561988,",38:64:cancer",at least 1 C-finding attributable to systemic mastocytosis (SM),"['at' 'least' '1' 'C-finding' 'attributable' 'to' 'systemic'
 'mastocytosis' '(' 'SM' ')']",[0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0.]
NCT02561104,1:9:chronic_disease,Hypotony,['Hypotony'],[2.]
NCT02560766,"12:50:chronic_disease,","History of suicidal behavior or suicidal ideation as indicated by the C-SSRS, administered at screening, and as per investigator's judgment","['History' 'of' 'suicidal' 'behavior' 'or' 'suicidal' 'ideation' 'as'
 'indicated' 'by' 'the' 'C-SSRS' ',' 'administered' 'at' 'screening' ','
 'and' 'as' 'per' 'investigator' ""'s"" 'judgment']",[0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02560623,33:53:treatment,Undergoing clinically indicated diagnostic endoscopy,['Undergoing' 'clinically' 'indicated' 'diagnostic' 'endoscopy'],[0. 0. 0. 1. 1.]
NCT02558972,"1:17:treatment,",Prior medication will be stopped for at least 2 weeks,['Prior' 'medication' 'will' 'be' 'stopped' 'for' 'at' 'least' '2' 'weeks'],[1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02558010,1:18:chronic_disease,Seizure Disorders,['Seizure' 'Disorders'],[2. 2.]
NCT02557321,",99:120:treatment",who have failed to achieve a complete or partial response within 24 weeks following initiation of checkpoint inhibition,"['who' 'have' 'failed' 'to' 'achieve' 'a' 'complete' 'or' 'partial'
 'response' 'within' '24' 'weeks' 'following' 'initiation' 'of'
 'checkpoint' 'inhibition']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02555280,"1:30:chronic_disease,,",Degenerative lumbar scoliosis (Cobb angle of greater than 25°),"['Degenerative' 'lumbar' 'scoliosis' '(' 'Cobb' 'angle' 'of' 'greater'
 'than' '25°' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02555280,",53:75:treatment",More than two contiguous vertebral levels requiring surgical decompression,"['More' 'than' 'two' 'contiguous' 'vertebral' 'levels' 'requiring'
 'surgical' 'decompression']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02555280,28:53:chronic_disease,Patients with up to stable Grade I spondylolisthesis at two contiguous levels,"['Patients' 'with' 'up' 'to' 'stable' 'Grade' 'I' 'spondylolisthesis' 'at'
 'two' 'contiguous' 'levels']",[0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0.]
NCT02555280,45:76:treatment,Subject is currently involved in a study of another investigational product for similar purpose,"['Subject' 'is' 'currently' 'involved' 'in' 'a' 'study' 'of' 'another'
 'investigational' 'product' 'for' 'similar' 'purpose']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0.]
NCT02555280,1:14:chronic_disease,pars fracture,['pars' 'fracture'],[2. 2.]
NCT02555189,16:26:treatment,The effects of ribociclib on the developing human fetus at the recommended therapeutic dose are unknown,"['The' 'effects' 'of' 'ribociclib' 'on' 'the' 'developing' 'human' 'fetus'
 'at' 'the' 'recommended' 'therapeutic' 'dose' 'are' 'unknown']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02554812,42:73:cancer,Histological or cytological diagnosis of advanced/metastatic solid tumor,"['Histological' 'or' 'cytological' 'diagnosis' 'of' 'advanced/metastatic'
 'solid' 'tumor']",[0. 0. 0. 0. 0. 3. 3. 3.]
NCT02554383,"1:11:treatment,",Antibiotic use within 15 days,['Antibiotic' 'use' 'within' '15' 'days'],[1. 0. 0. 0. 0.]
NCT02554253,26:48:treatment,procedures not requiring cardiopulmonary bypass,['procedures' 'not' 'requiring' 'cardiopulmonary' 'bypass'],[0. 0. 0. 1. 1.]
NCT02553642,",59:74:treatment,",Must have no evidence of progression for at least 4 weeks after treatment is complete and within 28 days prior to first dose of study drug administration,"['Must' 'have' 'no' 'evidence' 'of' 'progression' 'for' 'at' 'least' '4'
 'weeks' 'after' 'treatment' 'is' 'complete' 'and' 'within' '28' 'days'
 'prior' 'to' 'first' 'dose' 'of' 'study' 'drug' 'administration']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02553460,15:25:cancer,Patients with T-cell ALL,['Patients' 'with' 'T-cell' 'ALL'],[0. 0. 3. 3.]
NCT02553265,",30:56:chronic_disease",Male or female patients with familial dysautonomia (FD),"['Male' 'or' 'female' 'patients' 'with' 'familial' 'dysautonomia' '(' 'FD'
 ')']",[0. 0. 0. 0. 0. 2. 2. 2. 0. 0.]
NCT02553265,1:24:chronic_disease,Unstable blood pressure,['Unstable' 'blood' 'pressure'],[2. 2. 2.]
NCT02553161,45:63:chronic_disease,"has at least one first degree relative with Bipolar I Disorder, as assessed by the Structured Clinical Interview for DSM (SCID; First et al. 1995), the Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS-PL, Kaufman et al., 1997), and the Family History-Research Diagnostic Criteria (FH-RDC; Andreasen et al., 1977)","['has' 'at' 'least' 'one' 'first' 'degree' 'relative' 'with' 'Bipolar' 'I'
 'Disorder' ',' 'as' 'assessed' 'by' 'the' 'Structured' 'Clinical'
 'Interview' 'for' 'DSM' '(' 'SCID' ';' 'First' 'et' 'al' '.' '1995' ')'
 ',' 'the' 'Kiddie' 'Schedule' 'for' 'Affective' 'Disorders' 'and'
 'Schizophrenia' '(' 'KSADS-PL' ',' 'Kaufman' 'et' 'al.' ',' '1997' ')'
 ',' 'and' 'the' 'Family' 'History-Research' 'Diagnostic' 'Criteria' '('
 'FH-RDC' ';' 'Andreasen' 'et' 'al.' ',' '1977' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02551679,1:22:chronic_disease,Hypercoagulable state,['Hypercoagulable' 'state'],[2. 2.]
NCT02551679,46:83:chronic_disease,Subject has hemodynamic indicators of severe peripheral arterial occlusive disease,"['Subject' 'has' 'hemodynamic' 'indicators' 'of' 'severe' 'peripheral'
 'arterial' 'occlusive' 'disease']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2.]
NCT02549937,1:32:treatment,Alanine aminotransaminase (ALT),['Alanine' 'aminotransaminase' '(' 'ALT' ')'],[1. 1. 1. 0. 0.]
NCT02549833,1:29:treatment,Prior radiation therapy (RT) after the initial diagnosis will be allowed,"['Prior' 'radiation' 'therapy' '(' 'RT' ')' 'after' 'the' 'initial'
 'diagnosis' 'will' 'be' 'allowed']",[1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02548351,12:29:treatment,History of biliary diversion,['History' 'of' 'biliary' 'diversion'],[0. 0. 1. 1.]
NCT02548104,1:16:treatment,revision of TKA,['revision' 'of' 'TKA'],[1. 1. 1.]
NCT02547818,"1:17:chronic_disease,","Major depressive episode, as described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) within the past 6 months, which could lead to difficulty complying with the protocol","['Major' 'depressive' 'episode' ',' 'as' 'described' 'in' 'the'
 'Diagnostic' 'and' 'Statistical' 'Manual' 'of' 'Mental' 'Disorders' '('
 'DSM-IV' ')' 'within' 'the' 'past' '6' 'months' ',' 'which' 'could'
 'lead' 'to' 'difficulty' 'complying' 'with' 'the' 'protocol']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02547818,41:67:treatment,Visual and auditory acuity adequate for neuropsychological testing,"['Visual' 'and' 'auditory' 'acuity' 'adequate' 'for' 'neuropsychological'
 'testing']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02547662,",,,,,,,,284:321:treatment,,","Females of childbearing potential (FCBP)* must have a negative serum pregnancy test with a sensitivity of at least 50 mIU/mL within 10-14 days prior to and again within 24 hours prior to prescribing pomalidomide for cycle 1 (prescriptions must be filled within 7 days as required by RevAssist [lenalidomide REMS program]), and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method","['Females' 'of' 'childbearing' 'potential' '(' 'FCBP' ')' '*' 'must'
 'have' 'a' 'negative' 'serum' 'pregnancy' 'test' 'with' 'a' 'sensitivity'
 'of' 'at' 'least' '50' 'mIU/mL' 'within' '10-14' 'days' 'prior' 'to'
 'and' 'again' 'within' '24' 'hours' 'prior' 'to' 'prescribing'
 'pomalidomide' 'for' 'cycle' '1' '(' 'prescriptions' 'must' 'be' 'filled'
 'within' '7' 'days' 'as' 'required' 'by' 'RevAssist' '[' 'lenalidomide'
 'REMS' 'program' ']' ')' ',' 'and' 'must' 'either' 'commit' 'to'
 'continued' 'abstinence' 'from' 'heterosexual' 'intercourse' 'or' 'begin'
 'TWO' 'acceptable' 'methods' 'of' 'birth' 'control' ',' 'one' 'highly'
 'effective' 'method' 'and' 'one' 'additional' 'effective' 'method']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02544880,10:41:treatment,Positive Antinuclear Antibody Test (ANA),['Positive' 'Antinuclear' 'Antibody' 'Test' '(' 'ANA' ')'],[0. 1. 1. 1. 1. 0. 0.]
NCT02544503,8:49:treatment,Use of central nervous system (CNS) active drugs that block plasticity,"['Use' 'of' 'central' 'nervous' 'system' '(' 'CNS' ')' 'active' 'drugs'
 'that' 'block' 'plasticity']",[0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02543983,66:101:chronic_disease,"Participants who, in the investigator s judgment, pose a current homicidal risk or pose suicide risk that cannot be managed in a secure, voluntary inpatient setting","['Participants' 'who' ',' 'in' 'the' 'investigator' 's' 'judgment' ','
 'pose' 'a' 'current' 'homicidal' 'risk' 'or' 'pose' 'suicide' 'risk'
 'that' 'can' 'not' 'be' 'managed' 'in' 'a' 'secure' ',' 'voluntary'
 'inpatient' 'setting']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02543944,1:31:chronic_disease,Wolff-Parkinson White syndrome,['Wolff-Parkinson' 'White' 'syndrome'],[2. 2. 2.]
NCT02543944,1:25:chronic_disease,wide complex tachycardia,['wide' 'complex' 'tachycardia'],[2. 2. 2.]
NCT02543723,14:18:treatment,New cycle of OCAs,['New' 'cycle' 'of' 'OCAs'],[0. 0. 0. 1.]
NCT02542657,",69:109:treatment",Disease that has progressed during or within 6 months of coming off therapy with bortezomib and lenalidomide (either sequentially or concurrent); progressive disease,"['Disease' 'that' 'has' 'progressed' 'during' 'or' 'within' '6' 'months'
 'of' 'coming' 'off' 'therapy' 'with' 'bortezomib' 'and' 'lenalidomide'
 '(' 'either' 'sequentially' 'or' 'concurrent' ')' ';' 'progressive'
 'disease']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02541903,43:47:chronic_disease,Histologically or cytologically confirmed PSCC,['Histologically' 'or' 'cytologically' 'confirmed' 'PSCC'],[0. 0. 0. 0. 2.]
NCT02541903,13:37:cancer,Previous or concomitant malignancies at other sites,['Previous' 'or' 'concomitant' 'malignancies' 'at' 'other' 'sites'],[0. 0. 3. 3. 0. 0. 0.]
NCT02541565,",69:87:treatment",subjects must be planned to receive full course (6 cycles) of RCHOP chemoimmunotherapy as per clinical standard of care,"['subjects' 'must' 'be' 'planned' 'to' 'receive' 'full' 'course' '(' '6'
 'cycles' ')' 'of' 'RCHOP' 'chemoimmunotherapy' 'as' 'per' 'clinical'
 'standard' 'of' 'care']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02540330,1:48:treatment,Concurrent treatment with another anti-estrogen,['Concurrent' 'treatment' 'with' 'another' 'anti-estrogen'],[1. 1. 1. 1. 1.]
NCT02540330,13:29:chronic_disease,Presence of pleural effusion,['Presence' 'of' 'pleural' 'effusion'],[0. 0. 2. 2.]
NCT02538484,1:9:chronic_disease,Cachexia,['Cachexia'],[2.]
NCT02538198,11:31:treatment,Permitted concurrent therapies,['Permitted' 'concurrent' 'therapies'],[0. 1. 1.]
NCT02536794,7:40:chronic_disease,Known active or chronic viral hepatitis,['Known' 'active' 'or' 'chronic' 'viral' 'hepatitis'],[0. 2. 2. 2. 2. 2.]
NCT02536170,12:20:allergy_name,Allergy to arginine,['Allergy' 'to' 'arginine'],[0. 0. 4.]
NCT02535832,1:23:chronic_disease,Untreated osteoporosis,['Untreated' 'osteoporosis'],[2. 2.]
NCT02535312,",6:42:treatment",#ERROR!,['#' 'ERROR' '!'],[1. 1. 1.]
NCT02535312,1:22:treatment,intervening treatment is allowed,['intervening' 'treatment' 'is' 'allowed'],[1. 1. 0. 0.]
NCT02534922,25:58:treatment,Subjects shall have had cytoreductive (debulking) surgery,"['Subjects' 'shall' 'have' 'had' 'cytoreductive' '(' 'debulking' ')'
 'surgery']",[0. 0. 0. 0. 1. 1. 1. 0. 0.]
NCT02533674,54:72:treatment,Documented disease progression during or immediately after last therapy according to any of the aforementioned criteria,"['Documented' 'disease' 'progression' 'during' 'or' 'immediately' 'after'
 'last' 'therapy' 'according' 'to' 'any' 'of' 'the' 'aforementioned'
 'criteria']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02533674,22:30:treatment,Prior treatment with PM060184,['Prior' 'treatment' 'with' 'PM060184'],[0. 0. 0. 1.]
NCT02533674,",36:58:treatment",at least four weeks since the last MAb-containing therapy,"['at' 'least' 'four' 'weeks' 'since' 'the' 'last' 'MAb-containing'
 'therapy']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02532621,29:38:treatment,Subject is currently taking Aggrenox®,['Subject' 'is' 'currently' 'taking' 'Aggrenox®'],[1. 1. 1. 1. 1.]
NCT02532452,1:43:chronic_disease,Uncontrolled bacterial or fungal infection,['Uncontrolled' 'bacterial' 'or' 'fungal' 'infection'],[2. 2. 2. 2. 2.]
NCT02531880,25:48:treatment,On-going treatment with calcium-channel blocker,['On-going' 'treatment' 'with' 'calcium-channel' 'blocker'],[0. 0. 0. 1. 1.]
NCT02531711,12:25:allergy_name,History of specific food allergies that would prevent adherence to study diet,"['History' 'of' 'specific' 'food' 'allergies' 'that' 'would' 'prevent'
 'adherence' 'to' 'study' 'diet']",[0. 0. 4. 4. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02530463,25:34:treatment,Previously treated with HMA agent,['Previously' 'treated' 'with' 'HMA' 'agent'],[0. 0. 0. 1. 1.]
NCT02530073,",,77:109:treatment","Preterm labor, cervix shortened (<15 mm at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor, placenta previa","['Preterm' 'labor' ',' 'cervix' 'shortened' '(' '<' '15' 'mm' 'at'
 'enrollment' 'or' 'within' '24' 'hours' 'of' 'FETO' 'balloon' 'insertion'
 'procedure' ')' 'or' 'uterine' 'anomaly' 'strongly' 'predisposing' 'to'
 'preterm' 'labor' ',' 'placenta' 'previa']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02530034,1:38:cancer,chronic myelomonocytic leukemia (CMML),['chronic' 'myelomonocytic' 'leukemia' '(' 'CMML' ')'],[3. 3. 3. 3. 0. 0.]
NCT02527421,55:66:allergy_name,Subjects who have a history of an adverse reaction to cosyntropin injection or similar test reagents,"['Subjects' 'who' 'have' 'a' 'history' 'of' 'an' 'adverse' 'reaction' 'to'
 'cosyntropin' 'injection' 'or' 'similar' 'test' 'reagents']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0.]
NCT02527265,"17:43:treatment,","Exposure to any investigational product(s) in the past 3 months or 5 half-lives, whichever is more","['Exposure' 'to' 'any' 'investigational' 'product' '(' 's' ')' 'in' 'the'
 'past' '3' 'months' 'or' '5' 'half-lives' ',' 'whichever' 'is' 'more']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02525861,"12:46:treatment,,","Documented Alpha1-Proteinase Inhibitor (A1PI) genotype of Pi*Z/Z, Pi*Z/Null, Pi*Malton/Z, Pi*Null/Null, or other at-risk allelic combinations such as SZ (excluding MS and MZ) and an endogenous A1PI plasma levels of ≤11 μM","['Documented' 'Alpha1-Proteinase' 'Inhibitor' '(' 'A1PI' ')' 'genotype'
 'of' 'Pi' '*' 'Z/Z' ',' 'Pi' '*' 'Z/Null' ',' 'Pi' '*' 'Malton/Z' ','
 'Pi' '*' 'Null/Null' ',' 'or' 'other' 'at-risk' 'allelic' 'combinations'
 'such' 'as' 'SZ' '(' 'excluding' 'MS' 'and' 'MZ' ')' 'and' 'an'
 'endogenous' 'A1PI' 'plasma' 'levels' 'of' '≤11' 'μM']","[0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02524379,"7:19:chronic_disease,","Acute cervical SCI with ASIA Impairment Scale grade A, B or C on admission","['Acute' 'cervical' 'SCI' 'with' 'ASIA' 'Impairment' 'Scale' 'grade' 'A'
 ',' 'B' 'or' 'C' 'on' 'admission']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02524379,"26:43:chronic_disease,",Unconsciousness or other mental impairment that prevents neurological assessment within the first 8 hours,"['Unconsciousness' 'or' 'other' 'mental' 'impairment' 'that' 'prevents'
 'neurological' 'assessment' 'within' 'the' 'first' '8' 'hours']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02522715,"1:18:treatment,,,,",Aminoglutethimide; approximate half-life: 15 hours; washout period required: 4 days,"['Aminoglutethimide' ';' 'approximate' 'half-life' ':' '15' 'hours' ';'
 'washout' 'period' 'required' ':' '4' 'days']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02522715,1:16:treatment,Metastatic CRPC,['Metastatic' 'CRPC'],[1. 1.]
NCT02522468,1:20:treatment,Breast-conservation candidate,['Breast-conservation' 'candidate'],[1. 0.]
NCT02521818,1:14:allergy_name,multiple food allergies,['multiple' 'food' 'allergies'],[4. 4. 0.]
NCT02521103,36:52:allergy_name,Patient has a known sensitivity to device materials,['Patient' 'has' 'a' 'known' 'sensitivity' 'to' 'device' 'materials'],[0. 0. 0. 0. 0. 0. 4. 4.]
NCT02520791,24:66:treatment,Relapsed or refractory post autologous cell transplantation (HCT),"['Relapsed' 'or' 'refractory' 'post' 'autologous' 'cell' 'transplantation'
 '(' 'HCT' ')']",[0. 0. 0. 1. 1. 1. 1. 1. 0. 0.]
NCT02520778,32:39:allergy_name,History of hypersensitivity to AZD9291 (or drugs with a similar chemical structure or class to AZD9291) or any excipients of these agents,"['History' 'of' 'hypersensitivity' 'to' 'AZD9291' '(' 'or' 'drugs' 'with'
 'a' 'similar' 'chemical' 'structure' 'or' 'class' 'to' 'AZD9291' ')' 'or'
 'any' 'excipients' 'of' 'these' 'agents']",[0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02520778,"27:35:treatment,",must discontinue previous EGFR-TKI at least 7 days prior to study enrollment,"['must' 'discontinue' 'previous' 'EGFR-TKI' 'at' 'least' '7' 'days'
 'prior' 'to' 'study' 'enrollment']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02520713,1:43:cancer,Infantile fibrosarcoma without NTRK fusion,['Infantile' 'fibrosarcoma' 'without' 'NTRK' 'fusion'],[3. 3. 3. 3. 3.]
NCT02520713,1:25:cancer,Undifferentiated sarcoma,['Undifferentiated' 'sarcoma'],[3. 3.]
NCT02520427,1:30:cancer,promyelocytic leukemia (APML),['promyelocytic' 'leukemia' '(' 'APML' ')'],[3. 3. 3. 0. 0.]
NCT02520011,"12:46:treatment,",Received a hematopoietic stem cell transplant within the previous 2 months,"['Received' 'a' 'hematopoietic' 'stem' 'cell' 'transplant' 'within' 'the'
 'previous' '2' 'months']",[0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02519452,40:70:treatment,Participant has previously received an allogenic stem cell transplant,"['Participant' 'has' 'previously' 'received' 'an' 'allogenic' 'stem'
 'cell' 'transplant']",[0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02519452,"1:19:chronic_disease,",Refractory disease is defined as less than (<) 25 percent (%) reduction in M-protein or progression of disease during treatment,"['Refractory' 'disease' 'is' 'defined' 'as' 'less' 'than' '(' '<' ')' '25'
 'percent' '(' '%' ')' 'reduction' 'in' 'M-protein' 'or' 'progression'
 'of' 'disease' 'during' 'treatment']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02519348,19:42:treatment,Prior exposure to immune-mediated therapy,['Prior' 'exposure' 'to' 'immune-mediated' 'therapy'],[0. 0. 0. 1. 1.]
NCT02519283,48:51:chronic_disease,"Patients deemed by emergency physician to have AHF, who they plan to discharge or hold for brief ED-based observation","['Patients' 'deemed' 'by' 'emergency' 'physician' 'to' 'have' 'AHF' ','
 'who' 'they' 'plan' 'to' 'discharge' 'or' 'hold' 'for' 'brief' 'ED-based'
 'observation']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02518594,"13:58:chronic_disease,,",Evidence of severe IUGR (intrauterine growth restriction) (<5th percentile for gestational age) in either fetus,"['Evidence' 'of' 'severe' 'IUGR' '(' 'intrauterine' 'growth' 'restriction'
 ')' '(' '<' '5th' 'percentile' 'for' 'gestational' 'age' ')' 'in'
 'either' 'fetus']",[0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02518594,"1:31:chronic_disease,","Twin-twin transfusion syndrome, due to increased risk of adverse pregnancy outcome","['Twin-twin' 'transfusion' 'syndrome' ',' 'due' 'to' 'increased' 'risk'
 'of' 'adverse' 'pregnancy' 'outcome']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02516670,16:38:chronic_disease,Has history of calcium oxalate stones,['Has' 'history' 'of' 'calcium' 'oxalate' 'stones'],[0. 0. 0. 2. 2. 2.]
NCT02516241,37:65:treatment,Patients eligible or ineligible for cisplatin-based chemotherapy,"['Patients' 'eligible' 'or' 'ineligible' 'for' 'cisplatin-based'
 'chemotherapy']",[0. 0. 0. 0. 0. 1. 1.]
NCT02515708,1:22:treatment,Multiorgan transplant,['Multiorgan' 'transplant'],[1. 1.]
NCT02515110,12:57:treatment,History of ipsilateral or contralateral axillary surgery for any condition,"['History' 'of' 'ipsilateral' 'or' 'contralateral' 'axillary' 'surgery'
 'for' 'any' 'condition']",[0. 0. 1. 1. 1. 1. 1. 0. 0. 0.]
NCT02514915,",,79:106:treatment",Patients with a documented symptomatic lesion size smaller than 3cm requiring clinical surgical resection,"['Patients' 'with' 'a' 'documented' 'symptomatic' 'lesion' 'size'
 'smaller' 'than' '3cm' 'requiring' 'clinical' 'surgical' 'resection']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02514083,",,88:105:chronic_disease",Total bilirubin greater than or equal to 1.5 times upper limit of normal unless due to Gilbert s disease,"['Total' 'bilirubin' 'greater' 'than' 'or' 'equal' 'to' '1.5' 'times'
 'upper' 'limit' 'of' 'normal' 'unless' 'due' 'to' 'Gilbert' 's' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02513797,86:118:chronic_disease,Documented diagnosis of symptomatic continuous persistent or longstanding persistent non-valvular atrial fibrillation,"['Documented' 'diagnosis' 'of' 'symptomatic' 'continuous' 'persistent'
 'or' 'longstanding' 'persistent' 'non-valvular' 'atrial' 'fibrillation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02513797,1:33:chronic_disease,"Left atrial appendage morphology: Superior-posterior oriented left atrial appendage (i.e. superior C shape), that has Left atrial appendage distal apex extending posterior to the ostium of the appendage","['Left' 'atrial' 'appendage' 'morphology' ':' 'Superior-posterior'
 'oriented' 'left' 'atrial' 'appendage' '(' 'i.e' '.' 'superior' 'C'
 'shape' ')' ',' 'that' 'has' 'Left' 'atrial' 'appendage' 'distal' 'apex'
 'extending' 'posterior' 'to' 'the' 'ostium' 'of' 'the' 'appendage']","[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02512926,",46:49:treatment",At least 14 days must have elapsed for local XRT,['At' 'least' '14' 'days' 'must' 'have' 'elapsed' 'for' 'local' 'XRT'],[0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02512718,1:16:chronic_disease,Lipid nephrosis,['Lipid' 'nephrosis'],[2. 2.]
NCT02512497,"1:23:chronic_disease,,","Congenital QT syndrome, QTc >500 ms","['Congenital' 'QT' 'syndrome' ',' 'QTc' '>' '500' 'ms']",[2. 2. 2. 0. 0. 0. 0. 0.]
NCT02511301,33:40:cancer,Any biopsy or treatment for the BI-RADS category 4 or 5 abnormality,"['Any' 'biopsy' 'or' 'treatment' 'for' 'the' 'BI-RADS' 'category' '4' 'or'
 '5' 'abnormality']",[0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT02510417,11:15:chronic_disease,Available VSTs,['Available' 'VSTs'],[0. 2.]
NCT02509507,31:43:cancer,Subjects must have measurable liver tumors and lesions that are suitable for injection,"['Subjects' 'must' 'have' 'measurable' 'liver' 'tumors' 'and' 'lesions'
 'that' 'are' 'suitable' 'for' 'injection']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02509260,1:31:treatment,enterocutaneous fistula repair,['enterocutaneous' 'fistula' 'repair'],[1. 1. 1.]
NCT02509260,"30:40:treatment,",patients who had undergone a laparotomy within the preceding three months,"['patients' 'who' 'had' 'undergone' 'a' 'laparotomy' 'within' 'the'
 'preceding' 'three' 'months']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02508467,14:38:treatment,has declined treatment with sorafenib,['has' 'declined' 'treatment' 'with' 'sorafenib'],[0. 0. 1. 1. 1.]
NCT02508311,",,,50:60:chronic_disease",Neurological level of injury between T1-T6 (High Paraplegia),"['Neurological' 'level' 'of' 'injury' 'between' 'T1-T6' '(' 'High'
 'Paraplegia' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT02508038,84:104:chronic_disease,"Is free from risk factors for, and clinical evidence of, infection due to relevant communicable disease agents and diseases","['Is' 'free' 'from' 'risk' 'factors' 'for' ',' 'and' 'clinical' 'evidence'
 'of' ',' 'infection' 'due' 'to' 'relevant' 'communicable' 'disease'
 'agents' 'and' 'diseases']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0.]
NCT02508038,13:42:cancer,Relapsed or primary refractory metastatic,['Relapsed' 'or' 'primary' 'refractory' 'metastatic'],[0. 0. 3. 3. 3.]
NCT02508038,10:29:chronic_disease,signs of leukoencephalopathy,['signs' 'of' 'leukoencephalopathy'],[0. 0. 2.]
NCT02507505,9:48:treatment,Planned surgical treatment via hemiarthroplasty,['Planned' 'surgical' 'treatment' 'via' 'hemiarthroplasty'],[0. 1. 1. 1. 1.]
NCT02507011,"1:20:treatment,",RVEF by cardiac MRI < 45%,['RVEF' 'by' 'cardiac' 'MRI' '<' '45' '%'],[1. 1. 1. 1. 0. 0. 0.]
NCT02506192,1:27:chronic_disease,Inflammatory lung diseases,['Inflammatory' 'lung' 'diseases'],[2. 2. 2.]
NCT02506192,1:25:chronic_disease,acute Chronic Infections,['acute' 'Chronic' 'Infections'],[2. 2. 2.]
NCT02504866,12:32:chronic_disease,History of exercise intolerance,['History' 'of' 'exercise' 'intolerance'],[0. 0. 2. 2.]
NCT02503722,18:36:chronic_disease,Prior history of corneal ulceration,['Prior' 'history' 'of' 'corneal' 'ulceration'],[0. 0. 0. 2. 2.]
NCT02503722,",136:160:treatment",patients should not consume food or beverages containing the fruit or juice of grapefruits or Seville oranges within 7 days before the first dose of study drug and throughout the study,"['patients' 'should' 'not' 'consume' 'food' 'or' 'beverages' 'containing'
 'the' 'fruit' 'or' 'juice' 'of' 'grapefruits' 'or' 'Seville' 'oranges'
 'within' '7' 'days' 'before' 'the' 'first' 'dose' 'of' 'study' 'drug'
 'and' 'throughout' 'the' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 1. 1. 1. 0. 0. 0. 0.]"
NCT02502799,"14:44:chronic_disease,,,",Diagnosis of autism spectrum disorder (ASD) with a severity level of 2 or 3,"['Diagnosis' 'of' 'autism' 'spectrum' 'disorder' '(' 'ASD' ')' 'with' 'a'
 'severity' 'level' 'of' '2' 'or' '3']",[0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02501954,25:53:cancer,Patients with FIGO 2009 Stage IVB endometrial cancer,['Patients' 'with' 'FIGO' '2009' 'Stage' 'IVB' 'endometrial' 'cancer'],[0. 0. 0. 0. 3. 3. 3. 3.]
NCT02501954,1:18:chronic_disease,Pelvic lymph node sampling,['Pelvic' 'lymph' 'node' 'sampling'],[2. 2. 2. 0.]
NCT02501733,15:26:treatment,Patients with knee fusion to the affected joint,['Patients' 'with' 'knee' 'fusion' 'to' 'the' 'affected' 'joint'],[0. 0. 1. 1. 0. 0. 0. 0.]
NCT02501473,"12:30:treatment,",Received a live virus vaccine within 30 days of planned study start,"['Received' 'a' 'live' 'virus' 'vaccine' 'within' '30' 'days' 'of'
 'planned' 'study' 'start']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02500407,"1:38:treatment,",Systemic immunosuppressive medication within 2 weeks prior to study drug,"['Systemic' 'immunosuppressive' 'medication' 'within' '2' 'weeks' 'prior'
 'to' 'study' 'drug']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02498951,"1:32:treatment,",Vaccination with a live vaccine a minimum of 4 weeks prior to study enrollment,"['Vaccination' 'with' 'a' 'live' 'vaccine' 'a' 'minimum' 'of' '4' 'weeks'
 'prior' 'to' 'study' 'enrollment']",[1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02498613,"30:57:cancer,",Patients with concomitant or prior invasive malignancies within the past 3 years,"['Patients' 'with' 'concomitant' 'or' 'prior' 'invasive' 'malignancies'
 'within' 'the' 'past' '3' 'years']",[0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0.]
NCT02498535,"17:31:treatment,","For subjects on cycled therapy, at least 2 cycles of drug need to have been completed prior to baseline","['For' 'subjects' 'on' 'cycled' 'therapy' ',' 'at' 'least' '2' 'cycles'
 'of' 'drug' 'need' 'to' 'have' 'been' 'completed' 'prior' 'to' 'baseline']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02498301,"13:27:chronic_disease,",Subject has acute diarrhea within 7 days prior to enrollment,"['Subject' 'has' 'acute' 'diarrhea' 'within' '7' 'days' 'prior' 'to'
 'enrollment']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02498262,79:94:chronic_disease,Participants will include individuals that have suffered a moderate to severe traumatic brain,"['Participants' 'will' 'include' 'individuals' 'that' 'have' 'suffered'
 'a' 'moderate' 'to' 'severe' 'traumatic' 'brain']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02497300,"1:25:chronic_disease,,",Diabetes mellitus type 2 with glycosylated hemoglobin ≥ 6.5%,"['Diabetes' 'mellitus' 'type' '2' 'with' 'glycosylated' 'hemoglobin' '≥'
 '6.5' '%']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02496611,12:26:chronic_disease,History of cholelithiasis,['History' 'of' 'cholelithiasis'],[0. 0. 2.]
NCT02496611,36:71:chronic_disease,Personal- and/or family history of multiple endocrine neoplasia type 2,"['Personal-' 'and/or' 'family' 'history' 'of' 'multiple' 'endocrine'
 'neoplasia' 'type' '2']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 2.]
NCT02496585,1:17:cancer,Liver metastases,['Liver' 'metastases'],[3. 3.]
NCT02496208,23:34:chronic_disease,appearance of one new bone lesion,['appearance' 'of' 'one' 'new' 'bone' 'lesion'],[0. 0. 0. 0. 2. 2.]
NCT02495545,133:143:treatment,Able to cooperate in the completion of a standardized neurological examination by ISNCSCI standards (includes patients who are on a ventilator),"['Able' 'to' 'cooperate' 'in' 'the' 'completion' 'of' 'a' 'standardized'
 'neurological' 'examination' 'by' 'ISNCSCI' 'standards' '(' 'includes'
 'patients' 'who' 'are' 'on' 'a' 'ventilator' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02495415,"46:73:treatment,",Growth factor(s): Must not have received any hematopoetic growth factors within 7 days of study entry,"['Growth' 'factor' '(' 's' ')' ':' 'Must' 'not' 'have' 'received' 'any'
 'hematopoetic' 'growth' 'factors' 'within' '7' 'days' 'of' 'study'
 'entry']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02495415,37:49:allergy_name,Patients with documented allergy to egg products,['Patients' 'with' 'documented' 'allergy' 'to' 'egg' 'products'],[0. 0. 0. 0. 0. 4. 4.]
NCT02495389,13:32:treatment,Patients on current OAB therapy will undergo a two-week drug washout period prior to baseline assessment,"['Patients' 'on' 'current' 'OAB' 'therapy' 'will' 'undergo' 'a' 'two-week'
 'drug' 'washout' 'period' 'prior' 'to' 'baseline' 'assessment']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02495168,"1:21:treatment,",Oral corticosteroids for 30 days,['Oral' 'corticosteroids' 'for' '30' 'days'],[1. 1. 0. 0. 0.]
NCT02495168,"49:54:treatment,",patients should be able to withhold all inhaled SABAs for at least 6 hours prior to lung function assessments on study visits,"['patients' 'should' 'be' 'able' 'to' 'withhold' 'all' 'inhaled' 'SABAs'
 'for' 'at' 'least' '6' 'hours' 'prior' 'to' 'lung' 'function'
 'assessments' 'on' 'study' 'visits']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02494869,25:29:cancer,Cytologically confirmed LCIS,['Cytologically' 'confirmed' 'LCIS'],[0. 0. 3.]
NCT02494869,1:18:chronic_disease,Recurrent syncope,['Recurrent' 'syncope'],[2. 2.]
NCT02494869,1:27:chronic_disease,Uncontrolled heart failure,['Uncontrolled' 'heart' 'failure'],[2. 2. 2.]
NCT02494141,20:39:treatment,Currently taking a curcumin supplement,['Currently' 'taking' 'a' 'curcumin' 'supplement'],[0. 0. 0. 1. 1.]
NCT02493530,1:23:treatment,bone marrow transplant,['bone' 'marrow' 'transplant'],[1. 1. 1.]
NCT02493257,1:18:chronic_disease,Allergic rhinitis,['Allergic' 'rhinitis'],[2. 2.]
NCT02493257,1:31:treatment,Radiation to the head and neck,['Radiation' 'to' 'the' 'head' 'and' 'neck'],[1. 1. 1. 1. 1. 1.]
NCT02490943,25:46:allergy_name,Any contraindication to warm or cold compress,['Any' 'contraindication' 'to' 'warm' 'or' 'cold' 'compress'],[0. 0. 0. 4. 4. 4. 4.]
NCT02490631,1:28:chronic_disease,intradural spinal pathology,['intradural' 'spinal' 'pathology'],[2. 2. 2.]
NCT02489539,13:25:chronic_disease,Patient has body habitus or other medical condition which prevents adequate delineation of the aorta,"['Patient' 'has' 'body' 'habitus' 'or' 'other' 'medical' 'condition'
 'which' 'prevents' 'adequate' 'delineation' 'of' 'the' 'aorta']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02489045,15:44:chronic_disease,Patients with respiratory distress syndrome,['Patients' 'with' 'respiratory' 'distress' 'syndrome'],[0. 0. 2. 2. 2.]
NCT02488967,"1:4:chronic_disease,,,,","ISH non-amplified with a ratio of HER2 to CEP17 < 2.0, and if reported, average HER2 gene copy number < 4 signals/cells","['ISH' 'non-amplified' 'with' 'a' 'ratio' 'of' 'HER2' 'to' 'CEP17' '<'
 '2.0' ',' 'and' 'if' 'reported' ',' 'average' 'HER2' 'gene' 'copy'
 'number' '<' '4' 'signals/cells']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02487797,12:53:treatment,History of prior cesarean section or uterine surgery,['History' 'of' 'prior' 'cesarean' 'section' 'or' 'uterine' 'surgery'],[0. 0. 1. 1. 1. 1. 1. 1.]
NCT02487082,1:24:chronic_disease,Cardiovascular problems,['Cardiovascular' 'problems'],[2. 2.]
NCT02485639,32:43:treatment,who have not received seasonal flu vaccine for the current year (September - June),"['who' 'have' 'not' 'received' 'seasonal' 'flu' 'vaccine' 'for' 'the'
 'current' 'year' '(' 'September' '-' 'June' ')']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02484404,43:47:cancer,Histologically or cytologically confirmed SCLC,['Histologically' 'or' 'cytologically' 'confirmed' 'SCLC'],[0. 0. 0. 0. 3.]
NCT02484404,23:34:treatment,Patients who have had prior PARPi are not eligible,['Patients' 'who' 'have' 'had' 'prior' 'PARPi' 'are' 'not' 'eligible'],[0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT02484404,28:50:treatment,Patients who have received radionuclide treatment,['Patients' 'who' 'have' 'received' 'radionuclide' 'treatment'],[0. 0. 0. 0. 1. 1.]
NCT02484300,1:34:treatment,Prior or current use of melatonin,['Prior' 'or' 'current' 'use' 'of' 'melatonin'],[1. 1. 1. 1. 1. 1.]
NCT02483910,"21:105:treatment,",Currently receiving Direct Instruction Language for Learning (DI-LL) or participation in a DI-LL program in the past 2 years,"['Currently' 'receiving' 'Direct' 'Instruction' 'Language' 'for'
 'Learning' '(' 'DI-LL' ')' 'or' 'participation' 'in' 'a' 'DI-LL'
 'program' 'in' 'the' 'past' '2' 'years']",[0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02482376,17:35:cancer,Clinical T1N0M0 invasive carcinoma,['Clinical' 'T1N0M0' 'invasive' 'carcinoma'],[0. 0. 3. 3.]
NCT02481765,16:41:chronic_disease,The subject is severely hearing impaired,['The' 'subject' 'is' 'severely' 'hearing' 'impaired'],[0. 0. 0. 2. 2. 2.]
NCT02481310,1:19:treatment,Surgically sterile,['Surgically' 'sterile'],[1. 1.]
NCT02481245,21:44:chronic_disease,DSM IV diagnosis of Bipolar Disorder Type I,['DSM' 'IV' 'diagnosis' 'of' 'Bipolar' 'Disorder' 'Type' 'I'],[0. 0. 0. 0. 2. 2. 2. 2.]
NCT02481245,"45:66:treatment,",Taking an adequate dose of any FDA-approved anti-manic medication for at least two weeks prior to enrollment,"['Taking' 'an' 'adequate' 'dose' 'of' 'any' 'FDA-approved' 'anti-manic'
 'medication' 'for' 'at' 'least' 'two' 'weeks' 'prior' 'to' 'enrollment']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02480036,1:21:treatment,Previous kyphoplasty in the same area,['Previous' 'kyphoplasty' 'in' 'the' 'same' 'area'],[1. 1. 0. 0. 0. 0.]
NCT02479906,1:19:chronic_disease,Multiple sclerosis,['Multiple' 'sclerosis'],[2. 2.]
NCT02479698,1:50:cancer,Merkel polyoma-virus related Merkel cell tumor(s) with measurable disease on imaging per RECIST criteria,"['Merkel' 'polyoma-virus' 'related' 'Merkel' 'cell' 'tumor' '(' 's' ')'
 'with' 'measurable' 'disease' 'on' 'imaging' 'per' 'RECIST' 'criteria']",[3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02479620,9:36:treatment,Planned major index limb amputation,['Planned' 'major' 'index' 'limb' 'amputation'],[0. 1. 1. 1. 1.]
NCT02479230,36:69:treatment,There is no limit to the number of prior systemic treatment regimens,"['There' 'is' 'no' 'limit' 'to' 'the' 'number' 'of' 'prior' 'systemic'
 'treatment' 'regimens']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02477839,"5:15:treatment,",The VNS device must have been implanted for >=6 months prior to Visit 1,"['The' 'VNS' 'device' 'must' 'have' 'been' 'implanted' 'for' '>' '=6'
 'months' 'prior' 'to' 'Visit' '1']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02476409,22:38:chronic_disease,Clinical evidence of digoxin toxicity,['Clinical' 'evidence' 'of' 'digoxin' 'toxicity'],[0. 0. 0. 2. 2.]
NCT02476409,10:41:chronic_disease,Elevated jugular venous distension (JVD),['Elevated' 'jugular' 'venous' 'distension' '(' 'JVD' ')'],[0. 2. 2. 2. 2. 0. 0.]
NCT02476409,29:48:chronic_disease,Planned hospitalization for acute heart failure,['Planned' 'hospitalization' 'for' 'acute' 'heart' 'failure'],[0. 0. 0. 2. 2. 2.]
NCT02474927,8:31:chronic_disease,Active cytomegalovirus disease,['Active' 'cytomegalovirus' 'disease'],[0. 2. 2.]
NCT02474667,29:53:treatment,"Patients may participate in another concurrent study only if that study is a non-interventional, observational investigation","['Patients' 'may' 'participate' 'in' 'another' 'concurrent' 'study' 'only'
 'if' 'that' 'study' 'is' 'a' 'non-interventional' ',' 'observational'
 'investigation']",[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02474368,1:11:treatment,Amifostine,['Amifostine'],[1.]
NCT02474368,1:39:treatment,Granulocyte stimulating factor (G-CSF),['Granulocyte' 'stimulating' 'factor' '(' 'G-CSF' ')'],[1. 1. 1. 1. 0. 0.]
NCT02474199,14:22:treatment,Confirmatory chest CT,['Confirmatory' 'chest' 'CT'],[0. 1. 1.]
NCT02474199,1:31:chronic_disease,primary sclerosing cholangitis,['primary' 'sclerosing' 'cholangitis'],[2. 2. 2.]
NCT02473536,"1:15:cancer,",Tumor thrombus must be ≥ level II,['Tumor' 'thrombus' 'must' 'be' '≥' 'level' 'II'],[3. 3. 0. 0. 0. 0. 0.]
NCT02473354,101:113:treatment,has completed the appropriate fasting periods for solids and liquids prior to the administration of remifentanil,"['has' 'completed' 'the' 'appropriate' 'fasting' 'periods' 'for' 'solids'
 'and' 'liquids' 'prior' 'to' 'the' 'administration' 'of' 'remifentanil']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02473250,18:44:treatment,Participation in nuclear medicine protocols in the last year,"['Participation' 'in' 'nuclear' 'medicine' 'protocols' 'in' 'the' 'last'
 'year']",[0. 0. 1. 1. 1. 0. 0. 0. 0.]
NCT02473250,1:17:chronic_disease,blood dyscrasias,['blood' 'dyscrasias'],[2. 2.]
NCT02473250,1:14:chronic_disease,hypersplenism,['hypersplenism'],[2.]
NCT02472834,"20:46:treatment,",Taking any type of amino acid supplementation within the last 90 days,"['Taking' 'any' 'type' 'of' 'amino' 'acid' 'supplementation' 'within'
 'the' 'last' '90' 'days']",[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02472223,"6:50:chronic_disease,","Sex: Pink eye {adenoviral conjunctivitis (Ad-Cs)} occurs with equal prevalence in males and females, therefore we will recruit both genders","['Sex' ':' 'Pink' 'eye' '{' 'adenoviral' 'conjunctivitis' '(' 'Ad-Cs' ')'
 '}' 'occurs' 'with' 'equal' 'prevalence' 'in' 'males' 'and' 'females' ','
 'therefore' 'we' 'will' 'recruit' 'both' 'genders']","[0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02471911,",,,122:150:treatment",Women of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test prior to selinexor treatment,"['Women' 'of' 'childbearing' 'potential' 'must' 'agree' 'to' 'use' 'dual'
 'methods' 'of' 'contraception' 'and' 'have' 'a' 'negative' 'serum'
 'pregnancy' 'test' 'prior' 'to' 'selinexor' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02471430,27:37:chronic_disease,No clinically significant eye disease,['No' 'clinically' 'significant' 'eye' 'disease'],[0. 0. 0. 2. 2.]
NCT02470897,",20:76:treatment",#ERROR!,['#' 'ERROR' '!'],[0. 1. 0.]
NCT02469857,1:36:chronic_disease,Idiopathic Thrombocytopenia Purpura,['Idiopathic' 'Thrombocytopenia' 'Purpura'],[2. 2. 2.]
NCT02469662,23:38:chronic_disease,Patient has a current major infection distant from the operative site,"['Patient' 'has' 'a' 'current' 'major' 'infection' 'distant' 'from' 'the'
 'operative' 'site']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02469389,1:10:chronic_disease,anhedonia,['anhedonia'],[2.]
NCT02468778,"5:37:treatment,",Any prior coronary revascularization within the last 6 months,"['Any' 'prior' 'coronary' 'revascularization' 'within' 'the' 'last' '6'
 'months']",[0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02468778,20:48:chronic_disease,intervention of an unprotected left main artery,['intervention' 'of' 'an' 'unprotected' 'left' 'main' 'artery'],[0. 0. 0. 2. 2. 2. 2.]
NCT02468024,15:46:cancer,Patients with non-peripheral (central) tumors are NOT eligible,"['Patients' 'with' 'non-peripheral' '(' 'central' ')' 'tumors' 'are' 'NOT'
 'eligible']",[0. 0. 3. 3. 3. 0. 0. 0. 0. 0.]
NCT02467478,1:52:treatment,Treatment with cytochrome p450 (CYP 3A4) inhibitors,['Treatment' 'with' 'cytochrome' 'p450' '(' 'CYP' '3A4' ')' 'inhibitors'],[1. 1. 1. 1. 1. 1. 1. 0. 0.]
NCT02466971,32:58:cancer,Patient has another concurrent active invasive malignancy,['Patient' 'has' 'another' 'concurrent' 'active' 'invasive' 'malignancy'],[0. 0. 0. 0. 3. 3. 3.]
NCT02466750,"25:42:treatment,,",Have completed previous WEE vaccine study as a nonresponder (PRNT80 < 1:40),"['Have' 'completed' 'previous' 'WEE' 'vaccine' 'study' 'as' 'a'
 'nonresponder' '(' 'PRNT80' '<' '1:40' ')']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02466685,1:24:treatment,atypical antipsychotics,['atypical' 'antipsychotics'],[1. 1.]
NCT02465541,10:35:cancer,No prior type I endometrial cancer diagnosis,['No' 'prior' 'type' 'I' 'endometrial' 'cancer' 'diagnosis'],[0. 0. 3. 3. 3. 3. 0.]
NCT02465060,9:24:treatment,Chronic inhaled steroid use,['Chronic' 'inhaled' 'steroid' 'use'],[0. 1. 1. 0.]
NCT02465060,14:40:treatment,Stopping the anticoagulation for biopsy should be per site standard operating procedure (SOP),"['Stopping' 'the' 'anticoagulation' 'for' 'biopsy' 'should' 'be' 'per'
 'site' 'standard' 'operating' 'procedure' '(' 'SOP' ')']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02465034,22:55:treatment,Contraindications to Transcranial Magnetic Stimulation,['Contraindications' 'to' 'Transcranial' 'Magnetic' 'Stimulation'],[0. 0. 1. 1. 1.]
NCT02464904,58:77:treatment,Absence of or limited access to the pleural space during medical pleuroscopy,"['Absence' 'of' 'or' 'limited' 'access' 'to' 'the' 'pleural' 'space'
 'during' 'medical' 'pleuroscopy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02464878,22:41:treatment,Islet donor-directed anti-HLA antibodies detected by Luminex Single Antigen/specificity bead assay including weakly reactive antibodies that would not be detected by a flow cross-match,"['Islet' 'donor-directed' 'anti-HLA' 'antibodies' 'detected' 'by'
 'Luminex' 'Single' 'Antigen/specificity' 'bead' 'assay' 'including'
 'weakly' 'reactive' 'antibodies' 'that' 'would' 'not' 'be' 'detected'
 'by' 'a' 'flow' 'cross-match']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02464878,1:23:chronic_disease,nail fungal infections,['nail' 'fungal' 'infections'],[2. 2. 2.]
NCT02464696,15:61:chronic_disease,Patients with acute chronic obstructive disease exacerbation as the primary etiology for respiratory failure,"['Patients' 'with' 'acute' 'chronic' 'obstructive' 'disease'
 'exacerbation' 'as' 'the' 'primary' 'etiology' 'for' 'respiratory'
 'failure']",[0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02464696,1:29:chronic_disease,Supraventricular tachycardia,['Supraventricular' 'tachycardia'],[2. 2.]
NCT02464436,"1:12:chronic_disease,,",High myopia (>6 diopters) in the study eye,['High' 'myopia' '(' '>' '6' 'diopters' ')' 'in' 'the' 'study' 'eye'],[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02463305,1:32:treatment,Prior surgical bowel resections,['Prior' 'surgical' 'bowel' 'resections'],[1. 1. 1. 1.]
NCT02462590,29:47:chronic_disease,"primary diagnosis of severe acute pancreatitis, without reference to a Ranson score [Ranson 1974])","['primary' 'diagnosis' 'of' 'severe' 'acute' 'pancreatitis' ',' 'without'
 'reference' 'to' 'a' 'Ranson' 'score' '[' 'Ranson' '1974' ']' ')']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02461927,28:68:chronic_disease,Current or past history of psychotic features or psychotic disorder,"['Current' 'or' 'past' 'history' 'of' 'psychotic' 'features' 'or'
 'psychotic' 'disorder']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 2.]
NCT02460835,10:29:cancer,not have extrahepatic cancer,['not' 'have' 'extrahepatic' 'cancer'],[0. 0. 3. 3.]
NCT02460692,68:84:chronic_disease,Presence of another painful condition of greater severity than the neuropathic pain condition which is being studied,"['Presence' 'of' 'another' 'painful' 'condition' 'of' 'greater' 'severity'
 'than' 'the' 'neuropathic' 'pain' 'condition' 'which' 'is' 'being'
 'studied']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02458482,"98:128:treatment,",Patients who present from a referring facility or Primary Care Physician (PCP) and have received systemic corticosteroids (SCS) within one hour of initial AAIRS scoring will also be included,"['Patients' 'who' 'present' 'from' 'a' 'referring' 'facility' 'or'
 'Primary' 'Care' 'Physician' '(' 'PCP' ')' 'and' 'have' 'received'
 'systemic' 'corticosteroids' '(' 'SCS' ')' 'within' 'one' 'hour' 'of'
 'initial' 'AAIRS' 'scoring' 'will' 'also' 'be' 'included']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02457845,1:34:treatment,Autologous bone marrow transplant,['Autologous' 'bone' 'marrow' 'transplant'],[1. 1. 1. 1.]
NCT02457832,1:18:treatment,Metallic implants,['Metallic' 'implants'],[1. 1.]
NCT02457702,"35:45:treatment,",Significant weight loss or use of diet pills within previous 6 months,"['Significant' 'weight' 'loss' 'or' 'use' 'of' 'diet' 'pills' 'within'
 'previous' '6' 'months']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02454907,1:23:chronic_disease,Relapsing-remitting MS (2010 criteria),['Relapsing-remitting' 'MS' '(' '2010' 'criteria' ')'],[2. 2. 0. 0. 0. 0.]
NCT02453373,"1:25:chronic_disease,,",Ischemic cortical stroke with NIHSS > _5_,['Ischemic' 'cortical' 'stroke' 'with' 'NIHSS' '>' '_5_'],[2. 2. 2. 0. 0. 0. 0.]
NCT02453373,12:35:chronic_disease,history of cold agglutinin disease,['history' 'of' 'cold' 'agglutinin' 'disease'],[0. 0. 2. 2. 2.]
NCT02452697,25:41:chronic_disease,Those with a history of cardiac problems or abnormal cardiac findings by physical examination should undergo a stress evaluation or be evaluated by a cardiologist and deemed eligible to donate,"['Those' 'with' 'a' 'history' 'of' 'cardiac' 'problems' 'or' 'abnormal'
 'cardiac' 'findings' 'by' 'physical' 'examination' 'should' 'undergo' 'a'
 'stress' 'evaluation' 'or' 'be' 'evaluated' 'by' 'a' 'cardiologist' 'and'
 'deemed' 'eligible' 'to' 'donate']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02452203,34:54:chronic_disease,Participant meets criteria for a DSM5 Axis-1 disorder,['Participant' 'meets' 'criteria' 'for' 'a' 'DSM5' 'Axis-1' 'disorder'],[0. 0. 0. 0. 0. 2. 2. 2.]
NCT02451683,"1:16:chronic_disease,",Cervical injury at C8 or above,['Cervical' 'injury' 'at' 'C8' 'or' 'above'],[2. 2. 0. 0. 0. 0.]
NCT02451553,1:30:treatment,Prior treatment with afatinib,['Prior' 'treatment' 'with' 'afatinib'],[1. 1. 1. 1.]
NCT02451488,",,,122:149:treatment",who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and 2 weeks after cessation of the study drug,"['who' 'are' 'unwilling' 'or' 'unable' 'to' 'use' 'an' 'acceptable'
 'method' 'to' 'avoid' 'pregnancy' 'for' 'the' 'entire' 'study' 'period'
 'and' '2' 'weeks' 'after' 'cessation' 'of' 'the' 'study' 'drug']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 1. 1. 1.]"
NCT02451423,"1:23:chronic_disease,",BCG-refractory disease is defined as the absence of a complete response by 6 months in patients who have received induction,"['BCG-refractory' 'disease' 'is' 'defined' 'as' 'the' 'absence' 'of' 'a'
 'complete' 'response' 'by' '6' 'months' 'in' 'patients' 'who' 'have'
 'received' 'induction']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02451423,"20:33:chronic_disease,,",Patients with past HBV infection or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBc Ab] and absence of HBsAg) are eligible,"['Patients' 'with' 'past' 'HBV' 'infection' 'or' 'resolved' 'HBV'
 'infection' '(' 'defined' 'as' 'the' 'presence' 'of' 'hepatitis' 'B'
 'core' 'antibody' '[' 'HBc' 'Ab' ']' 'and' 'absence' 'of' 'HBsAg' ')'
 'are' 'eligible']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02451423,20:44:treatment,maintenance OR two induction courses of BCG,['maintenance' 'OR' 'two' 'induction' 'courses' 'of' 'BCG'],[0. 0. 0. 1. 1. 1. 1.]
NCT02451215,1:31:cancer,Choroid plexus papilloma (CPP),['Choroid' 'plexus' 'papilloma' '(' 'CPP' ')'],[3. 3. 3. 3. 0. 0.]
NCT02451215,1:14:cancer,Ganglioglioma,['Ganglioglioma'],[3.]
NCT02451215,1:11:cancer,Meningioma,['Meningioma'],[3.]
NCT02448381,44:68:cancer,"Subjects must have a clinical diagnosis of CTCL (mycosis fungoides), Stage IA, Stage IB, or Stage IIA","['Subjects' 'must' 'have' 'a' 'clinical' 'diagnosis' 'of' 'CTCL' '('
 'mycosis' 'fungoides' ')' ',' 'Stage' 'IA' ',' 'Stage' 'IB' ',' 'or'
 'Stage' 'IIA']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02446457,",64:91:chronic_disease",Have measurable disease (>= 1.5 cm in the longest diameter for nodal or extranodal disease),"['Have' 'measurable' 'disease' '(' '>' '=' '1.5' 'cm' 'in' 'the' 'longest'
 'diameter' 'for' 'nodal' 'or' 'extranodal' 'disease' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0.]
NCT02446236,",,,,,,149:160:chronic_disease,","Platelets > 75,000/μL and absolute neutrophils count (ANC) > 1,000/μL within 14 days of study registration (unless the treating physician deems the neutropenia is related to bone marrow involvement, then an ANC of > 750/mm 3 is allowed)","['Platelets' '>' '75,000/μL' 'and' 'absolute' 'neutrophils' 'count' '('
 'ANC' ')' '>' '1,000/μL' 'within' '14' 'days' 'of' 'study' 'registration'
 '(' 'unless' 'the' 'treating' 'physician' 'deems' 'the' 'neutropenia'
 'is' 'related' 'to' 'bone' 'marrow' 'involvement' ',' 'then' 'an' 'ANC'
 'of' '>' '750/mm' '3' 'is' 'allowed' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02445768,67:77:treatment,"exhibit contra-indications to enter the magnetic field of the 3T (pacemakers, metal parts in the body etc)","['exhibit' 'contra-indications' 'to' 'enter' 'the' 'magnetic' 'field' 'of'
 'the' '3T' '(' 'pacemakers' ',' 'metal' 'parts' 'in' 'the' 'body' 'etc'
 ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02442622,1:23:chronic_disease,radial tunnel syndrome,['radial' 'tunnel' 'syndrome'],[2. 2. 2.]
NCT02442323,1:26:cancer,papillary cystic neoplasm,['papillary' 'cystic' 'neoplasm'],[3. 3. 3.]
NCT02442102,33:53:cancer,"Head and/or neck disease (e.g., oropharyngeal cancer)","['Head' 'and/or' 'neck' 'disease' '(' 'e.g.' ',' 'oropharyngeal' 'cancer'
 ')']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 0.]
NCT02441101,"1:28:chronic_disease,",Acute Myocardial infarction within 6 months of entry into the study,"['Acute' 'Myocardial' 'infarction' 'within' '6' 'months' 'of' 'entry'
 'into' 'the' 'study']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02440581,"1:29:treatment,",Chronic maintenance dialysis of at least 3 months,['Chronic' 'maintenance' 'dialysis' 'of' 'at' 'least' '3' 'months'],[1. 1. 1. 0. 0. 0. 0. 0.]
NCT02439450,21:85:treatment,Arm 6: Suitable for front line maintenance treatment with pembrolizumab ± pemetrexed per the current approved package inserts,"['Arm' '6' ':' 'Suitable' 'for' 'front' 'line' 'maintenance' 'treatment'
 'with' 'pembrolizumab' '±' 'pemetrexed' 'per' 'the' 'current' 'approved'
 'package' 'inserts']",[0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02439450,1:19:treatment,fresh tumor biopsy at Week 10 when feasible,['fresh' 'tumor' 'biopsy' 'at' 'Week' '10' 'when' 'feasible'],[1. 1. 1. 0. 0. 0. 0. 0.]
NCT02438995,22:31:treatment,Previous exposure to Cetuximab,['Previous' 'exposure' 'to' 'Cetuximab'],[0. 0. 0. 1.]
NCT02437851,"1:12:cancer,",Anal cancer that cannot be completely excised with a >=1 mm clear margin from surrounding tissue or where excision to obtain a clear margin would compromise sphincter function or anal canal diameter,"['Anal' 'cancer' 'that' 'can' 'not' 'be' 'completely' 'excised' 'with' 'a'
 '>' '=1' 'mm' 'clear' 'margin' 'from' 'surrounding' 'tissue' 'or' 'where'
 'excision' 'to' 'obtain' 'a' 'clear' 'margin' 'would' 'compromise'
 'sphincter' 'function' 'or' 'anal' 'canal' 'diameter']","[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02437370,4:27:treatment,Be previously chemotherapy-treated,['Be' 'previously' 'chemotherapy-treated'],[0. 1. 1.]
NCT02437110,"5:17:treatment,",had neuroimaging within the last 18 months,['had' 'neuroimaging' 'within' 'the' 'last' '18' 'months'],[0. 1. 0. 0. 0. 0. 0.]
NCT02436070,1:20:chronic_disease,Sickle Cell disease,['Sickle' 'Cell' 'disease'],[2. 2. 2.]
NCT02435069,27:48:chronic_disease,children with preexisting electrolyte imbalance,['children' 'with' 'preexisting' 'electrolyte' 'imbalance'],[0. 0. 0. 2. 2.]
NCT02434809,32:38:allergy_name,History of hypersensitivity to nickel,['History' 'of' 'hypersensitivity' 'to' 'nickel'],[0. 0. 0. 0. 4.]
NCT02433977,"1:28:chronic_disease,",Respiratory tract infection within the last 4 weeks,['Respiratory' 'tract' 'infection' 'within' 'the' 'last' '4' 'weeks'],[2. 2. 2. 0. 0. 0. 0. 0.]
NCT02433158,15:29:treatment,Completion of Study B5201002,['Completion' 'of' 'Study' 'B5201002'],[0. 0. 1. 1.]
NCT02431806,24:48:chronic_disease,Clinically significant cardiovascular disorders,['Clinically' 'significant' 'cardiovascular' 'disorders'],[0. 0. 2. 2.]
NCT02430077,",,,78:109:treatment",Hepatic steatosis (>5.6% hepatic triglyceride content) as demonstrated by 1H magnetic resonance spectroscopy,"['Hepatic' 'steatosis' '(' '>' '5.6' '%' 'hepatic' 'triglyceride'
 'content' ')' 'as' 'demonstrated' 'by' '1H' 'magnetic' 'resonance'
 'spectroscopy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02430051,17:39:treatment,Prescription of anti-cholinergic drugs (which may alter EDA),"['Prescription' 'of' 'anti-cholinergic' 'drugs' '(' 'which' 'may' 'alter'
 'EDA' ')']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02429830,",,107:114:treatment",If the subject is of child bearing potential must have a negative pregnancy test within one week prior to implant and must agree to use effective means of birth control during the course of the study,"['If' 'the' 'subject' 'is' 'of' 'child' 'bearing' 'potential' 'must'
 'have' 'a' 'negative' 'pregnancy' 'test' 'within' 'one' 'week' 'prior'
 'to' 'implant' 'and' 'must' 'agree' 'to' 'use' 'effective' 'means' 'of'
 'birth' 'control' 'during' 'the' 'course' 'of' 'the' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02428205,1:18:chronic_disease,Major head trauma,['Major' 'head' 'trauma'],[2. 2. 2.]
NCT02427841,"13:42:chronic_disease,",No baseline peripheral sensory neuropathy >= grade 2,['No' 'baseline' 'peripheral' 'sensory' 'neuropathy' '>' '=' 'grade' '2'],[0. 0. 2. 2. 2. 0. 0. 0. 0.]
NCT02426476,36:53:treatment,an active prescription for certain heart medications,['an' 'active' 'prescription' 'for' 'certain' 'heart' 'medications'],[0. 0. 0. 0. 0. 1. 1.]
NCT02426047,14:22:treatment,Prior use of betaquik® at any time for any duration,['Prior' 'use' 'of' 'betaquik®' 'at' 'any' 'time' 'for' 'any' 'duration'],[0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02424968,",,50:66:treatment",Patients must be beyond day 30 and before day 60 after transplant,"['Patients' 'must' 'be' 'beyond' 'day' '30' 'and' 'before' 'day' '60'
 'after' 'transplant']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02423863,",82:91:treatment",Contraception must be continued for at least 2 months following the last dose of poly-ICLC,"['Contraception' 'must' 'be' 'continued' 'for' 'at' 'least' '2' 'months'
 'following' 'the' 'last' 'dose' 'of' 'poly-ICLC']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02423863,1:14:cancer,Squamous head,['Squamous' 'head'],[3. 3.]
NCT02423525,31:75:treatment,Current or anticipated use of enzyme-inducing anti-epileptic drugs (EIAED),"['Current' 'or' 'anticipated' 'use' 'of' 'enzyme-inducing'
 'anti-epileptic' 'drugs' '(' 'EIAED' ')']",[0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0.]
NCT02422641,1:16:cancer,Triple-negative patients will be defined per ASCO-CAP Guidelines (American Society of Clinical Oncology-College of American Pathologists),"['Triple-negative' 'patients' 'will' 'be' 'defined' 'per' 'ASCO-CAP'
 'Guidelines' '(' 'American' 'Society' 'of' 'Clinical' 'Oncology-College'
 'of' 'American' 'Pathologists' ')']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02421341,",80:116:chronic_disease","Will be matched for age, gender, height and weight and will have no history of cardiovascular related abnormalities","['Will' 'be' 'matched' 'for' 'age' ',' 'gender' ',' 'height' 'and'
 'weight' 'and' 'will' 'have' 'no' 'history' 'of' 'cardiovascular'
 'related' 'abnormalities']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02421315,27:40:treatment,Positive urine screen for illicit drugs,['Positive' 'urine' 'screen' 'for' 'illicit' 'drugs'],[0. 0. 0. 0. 1. 1.]
NCT02421276,"16:71:chronic_disease,,,",Diagnosed with idiopathic or secondary pulmonary arterial hypertension as defined by a mean pulmonary artery pressure > 25 mmHg at rest or > 30 mmHg with exercise,"['Diagnosed' 'with' 'idiopathic' 'or' 'secondary' 'pulmonary' 'arterial'
 'hypertension' 'as' 'defined' 'by' 'a' 'mean' 'pulmonary' 'artery'
 'pressure' '>' '25' 'mmHg' 'at' 'rest' 'or' '>' '30' 'mmHg' 'with'
 'exercise']","[0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02419560,29:32:cancer,Subject is at high risk for TLS,['Subject' 'is' 'at' 'high' 'risk' 'for' 'TLS'],[0. 0. 0. 0. 0. 0. 3.]
NCT02418195,1:17:chronic_disease,Anorexia nervosa,['Anorexia' 'nervosa'],[2. 2.]
NCT02418195,1:12:chronic_disease,Post-partum state,['Post-partum' 'state'],[2. 0.]
NCT02417701,15:79:treatment,Maintained on modern therapeutic regimens utilizing non-CYP-interactive agents,"['Maintained' 'on' 'modern' 'therapeutic' 'regimens' 'utilizing'
 'non-CYP-interactive' 'agents']",[0. 0. 1. 1. 1. 1. 1. 1.]
NCT02416102,12:33:chronic_disease,History of renal artery stenosis,['History' 'of' 'renal' 'artery' 'stenosis'],[0. 0. 2. 2. 2.]
NCT02415556,1:10:chronic_disease,Type 1 DM,['Type' '1' 'DM'],[2. 2. 2.]
NCT02414269,"15:18:chronic_disease,,",Patients with MPD aged ≥18 years,['Patients' 'with' 'MPD' 'aged' '≥18' 'years'],[0. 0. 2. 0. 0. 0.]
NCT02414178,1:22:chronic_disease,Severe claustrophobia,['Severe' 'claustrophobia'],[2. 2.]
NCT02414139,",72:84:treatment","Patients with characterized EGFR mutations that predict sensitivity to EGFR therapy, including, but not limited to exon 19 deletions and exon 21 mutations","['Patients' 'with' 'characterized' 'EGFR' 'mutations' 'that' 'predict'
 'sensitivity' 'to' 'EGFR' 'therapy' ',' 'including' ',' 'but' 'not'
 'limited' 'to' 'exon' '19' 'deletions' 'and' 'exon' '21' 'mutations']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02413047,1:28:treatment,Oral corticosteroid therapy,['Oral' 'corticosteroid' 'therapy'],[1. 1. 1.]
NCT02412540,1:15:chronic_disease,Wilson disease,['Wilson' 'disease'],[2. 2.]
NCT02411773,"1:20:chronic_disease,,",Metabolic Alkalosis (serum bicarbonate > 28 meq/L),['Metabolic' 'Alkalosis' '(' 'serum' 'bicarbonate' '>' '28' 'meq/L' ')'],[2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02410954,17:75:chronic_disease,Current or past Axis I Diagnostic and Statistical Manual (DSM-IV) disorder based on the MINI,"['Current' 'or' 'past' 'Axis' 'I' 'Diagnostic' 'and' 'Statistical'
 'Manual' '(' 'DSM-IV' ')' 'disorder' 'based' 'on' 'the' 'MINI']",[0. 0. 0. 2. 2. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02409810,1:20:chronic_disease,Acute liver failure,['Acute' 'liver' 'failure'],[2. 2. 2.]
NCT02408861,50:66:allergy_name,delayed-type hypersensitivity reaction caused by contact allergen,"['delayed-type' 'hypersensitivity' 'reaction' 'caused' 'by' 'contact'
 'allergen']",[0. 0. 0. 0. 0. 4. 4.]
NCT02408120,31:47:treatment,Subjects receiving continuous insulin infusion,['Subjects' 'receiving' 'continuous' 'insulin' 'infusion'],[0. 0. 0. 1. 1.]
NCT02408120,1:24:treatment,non-insulin injectables,['non-insulin' 'injectables'],[1. 1.]
NCT02407028,"1:34:treatment,",First hyperbaric oxygen treatment cannot be initiated within 24 hours of injury,"['First' 'hyperbaric' 'oxygen' 'treatment' 'can' 'not' 'be' 'initiated'
 'within' '24' 'hours' 'of' 'injury']",[1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02406885,20:27:treatment,Strong inducers of CYP 3A4,['Strong' 'inducers' 'of' 'CYP' '3A4'],[0. 0. 0. 1. 1.]
NCT02406599,28:42:treatment,Patients for whom complete cavity shaving is planned (sites where this is the routine practice of the investigator will also be excluded from participation in the study),"['Patients' 'for' 'whom' 'complete' 'cavity' 'shaving' 'is' 'planned' '('
 'sites' 'where' 'this' 'is' 'the' 'routine' 'practice' 'of' 'the'
 'investigator' 'will' 'also' 'be' 'excluded' 'from' 'participation' 'in'
 'the' 'study' ')']","[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02404870,44:57:allergy_name,"Have previous hypersensitivity reaction to canagliflozin (including but not limited to rash, raised red patches on your skin (hives), swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing)","['Have' 'previous' 'hypersensitivity' 'reaction' 'to' 'canagliflozin' '('
 'including' 'but' 'not' 'limited' 'to' 'rash' ',' 'raised' 'red'
 'patches' 'on' 'your' 'skin' '(' 'hives' ')' ',' 'swelling' 'of' 'the'
 'face' ',' 'lips' ',' 'tongue' ',' 'and' 'throat' 'that' 'may' 'cause'
 'difficulty' 'in' 'breathing' 'or' 'swallowing' ')']","[0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02404155,21:39:chronic_disease,DSM-IV diagnosis of Mental Retardation,['DSM-IV' 'diagnosis' 'of' 'Mental' 'Retardation'],[0. 0. 0. 2. 2.]
NCT02403323,33:68:treatment,Patients previously enrolled in etrolizumab Phase III study GA29144 who meet the eligibility criteria for open-label etrolizumab as described in the protocol,"['Patients' 'previously' 'enrolled' 'in' 'etrolizumab' 'Phase' 'III'
 'study' 'GA29144' 'who' 'meet' 'the' 'eligibility' 'criteria' 'for'
 'open-label' 'etrolizumab' 'as' 'described' 'in' 'the' 'protocol']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02403128,",,31:50:treatment",CFT of 310 microns or more by spectral domain OCT or lipid in the center of the fovea,"['CFT' 'of' '310' 'microns' 'or' 'more' 'by' 'spectral' 'domain' 'OCT'
 'or' 'lipid' 'in' 'the' 'center' 'of' 'the' 'fovea']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02402660,",148:177:treatment",At least one eye (called the primary study eye) must have at least one well-demarcated area of significantly reduced autofluorescence as imaged by fundus autofluorescence (FAF),"['At' 'least' 'one' 'eye' '(' 'called' 'the' 'primary' 'study' 'eye' ')'
 'must' 'have' 'at' 'least' 'one' 'well-demarcated' 'area' 'of'
 'significantly' 'reduced' 'autofluorescence' 'as' 'imaged' 'by' 'fundus'
 'autofluorescence' '(' 'FAF' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 1. 0. 0.]"
NCT02402647,1:18:chronic_disease,Hoarding Disorder diagnosis outlined by the Diagnostic and Statistical Manual of Mental Disorders,"['Hoarding' 'Disorder' 'diagnosis' 'outlined' 'by' 'the' 'Diagnostic'
 'and' 'Statistical' 'Manual' 'of' 'Mental' 'Disorders']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02401347,52:59:allergy_name,Known hypersensitivity to any of the components of BMN 673,"['Known' 'hypersensitivity' 'to' 'any' 'of' 'the' 'components' 'of' 'BMN'
 '673']",[0. 0. 0. 0. 0. 0. 0. 0. 4. 4.]
NCT02401074,"1:38:chronic_disease,",Upper and lower respiratory infection within 1 month of screening,"['Upper' 'and' 'lower' 'respiratory' 'infection' 'within' '1' 'month' 'of'
 'screening']",[2. 2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02400463,1:14:chronic_disease,Malabsorption,['Malabsorption'],[2.]
NCT02400255,"8:18:chronic_disease,",Active GVHD grade ≥ 2,['Active' 'GVHD' 'grade' '≥' '2'],[0. 2. 2. 0. 0.]
NCT02398773,127:134:allergy_name,Patient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-FES,"['Patient' 'must' 'NOT' 'have' 'a' 'history' 'of' 'allergic' 'reaction'
 'attributable' 'to' 'compounds' 'of' 'similar' 'chemical' 'or' 'biologic'
 'composition' 'to' '18F-FES']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4.]
NCT02397889,12:23:chronic_disease,History of (hypo)mania,['History' 'of' '(' 'hypo' ')' 'mania'],[2. 2. 2. 2. 2. 2.]
NCT02397889,1:33:chronic_disease,gastro-esophageal reflux disease,['gastro-esophageal' 'reflux' 'disease'],[2. 2. 2.]
NCT02397083,"64:115:treatment,",Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing,"['Patients' 'who' 'are' 'currently' 'part' 'of' 'or' 'have' 'participated'
 'in' 'any' 'clinical' 'investigation' 'with' 'an' 'investigational'
 'drug' 'within' '1' 'month' 'prior' 'to' 'dosing']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02395614,26:69:treatment,candidates for immediate breast reconstruction with tissue expanders,"['candidates' 'for' 'immediate' 'breast' 'reconstruction' 'with' 'tissue'
 'expanders']",[0. 0. 0. 1. 1. 1. 1. 1.]
NCT02395393,55:96:treatment,to be undergoing surveillance or clinically indicated bronchoscopies with transbronchial biopsy as part of their routine care,"['to' 'be' 'undergoing' 'surveillance' 'or' 'clinically' 'indicated'
 'bronchoscopies' 'with' 'transbronchial' 'biopsy' 'as' 'part' 'of'
 'their' 'routine' 'care']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02394535,1:29:treatment,Prior abdominal radiotherapy,['Prior' 'abdominal' 'radiotherapy'],[1. 1. 1.]
NCT02394535,17:27:treatment,patients taking cimetidine must have this drug discontinued,"['patients' 'taking' 'cimetidine' 'must' 'have' 'this' 'drug'
 'discontinued']",[0. 0. 1. 0. 0. 0. 0. 0.]
NCT02393885,59:86:treatment,A condition or congenital anomaly which prevents required surgical or catheter access,"['A' 'condition' 'or' 'congenital' 'anomaly' 'which' 'prevents' 'required'
 'surgical' 'or' 'catheter' 'access']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02393885,"1:38:chronic_disease,,,","Stroke/cerebrovascular accident (CVA) within previous six months, carotid artery stenosis greater than 80%","['Stroke/cerebrovascular' 'accident' '(' 'CVA' ')' 'within' 'previous'
 'six' 'months' ',' 'carotid' 'artery' 'stenosis' 'greater' 'than' '80'
 '%']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02393742,",,34:37:chronic_disease",Body mass index (BMI) >40 kg/m2 (FMD measurements can be inaccurate in severely obese patients),"['Body' 'mass' 'index' '(' 'BMI' ')' '>' '40' 'kg/m2' '(' 'FMD'
 'measurements' 'can' 'be' 'inaccurate' 'in' 'severely' 'obese' 'patients'
 ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02393690,132:152:cancer,Modification of the RECIST v1.1 measurable disease criteria includes a change in the definition of what is considered a measurable malignant lymph node,"['Modification' 'of' 'the' 'RECIST' 'v1.1' 'measurable' 'disease'
 'criteria' 'includes' 'a' 'change' 'in' 'the' 'definition' 'of' 'what'
 'is' 'considered' 'a' 'measurable' 'malignant' 'lymph' 'node']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT02393157,32:71:treatment,Patients may not have received prior therapy with obinutuzumab (GA101),"['Patients' 'may' 'not' 'have' 'received' 'prior' 'therapy' 'with'
 'obinutuzumab' '(' 'GA101' ')']",[0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0.]
NCT02393157,1:24:treatment,Radiation Therapy (XRT),['Radiation' 'Therapy' '(' 'XRT' ')'],[1. 1. 1. 0. 0.]
NCT02392286,"13:44:treatment,",Patients on systemic corticosteroid therapy currently or within the past 8 weeks,"['Patients' 'on' 'systemic' 'corticosteroid' 'therapy' 'currently' 'or'
 'within' 'the' 'past' '8' 'weeks']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02390752,1:27:chronic_disease,Active untreated infection,['Active' 'untreated' 'infection'],[2. 2. 2.]
NCT02390752,",,167:174:treatment","Individuals who are pregnant or breast feeding or who become pregnant while enrolled on this trial will be excluded from participation, due to the unknown effects of PLX3397 on a growing fetus or newborn child","['Individuals' 'who' 'are' 'pregnant' 'or' 'breast' 'feeding' 'or' 'who'
 'become' 'pregnant' 'while' 'enrolled' 'on' 'this' 'trial' 'will' 'be'
 'excluded' 'from' 'participation' ',' 'due' 'to' 'the' 'unknown'
 'effects' 'of' 'PLX3397' 'on' 'a' 'growing' 'fetus' 'or' 'newborn'
 'child']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT02390752,65:83:treatment,Patients must have relapsed after or be refractory to effective standard therapies,"['Patients' 'must' 'have' 'relapsed' 'after' 'or' 'be' 'refractory' 'to'
 'effective' 'standard' 'therapies']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02389959,36:79:chronic_disease,The patient carries a diagnosis of hereditary hemorrhagic telangiectasia (HHT),"['The' 'patient' 'carries' 'a' 'diagnosis' 'of' 'hereditary' 'hemorrhagic'
 'telangiectasia' '(' 'HHT' ')']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02389517,",,72:103:treatment",Rate-corrected QT interval of electrocardiograph (QTc) > 470 msec on a 12-lead electrocardiogram (ECG) during screening,"['Rate-corrected' 'QT' 'interval' 'of' 'electrocardiograph' '(' 'QTc' ')'
 '>' '470' 'msec' 'on' 'a' '12-lead' 'electrocardiogram' '(' 'ECG' ')'
 'during' 'screening']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0.]
NCT02388685,1:33:treatment,Lower extremity vascular surgery,['Lower' 'extremity' 'vascular' 'surgery'],[1. 1. 1. 1.]
NCT02387905,25:40:chronic_disease,Patients who have frank mechanical pain,['Patients' 'who' 'have' 'frank' 'mechanical' 'pain'],[0. 0. 0. 0. 2. 2.]
NCT02385110,33:61:chronic_disease,"A documentation of diagnosis of hemophagocytic lymphocytosis, either newly diagnosed or relapsed/refractory by the treating physician and the PI in the patients chart","['A' 'documentation' 'of' 'diagnosis' 'of' 'hemophagocytic'
 'lymphocytosis' ',' 'either' 'newly' 'diagnosed' 'or'
 'relapsed/refractory' 'by' 'the' 'treating' 'physician' 'and' 'the' 'PI'
 'in' 'the' 'patients' 'chart']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02383927,1:24:chronic_disease,cerebro-vascular attack within the prior year,['cerebro-vascular' 'attack' 'within' 'the' 'prior' 'year'],[2. 2. 0. 0. 0. 0.]
NCT02382549,94:123:chronic_disease,Participants classified according to the New York Heart Association classification as having Class III or IV heart disease,"['Participants' 'classified' 'according' 'to' 'the' 'New' 'York' 'Heart'
 'Association' 'classification' 'as' 'having' 'Class' 'III' 'or' 'IV'
 'heart' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 2.]
NCT02382549,30:62:cancer,"Participants with measurable stage IIIB, IIIC, or IV melanoma that have clinical or radiological evidence of disease","['Participants' 'with' 'measurable' 'stage' 'IIIB' ',' 'IIIC' ',' 'or'
 'IV' 'melanoma' 'that' 'have' 'clinical' 'or' 'radiological' 'evidence'
 'of' 'disease']",[0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02382419,42:60:allergy_name,Any known allergy or hypersensitivity to vaginal lubricants or any component of study product,"['Any' 'known' 'allergy' 'or' 'hypersensitivity' 'to' 'vaginal'
 'lubricants' 'or' 'any' 'component' 'of' 'study' 'product']",[0. 0. 0. 0. 0. 0. 4. 4. 0. 0. 0. 0. 0. 0.]
NCT02379156,1:26:chronic_disease,Untreated thyroid disease,['Untreated' 'thyroid' 'disease'],[2. 2. 2.]
NCT02378714,",,,,95:141:chronic_disease",systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg after two readings or symptomatic uncontrolled stage II hypertension,"['systolic' 'blood' 'pressure' '>' '185' 'mmHg' 'or' 'diastolic' 'blood'
 'pressure' '>' '110' 'mmHg' 'after' 'two' 'readings' 'or' 'symptomatic'
 'uncontrolled' 'stage' 'II' 'hypertension']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2.]
NCT02378428,88:105:treatment,Patients with disease of any major organ system that would compromise their ability to withstand therapy,"['Patients' 'with' 'disease' 'of' 'any' 'major' 'organ' 'system' 'that'
 'would' 'compromise' 'their' 'ability' 'to' 'withstand' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02376153,1:18:treatment,Acetabular repair with instrumentation,['Acetabular' 'repair' 'with' 'instrumentation'],[1. 1. 0. 0.]
NCT02374333,18:41:chronic_disease,Any uncontrolled active medical disorder that would preclude participation as outlined,"['Any' 'uncontrolled' 'active' 'medical' 'disorder' 'that' 'would'
 'preclude' 'participation' 'as' 'outlined']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02374333,16:36:treatment,relapsed after prior autologous SCT,['relapsed' 'after' 'prior' 'autologous' 'SCT'],[0. 0. 1. 1. 1.]
NCT02374021,54:79:chronic_disease,"Prior patient reported, physician diagnosed clinical cardiovascular (CV) event","['Prior' 'patient' 'reported' ',' 'physician' 'diagnosed' 'clinical'
 'cardiovascular' '(' 'CV' ')' 'event']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0.]
NCT02374021,1:16:chronic_disease,macular disease,['macular' 'disease'],[2. 2.]
NCT02373644,1:17:treatment,ASIS distraction,['ASIS' 'distraction'],[1. 1.]
NCT02373644,1:19:treatment,Sacral compression,['Sacral' 'compression'],[1. 1.]
NCT02370693,"13:42:chronic_disease,",Patient has Grade 2 peripheral neuropathy by history within 14 days before enrollment,"['Patient' 'has' 'Grade' '2' 'peripheral' 'neuropathy' 'by' 'history'
 'within' '14' 'days' 'before' 'enrollment']",[0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02370095,"1:29:chronic_disease,,,",Severe chronic liver disease (Child-Pugh Score 11-15),['Severe' 'chronic' 'liver' 'disease' '(' 'Child-Pugh' 'Score' '11-15' ')'],[2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02370056,7:22:treatment,total proctocolectomy,['total' 'proctocolectomy'],[0. 1.]
NCT02369770,1:32:chronic_disease,Severe cardiovascular disorders that interfere with ability to perform moderate movement exercises,"['Severe' 'cardiovascular' 'disorders' 'that' 'interfere' 'with' 'ability'
 'to' 'perform' 'moderate' 'movement' 'exercises']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02367040,"1:24:cancer,,",Follicular lymphoma(FL) grade1-2-3a,['Follicular' 'lymphoma' '(' 'FL' ')' 'grade1-2-3a'],[3. 3. 0. 0. 0. 0.]
NCT02366871,1:26:chronic_disease,Active bleeding condition,['Active' 'bleeding' 'condition'],[2. 2. 2.]
NCT02366871,1:13:chronic_disease,haemophilias,['haemophilias'],[2.]
NCT02366871,1:21:chronic_disease,protein C deficiency,['protein' 'C' 'deficiency'],[2. 2. 2.]
NCT02366819,1:25:cancer,gross peritoneal disease,['gross' 'peritoneal' 'disease'],[3. 3. 3.]
NCT02365766,"1:17:chronic_disease,",Hearing impaired ≥grade 2 as assessed by treating physician (may or may not be enrolled in a monitoring program),"['Hearing' 'impaired' '≥grade' '2' 'as' 'assessed' 'by' 'treating'
 'physician' '(' 'may' 'or' 'may' 'not' 'be' 'enrolled' 'in' 'a'
 'monitoring' 'program' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02365467,16:65:chronic_disease,Subject has an acute dissection of the descending thoracic aorta,"['Subject' 'has' 'an' 'acute' 'dissection' 'of' 'the' 'descending'
 'thoracic' 'aorta']",[0. 0. 0. 2. 2. 2. 2. 2. 2. 2.]
NCT02365467,"19:51:chronic_disease,",Subject has had a cerebral vascular accident (CVA) within 3 months,"['Subject' 'has' 'had' 'a' 'cerebral' 'vascular' 'accident' '(' 'CVA' ')'
 'within' '3' 'months']",[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02365467,"3:20:chronic_disease,,,",a fusiform aneurysm with a diameter of ≥ 5.5 cm OR is > 2 times the diameter of the non-aneurysmal thoracic aorta,"['a' 'fusiform' 'aneurysm' 'with' 'a' 'diameter' 'of' '≥' '5.5' 'cm' 'OR'
 'is' '>' '2' 'times' 'the' 'diameter' 'of' 'the' 'non-aneurysmal'
 'thoracic' 'aorta']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02362308,22:37:chronic_disease,Previously diagnosed type 1 Diabetes,['Previously' 'diagnosed' 'type' '1' 'Diabetes'],[0. 0. 2. 2. 2.]
NCT02362308,1:17:chronic_disease,"Type II Diabetes, as defined by ADA criteria","['Type' 'II' 'Diabetes' ',' 'as' 'defined' 'by' 'ADA' 'criteria']",[2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02361554,",70:80:treatment","Subject is able to read English, understand and cooperate with study procedures, and has signed a written informed consent form prior to any study procedures","['Subject' 'is' 'able' 'to' 'read' 'English' ',' 'understand' 'and'
 'cooperate' 'with' 'study' 'procedures' ',' 'and' 'has' 'signed' 'a'
 'written' 'informed' 'consent' 'form' 'prior' 'to' 'any' 'study'
 'procedures']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02360579,21:53:treatment,Patients who are on chronic systemic steroid therapy for any reason,"['Patients' 'who' 'are' 'on' 'chronic' 'systemic' 'steroid' 'therapy'
 'for' 'any' 'reason']",[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0.]
NCT02359864,"15:25:treatment,,",Patient has a MMSE score of between 10-20,['Patient' 'has' 'a' 'MMSE' 'score' 'of' 'between' '10-20'],[0. 0. 0. 1. 1. 0. 0. 0.]
NCT02359825,43:63:treatment,unlikely to complete the normal regime of occupational therapy,"['unlikely' 'to' 'complete' 'the' 'normal' 'regime' 'of' 'occupational'
 'therapy']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02359097,42:57:treatment,Subjects who have a contraindication for 3 tesla (T) MRI,"['Subjects' 'who' 'have' 'a' 'contraindication' 'for' '3' 'tesla' '(' 'T'
 ')' 'MRI']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0.]
NCT02358187,",20:29:treatment",Interleukins (e.g. Proleukin®),['Interleukins' '(' 'e.g' '.' 'Proleukin®' ')'],[0. 0. 0. 0. 1. 0.]
NCT02357784,7:37:chronic_disease,has > Stage II pelvic organ prolapse,['has' '>' 'Stage' 'II' 'pelvic' 'organ' 'prolapse'],[0. 0. 2. 2. 2. 2. 2.]
NCT02356861,5:40:chronic_disease,"Had Gulf War Veterans' Illnesses (GWVI), but did not answer 'Yes' to the following questions: 1) Difficulty concentrating and/or 2) Difficulty remembering recent information","['Had' 'Gulf' 'War' 'Veterans' ""'"" 'Illnesses' '(' 'GWVI' ')' ',' 'but'
 'did' 'not' 'answer' ""'Yes"" ""'"" 'to' 'the' 'following' 'questions' ':'
 '1' ')' 'Difficulty' 'concentrating' 'and/or' '2' ')' 'Difficulty'
 'remembering' 'recent' 'information']","[0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02356705,23:47:treatment,scheduled for a minor Ear/Nose/Throat surgical procedure requiring mask anesthesia,"['scheduled' 'for' 'a' 'minor' 'Ear/Nose/Throat' 'surgical' 'procedure'
 'requiring' 'mask' 'anesthesia']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02356653,1:10:cancer,Lymphomas,['Lymphomas'],[3.]
NCT02355912,23:40:chronic_disease,cognitive deficits or visual impairment that would impair their ability to give informed consent or impair their ability to follow simple instructions during the experiments,"['cognitive' 'deficits' 'or' 'visual' 'impairment' 'that' 'would' 'impair'
 'their' 'ability' 'to' 'give' 'informed' 'consent' 'or' 'impair' 'their'
 'ability' 'to' 'follow' 'simple' 'instructions' 'during' 'the'
 'experiments']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02355535,1:54:treatment,Prior allogeneic bone marrow or organ transplantation,['Prior' 'allogeneic' 'bone' 'marrow' 'or' 'organ' 'transplantation'],[1. 1. 1. 1. 1. 1. 1.]
NCT02355002,1:17:treatment,vagal stimulator,['vagal' 'stimulator'],[1. 1.]
NCT02354703,12:28:chronic_disease,History of Long QT Syndrome or a first-degree biological family member with this condition,"['History' 'of' 'Long' 'QT' 'Syndrome' 'or' 'a' 'first-degree'
 'biological' 'family' 'member' 'with' 'this' 'condition']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02354547,",41:70:treatment",At least 21 days after the last dose of myelosuppressive chemotherapy,"['At' 'least' '21' 'days' 'after' 'the' 'last' 'dose' 'of'
 'myelosuppressive' 'chemotherapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02353819,1:15:cancer,Adenocarcinoma of the prostate,['Adenocarcinoma' 'of' 'the' 'prostate'],[3. 0. 0. 0.]
NCT02353728,1:34:chronic_disease,Complete left bundle branch block,['Complete' 'left' 'bundle' 'branch' 'block'],[2. 2. 2. 2. 2.]
NCT02353728,8:35:treatment,Use of ventricular-paced pacemaker,['Use' 'of' 'ventricular-paced' 'pacemaker'],[0. 0. 1. 1.]
NCT02351544,63:81:chronic_disease,"Patients deemed by the authors or the neurologist to not have migraine headaches, but an alternative diagnosis","['Patients' 'deemed' 'by' 'the' 'authors' 'or' 'the' 'neurologist' 'to'
 'not' 'have' 'migraine' 'headaches' ',' 'but' 'an' 'alternative'
 'diagnosis']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02350764,",,87:98:treatment,",Exception is made for patients with EGFR or ALK re-arrangements who must have stopped TKI therapy at least 7 days prior to C1D1,"['Exception' 'is' 'made' 'for' 'patients' 'with' 'EGFR' 'or' 'ALK'
 're-arrangements' 'who' 'must' 'have' 'stopped' 'TKI' 'therapy' 'at'
 'least' '7' 'days' 'prior' 'to' 'C1D1']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02349958,21:36:chronic_disease,"Patients with known extra-abdominal disease, or unresected bulky abdominal retroperitoneal lymph nodes","['Patients' 'with' 'known' 'extra-abdominal' 'disease' ',' 'or'
 'unresected' 'bulky' 'abdominal' 'retroperitoneal' 'lymph' 'nodes']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02349867,1:20:chronic_disease,Arterial thrombotic,['Arterial' 'thrombotic'],[2. 2.]
NCT02347995,29:49:chronic_disease,hemodynamically significant valvular dysfunction,['hemodynamically' 'significant' 'valvular' 'dysfunction'],[0. 0. 2. 2.]
NCT02347891,1:16:chronic_disease,Dermatomyositis patients that do not meet the MMT criteria,"['Dermatomyositis' 'patients' 'that' 'do' 'not' 'meet' 'the' 'MMT'
 'criteria']",[2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02347891,15:39:treatment,Have received treatment with Belimumab at any time prior to Screening,"['Have' 'received' 'treatment' 'with' 'Belimumab' 'at' 'any' 'time'
 'prior' 'to' 'Screening']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02347111,"1:28:treatment,",Cardiac or thoracic surgery within the previous 6 months,"['Cardiac' 'or' 'thoracic' 'surgery' 'within' 'the' 'previous' '6'
 'months']",[1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02347111,",20:24:treatment",Received 2 or more AADs in past,['Received' '2' 'or' 'more' 'AADs' 'in' 'past'],[0. 0. 0. 0. 1. 0. 0.]
NCT02346526,1:19:chronic_disease,Fecal incontinence,['Fecal' 'incontinence'],[2. 2.]
NCT02346253,"51:69:treatment,","Clinically negative lymph nodes as established by abdomino-pelvic CT, no more than 90 days prior toregistration","['Clinically' 'negative' 'lymph' 'nodes' 'as' 'established' 'by'
 'abdomino-pelvic' 'CT' ',' 'no' 'more' 'than' '90' 'days' 'prior'
 'toregistration']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02346201,30:54:chronic_disease,"Currently meets criteria for Major Depressive Episode, by Diagnostic Statistical Manual of Mental Disorder - IV (TR) criteria","['Currently' 'meets' 'criteria' 'for' 'Major' 'Depressive' 'Episode' ','
 'by' 'Diagnostic' 'Statistical' 'Manual' 'of' 'Mental' 'Disorder' '-'
 'IV' '(' 'TR' ')' 'criteria']",[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02343549,18:30:treatment,Have undergone a brain biopsy via stereotactic or open technique,"['Have' 'undergone' 'a' 'brain' 'biopsy' 'via' 'stereotactic' 'or' 'open'
 'technique']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02343549,13:38:chronic_disease,Significant liver function impairment,['Significant' 'liver' 'function' 'impairment'],[0. 2. 2. 2.]
NCT02343549,1:7:chronic_disease,nausea,['nausea'],[2.]
NCT02343042,"1:54:treatment,",Treatment with an investigational anti-cancer therapy within 3 weeks prior to C1D1,"['Treatment' 'with' 'an' 'investigational' 'anti-cancer' 'therapy'
 'within' '3' 'weeks' 'prior' 'to' 'C1D1']",[1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02342782,45:113:allergy_name,History of allergic reactions attributed to compounds of similar chemical or biologic composition to basiliximab,"['History' 'of' 'allergic' 'reactions' 'attributed' 'to' 'compounds' 'of'
 'similar' 'chemical' 'or' 'biologic' 'composition' 'to' 'basiliximab']",[0. 0. 0. 0. 0. 0. 4. 4. 4. 4. 4. 4. 4. 4. 4.]
NCT02342782,1:40:chronic_disease,psychosocial circumstances or illnesses that preclude protocol participation (to be determined by P.I.),"['psychosocial' 'circumstances' 'or' 'illnesses' 'that' 'preclude'
 'protocol' 'participation' '(' 'to' 'be' 'determined' 'by' 'P.I' '.' ')']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02341209,"75:95:treatment,,",The subject has resolution of all clinically significant toxic effects of prior cancer therapy to Grade ≤1 by the National Cancer Institute Common Terminology Criteria for Adverse Events,"['The' 'subject' 'has' 'resolution' 'of' 'all' 'clinically' 'significant'
 'toxic' 'effects' 'of' 'prior' 'cancer' 'therapy' 'to' 'Grade' '≤1' 'by'
 'the' 'National' 'Cancer' 'Institute' 'Common' 'Terminology' 'Criteria'
 'for' 'Adverse' 'Events']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02340156,22:42:cancer,Histology other than astrocytoma grade IV,['Histology' 'other' 'than' 'astrocytoma' 'grade' 'IV'],[0. 0. 0. 3. 3. 3.]
NCT02340156,1:11:treatment,Urinalysis: No clinically significant abnormalities,['Urinalysis' ':' 'No' 'clinically' 'significant' 'abnormalities'],[1. 0. 0. 0. 0. 0.]
NCT02339948,42:71:treatment,Tissue for diagnosis must be obtained by transrectal ultrasound biopsy,"['Tissue' 'for' 'diagnosis' 'must' 'be' 'obtained' 'by' 'transrectal'
 'ultrasound' 'biopsy']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02339922,56:74:cancer,Patients must have a diagnosis of one of the following B-NHL malignancies,"['Patients' 'must' 'have' 'a' 'diagnosis' 'of' 'one' 'of' 'the'
 'following' 'B-NHL' 'malignancies']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02339233,1:12:chronic_disease,hypovolemia,['hypovolemia'],[2.]
NCT02338999,27:31:allergy_name,Known hypersensitivity to TZDs,['Known' 'hypersensitivity' 'to' 'TZDs'],[0. 0. 0. 4.]
NCT02338232,1:35:cancer,Acute myeloid or lymphoid leukemia in remission,['Acute' 'myeloid' 'or' 'lymphoid' 'leukemia' 'in' 'remission'],[3. 3. 3. 3. 3. 0. 0.]
NCT02338232,1:29:treatment,Regimens for transplantation,['Regimens' 'for' 'transplantation'],[1. 1. 1.]
NCT02335905,33:44:allergy_name,Has had an allergic reaction to ceftaroline in the past,"['Has' 'had' 'an' 'allergic' 'reaction' 'to' 'ceftaroline' 'in' 'the'
 'past']",[0. 0. 0. 0. 0. 0. 4. 0. 0. 0.]
NCT02335671,36:64:cancer,Participants with prior history of ipsilateral breast carcinoma,"['Participants' 'with' 'prior' 'history' 'of' 'ipsilateral' 'breast'
 'carcinoma']",[0. 0. 0. 0. 0. 3. 3. 3.]
NCT02335242,"47:69:chronic_disease,",Be required to have the clinical diagnosis of lymphatic malformation that appears to be over 3 cm in greatest diameter in order to be evaluated for entry,"['Be' 'required' 'to' 'have' 'the' 'clinical' 'diagnosis' 'of' 'lymphatic'
 'malformation' 'that' 'appears' 'to' 'be' 'over' '3' 'cm' 'in' 'greatest'
 'diameter' 'in' 'order' 'to' 'be' 'evaluated' 'for' 'entry']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02335242,1:17:treatment,"Organic nitrates in any form, either regularly or intermittently","['Organic' 'nitrates' 'in' 'any' 'form' ',' 'either' 'regularly' 'or'
 'intermittently']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02333227,28:39:treatment,Willing to chew 1 piece of xylitol gum for 10 minutes after the morning and evening meal (intervention sites),"['Willing' 'to' 'chew' '1' 'piece' 'of' 'xylitol' 'gum' 'for' '10'
 'minutes' 'after' 'the' 'morning' 'and' 'evening' 'meal' '('
 'intervention' 'sites' ')']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02332928,"35:44:treatment,",Subjects who are currently taking melatonin must discontinue melatonin for 5 days before enrolling in the study,"['Subjects' 'who' 'are' 'currently' 'taking' 'melatonin' 'must'
 'discontinue' 'melatonin' 'for' '5' 'days' 'before' 'enrolling' 'in'
 'the' 'study']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02332863,1:5:allergy_name,Gold allergy,['Gold' 'allergy'],[4. 0.]
NCT02332850,1:15:treatment,prior surgical procedures,['prior' 'surgical' 'procedures'],[1. 1. 0.]
NCT02332668,",,,42:47:cancer",between 3 years and <18 years of age for rrcHL participants,"['between' '3' 'years' 'and' '<' '18' 'years' 'of' 'age' 'for' 'rrcHL'
 'participants']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0.]
NCT02332369,1:21:chronic_disease,Congenital cataracts,['Congenital' 'cataracts'],[2. 2.]
NCT02332369,1:7:chronic_disease,Iritis,['Iritis'],[2.]
NCT02332369,1:19:chronic_disease,Retinal detachment,['Retinal' 'detachment'],[2. 2.]
NCT02332291,"1:26:treatment,",Electroconvulsive therapy in last 6 months,['Electroconvulsive' 'therapy' 'in' 'last' '6' 'months'],[1. 1. 0. 0. 0. 0.]
NCT02332187,"8:37:treatment,",Use of neuromuscular blocking agents within the 48 hours preceding testing,"['Use' 'of' 'neuromuscular' 'blocking' 'agents' 'within' 'the' '48'
 'hours' 'preceding' 'testing']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02329652,1:43:chronic_disease,diabetes with peripheral nerve involvement,['diabetes' 'with' 'peripheral' 'nerve' 'involvement'],[2. 2. 2. 2. 2.]
NCT02328313,35:79:treatment,Scheduled to begin an appropriate adjuvant or neoadjuvant chemotherapy regimen as defined by NCCN guidelines (www.nccn.org),"['Scheduled' 'to' 'begin' 'an' 'appropriate' 'adjuvant' 'or' 'neoadjuvant'
 'chemotherapy' 'regimen' 'as' 'defined' 'by' 'NCCN' 'guidelines' '('
 'www.nccn.org' ')']",[0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02327403,11:15:chronic_disease,recurrent FSGS,['recurrent' 'FSGS'],[0. 2.]
NCT02327312,1:12:chronic_disease,choroiditis,['choroiditis'],[2.]
NCT02324582,1:31:chronic_disease,active urinary tract infection,['active' 'urinary' 'tract' 'infection'],[2. 2. 2. 2.]
NCT02324582,10:32:treatment,targeted small molecule therapy,['targeted' 'small' 'molecule' 'therapy'],[0. 1. 1. 1.]
NCT02324439,1:15:chronic_disease,Renal function,['Renal' 'function'],[2. 2.]
NCT02324387,15:45:treatment,scheduled for neoadjuvant chemotherapy (NAC),['scheduled' 'for' 'neoadjuvant' 'chemotherapy' '(' 'NAC' ')'],[0. 0. 1. 1. 1. 0. 0.]
NCT02323880,57:64:treatment,Parts B and C: Patients must have measurable disease on imaging,"['Parts' 'B' 'and' 'C' ':' 'Patients' 'must' 'have' 'measurable' 'disease'
 'on' 'imaging']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02323581,31:72:treatment,Suitable arterial anatomy for endovascular TAAA repair with TAAA device,"['Suitable' 'arterial' 'anatomy' 'for' 'endovascular' 'TAAA' 'repair'
 'with' 'TAAA' 'device']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 1.]
NCT02323126,1:67:treatment,Previous treatment with a c-MET inhibitor or HGF-targeting therapy (applies only to Group 2),"['Previous' 'treatment' 'with' 'a' 'c-MET' 'inhibitor' 'or'
 'HGF-targeting' 'therapy' '(' 'applies' 'only' 'to' 'Group' '2' ')']",[1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02323100,8:52:treatment,Taking pancreatic enzyme replacement therapy (PERT),['Taking' 'pancreatic' 'enzyme' 'replacement' 'therapy' '(' 'PERT' ')'],[0. 1. 1. 1. 1. 1. 0. 0.]
NCT02321501,1:38:treatment,enzyme-inducing anticonvulsive agents,['enzyme-inducing' 'anticonvulsive' 'agents'],[1. 1. 1.]
NCT02320292,4:18:cancer,No leukemic phase,['No' 'leukemic' 'phase'],[0. 3. 3.]
NCT02319369,37:62:treatment,Is able and willing to provide bone marrow biopsies/aspirates as requested by the protocol,"['Is' 'able' 'and' 'willing' 'to' 'provide' 'bone' 'marrow'
 'biopsies/aspirates' 'as' 'requested' 'by' 'the' 'protocol']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02319369,23:92:treatment,receiving concomitant treatment with a strong inhibitor or inducer of cytochrome P450 3A4/5,"['receiving' 'concomitant' 'treatment' 'with' 'a' 'strong' 'inhibitor'
 'or' 'inducer' 'of' 'cytochrome' 'P450' '3A4/5']",[0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT02317991,",30:64:treatment",Patients must have < Grade 2 pre-existing peripheral neuropathy (per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v 4.03),"['Patients' 'must' 'have' '<' 'Grade' '2' 'pre-existing' 'peripheral'
 'neuropathy' '(' 'per' 'National' 'Cancer' 'Institute' 'Common'
 'Terminology' 'Criteria' 'for' 'Adverse' 'Events' '[' 'NCI' 'CTCAE' ']'
 'v' '4.03' ')']","[0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02317523,"27:36:chronic_disease,,",Neither the caregiver nor Alzheimer's patient can be diagnosed with a terminal illness with a life expectancy of less than 1 year,"['Neither' 'the' 'caregiver' 'nor' 'Alzheimer' ""'s"" 'patient' 'can' 'be'
 'diagnosed' 'with' 'a' 'terminal' 'illness' 'with' 'a' 'life'
 'expectancy' 'of' 'less' 'than' '1' 'year']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02316886,"51:76:treatment,",Contraindication to or planned discontinuation of dual antiplatelet therapy within 1 year,"['Contraindication' 'to' 'or' 'planned' 'discontinuation' 'of' 'dual'
 'antiplatelet' 'therapy' 'within' '1' 'year']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0.]
NCT02316275,9:35:treatment,Planned mid-urethral sling surgery,['Planned' 'mid-urethral' 'sling' 'surgery'],[0. 1. 1. 1.]
NCT02315612,74:104:treatment,"In view of the PI and the primary oncologist, there must be no available alternative curative therapies","['In' 'view' 'of' 'the' 'PI' 'and' 'the' 'primary' 'oncologist' ','
 'there' 'must' 'be' 'no' 'available' 'alternative' 'curative' 'therapies']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02314221,"1:13:chronic_disease,,",Brain injury with score on mini-mental status examination less than 26,"['Brain' 'injury' 'with' 'score' 'on' 'mini-mental' 'status' 'examination'
 'less' 'than' '26']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02314221,8:34:chronic_disease,"Severe concurrent medical disease, illness or condition","['Severe' 'concurrent' 'medical' 'disease' ',' 'illness' 'or' 'condition']",[0. 2. 2. 2. 0. 0. 0. 0.]
NCT02313428,18:40:treatment,"Able to complete Topical Oxygen Therapy 4 day/week for 16 weeks (must be able to remove existing wound dressing and apply TO2 Boot/treatment, and then re-dress wound)","['Able' 'to' 'complete' 'Topical' 'Oxygen' 'Therapy' '4' 'day/week' 'for'
 '16' 'weeks' '(' 'must' 'be' 'able' 'to' 'remove' 'existing' 'wound'
 'dressing' 'and' 'apply' 'TO2' 'Boot/treatment' ',' 'and' 'then'
 're-dress' 'wound' ')']","[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02313428,1:11:chronic_disease,Foot Ulcer,['Foot' 'Ulcer'],[2. 2.]
NCT02312596,"10:48:treatment,",Received another investigational device or drug within 30 days of enrollment,"['Received' 'another' 'investigational' 'device' 'or' 'drug' 'within' '30'
 'days' 'of' 'enrollment']",[0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02312245,1:27:treatment,Vaccines and immunotherapy All of these exceptions should be confirmed with the Principal Investigator (PI) prior to registration,"['Vaccines' 'and' 'immunotherapy' 'All' 'of' 'these' 'exceptions' 'should'
 'be' 'confirmed' 'with' 'the' 'Principal' 'Investigator' '(' 'PI' ')'
 'prior' 'to' 'registration']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02311621,20:36:chronic_disease,Presence of active severe infection,['Presence' 'of' 'active' 'severe' 'infection'],[0. 0. 0. 2. 2.]
NCT02311621,",17:40:treatment",≥ 12 weeks from prior I131 MIBG therapy,['≥' '12' 'weeks' 'from' 'prior' 'I131' 'MIBG' 'therapy'],[0. 0. 0. 0. 1. 1. 1. 1.]
NCT02311361,1:18:cancer,Malignant ascites that is clinically detectable by physical examination or is symptomatic,"['Malignant' 'ascites' 'that' 'is' 'clinically' 'detectable' 'by'
 'physical' 'examination' 'or' 'is' 'symptomatic']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02310633,1:51:chronic_disease,Moderate to Severe Traumatic Brain Injury (M-STBI) (blast and blunt),"['Moderate' 'to' 'Severe' 'Traumatic' 'Brain' 'Injury' '(' 'M-STBI' ')'
 '(' 'blast' 'and' 'blunt' ')']",[2. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02310399,1:26:chronic_disease,Cochlear nerve deficiency,['Cochlear' 'nerve' 'deficiency'],[2. 2. 2.]
NCT02310399,73:111:treatment,Loss or lack of benefit from appropriate CI without the possibility for revision or contralateral implantation,"['Loss' 'or' 'lack' 'of' 'benefit' 'from' 'appropriate' 'CI' 'without'
 'the' 'possibility' 'for' 'revision' 'or' 'contralateral' 'implantation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02310399,14:30:chronic_disease,Severe inner ear malformation,['Severe' 'inner' 'ear' 'malformation'],[0. 0. 2. 2.]
NCT02309892,38:57:cancer,Histologic evidence of predominantly squamous cell NSCLC,['Histologic' 'evidence' 'of' 'predominantly' 'squamous' 'cell' 'NSCLC'],[0. 0. 0. 0. 3. 3. 3.]
NCT02307565,12:40:chronic_disease,History of Traumatic Brain Injury (TBI),['History' 'of' 'Traumatic' 'Brain' 'Injury' '(' 'TBI' ')'],[0. 0. 2. 2. 2. 2. 0. 0.]
NCT02307058,15:25:chronic_disease,Subjects with T3 disease based on digital rectal exam (DRE),"['Subjects' 'with' 'T3' 'disease' 'based' 'on' 'digital' 'rectal' 'exam'
 '(' 'DRE' ')']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02305537,1:12:chronic_disease,Agoraphobia,['Agoraphobia'],[2.]
NCT02304458,24:60:cancer,Part D6: Patients with relapsed or refractory neuroblastoma (MIBG evaluable disease without RECIST measurable lesion),"['Part' 'D6' ':' 'Patients' 'with' 'relapsed' 'or' 'refractory'
 'neuroblastoma' '(' 'MIBG' 'evaluable' 'disease' 'without' 'RECIST'
 'measurable' 'lesion' ')']",[0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02304458,",48:67:chronic_disease",Serum lipase =< ULN at baseline; patients with glucose intolerance should be on a stable regimen and be monitored,"['Serum' 'lipase' '=' '<' 'ULN' 'at' 'baseline' ';' 'patients' 'with'
 'glucose' 'intolerance' 'should' 'be' 'on' 'a' 'stable' 'regimen' 'and'
 'be' 'monitored']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02302235,15:29:treatment,non-cytotoxic hormonal agent,['non-cytotoxic' 'hormonal' 'agent'],[0. 1. 1.]
NCT02301611,"1:13:treatment,,",Vaccinations initiated between 3 weeks and 3 months from completion of SoC multi-modality cancer care,"['Vaccinations' 'initiated' 'between' '3' 'weeks' 'and' '3' 'months'
 'from' 'completion' 'of' 'SoC' 'multi-modality' 'cancer' 'care']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02299414,7:26:chronic_disease,Known major fetal anomaly,['Known' 'major' 'fetal' 'anomaly'],[0. 2. 2. 2.]
NCT02298504,30:42:chronic_disease,Pediatric patients with deep dental decay in primary molars,"['Pediatric' 'patients' 'with' 'deep' 'dental' 'decay' 'in' 'primary'
 'molars']",[0. 0. 0. 0. 2. 2. 0. 0. 0.]
NCT02296684,15:24:cancer,Patients with sinonasal SCCAs,['Patients' 'with' 'sinonasal' 'SCCAs'],[0. 0. 3. 0.]
NCT02293096,1:23:chronic_disease,end stage liver disease,['end' 'stage' 'liver' 'disease'],[2. 2. 2. 2.]
NCT02291978,15:39:chronic_disease,Patients with inflammatory arthritides,['Patients' 'with' 'inflammatory' 'arthritides'],[0. 0. 2. 2.]
NCT02290951,1:37:treatment,Allogeneic stem cell transplantation,['Allogeneic' 'stem' 'cell' 'transplantation'],[1. 1. 1. 1.]
NCT02290028,10:15:treatment,Standard CRT-D indication according to clinical routine,['Standard' 'CRT-D' 'indication' 'according' 'to' 'clinical' 'routine'],[0. 1. 0. 0. 0. 0. 0.]
NCT02287337,1:44:treatment,Prior surgery to the neck or thoracic spine,['Prior' 'surgery' 'to' 'the' 'neck' 'or' 'thoracic' 'spine'],[1. 1. 1. 1. 1. 1. 1. 1.]
NCT02285101,"8:31:treatment,",Use of investigational drug(s) within 4 weeks of enrollment,"['Use' 'of' 'investigational' 'drug' '(' 's' ')' 'within' '4' 'weeks' 'of'
 'enrollment']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02281409,12:26:cancer,metastatic gastric cancer,['metastatic' 'gastric' 'cancer'],[0. 3. 3.]
NCT02278315,",,97:109:treatment",25% increase in bone marrow plasma cell percentage from lowest response value during (or after) last therapy,"['25' '%' 'increase' 'in' 'bone' 'marrow' 'plasma' 'cell' 'percentage'
 'from' 'lowest' 'response' 'value' 'during' '(' 'or' 'after' ')' 'last'
 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02278315,",,47:69:treatment","Platelet count < 100,000/uL without full-dose anticogulation therapy","['Platelet' 'count' '<' '100,000/uL' 'without' 'full-dose'
 'anticogulation' 'therapy']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02278250,",23:53:treatment",More than 6 cycles of prior therapy with carboplatin,['More' 'than' '6' 'cycles' 'of' 'prior' 'therapy' 'with' 'carboplatin'],[0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02277613,14:61:chronic_disease,Diagnosis of non-ST elevation myocardial infarction (NSTEMI),"['Diagnosis' 'of' 'non-ST' 'elevation' 'myocardial' 'infarction' '('
 'NSTEMI' ')']",[0. 0. 2. 2. 2. 2. 2. 0. 0.]
NCT02276443,",,69:96:chronic_disease",Patients who have history of PR prolongation (grade 2 or higher) or atrioventricular (AV) block,"['Patients' 'who' 'have' 'history' 'of' 'PR' 'prolongation' '(' 'grade'
 '2' 'or' 'higher' ')' 'or' 'atrioventricular' '(' 'AV' ')' 'block']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0.]
NCT02273375,47:71:cancer,Histologically confirmed diagnosis of primary non-small cell carcinoma of the lung,"['Histologically' 'confirmed' 'diagnosis' 'of' 'primary' 'non-small'
 'cell' 'carcinoma' 'of' 'the' 'lung']",[0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0.]
NCT02273375,1:66:treatment,Pre-operative (neo-adjuvant) platinum based or other chemotherapy is not permissible,"['Pre-operative' '(' 'neo-adjuvant' ')' 'platinum' 'based' 'or' 'other'
 'chemotherapy' 'is' 'not' 'permissible']",[1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02273362,19:43:treatment,An indication for surgical liver resection,['An' 'indication' 'for' 'surgical' 'liver' 'resection'],[0. 0. 0. 1. 1. 1.]
NCT02272998,28:43:cancer,Patients with an inherited cancer syndrome or a medical history suggestive of an inherited cancer syndrome remain eligible,"['Patients' 'with' 'an' 'inherited' 'cancer' 'syndrome' 'or' 'a' 'medical'
 'history' 'suggestive' 'of' 'an' 'inherited' 'cancer' 'syndrome' 'remain'
 'eligible']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02272556,1:19:chronic_disease,Bleeding Disorders,['Bleeding' 'Disorders'],[2. 2.]
NCT02272218,"1:35:treatment,,",anterior-posterior (AP) radiograph of both knees with K-L grade < 2,"['anterior-posterior' '(' 'AP' ')' 'radiograph' 'of' 'both' 'knees' 'with'
 'K-L' 'grade' '<' '2']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02272049,12:24:chronic_disease,History of heart defect,['History' 'of' 'heart' 'defect'],[0. 0. 2. 2.]
NCT02271711,1:25:cancer,Extra-cranial metastasis,['Extra-cranial' 'metastasis'],[3. 3.]
NCT02270970,"1:23:chronic_disease,",Herpes zoster outbreak within three months of dosing,['Herpes' 'zoster' 'outbreak' 'within' 'three' 'months' 'of' 'dosing'],[2. 2. 2. 0. 0. 0. 0. 0.]
NCT02270619,1:36:treatment,non-steroid anti-inflammatory drugs,['non-steroid' 'anti-inflammatory' 'drugs'],[1. 1. 1.]
NCT02269293,46:58:treatment,Patients must be willing and able to swallow oral tablets,"['Patients' 'must' 'be' 'willing' 'and' 'able' 'to' 'swallow' 'oral'
 'tablets']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02268448,18:66:chronic_disease,Known history of central or peripheral nervous system dysfunction,"['Known' 'history' 'of' 'central' 'or' 'peripheral' 'nervous' 'system'
 'dysfunction']",[0. 0. 0. 2. 2. 2. 2. 2. 2.]
NCT02266784,32:48:chronic_disease,Has a primary diagnosis of any Axis II Disorder,['Has' 'a' 'primary' 'diagnosis' 'of' 'any' 'Axis' 'II' 'Disorder'],[0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02266329,26:67:treatment,Current participation in transcranial magnetic stimulation studies,"['Current' 'participation' 'in' 'transcranial' 'magnetic' 'stimulation'
 'studies']",[0. 0. 0. 1. 1. 1. 1.]
NCT02266329,1:31:chronic_disease,Structural brain abnormalities on any prior imaging with associated clinically evident manifestations,"['Structural' 'brain' 'abnormalities' 'on' 'any' 'prior' 'imaging' 'with'
 'associated' 'clinically' 'evident' 'manifestations']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02265315,"8:26:treatment,",Stable medication therapy for at least 3 months,['Stable' 'medication' 'therapy' 'for' 'at' 'least' '3' 'months'],[0. 1. 1. 0. 0. 0. 0. 0.]
NCT02264678,22:45:treatment,Contra-indicated for treatment with olaparib,['Contra-indicated' 'for' 'treatment' 'with' 'olaparib'],[0. 0. 1. 1. 1.]
NCT02264678,1:38:cancer,head and neck squamous cell carcinoma,['head' 'and' 'neck' 'squamous' 'cell' 'carcinoma'],[3. 3. 3. 3. 3. 3.]
NCT02262832,1:26:chronic_disease,Generalized lipodystrophy (either congenital or acquired),"['Generalized' 'lipodystrophy' '(' 'either' 'congenital' 'or' 'acquired'
 ')']",[2. 2. 0. 0. 0. 0. 0. 0.]
NCT02261558,6:15:cancer,past cancer(s),['past' 'cancer' '(' 's' ')'],[3. 3. 3. 3. 3.]
NCT02261519,"15:35:treatment,",The subject's anti-EPS medications dose or regimen has changed within 2 weeks prior to screening,"['The' 'subject' ""'s"" 'anti-EPS' 'medications' 'dose' 'or' 'regimen' 'has'
 'changed' 'within' '2' 'weeks' 'prior' 'to' 'screening']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02260856,49:63:treatment,Skeletally immature requiring isolated complete epiphysiodesis of the distal femur and/or proximal tibia,"['Skeletally' 'immature' 'requiring' 'isolated' 'complete'
 'epiphysiodesis' 'of' 'the' 'distal' 'femur' 'and/or' 'proximal' 'tibia']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02259621,1:25:cancer,Squamous or non-squamous histology,['Squamous' 'or' 'non-squamous' 'histology'],[3. 3. 3. 0.]
NCT02257424,"37:71:treatment,",Patients must not receive any other investigational anticancer therapy during the period on study or the four weeks prior to entry,"['Patients' 'must' 'not' 'receive' 'any' 'other' 'investigational'
 'anticancer' 'therapy' 'during' 'the' 'period' 'on' 'study' 'or' 'the'
 'four' 'weeks' 'prior' 'to' 'entry']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02255383,1:24:chronic_disease,Neuropathic arthropathy,['Neuropathic' 'arthropathy'],[2. 2.]
NCT02255383,73:107:treatment,the salvage of previously failed surgical attempts that did not include partial or total knee arthroplasty of the ipsilateral knee,"['the' 'salvage' 'of' 'previously' 'failed' 'surgical' 'attempts' 'that'
 'did' 'not' 'include' 'partial' 'or' 'total' 'knee' 'arthroplasty' 'of'
 'the' 'ipsilateral' 'knee']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0.]
NCT02254863,16:35:treatment,Requirement of ventilatory support,['Requirement' 'of' 'ventilatory' 'support'],[0. 0. 1. 1.]
NCT02253316,1:22:chronic_disease,secondary amyloidosis,['secondary' 'amyloidosis'],[2. 2.]
NCT02252432,15:42:treatment,scheduled for elective lumbar laminectomy,['scheduled' 'for' 'elective' 'lumbar' 'laminectomy'],[0. 0. 1. 1. 1.]
NCT02251431,1:27:chronic_disease,Collagen vascular diseases,['Collagen' 'vascular' 'diseases'],[2. 2. 2.]
NCT02251431,1:22:treatment,Renal transplantation,['Renal' 'transplantation'],[1. 1.]
NCT02249520,40:49:treatment,Outpatient undergoing standard-of-care 18FDG-PET at S. Mark Taper Foundation Imaging Center at CSMC,"['Outpatient' 'undergoing' 'standard-of-care' '18FDG-PET' 'at' 'S.' 'Mark'
 'Taper' 'Foundation' 'Imaging' 'Center' 'at' 'CSMC']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02249039,1:9:chronic_disease,Asphyxia,['Asphyxia'],[2.]
NCT02245841,1:5:treatment,IVIG,['IVIG'],[1.]
NCT02245841,1:31:chronic_disease,amyopathic dermatomyositis(AD),['amyopathic' 'dermatomyositis' '(' 'AD' ')'],[2. 2. 0. 0. 0.]
NCT02245841,1:22:treatment,mycophenolate mofetil,['mycophenolate' 'mofetil'],[1. 1.]
NCT02244814,16:36:chronic_disease,diagnosed with Gestational diabetes according to the criteria established by the American College of Obstetricians and Gynecologists,"['diagnosed' 'with' 'Gestational' 'diabetes' 'according' 'to' 'the'
 'criteria' 'established' 'by' 'the' 'American' 'College' 'of'
 'Obstetricians' 'and' 'Gynecologists']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02243813,23:52:treatment,Agree not to take any Pro-re-nata (PRN) medications on the mornings of drug sessions,"['Agree' 'not' 'to' 'take' 'any' 'Pro-re-nata' '(' 'PRN' ')' 'medications'
 'on' 'the' 'mornings' 'of' 'drug' 'sessions']",[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02243631,1:5:chronic_disease,CPPD diagnosed by Ryan /McCarty criteria,['CPPD' 'diagnosed' 'by' 'Ryan' '/McCarty' 'criteria'],[2. 0. 0. 0. 0. 0.]
NCT02242526,"1:9:chronic_disease,,",Upper GI with a documented hiatal hernia greater than 5cm,"['Upper' 'GI' 'with' 'a' 'documented' 'hiatal' 'hernia' 'greater' 'than'
 '5cm']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02240498,45:48:treatment,Approval by the primary care team to pursue PDT and discuss enrollment with the patient,"['Approval' 'by' 'the' 'primary' 'care' 'team' 'to' 'pursue' 'PDT' 'and'
 'discuss' 'enrollment' 'with' 'the' 'patient']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02240498,1:10:chronic_disease,abscesses not amenable to safe percutaneous image-guided drainage,"['abscesses' 'not' 'amenable' 'to' 'safe' 'percutaneous' 'image-guided'
 'drainage']",[2. 0. 0. 0. 0. 0. 0. 0.]
NCT02236377,8:30:chronic_disease,recent parasuicidal behaviors,['recent' 'parasuicidal' 'behaviors'],[0. 2. 2.]
NCT02236013,16:45:chronic_disease,Subject has an active uncontrolled infection,['Subject' 'has' 'an' 'active' 'uncontrolled' 'infection'],[0. 0. 0. 2. 2. 2.]
NCT02236000,52:77:chronic_disease,other disease or condition significantly affecting gastrointestinal function,"['other' 'disease' 'or' 'condition' 'significantly' 'affecting'
 'gastrointestinal' 'function']",[0. 0. 0. 0. 0. 0. 2. 2.]
NCT02234934,13:37:cancer,Evidence of active malignant disease,['Evidence' 'of' 'active' 'malignant' 'disease'],[0. 0. 3. 3. 3.]
NCT02234934,"9:22:treatment,,",Resting O2 saturation by pulse oximetry < 90% on room air,"['Resting' 'O2' 'saturation' 'by' 'pulse' 'oximetry' '<' '90' '%' 'on'
 'room' 'air']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02234557,1:45:chronic_disease,Comorbid oppositional defiant disorder (ODD) and simple phobias are permitted,"['Comorbid' 'oppositional' 'defiant' 'disorder' '(' 'ODD' ')' 'and'
 'simple' 'phobias' 'are' 'permitted']",[2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02234193,22:53:treatment,scheduled to undergo elective abdominoplasty surgery at MGH,"['scheduled' 'to' 'undergo' 'elective' 'abdominoplasty' 'surgery' 'at'
 'MGH']",[0. 0. 0. 1. 1. 1. 0. 0.]
NCT02233868,1:19:treatment,antianginal agents,['antianginal' 'agents'],[1. 1.]
NCT02233868,1:15:treatment,antihistamines (sedating),['antihistamines' '(' 'sedating' ')'],[1. 0. 0. 0.]
NCT02232516,1:38:cancer,Adult T-cell lymphoma/leukemia (ATLL),['Adult' 'T-cell' 'lymphoma/leukemia' '(' 'ATLL' ')'],[3. 3. 3. 3. 0. 0.]
NCT02232516,1:17:cancer,NK-cell leukemia,['NK-cell' 'leukemia'],[3. 3.]
NCT02232516,1:37:cancer,T-cell granular lymphocytic leukemia,['T-cell' 'granular' 'lymphocytic' 'leukemia'],[3. 3. 3. 3.]
NCT02232516,1:44:cancer,anaplastic large cell kinase (ALK)-negative,['anaplastic' 'large' 'cell' 'kinase' '(' 'ALK' ')' '-negative'],[3. 3. 3. 3. 3. 0. 0. 0.]
NCT02232165,1:22:chronic_disease,"Central cord syndrome, defined as ASIA C or D with mean lower extremity score greater than upper extremity score","['Central' 'cord' 'syndrome' ',' 'defined' 'as' 'ASIA' 'C' 'or' 'D' 'with'
 'mean' 'lower' 'extremity' 'score' 'greater' 'than' 'upper' 'extremity'
 'score']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02230605,9:33:treatment,Planned postoperative intubation,['Planned' 'postoperative' 'intubation'],[0. 1. 1.]
NCT02229565,11:40:cancer,Suspected malignancy of prostate cancer,['Suspected' 'malignancy' 'of' 'prostate' 'cancer'],[0. 3. 3. 3. 3.]
NCT02226341,1:23:chronic_disease,Active lupus nephritis,['Active' 'lupus' 'nephritis'],[2. 2. 2.]
NCT02226159,20:40:chronic_disease,Active progressive neurological deficit,['Active' 'progressive' 'neurological' 'deficit'],[0. 0. 2. 2.]
NCT02225548,21:38:chronic_disease,Subject with active peptic ulceration,['Subject' 'with' 'active' 'peptic' 'ulceration'],[0. 0. 0. 2. 2.]
NCT02222545,24:35:treatment,Have a positive direct Coombs test,['Have' 'a' 'positive' 'direct' 'Coombs' 'test'],[0. 0. 0. 0. 1. 1.]
NCT02219711,1:19:treatment,Standard treatment is not available,['Standard' 'treatment' 'is' 'not' 'available'],[1. 1. 0. 0. 0.]
NCT02219581,21:53:treatment,Patients undergoing primary total joint arthroplasty of the knee,"['Patients' 'undergoing' 'primary' 'total' 'joint' 'arthroplasty' 'of'
 'the' 'knee']",[0. 0. 1. 1. 1. 1. 0. 0. 0.]
NCT02219555,38:60:chronic_disease,patient have a clinical diagnosis of carpal tunnel syndrome,"['patient' 'have' 'a' 'clinical' 'diagnosis' 'of' 'carpal' 'tunnel'
 'syndrome']",[0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02217709,1:42:treatment,Post-primary androgen-deprivation therapy,['Post-primary' 'androgen-deprivation' 'therapy'],[1. 1. 1.]
NCT02216227,25:34:allergy_name,Documented allergies to mupirocin,['Documented' 'allergies' 'to' 'mupirocin'],[0. 0. 0. 4.]
NCT02215096,"1:24:treatment,,","Investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to enrollment","['Investigational' 'drug' '(' 's' ')' 'within' '30' 'days' 'or' '5'
 'half-lives' ',' 'whichever' 'is' 'longer' ',' 'prior' 'to' 'enrollment']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02214667,1:26:chronic_disease,schizophreniform disorder,['schizophreniform' 'disorder'],[2. 2.]
NCT02214550,20:52:cancer,presence of active pelvic or abdominal malignancies (primary or metastatic),"['presence' 'of' 'active' 'pelvic' 'or' 'abdominal' 'malignancies' '('
 'primary' 'or' 'metastatic' ')']",[0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0.]
NCT02213068,1:4:chronic_disease,EBV seropositive,['EBV' 'seropositive'],[2. 0.]
NCT02213068,17:31:chronic_disease,Recipients with EBV serostatus negative or unknown,['Recipients' 'with' 'EBV' 'serostatus' 'negative' 'or' 'unknown'],[0. 0. 2. 2. 0. 0. 0.]
NCT02210650,1:28:chronic_disease,primary hyperparathyroidism,['primary' 'hyperparathyroidism'],[2. 2.]
NCT02210078,"15:32:chronic_disease,,",Patients with active acute GVHD grades II-IV,['Patients' 'with' 'active' 'acute' 'GVHD' 'grades' 'II-IV'],[0. 0. 2. 2. 2. 0. 0.]
NCT02209636,11:28:treatment,Not using phosphate binders,['Not' 'using' 'phosphate' 'binders'],[0. 0. 1. 1.]
NCT02208362,",,162:173:treatment",Research participant does not require supplemental oxygen to keep saturation greater than 95% and/or does not have presence of any radiographic abnormalities on chest x-ray that are progressive,"['Research' 'participant' 'does' 'not' 'require' 'supplemental' 'oxygen'
 'to' 'keep' 'saturation' 'greater' 'than' '95' '%' 'and/or' 'does' 'not'
 'have' 'presence' 'of' 'any' 'radiographic' 'abnormalities' 'on' 'chest'
 'x-ray' 'that' 'are' 'progressive']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1. 0. 0. 0.]"
NCT02207465,1:17:cancer,Nodal metastases beyond the field of resection Borderline resectable,"['Nodal' 'metastases' 'beyond' 'the' 'field' 'of' 'resection' 'Borderline'
 'resectable']",[3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02207465,19:39:chronic_disease,Unreconstructible SMV/portal occlusion,['Unreconstructible' 'SMV/portal' 'occlusion'],[0. 2. 2.]
NCT02207439,",,,,,208:225:treatment","women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, during study, until 1 month after completion of the final FMISO PET/CT scan","['women' 'of' 'childbearing' 'potential' 'and' 'men' 'must' 'agree' 'to'
 'use' 'adequate' 'contraception' '(' 'hormonal' 'or' 'barrier' 'method'
 'of' 'birth' 'control' ')' 'prior' 'to' 'study' 'entry' ',' 'during'
 'study' ',' 'until' '1' 'month' 'after' 'completion' 'of' 'the' 'final'
 'FMISO' 'PET/CT' 'scan']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]"
NCT02204956,1:43:treatment,Mini-Mental State Examination (MMSE: [45]),['Mini-Mental' 'State' 'Examination' '(' 'MMSE' ':' '[' '45' ']' ')'],[1. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02204098,1:22:treatment,Investigational agent,['Investigational' 'agent'],[1. 1.]
NCT02203903,"4:29:treatment,","No investigational therapies (under IND, not extensively studied in the current clinical context) within the last 28 days","['No' 'investigational' 'therapies' '(' 'under' 'IND' ',' 'not'
 'extensively' 'studied' 'in' 'the' 'current' 'clinical' 'context' ')'
 'within' 'the' 'last' '28' 'days']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02203513,21:25:cancer,A family history of HBOC is defined by NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian guideline,"['A' 'family' 'history' 'of' 'HBOC' 'is' 'defined' 'by' 'NCCN'
 'Genetic/Familial' 'High-Risk' 'Assessment' ':' 'Breast' 'and' 'Ovarian'
 'guideline']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02203513,19:48:chronic_disease,Stable persistent grade 2 peripheral neuropathy may be allowed as determined on a case-by-case basis at the discretion of the PI,"['Stable' 'persistent' 'grade' '2' 'peripheral' 'neuropathy' 'may' 'be'
 'allowed' 'as' 'determined' 'on' 'a' 'case-by-case' 'basis' 'at' 'the'
 'discretion' 'of' 'the' 'PI']",[0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02202369,36:56:treatment,Subjects undergoing a single level lumbar decompression and fusion,"['Subjects' 'undergoing' 'a' 'single' 'level' 'lumbar' 'decompression'
 'and' 'fusion']",[0. 0. 0. 0. 0. 1. 1. 0. 0.]
NCT02200445,16:43:allergy_name,Allergy to any component of the study drug,['Allergy' 'to' 'any' 'component' 'of' 'the' 'study' 'drug'],[0. 0. 0. 4. 4. 4. 4. 4.]
NCT02199236,"17:34:treatment,,,,","Able to receive HDR brachytherapy ANC ≥ 1.5 cells/mm3 and PLT ≥100,000/mm3","['Able' 'to' 'receive' 'HDR' 'brachytherapy' 'ANC' '≥' '1.5' 'cells/mm3'
 'and' 'PLT' '≥100,000/mm3']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02196038,",57:61:chronic_disease","In the hospital setting >24 hours for the management of ADHF, or diagnosed with ADHF after being hospitalized for another reason","['In' 'the' 'hospital' 'setting' '>' '24' 'hours' 'for' 'the' 'management'
 'of' 'ADHF' ',' 'or' 'diagnosed' 'with' 'ADHF' 'after' 'being'
 'hospitalized' 'for' 'another' 'reason']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02195232,20:64:chronic_disease,Known diagnosis of disseminated intravascular coagulation (DIC),"['Known' 'diagnosis' 'of' 'disseminated' 'intravascular' 'coagulation' '('
 'DIC' ')']",[0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02193932,1:20:chronic_disease,"Refractory epilepsy cases, referred by the service of Neurology","['Refractory' 'epilepsy' 'cases' ',' 'referred' 'by' 'the' 'service' 'of'
 'Neurology']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02193490,13:30:allergy_name,Allergic to Deoxyribonuclease eye drops or any similar products,"['Allergic' 'to' 'Deoxyribonuclease' 'eye' 'drops' 'or' 'any' 'similar'
 'products']",[0. 0. 4. 0. 0. 0. 0. 0. 0.]
NCT02192398,",,,27:41:treatment","VAS score of 4-8, despite opioid therapy","['VAS' 'score' 'of' '4-8' ',' 'despite' 'opioid' 'therapy']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02192359,48:100:treatment,Prospective participant is unable to undergo a magnetic resonance imaging (MRI) with contrast agent,"['Prospective' 'participant' 'is' 'unable' 'to' 'undergo' 'a' 'magnetic'
 'resonance' 'imaging' '(' 'MRI' ')' 'with' 'contrast' 'agent']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 0. 0.]
NCT02189889,32:35:allergy_name,have known hypersensitivity to EPO or any of its components,"['have' 'known' 'hypersensitivity' 'to' 'EPO' 'or' 'any' 'of' 'its'
 'components']",[0. 0. 0. 0. 4. 0. 0. 0. 0. 0.]
NCT02189798,90:117:treatment,"Unrealistic expectations regarding potential benefits, risks and limitations inherent to implant surgical procedures as determined by the investigator","['Unrealistic' 'expectations' 'regarding' 'potential' 'benefits' ','
 'risks' 'and' 'limitations' 'inherent' 'to' 'implant' 'surgical'
 'procedures' 'as' 'determined' 'by' 'the' 'investigator']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02188745,1:23:chronic_disease,deep venous thrombosis,['deep' 'venous' 'thrombosis'],[2. 2. 2.]
NCT02187848,22:46:allergy_name,Known intolerance to infused protein products,['Known' 'intolerance' 'to' 'infused' 'protein' 'products'],[0. 0. 0. 4. 4. 4.]
NCT02187198,11:31:treatment,ever used heroin intravenously,['ever' 'used' 'heroin' 'intravenously'],[0. 0. 1. 1.]
NCT02186418,",,124:137:treatment",All participants of reproductive potential must agree to a contraceptive method for a period of no less than one year post gene transfer,"['All' 'participants' 'of' 'reproductive' 'potential' 'must' 'agree' 'to'
 'a' 'contraceptive' 'method' 'for' 'a' 'period' 'of' 'no' 'less' 'than'
 'one' 'year' 'post' 'gene' 'transfer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02184520,1:21:chronic_disease,Acute mental illness or substance abuse,['Acute' 'mental' 'illness' 'or' 'substance' 'abuse'],[2. 2. 2. 0. 0. 0.]
NCT02181478,16:55:treatment,Candidates for reduced intensity conditioning regimens,['Candidates' 'for' 'reduced' 'intensity' 'conditioning' 'regimens'],[0. 0. 1. 1. 1. 1.]
NCT02181257,1:8:chronic_disease,Aphakia or absence of ocular lenses,['Aphakia' 'or' 'absence' 'of' 'ocular' 'lenses'],[2. 0. 0. 0. 0. 0.]
NCT02180412,87:108:chronic_disease,Diagnosis of acute porphyria documented by a substantial increase in urinary or serum porphobilinogen (PBG),"['Diagnosis' 'of' 'acute' 'porphyria' 'documented' 'by' 'a' 'substantial'
 'increase' 'in' 'urinary' 'or' 'serum' 'porphobilinogen' '(' 'PBG' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0.]
NCT02180412,"1:19:treatment,",Therapy with hemin within 7 days prior to enrollment in this study,"['Therapy' 'with' 'hemin' 'within' '7' 'days' 'prior' 'to' 'enrollment'
 'in' 'this' 'study']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02179853,"11:26:treatment,",Use of an IL-1 antagonist within the 3 months prior to enrollment,"['Use' 'of' 'an' 'IL-1' 'antagonist' 'within' 'the' '3' 'months' 'prior'
 'to' 'enrollment']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02178566,35:47:allergy_name,Known hypersensitivity to inhaled nitric oxide,['Known' 'hypersensitivity' 'to' 'inhaled' 'nitric' 'oxide'],[0. 0. 0. 0. 4. 4.]
NCT02177838,8:53:treatment,use of highly active anti-retroviral therapy (HAART) is allowed,"['use' 'of' 'highly' 'active' 'anti-retroviral' 'therapy' '(' 'HAART' ')'
 'is' 'allowed']",[0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0.]
NCT02177695,24:76:treatment,have tumor tissue from transurethral resection of the bladder tumor (TURBT) available for submission that is sufficient for COXEN testing and must agree to submission of 20 (10 micron) slides plus 2 (5 micron) slides from the start and end of the 20 slides for a total of 22 unstained slides,"['have' 'tumor' 'tissue' 'from' 'transurethral' 'resection' 'of' 'the'
 'bladder' 'tumor' '(' 'TURBT' ')' 'available' 'for' 'submission' 'that'
 'is' 'sufficient' 'for' 'COXEN' 'testing' 'and' 'must' 'agree' 'to'
 'submission' 'of' '20' '(' '10' 'micron' ')' 'slides' 'plus' '2' '(' '5'
 'micron' ')' 'slides' 'from' 'the' 'start' 'and' 'end' 'of' 'the' '20'
 'slides' 'for' 'a' 'total' 'of' '22' 'unstained' 'slides']","[0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02176967,20:45:cancer,Only patients with MYCN non-amplified tumors,['Only' 'patients' 'with' 'MYCN' 'non-amplified' 'tumors'],[0. 0. 0. 3. 3. 3.]
NCT02176902,27:46:treatment,Patient elects to undergo active surveillance,['Patient' 'elects' 'to' 'undergo' 'active' 'surveillance'],[0. 0. 0. 0. 1. 1.]
NCT02176161,1:28:treatment,oral glucocorticoid therapy,['oral' 'glucocorticoid' 'therapy'],[1. 1. 1.]
NCT02174016,12:38:chronic_disease,History of inborn error of metabolism,['History' 'of' 'inborn' 'error' 'of' 'metabolism'],[0. 0. 2. 2. 2. 2.]
NCT02172651,21:43:cancer,History of prior or synchronous malignancy,['History' 'of' 'prior' 'or' 'synchronous' 'malignancy'],[0. 0. 0. 0. 3. 3.]
NCT02171104,1:21:chronic_disease,Adrenoleukodystrophy with cerebral involvement,['Adrenoleukodystrophy' 'with' 'cerebral' 'involvement'],[2. 0. 0. 0.]
NCT02171104,1:23:chronic_disease,CoA-Oxidase Deficiency,['CoA-Oxidase' 'Deficiency'],[2. 2.]
NCT02171104,1:33:chronic_disease,Glycoprotein Metabolic Disorders,['Glycoprotein' 'Metabolic' 'Disorders'],[2. 2. 2.]
NCT02171104,1:33:chronic_disease,MPS VI (Maroteaux-Lamy syndrome),['MPS' 'VI' '(' 'Maroteaux-Lamy' 'syndrome' ')'],[2. 2. 2. 2. 0. 0.]
NCT02171104,1:32:chronic_disease,Mucopolysaccharidosis Disorders,['Mucopolysaccharidosis' 'Disorders'],[2. 2.]
NCT02171104,1:22:chronic_disease,Peroxisomal Disorders,['Peroxisomal' 'Disorders'],[2. 2.]
NCT02169830,18:27:treatment,Patient is using marijuana for medical or other uses,['Patient' 'is' 'using' 'marijuana' 'for' 'medical' 'or' 'other' 'uses'],[0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02169739,"10:24:chronic_disease,",Clinical lacunar stroke syndrome within the past 6 months,"['Clinical' 'lacunar' 'stroke' 'syndrome' 'within' 'the' 'past' '6'
 'months']",[0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02169089,1:41:chronic_disease,Class III or IV Congestive Heart Failure,['Class' 'III' 'or' 'IV' 'Congestive' 'Heart' 'Failure'],[2. 2. 2. 2. 2. 2. 2.]
NCT02169089,1:27:chronic_disease,Primary Hyperaldosteronism,['Primary' 'Hyperaldosteronism'],[2. 2.]
NCT02169037,9:32:chronic_disease,extreme left atrial enlargement,['extreme' 'left' 'atrial' 'enlargement'],[0. 2. 2. 2.]
NCT02169037,"1:21:treatment,,",oral anticoagulation required for those subjects who have a score of two or more based on the following criteria (CHAD score),"['oral' 'anticoagulation' 'required' 'for' 'those' 'subjects' 'who' 'have'
 'a' 'score' 'of' 'two' 'or' 'more' 'based' 'on' 'the' 'following'
 'criteria' '(' 'CHAD' 'score' ')']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02167958,1:16:cancer,Acute Leukemias in 2nd or subsequent remission,['Acute' 'Leukemias' 'in' '2nd' 'or' 'subsequent' 'remission'],[3. 3. 0. 0. 0. 0. 0.]
NCT02167022,1:11:chronic_disease,spastic CP confirmed by a pediatric neurologist or pediatric rehabilitation specialist,"['spastic' 'CP' 'confirmed' 'by' 'a' 'pediatric' 'neurologist' 'or'
 'pediatric' 'rehabilitation' 'specialist']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02167009,",60:89:treatment",Patient has a prostate size larger than 90g as measured by transrectal ultrasound (TRUS),"['Patient' 'has' 'a' 'prostate' 'size' 'larger' 'than' '90g' 'as'
 'measured' 'by' 'transrectal' 'ultrasound' '(' 'TRUS' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0.]
NCT02166905,"18:82:treatment,",Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing of study drug,"['Participation' 'in' 'any' 'other' 'clinical' 'trial' 'involving'
 'another' 'investigational' 'agent' 'within' '4' 'weeks' 'prior' 'to'
 'first' 'dosing' 'of' 'study' 'drug']",[0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02165449,"15:43:treatment,",No changes in antidepressant medication(s) in the past one (1) month,"['No' 'changes' 'in' 'antidepressant' 'medication' '(' 's' ')' 'in' 'the'
 'past' 'one' '(' '1' ')' 'month']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02164734,18:21:chronic_disease,Mild-to-moderate RDS,['Mild-to-moderate' 'RDS'],[0. 2.]
NCT02163317,"42:84:treatment,",have a history/physical examination with digital rectal examination of the prostate within 90 days prior to screening,"['have' 'a' 'history/physical' 'examination' 'with' 'digital' 'rectal'
 'examination' 'of' 'the' 'prostate' 'within' '90' 'days' 'prior' 'to'
 'screening']",[0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02162420,1:56:chronic_disease,Dyskeratosis Congenita (DC) with evidence of BM failure,"['Dyskeratosis' 'Congenita' '(' 'DC' ')' 'with' 'evidence' 'of' 'BM'
 'failure']",[2. 2. 2. 2. 2. 2. 2. 2. 0. 0.]
NCT02162420,17:49:chronic_disease,With or without clonal cytogenetic abnormalities,['With' 'or' 'without' 'clonal' 'cytogenetic' 'abnormalities'],[0. 0. 0. 2. 2. 2.]
NCT02162420,1:17:cancer,oral leukoplakia,['oral' 'leukoplakia'],[3. 3.]
NCT02162420,1:22:treatment,transfusion dependent,['transfusion' 'dependent'],[1. 1.]
NCT02161211,1:33:chronic_disease,cognitive or physical impairment that precludes study participation,"['cognitive' 'or' 'physical' 'impairment' 'that' 'precludes' 'study'
 'participation']",[2. 2. 2. 2. 0. 0. 0. 0.]
NCT02160288,28:43:chronic_disease,Presence of full thickness rectal prolapse,['Presence' 'of' 'full' 'thickness' 'rectal' 'prolapse'],[0. 0. 0. 0. 2. 2.]
NCT02159703,75:89:cancer,Presence of close (2 mm) or positive margins PNI on TORS resection of the primary cancer,"['Presence' 'of' 'close' '(' '2' 'mm' ')' 'or' 'positive' 'margins' 'PNI'
 'on' 'TORS' 'resection' 'of' 'the' 'primary' 'cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02159560,21:45:treatment,Contraindication to epidural catheterization,['Contraindication' 'to' 'epidural' 'catheterization'],[0. 0. 1. 1.]
NCT02159495,104:138:treatment,"Related donor selection will be conducted in accordance with City of Hope's Department of Hematology & Hematopoietic Cell Transplantation criteria and, in the case of unrelated donor from a transplant center, will comply with the National Marrow Donor Program's (NMDP) donor selection standards","['Related' 'donor' 'selection' 'will' 'be' 'conducted' 'in' 'accordance'
 'with' 'City' 'of' 'Hope' ""'s"" 'Department' 'of' 'Hematology' '&'
 'Hematopoietic' 'Cell' 'Transplantation' 'criteria' 'and' ',' 'in' 'the'
 'case' 'of' 'unrelated' 'donor' 'from' 'a' 'transplant' 'center' ','
 'will' 'comply' 'with' 'the' 'National' 'Marrow' 'Donor' 'Program' ""'s""
 '(' 'NMDP' ')' 'donor' 'selection' 'standards']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02158858,",,44:70:treatment",ANC ≥ 1 x 10^9/L without the assistance of granulocyte growth factors,"['ANC' '≥' '1' 'x' '10^9/L' 'without' 'the' 'assistance' 'of'
 'granulocyte' 'growth' 'factors']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02158858,38:40:cancer,Patients with confirmed diagnosis of MF,['Patients' 'with' 'confirmed' 'diagnosis' 'of' 'MF'],[0. 0. 0. 0. 0. 3.]
NCT02158793,112:130:treatment,"Willingness to participate in ongoing psychiatric, psychological and social work evaluations prior to and post-transplant surgery","['Willingness' 'to' 'participate' 'in' 'ongoing' 'psychiatric' ','
 'psychological' 'and' 'social' 'work' 'evaluations' 'prior' 'to' 'and'
 'post-transplant' 'surgery']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02155699,7:24:chronic_disease,other physical disorder that could affect brain functioning,"['other' 'physical' 'disorder' 'that' 'could' 'affect' 'brain'
 'functioning']",[0. 2. 2. 0. 0. 0. 0. 0.]
NCT02152995,18:39:treatment,Current use of a prohibited medication,['Current' 'use' 'of' 'a' 'prohibited' 'medication'],[0. 0. 0. 0. 1. 1.]
NCT02152995,",30:54:treatment",The presence of at least one fluorodeoxyglucose (FDG) avid lesion,"['The' 'presence' 'of' 'at' 'least' 'one' 'fluorodeoxyglucose' '(' 'FDG'
 ')' 'avid' 'lesion']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02152995,",35:54:treatment",thyroid-stimulating hormone [TSH] suppressive therapy,['thyroid-stimulating' 'hormone' '[' 'TSH' ']' 'suppressive' 'therapy'],[0. 0. 0. 0. 0. 1. 1.]
NCT02152956,38:60:treatment,patients with relapsed disease after flotetuzumab treatment,['patients' 'with' 'relapsed' 'disease' 'after' 'flotetuzumab' 'treatment'],[0. 0. 0. 0. 0. 1. 1.]
NCT02150967,1:20:treatment,BGJ398/infigratinib (all cohorts),['BGJ398/infigratinib' '(' 'all' 'cohorts' ')'],[1. 0. 0. 0. 0.]
NCT02148796,49:63:allergy_name,Participant has known sensitivity to any of the study products and any of the ingredients to be administered,"['Participant' 'has' 'known' 'sensitivity' 'to' 'any' 'of' 'the' 'study'
 'products' 'and' 'any' 'of' 'the' 'ingredients' 'to' 'be' 'administered']",[0. 0. 0. 0. 0. 0. 0. 0. 4. 4. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02148796,1:38:chronic_disease,chronic gastroesophageal reflux (GER) requiring medical treatment,"['chronic' 'gastroesophageal' 'reflux' '(' 'GER' ')' 'requiring' 'medical'
 'treatment']",[2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02148263,13:54:treatment,Able to use Opti-Free PureMoist contact lens solution,['Able' 'to' 'use' 'Opti-Free' 'PureMoist' 'contact' 'lens' 'solution'],[0. 0. 0. 1. 1. 1. 1. 1.]
NCT02148003,41:56:chronic_disease,Subjects who have an active systemic or local infection,['Subjects' 'who' 'have' 'an' 'active' 'systemic' 'or' 'local' 'infection'],[0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02145351,9:33:chronic_disease,Chronic stable exertional angina,['Chronic' 'stable' 'exertional' 'angina'],[0. 2. 2. 2.]
NCT02145260,"1:11:chronic_disease,",Chronic HD (>90 days),['Chronic' 'HD' '(' '>' '90' 'days' ')'],[2. 2. 0. 0. 0. 0. 0.]
NCT02143830,1:31:cancer,Myelodysplastic Syndrome (MDS),['Myelodysplastic' 'Syndrome' '(' 'MDS' ')'],[3. 3. 3. 0. 0.]
NCT02143726,21:85:treatment,Chronic concomitant treatment with strong inhibitors of cytochrome P450 3A4 (CYP3A4),"['Chronic' 'concomitant' 'treatment' 'with' 'strong' 'inhibitors' 'of'
 'cytochrome' 'P450' '3A4' '(' 'CYP3A4' ')']",[0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0.]
NCT02143726,"13:37:treatment,",Patients on strong CYP3A4 inhibitors must discontinue the drug for 14 days prior to registration on the study,"['Patients' 'on' 'strong' 'CYP3A4' 'inhibitors' 'must' 'discontinue' 'the'
 'drug' 'for' '14' 'days' 'prior' 'to' 'registration' 'on' 'the' 'study']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02143726,",43:61:treatment",who have received greater than 600 mCi of radioactive iodine in their lifetime,"['who' 'have' 'received' 'greater' 'than' '600' 'mCi' 'of' 'radioactive'
 'iodine' 'in' 'their' 'lifetime']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT02141919,42:61:treatment,Subjects must not have received previous abdominal radiation,"['Subjects' 'must' 'not' 'have' 'received' 'previous' 'abdominal'
 'radiation']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02141074,"36:59:treatment,",Previously untreated or exposed to FIX containing products less than or equal to 3 exposure days (5 previous exposures to blood components is acceptable),"['Previously' 'untreated' 'or' 'exposed' 'to' 'FIX' 'containing'
 'products' 'less' 'than' 'or' 'equal' 'to' '3' 'exposure' 'days' '(' '5'
 'previous' 'exposures' 'to' 'blood' 'components' 'is' 'acceptable' ')']","[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02140554,"18:69:treatment,",Participation in another clinical study with an investigational drug within 30 days of Screening,"['Participation' 'in' 'another' 'clinical' 'study' 'with' 'an'
 'investigational' 'drug' 'within' '30' 'days' 'of' 'Screening']",[0. 0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02140255,"1:19:chronic_disease,","Maternal infection must be confirmed, with confirmatory results available within 10 business days of enrollment","['Maternal' 'infection' 'must' 'be' 'confirmed' ',' 'with' 'confirmatory'
 'results' 'available' 'within' '10' 'business' 'days' 'of' 'enrollment']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02139436,1:30:chronic_disease,peripheral nerve compressions or rotator cuff tears that limit ability to row,"['peripheral' 'nerve' 'compressions' 'or' 'rotator' 'cuff' 'tears' 'that'
 'limit' 'ability' 'to' 'row']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02138669,1:24:treatment,isotretinoin (Accutane),['isotretinoin' '(' 'Accutane' ')'],[1. 1. 0. 0.]
NCT02138617,20:37:treatment,Willing to undergo UGT1A1 genotyping,['Willing' 'to' 'undergo' 'UGT1A1' 'genotyping'],[0. 0. 0. 1. 1.]
NCT02138214,1:9:cancer,T4 tumor,['T4' 'tumor'],[3. 3.]
NCT02135874,15:42:cancer,Patients with active secondary malignancy will not be eligible unless approved by the principal investigator,"['Patients' 'with' 'active' 'secondary' 'malignancy' 'will' 'not' 'be'
 'eligible' 'unless' 'approved' 'by' 'the' 'principal' 'investigator']",[0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02135588,1:39:chronic_disease,Traumatic hemorrhagic pleural effusion,['Traumatic' 'hemorrhagic' 'pleural' 'effusion'],[2. 2. 2. 2.]
NCT02134392,48:52:allergy_name,Recent ingestion of a potential allergen (e.g. nuts) where recipient has a known allergy to this (these) agent(s),"['Recent' 'ingestion' 'of' 'a' 'potential' 'allergen' '(' 'e.g' '.' 'nuts'
 ')' 'where' 'recipient' 'has' 'a' 'known' 'allergy' 'to' 'this' '('
 'these' ')' 'agent' '(' 's' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02134392,1:23:chronic_disease,electrolyte imbalances on basic metabolic panel,['electrolyte' 'imbalances' 'on' 'basic' 'metabolic' 'panel'],[2. 2. 0. 0. 0. 0.]
NCT02133898,1:32:treatment,Electroconvulsive Therapy (ECT) failure in past,['Electroconvulsive' 'Therapy' '(' 'ECT' ')' 'failure' 'in' 'past'],[1. 1. 1. 0. 0. 0. 0. 0.]
NCT02133885,",49:73:chronic_disease",More than one in-patient hospitalization for an anti-hypertensive crisis within the year,"['More' 'than' 'one' 'in-patient' 'hospitalization' 'for' 'an'
 'anti-hypertensive' 'crisis' 'within' 'the' 'year']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0.]
NCT02133573,",,,,110:130:treatment",History of preterm birth or short cervix (defined as cervical length ≤ 25 mm at 18-24 weeks GA necessitating progesterone therapy,"['History' 'of' 'preterm' 'birth' 'or' 'short' 'cervix' '(' 'defined' 'as'
 'cervical' 'length' '≤' '25' 'mm' 'at' '18-24' 'weeks' 'GA'
 'necessitating' 'progesterone' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02133196,",16:44:treatment",Greater than 2 invasive thoracic procedures,['Greater' 'than' '2' 'invasive' 'thoracic' 'procedures'],[0. 0. 0. 1. 1. 1.]
NCT02132130,77:101:treatment,Abnormal vital signs and/or ECG that suggest potential contraindication for planned study anesthesia,"['Abnormal' 'vital' 'signs' 'and/or' 'ECG' 'that' 'suggest' 'potential'
 'contraindication' 'for' 'planned' 'study' 'anesthesia']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02132130,1:25:chronic_disease,central auditory lesions,['central' 'auditory' 'lesions'],[2. 2. 2.]
NCT02131467,21:31:allergy_name,Hypersensitivity to perampanel,['Hypersensitivity' 'to' 'perampanel'],[0. 0. 4.]
NCT02131467,1:11:treatment,nevirapine,['nevirapine'],[1.]
NCT02131389,5:22:chronic_disease,Has hip joint disease related to one or more,['Has' 'hip' 'joint' 'disease' 'related' 'to' 'one' 'or' 'more'],[0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02130687,16:29:treatment,Treatment with lithium salts,['Treatment' 'with' 'lithium' 'salts'],[0. 0. 1. 1.]
NCT02128906,47:67:cancer,Patients with a history of curatively-treated non-HNSCC malignancy,"['Patients' 'with' 'a' 'history' 'of' 'curatively-treated' 'non-HNSCC'
 'malignancy']",[0. 0. 0. 0. 0. 0. 3. 3.]
NCT02128230,53:66:chronic_disease,lower levels are explained by extensive bone marrow plasmacytosis,"['lower' 'levels' 'are' 'explained' 'by' 'extensive' 'bone' 'marrow'
 'plasmacytosis']",[0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02127398,1:19:chronic_disease,Short gut syndrome requiring total parenteral nutrition,['Short' 'gut' 'syndrome' 'requiring' 'total' 'parenteral' 'nutrition'],[2. 2. 2. 0. 0. 0. 0.]
NCT02125786,1:31:treatment,Prior craniospinal irradiation,['Prior' 'craniospinal' 'irradiation'],[1. 1. 1.]
NCT02124772,16:29:treatment,"Any prohibited medication(s), currently used or expected to be required","['Any' 'prohibited' 'medication' '(' 's' ')' ',' 'currently' 'used' 'or'
 'expected' 'to' 'be' 'required']",[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT02124772,68:95:treatment,Must have a disease that is relapsed/refractory to all potentially curative standard treatment regimens,"['Must' 'have' 'a' 'disease' 'that' 'is' 'relapsed/refractory' 'to' 'all'
 'potentially' 'curative' 'standard' 'treatment' 'regimens']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0.]
NCT02124174,1:35:chronic_disease,Active and uncontrolled infections will cause patients to be excluded,"['Active' 'and' 'uncontrolled' 'infections' 'will' 'cause' 'patients' 'to'
 'be' 'excluded']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02122328,1:22:chronic_disease,Dandy-Walker syndrome,['Dandy-Walker' 'syndrome'],[2. 2.]
NCT02122328,1:18:chronic_disease,holoprosencephaly,['holoprosencephaly'],[2.]
NCT02122185,",,,,79:107:cancer",carcinoembryonic antigen (CEA) ratio > 25 OR CA125 =< 250 with no evidence of gastrointestinal (GI) cancer,"['carcinoembryonic' 'antigen' '(' 'CEA' ')' 'ratio' '>' '25' 'OR' 'CA125'
 '=' '<' '250' 'with' 'no' 'evidence' 'of' 'gastrointestinal' '(' 'GI' ')'
 'cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0.]
NCT02122081,"29:103:treatment,",Interval between completing treatment with a hypomethylating agent or other non-cytotoxic chemotherapy and the start of conditioning regimen must be at least 10 days,"['Interval' 'between' 'completing' 'treatment' 'with' 'a'
 'hypomethylating' 'agent' 'or' 'other' 'non-cytotoxic' 'chemotherapy'
 'and' 'the' 'start' 'of' 'conditioning' 'regimen' 'must' 'be' 'at'
 'least' '10' 'days']",[0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02121158,45:61:chronic_disease,Irreversible brain damage from pre-existing cerebral disease,"['Irreversible' 'brain' 'damage' 'from' 'pre-existing' 'cerebral'
 'disease']",[0. 0. 0. 0. 0. 2. 2.]
NCT02121158,12:20:chronic_disease,documented prior MI,['documented' 'prior' 'MI'],[0. 2. 2.]
NCT02120222,1:20:chronic_disease,Serious psychiatric or medical conditions that could interfere with treatment,"['Serious' 'psychiatric' 'or' 'medical' 'conditions' 'that' 'could'
 'interfere' 'with' 'treatment']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02115685,1:27:chronic_disease,bladder or other infection,['bladder' 'or' 'other' 'infection'],[2. 2. 2. 2.]
NCT02115295,",,,,,,133:153:cancer,,,,,","Adequate organ function as defined below: liver function (bilirubin </=2mg/dL, AST and/or ALT </=3 x ULN- or <5 x ULN if related to leukemic involvement), kidney function (creatinine </=1.5 x ULN ), known cardiac ejection fraction of > or = 45% within the past 6 months","['Adequate' 'organ' 'function' 'as' 'defined' 'below' ':' 'liver'
 'function' '(' 'bilirubin' '<' '/=2mg/dL' ',' 'AST' 'and/or' 'ALT' '<'
 '/=3' 'x' 'ULN-' 'or' '<' '5' 'x' 'ULN' 'if' 'related' 'to' 'leukemic'
 'involvement' ')' ',' 'kidney' 'function' '(' 'creatinine' '<' '/=1.5'
 'x' 'ULN' ')' ',' 'known' 'cardiac' 'ejection' 'fraction' 'of' '>' 'or'
 '=' '45' '%' 'within' 'the' 'past' '6' 'months']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02111850,1:9:treatment,Serology,['Serology'],[1.]
NCT02110992,1:37:cancer,Primary tumors of the salivary gland,['Primary' 'tumors' 'of' 'the' 'salivary' 'gland'],[3. 3. 3. 3. 3. 3.]
NCT02110069,"1:26:chronic_disease,,,,","Kasabach Merritt Syndrome defined at a platelet counts less than 50,000 K/µl and/or fibrinogen level < 100 mg/dl at the time of diagnosis","['Kasabach' 'Merritt' 'Syndrome' 'defined' 'at' 'a' 'platelet' 'counts'
 'less' 'than' '50,000' 'K/µl' 'and/or' 'fibrinogen' 'level' '<' '100'
 'mg/dl' 'at' 'the' 'time' 'of' 'diagnosis']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02109627,1:42:cancer,Acute promyelocytic leukemia (FAB M3 AML),['Acute' 'promyelocytic' 'leukemia' '(' 'FAB' 'M3' 'AML' ')'],[3. 3. 3. 3. 3. 3. 0. 0.]
NCT02109081,",,65:90:chronic_disease",MMSE score of ≤ 20 out of 30 on preoperative testing (more than mild cognitive impairment) or delirium on preoperative CAM testing,"['MMSE' 'score' 'of' '≤' '20' 'out' 'of' '30' 'on' 'preoperative'
 'testing' '(' 'more' 'than' 'mild' 'cognitive' 'impairment' ')' 'or'
 'delirium' 'on' 'preoperative' 'CAM' 'testing']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02108860,"1:34:treatment,,",Treatment with methylprednisolone 1000 mg within 28 days prior to enrollment,"['Treatment' 'with' 'methylprednisolone' '1000' 'mg' 'within' '28' 'days'
 'prior' 'to' 'enrollment']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02107703,"32:84:treatment,",approved Receptor activator of nuclear factor kappa-B (RANK) ligand targeted agents <7 days prior to randomization,"['approved' 'Receptor' 'activator' 'of' 'nuclear' 'factor' 'kappa-B' '('
 'RANK' ')' 'ligand' 'targeted' 'agents' '<' '7' 'days' 'prior' 'to'
 'randomization']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02106988,43:65:treatment,with active infections requiring specific anti-infective therapy are not eligible until all signs of infections are resolved,"['with' 'active' 'infections' 'requiring' 'specific' 'anti-infective'
 'therapy' 'are' 'not' 'eligible' 'until' 'all' 'signs' 'of' 'infections'
 'are' 'resolved']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02106598,1:28:chronic_disease,chronic renal insufficiency,['chronic' 'renal' 'insufficiency'],[2. 2. 2.]
NCT02106052,24:58:chronic_disease,History of significant developmental or learning disorder that may affect participation and confound interpretation of study results,"['History' 'of' 'significant' 'developmental' 'or' 'learning' 'disorder'
 'that' 'may' 'affect' 'participation' 'and' 'confound' 'interpretation'
 'of' 'study' 'results']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02105766,",,103:113:treatment,",Red cell alloimmunization/ Transfusion dependent/ Total hemoglobin increases less than 1g/dL while on hydroxurea (hydroxurea for at least 6 months),"['Red' 'cell' 'alloimmunization/' 'Transfusion' 'dependent/' 'Total'
 'hemoglobin' 'increases' 'less' 'than' '1g/dL' 'while' 'on' 'hydroxurea'
 '(' 'hydroxurea' 'for' 'at' 'least' '6' 'months' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02105545,30:44:cancer,Subjects for whom sufficient cancer tissues are not available to meet the objectives of the study,"['Subjects' 'for' 'whom' 'sufficient' 'cancer' 'tissues' 'are' 'not'
 'available' 'to' 'meet' 'the' 'objectives' 'of' 'the' 'study']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02101944,",,,,134:159:treatment",Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL prior to starting therapy and prior to beginning another cycle,"['Females' 'of' 'childbearing' 'potential' '(' 'FCBP' ')' 'must' 'have'
 'a' 'negative' 'serum' 'or' 'urine' 'pregnancy' 'test' 'with' 'a'
 'sensitivity' 'of' 'at' 'least' '50' 'mIU/mL' 'prior' 'to' 'starting'
 'therapy' 'and' 'prior' 'to' 'beginning' 'another' 'cycle']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]"
NCT02101944,13:44:cancer,Presence of clonal bone marrow plasma cells,['Presence' 'of' 'clonal' 'bone' 'marrow' 'plasma' 'cells'],[0. 0. 3. 3. 3. 3. 3.]
NCT02101853,60:88:treatment,No waiting period for patients who relapse while receiving standard maintenance therapy,"['No' 'waiting' 'period' 'for' 'patients' 'who' 'relapse' 'while'
 'receiving' 'standard' 'maintenance' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02101736,"31:51:chronic_disease,",Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment,"['Any' 'other' 'signs' 'indicative' 'of' 'pulmonary' 'hemorrhage' 'within'
 '3' 'months' 'before' 'the' 'first' 'dose' 'of' 'study' 'treatment']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02101736,1:23:cancer,Plexiform neurofibroma that is progressive OR causing significant morbidity,"['Plexiform' 'neurofibroma' 'that' 'is' 'progressive' 'OR' 'causing'
 'significant' 'morbidity']",[3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02100956,"1:17:chronic_disease,",Neuropathic pain for > 6 months,['Neuropathic' 'pain' 'for' '>' '6' 'months'],[2. 2. 0. 0. 0. 0.]
NCT02100891,30:50:treatment,Patients who have received a prior allogeneic HCT are ineligible,"['Patients' 'who' 'have' 'received' 'a' 'prior' 'allogeneic' 'HCT' 'are'
 'ineligible']",[0. 0. 0. 0. 0. 1. 1. 1. 0. 0.]
NCT02099240,67:98:treatment,Isolation of an organism from bone culture that is susceptible to intravenous and oral antibiotic,"['Isolation' 'of' 'an' 'organism' 'from' 'bone' 'culture' 'that' 'is'
 'susceptible' 'to' 'intravenous' 'and' 'oral' 'antibiotic']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02099058,17:42:treatment,Subjects in the combination therapy Arm E,['Subjects' 'in' 'the' 'combination' 'therapy' 'Arm' 'E'],[0. 0. 0. 1. 1. 1. 1.]
NCT02098252,16:25:chronic_disease,patient with a brain AVM,['patient' 'with' 'a' 'brain' 'AVM'],[0. 0. 0. 2. 2.]
NCT02095808,"46:81:cancer,,","Patients must have suspicious or known to be malignant solitary pulmonary nodule,5cm or less in size","['Patients' 'must' 'have' 'suspicious' 'or' 'known' 'to' 'be' 'malignant'
 'solitary' 'pulmonary' 'nodule,5cm' 'or' 'less' 'in' 'size']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0.]
NCT02095678,61:75:treatment,Patients with ferromagnetic or otherwise non-MRI compatible aneurysm clips,"['Patients' 'with' 'ferromagnetic' 'or' 'otherwise' 'non-MRI' 'compatible'
 'aneurysm' 'clips']",[0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02094794,43:72:treatment,"All candidates for this study must have a human leukocyte antigen (HLA) (A, B, C, DR) identical siblings who is willing to donate bone marrow or primed blood stem cells or a 10/10 allele matched unrelated donor","['All' 'candidates' 'for' 'this' 'study' 'must' 'have' 'a' 'human'
 'leukocyte' 'antigen' '(' 'HLA' ')' '(' 'A' ',' 'B' ',' 'C' ',' 'DR' ')'
 'identical' 'siblings' 'who' 'is' 'willing' 'to' 'donate' 'bone' 'marrow'
 'or' 'primed' 'blood' 'stem' 'cells' 'or' 'a' '10/10' 'allele' 'matched'
 'unrelated' 'donor']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02094118,28:53:treatment,No plan for placement of a pulmonary artery catheter,['No' 'plan' 'for' 'placement' 'of' 'a' 'pulmonary' 'artery' 'catheter'],[0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02092324,15:39:chronic_disease,Subjects with end stage renal function,['Subjects' 'with' 'end' 'stage' 'renal' 'function'],[0. 0. 2. 2. 2. 2.]
NCT02091999,8:29:chronic_disease,Active Hepatitis C infection,['Active' 'Hepatitis' 'C' 'infection'],[0. 2. 2. 2.]
NCT02091999,28:80:treatment,Subject must have received prior treatment with a CPI in the metastatic setting,"['Subject' 'must' 'have' 'received' 'prior' 'treatment' 'with' 'a' 'CPI'
 'in' 'the' 'metastatic' 'setting']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT02091141,42:83:allergy_name,Known allergy or hypersensitivity to any component of the atezolizumab formulation,"['Known' 'allergy' 'or' 'hypersensitivity' 'to' 'any' 'component' 'of'
 'the' 'atezolizumab' 'formulation']",[0. 0. 0. 0. 0. 0. 4. 4. 4. 4. 4.]
NCT02091141,1:90:treatment,Previous treatment with atezolizumab or another programmed death-1 (PD-1)/PD-L1 inhibitor,"['Previous' 'treatment' 'with' 'atezolizumab' 'or' 'another' 'programmed'
 'death-1' '(' 'PD-1' ')' '/PD-L1' 'inhibitor']",[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0.]
NCT02089607,31:54:treatment,"In such a situation, multiple extra-anatomic bypasses may be necessary","['In' 'such' 'a' 'situation' ',' 'multiple' 'extra-anatomic' 'bypasses'
 'may' 'be' 'necessary']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT02089607,24:38:chronic_disease,Left (or right) common carotid artery,['Left' '(' 'or' 'right' ')' 'common' 'carotid' 'artery'],[0. 0. 0. 0. 0. 0. 2. 2.]
NCT02089607,46:66:chronic_disease,Presence of concomitant thoracoabdominal and aortic arch aneurysm meeting one of the above-mentioned criteria,"['Presence' 'of' 'concomitant' 'thoracoabdominal' 'and' 'aortic' 'arch'
 'aneurysm' 'meeting' 'one' 'of' 'the' 'above-mentioned' 'criteria']",[0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02089607,"1:33:chronic_disease,,",Thoracoabdominal aortic aneurysm with a diameter ≥ 5.5 cm or 2 times the normal aortic diameter,"['Thoracoabdominal' 'aortic' 'aneurysm' 'with' 'a' 'diameter' '≥' '5.5'
 'cm' 'or' '2' 'times' 'the' 'normal' 'aortic' 'diameter']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02088554,1:47:chronic_disease,Hypertrophic obstructive cardiomyopathy (HOCM),['Hypertrophic' 'obstructive' 'cardiomyopathy' '(' 'HOCM' ')'],[2. 2. 2. 2. 0. 0.]
NCT02088554,"15:55:chronic_disease,,","Patient has a non-cardiac major or progressive disease, with a life expectancy of less than 2 years","['Patient' 'has' 'a' 'non-cardiac' 'major' 'or' 'progressive' 'disease'
 ',' 'with' 'a' 'life' 'expectancy' 'of' 'less' 'than' '2' 'years']",[0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02088554,1:16:cancer,Terminal cancer,['Terminal' 'cancer'],[3. 3.]
NCT02086448,14:37:chronic_disease,diagnosis of pregestational diabetes,['diagnosis' 'of' 'pregestational' 'diabetes'],[0. 0. 2. 2.]
NCT02081404,1:24:treatment,Chronic anticoagulation,['Chronic' 'anticoagulation'],[1. 1.]
NCT02081404,18:36:treatment,Prior history of esophageal surgery,['Prior' 'history' 'of' 'esophageal' 'surgery'],[0. 0. 0. 1. 1.]
NCT02079857,48:71:treatment,Individuals currently receiving other types of complementary therapies,"['Individuals' 'currently' 'receiving' 'other' 'types' 'of'
 'complementary' 'therapies']",[0. 0. 0. 0. 0. 0. 1. 1.]
NCT02078102,33:65:treatment,Patients must not have received prior bone seeking radionuclides,"['Patients' 'must' 'not' 'have' 'received' 'prior' 'bone' 'seeking'
 'radionuclides']",[0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02076906,1:20:cancer,Lesion in the skull,['Lesion' 'in' 'the' 'skull'],[3. 3. 3. 3.]
NCT02076906,22:55:treatment,The last dose of all myelosuppressive anticancer drugs,['The' 'last' 'dose' 'of' 'all' 'myelosuppressive' 'anticancer' 'drugs'],[0. 0. 0. 0. 0. 1. 1. 1.]
NCT02075671,23:45:chronic_disease,Clinical diagnosis of papulopustular rosacea based on physician evaluation,"['Clinical' 'diagnosis' 'of' 'papulopustular' 'rosacea' 'based' 'on'
 'physician' 'evaluation']",[0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02075671,"8:31:treatment,",Use of topical corticosteroids (on the face) 1 month prior to Visit 1,"['Use' 'of' 'topical' 'corticosteroids' '(' 'on' 'the' 'face' ')' '1'
 'month' 'prior' 'to' 'Visit' '1']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02074631,22:37:cancer,History of a primary bone malignancy involving the lumbar spine,"['History' 'of' 'a' 'primary' 'bone' 'malignancy' 'involving' 'the'
 'lumbar' 'spine']",[0. 0. 0. 0. 3. 3. 0. 0. 0. 0.]
NCT02074436,"1:35:treatment,",Hematopoietic stem cell transplant recipient within 100 days post-transplant,"['Hematopoietic' 'stem' 'cell' 'transplant' 'recipient' 'within' '100'
 'days' 'post-transplant']",[1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02073292,1:28:chronic_disease,Systemic or local infection,['Systemic' 'or' 'local' 'infection'],[2. 2. 2. 2.]
NCT02070549,1:18:cancer,Colorectal cancer patients,['Colorectal' 'cancer' 'patients'],[3. 3. 0.]
NCT02069899,38:45:treatment,Having received at least one dose of NI-0501,['Having' 'received' 'at' 'least' 'one' 'dose' 'of' 'NI-0501'],[0. 0. 0. 0. 0. 0. 0. 1.]
NCT02067819,100:115:treatment,"Other dental health problems that might interfere with the assessment, installation, or wearing of orthotic device","['Other' 'dental' 'health' 'problems' 'that' 'might' 'interfere' 'with'
 'the' 'assessment' ',' 'installation' ',' 'or' 'wearing' 'of' 'orthotic'
 'device']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02064296,"1:12:treatment,",Acupuncture within last 6-months,['Acupuncture' 'within' 'last' '6-months'],[1. 0. 0. 0.]
NCT02064036,32:49:allergy_name,Prior allergic reaction to the hormones involved in this protocol,"['Prior' 'allergic' 'reaction' 'to' 'the' 'hormones' 'involved' 'in'
 'this' 'protocol']",[0. 0. 0. 0. 0. 4. 4. 0. 0. 0.]
NCT02063438,10:21:treatment,Previous thoracotomy on the operative side,['Previous' 'thoracotomy' 'on' 'the' 'operative' 'side'],[0. 1. 0. 0. 0. 0.]
NCT02061293,6:10:chronic_disease,with SCID (DSM-IV) diagnosis of alcohol dependence who,"['with' 'SCID' '(' 'DSM-IV' ')' 'diagnosis' 'of' 'alcohol' 'dependence'
 'who']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02059239,1:28:treatment,Prior autologous transplant,['Prior' 'autologous' 'transplant'],[1. 1. 1.]
NCT02058095,1:40:chronic_disease,Obstructive Hypertrophic cardiomyopathy,['Obstructive' 'Hypertrophic' 'cardiomyopathy'],[2. 2. 2.]
NCT02058095,1:10:treatment,Terazosin,['Terazosin'],[1.]
NCT02057133,156:217:treatment,"Have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study (for example, history of major surgical resection involving the stomach or small bowel)","['Have' 'serious' 'preexisting' 'medical' 'conditions' 'that' ',' 'in'
 'the' 'judgment' 'of' 'the' 'investigator' ',' 'would' 'preclude'
 'participation' 'in' 'this' 'study' '(' 'for' 'example' ',' 'history'
 'of' 'major' 'surgical' 'resection' 'involving' 'the' 'stomach' 'or'
 'small' 'bowel' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0.]"
NCT02056873,"43:69:treatment,,",Must be at minimum a single trial with an alpha-2 adrenergic agonist (0.1-0.3 mg/day),"['Must' 'be' 'at' 'minimum' 'a' 'single' 'trial' 'with' 'an' 'alpha-2'
 'adrenergic' 'agonist' '(' '0.1-0.3' 'mg/day' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0.]
NCT02056470,16:32:treatment,Previous major knee replacement of the affected knee joint,"['Previous' 'major' 'knee' 'replacement' 'of' 'the' 'affected' 'knee'
 'joint']",[0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02055053,20:44:chronic_disease,with unilateral or bilateral inguinal herna for laparoscopic repair,"['with' 'unilateral' 'or' 'bilateral' 'inguinal' 'herna' 'for'
 'laparoscopic' 'repair']",[0. 0. 0. 2. 2. 2. 0. 0. 0.]
NCT02053792,21:47:treatment,Currently receiving IV immunomodulating agents,['Currently' 'receiving' 'IV' 'immunomodulating' 'agents'],[0. 0. 1. 1. 1.]
NCT02053792,36:64:treatment,Never previously been treated with FIX clotting factor products,"['Never' 'previously' 'been' 'treated' 'with' 'FIX' 'clotting' 'factor'
 'products']",[0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02053792,20:104:treatment,subjects requiring major non-emergency surgery who have not previously completed a CSL-sponsored rIX-FP lead-in study,"['subjects' 'requiring' 'major' 'non-emergency' 'surgery' 'who' 'have'
 'not' 'previously' 'completed' 'a' 'CSL-sponsored' 'rIX-FP' 'lead-in'
 'study']",[0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0.]
NCT02053363,8:30:chronic_disease,Active intravascular clotting,['Active' 'intravascular' 'clotting'],[0. 2. 2.]
NCT02050347,"11:64:treatment,,",Available allogeneic activated peripheral blood T cell products with >=15% expression of CD19.CAR-CD28ζ determined by flow cytometry (cell dose is based on total cell numbers and not individual antileukemic cell numbers),"['Available' 'allogeneic' 'activated' 'peripheral' 'blood' 'T' 'cell'
 'products' 'with' '>' '=15' '%' 'expression' 'of' 'CD19.CAR-CD28ζ'
 'determined' 'by' 'flow' 'cytometry' '(' 'cell' 'dose' 'is' 'based' 'on'
 'total' 'cell' 'numbers' 'and' 'not' 'individual' 'antileukemic' 'cell'
 'numbers' ')']","[0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02050113,1:22:chronic_disease,Anaphylactic reaction to contrast that cannot be adequately pre-medicated,"['Anaphylactic' 'reaction' 'to' 'contrast' 'that' 'can' 'not' 'be'
 'adequately' 'pre-medicated']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02050113,"12:22:treatment,,",For use of Zenith TX2: diameter >38 mm or <24 mm (for proximal and distal neck diameter),"['For' 'use' 'of' 'Zenith' 'TX2' ':' 'diameter' '>' '38' 'mm' 'or' '<'
 '24' 'mm' '(' 'for' 'proximal' 'and' 'distal' 'neck' 'diameter' ')']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02048722,26:38:cancer,Histologically confirmed angiosarcoma,['Histologically' 'confirmed' 'angiosarcoma'],[0. 0. 3.]
NCT02048332,",42:60:treatment",Recipient must be at least 28 days after stem cell infusion,"['Recipient' 'must' 'be' 'at' 'least' '28' 'days' 'after' 'stem' 'cell'
 'infusion']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02046330,1:32:chronic_disease,"Major Depression Disorder (MDD) diagnosed by Structured Clinical Interview for DSM-IV (SCID I/DSM-IV), judged to be of disabling severity","['Major' 'Depression' 'Disorder' '(' 'MDD' ')' 'diagnosed' 'by'
 'Structured' 'Clinical' 'Interview' 'for' 'DSM-IV' '(' 'SCID' 'I/DSM-IV'
 ')' ',' 'judged' 'to' 'be' 'of' 'disabling' 'severity']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02043548,",20:30:treatment",2 week washout for etanercept,['2' 'week' 'washout' 'for' 'etanercept'],[0. 0. 0. 0. 1.]
NCT02042222,70:89:treatment,"A decision by the subject's family and primary clinician to initiate hydroxyurea therapy, made independently of recruitment for the study (not applicable for the biological arm patients)","['A' 'decision' 'by' 'the' 'subject' ""'s"" 'family' 'and' 'primary'
 'clinician' 'to' 'initiate' 'hydroxyurea' 'therapy' ',' 'made'
 'independently' 'of' 'recruitment' 'for' 'the' 'study' '(' 'not'
 'applicable' 'for' 'the' 'biological' 'arm' 'patients' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02041936,29:50:treatment,Unable to be treated with a muscle blockade agent,['Unable' 'to' 'be' 'treated' 'with' 'a' 'muscle' 'blockade' 'agent'],[0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02040610,"1:41:cancer,",Clinical stage T1-T2c (AJCC 7th edition) within 90 days of registration,"['Clinical' 'stage' 'T1-T2c' '(' 'AJCC' '7th' 'edition' ')' 'within' '90'
 'days' 'of' 'registration']",[3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02038257,12:26:chronic_disease,History of koebnerization (new patches of vitiligo at sites of injury or trauma),"['History' 'of' 'koebnerization' '(' 'new' 'patches' 'of' 'vitiligo' 'at'
 'sites' 'of' 'injury' 'or' 'trauma' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02037048,27:39:cancer,Patients with evidence of clinical T4b (unresectable),['Patients' 'with' 'evidence' 'of' 'clinical' 'T4b' '(' 'unresectable' ')'],[0. 0. 0. 0. 3. 3. 0. 0. 0.]
NCT02036853,31:43:treatment,Patients are able to tolerate triheptanoin if they have been (or are currently being) treated with this medication,"['Patients' 'are' 'able' 'to' 'tolerate' 'triheptanoin' 'if' 'they' 'have'
 'been' '(' 'or' 'are' 'currently' 'being' ')' 'treated' 'with' 'this'
 'medication']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02035137,24:42:treatment,They have had previous I-131 MIBG therapy,['They' 'have' 'had' 'previous' 'I-131' 'MIBG' 'therapy'],[0. 0. 0. 0. 1. 1. 1.]
NCT02033616,82:107:cancer,"Successful establishment of an autologous epithelial ovarian, fallopian tube, or primary peritoneal cancer cell line by AIVITA Biomedical, Inc","['Successful' 'establishment' 'of' 'an' 'autologous' 'epithelial'
 'ovarian' ',' 'fallopian' 'tube' ',' 'or' 'primary' 'peritoneal' 'cancer'
 'cell' 'line' 'by' 'AIVITA' 'Biomedical' ',' 'Inc']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02031250,14:33:treatment,referred for definitive chemo‐RT,['referred' 'for' 'definitive' 'chemo‐RT'],[0. 0. 1. 1.]
NCT02030015,33:42:allergy_name,Subjects who have an allergy to miglustat or any of the components within the drug product,"['Subjects' 'who' 'have' 'an' 'allergy' 'to' 'miglustat' 'or' 'any' 'of'
 'the' 'components' 'within' 'the' 'drug' 'product']",[0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02025465,"9:36:chronic_disease,,",Current Atrioventricular (AV) block (2nd or 3rd degree),"['Current' 'Atrioventricular' '(' 'AV' ')' 'block' '(' '2nd' 'or' '3rd'
 'degree' ')']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02021604,",96:121:treatment",Nursing mothers who are unwilling to discontinue breastfeeding their infant for 48 hours after Fluorodopa F 18 injection,"['Nursing' 'mothers' 'who' 'are' 'unwilling' 'to' 'discontinue'
 'breastfeeding' 'their' 'infant' 'for' '48' 'hours' 'after' 'Fluorodopa'
 'F' '18' 'injection']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02021279,26:45:cancer,"Subject has a history of pelvic organ cancer (e.g. uterine, ovarian, bladder, or cervical)","['Subject' 'has' 'a' 'history' 'of' 'pelvic' 'organ' 'cancer' '(' 'e.g'
 '.' 'uterine' ',' 'ovarian' ',' 'bladder' ',' 'or' 'cervical' ')']",[0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02020707,45:72:cancer,histologic proof of surgically unresectable stage IV malignant melanoma,"['histologic' 'proof' 'of' 'surgically' 'unresectable' 'stage' 'IV'
 'malignant' 'melanoma']",[0. 0. 0. 0. 0. 3. 3. 3. 3.]
NCT02020018,1:12:treatment,Thoracotomy,['Thoracotomy'],[1.]
NCT02019641,25:40:treatment,Active participation in ILD drug trials,['Active' 'participation' 'in' 'ILD' 'drug' 'trials'],[0. 0. 0. 1. 1. 1.]
NCT02019641,13:41:chronic_disease,Significant hepatic or renal dysfunction,['Significant' 'hepatic' 'or' 'renal' 'dysfunction'],[0. 2. 2. 2. 2.]
NCT02016781,27:34:treatment,"No intent to proceed with alloHCT using donor sources not specified in this protocol, including human leukocyte antigen (HLA)-mismatched related or unrelated donors","['No' 'intent' 'to' 'proceed' 'with' 'alloHCT' 'using' 'donor' 'sources'
 'not' 'specified' 'in' 'this' 'protocol' ',' 'including' 'human'
 'leukocyte' 'antigen' '(' 'HLA' ')' '-mismatched' 'related' 'or'
 'unrelated' 'donors']","[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02016781,1:17:treatment,Prior autologous,['Prior' 'autologous'],[1. 1.]
NCT02016781,1:56:chronic_disease,Refractory cytopenia with multilineage dysplasia (RCMD),['Refractory' 'cytopenia' 'with' 'multilineage' 'dysplasia' '(' 'RCMD' ')'],[2. 2. 2. 2. 2. 2. 0. 0.]
NCT02015390,28:45:allergy_name,Known allergic reaction to titanium implants,['Known' 'allergic' 'reaction' 'to' 'titanium' 'implants'],[0. 0. 0. 0. 4. 4.]
NCT02013492,63:85:cancer,Patients must have histologically-proven locally-recurrent or metastatic solid tumor,"['Patients' 'must' 'have' 'histologically-proven' 'locally-recurrent' 'or'
 'metastatic' 'solid' 'tumor']",[0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT02013154,1:46:treatment,Previously treated with an anti-DKK-1 therapy,['Previously' 'treated' 'with' 'an' 'anti-DKK-1' 'therapy'],[1. 1. 1. 1. 1. 1.]
NCT02012296,",44:96:treatment",a minimum washout of 28 days for any other anticancer therapy prior to first dose of study drug is required (only applicable for phase I),"['a' 'minimum' 'washout' 'of' '28' 'days' 'for' 'any' 'other' 'anticancer'
 'therapy' 'prior' 'to' 'first' 'dose' 'of' 'study' 'drug' 'is' 'required'
 '(' 'only' 'applicable' 'for' 'phase' 'I' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02011971,18:36:treatment,Use of centrally active medications,['Use' 'of' 'centrally' 'active' 'medications'],[0. 0. 0. 1. 1.]
NCT02008656,1:24:cancer,Recurrent rectal cancer,['Recurrent' 'rectal' 'cancer'],[3. 3. 3.]
NCT02007239,13:44:chronic_disease,Evidence of cytokine release syndrome (CRS),['Evidence' 'of' 'cytokine' 'release' 'syndrome' '(' 'CRS' ')'],[0. 0. 2. 2. 2. 2. 0. 0.]
NCT02007239,"29:49:treatment,",must be planned to initiate HLH-directed therapy within 24 hours of study enrollment,"['must' 'be' 'planned' 'to' 'initiate' 'HLH-directed' 'therapy' 'within'
 '24' 'hours' 'of' 'study' 'enrollment']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02004275,1:27:chronic_disease,Pomalidomide naive disease,['Pomalidomide' 'naive' 'disease'],[2. 2. 2.]
NCT02004028,18:40:chronic_disease,Known history of malignant hypertension,['Known' 'history' 'of' 'malignant' 'hypertension'],[0. 0. 0. 2. 2.]
NCT02003222,1:27:treatment,ALLOGENEIC TRANSPLANTATION,['ALLOGENEIC' 'TRANSPLANTATION'],[1. 1.]
NCT02003222,8:39:cancer,Mature B ALL (Burkitt's-like leukemia),"['Mature' 'B' 'ALL' '(' ""Burkitt's-like"" 'leukemia' ')']",[0. 3. 3. 3. 3. 0. 0.]
NCT02003222,"11:42:treatment,",pre-study bone marrow biopsy and aspirate must be completed =< 1 week prior to registration,"['pre-study' 'bone' 'marrow' 'biopsy' 'and' 'aspirate' 'must' 'be'
 'completed' '=' '<' '1' 'week' 'prior' 'to' 'registration']",[0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02000115,5:46:chronic_disease,has senile degenerative aortic valve stenosis with echocardiographically derived criteria,"['has' 'senile' 'degenerative' 'aortic' 'valve' 'stenosis' 'with'
 'echocardiographically' 'derived' 'criteria']",[0. 2. 2. 2. 2. 2. 0. 0. 0. 0.]
NCT01996449,1:14:treatment,phenylephrine,['phenylephrine'],[1.]
NCT01994382,1:22:cancer,Burkitt-like Lymphoma,['Burkitt-like' 'Lymphoma'],[3. 3.]
NCT01993810,"46:74:treatment,",non-operable disease will be determined by a multi-disciplinary treatment team within 60 days prior to registration,"['non-operable' 'disease' 'will' 'be' 'determined' 'by' 'a'
 'multi-disciplinary' 'treatment' 'team' 'within' '60' 'days' 'prior' 'to'
 'registration']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01990495,"24:42:treatment,",undergoing maintenance hemodialysis (MHD) for at least three months and without other active/uncontrolled disease will be studied,"['undergoing' 'maintenance' 'hemodialysis' '(' 'MHD' ')' 'for' 'at'
 'least' 'three' 'months' 'and' 'without' 'other' 'active/uncontrolled'
 'disease' 'will' 'be' 'studied']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01990209,15:46:cancer,Patients with metastases limited to the bones,['Patients' 'with' 'metastases' 'limited' 'to' 'the' 'bones'],[0. 0. 3. 3. 3. 3. 3.]
NCT01989585,16:26:treatment,Miscellaneous: conivaptan,['Miscellaneous' ':' 'conivaptan'],[0. 0. 1.]
NCT01989507,49:69:treatment,actively quitting smoking or current use of any nicotine replacement or other smoking cessation treatment,"['actively' 'quitting' 'smoking' 'or' 'current' 'use' 'of' 'any'
 'nicotine' 'replacement' 'or' 'other' 'smoking' 'cessation' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01988246,28:47:treatment,Patients who have received corneal transplants in the study eye,"['Patients' 'who' 'have' 'received' 'corneal' 'transplants' 'in' 'the'
 'study' 'eye']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT01983475,"1:37:treatment,",Anabolic or Steroid hormonal therapy; within the past year and longer than six months,"['Anabolic' 'or' 'Steroid' 'hormonal' 'therapy' ';' 'within' 'the' 'past'
 'year' 'and' 'longer' 'than' 'six' 'months']",[1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01980043,1:71:treatment,Previous Abdominal Surgeries including abdominal wall repair with mesh,"['Previous' 'Abdominal' 'Surgeries' 'including' 'abdominal' 'wall'
 'repair' 'with' 'mesh']",[1. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT01978509,1:16:chronic_disease,Toxic megacolon,['Toxic' 'megacolon'],[2. 2.]
NCT01976429,12:36:treatment,history of ossicular reconstruction,['history' 'of' 'ossicular' 'reconstruction'],[0. 0. 1. 1.]
NCT01974609,32:63:chronic_disease,patients with other medical or psychological health conditions that preclude then from receiving either intervention or returning for follow-up visits,"['patients' 'with' 'other' 'medical' 'or' 'psychological' 'health'
 'conditions' 'that' 'preclude' 'then' 'from' 'receiving' 'either'
 'intervention' 'or' 'returning' 'for' 'follow-up' 'visits']",[0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01973283,37:52:chronic_disease,Patient is considered a significant risk of suicide,['Patient' 'is' 'considered' 'a' 'significant' 'risk' 'of' 'suicide'],[0. 0. 0. 0. 0. 2. 2. 2.]
NCT01972113,21:70:chronic_disease,Subjects presenting chronic degenerative and/or inflammatory diseases,"['Subjects' 'presenting' 'chronic' 'degenerative' 'and/or' 'inflammatory'
 'diseases']",[0. 0. 2. 2. 2. 2. 2.]
NCT01970306,26:33:chronic_disease,Pathologically confirmed Gastric,['Pathologically' 'confirmed' 'Gastric'],[0. 0. 2.]
NCT01969643,"18:39:cancer,","Combination Arm: HER2-positive disease and received at least 2 prior cytotoxic regimens in the incurable, unresectable, LA/MBC setting (not enrolling new patients)","['Combination' 'Arm' ':' 'HER2-positive' 'disease' 'and' 'received' 'at'
 'least' '2' 'prior' 'cytotoxic' 'regimens' 'in' 'the' 'incurable' ','
 'unresectable' ',' 'LA/MBC' 'setting' '(' 'not' 'enrolling' 'new'
 'patients' ')']","[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01968590,1:31:treatment,anti-epileptic medical therapy,['anti-epileptic' 'medical' 'therapy'],[1. 1. 1.]
NCT01968590,"1:26:treatment,",oral or IV glucocorticoid use for over 3 months,['oral' 'or' 'IV' 'glucocorticoid' 'use' 'for' 'over' '3' 'months'],[1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT01967238,1:4:allergy_name,Egg allergy,['Egg' 'allergy'],[4. 0.]
NCT01966367,42:65:cancer,Additional eligibility for patients with non-malignant disorders receiving reduced intensity conditioning,"['Additional' 'eligibility' 'for' 'patients' 'with' 'non-malignant'
 'disorders' 'receiving' 'reduced' 'intensity' 'conditioning']",[0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0.]
NCT01964859,11:27:chronic_disease,An active nonhealing wound,['An' 'active' 'nonhealing' 'wound'],[0. 0. 2. 2.]
NCT01964261,1:28:chronic_disease,High cervical spinal lesion,['High' 'cervical' 'spinal' 'lesion'],[2. 2. 2. 2.]
NCT01962415,",,,,,,323:356:treatment","A 4/6, 5/6 or 6/6 HLA matched related or unrelated UCB unit available that will deliver a pre-cryopreservation total nucleated cell dose of ≥ 3 x 10e7 cells/kg, or double unit grafts, each cord blood unit delivering at least 2 x 10e7 cells/kg OR an 8 of 8 or 7 of 8 HLA allele level matched unrelated donor bone marrow or peripheral blood progenitor graft","['A' '4/6' ',' '5/6' 'or' '6/6' 'HLA' 'matched' 'related' 'or' 'unrelated'
 'UCB' 'unit' 'available' 'that' 'will' 'deliver' 'a'
 'pre-cryopreservation' 'total' 'nucleated' 'cell' 'dose' 'of' '≥' '3' 'x'
 '10e7' 'cells/kg' ',' 'or' 'double' 'unit' 'grafts' ',' 'each' 'cord'
 'blood' 'unit' 'delivering' 'at' 'least' '2' 'x' '10e7' 'cells/kg' 'OR'
 'an' '8' 'of' '8' 'or' '7' 'of' '8' 'HLA' 'allele' 'level' 'matched'
 'unrelated' 'donor' 'bone' 'marrow' 'or' 'peripheral' 'blood'
 'progenitor' 'graft']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]"
NCT01962415,1:8:chronic_disease,Chediak,['Chediak'],[2.]
NCT01962415,1:51:chronic_disease,Congenital Amegakaryocytic Thrombocytopenia (CAMT),['Congenital' 'Amegakaryocytic' 'Thrombocytopenia' '(' 'CAMT' ')'],[2. 2. 2. 2. 0. 0.]
NCT01962415,1:24:chronic_disease,Hurler syndrome (MPS I),['Hurler' 'syndrome' '(' 'MPS' 'I' ')'],[2. 2. 2. 2. 0. 0.]
NCT01962415,1:17:chronic_disease,Leukodystrophies,['Leukodystrophies'],[2.]
NCT01962415,1:15:chronic_disease,Omenn Syndrome,['Omenn' 'Syndrome'],[2. 2.]
NCT01962415,"1:29:treatment,,,,,,",Pulmonary evaluation testing demonstrating CVC or FEV1/FVC of ≥ 50% of predicted for age and/or resting pulse oximeter ≥ 92% on room air or clearance by the pediatric or adult pulmonologist,"['Pulmonary' 'evaluation' 'testing' 'demonstrating' 'CVC' 'or' 'FEV1/FVC'
 'of' '≥' '50' '%' 'of' 'predicted' 'for' 'age' 'and/or' 'resting' 'pulse'
 'oximeter' '≥' '92' '%' 'on' 'room' 'air' 'or' 'clearance' 'by' 'the'
 'pediatric' 'or' 'adult' 'pulmonologist']","[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01962415,1:26:chronic_disease,Sickle cell disease (SCD),['Sickle' 'cell' 'disease' '(' 'SCD' ')'],[2. 2. 2. 2. 0. 0.]
NCT01962415,1:19:chronic_disease,alpha mannosidosis,['alpha' 'mannosidosis'],[2. 2.]
NCT01961557,16:41:chronic_disease,Diagnosed with knee extension deficiency as indicated by a crouched posture during gait lacking,"['Diagnosed' 'with' 'knee' 'extension' 'deficiency' 'as' 'indicated' 'by'
 'a' 'crouched' 'posture' 'during' 'gait' 'lacking']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01959698,7:40:treatment,Prior high-dose chemotherapy (HDC)-ASCT,['Prior' 'high-dose' 'chemotherapy' '(' 'HDC' ')' '-ASCT'],[0. 1. 1. 1. 0. 0. 0.]
NCT01954576,166:176:cancer,"Because the genetic analyses described in Section 8.0 will be performed under HRPO# 201111001 (Analysis of Histological, Genomic, Molecular, and Clinical Factors in CNS Cancer: the Neuro-Oncology Group), for patients enrolling in this trial at WUSM, it is required that WUSM patients must also enroll in HRPO# 201111001. The genetic analyses for UF patients will take place at WUSM under the auspices of this protocol","['Because' 'the' 'genetic' 'analyses' 'described' 'in' 'Section' '8.0'
 'will' 'be' 'performed' 'under' 'HRPO' '#' '201111001' '(' 'Analysis'
 'of' 'Histological' ',' 'Genomic' ',' 'Molecular' ',' 'and' 'Clinical'
 'Factors' 'in' 'CNS' 'Cancer' ':' 'the' 'Neuro-Oncology' 'Group' ')' ','
 'for' 'patients' 'enrolling' 'in' 'this' 'trial' 'at' 'WUSM' ',' 'it'
 'is' 'required' 'that' 'WUSM' 'patients' 'must' 'also' 'enroll' 'in'
 'HRPO' '#' '201111001' '.' 'The' 'genetic' 'analyses' 'for' 'UF'
 'patients' 'will' 'take' 'place' 'at' 'WUSM' 'under' 'the' 'auspices'
 'of' 'this' 'protocol']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01954173,1:38:treatment,Prior radiation therapy to the pelvis,['Prior' 'radiation' 'therapy' 'to' 'the' 'pelvis'],[1. 1. 1. 1. 1. 1.]
NCT01953900,1:30:chronic_disease,Severe intercurrent infection,['Severe' 'intercurrent' 'infection'],[2. 2. 2.]
NCT01953575,28:56:chronic_disease,Medical conditions such as severe heart or lung disease that preclude safe performance of endoscopy,"['Medical' 'conditions' 'such' 'as' 'severe' 'heart' 'or' 'lung' 'disease'
 'that' 'preclude' 'safe' 'performance' 'of' 'endoscopy']",[0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT01953263,15:31:chronic_disease,Patients with vaginal prolapse beyond introitus,['Patients' 'with' 'vaginal' 'prolapse' 'beyond' 'introitus'],[0. 0. 2. 2. 0. 0.]
NCT01952730,27:95:cancer,Histologically documented hepatic colorectal cancer metastasis with resectable hepatic lesions,"['Histologically' 'documented' 'hepatic' 'colorectal' 'cancer'
 'metastasis' 'with' 'resectable' 'hepatic' 'lesions']",[0. 0. 3. 3. 3. 3. 3. 3. 3. 3.]
NCT01951885,1:15:cancer,Myelodysplasia,['Myelodysplasia'],[3.]
NCT01950351,"1:21:cancer,",Clinical stage T1-2b (American Joint Committee on Cancer [AJCC] 7th edition) and PSA,"['Clinical' 'stage' 'T1-2b' '(' 'American' 'Joint' 'Committee' 'on'
 'Cancer' '[' 'AJCC' ']' '7th' 'edition' ')' 'and' 'PSA']",[3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01947140,68:83:cancer,Patients must have histologically confirmed relapsed or refractory T-Cell Lymphoma (as defined by WHO criteria),"['Patients' 'must' 'have' 'histologically' 'confirmed' 'relapsed' 'or'
 'refractory' 'T-Cell' 'Lymphoma' '(' 'as' 'defined' 'by' 'WHO' 'criteria'
 ')']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT01945814,15:41:chronic_disease,Patients with Grade 3 hyperbilirubinemia,['Patients' 'with' 'Grade' '3' 'hyperbilirubinemia'],[0. 0. 2. 2. 2.]
NCT01943851,",51:70:cancer",Consult the GSK Medical Monitor if unsure whether second malignancies meet requirements specified above,"['Consult' 'the' 'GSK' 'Medical' 'Monitor' 'if' 'unsure' 'whether'
 'second' 'malignancies' 'meet' 'requirements' 'specified' 'above']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0.]
NCT01942018,1:22:cancer,Esophageal malignancy,['Esophageal' 'malignancy'],[3. 3.]
NCT01942018,76:93:chronic_disease,Mechanical obstruction to esophageal outflow or infiltrative esophageal or gastric disorders,"['Mechanical' 'obstruction' 'to' 'esophageal' 'outflow' 'or'
 'infiltrative' 'esophageal' 'or' 'gastric' 'disorders']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01941316,"36:58:chronic_disease,",All other required tests to assess non-measurable disease must be performed within 42 days prior to enrollment,"['All' 'other' 'required' 'tests' 'to' 'assess' 'non-measurable' 'disease'
 'must' 'be' 'performed' 'within' '42' 'days' 'prior' 'to' 'enrollment']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01941316,1:17:treatment,Prior irinotecan,['Prior' 'irinotecan'],[1. 1.]
NCT01940757,",39:75:treatment,",Pregnancy as determined by a positive urine human choriogonadotropin (hCG) (if female),"['Pregnancy' 'as' 'determined' 'by' 'a' 'positive' 'urine' 'human'
 'choriogonadotropin' '(' 'hCG' ')' '(' 'if' 'female' ')']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT01937884,"25:44:treatment,",Anticipate placement of central venous line within 24 hours of admission,"['Anticipate' 'placement' 'of' 'central' 'venous' 'line' 'within' '24'
 'hours' 'of' 'admission']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT01937884,9:29:treatment,Require artificial nutrition,['Require' 'artificial' 'nutrition'],[0. 1. 1.]
NCT01931202,1:17:chronic_disease,Anxiety Disorder,['Anxiety' 'Disorder'],[2. 2.]
NCT01925573,1:18:chronic_disease,Blood coagulation parameters,['Blood' 'coagulation' 'parameters'],[2. 2. 0.]
NCT01925131,",22:29:treatment",Patient is in second salvage or more,['Patient' 'is' 'in' 'second' 'salvage' 'or' 'more'],[0. 0. 0. 0. 1. 0. 0.]
NCT01925131,1:26:treatment,Pretreatment cytogenetics must be performed on all patients,"['Pretreatment' 'cytogenetics' 'must' 'be' 'performed' 'on' 'all'
 'patients']",[1. 1. 0. 0. 0. 0. 0. 0.]
NCT01925131,15:32:cancer,patients with bilineal leukemia are excluded,['patients' 'with' 'bilineal' 'leukemia' 'are' 'excluded'],[0. 0. 3. 3. 0. 0.]
NCT01921634,1:22:treatment,Previous appendectomy,['Previous' 'appendectomy'],[1. 1.]
NCT01920061,",4:78:treatment",>2 prior regimens containing cytotoxic chemotherapy in the metastatic setting,"['>' '2' 'prior' 'regimens' 'containing' 'cytotoxic' 'chemotherapy' 'in'
 'the' 'metastatic' 'setting']",[0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT01919619,20:54:cancer,adequately treated basal or squamous cell skin cancer,['adequately' 'treated' 'basal' 'or' 'squamous' 'cell' 'skin' 'cancer'],[0. 0. 3. 3. 3. 3. 3. 3.]
NCT01918683,10:43:treatment,Complete obstruction of portal venous flow to the segment of liver that includes the target lesion,"['Complete' 'obstruction' 'of' 'portal' 'venous' 'flow' 'to' 'the'
 'segment' 'of' 'liver' 'that' 'includes' 'the' 'target' 'lesion']",[0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01918644,13:41:cancer,early stage invasive carcinoma of breast,['early' 'stage' 'invasive' 'carcinoma' 'of' 'breast'],[0. 0. 3. 3. 3. 3.]
NCT01917929,16:72:treatment,Patient has an existing total hip replacement on the contralateral side,"['Patient' 'has' 'an' 'existing' 'total' 'hip' 'replacement' 'on' 'the'
 'contralateral' 'side']",[0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT01915095,"1:12:chronic_disease,",Chronic SCI ( 6 months of injury),['Chronic' 'SCI' '(' '6' 'months' 'of' 'injury' ')'],[2. 2. 0. 0. 0. 0. 0. 0.]
NCT01913106,13:31:cancer,Symptomatic metastasis disease,['Symptomatic' 'metastasis' 'disease'],[0. 3. 3.]
NCT01910818,",184:197:chronic_disease","The scars must be deemed stable for a period of 3 months or have a suitable contralateral control before initiation of treatment. This will be determined by objective measurements of scar erythema, pliability, induration, thickness at enrollment and again at 3 months","['The' 'scars' 'must' 'be' 'deemed' 'stable' 'for' 'a' 'period' 'of' '3'
 'months' 'or' 'have' 'a' 'suitable' 'contralateral' 'control' 'before'
 'initiation' 'of' 'treatment' '.' 'This' 'will' 'be' 'determined' 'by'
 'objective' 'measurements' 'of' 'scar' 'erythema' ',' 'pliability' ','
 'induration' ',' 'thickness' 'at' 'enrollment' 'and' 'again' 'at' '3'
 'months']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01908777,1:48:cancer,Central nervous system or meningeal involvement,['Central' 'nervous' 'system' 'or' 'meningeal' 'involvement'],[3. 3. 3. 3. 3. 3.]
NCT01908777,1:49:cancer,Primary cutaneous anaplastic large cell lymphoma,['Primary' 'cutaneous' 'anaplastic' 'large' 'cell' 'lymphoma'],[3. 3. 3. 3. 3. 3.]
NCT01906385,9:28:treatment,"Planned stereotactic biopsy as standard of care (ie, for confirmation of disease progression)","['Planned' 'stereotactic' 'biopsy' 'as' 'standard' 'of' 'care' '(' 'ie'
 ',' 'for' 'confirmation' 'of' 'disease' 'progression' ')']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01904136,"1:41:chronic_disease,",Central nervous system (CNS) involvement within 3 months,"['Central' 'nervous' 'system' '(' 'CNS' ')' 'involvement' 'within' '3'
 'months']",[2. 2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT01902810,"12:42:chronic_disease,,",History of Congestive Heart Failure (CHF) (ejection fraction < 20%),"['History' 'of' 'Congestive' 'Heart' 'Failure' '(' 'CHF' ')' '('
 'ejection' 'fraction' '<' '20' '%' ')']",[0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01901562,6:32:chronic_disease,Have bilateral nipple discharge,['Have' 'bilateral' 'nipple' 'discharge'],[0. 2. 2. 2.]
NCT01898793,1:32:cancer,Isolated extramedullary relapse (phase II only),['Isolated' 'extramedullary' 'relapse' '(' 'phase' 'II' 'only' ')'],[3. 3. 3. 0. 0. 0. 0. 0.]
NCT01896999,",51:61:treatment,,",all females of childbearing potential must have a blood test or urine study within 24 hours prior to enrollment to rule out pregnancy,"['all' 'females' 'of' 'childbearing' 'potential' 'must' 'have' 'a' 'blood'
 'test' 'or' 'urine' 'study' 'within' '24' 'hours' 'prior' 'to'
 'enrollment' 'to' 'rule' 'out' 'pregnancy']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01895881,20:48:cancer,Known or suspected estrogen-dependent neoplasia,['Known' 'or' 'suspected' 'estrogen-dependent' 'neoplasia'],[0. 0. 0. 3. 3.]
NCT01895777,"1:13:treatment,,","Transfusions during the screening period are allowed, provided that a satisfactory hemoglobin or platelet level is attained prior to visit 2","['Transfusions' 'during' 'the' 'screening' 'period' 'are' 'allowed' ','
 'provided' 'that' 'a' 'satisfactory' 'hemoglobin' 'or' 'platelet' 'level'
 'is' 'attained' 'prior' 'to' 'visit' '2']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01894061,",53:100:treatment",3 weeks must have elapsed since the completion of a non-nitrosourea-containing chemotherapy regimen,"['3' 'weeks' 'must' 'have' 'elapsed' 'since' 'the' 'completion' 'of' 'a'
 'non-nitrosourea-containing' 'chemotherapy' 'regimen']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT01893554,31:34:chronic_disease,Currently enrolled in another RSV study,['Currently' 'enrolled' 'in' 'another' 'RSV' 'study'],[0. 0. 0. 0. 2. 0.]
NCT01893307,1:53:cancer,"Distant Metastases (Stage IV C, any T, any N and M1)","['Distant' 'Metastases' '(' 'Stage' 'IV' 'C' ',' 'any' 'T' ',' 'any' 'N'
 'and' 'M1' ')']",[3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0.]
NCT01891812,1:20:chronic_disease,developmental delay,['developmental' 'delay'],[2. 2.]
NCT01890590,1:48:treatment,Prior upper abdominal external beam irradiation,['Prior' 'upper' 'abdominal' 'external' 'beam' 'irradiation'],[1. 1. 1. 1. 1. 1.]
NCT01884740,",,136:150:treatment,,",Females of childbearing potential and fertile men will be informed as to the potential risk of procreation while participating in this research trial and will be advised that they must use effective contraception during and for a period of three months after the treatment period,"['Females' 'of' 'childbearing' 'potential' 'and' 'fertile' 'men' 'will'
 'be' 'informed' 'as' 'to' 'the' 'potential' 'risk' 'of' 'procreation'
 'while' 'participating' 'in' 'this' 'research' 'trial' 'and' 'will' 'be'
 'advised' 'that' 'they' 'must' 'use' 'effective' 'contraception' 'during'
 'and' 'for' 'a' 'period' 'of' 'three' 'months' 'after' 'the' 'treatment'
 'period']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01884740,1:40:cancer,anaplastic mixed oligoastrocytoma (AOA),['anaplastic' 'mixed' 'oligoastrocytoma' '(' 'AOA' ')'],[3. 3. 3. 3. 0. 0.]
NCT01883076,",71:104:treatment","Any condition requiring urgent, or unplanned procedure within 15 days prior to Stage II surgical repair","['Any' 'condition' 'requiring' 'urgent' ',' 'or' 'unplanned' 'procedure'
 'within' '15' 'days' 'prior' 'to' 'Stage' 'II' 'surgical' 'repair']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1.]
NCT01882153,111:128:chronic_disease,Receiving or will receive a parent delivered intervention to alleviate symptoms related to their diagnosis of autistic disorder,"['Receiving' 'or' 'will' 'receive' 'a' 'parent' 'delivered' 'intervention'
 'to' 'alleviate' 'symptoms' 'related' 'to' 'their' 'diagnosis' 'of'
 'autistic' 'disorder']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01877382,18:59:cancer,Has a history of primary central nervous system malignancy,"['Has' 'a' 'history' 'of' 'primary' 'central' 'nervous' 'system'
 'malignancy']",[0. 0. 0. 0. 3. 3. 3. 3. 3.]
NCT01876511,28:49:cancer,Patients with MSI positive non-colorectal cancer,['Patients' 'with' 'MSI' 'positive' 'non-colorectal' 'cancer'],[0. 0. 0. 0. 3. 3.]
NCT01876511,5:160:treatment,"had prior treatment with anti-PD-1 (anti-programmed cell death protein 1), anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40, anti-CD40, or anti-CTLA-4 antibodies","['had' 'prior' 'treatment' 'with' 'anti-PD-1' '(' 'anti-programmed' 'cell'
 'death' 'protein' '1' ')' ',' 'anti-PD-L1' ',' 'anti-PD-L2' ','
 'anti-CD137' ',' 'anti-OX-40' ',' 'anti-CD40' ',' 'or' 'anti-CTLA-4'
 'antibodies']","[0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01872975,1:21:treatment,Sentinel node biopsy alone,['Sentinel' 'node' 'biopsy' 'alone'],[1. 1. 1. 0.]
NCT01871727,93:110:treatment,A shorter washout may be allowed if participant is experiencing progressive disease despite ongoing treatment,"['A' 'shorter' 'washout' 'may' 'be' 'allowed' 'if' 'participant' 'is'
 'experiencing' 'progressive' 'disease' 'despite' 'ongoing' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01871727,13:42:chronic_disease,Significant pulmonary symptoms or disease,['Significant' 'pulmonary' 'symptoms' 'or' 'disease'],[0. 2. 2. 2. 2.]
NCT01869114,",122:131:treatment",Pregnant or lactating patients are ineligible for this study due to the unknown human fetal or teratogenic toxicities of rapamycin,"['Pregnant' 'or' 'lactating' 'patients' 'are' 'ineligible' 'for' 'this'
 'study' 'due' 'to' 'the' 'unknown' 'human' 'fetal' 'or' 'teratogenic'
 'toxicities' 'of' 'rapamycin']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01865162,1:29:treatment,non-cytotoxic hormonal agent,['non-cytotoxic' 'hormonal' 'agent'],[1. 1. 1.]
NCT01864265,"11:20:chronic_disease,,",Must have active RA with a DAS28 ≥3.2,['Must' 'have' 'active' 'RA' 'with' 'a' 'DAS28' '≥3.2'],[0. 0. 2. 2. 0. 0. 0. 0.]
NCT01864109,19:47:chronic_disease,in the absence of hepatic involvement of tumor,['in' 'the' 'absence' 'of' 'hepatic' 'involvement' 'of' 'tumor'],[0. 0. 0. 0. 2. 2. 2. 2.]
NCT01859819,1:26:cancer,B-Lymphoblastic lymphomas,['B-Lymphoblastic' 'lymphomas'],[3. 3.]
NCT01853163,26:56:treatment,Patient scheduled for an orthopaedic surgical procedure,['Patient' 'scheduled' 'for' 'an' 'orthopaedic' 'surgical' 'procedure'],[0. 0. 0. 0. 1. 1. 1.]
NCT01851694,1:31:treatment,Prior lung or liver transplant,['Prior' 'lung' 'or' 'liver' 'transplant'],[1. 1. 1. 1. 1.]
NCT01850758,11:14:chronic_disease,A massive ACL tear or one that includes more than 2/3'rds of the ligament that's retracted,"['A' 'massive' 'ACL' 'tear' 'or' 'one' 'that' 'includes' 'more' 'than'
 ""2/3'rds"" 'of' 'the' 'ligament' 'that' ""'s"" 'retracted']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01849146,",,53:70:treatment",Pregnant women are excluded from this study because AZD1775 (MK-1775) has potential for teratogenic or abortifacients effects,"['Pregnant' 'women' 'are' 'excluded' 'from' 'this' 'study' 'because'
 'AZD1775' '(' 'MK-1775' ')' 'has' 'potential' 'for' 'teratogenic' 'or'
 'abortifacients' 'effects']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01842399,1:13:treatment,Amphetamines,['Amphetamines'],[1.]
NCT01841957,15:33:treatment,Candidate for topical anesthesia,['Candidate' 'for' 'topical' 'anesthesia'],[0. 0. 1. 1.]
NCT01841333,"5:34:treatment,,","For non-myeloablative transplants, ≥50% CD3 donor chimerism at screening","['For' 'non-myeloablative' 'transplants' ',' '≥50' '%' 'CD3' 'donor'
 'chimerism' 'at' 'screening']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01836354,1:4:chronic_disease,TIA based on a clinical definition of focal neurologic deficits consistent with a single vascular territory of the brain,"['TIA' 'based' 'on' 'a' 'clinical' 'definition' 'of' 'focal' 'neurologic'
 'deficits' 'consistent' 'with' 'a' 'single' 'vascular' 'territory' 'of'
 'the' 'brain']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01835626,",87:110:treatment","Recent (within 4 weeks of Registration), current, or planned participation in another experimental drug study","['Recent' '(' 'within' '4' 'weeks' 'of' 'Registration' ')' ',' 'current'
 ',' 'or' 'planned' 'participation' 'in' 'another' 'experimental' 'drug'
 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT01829958,1:21:chronic_disease,Ureteral compression,['Ureteral' 'compression'],[2. 2.]
NCT01823198,46:71:treatment,Failed to achieve a cytogenetic remission to tyrosine kinase inhibitor treatment or has a cytogenetic relapse,"['Failed' 'to' 'achieve' 'a' 'cytogenetic' 'remission' 'to' 'tyrosine'
 'kinase' 'inhibitor' 'treatment' 'or' 'has' 'a' 'cytogenetic' 'relapse']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT01822522,23:42:cancer,The participant has a primary brain tumor,['The' 'participant' 'has' 'a' 'primary' 'brain' 'tumor'],[0. 0. 0. 0. 3. 3. 3.]
NCT01822522,25:46:chronic_disease,participants with known hepatitis B infection should be screened for active disease prior to study participation,"['participants' 'with' 'known' 'hepatitis' 'B' 'infection' 'should' 'be'
 'screened' 'for' 'active' 'disease' 'prior' 'to' 'study' 'participation']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01819480,21:34:cancer,Diagnosis of either oropharyngeal,['Diagnosis' 'of' 'either' 'oropharyngeal'],[0. 0. 0. 3.]
NCT01817751,18:38:chronic_disease,Known history of retinitis pigmentosa,['Known' 'history' 'of' 'retinitis' 'pigmentosa'],[0. 0. 0. 2. 2.]
NCT01815359,1:45:chronic_disease,Restrictive or obstructive pulmonary disease that would limit study compliance or place the patient at unacceptable risk for participation in the study,"['Restrictive' 'or' 'obstructive' 'pulmonary' 'disease' 'that' 'would'
 'limit' 'study' 'compliance' 'or' 'place' 'the' 'patient' 'at'
 'unacceptable' 'risk' 'for' 'participation' 'in' 'the' 'study']",[2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01812174,21:51:chronic_disease,"Patients who have a noncardiac progressive disease, which in the investigator's experience produces an unacceptable increased risk to the patient","['Patients' 'who' 'have' 'a' 'noncardiac' 'progressive' 'disease' ','
 'which' 'in' 'the' 'investigator' ""'s"" 'experience' 'produces' 'an'
 'unacceptable' 'increased' 'risk' 'to' 'the' 'patient']",[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01811368,"1:24:chronic_disease,,",Chronic viral hepatitis with total serum bilirubin > 3 mg/dL,"['Chronic' 'viral' 'hepatitis' 'with' 'total' 'serum' 'bilirubin' '>' '3'
 'mg/dL']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT01811368,36:64:chronic_disease,Patients with any of the following liver function abnormalities,"['Patients' 'with' 'any' 'of' 'the' 'following' 'liver' 'function'
 'abnormalities']",[0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT01810588,35:71:cancer,Previously Relapsed or refractory acute leukemia (myeloid or lymphoid),"['Previously' 'Relapsed' 'or' 'refractory' 'acute' 'leukemia' '('
 'myeloid' 'or' 'lymphoid' ')']",[0. 0. 0. 0. 3. 3. 3. 3. 3. 0. 0.]
NCT01809002,1:22:chronic_disease,Peripheral Neuropathy,['Peripheral' 'Neuropathy'],[2. 2.]
NCT01807897,"24:45:chronic_disease,","Physician diagnosis of chronic heart failure, American Heart Association Stage C-D","['Physician' 'diagnosis' 'of' 'chronic' 'heart' 'failure' ',' 'American'
 'Heart' 'Association' 'Stage' 'C-D']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT01807091,27:57:treatment,The benefits/risks of the induction chemotherapy regimen will be reviewed,"['The' 'benefits/risks' 'of' 'the' 'induction' 'chemotherapy' 'regimen'
 'will' 'be' 'reviewed']",[0. 0. 0. 0. 1. 1. 1. 0. 0. 0.]
NCT01804634,52:66:treatment,Patients who relapse after either single or tandem autologous BMT are eligible,"['Patients' 'who' 'relapse' 'after' 'either' 'single' 'or' 'tandem'
 'autologous' 'BMT' 'are' 'eligible']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]
NCT01804465,14:132:treatment,A history of prior treatment with ipilimumab or prior cluster of differentiation 137 (CD137) agonist or CTLA-4 inhibitor or agonist,"['A' 'history' 'of' 'prior' 'treatment' 'with' 'ipilimumab' 'or' 'prior'
 'cluster' 'of' 'differentiation' '137' '(' 'CD137' ')' 'agonist' 'or'
 'CTLA-4' 'inhibitor' 'or' 'agonist']",[0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0.]
NCT01802346,19:31:treatment,Concurrent use of somatostatin,['Concurrent' 'use' 'of' 'somatostatin'],[0. 0. 0. 1.]
NCT01799538,14:17:chronic_disease,Diagnosis of LAM,['Diagnosis' 'of' 'LAM'],[0. 0. 2.]
NCT01799538,1:14:treatment,tissue biopsy,['tissue' 'biopsy'],[1. 1.]
NCT01795313,"1:16:treatment,",Tetanus vaccine during therapy or within 1 week prior to enrollment,"['Tetanus' 'vaccine' 'during' 'therapy' 'or' 'within' '1' 'week' 'prior'
 'to' 'enrollment']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01794793,48:75:treatment,"Patient has been permanently discontinued from pasireotide study treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason","['Patient' 'has' 'been' 'permanently' 'discontinued' 'from' 'pasireotide'
 'study' 'treatment' 'in' 'the' 'parent' 'study' 'due' 'to' 'unacceptable'
 'toxicity' ',' 'non-compliance' 'to' 'study' 'procedures' ','
 'withdrawal' 'of' 'consent' 'or' 'any' 'other' 'reason']","[0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01794559,24:50:chronic_disease,primary diagnosis of a DSM-IV depressive disorder,['primary' 'diagnosis' 'of' 'a' 'DSM-IV' 'depressive' 'disorder'],[0. 0. 0. 0. 2. 2. 2.]
NCT01791543,12:37:allergy_name,Allergy to radiographic contrast dye,['Allergy' 'to' 'radiographic' 'contrast' 'dye'],[0. 0. 4. 4. 4.]
NCT01791543,1:23:chronic_disease,Ventricular arrhythmia is recurrent and symptomatic,['Ventricular' 'arrhythmia' 'is' 'recurrent' 'and' 'symptomatic'],[2. 2. 0. 0. 0. 0.]
NCT01787682,"54:81:chronic_disease,,,","Clinically stable condition and not suffering from a respiratory tract infection or exacerbation of their disease (defined as a combination of increased cough, sputum purulence, shortness of breath, systemic symptoms such as fever, and a decrease in FEV1 > 10% compared with values when clinically stable in the preceding year) at least 4 weeks prior to the first test day","['Clinically' 'stable' 'condition' 'and' 'not' 'suffering' 'from' 'a'
 'respiratory' 'tract' 'infection' 'or' 'exacerbation' 'of' 'their'
 'disease' '(' 'defined' 'as' 'a' 'combination' 'of' 'increased' 'cough'
 ',' 'sputum' 'purulence' ',' 'shortness' 'of' 'breath' ',' 'systemic'
 'symptoms' 'such' 'as' 'fever' ',' 'and' 'a' 'decrease' 'in' 'FEV1' '>'
 '10' '%' 'compared' 'with' 'values' 'when' 'clinically' 'stable' 'in'
 'the' 'preceding' 'year' ')' 'at' 'least' '4' 'weeks' 'prior' 'to' 'the'
 'first' 'test' 'day']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01787682,"8:64:treatment,",Use of protein or amino acid containing nutritional supplements within 5 days of first study day,"['Use' 'of' 'protein' 'or' 'amino' 'acid' 'containing' 'nutritional'
 'supplements' 'within' '5' 'days' 'of' 'first' 'study' 'day']",[0. 0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01787409,13:38:cancer,Dim surface immunoglobulin expression,['Dim' 'surface' 'immunoglobulin' 'expression'],[0. 0. 3. 3.]
NCT01787409,26:100:treatment,patients can begin their chemotherapy while awaiting vitamin D results and treatment arm assignment,"['patients' 'can' 'begin' 'their' 'chemotherapy' 'while' 'awaiting'
 'vitamin' 'D' 'results' 'and' 'treatment' 'arm' 'assignment']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT01782599,"19:53:treatment,,",Be willing to use Nicotine Replacement Therapy (NRT) and the e-cigarette for a period of 2 to 3 weeks,"['Be' 'willing' 'to' 'use' 'Nicotine' 'Replacement' 'Therapy' '(' 'NRT'
 ')' 'and' 'the' 'e-cigarette' 'for' 'a' 'period' 'of' '2' 'to' '3'
 'weeks']",[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01776190,59:70:treatment,You will need to participate in four physician visits and blood draws,"['You' 'will' 'need' 'to' 'participate' 'in' 'four' 'physician' 'visits'
 'and' 'blood' 'draws']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01774019,57:78:treatment,"Surgically altered biliary tract anatomy, not including prior cholecystectomy","['Surgically' 'altered' 'biliary' 'tract' 'anatomy' ',' 'not' 'including'
 'prior' 'cholecystectomy']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01773707,38:51:chronic_disease,Have serological evidence of current CMV infection,['Have' 'serological' 'evidence' 'of' 'current' 'CMV' 'infection'],[0. 0. 0. 0. 0. 2. 2.]
NCT01773395,34:97:allergy_name,History of allergic reactions to compounds of similar chemical or biologic composition to GM-CSF,"['History' 'of' 'allergic' 'reactions' 'to' 'compounds' 'of' 'similar'
 'chemical' 'or' 'biologic' 'composition' 'to' 'GM-CSF']",[0. 0. 0. 0. 0. 4. 4. 4. 4. 4. 4. 4. 4. 4.]
NCT01766297,7:32:cancer,Known BRCA 1 or BRCA 2 mutation,['Known' 'BRCA' '1' 'or' 'BRCA' '2' 'mutation'],[0. 3. 3. 3. 3. 3. 3.]
NCT01766297,39:55:cancer,Patient does not have microscopically multifocal tumor,['Patient' 'does' 'not' 'have' 'microscopically' 'multifocal' 'tumor'],[0. 0. 0. 0. 0. 3. 3.]
NCT01760655,",16:41:chronic_disease",Greater than 3 cytogenetic abnormalities or any one of the following cytogenetic abnormalities,"['Greater' 'than' '3' 'cytogenetic' 'abnormalities' 'or' 'any' 'one' 'of'
 'the' 'following' 'cytogenetic' 'abnormalities']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01760005,"24:74:treatment,",Have been exposed to a monoclonal antibody targeting beta amyloid peptide within the past six months,"['Have' 'been' 'exposed' 'to' 'a' 'monoclonal' 'antibody' 'targeting'
 'beta' 'amyloid' 'peptide' 'within' 'the' 'past' 'six' 'months']",[0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT01757418,9:17:treatment,current estrogen use,['current' 'estrogen' 'use'],[0. 1. 0.]
NCT01756040,8:16:chronic_disease,Severe asphyxia,['Severe' 'asphyxia'],[0. 2.]
NCT01754779,1:15:chronic_disease,Hypercalciuric CaP stone formers,['Hypercalciuric' 'CaP' 'stone' 'formers'],[2. 0. 0. 0.]
NCT01754298,14:18:chronic_disease,Diagnosis of JOCD,['Diagnosis' 'of' 'JOCD'],[0. 0. 2.]
NCT01753986,18:53:treatment,Participation in Batterer Intervention Program in RI,['Participation' 'in' 'Batterer' 'Intervention' 'Program' 'in' 'RI'],[0. 0. 1. 1. 1. 1. 1.]
NCT01750567,24:39:chronic_disease,Patient with confirmed del11q mutation may be included if untreated,"['Patient' 'with' 'confirmed' 'del11q' 'mutation' 'may' 'be' 'included'
 'if' 'untreated']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT01742299,48:66:treatment,"Patient has been permanently discontinued from imatinib treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason","['Patient' 'has' 'been' 'permanently' 'discontinued' 'from' 'imatinib'
 'treatment' 'in' 'the' 'parent' 'study' 'due' 'to' 'unacceptable'
 'toxicity' ',' 'non-compliance' 'to' 'study' 'procedures' ','
 'withdrawal' 'of' 'consent' 'or' 'any' 'other' 'reason']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT01737502,1:25:cancer,Non-melanoma skin cancer,['Non-melanoma' 'skin' 'cancer'],[3. 3. 3.]
NCT01737502,1:26:cancer,localized prostate cancer,['localized' 'prostate' 'cancer'],[3. 3. 3.]
NCT01734512,1:22:cancer,Pilocytic Astrocytoma - 90600112,['Pilocytic' 'Astrocytoma' '-' '90600112'],[3. 3. 0. 0.]
NCT01730794,1:10:chronic_disease,Hypoxemic or hypercapnic acute respiratory failure,['Hypoxemic' 'or' 'hypercapnic' 'acute' 'respiratory' 'failure'],[2. 0. 0. 0. 0. 0.]
NCT01726257,30:43:treatment,Anatomic eligibility for the Nellix System per the instructions,"['Anatomic' 'eligibility' 'for' 'the' 'Nellix' 'System' 'per' 'the'
 'instructions']",[0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT01726257,1:12:chronic_disease,Psychiatric or other condition that may interfere with the study,"['Psychiatric' 'or' 'other' 'condition' 'that' 'may' 'interfere' 'with'
 'the' 'study']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01720836,1:15:cancer,Stage IA(T1NO),['Stage' 'IA' '(' 'T1NO' ')'],[3. 3. 0. 0. 0.]
NCT01716806,",56:78:treatment",Measurable disease of at least 1.5 cm as documented by radiographic technique,"['Measurable' 'disease' 'of' 'at' 'least' '1.5' 'cm' 'as' 'documented'
 'by' 'radiographic' 'technique']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01714596,48:59:treatment,Cultures positive in thio only after operative debridement,"['Cultures' 'positive' 'in' 'thio' 'only' 'after' 'operative'
 'debridement']",[0. 0. 0. 0. 0. 0. 0. 1.]
NCT01714596,124:155:treatment,"Patients who, based upon the clinical judgment of the treating clinician, are NOT equally suited for treatment with either oral or intravenous antibiotics (i.e., those for whom there is a clinical treatment preference)","['Patients' 'who' ',' 'based' 'upon' 'the' 'clinical' 'judgment' 'of'
 'the' 'treating' 'clinician' ',' 'are' 'NOT' 'equally' 'suited' 'for'
 'treatment' 'with' 'either' 'oral' 'or' 'intravenous' 'antibiotics' '('
 'i.e.' ',' 'those' 'for' 'whom' 'there' 'is' 'a' 'clinical' 'treatment'
 'preference' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01712308,"27:57:treatment,",Use of any MPN-associated myelofibrosis-directed therapy within 2 weeks prior to study day 1,"['Use' 'of' 'any' 'MPN-associated' 'myelofibrosis-directed' 'therapy'
 'within' '2' 'weeks' 'prior' 'to' 'study' 'day' '1']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01705119,9:32:treatment,who are mechanically ventilated,['who' 'are' 'mechanically' 'ventilated'],[0. 0. 1. 1.]
NCT01703117,1:20:chronic_disease,Lactose intolerance,['Lactose' 'intolerance'],[2. 2.]
NCT01703117,6:30:chronic_disease,with mild Alzheimer's disease determined after neurological and neuropsychological evaluation following the National Institute on Aging - Alzheimer's disease Association criteria that recently revisited the NINCDS-ADRDA criteria,"['with' 'mild' 'Alzheimer' ""'s"" 'disease' 'determined' 'after'
 'neurological' 'and' 'neuropsychological' 'evaluation' 'following' 'the'
 'National' 'Institute' 'on' 'Aging' '-' 'Alzheimer' ""'s"" 'disease'
 'Association' 'criteria' 'that' 'recently' 'revisited' 'the'
 'NINCDS-ADRDA' 'criteria']","[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT01697865,1:18:chronic_disease,Advanced dementia,['Advanced' 'dementia'],[2. 2.]
NCT01697371,1:23:chronic_disease,Active liver infection,['Active' 'liver' 'infection'],[2. 2. 2.]
NCT01697293,"1:24:treatment,,",Electrocardiogram (ECG) corrected QT (QTC) < 450 msec,"['Electrocardiogram' '(' 'ECG' ')' 'corrected' 'QT' '(' 'QTC' ')' '<'
 '450' 'msec']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01696734,"24:45:chronic_disease,,,,,,,,,",Clinically significant electrolyte disorders including sodium < 130 or > 145 and/or potassium < 3.0 or > 5.5 and/or magnesium < 1.6 or > 2.6,"['Clinically' 'significant' 'electrolyte' 'disorders' 'including' 'sodium'
 '<' '130' 'or' '>' '145' 'and/or' 'potassium' '<' '3.0' 'or' '>' '5.5'
 'and/or' 'magnesium' '<' '1.6' 'or' '>' '2.6']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT01696734,1:12:chronic_disease,heart block,['heart' 'block'],[2. 2.]
NCT01695967,1:23:chronic_disease,craniofacial anomalies,['craniofacial' 'anomalies'],[2. 2.]
NCT01690468,",,97:146:cancer",Patients must be disease-free of prior invasive malignancies for >2 years with the exception of basal cell or squamous cell carcinoma of the skin,"['Patients' 'must' 'be' 'disease-free' 'of' 'prior' 'invasive'
 'malignancies' 'for' '>' '2' 'years' 'with' 'the' 'exception' 'of'
 'basal' 'cell' 'or' 'squamous' 'cell' 'carcinoma' 'of' 'the' 'skin']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 3. 3.
 3.]"
NCT01688388,27:39:cancer,Any hormonal receptor and HER-2 status,['Any' 'hormonal' 'receptor' 'and' 'HER-2' 'status'],[0. 0. 0. 0. 3. 3.]
NCT01684904,1:22:treatment,Endoscopic ultrasound,['Endoscopic' 'ultrasound'],[1. 1.]
NCT01684397,13:46:chronic_disease,Symptomatic peripheral arterial disease (PAD),['Symptomatic' 'peripheral' 'arterial' 'disease' '(' 'PAD' ')'],[0. 2. 2. 2. 2. 0. 0.]
NCT01681589,13:33:chronic_disease,Presence of focal motor deficits in the upper extremities,"['Presence' 'of' 'focal' 'motor' 'deficits' 'in' 'the' 'upper'
 'extremities']",[0. 0. 2. 2. 2. 0. 0. 0. 0.]
NCT01676753,43:82:allergy_name,Patient has known hypersensitivity to the components of study drug or its analogs,"['Patient' 'has' 'known' 'hypersensitivity' 'to' 'the' 'components' 'of'
 'study' 'drug' 'or' 'its' 'analogs']",[0. 0. 0. 0. 0. 0. 4. 4. 4. 4. 4. 4. 4.]
NCT01676259,18:28:allergy_name,Known allergy to sesame oil,['Known' 'allergy' 'to' 'sesame' 'oil'],[0. 0. 0. 4. 4.]
NCT01676259,13:49:chronic_disease,symptomatic peripheral arterial vascular disease,['symptomatic' 'peripheral' 'arterial' 'vascular' 'disease'],[0. 2. 2. 2. 2.]
NCT01672138,27:44:treatment,Patients undergoing first catheter ablation for drug-refractory Persistent (PerAF) or long-standing persistent AF (LSPAF),"['Patients' 'undergoing' 'first' 'catheter' 'ablation' 'for'
 'drug-refractory' 'Persistent' '(' 'PerAF' ')' 'or' 'long-standing'
 'persistent' 'AF' '(' 'LSPAF' ')']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01668602,1:20:chronic_disease,Orthopedic problems in the lower limbs or spine (or other medical conditions) that limit walking,"['Orthopedic' 'problems' 'in' 'the' 'lower' 'limbs' 'or' 'spine' '(' 'or'
 'other' 'medical' 'conditions' ')' 'that' 'limit' 'walking']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01666665,1:26:chronic_disease,Acute or chronic acidosis (lactic or any other metabolic type),"['Acute' 'or' 'chronic' 'acidosis' '(' 'lactic' 'or' 'any' 'other'
 'metabolic' 'type' ')']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01666080,1:16:treatment,Transplantation using sufficiently matched related donors (such as matched siblings) or unrelated donors,"['Transplantation' 'using' 'sufficiently' 'matched' 'related' 'donors' '('
 'such' 'as' 'matched' 'siblings' ')' 'or' 'unrelated' 'donors']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01660607,1:29:chronic_disease,Myeloproliferative syndromes,['Myeloproliferative' 'syndromes'],[2. 2.]
NCT01660607,1:15:chronic_disease,hepatitis C ab,['hepatitis' 'C' 'ab'],[2. 2. 2.]
NCT01659203,23:73:cancer,Histologically proven primary soft tissue sarcoma of the retroperitoneum,"['Histologically' 'proven' 'primary' 'soft' 'tissue' 'sarcoma' 'of' 'the'
 'retroperitoneum']",[0. 0. 3. 3. 3. 3. 3. 3. 3.]
NCT01653093,8:43:treatment,in the perioperative liver transplantation period,['in' 'the' 'perioperative' 'liver' 'transplantation' 'period'],[0. 0. 1. 1. 1. 0.]
NCT01652092,1:19:chronic_disease,Griscelli Syndrome,['Griscelli' 'Syndrome'],[2. 2.]
NCT01652092,1:21:chronic_disease,Reticular dysgenesis,['Reticular' 'dysgenesis'],[2. 2.]
NCT01648023,"1:44:chronic_disease,","Active bacterial, viral or fungal infection within 72 hours of study entry","['Active' 'bacterial' ',' 'viral' 'or' 'fungal' 'infection' 'within' '72'
 'hours' 'of' 'study' 'entry']",[2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT01648023,84:101:treatment,that would place the patient at undue risk and that would preclude the safe use of chemoembolization or would interfere with study participation,"['that' 'would' 'place' 'the' 'patient' 'at' 'undue' 'risk' 'and' 'that'
 'would' 'preclude' 'the' 'safe' 'use' 'of' 'chemoembolization' 'or'
 'would' 'interfere' 'with' 'study' 'participation']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01647321,23:63:chronic_disease,clinical diagnosis of secondary progressive multiple sclerosis,"['clinical' 'diagnosis' 'of' 'secondary' 'progressive' 'multiple'
 'sclerosis']",[0. 0. 0. 2. 2. 2. 2.]
NCT01643460,",,77:101:treatment",Patients referred between January 2009 and February 2016 to EUS at IUMC for pancreatic cyst ablation and with no contraindications for anticipated safe and successful performance of the procedure,"['Patients' 'referred' 'between' 'January' '2009' 'and' 'February' '2016'
 'to' 'EUS' 'at' 'IUMC' 'for' 'pancreatic' 'cyst' 'ablation' 'and' 'with'
 'no' 'contraindications' 'for' 'anticipated' 'safe' 'and' 'successful'
 'performance' 'of' 'the' 'procedure']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT01639508,1:15:treatment,ROS1 infustion,['ROS1' 'infustion'],[1. 1.]
NCT01631617,1:18:chronic_disease,Atopic Dermatitis Patients,['Atopic' 'Dermatitis' 'Patients'],[2. 2. 0.]
NCT01631617,1:22:chronic_disease,chronic skin diseases,['chronic' 'skin' 'diseases'],[2. 2. 2.]
NCT01626079,61:77:treatment,Insufficient mobile leaflet available for grasping with the MitraClip device,"['Insufficient' 'mobile' 'leaflet' 'available' 'for' 'grasping' 'with'
 'the' 'MitraClip' 'device']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01626079,",,,63:76:treatment","New York Heart Association (NYHA) Functional Class II, III or ambulatory IV","['New' 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'Functional' 'Class'
 'II' ',' 'III' 'or' 'ambulatory' 'IV']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01626079,44:47:treatment,Subjects who have any contraindications to CPX and are not capable of performing CPX per investigator's assessment should not be registered in the CPX Sub-study,"['Subjects' 'who' 'have' 'any' 'contraindications' 'to' 'CPX' 'and' 'are'
 'not' 'capable' 'of' 'performing' 'CPX' 'per' 'investigator' ""'s""
 'assessment' 'should' 'not' 'be' 'registered' 'in' 'the' 'CPX'
 'Sub-study']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01626079,",,70:74:treatment",a greater than 100% increase or greater than 50% decrease in dose of GDMT,"['a' 'greater' 'than' '100' '%' 'increase' 'or' 'greater' 'than' '50' '%'
 'decrease' 'in' 'dose' 'of' 'GDMT']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01625234,15:33:cancer,Patients with primary CNS tumors,['Patients' 'with' 'primary' 'CNS' 'tumors'],[0. 0. 3. 3. 3.]
NCT01624090,",47:76:treatment",At least 3 half-lives must have elapsed since monoclonal antibody treatment,"['At' 'least' '3' 'half-lives' 'must' 'have' 'elapsed' 'since'
 'monoclonal' 'antibody' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT01624090,1:13:treatment,Dipyridamole,['Dipyridamole'],[1.]
NCT01624090,36:68:chronic_disease,Patients with any of the following pulmonary function abnormalities,"['Patients' 'with' 'any' 'of' 'the' 'following' 'pulmonary' 'function'
 'abnormalities']",[0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT01624090,1:14:treatment,Valproic acid,['Valproic' 'acid'],[1. 1.]
NCT01622868,7:11:treatment,Prior WBRT,['Prior' 'WBRT'],[0. 1.]
NCT01620216,1:10:treatment,Sorafenib,['Sorafenib'],[1.]
NCT01617161,",95:125:treatment,",Must have complete history and physical examination within 45 days of study entry and digital rectal examination of prostate within 180 days of study entry,"['Must' 'have' 'complete' 'history' 'and' 'physical' 'examination'
 'within' '45' 'days' 'of' 'study' 'entry' 'and' 'digital' 'rectal'
 'examination' 'of' 'prostate' 'within' '180' 'days' 'of' 'study' 'entry']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0.
 0.]"
NCT01614990,",54:69:treatment,,","Co-administration of drugs that prolong QT interval, CYP3A4 inducers, QTc equal to or greater than 450ms at screening","['Co-administration' 'of' 'drugs' 'that' 'prolong' 'QT' 'interval' ','
 'CYP3A4' 'inducers' ',' 'QTc' 'equal' 'to' 'or' 'greater' 'than' '450ms'
 'at' 'screening']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01614197,",64:73:treatment",At least 3 half-lives must have elapsed after the last dose of GVHD meds,"['At' 'least' '3' 'half-lives' 'must' 'have' 'elapsed' 'after' 'the'
 'last' 'dose' 'of' 'GVHD' 'meds']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01614197,108:119:treatment,Patients with known optic nerve and/or retinal involvement (because it may not be possible to safely delay irradiation) are not eligible,"['Patients' 'with' 'known' 'optic' 'nerve' 'and/or' 'retinal'
 'involvement' '(' 'because' 'it' 'may' 'not' 'be' 'possible' 'to'
 'safely' 'delay' 'irradiation' ')' 'are' 'not' 'eligible']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT01604512,25:56:treatment,Any contraindication to gadolinium intravenous contrast as per standard Department of Radiology contrast guidelines,"['Any' 'contraindication' 'to' 'gadolinium' 'intravenous' 'contrast' 'as'
 'per' 'standard' 'Department' 'of' 'Radiology' 'contrast' 'guidelines']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01600040,1:32:cancer,uterine papillary serous cancer,['uterine' 'papillary' 'serous' 'cancer'],[3. 3. 3. 3.]
NCT01597518,"21:41:treatment,",Able to receive the Investigational Drug within 12 hours of injury,"['Able' 'to' 'receive' 'the' 'Investigational' 'Drug' 'within' '12'
 'hours' 'of' 'injury']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01597518,21:42:chronic_disease,Injury arising from penetrating mechanism,['Injury' 'arising' 'from' 'penetrating' 'mechanism'],[0. 0. 0. 2. 2.]
NCT01597518,1:20:treatment,Phenylpropanolamine,['Phenylpropanolamine'],[1.]
NCT01597518,1:9:treatment,Zileuton,['Zileuton'],[1.]
NCT01595529,14:35:chronic_disease,A child with phenylketonuria (PKU),['A' 'child' 'with' 'phenylketonuria' '(' 'PKU' ')'],[0. 0. 0. 2. 2. 0. 0.]
NCT01595529,"15:39:treatment,",Enrollment in another antibiotic study less than 30 days prior to enrollment visit,"['Enrollment' 'in' 'another' 'antibiotic' 'study' 'less' 'than' '30'
 'days' 'prior' 'to' 'enrollment' 'visit']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01595529,1:15:chronic_disease,hydronephrosis,['hydronephrosis'],[2.]
NCT01591356,",,,,,,,,319:343:treatment","Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study and for at least 3 months after completion of EphA2 siRNA-DOPC therapy","['Female' 'subject' 'is' 'either' 'post-menopausal' 'or' 'surgically'
 'sterilized' 'or' 'willing' 'to' 'use' 'an' 'acceptable' 'method' 'of'
 'birth' 'control' '(' 'i.e.' ',' 'a' 'hormonal' 'contraceptive' ','
 'intrauterine' 'device' ',' 'diaphragm' 'with' 'spermicide' ',' 'condom'
 'with' 'spermicide' ',' 'or' 'abstinence' ')' 'for' 'the' 'duration' 'of'
 'the' 'study' 'and' 'for' 'at' 'least' '3' 'months' 'after' 'completion'
 'of' 'EphA2' 'siRNA-DOPC' 'therapy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 1.]"
NCT01589263,12:36:chronic_disease,History of bladder calculi (stones),['History' 'of' 'bladder' 'calculi' '(' 'stones' ')'],[0. 0. 2. 2. 2. 0. 0.]
NCT01589263,",45:90:treatment","This decision can be based on PSA velocity, previous TRUS (transrectal ultrasound) biopsy, percent free PSA, or other clinical estimations in keeping with sound urologic care","['This' 'decision' 'can' 'be' 'based' 'on' 'PSA' 'velocity' ',' 'previous'
 'TRUS' '(' 'transrectal' 'ultrasound' ')' 'biopsy' ',' 'percent' 'free'
 'PSA' ',' 'or' 'other' 'clinical' 'estimations' 'in' 'keeping' 'with'
 'sound' 'urologic' 'care']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT01584076,7:29:chronic_disease,Known psychological problems,['Known' 'psychological' 'problems'],[0. 2. 2.]
NCT01584076,12:51:treatment,history of prior amblyopia treatment with patching,['history' 'of' 'prior' 'amblyopia' 'treatment' 'with' 'patching'],[0. 0. 1. 1. 1. 1. 1.]
NCT01581580,19:42:treatment,good benefit from dopaminergic medication but associated with insufficient duration of action or unacceptable side-effects,"['good' 'benefit' 'from' 'dopaminergic' 'medication' 'but' 'associated'
 'with' 'insufficient' 'duration' 'of' 'action' 'or' 'unacceptable'
 'side-effects']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01573754,12:41:chronic_disease,Documented porphyria cutanea tarda (PCT),['Documented' 'porphyria' 'cutanea' 'tarda' '(' 'PCT' ')'],[0. 2. 2. 2. 2. 0. 0.]
NCT01572480,"1:14:treatment,",Immunoparesis with reduction of 2 uninvolved immunoglobulin isotypes,"['Immunoparesis' 'with' 'reduction' 'of' '2' 'uninvolved' 'immunoglobulin'
 'isotypes']",[1. 0. 0. 0. 0. 0. 0. 0.]
NCT01570998,1:11:cancer,High grade,['High' 'grade'],[3. 3.]
NCT01570998,1:14:cancer,Node positive patients,['Node' 'positive' 'patients'],[3. 3. 0.]
NCT01570816,1:22:chronic_disease,autoimmune deficiency,['autoimmune' 'deficiency'],[2. 2.]
NCT01568918,1:29:treatment,Cervical Anterior Corpectomy,['Cervical' 'Anterior' 'Corpectomy'],[1. 1. 1.]
NCT01568918,1:21:treatment,Cervical Laminectomy,['Cervical' 'Laminectomy'],[1. 1.]
NCT01568918,1:18:treatment,Lumbar Discectomy (METRx or Open),['Lumbar' 'Discectomy' '(' 'METRx' 'or' 'Open' ')'],[1. 1. 0. 0. 0. 0. 0.]
NCT01568918,1:29:treatment,Lumbar Posterolateral Fusion,['Lumbar' 'Posterolateral' 'Fusion'],[1. 1. 1.]
NCT01568255,1:15:chronic_disease,Myopathic pain that cannot be attributed to other medical conditions,"['Myopathic' 'pain' 'that' 'can' 'not' 'be' 'attributed' 'to' 'other'
 'medical' 'conditions']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01568177,1:17:chronic_disease,esophageal spasm,['esophageal' 'spasm'],[2. 2.]
NCT01562626,1:5:treatment,5-FC,['5-FC'],[1.]
NCT01562626,1:21:chronic_disease,patent foramen ovale,['patent' 'foramen' 'ovale'],[2. 2. 2.]
NCT01555905,19:40:chronic_disease,No diagnosis of a neuromusuclar disease,['No' 'diagnosis' 'of' 'a' 'neuromusuclar' 'disease'],[0. 0. 0. 0. 2. 2.]
NCT01555554,13:33:treatment,They are on beta blocker therapy at the time of the preoperative baseline assessment,"['They' 'are' 'on' 'beta' 'blocker' 'therapy' 'at' 'the' 'time' 'of' 'the'
 'preoperative' 'baseline' 'assessment']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01554371,62:86:cancer,Patient must have histologically or cytologically documented solid tumor malignancies,"['Patient' 'must' 'have' 'histologically' 'or' 'cytologically'
 'documented' 'solid' 'tumor' 'malignancies']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT01553942,8:22:chronic_disease,"Active hepatitis B, C","['Active' 'hepatitis' 'B' ',' 'C']",[0. 2. 2. 2. 0.]
NCT01553214,1:16:treatment,Lithium therapy,['Lithium' 'therapy'],[1. 1.]
NCT01547429,1:18:chronic_disease,Mentally retarded patients,['Mentally' 'retarded' 'patients'],[2. 2. 0.]
NCT01543490,13:24:chronic_disease,symptomatic blepharitis,['symptomatic' 'blepharitis'],[0. 2.]
NCT01539109,1:37:treatment,Concurrent upper limb rehabilitation,['Concurrent' 'upper' 'limb' 'rehabilitation'],[1. 1. 1. 1.]
NCT01538966,21:37:chronic_disease,"The patient has any mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study, and/or evidence of an uncooperative attitude","['The' 'patient' 'has' 'any' 'mental' 'condition' 'rendering' 'the'
 'patient' 'unable' 'to' 'understand' 'the' 'nature' ',' 'scope' ',' 'and'
 'possible' 'consequences' 'of' 'the' 'study' ',' 'and/or' 'evidence' 'of'
 'an' 'uncooperative' 'attitude']","[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01532687,5:37:treatment,Any prior treatment with gemcitabine,['Any' 'prior' 'treatment' 'with' 'gemcitabine'],[0. 1. 1. 1. 1.]
NCT01532687,1:24:treatment,Injectable progesterone,['Injectable' 'progesterone'],[1. 1.]
NCT01532687,1:38:treatment,prior to the first dose of study drug and for the duration of the study,"['prior' 'to' 'the' 'first' 'dose' 'of' 'study' 'drug' 'and' 'for' 'the'
 'duration' 'of' 'the' 'study']",[1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01530958,1:19:chronic_disease,impaired cognition,['impaired' 'cognition'],[2. 2.]
NCT01525901,1:13:chronic_disease,valvulopathy,['valvulopathy'],[2.]
NCT01522768,61:70:treatment,Known or suspected active drug or alcohol abuse. Restricted Therapies,"['Known' 'or' 'suspected' 'active' 'drug' 'or' 'alcohol' 'abuse' '.'
 'Restricted' 'Therapies']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01512888,25:32:chronic_disease,A clinical diagnosis of SCID-X1 documented in the medical record,"['A' 'clinical' 'diagnosis' 'of' 'SCID-X1' 'documented' 'in' 'the'
 'medical' 'record']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT01508390,48:61:treatment,Must be able to tolerate the confinement of an MRI procedure,"['Must' 'be' 'able' 'to' 'tolerate' 'the' 'confinement' 'of' 'an' 'MRI'
 'procedure']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01505569,1:15:cancer,Hepatoblastoma - metastatic at time of diagnosis and/or relapsed after therapy,"['Hepatoblastoma' '-' 'metastatic' 'at' 'time' 'of' 'diagnosis' 'and/or'
 'relapsed' 'after' 'therapy']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01505569,"17:27:cancer,,",Other High Risk CNS Tumors - to be approved by 2 or more physicians (at least one oncologist and one BMT physician),"['Other' 'High' 'Risk' 'CNS' 'Tumors' '-' 'to' 'be' 'approved' 'by' '2'
 'or' 'more' 'physicians' '(' 'at' 'least' 'one' 'oncologist' 'and' 'one'
 'BMT' 'physician' ')']",[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01505569,1:27:cancer,"extraneural metastases, M4","['extraneural' 'metastases' ',' 'M4']",[3. 3. 3. 0.]
NCT01505062,",,140:149:treatment",agree to use an effective form of contraception such as the contraceptive pill or intra uterine device for at least three months following SAR421869 administration,"['agree' 'to' 'use' 'an' 'effective' 'form' 'of' 'contraception' 'such'
 'as' 'the' 'contraceptive' 'pill' 'or' 'intra' 'uterine' 'device' 'for'
 'at' 'least' 'three' 'months' 'following' 'SAR421869' 'administration']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0.]"
NCT01504373,1:33:treatment,Uncuffed endotracheal tube (ETT),['Uncuffed' 'endotracheal' 'tube' '(' 'ETT' ')'],[1. 1. 1. 1. 0. 0.]
NCT01500551,1:11:chronic_disease,Infections,['Infections'],[2.]
NCT01495637,27:44:chronic_disease,"presence of a new, severe neurologic injury at the time of enrollment which, in the opinion of the treating physician, is highly likely to lead to a diagnosis of brain death","['presence' 'of' 'a' 'new' ',' 'severe' 'neurologic' 'injury' 'at' 'the'
 'time' 'of' 'enrollment' 'which' ',' 'in' 'the' 'opinion' 'of' 'the'
 'treating' 'physician' ',' 'is' 'highly' 'likely' 'to' 'lead' 'to' 'a'
 'diagnosis' 'of' 'brain' 'death']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01494662,68:89:treatment,These patients may include those who have received or not received previous treatment(s) for their CNS,"['These' 'patients' 'may' 'include' 'those' 'who' 'have' 'received' 'or'
 'not' 'received' 'previous' 'treatment' '(' 's' ')' 'for' 'their' 'CNS']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT01481974,6:31:chronic_disease,Have fulminant hepatic failure,['Have' 'fulminant' 'hepatic' 'failure'],[0. 2. 2. 2.]
NCT01474889,"8:14:treatment,,",Use of RT-CGM (continuous glucose monitor) within last 4 weeks,"['Use' 'of' 'RT-CGM' '(' 'continuous' 'glucose' 'monitor' ')' 'within'
 'last' '4' 'weeks']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01465100,7:34:chronic_disease,Known biopterin synthesis defects,['Known' 'biopterin' 'synthesis' 'defects'],[0. 2. 2. 2.]
NCT01464164,1:4:chronic_disease,DBA diagnosed,['DBA' 'diagnosed'],[2. 0.]
NCT01461837,1:33:chronic_disease,Hemoglobin S Beta0/+ thalassemia,['Hemoglobin' 'S' 'Beta0/+' 'thalassemia'],[2. 2. 2. 2.]
NCT01459107,158:185:treatment,"Conditions that, in the opinion of the study team, may impact the immunomodulatory protocol potentially exposing the recipient to an unacceptable risk under immunosuppressive treatment","['Conditions' 'that' ',' 'in' 'the' 'opinion' 'of' 'the' 'study' 'team'
 ',' 'may' 'impact' 'the' 'immunomodulatory' 'protocol' 'potentially'
 'exposing' 'the' 'recipient' 'to' 'an' 'unacceptable' 'risk' 'under'
 'immunosuppressive' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1.]"
NCT01459107,75:108:treatment,Patient agrees to comply with the protocol and states a dedication to the immunomodulatory treatment regime,"['Patient' 'agrees' 'to' 'comply' 'with' 'the' 'protocol' 'and' 'states'
 'a' 'dedication' 'to' 'the' 'immunomodulatory' 'treatment' 'regime']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT01459107,1:45:chronic_disease,Type I (insulin-dependent) diabetes mellitus,['Type' 'I' '(' 'insulin-dependent' ')' 'diabetes' 'mellitus'],[2. 2. 2. 2. 2. 0. 0.]
NCT01449149,1:19:cancer,cutaneous squamous,['cutaneous' 'squamous'],[3. 3.]
NCT01445821,"9:30:chronic_disease,,",Diffuse cutaneous scleroderma with involvement proximal to the elbow or knee and a Rodnan score (see Appendix V) of > 14,"['Diffuse' 'cutaneous' 'scleroderma' 'with' 'involvement' 'proximal' 'to'
 'the' 'elbow' 'or' 'knee' 'and' 'a' 'Rodnan' 'score' '(' 'see' 'Appendix'
 'V' ')' 'of' '>' '14']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01444209,36:74:treatment,Patients who are unable to undergo placement of a stereotactic head frame,"['Patients' 'who' 'are' 'unable' 'to' 'undergo' 'placement' 'of' 'a'
 'stereotactic' 'head' 'frame']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1.]
NCT01436968,21:75:treatment,Planning to undergo standard prostate-only external beam radiation therapy,"['Planning' 'to' 'undergo' 'standard' 'prostate-only' 'external' 'beam'
 'radiation' 'therapy']",[0. 0. 0. 1. 1. 1. 1. 1. 1.]
NCT01433315,41:68:treatment,those taking any medications other than non-sedating antihistamines or oral contraceptives,"['those' 'taking' 'any' 'medications' 'other' 'than' 'non-sedating'
 'antihistamines' 'or' 'oral' 'contraceptives']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT01430390,1:19:chronic_disease,cardiac conditions,['cardiac' 'conditions'],[2. 2.]
NCT01422746,24:56:chronic_disease,Significant history of cardiac or pulmonary dysfunction,['Significant' 'history' 'of' 'cardiac' 'or' 'pulmonary' 'dysfunction'],[0. 0. 0. 2. 2. 2. 2.]
NCT01421810,"10:43:treatment,",Abnormal thyroid stimulating hormone (TSH) for age,['Abnormal' 'thyroid' 'stimulating' 'hormone' '(' 'TSH' ')' 'for' 'age'],[0. 1. 1. 1. 1. 0. 0. 0. 0.]
NCT01421095,",41:61:treatment",A minimum of 1 year since completion of gonoadotoxic therapy,"['A' 'minimum' 'of' '1' 'year' 'since' 'completion' 'of' 'gonoadotoxic'
 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01421095,1:24:treatment,unilateral oophorectomy,['unilateral' 'oophorectomy'],[1. 1.]
NCT01419561,"19:33:chronic_disease,","Exposure risk for KSHV infection (including being a first or second generation immigrant from an endemic area, or male-to-male sexual activity) or evidence of KSHV infection","['Exposure' 'risk' 'for' 'KSHV' 'infection' '(' 'including' 'being' 'a'
 'first' 'or' 'second' 'generation' 'immigrant' 'from' 'an' 'endemic'
 'area' ',' 'or' 'male-to-male' 'sexual' 'activity' ')' 'or' 'evidence'
 'of' 'KSHV' 'infection']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT01415882,",69:97:treatment","Recovered (i.e., < grade 1 toxicity) from the reversible effects of prior antineoplastic therapy","['Recovered' '(' 'i.e.' ',' '<' 'grade' '1' 'toxicity' ')' 'from' 'the'
 'reversible' 'effects' 'of' 'prior' 'antineoplastic' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT01407809,1:18:chronic_disease,Visual field loss,['Visual' 'field' 'loss'],[2. 2. 2.]
NCT01389024,41:54:allergy_name,"Allergy or previous adverse reaction to pentobarbital, if used at the participating center","['Allergy' 'or' 'previous' 'adverse' 'reaction' 'to' 'pentobarbital' ','
 'if' 'used' 'at' 'the' 'participating' 'center']",[0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0.]
NCT01389024,",47:63:chronic_disease",Participants whose MRI show a silent or overt cerebral infarct,"['Participants' 'whose' 'MRI' 'show' 'a' 'silent' 'or' 'overt' 'cerebral'
 'infarct']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01379573,81:84:chronic_disease,"Identification of any of the following structural lesions considered causal for CHB, i.e., those that could account for block because of fibrous disruption between the atrium and AV node or due to absence of the penetrating bundles of the AV node","['Identification' 'of' 'any' 'of' 'the' 'following' 'structural' 'lesions'
 'considered' 'causal' 'for' 'CHB' ',' 'i.e.' ',' 'those' 'that' 'could'
 'account' 'for' 'block' 'because' 'of' 'fibrous' 'disruption' 'between'
 'the' 'atrium' 'and' 'AV' 'node' 'or' 'due' 'to' 'absence' 'of' 'the'
 'penetrating' 'bundles' 'of' 'the' 'AV' 'node']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01379573,1:12:chronic_disease,heterotaxia,['heterotaxia'],[2.]
NCT01373099,49:70:treatment,Infection of a revision as opposed to a primary total hip arthroplast,"['Infection' 'of' 'a' 'revision' 'as' 'opposed' 'to' 'a' 'primary' 'total'
 'hip' 'arthroplast']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT01367444,"5:28:treatment,",Any injectable intravitreal treatment to the treated eye or intravitreal device in the treated eye within 6 months prior to screening,"['Any' 'injectable' 'intravitreal' 'treatment' 'to' 'the' 'treated' 'eye'
 'or' 'intravitreal' 'device' 'in' 'the' 'treated' 'eye' 'within' '6'
 'months' 'prior' 'to' 'screening']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01367444,",,,107:131:treatment",Males must agree with their partner to use two forms of contraception for at least three months following SAR422459 administration,"['Males' 'must' 'agree' 'with' 'their' 'partner' 'to' 'use' 'two' 'forms'
 'of' 'contraception' 'for' 'at' 'least' 'three' 'months' 'following'
 'SAR422459' 'administration']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01367444,",,,,114:123:treatment",Reduction in macular mean sensitivity of ≥5 dB or reduction in hill of vision by >14 dB-sr as assessed by static perimetry,"['Reduction' 'in' 'macular' 'mean' 'sensitivity' 'of' '≥5' 'dB' 'or'
 'reduction' 'in' 'hill' 'of' 'vision' 'by' '>' '14' 'dB-sr' 'as'
 'assessed' 'by' 'static' 'perimetry']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01366612,1:29:chronic_disease,chronic myelogenous leukemia,['chronic' 'myelogenous' 'leukemia'],[2. 2. 2.]
NCT01360606,"11:29:cancer,","Extensive liver tumor burden, defined as more than 75% of the liver","['Extensive' 'liver' 'tumor' 'burden' ',' 'defined' 'as' 'more' 'than'
 '75' '%' 'of' 'the' 'liver']",[0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01356290,27:59:allergy_name,Known hypersensitivity to any of the drugs in the protocol,"['Known' 'hypersensitivity' 'to' 'any' 'of' 'the' 'drugs' 'in' 'the'
 'protocol']",[0. 0. 0. 4. 4. 4. 4. 4. 4. 4.]
NCT01345344,1:30:chronic_disease,comorbid acute pain condition,['comorbid' 'acute' 'pain' 'condition'],[2. 2. 2. 2.]
NCT01333046,15:44:chronic_disease,Patients with severe intercurrent infection,['Patients' 'with' 'severe' 'intercurrent' 'infection'],[0. 0. 2. 2. 2.]
NCT01326715,93:116:treatment,"Evidence of abnormal permeability of the brain or cerebrospinal fluid, based on a screening gadolinium-enhacned MRI scancan","['Evidence' 'of' 'abnormal' 'permeability' 'of' 'the' 'brain' 'or'
 'cerebrospinal' 'fluid' ',' 'based' 'on' 'a' 'screening'
 'gadolinium-enhacned' 'MRI' 'scancan']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT01313533,1:17:chronic_disease,Comorbid illness making 2 year survival unlikely,['Comorbid' 'illness' 'making' '2' 'year' 'survival' 'unlikely'],[2. 2. 0. 0. 0. 0. 0.]
NCT01312857,1:30:treatment,Prior treatment with HAI FUDR,['Prior' 'treatment' 'with' 'HAI' 'FUDR'],[1. 1. 1. 1. 1.]
NCT01293214,"24:64:treatment,",Willing to comply with extensive post-transplant rehabilitation for a minimum of two years,"['Willing' 'to' 'comply' 'with' 'extensive' 'post-transplant'
 'rehabilitation' 'for' 'a' 'minimum' 'of' 'two' 'years']",[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT01280669,"1:20:treatment,",Intraocular surgery within 90 days prior to Day 0 in the study eye,"['Intraocular' 'surgery' 'within' '90' 'days' 'prior' 'to' 'Day' '0' 'in'
 'the' 'study' 'eye']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01270724,15:21:cancer,Patients with ICGCTs who are newly diagnosed,['Patients' 'with' 'ICGCTs' 'who' 'are' 'newly' 'diagnosed'],[0. 0. 3. 0. 0. 0. 0.]
NCT01261728,9:85:treatment,Ongoing treatment with therapeutic doses of warfarin or low molecular weight heparin,"['Ongoing' 'treatment' 'with' 'therapeutic' 'doses' 'of' 'warfarin' 'or'
 'low' 'molecular' 'weight' 'heparin']",[0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT01261728,1:27:treatment,prior intravesical therapy,['prior' 'intravesical' 'therapy'],[1. 1. 1.]
NCT01245712,30:56:treatment,Treatment plan that includes regional nodal irradiation,['Treatment' 'plan' 'that' 'includes' 'regional' 'nodal' 'irradiation'],[0. 0. 0. 0. 1. 1. 1.]
NCT01243931,"109:112:treatment,",Patients with vision primarily limited by superficial opacities and irregularities that could be removed by PTK while leaving at least 250 µm,"['Patients' 'with' 'vision' 'primarily' 'limited' 'by' 'superficial'
 'opacities' 'and' 'irregularities' 'that' 'could' 'be' 'removed' 'by'
 'PTK' 'while' 'leaving' 'at' 'least' '250' 'µm']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01238120,",57:80:treatment,",Be scheduled to receive at least 2 additional cycles of oral or IV chemotherapy over the 42-day study period,"['Be' 'scheduled' 'to' 'receive' 'at' 'least' '2' 'additional' 'cycles'
 'of' 'oral' 'or' 'IV' 'chemotherapy' 'over' 'the' '42-day' 'study'
 'period']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT01220583,15:48:treatment,No concurrent erythropoiesis-stimulating agents,['No' 'concurrent' 'erythropoiesis-stimulating' 'agents'],[0. 0. 1. 1.]
NCT01189786,",,45:57:chronic_disease","Active, acute GvHD > grade II or extensive, chronic GvHD","['Active' ',' 'acute' 'GvHD' '>' 'grade' 'II' 'or' 'extensive' ','
 'chronic' 'GvHD']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01189786,"1:22:chronic_disease,,,","Pulmonary dysfunction (FEV1, FVC or DLCO 40% of predicted or 3 SD below normal)","['Pulmonary' 'dysfunction' '(' 'FEV1' ',' 'FVC' 'or' 'DLCO' '40' '%' 'of'
 'predicted' 'or' '3' 'SD' 'below' 'normal' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01187368,1:33:chronic_disease,Severe right ventricular failure,['Severe' 'right' 'ventricular' 'failure'],[2. 2. 2. 2.]
NCT01185210,"53:61:treatment,,,,",positive breath test after ingestion of 25 grams of fructose defined as either (a) ≥ 20 ppm rise of breath H2/CH4/both over baseline values or a successive rise of ≥ 5 ppm over baseline and in 3 consecutive breath samples,"['positive' 'breath' 'test' 'after' 'ingestion' 'of' '25' 'grams' 'of'
 'fructose' 'defined' 'as' 'either' '(' 'a' ')' '≥' '20' 'ppm' 'rise' 'of'
 'breath' 'H2/CH4/both' 'over' 'baseline' 'values' 'or' 'a' 'successive'
 'rise' 'of' '≥' '5' 'ppm' 'over' 'baseline' 'and' 'in' '3' 'consecutive'
 'breath' 'samples']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01185132,"1:4:chronic_disease,,",PTV to ipsilateral breast ratio (IBR) ≤ 25 %,['PTV' 'to' 'ipsilateral' 'breast' 'ratio' '(' 'IBR' ')' '≤' '25' '%'],[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01184547,1:10:chronic_disease,Arthritis,['Arthritis'],[2.]
NCT01175044,12:27:allergy_name,Allergy to povidone iodine,['Allergy' 'to' 'povidone' 'iodine'],[0. 0. 4. 4.]
NCT01174121,24:49:treatment,Refractory to approved standard systemic therapy,['Refractory' 'to' 'approved' 'standard' 'systemic' 'therapy'],[0. 0. 0. 1. 1. 1.]
NCT01140087,30:55:treatment,Willing and able to continue immunosuppression regimen as directed by treating physician,"['Willing' 'and' 'able' 'to' 'continue' 'immunosuppression' 'regimen' 'as'
 'directed' 'by' 'treating' 'physician']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01128816,15:45:treatment,Presence of a left-ventricular assist device,['Presence' 'of' 'a' 'left-ventricular' 'assist' 'device'],[0. 0. 0. 1. 1. 1.]
NCT01087294,",,140:160:treatment",Donors greater than or equal to 18 years of age must be the same individual whose cells were used as the source for the patient s original stem cell transplant,"['Donors' 'greater' 'than' 'or' 'equal' 'to' '18' 'years' 'of' 'age'
 'must' 'be' 'the' 'same' 'individual' 'whose' 'cells' 'were' 'used' 'as'
 'the' 'source' 'for' 'the' 'patient' 's' 'original' 'stem' 'cell'
 'transplant']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 1.]"
NCT01072370,19:38:chronic_disease,Presence of known chromosomal anomaly,['Presence' 'of' 'known' 'chromosomal' 'anomaly'],[0. 0. 0. 2. 2.]
NCT01061515,62:75:treatment,"Appropriate studies will be undertaken in patients receiving HAART therapy, when indicated","['Appropriate' 'studies' 'will' 'be' 'undertaken' 'in' 'patients'
 'receiving' 'HAART' 'therapy' ',' 'when' 'indicated']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT01059786,"1:11:treatment,",cladribine for 6 months prior to study entry,['cladribine' 'for' '6' 'months' 'prior' 'to' 'study' 'entry'],[1. 0. 0. 0. 0. 0. 0. 0.]
NCT01050855,1:34:chronic_disease,Severe combined immune deficiency,['Severe' 'combined' 'immune' 'deficiency'],[2. 2. 2. 2.]
NCT01045148,13:36:cancer,Evidence of distant metastases (M1),['Evidence' 'of' 'distant' 'metastases' '(' 'M1' ')'],[0. 0. 3. 3. 3. 0. 0.]
NCT01037790,",,,158:174:treatment",Sexually active subjects (male and female) must use accepted methods of contraception during the course of the study and for 3 months after the last dose of protocol drug(s),"['Sexually' 'active' 'subjects' '(' 'male' 'and' 'female' ')' 'must' 'use'
 'accepted' 'methods' 'of' 'contraception' 'during' 'the' 'course' 'of'
 'the' 'study' 'and' 'for' '3' 'months' 'after' 'the' 'last' 'dose' 'of'
 'protocol' 'drug' '(' 's' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]"
NCT01028846,1:21:chronic_disease,hypercholesterolemia,['hypercholesterolemia'],[2.]
NCT01011777,1:30:chronic_disease,Grade V vesicoureteral reflux (Grade IV findings plus loss of the papillary impression and ureteral tortuosity),"['Grade' 'V' 'vesicoureteral' 'reflux' '(' 'Grade' 'IV' 'findings' 'plus'
 'loss' 'of' 'the' 'papillary' 'impression' 'and' 'ureteral' 'tortuosity'
 ')']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01011777,"136:151:treatment,",Urinalysis and urine culture demonstrating either no bacterial growth or growth of an organism that can be treated with an appropriate oral antibiotic for 7 days preoperatively,"['Urinalysis' 'and' 'urine' 'culture' 'demonstrating' 'either' 'no'
 'bacterial' 'growth' 'or' 'growth' 'of' 'an' 'organism' 'that' 'can' 'be'
 'treated' 'with' 'an' 'appropriate' 'oral' 'antibiotic' 'for' '7' 'days'
 'preoperatively']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.
 0. 0. 0.]"
NCT00980538,79:82:allergy_name,Previously demonstrated clinically significant allergy or hypersensitivity to ETR or to any of the excipients of ETR,"['Previously' 'demonstrated' 'clinically' 'significant' 'allergy' 'or'
 'hypersensitivity' 'to' 'ETR' 'or' 'to' 'any' 'of' 'the' 'excipients'
 'of' 'ETR']",[0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00975520,26:54:cancer,Histologically confirmed neurotropic primary melanoma,['Histologically' 'confirmed' 'neurotropic' 'primary' 'melanoma'],[0. 0. 3. 3. 3.]
NCT00969332,1:36:treatment,Extracorporeal Membrane Oxygenation,['Extracorporeal' 'Membrane' 'Oxygenation'],[1. 1. 1.]
NCT00967785,29:48:chronic_disease,Signs or symptoms of active microbial infection,['Signs' 'or' 'symptoms' 'of' 'active' 'microbial' 'infection'],[0. 0. 0. 0. 0. 2. 2.]
NCT00967577,28:47:allergy_name,Prior allergic reaction to Gadolinium contrast,['Prior' 'allergic' 'reaction' 'to' 'Gadolinium' 'contrast'],[0. 0. 0. 0. 4. 4.]
NCT00959140,"1:14:treatment,",chest CT scan within 14 days of registration,['chest' 'CT' 'scan' 'within' '14' 'days' 'of' 'registration'],[1. 1. 1. 0. 0. 0. 0. 0.]
NCT00930228,10:13:treatment,Abnormal TSH,['Abnormal' 'TSH'],[0. 1.]
NCT00929006,12:37:chronic_disease,Persistent liver panel abnormalities,['Persistent' 'liver' 'panel' 'abnormalities'],[0. 2. 2. 2.]
NCT00926237,"1:9:chronic_disease,",Tinnitus present for at least 6 months and severe enough to seek medical attention,"['Tinnitus' 'present' 'for' 'at' 'least' '6' 'months' 'and' 'severe'
 'enough' 'to' 'seek' 'medical' 'attention']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00924027,81:96:cancer,Patients who can not undergo resection because of poor lung function or distant lung metastasis,"['Patients' 'who' 'can' 'not' 'undergo' 'resection' 'because' 'of' 'poor'
 'lung' 'function' 'or' 'distant' 'lung' 'metastasis']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0.]
NCT00919503,382:399:treatment,DONOR: HLA-matched sibling cord blood exclusions: Any cord blood units that have not passed donor screening for infectious disease markers as recommended by the National Marrow Donor Project (NMDP) will not be used unless a waiver is signed by the clinical attending allowing use of cord blood unit; cord blood units are presumed to be cytomegalovirus (CMV) negative regardless of serologic testing due to passive transmission of maternal CMV antibodies,"['DONOR' ':' 'HLA-matched' 'sibling' 'cord' 'blood' 'exclusions' ':' 'Any'
 'cord' 'blood' 'units' 'that' 'have' 'not' 'passed' 'donor' 'screening'
 'for' 'infectious' 'disease' 'markers' 'as' 'recommended' 'by' 'the'
 'National' 'Marrow' 'Donor' 'Project' '(' 'NMDP' ')' 'will' 'not' 'be'
 'used' 'unless' 'a' 'waiver' 'is' 'signed' 'by' 'the' 'clinical'
 'attending' 'allowing' 'use' 'of' 'cord' 'blood' 'unit' ';' 'cord'
 'blood' 'units' 'are' 'presumed' 'to' 'be' 'cytomegalovirus' '(' 'CMV'
 ')' 'negative' 'regardless' 'of' 'serologic' 'testing' 'due' 'to'
 'passive' 'transmission' 'of' 'maternal' 'CMV' 'antibodies']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT00914823,"17:34:chronic_disease,",Patients with a macroprolactinoma confirmed on MRI imaging,"['Patients' 'with' 'a' 'macroprolactinoma' 'confirmed' 'on' 'MRI'
 'imaging']",[0. 0. 0. 2. 0. 0. 0. 0.]
NCT00914628,21:39:treatment,Contraindication to haploidentical HCT as defined by the Investigator,"['Contraindication' 'to' 'haploidentical' 'HCT' 'as' 'defined' 'by' 'the'
 'Investigator']",[0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT00909909,1:31:cancer,Colloidal (mucinous) carcinoma,['Colloidal' '(' 'mucinous' ')' 'carcinoma'],[3. 3. 3. 0. 0.]
NCT00909909,4:31:cancer,No Paget disease of the nipple,['No' 'Paget' 'disease' 'of' 'the' 'nipple'],[0. 3. 3. 3. 3. 3.]
NCT00909909,1:18:cancer,Tubular carcinoma,['Tubular' 'carcinoma'],[3. 3.]
NCT00904046,"1:18:treatment,",Thiazolidinedione use in the preceding 18 months,['Thiazolidinedione' 'use' 'in' 'the' 'preceding' '18' 'months'],[1. 0. 0. 0. 0. 0. 0.]
NCT00896493,1:17:chronic_disease,HIV seronegative,['HIV' 'seronegative'],[2. 2.]
NCT00887146,70:82:treatment,Tissue must have been determined to have local 1p/9q co-deletion and IDH mutation prior to submission for central path review,"['Tissue' 'must' 'have' 'been' 'determined' 'to' 'have' 'local' '1p/9q'
 'co-deletion' 'and' 'IDH' 'mutation' 'prior' 'to' 'submission' 'for'
 'central' 'path' 'review']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT00881660,18:21:chronic_disease,Extremely Severe CDH,['Extremely' 'Severe' 'CDH'],[0. 0. 2.]
NCT00881660,46:60:chronic_disease,Suspicion of major recognized syndrome (e.g. Fryns syndrome) on ultrasound or MRI,"['Suspicion' 'of' 'major' 'recognized' 'syndrome' '(' 'e.g' '.' 'Fryns'
 'syndrome' ')' 'on' 'ultrasound' 'or' 'MRI']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT00871260,1:41:chronic_disease,Acute ST-elevation myocardial infarction,['Acute' 'ST-elevation' 'myocardial' 'infarction'],[2. 2. 2. 2.]
NCT00862433,1:18:treatment,Insulin treatment,['Insulin' 'treatment'],[1. 1.]
NCT00857207,12:42:chronic_disease,History of pre-morbid learning disability,['History' 'of' 'pre-morbid' 'learning' 'disability'],[0. 0. 2. 2. 2.]
NCT00840047,",17:26:treatment,",More than 6 MET PET scans within the previous 12 months,"['More' 'than' '6' 'MET' 'PET' 'scans' 'within' 'the' 'previous' '12'
 'months']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT00819208,1:11:cancer,T4 lesions,['T4' 'lesions'],[3. 3.]
NCT00799864,34:75:chronic_disease,Patient has any currently active Acquired Immunodeficiency Syndrome (AIDS) defining illness,"['Patient' 'has' 'any' 'currently' 'active' 'Acquired' 'Immunodeficiency'
 'Syndrome' '(' 'AIDS' ')' 'defining' 'illness']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0.]
NCT00788164,1:9:chronic_disease,Impetigo,['Impetigo'],[2.]
NCT00788164,15:51:cancer,No concurrent adenocarcinoma in situ of the cervix,['No' 'concurrent' 'adenocarcinoma' 'in' 'situ' 'of' 'the' 'cervix'],[0. 0. 3. 3. 3. 3. 3. 3.]
NCT00788164,21:47:chronic_disease,Proven or suspected immunosuppressive disorder,['Proven' 'or' 'suspected' 'immunosuppressive' 'disorder'],[0. 0. 0. 2. 2.]
NCT00788164,1:25:cancer,nonmelanoma skin lesions,['nonmelanoma' 'skin' 'lesions'],[3. 3. 3.]
NCT00737893,1:48:chronic_disease,Nonarteritic Anterior Ischemic Optic Neuropathy,['Nonarteritic' 'Anterior' 'Ischemic' 'Optic' 'Neuropathy'],[2. 2. 2. 2. 2.]
NCT00737893,49:92:allergy_name,The patient has contraindications to the use of phosphodiesterase type 5 (PDE 5) inhibitors,"['The' 'patient' 'has' 'contraindications' 'to' 'the' 'use' 'of'
 'phosphodiesterase' 'type' '5' '(' 'PDE' '5' ')' 'inhibitors']",[0. 0. 0. 0. 0. 0. 0. 0. 4. 4. 4. 4. 4. 4. 0. 0.]
NCT00737893,18:23:chronic_disease,condition called NAION,['condition' 'called' 'NAION'],[0. 0. 2.]
NCT00720785,1:29:chronic_disease,Active Hepatitis B infection (Hep B surface antigen positive),"['Active' 'Hepatitis' 'B' 'infection' '(' 'Hep' 'B' 'surface' 'antigen'
 'positive' ')']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT00720785,",,81:91:treatment","Peripheral neuropathy of grade greater than 1, which would require reduction of bortezomib dose","['Peripheral' 'neuropathy' 'of' 'grade' 'greater' 'than' '1' ',' 'which'
 'would' 'require' 'reduction' 'of' 'bortezomib' 'dose']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT00720785,1:32:cancer,metastatic epithelial neoplasms,['metastatic' 'epithelial' 'neoplasms'],[3. 3. 3.]
NCT00719888,"87:117:cancer,","Conditioning regimen selection should be based on the underlying disease, presence of minimum residual disease (MRD), age, co-morbidities, attending physician, and site preference","['Conditioning' 'regimen' 'selection' 'should' 'be' 'based' 'on' 'the'
 'underlying' 'disease' ',' 'presence' 'of' 'minimum' 'residual' 'disease'
 '(' 'MRD' ')' ',' 'age' ',' 'co-morbidities' ',' 'attending' 'physician'
 ',' 'and' 'site' 'preference']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT00719888,",,42:73:treatment",blasts must be < 10% by a representative bone marrow aspirate morphology,"['blasts' 'must' 'be' '<' '10' '%' 'by' 'a' 'representative' 'bone'
 'marrow' 'aspirate' 'morphology']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT00719888,90:107:treatment,to be eligible in first chronic phase (CP1) patient must have failed or be intolerant to imatinib mesylate,"['to' 'be' 'eligible' 'in' 'first' 'chronic' 'phase' '(' 'CP1' ')'
 'patient' 'must' 'have' 'failed' 'or' 'be' 'intolerant' 'to' 'imatinib'
 'mesylate']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT00716066,1:34:chronic_disease,Lambert-Eaton myasthenic syndrome,['Lambert-Eaton' 'myasthenic' 'syndrome'],[2. 2. 2.]
NCT00716066,73:106:chronic_disease,Patients must satisfy the criteria for a diagnosis of one of the severe neurological autoimmune disorders outlined,"['Patients' 'must' 'satisfy' 'the' 'criteria' 'for' 'a' 'diagnosis' 'of'
 'one' 'of' 'the' 'severe' 'neurological' 'autoimmune' 'disorders'
 'outlined']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0.]
NCT00716066,1:22:chronic_disease,Stiff Person Syndrome,['Stiff' 'Person' 'Syndrome'],[2. 2. 2.]
NCT00715611,",,42:72:cancer",at the participating site of stage I-III malignant pleural mesothelioma,"['at' 'the' 'participating' 'site' 'of' 'stage' 'I-III' 'malignant'
 'pleural' 'mesothelioma']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 3.]
NCT00713492,"25:56:treatment,",Daily or regular use of prescription or OTC medications known to interact with alcohol in the 2-week period prior to assessment,"['Daily' 'or' 'regular' 'use' 'of' 'prescription' 'or' 'OTC' 'medications'
 'known' 'to' 'interact' 'with' 'alcohol' 'in' 'the' '2-week' 'period'
 'prior' 'to' 'assessment']",[0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00711373,35:57:chronic_disease,No serious co-existing medical or psycho-social problems,['No' 'serious' 'co-existing' 'medical' 'or' 'psycho-social' 'problems'],[0. 0. 0. 0. 0. 2. 2.]
NCT00703105,28:53:treatment,Patients who have received prior anti-tumor vaccines are ineligible,"['Patients' 'who' 'have' 'received' 'prior' 'anti-tumor' 'vaccines' 'are'
 'ineligible']",[0. 0. 0. 0. 1. 1. 1. 0. 0.]
NCT00678145,1:13:chronic_disease,Heart attack,['Heart' 'attack'],[2. 2.]
NCT00673842,1:33:treatment,Cardiac Resynchronization device,['Cardiac' 'Resynchronization' 'device'],[1. 1. 1.]
NCT00673842,1:30:treatment,cardiac resynchronization ICD,['cardiac' 'resynchronization' 'ICD'],[1. 1. 1.]
NCT00670358,1:37:chronic_disease,Psychiatric illness/social situation that would preclude compliance with study requirements,"['Psychiatric' 'illness/social' 'situation' 'that' 'would' 'preclude'
 'compliance' 'with' 'study' 'requirements']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT00632853,10:46:treatment,No prior mediastinal or thoracic radiotherapy,['No' 'prior' 'mediastinal' 'or' 'thoracic' 'radiotherapy'],[0. 0. 1. 1. 1. 1.]
NCT00630253,",,,44:66:chronic_disease,","In patients 18-60 years of age, moderately severe aplastic anemia is defined as having at least one","['In' 'patients' '18-60' 'years' 'of' 'age' ',' 'moderately' 'severe'
 'aplastic' 'anemia' 'is' 'defined' 'as' 'having' 'at' 'least' 'one']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT00625417,1:19:treatment,radical mastectomy,['radical' 'mastectomy'],[1. 1.]
NCT00594217,",12:35:chronic_disease",Women with abnormal renal function,['Women' 'with' 'abnormal' 'renal' 'function'],[0. 0. 2. 2. 2.]
NCT00540761,1:21:chronic_disease,Kidney insufficiency,['Kidney' 'insufficiency'],[2. 2.]
NCT00539162,8:30:cancer,Active non-ovarian malignancy,['Active' 'non-ovarian' 'malignancy'],[0. 3. 3.]
NCT00488696,1:29:chronic_disease,Free rupture of the aneurysm,['Free' 'rupture' 'of' 'the' 'aneurysm'],[2. 2. 2. 2. 2.]
NCT00483249,1:17:chronic_disease,Aortic aneurysms,['Aortic' 'aneurysms'],[2. 2.]
NCT00472329,32:62:treatment,Any patient who has rejected a previous allogeneic transplant (related or unrelated) rejection based on chimerism data from peripheral blood specimens showing loss of donor T Cells,"['Any' 'patient' 'who' 'has' 'rejected' 'a' 'previous' 'allogeneic'
 'transplant' '(' 'related' 'or' 'unrelated' ')' 'rejection' 'based' 'on'
 'chimerism' 'data' 'from' 'peripheral' 'blood' 'specimens' 'showing'
 'loss' 'of' 'donor' 'T' 'Cells']","[0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT00467987,8:20:treatment,Use of testosterone in the past,['Use' 'of' 'testosterone' 'in' 'the' 'past'],[0. 0. 1. 0. 0. 0.]
NCT00409435,"30:44:treatment,",Patients must not have taken pyridostigmine in the past month,"['Patients' 'must' 'not' 'have' 'taken' 'pyridostigmine' 'in' 'the' 'past'
 'month']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT00391170,24:41:chronic_disease,Clinically significant oral chronic GVHD at the time of the screening,"['Clinically' 'significant' 'oral' 'chronic' 'GVHD' 'at' 'the' 'time' 'of'
 'the' 'screening']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT00383656,"22:37:treatment,",who have not been on gonadal steroid preparations for at least 1 month,"['who' 'have' 'not' 'been' 'on' 'gonadal' 'steroid' 'preparations' 'for'
 'at' 'least' '1' 'month']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT00358657,"15:41:chronic_disease,,","Patients with metabolic storage diseases who have severe central nervous system (CNS) involvement of disease, defined as intelligence quotient (IQ) score < 70","['Patients' 'with' 'metabolic' 'storage' 'diseases' 'who' 'have' 'severe'
 'central' 'nervous' 'system' '(' 'CNS' ')' 'involvement' 'of' 'disease'
 ',' 'defined' 'as' 'intelligence' 'quotient' '(' 'IQ' ')' 'score' '<'
 '70']","[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT00357565,"1:25:treatment,",Myeloablative transplant within the last 6 months,['Myeloablative' 'transplant' 'within' 'the' 'last' '6' 'months'],[1. 1. 0. 0. 0. 0. 0.]
NCT00351611,30:50:treatment,patients currently receiving pregabalin treatment,['patients' 'currently' 'receiving' 'pregabalin' 'treatment'],[0. 0. 0. 1. 1.]
NCT00338065,15:39:chronic_disease,Patients with normal-pressure glaucoma,['Patients' 'with' 'normal-pressure' 'glaucoma'],[0. 0. 2. 2.]
NCT00293475,56:66:treatment,cytology (analysis from cerebral spinal fluid [CSF] or vitrectomy),"['cytology' '(' 'analysis' 'from' 'cerebral' 'spinal' 'fluid' '[' 'CSF'
 ']' 'or' 'vitrectomy' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT00291525,1:28:treatment,Concomitant cardiac surgery,['Concomitant' 'cardiac' 'surgery'],[1. 1. 1.]
NCT00291525,1:20:chronic_disease,Neurological events,['Neurological' 'events'],[2. 2.]
NCT00291525,",17:45:treatment",Women receiving estrogen replacement therapy,['Women' 'receiving' 'estrogen' 'replacement' 'therapy'],[0. 0. 1. 1. 1.]
NCT00285935,"4:12:treatment,",No vaccines for at least 4 weeks prior to baseline blood draw (including the flu shot),"['No' 'vaccines' 'for' 'at' 'least' '4' 'weeks' 'prior' 'to' 'baseline'
 'blood' 'draw' '(' 'including' 'the' 'flu' 'shot' ')']",[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00230607,24:38:treatment,agree to adhere to the Fabry Registry recommended schedule of assessments for medical history,"['agree' 'to' 'adhere' 'to' 'the' 'Fabry' 'Registry' 'recommended'
 'schedule' 'of' 'assessments' 'for' 'medical' 'history']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT00209235,70:94:chronic_disease,the growth hormone sufficient participants must meet the criteria of idiopathic short stature or SGA indication,"['the' 'growth' 'hormone' 'sufficient' 'participants' 'must' 'meet' 'the'
 'criteria' 'of' 'idiopathic' 'short' 'stature' 'or' 'SGA' 'indication']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0.]
NCT00186927,23:26:chronic_disease,household member with URI,['household' 'member' 'with' 'URI'],[0. 0. 0. 2.]
NCT00147056,43:58:treatment,Able to communicate sensations during the ExAblate MRGFUS procedure,"['Able' 'to' 'communicate' 'sensations' 'during' 'the' 'ExAblate' 'MRGFUS'
 'procedure']",[0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT00147056,13:37:chronic_disease,Symptomatic coronary artery stenosis,['Symptomatic' 'coronary' 'artery' 'stenosis'],[0. 2. 2. 2.]
NCT00085982,25:50:chronic_disease,"Clinically significant, severe insulin resistance","['Clinically' 'significant' ',' 'severe' 'insulin' 'resistance']",[0. 0. 0. 2. 2. 2.]
NCT00085982,56:71:treatment,The inclusion criteria should include any patient with extreme insulin resistance who has appropriately low leptin levels,"['The' 'inclusion' 'criteria' 'should' 'include' 'any' 'patient' 'with'
 'extreme' 'insulin' 'resistance' 'who' 'has' 'appropriately' 'low'
 'leptin' 'levels']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT00044304,1:23:chronic_disease,dysplastic eosinophils on peripheral smear,['dysplastic' 'eosinophils' 'on' 'peripheral' 'smear'],[2. 2. 0. 0. 0.]
NCT00001651,79:93:treatment,"Adequate venous access in the arms for blood drawing and 5 day infusions, and lymphapheresis","['Adequate' 'venous' 'access' 'in' 'the' 'arms' 'for' 'blood' 'drawing'
 'and' '5' 'day' 'infusions' ',' 'and' 'lymphapheresis']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT00001337,1:31:cancer,mediastinal gray zone lymphoma,['mediastinal' 'gray' 'zone' 'lymphoma'],[3. 3. 3. 3.]
NCT02990481,"29:32:chronic_disease,34:45:chronic_disease,47:58:chronic_disease","Known active infection with HIV, hepatitis B, hepatitis C","['Known' 'active' 'infection' 'with' 'HIV' ',' 'hepatitis' 'B' ','
 'hepatitis' 'C']",[0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0.]
NCT02654236,"34:45:chronic_disease,47:58:chronic_disease,63:66:chronic_disease","Known co-existing infection with hepatitis C, hepatitis B, or HIV","['Known' 'co-existing' 'infection' 'with' 'hepatitis' 'C' ',' 'hepatitis'
 'B' ',' 'or' 'HIV']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 2.]
NCT02648282,"42:45:chronic_disease,47:58:chronic_disease,63:74:chronic_disease","who have known history of infection with HIV, hepatitis B, or hepatitis C","['who' 'have' 'known' 'history' 'of' 'infection' 'with' 'HIV' ','
 'hepatitis' 'B' ',' 'or' 'hepatitis' 'C']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0.]
NCT02579967,"1:4:chronic_disease,15:26:chronic_disease,63:74:chronic_disease","HIV negative, hepatitis B virus surface antigen negative, and hepatitis C virus antibody negative","['HIV' 'negative' ',' 'hepatitis' 'B' 'virus' 'surface' 'antigen'
 'negative' ',' 'and' 'hepatitis' 'C' 'virus' 'antibody' 'negative']",[2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02574455,"22:25:chronic_disease,36:47:chronic_disease,61:72:chronic_disease","Patients known to be HIV positive, hepatitis B positive, or hepatitis C positive","['Patients' 'known' 'to' 'be' 'HIV' 'positive' ',' 'hepatitis' 'B'
 'positive' ',' 'or' 'hepatitis' 'C' 'positive']",[0. 0. 0. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02281409,"26:29:chronic_disease,31:42:chronic_disease,44:55:chronic_disease","An existing diagnosis of HIV, hepatitis B, hepatitis C, or any current laboratory findings or clinical signs and symptoms that suggest these conditions","['An' 'existing' 'diagnosis' 'of' 'HIV' ',' 'hepatitis' 'B' ','
 'hepatitis' 'C' ',' 'or' 'any' 'current' 'laboratory' 'findings' 'or'
 'clinical' 'signs' 'and' 'symptoms' 'that' 'suggest' 'these' 'conditions']","[0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02278315,"18:21:chronic_disease,23:34:chronic_disease,38:49:chronic_disease","Known history of HIV, hepatitis C or hepatitis B infection","['Known' 'history' 'of' 'HIV' ',' 'hepatitis' 'C' 'or' 'hepatitis' 'B'
 'infection']",[0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0.]
NCT01876511,"51:54:chronic_disease,56:67:chronic_disease,72:83:chronic_disease","Patients who have known history of infection with HIV, hepatitis B, or hepatitis C","['Patients' 'who' 'have' 'known' 'history' 'of' 'infection' 'with' 'HIV'
 ',' 'hepatitis' 'B' ',' 'or' 'hepatitis' 'C']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0.]
NCT01087294,"16:19:chronic_disease,30:41:chronic_disease,72:83:chronic_disease","Donors must be HIV negative, hepatitis B surface antigen negative, and hepatitis C antibody negative","['Donors' 'must' 'be' 'HIV' 'negative' ',' 'hepatitis' 'B' 'surface'
 'antigen' 'negative' ',' 'and' 'hepatitis' 'C' 'antibody' 'negative']",[0. 0. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03152058,",12:15:chronic_disease,17:28:chronic_disease,32:43:chronic_disease","Women with HIV, Hepatitis B or Hepatitis C positive status","['Women' 'with' 'HIV' ',' 'Hepatitis' 'B' 'or' 'Hepatitis' 'C' 'positive'
 'status']",[0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT03113760,"39:42:chronic_disease,44:55:chronic_disease,59:70:chronic_disease","Positive test for or prior history of HIV, Hepatitis B or Hepatitis C (serology)","['Positive' 'test' 'for' 'or' 'prior' 'history' 'of' 'HIV' ',' 'Hepatitis'
 'B' 'or' 'Hepatitis' 'C' '(' 'serology' ')']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02465268,"1:4:chronic_disease,6:17:chronic_disease,22:33:chronic_disease","HIV, Hepatitis B, or Hepatitis C seropositive","['HIV' ',' 'Hepatitis' 'B' ',' 'or' 'Hepatitis' 'C' 'seropositive']",[2. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02311621,"10:13:chronic_disease,36:47:chronic_disease,68:79:chronic_disease,","Negative HIV antigen and antibody, Hepatitis B surface antigen and Hepatitis C antibody within 3 months prior to enrollment","['Negative' 'HIV' 'antigen' 'and' 'antibody' ',' 'Hepatitis' 'B' 'surface'
 'antigen' 'and' 'Hepatitis' 'C' 'antibody' 'within' '3' 'months' 'prior'
 'to' 'enrollment']",[0. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01883076,"49:52:chronic_disease,54:65:chronic_disease,71:82:chronic_disease","Mother's serology test results are negative for HIV, Hepatitis B, and Hepatitis C","['Mother' ""'s"" 'serology' 'test' 'results' 'are' 'negative' 'for' 'HIV'
 ',' 'Hepatitis' 'B' ',' 'and' 'Hepatitis' 'C']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0.]
NCT01087294,"18:21:chronic_disease,32:43:chronic_disease,65:76:chronic_disease","Patients must be HIV negative, Hepatitis B surface antigen, and Hepatitis C antibody negative","['Patients' 'must' 'be' 'HIV' 'negative' ',' 'Hepatitis' 'B' 'surface'
 'antigen' ',' 'and' 'Hepatitis' 'C' 'antibody' 'negative']",[0. 0. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02542202,"1:16:chronic_disease,20:36:chronic_disease,47:70:treatment",Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration,"['Acute' 'bacterial' 'or' 'fungal' 'infection' 'requiring' 'intravenous'
 'antibiotics' 'at' 'the' 'time' 'of' 'registration']",[2. 2. 0. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02470897,"1:16:chronic_disease,20:36:chronic_disease,47:70:treatment",Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration,"['Acute' 'bacterial' 'or' 'fungal' 'infection' 'requiring' 'intravenous'
 'antibiotics' 'at' 'the' 'time' 'of' 'registration']",[2. 2. 0. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01622868,"1:16:chronic_disease,20:36:chronic_disease,47:70:treatment",Acute bacterial or fungal infection requiring intravenous antibiotics at the time of study entry,"['Acute' 'bacterial' 'or' 'fungal' 'infection' 'requiring' 'intravenous'
 'antibiotics' 'at' 'the' 'time' 'of' 'study' 'entry']",[2. 2. 0. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT01617161,"1:16:chronic_disease,20:36:chronic_disease,47:70:treatment",Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration,"['Acute' 'bacterial' 'or' 'fungal' 'infection' 'requiring' 'intravenous'
 'antibiotics' 'at' 'the' 'time' 'of' 'registration']",[2. 2. 0. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01220583,"1:16:chronic_disease,20:36:chronic_disease,47:70:treatment",Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration,"['Acute' 'bacterial' 'or' 'fungal' 'infection' 'requiring' 'intravenous'
 'antibiotics' 'at' 'the' 'time' 'of' 'registration']",[2. 2. 0. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02547662,"7:36:chronic_disease,40:52:treatment,115:123:treatment",Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing,"['Known' 'gastrointestinal' '(' 'GI' ')' 'disease' 'or' 'GI' 'procedure'
 'that' 'could' 'interfere' 'with' 'the' 'oral' 'absorption' 'or'
 'tolerance' 'of' 'ixazomib' 'including' 'difficulty' 'swallowing']",[0. 2. 2. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02481310,"27:56:chronic_disease,60:72:treatment,135:143:treatment",Patients who have a known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing,"['Patients' 'who' 'have' 'a' 'known' 'gastrointestinal' '(' 'GI' ')'
 'disease' 'or' 'GI' 'procedure' 'that' 'could' 'interfere' 'with' 'the'
 'oral' 'absorption' 'or' 'tolerance' 'of' 'ixazomib' 'including'
 'difficulty' 'swallowing']","[0. 0. 0. 0. 0. 2. 2. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0. 0. 0.]"
NCT02389517,"7:36:chronic_disease,40:52:treatment,115:123:treatment",Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing,"['Known' 'gastrointestinal' '(' 'GI' ')' 'disease' 'or' 'GI' 'procedure'
 'that' 'could' 'interfere' 'with' 'the' 'oral' 'absorption' 'or'
 'tolerance' 'of' 'ixazomib' 'including' 'difficulty' 'swallowing']",[0. 2. 2. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02339922,"7:36:chronic_disease,40:52:treatment,115:123:treatment",Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing,"['Known' 'gastrointestinal' '(' 'GI' ')' 'disease' 'or' 'GI' 'procedure'
 'that' 'could' 'interfere' 'with' 'the' 'oral' 'absorption' 'or'
 'tolerance' 'of' 'ixazomib' 'including' 'difficulty' 'swallowing']",[0. 2. 2. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02346253,"7:16:chronic_disease,20:36:chronic_disease,47:70:treatment",Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration,"['Acute' 'bacterial' 'or' 'fungal' 'infection' 'requiring' 'intravenous'
 'antibiotics' 'at' 'the' 'time' 'of' 'registration']",[0. 2. 0. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02163317,"7:16:chronic_disease,20:36:chronic_disease,47:70:treatment",Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration,"['Acute' 'bacterial' 'or' 'fungal' 'infection' 'requiring' 'intravenous'
 'antibiotics' 'at' 'the' 'time' 'of' 'registration']",[0. 2. 0. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01972919,"7:16:chronic_disease,20:36:chronic_disease,47:70:treatment",Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration,"['Acute' 'bacterial' 'or' 'fungal' 'infection' 'requiring' 'intravenous'
 'antibiotics' 'at' 'the' 'time' 'of' 'registration']",[0. 2. 0. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01954173,"7:16:chronic_disease,20:36:chronic_disease,47:70:treatment",Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration,"['Acute' 'bacterial' 'or' 'fungal' 'infection' 'requiring' 'intravenous'
 'antibiotics' 'at' 'the' 'time' 'of' 'registration']",[0. 2. 0. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT03121352,"28:48:chronic_disease,90:106:chronic_disease,120:144:chronic_disease,146:170:chronic_disease,172:190:chronic_disease,195:232:chronic_disease","Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Subjects' 'with' 'uncontrolled' 'intercurrent' 'illness' 'including' ','
 'but' 'not' 'limited' 'to' 'ongoing' 'or' 'active' 'infection' ','
 'symptomatic' 'congestive' 'heart' 'failure' ',' 'unstable' 'angina'
 'pectoris' ',' 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric'
 'illness/social' 'situations' 'that' 'would' 'limit' 'compliance' 'with'
 'study' 'requirements']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2.
 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02985554,"14:34:chronic_disease,77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0.
 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT01494662,"14:34:chronic_disease,76:92:chronic_disease,106:130:chronic_disease,132:156:chronic_disease,158:176:chronic_disease,181:218:chronic_disease","Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2.
 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02880215,"17:35:chronic_disease,37:53:chronic_disease,58:71:chronic_disease","current or past psychotic disorder, bipolar disorder, or schizophrenia","['current' 'or' 'past' 'psychotic' 'disorder' ',' 'bipolar' 'disorder' ','
 'or' 'schizophrenia']",[0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 2.]
NCT02502799,"14:30:chronic_disease,32:45:chronic_disease,60:78:chronic_disease","Diagnosis of bipolar disorder, schizophrenia, and/or other psychotic disorder","['Diagnosis' 'of' 'bipolar' 'disorder' ',' 'schizophrenia' ',' 'and/or'
 'other' 'psychotic' 'disorder']",[0. 0. 2. 2. 0. 2. 0. 0. 0. 2. 2.]
NCT01986075,"26:42:chronic_disease,44:57:chronic_disease,65:83:chronic_disease","Meets DSM-V criteria for bipolar disorder, schizophrenia or any psychotic disorder other than transient psychosis due to drug abuse","['Meets' 'DSM-V' 'criteria' 'for' 'bipolar' 'disorder' ',' 'schizophrenia'
 'or' 'any' 'psychotic' 'disorder' 'other' 'than' 'transient' 'psychosis'
 'due' 'to' 'drug' 'abuse']",[0. 0. 0. 0. 2. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02512497,"1:26:chronic_disease,30:56:chronic_disease,62:77:treatment",Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes,"['Hypertrophic' 'cardiomegaly' 'or' 'restrictive' 'cardiomyopathy' 'from'
 'prior' 'treatment' 'or' 'other' 'causes']",[2. 2. 0. 2. 2. 0. 1. 1. 0. 0. 0.]
NCT02393794,"1:26:chronic_disease,30:56:chronic_disease,62:77:treatment",Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes,"['Hypertrophic' 'cardiomegaly' 'or' 'restrictive' 'cardiomyopathy' 'from'
 'prior' 'treatment' 'or' 'other' 'causes']",[2. 2. 0. 2. 2. 0. 1. 1. 0. 0. 0.]
NCT01908777,"1:26:chronic_disease,30:56:chronic_disease,62:77:treatment",Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes,"['Hypertrophic' 'cardiomegaly' 'or' 'restrictive' 'cardiomyopathy' 'from'
 'prior' 'treatment' 'or' 'other' 'causes']",[2. 2. 0. 2. 2. 0. 1. 1. 0. 0. 0.]
NCT02451683,"41:50:chronic_disease,52:66:chronic_disease,70:88:chronic_disease","Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease","['Uncontrolled' 'medical' 'problems' 'including' 'pulmonary' ','
 'cardiovascular' 'or' 'orthopedic' 'disease']",[0. 0. 0. 0. 2. 0. 2. 0. 2. 2.]
NCT02446210,"41:50:chronic_disease,52:66:chronic_disease,70:88:chronic_disease","Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease","['Uncontrolled' 'medical' 'problems' 'including' 'pulmonary' ','
 'cardiovascular' 'or' 'orthopedic' 'disease']",[0. 0. 0. 0. 2. 0. 2. 0. 2. 2.]
NCT01915095,"41:50:chronic_disease,52:66:chronic_disease,70:88:chronic_disease","Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease","['Uncontrolled' 'medical' 'problems' 'including' 'pulmonary' ','
 'cardiovascular' 'or' 'orthopedic' 'disease']",[0. 0. 0. 0. 2. 0. 2. 0. 2. 2.]
NCT02312596,"1:18:treatment,20:32:treatment,34:49:treatment,57:82:treatment,","Radiation therapy, chemotherapy, chronic steroid use or immunosuppressive therapy within 30 days of enrollment","['Radiation' 'therapy' ',' 'chemotherapy' ',' 'chronic' 'steroid' 'use'
 'or' 'immunosuppressive' 'therapy' 'within' '30' 'days' 'of' 'enrollment']",[1. 1. 0. 1. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02312570,",,,106:123:treatment,125:137:treatment,139:164:treatment,168:183:treatment,","WBC >13,000/cm3 or < 5, 000 cm3, or electrolytes that are outside the host institution's range of normal Radiation therapy, chemotherapy, immunosuppressive therapy or chronic steroid use within 30 days of enrollment","['WBC' '>' '13,000/cm3' 'or' '<' '5' ',' '000' 'cm3' ',' 'or'
 'electrolytes' 'that' 'are' 'outside' 'the' 'host' 'institution' ""'s""
 'range' 'of' 'normal' 'Radiation' 'therapy' ',' 'chemotherapy' ','
 'immunosuppressive' 'therapy' 'or' 'chronic' 'steroid' 'use' 'within'
 '30' 'days' 'of' 'enrollment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 0. 1. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0.]"
NCT02312518,",,,,268:285:treatment,287:299:treatment,301:326:treatment,330:345:treatment,","Presence of additional abnormal lab values obtained within 7 days prior to the Day 0 visit determined to be clinically significant by the investigator including: WBC >13,000/cm3 or < 5, 000 cm3, or electrolytes that are outside the host institution's range of normal Radiation therapy, chemotherapy, immunosuppressive therapy or chronic steroid use within 30 days of enrollment","['Presence' 'of' 'additional' 'abnormal' 'lab' 'values' 'obtained'
 'within' '7' 'days' 'prior' 'to' 'the' 'Day' '0' 'visit' 'determined'
 'to' 'be' 'clinically' 'significant' 'by' 'the' 'investigator'
 'including' ':' 'WBC' '>' '13,000/cm3' 'or' '<' '5' ',' '000' 'cm3' ','
 'or' 'electrolytes' 'that' 'are' 'outside' 'the' 'host' 'institution'
 ""'s"" 'range' 'of' 'normal' 'Radiation' 'therapy' ',' 'chemotherapy' ','
 'immunosuppressive' 'therapy' 'or' 'chronic' 'steroid' 'use' 'within'
 '30' 'days' 'of' 'enrollment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1. 0. 1. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0.]"
NCT01928576,"79:90:treatment,96:106:treatment,114:123:treatment,,","Because no dosing or adverse event data are currently available on the use of azacitidine with entinostat, or of Nivolumab, in patients <18 years of age, children are excluded from this study","['Because' 'no' 'dosing' 'or' 'adverse' 'event' 'data' 'are' 'currently'
 'available' 'on' 'the' 'use' 'of' 'azacitidine' 'with' 'entinostat' ','
 'or' 'of' 'Nivolumab' ',' 'in' 'patients' '<' '18' 'years' 'of' 'age' ','
 'children' 'are' 'excluded' 'from' 'this' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01928576,"102:112:allergy_name,114:125:allergy_name,130:139:allergy_name","History of allergic reactions attributed to compounds of similar chemical or biologic composition to entinostat, azacitidine, or Nivolumab","['History' 'of' 'allergic' 'reactions' 'attributed' 'to' 'compounds' 'of'
 'similar' 'chemical' 'or' 'biologic' 'composition' 'to' 'entinostat' ','
 'azacitidine' ',' 'or' 'Nivolumab']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 0. 4.]
NCT01928576,"16:26:treatment,28:39:treatment,45:54:treatment","The effects of entinostat, azacitidine, and Nivolumab, on the developing human fetus are unknown","['The' 'effects' 'of' 'entinostat' ',' 'azacitidine' ',' 'and' 'Nivolumab'
 ',' 'on' 'the' 'developing' 'human' 'fetus' 'are' 'unknown']",[0. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03110354,"24:31:chronic_disease,33:46:chronic_disease,51:68:chronic_disease","Has substance abuse or medical, psychological, or social conditions that, in the opinion of the Investigator, may interfere with the subject's participation in the clinical study or evaluation of the clinical study results","['Has' 'substance' 'abuse' 'or' 'medical' ',' 'psychological' ',' 'or'
 'social' 'conditions' 'that' ',' 'in' 'the' 'opinion' 'of' 'the'
 'Investigator' ',' 'may' 'interfere' 'with' 'the' 'subject' ""'s""
 'participation' 'in' 'the' 'clinical' 'study' 'or' 'evaluation' 'of'
 'the' 'clinical' 'study' 'results']","[0. 0. 0. 0. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01360606,"18:25:chronic_disease,27:40:chronic_disease,44:61:chronic_disease","Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results","['Substance' 'abuse' ',' 'medical' ',' 'psychological' 'or' 'social'
 'conditions' 'that' 'may' 'interfere' 'with' 'the' 'patient' ""'s""
 'participation' 'in' 'the' 'study' 'or' 'evaluation' 'of' 'the' 'study'
 'results']","[0. 0. 0. 2. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT03043794,"75:80:chronic_disease,82:102:chronic_disease,104:115:chronic_disease","Medical conditions that may increase risk for poor cosmetic outcome (i.e. Lupus, rheumatoid arthritis, scleroderma","['Medical' 'conditions' 'that' 'may' 'increase' 'risk' 'for' 'poor'
 'cosmetic' 'outcome' '(' 'i.e' '.' 'Lupus' ',' 'rheumatoid' 'arthritis'
 ',' 'scleroderma']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 2.]
NCT02482376,"75:80:chronic_disease,82:102:chronic_disease,104:115:chronic_disease","Medical conditions that may increase risk for poor cosmetic outcome (i.e. Lupus, rheumatoid arthritis, scleroderma)","['Medical' 'conditions' 'that' 'may' 'increase' 'risk' 'for' 'poor'
 'cosmetic' 'outcome' '(' 'i.e' '.' 'Lupus' ',' 'rheumatoid' 'arthritis'
 ',' 'scleroderma' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 2. 0.]
NCT03008408,"30:50:treatment,,146:158:treatment,160:177:treatment,179:201:treatment","Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc","['Patients' 'currently' 'receiving' 'anticancer' 'therapies' 'or' 'who'
 'have' 'received' 'anticancer' 'therapies' 'within' '4' 'weeks' 'of'
 'the' 'start' 'of' 'study' 'drug' '(' 'including' 'chemotherapy' ','
 'radiation' 'therapy' ',' 'antibody' 'based' 'therapy' ',' 'etc']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 1. 1. 0. 1. 1. 1. 0. 0.]"
NCT02321501,"30:50:treatment,,118:130:treatment,132:149:treatment,151:173:treatment","Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks including chemotherapy, radiation therapy, antibody based therapy, etc","['Patients' 'currently' 'receiving' 'anticancer' 'therapies' 'or' 'who'
 'have' 'received' 'anticancer' 'therapies' 'within' '4' 'weeks'
 'including' 'chemotherapy' ',' 'radiation' 'therapy' ',' 'antibody'
 'based' 'therapy' ',' 'etc']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 1. 1. 1. 0.
 0.]"
NCT02910700,"75:84:allergy_name,86:96:allergy_name,101:111:allergy_name","History of allergy or adverse drug reaction to the study drug components (nivolumab, dabrafenib, or trametinib) or drugs of similar chemical or biologic composition","['History' 'of' 'allergy' 'or' 'adverse' 'drug' 'reaction' 'to' 'the'
 'study' 'drug' 'components' '(' 'nivolumab' ',' 'dabrafenib' ',' 'or'
 'trametinib' ')' 'or' 'drugs' 'of' 'similar' 'chemical' 'or' 'biologic'
 'composition']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 0. 4. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02910700,"68:77:treatment,79:89:treatment,95:105:treatment","breastfeeding should be discontinued if the mother is treated with nivolumab, dabrafenib, and trametinib","['breastfeeding' 'should' 'be' 'discontinued' 'if' 'the' 'mother' 'is'
 'treated' 'with' 'nivolumab' ',' 'dabrafenib' ',' 'and' 'trametinib']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1.]
NCT02833805,"14:23:chronic_disease,25:30:chronic_disease,35:51:chronic_disease","Uncontrolled bacterial, viral, or fungal infection","['Uncontrolled' 'bacterial' ',' 'viral' ',' 'or' 'fungal' 'infection']",[0. 2. 0. 2. 0. 0. 2. 2.]
NCT01966367,"14:23:chronic_disease,25:30:chronic_disease,34:50:chronic_disease","Uncontrolled bacterial, viral or fungal infection in the past month","['Uncontrolled' 'bacterial' ',' 'viral' 'or' 'fungal' 'infection' 'in'
 'the' 'past' 'month']",[0. 2. 0. 2. 0. 2. 2. 0. 0. 0. 0.]
NCT02695433,"12:25:chronic_disease,27:38:chronic_disease,40:45:chronic_disease,47:63:chronic_disease,67:82:chronic_disease","History of heart disease, respiratory, renal, gastrointestinal or hepatic disease","['History' 'of' 'heart' 'disease' ',' 'respiratory' ',' 'renal' ','
 'gastrointestinal' 'or' 'hepatic' 'disease']",[0. 0. 2. 2. 0. 2. 0. 2. 0. 2. 0. 2. 2.]
NCT02695433,"12:25:chronic_disease,27:38:chronic_disease,40:45:chronic_disease,47:63:chronic_disease,68:83:chronic_disease","history of heart disease, respiratory, renal, gastrointestinal, or hepatic disease","['history' 'of' 'heart' 'disease' ',' 'respiratory' ',' 'renal' ','
 'gastrointestinal' ',' 'or' 'hepatic' 'disease']",[0. 0. 2. 2. 0. 2. 0. 2. 0. 2. 0. 0. 2. 2.]
NCT02646787,"15:23:chronic_disease,25:34:chronic_disease,50:72:chronic_disease","Demonstrating delirium, psychosis or any form of Organic Brain Disorder and associated memory problems","['Demonstrating' 'delirium' ',' 'psychosis' 'or' 'any' 'form' 'of'
 'Organic' 'Brain' 'Disorder' 'and' 'associated' 'memory' 'problems']",[0. 2. 0. 2. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0.]
NCT02646787,"19:27:chronic_disease,29:38:chronic_disease,54:76:chronic_disease","Not demonstrating delirium, psychosis or any form of Organic Brain Disorder","['Not' 'demonstrating' 'delirium' ',' 'psychosis' 'or' 'any' 'form' 'of'
 'Organic' 'Brain' 'Disorder']",[0. 0. 2. 0. 2. 0. 0. 0. 0. 2. 2. 2.]
NCT02581982,"14:53:cancer,61:85:cancer,120:136:cancer,,273:288:treatment,418:426:treatment,","Known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment; this exception does not include carcinomatous meningitis which is excluded regardless of clinical stability","['Known' 'active' 'central' 'nervous' 'system' '(' 'CNS' ')' 'metastases'
 'and/or' 'carcinomatous' 'meningitis' ';' 'subjects' 'with' 'previously'
 'treated' 'brain' 'metastases' 'may' 'participate' 'provided' 'they'
 'are' 'stable' '(' 'without' 'evidence' 'of' 'progression' 'by' 'imaging'
 'for' 'at' 'least' 'four' 'weeks' 'prior' 'to' 'the' 'first' 'dose' 'of'
 'trial' 'treatment' 'and' 'any' 'neurologic' 'symptoms' 'have' 'returned'
 'to' 'baseline' ')' ',' 'have' 'no' 'evidence' 'of' 'new' 'or'
 'enlarging' 'brain' 'metastases' ',' 'and' 'are' 'not' 'using' 'steroids'
 'for' 'at' 'least' '7' 'days' 'prior' 'to' 'trial' 'treatment' ';' 'this'
 'exception' 'does' 'not' 'include' 'carcinomatous' 'meningitis' 'which'
 'is' 'excluded' 'regardless' 'of' 'clinical' 'stability']","[0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02541565,"18:57:cancer,65:89:cancer,124:140:cancer,,277:292:treatment,422:430:treatment","Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids","['Has' 'known' 'active' 'central' 'nervous' 'system' '(' 'CNS' ')'
 'metastases' 'and/or' 'carcinomatous' 'meningitis' ';' 'subjects' 'with'
 'previously' 'treated' 'brain' 'metastases' 'may' 'participate'
 'provided' 'they' 'are' 'stable' '(' 'without' 'evidence' 'of'
 'progression' 'by' 'imaging' 'for' 'at' 'least' 'four' 'weeks' 'prior'
 'to' 'the' 'first' 'dose' 'of' 'trial' 'treatment' 'and' 'any'
 'neurologic' 'symptoms' 'have' 'returned' 'to' 'baseline' ')' ',' 'have'
 'no' 'evidence' 'of' 'new' 'or' 'enlarging' 'brain' 'metastases' ','
 'and' 'are' 'not' 'using' 'steroids']","[0. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02576444,"1:14:treatment,7:14:treatment,,53:68:treatment","Major surgery within 3 weeks prior to first dose of study treatment, and patients must have recovered from the effects of surgery","['Major' 'surgery' 'within' '3' 'weeks' 'prior' 'to' 'first' 'dose' 'of'
 'study' 'treatment' ',' 'and' 'patients' 'must' 'have' 'recovered' 'from'
 'the' 'effects' 'of' 'surgery']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02451553,"1:14:treatment,7:14:treatment,,46:61:treatment",Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study,"['Major' 'surgery' 'within' '4' 'weeks' 'before' 'starting' 'study'
 'treatment' 'or' 'scheduled' 'for' 'surgery' 'during' 'the' 'projected'
 'course' 'of' 'the' 'study']",[1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02553941,"5:29:chronic_disease,31:48:chronic_disease,53:77:chronic_disease","Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk","['Any' 'life-threatening' 'illness' ',' 'medical' 'condition' ',' 'or'
 'organ' 'system' 'dysfunction' 'that' ',' 'in' 'the' 'investigator' ""'s""
 'opinion' ',' 'could' 'compromise' 'the' 'subject' ""'s"" 'safety' 'or'
 'put' 'the' 'study' 'outcomes' 'at' 'undue' 'risk']","[0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02309580,"5:29:chronic_disease,31:48:chronic_disease,53:77:chronic_disease","Any life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk","['Any' 'life-threatening' 'illness' ',' 'medical' 'condition' ',' 'or'
 'organ' 'system' 'dysfunction' 'that' ',' 'in' 'the' 'opinion' 'of' 'the'
 'investigator' ',' 'could' 'compromise' 'the' 'subject' ""'s"" 'safety'
 'or' 'put' 'the' 'study' 'outcomes' 'at' 'undue' 'risk']","[0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02547662,"34:59:chronic_disease,71:90:chronic_disease,92:116:chronic_disease,118:124:chronic_disease,129:150:chronic_disease,","Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure, angina, or myocardial infarction within the past 6 months","['Evidence' 'of' 'current' 'uncontrolled' 'cardiovascular' 'conditions'
 ',' 'including' 'cardiac' 'arrhythmias' ',' 'congestive' 'heart'
 'failure' ',' 'angina' ',' 'or' 'myocardial' 'infarction' 'within' 'the'
 'past' '6' 'months']","[0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 2. 2. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0.
 0.]"
NCT01415882,"34:59:chronic_disease,71:90:chronic_disease,92:116:chronic_disease,118:124:chronic_disease,129:150:chronic_disease,","Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure, angina, or myocardial infarction within the past 6 months","['Evidence' 'of' 'current' 'uncontrolled' 'cardiovascular' 'conditions'
 ',' 'including' 'cardiac' 'arrhythmias' ',' 'congestive' 'heart'
 'failure' ',' 'angina' ',' 'or' 'myocardial' 'infarction' 'within' 'the'
 'past' '6' 'months']","[0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 2. 2. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0.
 0.]"
NCT02542202,"1:51:chronic_disease,61:80:chronic_disease,121:134:treatment,",Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration,"['Chronic' 'obstructive' 'pulmonary' 'disease' 'exacerbation' 'or' 'other'
 'respiratory' 'illness' 'requiring' 'hospitalization' 'or' 'precluding'
 'study' 'therapy' 'within' '30' 'days' 'prior' 'to' 'registration']",[2. 2. 2. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT01954173,"1:51:chronic_disease,61:80:chronic_disease,121:134:treatment",Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration,"['Chronic' 'obstructive' 'pulmonary' 'disease' 'exacerbation' 'or' 'other'
 'respiratory' 'illness' 'requiring' 'hospitalization' 'or' 'precluding'
 'study' 'therapy' 'at' 'the' 'time' 'of' 'registration']",[2. 2. 2. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02532452,"40:48:treatment,40:47:treatment,,63:73:treatment",Clinical status must allow tapering of steroids to < 0.5mg/kg prednisone or other steroid equivalent,"['Clinical' 'status' 'must' 'allow' 'tapering' 'of' 'steroids' 'to' '<'
 '0.5mg/kg' 'prednisone' 'or' 'other' 'steroid' 'equivalent']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 0. 1. 0.]
NCT02048332,"40:47:treatment,40:48:treatment,61:71:treatment",Clinical status must allow tapering of steroids to 0.5mg/kg prednisone or other steroid equivalent,"['Clinical' 'status' 'must' 'allow' 'tapering' 'of' 'steroids' 'to'
 '0.5mg/kg' 'prednisone' 'or' 'other' 'steroid' 'equivalent']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 0. 1. 0.]
NCT02520778,"91:107:chronic_disease,121:145:chronic_disease,147:162:chronic_disease,173:191:chronic_disease,193:217:chronic_disease,241:248:treatment,259:281:treatment,285:311:chronic_disease,315:334:chronic_disease","Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, gastrointestinal disease limiting absorption of AZD9291 such as a malabsorption syndrome or inflammatory bowel disease or psychiatric illness/social situations that would limit compliance with study requirements","['Patients' 'with' 'uncontrolled' 'intercurrent' 'illness' 'including' ','
 'but' 'not' 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ','
 'symptomatic' 'congestive' 'heart' 'failure' ',' 'unstable' 'angina'
 'pectoris' ',' 'cardiac' 'arrhythmia' ',' 'gastrointestinal' 'disease'
 'limiting' 'absorption' 'of' 'AZD9291' 'such' 'as' 'a' 'malabsorption'
 'syndrome' 'or' 'inflammatory' 'bowel' 'disease' 'or' 'psychiatric'
 'illness/social' 'situations' 'that' 'would' 'limit' 'compliance' 'with'
 'study' 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2.
 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 1. 0. 0. 0. 1. 1. 0. 2. 2. 2. 0. 2. 2. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02496663,"77:93:chronic_disease,107:131:chronic_disease,133:148:chronic_disease,159:177:chronic_disease,179:203:chronic_disease,227:234:treatment,245:267:chronic_disease,271:297:chronic_disease,301:320:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, gastrointestinal disease limiting absorption of AZD9291 such as a malabsorption syndrome or inflammatory bowel disease or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'gastrointestinal' 'disease' 'limiting'
 'absorption' 'of' 'AZD9291' 'such' 'as' 'a' 'malabsorption' 'syndrome'
 'or' 'inflammatory' 'bowel' 'disease' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0.
 2. 2. 0. 2. 2. 0. 0. 0. 1. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02516670,"1:22:chronic_disease,24:34:treatment,36:46:treatment","Gastrointestinal (GI): cimetidine, aprepitant","['Gastrointestinal' '(' 'GI' ')' ':' 'cimetidine' ',' 'aprepitant']",[2. 2. 0. 0. 0. 1. 0. 1.]
NCT01822522,"1:22:chronic_disease,24:34:treatment,36:46:treatment","Gastrointestinal (GI): cimetidine, aprepitant","['Gastrointestinal' '(' 'GI' ')' ':' 'cimetidine' ',' 'aprepitant']",[2. 2. 0. 0. 0. 1. 0. 1.]
NCT02512497,"8:30:chronic_disease,32:37:chronic_disease,41:58:chronic_disease","Active uncontrolled bacterial, viral or fungal infections","['Active' 'uncontrolled' 'bacterial' ',' 'viral' 'or' 'fungal'
 'infections']",[0. 2. 2. 0. 2. 0. 2. 2.]
NCT02105766,"13:35:chronic_disease,37:42:chronic_disease,47:64:chronic_disease,","Evidence of uncontrolled bacterial, viral, or fungal infections (currently taking medication and progression of clinical symptoms) within one month prior to starting the conditioning regimen","['Evidence' 'of' 'uncontrolled' 'bacterial' ',' 'viral' ',' 'or' 'fungal'
 'infections' '(' 'currently' 'taking' 'medication' 'and' 'progression'
 'of' 'clinical' 'symptoms' ')' 'within' 'one' 'month' 'prior' 'to'
 'starting' 'the' 'conditioning' 'regimen']","[0. 0. 2. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02496208,"12:37:chronic_disease,,,,,,131:165:treatment,156:165:treatment,","Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mmHg systolic, or > 90 mmHg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment","['Concurrent' 'uncontrolled' 'hypertension' 'defined' 'as' 'sustained'
 'blood' 'pressure' '(' 'BP' ')' '>' '140' 'mmHg' 'systolic' ',' 'or' '>'
 '90' 'mmHg' 'diastolic' 'despite' 'optimal' 'antihypertensive'
 'treatment' 'within' '7' 'days' 'of' 'the' 'first' 'dose' 'of' 'study'
 'treatment']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02132598,"12:37:chronic_disease,,,,116:150:treatment,141:150:treatment,","Concurrent uncontrolled hypertension defined as sustained BP > 140 mm Hg systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment","['Concurrent' 'uncontrolled' 'hypertension' 'defined' 'as' 'sustained'
 'BP' '>' '140' 'mm' 'Hg' 'systolic' ',' 'or' '>' '90' 'mm' 'Hg'
 'diastolic' 'despite' 'optimal' 'antihypertensive' 'treatment' 'within'
 '7' 'days' 'of' 'the' 'first' 'dose' 'of' 'study' 'treatment']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02484937,"49:62:chronic_disease,64:80:chronic_disease,85:102:chronic_disease","Significant psychiatric history: a diagnosis of schizophrenia, bipolar disorder, or severe depression","['Significant' 'psychiatric' 'history' ':' 'a' 'diagnosis' 'of'
 'schizophrenia' ',' 'bipolar' 'disorder' ',' 'or' 'severe' 'depression']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 2. 2.]
NCT02341963,"49:62:chronic_disease,64:80:chronic_disease,85:102:chronic_disease","Significant psychiatric history; a diagnosis of schizophrenia, bipolar disorder, or severe depression","['Significant' 'psychiatric' 'history' ';' 'a' 'diagnosis' 'of'
 'schizophrenia' ',' 'bipolar' 'disorder' ',' 'or' 'severe' 'depression']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 2. 2.]
NCT02466009,"1:14:chronic_disease,25:29:treatment,34:53:treatment",Renal failure requiring hemo- or peritoneal dialysis,['Renal' 'failure' 'requiring' 'hemo-' 'or' 'peritoneal' 'dialysis'],[2. 2. 0. 1. 0. 1. 1.]
NCT02459119,"1:14:chronic_disease,25:29:treatment,33:52:treatment",Renal failure requiring hemo-or peritoneal dialysis,['Renal' 'failure' 'requiring' 'hemo-or' 'peritoneal' 'dialysis'],[2. 2. 0. 1. 1. 1.]
NCT02429557,"13:20:chronic_disease,22:27:chronic_disease,31:46:chronic_disease","Significant cardiac, renal or hepatic illness, or with contraindications to administration of pressor agents or external abdominal compression","['Significant' 'cardiac' ',' 'renal' 'or' 'hepatic' 'illness' ',' 'or'
 'with' 'contraindications' 'to' 'administration' 'of' 'pressor' 'agents'
 'or' 'external' 'abdominal' 'compression']",[0. 2. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02417415,"13:20:chronic_disease,22:27:chronic_disease,31:46:chronic_disease","Significant cardiac, renal or hepatic illness","['Significant' 'cardiac' ',' 'renal' 'or' 'hepatic' 'illness']",[0. 2. 0. 2. 0. 2. 2.]
NCT02408861,"48:57:treatment,62:65:chronic_disease,62:75:chronic_disease,87:113:treatment","Participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications when clinically indicated, and should be under the care of a physician experienced in HIV management","['Participants' 'MUST' 'receive' 'appropriate' 'care' 'and' 'treatment'
 'for' 'HIV' 'infection' ',' 'including' 'antiretroviral' 'medications'
 'when' 'clinically' 'indicated' ',' 'and' 'should' 'be' 'under' 'the'
 'care' 'of' 'a' 'physician' 'experienced' 'in' 'HIV' 'management']","[0. 0. 0. 0. 0. 0. 1. 0. 2. 2. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT01822522,"62:71:treatment,76:79:treatment,76:89:chronic_disease,101:127:treatment","Participating participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications, when clinically indicated and should be under the care of a physician experienced in HIV management","['Participating' 'participants' 'MUST' 'receive' 'appropriate' 'care'
 'and' 'treatment' 'for' 'HIV' 'infection' ',' 'including'
 'antiretroviral' 'medications' ',' 'when' 'clinically' 'indicated' 'and'
 'should' 'be' 'under' 'the' 'care' 'of' 'a' 'physician' 'experienced'
 'in' 'HIV' 'management']","[0. 0. 0. 0. 0. 0. 0. 1. 0. 2. 2. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02393690,"21:42:treatment,74:83:treatment,92:108:cancer",Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm,"['Receiving' 'any' 'other' 'investigational' 'agent' 'which' 'would' 'be'
 'considered' 'as' 'a' 'treatment' 'for' 'the' 'primary' 'neoplasm']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 3. 3.]
NCT02312245,"21:42:treatment,74:83:treatment,92:108:cancer",Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm,"['Receiving' 'any' 'other' 'investigational' 'agent' 'which' 'would' 'be'
 'considered' 'as' 'a' 'treatment' 'for' 'the' 'primary' 'neoplasm']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 3. 3.]
NCT02382549,"22:29:treatment,32:39:treatment,42:50:treatment","Growth factors (e.g. Procrit®, Aranesp®, Neulasta®)","['Growth' 'factors' '(' 'e.g' '.' 'Procrit®' ',' 'Aranesp®' ','
 'Neulasta®' ')']",[0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0.]
NCT02358187,"22:29:treatment,32:39:treatment,42:50:treatment","Growth factors (e.g. Procrit®, Aranesp®, Neulasta®)","['Growth' 'factors' '(' 'e.g' '.' 'Procrit®' ',' 'Aranesp®' ','
 'Neulasta®' ')']",[0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0.]
NCT02352480,"35:51:allergy_name,53:69:allergy_name,71:79:allergy_name,81:94:allergy_name,103:129:allergy_name","Subjects known to be sensitive to Aurix components (calcium chloride, thrombin, ascorbic acid) and/or materials of bovine origin","['Subjects' 'known' 'to' 'be' 'sensitive' 'to' 'Aurix' 'components' '('
 'calcium' 'chloride' ',' 'thrombin' ',' 'ascorbic' 'acid' ')' 'and/or'
 'materials' 'of' 'bovine' 'origin']",[0. 0. 0. 0. 0. 0. 4. 4. 0. 4. 4. 0. 4. 0. 4. 4. 0. 0. 4. 4. 4. 4.]
NCT02352467,"35:51:allergy_name,53:69:allergy_name,71:79:allergy_name,81:94:allergy_name,103:129:allergy_name","Subjects known to be sensitive to Aurix components (calcium chloride, thrombin, ascorbic acid) and/or materials of bovine origin","['Subjects' 'known' 'to' 'be' 'sensitive' 'to' 'Aurix' 'components' '('
 'calcium' 'chloride' ',' 'thrombin' ',' 'ascorbic' 'acid' ')' 'and/or'
 'materials' 'of' 'bovine' 'origin']",[0. 0. 0. 0. 0. 0. 4. 4. 0. 4. 4. 0. 4. 0. 4. 4. 0. 0. 4. 4. 4. 4.]
NCT02323945,"12:20:chronic_disease,22:34:chronic_disease,43:51:chronic_disease","History of seizures, brain injury, and/or epilepsy","['History' 'of' 'seizures' ',' 'brain' 'injury' ',' 'and/or' 'epilepsy']",[0. 0. 2. 0. 2. 2. 0. 0. 2.]
NCT02323698,"12:20:chronic_disease,22:34:chronic_disease,43:51:chronic_disease","History of seizures, brain injury, and/or epilepsy","['History' 'of' 'seizures' ',' 'brain' 'injury' ',' 'and/or' 'epilepsy']",[0. 0. 2. 0. 2. 2. 0. 0. 2.]
NCT02315196,"13:29:chronic_disease,37:52:chronic_disease,54:71:chronic_disease","Significant vascular disease (e.g., aortic aneurysm, aortic dissection)","['Significant' 'vascular' 'disease' '(' 'e.g.' ',' 'aortic' 'aneurysm' ','
 'aortic' 'dissection' ')']",[0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02314377,"36:52:chronic_disease,60:75:chronic_disease,77:94:chronic_disease","Patients must not have significant vascular disease (e.g., aortic aneurysm, aortic dissection)","['Patients' 'must' 'not' 'have' 'significant' 'vascular' 'disease' '('
 'e.g.' ',' 'aortic' 'aneurysm' ',' 'aortic' 'dissection' ')']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02302235,"1:20:cancer,22:45:cancer,47:50:cancer","Astrocytoma grade 4 (glioblastoma multiforme, GBM, histologically confirmed, WHO criteria)","['Astrocytoma' 'grade' '4' '(' 'glioblastoma' 'multiforme' ',' 'GBM' ','
 'histologically' 'confirmed' ',' 'WHO' 'criteria' ')']",[3. 3. 3. 0. 3. 3. 0. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT01865162,"1:20:cancer,22:45:cancer,47:50:cancer","Astrocytoma grade 4 (glioblastoma multiforme, GBM, histologically confirmed, WHO criteria)","['Astrocytoma' 'grade' '4' '(' 'glioblastoma' 'multiforme' ',' 'GBM' ','
 'histologically' 'confirmed' ',' 'WHO' 'criteria' ')']",[3. 3. 3. 0. 3. 3. 0. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT02192398,"17:39:treatment,49:61:treatment,78:89:chronic_disease,97:108:treatment","Subjects are on antihypertensive drugs (e.g., a beta-blocker) that result in hypotension and/or bradycardia as defined above","['Subjects' 'are' 'on' 'antihypertensive' 'drugs' '(' 'e.g.' ',' 'a'
 'beta-blocker' ')' 'that' 'result' 'in' 'hypotension' 'and/or'
 'bradycardia' 'as' 'defined' 'above']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 2. 0. 1. 0. 0. 0.]
NCT01681264,"17:39:treatment,49:61:treatment,78:89:chronic_disease,97:108:chronic_disease","Subjects are on antihypertensive drugs (e.g., a beta-blocker) that result in hypotension and/or bradycardia as defined above","['Subjects' 'are' 'on' 'antihypertensive' 'drugs' '(' 'e.g.' ',' 'a'
 'beta-blocker' ')' 'that' 'result' 'in' 'hypotension' 'and/or'
 'bradycardia' 'as' 'defined' 'above']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 2. 0. 2. 0. 0. 0.]
NCT02163317,"1:38:chronic_disease,61:80:chronic_disease,121:134:treatment",Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration,"['Chronic' 'obstructive' 'pulmonary' 'disease' 'exacerbation' 'or' 'other'
 'respiratory' 'illness' 'requiring' 'hospitalization' 'or' 'precluding'
 'study' 'therapy' 'at' 'the' 'time' 'of' 'registration']",[2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01622868,"1:38:chronic_disease,61:80:chronic_disease,121:134:treatment",Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of study entry,"['Chronic' 'obstructive' 'pulmonary' 'disease' 'exacerbation' 'or' 'other'
 'respiratory' 'illness' 'requiring' 'hospitalization' 'or' 'precluding'
 'study' 'therapy' 'at' 'the' 'time' 'of' 'study' 'entry']",[2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02133196,"1:8:cancer,37:62:treatment,,107:116:treatment",Lesions that have been treated with stereotactic radiosurgery must be clinically stable for 1 month after treatment for the patient,"['Lesions' 'that' 'have' 'been' 'treated' 'with' 'stereotactic'
 'radiosurgery' 'must' 'be' 'clinically' 'stable' 'for' '1' 'month'
 'after' 'treatment' 'for' 'the' 'patient']",[3. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT01967823,"1:8:cancer,37:62:treatment,,107:116:treatment",Lesions that have been treated with stereotactic radiosurgery must be clinically stable for 1 month after treatment for the patient to be eligible,"['Lesions' 'that' 'have' 'been' 'treated' 'with' 'stereotactic'
 'radiosurgery' 'must' 'be' 'clinically' 'stable' 'for' '1' 'month'
 'after' 'treatment' 'for' 'the' 'patient' 'to' 'be' 'eligible']",[3. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01993810,"1:19:treatment,47:53:cancer,86:103:treatment",Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields,"['Prior' 'radiotherapy' 'to' 'the' 'region' 'of' 'the' 'study' 'cancer'
 'that' 'would' 'result' 'in' 'overlap' 'of' 'radiation' 'therapy'
 'fields']",[1. 1. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT01972919,"1:19:treatment,47:53:cancer,86:103:treatment",Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields,"['Prior' 'radiotherapy' 'to' 'the' 'region' 'of' 'the' 'study' 'cancer'
 'that' 'would' 'result' 'in' 'overlap' 'of' 'radiation' 'therapy'
 'fields']",[1. 1. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT01896999,"22:32:cancer,59:83:cancer,85:111:cancer","No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma","['No' 'evidence' 'of' 'prior' 'malignancy' 'except' 'adequately' 'treated'
 'non-melanoma' 'skin' 'cancer' ',' 'in' 'situ' 'cervical' 'carcinoma']",[0. 0. 0. 0. 3. 0. 0. 0. 3. 3. 3. 0. 3. 3. 3. 3.]
NCT01415752,"22:32:cancer,59:83:cancer,85:111:cancer,","No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma, or any surgically or radiation-cured malignancy continuously disease free for ≥ 5 years so as not to interfere with interpretation of radiographic response","['No' 'evidence' 'of' 'prior' 'malignancy' 'except' 'adequately' 'treated'
 'non-melanoma' 'skin' 'cancer' ',' 'in' 'situ' 'cervical' 'carcinoma' ','
 'or' 'any' 'surgically' 'or' 'radiation-cured' 'malignancy'
 'continuously' 'disease' 'free' 'for' '≥' '5' 'years' 'so' 'as' 'not'
 'to' 'interfere' 'with' 'interpretation' 'of' 'radiographic' 'response']","[0. 0. 0. 0. 3. 0. 0. 0. 3. 3. 3. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01795313,"20:27:chronic_disease,29:45:chronic_disease,47:56:chronic_disease,61:80:chronic_disease","must have no overt cardiac, gastrointestinal, pulmonary, or psychiatric disease","['must' 'have' 'no' 'overt' 'cardiac' ',' 'gastrointestinal' ','
 'pulmonary' ',' 'or' 'psychiatric' 'disease']",[0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 0. 2. 2.]
NCT01130077,"10:17:chronic_disease,19:35:chronic_disease,37:46:chronic_disease,50:69:chronic_disease","No overt cardiac, gastrointestinal, pulmonary or psychiatric disease","['No' 'overt' 'cardiac' ',' 'gastrointestinal' ',' 'pulmonary' 'or'
 'psychiatric' 'disease']",[0. 0. 2. 0. 2. 0. 2. 0. 2. 2.]
NCT01438073,"17:32:chronic_disease,34:43:chronic_disease,47:51:chronic_disease",no evidence for androgen excess (hirsutism or acne),['no' 'evidence' 'for' 'androgen' 'excess' '(' 'hirsutism' 'or' 'acne' ')'],[0. 0. 0. 2. 2. 0. 2. 0. 2. 0.]
NCT00914823,"17:32:chronic_disease,34:43:chronic_disease,47:51:chronic_disease",no evidence for androgen excess (hirsutism or acne),['no' 'evidence' 'for' 'androgen' 'excess' '(' 'hirsutism' 'or' 'acne' ')'],[0. 0. 0. 2. 2. 0. 2. 0. 2. 0.]
NCT03188185,"14:49:treatment,,96:99:treatment,122:149:treatment",Has received electroconvulsive therapy treatment within the last 2 years or within the current MDE or failed a course of electroconvulsive treatment at any time,"['Has' 'received' 'electroconvulsive' 'therapy' 'treatment' 'within' 'the'
 'last' '2' 'years' 'or' 'within' 'the' 'current' 'MDE' 'or' 'failed' 'a'
 'course' 'of' 'electroconvulsive' 'treatment' 'at' 'any' 'time']","[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT03188042,"10:28:chronic_disease,36:44:chronic_disease,63:83:chronic_disease","Unstable medical conditions (e.g., diabetes, diabetes causing diabetic retinopathy)","['Unstable' 'medical' 'conditions' '(' 'e.g.' ',' 'diabetes' ','
 'diabetes' 'causing' 'diabetic' 'retinopathy' ')']",[0. 2. 2. 0. 0. 0. 2. 0. 0. 0. 2. 2. 0.]
NCT03183128,"32:44:treatment,46:58:treatment,63:81:treatment,86:103:cancer","Concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for active malignancy (subjects on maintenance chemotherapy may only be enrolled after consultation with the study medical monitor)","['Concurrent' 'intensive' 'induction' 'chemotherapy' ',' 'radiotherapy'
 ',' 'or' 'biologic' 'treatment' 'for' 'active' 'malignancy' '('
 'subjects' 'on' 'maintenance' 'chemotherapy' 'may' 'only' 'be' 'enrolled'
 'after' 'consultation' 'with' 'the' 'study' 'medical' 'monitor' ')']","[0. 0. 0. 1. 0. 1. 0. 0. 1. 1. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT03182751,"18:33:chronic_disease,35:57:chronic_disease,59:84:chronic_disease,86:110:chronic_disease,112:147:chronic_disease,149:167:chronic_disease","Known history of Factor V Leiden, protein C/S deficiency, prothrombin gene mutation, anti-thrombin deficiency, anti-phospholipid antibody syndrome, lupus anticoagulan","['Known' 'history' 'of' 'Factor' 'V' 'Leiden' ',' 'protein' 'C/S'
 'deficiency' ',' 'prothrombin' 'gene' 'mutation' ',' 'anti-thrombin'
 'deficiency' ',' 'anti-phospholipid' 'antibody' 'syndrome' ',' 'lupus'
 'anticoagulan']",[0. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2.]
NCT03181516,"12:25:chronic_disease,37:51:chronic_disease,55:70:chronic_disease,76:94:treatment,98:108:treatment","History of heart disease, including valvulopathies or cardiac surgery, any implantable device or prosthetic","['History' 'of' 'heart' 'disease' ',' 'including' 'valvulopathies' 'or'
 'cardiac' 'surgery' ',' 'any' 'implantable' 'device' 'or' 'prosthetic']",[0. 0. 2. 2. 0. 0. 2. 0. 2. 2. 0. 0. 1. 1. 0. 1.]
NCT03179995,"20:32:cancer,45:66:treatment,,143:156:chronic_disease,191:200:chronic_disease,201:222:chronic_disease","Patients must have liver tumors requiring a major liver resection, defined as removing at least three anatomical segments in patients without liver disease and two segments in patients with cirrhosis/fibrosis of the liver","['Patients' 'must' 'have' 'liver' 'tumors' 'requiring' 'a' 'major' 'liver'
 'resection' ',' 'defined' 'as' 'removing' 'at' 'least' 'three'
 'anatomical' 'segments' 'in' 'patients' 'without' 'liver' 'disease' 'and'
 'two' 'segments' 'in' 'patients' 'with' 'cirrhosis/fibrosis' 'of' 'the'
 'liver']","[0. 0. 0. 2. 2. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 2. 2. 2. 2.]"
NCT03179397,"38:54:chronic_disease,61:81:chronic_disease,91:108:chronic_disease,,",Subjects with diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders) that are predicted to cause future acuity losses to a level worse than 0.2 LogMAR (20/32),"['Subjects' 'with' 'diagnosed' 'degenerative' 'visual' 'disorders' '('
 'e.g' '.' 'macular' 'degeneration' 'or' 'other' 'retinal' 'disorders' ')'
 'that' 'are' 'predicted' 'to' 'cause' 'future' 'acuity' 'losses' 'to' 'a'
 'level' 'worse' 'than' '0.2' 'LogMAR' '(' '20/32' ')']","[0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03178617,"22:36:cancer,28:36:cancer,43:77:cancer,74:76:cancer,79:107:cancer,,,","Children treated for acute leukemia (e.g. acute lymphoblastic leukemia [ALL], acute myeloid leukemia [AML]), LL, or other types of leukemia (if treated intensively) aged 5-12 years and their parents/caregivers","['Children' 'treated' 'for' 'acute' 'leukemia' '(' 'e.g' '.' 'acute'
 'lymphoblastic' 'leukemia' '[' 'ALL' ']' ',' 'acute' 'myeloid' 'leukemia'
 '[' 'AML' ']' ')' ',' 'LL' ',' 'or' 'other' 'types' 'of' 'leukemia' '('
 'if' 'treated' 'intensively' ')' 'aged' '5-12' 'years' 'and' 'their'
 'parents/caregivers']","[0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03176784,"18:28:treatment,30:35:treatment,40:50:treatment","currently taking Wellbutrin, Zyban, or Buproprion (Contrave is a weight-loss drug that has Wellbutrin in it) for reasons other than to quit smoking","['currently' 'taking' 'Wellbutrin' ',' 'Zyban' ',' 'or' 'Buproprion' '('
 'Contrave' 'is' 'a' 'weight-loss' 'drug' 'that' 'has' 'Wellbutrin' 'in'
 'it' ')' 'for' 'reasons' 'other' 'than' 'to' 'quit' 'smoking']","[0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT03175978,"14:17:cancer,18:22:cancer,62:78:treatment,71:78:treatment",Diagnosis of MDS/CMML that is refractory to or intolerant to standard therapy and is no longer likely to respond to such therapy (at least one line of therapy),"['Diagnosis' 'of' 'MDS/CMML' 'that' 'is' 'refractory' 'to' 'or'
 'intolerant' 'to' 'standard' 'therapy' 'and' 'is' 'no' 'longer' 'likely'
 'to' 'respond' 'to' 'such' 'therapy' '(' 'at' 'least' 'one' 'line' 'of'
 'therapy' ')']","[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT03171493,"37:49:treatment,,83:99:treatment,,133:150:treatment",Any of the following prior therapy: Chemotherapy ≤ 3 weeks prior to registration. Biologic therapy ≤ 4 weeks prior to registration. Radiation therapy ≤ 3 weeks prior to registration,"['Any' 'of' 'the' 'following' 'prior' 'therapy' ':' 'Chemotherapy' '≤' '3'
 'weeks' 'prior' 'to' 'registration' '.' 'Biologic' 'therapy' '≤' '4'
 'weeks' 'prior' 'to' 'registration' '.' 'Radiation' 'therapy' '≤' '3'
 'weeks' 'prior' 'to' 'registration']","[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 1. 1. 0. 0. 0. 0. 0. 0.]"
NCT03171480,"1:23:treatment,55:82:chronic_disease,110:162:chronic_disease,167:213:chronic_disease,215:240:chronic_disease,242:271:chronic_disease,273:301:chronic_disease,306:362:chronic_disease,379:390:chronic_disease,405:424:chronic_disease","Isosorbide mononitrate should not be used in cases of acute myocardial infarction with low filling pressure, acute circulatory failure (shock, vascular collapse), or hypertrophic obstructive cardiomyopathy (HOCM), constrictive pericarditis, low cardiac filling pressures, aortic/mitral valve stenosis and diseases associated with a raised intra-cranial pressure e.g following a head trauma and including cerebral hemorrhage","['Isosorbide' 'mononitrate' 'should' 'not' 'be' 'used' 'in' 'cases' 'of'
 'acute' 'myocardial' 'infarction' 'with' 'low' 'filling' 'pressure' ','
 'acute' 'circulatory' 'failure' '(' 'shock' ',' 'vascular' 'collapse' ')'
 ',' 'or' 'hypertrophic' 'obstructive' 'cardiomyopathy' '(' 'HOCM' ')' ','
 'constrictive' 'pericarditis' ',' 'low' 'cardiac' 'filling' 'pressures'
 ',' 'aortic/mitral' 'valve' 'stenosis' 'and' 'diseases' 'associated'
 'with' 'a' 'raised' 'intra-cranial' 'pressure' 'e.g' 'following' 'a'
 'head' 'trauma' 'and' 'including' 'cerebral' 'hemorrhage']","[1. 1. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 2.
 2. 2. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 0. 2. 2.]"
NCT03170375,"12:27:chronic_disease,38:45:treatment,66:78:chronic_disease,96:105:treatment","unoperated aortic aneurysm for which surgery is indicated, prior hyperkalemia requiring urgent treatment","['unoperated' 'aortic' 'aneurysm' 'for' 'which' 'surgery' 'is' 'indicated'
 ',' 'prior' 'hyperkalemia' 'requiring' 'urgent' 'treatment']",[0. 2. 2. 0. 0. 1. 0. 0. 0. 0. 2. 0. 0. 1.]
NCT03168971,"24:30:cancer,32:40:cancer,42:50:cancer,52:56:cancer,61:81:cancer,103:112:treatment,","Confirmed diagnosis of breast, lymphoma, prostate, lung, or gynecological cancer, currently on active treatment or within six months of completion of treatment","['Confirmed' 'diagnosis' 'of' 'breast' ',' 'lymphoma' ',' 'prostate' ','
 'lung' ',' 'or' 'gynecological' 'cancer' ',' 'currently' 'on' 'active'
 'treatment' 'or' 'within' 'six' 'months' 'of' 'completion' 'of'
 'treatment']","[0. 0. 0. 3. 0. 3. 0. 3. 0. 3. 0. 0. 3. 3. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT03166371,"16:22:cancer,,79:89:cancer,93:128:cancer,132:147:cancer",Current active cancer or recently (within 6 months) treated cancer other than basal cell or squamous cell carcinoma of the skin or prostate cancer,"['Current' 'active' 'cancer' 'or' 'recently' '(' 'within' '6' 'months' ')'
 'treated' 'cancer' 'other' 'than' 'basal' 'cell' 'or' 'squamous' 'cell'
 'carcinoma' 'of' 'the' 'skin' 'or' 'prostate' 'cancer']","[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 3. 3. 3. 3. 3. 3. 0.
 3. 3.]"
NCT03165227,"1:10:treatment,16:32:treatment,40:68:treatment,70:78:treatment,82:91:treatment","Treatment with SGLT2 inhibitors and/or phosphodiesterase inhibitors, nitrates or riociguat, from screening (Visit 1) or within 5 half-lives before randomisation whatever is earlier","['Treatment' 'with' 'SGLT2' 'inhibitors' 'and/or' 'phosphodiesterase'
 'inhibitors' ',' 'nitrates' 'or' 'riociguat' ',' 'from' 'screening' '('
 'Visit' '1' ')' 'or' 'within' '5' 'half-lives' 'before' 'randomisation'
 'whatever' 'is' 'earlier']","[1. 0. 1. 1. 0. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT03162731,"5:18:treatment,24:33:treatment,35:45:treatment,47:67:treatment","Any prior therapy with anti-PD-1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways","['Any' 'prior' 'therapy' 'with' 'anti-PD-1' ',' 'anti-PD-L2' ','
 'anti-CTLA-4' 'antibody' ',' 'or' 'any' 'other' 'antibody' 'or' 'drug'
 'specifically' 'targeting' 'T-cell' 'co-stimulation' 'or' 'immune'
 'checkpoint' 'pathways']","[0. 1. 1. 0. 1. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT03162731,"1:27:cancer,31:54:cancer,86:102:treatment",superficial bladder cancer or in situ cervical cancer that has undergone potentially curative therapy,"['superficial' 'bladder' 'cancer' 'or' 'in' 'situ' 'cervical' 'cancer'
 'that' 'has' 'undergone' 'potentially' 'curative' 'therapy']",[3. 3. 3. 0. 3. 3. 3. 3. 0. 0. 0. 0. 1. 1.]
NCT03161028,"1:27:chronic_disease,19:27:chronic_disease,58:83:treatment",Insulin-dependent diabetes or diabetes not controlled on oral diabetes medications,"['Insulin-dependent' 'diabetes' 'or' 'diabetes' 'not' 'controlled' 'on'
 'oral' 'diabetes' 'medications']",[2. 2. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT03157167,"11:23:cancer,24:36:chronic_disease,42:47:chronic_disease",Confirmed cutaneous KS/oral lesions with edema,['Confirmed' 'cutaneous' 'KS/oral' 'lesions' 'with' 'edema'],[0. 3. 2. 2. 0. 2.]
NCT03154580,"1:18:chronic_disease,25:34:chronic_disease,36:46:chronic_disease,48:64:chronic_disease","Systemic diseases (e.g. hepatitis, autoimmune, Cushing syndrome)","['Systemic' 'diseases' '(' 'e.g' '.' 'hepatitis' ',' 'autoimmune' ','
 'Cushing' 'syndrome' ')']",[2. 2. 0. 0. 0. 2. 0. 2. 0. 2. 2. 0.]
NCT03153982,"9:25:chronic_disease,36:55:treatment,59:77:treatment",Current active infection requiring systemic antibiotic or antifungal therapy,"['Current' 'active' 'infection' 'requiring' 'systemic' 'antibiotic' 'or'
 'antifungal' 'therapy']",[0. 2. 2. 0. 1. 1. 0. 1. 1.]
NCT03153982,"8:25:treatment,84:95:treatment,127:137:treatment,139:153:treatment,155:165:treatment,167:176:treatment,178:190:treatment,192:204:treatment,206:215:treatment,217:227:treatment,229:239:treatment,241:251:treatment,253:265:treatment,267:276:treatment,278:288:treatment,290:300:treatment,302:315:treatment,320:332:treatment","Strong CYP3A4 inhibitors: (Patients must discontinue drug 7 days prior to starting ruxolitinib), including but not limited to boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, or voriconazole. In addition, patients will be instructed to avoid grapefruit or grapefruit juice, starfruit, or seville oranges","['Strong' 'CYP3A4' 'inhibitors' ':' '(' 'Patients' 'must' 'discontinue'
 'drug' '7' 'days' 'prior' 'to' 'starting' 'ruxolitinib' ')' ','
 'including' 'but' 'not' 'limited' 'to' 'boceprevir' ',' 'clarithromycin'
 ',' 'conivaptan' ',' 'indinavir' ',' 'itraconazole' ',' 'ketoconazole'
 ',' 'lopinavir' ',' 'mibefradil' ',' 'nefazodone' ',' 'nelfinavir' ','
 'posaconazole' ',' 'ritonavir' ',' 'saquinavir' ',' 'telaprevir' ','
 'telithromycin' ',' 'or' 'voriconazole' '.' 'In' 'addition' ','
 'patients' 'will' 'be' 'instructed' 'to' 'avoid' 'grapefruit' 'or'
 'grapefruit' 'juice' ',' 'starfruit' ',' 'or' 'seville' 'oranges']","[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0.
 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT03153410,"40:46:allergy_name,48:58:allergy_name,60:64:treatment,66:74:allergy_name,75:84:allergy_name,86:104:allergy_name,106:113:allergy_name,132:137:allergy_name,151:185:allergy_name","Known or suspected hypersensitivity to GM-CSF, hetastarch, corn, dimethyl sulfoxide, fetal bovine serum, trypsin (porcine origin), yeast or any other component of GVAX pancreas vaccine","['Known' 'or' 'suspected' 'hypersensitivity' 'to' 'GM-CSF' ','
 'hetastarch' ',' 'corn' ',' 'dimethyl' 'sulfoxide' ',' 'fetal' 'bovine'
 'serum' ',' 'trypsin' '(' 'porcine' 'origin' ')' ',' 'yeast' 'or' 'any'
 'other' 'component' 'of' 'GVAX' 'pancreas' 'vaccine']","[0. 0. 0. 0. 0. 4. 0. 4. 0. 1. 0. 4. 4. 0. 4. 4. 4. 0. 4. 0. 0. 0. 0. 0.
 4. 0. 0. 0. 4. 4. 4. 4. 4.]"
NCT03153319,"1:26:chronic_disease,34:46:chronic_disease,48:63:chronic_disease","Hematologic abnormalities (e.g., pancytopenia, aplastic anemia)","['Hematologic' 'abnormalities' '(' 'e.g.' ',' 'pancytopenia' ','
 'aplastic' 'anemia' ')']",[2. 2. 0. 0. 0. 2. 0. 2. 2. 0.]
NCT03151434,"83:91:allergy_name,93:104:allergy_name,106:117:allergy_name","Known allergy or other contraindications to the study medications , which include dilaudid, bupivacaine, ropivacaine","['Known' 'allergy' 'or' 'other' 'contraindications' 'to' 'the' 'study'
 'medications' ',' 'which' 'include' 'dilaudid' ',' 'bupivacaine' ','
 'ropivacaine']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 4.]
NCT03148795,"11:35:chronic_disease,39:60:chronic_disease,82:91:chronic_disease,326:343:chronic_disease","Any other acute or chronic medical or psychiatric condition (concurrent disease, infection, or comorbidity) that interferes with ability to participate in the study, causes undue risk, or complicates the interpretation of data, in the opinion of the investigator or sponsor, including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study","['Any' 'other' 'acute' 'or' 'chronic' 'medical' 'or' 'psychiatric'
 'condition' '(' 'concurrent' 'disease' ',' 'infection' ',' 'or'
 'comorbidity' ')' 'that' 'interferes' 'with' 'ability' 'to' 'participate'
 'in' 'the' 'study' ',' 'causes' 'undue' 'risk' ',' 'or' 'complicates'
 'the' 'interpretation' 'of' 'data' ',' 'in' 'the' 'opinion' 'of' 'the'
 'investigator' 'or' 'sponsor' ',' 'including' 'recent' '(' 'within' 'the'
 'past' 'year' ')' 'or' 'active' 'suicidal' 'ideation' 'or' 'behavior'
 'or' 'laboratory' 'abnormality' 'that' 'may' 'increase' 'the' 'risk'
 'associated' 'with' 'study' 'participation' 'or' 'investigational'
 'product' 'administration' 'or' 'may' 'interfere' 'with' 'the'
 'interpretation' 'of' 'study' 'results' 'and' ',' 'in' 'the' 'judgment'
 'of' 'the' 'investigator' ',' 'would' 'make' 'the' 'patient'
 'inappropriate' 'for' 'entry' 'into' 'this' 'study']","[0. 0. 2. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03148795,"40:52:treatment,56:67:treatment,,83:105:treatment,107:119:treatment,127:146:treatment,147:157:treatment,167:176:treatment,180:195:cancer,213:232:treatment,241:265:cancer,269:292:cancer","Documented disease progression (either radiographic or biochemical) on at least 1 novel hormonal therapy (enzalutamide and/or abiraterone acetate/prednisone) for the treatment of metastatic CRPC, irrespective of prior NHT treatment for non castrate prostate cancer or nonmetastatic (M0) CRPC","['Documented' 'disease' 'progression' '(' 'either' 'radiographic' 'or'
 'biochemical' ')' 'on' 'at' 'least' '1' 'novel' 'hormonal' 'therapy' '('
 'enzalutamide' 'and/or' 'abiraterone' 'acetate/prednisone' ')' 'for'
 'the' 'treatment' 'of' 'metastatic' 'CRPC' ',' 'irrespective' 'of'
 'prior' 'NHT' 'treatment' 'for' 'non' 'castrate' 'prostate' 'cancer' 'or'
 'nonmetastatic' '(' 'M0' ')' 'CRPC']","[0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 0. 1. 1. 0. 0. 0.
 1. 0. 3. 3. 0. 0. 0. 1. 1. 1. 0. 0. 3. 3. 3. 0. 3. 3. 3. 0. 0.]"
NCT03146663,"1:19:treatment,21:30:treatment,107:121:treatment,123:137:treatment,141:154:treatment,","Prior chemotherapy, radiation (other than short cycle of radiation to reduce bone pain), treatment with a VEGF inhibitor, PARP inhibitor or immunotherapy within 21 days of first receipt of study drug","['Prior' 'chemotherapy' ',' 'radiation' '(' 'other' 'than' 'short' 'cycle'
 'of' 'radiation' 'to' 'reduce' 'bone' 'pain' ')' ',' 'treatment' 'with'
 'a' 'VEGF' 'inhibitor' ',' 'PARP' 'inhibitor' 'or' 'immunotherapy'
 'within' '21' 'days' 'of' 'first' 'receipt' 'of' 'study' 'drug']","[1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1.
 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03145298,"14:17:chronic_disease,29:33:chronic_disease,35:39:chronic_disease,41:48:chronic_disease,52:59:chronic_disease","Diagnosis of PAH other than IPAH, HPAH, PAH-CTD or PAH-HIV","['Diagnosis' 'of' 'PAH' 'other' 'than' 'IPAH' ',' 'HPAH' ',' 'PAH-CTD'
 'or' 'PAH-HIV']",[0. 0. 2. 0. 0. 2. 0. 2. 0. 2. 0. 2.]
NCT03145181,"1:24:treatment,74:90:treatment,92:110:treatment,115:153:treatment,165:204:treatment,,","Prior antitumor therapy as follows, before the first dose of study drug: Targeted therapy, epigenetic therapy, or treatment with an investigational drug or used an invasive investigational medical device within 21 days or at least 5 half-lives, whichever is less","['Prior' 'antitumor' 'therapy' 'as' 'follows' ',' 'before' 'the' 'first'
 'dose' 'of' 'study' 'drug' ':' 'Targeted' 'therapy' ',' 'epigenetic'
 'therapy' ',' 'or' 'treatment' 'with' 'an' 'investigational' 'drug' 'or'
 'used' 'an' 'invasive' 'investigational' 'medical' 'device' 'within' '21'
 'days' 'or' 'at' 'least' '5' 'half-lives' ',' 'whichever' 'is' 'less']","[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 1. 1. 1.
 1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03144245,"1:10:chronic_disease,12:17:chronic_disease,19:26:chronic_disease,28:44:chronic_disease,46:58:chronic_disease,62:81:chronic_disease","Pulmonary, renal, hepatic, gastrointestinal, neurological or psychiatric disease that would limit compliance with study requirements","['Pulmonary' ',' 'renal' ',' 'hepatic' ',' 'gastrointestinal' ','
 'neurological' 'or' 'psychiatric' 'disease' 'that' 'would' 'limit'
 'compliance' 'with' 'study' 'requirements']",[2. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT03143985,"24:46:chronic_disease,74:120:chronic_disease,122:146:chronic_disease,164:179:chronic_disease,192:213:chronic_disease,217:223:chronic_disease,,288:299:chronic_disease","Clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association (NYHA) Class 3 or 4, congestive heart failure, uncontrolled or unstable angina, history of myocardial infarction or stroke within 6 months prior to study entry, or clinically significant arrhythmias not controlled by medication","['Clinically' 'significant' 'cardiovascular' 'disease' '(' 'e.g.' ','
 'uncontrolled' 'or' 'any' 'New' 'York' 'Heart' 'Association' '(' 'NYHA'
 ')' 'Class' '3' 'or' '4' ',' 'congestive' 'heart' 'failure' ','
 'uncontrolled' 'or' 'unstable' 'angina' ',' 'history' 'of' 'myocardial'
 'infarction' 'or' 'stroke' 'within' '6' 'months' 'prior' 'to' 'study'
 'entry' ',' 'or' 'clinically' 'significant' 'arrhythmias' 'not'
 'controlled' 'by' 'medication']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 2. 2. 2. 0. 0. 0. 2. 2.
 2. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 0. 0. 0. 0.]"
NCT03143985,"1:26:treatment,28:40:treatment,42:50:treatment,59:71:treatment,77:90:treatment,,128:145:treatment,153:162:treatment,","Prior anti-cancer therapy (chemotherapy, targeted agents, radiotherapy, and immunotherapy) within the prior 21 days except for alkylating agents (e.g., melphalan) within the prior 28 days","['Prior' 'anti-cancer' 'therapy' '(' 'chemotherapy' ',' 'targeted'
 'agents' ',' 'radiotherapy' ',' 'and' 'immunotherapy' ')' 'within' 'the'
 'prior' '21' 'days' 'except' 'for' 'alkylating' 'agents' '(' 'e.g.' ','
 'melphalan' ')' 'within' 'the' 'prior' '28' 'days']","[1. 1. 1. 0. 1. 0. 1. 0. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.
 0. 0. 1. 0. 0. 0. 0. 0. 0.]"
NCT03141359,"23:38:treatment,98:115:treatment,178:187:treatment,201:211:cancer",Subjects who have had prior radiation to the region of the chest that would result in overlap of radiation therapy fields and determined by the treating physician to impede the treatment of the study malignancy,"['Subjects' 'who' 'have' 'had' 'prior' 'radiation' 'to' 'the' 'region'
 'of' 'the' 'chest' 'that' 'would' 'result' 'in' 'overlap' 'of'
 'radiation' 'therapy' 'fields' 'and' 'determined' 'by' 'the' 'treating'
 'physician' 'to' 'impede' 'the' 'treatment' 'of' 'the' 'study'
 'malignancy']","[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 3.]"
NCT03140527,"1:7:cancer,,43:66:cancer,72:88:treatment,,134:158:cancer",cancer within the past 5 years (excluding cervical cancer in situ with curative therapy for at least one year prior to screening and non-melanoma skin cancer),"['cancer' 'within' 'the' 'past' '5' 'years' '(' 'excluding' 'cervical'
 'cancer' 'in' 'situ' 'with' 'curative' 'therapy' 'for' 'at' 'least' 'one'
 'year' 'prior' 'to' 'screening' 'and' 'non-melanoma' 'skin' 'cancer' ')']","[3. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 3. 3. 3. 0.]"
NCT03139227,"19:28:treatment,30:40:treatment,56:76:treatment","Concurrent use of tamoxifen, raloxifene, or any of the aromatase inhibitors","['Concurrent' 'use' 'of' 'tamoxifen' ',' 'raloxifene' ',' 'or' 'any' 'of'
 'the' 'aromatase' 'inhibitors']",[0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 1. 1.]
NCT03138733,"1:10:treatment,39:58:treatment,60:92:treatment,,",Treatment with potentially effective (anti-staphylococcal) systemic antibacterial treatment for more than 48 h within the 7 days prior to randomization,"['Treatment' 'with' 'potentially' 'effective' '(' 'anti-staphylococcal'
 ')' 'systemic' 'antibacterial' 'treatment' 'for' 'more' 'than' '48' 'h'
 'within' 'the' '7' 'days' 'prior' 'to' 'randomization']",[1. 0. 0. 0. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03137771,"43:56:treatment,78:86:treatment,106:124:chronic_disease,149:167:treatment,,197:212:treatment,214:238:treatment,243:266:treatment","Patients who received prior non-induction pembrolizumab, patients on chronic steroids or who have active autoimmune disease for which they received systemic treatment in the previous 2 years with corticosteroids, disease modifying agents, or immunosuppressive drugs","['Patients' 'who' 'received' 'prior' 'non-induction' 'pembrolizumab' ','
 'patients' 'on' 'chronic' 'steroids' 'or' 'who' 'have' 'active'
 'autoimmune' 'disease' 'for' 'which' 'they' 'received' 'systemic'
 'treatment' 'in' 'the' 'previous' '2' 'years' 'with' 'corticosteroids'
 ',' 'disease' 'modifying' 'agents' ',' 'or' 'immunosuppressive' 'drugs']","[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 2. 1. 1. 1. 0. 0. 1. 1. 0.
 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT03137758,"10:32:treatment,55:59:cancer,63:67:cancer,,",received cytotoxic chemotherapy for either metastatic HSPC or CRPC within the last 12 weeks or other investigational agents within 4 weeks,"['received' 'cytotoxic' 'chemotherapy' 'for' 'either' 'metastatic' 'HSPC'
 'or' 'CRPC' 'within' 'the' 'last' '12' 'weeks' 'or' 'other'
 'investigational' 'agents' 'within' '4' 'weeks']",[0. 1. 1. 0. 0. 0. 3. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03137498,"32:41:allergy_name,45:64:allergy_name,68:76:allergy_name,78:82:allergy_name,84:91:allergy_name,93:102:allergy_name","Reported/documented allergy to lidocaine OR ketorolac (Toradol) OR morphine, corn, aspirin, ibuprofen","['Reported/documented' 'allergy' 'to' 'lidocaine' 'OR' 'ketorolac' '('
 'Toradol' ')' 'OR' 'morphine' ',' 'corn' ',' 'aspirin' ',' 'ibuprofen']",[0. 0. 0. 4. 0. 4. 4. 0. 0. 0. 4. 0. 4. 0. 4. 0. 4.]
NCT03137121,"12:23:chronic_disease,30:46:cancer,48:64:chronic_disease","History of CNS disease (e.g. brain metastases, seizure disorder)","['History' 'of' 'CNS' 'disease' '(' 'e.g' '.' 'brain' 'metastases' ','
 'seizure' 'disorder' ')']",[0. 0. 2. 2. 0. 0. 0. 3. 3. 0. 2. 2. 0.]
NCT03135990,"33:75:chronic_disease,83:115:chronic_disease,119:144:chronic_disease",A prior or present diagnosis of receptive and expressive language disorder and/or pervasive developmental disorder or severe mental retardation,"['A' 'prior' 'or' 'present' 'diagnosis' 'of' 'receptive' 'and'
 'expressive' 'language' 'disorder' 'and/or' 'pervasive' 'developmental'
 'disorder' 'or' 'severe' 'mental' 'retardation']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2.]
NCT03135171,"10:19:treatment,25:36:treatment,46:110:treatment,122:132:treatment,134:146:treatment,148:158:treatment,160:169:treatment,171:181:treatment,183:191:treatment,","Previous treatment with tocilizumab or other cytokine-targeted biologic disease modifying antirheumatic drugs (including adalimumab, certolizumab, etanercept, golimumab, infliximab, anakinra) within 3 months of enrollment","['Previous' 'treatment' 'with' 'tocilizumab' 'or' 'other'
 'cytokine-targeted' 'biologic' 'disease' 'modifying' 'antirheumatic'
 'drugs' '(' 'including' 'adalimumab' ',' 'certolizumab' ',' 'etanercept'
 ',' 'golimumab' ',' 'infliximab' ',' 'anakinra' ')' 'within' '3' 'months'
 'of' 'enrollment']","[0. 1. 0. 1. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0.
 1. 0. 0. 0. 0. 0. 0.]"
NCT03133013,"12:22:treatment,38:48:treatment,50:62:treatment,64:71:treatment,73:79:treatment,91:99:treatment","Prescribed interferon regularly with stimulants, opioid drugs (Ritalin, Opioid, etc.) and steroids","['Prescribed' 'interferon' 'regularly' 'with' 'stimulants' ',' 'opioid'
 'drugs' '(' 'Ritalin' ',' 'Opioid' ',' 'etc' '.' ')' 'and' 'steroids']",[0. 1. 0. 0. 1. 0. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 1.]
NCT03131635,"1:17:treatment,25:50:treatment,53:67:treatment,69:95:treatment,99:125:treatment,","Stable treatment (e.g., applied behavior analysis), speech therapy, psychotropic medication(s) or biomedical intervention(s) for at least 1 month prior to baseline measurements with no anticipated changes during study participation","['Stable' 'treatment' '(' 'e.g.' ',' 'applied' 'behavior' 'analysis' ')'
 ',' 'speech' 'therapy' ',' 'psychotropic' 'medication' '(' 's' ')' 'or'
 'biomedical' 'intervention' '(' 's' ')' 'for' 'at' 'least' '1' 'month'
 'prior' 'to' 'baseline' 'measurements' 'with' 'no' 'anticipated'
 'changes' 'during' 'study' 'participation']","[1. 1. 0. 0. 0. 1. 1. 1. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03131037,"1:30:treatment,61:92:treatment,101:118:treatment",Prior bone marrow transplants (including stem cells) except autologous stem cell transplant without immunosuppression is NOT considered an exclusion,"['Prior' 'bone' 'marrow' 'transplants' '(' 'including' 'stem' 'cells' ')'
 'except' 'autologous' 'stem' 'cell' 'transplant' 'without'
 'immunosuppression' 'is' 'NOT' 'considered' 'an' 'exclusion']",[1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 1. 0. 0. 0. 0. 0.]
NCT03130218,"8:31:chronic_disease,40:46:chronic_disease,50:94:chronic_disease",Severe reactive airway disease such as asthma or chronic obstructive pulmonary disease (COPD),"['Severe' 'reactive' 'airway' 'disease' 'such' 'as' 'asthma' 'or'
 'chronic' 'obstructive' 'pulmonary' 'disease' '(' 'COPD' ')']",[0. 2. 2. 2. 0. 0. 2. 0. 2. 2. 2. 2. 2. 0. 0.]
NCT03126370,"18:21:treatment,28:37:treatment,42:79:treatment,109:118:treatment,122:125:chronic_disease",Have been taking TDF and a ritonavir- or cobicistat-boosted protease inhibitor as part of standard care for treatment of HIV,"['Have' 'been' 'taking' 'TDF' 'and' 'a' 'ritonavir-' 'or'
 'cobicistat-boosted' 'protease' 'inhibitor' 'as' 'part' 'of' 'standard'
 'care' 'for' 'treatment' 'of' 'HIV']",[0. 0. 0. 1. 0. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 2.]
NCT03125902,"1:24:chronic_disease,55:62:treatment,70:79:treatment",Spinal cord compression not definitively treated with surgery and/or radiation,"['Spinal' 'cord' 'compression' 'not' 'definitively' 'treated' 'with'
 'surgery' 'and/or' 'radiation']",[2. 2. 2. 0. 0. 0. 0. 1. 0. 1.]
NCT03124355,"37:57:chronic_disease,65:76:chronic_disease,78:89:treatment","Medical conditions that can explain postural tachycardia (e.g., dehydration, medications)","['Medical' 'conditions' 'that' 'can' 'explain' 'postural' 'tachycardia'
 '(' 'e.g.' ',' 'dehydration' ',' 'medications' ')']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 0. 1. 0.]
NCT03123783,"55:80:treatment,99:118:cancer,122:127:cancer",History of life-threatening toxicity related to prior anti-PD-1/PD-L1 treatment for subjects with metastatic melanoma or NSCLC,"['History' 'of' 'life-threatening' 'toxicity' 'related' 'to' 'prior'
 'anti-PD-1/PD-L1' 'treatment' 'for' 'subjects' 'with' 'metastatic'
 'melanoma' 'or' 'NSCLC']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 3. 3. 0. 3.]
NCT03123198,"92:105:chronic_disease,126:134:chronic_disease,167:197:treatment","Clients who need mental health services not available at the DBT-RU, such as treatment for schizophrenia or life-threatening anorexia, or who are currently obtaining optimum professional treatment that should not be ended","['Clients' 'who' 'need' 'mental' 'health' 'services' 'not' 'available'
 'at' 'the' 'DBT-RU' ',' 'such' 'as' 'treatment' 'for' 'schizophrenia'
 'or' 'life-threatening' 'anorexia' ',' 'or' 'who' 'are' 'currently'
 'obtaining' 'optimum' 'professional' 'treatment' 'that' 'should' 'not'
 'be' 'ended']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 2. 0. 0. 0. 0.
 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]"
NCT03123055,"32:61:chronic_disease,63:83:chronic_disease,98:109:chronic_disease,111:133:chronic_disease","Participants with a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on the Screening chest CT scan","['Participants' 'with' 'a' 'history' 'of' 'idiopathic' 'pulmonary'
 'fibrosis' ',' 'organizing' 'pneumonia' ',' 'drug-induced' 'pneumonitis'
 ',' 'idiopathic' 'pneumonitis' ',' 'or' 'evidence' 'of' 'active'
 'pneumonitis' 'on' 'the' 'Screening' 'chest' 'CT' 'scan']","[0. 0. 0. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT03122912,"10:15:treatment,44:51:treatment,79:85:treatment,",Frequent NSAID use (not including low dose aspirin) and not willing to go off NSAIDS for 3 weeks prior to enrollment and to end of study,"['Frequent' 'NSAID' 'use' '(' 'not' 'including' 'low' 'dose' 'aspirin' ')'
 'and' 'not' 'willing' 'to' 'go' 'off' 'NSAIDS' 'for' '3' 'weeks' 'prior'
 'to' 'enrollment' 'and' 'to' 'end' 'of' 'study']","[0. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT03122691,"12:34:chronic_disease,55:64:chronic_disease,66:91:chronic_disease","History of xerostomia (dry mouth), or the presence of mucositis, gum infection or bleeding, or other significant oral cavity disease or disorder that in the investigator's opinion may affect the collection of oral fluid samples","['History' 'of' 'xerostomia' '(' 'dry' 'mouth' ')' ',' 'or' 'the'
 'presence' 'of' 'mucositis' ',' 'gum' 'infection' 'or' 'bleeding' ','
 'or' 'other' 'significant' 'oral' 'cavity' 'disease' 'or' 'disorder'
 'that' 'in' 'the' 'investigator' ""'s"" 'opinion' 'may' 'affect' 'the'
 'collection' 'of' 'oral' 'fluid' 'samples']","[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03121352,"45:116:allergy_name,118:129:allergy_name,131:144:allergy_name,149:161:allergy_name","History of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-paclitaxel, carboplatin, pembrolizumab, or other agents used in this study","['History' 'of' 'allergic' 'reactions' 'attributed' 'to' 'compounds' 'of'
 'similar' 'chemical' 'or' 'biologic' 'composition' 'to' 'nab-paclitaxel'
 ',' 'carboplatin' ',' 'pembrolizumab' ',' 'or' 'other' 'agents' 'used'
 'in' 'this' 'study']","[0. 0. 0. 0. 0. 0. 4. 4. 4. 4. 4. 4. 4. 4. 4. 0. 4. 0. 4. 0. 0. 4. 4. 0.
 0. 0. 0.]"
NCT03120728,"71:97:treatment,99:107:treatment,109:118:treatment,120:133:treatment","Use of medications that interact with contraceptive steroid hormones: anti-epileptic medications, rifampin, rifabutin, fosamprenavir, etc","['Use' 'of' 'medications' 'that' 'interact' 'with' 'contraceptive'
 'steroid' 'hormones' ':' 'anti-epileptic' 'medications' ',' 'rifampin'
 ',' 'rifabutin' ',' 'fosamprenavir' ',' 'etc']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 1. 0. 0.]
NCT03119363,"24:41:chronic_disease,80:86:chronic_disease,105:115:treatment,,","Confounding underlying medical illnesses which may cause fatigue (e.g., severe Anemia not controlled by medication, per self-report corroborated by medical chart review (e.g., Hb<10gm/dl)","['Confounding' 'underlying' 'medical' 'illnesses' 'which' 'may' 'cause'
 'fatigue' '(' 'e.g.' ',' 'severe' 'Anemia' 'not' 'controlled' 'by'
 'medication' ',' 'per' 'self-report' 'corroborated' 'by' 'medical'
 'chart' 'review' '(' 'e.g.' ',' 'Hb' '<' '10gm/dl' ')']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03118973,"1:17:chronic_disease,19:31:chronic_disease,59:83:treatment","Thrombocytopenia, coagulopathy, or indication for ongoing anti-coagulation therapy","['Thrombocytopenia' ',' 'coagulopathy' ',' 'or' 'indication' 'for'
 'ongoing' 'anti-coagulation' 'therapy']",[2. 0. 2. 0. 0. 0. 0. 0. 1. 1.]
NCT03116685,"18:41:chronic_disease,28:41:chronic_disease,69:86:treatment,98:123:chronic_disease,132:147:chronic_disease,157:183:chronic_disease,188:208:chronic_disease","The existence of secondary hyperoxaluria, e.g. hyperoxaluria due to bariatric surgery or chronic gastrointestinal diseases such as cystic fibrosis, chronic inflammatory bowel disease and short-bowel syndrome","['The' 'existence' 'of' 'secondary' 'hyperoxaluria' ',' 'e.g' '.'
 'hyperoxaluria' 'due' 'to' 'bariatric' 'surgery' 'or' 'chronic'
 'gastrointestinal' 'diseases' 'such' 'as' 'cystic' 'fibrosis' ','
 'chronic' 'inflammatory' 'bowel' 'disease' 'and' 'short-bowel' 'syndrome']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 2. 2. 0. 0. 2. 2. 0. 0. 2.
 2. 2. 0. 2. 2.]"
NCT03115398,"14:46:cancer,48:68:cancer,70:74:cancer,76:98:cancer,103:117:cancer","Diagnosis of invasive malignancy of the brain, head and neck region, lung, gastrointestinal tract, or uterine cervix","['Diagnosis' 'of' 'invasive' 'malignancy' 'of' 'the' 'brain' ',' 'head'
 'and' 'neck' 'region' ',' 'lung' ',' 'gastrointestinal' 'tract' ',' 'or'
 'uterine' 'cervix']",[0. 0. 3. 3. 3. 3. 3. 0. 3. 3. 3. 3. 0. 3. 0. 3. 3. 0. 0. 3. 3.]
NCT03114020,",,84:103:treatment,105:123:treatment,125:148:treatment,153:156:treatment,","men who are sexually active must agree to use an adequate method of contraception (oral contraceptives, depot progesterone, condom plus spermicidal, or IUD) during the study and for 1 month after the final dose of study drug","['men' 'who' 'are' 'sexually' 'active' 'must' 'agree' 'to' 'use' 'an'
 'adequate' 'method' 'of' 'contraception' '(' 'oral' 'contraceptives' ','
 'depot' 'progesterone' ',' 'condom' 'plus' 'spermicidal' ',' 'or' 'IUD'
 ')' 'during' 'the' 'study' 'and' 'for' '1' 'month' 'after' 'the' 'final'
 'dose' 'of' 'study' 'drug']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 1. 1. 1.
 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03113825,"1:24:treatment,28:44:treatment,57:70:cancer,,95:110:treatment",Prior neoadjuvant chemo or biologic therapy for current breast cancer within 4 weeks prior to planned surgery [Period 1],"['Prior' 'neoadjuvant' 'chemo' 'or' 'biologic' 'therapy' 'for' 'current'
 'breast' 'cancer' 'within' '4' 'weeks' 'prior' 'to' 'planned' 'surgery'
 '[' 'Period' '1' ']']",[1. 1. 1. 0. 1. 1. 0. 0. 3. 3. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT03112863,"29:37:treatment,41:59:treatment,,123:140:chronic_disease,150:176:treatment,178:192:treatment,194:215:treatment,232:251:treatment","Those who have had a recent surgical or cosmetic procedure in the last 3 months that can affect facial wrinkles or facial hyperpigmentation, such as botulinum toxin injections, chemical peels, laser based therapies to the face, or face lift surgeries","['Those' 'who' 'have' 'had' 'a' 'recent' 'surgical' 'or' 'cosmetic'
 'procedure' 'in' 'the' 'last' '3' 'months' 'that' 'can' 'affect' 'facial'
 'wrinkles' 'or' 'facial' 'hyperpigmentation' ',' 'such' 'as' 'botulinum'
 'toxin' 'injections' ',' 'chemical' 'peels' ',' 'laser' 'based'
 'therapies' 'to' 'the' 'face' ',' 'or' 'face' 'lift' 'surgeries']","[0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0.
 0. 0. 1. 1. 1. 0. 1. 1. 0. 1. 1. 1. 0. 0. 1. 1. 1. 0. 0. 0.]"
NCT03112603,"205:239:treatment,250:268:treatment,270:297:treatment,299:340:treatment,342:352:treatment,354:363:treatment,365:376:treatment,378:386:treatment,388:397:treatment","must accept to be treated with only one of the following BAT options on Cycle 1 Day 1 (additions and changes are allowed during the course of the study, but only with BAT from the following BAT options): extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, ibrutinib","['must' 'accept' 'to' 'be' 'treated' 'with' 'only' 'one' 'of' 'the'
 'following' 'BAT' 'options' 'on' 'Cycle' '1' 'Day' '1' '(' 'additions'
 'and' 'changes' 'are' 'allowed' 'during' 'the' 'course' 'of' 'the'
 'study' ',' 'but' 'only' 'with' 'BAT' 'from' 'the' 'following' 'BAT'
 'options' ')' ':' 'extracorporeal' 'photopheresis' '(' 'ECP' ')' ','
 'low-dose' 'methotrexate' '(' 'MTX' ')' ',' 'mycophenolate' 'mofetil' '('
 'MMF' ')' ',' 'mTOR' 'inhibitors' '(' 'everolimus' 'or' 'sirolimus' ')'
 ',' 'infliximab' ',' 'rituximab' ',' 'pentostatin' ',' 'imatinib' ','
 'ibrutinib']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0.
 0. 1. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0.
 1. 0. 1. 0. 1.]"
NCT03112590,"31:54:treatment,75:86:treatment,91:101:treatment",Must be candidates to receive paclitaxel chemotherapy in combination with trastuzumab and pertuzumab,"['Must' 'be' 'candidates' 'to' 'receive' 'paclitaxel' 'chemotherapy' 'in'
 'combination' 'with' 'trastuzumab' 'and' 'pertuzumab']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1.]
NCT03112174,"26:29:cancer,230:270:treatment,275:306:treatment","Pathologically confirmed MCL (in tumor tissue), with documentation of either overexpression of cyclin D1 in association with other relevant markers (eg, CD19, CD20, PAX5, CD5) or evidence of t(11;14) as assessed by cytogenetics, fluorescent in situ hybridization (FISH), or polymerase chain reaction (PCR)","['Pathologically' 'confirmed' 'MCL' '(' 'in' 'tumor' 'tissue' ')' ','
 'with' 'documentation' 'of' 'either' 'overexpression' 'of' 'cyclin' 'D1'
 'in' 'association' 'with' 'other' 'relevant' 'markers' '(' 'eg' ','
 'CD19' ',' 'CD20' ',' 'PAX5' ',' 'CD5' ')' 'or' 'evidence' 'of' 't' '('
 '11' ';' '14' ')' 'as' 'assessed' 'by' 'cytogenetics' ',' 'fluorescent'
 'in' 'situ' 'hybridization' '(' 'FISH' ')' ',' 'or' 'polymerase' 'chain'
 'reaction' '(' 'PCR' ')']","[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1. 1. 1. 1. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0.]"
NCT03110354,"32:50:cancer,59:70:cancer,74:82:cancer,96:105:treatment",Has a second concurrent active primary malignancy such as solid tumor or lymphoma under active treatment,"['Has' 'a' 'second' 'concurrent' 'active' 'primary' 'malignancy' 'such'
 'as' 'solid' 'tumor' 'or' 'lymphoma' 'under' 'active' 'treatment']",[0. 0. 0. 0. 0. 3. 3. 0. 0. 3. 3. 0. 3. 0. 0. 1.]
NCT03110107,"19:43:cancer,48:54:cancer,60:74:cancer","Participants with primary CNS malignancies, or tumors with CNS metastases as the only site of disease, will be excluded","['Participants' 'with' 'primary' 'CNS' 'malignancies' ',' 'or' 'tumors'
 'with' 'CNS' 'metastases' 'as' 'the' 'only' 'site' 'of' 'disease' ','
 'will' 'be' 'excluded']",[0. 0. 3. 3. 3. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03109210,"11:31:chronic_disease,39:55:chronic_disease,122:132:treatment","untreated psychiatric disorder (e.g., major depression) found on structured interviews as these conditions have specific treatments and it would be inappropriate not to offer those treatments","['untreated' 'psychiatric' 'disorder' '(' 'e.g.' ',' 'major' 'depression'
 ')' 'found' 'on' 'structured' 'interviews' 'as' 'these' 'conditions'
 'have' 'specific' 'treatments' 'and' 'it' 'would' 'be' 'inappropriate'
 'not' 'to' 'offer' 'those' 'treatments']","[0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT03104725,"14:34:chronic_disease,49:58:treatment,66:77:treatment",History of a post-spinal headache that required treatment with a blood patch,"['History' 'of' 'a' 'post-spinal' 'headache' 'that' 'required' 'treatment'
 'with' 'a' 'blood' 'patch']",[0. 0. 0. 2. 2. 0. 0. 1. 0. 0. 1. 1.]
NCT03104699,"1:14:treatment,24:98:treatment,107:116:treatment,118:128:treatment,133:190:treatment","Prior therapy with any antibody/drug targeting T-cell co-regulatory proteins (immune checkpoints) such as anti-PD-1, anti-PD-L1, or anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibodies","['Prior' 'therapy' 'with' 'any' 'antibody/drug' 'targeting' 'T-cell'
 'co-regulatory' 'proteins' '(' 'immune' 'checkpoints' ')' 'such' 'as'
 'anti-PD-1' ',' 'anti-PD-L1' ',' 'or' 'anti-cytotoxic' 'T-lymphocyte'
 'antigen' '4' '(' 'CTLA-4' ')' 'antibodies']","[1. 1. 0. 0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 1. 1. 1.
 1. 1. 0. 0.]"
NCT03104699,"15:58:cancer,78:87:treatment,93:154:treatment","subjects with castration-resistant prostate cancer (CRPC), who may remain on treatment with luteinizing hormone-releasing hormone agonists or antagonists","['subjects' 'with' 'castration-resistant' 'prostate' 'cancer' '(' 'CRPC'
 ')' ',' 'who' 'may' 'remain' 'on' 'treatment' 'with' 'luteinizing'
 'hormone-releasing' 'hormone' 'agonists' 'or' 'antagonists']",[0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 1. 1. 1.]
NCT03101566,"12:28:treatment,,,82:92:treatment,144:162:chronic_disease","Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease","['Inhaled' 'or' 'topical' 'steroids' ',' 'and' 'adrenal' 'replacement'
 'steroid' 'doses' '>' '10' 'mg' 'daily' 'prednisone' 'equivalent' ','
 'are' 'permitted' 'in' 'the' 'absence' 'of' 'active' 'autoimmune'
 'disease']","[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 2.]"
NCT03101566,"32:56:treatment,58:70:treatment,74:90:treatment,105:131:cancer",Patients may not have received prior systemic treatment (chemotherapy or targeted therapy) for advanced BTC (biliary tract cancer),"['Patients' 'may' 'not' 'have' 'received' 'prior' 'systemic' 'treatment'
 '(' 'chemotherapy' 'or' 'targeted' 'therapy' ')' 'for' 'advanced' 'BTC'
 '(' 'biliary' 'tract' 'cancer' ')']",[0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 0. 1. 1. 0. 0. 0. 3. 3. 3. 3. 0. 0.]
NCT03100435,"36:57:allergy_name,67:104:chronic_disease,108:126:chronic_disease","Subjects with contraindications to wearing a mouth guard, such as chronic obstructive pulmonary disease or severe sleep apnea","['Subjects' 'with' 'contraindications' 'to' 'wearing' 'a' 'mouth' 'guard'
 ',' 'such' 'as' 'chronic' 'obstructive' 'pulmonary' 'disease' 'or'
 'severe' 'sleep' 'apnea']",[0. 0. 0. 0. 4. 4. 4. 4. 0. 0. 0. 2. 2. 2. 2. 0. 2. 2. 2.]
NCT03097588,"125:135:allergy_name,137:149:allergy_name,151:164:allergy_name","Subjects with known hypersensitivity or other allergic reactions attributed to compounds of similar biologic composition to netupitant, palonosetron, dexamethasone, or other agents used in the study","['Subjects' 'with' 'known' 'hypersensitivity' 'or' 'other' 'allergic'
 'reactions' 'attributed' 'to' 'compounds' 'of' 'similar' 'biologic'
 'composition' 'to' 'netupitant' ',' 'palonosetron' ',' 'dexamethasone'
 ',' 'or' 'other' 'agents' 'used' 'in' 'the' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 4. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT03095118,"27:52:treatment,63:79:treatment,81:84:treatment,86:98:treatment,100:110:treatment,114:126:treatment,","Patients who had received immunosuppressive therapy including cyclophosphamide, MMF, cyclosporine, tacrolimus or azathioprine in the last 3 months","['Patients' 'who' 'had' 'received' 'immunosuppressive' 'therapy'
 'including' 'cyclophosphamide' ',' 'MMF' ',' 'cyclosporine' ','
 'tacrolimus' 'or' 'azathioprine' 'in' 'the' 'last' '3' 'months']",[0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0.]
NCT03093909,"77:93:chronic_disease,95:106:chronic_disease,119:134:chronic_disease,136:155:chronic_disease,157:193:chronic_disease,195:219:chronic_disease,221:239:chronic_disease,244:281:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, bradycardia, related to cardiac disease, bundle branch block, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'bradycardia'
 ',' 'related' 'to' 'cardiac' 'disease' ',' 'bundle' 'branch' 'block' ','
 'symptomatic' 'congestive' 'heart' 'failure' ',' 'unstable' 'angina'
 'pectoris' ',' 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric'
 'illness/social' 'situations' 'that' 'would' 'limit' 'compliance' 'with'
 'study' 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 0. 0. 2. 2. 0. 2. 2.
 2. 0. 2. 2. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.
 0.]"
NCT03093272,"1:10:treatment,16:35:treatment,40:44:chronic_disease",Treatment with abiraterone acetate for CRPC in the past is required,"['Treatment' 'with' 'abiraterone' 'acetate' 'for' 'CRPC' 'in' 'the' 'past'
 'is' 'required']",[1. 0. 1. 1. 0. 2. 0. 0. 0. 0. 0.]
NCT03092635,"16:32:cancer,82:90:treatment,94:118:treatment","Treated stable brain metastases are allowed, as long as patient does not require steroids or anti-seizure medications","['Treated' 'stable' 'brain' 'metastases' 'are' 'allowed' ',' 'as' 'long'
 'as' 'patient' 'does' 'not' 'require' 'steroids' 'or' 'anti-seizure'
 'medications']",[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1.]
NCT03090607,"12:31:chronic_disease,33:46:chronic_disease,83:119:treatment","History of heartburn-like pain, regurgitation, or both prior to the initiation of proton pump inhibitor (PPIs) therapy","['History' 'of' 'heartburn-like' 'pain' ',' 'regurgitation' ',' 'or'
 'both' 'prior' 'to' 'the' 'initiation' 'of' 'proton' 'pump' 'inhibitor'
 '(' 'PPIs' ')' 'therapy']",[0. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0.]
NCT03089554,"14:34:chronic_disease,77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease,253:269:treatment","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with targeted therapy, in the opinion of the treating physician","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'targeted'
 'therapy' ',' 'in' 'the' 'opinion' 'of' 'the' 'treating' 'physician']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0.
 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03088072,"1:11:chronic_disease,16:30:chronic_disease,44:64:chronic_disease","AV fistula, or pseudoaneurysm), or serious pericardial effusion)","['AV' 'fistula' ',' 'or' 'pseudoaneurysm' ')' ',' 'or' 'serious'
 'pericardial' 'effusion' ')']",[2. 2. 0. 0. 2. 0. 0. 0. 0. 2. 2. 0.]
NCT03088033,"13:15:chronic_disease,34:43:treatment,49:58:treatment,",Symptoms of HF requiring current treatment with diuretics for > 30 days,"['Symptoms' 'of' 'HF' 'requiring' 'current' 'treatment' 'with' 'diuretics'
 'for' '>' '30' 'days']",[0. 0. 2. 0. 0. 1. 0. 1. 0. 0. 0. 0.]
NCT03087903,"15:40:chronic_disease,54:88:treatment,100:131:treatment",Patients with hormone sensitive disease who received prior androgen deprivation therapy as part of primary/salvage local treatment,"['Patients' 'with' 'hormone' 'sensitive' 'disease' 'who' 'received'
 'prior' 'androgen' 'deprivation' 'therapy' 'as' 'part' 'of'
 'primary/salvage' 'local' 'treatment']",[0. 0. 2. 2. 2. 0. 0. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1.]
NCT03085485,"24:35:chronic_disease,46:70:treatment,74:98:chronic_disease",Clinically significant arrhythmias requiring anti-arrhythmic agent(s) or conduction abnormalities that in the opinion of the investigator that affect patient safety,"['Clinically' 'significant' 'arrhythmias' 'requiring' 'anti-arrhythmic'
 'agent' '(' 's' ')' 'or' 'conduction' 'abnormalities' 'that' 'in' 'the'
 'opinion' 'of' 'the' 'investigator' 'that' 'affect' 'patient' 'safety']",[0. 0. 2. 0. 1. 1. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03085095,"118:125:treatment,127:144:treatment,146:157:treatment,212:240:treatment","Evidence of biochemical (PSA) or clinical relapse following local primary intervention with curative intent, such as surgery, radiation therapy, cryotherapy, or high-frequency ultrasound and not a candidate for salvage treatment by surgery","['Evidence' 'of' 'biochemical' '(' 'PSA' ')' 'or' 'clinical' 'relapse'
 'following' 'local' 'primary' 'intervention' 'with' 'curative' 'intent'
 ',' 'such' 'as' 'surgery' ',' 'radiation' 'therapy' ',' 'cryotherapy' ','
 'or' 'high-frequency' 'ultrasound' 'and' 'not' 'a' 'candidate' 'for'
 'salvage' 'treatment' 'by' 'surgery']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]"
NCT03084640,"21:36:chronic_disease,,109:121:chronic_disease,123:138:chronic_disease,140:166:chronic_disease,170:200:chronic_disease","Severe uncontrolled cardiac disease within 6 months of screening, including but not limited to uncontrolled hypertension; unstable angina; myocardial infarction (MI) or cerebrovascular accident (CVA)","['Severe' 'uncontrolled' 'cardiac' 'disease' 'within' '6' 'months' 'of'
 'screening' ',' 'including' 'but' 'not' 'limited' 'to' 'uncontrolled'
 'hypertension' ';' 'unstable' 'angina' ';' 'myocardial' 'infarction' '('
 'MI' ')' 'or' 'cerebrovascular' 'accident' '(' 'CVA' ')']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 2. 2. 2.
 0. 0. 0. 2. 2. 2. 0. 0.]"
NCT03079297,"1:24:treatment,26:29:treatment,34:38:treatment,49:81:treatment","Vagus nerve stimulation, ECT, or rTMS, or other somatic antidepressant treatment during current episode","['Vagus' 'nerve' 'stimulation' ',' 'ECT' ',' 'or' 'rTMS' ',' 'or' 'other'
 'somatic' 'antidepressant' 'treatment' 'during' 'current' 'episode']",[1. 1. 1. 0. 1. 0. 0. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0.]
NCT03078530,"32:46:chronic_disease,58:66:chronic_disease,71:77:chronic_disease",Normal gross appearance of the colonic mucosa other than erythema and polyps,"['Normal' 'gross' 'appearance' 'of' 'the' 'colonic' 'mucosa' 'other'
 'than' 'erythema' 'and' 'polyps']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 0. 2.]
NCT03078192,"27:30:chronic_disease,32:59:chronic_disease,63:75:chronic_disease,77:114:chronic_disease,118:143:chronic_disease,148:153:chronic_disease","Either has a diagnosis of PAH, isolated left heart disease or lung disease (chronic obstructive pulmonary disease or interstitial lung disease) or CTEPH using established clinical criteria","['Either' 'has' 'a' 'diagnosis' 'of' 'PAH' ',' 'isolated' 'left' 'heart'
 'disease' 'or' 'lung' 'disease' '(' 'chronic' 'obstructive' 'pulmonary'
 'disease' 'or' 'interstitial' 'lung' 'disease' ')' 'or' 'CTEPH' 'using'
 'established' 'clinical' 'criteria']","[0. 0. 0. 0. 0. 2. 0. 2. 2. 2. 2. 0. 2. 2. 0. 2. 2. 2. 2. 0. 2. 2. 2. 0.
 0. 2. 0. 0. 0. 0.]"
NCT03077412,"12:33:treatment,35:50:treatment,64:73:treatment,77:86:treatment,114:121:treatment","History of total proctocolectomy, total colectomy, presence of ileostomy or colostomy, or likely requirement for surgery during the study","['History' 'of' 'total' 'proctocolectomy' ',' 'total' 'colectomy' ','
 'presence' 'of' 'ileostomy' 'or' 'colostomy' ',' 'or' 'likely'
 'requirement' 'for' 'surgery' 'during' 'the' 'study']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT03077243,"1:38:chronic_disease,61:80:chronic_disease,127:134:treatment",Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration,"['Chronic' 'Obstructive' 'Pulmonary' 'Disease' 'exacerbation' 'or' 'other'
 'respiratory' 'illness' 'requiring' 'hospitalization' 'or' 'precluding'
 'study' 'therapy' 'at' 'the' 'time' 'of' 'registration']",[2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT03075826,"14:26:treatment,62:73:treatment,91:103:treatment,,",have had any chemotherapy (investigational or FDA approved) (hydroxyurea is permitted) or radiotherapy within 2 weeks prior to study entry or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier,"['have' 'had' 'any' 'chemotherapy' '(' 'investigational' 'or' 'FDA'
 'approved' ')' '(' 'hydroxyurea' 'is' 'permitted' ')' 'or' 'radiotherapy'
 'within' '2' 'weeks' 'prior' 'to' 'study' 'entry' 'or' 'those' 'who'
 'have' 'not' 'recovered' 'from' 'adverse' 'events' 'due' 'to' 'agents'
 'administered' 'more' 'than' '2' 'weeks' 'earlier']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03073785,"1:23:cancer,67:81:cancer,90:116:cancer,131:148:chronic_disease,171:186:cancer","T 1-2N+MO or T3-4 NxMo, or borderline resectable and unresectable adenocarcinoma without distant metastatic disease or resectable T3-4 NxMo disease or M1 with controlled distant disease","['T' '1-2N+MO' 'or' 'T3-4' 'NxMo' ',' 'or' 'borderline' 'resectable' 'and'
 'unresectable' 'adenocarcinoma' 'without' 'distant' 'metastatic'
 'disease' 'or' 'resectable' 'T3-4' 'NxMo' 'disease' 'or' 'M1' 'with'
 'controlled' 'distant' 'disease']","[3. 3. 3. 2. 2. 2. 0. 0. 0. 0. 0. 3. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT03073343,"13:26:chronic_disease,38:71:chronic_disease,75:104:chronic_disease",Evidence of liver disease other than non-alcoholic fatty liver disease or non-alcoholic steatohepatitis,"['Evidence' 'of' 'liver' 'disease' 'other' 'than' 'non-alcoholic' 'fatty'
 'liver' 'disease' 'or' 'non-alcoholic' 'steatohepatitis']",[0. 0. 2. 2. 0. 0. 2. 2. 2. 2. 0. 0. 0.]
NCT03072238,"21:35:chronic_disease,37:46:chronic_disease,51:72:chronic_disease","Any other diseases, cardiovascular, pulmonary, or metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the participants at high risk from treatment complications","['Any' 'other' 'diseases' ',' 'cardiovascular' ',' 'pulmonary' ',' 'or'
 'metabolic' 'dysfunction' ',' 'physical' 'examination' 'finding' ',' 'or'
 'clinical' 'laboratory' 'finding' 'giving' 'reasonable' 'suspicion' 'of'
 'a' 'disease' 'or' 'condition' 'that' 'contraindicates' 'the' 'use' 'of'
 'an' 'investigational' 'drug' 'or' 'that' 'may' 'affect' 'the'
 'interpretation' 'of' 'the' 'results' 'or' 'renders' 'the' 'participants'
 'at' 'high' 'risk' 'from' 'treatment' 'complications']","[0. 0. 0. 0. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT03072238,"27:66:cancer,93:119:treatment,123:138:treatment",Known untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsant medications or corticosteroids for symptomatic control),"['Known' 'untreated' 'or' 'active' 'central' 'nervous' 'system' '(' 'CNS'
 ')' 'metastases' '(' 'progressing' 'or' 'requiring' 'anticonvulsant'
 'medications' 'or' 'corticosteroids' 'for' 'symptomatic' 'control' ')']",[0. 0. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0.]
NCT03072238,"1:33:treatment,56:72:treatment,80:92:treatment,94:103:treatment","Prior treatment with abiraterone or other known potent CYP17 inhibitors (e.g., ketoconazole, orteronel) or investigational agents that block androgen synthesis","['Prior' 'treatment' 'with' 'abiraterone' 'or' 'other' 'known' 'potent'
 'CYP17' 'inhibitors' '(' 'e.g.' ',' 'ketoconazole' ',' 'orteronel' ')'
 'or' 'investigational' 'agents' 'that' 'block' 'androgen' 'synthesis']",[1. 1. 1. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03072238,"1:25:chronic_disease,40:77:chronic_disease,79:107:chronic_disease","structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy)","['structural' 'heart' 'disease' '(' 'e.g.' ',' 'severe' 'left'
 'ventricular' 'systolic' 'dysfunction' ',' 'left' 'ventricular'
 'hypertrophy' ')']",[2. 2. 2. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT03071692,"1:16:chronic_disease,8:16:chronic_disease,,,,,,,,,,409:418:treatment","Type 2 diabetes of longer than 12 weeks duration documented in medical records, for example: local laboratory evidence through medical record review of elevated HbA1c (≥ 6.5% [48 mmol/mol]), elevated plasma glucose (fasting ≥ 126 mg/dL [7.0 mmol/L], 2-hour ≥ 200 mg/dL [11.1 mmol/L] during oral glucose tolerance testing, or random value ≥ 200 mg/dL with classic symptoms, or currently taking medication for treatment of diabetes; AND either","['Type' '2' 'diabetes' 'of' 'longer' 'than' '12' 'weeks' 'duration'
 'documented' 'in' 'medical' 'records' ',' 'for' 'example' ':' 'local'
 'laboratory' 'evidence' 'through' 'medical' 'record' 'review' 'of'
 'elevated' 'HbA1c' '(' '≥' '6.5' '%' '[' '48' 'mmol/mol' ']' ')' ','
 'elevated' 'plasma' 'glucose' '(' 'fasting' '≥' '126' 'mg/dL' '[' '7.0'
 'mmol/L' ']' ',' '2-hour' '≥' '200' 'mg/dL' '[' '11.1' 'mmol/L' ']'
 'during' 'oral' 'glucose' 'tolerance' 'testing' ',' 'or' 'random' 'value'
 '≥' '200' 'mg/dL' 'with' 'classic' 'symptoms' ',' 'or' 'currently'
 'taking' 'medication' 'for' 'treatment' 'of' 'diabetes' ';' 'AND'
 'either']","[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]"
NCT03070535,"17:42:chronic_disease,61:81:treatment,85:92:treatment","Diabetes: Known type 1 or Type 2 diabetes, currently taking diabetic medications or insulin","['Diabetes' ':' 'Known' 'type' '1' 'or' 'Type' '2' 'diabetes' ','
 'currently' 'taking' 'diabetic' 'medications' 'or' 'insulin']",[0. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 1. 1. 0. 1.]
NCT03070535,"7:26:chronic_disease,37:64:chronic_disease,66:90:chronic_disease,96:110:chronic_disease","Major digestive disorders including inflammatory bowel diseases, irritable bowel syndrome, and celiac disease","['Major' 'digestive' 'disorders' 'including' 'inflammatory' 'bowel'
 'diseases' ',' 'irritable' 'bowel' 'syndrome' ',' 'and' 'celiac'
 'disease']",[0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 0. 2. 2.]
NCT03070535,"8:16:treatment,18:30:treatment,47:74:treatment","Use of estrogen, testosterone, and continuous corticosteroid replacements will be excluded, as these may have effects on study outcomes","['Use' 'of' 'estrogen' ',' 'testosterone' ',' 'and' 'continuous'
 'corticosteroid' 'replacements' 'will' 'be' 'excluded' ',' 'as' 'these'
 'may' 'have' 'effects' 'on' 'study' 'outcomes']",[0. 0. 1. 0. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03070340,"28:38:allergy_name,111:114:treatment,179:193:treatment",Known allergic reaction to gadolinium; patient may be eligible if the referring physician determines that the MRI is medically necessary and if the patient is willing to undergo pre-medication for contrast allergy,"['Known' 'allergic' 'reaction' 'to' 'gadolinium' ';' 'patient' 'may' 'be'
 'eligible' 'if' 'the' 'referring' 'physician' 'determines' 'that' 'the'
 'MRI' 'is' 'medically' 'necessary' 'and' 'if' 'the' 'patient' 'is'
 'willing' 'to' 'undergo' 'pre-medication' 'for' 'contrast' 'allergy']","[0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0. 0. 0.]"
NCT03070145,"24:39:chronic_disease,48:69:chronic_disease,71:105:chronic_disease,111:125:chronic_disease","Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement","['Examples' 'would' 'include' 'unstable' 'angina' ',' 'recent'
 'myocardial' 'infarction' ',' 'oxygen-dependent' 'pulmonary' 'disease'
 ',' 'and' 'osteoarthritis' 'requiring' 'imminent' 'joint' 'replacement']",[0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 2. 2. 2. 0. 0. 2. 0. 0. 0. 0.]
NCT03069469,"7:35:chronic_disease,44:55:chronic_disease,64:75:chronic_disease,87:123:chronic_disease","Known human immunodeficiency virus, active hepatitis B, active hepatitis C, or active mycobacterium tuberculosis infection","['Known' 'human' 'immunodeficiency' 'virus' ',' 'active' 'hepatitis' 'B'
 ',' 'active' 'hepatitis' 'C' ',' 'or' 'active' 'mycobacterium'
 'tuberculosis' 'infection']",[0. 2. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT03068442,"24:38:chronic_disease,50:69:chronic_disease,110:130:chronic_disease,134:151:cancer,153:165:chronic_disease,,","Other known sources of cardioembolism, including atrial fibrillation, mechanical heart valve, left atrial or ventricular thrombus or intracardiac mass, endocarditis, EF <30%","['Other' 'known' 'sources' 'of' 'cardioembolism' ',' 'including' 'atrial'
 'fibrillation' ',' 'mechanical' 'heart' 'valve' ',' 'left' 'atrial' 'or'
 'ventricular' 'thrombus' 'or' 'intracardiac' 'mass' ',' 'endocarditis'
 ',' 'EF' '<' '30' '%']","[0. 0. 0. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 3. 3. 0. 2.
 0. 0. 0. 0. 0.]"
NCT03067051,",,,,134:154:treatment,156:173:chronic_disease,188:197:treatment",history of CTCAE v4 grade 3 or greater or persistent (>1 separate episode or symptoms lasting more than 3 months after initiation of medical intervention) grade 2 proctitis attributed to radiation,"['history' 'of' 'CTCAE' 'v4' 'grade' '3' 'or' 'greater' 'or' 'persistent'
 '(' '>' '1' 'separate' 'episode' 'or' 'symptoms' 'lasting' 'more' 'than'
 '3' 'months' 'after' 'initiation' 'of' 'medical' 'intervention' ')'
 'grade' '2' 'proctitis' 'attributed' 'to' 'radiation']","[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 0. 0. 0. 0. 0. 0. 1.]"
NCT03061201,",23:37:chronic_disease,41:53:treatment,91:102:chronic_disease,119:140:chronic_disease",Presence of > grade 2 liver fibrosis on elastography for subjects with history of treated Hepatitis C or suspicion of chronic liver disease,"['Presence' 'of' '>' 'grade' '2' 'liver' 'fibrosis' 'on' 'elastography'
 'for' 'subjects' 'with' 'history' 'of' 'treated' 'Hepatitis' 'C' 'or'
 'suspicion' 'of' 'chronic' 'liver' 'disease']",[0. 0. 0. 0. 0. 2. 2. 0. 1. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 2.]
NCT03059888,"61:71:chronic_disease,135:146:chronic_disease,148:159:chronic_disease,163:166:chronic_disease","Subject has evidence of active or latent bacterial or viral infections, including positive infectious disease laboratory test result (Hepatitis B, Hepatitis C or HIV)","['Subject' 'has' 'evidence' 'of' 'active' 'or' 'latent' 'bacterial' 'or'
 'viral' 'infections' ',' 'including' 'positive' 'infectious' 'disease'
 'laboratory' 'test' 'result' '(' 'Hepatitis' 'B' ',' 'Hepatitis' 'C' 'or'
 'HIV' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0.
 0. 0. 2. 0.]"
NCT03059030,"56:71:allergy_name,73:82:allergy_name,84:93:allergy_name,97:105:allergy_name","History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically","['History' 'of' 'severe' 'peripheral' 'allergy' 'or' 'intolerance' 'to'
 'contrast' 'agents' ',' 'narcotics' ',' 'sedatives' 'or' 'atropine'
 'that' 'can' 'not' 'be' 'managed' 'medically']",[0. 0. 0. 0. 0. 0. 0. 0. 4. 4. 0. 4. 0. 4. 0. 4. 0. 0. 0. 0. 0. 0.]
NCT03058679,",25:40:treatment,,,88:98:treatment,102:112:treatment",Start or change dose of corticosteroids within 1 week of screening or a dose >20mg/day prednisone or equivalent,"['Start' 'or' 'change' 'dose' 'of' 'corticosteroids' 'within' '1' 'week'
 'of' 'screening' 'or' 'a' 'dose' '>' '20mg/day' 'prednisone' 'or'
 'equivalent']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.]
NCT03058146,"12:33:chronic_disease,35:56:chronic_disease,58:64:chronic_disease","History of major vascular events (myocardial infarction, stroke, etc)","['History' 'of' 'major' 'vascular' 'events' '(' 'myocardial' 'infarction'
 ',' 'stroke' ',' 'etc' ')']",[0. 0. 2. 2. 2. 0. 2. 2. 0. 2. 0. 0. 0.]
NCT03058029,"1:7:chronic_disease,9:24:treatment,29:50:chronic_disease,","Angina, coronary bypass, or myocardial infarction within six(6)months prior to Screening Visit","['Angina' ',' 'coronary' 'bypass' ',' 'or' 'myocardial' 'infarction'
 'within' 'six' '(' '6' ')' 'months' 'prior' 'to' 'Screening' 'Visit']",[2. 0. 1. 1. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03056339,"23:49:treatment,59:77:treatment,,130:158:treatment",Patients may continue tyrosine kinase inhibitors or other targeted therapies until at least two weeks prior to administration of lymphodepleting chemotherapy,"['Patients' 'may' 'continue' 'tyrosine' 'kinase' 'inhibitors' 'or' 'other'
 'targeted' 'therapies' 'until' 'at' 'least' 'two' 'weeks' 'prior' 'to'
 'administration' 'of' 'lymphodepleting' 'chemotherapy']",[0. 0. 0. 1. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT03056287,"12:36:chronic_disease,38:66:chronic_disease,68:95:chronic_disease,97:119:chronic_disease,121:127:chronic_disease,131:138:chronic_disease","history of congestive heart failure, unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during ADL's","['history' 'of' 'congestive' 'heart' 'failure' ',' 'unstable' 'cardiac'
 'arrhythmias' ',' 'hypertrophic' 'cardiomyopathy' ',' 'severe' 'aortic'
 'stenosis' ',' 'angina' 'or' 'dyspnea' 'at' 'rest' 'or' 'during' 'ADL'
 ""'s""]","[0. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 2. 0. 2. 0. 2. 0. 0. 0. 0.
 0. 0.]"
NCT03053453,"7:31:treatment,40:63:treatment,67:76:treatment",Prior ipsilateral knee surgery such as ligament reconstruction or osteotomy,"['Prior' 'ipsilateral' 'knee' 'surgery' 'such' 'as' 'ligament'
 'reconstruction' 'or' 'osteotomy']",[0. 1. 1. 1. 0. 0. 1. 1. 0. 1.]
NCT03050801,"13:31:chronic_disease,35:55:chronic_disease,69:72:chronic_disease,103:109:chronic_disease,111:128:chronic_disease,130:147:chronic_disease,149:162:chronic_disease,166:182:chronic_disease","Any current major neurological or psychiatric disorder unrelated to TBI, such as (but not limited to) stroke, Parkinson disease, Alzheimer disease, schizophrenia or major depression","['Any' 'current' 'major' 'neurological' 'or' 'psychiatric' 'disorder'
 'unrelated' 'to' 'TBI' ',' 'such' 'as' '(' 'but' 'not' 'limited' 'to' ')'
 'stroke' ',' 'Parkinson' 'disease' ',' 'Alzheimer' 'disease' ','
 'schizophrenia' 'or' 'major' 'depression']","[0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0.
 2. 2. 0. 2. 0. 0. 0.]"
NCT03049189,"1:6:chronic_disease,8:15:chronic_disease,17:31:chronic_disease,36:68:chronic_disease","Renal, hepatic, cardiovascular, or haematological organ dysfunction, potentially interfering with the safety of the study treatments","['Renal' ',' 'hepatic' ',' 'cardiovascular' ',' 'or' 'haematological'
 'organ' 'dysfunction' ',' 'potentially' 'interfering' 'with' 'the'
 'safety' 'of' 'the' 'study' 'treatments']",[2. 0. 2. 0. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT03046017,"38:50:treatment,65:82:treatment,84:98:treatment,100:114:chronic_disease,,150:162:treatment","Presence of any contraindications to MRI scanning. For example: cardiac pacemaker, metal implants, claustrophobia, pregnancy, cannot lie still in an fMRI scanner","['Presence' 'of' 'any' 'contraindications' 'to' 'MRI' 'scanning' '.' 'For'
 'example' ':' 'cardiac' 'pacemaker' ',' 'metal' 'implants' ','
 'claustrophobia' ',' 'pregnancy' ',' 'can' 'not' 'lie' 'still' 'in' 'an'
 'fMRI' 'scanner']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1.]"
NCT03043807,"1:14:treatment,21:33:treatment,35:45:treatment","Antiandrogens (e.g. bicalutamide, nilutamide)","['Antiandrogens' '(' 'e.g' '.' 'bicalutamide' ',' 'nilutamide' ')']",[1. 0. 0. 0. 1. 0. 1. 0.]
NCT03043794,"20:25:cancer,29:61:treatment,57:60:treatment","Clearly demarcated tumor on magnetic resonance imaging (MRI), as determined by treating physician (MRI may be done after enrollment if not done prior)","['Clearly' 'demarcated' 'tumor' 'on' 'magnetic' 'resonance' 'imaging' '('
 'MRI' ')' ',' 'as' 'determined' 'by' 'treating' 'physician' '(' 'MRI'
 'may' 'be' 'done' 'after' 'enrollment' 'if' 'not' 'done' 'prior' ')']","[0. 0. 3. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT03042767,"1:41:chronic_disease,65:77:treatment,81:84:treatment",Nonalcoholic fatty liver disease (NAFLD) diagnosis confirmed by liver biopsy or MRI,"['Nonalcoholic' 'fatty' 'liver' 'disease' '(' 'NAFLD' ')' 'diagnosis'
 'confirmed' 'by' 'liver' 'biopsy' 'or' 'MRI']",[2. 2. 1. 1. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03042689,"1:14:cancer,32:43:treatment,71:78:treatment",myelofibrosis that have failed ruxolitinib or are ineligible for this therapy,"['myelofibrosis' 'that' 'have' 'failed' 'ruxolitinib' 'or' 'are'
 'ineligible' 'for' 'this' 'therapy']",[3. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1.]
NCT03040726,"23:39:treatment,43:58:treatment,63:74:treatment",Expected to use other 5HT3 antagonists or NK1 antagonists for prophylaxis during the study,"['Expected' 'to' 'use' 'other' '5HT3' 'antagonists' 'or' 'NK1'
 'antagonists' 'for' 'prophylaxis' 'during' 'the' 'study']",[0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 1. 0. 0. 0.]
NCT03040726,"1:21:treatment,23:30:treatment,32:48:treatment,54:70:treatment,,","Total (T.) bilirubin, albumin, prothrombin time, and serum creatinine tests can be done within 14 days of study enrollment (only if not performed in the last 14 days)","['Total' '(' 'T.' ')' 'bilirubin' ',' 'albumin' ',' 'prothrombin' 'time'
 ',' 'and' 'serum' 'creatinine' 'tests' 'can' 'be' 'done' 'within' '14'
 'days' 'of' 'study' 'enrollment' '(' 'only' 'if' 'not' 'performed' 'in'
 'the' 'last' '14' 'days' ')']","[1. 1. 1. 0. 0. 0. 1. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03038620,"18:46:chronic_disease,54:67:chronic_disease,69:85:chronic_disease","History of other severe psychiatric disorders, e.g., schizophrenia, bipolar disorder","['History' 'of' 'other' 'severe' 'psychiatric' 'disorders' ',' 'e.g.' ','
 'schizophrenia' ',' 'bipolar' 'disorder']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 2. 0. 2. 2.]
NCT03037931,"1:28:chronic_disease,30:53:chronic_disease,55:80:chronic_disease,85:91:chronic_disease,","Acute myocardial infarction, acute coronary syndrome, transient ischemic attack, or stroke within 30 days of enrollment","['Acute' 'myocardial' 'infarction' ',' 'acute' 'coronary' 'syndrome' ','
 'transient' 'ischemic' 'attack' ',' 'or' 'stroke' 'within' '30' 'days'
 'of' 'enrollment']",[2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT03037931,",41:73:treatment,75:90:treatment,95:112:treatment","the recent receipt (within 3 months) of erythropoietin stimulating agent, IV iron therapy, or blood transfusion","['the' 'recent' 'receipt' '(' 'within' '3' 'months' ')' 'of'
 'erythropoietin' 'stimulating' 'agent' ',' 'IV' 'iron' 'therapy' ',' 'or'
 'blood' 'transfusion']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 1. 0. 0. 1. 1.]
NCT03037385,"58:107:cancer,73:78:cancer,132:135:treatment","have a pathologically documented, definitively diagnosed advanced solid tumor with an oncogenic RET fusion previously treated with SOC appropriate for the tumor type and not eligible for any of the other groups","['have' 'a' 'pathologically' 'documented' ',' 'definitively' 'diagnosed'
 'advanced' 'solid' 'tumor' 'with' 'an' 'oncogenic' 'RET' 'fusion'
 'previously' 'treated' 'with' 'SOC' 'appropriate' 'for' 'the' 'tumor'
 'type' 'and' 'not' 'eligible' 'for' 'any' 'of' 'the' 'other' 'groups']","[0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03036098,"1:16:treatment,25:33:treatment,35:44:treatment,46:55:treatment,57:67:treatment,72:91:treatment,146:167:treatment,171:190:treatment","Prior treatment with an anti-PD1, anti-PDL1, anti-PDL2, anti-CD137, or anti-CTLA4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways","['Prior' 'treatment' 'with' 'an' 'anti-PD1' ',' 'anti-PDL1' ','
 'anti-PDL2' ',' 'anti-CD137' ',' 'or' 'anti-CTLA4' 'antibody' ',' 'or'
 'any' 'other' 'antibody' 'or' 'drug' 'specifically' 'targeting' 'T-cell'
 'co-stimulation' 'or' 'checkpoint' 'pathways']","[1. 1. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1. 0. 1. 1.]"
NCT03035474,",,50:66:treatment,68:95:treatment,97:130:treatment,132:158:treatment,163:186:treatment","LVEF ≤ 40% based on last local measurement using echocardiography, multigated acquisition scan, computed tomography (CT) scanning, magnetic resonance imaging, or ventricular angiography","['LVEF' '≤' '40' '%' 'based' 'on' 'last' 'local' 'measurement' 'using'
 'echocardiography' ',' 'multigated' 'acquisition' 'scan' ',' 'computed'
 'tomography' '(' 'CT' ')' 'scanning' ',' 'magnetic' 'resonance' 'imaging'
 ',' 'or' 'ventricular' 'angiography']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 1.
 1. 1. 0. 0. 1. 1.]"
NCT03034772,"43:55:treatment,63:74:chronic_disease,76:103:chronic_disease,105:142:chronic_disease,144:167:chronic_disease,169:175:chronic_disease","Any contraindication for topical use of a beta-blocker (e.g., bradycardia, decompensated heart failure, chronic obstructive pulmonary disease, reactive airway disease, asthma, etc.)","['Any' 'contraindication' 'for' 'topical' 'use' 'of' 'a' 'beta-blocker'
 '(' 'e.g.' ',' 'bradycardia' ',' 'decompensated' 'heart' 'failure' ','
 'chronic' 'obstructive' 'pulmonary' 'disease' ',' 'reactive' 'airway'
 'disease' ',' 'asthma' ',' 'etc' '.' ')']","[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 2. 0. 2. 2. 2. 0. 2. 2. 2. 2. 0. 2. 2.
 2. 0. 2. 0. 0. 0. 0.]"
NCT03034213,"7:24:cancer,44:56:treatment,,,156:176:cancer,178:201:cancer,206:229:cancer","Known active malignancy present and/or had chemotherapy 12 weeks prior to screening or planned chemotherapy within 12 weeks of treatment with exception of basal cell carcinoma, squamous cell carcinoma, or prostate cancer in situ","['Known' 'active' 'malignancy' 'present' 'and/or' 'had' 'chemotherapy'
 '12' 'weeks' 'prior' 'to' 'screening' 'or' 'planned' 'chemotherapy'
 'within' '12' 'weeks' 'of' 'treatment' 'with' 'exception' 'of' 'basal'
 'cell' 'carcinoma' ',' 'squamous' 'cell' 'carcinoma' ',' 'or' 'prostate'
 'cancer' 'in' 'situ']","[0. 3. 3. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.
 3. 3. 0. 3. 3. 3. 0. 0. 3. 3. 3. 3.]"
NCT03033212,"7:21:treatment,32:43:treatment,44:54:treatment",Prior spinal surgery excluding laminectomy/discectomy,['Prior' 'spinal' 'surgery' 'excluding' 'laminectomy/discectomy'],[0. 1. 1. 0. 1.]
NCT03030118,"28:62:chronic_disease,64:75:chronic_disease,80:91:chronic_disease","Evidence of infection with human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C","['Evidence' 'of' 'infection' 'with' 'human' 'immunodeficiency' 'virus' '('
 'HIV' ')' ',' 'Hepatitis' 'B' ',' 'or' 'Hepatitis' 'C']",[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT03029884,"1:18:chronic_disease,,,39:84:chronic_disease,86:117:chronic_disease,119:132:chronic_disease,134:150:chronic_disease,152:187:chronic_disease","Active depression (BDI > 20) or other untreated or uncontrolled psychiatric illness (active general anxiety disorder, schizophrenia, bipolar disorder, obsessive-compulsive disorder (OCD)","['Active' 'depression' '(' 'BDI' '>' '20' ')' 'or' 'other' 'untreated'
 'or' 'uncontrolled' 'psychiatric' 'illness' '(' 'active' 'general'
 'anxiety' 'disorder' ',' 'schizophrenia' ',' 'bipolar' 'disorder' ','
 'obsessive-compulsive' 'disorder' '(' 'OCD' ')']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 2. 2. 2. 2. 0. 2. 0. 2. 2.
 0. 2. 2. 2. 0. 0.]"
NCT03029884,"1:4:treatment,,58:65:treatment,74:78:chronic_disease,80:86:chronic_disease,88:98:chronic_disease","MRI done within one year not showing contraindication to surgery such as mass, lesion, hemorrhage or other abnormality near target","['MRI' 'done' 'within' 'one' 'year' 'not' 'showing' 'contraindication'
 'to' 'surgery' 'such' 'as' 'mass' ',' 'lesion' ',' 'hemorrhage' 'or'
 'other' 'abnormality' 'near' 'target']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 2. 0. 2. 0. 2. 0. 0. 0. 0. 0.]
NCT03029806,"15:27:chronic_disease,29:37:chronic_disease,39:45:chronic_disease,47:70:chronic_disease,72:86:chronic_disease,88:94:cancer,96:111:chronic_disease,113:125:chronic_disease,130:146:treatment,","No history of hypertension, diabetes, stroke, coronary artery disease, kidney disease, cancer, thyroid disease, preeclampsia, or hospitalizations in 6 months","['No' 'history' 'of' 'hypertension' ',' 'diabetes' ',' 'stroke' ','
 'coronary' 'artery' 'disease' ',' 'kidney' 'disease' ',' 'cancer' ','
 'thyroid' 'disease' ',' 'preeclampsia' ',' 'or' 'hospitalizations' 'in'
 '6' 'months']","[0. 0. 0. 2. 0. 2. 0. 2. 0. 2. 2. 2. 0. 2. 2. 0. 3. 0. 2. 2. 0. 2. 0. 0.
 1. 0. 0. 0.]"
NCT03028350,"12:57:treatment,88:109:treatment,,148:157:treatment",Any use of nonsteroidal anti-inflammatory drugs (NSAIDs) or any drug that inhibits the cyclooxygenase enzyme in the last two weeks before starting treatment,"['Any' 'use' 'of' 'nonsteroidal' 'anti-inflammatory' 'drugs' '(' 'NSAIDs'
 ')' 'or' 'any' 'drug' 'that' 'inhibits' 'the' 'cyclooxygenase' 'enzyme'
 'in' 'the' 'last' 'two' 'weeks' 'before' 'starting' 'treatment']","[0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 1.]"
NCT03027388,"27:45:treatment,49:65:treatment,,143:159:treatment","Patients may not have had prior chemotherapy or biologic therapy in the 4 weeks prior to study entry. For patients who have been treated with targeted therapy, 5 half-lives of that therapy (or 28 days, whichever is shorter) must have passed prior to enrollment in the study","['Patients' 'may' 'not' 'have' 'had' 'prior' 'chemotherapy' 'or'
 'biologic' 'therapy' 'in' 'the' '4' 'weeks' 'prior' 'to' 'study' 'entry'
 '.' 'For' 'patients' 'who' 'have' 'been' 'treated' 'with' 'targeted'
 'therapy' ',' '5' 'half-lives' 'of' 'that' 'therapy' '(' 'or' '28' 'days'
 ',' 'whichever' 'is' 'shorter' ')' 'must' 'have' 'passed' 'prior' 'to'
 'enrollment' 'in' 'the' 'study']","[0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT03025139,"20:27:treatment,29:38:treatment,47:70:treatment,","Have completed all surgery, radiation, and/or chemotherapy treatments at least 6 months previously","['Have' 'completed' 'all' 'surgery' ',' 'radiation' ',' 'and/or'
 'chemotherapy' 'treatments' 'at' 'least' '6' 'months' 'previously']",[0. 0. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT03023449,"12:37:chronic_disease,46:52:chronic_disease,56:93:chronic_disease",History of chronic pulmonary disease such as asthma or chronic obstructive pulmonary disease,"['History' 'of' 'chronic' 'pulmonary' 'disease' 'such' 'as' 'asthma' 'or'
 'chronic' 'obstructive' 'pulmonary' 'disease']",[0. 0. 2. 2. 2. 2. 0. 2. 0. 0. 0. 0. 0.]
NCT03022292,"5:39:treatment,85:146:treatment,148:174:treatment,176:193:treatment,195:219:treatment,221:247:treatment,249:272:treatment,288:336:treatment","Any prior treatment of neovascular AMD in the eye proposed for enrollment including previous anti-vascular endothelial factor (anti-VEGF) therapy, photodynamic therapy (PDT), radiation therapy, corticosteroid treatment, surgical treatment for CNV, thermal laser treatment, and any other prior intravitreal treatment for neovascular AMD (except minerals and vitamins)","['Any' 'prior' 'treatment' 'of' 'neovascular' 'AMD' 'in' 'the' 'eye'
 'proposed' 'for' 'enrollment' 'including' 'previous' 'anti-vascular'
 'endothelial' 'factor' '(' 'anti-VEGF' ')' 'therapy' ',' 'photodynamic'
 'therapy' '(' 'PDT' ')' ',' 'radiation' 'therapy' ',' 'corticosteroid'
 'treatment' ',' 'surgical' 'treatment' 'for' 'CNV' ',' 'thermal' 'laser'
 'treatment' ',' 'and' 'any' 'other' 'prior' 'intravitreal' 'treatment'
 'for' 'neovascular' 'AMD' '(' 'except' 'minerals' 'and' 'vitamins' ')']","[0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1.
 1. 0. 0. 0. 1. 1. 0. 1. 1. 0. 1. 1. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03021538,"1:16:chronic_disease,17:31:chronic_disease,42:51:chronic_disease,115:127:treatment",Cystic fibrosis/bronchiectasis/resistant infection patients where surgeon will need to remove both lungs prior to implantation,"['Cystic' 'fibrosis/bronchiectasis/resistant' 'infection' 'patients'
 'where' 'surgeon' 'will' 'need' 'to' 'remove' 'both' 'lungs' 'prior' 'to'
 'implantation']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT03019133,"11:31:chronic_disease,33:43:chronic_disease,45:72:chronic_disease,74:84:chronic_disease,86:107:chronic_disease,117:131:chronic_disease","Untreated sleep apnea disorder, narcolepsy, REM sleep behavior disorder, parasomnia, restless leg syndrome or other sleep disorder","['Untreated' 'sleep' 'apnea' 'disorder' ',' 'narcolepsy' ',' 'REM' 'sleep'
 'behavior' 'disorder' ',' 'parasomnia' ',' 'restless' 'leg' 'syndrome'
 'or' 'other' 'sleep' 'disorder']",[0. 2. 2. 2. 0. 2. 0. 2. 2. 2. 2. 0. 2. 0. 2. 2. 2. 0. 0. 0. 0.]
NCT03016871,"34:44:cancer,,97:115:treatment,119:139:cancer,143:178:cancer,183:201:cancer,206:230:cancer,237:253:treatment","Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy","['Diagnosed' 'or' 'treated' 'for' 'another' 'malignancy' 'within' '3'
 'years' 'of' 'enrollment' ',' 'with' 'the' 'exception' 'of' 'complete'
 'resection' 'of' 'basal' 'cell' 'carcinoma' 'or' 'squamous' 'cell'
 'carcinoma' 'of' 'the' 'skin' ',' 'an' 'in' 'situ' 'malignancy' ',' 'or'
 'low-risk' 'prostate' 'cancer' 'after' 'curative' 'therapy']","[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 3. 3. 3. 0. 3.
 3. 3. 3. 3. 3. 0. 0. 3. 3. 3. 0. 0. 3. 3. 3. 0. 1. 1.]"
NCT03016130,"1:35:cancer,49:81:treatment,89:100:treatment,102:111:treatment,113:129:treatment,,","Acute lymphoblastic leukemia (ALL) receiving an intensive induction chemotherapy (e.g., HyperCVAD±R, CALGB9251, Larsons protocol) with an expected duration of neutropenia of ≥7 days","['Acute' 'lymphoblastic' 'leukemia' '(' 'ALL' ')' 'receiving' 'an'
 'intensive' 'induction' 'chemotherapy' '(' 'e.g.' ',' 'HyperCVAD±R' ','
 'CALGB9251' ',' 'Larsons' 'protocol' ')' 'with' 'an' 'expected'
 'duration' 'of' 'neutropenia' 'of' '≥7' 'days']","[3. 3. 3. 3. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT03013543,"14:27:chronic_disease,29:45:chronic_disease,47:67:chronic_disease,234:258:chronic_disease","Diagnosis of schizophrenia, bipolar disorder, personality disorder or other Diagnostic and Statistical Manual of Mental Disorders (DSM-III) disorders that the investigator believes will interfere significantly with study compliance. Neurocognitive disorders affecting ability to consent will not be disqualifying as long as an appropriate guardian able to give consent has been appointed","['Diagnosis' 'of' 'schizophrenia' ',' 'bipolar' 'disorder' ','
 'personality' 'disorder' 'or' 'other' 'Diagnostic' 'and' 'Statistical'
 'Manual' 'of' 'Mental' 'Disorders' '(' 'DSM-III' ')' 'disorders' 'that'
 'the' 'investigator' 'believes' 'will' 'interfere' 'significantly' 'with'
 'study' 'compliance' '.' 'Neurocognitive' 'disorders' 'affecting'
 'ability' 'to' 'consent' 'will' 'not' 'be' 'disqualifying' 'as' 'long'
 'as' 'an' 'appropriate' 'guardian' 'able' 'to' 'give' 'consent' 'has'
 'been' 'appointed']","[0. 0. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT03011567,"1:10:chronic_disease,12:34:chronic_disease,36:65:chronic_disease","Hemolysis, Elevated Liver Enzymes, Low Platelet (HELLP) Syndrome","['Hemolysis' ',' 'Elevated' 'Liver' 'Enzymes' ',' 'Low' 'Platelet' '('
 'HELLP' ')' 'Syndrome']",[2. 0. 2. 2. 2. 0. 2. 2. 2. 2. 0. 0.]
NCT03009981,"58:72:treatment,,97:107:treatment,108:120:treatment",Any chronic medical condition requiring a higher dose of corticosteroid than equivalent of 5 mg prednisone/prednisolone once daily,"['Any' 'chronic' 'medical' 'condition' 'requiring' 'a' 'higher' 'dose'
 'of' 'corticosteroid' 'than' 'equivalent' 'of' '5' 'mg'
 'prednisone/prednisolone' 'once' 'daily']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT03009981,"1:35:treatment,80:92:treatment,94:104:treatment,106:115:treatment,145:160:cancer","Prior androgen deprivation therapy and/or first generation anti-androgen (e.g. bicalutamide, nilutamide, flutamide) for biochemically recurrent prostate cancer","['Prior' 'androgen' 'deprivation' 'therapy' 'and/or' 'first' 'generation'
 'anti-androgen' '(' 'e.g' '.' 'bicalutamide' ',' 'nilutamide' ','
 'flutamide' ')' 'for' 'biochemically' 'recurrent' 'prostate' 'cancer']",[1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 3. 3.]
NCT03008408,"12:36:chronic_disease,48:69:chronic_disease,71:86:chronic_disease,88:119:chronic_disease,121:141:chronic_disease,171:183:chronic_disease,","History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within 6 months prior to screening","['History' 'of' 'acute' 'coronary' 'syndromes' '(' 'including'
 'myocardial' 'infarction' ',' 'unstable' 'angina' ',' 'coronary' 'artery'
 'bypass' 'grafting' ',' 'coronary' 'angioplasty' ',' 'or' 'stenting' ')'
 'or' 'symptomatic' 'pericarditis' 'within' '6' 'months' 'prior' 'to'
 'screening']","[0. 0. 2. 2. 2. 2. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 2. 0. 0. 0. 0. 0. 0.]"
NCT03008408,"18:42:chronic_disease,53:76:chronic_disease,80:94:chronic_disease,107:122:chronic_disease,173:184:chronic_disease","Risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia","['Risk' 'factors' 'for' 'Torsades' 'de' 'Pointe' '(' 'TdP' ')' 'including'
 'uncorrected' 'hypokalemia' 'or' 'hypomagnesemia' ',' 'history' 'of'
 'cardiac' 'failure' ',' 'or' 'history' 'of' 'clinically'
 'significant/symptomatic' 'bradycardia']","[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.
 0. 2.]"
NCT03008070,"24:44:chronic_disease,65:87:chronic_disease,105:126:chronic_disease","History of, or current cardiac dysrhythmias and/or a history of cardiovascular disease event, including myocardial infarction, except patients with only well controlled hypertension","['History' 'of' ',' 'or' 'current' 'cardiac' 'dysrhythmias' 'and/or' 'a'
 'history' 'of' 'cardiovascular' 'disease' 'event' ',' 'including'
 'myocardial' 'infarction' ',' 'except' 'patients' 'with' 'only' 'well'
 'controlled' 'hypertension']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT03007745,"10:19:treatment,25:49:treatment,51:68:treatment,73:76:chronic_disease,96:115:treatment","Previous treatment with positive airway pressure, non-nasal surgery for OSA, or current use of supplemental oxygen","['Previous' 'treatment' 'with' 'positive' 'airway' 'pressure' ','
 'non-nasal' 'surgery' 'for' 'OSA' ',' 'or' 'current' 'use' 'of'
 'supplemental' 'oxygen']",[0. 1. 0. 1. 1. 1. 0. 1. 1. 0. 2. 0. 0. 0. 0. 0. 1. 1.]
NCT03006302,"1:13:treatment,15:24:treatment,29:54:treatment,","Chemotherapy, radiation, or biological cancer therapy within 14 days of study treatment","['Chemotherapy' ',' 'radiation' ',' 'or' 'biological' 'cancer' 'therapy'
 'within' '14' 'days' 'of' 'study' 'treatment']",[1. 0. 1. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT03006302,"1:33:treatment,35:44:treatment,46:56:treatment,61:71:treatment,81:94:treatment","Prior treatment with anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti PD-L2, or with IDO inhibitor","['Prior' 'treatment' 'with' 'anti-CTLA-4' ',' 'anti-PD-1' ',' 'anti-PD-L1'
 ',' 'or' 'anti' 'PD-L2' ',' 'or' 'with' 'IDO' 'inhibitor']",[1. 1. 1. 1. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT03004807,"1:14:chronic_disease,18:40:chronic_disease,60:68:chronic_disease","psychological or neurological disorders, or a diagnosis of dementia","['psychological' 'or' 'neurological' 'disorders' ',' 'or' 'a' 'diagnosis'
 'of' 'dementia']",[2. 0. 2. 2. 0. 0. 0. 0. 0. 2.]
NCT03001882,"27:75:cancer,84:117:treatment,127:142:treatment,159:177:cancer","Histologically confirmed, stage IV or recurrent non-small cell lung cancer with no prior systemic anticancer therapy given as primary therapy for advanced or metastatic disease","['Histologically' 'confirmed' ',' 'stage' 'IV' 'or' 'recurrent'
 'non-small' 'cell' 'lung' 'cancer' 'with' 'no' 'prior' 'systemic'
 'anticancer' 'therapy' 'given' 'as' 'primary' 'therapy' 'for' 'advanced'
 'or' 'metastatic' 'disease']","[0. 0. 0. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 1. 1. 1. 1. 0. 0. 1. 1. 0. 0. 0.
 3. 3.]"
NCT03001765,"34:52:chronic_disease,56:70:chronic_disease,72:85:chronic_disease,87:90:chronic_disease","Previous documented diagnosis of cardiac arrhythmia by holter monitor, event monitor, ECG","['Previous' 'documented' 'diagnosis' 'of' 'cardiac' 'arrhythmia' 'by'
 'holter' 'monitor' ',' 'event' 'monitor' ',' 'ECG']",[0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 2.]
NCT03000257,"34:60:chronic_disease,62:73:chronic_disease,84:107:cancer","Participant has known history or inflammatory bowel disease, pneumonitis, or known uncontrolled metastases to the central nervous system (CNS) (with certain exceptions)","['Participant' 'has' 'known' 'history' 'or' 'inflammatory' 'bowel'
 'disease' ',' 'pneumonitis' ',' 'or' 'known' 'uncontrolled' 'metastases'
 'to' 'the' 'central' 'nervous' 'system' '(' 'CNS' ')' '(' 'with'
 'certain' 'exceptions' ')']","[0. 0. 0. 0. 0. 2. 2. 2. 0. 2. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02996227,"1:15:treatment,56:64:treatment,68:78:treatment",Anticoagulants considered to be a contraindication for epidural or TAP blocks,"['Anticoagulants' 'considered' 'to' 'be' 'a' 'contraindication' 'for'
 'epidural' 'or' 'TAP' 'blocks']",[1. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1.]
NCT02995590,"12:14:chronic_disease,16:22:chronic_disease,48:60:chronic_disease","History of MI, stroke and/or poorly controlled hypertension","['History' 'of' 'MI' ',' 'stroke' 'and/or' 'poorly' 'controlled'
 'hypertension']",[0. 0. 2. 0. 2. 0. 0. 0. 2.]
NCT02995330,"1:14:treatment,36:52:treatment,70:82:treatment,84:94:treatment,96:105:treatment,107:119:treatment,121:132:treatment,134:146:treatment,148:155:treatment","Prior therapy with one second line hormonal therapy is allowed (i.e. bicalutamide, nilutamide, flutamide, ketoconazole, abiraterone, enzalutamide, ARN-509)","['Prior' 'therapy' 'with' 'one' 'second' 'line' 'hormonal' 'therapy' 'is'
 'allowed' '(' 'i.e' '.' 'bicalutamide' ',' 'nilutamide' ',' 'flutamide'
 ',' 'ketoconazole' ',' 'abiraterone' ',' 'enzalutamide' ',' 'ARN-509' ')']","[1. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1.
 0. 1. 0.]"
NCT02994043,"55:76:chronic_disease,88:111:chronic_disease,113:127:chronic_disease,133:142:chronic_disease","Currently taking any medications for the treatment of psychiatric disorders, including substance use disorders, mood disorders, and psychosis","['Currently' 'taking' 'any' 'medications' 'for' 'the' 'treatment' 'of'
 'psychiatric' 'disorders' ',' 'including' 'substance' 'use' 'disorders'
 ',' 'mood' 'disorders' ',' 'and' 'psychosis']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 2.]
NCT02992275,"22:41:allergy_name,80:92:chronic_disease,96:112:chronic_disease,133:141:chronic_disease,154:179:chronic_disease","Contraindications to resistance training, including a self-reported history of intracranial or retinal bleeding in the last year or Diabetes with active proliferative retinopathy","['Contraindications' 'to' 'resistance' 'training' ',' 'including' 'a'
 'self-reported' 'history' 'of' 'intracranial' 'or' 'retinal' 'bleeding'
 'in' 'the' 'last' 'year' 'or' 'Diabetes' 'with' 'active' 'proliferative'
 'retinopathy']",[0. 0. 4. 4. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 2. 0. 0. 2. 2.]
NCT02991248,"24:54:chronic_disease,61:82:chronic_disease,86:124:chronic_disease",concomitant central or peripheral neurological injury (e.g. traumatic head injury or peripheral nerve damage in lower limbs),"['concomitant' 'central' 'or' 'peripheral' 'neurological' 'injury' '('
 'e.g' '.' 'traumatic' 'head' 'injury' 'or' 'peripheral' 'nerve' 'damage'
 'in' 'lower' 'limbs' ')']",[0. 0. 0. 2. 2. 2. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02990481,"1:6:cancer,53:65:treatment,126:144:treatment",Tumor progression after receiving standard/approved chemotherapy or where there is no approved therapy or not amendable to a curative treatment,"['Tumor' 'progression' 'after' 'receiving' 'standard/approved'
 'chemotherapy' 'or' 'where' 'there' 'is' 'no' 'approved' 'therapy' 'or'
 'not' 'amendable' 'to' 'a' 'curative' 'treatment']",[3. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02988960,"21:32:treatment,60:71:cancer,95:113:treatment,104:113:treatment",Participants in all monotherapy arms must have an advanced solid tumor that has progressed on standard therapies known to provide clinical benefit or the participants are intolerant to such therapies,"['Participants' 'in' 'all' 'monotherapy' 'arms' 'must' 'have' 'an'
 'advanced' 'solid' 'tumor' 'that' 'has' 'progressed' 'on' 'standard'
 'therapies' 'known' 'to' 'provide' 'clinical' 'benefit' 'or' 'the'
 'participants' 'are' 'intolerant' 'to' 'such' 'therapies']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02985554,"43:47:chronic_disease,,80:95:chronic_disease,108:113:chronic_disease","Patients who have disease relapse, active GVHD or history of more than Stage 1 skin acute GVHD, history of cGVHD","['Patients' 'who' 'have' 'disease' 'relapse' ',' 'active' 'GVHD' 'or'
 'history' 'of' 'more' 'than' 'Stage' '1' 'skin' 'acute' 'GVHD' ','
 'history' 'of' 'cGVHD']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 2.]
NCT02985554,"15:39:cancer,47:66:treatment,111:115:chronic_disease,,148:163:chronic_disease","Patients with hematologic malignancies status post allogeneic SCT without evidence of disease relapse, active GVHD or history of more than Stage I skin acute GVHD","['Patients' 'with' 'hematologic' 'malignancies' 'status' 'post'
 'allogeneic' 'SCT' 'without' 'evidence' 'of' 'disease' 'relapse' ','
 'active' 'GVHD' 'or' 'history' 'of' 'more' 'than' 'Stage' 'I' 'skin'
 'acute' 'GVHD']","[0. 0. 3. 3. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 2.]"
NCT02981173,"8:26:chronic_disease,33:46:chronic_disease,48:57:chronic_disease,59:84:chronic_disease","Axis I psychotic disorder (e.g. schizophrenia, bipolar I, depression with psychosis)","['Axis' 'I' 'psychotic' 'disorder' '(' 'e.g' '.' 'schizophrenia' ','
 'bipolar' 'I' ',' 'depression' 'with' 'psychosis' ')']",[0. 0. 2. 2. 0. 0. 0. 2. 0. 2. 2. 0. 2. 2. 2. 0.]
NCT02979574,"1:23:chronic_disease,37:60:treatment,67:87:chronic_disease",Inflammatory arthritis that require disease modifying drugs (e.g. rheumatoid arthritis),"['Inflammatory' 'arthritis' 'that' 'require' 'disease' 'modifying' 'drugs'
 '(' 'e.g' '.' 'rheumatoid' 'arthritis' ')']",[2. 2. 0. 0. 1. 1. 1. 0. 0. 0. 2. 2. 0.]
NCT02978443,"28:44:cancer,81:88:treatment,92:101:treatment,,175:183:treatment,187:195:treatment",Patients with a history of brain metastases must have completed treatment (i.e. surgery or radiation) 1 month prior to enrollment and have no evidence of disease or edema on brain CT or head MRI,"['Patients' 'with' 'a' 'history' 'of' 'brain' 'metastases' 'must' 'have'
 'completed' 'treatment' '(' 'i.e' '.' 'surgery' 'or' 'radiation' ')' '1'
 'month' 'prior' 'to' 'enrollment' 'and' 'have' 'no' 'evidence' 'of'
 'disease' 'or' 'edema' 'on' 'brain' 'CT' 'or' 'head' 'MRI']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02977468,"9:41:cancer,43:78:cancer,80:98:cancer,106:126:cancer,158:174:treatment","include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, DCIS of the breast, or in situ cervical cancer that has undergone potentially curative therapy","['include' 'basal' 'cell' 'carcinoma' 'of' 'the' 'skin' ',' 'squamous'
 'cell' 'carcinoma' 'of' 'the' 'skin' ',' 'DCIS' 'of' 'the' 'breast' ','
 'or' 'in' 'situ' 'cervical' 'cancer' 'that' 'has' 'undergone'
 'potentially' 'curative' 'therapy']","[0. 3. 3. 3. 3. 3. 3. 0. 3. 3. 3. 3. 3. 3. 0. 3. 3. 3. 3. 0. 0. 0. 3. 3.
 3. 0. 0. 0. 0. 1. 1.]"
NCT02974686,"21:31:allergy_name,33:42:allergy_name,53:75:allergy_name","Hypersensitivity to everolimus, sirolimus, or other rapamycin deriviatives","['Hypersensitivity' 'to' 'everolimus' ',' 'sirolimus' ',' 'or' 'other'
 'rapamycin' 'deriviatives']",[0. 0. 4. 0. 4. 0. 0. 0. 4. 4.]
NCT02972840,"13:35:chronic_disease,60:83:chronic_disease,85:109:chronic_disease,114:135:chronic_disease,,188:216:chronic_disease,,","Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of first dose of study drug, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or corrected QT interval (QTc) > 480 msec (calculated using Friderica's formula: QT/RR0.33) at screening","['Significant' 'cardiovascular' 'disease' 'such' 'as' 'uncontrolled' 'or'
 'symptomatic' 'arrhythmias' ',' 'congestive' 'heart' 'failure' ',' 'or'
 'myocardial' 'infarction' 'within' '6' 'months' 'of' 'first' 'dose' 'of'
 'study' 'drug' ',' 'or' 'any' 'Class' '3' 'or' '4' 'cardiac' 'disease'
 'as' 'defined' 'by' 'the' 'New' 'York' 'Heart' 'Association' 'Functional'
 'Classification' ',' 'or' 'corrected' 'QT' 'interval' '(' 'QTc' ')' '>'
 '480' 'msec' '(' 'calculated' 'using' 'Friderica' ""'s"" 'formula' ':'
 'QT/RR0.33' ')' 'at' 'screening']","[0. 2. 2. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02967315,"122:154:chronic_disease,215:238:chronic_disease,256:278:chronic_disease","Patients who have lesions predisposing to chronic volume overload (i.e. patients with significant residual postoperative ventricular septal defects (VSD), or large aorto-pulmonary collaterals or more than moderate tricuspid insufficiency) since all these hemodynamic conditions can influence the late function of the right ventricle and potentially affect the response of the right side of the heart in changes in volume status","['Patients' 'who' 'have' 'lesions' 'predisposing' 'to' 'chronic' 'volume'
 'overload' '(' 'i.e' '.' 'patients' 'with' 'significant' 'residual'
 'postoperative' 'ventricular' 'septal' 'defects' '(' 'VSD' ')' ',' 'or'
 'large' 'aorto-pulmonary' 'collaterals' 'or' 'more' 'than' 'moderate'
 'tricuspid' 'insufficiency' ')' 'since' 'all' 'these' 'hemodynamic'
 'conditions' 'can' 'influence' 'the' 'late' 'function' 'of' 'the' 'right'
 'ventricle' 'and' 'potentially' 'affect' 'the' 'response' 'of' 'the'
 'right' 'side' 'of' 'the' 'heart' 'in' 'changes' 'in' 'volume' 'status']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02966444,"12:21:chronic_disease,25:42:chronic_disease,44:70:chronic_disease","Reports of metabolic or endocrine disease, gastrointestinal disorders, or history of medical or surgical events","['Reports' 'of' 'metabolic' 'or' 'endocrine' 'disease' ','
 'gastrointestinal' 'disorders' ',' 'or' 'history' 'of' 'medical' 'or'
 'surgical' 'events']",[0. 0. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02963831,"9:26:chronic_disease,48:55:chronic_disease,81:113:chronic_disease,,171:208:treatment","Ongoing bowel perforation or presence of bowel fistula or abscess or history of small or large bowel obstruction within 3 months of registration, including subjects with palliative gastric drainage catheters","['Ongoing' 'bowel' 'perforation' 'or' 'presence' 'of' 'bowel' 'fistula'
 'or' 'abscess' 'or' 'history' 'of' 'small' 'or' 'large' 'bowel'
 'obstruction' 'within' '3' 'months' 'of' 'registration' ',' 'including'
 'subjects' 'with' 'palliative' 'gastric' 'drainage' 'catheters']","[0. 2. 2. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 1. 1.]"
NCT02963831,"1:40:treatment,,110:130:treatment,132:184:treatment,186:224:treatment,228:272:treatment","Treatment with an investigational agent within 4 weeks of starting study treatment or prior treatment with a checkpoint inhibitor (cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) antibodies)","['Treatment' 'with' 'an' 'investigational' 'agent' 'within' '4' 'weeks'
 'of' 'starting' 'study' 'treatment' 'or' 'prior' 'treatment' 'with' 'a'
 'checkpoint' 'inhibitor' '(' 'cytotoxic' 'T-lymphocyte-associated'
 'protein' '4' '(' 'CTLA-4' ')' ',' 'programmed' 'cell' 'death' 'protein'
 '1' '(' 'PD-1' ')' 'or' 'programmed' 'death' 'ligand' '1' '(' 'PD-L1' ')'
 'antibodies' ')']","[1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 1. 1.
 1. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02962128,"8:15:treatment,,32:38:treatment,42:62:treatment","use of aspirin (>100 mg /day), NSAIDS or oral corticosteroids","['use' 'of' 'aspirin' '(' '>' '100' 'mg' '/day' ')' ',' 'NSAIDS' 'or'
 'oral' 'corticosteroids']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1.]
NCT02960555,"1:16:treatment,42:53:treatment,55:70:treatment,72:83:treatment,85:96:treatment,98:109:treatment","Bisphosphonates are permitted, including pamidronate, zoledronic acid, alendronate, ibandronate, risedronate","['Bisphosphonates' 'are' 'permitted' ',' 'including' 'pamidronate' ','
 'zoledronic' 'acid' ',' 'alendronate' ',' 'ibandronate' ',' 'risedronate']",[1. 0. 0. 0. 0. 1. 0. 1. 1. 0. 1. 0. 1. 0. 1.]
NCT02960113,",38:50:chronic_disease,52:65:chronic_disease,56:65:chronic_disease","Current history of pregnancy induced hypertension, pre-eclampsia, or eclampsia","['Current' 'history' 'of' 'pregnancy' 'induced' 'hypertension' ','
 'pre-eclampsia' ',' 'or' 'eclampsia']",[0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 0.]
NCT02958462,"1:25:chronic_disease,31:49:cancer,66:86:cancer,88:118:chronic_disease","Marrow failure syndromes with myeloid malignancy predisposition- telomere dysfunction, chromosomal breakage disorders, etc","['Marrow' 'failure' 'syndromes' 'with' 'myeloid' 'malignancy'
 'predisposition-' 'telomere' 'dysfunction' ',' 'chromosomal' 'breakage'
 'disorders' ',' 'etc']",[2. 2. 2. 0. 3. 3. 0. 3. 3. 0. 2. 2. 2. 0. 0.]
NCT02956486,"13:33:chronic_disease,85:111:treatment,115:139:treatment",Any chronic inflammatory disease that is not adequately controlled or that requires systemic immunosuppressive or immunomodulatory therapy,"['Any' 'chronic' 'inflammatory' 'disease' 'that' 'is' 'not' 'adequately'
 'controlled' 'or' 'that' 'requires' 'systemic' 'immunosuppressive' 'or'
 'immunomodulatory' 'therapy']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1.]
NCT02955537,"1:8:treatment,19:25:chronic_disease,29:38:chronic_disease",Steroid dependent asthma or emphysema,['Steroid' 'dependent' 'asthma' 'or' 'emphysema'],[1. 0. 2. 0. 2.]
NCT02953860,"5:13:treatment,16:28:treatment,19:28:treatment,40:52:treatment,","two biopsies - pretreatment as regards enzalutamide, and during treatment at 4 weeks","['two' 'biopsies' '-' 'pretreatment' 'as' 'regards' 'enzalutamide' ','
 'and' 'during' 'treatment' 'at' '4' 'weeks']",[0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 1. 0. 0. 0.]
NCT02951455,"1:14:chronic_disease,16:26:chronic_disease,52:68:chronic_disease,74:83:chronic_disease","schizophrenia, depression with psychotic features, bipolar disorder, any psychosis","['schizophrenia' ',' 'depression' 'with' 'psychotic' 'features' ','
 'bipolar' 'disorder' ',' 'any' 'psychosis']",[2. 0. 2. 0. 0. 0. 0. 2. 2. 0. 0. 2.]
NCT02949726,"55:68:cancer,87:124:treatment,129:148:treatment,175:187:treatment,189:199:treatment,203:228:treatment","Participants must have been clinically diagnosed with breast cancer and scheduled for axillary lymph node dissection (ALND) and radiation treatment at MD Anderson (receiving chemotherapy, mastectomy or breast-conserving surgery","['Participants' 'must' 'have' 'been' 'clinically' 'diagnosed' 'with'
 'breast' 'cancer' 'and' 'scheduled' 'for' 'axillary' 'lymph' 'node'
 'dissection' '(' 'ALND' ')' 'and' 'radiation' 'treatment' 'at' 'MD'
 'Anderson' '(' 'receiving' 'chemotherapy' ',' 'mastectomy' 'or'
 'breast-conserving' 'surgery']","[0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 0. 1. 0. 1. 0. 1. 1.]"
NCT02947945,"30:42:treatment,44:56:treatment,61:82:treatment,","Subjects who have received a methotrexate, azathioprine, or mycophenolate mofetil induction regimen may be included if on a stable dose for at least 4 weeks prior to visit 1","['Subjects' 'who' 'have' 'received' 'a' 'methotrexate' ',' 'azathioprine'
 ',' 'or' 'mycophenolate' 'mofetil' 'induction' 'regimen' 'may' 'be'
 'included' 'if' 'on' 'a' 'stable' 'dose' 'for' 'at' 'least' '4' 'weeks'
 'prior' 'to' 'visit' '1']","[0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02947165,"15:38:treatment,,129:162:treatment,203:215:treatment",Resistance to anti-PD-1/PD-L1 therapy is defined as: Documented progressive disease occurring while on/or within 6 months after anti-PD-1 and/or anti-PD-L1 agent (single or combination) received as the last therapy prior to enrollment,"['Resistance' 'to' 'anti-PD-1/PD-L1' 'therapy' 'is' 'defined' 'as' ':'
 'Documented' 'progressive' 'disease' 'occurring' 'while' 'on/or' 'within'
 '6' 'months' 'after' 'anti-PD-1' 'and/or' 'anti-PD-L1' 'agent' '('
 'single' 'or' 'combination' ')' 'received' 'as' 'the' 'last' 'therapy'
 'prior' 'to' 'enrollment']","[0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]"
NCT02946892,"29:40:treatment,,76:90:treatment,92:116:treatment,118:132:treatment,134:147:treatment,149:161:treatment,163:173:treatment,175:184:treatment,186:196:treatment,198:209:treatment,211:218:treatment,223:247:treatment","Use of any of the following medications within two weeks of randomization: MAO inhibitors, Calcium channel blockers, alpha blockers, beta blockers, disopyramide, flecainide, encainide, moricizine, propafenone, sotalol, or beta adrenergic agonists","['Use' 'of' 'any' 'of' 'the' 'following' 'medications' 'within' 'two'
 'weeks' 'of' 'randomization' ':' 'MAO' 'inhibitors' ',' 'Calcium'
 'channel' 'blockers' ',' 'alpha' 'blockers' ',' 'beta' 'blockers' ','
 'disopyramide' ',' 'flecainide' ',' 'encainide' ',' 'moricizine' ','
 'propafenone' ',' 'sotalol' ',' 'or' 'beta' 'adrenergic' 'agonists']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 1. 0. 1. 1. 0. 1.
 1. 1. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0.]"
NCT02946268,"31:58:treatment,104:136:treatment,138:151:treatment,153:169:treatment,175:201:treatment","Patients scheduled to undergo unilateral shoulder surgery at Duke University Medical Center, including arthroscopic rotator cuff repair, acromioplasty, hemiarthroplasty, and total shoulder replacement","['Patients' 'scheduled' 'to' 'undergo' 'unilateral' 'shoulder' 'surgery'
 'at' 'Duke' 'University' 'Medical' 'Center' ',' 'including'
 'arthroscopic' 'rotator' 'cuff' 'repair' ',' 'acromioplasty' ','
 'hemiarthroplasty' ',' 'and' 'total' 'shoulder' 'replacement']","[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 1. 0. 1. 0. 0.
 1. 1. 1.]"
NCT02945800,"1:30:treatment,23:30:treatment,55:84:treatment,",Myelosuppressive chemotherapy: Must not have received myelosuppressive chemotherapy within 3 weeks of protocol therapy on this study,"['Myelosuppressive' 'chemotherapy' ':' 'Must' 'not' 'have' 'received'
 'myelosuppressive' 'chemotherapy' 'within' '3' 'weeks' 'of' 'protocol'
 'therapy' 'on' 'this' 'study']",[1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02942095,"80:118:allergy_name,123:133:allergy_name,140:165:allergy_name","Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO)","['Have' 'a' 'known' 'immediate' 'or' 'delayed' 'hypersensitivity'
 'reaction' 'or' 'idiosyncrasy' 'to' 'drugs' 'chemically' 'related' 'to'
 'study' 'drug' ',' 'or' 'excipients' 'or' 'to' 'dimethyl' 'sulfoxide' '('
 'DMSO' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 4. 4. 4. 4. 4. 0. 0. 4. 0. 0. 4. 4.
 4. 0. 0.]"
NCT02940288,"46:53:treatment,,85:97:treatment,123:135:treatment",Patients will be withdrawn from the study if surgery time exceeds 90 minutes or the laparoscopic procedure turned into an open surgery,"['Patients' 'will' 'be' 'withdrawn' 'from' 'the' 'study' 'if' 'surgery'
 'time' 'exceeds' '90' 'minutes' 'or' 'the' 'laparoscopic' 'procedure'
 'turned' 'into' 'an' 'open' 'surgery']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 1.]
NCT02938559,"17:33:chronic_disease,64:74:chronic_disease,102:104:treatment","Evidence of any medical disorder or condition that could cause depression, preclude participation in CT, or is associated with memory problems, that is not currently stabilized and/or managed under the care of a physician","['Evidence' 'of' 'any' 'medical' 'disorder' 'or' 'condition' 'that'
 'could' 'cause' 'depression' ',' 'preclude' 'participation' 'in' 'CT' ','
 'or' 'is' 'associated' 'with' 'memory' 'problems' ',' 'that' 'is' 'not'
 'currently' 'stabilized' 'and/or' 'managed' 'under' 'the' 'care' 'of' 'a'
 'physician']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02937402,"1:20:chronic_disease,,50:74:treatment,78:91:treatment,95:117:treatment,",Respiratory failure requiring greater than 6 Lpm supplemental oxygen (O2) by nasal cannula or mechanical ventilation within the past six weeks,"['Respiratory' 'failure' 'requiring' 'greater' 'than' '6' 'Lpm'
 'supplemental' 'oxygen' '(' 'O2' ')' 'by' 'nasal' 'cannula' 'or'
 'mechanical' 'ventilation' 'within' 'the' 'past' 'six' 'weeks']",[2. 2. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02931110,"19:24:cancer,26:28:cancer,30:33:cancer,35:37:cancer,42:45:cancer,46:49:cancer,,","For subjects with DLBCL, FL, MCL, HL, or CLL/SLL: presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ≥1 lesion that measures ≥2.0 cm in the longest dimension [LD] and ≥1.0 cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT])","['For' 'subjects' 'with' 'DLBCL' ',' 'FL' ',' 'MCL' ',' 'HL' ',' 'or'
 'CLL/SLL' ':' 'presence' 'of' 'radiographically' 'measurable'
 'lymphadenopathy' 'or' 'extranodal' 'lymphoid' 'malignancy' '(' 'defined'
 'as' 'the' 'presence' 'of' '≥1' 'lesion' 'that' 'measures' '≥2.0' 'cm'
 'in' 'the' 'longest' 'dimension' '[' 'LD' ']' 'and' '≥1.0' 'cm' 'in'
 'the' 'longest' 'perpendicular' 'dimension' '[' 'LPD' ']' 'as' 'assessed'
 'by' 'computed' 'tomography' '[' 'CT' ']' ')']","[0. 0. 0. 3. 0. 3. 0. 3. 0. 3. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02930018,"71:93:chronic_disease,127:150:treatment,203:228:treatment","Clinical history, past imaging or clinical judgment suggests that the intracranial occlusion is chronic or there is suspected intracranial dissection such that there is a predicted lack of success with endovascular intervention","['Clinical' 'history' ',' 'past' 'imaging' 'or' 'clinical' 'judgment'
 'suggests' 'that' 'the' 'intracranial' 'occlusion' 'is' 'chronic' 'or'
 'there' 'is' 'suspected' 'intracranial' 'dissection' 'such' 'that'
 'there' 'is' 'a' 'predicted' 'lack' 'of' 'success' 'with' 'endovascular'
 'intervention']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02929589,"85:94:allergy_name,96:105:allergy_name,110:134:allergy_name","Those patients who are allergic to, refuse to take, or are otherwise unable to take oxycodone, ibuprofen, or acetaminophen medication orally for post-operative pain management","['Those' 'patients' 'who' 'are' 'allergic' 'to' ',' 'refuse' 'to' 'take'
 ',' 'or' 'are' 'otherwise' 'unable' 'to' 'take' 'oxycodone' ','
 'ibuprofen' ',' 'or' 'acetaminophen' 'medication' 'orally' 'for'
 'post-operative' 'pain' 'management']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 0. 4. 4.
 0. 0. 0. 0. 0.]"
NCT02926378,"10:19:treatment,21:34:treatment,55:68:treatment","having a pacemaker, defibrillator or wires other than sternal wires","['having' 'a' 'pacemaker' ',' 'defibrillator' 'or' 'wires' 'other' 'than'
 'sternal' 'wires']",[0. 0. 1. 0. 1. 0. 0. 0. 0. 1. 1.]
NCT02926248,"1:13:treatment,15:26:treatment,28:39:treatment,41:52:treatment,54:62:treatment,64:75:treatment,77:84:treatment","atorvastatin, fluvastatin, pravastatin, simvastatin, fibrates, gemfibrozil, digoxin","['atorvastatin' ',' 'fluvastatin' ',' 'pravastatin' ',' 'simvastatin' ','
 'fibrates' ',' 'gemfibrozil' ',' 'digoxin']",[1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1.]
NCT02924402,"25:34:chronic_disease,36:41:chronic_disease,43:82:chronic_disease,","Evidence of any serious bacterial, viral, parasitic or systemic fungal infections within the 30 days prior to study entry","['Evidence' 'of' 'any' 'serious' 'bacterial' ',' 'viral' ',' 'parasitic'
 'or' 'systemic' 'fungal' 'infections' 'within' 'the' '30' 'days' 'prior'
 'to' 'study' 'entry']",[0. 0. 0. 0. 2. 0. 2. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02924194,"59:70:treatment,63:70:treatment,76:85:chronic_disease,87:99:chronic_disease","Subjects with any medical contraindications to undergoing DBS surgery (eg, infection, coagulopathy, or significant cardiac or other medical risk factors for surgery)","['Subjects' 'with' 'any' 'medical' 'contraindications' 'to' 'undergoing'
 'DBS' 'surgery' '(' 'eg' ',' 'infection' ',' 'coagulopathy' ',' 'or'
 'significant' 'cardiac' 'or' 'other' 'medical' 'risk' 'factors' 'for'
 'surgery' ')']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02923921,"28:45:treatment,77:87:treatment,89:97:treatment,99:109:treatment","Prior history of receiving immune modulators including, but not limited to, anti-CTLA4, anti-PD1, anti-PD-L1","['Prior' 'history' 'of' 'receiving' 'immune' 'modulators' 'including' ','
 'but' 'not' 'limited' 'to' ',' 'anti-CTLA4' ',' 'anti-PD1' ','
 'anti-PD-L1']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1.]
NCT02922881,"1:18:treatment,8:18:treatment,20:23:treatment,24:28:treatment,",Stable medication (IMM/5ASA) use or no medication use for the past 6 weeks,"['Stable' 'medication' '(' 'IMM/5ASA' ')' 'use' 'or' 'no' 'medication'
 'use' 'for' 'the' 'past' '6' 'weeks']",[1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02920788,"55:81:chronic_disease,93:103:chronic_disease,108:112:chronic_disease","Eligible participants may have other co-morbid stable neuropsychiatric disorders, including depression and PTSD","['Eligible' 'participants' 'may' 'have' 'other' 'co-morbid' 'stable'
 'neuropsychiatric' 'disorders' ',' 'including' 'depression' 'and' 'PTSD']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 0. 2.]
NCT02919436,"12:25:chronic_disease,27:43:chronic_disease,47:64:cancer","History of spinal trauma, spinal infection or spinal cord tumor","['History' 'of' 'spinal' 'trauma' ',' 'spinal' 'infection' 'or' 'spinal'
 'cord' 'tumor']",[0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0.]
NCT02916524,"18:29:treatment,106:118:treatment,120:128:treatment,130:159:treatment","Currently taking medications that are known to exert significant effects on cognitive processes, such as neuroleptics, steroids, anticholinesterase inhibitors, etc","['Currently' 'taking' 'medications' 'that' 'are' 'known' 'to' 'exert'
 'significant' 'effects' 'on' 'cognitive' 'processes' ',' 'such' 'as'
 'neuroleptics' ',' 'steroids' ',' 'anticholinesterase' 'inhibitors' ','
 'etc']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 1. 0. 0.]
NCT02915744,"1:14:treatment,36:47:treatment,39:47:treatment,66:84:treatment,94:107:treatment,111:117:treatment,123:135:treatment,137:156:treatment","prior therapy (administered in the neoadjuvant, adjuvant, and/or metastatic setting) with an anthracycline, a taxane, and capecitabine (prior anthracycline can be omitted if not medically appropriate or contraindicated for the patient)","['prior' 'therapy' '(' 'administered' 'in' 'the' 'neoadjuvant' ','
 'adjuvant' ',' 'and/or' 'metastatic' 'setting' ')' 'with' 'an'
 'anthracycline' ',' 'a' 'taxane' ',' 'and' 'capecitabine' '(' 'prior'
 'anthracycline' 'can' 'be' 'omitted' 'if' 'not' 'medically' 'appropriate'
 'or' 'contraindicated' 'for' 'the' 'patient' ')']","[1. 1. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 1. 0. 0. 1. 0. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02914509,"25:44:chronic_disease,,,98:117:chronic_disease,126:143:chronic_disease,181:206:chronic_disease",Documented diagnosis of ocular hypertension with an open angle of Schaffer Grade 3 or greater or open-angle glaucoma without pseudoexfoliation or pigment dispersion or evidence of traumatic angle recession,"['Documented' 'diagnosis' 'of' 'ocular' 'hypertension' 'with' 'an' 'open'
 'angle' 'of' 'Schaffer' 'Grade' '3' 'or' 'greater' 'or' 'open-angle'
 'glaucoma' 'without' 'pseudoexfoliation' 'or' 'pigment' 'dispersion' 'or'
 'evidence' 'of' 'traumatic' 'angle' 'recession']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 0. 0. 0.
 0. 0. 2. 2. 2.]"
NCT02913430,"40:51:treatment,59:67:treatment,69:81:treatment,85:103:treatment","Patients must have previously received palbociclib in the adjuvant, neo-adjuvant or metastatic setting","['Patients' 'must' 'have' 'previously' 'received' 'palbociclib' 'in' 'the'
 'adjuvant' ',' 'neo-adjuvant' 'or' 'metastatic' 'setting']",[0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 1. 0. 1. 1.]
NCT02912572,"1:11:treatment,13:20:treatment,22:38:treatment,43:67:treatment,73:98:treatment","Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection)","['Intranasal' ',' 'inhaled' ',' 'topical' 'steroids' ',' 'or' 'local'
 'steroid' 'injections' '(' 'eg' ',' 'intra-articular' 'injection' ')']",[1. 0. 1. 0. 1. 1. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 0.]
NCT02912572,"8:24:chronic_disease,81:98:chronic_disease,,149:157:chronic_disease,,213:239:chronic_disease","Severe gastrointestinal conditions such as clinical or radiological evidence of bowel obstruction within 4 weeks prior to study entry, uncontrolled diarrhea in the last 4 weeks prior to enrollment, or history of inflammatory bowel disease","['Severe' 'gastrointestinal' 'conditions' 'such' 'as' 'clinical' 'or'
 'radiological' 'evidence' 'of' 'bowel' 'obstruction' 'within' '4' 'weeks'
 'prior' 'to' 'study' 'entry' ',' 'uncontrolled' 'diarrhea' 'in' 'the'
 'last' '4' 'weeks' 'prior' 'to' 'enrollment' ',' 'or' 'history' 'of'
 'inflammatory' 'bowel' 'disease']","[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]"
NCT02911831,"32:43:treatment,45:57:treatment,59:83:treatment,85:95:treatment,97:117:treatment,119:129:treatment,131:146:treatment","Can be previously treated with Depo-Lupron, Depo-Provera, Oral Contraceptive pills, Mirena IUD, endometrial ablation, myomectomy, oral progestins","['Can' 'be' 'previously' 'treated' 'with' 'Depo-Lupron' ',' 'Depo-Provera'
 ',' 'Oral' 'Contraceptive' 'pills' ',' 'Mirena' 'IUD' ',' 'endometrial'
 'ablation' ',' 'myomectomy' ',' 'oral' 'progestins']",[0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 1. 1. 0. 1. 1. 0. 1. 1. 0. 1. 0. 1. 1.]
NCT02911831,"72:88:chronic_disease,102:126:chronic_disease,128:151:chronic_disease,153:177:chronic_disease,179:197:chronic_disease,202:221:chronic_disease","Uncontrolled current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, subarachnoid hemorrhage, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'current' 'illness' 'including' ',' 'but' 'not' 'limited'
 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'subarachnoid' 'hemorrhage' ','
 'unstable' 'angina' 'pectoris' ',' 'cardiac' 'arrhythmia' ',' 'or'
 'psychiatric' 'illness/social' 'situations' 'that' 'would' 'limit'
 'compliance' 'with' 'study' 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0. 2.
 2. 2. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02911467,"13:29:chronic_disease,63:72:treatment,89:101:treatment",Patients on anti-coagulation they must be able to safely stop treatment for purposes of tumor biopsy,"['Patients' 'on' 'anti-coagulation' 'they' 'must' 'be' 'able' 'to'
 'safely' 'stop' 'treatment' 'for' 'purposes' 'of' 'tumor' 'biopsy']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 1.]
NCT02910700,"38:55:chronic_disease,59:76:chronic_disease,88:114:chronic_disease",Known history of a positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection,"['Known' 'history' 'of' 'a' 'positive' 'test' 'for' 'hepatitis' 'B'
 'virus' 'or' 'hepatitis' 'C' 'virus' 'indicating' 'acute' 'or' 'chronic'
 'infection']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 2. 2.]
NCT02909387,"13:22:chronic_disease,26:33:chronic_disease,55:60:treatment",Is severely depressed or anxious as determined by the PHQ-4,"['Is' 'severely' 'depressed' 'or' 'anxious' 'as' 'determined' 'by' 'the'
 'PHQ-4']",[0. 0. 2. 0. 2. 0. 0. 0. 0. 1.]
NCT02907983,"1:11:treatment,13:22:treatment,64:84:treatment","pregabalin, clonidine, selective estrogen receptor modulators, aromatase inhibitors, tissue selective estrogen complexes","['pregabalin' ',' 'clonidine' ',' 'selective' 'estrogen' 'receptor'
 'modulators' ',' 'aromatase' 'inhibitors' ',' 'tissue' 'selective'
 'estrogen' 'complexes']",[1. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02905578,"1:4:chronic_disease,37:44:treatment,88:108:treatment,123:140:treatment",HIV positive individuals undergoing therapy due to known drug:drug interaction between antiretroviral drugs and high-dose ascorbate therapy,"['HIV' 'positive' 'individuals' 'undergoing' 'therapy' 'due' 'to' 'known'
 'drug' ':' 'drug' 'interaction' 'between' 'antiretroviral' 'drugs' 'and'
 'high-dose' 'ascorbate' 'therapy']",[2. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1.]
NCT02901314,"38:49:chronic_disease,61:69:chronic_disease,71:84:chronic_disease,92:104:chronic_disease","adhere to self-care recommendations (Alzheimer's condition, dementia, schizophrenia, other neurological history that impairs memory)","['adhere' 'to' 'self-care' 'recommendations' '(' 'Alzheimer' ""'s""
 'condition' ',' 'dementia' ',' 'schizophrenia' ',' 'other' 'neurological'
 'history' 'that' 'impairs' 'memory' ')']",[2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.]
NCT02900794,"21:37:chronic_disease,39:58:chronic_disease,60:81:chronic_disease","Patients with known immunodeficiency, ciliary dysfunction, uncontrolled diabetes","['Patients' 'with' 'known' 'immunodeficiency' ',' 'ciliary' 'dysfunction'
 ',' 'uncontrolled' 'diabetes']",[0. 0. 0. 2. 0. 2. 2. 0. 2. 2.]
NCT02893982,"21:47:treatment,,108:127:treatment,132:140:treatment,,",Patients who are on anticoagulation medication that may not be safely held for the procedure (≥ 5 days for antiplatelet agents and warfarin; ≥ 24 hours for low-molecular weight heparin formulations) will be excluded,"['Patients' 'who' 'are' 'on' 'anticoagulation' 'medication' 'that' 'may'
 'not' 'be' 'safely' 'held' 'for' 'the' 'procedure' '(' '≥' '5' 'days'
 'for' 'antiplatelet' 'agents' 'and' 'warfarin' ';' '≥' '24' 'hours' 'for'
 'low-molecular' 'weight' 'heparin' 'formulations' ')' 'will' 'be'
 'excluded']","[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02891564,"8:26:treatment,30:55:treatment,81:96:treatment",use of psychotropic drugs or cholinesterase inhibitors other than mild doses of benzodiazepines,"['use' 'of' 'psychotropic' 'drugs' 'or' 'cholinesterase' 'inhibitors'
 'other' 'than' 'mild' 'doses' 'of' 'benzodiazepines']",[0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 1.]
NCT02890979,"32:53:cancer,64:71:chronic_disease,88:126:chronic_disease",Subjects with risk factors for esophageal malignancy including Barrett?s esophagus and gastroesophageal reflux disease (GERD),"['Subjects' 'with' 'risk' 'factors' 'for' 'esophageal' 'malignancy'
 'including' 'Barrett' '?' 's' 'esophagus' 'and' 'gastroesophageal'
 'reflux' 'disease' '(' 'GERD' ')']",[0. 0. 0. 0. 0. 3. 3. 0. 2. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02885649,"83:104:chronic_disease,106:129:treatment,131:146:chronic_disease,148:167:chronic_disease,188:212:chronic_disease,217:241:chronic_disease,","Any unstable, serious co-existing medical conditions including but not limited to myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within twelve (12) months prior to screening","['Any' 'unstable' ',' 'serious' 'co-existing' 'medical' 'conditions'
 'including' 'but' 'not' 'limited' 'to' 'myocardial' 'infarction' ','
 'coronary' 'bypass' 'surgery' ',' 'unstable' 'angina' ',' 'cardiac'
 'arrhythmias' ',' 'clinically' 'evident' 'congestive' 'heart' 'failure'
 ',' 'or' 'cerebrovascular' 'accident' 'within' 'twelve' '(' '12' ')'
 'months' 'prior' 'to' 'screening']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 1. 1. 1. 0. 0. 0. 0. 2. 2.
 0. 0. 0. 2. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02881242,"5:18:treatment,20:42:treatment,44:78:treatment,44:56:treatment,80:96:treatment,101:114:treatment,,","Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 30 days of enrollment and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days of enrollment","['Any' 'major' 'surgery' ',' 'extensive' 'radiotherapy' ',' 'chemotherapy'
 'with' 'delayed' 'toxicity' ',' 'biologic' 'therapy' ',' 'or'
 'immunotherapy' 'within' '30' 'days' 'of' 'enrollment' 'and/or' 'daily'
 'or' 'weekly' 'chemotherapy' 'without' 'the' 'potential' 'for' 'delayed'
 'toxicity' 'within' '14' 'days' 'of' 'enrollment']","[0. 1. 1. 0. 1. 1. 0. 1. 1. 1. 1. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02879136,"99:109:chronic_disease,111:124:chronic_disease,134:155:chronic_disease","Concomitant conditions that may affect significantly the evaluation of balance or gait, including orthopedic, rheumatologic or other neurological diseases","['Concomitant' 'conditions' 'that' 'may' 'affect' 'significantly' 'the'
 'evaluation' 'of' 'balance' 'or' 'gait' ',' 'including' 'orthopedic' ','
 'rheumatologic' 'or' 'other' 'neurological' 'diseases']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 2. 2.]
NCT02877394,"16:25:treatment,27:34:treatment,36:42:treatment,44:49:treatment,51:69:treatment,72:83:treatment,85:97:treatment,103:115:treatment,,","Current use of laxatives (MiraLax, Ex-lax, senna, herbal supplements), linaclotide, lubiprostone, and prucalopride to treat constipation- patients using these medications will be eligible to participate if they can discontinue the medication at least 3 days (72 hrs.) before the date of screening and are willing to stay off them till the study is complete","['Current' 'use' 'of' 'laxatives' '(' 'MiraLax' ',' 'Ex-lax' ',' 'senna'
 ',' 'herbal' 'supplements' ')' ',' 'linaclotide' ',' 'lubiprostone' ','
 'and' 'prucalopride' 'to' 'treat' 'constipation-' 'patients' 'using'
 'these' 'medications' 'will' 'be' 'eligible' 'to' 'participate' 'if'
 'they' 'can' 'discontinue' 'the' 'medication' 'at' 'least' '3' 'days' '('
 '72' 'hrs' '.' ')' 'before' 'the' 'date' 'of' 'screening' 'and' 'are'
 'willing' 'to' 'stay' 'off' 'them' 'till' 'the' 'study' 'is' 'complete']","[0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 1. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02877134,"1:21:treatment,,,112:122:treatment,136:163:treatment","Oral corticosteroids at a prednisone-equivalent dose at or below 40 milligram per day (mg/day), or 9 mg/day of budesonide, or 5 mg/day beclomethasone dipropionate","['Oral' 'corticosteroids' 'at' 'a' 'prednisone-equivalent' 'dose' 'at'
 'or' 'below' '40' 'milligram' 'per' 'day' '(' 'mg/day' ')' ',' 'or' '9'
 'mg/day' 'of' 'budesonide' ',' 'or' '5' 'mg/day' 'beclomethasone'
 'dipropionate']","[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0. 1. 1.]"
NCT02876302,"32:39:cancer,,103:126:cancer,132:181:cancer","Individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin","['Individuals' 'with' 'the' 'following' 'cancers' 'are' 'eligible' 'if'
 'diagnosed' 'and' 'treated' 'within' 'the' 'past' '3' 'years' ':'
 'cervical' 'cancer' 'in' 'situ' ',' 'and' 'basal' 'cell' 'or' 'squamous'
 'cell' 'carcinoma' 'of' 'the' 'skin']","[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 3.
 3. 3. 3. 3. 3. 3. 3. 3.]"
NCT02876302,",,53:63:treatment,65:76:treatment,82:98:treatment","Pregnant women are excluded from this study because paclitaxel, doxorubicin, and cyclophosphamide have the potential for teratogenic or abortifacient effects","['Pregnant' 'women' 'are' 'excluded' 'from' 'this' 'study' 'because'
 'paclitaxel' ',' 'doxorubicin' ',' 'and' 'cyclophosphamide' 'have' 'the'
 'potential' 'for' 'teratogenic' 'or' 'abortifacient' 'effects']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02873598,",,82:103:treatment,123:133:treatment,137:148:treatment,153:167:treatment,,","Completion of at least 3 months, but no more than 6 months of standard induction chemotherapy for LAPC, which may include FOLFIRINOX or gemcitabine and nab-paclitaxel, preferably within 2-4 weeks but no longer than 8 weeks","['Completion' 'of' 'at' 'least' '3' 'months' ',' 'but' 'no' 'more' 'than'
 '6' 'months' 'of' 'standard' 'induction' 'chemotherapy' 'for' 'LAPC' ','
 'which' 'may' 'include' 'FOLFIRINOX' 'or' 'gemcitabine' 'and'
 'nab-paclitaxel' ',' 'preferably' 'within' '2-4' 'weeks' 'but' 'no'
 'longer' 'than' '8' 'weeks']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 1.
 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02867696,"17:35:chronic_disease,37:43:chronic_disease,58:68:chronic_disease,114:140:chronic_disease,142:173:treatment,177:188:treatment,196:217:chronic_disease,244:267:treatment","Reports current congestive failure, angina, uncontrolled arrhythmia, symptoms indicative of increased risk of an acute cardiovascular event, coronary artery bypass grafting or angioplasty, prior myocardial infarction, and conditions requiring anticoagulation therapy (deep vein thrombosis)","['Reports' 'current' 'congestive' 'failure' ',' 'angina' ','
 'uncontrolled' 'arrhythmia' ',' 'symptoms' 'indicative' 'of' 'increased'
 'risk' 'of' 'an' 'acute' 'cardiovascular' 'event' ',' 'coronary' 'artery'
 'bypass' 'grafting' 'or' 'angioplasty' ',' 'prior' 'myocardial'
 'infarction' ',' 'and' 'conditions' 'requiring' 'anticoagulation'
 'therapy' '(' 'deep' 'vein' 'thrombosis' ')']","[0. 0. 2. 2. 0. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 1. 1. 1.
 1. 0. 1. 0. 0. 2. 2. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]"
NCT02865135,"1:17:chronic_disease,25:28:chronic_disease,63:88:treatment,134:149:treatment","Active hepatitis, known HIV, or other condition that requires immunosuppressive therapy, including current use of high dose systemic corticosteroids","['Active' 'hepatitis' ',' 'known' 'HIV' ',' 'or' 'other' 'condition'
 'that' 'requires' 'immunosuppressive' 'therapy' ',' 'including' 'current'
 'use' 'of' 'high' 'dose' 'systemic' 'corticosteroids']",[2. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02865135,"14:53:cancer,66:77:cancer,163:178:treatment","Uncontrolled central nervous system (CNS) metastases (i.e. known CNS lesions that are radiographically unstable, symptomatic and/or requiring escalating doses of corticosteroids)","['Uncontrolled' 'central' 'nervous' 'system' '(' 'CNS' ')' 'metastases'
 '(' 'i.e' '.' 'known' 'CNS' 'lesions' 'that' 'are' 'radiographically'
 'unstable' ',' 'symptomatic' 'and/or' 'requiring' 'escalating' 'doses'
 'of' 'corticosteroids' ')']","[0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0.]"
NCT02864862,"8:29:chronic_disease,31:43:chronic_disease,57:76:treatment","severe parafunctional habits, malocclusion or intent of orthodontic therapy in the future","['severe' 'parafunctional' 'habits' ',' 'malocclusion' 'or' 'intent' 'of'
 'orthodontic' 'therapy' 'in' 'the' 'future']",[0. 2. 2. 0. 2. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT02864147,"13:33:cancer,45:48:chronic_disease,66:88:treatment",evidence of endocervical disease defined as CIN 2/3 diagnosed on endocervical curettage,"['evidence' 'of' 'endocervical' 'disease' 'defined' 'as' 'CIN' '2/3'
 'diagnosed' 'on' 'endocervical' 'curettage']",[0. 0. 1. 1. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02862938,"17:45:chronic_disease,,71:91:chronic_disease,113:133:chronic_disease","Participant has choroidal neovascularization secondary to age related macular degeneration or any other type of retinal degeneration that may interfere with the study procedures, evaluations and outcome assessments","['Participant' 'has' 'choroidal' 'neovascularization' 'secondary' 'to'
 'age' 'related' 'macular' 'degeneration' 'or' 'any' 'other' 'type' 'of'
 'retinal' 'degeneration' 'that' 'may' 'interfere' 'with' 'the' 'study'
 'procedures' ',' 'evaluations' 'and' 'outcome' 'assessments']","[0. 0. 2. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02860000,",114:125:treatment,,148:177:treatment,197:234:treatment,239:271:treatment","A non-nodal lesion is considered measurable if its longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with computed tomography (CT) scan, CT component of a positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI)","['A' 'non-nodal' 'lesion' 'is' 'considered' 'measurable' 'if' 'its'
 'longest' 'diameter' 'can' 'be' 'accurately' 'measured' 'as' '>' '='
 '2.0' 'cm' 'with' 'chest' 'x-ray' ',' 'or' 'as' '>' '=' '1.0' 'cm' 'with'
 'computed' 'tomography' '(' 'CT' ')' 'scan' ',' 'CT' 'component' 'of' 'a'
 'positron' 'emission' 'tomography' '(' 'PET' ')' '/CT' ',' 'or'
 'magnetic' 'resonance' 'imaging' '(' 'MRI' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0.
 0. 0. 1. 1. 1. 1. 0. 0.]"
NCT02857218,"15:23:cancer,27:57:cancer,126:135:treatment,147:188:treatment,201:214:treatment","Subjects with cervical or Siewert 3 esophageal carcinoma, that are recommended by the multi-disciplinary tumor board to have treatment other than tri-modality chemo-radiation therapy (RT) followed by esophagectomy","['Subjects' 'with' 'cervical' 'or' 'Siewert' '3' 'esophageal' 'carcinoma'
 ',' 'that' 'are' 'recommended' 'by' 'the' 'multi-disciplinary' 'tumor'
 'board' 'to' 'have' 'treatment' 'other' 'than' 'tri-modality'
 'chemo-radiation' 'therapy' '(' 'RT' ')' 'followed' 'by' 'esophagectomy']","[0. 0. 3. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1.
 1. 1. 0. 0. 0. 0. 1.]"
NCT02851407,"37:58:treatment,81:90:treatment,94:97:chronic_disease",Patient is using or plans to use an investigational agent for the prevention or treatment of VOD,"['Patient' 'is' 'using' 'or' 'plans' 'to' 'use' 'an' 'investigational'
 'agent' 'for' 'the' 'prevention' 'or' 'treatment' 'of' 'VOD']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 0. 2.]
NCT02849457,"18:43:treatment,54:64:treatment,72:102:treatment,113:124:treatment","Has received any anticonvulsant medication including vigabatrin, other anti-seizure therapeutic agent including cannabidiol","['Has' 'received' 'any' 'anticonvulsant' 'medication' 'including'
 'vigabatrin' ',' 'other' 'anti-seizure' 'therapeutic' 'agent' 'including'
 'cannabidiol']",[0. 0. 0. 1. 1. 0. 1. 0. 0. 1. 1. 1. 0. 1.]
NCT02845453,"26:42:chronic_disease,46:84:chronic_disease,108:125:chronic_disease",Meets DSM-5 criteria for bipolar disorder or disruptive mood dysregulation disorder or DSM IV criteria for mood disorder NOS,"['Meets' 'DSM-5' 'criteria' 'for' 'bipolar' 'disorder' 'or' 'disruptive'
 'mood' 'dysregulation' 'disorder' 'or' 'DSM' 'IV' 'criteria' 'for' 'mood'
 'disorder' 'NOS']",[0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02844504,"77:83:treatment,85:95:treatment,97:108:treatment,112:127:treatment","Current medication believed to affect cognitive/psychomotor function (i.e., opioid, analgesics, anxiolytics or antidepressants)","['Current' 'medication' 'believed' 'to' 'affect' 'cognitive/psychomotor'
 'function' '(' 'i.e.' ',' 'opioid' ',' 'analgesics' ',' 'anxiolytics'
 'or' 'antidepressants' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0.]
NCT02843568,"25:51:cancer,55:70:cancer,78:89:cancer",Histologic diagnosis of non-small cell lung cancer or lung metastasis from a solid tumor,"['Histologic' 'diagnosis' 'of' 'non-small' 'cell' 'lung' 'cancer' 'or'
 'lung' 'metastasis' 'from' 'a' 'solid' 'tumor']",[0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 3. 3.]
NCT02841540,"19:23:chronic_disease,,71:78:treatment,80:91:treatment,97:124:treatment",Participants with CMML must have been treated with at least one prior therapy (hydroxyurea or a hypomethylating agent [HMA]),"['Participants' 'with' 'CMML' 'must' 'have' 'been' 'treated' 'with' 'at'
 'least' 'one' 'prior' 'therapy' '(' 'hydroxyurea' 'or' 'a'
 'hypomethylating' 'agent' '[' 'HMA' ']' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 1. 1. 0. 0. 0.]
NCT02837510,"47:56:chronic_disease,58:74:chronic_disease,76:89:chronic_disease,99:115:chronic_disease","Self-reported history or current diagnosis of psychosis, bipolar disorder, schizophrenia, current major depression","['Self-reported' 'history' 'or' 'current' 'diagnosis' 'of' 'psychosis' ','
 'bipolar' 'disorder' ',' 'schizophrenia' ',' 'current' 'major'
 'depression']",[0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 2. 0. 0. 2. 2.]
NCT02836574,"1:24:treatment,9:24:treatment,29:61:treatment,,182:188:chronic_disease","inhaled corticosteroids and chronic low-dose corticosteroids (less than or equal to 7.5 mg per day) are permitted as are brief pulsed corticosteroids for intermittent symptoms (eg, asthma)","['inhaled' 'corticosteroids' 'and' 'chronic' 'low-dose' 'corticosteroids'
 '(' 'less' 'than' 'or' 'equal' 'to' '7.5' 'mg' 'per' 'day' ')' 'are'
 'permitted' 'as' 'are' 'brief' 'pulsed' 'corticosteroids' 'for'
 'intermittent' 'symptoms' '(' 'eg' ',' 'asthma' ')']","[1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 2. 0.]"
NCT02835729,"1:26:chronic_disease,31:62:chronic_disease,95:122:chronic_disease,126:134:chronic_disease",Active autoimmune disease and chronic inflammatory conditions requiring concurrent use of any systemic immunosuppressants or steroids,"['Active' 'autoimmune' 'disease' 'and' 'chronic' 'inflammatory'
 'conditions' 'requiring' 'concurrent' 'use' 'of' 'any' 'systemic'
 'immunosuppressants' 'or' 'steroids']",[2. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 0. 2.]
NCT02834403,"12:33:chronic_disease,35:41:chronic_disease,43:65:chronic_disease,70:104:chronic_disease,","History of myocardial infarction, stroke, ventricular arrhythmia, or symptomatic conduction abnormality within the past 12 months","['History' 'of' 'myocardial' 'infarction' ',' 'stroke' ',' 'ventricular'
 'arrhythmia' ',' 'or' 'symptomatic' 'conduction' 'abnormality' 'within'
 'the' 'past' '12' 'months']",[0. 0. 2. 2. 0. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02833792,"12:24:chronic_disease,26:34:chronic_disease,39:62:chronic_disease","History of intracranial, subdural, or subarachnoid hemorrhage","['History' 'of' 'intracranial' ',' 'subdural' ',' 'or' 'subarachnoid'
 'hemorrhage']",[0. 0. 2. 0. 2. 0. 0. 2. 2.]
NCT02832167,"25:32:treatment,34:42:treatment,44:52:treatment,54:63:treatment,68:86:treatment","Prior treatment with an antiPD1, antiPDL1, antiPDL2, antiCD137, or antiCTLA4 antibody, or any other antibody or drug specifically targeting Tcell co-stimulation or checkpoint pathways","['Prior' 'treatment' 'with' 'an' 'antiPD1' ',' 'antiPDL1' ',' 'antiPDL2'
 ',' 'antiCD137' ',' 'or' 'antiCTLA4' 'antibody' ',' 'or' 'any' 'other'
 'antibody' 'or' 'drug' 'specifically' 'targeting' 'Tcell'
 'co-stimulation' 'or' 'checkpoint' 'pathways']","[0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02830360,"22:24:chronic_disease,61:71:treatment,73:80:treatment,93:133:treatment,","One of the following VT events while not being treated with amiodarone, sotalol, or another class I or class III antiarrhythmic drug) within the last 6 months","['One' 'of' 'the' 'following' 'VT' 'events' 'while' 'not' 'being'
 'treated' 'with' 'amiodarone' ',' 'sotalol' ',' 'or' 'another' 'class'
 'I' 'or' 'class' 'III' 'antiarrhythmic' 'drug' ')' 'within' 'the' 'last'
 '6' 'months']","[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1.
 0. 0. 0. 0. 0. 0.]"
NCT02826681,",61:64:chronic_disease,71:78:treatment,80:117:treatment,119:135:treatment,137:172:treatment,177:208:treatment","Current (past 4 weeks) use of drugs that may cause or treat RLS, e.g. opioids, calcium channel alpha-2-delta ligands, anti-depressants, dopaminergic agonist or antagonists, or centrally-acting antihistamines","['Current' '(' 'past' '4' 'weeks' ')' 'use' 'of' 'drugs' 'that' 'may'
 'cause' 'or' 'treat' 'RLS' ',' 'e.g' '.' 'opioids' ',' 'calcium'
 'channel' 'alpha-2-delta' 'ligands' ',' 'anti-depressants' ','
 'dopaminergic' 'agonist' 'or' 'antagonists' ',' 'or' 'centrally-acting'
 'antihistamines']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 1. 0. 1. 1. 1. 1.
 0. 1. 0. 1. 1. 1. 1. 0. 0. 1. 1.]"
NCT02826681,"26:36:treatment,39:42:treatment,46:52:treatment,59:73:treatment",Previously randomized to Injectafer® (FCM or VIT-45) in a clinical trial,"['Previously' 'randomized' 'to' 'Injectafer®' '(' 'FCM' 'or' 'VIT-45' ')'
 'in' 'a' 'clinical' 'trial']",[0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 1. 1.]
NCT02824276,"13:21:chronic_disease,23:31:chronic_disease,33:42:chronic_disease,53:73:chronic_disease","evidence of delirium, dementia, psychosis, or other cognitive impairment preventing completion of study procedures","['evidence' 'of' 'delirium' ',' 'dementia' ',' 'psychosis' ',' 'or'
 'other' 'cognitive' 'impairment' 'preventing' 'completion' 'of' 'study'
 'procedures']",[0. 0. 2. 0. 2. 0. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02820350,"1:4:chronic_disease,40:60:chronic_disease,62:86:chronic_disease,88:102:chronic_disease,104:138:treatment,140:152:treatment,157:182:treatment","AKI occurring in the setting of burns, obstructive uropathy, scleroderma renal crisis, atheroembolism, functional or surgical nephrectomy, cyclosporine, or tacrolimus nephrotoxicity","['AKI' 'occurring' 'in' 'the' 'setting' 'of' 'burns' ',' 'obstructive'
 'uropathy' ',' 'scleroderma' 'renal' 'crisis' ',' 'atheroembolism' ','
 'functional' 'or' 'surgical' 'nephrectomy' ',' 'cyclosporine' ',' 'or'
 'tacrolimus' 'nephrotoxicity']","[2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 2. 0. 1. 1. 1. 1. 0. 1. 0.
 0. 1. 1.]"
NCT02820350,"34:55:chronic_disease,63:67:chronic_disease,79:112:treatment,179:207:chronic_disease,,","Presence of preexisting advanced chronic renal failure (i.e., ESRD) requiring chronic renal replacement therapy prior to this episode of acute kidney injury or with pre-existing chronic kidney disease (CKD) defined as a eGFR<30ml/min/1.73m2","['Presence' 'of' 'preexisting' 'advanced' 'chronic' 'renal' 'failure' '('
 'i.e.' ',' 'ESRD' ')' 'requiring' 'chronic' 'renal' 'replacement'
 'therapy' 'prior' 'to' 'this' 'episode' 'of' 'acute' 'kidney' 'injury'
 'or' 'with' 'pre-existing' 'chronic' 'kidney' 'disease' '(' 'CKD' ')'
 'defined' 'as' 'a' 'eGFR' '<' '30ml/min/1.73m2']","[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02819843,"7:24:chronic_disease,49:72:chronic_disease,76:102:chronic_disease",Known severe congenital or acquired cellular or humoral immunodeficient or immunocompromised patients,"['Known' 'severe' 'congenital' 'or' 'acquired' 'cellular' 'or' 'humoral'
 'immunodeficient' 'or' 'immunocompromised' 'patients']",[0. 2. 2. 0. 0. 0. 0. 2. 2. 0. 2. 2.]
NCT02819440,"16:32:treatment,34:44:treatment,46:55:treatment,57:67:treatment","Current use of PDE-5 inhibitors (sildenafil, tadalafil, vardenafil)","['Current' 'use' 'of' 'PDE-5' 'inhibitors' '(' 'sildenafil' ','
 'tadalafil' ',' 'vardenafil' ')']",[0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 1. 0.]
NCT02819141,",,104:112:treatment,114:127:treatment,129:137:treatment,139:147:treatment,149:158:treatment,160:168:treatment,170:179:treatment,181:189:treatment,191:202:treatment,204:219:treatment","received at least one intravenous bolus dose of a sedative/opioid medication in the previous 24 hours (fentanyl, hydromorphone, ketamine, morphine, midazolam, diazepam, lorazepam, propofol, haloperidol, dexmedetomidine)","['received' 'at' 'least' 'one' 'intravenous' 'bolus' 'dose' 'of' 'a'
 'sedative/opioid' 'medication' 'in' 'the' 'previous' '24' 'hours' '('
 'fentanyl' ',' 'hydromorphone' ',' 'ketamine' ',' 'morphine' ','
 'midazolam' ',' 'diazepam' ',' 'lorazepam' ',' 'propofol' ','
 'haloperidol' ',' 'dexmedetomidine' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1.
 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0.]"
NCT02818972,"47:73:chronic_disease,85:106:chronic_disease,118:141:chronic_disease,150:174:chronic_disease,176:182:chronic_disease,190:216:chronic_disease,241:258:chronic_disease,270:283:chronic_disease","Subjects with disease, for example: suspected connective tissue disorder, specified coagulation disorders, specified coronary artery disease, severe congestive heart failure, stroke and/or Myocardial Infarction (MI) as specified, specified pulmonary disease, specified renal failure","['Subjects' 'with' 'disease' ',' 'for' 'example' ':' 'suspected'
 'connective' 'tissue' 'disorder' ',' 'specified' 'coagulation'
 'disorders' ',' 'specified' 'coronary' 'artery' 'disease' ',' 'severe'
 'congestive' 'heart' 'failure' ',' 'stroke' 'and/or' 'Myocardial'
 'Infarction' '(' 'MI' ')' 'as' 'specified' ',' 'specified' 'pulmonary'
 'disease' ',' 'specified' 'renal' 'failure']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 2. 2.
 2. 0. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2.]"
NCT02815917,"12:49:chronic_disease,51:67:chronic_disease,69:82:chronic_disease,86:104:chronic_disease","History of Post-Traumatic Stress Disorder (PTSD), bipolar disorder, schizophrenia or psychotic disorder as assessed by medical record review and/or self-reported","['History' 'of' 'Post-Traumatic' 'Stress' 'Disorder' '(' 'PTSD' ')' ','
 'bipolar' 'disorder' ',' 'schizophrenia' 'or' 'psychotic' 'disorder' 'as'
 'assessed' 'by' 'medical' 'record' 'review' 'and/or' 'self-reported']",[0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02813889,"32:39:chronic_disease,41:51:chronic_disease,55:77:chronic_disease","have no history of significant cardiac, orthopedic or neurological condition","['have' 'no' 'history' 'of' 'significant' 'cardiac' ',' 'orthopedic' 'or'
 'neurological' 'condition']",[0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 2.]
NCT02811679,"25:40:treatment,33:40:treatment,,,139:200:treatment",Subjects who respond to initial therapy for greater than one year must have had at least 2 prior lines of therapy including one line with chemoimmunotherapy including an anti-CD20 monoclonal antibody,"['Subjects' 'who' 'respond' 'to' 'initial' 'therapy' 'for' 'greater'
 'than' 'one' 'year' 'must' 'have' 'had' 'at' 'least' '2' 'prior' 'lines'
 'of' 'therapy' 'including' 'one' 'line' 'with' 'chemoimmunotherapy'
 'including' 'an' 'anti-CD20' 'monoclonal' 'antibody']","[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 1. 1. 1. 1.]"
NCT02810704,"137:144:treatment,146:154:treatment,159:170:treatment","Concurrently enrolled in another active interventional clinical trial testing a drug or intervention known or believed to interact with aspirin, warfarin, or rivaroxaban","['Concurrently' 'enrolled' 'in' 'another' 'active' 'interventional'
 'clinical' 'trial' 'testing' 'a' 'drug' 'or' 'intervention' 'known' 'or'
 'believed' 'to' 'interact' 'with' 'aspirin' ',' 'warfarin' ',' 'or'
 'rivaroxaban']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0.
 1.]"
NCT02809677,"1:27:chronic_disease,37:43:chronic_disease,45:61:chronic_disease,63:76:chronic_disease","severe psychiatric illness, such as autism, bipolar disorder, schizophrenia or current drug/alcohol abuse/dependence","['severe' 'psychiatric' 'illness' ',' 'such' 'as' 'autism' ',' 'bipolar'
 'disorder' ',' 'schizophrenia' 'or' 'current' 'drug/alcohol'
 'abuse/dependence']",[2. 2. 2. 0. 0. 0. 2. 0. 2. 2. 0. 2. 0. 0. 0. 0.]
NCT02807272,"9:18:treatment,27:43:treatment,48:52:cancer",Ongoing treatment with an anticancer agent for CMML not contemplated in this protocol,"['Ongoing' 'treatment' 'with' 'an' 'anticancer' 'agent' 'for' 'CMML' 'not'
 'contemplated' 'in' 'this' 'protocol']",[0. 1. 0. 0. 1. 1. 0. 3. 0. 0. 0. 0. 0.]
NCT02806570,"18:25:allergy_name,27:36:allergy_name,41:53:allergy_name","Known allergy to nitinol, polyester, or polyethylene","['Known' 'allergy' 'to' 'nitinol' ',' 'polyester' ',' 'or' 'polyethylene']",[0. 0. 0. 4. 0. 4. 0. 0. 4.]
NCT02802176,"1:29:chronic_disease,52:60:chronic_disease,64:76:chronic_disease",Uncontrolled chronic disease (such as uncontrolled diabetes or hypertension),"['Uncontrolled' 'chronic' 'disease' '(' 'such' 'as' 'uncontrolled'
 'diabetes' 'or' 'hypertension' ')']",[2. 2. 2. 0. 0. 0. 0. 2. 0. 2. 0.]
NCT02799095,"52:70:treatment,72:85:treatment,93:126:treatment,128:140:treatment,144:151:treatment","Subjects must be recovered from the effects of any prior chemotherapy, immunotherapy, other prior systemic anticancer therapy, radiotherapy or surgery","['Subjects' 'must' 'be' 'recovered' 'from' 'the' 'effects' 'of' 'any'
 'prior' 'chemotherapy' ',' 'immunotherapy' ',' 'other' 'prior' 'systemic'
 'anticancer' 'therapy' ',' 'radiotherapy' 'or' 'surgery']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.]
NCT02797795,"5:17:treatment,19:48:treatment,50:81:treatment,83:108:treatment,,138:148:treatment,230:253:treatment,","Any chemotherapy, immunomodulatory drug therapy, antineoplastic hormonal therapy, immunosuppressive therapy, corticosteroids > 20 mg/day prednisone or equivalent (unless administered to prevent contrast material reactions during radiographic procedures), or growth factor treatment (e.g., erythropoietin) within 14 days before first NEV801 dose","['Any' 'chemotherapy' ',' 'immunomodulatory' 'drug' 'therapy' ','
 'antineoplastic' 'hormonal' 'therapy' ',' 'immunosuppressive' 'therapy'
 ',' 'corticosteroids' '>' '20' 'mg/day' 'prednisone' 'or' 'equivalent'
 '(' 'unless' 'administered' 'to' 'prevent' 'contrast' 'material'
 'reactions' 'during' 'radiographic' 'procedures' ')' ',' 'or' 'growth'
 'factor' 'treatment' '(' 'e.g.' ',' 'erythropoietin' ')' 'within' '14'
 'days' 'before' 'first' 'NEV801' 'dose']","[0. 1. 0. 1. 1. 1. 0. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02792582,"1:16:treatment,22:38:treatment,42:63:treatment",Prior treatment with intracystic P-32 or intracystic bleomycin,"['Prior' 'treatment' 'with' 'intracystic' 'P-32' 'or' 'intracystic'
 'bleomycin']",[1. 1. 0. 1. 1. 0. 0. 0.]
NCT02786251,"81:110:treatment,112:128:treatment,133:147:treatment,188:209:chronic_disease","Conditions that render subject unable to complete all testing procedures (e.g., severe ambulatory impairments, limb amputations, or metal implants that interfere with imaging procedures; coagulation disorders)","['Conditions' 'that' 'render' 'subject' 'unable' 'to' 'complete' 'all'
 'testing' 'procedures' '(' 'e.g.' ',' 'severe' 'ambulatory' 'impairments'
 ',' 'limb' 'amputations' ',' 'or' 'metal' 'implants' 'that' 'interfere'
 'with' 'imaging' 'procedures' ';' 'coagulation' 'disorders' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 0. 0. 1. 1. 0.
 0. 0. 0. 0. 0. 2. 2. 0.]"
NCT02783716,"26:31:treatment,35:40:treatment,45:63:chronic_disease,,,,,,,","Patients recommended for CRT-P or CRT-D for heart failure (HF) according to current American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm Society (HRS) guidelines of Left Ventricle Ejection Fraction (LVEF)<35%, Left Bundle Branch Block (LBBB)>120 ms, New York Heart Association (NYHA) Class II-III)","['Patients' 'recommended' 'for' 'CRT-P' 'or' 'CRT-D' 'for' 'heart'
 'failure' '(' 'HF' ')' 'according' 'to' 'current' 'American' 'Heart'
 'Association' '(' 'AHA' ')' '/American' 'College' 'of' 'Cardiology' '('
 'ACC' ')' '/Heart' 'Rhythm' 'Society' '(' 'HRS' ')' 'guidelines' 'of'
 'Left' 'Ventricle' 'Ejection' 'Fraction' '(' 'LVEF' ')' '<' '35' '%' ','
 'Left' 'Bundle' 'Branch' 'Block' '(' 'LBBB' ')' '>' '120' 'ms' ',' 'New'
 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'Class' 'II-III' ')']","[0. 0. 0. 1. 0. 1. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02780401,"15:29:cancer,31:44:cancer,46:73:cancer","Patients with non-metastatic, node positive, HER2 negative breast cancer, confirmed by pathology report, who are in remission and defined as having no evidence of disease (NED)","['Patients' 'with' 'non-metastatic' ',' 'node' 'positive' ',' 'HER2'
 'negative' 'breast' 'cancer' ',' 'confirmed' 'by' 'pathology' 'report'
 ',' 'who' 'are' 'in' 'remission' 'and' 'defined' 'as' 'having' 'no'
 'evidence' 'of' 'disease' '(' 'NED' ')']","[0. 0. 3. 0. 3. 3. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02778282,"45:59:chronic_disease,61:68:chronic_disease,70:75:chronic_disease,77:88:chronic_disease,90:99:chronic_disease,101:113:chronic_disease,118:139:chronic_disease,170:179:treatment,","Serious unstable medical illness including, cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease such that hospitalization for treatment of that illness is likely within the next 3 months","['Serious' 'unstable' 'medical' 'illness' 'including' ',' 'cardiovascular'
 ',' 'hepatic' ',' 'renal' ',' 'respiratory' ',' 'endocrine' ','
 'neurological' ',' 'or' 'hematological' 'disease' 'such' 'that'
 'hospitalization' 'for' 'treatment' 'of' 'that' 'illness' 'is' 'likely'
 'within' 'the' 'next' '3' 'months']","[0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02776761,"28:45:chronic_disease,49:74:chronic_disease,86:130:chronic_disease","Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection","['Any' 'confirmed' 'or' 'suspected' 'immunosuppressive' 'or'
 'immunodeficient' 'condition' ',' 'including' 'human' 'immunodeficiency'
 'virus' '(' 'HIV' ')' 'infection']",[0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 2. 2. 2. 2. 2. 0. 0.]
NCT02775162,"47:62:treatment,64:78:treatment,80:97:treatment,99:124:treatment","requiring all of the following at the time of transplantation: oxygen therapy, inotropic support, renal replacement therapy","['requiring' 'all' 'of' 'the' 'following' 'at' 'the' 'time' 'of'
 'transplantation' ':' 'oxygen' 'therapy' ',' 'inotropic' 'support' ','
 'renal' 'replacement' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 1. 1. 0. 1. 1. 1.]
NCT02772562,"61:82:allergy_name,91:137:allergy_name,142:159:allergy_name","Prior history of serious toxicity or a systemic reaction to vaccinia immunization such as myopericarditis progressive vaccinia infection, or eczema vaccinatum","['Prior' 'history' 'of' 'serious' 'toxicity' 'or' 'a' 'systemic'
 'reaction' 'to' 'vaccinia' 'immunization' 'such' 'as' 'myopericarditis'
 'progressive' 'vaccinia' 'infection' ',' 'or' 'eczema' 'vaccinatum']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 4. 0. 0. 4. 4. 4. 4. 0. 0. 4. 4.]
NCT02771626,"25:43:treatment,56:71:treatment,,87:97:treatment,119:157:treatment,",Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other systemic immunosuppressive medications within 2 weeks,"['Any' 'condition' 'requiring' 'systemic' 'treatment' 'with' 'either'
 'corticosteroids' '(' '>' '10' 'mg' 'daily' 'prednisone' 'equivalent' ')'
 'or' 'other' 'systemic' 'immunosuppressive' 'medications' 'within' '2'
 'weeks']",[0. 0. 0. 1. 1. 1. 0. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02770547,"1:23:chronic_disease,,,37:74:treatment,78:82:treatment,86:109:treatment",Chronic kidney disease (eGFR <30 by Modification of Diet in Renal Disease or Mayo or Cockcroft-Gault formula),"['Chronic' 'kidney' 'disease' '(' 'eGFR' '<' '30' 'by' 'Modification' 'of'
 'Diet' 'in' 'Renal' 'Disease' 'or' 'Mayo' 'or' 'Cockcroft-Gault'
 'formula' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 1. 0. 1. 1. 0.]
NCT02769611,",,,19:32:chronic_disease,19:37:chronic_disease,48:85:chronic_disease,,,189:205:treatment,209:220:treatment,",NYHA Class III-IV heart failure (HF) confirmed left ventricular systolic dysfunction with left ventricular ejection fraction (LVEF) <40% as assessed by noninvasive imaging studies such as echocardiography or cardiac MRI within the last 6 months admitted with decompensated heart failure and almost ready for clinical discharge,"['NYHA' 'Class' 'III-IV' 'heart' 'failure' '(' 'HF' ')' 'confirmed' 'left'
 'ventricular' 'systolic' 'dysfunction' 'with' 'left' 'ventricular'
 'ejection' 'fraction' '(' 'LVEF' ')' '<' '40' '%' 'as' 'assessed' 'by'
 'noninvasive' 'imaging' 'studies' 'such' 'as' 'echocardiography' 'or'
 'cardiac' 'MRI' 'within' 'the' 'last' '6' 'months' 'admitted' 'with'
 'decompensated' 'heart' 'failure' 'and' 'almost' 'ready' 'for' 'clinical'
 'discharge']","[0. 0. 0. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02763033,"1:17:chronic_disease,60:116:treatment,147:159:chronic_disease",Active infection is defined as a stool sample positive for Clostridium difficile toxin via EIA (enzyme immunoassay) and either symptoms (frequent loose stools),"['Active' 'infection' 'is' 'defined' 'as' 'a' 'stool' 'sample' 'positive'
 'for' 'Clostridium' 'difficile' 'toxin' 'via' 'EIA' '(' 'enzyme'
 'immunoassay' ')' 'and' 'either' 'symptoms' '(' 'frequent' 'loose'
 'stools' ')']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 2. 2. 0.]"
NCT02762006,"13:22:treatment,28:41:treatment,50:60:cancer,71:79:cancer,81:99:treatment,101:117:chronic_disease","No previous treatment with immunotherapy for any malignancy including cytokine, anti-tumor vaccine, T-cell activator, co-stimulator or immune checkpoint inhibitor","['No' 'previous' 'treatment' 'with' 'immunotherapy' 'for' 'any'
 'malignancy' 'including' 'cytokine' ',' 'anti-tumor' 'vaccine' ','
 'T-cell' 'activator' ',' 'co-stimulator' 'or' 'immune' 'checkpoint'
 'inhibitor']",[0. 0. 1. 0. 1. 0. 0. 3. 0. 3. 0. 1. 1. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02760498,"16:50:chronic_disease,58:82:chronic_disease,88:105:chronic_disease,109:126:chronic_disease",Infection with human immunodeficiency virus (HIV) and/or chronic/active infection with hepatitis B virus or hepatitis C virus,"['Infection' 'with' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')'
 'and/or' 'chronic/active' 'infection' 'with' 'hepatitis' 'B' 'virus' 'or'
 'hepatitis' 'C' 'virus']",[0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0.]
NCT02759120,"32:45:allergy_name,50:62:allergy_name,64:76:allergy_name","Allergy or intolerance to both tetracyclines AND trimethoprim, sulfonamides or their combination","['Allergy' 'or' 'intolerance' 'to' 'both' 'tetracyclines' 'AND'
 'trimethoprim' ',' 'sulfonamides' 'or' 'their' 'combination']",[0. 0. 0. 0. 0. 4. 0. 4. 0. 4. 0. 0. 0.]
NCT02755896,"29:60:cancer,68:88:treatment,114:151:cancer",Presence of a proportion of Ductal Carcinoma in-situ (DCIS) in the core biopsy specimen which is compatible with extensive intraductal component (EIC),"['Presence' 'of' 'a' 'proportion' 'of' 'Ductal' 'Carcinoma' 'in-situ' '('
 'DCIS' ')' 'in' 'the' 'core' 'biopsy' 'specimen' 'which' 'is'
 'compatible' 'with' 'extensive' 'intraductal' 'component' '(' 'EIC' ')']","[0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 3. 3. 3. 3.
 0. 0.]"
NCT02753283,"10:43:treatment,45:55:treatment,60:90:treatment,182:191:treatment","Those on hormone replacement therapy (HRT), raloxifene, or prescribed protective hip pads by their Primary Care Physician (PCP) will be allowed to participate and continue on these therapies","['Those' 'on' 'hormone' 'replacement' 'therapy' '(' 'HRT' ')' ','
 'raloxifene' ',' 'or' 'prescribed' 'protective' 'hip' 'pads' 'by' 'their'
 'Primary' 'Care' 'Physician' '(' 'PCP' ')' 'will' 'be' 'allowed' 'to'
 'participate' 'and' 'continue' 'on' 'these' 'therapies']","[0. 0. 1. 1. 1. 1. 0. 0. 0. 1. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02747888,"15:29:cancer,46:62:chronic_disease,88:95:cancer,146:162:chronic_disease","Families with thyroid cancer and a suspected genetic syndrome (e.g. multiple childhood cancers in the family, multiple primary cancers, multiple endocrinopathies, etc.)","['Families' 'with' 'thyroid' 'cancer' 'and' 'a' 'suspected' 'genetic'
 'syndrome' '(' 'e.g' '.' 'multiple' 'childhood' 'cancers' 'in' 'the'
 'family' ',' 'multiple' 'primary' 'cancers' ',' 'multiple'
 'endocrinopathies' ',' 'etc' '.' ')']","[0. 0. 3. 3. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 0. 0. 0. 0.]"
NCT02744391,"38:55:chronic_disease,57:75:chronic_disease,77:103:chronic_disease,118:140:chronic_disease,185:208:chronic_disease","Presence of a clinically significant brain abnormality, significant anemia, insulin dependent diabetes, a history of cardiovascular disease, or uncontrolled/untreated risk factors for coronary artery disease","['Presence' 'of' 'a' 'clinically' 'significant' 'brain' 'abnormality' ','
 'significant' 'anemia' ',' 'insulin' 'dependent' 'diabetes' ',' 'a'
 'history' 'of' 'cardiovascular' 'disease' ',' 'or'
 'uncontrolled/untreated' 'risk' 'factors' 'for' 'coronary' 'artery'
 'disease']","[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.
 0. 0. 2. 2. 2.]"
NCT02742454,"43:57:chronic_disease,59:89:chronic_disease,91:121:chronic_disease","Life-threatening condition of fetus (e.g. severe hydrops, lethal chromosomal abnormality, severe congenital malformation)","['Life-threatening' 'condition' 'of' 'fetus' '(' 'e.g' '.' 'severe'
 'hydrops' ',' 'lethal' 'chromosomal' 'abnormality' ',' 'severe'
 'congenital' 'malformation' ')']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02740361,"1:39:chronic_disease,48:56:chronic_disease,60:66:chronic_disease",substantial neurocognitive impairments such as dementia or autism,"['substantial' 'neurocognitive' 'impairments' 'such' 'as' 'dementia' 'or'
 'autism']",[2. 2. 2. 0. 0. 2. 0. 2.]
NCT02739620,"11:22:treatment,26:47:treatment,64:73:treatment",receiving neoadjuvant or adjuvant chemotherapy with or without radiation,"['receiving' 'neoadjuvant' 'or' 'adjuvant' 'chemotherapy' 'with' 'or'
 'without' 'radiation']",[0. 1. 0. 1. 1. 0. 0. 0. 1.]
NCT02737202,"10:21:chronic_disease,23:28:chronic_disease,30:37:chronic_disease,39:59:chronic_disease,63:81:chronic_disease,,","Advanced hematologic, renal, hepatic, non-LAM lung disease or metabolic diseases; or BMI of >35","['Advanced' 'hematologic' ',' 'renal' ',' 'hepatic' ',' 'non-LAM' 'lung'
 'disease' 'or' 'metabolic' 'diseases' ';' 'or' 'BMI' 'of' '>' '35']",[0. 2. 0. 2. 0. 2. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02734771,",28:51:chronic_disease,,,93:107:treatment,111:146:treatment",New York Heart Association class III heart failure or ejection fraction of less than 30% on echocardiogram or Multi Gated Acquisition Scan (MUGA),"['New' 'York' 'Heart' 'Association' 'class' 'III' 'heart' 'failure' 'or'
 'ejection' 'fraction' 'of' 'less' 'than' '30' '%' 'on' 'echocardiogram'
 'or' 'Multi' 'Gated' 'Acquisition' 'Scan' '(' 'MUGA' ')']","[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 1. 1.
 0. 0.]"
NCT02734134,"48:62:treatment,64:80:treatment,85:117:treatment","Resistant organisms not sensitive to available IV antibiotics, oral antibiotics, or heat stable antibiotic additives to bone cement with documented elution characteristics","['Resistant' 'organisms' 'not' 'sensitive' 'to' 'available' 'IV'
 'antibiotics' ',' 'oral' 'antibiotics' ',' 'or' 'heat' 'stable'
 'antibiotic' 'additives' 'to' 'bone' 'cement' 'with' 'documented'
 'elution' 'characteristics']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02728050,"1:4:cancer,16:50:cancer,,170:186:cancer",AML other than acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) or variants according to the 2008 World Health Organization (WHO) classification; patients with biphenotypic AML,"['AML' 'other' 'than' 'acute' 'promyelocytic' 'leukemia' '(' 'APL' ')'
 'with' 't' '(' '15' ';' '17' ')' '(' 'q22' ';' 'q12' ')' 'or' 'variants'
 'according' 'to' 'the' '2008' 'World' 'Health' 'Organization' '(' 'WHO'
 ')' 'classification' ';' 'patients' 'with' 'biphenotypic' 'AML']","[3. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]"
NCT02727972,"14:31:chronic_disease,56:70:treatment,80:88:treatment,90:97:treatment,99:106:treatment,108:115:treatment","history of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto)","['history' 'of' 'a' 'bleeding' 'disorder' 'or' 'are' 'currently' 'taking'
 'anticoagulants' '(' 'such' 'as' 'Coumadin' ',' 'Heparin' ',' 'Pradaxa'
 ',' 'Xarelto' ')']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0.]
NCT02725177,"21:31:cancer,55:85:cancer,89:116:cancer,121:147:cancer,","Have any history of malignancy, except fully resected cutaneous squamous cell cancer or cutaneous basal cell cancer, or cervical carcinoma in-situ with a minimum of 5 years period without recurrence","['Have' 'any' 'history' 'of' 'malignancy' ',' 'except' 'fully' 'resected'
 'cutaneous' 'squamous' 'cell' 'cancer' 'or' 'cutaneous' 'basal' 'cell'
 'cancer' ',' 'or' 'cervical' 'carcinoma' 'in-situ' 'with' 'a' 'minimum'
 'of' '5' 'years' 'period' 'without' 'recurrence']","[0. 0. 0. 0. 3. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02724540,",44:62:treatment,64:68:treatment,70:78:treatment,82:89:treatment,119:148:treatment","Patients must be at least one month beyond prior chemotherapy, PRRT, ablation or surgery, and have recovered from all therapy-associated toxicities","['Patients' 'must' 'be' 'at' 'least' 'one' 'month' 'beyond' 'prior'
 'chemotherapy' ',' 'PRRT' ',' 'ablation' 'or' 'surgery' ',' 'and' 'have'
 'recovered' 'from' 'all' 'therapy-associated' 'toxicities']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02721381,"24:36:chronic_disease,44:56:chronic_disease,60:77:chronic_disease","history of significant brain injury, known neurological or genetic condition","['history' 'of' 'significant' 'brain' 'injury' ',' 'known' 'neurological'
 'or' 'genetic' 'condition']",[0. 0. 0. 2. 2. 0. 0. 2. 0. 2. 2.]
NCT02712736,"15:18:chronic_disease,33:49:treatment,51:58:treatment,67:79:treatment","patients with PSC, confirmed by laboratory tests, imaging, and/or liver biopsy","['patients' 'with' 'PSC' ',' 'confirmed' 'by' 'laboratory' 'tests' ','
 'imaging' ',' 'and/or' 'liver' 'biopsy']",[0. 0. 2. 0. 0. 0. 1. 1. 0. 1. 0. 0. 1. 1.]
NCT02706353,"43:71:cancer,76:92:cancer,99:114:cancer","Histologically or cytologically confirmed malignant melanoma from skin, or mucosal melanoma (i.e. ocular melanoma subjects are not eligible)","['Histologically' 'or' 'cytologically' 'confirmed' 'malignant' 'melanoma'
 'from' 'skin' ',' 'or' 'mucosal' 'melanoma' '(' 'i.e' '.' 'ocular'
 'melanoma' 'subjects' 'are' 'not' 'eligible' ')']",[0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 3. 3. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT02706249,"79:101:cancer,103:111:cancer,115:131:cancer","Participants must have histologically or cytologically confirmed diagnosis of solid tumor malignancy, lymphoma or multiple myeloma","['Participants' 'must' 'have' 'histologically' 'or' 'cytologically'
 'confirmed' 'diagnosis' 'of' 'solid' 'tumor' 'malignancy' ',' 'lymphoma'
 'or' 'multiple' 'myeloma']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 3. 0. 3. 3.]
NCT02703220,"27:45:chronic_disease,117:145:chronic_disease,146:166:chronic_disease,,","Patients with significant pulmonary diseases by history and abnormal pulmonary function testing, including moderate obstructive/restrictive lung/chest wall disorders with resting oxygen saturation of <96% or on supplemental oxygen","['Patients' 'with' 'significant' 'pulmonary' 'diseases' 'by' 'history'
 'and' 'abnormal' 'pulmonary' 'function' 'testing' ',' 'including'
 'moderate' 'obstructive/restrictive' 'lung/chest' 'wall' 'disorders'
 'with' 'resting' 'oxygen' 'saturation' 'of' '<' '96' '%' 'or' 'on'
 'supplemental' 'oxygen']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02701998,"42:56:chronic_disease,58:67:chronic_disease,72:89:chronic_disease","No major signs or symptoms suggestive of cardiovascular, pulmonary, or metabolic disease (as determined by attending physician)","['No' 'major' 'signs' 'or' 'symptoms' 'suggestive' 'of' 'cardiovascular'
 ',' 'pulmonary' ',' 'or' 'metabolic' 'disease' '(' 'as' 'determined' 'by'
 'attending' 'physician' ')']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02699697,"1:11:cancer,19:24:cancer,26:31:cancer,33:37:cancer,55:64:treatment","Metastases to the skull, hands, feet are not eligible treatment sites","['Metastases' 'to' 'the' 'skull' ',' 'hands' ',' 'feet' 'are' 'not'
 'eligible' 'treatment' 'sites']",[3. 0. 0. 3. 0. 3. 0. 3. 0. 0. 0. 1. 0.]
NCT02693080,"21:25:treatment,49:59:cancer,74:100:cancer,104:119:cancer","Patients undergoing SABR for the treatment of a lung tumor, inclusive of non-small cell lung cancer or lung metastases","['Patients' 'undergoing' 'SABR' 'for' 'the' 'treatment' 'of' 'a' 'lung'
 'tumor' ',' 'inclusive' 'of' 'non-small' 'cell' 'lung' 'cancer' 'or'
 'lung' 'metastases']",[0. 0. 1. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0.]
NCT02688647,"51:54:chronic_disease,51:64:chronic_disease,,129:136:treatment",Documented sustained improvement of the subject's IPF condition up to 12 months before study entry with or without IPF-specific therapy,"['Documented' 'sustained' 'improvement' 'of' 'the' 'subject' ""'s"" 'IPF'
 'condition' 'up' 'to' '12' 'months' 'before' 'study' 'entry' 'with' 'or'
 'without' 'IPF-specific' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02688647,"1:19:treatment,,59:73:treatment,77:87:treatment,89:99:treatment,104:113:treatment","Systemic treatment within 4 weeks before study entry with cyclosporine A or tacrolimus, everolimus, or sirolimus (calcineurin or mammalian target of rapamycin inhibitors)","['Systemic' 'treatment' 'within' '4' 'weeks' 'before' 'study' 'entry'
 'with' 'cyclosporine' 'A' 'or' 'tacrolimus' ',' 'everolimus' ',' 'or'
 'sirolimus' '(' 'calcineurin' 'or' 'mammalian' 'target' 'of' 'rapamycin'
 'inhibitors' ')']","[1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02687906,"25:40:chronic_disease,73:94:chronic_disease,98:120:chronic_disease","Evidence of significant hepatic disease or dysfunction, including known acute viral hepatitis or hepatic encephalopathy","['Evidence' 'of' 'significant' 'hepatic' 'disease' 'or' 'dysfunction' ','
 'including' 'known' 'acute' 'viral' 'hepatitis' 'or' 'hepatic'
 'encephalopathy']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0.]
NCT02682407,"22:26:chronic_disease,28:43:chronic_disease,45:47:chronic_disease,52:69:chronic_disease,80:101:chronic_disease","Have a diagnosis of: IgAN, Lupus Nephritis, MN, or C3 Glomerulopathy including Dense Deposit Disease","['Have' 'a' 'diagnosis' 'of' ':' 'IgAN' ',' 'Lupus' 'Nephritis' ',' 'MN'
 ',' 'or' 'C3' 'Glomerulopathy' 'including' 'Dense' 'Deposit' 'Disease']",[0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 2. 0. 0. 2. 2. 0. 2. 2. 2.]
NCT02681614,"90:106:chronic_disease,108:144:chronic_disease,146:170:chronic_disease,172:190:chronic_disease,195:232:chronic_disease","Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Patients' 'with' 'uncontrolled' 'intercurrent' 'illness' 'including' ','
 'but' 'not' 'limited' 'to' 'ongoing' 'or' 'active' 'infection' ','
 'symptomatic' 'congestive' 'heart' 'failure' ',' 'unstable' 'angina'
 'pectoris' ',' 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric'
 'illness/social' 'situations' 'that' 'would' 'limit' 'compliance' 'with'
 'study' 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 2. 0. 2. 2. 2.
 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02679560,"8:34:treatment,36:47:treatment,49:59:treatment,61:70:treatment,72:92:treatment,98:125:treatment,127:138:treatment,140:148:treatment,150:158:treatment","Use of direct thrombin inhibitors (bivalirudin, argatroban, desirudin, dabigatran etexilate), or direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban)","['Use' 'of' 'direct' 'thrombin' 'inhibitors' '(' 'bivalirudin' ','
 'argatroban' ',' 'desirudin' ',' 'dabigatran' 'etexilate' ')' ',' 'or'
 'direct' 'factor' 'Xa' 'inhibitors' '(' 'rivaroxaban' ',' 'apixaban' ','
 'edoxaban' ')']","[0. 0. 1. 1. 1. 1. 1. 0. 1. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 1. 0. 1. 0.]"
NCT02672098,"43:55:cancer,86:96:cancer,98:125:cancer,130:156:cancer","Histologic types feature would be serous, endometrioid, clear cell, undifferentiated carcinomas, transitional cell carcinoma, or mixed epithelial carcinoma • No End organ function","['Histologic' 'types' 'feature' 'would' 'be' 'serous' ',' 'endometrioid'
 ',' 'clear' 'cell' ',' 'undifferentiated' 'carcinomas' ',' 'transitional'
 'cell' 'carcinoma' ',' 'or' 'mixed' 'epithelial' 'carcinoma' '•' 'No'
 'End' 'organ' 'function']","[0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 3. 0. 3. 3. 3. 0. 0. 3. 3. 3. 0.
 0. 0. 0. 0.]"
NCT02670044,"14:37:chronic_disease,39:74:chronic_disease,96:99:chronic_disease,101:111:cancer,113:129:chronic_disease,134:163:chronic_disease","Positive for hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg) and known history of HIV, malignancy, active infection and cardiovascular diseases (CVs)","['Positive' 'for' 'hepatitis' 'C' 'virus' '(' 'HCV' ')' ',' 'hepatitis'
 'B' 'surface' 'antigen' '(' 'HBsAg' ')' 'and' 'known' 'history' 'of'
 'HIV' ',' 'malignancy' ',' 'active' 'infection' 'and' 'cardiovascular'
 'diseases' '(' 'CVs' ')']","[0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 3. 0.
 2. 2. 0. 2. 2. 2. 0. 0.]"
NCT02669173,"1:24:cancer,32:47:chronic_disease,49:70:chronic_disease,72:78:chronic_disease,","Arterial ischemic event (e.g., unstable angina, myocardial infarction, stroke) within 6 months of study entry","['Arterial' 'ischemic' 'event' '(' 'e.g.' ',' 'unstable' 'angina' ','
 'myocardial' 'infarction' ',' 'stroke' ')' 'within' '6' 'months' 'of'
 'study' 'entry']",[3. 3. 3. 0. 0. 0. 2. 2. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02668744,"5:13:chronic_disease,15:24:chronic_disease,29:53:chronic_disease","Any physical, cognitive, or psychological disability that would prevent participation in the study","['Any' 'physical' ',' 'cognitive' ',' 'or' 'psychological' 'disability'
 'that' 'would' 'prevent' 'participation' 'in' 'the' 'study']",[0. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02665962,"26:45:cancer,,103:119:treatment,132:154:treatment,158:167:treatment","Diagnosed with any other invasive malignancy currently, in the last five years or expected to undergo active treatment with either cytotoxic chemotherapy or radiation during the 6 week caloric restriction period","['Diagnosed' 'with' 'any' 'other' 'invasive' 'malignancy' 'currently' ','
 'in' 'the' 'last' 'five' 'years' 'or' 'expected' 'to' 'undergo' 'active'
 'treatment' 'with' 'either' 'cytotoxic' 'chemotherapy' 'or' 'radiation'
 'during' 'the' '6' 'week' 'caloric' 'restriction' 'period']","[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 0.
 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT02664909,"8:16:treatment,18:28:treatment,30:41:treatment,43:51:treatment,57:76:treatment","taking Warfarin, Dabigatran, Rivaroxaban, Apixaban, and Fresh Frozen Plasma","['taking' 'Warfarin' ',' 'Dabigatran' ',' 'Rivaroxaban' ',' 'Apixaban' ','
 'and' 'Fresh' 'Frozen' 'Plasma']",[0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1. 1.]
NCT02661386,"1:14:treatment,29:36:treatment,40:46:treatment",Anticoagulant usage such as heparin or Plavix,['Anticoagulant' 'usage' 'such' 'as' 'heparin' 'or' 'Plavix'],[1. 0. 0. 0. 1. 0. 1.]
NCT02660528,"18:44:chronic_disease,58:68:chronic_disease,70:80:chronic_disease,82:91:chronic_disease,97:111:chronic_disease","Patients with an active or recent infection, for example cellulitis, bacteremia, pneumonia, and pyelonephritis","['Patients' 'with' 'an' 'active' 'or' 'recent' 'infection' ',' 'for'
 'example' 'cellulitis' ',' 'bacteremia' ',' 'pneumonia' ',' 'and'
 'pyelonephritis']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 0. 2. 0. 2. 0. 0. 2.]
NCT02657993,"16:31:treatment,44:48:treatment,50:66:treatment,71:100:treatment,","Current use of corticosteroids, defined as oral, intravenous (IV), or injections of corticosteroids in the past 4 weeks","['Current' 'use' 'of' 'corticosteroids' ',' 'defined' 'as' 'oral' ','
 'intravenous' '(' 'IV' ')' ',' 'or' 'injections' 'of' 'corticosteroids'
 'in' 'the' 'past' '4' 'weeks']",[0. 0. 0. 1. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02656706,"7:17:cancer,,80:87:cancer,129:163:cancer,165:191:cancer,196:229:cancer","Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast","['Prior' 'malignancy' 'active' 'within' 'the' 'previous' '2' 'years'
 'except' 'for' 'locally' 'curable' 'cancers' 'that' 'have' 'been'
 'apparently' 'cured' ',' 'such' 'as' 'basal' 'or' 'squamous' 'cell'
 'skin' 'cancer' ',' 'superficial' 'bladder' 'cancer' ',' 'or' 'carcinoma'
 'in' 'situ' 'of' 'the' 'prostate' ',' 'cervix' ',' 'or' 'breast']","[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3.
 3. 3. 3. 0. 3. 3. 3. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0.]"
NCT02649790,"20:65:treatment,69:126:treatment,,155:159:treatment",Patients receiving granulocyte-colony stimulating factor (G-CSF) or granulocyte macrophage-colony stimulating factor (GM-CSF) within the 3 weeks prior to C1D1,"['Patients' 'receiving' 'granulocyte-colony' 'stimulating' 'factor' '('
 'G-CSF' ')' 'or' 'granulocyte' 'macrophage-colony' 'stimulating' 'factor'
 '(' 'GM-CSF' ')' 'within' 'the' '3' 'weeks' 'prior' 'to' 'C1D1']",[0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02648282,"15:26:treatment,30:41:treatment,43:51:treatment,58:70:treatment,,",have received mFOLFIRINOX or Gemcitabine/ Abraxane based chemotherapy for 4 cycles with last dose of therapy between 2-5 weeks of study enrollment,"['have' 'received' 'mFOLFIRINOX' 'or' 'Gemcitabine/' 'Abraxane' 'based'
 'chemotherapy' 'for' '4' 'cycles' 'with' 'last' 'dose' 'of' 'therapy'
 'between' '2-5' 'weeks' 'of' 'study' 'enrollment']",[0. 0. 1. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02645539,"51:55:treatment,57:64:treatment,66:91:treatment,100:111:treatment","Currently receiving circulatory support including ECMO, Impella, TandemLife or equivalents; or any durable VAD","['Currently' 'receiving' 'circulatory' 'support' 'including' 'ECMO' ','
 'Impella' ',' 'TandemLife' 'or' 'equivalents' ';' 'or' 'any' 'durable'
 'VAD']",[0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 1. 1. 0. 0. 0. 1. 1.]
NCT02642939,"84:94:cancer,96:106:cancer,110:118:cancer,120:125:cancer","Histological or cytological documented diagnosis of locally advanced, recurrent or metastatic (Stage IIIB or Stage IV) NSCLC","['Histological' 'or' 'cytological' 'documented' 'diagnosis' 'of' 'locally'
 'advanced' ',' 'recurrent' 'or' 'metastatic' '(' 'Stage' 'IIIB' 'or'
 'Stage' 'IV' ')' 'NSCLC']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 0. 0. 0. 0. 3.]
NCT02640950,"12:23:chronic_disease,25:33:chronic_disease,37:53:chronic_disease,55:86:treatment","History of head injury, epilepsy or seizure disorder, non-removable metallic implants or objects in or around the head","['History' 'of' 'head' 'injury' ',' 'epilepsy' 'or' 'seizure' 'disorder'
 ',' 'non-removable' 'metallic' 'implants' 'or' 'objects' 'in' 'or'
 'around' 'the' 'head']",[0. 0. 2. 2. 0. 2. 0. 2. 2. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02639546,"1:6:cancer,17:32:treatment,93:109:treatment",Tumor for which prior treatment has proven to be ineffective or intolerable or for which no standard therapy exists,"['Tumor' 'for' 'which' 'prior' 'treatment' 'has' 'proven' 'to' 'be'
 'ineffective' 'or' 'intolerable' 'or' 'for' 'which' 'no' 'standard'
 'therapy' 'exists']",[3. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT02639065,"20:59:treatment,52:59:treatment,69:94:treatment,",Patients receiving chronic systemic corticosteroid therapy or other immunosuppressive therapy within 28 days prior to registration for protocol therapy,"['Patients' 'receiving' 'chronic' 'systemic' 'corticosteroid' 'therapy'
 'or' 'other' 'immunosuppressive' 'therapy' 'within' '28' 'days' 'prior'
 'to' 'registration' 'for' 'protocol' 'therapy']",[0. 0. 1. 1. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02635893,"78:97:chronic_disease,106:121:chronic_disease,123:135:chronic_disease,139:162:chronic_disease","Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida or herniated cervical disk","['Ongoing' 'cord' 'compression' 'or' 'a' 'syrinx' 'in' 'the' 'spinal'
 'cord' 'or' 'who' 'suffer' 'from' 'a' 'spinal' 'cord' 'disease' 'such'
 'as' 'spinal' 'stenosis' ',' 'spina' 'bifida' 'or' 'herniated' 'cervical'
 'disk']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 0. 2. 2. 2.]"
NCT02633163,"1:14:chronic_disease,,46:55:chronic_disease,85:96:treatment,100:125:treatment,",Herpes zoster within the past 90 days or any infection requiring hospitalization or intravenous or intramuscular antibiotics within the past 60 days,"['Herpes' 'zoster' 'within' 'the' 'past' '90' 'days' 'or' 'any'
 'infection' 'requiring' 'hospitalization' 'or' 'intravenous' 'or'
 'intramuscular' 'antibiotics' 'within' 'the' 'past' '60' 'days']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02633111,"1:38:cancer,71:106:cancer,111:138:cancer",De novo diffuse large B-cell lymphoma (including all subtypes such as primary mediastinal B-cell lymphoma and T-cell rich B-cell lymphoma),"['De' 'novo' 'diffuse' 'large' 'B-cell' 'lymphoma' '(' 'including' 'all'
 'subtypes' 'such' 'as' 'primary' 'mediastinal' 'B-cell' 'lymphoma' 'and'
 'T-cell' 'rich' 'B-cell' 'lymphoma' ')']",[3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 3. 3. 3. 3. 0.]
NCT02632422,"1:26:chronic_disease,55:63:chronic_disease,65:83:chronic_disease,87:108:chronic_disease","severe concurrent illness or pain, including unhealed decubiti, severe neuropathic or chronic pain syndrome, infection (e.g. bladder)","['severe' 'concurrent' 'illness' 'or' 'pain' ',' 'including' 'unhealed'
 'decubiti' ',' 'severe' 'neuropathic' 'or' 'chronic' 'pain' 'syndrome'
 ',' 'infection' '(' 'e.g' '.' 'bladder' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02628535,",85:94:chronic_disease,96:107:chronic_disease,188:204:chronic_disease,227:241:treatment,,286:307:chronic_disease","Clinically significant pulmonary compromise within 28 days of first dose, including pneumonia, pneumonitis, requirement for supplemental oxygen). use to maintain adequate oxygenation, or pleural effusion sufficient to warrant pleurocentesis or any history of ≥ Grade 3 drug induced or radiation pneumonitis","['Clinically' 'significant' 'pulmonary' 'compromise' 'within' '28' 'days'
 'of' 'first' 'dose' ',' 'including' 'pneumonia' ',' 'pneumonitis' ','
 'requirement' 'for' 'supplemental' 'oxygen' ')' '.' 'use' 'to' 'maintain'
 'adequate' 'oxygenation' ',' 'or' 'pleural' 'effusion' 'sufficient' 'to'
 'warrant' 'pleurocentesis' 'or' 'any' 'history' 'of' '≥' 'Grade' '3'
 'drug' 'induced' 'or' 'radiation' 'pneumonitis']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]"
NCT02627495,"10:28:chronic_disease,35:56:chronic_disease,58:86:chronic_disease,88:101:chronic_disease,105:142:chronic_disease","Unstable medical conditions (e.g. uncontrolled diabetes, uncompensated cardiac issues, heart failure or chronic obstructive pulmonary disease)","['Unstable' 'medical' 'conditions' '(' 'e.g' '.' 'uncontrolled' 'diabetes'
 ',' 'uncompensated' 'cardiac' 'issues' ',' 'heart' 'failure' 'or'
 'chronic' 'obstructive' 'pulmonary' 'disease' ')']",[0. 2. 2. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 2. 2. 0.]
NCT02624258,"15:17:chronic_disease,36:54:treatment,72:86:treatment",subjects with HL with no available curative treatment options (such as autologous SCT),"['subjects' 'with' 'HL' 'with' 'no' 'available' 'curative' 'treatment'
 'options' '(' 'such' 'as' 'autologous' 'SCT' ')']",[0. 0. 2. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1. 0.]
NCT02616185,"8:46:treatment,53:65:treatment,67:78:treatment,140:144:cancer","Failed prior therapy with a secondary hormone (e.g. enzalutamide, abiraterone) with documented progressive disease (post-secondary hormone CRPC)","['Failed' 'prior' 'therapy' 'with' 'a' 'secondary' 'hormone' '(' 'e.g' '.'
 'enzalutamide' ',' 'abiraterone' ')' 'with' 'documented' 'progressive'
 'disease' '(' 'post-secondary' 'hormone' 'CRPC' ')']",[0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0.]
NCT02616185,"26:45:treatment,56:84:treatment,86:112:cancer",Progressive disease post-surgical castration or during androgen suppression therapy (pre-secondary hormone CRPC),"['Progressive' 'disease' 'post-surgical' 'castration' 'or' 'during'
 'androgen' 'suppression' 'therapy' '(' 'pre-secondary' 'hormone' 'CRPC'
 ')']",[0. 0. 1. 1. 0. 0. 1. 1. 1. 0. 3. 3. 3. 0.]
NCT02615249,"41:61:treatment,63:72:treatment,76:82:treatment,","Participation in a clinical trial of an investigational drug, treatment or device during this study or 3 weeks prior to inclusion in this study","['Participation' 'in' 'a' 'clinical' 'trial' 'of' 'an' 'investigational'
 'drug' ',' 'treatment' 'or' 'device' 'during' 'this' 'study' 'or' '3'
 'weeks' 'prior' 'to' 'inclusion' 'in' 'this' 'study']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02611063,"64:74:cancer,75:137:treatment,142:163:treatment",All patients must have undergone appropriate staging for their malignancy prior to transplantation including bone marrow aspirate/biopsy and radiographic scanning if indicated,"['All' 'patients' 'must' 'have' 'undergone' 'appropriate' 'staging' 'for'
 'their' 'malignancy' 'prior' 'to' 'transplantation' 'including' 'bone'
 'marrow' 'aspirate/biopsy' 'and' 'radiographic' 'scanning' 'if'
 'indicated']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 1. 1. 1. 1. 1. 1. 1. 0. 1. 1. 0. 0.]
NCT02610374,"1:25:chronic_disease,34:50:chronic_disease,64:74:cancer,89:110:treatment",Active chronic infection such as hepatitis B or C or an active malignancy that requires systemic chemotherapy,"['Active' 'chronic' 'infection' 'such' 'as' 'hepatitis' 'B' 'or' 'C' 'or'
 'an' 'active' 'malignancy' 'that' 'requires' 'systemic' 'chemotherapy']",[2. 2. 2. 0. 0. 2. 2. 2. 2. 0. 0. 0. 3. 0. 0. 1. 1.]
NCT02608125,"73:94:chronic_disease,96:102:chronic_disease,104:112:chronic_disease,121:130:chronic_disease","Patients with other major uncontrolled medical conditions, e.g., recent myocardial infarction, stroke, diabetes, active hepatitis","['Patients' 'with' 'other' 'major' 'uncontrolled' 'medical' 'conditions'
 ',' 'e.g.' ',' 'recent' 'myocardial' 'infarction' ',' 'stroke' ','
 'diabetes' ',' 'active' 'hepatitis']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 0. 0. 2.]
NCT02607748,"1:17:chronic_disease,56:88:treatment,,148:151:chronic_disease,,","Asymptomatic CAD group: 40 patients who have undergone Coronary Artery Calcium scanning within 6 months prior to the imaging visit, matched to the ACS patients for age, gender, and CAC score","['Asymptomatic' 'CAD' 'group' ':' '40' 'patients' 'who' 'have' 'undergone'
 'Coronary' 'Artery' 'Calcium' 'scanning' 'within' '6' 'months' 'prior'
 'to' 'the' 'imaging' 'visit' ',' 'matched' 'to' 'the' 'ACS' 'patients'
 'for' 'age' ',' 'gender' ',' 'and' 'CAC' 'score']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02606305,"8:26:chronic_disease,37:53:treatment,,71:78:treatment,83:96:treatment",Active autoimmune disease requiring systemic therapy in past 2 years (IMGN853 and pembrolizumab only),"['Active' 'autoimmune' 'disease' 'requiring' 'systemic' 'therapy' 'in'
 'past' '2' 'years' '(' 'IMGN853' 'and' 'pembrolizumab' 'only' ')']",[0. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0.]
NCT02606045,"1:10:treatment,16:21:treatment,23:38:treatment,40:51:treatment,53:59:treatment,64:97:treatment,","Treatment with DDAVP, cryoprecipitate, whole blood, plasma and plasma derivatives containing VWF within 5 days of study","['Treatment' 'with' 'DDAVP' ',' 'cryoprecipitate' ',' 'whole' 'blood' ','
 'plasma' 'and' 'plasma' 'derivatives' 'containing' 'VWF' 'within' '5'
 'days' 'of' 'study']",[1. 0. 1. 0. 1. 0. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02600897,"16:45:treatment,50:75:treatment,88:100:treatment,102:113:treatment,118:129:treatment,,148:168:treatment,,186:189:treatment,193:216:treatment,,236:248:treatment,249:261:treatment,262:277:treatment,278:309:treatment,","Current use of systemic immunosuppressant(s), or prior anti-cancer therapy to include: lenalidomide, fludarabine, or alemtuzumab within 12 months; radioimmunoconjugate within 12 weeks; mAb or antibody-drug conjugate within 4 weeks; or radiotherapy/chemotherapy/hormone therapy/targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1","['Current' 'use' 'of' 'systemic' 'immunosuppressant' '(' 's' ')' ',' 'or'
 'prior' 'anti-cancer' 'therapy' 'to' 'include' ':' 'lenalidomide' ','
 'fludarabine' ',' 'or' 'alemtuzumab' 'within' '12' 'months' ';'
 'radioimmunoconjugate' 'within' '12' 'weeks' ';' 'mAb' 'or'
 'antibody-drug' 'conjugate' 'within' '4' 'weeks' ';' 'or'
 'radiotherapy/chemotherapy/hormone' 'therapy/targeted' 'small-molecule'
 'therapy' 'within' '2' 'weeks' 'prior' 'to' 'Day' '1' 'of' 'Cycle' '1']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0.
 0. 0. 1. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02595866,"12:23:chronic_disease,47:68:treatment,197:210:chronic_disease","A positive hepatitis B serology indicative of previous immunization (i.e., hepatitis B surface antibody [HBsAb] positive and hepatitis B core antibody [HBcAb] negative), or a fully resolved acute HBV infection","['A' 'positive' 'hepatitis' 'B' 'serology' 'indicative' 'of' 'previous'
 'immunization' '(' 'i.e.' ',' 'hepatitis' 'B' 'surface' 'antibody' '['
 'HBsAb' ']' 'positive' 'and' 'hepatitis' 'B' 'core' 'antibody' '['
 'HBcAb' ']' 'negative' ')' ',' 'or' 'a' 'fully' 'resolved' 'acute' 'HBV'
 'infection']","[0. 0. 2. 2. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]"
NCT02595372,"1:11:treatment,13:21:treatment,23:30:treatment","Omeprazole (Prilosec, Zegerid)","['Omeprazole' '(' 'Prilosec' ',' 'Zegerid' ')']",[1. 0. 1. 0. 1. 0.]
NCT02594501,",,52:58:chronic_disease,62:77:chronic_disease,81:87:chronic_disease,96:106:chronic_disease,131:151:treatment,168:187:chronic_disease,,,",Patients older than age 18 with ischemic symptoms (stable or unstable angina or NSTEMI without thrombosis of the target lesion on coronary angiography) or evidence of myocardial ischemia in the presence of ≥ 50% de novo stenosis located in native coronary vessels (max. 2 lesions in one or 2 separate vessels),"['Patients' 'older' 'than' 'age' '18' 'with' 'ischemic' 'symptoms' '('
 'stable' 'or' 'unstable' 'angina' 'or' 'NSTEMI' 'without' 'thrombosis'
 'of' 'the' 'target' 'lesion' 'on' 'coronary' 'angiography' ')' 'or'
 'evidence' 'of' 'myocardial' 'ischemia' 'in' 'the' 'presence' 'of' '≥'
 '50' '%' 'de' 'novo' 'stenosis' 'located' 'in' 'native' 'coronary'
 'vessels' '(' 'max' '.' '2' 'lesions' 'in' 'one' 'or' '2' 'separate'
 'vessels' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 2. 0. 2. 0. 0. 0. 0. 0. 1. 1.
 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02594384,"15:20:cancer,122:142:treatment,146:168:treatment","Patients with DLBCL: Cancer progression after transplant, or be unwilling, unable or not an appropriate candidate for an autologous stem cell or bone marrow transplant","['Patients' 'with' 'DLBCL' ':' 'Cancer' 'progression' 'after' 'transplant'
 ',' 'or' 'be' 'unwilling' ',' 'unable' 'or' 'not' 'an' 'appropriate'
 'candidate' 'for' 'an' 'autologous' 'stem' 'cell' 'or' 'bone' 'marrow'
 'transplant']","[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.
 0. 1. 1. 1.]"
NCT02593110,"1:8:treatment,35:52:treatment,54:80:treatment","Surgery including lower extremity revascularization, coronary revascularization with stenting","['Surgery' 'including' 'lower' 'extremity' 'revascularization' ','
 'coronary' 'revascularization' 'with' 'stenting']",[1. 0. 0. 0. 1. 0. 1. 1. 0. 0.]
NCT02592707,"27:32:allergy_name,37:41:allergy_name,46:50:allergy_name,68:94:allergy_name","Known hypersensitivity to 177Lu, to DOTA, to JR11 or to any of the excipients of 177Lu-OPS201","['Known' 'hypersensitivity' 'to' '177Lu' ',' 'to' 'DOTA' ',' 'to' 'JR11'
 'or' 'to' 'any' 'of' 'the' 'excipients' 'of' '177Lu-OPS201']",[0. 0. 0. 4. 0. 0. 4. 0. 0. 4. 0. 0. 0. 0. 0. 4. 4. 4.]
NCT02592551,"5:8:cancer,20:30:cancer,39:50:cancer","Any MPM histology (epithelial, mixed, sarcomatoid)","['Any' 'MPM' 'histology' '(' 'epithelial' ',' 'mixed' ',' 'sarcomatoid'
 ')']",[0. 3. 0. 0. 3. 0. 0. 0. 3. 0.]
NCT02592551,"23:31:treatment,,119:127:treatment,131:150:treatment",Receipt of drugs with laxative properties and herbal or natural remedies for constipation within 90 days of receiving MEDI4736 or MEDI + tremelimumab,"['Receipt' 'of' 'drugs' 'with' 'laxative' 'properties' 'and' 'herbal' 'or'
 'natural' 'remedies' 'for' 'constipation' 'within' '90' 'days' 'of'
 'receiving' 'MEDI4736' 'or' 'MEDI' '+' 'tremelimumab']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1.]
NCT02592551,"77:93:chronic_disease,107:131:chronic_disease,146:158:chronic_disease,160:184:chronic_disease,186:204:chronic_disease,213:233:chronic_disease,237:246:chronic_disease,255:273:chronic_disease,322:350:chronic_disease,352:363:chronic_disease,367:401:chronic_disease,406:443:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'uncontrolled' 'hypertension' ','
 'unstable' 'angina' 'pectoris' ',' 'cardiac' 'arrhythmia' ',' 'active'
 'peptic' 'ulcer' 'disease' 'or' 'gastritis' ',' 'active' 'bleeding'
 'diatheses' 'including' 'any' 'subject' 'known' 'to' 'have' 'evidence'
 'of' 'acute' 'or' 'chronic' 'hepatitis' 'B' ',' 'hepatitis' 'C' 'or'
 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' ',' 'or' 'psychiatric'
 'illness/social' 'situations' 'that' 'would' 'limit' 'compliance' 'with'
 'study' 'requirements' 'or' 'compromise' 'the' 'ability' 'of' 'the'
 'subject' 'to' 'give' 'written' 'informed' 'consent']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 2. 0. 2.
 2. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 2. 2. 2. 2. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02592473,"15:39:chronic_disease,,52:63:chronic_disease,68:89:chronic_disease","Patients with urinary tract infections (> 2/year), prostatitis, or interstitial cystitis","['Patients' 'with' 'urinary' 'tract' 'infections' '(' '>' '2/year' ')' ','
 'prostatitis' ',' 'or' 'interstitial' 'cystitis']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 2. 0. 0. 2. 2.]
NCT02589522,",,,61:64:treatment,71:94:chronic_disease,,,,154:194:treatment,247:251:treatment","Patients with 1-3 brain metastases, each < 3 cm by contrast MRI, with stable systemic disease and ECOG score of 0-2, who would otherwise be eligible for SRS/stereotactic radiation therapy (SRT) alone should not be enrolled into this study unless WBRT is recommended due to any medical reasons or logistic limitations as determined by the treating physician","['Patients' 'with' '1-3' 'brain' 'metastases' ',' 'each' '<' '3' 'cm' 'by'
 'contrast' 'MRI' ',' 'with' 'stable' 'systemic' 'disease' 'and' 'ECOG'
 'score' 'of' '0-2' ',' 'who' 'would' 'otherwise' 'be' 'eligible' 'for'
 'SRS/stereotactic' 'radiation' 'therapy' '(' 'SRT' ')' 'alone' 'should'
 'not' 'be' 'enrolled' 'into' 'this' 'study' 'unless' 'WBRT' 'is'
 'recommended' 'due' 'to' 'any' 'medical' 'reasons' 'or' 'logistic'
 'limitations' 'as' 'determined' 'by' 'the' 'treating' 'physician']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02589353,"13:25:chronic_disease,27:39:chronic_disease,44:53:chronic_disease","has current oral lesions, canker sores, or piercings","['has' 'current' 'oral' 'lesions' ',' 'canker' 'sores' ',' 'or'
 'piercings']",[0. 0. 2. 2. 0. 2. 2. 0. 0. 2.]
NCT02588612,"1:26:treatment,,51:64:treatment,66:98:treatment,,223:243:treatment,,294:340:treatment",Investigational treatment within 4 weeks prior to leukapheresis; experimental anti-cancer vaccine within 2 months prior to leukapheresis in the absence of response or in the opinion of the Investigator is responding to an experimental vaccine given within 6 months prior to leukapheresis; any prior gene therapy using an integrating vector,"['Investigational' 'treatment' 'within' '4' 'weeks' 'prior' 'to'
 'leukapheresis' ';' 'experimental' 'anti-cancer' 'vaccine' 'within' '2'
 'months' 'prior' 'to' 'leukapheresis' 'in' 'the' 'absence' 'of'
 'response' 'or' 'in' 'the' 'opinion' 'of' 'the' 'Investigator' 'is'
 'responding' 'to' 'an' 'experimental' 'vaccine' 'given' 'within' '6'
 'months' 'prior' 'to' 'leukapheresis' ';' 'any' 'prior' 'gene' 'therapy'
 'using' 'an' 'integrating' 'vector']","[1. 1. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02588612,"74:77:treatment,175:185:treatment,196:226:treatment","Subjects with known epidermal growth factor receptor (EGFR) mutations or ALK or ROS1 gene rearrangements must have failed (disease progression [PD] or unacceptable toxicity) prior EGFR or ALK or ROS1 tyrosine kinase inhibitor, respectively (PD or unacceptable toxicity)","['Subjects' 'with' 'known' 'epidermal' 'growth' 'factor' 'receptor' '('
 'EGFR' ')' 'mutations' 'or' 'ALK' 'or' 'ROS1' 'gene' 'rearrangements'
 'must' 'have' 'failed' '(' 'disease' 'progression' '[' 'PD' ']' 'or'
 'unacceptable' 'toxicity' ')' 'prior' 'EGFR' 'or' 'ALK' 'or' 'ROS1'
 'tyrosine' 'kinase' 'inhibitor' ',' 'respectively' '(' 'PD' 'or'
 'unacceptable' 'toxicity' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02588326,"16:29:treatment,82:104:chronic_disease,106:115:chronic_disease,117:133:chronic_disease,165:177:chronic_disease","Any history of nasal surgery or known clinically relevant abnormalities, such as rhinitis medicamentosa, polyposis, septum deviation with clinical symptoms, recent nasal trauma, or nasal structural abnormalities","['Any' 'history' 'of' 'nasal' 'surgery' 'or' 'known' 'clinically'
 'relevant' 'abnormalities' ',' 'such' 'as' 'rhinitis' 'medicamentosa' ','
 'polyposis' ',' 'septum' 'deviation' 'with' 'clinical' 'symptoms' ','
 'recent' 'nasal' 'trauma' ',' 'or' 'nasal' 'structural' 'abnormalities']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 2. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02588326,"13:21:chronic_disease,23:32:chronic_disease,34:55:chronic_disease,59:68:cancer,81:91:cancer","Presence of glaucoma, cataracts, ocular herpes simplex or carcinoma (other than basal cell)","['Presence' 'of' 'glaucoma' ',' 'cataracts' ',' 'ocular' 'herpes'
 'simplex' 'or' 'carcinoma' '(' 'other' 'than' 'basal' 'cell' ')']",[0. 0. 2. 0. 2. 0. 2. 2. 2. 0. 3. 0. 0. 0. 3. 3. 0.]
NCT02588326,"12:36:treatment,64:84:treatment,86:94:treatment,","Use of any topically applied agents to the nasal mucosa (i.e., antibacterial creams, Vaseline) within 30 days of enrollment","['Use' 'of' 'any' 'topically' 'applied' 'agents' 'to' 'the' 'nasal'
 'mucosa' '(' 'i.e.' ',' 'antibacterial' 'creams' ',' 'Vaseline' ')'
 'within' '30' 'days' 'of' 'enrollment']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02587962,"62:88:cancer,145:153:cancer,157:167:cancer,186:193:treatment,290:302:cancer,311:337:cancer","Patients must have histologically or cytologically confirmed carcinoma of the esophagus including the gastroesophageal junction that is locally advanced or metastatic with no available therapy options that are known to provide clinical benefit per institutional standard of care. (various solid tumors cohort, gastroesophageal carcinoma group only)","['Patients' 'must' 'have' 'histologically' 'or' 'cytologically'
 'confirmed' 'carcinoma' 'of' 'the' 'esophagus' 'including' 'the'
 'gastroesophageal' 'junction' 'that' 'is' 'locally' 'advanced' 'or'
 'metastatic' 'with' 'no' 'available' 'therapy' 'options' 'that' 'are'
 'known' 'to' 'provide' 'clinical' 'benefit' 'per' 'institutional'
 'standard' 'of' 'care' '.' '(' 'various' 'solid' 'tumors' 'cohort' ','
 'gastroesophageal' 'carcinoma' 'group' 'only' ')']","[0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 3. 3. 0. 0. 0. 3. 0. 3. 0. 0. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02587962,"62:74:cancer,132:139:treatment,236:248:cancer","Patients must have histologically or cytologically confirmed mesothelioma that is locally advanced or metastatic with no available therapy options that are known to provide clinical benefit per institutional standard of care. (various solid tumors cohort, mesothelioma group only)","['Patients' 'must' 'have' 'histologically' 'or' 'cytologically'
 'confirmed' 'mesothelioma' 'that' 'is' 'locally' 'advanced' 'or'
 'metastatic' 'with' 'no' 'available' 'therapy' 'options' 'that' 'are'
 'known' 'to' 'provide' 'clinical' 'benefit' 'per' 'institutional'
 'standard' 'of' 'care' '.' '(' 'various' 'solid' 'tumors' 'cohort' ','
 'mesothelioma' 'group' 'only' ')']","[0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0.]"
NCT02587962,"1:32:treatment,34:44:treatment,46:56:treatment,58:68:treatment,73:130:treatment","Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody","['Prior' 'therapy' 'with' 'an' 'anti-PD-1' ',' 'anti-PD-L1' ','
 'anti-PD-L2' ',' 'anti-CD137' ',' 'or' 'anti-Cytotoxic'
 'T-lymphocyte-associated' 'antigen-4' '(' 'CTLA-4' ')' 'antibody']",[1. 1. 1. 1. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1. 1. 1. 0. 0. 0.]
NCT02587598,"10:44:treatment,,102:112:treatment,,133:144:treatment,148:160:treatment,,186:196:treatment,200:220:treatment","Received non-biologic anticancer medication within 5 half-lives prior to receiving the first dose of study drug (within 6 weeks for mitomycin-C or nitrosoureas), within 28 days for any antibodies or biological therapies","['Received' 'non-biologic' 'anticancer' 'medication' 'within' '5'
 'half-lives' 'prior' 'to' 'receiving' 'the' 'first' 'dose' 'of' 'study'
 'drug' '(' 'within' '6' 'weeks' 'for' 'mitomycin-C' 'or' 'nitrosoureas'
 ')' ',' 'within' '28' 'days' 'for' 'any' 'antibodies' 'or' 'biological'
 'therapies']","[0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 1.
 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1.]"
NCT02585973,"1:7:treatment,15:38:cancer,40:46:cancer,48:59:cancer,64:75:cancer,,","Biopsy proven HNSCC of the oropharynx, larynx, hypopharynx, or oral cavity Stage III-IVB as defined by American Joint Committee on Cancer (AJCC) T0-T4, N0 - N3, M0","['Biopsy' 'proven' 'HNSCC' 'of' 'the' 'oropharynx' ',' 'larynx' ','
 'hypopharynx' ',' 'or' 'oral' 'cavity' 'Stage' 'III-IVB' 'as' 'defined'
 'by' 'American' 'Joint' 'Committee' 'on' 'Cancer' '(' 'AJCC' ')' 'T0-T4'
 ',' 'N0' '-' 'N3' ',' 'M0']","[1. 0. 3. 3. 3. 3. 0. 3. 0. 3. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02585973,",69:78:treatment,80:97:treatment,101:122:treatment","Receiving or less than 21 days since receiving any other concurrent cytotoxic, biologic agent(s) or investigational agent","['Receiving' 'or' 'less' 'than' '21' 'days' 'since' 'receiving' 'any'
 'other' 'concurrent' 'cytotoxic' ',' 'biologic' 'agent' '(' 's' ')' 'or'
 'investigational' 'agent']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 1. 1.]
NCT02585791,"15:36:chronic_disease,58:78:treatment,86:97:treatment,",Subjects with respiratory infection that required use of oral corticosteroids and/or antibiotics within the prior 3 months,"['Subjects' 'with' 'respiratory' 'infection' 'that' 'required' 'use' 'of'
 'oral' 'corticosteroids' 'and/or' 'antibiotics' 'within' 'the' 'prior'
 '3' 'months']",[0. 0. 2. 2. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0.]
NCT02584647,"1:4:chronic_disease,38:60:treatment,139:146:treatment",HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with PLX3397,"['HIV-positive' 'patients' 'on' 'combination' 'antiretroviral' 'therapy'
 'are' 'ineligible' 'because' 'of' 'the' 'potential' 'for'
 'pharmacokinetic' 'interactions' 'with' 'PLX3397']",[2. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02584647,",,53:60:treatment,65:74:treatment,109:120:treatment,124:137:treatment",Pregnant women are excluded from this study because PLX3397 and sirolimus are agents with the potential for teratogenic or abortifacient effects,"['Pregnant' 'women' 'are' 'excluded' 'from' 'this' 'study' 'because'
 'PLX3397' 'and' 'sirolimus' 'are' 'agents' 'with' 'the' 'potential' 'for'
 'teratogenic' 'or' 'abortifacient' 'effects']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0.]
NCT02584647,"15:30:treatment,32:52:treatment,58:73:treatment","These include anticonvulsants, mycin antimicrobials, and antiretrovirals","['These' 'include' 'anticonvulsants' ',' 'mycin' 'antimicrobials' ','
 'and' 'antiretrovirals']",[0. 0. 1. 0. 1. 1. 0. 0. 1.]
NCT02584309,"7:10:chronic_disease,37:59:treatment,89:134:treatment",Known HIV-positivity on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with dexrazoxane,"['Known' 'HIV-positivity' 'on' 'combination' 'antiretroviral' 'therapy'
 'because' 'of' 'the' 'potential' 'for' 'pharmacokinetic' 'interactions'
 'with' 'dexrazoxane']",[0. 2. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02584309,"1:8:treatment,24:42:cancer,49:61:treatment",Surgery for primary or metastatic disease after chemotherapy following a response is allowed,"['Surgery' 'for' 'primary' 'or' 'metastatic' 'disease' 'after'
 'chemotherapy' 'following' 'a' 'response' 'is' 'allowed']",[1. 0. 0. 0. 3. 3. 0. 1. 0. 0. 0. 0. 0.]
NCT02584244,"34:52:treatment,62:68:cancer,78:103:treatment,107:123:treatment","Subjects previously treated with systemic therapies to treat cancer, such as neo-adjuvant chemotherapy or hormonal therapy","['Subjects' 'previously' 'treated' 'with' 'systemic' 'therapies' 'to'
 'treat' 'cancer' ',' 'such' 'as' 'neo-adjuvant' 'chemotherapy' 'or'
 'hormonal' 'therapy']",[0. 0. 0. 0. 1. 1. 0. 0. 3. 0. 0. 0. 1. 1. 0. 1. 1.]
NCT02583893,"22:32:cancer,,,104:120:cancer,133:147:cancer,152:169:cancer","Previously untreated non-M3 AML age >60 with no evidence of favorable karyotype defined by presence of t(8;21)(q22;q22) [AML1-ETO], inv16(p13;q22), or t(16;16)(p13;q22) [CBFβ;MYH11] by cytogenetics, FISH, or RT-PCR","['Previously' 'untreated' 'non-M3' 'AML' 'age' '>' '60' 'with' 'no'
 'evidence' 'of' 'favorable' 'karyotype' 'defined' 'by' 'presence' 'of'
 't' '(' '8' ';' '21' ')' '(' 'q22' ';' 'q22' ')' '[' 'AML1-ETO' ']' ','
 'inv16' '(' 'p13' ';' 'q22' ')' ',' 'or' 't' '(' '16' ';' '16' ')' '('
 'p13' ';' 'q22' ')' '[' 'CBFβ' ';' 'MYH11' ']' 'by' 'cytogenetics' ','
 'FISH' ',' 'or' 'RT-PCR']","[3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3.
 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3.
 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3.]"
NCT02583360,"1:13:chronic_disease,15:21:chronic_disease,25:46:chronic_disease","Craniofacial, airway or foregut malformations","['Craniofacial' ',' 'airway' 'or' 'foregut' 'malformations']",[2. 0. 2. 0. 2. 2.]
NCT02582957,"13:23:cancer,,,,135:156:chronic_disease,,,,216:225:treatment","Presence of malignancy or other irreversible disease or condition for which the six month mortality is estimated to exceed 50% (e.g., chronic liver disease with a Child-Pugh Score of 10-15, malignancy refractory to treatment) as this could affect the clinical course and cloud interpretation of the endpoints","['Presence' 'of' 'malignancy' 'or' 'other' 'irreversible' 'disease' 'or'
 'condition' 'for' 'which' 'the' 'six' 'month' 'mortality' 'is'
 'estimated' 'to' 'exceed' '50' '%' '(' 'e.g.' ',' 'chronic' 'liver'
 'disease' 'with' 'a' 'Child-Pugh' 'Score' 'of' '10-15' ',' 'malignancy'
 'refractory' 'to' 'treatment' ')' 'as' 'this' 'could' 'affect' 'the'
 'clinical' 'course' 'and' 'cloud' 'interpretation' 'of' 'the' 'endpoints']","[0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02582905,",,,,,51:60:chronic_disease,51:58:chronic_disease,64:75:chronic_disease,79:103:chronic_disease",Outpatient men and women age 18-70 years old with bipolar I or II disorder or schizoaffective disorder (bipolar type),"['Outpatient' 'men' 'and' 'women' 'age' '18-70' 'years' 'old' 'with'
 'bipolar' 'I' 'or' 'II' 'disorder' 'or' 'schizoaffective' 'disorder' '('
 'bipolar' 'type' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0.]
NCT02582827,"18:25:chronic_disease,29:40:chronic_disease,136:143:treatment",Any uncontrolled medical or psychiatric risk factors that would contraindicate the use or impair the ability of the patient to receive therapy per protocol or that may impose excessive risk to the patient,"['Any' 'uncontrolled' 'medical' 'or' 'psychiatric' 'risk' 'factors' 'that'
 'would' 'contraindicate' 'the' 'use' 'or' 'impair' 'the' 'ability' 'of'
 'the' 'patient' 'to' 'receive' 'therapy' 'per' 'protocol' 'or' 'that'
 'may' 'impose' 'excessive' 'risk' 'to' 'the' 'patient']","[0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02582827,",44:65:chronic_disease,69:77:chronic_disease,81:105:chronic_disease",History (within prior 24 months) of either myocardial infarction or unstable or poorly controlled angina,"['History' '(' 'within' 'prior' '24' 'months' ')' 'of' 'either'
 'myocardial' 'infarction' 'or' 'unstable' 'or' 'poorly' 'controlled'
 'angina']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 2. 2.]
NCT02582827,"24:51:chronic_disease,83:104:treatment,108:123:treatment,136:143:treatment",History of symptomatic peripheral vascular disease (venous or arterial) requiring surgical intervention or chronic therapy (other than aspirin),"['History' 'of' 'symptomatic' 'peripheral' 'vascular' 'disease' '('
 'venous' 'or' 'arterial' ')' 'requiring' 'surgical' 'intervention' 'or'
 'chronic' 'therapy' '(' 'other' 'than' 'aspirin' ')']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 1. 0.]
NCT02582827,"20:47:treatment,54:62:treatment,85:92:treatment,103:116:treatment,141:159:chronic_disease,161:168:treatment","Patients requiring therapeutic anticoagulation (e.g. warfarin, low-molecular weight heparin, or other anticoagulant) or with history of any bleeding diathesis. Aspirin or low-dose warfarin for catheter maintenance is allowed","['Patients' 'requiring' 'therapeutic' 'anticoagulation' '(' 'e.g' '.'
 'warfarin' ',' 'low-molecular' 'weight' 'heparin' ',' 'or' 'other'
 'anticoagulant' ')' 'or' 'with' 'history' 'of' 'any' 'bleeding'
 'diathesis' '.' 'Aspirin' 'or' 'low-dose' 'warfarin' 'for' 'catheter'
 'maintenance' 'is' 'allowed']","[0. 0. 1. 1. 0. 0. 0. 1. 0. 0. 0. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 2. 2.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02582775,"29:31:chronic_disease,49:57:chronic_disease,59:66:chronic_disease,68:76:chronic_disease,78:85:chronic_disease,89:106:chronic_disease,111:171:treatment,175:216:treatment","Diagnosis of severe form of EB characterized by collagen, laminin, integrin, keratin or plakin deficiency (by immunofluorescence staining with protein specific antibodies or Western blotting and by mutation analysis)","['Diagnosis' 'of' 'severe' 'form' 'of' 'EB' 'characterized' 'by'
 'collagen' ',' 'laminin' ',' 'integrin' ',' 'keratin' 'or' 'plakin'
 'deficiency' '(' 'by' 'immunofluorescence' 'staining' 'with' 'protein'
 'specific' 'antibodies' 'or' 'Western' 'blotting' 'and' 'by' 'mutation'
 'analysis' ')']","[0. 0. 0. 0. 0. 2. 0. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 2. 0. 0. 1. 1. 1. 1.
 1. 1. 0. 1. 1. 1. 1. 1. 1. 0.]"
NCT02581982,"21:34:allergy_name,47:57:treatment,59:69:treatment","Hypersensitivity to pembrolizumab, any of its excipients, paclitaxel, or any of its excipients","['Hypersensitivity' 'to' 'pembrolizumab' ',' 'any' 'of' 'its' 'excipients'
 ',' 'paclitaxel' ',' 'or' 'any' 'of' 'its' 'excipients']",[0. 0. 4. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02581787,"21:39:treatment,30:39:treatment,41:53:treatment,55:71:treatment,76:89:treatment","No prior receipt of systemic treatment (chemotherapy, targeted therapy, or immunotherapy) for the lesion under consideration of treatment","['No' 'prior' 'receipt' 'of' 'systemic' 'treatment' '(' 'chemotherapy' ','
 'targeted' 'therapy' ',' 'or' 'immunotherapy' ')' 'for' 'the' 'lesion'
 'under' 'consideration' 'of' 'treatment']",[0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02581215,"1:10:chronic_disease,,52:61:chronic_disease,93:115:chronic_disease,139:146:chronic_disease,272:281:treatment,287:296:treatment,304:316:treatment",Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) with a history of hepatic encephalopathy or clinical meaningful ascites resulting from cirrhosis; clinically meaningful ascites is defined as ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis,"['Cirrhosis' 'at' 'a' 'level' 'of' 'Child-Pugh' 'B' '(' 'or' 'worse' ')'
 'or' 'cirrhosis' '(' 'any' 'degree' ')' 'with' 'a' 'history' 'of'
 'hepatic' 'encephalopathy' 'or' 'clinical' 'meaningful' 'ascites'
 'resulting' 'from' 'cirrhosis' ';' 'clinically' 'meaningful' 'ascites'
 'is' 'defined' 'as' 'ascites' 'resulting' 'from' 'cirrhosis' 'and'
 'requiring' 'ongoing' 'treatment' 'with' 'diuretics' 'and/or'
 'paracentesis']","[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.
 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0.
 1.]"
NCT02581215,"1:17:treatment,21:37:treatment,41:63:treatment",Prior autologous or allogeneic organ or tissue transplantation,"['Prior' 'autologous' 'or' 'allogeneic' 'organ' 'or' 'tissue'
 'transplantation']",[1. 1. 0. 1. 1. 0. 1. 1.]
NCT02581215,"36:50:cancer,70:91:cancer,93:111:cancer,113:120:cancer,124:132:cancer","Subjects with histology other than adenocarcinoma; Examples include: neuroendocrine tumors, acinar cell cancer, sarcoma or lymphoma of the pancreas","['Subjects' 'with' 'histology' 'other' 'than' 'adenocarcinoma' ';'
 'Examples' 'include' ':' 'neuroendocrine' 'tumors' ',' 'acinar' 'cell'
 'cancer' ',' 'sarcoma' 'or' 'lymphoma' 'of' 'the' 'pancreas']",[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 3. 3. 0. 3. 3. 3. 0. 3. 0. 3. 0. 0. 0.]
NCT02580162,"11:26:chronic_disease,34:50:chronic_disease,52:67:chronic_disease,69:90:chronic_disease","Diagnosed eating disorder (i.e., anorexia nervosa, bulimia nervosa, binge eating disorder) in either parent (participating and nonparticipating) and/or the participating child","['Diagnosed' 'eating' 'disorder' '(' 'i.e.' ',' 'anorexia' 'nervosa' ','
 'bulimia' 'nervosa' ',' 'binge' 'eating' 'disorder' ')' 'in' 'either'
 'parent' '(' 'participating' 'and' 'nonparticipating' ')' 'and/or' 'the'
 'participating' 'child']","[0. 2. 2. 0. 0. 0. 2. 2. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02579967,"52:70:chronic_disease,72:77:chronic_disease,79:113:chronic_disease,114:144:chronic_disease,146:156:chronic_disease,158:170:chronic_disease,175:190:chronic_disease","Evidence of immune dysregulation, as manifested by autoimmune disease, atopy, hemophagocytic lymphohistiocytosis/macrophage activation syndrome, granulomas, splenomegaly, or lymphadenopathy","['Evidence' 'of' 'immune' 'dysregulation' ',' 'as' 'manifested' 'by'
 'autoimmune' 'disease' ',' 'atopy' ',' 'hemophagocytic'
 'lymphohistiocytosis/macrophage' 'activation' 'syndrome' ',' 'granulomas'
 ',' 'splenomegaly' ',' 'or' 'lymphadenopathy']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 2. 2. 2. 0. 2. 0. 2. 0. 0. 2.]
NCT02579967,"40:60:treatment,68:96:treatment,131:138:chronic_disease",MagT1 mutation and active need to take anti-platelet agents and/or therapeutic anti-coagulation that cannot be interrupted during aplasia,"['MagT1' 'mutation' 'and' 'active' 'need' 'to' 'take' 'anti-platelet'
 'agents' 'and/or' 'therapeutic' 'anti-coagulation' 'that' 'can' 'not'
 'be' 'interrupted' 'during' 'aplasia']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 2.]
NCT02579967,"31:55:chronic_disease,71:87:chronic_disease,89:109:chronic_disease,114:124:cancer,137:164:cancer,175:198:cancer","Related donors: No history of opportunistic infections, autoimmunity, hemoglobinopathy, red cell enzymopathy, or malignancy, apart from nonmelanomatous skin cancer or healed cervical cancer in situ","['Related' 'donors' ':' 'No' 'history' 'of' 'opportunistic' 'infections'
 ',' 'autoimmunity' ',' 'hemoglobinopathy' ',' 'red' 'cell' 'enzymopathy'
 ',' 'or' 'malignancy' ',' 'apart' 'from' 'nonmelanomatous' 'skin'
 'cancer' 'or' 'healed' 'cervical' 'cancer' 'in' 'situ']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 0. 2. 2. 2. 0. 0. 3. 0. 0. 0. 3. 3.
 3. 0. 0. 3. 3. 3. 3.]"
NCT02579096,"60:84:treatment,86:96:treatment,98:106:treatment,110:125:treatment","Patients who are not candidates for any of the recommended prophylactic medications (colchicine, naprosyn or glucocorticoids)","['Patients' 'who' 'are' 'not' 'candidates' 'for' 'any' 'of' 'the'
 'recommended' 'prophylactic' 'medications' '(' 'colchicine' ','
 'naprosyn' 'or' 'glucocorticoids' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 1. 0.]
NCT02579044,"45:56:treatment,51:83:treatment,75:83:chronic_disease","Other than the drugs used in this protocol, other drugs targeted to treat progeria are excluded","['Other' 'than' 'the' 'drugs' 'used' 'in' 'this' 'protocol' ',' 'other'
 'drugs' 'targeted' 'to' 'treat' 'progeria' 'are' 'excluded']",[0. 0. 0. 1. 1. 1. 1. 1. 0. 1. 1. 0. 0. 0. 2. 0. 0.]
NCT02578901,"45:66:treatment,68:86:treatment,88:111:treatment,121:141:treatment","Subjects enrolled in other trials involving platelet transfusions, anti-fibrinolytics, platelet growth factors or other pro-coagulant agents","['Subjects' 'enrolled' 'in' 'other' 'trials' 'involving' 'platelet'
 'transfusions' ',' 'anti-fibrinolytics' ',' 'platelet' 'growth' 'factors'
 'or' 'other' 'pro-coagulant' 'agents']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02578901,"23:35:treatment,37:50:treatment,55:94:treatment","Undergoing or planned chemotherapy, immunotherapy, or hematopoietic stem cell transplantation","['Undergoing' 'or' 'planned' 'chemotherapy' ',' 'immunotherapy' ',' 'or'
 'hematopoietic' 'stem' 'cell' 'transplantation']",[0. 0. 0. 1. 0. 1. 0. 0. 1. 1. 1. 1.]
NCT02578732,"15:31:chronic_disease,54:65:treatment,194:197:chronic_disease,199:210:chronic_disease,215:226:chronic_disease","Patients with active infection or fever (patients on antibiotics for infection or patients getting over a cold or seasonal virus are not excluded), or known historical or active infection with HIV, hepatitis B, or hepatitis C","['Patients' 'with' 'active' 'infection' 'or' 'fever' '(' 'patients' 'on'
 'antibiotics' 'for' 'infection' 'or' 'patients' 'getting' 'over' 'a'
 'cold' 'or' 'seasonal' 'virus' 'are' 'not' 'excluded' ')' ',' 'or'
 'known' 'historical' 'or' 'active' 'infection' 'with' 'HIV' ','
 'hepatitis' 'B' ',' 'or' 'hepatitis' 'C']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0.]"
NCT02577731,"33:55:chronic_disease,57:63:cancer,76:79:chronic_disease,95:120:chronic_disease","Pre-existing conditions such as pathological fractures, cancer, history of HIV, or history of connective tissue disease","['Pre-existing' 'conditions' 'such' 'as' 'pathological' 'fractures' ','
 'cancer' ',' 'history' 'of' 'HIV' ',' 'or' 'history' 'of' 'connective'
 'tissue' 'disease']",[0. 0. 0. 0. 2. 2. 0. 3. 0. 0. 0. 2. 0. 0. 0. 0. 2. 2. 2.]
NCT02577406,"27:80:treatment,86:90:treatment,92:103:treatment,107:117:treatment","Refractory to or relapsed after second- or third-line low-intensity AML therapy (eg, LDAC, azacitidine or decitabine)","['Refractory' 'to' 'or' 'relapsed' 'after' 'second-' 'or' 'third-line'
 'low-intensity' 'AML' 'therapy' '(' 'eg' ',' 'LDAC' ',' 'azacitidine'
 'or' 'decitabine' ')']",[0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0.]
NCT02577406,"67:75:cancer,97:105:chronic_disease,107:116:chronic_disease,122:129:chronic_disease,133:138:chronic_disease,147:185:chronic_disease","Subject has immediately life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation","['Subject' 'has' 'immediately' 'life-threatening' ',' 'severe'
 'complications' 'of' 'leukemia' 'such' 'as' 'uncontrolled' 'bleeding' ','
 'pneumonia' 'with' 'hypoxia' 'or' 'shock' ',' 'and/or' 'disseminated'
 'intravascular' 'coagulation']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 2. 0. 2. 0. 2. 0. 2. 0. 0. 2. 2. 2.]
NCT02577406,"32:47:chronic_disease,,86:101:treatment,,,,163:187:chronic_disease","Subject has significant active cardiac disease within 6 months prior to the start of study treatment, including New York Heart Association (NYHA) class III or IV congestive heart failure","['Subject' 'has' 'significant' 'active' 'cardiac' 'disease' 'within' '6'
 'months' 'prior' 'to' 'the' 'start' 'of' 'study' 'treatment' ','
 'including' 'New' 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'class'
 'III' 'or' 'IV' 'congestive' 'heart' 'failure']","[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 2. 2. 2.]"
NCT02577406,"84:96:treatment,100:133:treatment,154:164:treatment","Subjects with degenerative and toxic encephalopathies, especially after the use of methotrexate or treatment with ionizing radiation, should not receive cytarabine","['Subjects' 'with' 'degenerative' 'and' 'toxic' 'encephalopathies' ','
 'especially' 'after' 'the' 'use' 'of' 'methotrexate' 'or' 'treatment'
 'with' 'ionizing' 'radiation' ',' 'should' 'not' 'receive' 'cytarabine']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 1.]
NCT02577367,"31:42:treatment,87:101:treatment,103:113:treatment,115:125:treatment,127:134:treatment,136:144:treatment,146:156:treatment,161:169:treatment","Concomitant administration of medications that affect thyroid function test including Cholestyramine, Sucralfate, Amiodarone, Lithium, Dopamine, Dobutamine and Dilantin at enrollment","['Concomitant' 'administration' 'of' 'medications' 'that' 'affect'
 'thyroid' 'function' 'test' 'including' 'Cholestyramine' ',' 'Sucralfate'
 ',' 'Amiodarone' ',' 'Lithium' ',' 'Dopamine' ',' 'Dobutamine' 'and'
 'Dilantin' 'at' 'enrollment']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0.
 0.]"
NCT02576444,"1:18:chronic_disease,91:125:chronic_disease,144:161:treatment","Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV) and are receiving antiviral therapy (testing is not part of the protocol)","['Immunocompromised' 'patients' ',' 'e.g.' ',' 'patients' 'who' 'are'
 'known' 'to' 'be' 'serologically' 'positive' 'for' 'human'
 'immunodeficiency' 'virus' '(' 'HIV' ')' 'and' 'are' 'receiving'
 'antiviral' 'therapy' '(' 'testing' 'is' 'not' 'part' 'of' 'the'
 'protocol' ')']","[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02576444,"28:58:treatment,77:103:chronic_disease,147:163:treatment",Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication,"['Patients' 'unable' 'to' 'swallow' 'orally' 'administered' 'medication'
 'and' 'patients' 'with' 'gastrointestinal' 'disorders' 'likely' 'to'
 'interfere' 'with' 'absorption' 'of' 'the' 'study' 'medication']",[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02576444,"30:36:cancer,65:89:cancer,110:125:cancer,127:133:cancer,135:141:cancer,143:148:cancer,150:154:cancer,159:167:cancer,,210:222:cancer,","Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated stage I cancers (cervix, breast, colon, lung, or prostate as examples) or other advanced (> Stage I)solid tumors curatively treated with no evidence of disease for ≥ 5 years","['Patients' 'with' 'second' 'primary' 'cancer' ',' 'except' ':'
 'adequately' 'treated' 'non-melanoma' 'skin' 'cancer' ',' 'curatively'
 'treated' 'stage' 'I' 'cancers' '(' 'cervix' ',' 'breast' ',' 'colon' ','
 'lung' ',' 'or' 'prostate' 'as' 'examples' ')' 'or' 'other' 'advanced'
 '(' '>' 'Stage' 'I' ')' 'solid' 'tumors' 'curatively' 'treated' 'with'
 'no' 'evidence' 'of' 'disease' 'for' '≥' '5' 'years']","[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 3. 3. 3. 0. 3. 0. 3. 0.
 3. 0. 3. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02576431,"30:39:chronic_disease,41:46:chronic_disease,51:67:chronic_disease,78:100:chronic_disease,111:127:chronic_disease","Active uncontrolled systemic bacterial, viral, or fungal infection, unstable cardiovascular disease, or other systemic disease that would limit compliance with study procedures","['Active' 'uncontrolled' 'systemic' 'bacterial' ',' 'viral' ',' 'or'
 'fungal' 'infection' ',' 'unstable' 'cardiovascular' 'disease' ',' 'or'
 'other' 'systemic' 'disease' 'that' 'would' 'limit' 'compliance' 'with'
 'study' 'procedures']","[0. 0. 2. 2. 0. 2. 0. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02575404,"15:50:cancer,60:69:treatment,75:88:treatment",Patients with metastatic or unresectable melanoma for whom treatment with pembrolizumab is indicated,"['Patients' 'with' 'metastatic' 'or' 'unresectable' 'melanoma' 'for'
 'whom' 'treatment' 'with' 'pembrolizumab' 'is' 'indicated']",[0. 0. 3. 3. 3. 3. 0. 0. 1. 0. 1. 0. 0.]
NCT02574910,"11:44:chronic_disease,140:152:chronic_disease,157:169:chronic_disease,","Confirmed classic 21-hydroxylase deficiency evident by genotype groups A, A1 or B or clinical course (e.g., adrenal crisis with documented hyperkalemia and hyponatremia, at diagnosis or during a later evaluation; ambiguous genitalia in females)","['Confirmed' 'classic' '21-hydroxylase' 'deficiency' 'evident' 'by'
 'genotype' 'groups' 'A' ',' 'A1' 'or' 'B' 'or' 'clinical' 'course' '('
 'e.g.' ',' 'adrenal' 'crisis' 'with' 'documented' 'hyperkalemia' 'and'
 'hyponatremia' ',' 'at' 'diagnosis' 'or' 'during' 'a' 'later'
 'evaluation' ';' 'ambiguous' 'genitalia' 'in' 'females' ')']","[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02574455,",25:40:treatment,42:54:treatment,56:77:treatment,88:114:treatment,116:133:treatment,135:148:treatment,156:173:treatment,178:191:treatment","At least 2 weeks beyond prior treatment (chemotherapy, investigational drugs including small molecular inhibitors, endocrine therapy, immunotherapy and/or radiation therapy) or major surgery","['At' 'least' '2' 'weeks' 'beyond' 'prior' 'treatment' '(' 'chemotherapy'
 ',' 'investigational' 'drugs' 'including' 'small' 'molecular'
 'inhibitors' ',' 'endocrine' 'therapy' ',' 'immunotherapy' 'and/or'
 'radiation' 'therapy' ')' 'or' 'major' 'surgery']","[0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 1. 0. 1. 1. 1. 0. 1. 1. 0. 1. 0. 1. 1.
 0. 0. 1. 1.]"
NCT02573883,"1:17:chronic_disease,8:17:chronic_disease,19:26:chronic_disease,28:34:chronic_disease,36:55:chronic_disease,57:71:chronic_disease","vulvar infection (candida, herpes, bacterial vaginosis, trichomoniasis or other infection)","['vulvar' 'infection' '(' 'candida' ',' 'herpes' ',' 'bacterial'
 'vaginosis' ',' 'trichomoniasis' 'or' 'other' 'infection' ')']",[2. 2. 0. 2. 0. 2. 0. 2. 2. 0. 2. 0. 0. 0. 0.]
NCT02573493,"66:101:chronic_disease,103:139:chronic_disease,141:165:chronic_disease,167:185:chronic_disease,190:235:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or serious psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'serious' 'infection' ','
 'symptomatic' 'congestive' 'heart' 'failure' ',' 'unstable' 'angina'
 'pectoris' ',' 'cardiac' 'arrhythmia' ',' 'or' 'serious' 'psychiatric'
 'illness/social' 'situations' 'that' 'would' 'limit' 'compliance' 'with'
 'study' 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 0. 2. 2. 2.
 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02573376,"12:31:treatment,36:48:treatment,86:95:chronic_disease","Receipt of prior HCV treatment and radiographic, histologic, or clinical evidence of cirrhosis","['Receipt' 'of' 'prior' 'HCV' 'treatment' 'and' 'radiographic' ','
 'histologic' ',' 'or' 'clinical' 'evidence' 'of' 'cirrhosis']",[0. 0. 1. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02573246,"23:30:chronic_disease,86:107:chronic_disease,144:150:chronic_disease,173:183:treatment,223:233:treatment,235:243:treatment,245:253:treatment","Has increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure (such as after large infarctions or trauma), or currently taking medication that lowers the seizure threshold (e.g Wellbutrin, Adderall, Clozaril)","['Has' 'increased' 'risk' 'of' 'seizure' 'for' 'any' 'reason' ','
 'including' 'prior' 'diagnosis' 'of' 'increased' 'intracranial'
 'pressure' '(' 'such' 'as' 'after' 'large' 'infarctions' 'or' 'trauma'
 ')' ',' 'or' 'currently' 'taking' 'medication' 'that' 'lowers' 'the'
 'seizure' 'threshold' '(' 'e.g' 'Wellbutrin' ',' 'Adderall' ','
 'Clozaril' ')']","[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2.
 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0.]"
NCT02573246,"1:26:chronic_disease,7:26:chronic_disease,28:58:chronic_disease,60:74:chronic_disease,76:87:chronic_disease,89:112:chronic_disease,96:112:chronic_disease,114:129:chronic_disease,131:159:chronic_disease,161:190:chronic_disease,192:208:chronic_disease,210:230:chronic_disease,232:249:chronic_disease,251:275:chronic_disease,340:369:chronic_disease,371:392:chronic_disease,394:414:chronic_disease,416:440:chronic_disease,442:461:chronic_disease,463:479:chronic_disease,481:496:chronic_disease,498:519:chronic_disease,521:552:chronic_disease,532:552:chronic_disease,554:587:chronic_disease,589:620:chronic_disease,622:653:chronic_disease,655:684:chronic_disease,686:715:chronic_disease,717:749:chronic_disease,751:780:chronic_disease,782:812:chronic_disease,814:855:chronic_disease","major depressive disorder, persistent depressive disorder, panic disorder, agoraphobia, social anxiety disorder, specific phobia, generalized anxiety disorder, obsessive-compulsive disorder, trichotillomania, excoriation disorder, hoarding disorder, body dysmorphic disorder, other specified, or unspecified obsessive-compulsive disorder, posttraumatic stress disorder, acute stress disorder, adjustment disorders, somatic symptom disorder, conversion disorder, anorexia nervosa, bulimia nervosa, binge-eating disorder, borderline personality disorder, narcissistic personality disorder, histrionic personality disorder, antisocial personality disorder, paranoid personality disorder, schizoid personality disorder, schizotypal personality disorder, avoidant personality disorder, dependent personality disorder, obsessive-compulsive personality disorder, personality disorder unspecified, depressive disorder unspecified, anxiety disorder unspecified","['major' 'depressive' 'disorder' ',' 'persistent' 'depressive' 'disorder'
 ',' 'panic' 'disorder' ',' 'agoraphobia' ',' 'social' 'anxiety'
 'disorder' ',' 'specific' 'phobia' ',' 'generalized' 'anxiety' 'disorder'
 ',' 'obsessive-compulsive' 'disorder' ',' 'trichotillomania' ','
 'excoriation' 'disorder' ',' 'hoarding' 'disorder' ',' 'body'
 'dysmorphic' 'disorder' ',' 'other' 'specified' ',' 'or' 'unspecified'
 'obsessive-compulsive' 'disorder' ',' 'posttraumatic' 'stress' 'disorder'
 ',' 'acute' 'stress' 'disorder' ',' 'adjustment' 'disorders' ','
 'somatic' 'symptom' 'disorder' ',' 'conversion' 'disorder' ',' 'anorexia'
 'nervosa' ',' 'bulimia' 'nervosa' ',' 'binge-eating' 'disorder' ','
 'borderline' 'personality' 'disorder' ',' 'narcissistic' 'personality'
 'disorder' ',' 'histrionic' 'personality' 'disorder' ',' 'antisocial'
 'personality' 'disorder' ',' 'paranoid' 'personality' 'disorder' ','
 'schizoid' 'personality' 'disorder' ',' 'schizotypal' 'personality'
 'disorder' ',' 'avoidant' 'personality' 'disorder' ',' 'dependent'
 'personality' 'disorder' ',' 'obsessive-compulsive' 'personality'
 'disorder' ',' 'personality' 'disorder' 'unspecified' ',' 'depressive'
 'disorder' 'unspecified' ',' 'anxiety' 'disorder' 'unspecified']","[2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 2. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 2. 0.
 2. 2. 2. 2. 0. 2. 2. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 2.
 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2.
 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02572323,"8:18:cancer,30:35:cancer,39:59:cancer",Active malignancy other than basal or squamous skin cancer,"['Active' 'malignancy' 'other' 'than' 'basal' 'or' 'squamous' 'skin'
 'cancer']",[0. 3. 0. 0. 3. 0. 3. 3. 3.]
NCT02572323,"1:23:treatment,55:104:treatment,,,160:163:chronic_disease,",Antiretroviral therapy: Patient currently receiving a combination antiretroviral therapy (cART) regimen ≥12 weeks with no interruptions longer than 7 days and HIV <500 copies/ml during that time,"['Antiretroviral' 'therapy' ':' 'Patient' 'currently' 'receiving' 'a'
 'combination' 'antiretroviral' 'therapy' '(' 'cART' ')' 'regimen' '≥12'
 'weeks' 'with' 'no' 'interruptions' 'longer' 'than' '7' 'days' 'and'
 'HIV' '<' '500' 'copies/ml' 'during' 'that' 'time']","[1. 1. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 0. 0. 0. 0. 0. 0.]"
NCT02572323,"26:30:treatment,32:49:treatment,98:115:treatment,125:133:treatment,135:146:treatment,148:156:treatment","active or planned use of rhGH, anabolic steroids (other than replacement doses of testosterone), anti-TNFa therapy or other biologic (tocilizumab, Xelijanz, etc.)","['active' 'or' 'planned' 'use' 'of' 'rhGH' ',' 'anabolic' 'steroids' '('
 'other' 'than' 'replacement' 'doses' 'of' 'testosterone' ')' ','
 'anti-TNFa' 'therapy' 'or' 'other' 'biologic' '(' 'tocilizumab' ','
 'Xelijanz' ',' 'etc' '.' ')']","[0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 0.
 1. 0. 1. 0. 0. 0. 0.]"
NCT02570984,"1:11:treatment,15:41:treatment,53:68:treatment",Prior IVIG or systemic immunosuppressant other than corticosteroids,"['Prior' 'IVIG' 'or' 'systemic' 'immunosuppressant' 'other' 'than'
 'corticosteroids']",[1. 1. 0. 1. 1. 0. 0. 1.]
NCT02570854,"1:14:chronic_disease,15:26:chronic_disease,,,51:73:treatment,75:88:treatment,113:138:chronic_disease","Liver disease/dysfunction (Child-Pugh score ≥ 6), prior liver transplant, heart failure (NYHA Class III or IV); gastrointestinal bleeding","['Liver' 'disease/dysfunction' '(' 'Child-Pugh' 'score' '≥' '6' ')' ','
 'prior' 'liver' 'transplant' ',' 'heart' 'failure' '(' 'NYHA' 'Class'
 'III' 'or' 'IV' ')' ';' 'gastrointestinal' 'bleeding']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2.]"
NCT02570672,"1:13:chronic_disease,23:35:treatment,,,137:145:chronic_disease,","Pre-diabetic based on oral glucose tolerance test with 2 hour values of 140 - 199 mg/dL after an oral glucose load, and no diagnosis of diabetes in the past 12 months","['Pre-diabetic' 'based' 'on' 'oral' 'glucose' 'tolerance' 'test' 'with'
 '2' 'hour' 'values' 'of' '140' '-' '199' 'mg/dL' 'after' 'an' 'oral'
 'glucose' 'load' ',' 'and' 'no' 'diagnosis' 'of' 'diabetes' 'in' 'the'
 'past' '12' 'months']","[2. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 2. 0. 0. 0. 0. 0.]"
NCT02568267,"1:16:treatment,34:53:treatment,55:59:treatment,64:78:treatment,100:106:cancer","Prior treatment with approved or investigational Trk, ROS1, or ALK inhibitors in patients who have tumors that harbor those respective gene rearrangements","['Prior' 'treatment' 'with' 'approved' 'or' 'investigational' 'Trk' ','
 'ROS1' ',' 'or' 'ALK' 'inhibitors' 'in' 'patients' 'who' 'have' 'tumors'
 'that' 'harbor' 'those' 'respective' 'gene' 'rearrangements']",[1. 1. 0. 0. 0. 1. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0.]
NCT02567448,"1:21:chronic_disease,34:49:chronic_disease,39:49:chronic_disease,56:69:chronic_disease,71:87:chronic_disease,107:133:chronic_disease","psychiatric disorder, other than mild depression; e.g. schizophrenia, bipolar disorder, major depression, panic or anxiety disorders","['psychiatric' 'disorder' ',' 'other' 'than' 'mild' 'depression' ';' 'e.g'
 '.' 'schizophrenia' ',' 'bipolar' 'disorder' ',' 'major' 'depression' ','
 'panic' 'or' 'anxiety' 'disorders']",[2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 2. 2. 2. 2.]
NCT02567422,"13:23:treatment,37:55:treatment,90:99:treatment",Patients on tacrolimus or any other immunosuppressants with significant interaction with cisplatin,"['Patients' 'on' 'tacrolimus' 'or' 'any' 'other' 'immunosuppressants'
 'with' 'significant' 'interaction' 'with' 'cisplatin']",[0. 0. 1. 0. 0. 0. 1. 0. 0. 0. 0. 1.]
NCT02567266,",,145:161:chronic_disease,169:197:chronic_disease,199:212:chronic_disease,214:230:chronic_disease,232:259:chronic_disease,264:283:chronic_disease,291:316:chronic_disease,318:348:chronic_disease,357:376:chronic_disease","Evidence of clinically significant symptoms will be defined as a Clinical Severity Rating (CSR) greater than or equal to 4 on any DSM-5 defined anxiety disorder (e.g., generalized anxiety disorder, social phobia, selective mutism, separation anxiety disorder) or depressive disorder (e.g., major depressive disorder, persistent depressive disorder), or an adjustment disorder with depressed mood, anxiety, or mixed anxiety and depressed mood","['Evidence' 'of' 'clinically' 'significant' 'symptoms' 'will' 'be'
 'defined' 'as' 'a' 'Clinical' 'Severity' 'Rating' '(' 'CSR' ')' 'greater'
 'than' 'or' 'equal' 'to' '4' 'on' 'any' 'DSM-5' 'defined' 'anxiety'
 'disorder' '(' 'e.g.' ',' 'generalized' 'anxiety' 'disorder' ',' 'social'
 'phobia' ',' 'selective' 'mutism' ',' 'separation' 'anxiety' 'disorder'
 ')' 'or' 'depressive' 'disorder' '(' 'e.g.' ',' 'major' 'depressive'
 'disorder' ',' 'persistent' 'depressive' 'disorder' ')' ',' 'or' 'an'
 'adjustment' 'disorder' 'with' 'depressed' 'mood' ',' 'anxiety' ',' 'or'
 'mixed' 'anxiety' 'and' 'depressed' 'mood']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 2. 2. 0. 0. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 0. 2. 2. 2. 0. 0. 2. 2.
 0. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02566304,"1:3:chronic_disease,7:11:chronic_disease,43:53:treatment,66:75:treatment",RA or RARS or isolated 5q- can proceed to transplant without any treatment,"['RA' 'or' 'RARS' 'or' 'isolated' '5q-' 'can' 'proceed' 'to' 'transplant'
 'without' 'any' 'treatment']",[2. 0. 2. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1.]
NCT02565901,"24:37:chronic_disease,54:75:chronic_disease,80:106:chronic_disease,,129:154:chronic_disease,,,","Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) class II-IV heart disease","['Clinically' 'significant' 'heart' 'disease' 'as' 'evidenced' 'by'
 'myocardial' 'infarction' ',' 'or' 'arterial' 'thrombotic' 'events' 'in'
 'the' 'past' '6' 'months' ',' 'severe' 'or' 'unstable' 'angina' ',' 'or'
 'New' 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'class' 'II-IV' 'heart'
 'disease']","[0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02565901,"1:16:treatment,20:29:treatment,91:100:treatment",bisphosphonates or denosumab should not be initiated after registration and during active treatment,"['bisphosphonates' 'or' 'denosumab' 'should' 'not' 'be' 'initiated'
 'after' 'registration' 'and' 'during' 'active' 'treatment']",[1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02565446,"29:36:treatment,52:65:chronic_disease,76:104:treatment,112:128:treatment,130:154:treatment,156:190:treatment,196:233:treatment,267:279:treatment","Current or prior history of therapy for underlying liver disease including interferon-based medications, other antiviral agents, immunomodulatory therapy, biologic response modifier therapy, and complementary/alternative medications including (but not encompassing) milk thistle","['Current' 'or' 'prior' 'history' 'of' 'therapy' 'for' 'underlying'
 'liver' 'disease' 'including' 'interferon-based' 'medications' ','
 'other' 'antiviral' 'agents' ',' 'immunomodulatory' 'therapy' ','
 'biologic' 'response' 'modifier' 'therapy' ',' 'and'
 'complementary/alternative' 'medications' 'including' '(' 'but' 'not'
 'encompassing' ')' 'milk' 'thistle']","[0. 0. 0. 0. 0. 1. 0. 0. 2. 2. 0. 1. 1. 0. 0. 1. 1. 0. 1. 1. 0. 1. 1. 1.
 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02564978,"21:55:chronic_disease,51:54:chronic_disease,112:122:treatment",Current evidence of choroidal neovascularization (CNV) as determined by the treating physician or a history of treatments for CNV,"['Current' 'evidence' 'of' 'choroidal' 'neovascularization' '(' 'CNV' ')'
 'as' 'determined' 'by' 'the' 'treating' 'physician' 'or' 'a' 'history'
 'of' 'treatments' 'for' 'CNV']",[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT02564978,"1:39:chronic_disease,5:39:chronic_disease,,61:72:chronic_disease,76:90:chronic_disease","non-proliferative diabetic retinopathy involving 10 or more hemorrhages or microaneurysms, or active proliferative diabetic retinopathy","['non-proliferative' 'diabetic' 'retinopathy' 'involving' '10' 'or' 'more'
 'hemorrhages' 'or' 'microaneurysms' ',' 'or' 'active' 'proliferative'
 'diabetic' 'retinopathy']",[2. 2. 2. 0. 0. 0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02564744,",53:69:treatment,62:69:treatment,,116:137:treatment,,268:280:treatment,286:332:treatment","Participants who received at least only one line of previous therapy and achieved either complete response (CR) or partial response (PR) for at least 24 weeks (from the last day of the last cycle) after their first line of therapy, but are not eligible for high dose chemotherapy with autologous stem cell transplantation (HD-ASCT)","['Participants' 'who' 'received' 'at' 'least' 'only' 'one' 'line' 'of'
 'previous' 'therapy' 'and' 'achieved' 'either' 'complete' 'response' '('
 'CR' ')' 'or' 'partial' 'response' '(' 'PR' ')' 'for' 'at' 'least' '24'
 'weeks' '(' 'from' 'the' 'last' 'day' 'of' 'the' 'last' 'cycle' ')'
 'after' 'their' 'first' 'line' 'of' 'therapy' ',' 'but' 'are' 'not'
 'eligible' 'for' 'high' 'dose' 'chemotherapy' 'with' 'autologous' 'stem'
 'cell' 'transplantation' '(' 'HD-ASCT' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 1. 1. 0. 0.]"
NCT02563678,"1:11:treatment,29:37:chronic_disease,48:57:chronic_disease",Hyperbaric patients without diabetes or active infection,['Hyperbaric' 'patients' 'without' 'diabetes' 'or' 'active' 'infection'],[1. 0. 0. 2. 0. 0. 2.]
NCT02562755,"16:19:cancer,21:57:cancer,75:134:chronic_disease",Advanced stage HCC (Barcelona Clinic Liver Cancer [BCLC] Stage C or B per American Association for the Study of Liver Disease [AASLD] guidelines),"['Advanced' 'stage' 'HCC' '(' 'Barcelona' 'Clinic' 'Liver' 'Cancer' '['
 'BCLC' ']' 'Stage' 'C' 'or' 'B' 'per' 'American' 'Association' 'for'
 'the' 'Study' 'of' 'Liver' 'Disease' '[' 'AASLD' ']' 'guidelines' ')']","[0. 0. 3. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 2. 2.
 2. 0. 0. 0. 0.]"
NCT02562755,"1:36:chronic_disease,54:65:treatment,69:77:treatment","significant coronary artery disease (e.g., requiring angioplasty or stenting)","['significant' 'coronary' 'artery' 'disease' '(' 'e.g.' ',' 'requiring'
 'angioplasty' 'or' 'stenting' ')']",[2. 2. 2. 2. 0. 0. 0. 0. 1. 0. 1. 0.]
NCT02562716,"10:20:cancer,62:67:cancer,72:85:cancer,87:98:cancer,92:98:cancer,100:123:cancer,125:166:cancer,227:236:treatment,","No prior malignancy is allowed except for adequately treated basal (or squamous cell) skin cancer, in situ cervical cancer, in situ breast (ductal or lobular) cancer, or other cancer for which the patient has been disease and treatment-free for two years","['No' 'prior' 'malignancy' 'is' 'allowed' 'except' 'for' 'adequately'
 'treated' 'basal' '(' 'or' 'squamous' 'cell' ')' 'skin' 'cancer' ',' 'in'
 'situ' 'cervical' 'cancer' ',' 'in' 'situ' 'breast' '(' 'ductal' 'or'
 'lobular' ')' 'cancer' ',' 'or' 'other' 'cancer' 'for' 'which' 'the'
 'patient' 'has' 'been' 'disease' 'and' 'treatment-free' 'for' 'two'
 'years']","[0. 0. 3. 0. 0. 0. 0. 0. 0. 3. 0. 0. 3. 3. 0. 3. 3. 0. 3. 3. 3. 3. 3. 3.
 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]"
NCT02562430,"44:53:treatment,72:80:chronic_disease,95:140:chronic_disease,","Subjects with medical contraindications to bupropion (e.g., history of seizures, uncontrolled electrolyte imbalance due to eating disorders, etc.) unless stable for 8 weeks prior to screening and there will be no changes during participation in the study","['Subjects' 'with' 'medical' 'contraindications' 'to' 'bupropion' '('
 'e.g.' ',' 'history' 'of' 'seizures' ',' 'uncontrolled' 'electrolyte'
 'imbalance' 'due' 'to' 'eating' 'disorders' ',' 'etc' '.' ')' 'unless'
 'stable' 'for' '8' 'weeks' 'prior' 'to' 'screening' 'and' 'there' 'will'
 'be' 'no' 'changes' 'during' 'participation' 'in' 'the' 'study']","[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 2. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02562430,"21:35:treatment,111:120:treatment,124:131:treatment","currently taking an antidepressant as defined by the MGH-ATRQ, in the current episode and are willing to take bupropion or placebo as augmentation, since we are using subjects as their own controls and we are comparing changes within subjects","['currently' 'taking' 'an' 'antidepressant' 'as' 'defined' 'by' 'the'
 'MGH-ATRQ' ',' 'in' 'the' 'current' 'episode' 'and' 'are' 'willing' 'to'
 'take' 'bupropion' 'or' 'placebo' 'as' 'augmentation' ',' 'since' 'we'
 'are' 'using' 'subjects' 'as' 'their' 'own' 'controls' 'and' 'we' 'are'
 'comparing' 'changes' 'within' 'subjects']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02562235,"14:17:chronic_disease,31:64:treatment,60:63:treatment,,157:170:treatment",Diagnosis of PAH confirmed by right heart catheterization (RHC) at any time prior to enrolment (for patients with closed shunts - RHC no less than 4 months after surgery),"['Diagnosis' 'of' 'PAH' 'confirmed' 'by' 'right' 'heart' 'catheterization'
 '(' 'RHC' ')' 'at' 'any' 'time' 'prior' 'to' 'enrolment' '(' 'for'
 'patients' 'with' 'closed' 'shunts' '-' 'RHC' 'no' 'less' 'than' '4'
 'months' 'after' 'surgery' ')']","[0. 0. 2. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 0.]"
NCT02562235,"8:44:chronic_disease,46:52:chronic_disease,58:67:chronic_disease","Severe congenital abnormalities of the lung, thorax, and diaphragm","['Severe' 'congenital' 'abnormalities' 'of' 'the' 'lung' ',' 'thorax' ','
 'and' 'diaphragm']",[0. 2. 2. 2. 2. 2. 0. 2. 0. 0. 2.]
NCT02562066,"1:39:treatment,52:75:treatment,78:84:treatment,89:105:treatment,","Treatment with an investigational drug (other than amifampridine phosphate), device, or biological agent within 30 days before Screening or while participating in this study","['Treatment' 'with' 'an' 'investigational' 'drug' '(' 'other' 'than'
 'amifampridine' 'phosphate' ')' ',' 'device' ',' 'or' 'biological'
 'agent' 'within' '30' 'days' 'before' 'Screening' 'or' 'while'
 'participating' 'in' 'this' 'study']","[1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 0. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02562040,"1:33:chronic_disease,42:57:chronic_disease,63:87:chronic_disease","Severe cardiopulmonary disorders such as cystic fibrosis, and congenital heart disease","['Severe' 'cardiopulmonary' 'disorders' 'such' 'as' 'cystic' 'fibrosis'
 ',' 'and' 'congenital' 'heart' 'disease']",[2. 2. 2. 0. 0. 2. 2. 0. 0. 2. 2. 2.]
NCT02561988,",,100:119:chronic_disease,123:151:chronic_disease,160:166:treatment,206:229:chronic_disease",alkaline phosphatase (> 2.5 × ULN) with 1 of the following present: ascites or clinically relevant portal hypertension or liver mast cell infiltration that is biopsy-proven or no other identified cause of abnormal liver function,"['alkaline' 'phosphatase' '(' '>' '2.5' '×' 'ULN' ')' 'with' '1' 'of'
 'the' 'following' 'present' ':' 'ascites' 'or' 'clinically' 'relevant'
 'portal' 'hypertension' 'or' 'liver' 'mast' 'cell' 'infiltration' 'that'
 'is' 'biopsy-proven' 'or' 'no' 'other' 'identified' 'cause' 'of'
 'abnormal' 'liver' 'function']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2.
 2. 2. 0. 0. 1. 0. 0. 0. 0. 0. 0. 2. 2. 2.]"
NCT02561104,"91:100:treatment,120:140:chronic_disease,151:169:chronic_disease,171:194:chronic_disease,196:205:chronic_disease,207:226:chronic_disease","Subject eyes will lack other pre‐existing ocular pathology or condition that may confound treatment effects, including diabetic retinopathy, previous retinal detachment, iris neovascularization, amblyopia, optic nerve atrophy or recurrent severe anterior or posterior segment inflammation of unknown etiology","['Subject' 'eyes' 'will' 'lack' 'other' 'pre‐existing' 'ocular'
 'pathology' 'or' 'condition' 'that' 'may' 'confound' 'treatment'
 'effects' ',' 'including' 'diabetic' 'retinopathy' ',' 'previous'
 'retinal' 'detachment' ',' 'iris' 'neovascularization' ',' 'amblyopia'
 ',' 'optic' 'nerve' 'atrophy' 'or' 'recurrent' 'severe' 'anterior' 'or'
 'posterior' 'segment' 'inflammation' 'of' 'unknown' 'etiology']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 2. 2. 0. 0. 2. 2. 0.
 2. 2. 0. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02560766,"19:30:chronic_disease,56:79:chronic_disease,90:124:chronic_disease","Positive test for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody at screening","['Positive' 'test' 'for' 'hepatitis' 'B' 'surface' 'antigen' '(' 'HBsAg'
 ')' ',' 'hepatitis' 'C' 'virus' '(' 'HCV' ')' 'antibody' ',' 'human'
 'immunodeficiency' 'virus' '(' 'HIV' ')' 'antibody' 'at' 'screening']","[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0.
 0. 0. 0. 0.]"
NCT02560623,"32:40:treatment,42:62:treatment,64:87:treatment,89:100:treatment,102:126:treatment","Patients with prior history of ablation (photodynamic therapy, radiofrequency ablation, cryotherapy, argon plasma coagulation)","['Patients' 'with' 'prior' 'history' 'of' 'ablation' '(' 'photodynamic'
 'therapy' ',' 'radiofrequency' 'ablation' ',' 'cryotherapy' ',' 'argon'
 'plasma' 'coagulation' ')']",[0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 1. 1. 0. 1. 0. 1. 1. 1. 0.]
NCT02557321,"24:29:chronic_disease,33:56:chronic_disease,58:82:chronic_disease,84:89:chronic_disease,91:107:chronic_disease,109:118:chronic_disease,120:133:chronic_disease,135:144:chronic_disease,149:181:chronic_disease","Clinically significant acute or unstable cardiovascular, cerebrovascular (stroke), renal, gastrointestinal, pulmonary, immunological, endocrine, or central nervous system disorders","['Clinically' 'significant' 'acute' 'or' 'unstable' 'cardiovascular' ','
 'cerebrovascular' '(' 'stroke' ')' ',' 'renal' ',' 'gastrointestinal' ','
 'pulmonary' ',' 'immunological' ',' 'endocrine' ',' 'or' 'central'
 'nervous' 'system' 'disorders']","[0. 0. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 0. 0. 2.
 2. 2. 2.]"
NCT02557321,"37:48:chronic_disease,52:65:treatment,,89:111:treatment,119:136:treatment",there is no evidence of progressive CNS disease on brain imaging at least 90 days after treatment with surgery and/or radiation therapy,"['there' 'is' 'no' 'evidence' 'of' 'progressive' 'CNS' 'disease' 'on'
 'brain' 'imaging' 'at' 'least' '90' 'days' 'after' 'treatment' 'with'
 'surgery' 'and/or' 'radiation' 'therapy']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1.]
NCT02556619,"28:49:treatment,51:60:treatment,80:83:treatment,85:103:treatment,105:113:treatment,117:137:treatment","Child-Pugh C, eligible for systemic chemotherapy (Sorafenib), not eligible for TXP, surgical resection, ablation or locoregional therapy","['Child-Pugh' 'C' ',' 'eligible' 'for' 'systemic' 'chemotherapy' '('
 'Sorafenib' ')' ',' 'not' 'eligible' 'for' 'TXP' ',' 'surgical'
 'resection' ',' 'ablation' 'or' 'locoregional' 'therapy']",[0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 1. 0. 1. 1.]
NCT02556606,"12:25:chronic_disease,27:51:chronic_disease,59:77:chronic_disease,82:98:chronic_disease","History of schizophrenia, schizoaffective disorder or any psychotic disorder, or bipolar disorder","['History' 'of' 'schizophrenia' ',' 'schizoaffective' 'disorder' 'or'
 'any' 'psychotic' 'disorder' ',' 'or' 'bipolar' 'disorder']",[0. 0. 2. 0. 2. 2. 0. 0. 2. 2. 0. 0. 2. 2.]
NCT02556606,"72:83:chronic_disease,189:211:chronic_disease,229:241:chronic_disease,281:299:chronic_disease","Serious, unstable medical illnesses including respiratory [obstructive sleep apnea, or history of difficulty with airway management during previous anesthetics], cardiovascular [including ischemic heart disease and uncontrolled hypertension], and neurologic [including history of severe head injury]","['Serious' ',' 'unstable' 'medical' 'illnesses' 'including' 'respiratory'
 '[' 'obstructive' 'sleep' 'apnea' ',' 'or' 'history' 'of' 'difficulty'
 'with' 'airway' 'management' 'during' 'previous' 'anesthetics' ']' ','
 'cardiovascular' '[' 'including' 'ischemic' 'heart' 'disease' 'and'
 'uncontrolled' 'hypertension' ']' ',' 'and' 'neurologic' '[' 'including'
 'history' 'of' 'severe' 'head' 'injury' ']']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 2. 2. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0.]"
NCT02555280,"20:43:treatment,112:120:treatment,139:155:treatment","Chronically taking medications or any drug known to potentially interfere with bone/soft tissue healing (e.g., steroids), not including a medrol dose pack","['Chronically' 'taking' 'medications' 'or' 'any' 'drug' 'known' 'to'
 'potentially' 'interfere' 'with' 'bone/soft' 'tissue' 'healing' '('
 'e.g.' ',' 'steroids' ')' ',' 'not' 'including' 'a' 'medrol' 'dose'
 'pack']","[0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1.
 1. 1.]"
NCT02555280,"1:11:chronic_disease,43:53:chronic_disease,157:196:treatment","Osteopenia: A screening questionnaire for osteopenia, SCORE (Simple Calculated Osteoporosis Risk Estimation), will be used to screen patients who require a DEXA (dual-energy x-ray absorptiometry) bone mineral density measurement","['Osteopenia' ':' 'A' 'screening' 'questionnaire' 'for' 'osteopenia' ','
 'SCORE' '(' 'Simple' 'Calculated' 'Osteoporosis' 'Risk' 'Estimation' ')'
 ',' 'will' 'be' 'used' 'to' 'screen' 'patients' 'who' 'require' 'a'
 'DEXA' '(' 'dual-energy' 'x-ray' 'absorptiometry' ')' 'bone' 'mineral'
 'density' 'measurement']","[2. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]"
NCT02555189,"5:11:treatment,13:24:treatment,29:45:treatment,53:60:treatment,62:74:treatment,76:88:treatment,177:190:treatment,192:199:treatment,204:213:treatment","All herbal, alternative and food supplements (i.e., PC-Spes, Saw Palmetto, St John Wort, etc.). They must be discontinued prior to enrollment. Patients may continue on a daily Multi-Vitamin, calcium and Vitamin D","['All' 'herbal' ',' 'alternative' 'and' 'food' 'supplements' '(' 'i.e.'
 ',' 'PC-Spes' ',' 'Saw' 'Palmetto' ',' 'St' 'John' 'Wort' ',' 'etc.' ')'
 '.' 'They' 'must' 'be' 'discontinued' 'prior' 'to' 'enrollment' '.'
 'Patients' 'may' 'continue' 'on' 'a' 'daily' 'Multi-Vitamin' ','
 'calcium' 'and' 'Vitamin' 'D']","[0. 1. 0. 1. 0. 1. 1. 0. 0. 0. 1. 0. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0.]"
NCT02555189,"1:23:treatment,35:38:treatment,40:51:treatment,57:71:treatment,90:118:treatment","Hormonal-acting agents (including DES, aldosterone, and spironolactone but not including GnRH agonists or antagonists) are forbidden during the trial and must be stopped prior to enrollment. No washout period will be required for any of these agents","['Hormonal-acting' 'agents' '(' 'including' 'DES' ',' 'aldosterone' ','
 'and' 'spironolactone' 'but' 'not' 'including' 'GnRH' 'agonists' 'or'
 'antagonists' ')' 'are' 'forbidden' 'during' 'the' 'trial' 'and' 'must'
 'be' 'stopped' 'prior' 'to' 'enrollment' '.' 'No' 'washout' 'period'
 'will' 'be' 'required' 'for' 'any' 'of' 'these' 'agents']","[1. 1. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02555189,"32:40:treatment,67:80:treatment,85:94:treatment,96:107:treatment","Patient is currently receiving warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or otherwise","['Patient' 'is' 'currently' 'receiving' 'warfarin' 'or' 'other'
 'coumarin-derived' 'anticoagulant' 'for' 'treatment' ',' 'prophylaxis'
 'or' 'otherwise']",[0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0.]
NCT02555189,"29:44:treatment,48:57:treatment,,144:154:treatment",Patients on stable doses of bisphosphonates or denosumab which have been started no less than 4 weeks prior to enrollment may continue on this medication,"['Patients' 'on' 'stable' 'doses' 'of' 'bisphosphonates' 'or' 'denosumab'
 'which' 'have' 'been' 'started' 'no' 'less' 'than' '4' 'weeks' 'prior'
 'to' 'enrollment' 'may' 'continue' 'on' 'this' 'medication']","[0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1.]"
NCT02555189,"23:46:treatment,35:46:treatment,48:61:treatment,63:91:treatment,93:107:treatment,109:133:treatment,135:147:treatment","Use of any prohibited concomitant medications: immunotherapy, 5 alpha reductase inhibitors, spironolactone, diethylstilbestrol (DES), ketoconazole, newer medications targeting ARs","['Use' 'of' 'any' 'prohibited' 'concomitant' 'medications' ':'
 'immunotherapy' ',' '5' 'alpha' 'reductase' 'inhibitors' ','
 'spironolactone' ',' 'diethylstilbestrol' '(' 'DES' ')' ','
 'ketoconazole' ',' 'newer' 'medications' 'targeting' 'ARs']","[0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 1. 1. 1. 0. 1. 0. 1. 1. 0. 0. 0. 1. 0. 0.
 0. 0. 0.]"
NCT02554903,"1:35:treatment,43:51:treatment,53:65:treatment,70:82:treatment,,126:135:treatment","Treatment with inhaled prostanoids (e.g., iloprost, epoprostenol) or nitric oxide within 24 h prior to Baseline RHC or study treatment initiation","['Treatment' 'with' 'inhaled' 'prostanoids' '(' 'e.g.' ',' 'iloprost' ','
 'epoprostenol' ')' 'or' 'nitric' 'oxide' 'within' '24' 'h' 'prior' 'to'
 'Baseline' 'RHC' 'or' 'study' 'treatment' 'initiation']","[1. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0.]"
NCT02554812,"49:61:cancer,63:68:cancer,70:75:cancer,77:85:cancer,111:127:treatment","Combination B: Phase 1b, patients with advanced solid tumors (NSCLC, SCCHN, melanoma) that have progressed on standard therapy or for which no standard therapy is available, and Phase 2, patients with NSCLC, melanoma, or SCCHN","['Combination' 'B' ':' 'Phase' '1b' ',' 'patients' 'with' 'advanced'
 'solid' 'tumors' '(' 'NSCLC' ',' 'SCCHN' ',' 'melanoma' ')' 'that' 'have'
 'progressed' 'on' 'standard' 'therapy' 'or' 'for' 'which' 'no' 'standard'
 'therapy' 'is' 'available' ',' 'and' 'Phase' '2' ',' 'patients' 'with'
 'NSCLC' ',' 'melanoma' ',' 'or' 'SCCHN']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 3. 0. 3. 0. 3. 0. 0. 0. 0. 0. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02554786,"31:34:treatment,50:54:treatment,76:82:chronic_disease,,",have used medium or high dose ICS or low dose of LABA/ICS combinations for asthma for at least 3 months and at stable doses for at least 1 month prior to Visit 1,"['have' 'used' 'medium' 'or' 'high' 'dose' 'ICS' 'or' 'low' 'dose' 'of'
 'LABA/ICS' 'combinations' 'for' 'asthma' 'for' 'at' 'least' '3' 'months'
 'and' 'at' 'stable' 'doses' 'for' 'at' 'least' '1' 'month' 'prior' 'to'
 'Visit' '1']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02554253,"9:24:treatment,17:24:treatment,,89:115:treatment,129:157:treatment","Complex cardiac surgery will be defined as surgery involving more than one heart valve, redo-sternotomy procedures, or combined valvular and CABG procedures","['Complex' 'cardiac' 'surgery' 'will' 'be' 'defined' 'as' 'surgery'
 'involving' 'more' 'than' 'one' 'heart' 'valve' ',' 'redo-sternotomy'
 'procedures' ',' 'or' 'combined' 'valvular' 'and' 'CABG' 'procedures']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 1. 1.]
NCT02553941,"10:64:treatment,66:77:treatment,79:112:treatment","Requires treatment with a strong cytochrome P450 (CYP) family 3, subfamily A, polypeptide 4/5 (3A4/5) inhibitor","['Requires' 'treatment' 'with' 'a' 'strong' 'cytochrome' 'P450' '(' 'CYP'
 ')' 'family' '3' ',' 'subfamily' 'A' ',' 'polypeptide' '4/5' '(' '3A4/5'
 ')' 'inhibitor']",[0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 0. 1. 1. 1. 1. 0. 0.]
NCT02553642,"65:77:treatment,79:95:treatment,97:120:treatment,128:141:treatment,143:160:treatment,164:177:treatment,189:207:treatment,,269:278:treatment","At the time of day 1 of the study, patients must have completed chemotherapy, targeted therapy, investigational therapy, other immunotherapy, radiation therapy or major surgery (requiring general anesthesia) at least 28 days before administration of the first dose of nivolumab","['At' 'the' 'time' 'of' 'day' '1' 'of' 'the' 'study' ',' 'patients' 'must'
 'have' 'completed' 'chemotherapy' ',' 'targeted' 'therapy' ','
 'investigational' 'therapy' ',' 'other' 'immunotherapy' ',' 'radiation'
 'therapy' 'or' 'major' 'surgery' '(' 'requiring' 'general' 'anesthesia'
 ')' 'at' 'least' '28' 'days' 'before' 'administration' 'of' 'the' 'first'
 'dose' 'of' 'nivolumab']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 1. 1. 0. 0. 1.
 0. 1. 1. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02553642,"57:81:treatment,,95:105:treatment,,149:159:treatment",Must have no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration,"['Must' 'have' 'no' 'requirement' 'for' 'immunosuppressive' 'doses' 'of'
 'systemic' 'corticosteroids' '(' '>' '10' 'mg/day' 'prednisone'
 'equivalents' ')' 'for' 'at' 'least' '2' 'weeks' 'prior' 'to' 'study'
 'drug' 'administration']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1. 0.]"
NCT02553642,"55:60:cancer,68:95:treatment,144:156:treatment",Subjects must consent to allow for the acquisition of tumor sample prior to starting treatment on study (in most cases patients will require a tumor biopsy),"['Subjects' 'must' 'consent' 'to' 'allow' 'for' 'the' 'acquisition' 'of'
 'tumor' 'sample' 'prior' 'to' 'starting' 'treatment' 'on' 'study' '('
 'in' 'most' 'cases' 'patients' 'will' 'require' 'a' 'tumor' 'biopsy' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02553642,"90:121:cancer,101:121:cancer,297:311:cancer","Subjects with histologically or cytologically confirmed locally advanced/unresectable or metastatic urothelial carcinoma (including mixed histologies of urothelial carcinoma with elements of other subtypes) of the renal pelvis, ureter, bladder or urethra (referred to broadly in this protocol as bladder cancer)","['Subjects' 'with' 'histologically' 'or' 'cytologically' 'confirmed'
 'locally' 'advanced/unresectable' 'or' 'metastatic' 'urothelial'
 'carcinoma' '(' 'including' 'mixed' 'histologies' 'of' 'urothelial'
 'carcinoma' 'with' 'elements' 'of' 'other' 'subtypes' ')' 'of' 'the'
 'renal' 'pelvis' ',' 'ureter' ',' 'bladder' 'or' 'urethra' '(' 'referred'
 'to' 'broadly' 'in' 'this' 'protocol' 'as' 'bladder' 'cancer' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02553642,"30:42:treatment,51:60:treatment,64:74:cancer,,221:232:treatment,236:257:treatment","The subject actively refuses chemotherapy for the treatment of metastatic or locally advanced disease considered as standard treatment for this disease stage (i.e. a patient who has relapsed >1 year after treatment with neoadjuvant or adjuvant chemotherapy), despite being informed by the investigator about the treatment options","['The' 'subject' 'actively' 'refuses' 'chemotherapy' 'for' 'the'
 'treatment' 'of' 'metastatic' 'or' 'locally' 'advanced' 'disease'
 'considered' 'as' 'standard' 'treatment' 'for' 'this' 'disease' 'stage'
 '(' 'i.e' '.' 'a' 'patient' 'who' 'has' 'relapsed' '>' '1' 'year' 'after'
 'treatment' 'with' 'neoadjuvant' 'or' 'adjuvant' 'chemotherapy' ')' ','
 'despite' 'being' 'informed' 'by' 'the' 'investigator' 'about' 'the'
 'treatment' 'options']","[0. 0. 0. 0. 1. 0. 0. 1. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02553265,"18:32:treatment,34:45:treatment,47:58:treatment,62:85:treatment","Patients taking: metoclopramide, domperidone, risperidone or other dopamine blockers","['Patients' 'taking' ':' 'metoclopramide' ',' 'domperidone' ','
 'risperidone' 'or' 'other' 'dopamine' 'blockers']",[0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 1. 1.]
NCT02552953,",14:32:treatment,,47:58:treatment,63:74:treatment,78:91:treatment,93:128:treatment,130:147:treatment","4 weeks from prior chemotherapy ( 6 weeks for mitomycin C and nitrosourea) , immunotherapy, investigational anti-cancer therapy, radiation therapy; and have recovered from prior toxicities","['4' 'weeks' 'from' 'prior' 'chemotherapy' '(' '6' 'weeks' 'for'
 'mitomycin' 'C' 'and' 'nitrosourea' ')' ',' 'immunotherapy' ','
 'investigational' 'anti-cancer' 'therapy' ',' 'radiation' 'therapy' ';'
 'and' 'have' 'recovered' 'from' 'prior' 'toxicities']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 1. 0. 1. 1. 1. 0. 1. 1. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02551679,"58:74:chronic_disease,121:137:treatment,195:215:treatment","Subjects who, in the opinion of the investigator, have a vascular disease prognosis that indicates they would require a major amputation in a time frame shortly after administration of the IMP (investigational drug or placebo)","['Subjects' 'who' ',' 'in' 'the' 'opinion' 'of' 'the' 'investigator' ','
 'have' 'a' 'vascular' 'disease' 'prognosis' 'that' 'indicates' 'they'
 'would' 'require' 'a' 'major' 'amputation' 'in' 'a' 'time' 'frame'
 'shortly' 'after' 'administration' 'of' 'the' 'IMP' '(' 'investigational'
 'drug' 'or' 'placebo' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]"
NCT02549937,"19:29:treatment,38:47:chronic_disease,61:74:chronic_disease,90:106:treatment,119:143:chronic_disease,223:246:treatment","Inability to take medication orally, dysphagia or an active gastric ulcer resulting from previous surgery or a severe gastrointestinal disease,or any other condition that investigators believe may affect absorption of the investigational product","['Inability' 'to' 'take' 'medication' 'orally' ',' 'dysphagia' 'or' 'an'
 'active' 'gastric' 'ulcer' 'resulting' 'from' 'previous' 'surgery' 'or'
 'a' 'severe' 'gastrointestinal' 'disease' ',' 'or' 'any' 'other'
 'condition' 'that' 'investigators' 'believe' 'may' 'affect' 'absorption'
 'of' 'the' 'investigational' 'product']","[0. 0. 0. 1. 0. 0. 2. 0. 0. 0. 2. 2. 0. 0. 1. 1. 0. 0. 0. 2. 2. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02549937,"1:16:treatment,20:40:treatment,,81:96:treatment,,110:124:treatment",Strong inducers or inhibitors of CYP3A4 within 2 weeks before the first dose of study treatment (3 weeks for St John‟s Wort),"['Strong' 'inducers' 'or' 'inhibitors' 'of' 'CYP3A4' 'within' '2' 'weeks'
 'before' 'the' 'first' 'dose' 'of' 'study' 'treatment' '(' '3' 'weeks'
 'for' 'St' 'John‟s' 'Wort' ')']",[1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1. 1. 0.]
NCT02549937,"8:23:chronic_disease,36:67:treatment,,,,109:133:chronic_disease,135:158:chronic_disease,169:178:treatment,,","severe/unstable angina pectoris or coronary artery bypass grafting, New York Heart Association Class III/IV congestive heart failure, ventricular arrhythmias requiring treatment or left ventricular ejection fraction (LVEF) < 50%","['severe/unstable' 'angina' 'pectoris' 'or' 'coronary' 'artery' 'bypass'
 'grafting' ',' 'New' 'York' 'Heart' 'Association' 'Class' 'III/IV'
 'congestive' 'heart' 'failure' ',' 'ventricular' 'arrhythmias'
 'requiring' 'treatment' 'or' 'left' 'ventricular' 'ejection' 'fraction'
 '(' 'LVEF' ')' '<' '50' '%']","[2. 2. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 2. 2. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02549833,"53:59:cancer,75:86:cancer,88:105:cancer,110:126:cancer,191:200:treatment,237:243:treatment","must have newly diagnosed or recurrent WHO grade II glioma (defined as an astrocytoma, oligodendroglioma, or oligoastrocytoma) that is to be histologically confirmed by clinically indicated resection. If patients have already undergone biopsy and have pathological diagnosis of WHO grade II glioma, pathology must be reviewed and confirmed at UCSF","['must' 'have' 'newly' 'diagnosed' 'or' 'recurrent' 'WHO' 'grade' 'II'
 'glioma' '(' 'defined' 'as' 'an' 'astrocytoma' ',' 'oligodendroglioma'
 ',' 'or' 'oligoastrocytoma' ')' 'that' 'is' 'to' 'be' 'histologically'
 'confirmed' 'by' 'clinically' 'indicated' 'resection' '.' 'If' 'patients'
 'have' 'already' 'undergone' 'biopsy' 'and' 'have' 'pathological'
 'diagnosis' 'of' 'WHO' 'grade' 'II' 'glioma' ',' 'pathology' 'must' 'be'
 'reviewed' 'and' 'confirmed' 'at' 'UCSF']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 3. 0. 3. 0. 0. 3. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02548351,"86:90:treatment,91:101:treatment,105:114:treatment,","For subjects with a historical biopsy, is either not taking or is on stable doses of TZDs/glitazones or vitamin E for 6 months before Day 1","['For' 'subjects' 'with' 'a' 'historical' 'biopsy' ',' 'is' 'either' 'not'
 'taking' 'or' 'is' 'on' 'stable' 'doses' 'of' 'TZDs/glitazones' 'or'
 'vitamin' 'E' 'for' '6' 'months' 'before' 'Day' '1']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0.
 0. 0. 0.]"
NCT02547818,"22:29:treatment,81:96:treatment,115:121:chronic_disease",Chronic daily use of aspirin exceeding standard of care guidelines for low dose aspirin therapy for prevention of stroke and/or other recommended uses,"['Chronic' 'daily' 'use' 'of' 'aspirin' 'exceeding' 'standard' 'of' 'care'
 'guidelines' 'for' 'low' 'dose' 'aspirin' 'therapy' 'for' 'prevention'
 'of' 'stroke' 'and/or' 'other' 'recommended' 'uses']",[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT02547662,"19:47:chronic_disease,70:94:treatment,91:93:treatment,98:130:treatment,156:193:treatment,,,",For patients with extramedullary disease (EMD) measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) or the CT portion of the positron emission tomography (PET)/CT: must have at least one lesion that has a single diameter of >= 2 cm; skin lesions can be used if the area is >= 2 cm in at least one diameter and measured with a ruler,"['For' 'patients' 'with' 'extramedullary' 'disease' '(' 'EMD' ')'
 'measurable' 'disease' 'by' 'computed' 'tomography' '(' 'CT' ')' 'or'
 'magnetic' 'resonance' 'imaging' '(' 'MRI' ')' 'or' 'the' 'CT' 'portion'
 'of' 'the' 'positron' 'emission' 'tomography' '(' 'PET' ')' '/CT' ':'
 'must' 'have' 'at' 'least' 'one' 'lesion' 'that' 'has' 'a' 'single'
 'diameter' 'of' '>' '=' '2' 'cm' ';' 'skin' 'lesions' 'can' 'be' 'used'
 'if' 'the' 'area' 'is' '>' '=' '2' 'cm' 'in' 'at' 'least' 'one'
 'diameter' 'and' 'measured' 'with' 'a' 'ruler']","[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 1. 1. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02547662,",43:55:treatment,,,,213:222:treatment,294:315:treatment",at least 28 days before she starts taking pomalidomide FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy; patient must follow pregnancy testing requirements as outlined in the POMALYST REMS program,"['at' 'least' '28' 'days' 'before' 'she' 'starts' 'taking' 'pomalidomide'
 'FCBP' 'must' 'also' 'agree' 'to' 'ongoing' 'pregnancy' 'testing' ';'
 'men' 'must' 'agree' 'to' 'use' 'a' 'latex' 'condom' 'during' 'sexual'
 'contact' 'with' 'a' 'FCBP' 'even' 'if' 'they' 'have' 'had' 'a'
 'successful' 'vasectomy' ';' 'patient' 'must' 'follow' 'pregnancy'
 'testing' 'requirements' 'as' 'outlined' 'in' 'the' 'POMALYST' 'REMS'
 'program']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 1.]"
NCT02544880,"86:96:cancer,103:106:chronic_disease,110:127:treatment",Immunosuppression or immunocompromised for reasons not directly related to patient's malignancy (e.g. HIV or kidney transplant),"['Immunosuppression' 'or' 'immunocompromised' 'for' 'reasons' 'not'
 'directly' 'related' 'to' 'patient' ""'s"" 'malignancy' '(' 'e.g' '.' 'HIV'
 'or' 'kidney' 'transplant' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 2. 0. 1. 1. 0.]
NCT02544880,"1:16:treatment,34:47:treatment,55:67:treatment,105:114:treatment,118:142:cancer,144:154:cancer,156:167:cancer,171:177:cancer","Prior radiation, with or without prior surgery and/or chemotherapy, to the head and neck for definitive treatment of HNSCC of the oral cavity, oropharynx, hypopharynx or larynx with previously documented complete clinical or radiographic response to initial treatment","['Prior' 'radiation' ',' 'with' 'or' 'without' 'prior' 'surgery' 'and/or'
 'chemotherapy' ',' 'to' 'the' 'head' 'and' 'neck' 'for' 'definitive'
 'treatment' 'of' 'HNSCC' 'of' 'the' 'oral' 'cavity' ',' 'oropharynx' ','
 'hypopharynx' 'or' 'larynx' 'with' 'previously' 'documented' 'complete'
 'clinical' 'or' 'radiographic' 'response' 'to' 'initial' 'treatment']","[1. 1. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 3. 3. 3. 3.
 3. 0. 3. 0. 3. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02544880,"8:23:treatment,32:53:treatment,55:74:treatment,80:108:treatment,","Use of PDE5 inhibitors such as vardenafil (Levitra®), Tadalafil (Cialis®), and sildenafil citrate (Viagra®) ≤15-days prior to (intended) enrollment","['Use' 'of' 'PDE5' 'inhibitors' 'such' 'as' 'vardenafil' '(' 'Levitra®'
 ')' ',' 'Tadalafil' '(' 'Cialis®' ')' ',' 'and' 'sildenafil' 'citrate'
 '(' 'Viagra®' ')' '≤15-days' 'prior' 'to' '(' 'intended' ')' 'enrollment']","[0. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02544373,"9:12:chronic_disease,37:63:chronic_disease,,,112:129:chronic_disease","extreme OSA accompanied by signs of cardiopulmonary compromise (RDI>60 respiratory events per hour with severe nocturnal hypoxia or unstable ECG rhythms on PSG), will be excluded unless they are randomized to immediate PAP arm","['extreme' 'OSA' 'accompanied' 'by' 'signs' 'of' 'cardiopulmonary'
 'compromise' '(' 'RDI' '>' '60' 'respiratory' 'events' 'per' 'hour'
 'with' 'severe' 'nocturnal' 'hypoxia' 'or' 'unstable' 'ECG' 'rhythms'
 'on' 'PSG' ')' ',' 'will' 'be' 'excluded' 'unless' 'they' 'are'
 'randomized' 'to' 'immediate' 'PAP' 'arm']","[0. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02543983,"87:99:chronic_disease,101:109:chronic_disease,133:144:treatment","Presence of medical illness likely to alter brain morphology and/or physiology (e.g., hypertension, diabetes) even if controlled by medications","['Presence' 'of' 'medical' 'illness' 'likely' 'to' 'alter' 'brain'
 'morphology' 'and/or' 'physiology' '(' 'e.g.' ',' 'hypertension' ','
 'diabetes' ')' 'even' 'if' 'controlled' 'by' 'medications']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 1.]
NCT02543944,"6:22:chronic_disease,26:42:chronic_disease,53:76:chronic_disease",have major depression or anxiety disorder requiring psychoactive medication (as determined by physician),"['have' 'major' 'depression' 'or' 'anxiety' 'disorder' 'requiring'
 'psychoactive' 'medication' '(' 'as' 'determined' 'by' 'physician' ')']",[0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02543866,"38:71:treatment,101:120:treatment,129:136:treatment,138:143:treatment,148:164:treatment,168:192:treatment","Patients with past or current use of systemic immunosuppressive agents will be excluded. Receipt of non-systemic agents such as inhaled, nasal, or topical steroids or immune-modulating agents","['Patients' 'with' 'past' 'or' 'current' 'use' 'of' 'systemic'
 'immunosuppressive' 'agents' 'will' 'be' 'excluded' '.' 'Receipt' 'of'
 'non-systemic' 'agents' 'such' 'as' 'inhaled' ',' 'nasal' ',' 'or'
 'topical' 'steroids' 'or' 'immune-modulating' 'agents']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 0. 1. 0.
 0. 1. 1. 0. 1. 1.]"
NCT02542657,"1:14:chronic_disease,,,70:77:cancer,112:126:treatment",Hypercalcemia (corrected serum calcium > 11.5 mg/dL) attributable to myeloma (e.g. not due to omitted doses of bisphosphonate),"['Hypercalcemia' '(' 'corrected' 'serum' 'calcium' '>' '11.5' 'mg/dL' ')'
 'attributable' 'to' 'myeloma' '(' 'e.g' '.' 'not' 'due' 'to' 'omitted'
 'doses' 'of' 'bisphosphonate' ')']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02542202,"23:33:cancer,45:65:cancer,73:97:cancer",Known active invasive malignancy except for renal cell carcinoma and/or non-melanoma skin cancer,"['Known' 'active' 'invasive' 'malignancy' 'except' 'for' 'renal' 'cell'
 'carcinoma' 'and/or' 'non-melanoma' 'skin' 'cancer']",[0. 0. 0. 3. 0. 0. 3. 3. 3. 0. 3. 3. 3.]
NCT02542202,"40:53:cancer,79:98:treatment,103:120:treatment",Patients who have an intact unresected primary tumor should be considered for radical nephrectomy and primary resection prior to enrollment in the study,"['Patients' 'who' 'have' 'an' 'intact' 'unresected' 'primary' 'tumor'
 'should' 'be' 'considered' 'for' 'radical' 'nephrectomy' 'and' 'primary'
 'resection' 'prior' 'to' 'enrollment' 'in' 'the' 'study']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02541903,"8:19:chronic_disease,20:29:chronic_disease,54:62:chronic_disease,54:59:chronic_disease,",Active hepatitis B infection (defined as presence of Hep BsAg and/ or Hep B DNA),"['Active' 'hepatitis' 'B' 'infection' '(' 'defined' 'as' 'presence' 'of'
 'Hep' 'BsAg' 'and/' 'or' 'Hep' 'B' 'DNA' ')']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02541565,"20:36:chronic_disease,53:77:treatment,99:124:treatment,,172:181:treatment",Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment,"['Has' 'a' 'diagnosis' 'of' 'immunodeficiency' 'or' 'is' 'receiving'
 'systemic' 'steroid' 'therapy' 'or' 'any' 'other' 'form' 'of'
 'immunosuppressive' 'therapy' 'within' '7' 'days' 'prior' 'to' 'the'
 'first' 'dose' 'of' 'trial' 'treatment']","[0. 0. 0. 0. 2. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1.]"
NCT02541565,"1:33:cancer,35:70:cancer,78:98:cancer,130:146:treatment","basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy","['basal' 'cell' 'carcinoma' 'of' 'the' 'skin' ',' 'squamous' 'cell'
 'carcinoma' 'of' 'the' 'skin' ',' 'or' 'in' 'situ' 'cervical' 'cancer'
 'that' 'has' 'undergone' 'potentially' 'curative' 'therapy']","[3. 3. 3. 3. 3. 3. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 1.
 1.]"
NCT02540330,"27:56:cancer,60:84:cancer,95:105:treatment",Pathological diagnosis of Invasive Ductal Breast Cancer or Ductal Carcinoma in Situ requiring mastectomy,"['Pathological' 'diagnosis' 'of' 'Invasive' 'Ductal' 'Breast' 'Cancer'
 'or' 'Ductal' 'Carcinoma' 'in' 'Situ' 'requiring' 'mastectomy']",[0. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 1.]
NCT02540330,"27:38:allergy_name,86:96:allergy_name,98:105:allergy_name,107:121:allergy_name,127:142:allergy_name","known hypersensitivity to fulvestrant or any of its formulation components including castor oil, alcohol, benzyl alcohol, and benzyl benzoate","['known' 'hypersensitivity' 'to' 'fulvestrant' 'or' 'any' 'of' 'its'
 'formulation' 'components' 'including' 'castor' 'oil' ',' 'alcohol' ','
 'benzyl' 'alcohol' ',' 'and' 'benzyl' 'benzoate']",[0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 4. 4. 0. 4. 0. 4. 4. 0. 0. 0. 0.]
NCT02539160,"1:13:treatment,15:27:treatment,29:41:treatment,43:57:treatment,59:69:treatment,71:80:treatment,82:92:treatment,94:104:treatment,106:115:treatment,117:127:treatment,132:145:treatment","ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin","['ketoconazole' ',' 'itraconazole' ',' 'voriconazole' ',' 'clarithromycin'
 ',' 'nefazodone' ',' 'ritonavir' ',' 'saquinavir' ',' 'nelfinavir' ','
 'indinavir' ',' 'atazanavir' 'and' 'telithromycin']",[1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1.]
NCT02538198,"77:86:chronic_disease,90:109:chronic_disease,110:127:chronic_disease",Uncontrolled intercurrent illness including but not limited to uncontrolled infection or psychiatric illness/social situations that would compromise compliance with study requirements,"['Uncontrolled' 'intercurrent' 'illness' 'including' 'but' 'not' 'limited'
 'to' 'uncontrolled' 'infection' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'compromise' 'compliance' 'with' 'study'
 'requirements']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02536846,"11:28:chronic_disease,43:55:chronic_disease,64:75:chronic_disease,77:100:chronic_disease,102:120:chronic_disease,122:130:chronic_disease,132:148:chronic_disease,176:197:chronic_disease,199:219:chronic_disease,271:284:allergy_name","Diagnosis diabetes mellitus, uncontrolled hypertension, severe hypotension, coronary artery disease, metabolic syndrome, glaucoma, liver impairment, decreased renal function, respiratory disorders, peptic ulcer disease (absolute and relative contraindications to use of antipsychotic drugs)","['Diagnosis' 'diabetes' 'mellitus' ',' 'uncontrolled' 'hypertension' ','
 'severe' 'hypotension' ',' 'coronary' 'artery' 'disease' ',' 'metabolic'
 'syndrome' ',' 'glaucoma' ',' 'liver' 'impairment' ',' 'decreased'
 'renal' 'function' ',' 'respiratory' 'disorders' ',' 'peptic' 'ulcer'
 'disease' '(' 'absolute' 'and' 'relative' 'contraindications' 'to' 'use'
 'of' 'antipsychotic' 'drugs' ')']","[0. 2. 2. 0. 0. 2. 0. 0. 2. 0. 2. 2. 2. 0. 2. 2. 0. 2. 0. 2. 2. 0. 0. 0.
 0. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 0.]"
NCT02536794,"5:10:cancer,41:82:treatment,102:115:cancer",the tumor must be non-gene amplified by fluorescence in situ hybridization (FISH) performed upon the primary tumor,"['the' 'tumor' 'must' 'be' 'non-gene' 'amplified' 'by' 'fluorescence' 'in'
 'situ' 'hybridization' '(' 'FISH' ')' 'performed' 'upon' 'the' 'primary'
 'tumor']",[0. 3. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 3. 3.]
NCT02535832,"24:31:chronic_disease,33:40:chronic_disease,44:60:chronic_disease","Clinically significant hepatic, cardiac or renal impairment","['Clinically' 'significant' 'hepatic' ',' 'cardiac' 'or' 'renal'
 'impairment']",[0. 0. 2. 0. 2. 0. 2. 2.]
NCT02535325,"51:61:treatment,107:138:chronic_disease,146:168:chronic_disease,178:211:treatment","Ability to swallow and retain orally-administered medication and does not have any clinically significant gastro-intestinal abnormalities (e.g., malabsorption syndrome or major resection of the stomach or bowel)","['Ability' 'to' 'swallow' 'and' 'retain' 'orally-administered'
 'medication' 'and' 'does' 'not' 'have' 'any' 'clinically' 'significant'
 'gastro-intestinal' 'abnormalities' '(' 'e.g.' ',' 'malabsorption'
 'syndrome' 'or' 'major' 'resection' 'of' 'the' 'stomach' 'or' 'bowel' ')']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 1.
 1. 1. 1. 1. 1. 0.]"
NCT02535312,"12:24:treatment,28:40:treatment,132:146:chronic_disease,377:388:treatment","documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by ultrasound; tubal ligation must be confirmed with medical records of the actual procedure otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit though 4 months after the last dose of study drugs","['documented' 'hysterectomy' 'or' 'oophorectomy' 'must' 'be' 'confirmed'
 'with' 'medical' 'records' 'of' 'the' 'actual' 'procedure' 'or'
 'confirmed' 'by' 'ultrasound' ';' 'tubal' 'ligation' 'must' 'be'
 'confirmed' 'with' 'medical' 'records' 'of' 'the' 'actual' 'procedure'
 'otherwise' 'the' 'patient' 'must' 'be' 'willing' 'to' 'use' '2'
 'adequate' 'barrier' 'methods' 'throughout' 'the' 'study' ',' 'starting'
 'with' 'the' 'screening' 'visit' 'though' '4' 'months' 'after' 'the'
 'last' 'dose' 'of' 'study' 'drugs']","[0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02535286,"5:18:treatment,20:32:treatment,36:49:treatment,","Any major surgery, chemotherapy or immunotherapy within the last 14 days","['Any' 'major' 'surgery' ',' 'chemotherapy' 'or' 'immunotherapy' 'within'
 'the' 'last' '14' 'days']",[0. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0.]
NCT02534922,"27:39:cancer,67:84:cancer,102:139:cancer","Have any other concurrent malignancies, except adequately treated in situ carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin","['Have' 'any' 'other' 'concurrent' 'malignancies' ',' 'except'
 'adequately' 'treated' 'in' 'situ' 'carcinoma' 'of' 'the' 'cervix' 'or'
 'basal' 'cell' 'or' 'squamous' 'cell' 'carcinoma' 'of' 'the' 'skin']","[0. 0. 0. 0. 3. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0.
 0.]"
NCT02534922,"44:69:cancer,71:96:cancer,100:121:cancer,163:176:cancer","Subjects must have recurrent or persistent epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. Histologic confirmation of the original primary tumor is required","['Subjects' 'must' 'have' 'recurrent' 'or' 'persistent' 'epithelial'
 'ovarian' 'cancer' ',' 'primary' 'peritoneal' 'cancer' 'or' 'fallopian'
 'tube' 'cancer' '.' 'Histologic' 'confirmation' 'of' 'the' 'original'
 'primary' 'tumor' 'is' 'required']","[0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 3. 3. 3. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02533674,"1:16:treatment,22:52:treatment,75:91:treatment,,","Prior treatment with gemcitabine-containing therapy for advanced disease (adjuvant therapy is allowed, provided not more than six cycles were administered and relapse occurred more than six months after the last drug administration)","['Prior' 'treatment' 'with' 'gemcitabine-containing' 'therapy' 'for'
 'advanced' 'disease' '(' 'adjuvant' 'therapy' 'is' 'allowed' ','
 'provided' 'not' 'more' 'than' 'six' 'cycles' 'were' 'administered' 'and'
 'relapse' 'occurred' 'more' 'than' 'six' 'months' 'after' 'the' 'last'
 'drug' 'administration' ')']","[1. 1. 0. 1. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02532595,"159:180:chronic_disease,182:190:chronic_disease,194:212:chronic_disease,214:224:chronic_disease,226:245:chronic_disease,249:276:chronic_disease","Vascular or sensory disturbances in the lower leg which include but is not limited to injury to the nerve root or peripheral nerve in the affected lower leg, inflammatory diseases, bleeding or clotting disorders, lymphedema, peripheral vascular or peripheral arterial disease","['Vascular' 'or' 'sensory' 'disturbances' 'in' 'the' 'lower' 'leg' 'which'
 'include' 'but' 'is' 'not' 'limited' 'to' 'injury' 'to' 'the' 'nerve'
 'root' 'or' 'peripheral' 'nerve' 'in' 'the' 'affected' 'lower' 'leg' ','
 'inflammatory' 'diseases' ',' 'bleeding' 'or' 'clotting' 'disorders' ','
 'lymphedema' ',' 'peripheral' 'vascular' 'or' 'peripheral' 'arterial'
 'disease']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.
 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02532231,"35:59:treatment,75:87:treatment,91:102:treatment",Patients with history of previous immunomodulatory therapy (not including lenalidomide or thalidomide),"['Patients' 'with' 'history' 'of' 'previous' 'immunomodulatory' 'therapy'
 '(' 'not' 'including' 'lenalidomide' 'or' 'thalidomide' ')']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0.]
NCT02531932,"1:40:chronic_disease,44:68:chronic_disease,116:126:treatment,134:152:chronic_disease,185:193:chronic_disease,195:217:chronic_disease,221:242:treatment","Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of Everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)","['Impairment' 'of' 'gastrointestinal' 'function' 'or' 'gastrointestinal'
 'disease' 'that' 'may' 'significantly' 'alter' 'the' 'absorption' 'of'
 'Everolimus' '(' 'e.g.' ',' 'ulcerative' 'disease' ',' 'uncontrolled'
 'nausea' ',' 'vomiting' ',' 'diarrhea' ',' 'malabsorption' 'syndrome'
 'or' 'small' 'bowel' 'resection' ')']","[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 2. 2. 0. 0. 0. 0.
 0. 0. 2. 0. 2. 2. 0. 1. 1. 1. 0.]"
NCT02531932,"43:53:allergy_name,63:73:allergy_name,75:84:allergy_name,86:98:allergy_name","Patients with a known hypersensitivity to Everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients","['Patients' 'with' 'a' 'known' 'hypersensitivity' 'to' 'Everolimus' 'or'
 'other' 'rapamycins' '(' 'sirolimus' ',' 'temsirolimus' ')' 'or' 'to'
 'its' 'excipients']",[0. 0. 0. 0. 0. 0. 4. 0. 0. 4. 0. 4. 0. 4. 0. 0. 0. 0. 0.]
NCT02531932,"20:43:cancer,47:52:cancer,56:92:cancer",adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin,"['adequately' 'treated' 'carcinoma' 'of' 'the' 'cervix' 'or' 'basal' 'or'
 'squamous' 'cell' 'carcinomas' 'of' 'the' 'skin']",[0. 0. 3. 3. 3. 3. 0. 3. 0. 3. 3. 3. 3. 3. 3.]
NCT02531880,"29:41:cancer,42:48:chronic_disease,117:125:treatment","Brain abnormality such as a brain tumor, stroke, brain damage from head trauma or blood vessel abnormalities, on an MRI scan","['Brain' 'abnormality' 'such' 'as' 'a' 'brain' 'tumor' ',' 'stroke' ','
 'brain' 'damage' 'from' 'head' 'trauma' 'or' 'blood' 'vessel'
 'abnormalities' ',' 'on' 'an' 'MRI' 'scan']",[0. 0. 0. 0. 0. 3. 3. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02531711,"12:22:chronic_disease,24:41:cancer,43:60:chronic_disease,98:106:treatment","History of vasculitis, intracranial mass, clotting disorder (including medication-induced, e.g., warfarin)","['History' 'of' 'vasculitis' ',' 'intracranial' 'mass' ',' 'clotting'
 'disorder' '(' 'including' 'medication-induced' ',' 'e.g.' ',' 'warfarin'
 ')']",[0. 0. 2. 0. 3. 3. 0. 2. 2. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02531295,"22:44:chronic_disease,83:92:chronic_disease,110:132:chronic_disease,152:178:chronic_disease,195:212:treatment,216:267:treatment,273:291:chronic_disease","Any known history of liver-related diseases including but not limited to: hepatic cirrhosis of decompensated chronic liver diseases; clinically active hepatitis B or C infection as evidenced by clinical jaundice or Grade 2 or higher liver function test abnormalities; any hepatic impairment, regardless of the graded liver function test abnormalities","['Any' 'known' 'history' 'of' 'liver-related' 'diseases' 'including' 'but'
 'not' 'limited' 'to' ':' 'hepatic' 'cirrhosis' 'of' 'decompensated'
 'chronic' 'liver' 'diseases' ';' 'clinically' 'active' 'hepatitis' 'B'
 'or' 'C' 'infection' 'as' 'evidenced' 'by' 'clinical' 'jaundice' 'or'
 'Grade' '2' 'or' 'higher' 'liver' 'function' 'test' 'abnormalities' ';'
 'any' 'hepatic' 'impairment' ',' 'regardless' 'of' 'the' 'graded' 'liver'
 'function' 'test' 'abnormalities']","[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 2. 2.
 2. 2. 2. 0. 0. 0. 1. 1. 0. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02530463,"1:16:treatment,28:52:treatment,56:94:treatment",Current therapy with other systemic anti-neoplastic or anti-neoplastic investigational agents,"['Current' 'therapy' 'with' 'other' 'systemic' 'anti-neoplastic' 'or'
 'anti-neoplastic' 'investigational' 'agents']",[1. 1. 0. 0. 1. 1. 1. 1. 0. 0.]
NCT02530463,"31:38:treatment,54:64:treatment,,91:121:treatment",Patients who are on high dose steroid (equivalent of prednisone more than 10 mg a day) or immune suppression medications,"['Patients' 'who' 'are' 'on' 'high' 'dose' 'steroid' '(' 'equivalent' 'of'
 'prednisone' 'more' 'than' '10' 'mg' 'a' 'day' ')' 'or' 'immune'
 'suppression' 'medications']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02530034,"30:38:treatment,42:67:treatment,78:100:cancer",Patients receiving any other standard or investigational treatment for their hematologic malignancy other than supportive care,"['Patients' 'receiving' 'any' 'other' 'standard' 'or' 'investigational'
 'treatment' 'for' 'their' 'hematologic' 'malignancy' 'other' 'than'
 'supportive' 'care']",[0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 3. 3. 0. 0. 0. 0.]
NCT02530034,"1:14:cancer,21:57:chronic_disease,59:65:chronic_disease,69:75:chronic_disease,,254:295:treatment","high-risk MDS (i.e. refractory anemia with excess blasts [RAEB-1 or RAEB-2] by World Health Organization [WHO] classification, or any WHO subset with International Prognostic Scoring System [IPSS] intermediate-2 or high, or any patients that has failed prior therapy with hypomethylating agents)","['high-risk' 'MDS' '(' 'i.e' '.' 'refractory' 'anemia' 'with' 'excess'
 'blasts' '[' 'RAEB-1' 'or' 'RAEB-2' ']' 'by' 'World' 'Health'
 'Organization' '[' 'WHO' ']' 'classification' ',' 'or' 'any' 'WHO'
 'subset' 'with' 'International' 'Prognostic' 'Scoring' 'System' '['
 'IPSS' ']' 'intermediate-2' 'or' 'high' ',' 'or' 'any' 'patients' 'that'
 'has' 'failed' 'prior' 'therapy' 'with' 'hypomethylating' 'agents' ')']","[3. 3. 0. 0. 0. 2. 2. 2. 2. 2. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 1. 1. 1. 0.]"
NCT02527564,"68:97:treatment,99:118:treatment,120:164:treatment,166:193:treatment","Clinically significant abnormalities on baseline laboratory tests (comprehensive metabolic panel, fasting lipid panel, Complete Blood Count (CBC) with differential, thyroid stimulating hormone)","['Clinically' 'significant' 'abnormalities' 'on' 'baseline' 'laboratory'
 'tests' '(' 'comprehensive' 'metabolic' 'panel' ',' 'fasting' 'lipid'
 'panel' ',' 'Complete' 'Blood' 'Count' '(' 'CBC' ')' 'with'
 'differential' ',' 'thyroid' 'stimulating' 'hormone' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 1. 0. 1. 1. 1. 1. 1. 1. 0. 0.
 0. 1. 1. 1. 0.]"
NCT02527421,"1:33:treatment,41:53:treatment,55:67:treatment,69:80:treatment","systemic antipsoriatic treatment (e.g., methotrexate, cyclosporine, hydroxyurea),","['systemic' 'antipsoriatic' 'treatment' '(' 'e.g.' ',' 'methotrexate' ','
 'cyclosporine' ',' 'hydroxyurea' ')' ',']",[1. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0.]
NCT02527265,"1:28:chronic_disease,19:28:chronic_disease,,100:109:treatment,",Respiratory tract infection within 30 days before screening or between screening and initiation of treatment period; subject may return 4 weeks after resolution of the infection for rescreening,"['Respiratory' 'tract' 'infection' 'within' '30' 'days' 'before'
 'screening' 'or' 'between' 'screening' 'and' 'initiation' 'of'
 'treatment' 'period' ';' 'subject' 'may' 'return' '4' 'weeks' 'after'
 'resolution' 'of' 'the' 'infection' 'for' 'rescreening']","[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02526511,"15:33:cancer,52:69:treatment,77:99:treatment,185:194:treatment",Patients with metastatic disease may have received prior nephrectomy and/or prior systemic therapy (no limit on number); their baseline pMRI would be performed prior to starting a new treatment,"['Patients' 'with' 'metastatic' 'disease' 'may' 'have' 'received' 'prior'
 'nephrectomy' 'and/or' 'prior' 'systemic' 'therapy' '(' 'no' 'limit' 'on'
 'number' ')' ';' 'their' 'baseline' 'pMRI' 'would' 'be' 'performed'
 'prior' 'to' 'starting' 'a' 'new' 'treatment']","[0. 0. 3. 3. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02525861,"57:68:allergy_name,128:140:treatment,141:155:treatment,165:182:allergy_name,184:193:allergy_name,195:218:allergy_name","Known history of allergic/hypersensitivity reactions to medications used during and for perioperative care associated with the bronchoscopy/BAL procedures, such as local anesthetics, sedatives, pain control medication","['Known' 'history' 'of' 'allergic/hypersensitivity' 'reactions' 'to'
 'medications' 'used' 'during' 'and' 'for' 'perioperative' 'care'
 'associated' 'with' 'the' 'bronchoscopy/BAL' 'procedures' ',' 'such' 'as'
 'local' 'anesthetics' ',' 'sedatives' ',' 'pain' 'control' 'medication']","[0. 0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 4. 4. 0.
 4. 0. 4. 4. 4.]"
NCT02525861,"48:55:chronic_disease,57:68:chronic_disease,73:90:chronic_disease,141:156:chronic_disease,158:183:chronic_disease","The participant has any clinically significant medical, psychiatric, or cognitive illness, or any other uncontrolled medical condition (eg, unstable angina, transient ischemic attack) that, in the opinion of the investigator, would impede the participant's ability to comply with the study procedures, pose increased risk to the participant's safety, or confound the interpretation of study results","['The' 'participant' 'has' 'any' 'clinically' 'significant' 'medical' ','
 'psychiatric' ',' 'or' 'cognitive' 'illness' ',' 'or' 'any' 'other'
 'uncontrolled' 'medical' 'condition' '(' 'eg' ',' 'unstable' 'angina' ','
 'transient' 'ischemic' 'attack' ')' 'that' ',' 'in' 'the' 'opinion' 'of'
 'the' 'investigator' ',' 'would' 'impede' 'the' 'participant' ""'s""
 'ability' 'to' 'comply' 'with' 'the' 'study' 'procedures' ',' 'pose'
 'increased' 'risk' 'to' 'the' 'participant' ""'s"" 'safety' ',' 'or'
 'confound' 'the' 'interpretation' 'of' 'study' 'results']","[0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02525861,"43:53:cancer,,176:186:cancer,190:225:cancer,227:258:cancer,270:285:cancer,300:309:treatment","The participant is experiencing an active malignancy or has a history of malignancy within 5 years prior to screening, with the exception of the following: adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or stable prostate cancer not requiring treatment","['The' 'participant' 'is' 'experiencing' 'an' 'active' 'malignancy' 'or'
 'has' 'a' 'history' 'of' 'malignancy' 'within' '5' 'years' 'prior' 'to'
 'screening' ',' 'with' 'the' 'exception' 'of' 'the' 'following' ':'
 'adequately' 'treated' 'basal' 'cell' 'or' 'squamous' 'cell' 'carcinoma'
 'of' 'the' 'skin' ',' 'carcinoma' 'in' 'situ' 'of' 'the' 'cervix' ','
 'or' 'stable' 'prostate' 'cancer' 'not' 'requiring' 'treatment']","[0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 3. 3. 0. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.
 3. 3. 0. 0. 1.]"
NCT02525692,",41:56:treatment,58:70:treatment,72:84:treatment,93:100:treatment,131:139:chronic_disease","All adverse events Grade > 1 related to prior therapies (chemotherapy, radiotherapy, and/or surgery) must be resolved, except for alopecia","['All' 'adverse' 'events' 'Grade' '>' '1' 'related' 'to' 'prior'
 'therapies' '(' 'chemotherapy' ',' 'radiotherapy' ',' 'and/or' 'surgery'
 ')' 'must' 'be' 'resolved' ',' 'except' 'for' 'alopecia']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 2.]"
NCT02525692,"27:44:treatment,60:104:treatment,134:143:treatment,","Concomitant use of potent CYP3A4/5 inducers, which include enzyme inducing antiepileptic drugs (EIAEDs) (see Appendix B), during the treatment phase of the study and within 2 weeks prior to starting treatment","['Concomitant' 'use' 'of' 'potent' 'CYP3A4/5' 'inducers' ',' 'which'
 'include' 'enzyme' 'inducing' 'antiepileptic' 'drugs' '(' 'EIAEDs' ')'
 '(' 'see' 'Appendix' 'B' ')' ',' 'during' 'the' 'treatment' 'phase' 'of'
 'the' 'study' 'and' 'within' '2' 'weeks' 'prior' 'to' 'starting'
 'treatment']","[0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02525692,"18:37:chronic_disease,48:67:chronic_disease,69:85:chronic_disease,89:100:chronic_disease,112:130:treatment,189:192:chronic_disease","Known history of cardiac arrhythmias including atrial fibrillation, tachyarrhythmias or bradycardia. Receiving therapeutic agents known to prolong QT interval will be excluded. History of CHF","['Known' 'history' 'of' 'cardiac' 'arrhythmias' 'including' 'atrial'
 'fibrillation' ',' 'tachyarrhythmias' 'or' 'bradycardia' '.' 'Receiving'
 'therapeutic' 'agents' 'known' 'to' 'prolong' 'QT' 'interval' 'will' 'be'
 'excluded' '.' 'History' 'of' 'CHF']","[0. 0. 0. 2. 2. 0. 2. 2. 0. 2. 0. 2. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 2.]"
NCT02525692,"1:7:cancer,82:102:treatment,169:176:cancer,169:175:cancer","Tumors with isocitrate dehydrogenase 1 (IDH1) or IDH2 mutations as determined by immunohistochemistry for the IDH1 R132H variant or by direct sequencing. IDH1/2-mutant gliomas have a markedly longer overall survival rate compared to those with IDH1/2-wildtype glioma (Parsons et al., 2008; Yan et al., 2009), indicating IDH1/2-mutant gliomas have a distinct natural history","['Tumors' 'with' 'isocitrate' 'dehydrogenase' '1' '(' 'IDH1' ')' 'or'
 'IDH2' 'mutations' 'as' 'determined' 'by' 'immunohistochemistry' 'for'
 'the' 'IDH1' 'R132H' 'variant' 'or' 'by' 'direct' 'sequencing' '.'
 'IDH1/2-mutant' 'gliomas' 'have' 'a' 'markedly' 'longer' 'overall'
 'survival' 'rate' 'compared' 'to' 'those' 'with' 'IDH1/2-wildtype'
 'glioma' '(' 'Parsons' 'et' 'al.' ',' '2008' ';' 'Yan' 'et' 'al.' ','
 '2009' ')' ',' 'indicating' 'IDH1/2-mutant' 'gliomas' 'have' 'a'
 'distinct' 'natural' 'history']","[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02525029,"9:31:chronic_disease,52:67:treatment,89:114:treatment",Current thromboembolic disease requiring full-dose anticoagulation - patients receiving pharmacologic prophylaxis for thromboembolic disease will be eligible,"['Current' 'thromboembolic' 'disease' 'requiring' 'full-dose'
 'anticoagulation' '-' 'patients' 'receiving' 'pharmacologic'
 'prophylaxis' 'for' 'thromboembolic' 'disease' 'will' 'be' 'eligible']",[0. 2. 2. 0. 0. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02525029,"16:26:chronic_disease,,44:68:treatment,,89:99:treatment",Progression of acute GVHD within 3 days of systemic corticosteroids of at least 2 mg/kg prednisone or equivalent,"['Progression' 'of' 'acute' 'GVHD' 'within' '3' 'days' 'of' 'systemic'
 'corticosteroids' 'of' 'at' 'least' '2' 'mg/kg' 'prednisone' 'or'
 'equivalent']",[0. 0. 2. 2. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0.]
NCT02524275,"7:17:cancer,49:59:cancer,63:98:cancer,103:117:cancer","Prior malignancy, except for adequately treated basal cell or squamous cell carcinoma of the skin, or thyroid cancer","['Prior' 'malignancy' ',' 'except' 'for' 'adequately' 'treated' 'basal'
 'cell' 'or' 'squamous' 'cell' 'carcinoma' 'of' 'the' 'skin' ',' 'or'
 'thyroid' 'cancer']",[0. 3. 0. 0. 0. 0. 0. 3. 3. 0. 3. 3. 3. 3. 3. 3. 0. 0. 3. 3.]
NCT02523443,"21:35:treatment,36:57:treatment,64:77:treatment",Patients taking any opioid agonist/antagonist medication (i.e. Buprenorphine),"['Patients' 'taking' 'any' 'opioid' 'agonist/antagonist' 'medication' '('
 'i.e' '.' 'Buprenorphine' ')']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 0.]
NCT02522715,",52:81:treatment,85:111:treatment,115:127:treatment,","Must have appropriate wash out (> 6 half-lives) of androgen receptor antagonists, 5 alpha reductase inhibitors or ketoconazole prior to the start of cycle 1; if the agent is not in the table below, the washout should be 2 weeks","['Must' 'have' 'appropriate' 'wash' 'out' '(' '>' '6' 'half-lives' ')'
 'of' 'androgen' 'receptor' 'antagonists' ',' '5' 'alpha' 'reductase'
 'inhibitors' 'or' 'ketoconazole' 'prior' 'to' 'the' 'start' 'of' 'cycle'
 '1' ';' 'if' 'the' 'agent' 'is' 'not' 'in' 'the' 'table' 'below' ','
 'the' 'washout' 'should' 'be' '2' 'weeks']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 1. 1. 1. 0. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02522715,"57:78:chronic_disease,80:103:chronic_disease,111:132:chronic_disease","clinical signs suggestive of high or imminent risks for pathological fracture, spinal cord compression and/or cauda equina syndrome","['clinical' 'signs' 'suggestive' 'of' 'high' 'or' 'imminent' 'risks' 'for'
 'pathological' 'fracture' ',' 'spinal' 'cord' 'compression' 'and/or'
 'cauda' 'equina' 'syndrome']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 2.]
NCT02522715,"23:35:treatment,39:46:treatment,56:84:treatment",may not have received enzalutamide or ARN-509 (another androgen receptor antagonist) in the past,"['may' 'not' 'have' 'received' 'enzalutamide' 'or' 'ARN-509' '(' 'another'
 'androgen' 'receptor' 'antagonist' ')' 'in' 'the' 'past']",[0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 1. 1. 0. 0. 0. 0.]
NCT02521493,"14:24:chronic_disease,,103:106:cancer,,218:248:cancer",Patients has cytopenias and/or bone marrow blasts but does not meet the criteria for the diagnosis of AML (WHO Myeloid Neoplasm classification) because of < 20% marrow blasts and meets the criteria for a diagnosis of myelodysplastic syndrome (MDS),"['Patients' 'has' 'cytopenias' 'and/or' 'bone' 'marrow' 'blasts' 'but'
 'does' 'not' 'meet' 'the' 'criteria' 'for' 'the' 'diagnosis' 'of' 'AML'
 '(' 'WHO' 'Myeloid' 'Neoplasm' 'classification' ')' 'because' 'of' '<'
 '20' '%' 'marrow' 'blasts' 'and' 'meets' 'the' 'criteria' 'for' 'a'
 'diagnosis' 'of' 'myelodysplastic' 'syndrome' '(' 'MDS' ')']","[0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0.]"
NCT02520791,"39:56:chronic_disease,95:101:chronic_disease,105:124:chronic_disease,323:332:chronic_disease,365:374:chronic_disease,520:549:treatment","All potential patients must undergo a tuberculosis (TB) test prior to study entry to rule out active or latent tuberculosis (either purified protein derivative [PPD] or QuantiFERON-TB Gold, whichever is preferred and available at the institution); patients with a history of TB (even if treated), or evidence of active or latent TB, are excluded; the diagnosis of active TB is defined per current guidelines; patients with a positive TB test (e.g. PPD or QuantiFERON-TB Gold) will be excluded; patients with history of Bacille-Calmette-Guerin (BCG) vaccination will be tested with QuantiFERON-TB Gold test in order to rule out exposure to TB","['All' 'potential' 'patients' 'must' 'undergo' 'a' 'tuberculosis' '(' 'TB'
 ')' 'test' 'prior' 'to' 'study' 'entry' 'to' 'rule' 'out' 'active' 'or'
 'latent' 'tuberculosis' '(' 'either' 'purified' 'protein' 'derivative'
 '[' 'PPD' ']' 'or' 'QuantiFERON-TB' 'Gold' ',' 'whichever' 'is'
 'preferred' 'and' 'available' 'at' 'the' 'institution' ')' ';' 'patients'
 'with' 'a' 'history' 'of' 'TB' '(' 'even' 'if' 'treated' ')' ',' 'or'
 'evidence' 'of' 'active' 'or' 'latent' 'TB' ',' 'are' 'excluded' ';'
 'the' 'diagnosis' 'of' 'active' 'TB' 'is' 'defined' 'per' 'current'
 'guidelines' ';' 'patients' 'with' 'a' 'positive' 'TB' 'test' '(' 'e.g'
 '.' 'PPD' 'or' 'QuantiFERON-TB' 'Gold' ')' 'will' 'be' 'excluded' ';'
 'patients' 'with' 'history' 'of' 'Bacille-Calmette-Guerin' '(' 'BCG' ')'
 'vaccination' 'will' 'be' 'tested' 'with' 'QuantiFERON-TB' 'Gold' 'test'
 'in' 'order' 'to' 'rule' 'out' 'exposure' 'to' 'TB']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02520791,"13:29:chronic_disease,33:53:chronic_disease,33:44:chronic_disease,55:77:chronic_disease,97:108:chronic_disease,134:144:chronic_disease,153:166:chronic_disease,249:277:treatment,330:341:treatment,","Evidence of active infection by hepatitis B and/or C; active viral infection by hepatitis B and hepatitis C could be associated with cytopenias (due to hypersplenism or due to the active virus itself), which could add further risk when a potential immunosuppressive medication is used; for patients with hepatitis B treated with anti-virals to undetectable viral load, and for patients with hepatitis C with undetectable ribonucleic acid (RNA) levels and no evidence of liver damage, enrollment may be considered","['Evidence' 'of' 'active' 'infection' 'by' 'hepatitis' 'B' 'and/or' 'C'
 ';' 'active' 'viral' 'infection' 'by' 'hepatitis' 'B' 'and' 'hepatitis'
 'C' 'could' 'be' 'associated' 'with' 'cytopenias' '(' 'due' 'to'
 'hypersplenism' 'or' 'due' 'to' 'the' 'active' 'virus' 'itself' ')' ','
 'which' 'could' 'add' 'further' 'risk' 'when' 'a' 'potential'
 'immunosuppressive' 'medication' 'is' 'used' ';' 'for' 'patients' 'with'
 'hepatitis' 'B' 'treated' 'with' 'anti-virals' 'to' 'undetectable'
 'viral' 'load' ',' 'and' 'for' 'patients' 'with' 'hepatitis' 'C' 'with'
 'undetectable' 'ribonucleic' 'acid' '(' 'RNA' ')' 'levels' 'and' 'no'
 'evidence' 'of' 'liver' 'damage' ',' 'enrollment' 'may' 'be' 'considered']","[0. 0. 2. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02520791,"24:40:treatment,48:65:treatment,69:85:treatment,91:138:treatment,","Patients not receiving systemic therapy (i.e., systemic steroids or biologic therapy with disease modifying anti-rheumatic drugs [DMARDs]) within 2 years","['Patients' 'not' 'receiving' 'systemic' 'therapy' '(' 'i.e.' ','
 'systemic' 'steroids' 'or' 'biologic' 'therapy' 'with' 'disease'
 'modifying' 'anti-rheumatic' 'drugs' '[' 'DMARDs' ']' ')' 'within' '2'
 'years']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.
 0.]"
NCT02520778,"118:151:chronic_disease,153:177:chronic_disease,179:204:chronic_disease","Any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiogram (ECG) (e.g., complete left bundle branch block, third degree heart block, second degree heart block)","['Any' 'clinically' 'important' 'abnormalities' 'in' 'rhythm' ','
 'conduction' 'or' 'morphology' 'of' 'resting' 'electrocardiogram' '('
 'ECG' ')' '(' 'e.g.' ',' 'complete' 'left' 'bundle' 'branch' 'block' ','
 'third' 'degree' 'heart' 'block' ',' 'second' 'degree' 'heart' 'block'
 ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2.
 0. 2. 2. 2. 2. 0. 2. 2. 2. 2. 0.]"
NCT02520778,"15:49:chronic_disease,53:75:treatment,120:161:treatment",Patients with human immunodeficiency virus (HIV) on antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with AZD9291,"['Patients' 'with' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'on'
 'antiretroviral' 'therapy' 'are' 'ineligible' 'because' 'of' 'the'
 'potential' 'for' 'pharmacokinetic' 'interactions' 'with' 'AZD9291']",[0. 0. 2. 2. 2. 2. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]
NCT02520778,"11:26:treatment,30:51:treatment,84:100:chronic_disease,106:116:treatment",receiving anticoagulation or anti-platelet therapy are excluded due to the risk of thrombocytopenia with navitoclax,"['receiving' 'anticoagulation' 'or' 'anti-platelet' 'therapy' 'are'
 'excluded' 'due' 'to' 'the' 'risk' 'of' 'thrombocytopenia' 'with'
 'navitoclax']",[0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 2. 0. 1.]
NCT02520427,"1:18:treatment,20:32:treatment,34:50:treatment,52:78:treatment,80:96:treatment,101:122:treatment,,","Antitumor therapy (chemotherapy, antibody therapy, molecular-targeted therapy, retinoid therapy, or investigational agent) within 14 days or 5 half-lives of day 1","['Antitumor' 'therapy' '(' 'chemotherapy' ',' 'antibody' 'therapy' ','
 'molecular-targeted' 'therapy' ',' 'retinoid' 'therapy' ',' 'or'
 'investigational' 'agent' ')' 'within' '14' 'days' 'or' '5' 'half-lives'
 'of' 'day' '1']","[1. 1. 0. 1. 0. 1. 1. 0. 1. 1. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02520011,",,62:78:chronic_disease,80:89:chronic_disease,94:102:cancer","Have a total bilirubin level ≤2.0 mg/dL (unless secondary to Gilbert syndrome, hemolysis, or leukemia)","['Have' 'a' 'total' 'bilirubin' 'level' '≤2.0' 'mg/dL' '(' 'unless'
 'secondary' 'to' 'Gilbert' 'syndrome' ',' 'hemolysis' ',' 'or' 'leukemia'
 ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 0. 3. 0.]
NCT02520011,",32:49:treatment,54:57:cancer,59:81:treatment,93:111:treatment,185:196:treatment",Received more than 2 cycles of induction therapy for AML. Investigational agents as part of front-line therapy for AML may by acceptable following discussion with the Medical Monitor. Hydroxyurea is permitted (see #5 below),"['Received' 'more' 'than' '2' 'cycles' 'of' 'induction' 'therapy' 'for'
 'AML' '.' 'Investigational' 'agents' 'as' 'part' 'of' 'front-line'
 'therapy' 'for' 'AML' 'may' 'by' 'acceptable' 'following' 'discussion'
 'with' 'the' 'Medical' 'Monitor' '.' 'Hydroxyurea' 'is' 'permitted' '('
 'see' '#' '5' 'below' ')']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 3. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02519452,"6:27:treatment,78:87:treatment,89:128:treatment,137:156:treatment,158:170:treatment,172:187:treatment","Each prior line of therapy may consist of one or more agents and may include induction, hematopoietic stem cell transplantation, and/or maintenance therapy. Radiotherapy, bisphosphonates","['Each' 'prior' 'line' 'of' 'therapy' 'may' 'consist' 'of' 'one' 'or'
 'more' 'agents' 'and' 'may' 'include' 'induction' ',' 'hematopoietic'
 'stem' 'cell' 'transplantation' ',' 'and/or' 'maintenance' 'therapy' '.'
 'Radiotherapy' ',' 'bisphosphonates']","[0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 1. 0. 0. 1.
 1. 0. 1. 0. 1.]"
NCT02519348,"16:28:treatment,30:43:treatment,48:76:treatment,81:87:cancer,88:97:treatment","Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment","['Any' 'concurrent' 'chemotherapy' ',' 'immunotherapy' ',' 'or' 'biologic'
 'or' 'hormonal' 'therapy' 'for' 'cancer' 'treatment']",[0. 0. 1. 0. 1. 0. 0. 1. 1. 1. 1. 0. 3. 1.]
NCT02519348,"1:23:chronic_disease,9:23:chronic_disease,,65:76:treatment",Hepatic encephalopathy within past 12 months or requirement for medications to prevent or control encephalopathy,"['Hepatic' 'encephalopathy' 'within' 'past' '12' 'months' 'or'
 'requirement' 'for' 'medications' 'to' 'prevent' 'or' 'control'
 'encephalopathy']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02519322,"16:30:treatment,32:40:treatment,42:49:treatment,51:77:treatment","Current use of anticoagulants (warfarin, heparin, direct thrombin inhibitors) at therapeutic levels","['Current' 'use' 'of' 'anticoagulants' '(' 'warfarin' ',' 'heparin' ','
 'direct' 'thrombin' 'inhibitors' ')' 'at' 'therapeutic' 'levels']",[0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0.]
NCT02519322,",,53:89:treatment,105:134:treatment,,156:172:treatment",Left ventricular ejection fraction (LVEF) >= 50% by transthoracic echocardiography (TTE) (preferred) or multigated acquisition (MUGA) within 6 months from first study drug administration,"['Left' 'ventricular' 'ejection' 'fraction' '(' 'LVEF' ')' '>' '=' '50'
 '%' 'by' 'transthoracic' 'echocardiography' '(' 'TTE' ')' '(' 'preferred'
 ')' 'or' 'multigated' 'acquisition' '(' 'MUGA' ')' 'within' '6' 'months'
 'from' 'first' 'study' 'drug' 'administration']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1. 1.
 0. 0. 0. 0. 0. 0. 1. 1. 1. 0.]"
NCT02519322,"7:17:cancer,,93:101:cancer,122:129:cancer,171:176:cancer,180:205:cancer,207:233:cancer,238:271:cancer,273:279:cancer,284:290:cancer,320:327:treatment,329:338:treatment","Prior malignancy active within the previous 3 years except for patient's prior diagnosis of melanoma and locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast with local control measures (surgery, radiation)","['Prior' 'malignancy' 'active' 'within' 'the' 'previous' '3' 'years'
 'except' 'for' 'patient' ""'s"" 'prior' 'diagnosis' 'of' 'melanoma' 'and'
 'locally' 'curable' 'cancers' 'that' 'have' 'been' 'apparently' 'cured'
 ',' 'such' 'as' 'basal' 'or' 'squamous' 'cell' 'skin' 'cancer' ','
 'superficial' 'bladder' 'cancer' ',' 'or' 'carcinoma' 'in' 'situ' 'of'
 'the' 'prostate' ',' 'cervix' ',' 'or' 'breast' 'with' 'local' 'control'
 'measures' '(' 'surgery' ',' 'radiation' ')']","[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 3. 0. 0. 0. 0.
 0. 0. 0. 0. 3. 0. 3. 3. 3. 3. 0. 3. 3. 3. 0. 0. 3. 3. 3. 3. 3. 3. 0. 3.
 0. 0. 3. 0. 0. 0. 0. 0. 1. 0. 1. 0.]"
NCT02519322,",,,117:126:treatment,134:144:treatment,193:203:treatment",men who are sexually active with WOCBP must continue contraception for 33 weeks (90 days plus the time required for nivolumab and/or relatlimab to undergo 5 half-lives) after the last dose of study drug,"['men' 'who' 'are' 'sexually' 'active' 'with' 'WOCBP' 'must' 'continue'
 'contraception' 'for' '33' 'weeks' '(' '90' 'days' 'plus' 'the' 'time'
 'required' 'for' 'nivolumab' 'and/or' 'relatlimab' 'to' 'undergo' '5'
 'half-lives' ')' 'after' 'the' 'last' 'dose' 'of' 'study' 'drug']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02518594,"12:24:allergy_name,26:34:allergy_name,57:67:treatment,79:86:allergy_name,90:100:allergy_name,122:129:allergy_name","Allergy to progesterone, silicone, or excipients in the study drug, including peanuts or peanut oil in the study drug or placebo","['Allergy' 'to' 'progesterone' ',' 'silicone' ',' 'or' 'excipients' 'in'
 'the' 'study' 'drug' ',' 'including' 'peanuts' 'or' 'peanut' 'oil' 'in'
 'the' 'study' 'drug' 'or' 'placebo']",[0. 0. 4. 0. 4. 0. 0. 0. 0. 0. 1. 1. 0. 0. 4. 0. 4. 4. 0. 0. 0. 0. 0. 4.]
NCT02518594,"7:24:chronic_disease,44:57:chronic_disease,94:110:treatment",Known liver dysfunction or disease because liver disease is a contraindication to the active study medication,"['Known' 'liver' 'dysfunction' 'or' 'disease' 'because' 'liver' 'disease'
 'is' 'a' 'contraindication' 'to' 'the' 'active' 'study' 'medication']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02517307,"24:29:chronic_disease,31:36:chronic_disease,38:41:chronic_disease,45:60:chronic_disease,,,109:138:chronic_disease","confirmed diagnosis of VLCAD, LCHAD, TFP or MCAD deficiency or same gender, age and BMI as a subject with a fatty acid oxidation disorder","['confirmed' 'diagnosis' 'of' 'VLCAD' ',' 'LCHAD' ',' 'TFP' 'or' 'MCAD'
 'deficiency' 'or' 'same' 'gender' ',' 'age' 'and' 'BMI' 'as' 'a'
 'subject' 'with' 'a' 'fatty' 'acid' 'oxidation' 'disorder']","[0. 0. 0. 2. 0. 2. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 2. 2.]"
NCT02516969,"1:22:cancer,68:87:cancer,89:102:cancer,104:126:cancer","extra-nodal extension (patient with other high-risk features gross perinueral invasion, bone invasion, angiolyphatic invasion, or a constellation of these factors may be eligible based on case-by-case basis at discretion of principal investigator)","['extra-nodal' 'extension' '(' 'patient' 'with' 'other' 'high-risk'
 'features' 'gross' 'perinueral' 'invasion' ',' 'bone' 'invasion' ','
 'angiolyphatic' 'invasion' ',' 'or' 'a' 'constellation' 'of' 'these'
 'factors' 'may' 'be' 'eligible' 'based' 'on' 'case-by-case' 'basis' 'at'
 'discretion' 'of' 'principal' 'investigator' ')']","[3. 3. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 3. 3. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02516813,"58:71:treatment,75:94:treatment,103:145:treatment,103:111:treatment,138:145:chronic_disease,149:165:chronic_disease","History of any other significant medical disease such as major gastric or small bowel surgery, recent drainage of significant volumes of ascites or pleural effusion (as per Investigator's judgement) or a psychiatric condition that might impair the subject's well-being or preclude full participation in the trial","['History' 'of' 'any' 'other' 'significant' 'medical' 'disease' 'such'
 'as' 'major' 'gastric' 'or' 'small' 'bowel' 'surgery' ',' 'recent'
 'drainage' 'of' 'significant' 'volumes' 'of' 'ascites' 'or' 'pleural'
 'effusion' '(' 'as' 'per' 'Investigator' ""'s"" 'judgement' ')' 'or' 'a'
 'psychiatric' 'condition' 'that' 'might' 'impair' 'the' 'subject' ""'s""
 'well-being' 'or' 'preclude' 'full' 'participation' 'in' 'the' 'trial']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 1. 0. 0. 1. 1. 1. 1. 1. 2. 0.
 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02516813,"1:9:treatment,,78:84:cancer,178:187:treatment,208:213:cancer,258:277:cancer","Prior RT to the same region within 12 months (Phase Ia, Arm A; subjects with tumors localized in the head and neck region or thorax) or at any time previously (Phase Ia, Arm B; treatment-naïve subjects with SCCHN and Phase Ib; treatment-naïve subjects with Stage III A/B NSCLC or SCCHN)","['Prior' 'RT' 'to' 'the' 'same' 'region' 'within' '12' 'months' '('
 'Phase' 'Ia' ',' 'Arm' 'A' ';' 'subjects' 'with' 'tumors' 'localized'
 'in' 'the' 'head' 'and' 'neck' 'region' 'or' 'thorax' ')' 'or' 'at' 'any'
 'time' 'previously' '(' 'Phase' 'Ia' ',' 'Arm' 'B' ';' 'treatment-naïve'
 'subjects' 'with' 'SCCHN' 'and' 'Phase' 'Ib' ';' 'treatment-naïve'
 'subjects' 'with' 'Stage' 'III' 'A/B' 'NSCLC' 'or' 'SCCHN' ')']","[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 3. 0. 0. 0.
 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0.]"
NCT02516813,"30:40:treatment,44:66:treatment,,115:130:treatment",Subjects currently receiving H2-blocker or proton pump inhibitors (or unable to stop at least 5 days prior to the first treatment),"['Subjects' 'currently' 'receiving' 'H2-blocker' 'or' 'proton' 'pump'
 'inhibitors' '(' 'or' 'unable' 'to' 'stop' 'at' 'least' '5' 'days'
 'prior' 'to' 'the' 'first' 'treatment' ')']",[0. 0. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT02516696,"17:38:chronic_disease,,,,,132:145:chronic_disease,,,190:209:chronic_disease,231:254:chronic_disease,295:303:chronic_disease","Subject has had myocardial infarction within 6 months prior to enrollment , or NYHA(New York Hospital Association) Class III or IV heart failure (see APPENDIX VI), Ejection Fraction < 35%, uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia or active conduction system abnormalities","['Subject' 'has' 'had' 'myocardial' 'infarction' 'within' '6' 'months'
 'prior' 'to' 'enrollment' ',' 'or' 'NYHA' '(' 'New' 'York' 'Hospital'
 'Association' ')' 'Class' 'III' 'or' 'IV' 'heart' 'failure' '(' 'see'
 'APPENDIX' 'VI' ')' ',' 'Ejection' 'Fraction' '<' '35' '%' ','
 'uncontrolled' 'angina' ',' 'severe' 'uncontrolled' 'ventricular'
 'arrhythmias' ',' 'electrocardiographic' 'evidence' 'of' 'acute'
 'ischemia' 'or' 'active' 'conduction' 'system' 'abnormalities']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0.
 0. 0. 2. 0. 0. 0. 0. 0.]"
NCT02516696,"16:52:treatment,,91:106:treatment,118:133:treatment,,194:207:treatment",Subject has no prior anti-myeloma treatment therapy within 14 days prior to initiation of study treatment except for corticosteroids with a maximum allowed dosage equivalent to three pulses of dexamethasone (40mg daily for 4 days equals one pulse),"['Subject' 'has' 'no' 'prior' 'anti-myeloma' 'treatment' 'therapy'
 'within' '14' 'days' 'prior' 'to' 'initiation' 'of' 'study' 'treatment'
 'except' 'for' 'corticosteroids' 'with' 'a' 'maximum' 'allowed' 'dosage'
 'equivalent' 'to' 'three' 'pulses' 'of' 'dexamethasone' '(' '40mg'
 'daily' 'for' '4' 'days' 'equals' 'one' 'pulse' ')']","[0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02516670,"25:59:chronic_disease,55:58:chronic_disease,82:93:chronic_disease,98:119:chronic_disease","Have a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies), hepatitis B, or hepatitis C infection","['Have' 'a' 'known' 'history' 'of' 'human' 'immunodeficiency' 'virus' '('
 'HIV' ')' '(' 'HIV' '1/2' 'antibodies' ')' ',' 'hepatitis' 'B' ',' 'or'
 'hepatitis' 'C' 'infection']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0.]
NCT02516670,"10:28:treatment,33:51:cancer,55:91:cancer,116:141:cancer,","Have had prior chemotherapy for metastatic disease in castration-resistant prostate cancer (prior chemotherapy for hormone-sensitive disease, more than twelve months prior to registration, is acceptable)","['Have' 'had' 'prior' 'chemotherapy' 'for' 'metastatic' 'disease' 'in'
 'castration-resistant' 'prostate' 'cancer' '(' 'prior' 'chemotherapy'
 'for' 'hormone-sensitive' 'disease' ',' 'more' 'than' 'twelve' 'months'
 'prior' 'to' 'registration' ',' 'is' 'acceptable' ')']","[0. 0. 1. 1. 0. 3. 3. 0. 3. 3. 3. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02516332,"28:35:chronic_disease,,,,188:203:chronic_disease,205:219:chronic_disease,224:238:chronic_disease","Patients also will have an anxiety symptom severity score of at least 8 on the Hospital Anxiety and Depression-Anxiety scale (HADS-A) or a DSM-5 diagnosis of an Anxiety Disorder, such as General Anxiety, Social Anxiety, or Panic Disorder","['Patients' 'also' 'will' 'have' 'an' 'anxiety' 'symptom' 'severity'
 'score' 'of' 'at' 'least' '8' 'on' 'the' 'Hospital' 'Anxiety' 'and'
 'Depression-Anxiety' 'scale' '(' 'HADS-A' ')' 'or' 'a' 'DSM-5'
 'diagnosis' 'of' 'an' 'Anxiety' 'Disorder' ',' 'such' 'as' 'General'
 'Anxiety' ',' 'Social' 'Anxiety' ',' 'or' 'Panic' 'Disorder']","[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2.]"
NCT02516241,"28:38:chronic_disease,42:64:chronic_disease,130:138:chronic_disease,142:150:chronic_disease,167:181:chronic_disease,197:215:chronic_disease,227:246:treatment,298:314:treatment,,446:460:chronic_disease","Active or prior documented autoimmune or inflammatory disorders. The following are exceptions to this criterion: • Patients with vitiligo or alopecia • Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement • Any chronic skin condition that does not require systemic therapy • Patients without active disease in the last 3 years may be included but only after consultation with AstraZeneca • Patients with celiac disease controlled by diet alone may be included but only after consultation with AstraZeneca","['Active' 'or' 'prior' 'documented' 'autoimmune' 'or' 'inflammatory'
 'disorders' '.' 'The' 'following' 'are' 'exceptions' 'to' 'this'
 'criterion' ':' '•' 'Patients' 'with' 'vitiligo' 'or' 'alopecia' '•'
 'Patients' 'with' 'hypothyroidism' '(' 'eg' ',' 'following' 'Hashimoto'
 'syndrome' ')' 'stable' 'on' 'hormone' 'replacement' '•' 'Any' 'chronic'
 'skin' 'condition' 'that' 'does' 'not' 'require' 'systemic' 'therapy' '•'
 'Patients' 'without' 'active' 'disease' 'in' 'the' 'last' '3' 'years'
 'may' 'be' 'included' 'but' 'only' 'after' 'consultation' 'with'
 'AstraZeneca' '•' 'Patients' 'with' 'celiac' 'disease' 'controlled' 'by'
 'diet' 'alone' 'may' 'be' 'included' 'but' 'only' 'after' 'consultation'
 'with' 'AstraZeneca']","[0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0.
 0. 0. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02516241,"19:42:treatment,80:137:treatment,139:148:treatment,150:160:treatment,165:186:treatment,198:229:treatment,243:268:treatment,272:285:treatment,","Prior exposure to immune-mediated therapy, including but not limited to, other anti cytotoxic T-lymphocyte-associated protein 4 (CTLA 4), anti-PD-1, anti-PD-L1, or anti-PD-L2 antibodies, including therapeutic anticancer vaccines. Prior local intervesical chemotherapy or immunotherapy is allowed if completed at least 28 days prior to the initiation of study treatment","['Prior' 'exposure' 'to' 'immune-mediated' 'therapy' ',' 'including' 'but'
 'not' 'limited' 'to' ',' 'other' 'anti' 'cytotoxic'
 'T-lymphocyte-associated' 'protein' '4' '(' 'CTLA' '4' ')' ','
 'anti-PD-1' ',' 'anti-PD-L1' ',' 'or' 'anti-PD-L2' 'antibodies' ','
 'including' 'therapeutic' 'anticancer' 'vaccines' '.' 'Prior' 'local'
 'intervesical' 'chemotherapy' 'or' 'immunotherapy' 'is' 'allowed' 'if'
 'completed' 'at' 'least' '28' 'days' 'prior' 'to' 'the' 'initiation' 'of'
 'study' 'treatment']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 1.
 0. 1. 0. 0. 1. 1. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02515110,"32:44:treatment,49:60:cancer,64:100:cancer,119:137:cancer,151:173:treatment","Any history, not including the index cancer, of ipsilateral or contralateral invasive breast cancer or ipsilateral or contralateral DCIS treated with radiation therapy (RT)","['Any' 'history' ',' 'not' 'including' 'the' 'index' 'cancer' ',' 'of'
 'ipsilateral' 'or' 'contralateral' 'invasive' 'breast' 'cancer' 'or'
 'ipsilateral' 'or' 'contralateral' 'DCIS' 'treated' 'with' 'radiation'
 'therapy' '(' 'RT' ')']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 3. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 1. 0. 0.]"
NCT02515110,"23:43:cancer,47:82:cancer,91:109:cancer,110:132:treatment",complete resection of basal cell carcinoma or squamous cell carcinoma of the skin and any in situ malignancy after curative therapy,"['complete' 'resection' 'of' 'basal' 'cell' 'carcinoma' 'or' 'squamous'
 'cell' 'carcinoma' 'of' 'the' 'skin' 'and' 'any' 'in' 'situ' 'malignancy'
 'after' 'curative' 'therapy']",[0. 0. 0. 3. 3. 3. 0. 3. 3. 3. 3. 3. 3. 0. 0. 3. 3. 3. 1. 1. 1.]
NCT02514083,"42:64:chronic_disease,101:112:chronic_disease,114:151:chronic_disease,236:257:chronic_disease,261:276:chronic_disease,281:304:chronic_disease,","Currently active, clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, Class 3 or 4 congestive heart failure as defined by New York Heart Association Functional Classification, or a history of myocardial infarction or unstable angina, or acute coronary syndrome within 6 months of screening","['Currently' 'active' ',' 'clinically' 'significant' 'cardiovascular'
 'disease' 'such' 'as' 'uncontrolled' 'or' 'symptomatic' 'arrhythmias' ','
 'Class' '3' 'or' '4' 'congestive' 'heart' 'failure' 'as' 'defined' 'by'
 'New' 'York' 'Heart' 'Association' 'Functional' 'Classification' ',' 'or'
 'a' 'history' 'of' 'myocardial' 'infarction' 'or' 'unstable' 'angina' ','
 'or' 'acute' 'coronary' 'syndrome' 'within' '6' 'months' 'of' 'screening']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 2. 0. 2. 2. 2. 2. 2. 2. 2. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0.
 0. 0.]"
NCT02514083,"1:25:chronic_disease,27:44:chronic_disease,48:72:chronic_disease,197:206:treatment,211:222:treatment","Life-threatening illness, medical condition or organ system dysfunction which, in the investigator s opinion, could compromise the subject s safety, interfere with the absorption or metabolism of ibrutinib and fludarabine, or put the study outcomes at undue risk","['Life-threatening' 'illness' ',' 'medical' 'condition' 'or' 'organ'
 'system' 'dysfunction' 'which' ',' 'in' 'the' 'investigator' 's'
 'opinion' ',' 'could' 'compromise' 'the' 'subject' 's' 'safety' ','
 'interfere' 'with' 'the' 'absorption' 'or' 'metabolism' 'of' 'ibrutinib'
 'and' 'fludarabine' ',' 'or' 'put' 'the' 'study' 'outcomes' 'at' 'undue'
 'risk']","[2. 2. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02514083,"32:66:treatment,74:86:treatment,108:117:treatment,153:162:treatment",Subjects who received a strong cytochrome P450 (CYP) 3A inhibitor within 7 days prior to the first dose of ibrutinib or subjects who require continuous treatment with a strong CYP3A inhibitor,"['Subjects' 'who' 'received' 'a' 'strong' 'cytochrome' 'P450' '(' 'CYP'
 ')' '3A' 'inhibitor' 'within' '7' 'days' 'prior' 'to' 'the' 'first'
 'dose' 'of' 'ibrutinib' 'or' 'subjects' 'who' 'require' 'continuous'
 'treatment' 'with' 'a' 'strong' 'CYP3A' 'inhibitor']","[0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0. 0. 1. 0. 0. 0. 0. 0.]"
NCT02514070,"33:37:allergy_name,39:48:allergy_name,52:83:allergy_name","Known sensitivity or allergy to fish, shellfish or omega-3 fatty acids supplements","['Known' 'sensitivity' 'or' 'allergy' 'to' 'fish' ',' 'shellfish' 'or'
 'omega-3' 'fatty' 'acids' 'supplements']",[0. 0. 0. 0. 0. 4. 0. 4. 0. 4. 4. 4. 4.]
NCT02514070,"32:43:treatment,,111:131:treatment,133:155:treatment,157:181:treatment,183:191:treatment,193:200:treatment,204:210:treatment","Subjects taking supplements or medications that affect lipoproteins for at least the past six weeks including fish oil supplements, bile-acid sequestrants, plant sterol supplements, fibrates, statins or Niacin","['Subjects' 'taking' 'supplements' 'or' 'medications' 'that' 'affect'
 'lipoproteins' 'for' 'at' 'least' 'the' 'past' 'six' 'weeks' 'including'
 'fish' 'oil' 'supplements' ',' 'bile-acid' 'sequestrants' ',' 'plant'
 'sterol' 'supplements' ',' 'fibrates' ',' 'statins' 'or' 'Niacin']","[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 0. 1.
 1. 1. 0. 1. 0. 1. 0. 1.]"
NCT02513797,"25:31:treatment,33:52:treatment,73:92:treatment,103:115:treatment,117:128:treatment,137:155:treatment","Any contraindication to suture, endovascular device, or other minimally invasive techniques including percutaneous, transseptal, and/or sub-xiphoid access","['Any' 'contraindication' 'to' 'suture' ',' 'endovascular' 'device' ','
 'or' 'other' 'minimally' 'invasive' 'techniques' 'including'
 'percutaneous' ',' 'transseptal' ',' 'and/or' 'sub-xiphoid' 'access']",[0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 1. 1.]
NCT02513797,"23:40:chronic_disease,42:65:chronic_disease,73:90:chronic_disease,100:140:treatment,","Documented history of cardiogenic shock, hemodynamic instability or any medical condition in which intra-aortic balloon pump (IABP) therapy is clinically indicated within 3 months prior to the planned study intervention","['Documented' 'history' 'of' 'cardiogenic' 'shock' ',' 'hemodynamic'
 'instability' 'or' 'any' 'medical' 'condition' 'in' 'which'
 'intra-aortic' 'balloon' 'pump' '(' 'IABP' ')' 'therapy' 'is'
 'clinically' 'indicated' 'within' '3' 'months' 'prior' 'to' 'the'
 'planned' 'study' 'intervention']","[0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02513485,"1:18:chronic_disease,25:41:chronic_disease,45:83:chronic_disease",Chronic infection (e.g. hepatitis B or C or Human Immunodeficiency Virus infection),"['Chronic' 'infection' '(' 'e.g' '.' 'hepatitis' 'B' 'or' 'C' 'or' 'Human'
 'Immunodeficiency' 'Virus' 'infection' ')']",[2. 2. 0. 0. 0. 2. 2. 2. 2. 0. 2. 2. 2. 2. 0.]
NCT02513485,"1:26:treatment,28:39:treatment,48:67:treatment,69:85:treatment,106:120:chronic_disease","Embedded metallic objects, prosthetics made of paramagnetic metals, aneurysmal clips and/or a history of claustrophobia","['Embedded' 'metallic' 'objects' ',' 'prosthetics' 'made' 'of'
 'paramagnetic' 'metals' ',' 'aneurysmal' 'clips' 'and/or' 'a' 'history'
 'of' 'claustrophobia']",[1. 1. 1. 0. 1. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 2.]
NCT02512926,",39:54:treatment,,70:76:treatment,82:87:treatment,98:131:treatment,142:145:chronic_disease","At least 90 days must have elapsed if prior radiation to ≥50% of the pelvis, the spine, or other substantial bone marrow radiation including TBI","['At' 'least' '90' 'days' 'must' 'have' 'elapsed' 'if' 'prior' 'radiation'
 'to' '≥50' '%' 'of' 'the' 'pelvis' ',' 'the' 'spine' ',' 'or' 'other'
 'substantial' 'bone' 'marrow' 'radiation' 'including' 'TBI']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 0. 0. 1. 1.
 1. 1. 0. 2.]"
NCT02512926,",103:125:chronic_disease,132:141:cancer,143:155:chronic_disease","Patients must meet the WHO classification with ≥ 5% blasts in the bone marrow or must have definitive extramedullary disease (e.g. chloromas, skin lesions)","['Patients' 'must' 'meet' 'the' 'WHO' 'classification' 'with' '≥' '5' '%'
 'blasts' 'in' 'the' 'bone' 'marrow' 'or' 'must' 'have' 'definitive'
 'extramedullary' 'disease' '(' 'e.g' '.' 'chloromas' ',' 'skin' 'lesions'
 ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0.
 3. 0. 2. 2. 0.]"
NCT02512718,"8:14:chronic_disease,16:34:chronic_disease,38:46:chronic_disease","Recent stroke, cardiac infarction or embolism","['Recent' 'stroke' ',' 'cardiac' 'infarction' 'or' 'embolism']",[0. 2. 0. 2. 2. 0. 2.]
NCT02512497,"21:46:cancer,48:73:cancer,75:104:cancer,106:139:cancer,144:170:cancer,172:202:cancer,212:248:treatment","Diagnosis of either Cutaneous T-Cell Lymphoma; T-Prolymphocytic Leukemia; T-Large Granulocytic Leukemia; T-Lymphoblastic Leukemia/lymphoma; or Peripheral T-Cell Lymphoma, Natural Killer/T-cell lymphoma for whom allogeneic stem cell transplantation is indicated","['Diagnosis' 'of' 'either' 'Cutaneous' 'T-Cell' 'Lymphoma' ';'
 'T-Prolymphocytic' 'Leukemia' ';' 'T-Large' 'Granulocytic' 'Leukemia' ';'
 'T-Lymphoblastic' 'Leukemia/lymphoma' ';' 'or' 'Peripheral' 'T-Cell'
 'Lymphoma' ',' 'Natural' 'Killer/T-cell' 'lymphoma' 'for' 'whom'
 'allogeneic' 'stem' 'cell' 'transplantation' 'is' 'indicated']","[0. 0. 0. 3. 3. 3. 0. 3. 3. 0. 3. 3. 3. 0. 3. 3. 0. 0. 3. 3. 3. 0. 3. 3.
 3. 0. 0. 1. 1. 1. 1. 0. 0.]"
NCT02512445,"20:40:chronic_disease,48:59:chronic_disease,76:98:chronic_disease,110:128:chronic_disease","Moderate or severe cognitive impairment, acute suicidality, current severe substance use disorder, unmanaged psychosis or mania","['Moderate' 'or' 'severe' 'cognitive' 'impairment' ',' 'acute'
 'suicidality' ',' 'current' 'severe' 'substance' 'use' 'disorder' ','
 'unmanaged' 'psychosis' 'or' 'mania']",[0. 0. 0. 2. 2. 0. 0. 2. 0. 0. 0. 2. 2. 2. 0. 0. 2. 2. 2.]
NCT02510456,"13:56:treatment,61:79:treatment,83:105:cancer,130:154:treatment",Planned for primary systemic (neoadjuvant) chemotherapy and surgical resection of residual primary tumor following completion of neoadjuvant chemotherapy,"['Planned' 'for' 'primary' 'systemic' '(' 'neoadjuvant' ')' 'chemotherapy'
 'and' 'surgical' 'resection' 'of' 'residual' 'primary' 'tumor'
 'following' 'completion' 'of' 'neoadjuvant' 'chemotherapy']",[0. 0. 1. 1. 1. 1. 1. 0. 0. 1. 1. 0. 3. 3. 3. 0. 0. 0. 0. 0.]
NCT02509546,"1:12:cancer,35:37:treatment,55:62:treatment",De novo AML who have not achieved CR after 2 lines of therapy,"['De' 'novo' 'AML' 'who' 'have' 'not' 'achieved' 'CR' 'after' '2' 'lines'
 'of' 'therapy']",[3. 3. 3. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1.]
NCT02509507,"9:12:cancer,56:79:chronic_disease,83:116:chronic_disease","For non-HCC, there must not be acute or chronic active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection","['For' 'non-HCC' ',' 'there' 'must' 'not' 'be' 'acute' 'or' 'chronic'
 'active' 'hepatitis' 'B' 'virus' '(' 'HBV' ')' 'or' 'hepatitis' 'C'
 'virus' '(' 'HCV' ')' 'infection']","[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02509507,"30:69:cancer,74:98:cancer,106:120:cancer,158:177:cancer,187:192:cancer,194:197:cancer,212:220:cancer","Subjects must either have no central nervous system (CNS) metastasis, or carcinomatous meningitis, or if CNS metastasis is present, must have stable treated cerebral metastases from BC, NSCLC, RCC, CRC, GEC, or melanoma","['Subjects' 'must' 'either' 'have' 'no' 'central' 'nervous' 'system' '('
 'CNS' ')' 'metastasis' ',' 'or' 'carcinomatous' 'meningitis' ',' 'or'
 'if' 'CNS' 'metastasis' 'is' 'present' ',' 'must' 'have' 'stable'
 'treated' 'cerebral' 'metastases' 'from' 'BC' ',' 'NSCLC' ',' 'RCC' ','
 'CRC' ',' 'GEC' ',' 'or' 'melanoma']","[0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 3. 3. 0. 0. 0. 3. 0. 3. 0. 0. 0. 0. 0. 0. 3.]"
NCT02509507,"16:30:treatment,113:123:cancer,128:148:treatment",expected other cancer therapy while on study with the exception of local radiation to the site of bone or other metastasis for palliative treatment,"['expected' 'other' 'cancer' 'therapy' 'while' 'on' 'study' 'with' 'the'
 'exception' 'of' 'local' 'radiation' 'to' 'the' 'site' 'of' 'bone' 'or'
 'other' 'metastasis' 'for' 'palliative' 'treatment']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 1. 1.]
NCT02508038,"1:4:treatment,9:24:chronic_disease,26:33:treatment",NAT for West Nile Virus (WNV-PCR),['NAT' 'for' 'West' 'Nile' 'Virus' '(' 'WNV-PCR' ')'],[1. 0. 2. 2. 2. 0. 1. 0.]
NCT02508038,"21:41:chronic_disease,55:61:cancer,69:78:treatment,",Significant serious intercurrent illness unrelated to cancer or its treatment not covered by other exclusion criteria expected to significantly increase the risk of HSCT,"['Significant' 'serious' 'intercurrent' 'illness' 'unrelated' 'to'
 'cancer' 'or' 'its' 'treatment' 'not' 'covered' 'by' 'other' 'exclusion'
 'criteria' 'expected' 'to' 'significantly' 'increase' 'the' 'risk' 'of'
 'HSCT']",[0. 0. 2. 2. 0. 0. 3. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02507232,"31:46:treatment,48:60:treatment,62:74:treatment,85:110:treatment,127:138:cancer","Disease that has not received prior radiation, radiosurgery, chemotherapy, or other investigational treatment directed at the brain tumor at any time. Previous surgical procedures","['Disease' 'that' 'has' 'not' 'received' 'prior' 'radiation' ','
 'radiosurgery' ',' 'chemotherapy' ',' 'or' 'other' 'investigational'
 'treatment' 'directed' 'at' 'the' 'brain' 'tumor' 'at' 'any' 'time' '.'
 'Previous' 'surgical' 'procedures']","[0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 0. 1. 1. 0. 0. 0. 3. 3. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02507232,"8:29:chronic_disease,8:15:chronic_disease,,,,93:116:chronic_disease","Severe cardiac insufficiency (NYHA III or IV), with uncontrolled and/or unstable cardiac or coronary artery disease","['Severe' 'cardiac' 'insufficiency' '(' 'NYHA' 'III' 'or' 'IV' ')' ','
 'with' 'uncontrolled' 'and/or' 'unstable' 'cardiac' 'or' 'coronary'
 'artery' 'disease']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02506192,"16:26:treatment,30:45:treatment,37:45:treatment,58:65:treatment",Chronic use of Prednisone or Corticosteroids (occasional inhaled use of steroids acceptable),"['Chronic' 'use' 'of' 'Prednisone' 'or' 'Corticosteroids' '(' 'occasional'
 'inhaled' 'use' 'of' 'steroids' 'acceptable' ')']",[0. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 1. 0. 0.]
NCT02506192,"1:15:chronic_disease,17:28:chronic_disease,,53:62:treatment",Kidney Disease (Hep B and C ok if after 6 months of treatment),"['Kidney' 'Disease' '(' 'Hep' 'B' 'and' 'C' 'ok' 'if' 'after' '6' 'months'
 'of' 'treatment' ')']",[2. 2. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02505035,"1:9:chronic_disease,53:95:treatment,,120:136:treatment,",Dementia admitted from a long-term care facility or prior placement of a surgical feeding tube or 2 or more additional hospitalizations in the past 12 months,"['Dementia' 'admitted' 'from' 'a' 'long-term' 'care' 'facility' 'or'
 'prior' 'placement' 'of' 'a' 'surgical' 'feeding' 'tube' 'or' '2' 'or'
 'more' 'additional' 'hospitalizations' 'in' 'the' 'past' '12' 'months']","[2. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 0. 0.]"
NCT02504489,"37:46:treatment,63:83:treatment,84:102:treatment,110:122:treatment,124:140:treatment,142:160:treatment,165:178:treatment,183:204:cancer,208:237:cancer","Disease progression during or after treatment with one or two treatment regimen(s) Treatment regimens can be chemotherapy, targeted therapy, biological therapy, or immunotherapy for advanced (Stage IIIB) or metastatic disease (Stage IV)","['Disease' 'progression' 'during' 'or' 'after' 'treatment' 'with' 'one'
 'or' 'two' 'treatment' 'regimen' '(' 's' ')' 'Treatment' 'regimens' 'can'
 'be' 'chemotherapy' ',' 'targeted' 'therapy' ',' 'biological' 'therapy'
 ',' 'or' 'immunotherapy' 'for' 'advanced' '(' 'Stage' 'IIIB' ')' 'or'
 'metastatic' 'disease' '(' 'Stage' 'IV' ')']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 0. 1. 1. 0.
 1. 1. 0. 0. 1. 0. 3. 3. 3. 0. 0. 0. 3. 3. 3. 3. 0. 0.]"
NCT02503722,"1:25:chronic_disease,58:74:treatment,123:129:chronic_disease,134:142:chronic_disease,144:177:chronic_disease","Gastrointestinal disease limiting the ability to swallow oral medications or absorb oral medications including refractory nausea and vomiting, chronic gastrointestinal diseases, inflammatory bowel disease","['Gastrointestinal' 'disease' 'limiting' 'the' 'ability' 'to' 'swallow'
 'oral' 'medications' 'or' 'absorb' 'oral' 'medications' 'including'
 'refractory' 'nausea' 'and' 'vomiting' ',' 'chronic' 'gastrointestinal'
 'diseases' ',' 'inflammatory' 'bowel' 'disease']","[2. 2. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 2. 2. 0. 0.
 0. 0.]"
NCT02503722,"20:44:treatment,53:55:treatment,59:72:treatment,84:92:treatment,96:132:treatment,,191:201:treatment","Patients receiving systemic corticosteroids (either IV or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within 1 week before administration of the first dose of study drug","['Patients' 'receiving' 'systemic' 'corticosteroids' '(' 'either' 'IV'
 'or' 'oral' 'steroids' ',' 'excluding' 'inhalers' 'or' 'low-dose'
 'hormone' 'replacement' 'therapy' ')' 'within' '1' 'week' 'before'
 'administration' 'of' 'the' 'first' 'dose' 'of' 'study' 'drug']","[0. 0. 1. 1. 0. 0. 1. 0. 1. 1. 0. 0. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1.]"
NCT02503722,"1:10:treatment,,61:78:treatment,61:70:treatment,138:146:chronic_disease",Radiation: A minimum of 14 days must have elapsed following radiation therapy and resolution of all radiation induced toxicity excluding alopecia,"['Radiation' ':' 'A' 'minimum' 'of' '14' 'days' 'must' 'have' 'elapsed'
 'following' 'radiation' 'therapy' 'and' 'resolution' 'of' 'all'
 'radiation' 'induced' 'toxicity' 'excluding' 'alopecia']",[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 2.]
NCT02503722,"34:43:treatment,45:54:treatment,58:66:treatment,75:102:treatment","have progression of disease with erlotinib, gefitinib or afatinib as last previous systemic treatment","['have' 'progression' 'of' 'disease' 'with' 'erlotinib' ',' 'gefitinib'
 'or' 'afatinib' 'as' 'last' 'previous' 'systemic' 'treatment']",[0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1. 1.]
NCT02503709,",,,,,112:137:treatment,166:183:chronic_disease,217:240:chronic_disease","Consistent corrected QT (QTc) > 450 msec for men and > 470 msec for women by Fridericia formula, on 3 separate electrocardiograms (ECGs); patients with a history of long QTc syndrome or personal or family history of ventricular arrhythmias will be excluded","['Consistent' 'corrected' 'QT' '(' 'QTc' ')' '>' '450' 'msec' 'for' 'men'
 'and' '>' '470' 'msec' 'for' 'women' 'by' 'Fridericia' 'formula' ',' 'on'
 '3' 'separate' 'electrocardiograms' '(' 'ECGs' ')' ';' 'patients' 'with'
 'a' 'history' 'of' 'long' 'QTc' 'syndrome' 'or' 'personal' 'or' 'family'
 'history' 'of' 'ventricular' 'arrhythmias' 'will' 'be' 'excluded']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0.]"
NCT02503709,"16:37:treatment,,,,,,,,,,,,786:836:treatment,895:929:treatment","The effects of onalespib and AT7519M on the developing human fetus are unknown; for this reason, women of childbearing potential and male patients with partners of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry, for the duration of study participation, and for 2 months after completion of study; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; women of childbearing potential enrolling on study must have a negative pregnancy test within 72 hours of enrollment in order to be eligible; because there is an unknown but potential risk to nursing infants secondary to treatment of the mother with onalespib and AT7519M, breastfeeding should be discontinued while the mother is treated with onalespib and AT7519M","['The' 'effects' 'of' 'onalespib' 'and' 'AT7519M' 'on' 'the' 'developing'
 'human' 'fetus' 'are' 'unknown' ';' 'for' 'this' 'reason' ',' 'women'
 'of' 'childbearing' 'potential' 'and' 'male' 'patients' 'with' 'partners'
 'of' 'childbearing' 'potential' 'must' 'agree' 'to' 'use' 'adequate'
 'contraception' '(' 'hormonal' 'or' 'barrier' 'method' 'of' 'birth'
 'control' 'or' 'abstinence' ')' 'prior' 'to' 'study' 'entry' ',' 'for'
 'the' 'duration' 'of' 'study' 'participation' ',' 'and' 'for' '2'
 'months' 'after' 'completion' 'of' 'study' ';' 'should' 'a' 'woman'
 'become' 'pregnant' 'or' 'suspect' 'she' 'is' 'pregnant' 'while' 'she'
 'or' 'her' 'partner' 'is' 'participating' 'in' 'this' 'study' ',' 'she'
 'should' 'inform' 'her' 'treating' 'physician' 'immediately' ';' 'women'
 'of' 'childbearing' 'potential' 'enrolling' 'on' 'study' 'must' 'have'
 'a' 'negative' 'pregnancy' 'test' 'within' '72' 'hours' 'of' 'enrollment'
 'in' 'order' 'to' 'be' 'eligible' ';' 'because' 'there' 'is' 'an'
 'unknown' 'but' 'potential' 'risk' 'to' 'nursing' 'infants' 'secondary'
 'to' 'treatment' 'of' 'the' 'mother' 'with' 'onalespib' 'and' 'AT7519M'
 ',' 'breastfeeding' 'should' 'be' 'discontinued' 'while' 'the' 'mother'
 'is' 'treated' 'with' 'onalespib' 'and' 'AT7519M']","[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1.]"
NCT02503358,"40:56:chronic_disease,100:116:chronic_disease,125:143:chronic_disease,147:163:treatment,201:212:chronic_disease,214:225:chronic_disease,230:263:chronic_disease","Any evidence of severe or uncontrolled systemic disease, including, but not limited to, ongoing or active infection, active bleeding diatheses or renal transplant, including any patient known to have hepatitis B, hepatitis C, or human immunodeficiency virus (HIV","['Any' 'evidence' 'of' 'severe' 'or' 'uncontrolled' 'systemic' 'disease'
 ',' 'including' ',' 'but' 'not' 'limited' 'to' ',' 'ongoing' 'or'
 'active' 'infection' ',' 'active' 'bleeding' 'diatheses' 'or' 'renal'
 'transplant' ',' 'including' 'any' 'patient' 'known' 'to' 'have'
 'hepatitis' 'B' ',' 'hepatitis' 'C' ',' 'or' 'human' 'immunodeficiency'
 'virus' '(' 'HIV']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2.
 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0.]"
NCT02503358,",,113:122:treatment,,,203:224:treatment,238:252:treatment","Males of child bearing potential must agree to practice effective barrier contraception during the entire study treatment period and through 6 months) after the last dose of study drug, (includes males surgically sterilized (i.e. status post vasectomy)","['Males' 'of' 'child' 'bearing' 'potential' 'must' 'agree' 'to' 'practice'
 'effective' 'barrier' 'contraception' 'during' 'the' 'entire' 'study'
 'treatment' 'period' 'and' 'through' '6' 'months' ')' 'after' 'the'
 'last' 'dose' 'of' 'study' 'drug' ',' '(' 'includes' 'males' 'surgically'
 'sterilized' '(' 'i.e' '.' 'status' 'post' 'vasectomy' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1. 0.]"
NCT02502708,"44:61:cancer,86:96:cancer,98:113:cancer,124:160:cancer","histologically proven initial diagnosis of high-grade glioma (WHO grade III and IV), ependymoma, medulloblastoma, or other primary central nervous system tumor","['histologically' 'proven' 'initial' 'diagnosis' 'of' 'high-grade'
 'glioma' '(' 'WHO' 'grade' 'III' 'and' 'IV' ')' ',' 'ependymoma' ','
 'medulloblastoma' ',' 'or' 'other' 'primary' 'central' 'nervous' 'system'
 'tumor']","[0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 0. 0. 0. 3. 3. 3.
 3. 3.]"
NCT02502006,"1:12:chronic_disease,14:22:chronic_disease,26:41:chronic_disease","coagulation, bleeding or blood disorders","['coagulation' ',' 'bleeding' 'or' 'blood' 'disorders']",[2. 0. 2. 0. 2. 2.]
NCT02501954,"1:8:treatment,30:42:treatment,47:77:treatment",Surgery must have included a hysterectomy and bilateral salpingooophorectomy,"['Surgery' 'must' 'have' 'included' 'a' 'hysterectomy' 'and' 'bilateral'
 'salpingooophorectomy']",[1. 0. 0. 0. 0. 1. 0. 1. 1.]
NCT02501473,"1:4:treatment,48:58:chronic_disease,62:70:chronic_disease",ECG without evidence of clinically significant arrhythmia or ischemia,"['ECG' 'without' 'evidence' 'of' 'clinically' 'significant' 'arrhythmia'
 'or' 'ischemia']",[1. 0. 0. 0. 0. 0. 2. 0. 2.]
NCT02501473,"12:17:cancer,42:64:treatment,85:94:treatment",Measurable tumor mass(es) accessible for intratumoral injection must be present for treatment and assessment of response,"['Measurable' 'tumor' 'mass' '(' 'es' ')' 'accessible' 'for'
 'intratumoral' 'injection' 'must' 'be' 'present' 'for' 'treatment' 'and'
 'assessment' 'of' 'response']",[0. 3. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02501473,"13:31:chronic_disease,65:76:chronic_disease,100:108:chronic_disease,110:118:chronic_disease,120:134:chronic_disease,264:271:treatment","Significant autoimmune disease, including active non-infectious pneumonitis, with the exception of alopecia, vitiligo, hypothyroidism or other conditions that have never been clinically active or were transient and have completely resolved and require no ongoing therapy","['Significant' 'autoimmune' 'disease' ',' 'including' 'active'
 'non-infectious' 'pneumonitis' ',' 'with' 'the' 'exception' 'of'
 'alopecia' ',' 'vitiligo' ',' 'hypothyroidism' 'or' 'other' 'conditions'
 'that' 'have' 'never' 'been' 'clinically' 'active' 'or' 'were'
 'transient' 'and' 'have' 'completely' 'resolved' 'and' 'require' 'no'
 'ongoing' 'therapy']","[0. 2. 2. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02501096,"9:35:cancer,81:210:treatment,234:245:treatment,276:297:treatment,307:316:treatment","For the renal cell carcinoma (RCC) cohort, participants must have progressed on treatment with an anti- programmed death receptor-1 /programmed death receptor-ligand 1 monoclonal antibody (anti-PD-1/PD-L1 mAb) administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies","['For' 'the' 'renal' 'cell' 'carcinoma' '(' 'RCC' ')' 'cohort' ','
 'participants' 'must' 'have' 'progressed' 'on' 'treatment' 'with' 'an'
 'anti-' 'programmed' 'death' 'receptor-1' '/programmed' 'death'
 'receptor-ligand' '1' 'monoclonal' 'antibody' '(' 'anti-PD-1/PD-L1' 'mAb'
 ')' 'administered' 'either' 'as' 'monotherapy' ',' 'or' 'in'
 'combination' 'with' 'other' 'checkpoint' 'inhibitors' 'or' 'other'
 'therapies']","[0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1.
 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1.]"
NCT02501096,"47:57:cancer,67:78:cancer,112:121:treatment,136:145:treatment",Histologically and/or cytologically confirmed metastatic selected solid tumor types that have progressed after treatment with approved therapies or for which there are no standard effective therapies available,"['Histologically' 'and/or' 'cytologically' 'confirmed' 'metastatic'
 'selected' 'solid' 'tumor' 'types' 'that' 'have' 'progressed' 'after'
 'treatment' 'with' 'approved' 'therapies' 'or' 'for' 'which' 'there'
 'are' 'no' 'standard' 'effective' 'therapies' 'available']","[0. 0. 0. 0. 3. 0. 3. 3. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02501096,"41:75:chronic_disease,77:88:chronic_disease,93:104:chronic_disease","Participant is known to be positive for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C","['Participant' 'is' 'known' 'to' 'be' 'positive' 'for' 'Human'
 'Immunodeficiency' 'Virus' '(' 'HIV' ')' ',' 'Hepatitis' 'B' ',' 'or'
 'Hepatitis' 'C']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT02501096,"9:25:cancer,27:32:cancer,36:71:cancer,76:108:cancer,112:118:cancer","treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the bladder or cervix","['treated' 'melanoma' 'in-situ' ',' 'basal' 'or' 'squamous' 'cell'
 'carcinoma' 'of' 'the' 'skin' ',' 'or' 'carcinoma' 'in-situ' 'of' 'the'
 'bladder' 'or' 'cervix']",[0. 3. 3. 0. 3. 0. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 3.]
NCT02500602,"25:35:treatment,37:51:treatment,56:84:treatment,","Subjects on maintenance anxiolytic, antidepressant, or mood stabilizing medications which have been initiated during the past four weeks","['Subjects' 'on' 'maintenance' 'anxiolytic' ',' 'antidepressant' ',' 'or'
 'mood' 'stabilizing' 'medications' 'which' 'have' 'been' 'initiated'
 'during' 'the' 'past' 'four' 'weeks']",[0. 0. 0. 1. 0. 1. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02500407,"1:43:treatment,,69:79:treatment,88:108:treatment,112:139:treatment","Autologous stem cell transplantation (SCT) within 100 days prior to study drug, or any prior allogeneic SCT or solid organ transplantation","['Autologous' 'stem' 'cell' 'transplantation' '(' 'SCT' ')' 'within' '100'
 'days' 'prior' 'to' 'study' 'drug' ',' 'or' 'any' 'prior' 'allogeneic'
 'SCT' 'or' 'solid' 'organ' 'transplantation']",[1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02500381,"21:30:treatment,46:68:treatment,81:92:treatment,",Current or previous treatment with any other experimental treatment (other than deflazacort) within 12 weeks prior to Week 1,"['Current' 'or' 'previous' 'treatment' 'with' 'any' 'other' 'experimental'
 'treatment' '(' 'other' 'than' 'deflazacort' ')' 'within' '12' 'weeks'
 'prior' 'to' 'Week' '1']",[0. 0. 0. 1. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02500147,"6:31:chronic_disease,39:56:chronic_disease,58:79:chronic_disease,81:95:chronic_disease,99:109:chronic_disease","With clinical hyperandrogenism and/or hyperandrogenemia, menstrual dysfunction (oligomenorrhea or amenorrhea)","['With' 'clinical' 'hyperandrogenism' 'and/or' 'hyperandrogenemia' ','
 'menstrual' 'dysfunction' '(' 'oligomenorrhea' 'or' 'amenorrhea' ')']",[0. 2. 2. 0. 2. 0. 2. 2. 0. 2. 0. 2. 0.]
NCT02498613,"3:27:treatment,29:40:treatment,,107:116:treatment,118:153:treatment","A major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib (percutaneous/endobronchial biopsies are allowed)","['A' 'major' 'surgical' 'procedure' ',' 'open' 'biopsy' ',' 'or'
 'significant' 'traumatic' 'injury' 'within' '28' 'days' 'prior' 'to'
 'starting' 'cediranib' '(' 'percutaneous/endobronchial' 'biopsies' 'are'
 'allowed' ')']","[0. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0.
 0.]"
NCT02498613,"28:39:treatment,96:111:treatment,113:121:treatment,123:134:treatment,136:158:treatment","Participants receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) are ineligible","['Participants' 'receiving' 'any' 'medications' 'or' 'substances' 'that'
 'are' 'strong' 'inhibitors' 'or' 'inducers' 'of' 'cytochrome' 'P450' ','
 'family' '3' ',' 'subfamily' 'A' ',' 'polypeptide' '4' '(' 'CYP3A4' ')'
 'are' 'ineligible']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 1. 1. 0. 1. 1.
 1. 0. 0. 0. 0.]"
NCT02498613,"23:35:treatment,39:41:treatment,,79:91:treatment,","Patients who have had chemotherapy or RT within 3 weeks prior to start of the study agents, or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier","['Patients' 'who' 'have' 'had' 'chemotherapy' 'or' 'RT' 'within' '3'
 'weeks' 'prior' 'to' 'start' 'of' 'the' 'study' 'agents' ',' 'or' 'those'
 'who' 'have' 'not' 'recovered' 'from' 'adverse' 'events' 'due' 'to'
 'agents' 'administered' 'more' 'than' '3' 'weeks' 'earlier']","[0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02498613,"46:62:treatment,,,119:136:treatment,140:171:treatment,180:188:treatment",The lesions have improved or remained stable radiographically and clinically for at least 6 weeks after completion of brain irradiation or stereotactic brain radiosurgery and off steroids for at least 6 weeks,"['The' 'lesions' 'have' 'improved' 'or' 'remained' 'stable'
 'radiographically' 'and' 'clinically' 'for' 'at' 'least' '6' 'weeks'
 'after' 'completion' 'of' 'brain' 'irradiation' 'or' 'stereotactic'
 'brain' 'radiosurgery' 'and' 'off' 'steroids' 'for' 'at' 'least' '6'
 'weeks']","[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 1.
 0. 0. 1. 0. 0. 0. 0. 0.]"
NCT02498613,"11:20:treatment,17:20:treatment,25:27:treatment,97:102:cancer,98:102:cancer,104:108:cancer","screening brain MRI (or CT if MRI contraindicated) will be required for patients with recurrent NSCLC, TNBC, or SCLC; brain MRI (or CT if MRI contraindicated) is required for PDAC if clinically suspected by patient's symptoms or neurological exam","['screening' 'brain' 'MRI' '(' 'or' 'CT' 'if' 'MRI' 'contraindicated' ')'
 'will' 'be' 'required' 'for' 'patients' 'with' 'recurrent' 'NSCLC' ','
 'TNBC' ',' 'or' 'SCLC' ';' 'brain' 'MRI' '(' 'or' 'CT' 'if' 'MRI'
 'contraindicated' ')' 'is' 'required' 'for' 'PDAC' 'if' 'clinically'
 'suspected' 'by' 'patient' ""'s"" 'symptoms' 'or' 'neurological' 'exam']","[0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 0. 0. 3. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02498535,"10:34:treatment,43:56:treatment,106:115:treatment,117:127:treatment,129:139:treatment,143:150:treatment","Use of a nitric oxide donor agent such as nitroglycerin or drugs known to increase methemoglobin such as lidocaine, prilocaine, benzocaine or dapsone at screening","['Use' 'of' 'a' 'nitric' 'oxide' 'donor' 'agent' 'such' 'as'
 'nitroglycerin' 'or' 'drugs' 'known' 'to' 'increase' 'methemoglobin'
 'such' 'as' 'lidocaine' ',' 'prilocaine' ',' 'benzocaine' 'or' 'dapsone'
 'at' 'screening']","[0. 0. 0. 1. 1. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0.
 1. 0. 0.]"
NCT02496663,"129:153:chronic_disease,155:179:chronic_disease,181:206:chronic_disease","Any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiography (ECG) (e.g., complete left bundle branch block, third degree heart block, second degree heart block)","['Any' 'clinically' 'important' 'abnormalities' 'in' 'rhythm' ','
 'conduction' 'or' 'morphology' 'of' 'resting' 'electrocardiography' '('
 'ECG' ')' '(' 'e.g.' ',' 'complete' 'left' 'bundle' 'branch' 'block' ','
 'third' 'degree' 'heart' 'block' ',' 'second' 'degree' 'heart' 'block'
 ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2.
 0. 2. 2. 2. 2. 0. 2. 2. 2. 2. 0.]"
NCT02496663,"35:47:treatment,,62:74:treatment,,105:116:treatment",Patients must have completed last chemotherapy >= 3 weeks or radiotherapy >= 2 weeks prior to receiving study drugs,"['Patients' 'must' 'have' 'completed' 'last' 'chemotherapy' '>' '=' '3'
 'weeks' 'or' 'radiotherapy' '>' '=' '2' 'weeks' 'prior' 'to' 'receiving'
 'study' 'drugs']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02496663,"4:13:treatment,49:57:treatment,,65:76:treatment,78:88:treatment,90:97:treatment,190:199:treatment,201:210:treatment,212:220:treatment,","be treatment naïve to 3rd generation and beyond EGFR-TKI (i.e., osimertinib, poziotinib, TAK-778) and EGFR monoclonal antibody; patient who received 1st or 2nd generation EGFR-TKI (such as erlotinib, gefitinib, afatinib) are eligible provided that they did not achieve a response to treatment or they did not have a duration of treatment on EGFR-TKI of 6 months or more","['be' 'treatment' 'naïve' 'to' '3rd' 'generation' 'and' 'beyond'
 'EGFR-TKI' '(' 'i.e.' ',' 'osimertinib' ',' 'poziotinib' ',' 'TAK-778'
 ')' 'and' 'EGFR' 'monoclonal' 'antibody' ';' 'patient' 'who' 'received'
 '1st' 'or' '2nd' 'generation' 'EGFR-TKI' '(' 'such' 'as' 'erlotinib' ','
 'gefitinib' ',' 'afatinib' ')' 'are' 'eligible' 'provided' 'that' 'they'
 'did' 'not' 'achieve' 'a' 'response' 'to' 'treatment' 'or' 'they' 'did'
 'not' 'have' 'a' 'duration' 'of' 'treatment' 'on' 'EGFR-TKI' 'of' '6'
 'months' 'or' 'more']","[0. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02496663,"66:73:treatment,75:86:treatment,88:95:treatment","have progression of disease on a 3rd generation EGFR-TKI such as AZD9291, rociletinib, HM61713","['have' 'progression' 'of' 'disease' 'on' 'a' '3rd' 'generation'
 'EGFR-TKI' 'such' 'as' 'AZD9291' ',' 'rociletinib' ',' 'HM61713']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1.]
NCT02496611,"1:8:chronic_disease,25:41:chronic_disease,43:62:chronic_disease",Obesity associated with genetic disorder (monogenetic obesity),"['Obesity' 'associated' 'with' 'genetic' 'disorder' '(' 'monogenetic'
 'obesity' ')']",[2. 0. 0. 2. 2. 0. 2. 2. 0.]
NCT02496585,"1:14:treatment,16:25:treatment,27:35:treatment,44:62:treatment","Pembrolizumab, Nivolumab, Afatinib and all hormonal therapies","['Pembrolizumab' ',' 'Nivolumab' ',' 'Afatinib' 'and' 'all' 'hormonal'
 'therapies']",[1. 0. 1. 0. 1. 0. 0. 1. 1.]
NCT02496208,",51:67:treatment,60:67:treatment,88:106:treatment,188:208:cancer,334:356:treatment",Patients must have either progressed on least one standard therapy or there must be no standard treatment that has been shown to prolong survival for the patient's disease (patients with urothelial carcinoma who are cisplatin-ineligible may receive protocol therapy as a first line therapy); patients may have received any number of prior cytotoxic agents,"['Patients' 'must' 'have' 'either' 'progressed' 'on' 'least' 'one'
 'standard' 'therapy' 'or' 'there' 'must' 'be' 'no' 'standard' 'treatment'
 'that' 'has' 'been' 'shown' 'to' 'prolong' 'survival' 'for' 'the'
 'patient' ""'s"" 'disease' '(' 'patients' 'with' 'urothelial' 'carcinoma'
 'who' 'are' 'cisplatin-ineligible' 'may' 'receive' 'protocol' 'therapy'
 'as' 'a' 'first' 'line' 'therapy' ')' ';' 'patients' 'may' 'have'
 'received' 'any' 'number' 'of' 'prior' 'cytotoxic' 'agents']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]"
NCT02496208,"9:26:chronic_disease,27:32:chronic_disease,,87:102:treatment",Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment,"['Serious' 'non-healing' 'wound/ulcer/bone' 'fracture' 'within' '28'
 'days' 'before' 'the' 'first' 'dose' 'of' 'study' 'treatment']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02496208,"29:34:cancer,77:86:cancer,88:95:cancer,97:117:cancer,119:125:cancer,129:133:cancer,155:167:cancer,171:190:cancer,,231:243:treatment","The subject has evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib","['The' 'subject' 'has' 'evidence' 'of' 'tumor' 'invading' 'the'
 'gastrointestinal' '(' 'GI' ')' 'tract' '(' 'esophagus' ',' 'stomach' ','
 'small' 'or' 'large' 'bowel' ',' 'rectum' 'or' 'anus' ')' ',' 'or' 'any'
 'evidence' 'of' 'endotracheal' 'or' 'endobronchial' 'tumor' 'within' '28'
 'days' 'before' 'the' 'first' 'dose' 'of' 'cabozantinib']","[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 0. 3. 3. 3. 3. 0. 3.
 0. 3. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02496208,"22:43:treatment,72:86:treatment,95:103:treatment,132:140:treatment,144:164:treatment,166:173:treatment,,194:211:treatment,,227:291:treatment","The subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, thrombin or factor Xa inhibitors; aspirin (up to 325 mg/day), low-dose warfarin (=< 1 mg/day), prophylactic and therapeutic low molecular weight heparin (LMWH)","['The' 'subject' 'requires' 'concomitant' 'treatment' ',' 'in'
 'therapeutic' 'doses' ',' 'with' 'anticoagulants' 'such' 'as' 'warfarin'
 'or' 'warfarin-related' 'agents' ',' 'thrombin' 'or' 'factor' 'Xa'
 'inhibitors' ';' 'aspirin' '(' 'up' 'to' '325' 'mg/day' ')' ','
 'low-dose' 'warfarin' '(' '=' '<' '1' 'mg/day' ')' ',' 'prophylactic'
 'and' 'therapeutic' 'low' 'molecular' 'weight' 'heparin' '(' 'LMWH' ')']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 0. 0. 0. 1. 0. 1. 1. 1.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1.
 1. 1. 0. 0.]"
NCT02495545,"8:18:cancer,,103:135:cancer,139:174:cancer,223:262:cancer,","Active malignancy or history of invasive malignancy within the last five years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitely treated. Patients with carcinoma in situ of the uterine cervix treated definitely more than 1 year prior to enrollment may enter the study","['Active' 'malignancy' 'or' 'history' 'of' 'invasive' 'malignancy'
 'within' 'the' 'last' 'five' 'years' ',' 'with' 'the' 'exception' 'of'
 'superficial' 'basal' 'cell' 'carcinoma' 'or' 'squamous' 'cell'
 'carcinoma' 'of' 'the' 'skin' 'that' 'has' 'been' 'definitely' 'treated'
 '.' 'Patients' 'with' 'carcinoma' 'in' 'situ' 'of' 'the' 'uterine'
 'cervix' 'treated' 'definitely' 'more' 'than' '1' 'year' 'prior' 'to'
 'enrollment' 'may' 'enter' 'the' 'study']","[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 3.
 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02495415,"41:62:treatment,51:55:treatment,78:94:treatment,119:131:cancer","For patients with persistent disease, a biopsy of bone marrow, or bone, or a soft tissue site, must have demonstrated viable tumor","['For' 'patients' 'with' 'persistent' 'disease' ',' 'a' 'biopsy' 'of'
 'bone' 'marrow' ',' 'or' 'bone' ',' 'or' 'a' 'soft' 'tissue' 'site' ','
 'must' 'have' 'demonstrated' 'viable' 'tumor']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0.
 3. 3.]"
NCT02495415,"72:90:treatment,92:105:treatment,110:128:treatment","patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study","['patients' 'must' 'have' 'fully' 'recovered' 'from' 'the' 'acute' 'toxic'
 'effects' 'of' 'all' 'prior' 'chemotherapy' ',' 'immunotherapy' ',' 'or'
 'radiotherapy' 'prior' 'to' 'entering' 'this' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02495168,"17:30:treatment,102:108:chronic_disease,129:151:treatment",Patients taking medication(s) (either daily or as needed) with the potential to affect the course of asthma or to interact with sympathomimetic amines,"['Patients' 'taking' 'medication' '(' 's' ')' '(' 'either' 'daily' 'or'
 'as' 'needed' ')' 'with' 'the' 'potential' 'to' 'affect' 'the' 'course'
 'of' 'asthma' 'or' 'to' 'interact' 'with' 'sympathomimetic' 'amines']","[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 2. 1. 1.
 1. 1. 1. 1.]"
NCT02495168,"24:42:treatment,44:47:treatment,52:57:treatment",Willing to discontinue asthma medications (ICS and LABAs) during the Run-in Period and for the remainder of the study,"['Willing' 'to' 'discontinue' 'asthma' 'medications' '(' 'ICS' 'and'
 'LABAs' ')' 'during' 'the' 'Run-in' 'Period' 'and' 'for' 'the'
 'remainder' 'of' 'the' 'study']",[0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02494869,"1:36:chronic_disease,109:118:chronic_disease,120:133:chronic_disease,135:149:chronic_disease","Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e. infection, renal failure, thyrotoxicosis)","['Acute' 'non-cardiopulmonary' 'disorders' 'that' 'may' 'affect'
 'exercise' 'performance' 'or' 'be' 'aggravated' 'by' 'exercise' '(' 'i.e'
 '.' 'infection' ',' 'renal' 'failure' ',' 'thyrotoxicosis' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 2. 0.]
NCT02494141,"59:62:treatment,80:94:chronic_disease,96:104:treatment","Inability to cooperate with/clinical contraindication for MRI including severe claustrophobia, implants, devices, or non-removable body piercings","['Inability' 'to' 'cooperate' 'with/clinical' 'contraindication' 'for'
 'MRI' 'including' 'severe' 'claustrophobia' ',' 'implants' ',' 'devices'
 ',' 'or' 'non-removable' 'body' 'piercings']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 2. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02493530,"22:45:treatment,38:45:treatment,57:103:treatment,,126:141:treatment,,191:202:treatment",Patient has received wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) ≤ 28 days or limited field radiation for palliation ≤ 14 days prior to starting trial medications or has not recovered from side effects of such therapy,"['Patient' 'has' 'received' 'wide' 'field' 'radiotherapy' '(' 'including'
 'therapeutic' 'radioisotopes' 'such' 'as' 'strontium' '89' ')' '≤' '28'
 'days' 'or' 'limited' 'field' 'radiation' 'for' 'palliation' '≤' '14'
 'days' 'prior' 'to' 'starting' 'trial' 'medications' 'or' 'has' 'not'
 'recovered' 'from' 'side' 'effects' 'of' 'such' 'therapy']","[0. 0. 0. 1. 1. 1. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02489591,"1:27:chronic_disease,29:37:chronic_disease,39:49:chronic_disease,51:70:chronic_disease,74:84:chronic_disease","Concurrent sleep disorders (insomnia, narcolepsy, central sleep apnea or parasomnia)","['Concurrent' 'sleep' 'disorders' '(' 'insomnia' ',' 'narcolepsy' ','
 'central' 'sleep' 'apnea' 'or' 'parasomnia' ')']",[2. 2. 2. 0. 2. 0. 2. 0. 2. 2. 2. 0. 2. 0.]
NCT02489045,"22:31:chronic_disease,33:53:chronic_disease,71:87:chronic_disease","Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli","['Patients' 'with' 'severe' 'emphysema' ',' 'pulmonary' 'vasculitis' ','
 'or' 'a' 'history' 'of' 'pulmonary' 'emboli']",[0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02488967,"26:36:treatment,106:120:cancer,125:156:cancer","For patients who undergo lumpectomy, the margins of the resected specimen must be histologically free of invasive tumor and ductal carcinoma in situ (DCIS) as determined by the local pathologist","['For' 'patients' 'who' 'undergo' 'lumpectomy' ',' 'the' 'margins' 'of'
 'the' 'resected' 'specimen' 'must' 'be' 'histologically' 'free' 'of'
 'invasive' 'tumor' 'and' 'ductal' 'carcinoma' 'in' 'situ' '(' 'DCIS' ')'
 'as' 'determined' 'by' 'the' 'local' 'pathologist']","[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 3. 3. 3. 3.
 3. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02488967,",,137:146:treatment,148:159:treatment,164:172:treatment,,242:260:cancer","Patients with alkaline phosphatase that is > ULN but =< 2.5 x ULN or unexplained bone pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan performed within 90 days prior to randomization does not demonstrate metastatic disease","['Patients' 'with' 'alkaline' 'phosphatase' 'that' 'is' '>' 'ULN' 'but'
 '=' '<' '2.5' 'x' 'ULN' 'or' 'unexplained' 'bone' 'pain' 'are' 'eligible'
 'for' 'inclusion' 'in' 'the' 'study' 'if' 'a' 'bone' 'scan' ',' 'PET-CT'
 'scan' ',' 'or' 'PET' 'scan' 'performed' 'within' '90' 'days' 'prior'
 'to' 'randomization' 'does' 'not' 'demonstrate' 'metastatic' 'disease']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]"
NCT02487095,"30:34:cancer,39:71:cancer,146:155:treatment","Histological confirmation of SCLC, or extrapulmonary small cell cancer. Although NCI confirmation of pathology is not required prior to starting treatment, every effort will be made to obtain outside pathology to be reviewed by an NCI pathologist","['Histological' 'confirmation' 'of' 'SCLC' ',' 'or' 'extrapulmonary'
 'small' 'cell' 'cancer' '.' 'Although' 'NCI' 'confirmation' 'of'
 'pathology' 'is' 'not' 'required' 'prior' 'to' 'starting' 'treatment' ','
 'every' 'effort' 'will' 'be' 'made' 'to' 'obtain' 'outside' 'pathology'
 'to' 'be' 'reviewed' 'by' 'an' 'NCI' 'pathologist']","[0. 0. 0. 3. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02487095,"40:44:cancer,46:51:cancer,53:67:cancer,69:84:cancer,90:112:cancer","Subjects with histologically confirmed SCLC, NSCLC, ovarian cancer, cervical cancer, and neuroendocrine cancers","['Subjects' 'with' 'histologically' 'confirmed' 'SCLC' ',' 'NSCLC' ','
 'ovarian' 'cancer' ',' 'cervical' 'cancer' ',' 'and' 'neuroendocrine'
 'cancers']",[0. 0. 0. 0. 3. 0. 3. 0. 3. 3. 0. 3. 3. 0. 0. 3. 3.]
NCT02485639,"38:42:allergy_name,38:41:allergy_name,51:66:allergy_name,107:120:allergy_name","known hypersensitivity or allergy to eggs, egg or chicken protein, report of allergy to components of the study vaccine or other components of the study vaccine","['known' 'hypersensitivity' 'or' 'allergy' 'to' 'eggs' ',' 'egg' 'or'
 'chicken' 'protein' ',' 'report' 'of' 'allergy' 'to' 'components' 'of'
 'the' 'study' 'vaccine' 'or' 'other' 'components' 'of' 'the' 'study'
 'vaccine']","[0. 0. 0. 0. 0. 4. 0. 4. 0. 4. 4. 0. 0. 0. 0. 0. 0. 0. 0. 4. 4. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02484404,"24:51:chronic_disease,35:51:chronic_disease,99:114:chronic_disease,118:143:chronic_disease","Clinically significant peripheral vascular disease or vascular disease, including rapidly growing aortic aneurysm or abdominal aortic aneurysm","['Clinically' 'significant' 'peripheral' 'vascular' 'disease' 'or'
 'vascular' 'disease' ',' 'including' 'rapidly' 'growing' 'aortic'
 'aneurysm' 'or' 'abdominal' 'aortic' 'aneurysm']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2.]
NCT02484404,"86:93:cancer,95:109:cancer,114:139:cancer","Patients must have histologically or cytologically confirmed persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer","['Patients' 'must' 'have' 'histologically' 'or' 'cytologically'
 'confirmed' 'persistent' 'or' 'recurrent' 'ovarian' ',' 'fallopian'
 'tube' ',' 'or' 'primary' 'peritoneal' 'cancer']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 0. 0. 3. 3. 3.]
NCT02484404,"38:53:cancer,57:82:treatment,87:113:cancer",Patients who have had progression of prostate cancer on prior docetaxel treatment for castrate sensitive disease are ineligible,"['Patients' 'who' 'have' 'had' 'progression' 'of' 'prostate' 'cancer' 'on'
 'prior' 'docetaxel' 'treatment' 'for' 'castrate' 'sensitive' 'disease'
 'are' 'ineligible']",[0. 0. 0. 0. 0. 0. 3. 3. 0. 1. 1. 1. 0. 3. 3. 3. 0. 0.]
NCT02484404,"7:25:chronic_disease,36:55:chronic_disease,60:74:chronic_disease,116:125:treatment,131:145:treatment","Prior cardiac arrhythmia including atrial fibrillation and atrial flutter, or requiring concurrent use of drugs or biologics with pro-arrhythmic potential","['Prior' 'cardiac' 'arrhythmia' 'including' 'atrial' 'fibrillation' 'and'
 'atrial' 'flutter' ',' 'or' 'requiring' 'concurrent' 'use' 'of' 'drugs'
 'or' 'biologics' 'with' 'pro-arrhythmic' 'potential']",[0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0.]
NCT02484300,"8:37:treatment,39:83:treatment,85:99:treatment,164:172:treatment,183:225:treatment,228:265:treatment,303:322:treatment,324:332:treatment,340:352:treatment","Use of serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, ACE inhibitors or any drugs which interfere with the renin-Angiotensin system, Losartan (or other Angiotensin II type 1 receptor antagonists), non-specific calcium channel blockers (L channel specific are acceptable), anti-inflammatories, vitamins or any antioxidants","['Use' 'of' 'serotonin' 'reuptake' 'inhibitors' ','
 'serotonin-norepinephrine' 'reuptake' 'inhibitors' ',' 'ACE' 'inhibitors'
 'or' 'any' 'drugs' 'which' 'interfere' 'with' 'the' 'renin-Angiotensin'
 'system' ',' 'Losartan' '(' 'or' 'other' 'Angiotensin' 'II' 'type' '1'
 'receptor' 'antagonists' ')' ',' 'non-specific' 'calcium' 'channel'
 'blockers' '(' 'L' 'channel' 'specific' 'are' 'acceptable' ')' ','
 'anti-inflammatories' ',' 'vitamins' 'or' 'any' 'antioxidants']","[0. 0. 1. 1. 1. 0. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 1. 0. 0. 1.]"
NCT02484248,"1:10:treatment,16:31:treatment,35:55:treatment,",treatment with corticosteroids or oral cromolyn sodium in the four weeks prior to enrollment,"['treatment' 'with' 'corticosteroids' 'or' 'oral' 'cromolyn' 'sodium' 'in'
 'the' 'four' 'weeks' 'prior' 'to' 'enrollment']",[1. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02482376,",14:20:treatment,41:65:cancer,69:101:cancer",Women with a biopsy proven diagnosis of ductal carcinoma in situ or invasive carcinoma of the breast,"['Women' 'with' 'a' 'biopsy' 'proven' 'diagnosis' 'of' 'ductal'
 'carcinoma' 'in' 'situ' 'or' 'invasive' 'carcinoma' 'of' 'the' 'breast']",[0. 0. 0. 1. 0. 0. 0. 3. 3. 3. 3. 0. 3. 3. 3. 3. 3.]
NCT02481310,"1:38:cancer,92:118:cancer,114:117:cancer,134:158:treatment","Diffuse large b-cell lymphoma (DLBCL) (including transformation from a previously indolent non-Hodgkin lymphoma [NHL], so long as no prior systemic treatment was given for the indolent NHL)","['Diffuse' 'large' 'b-cell' 'lymphoma' '(' 'DLBCL' ')' '(' 'including'
 'transformation' 'from' 'a' 'previously' 'indolent' 'non-Hodgkin'
 'lymphoma' '[' 'NHL' ']' ',' 'so' 'long' 'as' 'no' 'prior' 'systemic'
 'treatment' 'was' 'given' 'for' 'the' 'indolent' 'NHL' ')']","[3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0.
 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT02481245,"22:39:chronic_disease,22:38:chronic_disease,103:112:treatment",Primary diagnosis of anxiety disorders or patients where the anxiety disorder is the primary focus of treatment,"['Primary' 'diagnosis' 'of' 'anxiety' 'disorders' 'or' 'patients' 'where'
 'the' 'anxiety' 'disorder' 'is' 'the' 'primary' 'focus' 'of' 'treatment']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02480036,"14:29:chronic_disease,72:88:chronic_disease,102:126:chronic_disease,128:152:chronic_disease,154:172:chronic_disease,177:214:chronic_disease","Uncontrolled medical illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'medical' 'illness' 'including' ',' 'but' 'not' 'limited'
 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0.
 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02479698,"5:22:chronic_disease,12:21:chronic_disease,70:89:treatment,137:149:treatment",For fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment,"['For' 'fungal' 'infections' 'patients' 'must' 'be' 'receiving'
 'definitive' 'systemic' 'anti-fungal' 'therapy' 'and' 'have' 'no' 'signs'
 'of' 'progressing' 'infection' 'for' '1' 'week' 'prior' 'to' 'enrollment']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 2. 0. 1. 1. 1. 0. 0.]
NCT02479230,"31:38:chronic_disease,42:64:chronic_disease,158:168:treatment","Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study","['Other' 'severe' 'acute' 'or' 'chronic' 'medical' 'or' 'psychiatric'
 'conditions' ',' 'or' 'laboratory' 'abnormality' 'that' 'may' 'increase'
 'the' 'risk' 'associated' 'with' 'study' 'participation' 'or' 'study'
 'drug' 'administration' ',' 'or' 'may' 'interfere' 'with' 'the'
 'interpretation' 'of' 'study' 'results' ',' 'and' 'in' 'the' 'judgment'
 'of' 'the' 'investigator' 'would' 'make' 'the' 'patient' 'inappropriate'
 'for' 'entry' 'into' 'this' 'study']","[0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02477839,"13:21:chronic_disease,49:65:chronic_disease,93:118:chronic_disease,120:141:cancer,145:163:chronic_disease",Subject has epilepsy secondary to a progressing cerebral disease or any other progressively neurodegenerative disease (malignant brain tumor or Rasmussen Syndrome),"['Subject' 'has' 'epilepsy' 'secondary' 'to' 'a' 'progressing' 'cerebral'
 'disease' 'or' 'any' 'other' 'progressively' 'neurodegenerative'
 'disease' '(' 'malignant' 'brain' 'tumor' 'or' 'Rasmussen' 'Syndrome' ')']",[0. 0. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 2. 2. 0. 3. 3. 3. 0. 2. 2. 0.]
NCT02477826,"23:40:chronic_disease,44:61:chronic_disease,65:99:chronic_disease,111:137:chronic_disease",Any positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV) indicating acute or chronic infection,"['Any' 'positive' 'test' 'for' 'hepatitis' 'B' 'virus' 'or' 'hepatitis'
 'C' 'virus' 'or' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')'
 'indicating' 'acute' 'or' 'chronic' 'infection']",[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2.]
NCT02476786,"20:30:cancer,,71:90:treatment,100:106:cancer",A history of other malignancy ≤ 5 years previous which would preclude endocrine treatment of their cancer,"['A' 'history' 'of' 'other' 'malignancy' '≤' '5' 'years' 'previous'
 'which' 'would' 'preclude' 'endocrine' 'treatment' 'of' 'their' 'cancer']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 3.]
NCT02475707,"5:13:cancer,112:126:treatment,132:147:treatment",Any leukemia-specific marker (such as t(12;21); t(9;22) or t(4;11)) documented in the patient's leukemia cells pre-transplant on a post-transplant evaluation,"['Any' 'leukemia-specific' 'marker' '(' 'such' 'as' 't' '(' '12' ';' '21'
 ')' ';' 't' '(' '9' ';' '22' ')' 'or' 't' '(' '4' ';' '11' ')' ')'
 'documented' 'in' 'the' 'patient' ""'s"" 'leukemia' 'cells'
 'pre-transplant' 'on' 'a' 'post-transplant' 'evaluation']","[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0.]"
NCT02474667,"74:89:treatment,99:114:treatment,142:167:treatment",Has measurable donor-specific antibody or positive cross-match requiring desensitization prior to transplantation or deviation from standard immunosuppressive therapy,"['Has' 'measurable' 'donor-specific' 'antibody' 'or' 'positive'
 'cross-match' 'requiring' 'desensitization' 'prior' 'to'
 'transplantation' 'or' 'deviation' 'from' 'standard' 'immunosuppressive'
 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 0. 0. 0. 1. 1.]
NCT02474368,"1:4:chronic_disease,41:63:treatment,128:153:treatment,155:159:treatment,164:190:treatment","HIV-positive individuals on combination antiretroviral therapy are ineligible because of the potential for interaction between conventional radiotherapy, SBRT and antiretroviral medications","['HIV-positive' 'individuals' 'on' 'combination' 'antiretroviral'
 'therapy' 'are' 'ineligible' 'because' 'of' 'the' 'potential' 'for'
 'interaction' 'between' 'conventional' 'radiotherapy' ',' 'SBRT' 'and'
 'antiretroviral' 'medications']",[2. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0.]
NCT02474199,"1:28:treatment,,,82:90:treatment,,116:124:treatment",Mycophenolate mofetil (MMF): maximum dose of 500 mg administered twice daily for Cellcept or 360mg twice daily for Myfortic,"['Mycophenolate' 'mofetil' '(' 'MMF' ')' ':' 'maximum' 'dose' 'of' '500'
 'mg' 'administered' 'twice' 'daily' 'for' 'Cellcept' 'or' '360mg' 'twice'
 'daily' 'for' 'Myfortic']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1.]
NCT02474173,"15:30:treatment,35:59:cancer,46:59:cancer,161:177:treatment",Any number of prior therapies for metastatic breast cancer is allowed; patients with weakly estrogen receptor positive breast cancer who received any number of endocrine agents for metastatic breast cancer,"['Any' 'number' 'of' 'prior' 'therapies' 'for' 'metastatic' 'breast'
 'cancer' 'is' 'allowed' ';' 'patients' 'with' 'weakly' 'estrogen'
 'receptor' 'positive' 'breast' 'cancer' 'who' 'received' 'any' 'number'
 'of' 'endocrine' 'agents' 'for' 'metastatic' 'breast' 'cancer']","[0. 0. 0. 1. 1. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 0. 0. 0. 0.]"
NCT02474173,"16:23:treatment,95:105:treatment,,,,,312:327:treatment,,,,,,,,","The effects of AT13387 on the developing human fetus are unknown; for this reason and because paclitaxel are known to be teratogenic; women of child-bearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation and 3 months after completion of study treatment administration; adequate contraception includes methods such as oral contraceptives, double barrier method (condom plus spermicide or diaphragm), or abstaining from sexual intercourse; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately","['The' 'effects' 'of' 'AT13387' 'on' 'the' 'developing' 'human' 'fetus'
 'are' 'unknown' ';' 'for' 'this' 'reason' 'and' 'because' 'paclitaxel'
 'are' 'known' 'to' 'be' 'teratogenic' ';' 'women' 'of' 'child-bearing'
 'potential' 'and' 'men' 'must' 'agree' 'to' 'use' 'adequate'
 'contraception' 'prior' 'to' 'study' 'entry' ',' 'for' 'the' 'duration'
 'of' 'study' 'participation' 'and' '3' 'months' 'after' 'completion' 'of'
 'study' 'treatment' 'administration' ';' 'adequate' 'contraception'
 'includes' 'methods' 'such' 'as' 'oral' 'contraceptives' ',' 'double'
 'barrier' 'method' '(' 'condom' 'plus' 'spermicide' 'or' 'diaphragm' ')'
 ',' 'or' 'abstaining' 'from' 'sexual' 'intercourse' ';' 'should' 'a'
 'woman' 'become' 'pregnant' 'or' 'suspect' 'she' 'is' 'pregnant' 'while'
 'she' 'or' 'her' 'partner' 'is' 'participating' 'in' 'this' 'study' ','
 'she' 'should' 'inform' 'her' 'treating' 'physician' 'immediately']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02473250,"10:18:chronic_disease,132:142:treatment,146:155:treatment","Actively suicidal, as defined by expressing ideation with a plan for suicide or develops suicidal ideation that requires immediate medication or treatment intervention","['Actively' 'suicidal' ',' 'as' 'defined' 'by' 'expressing' 'ideation'
 'with' 'a' 'plan' 'for' 'suicide' 'or' 'develops' 'suicidal' 'ideation'
 'that' 'requires' 'immediate' 'medication' 'or' 'treatment'
 'intervention']",[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0.]
NCT02473250,"26:36:treatment,41:51:treatment,92:108:treatment,,143:152:treatment,","Previous failed trial of fluoxetine and citalopram by themselves or in combination with an anti-manic agent, defined as at least six weeks of treatment at the dose of 20 mg per day or more","['Previous' 'failed' 'trial' 'of' 'fluoxetine' 'and' 'citalopram' 'by'
 'themselves' 'or' 'in' 'combination' 'with' 'an' 'anti-manic' 'agent' ','
 'defined' 'as' 'at' 'least' 'six' 'weeks' 'of' 'treatment' 'at' 'the'
 'dose' 'of' '20' 'mg' 'per' 'day' 'or' 'more']","[0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02471911,"29:41:cancer,54:70:cancer,,121:131:cancer,133:168:cancer,173:204:cancer,208:214:cancer","Patients who have had prior malignancies (other than B-cell lymphomas) for ≤5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast","['Patients' 'who' 'have' 'had' 'prior' 'malignancies' '(' 'other' 'than'
 'B-cell' 'lymphomas' ')' 'for' '≤5' 'years' 'with' 'exception' 'of'
 'currently' 'treated' 'basal' 'cell' ',' 'squamous' 'cell' 'carcinoma'
 'of' 'the' 'skin' ',' 'or' 'carcinoma' 'in' 'situ' 'of' 'the' 'cervix'
 'or' 'breast']","[0. 0. 0. 0. 0. 3. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 3.
 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 3.]"
NCT02471430,"15:24:chronic_disease,26:32:chronic_disease,34:39:chronic_disease,43:62:chronic_disease,73:104:treatment","Presence of a bacterial, fungal, viral or protozoal infection requiring systemic anti-infective therapy","['Presence' 'of' 'a' 'bacterial' ',' 'fungal' ',' 'viral' 'or' 'protozoal'
 'infection' 'requiring' 'systemic' 'anti-infective' 'therapy']",[0. 0. 0. 2. 0. 2. 0. 2. 0. 2. 2. 0. 1. 1. 1.]
NCT02470897,"18:25:treatment,27:40:treatment,45:56:treatment,61:76:cancer",Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer,"['Previous' 'radical' 'surgery' '(' 'prostatectomy' ')' 'or' 'cryosurgery'
 'for' 'prostate' 'cancer']",[0. 0. 1. 0. 1. 0. 0. 1. 0. 3. 3.]
NCT02469857,"31:43:treatment,47:77:treatment,87:118:treatment,123:129:cancer,134:155:cancer",Receiving or about to receive chemotherapy or biologic anti-cancer treatment although hormonal manipulation therapies for breast and prostate malignancies are permitted,"['Receiving' 'or' 'about' 'to' 'receive' 'chemotherapy' 'or' 'biologic'
 'anti-cancer' 'treatment' 'although' 'hormonal' 'manipulation'
 'therapies' 'for' 'breast' 'and' 'prostate' 'malignancies' 'are'
 'permitted']",[0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 0. 1. 1. 1. 0. 3. 0. 3. 3. 0. 0.]
NCT02469129,"15:21:treatment,42:84:cancer,70:76:cancer,116:127:cancer,181:208:treatment,212:230:treatment,269:276:cancer,278:285:cancer,291:309:cancer","Patients with biopsy-proven diagnosis of head and neck squamous cell cancer (HNSCC) or any histopathologic type of lung cancer or any other type of cancer that can be treated with platinum-based chemotherapy as first-line therapy (which includes but is not limited to ovarian, gastric, and pancreatic cancers)","['Patients' 'with' 'biopsy-proven' 'diagnosis' 'of' 'head' 'and' 'neck'
 'squamous' 'cell' 'cancer' '(' 'HNSCC' ')' 'or' 'any' 'histopathologic'
 'type' 'of' 'lung' 'cancer' 'or' 'any' 'other' 'type' 'of' 'cancer'
 'that' 'can' 'be' 'treated' 'with' 'platinum-based' 'chemotherapy' 'as'
 'first-line' 'therapy' '(' 'which' 'includes' 'but' 'is' 'not' 'limited'
 'to' 'ovarian' ',' 'gastric' ',' 'and' 'pancreatic' 'cancers' ')']","[0. 0. 1. 0. 0. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3.
 0. 0. 3. 3. 0.]"
NCT02468778,"8:35:chronic_disease,68:85:treatment,130:152:treatment","Severe peripheral vascular disease that will preclude the use of a 14F access sheath, which is required for the insertion of the HeartMate PHP catheter","['Severe' 'peripheral' 'vascular' 'disease' 'that' 'will' 'preclude' 'the'
 'use' 'of' 'a' '14F' 'access' 'sheath' ',' 'which' 'is' 'required' 'for'
 'the' 'insertion' 'of' 'the' 'HeartMate' 'PHP' 'catheter']","[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 1.]"
NCT02468453,"34:43:treatment,55:61:cancer,86:97:cancer,156:173:chronic_disease,187:231:cancer","Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including actinic keratosis, presence of malignant or pre-malignant pigmented lesions","['Having' 'or' 'undergoing' 'any' 'form' 'of' 'treatment' 'for' 'active'
 'cancer' ',' 'or' 'having' 'a' 'history' 'of' 'skin' 'cancer' 'or' 'any'
 'other' 'cancer' 'in' 'the' 'areas' 'to' 'be' 'treated' ',' 'including'
 'actinic' 'keratosis' ',' 'presence' 'of' 'malignant' 'or'
 'pre-malignant' 'pigmented' 'lesions']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 3. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 3. 3. 3. 3. 3.]"
NCT02468453,"21:58:chronic_disease,60:76:chronic_disease,78:89:chronic_disease,99:117:chronic_disease,124:144:chronic_disease,146:151:chronic_disease","Subject has a known collagen (connective tissue) disorder, vascular disease, scleroderma or other autoimmune disease (i.e. rheumatoid arthritis, lupus)","['Subject' 'has' 'a' 'known' 'collagen' '(' 'connective' 'tissue' ')'
 'disorder' ',' 'vascular' 'disease' ',' 'scleroderma' 'or' 'other'
 'autoimmune' 'disease' '(' 'i.e' '.' 'rheumatoid' 'arthritis' ',' 'lupus'
 ')']","[0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 2. 2.
 0. 2. 0.]"
NCT02468453,"31:40:treatment,42:54:treatment,58:102:treatment,,122:131:treatment","Subject has systemically used retinoids, antioxidants or medical grade of skin nourishing supplements within 2 months of treatment or during the study","['Subject' 'has' 'systemically' 'used' 'retinoids' ',' 'antioxidants' 'or'
 'medical' 'grade' 'of' 'skin' 'nourishing' 'supplements' 'within' '2'
 'months' 'of' 'treatment' 'or' 'during' 'the' 'study']",[0. 0. 0. 0. 1. 0. 1. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02468453,"75:92:chronic_disease,94:117:chronic_disease,132:154:chronic_disease","Subject is suffering from significant concurrent illness, such as such as cardiac disorders, diabetes (type I or II), or pertinent neurological disorders","['Subject' 'is' 'suffering' 'from' 'significant' 'concurrent' 'illness'
 ',' 'such' 'as' 'such' 'as' 'cardiac' 'disorders' ',' 'diabetes' '('
 'type' 'I' 'or' 'II' ')' ',' 'or' 'pertinent' 'neurological' 'disorders']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0.
 0. 2. 2.]"
NCT02467478,"10:24:chronic_disease,28:43:chronic_disease,,131:164:chronic_disease",Previous cardiovascular or cerebrovascular event within 6 months of screening or active or clinically significant coronary and/or Peripheral Vascular Disease (PVD),"['Previous' 'cardiovascular' 'or' 'cerebrovascular' 'event' 'within' '6'
 'months' 'of' 'screening' 'or' 'active' 'or' 'clinically' 'significant'
 'coronary' 'and/or' 'Peripheral' 'Vascular' 'Disease' '(' 'PVD' ')']",[0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02466971,"30:51:treatment,60:69:treatment,73:79:cancer",Patient is receiving another investigational agent for the treatment of cancer,"['Patient' 'is' 'receiving' 'another' 'investigational' 'agent' 'for'
 'the' 'treatment' 'of' 'cancer']",[0. 0. 0. 0. 1. 1. 0. 0. 1. 0. 3.]
NCT02466750,"32:39:treatment,43:66:treatment,,85:100:treatment",Have administration of another vaccine or investigational product within 28 days of WEE vaccination,"['Have' 'administration' 'of' 'another' 'vaccine' 'or' 'investigational'
 'product' 'within' '28' 'days' 'of' 'WEE' 'vaccination']",[0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 1. 1.]
NCT02466685,"25:47:treatment,55:62:treatment,64:73:treatment,78:86:treatment,","Individuals receiving a single mood stabilizer (e.g., lithium. valproate, or lamictal) are allowed if a stable dose has been maintained for at least 2 months prior to screening","['Individuals' 'receiving' 'a' 'single' 'mood' 'stabilizer' '(' 'e.g.' ','
 'lithium' '.' 'valproate' ',' 'or' 'lamictal' ')' 'are' 'allowed' 'if'
 'a' 'stable' 'dose' 'has' 'been' 'maintained' 'for' 'at' 'least' '2'
 'months' 'prior' 'to' 'screening']","[0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02466009,"1:17:chronic_disease,21:28:chronic_disease,65:80:chronic_disease","Pleural effusion or ascites that causes respiratory compromise, grade 2 dyspnea","['Pleural' 'effusion' 'or' 'ascites' 'that' 'causes' 'respiratory'
 'compromise' ',' 'grade' '2' 'dyspnea']",[2. 2. 0. 2. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT02465541,"23:83:cancer,85:99:cancer,121:142:treatment,147:156:treatment","Previous diagnosis of grade 1 or 2, stage I or II endometrioid endometrial cancers (type I cancers) as confirmed during surgical intervention for treatment","['Previous' 'diagnosis' 'of' 'grade' '1' 'or' '2' ',' 'stage' 'I' 'or'
 'II' 'endometrioid' 'endometrial' 'cancers' '(' 'type' 'I' 'cancers' ')'
 'as' 'confirmed' 'during' 'surgical' 'intervention' 'for' 'treatment']","[0. 0. 0. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 3. 3. 3. 0. 0. 0. 0. 1.
 1. 0. 1.]"
NCT02465268,"21:50:treatment,54:59:cancer,,170:173:treatment",Must have undergone definitive surgical resection of tumor with less than approximately 3cm x 3cm residual enhancing tumor as product of longest perpendicular planes by MRI,"['Must' 'have' 'undergone' 'definitive' 'surgical' 'resection' 'of'
 'tumor' 'with' 'less' 'than' 'approximately' '3cm' 'x' '3cm' 'residual'
 'enhancing' 'tumor' 'as' 'product' 'of' 'longest' 'perpendicular'
 'planes' 'by' 'MRI']","[0. 0. 0. 1. 1. 1. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1.]"
NCT02465060,"92:105:chronic_disease,118:134:chronic_disease,174:198:chronic_disease","No factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death","['No' 'factors' 'that' 'increase' 'the' 'risk' 'of' 'QTc' 'prolongation'
 'or' 'risk' 'of' 'arrhythmic' 'events' 'such' 'as' 'heart' 'failure' ','
 'congenital' 'long' 'QT' 'syndrome' ',' 'family' 'history' 'of' 'long'
 'QT' 'syndrome' 'or' 'unexplained' 'sudden' 'death']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0.
 0. 0. 0. 0. 0. 0. 0. 2. 2. 2.]"
NCT02465060,"27:40:treatment,,86:94:chronic_disease,99:110:chronic_disease,124:133:treatment",all adverse events due to prior therapy have resolved to a grade 1 or better (except alopecia and lymphopenia) by start of treatment,"['all' 'adverse' 'events' 'due' 'to' 'prior' 'therapy' 'have' 'resolved'
 'to' 'a' 'grade' '1' 'or' 'better' '(' 'except' 'alopecia' 'and'
 'lymphopenia' ')' 'by' 'start' 'of' 'treatment']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 0. 0.
 1.]"
NCT02464878,"3:20:treatment,34:49:chronic_disease,,,91:110:chronic_disease",A kidney transplant patient with type 1 diabetes who has an HbA1c < 7.5 and no history of severe hypoglycemia,"['A' 'kidney' 'transplant' 'patient' 'with' 'type' '1' 'diabetes' 'who'
 'has' 'an' 'HbA1c' '<' '7.5' 'and' 'no' 'history' 'of' 'severe'
 'hypoglycemia']",[0. 1. 1. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02464878,"24:40:chronic_disease,51:62:chronic_disease,64:75:chronic_disease,77:80:chronic_disease,85:102:chronic_disease","Presence or history of active infection including hepatitis B, hepatitis C, HIV, or tuberculosis (TB)","['Presence' 'or' 'history' 'of' 'active' 'infection' 'including'
 'hepatitis' 'B' ',' 'hepatitis' 'C' ',' 'HIV' ',' 'or' 'tuberculosis' '('
 'TB' ')']",[0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 2. 0. 0. 2. 2. 0. 0.]
NCT02464696,"1:17:treatment,21:28:treatment,,85:92:cancer,96:130:cancer,134:147:cancer,174:199:chronic_disease",Chest radiograph or CT scan within </= 3 months prior to study enrollment rules out primary or metastatic malignancy in the lungs or pleural space as a significant cause of respiratory insufficiency,"['Chest' 'radiograph' 'or' 'CT' 'scan' 'within' '<' '/=' '3' 'months'
 'prior' 'to' 'study' 'enrollment' 'rules' 'out' 'primary' 'or'
 'metastatic' 'malignancy' 'in' 'the' 'lungs' 'or' 'pleural' 'space' 'as'
 'a' 'significant' 'cause' 'of' 'respiratory' 'insufficiency']","[1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 3. 3. 3. 0.
 3. 3. 0. 0. 0. 0. 0. 2. 2.]"
NCT02464436,"1:17:treatment,38:52:treatment,,236:245:treatment",Cataract surgery in the study eye or ocular surgery in either eye (which in the opinion of the investigator may have an impact on patient safety or the integrity of data from the study eye) during the study or within 3 months prior to treatment,"['Cataract' 'surgery' 'in' 'the' 'study' 'eye' 'or' 'ocular' 'surgery'
 'in' 'either' 'eye' '(' 'which' 'in' 'the' 'opinion' 'of' 'the'
 'investigator' 'may' 'have' 'an' 'impact' 'on' 'patient' 'safety' 'or'
 'the' 'integrity' 'of' 'data' 'from' 'the' 'study' 'eye' ')' 'during'
 'the' 'study' 'or' 'within' '3' 'months' 'prior' 'to' 'treatment']","[1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02464436,"15:25:cancer,34:58:cancer,60:84:cancer,89:103:cancer","No history of malignancy, except non-melanoma skin cancer; pre-malignant conditions and cancer in situ","['No' 'history' 'of' 'malignancy' ',' 'except' 'non-melanoma' 'skin'
 'cancer' ';' 'pre-malignant' 'conditions' 'and' 'cancer' 'in' 'situ']",[0. 0. 0. 3. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0.]
NCT02463305,"34:39:chronic_disease,41:48:chronic_disease,50:57:chronic_disease,59:68:chronic_disease,72:82:cancer,128:156:treatment,160:181:treatment","Concomitant major comorbidities (renal, hepatic, cardiac, pulmonary or malignancy) to include any medical conditions requiring therapeutic anti-coagulation or anti-platelet therapy","['Concomitant' 'major' 'comorbidities' '(' 'renal' ',' 'hepatic' ','
 'cardiac' ',' 'pulmonary' 'or' 'malignancy' ')' 'to' 'include' 'any'
 'medical' 'conditions' 'requiring' 'therapeutic' 'anti-coagulation' 'or'
 'anti-platelet' 'therapy']","[0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 2. 0. 3. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1.
 1.]"
NCT02462590,"22:44:chronic_disease,68:91:chronic_disease,93:117:chronic_disease,139:163:chronic_disease,176:209:chronic_disease,215:259:treatment,261:304:treatment,327:339:chronic_disease,351:371:treatment,379:398:treatment,406:428:treatment,501:527:treatment,529:553:treatment,556:605:treatment,607:617:treatment,621:635:treatment,651:685:treatment,687:720:treatment,724:771:treatment,807:829:treatment,831:867:treatment,871:890:treatment,923:944:treatment,948:969:treatment","Patients at risk for endovascular infection (previously documented rheumatic heart disease, congenital valve disease, surgically repaired congenital heart disease, unrepaired cyanotic congenital heart disease, any intracardiac repair with prosthetic material [mechanical or bio-prosthetic cardiac valves], previous or current endocarditis, permanent endovascular devices (e.g., endovascular grafts [e.g., aortic aneurysm repair, stents involving large arteries such as aorta, femorals and carotids], inferior vena cava filters, dialysis vascular grafts), tunnelled (not short-term) hemodialysis catheters, pacemakers or defibrillators. Patients with temporary central venous catheters, central venous dialysis catheters or peripherally inserted central catheters (PICCs) are not excluded and patients with coronary artery stents, coronary artery bypass grafts (CABG) or neurovascular coils are not excluded; patients with mitral valve prolapse or bicuspid aortic valve","['Patients' 'at' 'risk' 'for' 'endovascular' 'infection' '(' 'previously'
 'documented' 'rheumatic' 'heart' 'disease' ',' 'congenital' 'valve'
 'disease' ',' 'surgically' 'repaired' 'congenital' 'heart' 'disease' ','
 'unrepaired' 'cyanotic' 'congenital' 'heart' 'disease' ',' 'any'
 'intracardiac' 'repair' 'with' 'prosthetic' 'material' '[' 'mechanical'
 'or' 'bio-prosthetic' 'cardiac' 'valves' ']' ',' 'previous' 'or'
 'current' 'endocarditis' ',' 'permanent' 'endovascular' 'devices' '('
 'e.g.' ',' 'endovascular' 'grafts' '[' 'e.g.' ',' 'aortic' 'aneurysm'
 'repair' ',' 'stents' 'involving' 'large' 'arteries' 'such' 'as' 'aorta'
 ',' 'femorals' 'and' 'carotids' ']' ',' 'inferior' 'vena' 'cava'
 'filters' ',' 'dialysis' 'vascular' 'grafts' ')' ',' 'tunnelled' '('
 'not' 'short-term' ')' 'hemodialysis' 'catheters' ',' 'pacemakers' 'or'
 'defibrillators' '.' 'Patients' 'with' 'temporary' 'central' 'venous'
 'catheters' ',' 'central' 'venous' 'dialysis' 'catheters' 'or'
 'peripherally' 'inserted' 'central' 'catheters' '(' 'PICCs' ')' 'are'
 'not' 'excluded' 'and' 'patients' 'with' 'coronary' 'artery' 'stents' ','
 'coronary' 'artery' 'bypass' 'grafts' '(' 'CABG' ')' 'or' 'neurovascular'
 'coils' 'are' 'not' 'excluded' ';' 'patients' 'with' 'mitral' 'valve'
 'prolapse' 'or' 'bicuspid' 'aortic' 'valve']","[0. 0. 0. 0. 1. 1. 0. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 2. 2. 2. 0. 0. 1. 1. 1. 1. 1. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 2. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1. 1. 1. 0. 1. 1. 1. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 0.
 1. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1.
 1. 1. 0. 1. 1. 1.]"
NCT02461927,"42:50:allergy_name,52:61:allergy_name,63:73:allergy_name,78:87:allergy_name","Unstable medical condition or allergy to ketamine, midazolam, naltrexone, or lorazepam---clinically determined by a physician","['Unstable' 'medical' 'condition' 'or' 'allergy' 'to' 'ketamine' ','
 'midazolam' ',' 'naltrexone' ',' 'or' 'lorazepam' '--' '-clinically'
 'determined' 'by' 'a' 'physician']",[0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 4. 0. 0. 4. 0. 0. 0. 0. 0. 0.]
NCT02460783,"22:24:treatment,34:42:treatment,44:56:treatment","Contraindications to LP, such as Coumadin, coagulopathy","['Contraindications' 'to' 'LP' ',' 'such' 'as' 'Coumadin' ','
 'coagulopathy']",[0. 0. 1. 0. 0. 0. 1. 0. 1.]
NCT02459769,"16:31:treatment,33:45:treatment,54:63:treatment","have completed primary surgery, chemotherapy, and/or radiation","['have' 'completed' 'primary' 'surgery' ',' 'chemotherapy' ',' 'and/or'
 'radiation']",[0. 0. 1. 1. 0. 1. 0. 0. 1.]
NCT02459119,"1:24:treatment,117:129:treatment,,293:312:chronic_disease","Prior radiation therapy is allowed as long as the irradiated area was not the sole source of measurable disease and radiotherapy was completed with recovery from toxicity, at least three weeks prior to enrollment. If the irradiated area is the only site of disease, there must be evidence of progressive disease","['Prior' 'radiation' 'therapy' 'is' 'allowed' 'as' 'long' 'as' 'the'
 'irradiated' 'area' 'was' 'not' 'the' 'sole' 'source' 'of' 'measurable'
 'disease' 'and' 'radiotherapy' 'was' 'completed' 'with' 'recovery' 'from'
 'toxicity' ',' 'at' 'least' 'three' 'weeks' 'prior' 'to' 'enrollment' '.'
 'If' 'the' 'irradiated' 'area' 'is' 'the' 'only' 'site' 'of' 'disease'
 ',' 'there' 'must' 'be' 'evidence' 'of' 'progressive' 'disease']","[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 2. 2.]"
NCT02459119,"103:110:treatment,127:149:treatment,168:173:treatment,177:190:treatment",Wounds must be completely healed prior to study entry and patients recovered from all toxicities from surgery. Placement of a vascular access device is not considered major or minor surgery in this regard,"['Wounds' 'must' 'be' 'completely' 'healed' 'prior' 'to' 'study' 'entry'
 'and' 'patients' 'recovered' 'from' 'all' 'toxicities' 'from' 'surgery'
 '.' 'Placement' 'of' 'a' 'vascular' 'access' 'device' 'is' 'not'
 'considered' 'major' 'or' 'minor' 'surgery' 'in' 'this' 'regard']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 1. 1.
 0. 0. 0. 1. 0. 1. 1. 0. 0. 0.]"
NCT02458482,"42:62:chronic_disease,70:79:chronic_disease,81:96:chronic_disease,98:109:allergy_name","other medical conditions contributing to respiratory distress (e.g., pneumonia, cystic fibrosis, anaphylaxis)","['other' 'medical' 'conditions' 'contributing' 'to' 'respiratory'
 'distress' '(' 'e.g.' ',' 'pneumonia' ',' 'cystic' 'fibrosis' ','
 'anaphylaxis' ')']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 0. 2. 2. 0. 4. 0.]
NCT02457845,",,96:111:treatment,127:137:cancer,153:173:treatment,",>24 Gy) or total body irradiation ≥ 3 months prior to study entry. Patients must have received focal radiation to symptomatic metastatic sites or local palliative radiation > 4 weeks prior to study entry,"['>' '24' 'Gy' ')' 'or' 'total' 'body' 'irradiation' '≥' '3' 'months'
 'prior' 'to' 'study' 'entry' '.' 'Patients' 'must' 'have' 'received'
 'focal' 'radiation' 'to' 'symptomatic' 'metastatic' 'sites' 'or' 'local'
 'palliative' 'radiation' '>' '4' 'weeks' 'prior' 'to' 'study' 'entry']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 3. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT02457845,"47:56:treatment,83:101:treatment,103:116:treatment,120:138:treatment","Patients must have fully recovered from acute treatment related toxicities of all prior chemotherapy, immunotherapy or radiotherapy prior to entering this study","['Patients' 'must' 'have' 'fully' 'recovered' 'from' 'acute' 'treatment'
 'related' 'toxicities' 'of' 'all' 'prior' 'chemotherapy' ','
 'immunotherapy' 'or' 'radiotherapy' 'prior' 'to' 'entering' 'this'
 'study']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 1. 0. 0. 0. 0.]
NCT02456857,"42:59:allergy_name,66:75:allergy_name,77:89:allergy_name","Known intolerance or hypersensitivity to rapamycin analogs (e.g. sirolimus, temsirolimus)","['Known' 'intolerance' 'or' 'hypersensitivity' 'to' 'rapamycin' 'analogs'
 '(' 'e.g' '.' 'sirolimus' ',' 'temsirolimus' ')']",[0. 0. 0. 0. 0. 4. 4. 0. 0. 0. 4. 0. 4. 0.]
NCT02456857,"7:14:treatment,20:31:treatment,33:54:treatment,59:69:treatment","Prior therapy with bevacizumab, liposomal doxorubicin, or everolimus","['Prior' 'therapy' 'with' 'bevacizumab' ',' 'liposomal' 'doxorubicin' ','
 'or' 'everolimus']",[0. 1. 0. 1. 0. 1. 1. 0. 0. 1.]
NCT02455193,"13:40:chronic_disease,48:73:chronic_disease,82:102:chronic_disease","Significant endocrine/metabolic disease (e.g., uncontrolled hypertension, severe hypertriglyceridemia)","['Significant' 'endocrine/metabolic' 'disease' '(' 'e.g.' ','
 'uncontrolled' 'hypertension' ',' 'severe' 'hypertriglyceridemia' ')']",[0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 2. 0.]
NCT02454010,",34:46:treatment,,110:122:treatment,124:137:treatment,141:163:treatment,","At least 4 weeks beyond the last chemotherapy (or ≥ 5 half-lives for targeted agents, whichever is shorter), radiotherapy, major surgery or experimental treatment and recovered from all acute toxicities (≤ Grade 1)","['At' 'least' '4' 'weeks' 'beyond' 'the' 'last' 'chemotherapy' '(' 'or'
 '≥' '5' 'half-lives' 'for' 'targeted' 'agents' ',' 'whichever' 'is'
 'shorter' ')' ',' 'radiotherapy' ',' 'major' 'surgery' 'or'
 'experimental' 'treatment' 'and' 'recovered' 'from' 'all' 'acute'
 'toxicities' '(' '≤' 'Grade' '1' ')']","[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02453373,"16:37:chronic_disease,44:52:chronic_disease,56:82:chronic_disease",A history of a brain vascular lesion (e.G. aneurism or arteriovenous malformation),"['A' 'history' 'of' 'a' 'brain' 'vascular' 'lesion' '(' 'e.G' '.'
 'aneurism' 'or' 'arteriovenous' 'malformation' ')']",[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 2. 0. 2. 2. 0.]
NCT02453373,"8:32:chronic_disease,44:46:chronic_disease,50:52:chronic_disease,80:91:chronic_disease,,,140:151:treatment",severe ventricular dysrhythmias (sustained VT or VF) ) which cause significant hypotension (SBP ≤ 120 mmHg requiring more than two pressor medications),"['severe' 'ventricular' 'dysrhythmias' '(' 'sustained' 'VT' 'or' 'VF' ')'
 ')' 'which' 'cause' 'significant' 'hypotension' '(' 'SBP' '≤' '120'
 'mmHg' 'requiring' 'more' 'than' 'two' 'pressor' 'medications' ')']","[0. 2. 2. 0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0.]"
NCT02452697,"29:33:chronic_disease,62:69:treatment,86:111:treatment,",Patients with treated acute GVHD must be on a stable dose of therapy (no increase in immunosuppressive therapy for the 2 weeks before planned NK cell-enriched DLIs),"['Patients' 'with' 'treated' 'acute' 'GVHD' 'must' 'be' 'on' 'a' 'stable'
 'dose' 'of' 'therapy' '(' 'no' 'increase' 'in' 'immunosuppressive'
 'therapy' 'for' 'the' '2' 'weeks' 'before' 'planned' 'NK' 'cell-enriched'
 'DLIs' ')']","[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02452268,"1:22:treatment,26:43:treatment,45:58:treatment,60:72:treatment,74:87:treatment,89:107:treatment,111:132:treatment,,191:202:treatment,206:220:treatment,224:236:treatment,240:251:treatment,","Prior IL-15 treatment or cytotoxic therapy, immunotherapy, radiotherapy, major surgery, antitumor vaccines or monoclonal antibodies in the 4 weeks prior or for checkpoint inhibitors such as anti-CTLA-4 or anti PD1/PD-L1 or nitrosoureas or mitomycin C for 6 weeks prior to C1D1","['Prior' 'IL-15' 'treatment' 'or' 'cytotoxic' 'therapy' ','
 'immunotherapy' ',' 'radiotherapy' ',' 'major' 'surgery' ',' 'antitumor'
 'vaccines' 'or' 'monoclonal' 'antibodies' 'in' 'the' '4' 'weeks' 'prior'
 'or' 'for' 'checkpoint' 'inhibitors' 'such' 'as' 'anti-CTLA-4' 'or'
 'anti' 'PD1/PD-L1' 'or' 'nitrosoureas' 'or' 'mitomycin' 'C' 'for' '6'
 'weeks' 'prior' 'to' 'C1D1']","[1. 1. 1. 0. 1. 1. 0. 1. 0. 1. 0. 1. 1. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0.]"
NCT02452203,"1:4:treatment,34:51:treatment,53:97:treatment,99:120:treatment,122:132:treatment,134:171:treatment,173:184:treatment,186:209:treatment,211:240:treatment,242:252:treatment,254:285:treatment,290:323:treatment,399:410:treatment,,,545:563:treatment,","MRI contraindications including: cardiac pacemaker, metal fragments in eyes/skin/body (shrapnel), aortic/aneurysm clips, prosthesis, by-pass surgery/coronary artery clips, hearing aid, heart valve replacement, shunt (ventricular or spinal), electrodes, metal plates/pins/screws/ wires, or neuro/bio-stimulators (TENS unit), persons who have ever been a professional metal worker/welder, history of eye surgery/eyes washed out because of metal, vision problems uncorrectable with lenses, inability to lie still on one's back for 60-120 minutes; prior neurosurgery; tattoos or cosmetic makeup with metal dyes, unwillingness to remove body piercings, and pregnancy","['MRI' 'contraindications' 'including' ':' 'cardiac' 'pacemaker' ','
 'metal' 'fragments' 'in' 'eyes/skin/body' '(' 'shrapnel' ')' ','
 'aortic/aneurysm' 'clips' ',' 'prosthesis' ',' 'by-pass'
 'surgery/coronary' 'artery' 'clips' ',' 'hearing' 'aid' ',' 'heart'
 'valve' 'replacement' ',' 'shunt' '(' 'ventricular' 'or' 'spinal' ')' ','
 'electrodes' ',' 'metal' 'plates/pins/screws/' 'wires' ',' 'or'
 'neuro/bio-stimulators' '(' 'TENS' 'unit' ')' ',' 'persons' 'who' 'have'
 'ever' 'been' 'a' 'professional' 'metal' 'worker/welder' ',' 'history'
 'of' 'eye' 'surgery/eyes' 'washed' 'out' 'because' 'of' 'metal' ','
 'vision' 'problems' 'uncorrectable' 'with' 'lenses' ',' 'inability' 'to'
 'lie' 'still' 'on' 'one' ""'s"" 'back' 'for' '60-120' 'minutes' ';' 'prior'
 'neurosurgery' ';' 'tattoos' 'or' 'cosmetic' 'makeup' 'with' 'metal'
 'dyes' ',' 'unwillingness' 'to' 'remove' 'body' 'piercings' ',' 'and'
 'pregnancy']","[1. 0. 0. 0. 1. 1. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 0. 1. 0. 1. 1. 1. 1.
 0. 1. 1. 0. 1. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02452008,"1:19:treatment,24:34:cancer,46:82:cancer",Prior chemotherapy for metastatic disease in castration-resistant prostate cancer,"['Prior' 'chemotherapy' 'for' 'metastatic' 'disease' 'in'
 'castration-resistant' 'prostate' 'cancer']",[1. 1. 0. 3. 0. 0. 3. 3. 3.]
NCT02451683,"9:25:chronic_disease,31:56:chronic_disease,78:97:chronic_disease,106:121:chronic_disease,123:135:chronic_disease,139:162:chronic_disease","Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida or herniated cervical disk","['Ongoing' 'cord' 'compression' 'or' 'a' 'syrinx' 'in' 'the' 'spinal'
 'cord' 'or' 'who' 'suffer' 'from' 'a' 'spinal' 'cord' 'disease' 'such'
 'as' 'spinal' 'stenosis' ',' 'spina' 'bifida' 'or' 'herniated' 'cervical'
 'disk']","[0. 2. 2. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 0. 2. 2. 2.]"
NCT02451553,"1:31:chronic_disease,87:102:treatment,124:153:treatment,155:180:treatment,210:230:chronic_disease,234:250:chronic_disease","Gastrointestinal tract disease or any other reasons resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, active peptic ulcer disease or chronic diarrhea","['Gastrointestinal' 'tract' 'disease' 'or' 'any' 'other' 'reasons'
 'resulting' 'in' 'an' 'inability' 'to' 'take' 'oral' 'medication' 'or'
 'a' 'requirement' 'for' 'intravenous' '(' 'IV' ')' 'alimentation' ','
 'prior' 'surgical' 'procedures' 'affecting' 'absorption' ',' 'active'
 'peptic' 'ulcer' 'disease' 'or' 'chronic' 'diarrhea']","[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1. 1. 0. 0.
 0. 1. 1. 1. 0. 0. 0. 0. 2. 2. 2. 0. 2. 2.]"
NCT02451553,"1:13:treatment,6:13:treatment,,64:73:treatment,102:115:cancer,",Radiotherapy within 4 weeks prior to therapy except palliative radiation to target organs other than primary tumor may be allowed up to 2 weeks prior to registration,"['Radiotherapy' 'within' '4' 'weeks' 'prior' 'to' 'therapy' 'except'
 'palliative' 'radiation' 'to' 'target' 'organs' 'other' 'than' 'primary'
 'tumor' 'may' 'be' 'allowed' 'up' 'to' '2' 'weeks' 'prior' 'to'
 'registration']","[1. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02451488,"1:28:chronic_disease,34:37:chronic_disease,39:50:chronic_disease,54:65:chronic_disease","Active or chronic infection with HIV, hepatitis B or hepatitis C","['Active' 'or' 'chronic' 'infection' 'with' 'HIV' ',' 'hepatitis' 'B' 'or'
 'hepatitis' 'C']",[2. 2. 2. 2. 0. 2. 0. 2. 2. 0. 0. 0.]
NCT02451488,",92:114:treatment,116:128:treatment,132:154:treatment",WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy or bilateral oophorectomy) or is not postmenopausal,"['WOCBP' 'include' 'any' 'female' 'who' 'has' 'experienced' 'menarche'
 'and' 'who' 'has' 'not' 'undergone' 'successful' 'surgical'
 'sterilization' '(' 'hysterectomy' 'or' 'bilateral' 'oophorectomy' ')'
 'or' 'is' 'not' 'postmenopausal']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 1. 0. 0. 0.
 0. 0.]"
NCT02451423,"12:33:chronic_disease,12:21:treatment,58:66:chronic_disease",History of radiation pneumonitis in the radiation field (fibrosis) is permitted,"['History' 'of' 'radiation' 'pneumonitis' 'in' 'the' 'radiation' 'field'
 '(' 'fibrosis' ')' 'is' 'permitted']",[0. 0. 1. 2. 0. 0. 0. 0. 0. 2. 0. 0. 0.]
NCT02451423,"45:83:treatment,110:123:treatment,128:134:chronic_disease","Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in the study after discussion with and approval by the Study Chair","['Patients' 'who' 'have' 'received' 'acute' ',' 'low-dose' ',' 'systemic'
 'immunosuppressant' 'medications' '(' 'e.g.' ',' 'a' 'one-time' 'dose'
 'of' 'dexamethasone' 'for' 'nausea' ')' 'may' 'be' 'enrolled' 'in' 'the'
 'study' 'after' 'discussion' 'with' 'and' 'approval' 'by' 'the' 'Study'
 'Chair']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 2. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02451423,"8:17:chronic_disease,8:18:chronic_disease,,136:146:chronic_disease,158:167:chronic_disease","Severe infections within 4 weeks prior to Cycle 1, Day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia","['Severe' 'infections' 'within' '4' 'weeks' 'prior' 'to' 'Cycle' '1' ','
 'Day' '1' ',' 'including' 'but' 'not' 'limited' 'to' 'hospitalization'
 'for' 'complications' 'of' 'infection' ',' 'bacteremia' ',' 'or' 'severe'
 'pneumonia']","[0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0.
 2. 0. 0. 0. 2.]"
NCT02451423,"12:35:treatment,40:58:treatment,66:81:treatment,86:107:chronic_disease","The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone for adrenal insufficiency) is allowed","['The' 'use' 'of' 'inhaled' 'corticosteroids' 'and' 'mineralocorticoids'
 '(' 'e.g.' ',' 'fludrocortisone' 'for' 'adrenal' 'insufficiency' ')' 'is'
 'allowed']",[0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 1. 0. 2. 2. 0. 0. 0.]
NCT02451423,"95:126:cancer,128:133:cancer,137:162:cancer,174:189:cancer,250:274:cancer","death treated with expected curative outcome (such as, but not limited to, adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated with curative intent and absence of PSA relapse, or ductal carcinoma in situ of the breast treated surgically with curative intent)","['death' 'treated' 'with' 'expected' 'curative' 'outcome' '(' 'such' 'as'
 ',' 'but' 'not' 'limited' 'to' ',' 'adequately' 'treated' 'carcinoma'
 'in' 'situ' 'of' 'the' 'cervix' ',' 'basal' 'or' 'squamous' 'cell' 'skin'
 'cancer' ',' 'localized' 'prostate' 'cancer' 'treated' 'with' 'curative'
 'intent' 'and' 'absence' 'of' 'PSA' 'relapse' ',' 'or' 'ductal'
 'carcinoma' 'in' 'situ' 'of' 'the' 'breast' 'treated' 'surgically' 'with'
 'curative' 'intent' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 0.
 3. 0. 3. 3. 3. 3. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3.
 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02448173,"30:42:cancer,44:57:cancer,59:72:cancer","Patients must have Stage II (IIA = T3N0M0, IIB = T4aN0M0, IIC = T4bN0M0) disease","['Patients' 'must' 'have' 'Stage' 'II' '(' 'IIA' '=' 'T3N0M0' ',' 'IIB'
 '=' 'T4aN0M0' ',' 'IIC' '=' 'T4bN0M0' ')' 'disease']",[0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 3. 3. 3. 0. 3. 3. 3. 0. 0.]
NCT02446886,"13:34:chronic_disease,46:50:chronic_disease,54:58:chronic_disease",Progressive neurological disorder other than RRMS or SPMS,['Progressive' 'neurological' 'disorder' 'other' 'than' 'RRMS' 'or' 'SPMS'],[0. 2. 2. 0. 0. 2. 0. 2.]
NCT02446457,"11:29:chronic_disease,92:103:chronic_disease,111:134:chronic_disease,","Has known active hepatitis B (e.g., hepatitis B virus surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] qualitative is detected)","['Has' 'known' 'active' 'hepatitis' 'B' '(' 'e.g.' ',' 'hepatitis' 'B'
 'virus' 'surface' 'antigen' '[' 'HBsAg' ']' 'reactive' ')' 'or'
 'hepatitis' 'C' '(' 'e.g.' ',' 'hepatitis' 'C' 'virus' '[' 'HCV' ']'
 'ribonucleic' 'acid' '[' 'RNA' ']' 'qualitative' 'is' 'detected' ')']","[0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02446457,"11:35:treatment,57:82:treatment,,124:139:treatment",receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment,"['receiving' 'systemic' 'steroid' 'therapy' 'or' 'any' 'other' 'form' 'of'
 'immunosuppressive' 'therapy' 'within' '7' 'days' 'prior' 'to' 'the'
 'first' 'dose' 'of' 'trial' 'treatment']",[0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02446457,"26:45:cancer,,93:115:treatment,130:139:treatment,150:174:treatment","with histologic proof of follicular lymphoma grade 1, 2, or 3a relapsing after at least one prior systemic therapy that included rituximab (or other monoclonal CD20 antibody)","['with' 'histologic' 'proof' 'of' 'follicular' 'lymphoma' 'grade' '1' ','
 '2' ',' 'or' '3a' 'relapsing' 'after' 'at' 'least' 'one' 'prior'
 'systemic' 'therapy' 'that' 'included' 'rituximab' '(' 'or' 'other'
 'monoclonal' 'CD20' 'antibody' ')']","[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 1.
 0. 0. 0. 1. 1. 1. 0.]"
NCT02446236,"14:21:treatment,,,46:75:treatment,112:140:treatment",Able to take aspirin (81 or 325 mg) daily as prophylactic anti-coagulation (patients intolerant to ASA may use low molecular weight heparin),"['Able' 'to' 'take' 'aspirin' '(' '81' 'or' '325' 'mg' ')' 'daily' 'as'
 'prophylactic' 'anti-coagulation' '(' 'patients' 'intolerant' 'to' 'ASA'
 'may' 'use' 'low' 'molecular' 'weight' 'heparin' ')']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.
 1. 0.]"
NCT02446210,"81:88:chronic_disease,128:142:treatment,144:153:treatment,158:183:treatment","Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold such as antipsychotic drugs (chlorpromazine, clozapine) or tricyclic antidepressants","['Receiving' 'drugs' 'acting' 'primarily' 'on' 'the' 'central' 'nervous'
 'system' ',' 'which' 'lower' 'the' 'seizure' 'threshold' 'such' 'as'
 'antipsychotic' 'drugs' '(' 'chlorpromazine' ',' 'clozapine' ')' 'or'
 'tricyclic' 'antidepressants']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0.
 0. 1. 1.]"
NCT02445339,"22:37:treatment,76:85:treatment,95:122:chronic_disease",Currently prescribed pharmacotherapy for alcohol dependence (not including treatment of acute alcohol withdrawal syndrome),"['Currently' 'prescribed' 'pharmacotherapy' 'for' 'alcohol' 'dependence'
 '(' 'not' 'including' 'treatment' 'of' 'acute' 'alcohol' 'withdrawal'
 'syndrome' ')']",[0. 0. 1. 0. 2. 2. 2. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02442102,"6:17:treatment,21:50:treatment,66:73:treatment,",Ever tracheotomy or prior endotracheal intubation other than for surgery (≤ 1 year),"['Ever' 'tracheotomy' 'or' 'prior' 'endotracheal' 'intubation' 'other'
 'than' 'for' 'surgery' '(' '≤' '1' 'year' ')']",[0. 1. 0. 1. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT02441140,"1:31:treatment,35:47:treatment,71:88:treatment",Prior bilateral tubal ligation or hysterectomy (as this would prevent chromopertubation),"['Prior' 'bilateral' 'tubal' 'ligation' 'or' 'hysterectomy' '(' 'as'
 'this' 'would' 'prevent' 'chromopertubation' ')']",[1. 1. 1. 1. 0. 1. 0. 0. 0. 0. 0. 1. 0.]
NCT02441062,"1:45:treatment,,78:81:treatment,82:89:treatment",Peptide receptor radionuclide therapy (PRRT) within 4 weeks of Ga-68 DOTATOC PET/CT scan,"['Peptide' 'receptor' 'radionuclide' 'therapy' '(' 'PRRT' ')' 'within' '4'
 'weeks' 'of' 'Ga-68' 'DOTATOC' 'PET/CT' 'scan']",[1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02440581,"1:31:chronic_disease,72:81:chronic_disease,85:94:chronic_disease",Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia,"['Abnormalities' 'of' 'the' 'esophagus' 'which' 'delay' 'esophageal'
 'emptying' 'such' 'as' 'stricture' 'or' 'achalasia']",[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 2. 0. 2.]
NCT02440581,",85:100:treatment,105:117:treatment,145:155:treatment,157:174:treatment,182:195:treatment","Treatment within last 6 months with drugs that may affect bone metabolism including bisphosphonates and teriparatide (except for treatment with calcitriol, vitamin D analogs and/or calcimimetics)","['Treatment' 'within' 'last' '6' 'months' 'with' 'drugs' 'that' 'may'
 'affect' 'bone' 'metabolism' 'including' 'bisphosphonates' 'and'
 'teriparatide' '(' 'except' 'for' 'treatment' 'with' 'calcitriol' ','
 'vitamin' 'D' 'analogs' 'and/or' 'calcimimetics' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 1. 0. 1.
 1. 1. 0. 1. 0.]"
NCT02439450,"1:31:chronic_disease,35:53:chronic_disease,72:77:cancer,89:103:treatment","severe/uncontrolled infections or concurrent illness, unrelated to the tumor, requiring active therapy","['severe/uncontrolled' 'infections' 'or' 'concurrent' 'illness' ','
 'unrelated' 'to' 'the' 'tumor' ',' 'requiring' 'active' 'therapy']",[2. 2. 0. 2. 2. 0. 0. 0. 0. 3. 0. 0. 1. 1.]
NCT02438995,"51:85:cancer,87:110:cancer,122:143:cancer,148:172:cancer","Patients with a documented diagnosis of recurrent head and neck squamous cell cancer (squamous cell carcinoma, including nasopharyngeal cancer, or adenoid cystic carcinoma)","['Patients' 'with' 'a' 'documented' 'diagnosis' 'of' 'recurrent' 'head'
 'and' 'neck' 'squamous' 'cell' 'cancer' '(' 'squamous' 'cell' 'carcinoma'
 ',' 'including' 'nasopharyngeal' 'cancer' ',' 'or' 'adenoid' 'cystic'
 'carcinoma' ')']","[0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 3.
 3. 3. 0.]"
NCT02437851,"17:22:cancer,26:39:chronic_disease,43:52:chronic_disease",Concurrent anal canal or perianal HSIL or condyloma that in the judgment of the clinician cannot be cleared or can only be cleared with undue morbidity to the patient,"['Concurrent' 'anal' 'canal' 'or' 'perianal' 'HSIL' 'or' 'condyloma'
 'that' 'in' 'the' 'judgment' 'of' 'the' 'clinician' 'can' 'not' 'be'
 'cleared' 'or' 'can' 'only' 'be' 'cleared' 'with' 'undue' 'morbidity'
 'to' 'the' 'patient']","[0. 0. 3. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02437851,"16:37:treatment,49:56:treatment,60:106:treatment,134:153:treatment",Ongoing use of anticoagulant therapy other than aspirin or non-steroidal anti-inflammatory drugs (NSAIDS) that cannot be stopped for surgical procedures,"['Ongoing' 'use' 'of' 'anticoagulant' 'therapy' 'other' 'than' 'aspirin'
 'or' 'non-steroidal' 'anti-inflammatory' 'drugs' '(' 'NSAIDS' ')' 'that'
 'can' 'not' 'be' 'stopped' 'for' 'surgical' 'procedures']",[0. 0. 0. 1. 1. 0. 0. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02437812,"16:34:cancer,36:50:cancer,55:80:cancer","Advanced stage epithelial ovarian, fallopian tube, or primary peritoneal cancer","['Advanced' 'stage' 'epithelial' 'ovarian' ',' 'fallopian' 'tube' ',' 'or'
 'primary' 'peritoneal' 'cancer']",[0. 0. 3. 3. 0. 3. 3. 0. 0. 3. 3. 3.]
NCT02437370,"24:34:cancer,74:83:treatment,104:136:cancer,138:173:cancer,178:201:cancer,233:249:treatment,","Has a known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy; free of disease for more than 5 years","['Has' 'a' 'known' 'additional' 'malignancy' 'that' 'is' 'progressing'
 'or' 'requires' 'active' 'treatment' ';' 'exceptions' 'include' 'basal'
 'cell' 'carcinoma' 'of' 'the' 'skin' ',' 'squamous' 'cell' 'carcinoma'
 'of' 'the' 'skin' ',' 'or' 'in' 'situ' 'cervical' 'cancer' 'that' 'has'
 'undergone' 'potentially' 'curative' 'therapy' ';' 'free' 'of' 'disease'
 'for' 'more' 'than' '5' 'years']","[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 3. 3.
 3. 3. 3. 3. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02437370,"18:29:chronic_disease,86:97:chronic_disease,105:128:chronic_disease","Has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)","['Has' 'known' 'active' 'hepatitis' 'B' '(' 'e.g.' ',' 'hepatitis' 'B'
 'surface' 'antigen' '[' 'HBsAg' ']' 'reactive' ')' 'or' 'hepatitis' 'C'
 '(' 'e.g.' ',' 'hepatitis' 'C' 'virus' '[' 'HCV' ']' 'ribonucleic' 'acid'
 '[' 'RNA' ']' '[' 'qualitative' ']' 'is' 'detected' ')']","[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02437110,"10:29:chronic_disease,41:50:chronic_disease,64:80:chronic_disease,",Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days of the screening visit,"['Unstable' 'psychiatric' 'illness' 'defined' 'as' 'psychosis' 'or'
 'untreated' 'major' 'depression' 'within' '90' 'days' 'of' 'the'
 'screening' 'visit']",[0. 2. 2. 0. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02435992,"18:30:treatment,32:46:treatment,51:63:treatment","Can be receiving azathioprine, mercaptopurine, or methotrexate, but treatment will be stopped prior to randomization","['Can' 'be' 'receiving' 'azathioprine' ',' 'mercaptopurine' ',' 'or'
 'methotrexate' ',' 'but' 'treatment' 'will' 'be' 'stopped' 'prior' 'to'
 'randomization']",[0. 0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02434809,"35:45:treatment,47:61:treatment,67:86:treatment,112:136:treatment","Active implanted devices, such as pacemakers, defibrillators, and drug infusion pumps since the effects of the Calypso System operation on these devices are unknown","['Active' 'implanted' 'devices' ',' 'such' 'as' 'pacemakers' ','
 'defibrillators' ',' 'and' 'drug' 'infusion' 'pumps' 'since' 'the'
 'effects' 'of' 'the' 'Calypso' 'System' 'operation' 'on' 'these'
 'devices' 'are' 'unknown']","[0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0.
 0. 0. 0.]"
NCT02433977,"1:17:treatment,28:34:chronic_disease,45:58:treatment,60:78:treatment",Systemic steroid dependent asthma (no daily oral steroids- short term therapy for asthma exacerbation is permitted),"['Systemic' 'steroid' 'dependent' 'asthma' '(' 'no' 'daily' 'oral'
 'steroids-' 'short' 'term' 'therapy' 'for' 'asthma' 'exacerbation' 'is'
 'permitted' ')']",[1. 1. 0. 2. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02433626,"9:16:cancer,18:32:cancer,34:52:cancer,54:65:cancer,70:85:cancer","Part 1: Ovarian, fallopian tube, primary peritoneal, endometrial, or cervical cancer","['Part' '1' ':' 'Ovarian' ',' 'fallopian' 'tube' ',' 'primary'
 'peritoneal' ',' 'endometrial' ',' 'or' 'cervical' 'cancer']",[0. 0. 0. 3. 0. 3. 3. 0. 3. 3. 0. 3. 0. 0. 3. 3.]
NCT02433158,"45:68:chronic_disease,120:134:treatment,155:165:treatment,241:251:treatment",Occurrence of any severe and/or generalized cutaneous manifestation or any other adverse event during participation in Study B5201002 that was related to study drug and which would therefore make it inappropriate for the subject to receive rivipansel in the current study,"['Occurrence' 'of' 'any' 'severe' 'and/or' 'generalized' 'cutaneous'
 'manifestation' 'or' 'any' 'other' 'adverse' 'event' 'during'
 'participation' 'in' 'Study' 'B5201002' 'that' 'was' 'related' 'to'
 'study' 'drug' 'and' 'which' 'would' 'therefore' 'make' 'it'
 'inappropriate' 'for' 'the' 'subject' 'to' 'receive' 'rivipansel' 'in'
 'the' 'current' 'study']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]"
NCT02431806,"33:48:chronic_disease,60:63:chronic_disease,93:102:treatment",DSM-IV-TR-based diagnosis of an axis I disorder other than MDD that is the primary focus of treatment,"['DSM-IV-TR-based' 'diagnosis' 'of' 'an' 'axis' 'I' 'disorder' 'other'
 'than' 'MDD' 'that' 'is' 'the' 'primary' 'focus' 'of' 'treatment']",[0. 0. 0. 0. 2. 2. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 1.]
NCT02430077,"33:45:treatment,47:61:treatment,65:74:treatment","surgical sterilization, such as hysterectomy, tubal ligation or vasectomy","['surgical' 'sterilization' ',' 'such' 'as' 'hysterectomy' ',' 'tubal'
 'ligation' 'or' 'vasectomy']",[0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 1.]
NCT02429934,"15:31:chronic_disease,42:46:treatment,50:64:treatment,,99:115:treatment",Subjects with active infection requiring oral or IV antibiotics within one month of first dose of study medication,"['Subjects' 'with' 'active' 'infection' 'requiring' 'oral' 'or' 'IV'
 'antibiotics' 'within' 'one' 'month' 'of' 'first' 'dose' 'of' 'study'
 'medication']",[0. 0. 2. 2. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02429830,"19:47:chronic_disease,75:84:chronic_disease,86:106:chronic_disease,111:135:chronic_disease,139:155:chronic_disease","Diagnosed with an esophageal motility disorder such as but not limited to achalasia, nutcracker esophagus, or diffuse esophageal spasm or hypertensive LES","['Diagnosed' 'with' 'an' 'esophageal' 'motility' 'disorder' 'such' 'as'
 'but' 'not' 'limited' 'to' 'achalasia' ',' 'nutcracker' 'esophagus' ','
 'or' 'diffuse' 'esophageal' 'spasm' 'or' 'hypertensive' 'LES']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2.]
NCT02429830,"24:34:cancer,38:52:cancer,56:91:treatment,95:118:treatment,123:127:chronic_disease,151:169:treatment",Suspected or confirmed esophageal or gastric cancer or prior gastric or esophageal surgery or endoscopic intervention for GERD (with the exception of sleeve gastrectomy),"['Suspected' 'or' 'confirmed' 'esophageal' 'or' 'gastric' 'cancer' 'or'
 'prior' 'gastric' 'or' 'esophageal' 'surgery' 'or' 'endoscopic'
 'intervention' 'for' 'GERD' '(' 'with' 'the' 'exception' 'of' 'sleeve'
 'gastrectomy' ')']","[0. 0. 0. 3. 0. 3. 3. 0. 1. 1. 1. 1. 1. 0. 1. 1. 0. 2. 0. 0. 0. 0. 0. 1.
 1. 0.]"
NCT02429349,"34:41:cancer,60:78:cancer,87:95:cancer,100:120:cancer","include, but are not limited to, cancers with high risk of ovarian metastasis such as leukemia and non-Hodgkin lymphoma","['include' ',' 'but' 'are' 'not' 'limited' 'to' ',' 'cancers' 'with'
 'high' 'risk' 'of' 'ovarian' 'metastasis' 'such' 'as' 'leukemia' 'and'
 'non-Hodgkin' 'lymphoma']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 3. 3. 0. 0. 3. 0. 3. 3.]
NCT02427997,"13:34:treatment,57:65:treatment,,114:131:treatment,,163:180:treatment,","have stable MS disease treatments (e.g., last intake of steroids occurred at least 50 days before the enrolment, MS-specific drugs stable from at least 3 months, symptomatic drugs stable from at least 1 month before the enrolment)","['have' 'stable' 'MS' 'disease' 'treatments' '(' 'e.g.' ',' 'last'
 'intake' 'of' 'steroids' 'occurred' 'at' 'least' '50' 'days' 'before'
 'the' 'enrolment' ',' 'MS-specific' 'drugs' 'stable' 'from' 'at' 'least'
 '3' 'months' ',' 'symptomatic' 'drugs' 'stable' 'from' 'at' 'least' '1'
 'month' 'before' 'the' 'enrolment' ')']","[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02427841,"18:21:chronic_disease,25:27:chronic_disease,96:117:treatment",Occlusion of the SMV or PV with insufficient normal vein above and below with which to perform venous reconstruction,"['Occlusion' 'of' 'the' 'SMV' 'or' 'PV' 'with' 'insufficient' 'normal'
 'vein' 'above' 'and' 'below' 'with' 'which' 'to' 'perform' 'venous'
 'reconstruction']",[0. 0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02427581,"10:22:treatment,24:36:treatment,41:57:treatment,,83:107:treatment","Received chemotherapy, radiotherapy, or biologic therapy within the last 30 days (neoadjuvant chemotherapy excluded)","['Received' 'chemotherapy' ',' 'radiotherapy' ',' 'or' 'biologic'
 'therapy' 'within' 'the' 'last' '30' 'days' '(' 'neoadjuvant'
 'chemotherapy' 'excluded' ')']",[0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]
NCT02426476,"14:36:chronic_disease,38:54:treatment,56:78:treatment,","a history of ischemic heart disease, heart transplant, cardiovascular surgery within 1 year","['a' 'history' 'of' 'ischemic' 'heart' 'disease' ',' 'heart' 'transplant'
 ',' 'cardiovascular' 'surgery' 'within' '1' 'year']",[0. 0. 0. 2. 1. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT02425904,"45:80:treatment,96:99:chronic_disease,126:135:treatment,141:155:treatment,157:160:chronic_disease,226:257:treatment","In stratum 1, patients must have failed one prior systemic chemotherapy regimen. In stratum 2, RDD patients must have failed treatment with corticosteroid. ECD patients who have confirmed BRAF V600E mutation must have failed treatment with a BRAF inhibitor or are not considered to be eligible for such treatment","['In' 'stratum' '1' ',' 'patients' 'must' 'have' 'failed' 'one' 'prior'
 'systemic' 'chemotherapy' 'regimen' '.' 'In' 'stratum' '2' ',' 'RDD'
 'patients' 'must' 'have' 'failed' 'treatment' 'with' 'corticosteroid' '.'
 'ECD' 'patients' 'who' 'have' 'confirmed' 'BRAF' 'V600E' 'mutation'
 'must' 'have' 'failed' 'treatment' 'with' 'a' 'BRAF' 'inhibitor' 'or'
 'are' 'not' 'considered' 'to' 'be' 'eligible' 'for' 'such' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 1.
 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02425904,"28:80:treatment,156:162:chronic_disease,164:173:chronic_disease,184:193:chronic_disease,208:234:chronic_disease,251:260:chronic_disease","Patients with a history of prior hematopoietic stem cell transplantation (HSCT), elevated conjugated serum bilirubin at study entry, uncontrolled systemic fungal, bacterial, or other infection, a history of hepatitis B or C infection or a history of cirrhosis","['Patients' 'with' 'a' 'history' 'of' 'prior' 'hematopoietic' 'stem'
 'cell' 'transplantation' '(' 'HSCT' ')' ',' 'elevated' 'conjugated'
 'serum' 'bilirubin' 'at' 'study' 'entry' ',' 'uncontrolled' 'systemic'
 'fungal' ',' 'bacterial' ',' 'or' 'other' 'infection' ',' 'a' 'history'
 'of' 'hepatitis' 'B' 'or' 'C' 'infection' 'or' 'a' 'history' 'of'
 'cirrhosis']","[0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 0. 2. 0. 0. 0. 2. 0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 2.]"
NCT02424968,"30:41:chronic_disease,43:54:chronic_disease,72:83:chronic_disease,94:127:chronic_disease,138:182:chronic_disease","Must not be seropositive for HIV 1 and 2, hepatitis B surface antigen, hepatitis C antibody, human T-lymphotropic virus (HTLV) antibody, cytomegalovirus (CMV) immunoglobulin M (IgM), or rapid plasma reagin (RPR) (Treponema)","['Must' 'not' 'be' 'seropositive' 'for' 'HIV' '1' 'and' '2' ','
 'hepatitis' 'B' 'surface' 'antigen' ',' 'hepatitis' 'C' 'antibody' ','
 'human' 'T-lymphotropic' 'virus' '(' 'HTLV' ')' 'antibody' ','
 'cytomegalovirus' '(' 'CMV' ')' 'immunoglobulin' 'M' '(' 'IgM' ')' ','
 'or' 'rapid' 'plasma' 'reagin' '(' 'RPR' ')' '(' 'Treponema' ')']","[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0.
 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02424955,"22:33:cancer,37:47:cancer,62:103:treatment",Patient with primary liver tumor or metastasis scheduled for Stereotactic Ablative Radiotherapy (SABR),"['Patient' 'with' 'primary' 'liver' 'tumor' 'or' 'metastasis' 'scheduled'
 'for' 'Stereotactic' 'Ablative' 'Radiotherapy' '(' 'SABR' ')']",[0. 0. 0. 3. 3. 0. 3. 0. 0. 1. 1. 1. 1. 0. 0.]
NCT02423863,"1:21:cancer,36:41:cancer,143:148:chronic_disease,177:196:treatment",Head and neck cancer patients with tumor invading major blood vessels for whom there may be a risk of blockage or bleeding if inflammation or edema is transiently increased by Hiltonol injections,"['Head' 'and' 'neck' 'cancer' 'patients' 'with' 'tumor' 'invading' 'major'
 'blood' 'vessels' 'for' 'whom' 'there' 'may' 'be' 'a' 'risk' 'of'
 'blockage' 'or' 'bleeding' 'if' 'inflammation' 'or' 'edema' 'is'
 'transiently' 'increased' 'by' 'Hiltonol' 'injections']","[3. 3. 3. 3. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 2. 0. 0. 0. 0. 1. 1.]"
NCT02423772,"12:19:treatment,28:37:treatment,41:53:chronic_disease,",Prescribed opioids for the treatment of chronic pain for the past 90 days or longer,"['Prescribed' 'opioids' 'for' 'the' 'treatment' 'of' 'chronic' 'pain'
 'for' 'the' 'past' '90' 'days' 'or' 'longer']",[0. 1. 0. 0. 1. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02423525,"81:106:chronic_disease,108:132:chronic_disease,,,,193:208:chronic_disease,230:240:chronic_disease,245:266:chronic_disease,","History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of 3 or 4, unstable angina or poorly controlled arrhythmia, or myocardial infarction within 6 months prior to enrollment","['History' 'or' 'presence' 'of' 'clinically' 'relevant' 'cardiovascular'
 'abnormalities' 'such' 'as' 'uncontrolled' 'hypertension' ','
 'congestive' 'heart' 'failure' 'New' 'York' 'Heart' 'Association' '('
 'NYHA' ')' 'classification' 'of' '3' 'or' '4' ',' 'unstable' 'angina'
 'or' 'poorly' 'controlled' 'arrhythmia' ',' 'or' 'myocardial'
 'infarction' 'within' '6' 'months' 'prior' 'to' 'enrollment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]"
NCT02422641,"1:11:treatment,15:44:treatment,46:58:treatment,60:72:treatment,76:102:treatment,129:142:cancer","Concurrent or planned systemic chemotherapy, radiotherapy, new hormonal or anti-HER2 directed therapy directed at management of breast cancer","['Concurrent' 'or' 'planned' 'systemic' 'chemotherapy' ',' 'radiotherapy'
 ',' 'new' 'hormonal' 'or' 'anti-HER2' 'directed' 'therapy' 'directed'
 'at' 'management' 'of' 'breast' 'cancer']",[1. 0. 1. 1. 1. 0. 1. 0. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 3. 3.]
NCT02422641,"1:16:cancer,18:29:cancer,31:42:cancer,48:61:cancer","TRIPLE NEGATIVE (ER-negative, PR-negative, and HER2-negative disease)","['TRIPLE' 'NEGATIVE' '(' 'ER-negative' ',' 'PR-negative' ',' 'and'
 'HER2-negative' 'disease' ')']",[3. 3. 0. 3. 0. 3. 0. 0. 3. 0. 0.]
NCT02421315,"41:44:treatment,61:74:treatment,79:103:treatment","Individuals who are currently receiving CBT, other forms of psychotherapy, or psychotropic medications","['Individuals' 'who' 'are' 'currently' 'receiving' 'CBT' ',' 'other'
 'forms' 'of' 'psychotherapy' ',' 'or' 'psychotropic' 'medications']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 0. 1. 1.]
NCT02419495,"28:43:cancer,37:43:cancer,,97:102:cancer,106:141:cancer",Diagnosis or recurrence of invasive cancer other than the present cancer within 3 years (except basal or squamous cell carcinoma of the skin that has been definitively treated),"['Diagnosis' 'or' 'recurrence' 'of' 'invasive' 'cancer' 'other' 'than'
 'the' 'present' 'cancer' 'within' '3' 'years' '(' 'except' 'basal' 'or'
 'squamous' 'cell' 'carcinoma' 'of' 'the' 'skin' 'that' 'has' 'been'
 'definitively' 'treated' ')']","[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 3. 3. 3. 3.
 0. 0. 0. 0. 0. 0.]"
NCT02419495,"35:55:chronic_disease,158:181:chronic_disease,218:256:chronic_disease,260:310:chronic_disease,311:343:chronic_disease,370:400:chronic_disease,,,453:479:chronic_disease,","Unstable cardiovascular function: symptomatic ischemia (chest pain of cardiac origin), or uncontrolled clinically significant conduction abnormalities (e.g. ventricular tachycardia on antiarrhythmics are excluded and 1st degree atrioventricular [AV] block or asymptomatic left anterior fascicular block [LAFB]/right bundle branch block [RBBB] will not be excluded), or congestive heart failure (CHF) of New York Heart Association (NYHA) class >= 3, or myocardial infarction (MI) within 3 months of consent date","['Unstable' 'cardiovascular' 'function' ':' 'symptomatic' 'ischemia' '('
 'chest' 'pain' 'of' 'cardiac' 'origin' ')' ',' 'or' 'uncontrolled'
 'clinically' 'significant' 'conduction' 'abnormalities' '(' 'e.g' '.'
 'ventricular' 'tachycardia' 'on' 'antiarrhythmics' 'are' 'excluded' 'and'
 '1st' 'degree' 'atrioventricular' '[' 'AV' ']' 'block' 'or'
 'asymptomatic' 'left' 'anterior' 'fascicular' 'block' '[' 'LAFB' ']'
 '/right' 'bundle' 'branch' 'block' '[' 'RBBB' ']' 'will' 'not' 'be'
 'excluded' ')' ',' 'or' 'congestive' 'heart' 'failure' '(' 'CHF' ')' 'of'
 'New' 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'class' '>' '=' '3' ','
 'or' 'myocardial' 'infarction' '(' 'MI' ')' 'within' '3' 'months' 'of'
 'consent' 'date']","[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 2. 2.
 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02419495,"20:52:treatment,,89:99:treatment,129:154:treatment,,200:209:treatment",subjects receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or other form of immunosuppressive therapy within 7 days before the first dose of study treatment,"['subjects' 'receiving' 'chronic' 'systemic' 'steroid' 'therapy' '(' 'in'
 'dosing' 'exceeding' '10' 'mg' 'daily' 'of' 'prednisone' 'equivalent' ')'
 'or' 'other' 'form' 'of' 'immunosuppressive' 'therapy' 'within' '7'
 'days' 'before' 'the' 'first' 'dose' 'of' 'study' 'treatment']","[0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02418195,"1:4:chronic_disease,26:41:chronic_disease,51:68:chronic_disease","MDD Participants without Suicide Attempt, without SUicidal Ideation","['MDD' 'Participants' 'without' 'Suicide' 'Attempt' ',' 'without'
 'SUicidal' 'Ideation']",[2. 0. 0. 2. 2. 0. 0. 2. 2.]
NCT02417701,"10:53:treatment,94:105:treatment,,155:165:treatment",Patients receiving histamine H2 receptor antagonists before enrollment must stop using these medications for at least 24 hours before their first dose of study drug,"['Patients' 'receiving' 'histamine' 'H2' 'receptor' 'antagonists' 'before'
 'enrollment' 'must' 'stop' 'using' 'these' 'medications' 'for' 'at'
 'least' '24' 'hours' 'before' 'their' 'first' 'dose' 'of' 'study' 'drug']","[0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1.]"
NCT02416102,"13:29:chronic_disease,41:45:chronic_disease,50:68:chronic_disease,78:92:chronic_disease,97:103:chronic_disease","Concomitant airway disorders other than COPD and chronic bronchitis, such as bronchiectasis and asthma (history and reversible airflow obstruction by American Thoracic Society (ATS) criteria)","['Concomitant' 'airway' 'disorders' 'other' 'than' 'COPD' 'and' 'chronic'
 'bronchitis' ',' 'such' 'as' 'bronchiectasis' 'and' 'asthma' '('
 'history' 'and' 'reversible' 'airflow' 'obstruction' 'by' 'American'
 'Thoracic' 'Society' '(' 'ATS' ')' 'criteria' ')']","[0. 2. 2. 0. 0. 2. 0. 2. 2. 0. 0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02415660,"126:155:chronic_disease,162:171:chronic_disease,173:190:chronic_disease,192:207:chronic_disease,212:247:chronic_disease","Signs and symptoms consistent with nerve root compression (i.e. diminished upper extremity strength, sensation or reflexes), cervical artery insufficiency (i.e. nystagmus, gait disturbances, Horner Syndrome) or upper cervical ligament instability (i.e. Sharp-Purser, alar ligament, transverse ligament tests)","['Signs' 'and' 'symptoms' 'consistent' 'with' 'nerve' 'root' 'compression'
 '(' 'i.e' '.' 'diminished' 'upper' 'extremity' 'strength' ',' 'sensation'
 'or' 'reflexes' ')' ',' 'cervical' 'artery' 'insufficiency' '(' 'i.e' '.'
 'nystagmus' ',' 'gait' 'disturbances' ',' 'Horner' 'Syndrome' ')' 'or'
 'upper' 'cervical' 'ligament' 'instability' '(' 'i.e' '.' 'Sharp-Purser'
 ',' 'alar' 'ligament' ',' 'transverse' 'ligament' 'tests' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 2.
 0. 0. 0. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02415556,"23:27:chronic_disease,43:75:chronic_disease,,,,,186:198:chronic_disease",Safety substudy in 20 IDDM patients only: Insulin-treated type 2 diabetics with a C-peptide of <0.8 ng/mLd and fasting blood glucose >150 mg/dL will be excluded even without history of hypoglycemia during finger stick measurements,"['Safety' 'substudy' 'in' '20' 'IDDM' 'patients' 'only' ':'
 'Insulin-treated' 'type' '2' 'diabetics' 'with' 'a' 'C-peptide' 'of' '<'
 '0.8' 'ng/mLd' 'and' 'fasting' 'blood' 'glucose' '>' '150' 'mg/dL' 'will'
 'be' 'excluded' 'even' 'without' 'history' 'of' 'hypoglycemia' 'during'
 'finger' 'stick' 'measurements']","[0. 0. 0. 0. 2. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0.]"
NCT02415387,",,,49:62:cancer,,,120:144:treatment,156:186:treatment,188:197:treatment,199:219:treatment","Women who have been diagnosed with stage I-IIIA breast cancer will be recruited 1-10 years after the completion of all primary cancer treatment except for longer-term hormonal therapies (tamoxifen, aromatase inhibitors)","['Women' 'who' 'have' 'been' 'diagnosed' 'with' 'stage' 'I-IIIA' 'breast'
 'cancer' 'will' 'be' 'recruited' '1-10' 'years' 'after' 'the'
 'completion' 'of' 'all' 'primary' 'cancer' 'treatment' 'except' 'for'
 'longer-term' 'hormonal' 'therapies' '(' 'tamoxifen' ',' 'aromatase'
 'inhibitors' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0.
 0. 1. 1. 1. 0. 1. 0. 1. 1. 0.]"
NCT02414269,"41:53:treatment,55:67:treatment,72:91:treatment,","All acute toxic effects of any previous radiotherapy, chemotherapy, or surgical procedures must have resolved to grade I or lower according to CTCAE (version 4.0)","['All' 'acute' 'toxic' 'effects' 'of' 'any' 'previous' 'radiotherapy' ','
 'chemotherapy' ',' 'or' 'surgical' 'procedures' 'must' 'have' 'resolved'
 'to' 'grade' 'I' 'or' 'lower' 'according' 'to' 'CTCAE' '(' 'version'
 '4.0' ')']","[0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02414269,"1:13:treatment,15:31:treatment,43:68:treatment,73:85:treatment,","Chemotherapy, targeted therapy (such as a tyrosine kinase inhibitor) or radiotherapy must have been completed at least 14 days prior to administration of T cells","['Chemotherapy' ',' 'targeted' 'therapy' '(' 'such' 'as' 'a' 'tyrosine'
 'kinase' 'inhibitor' ')' 'or' 'radiotherapy' 'must' 'have' 'been'
 'completed' 'at' 'least' '14' 'days' 'prior' 'to' 'administration' 'of'
 'T' 'cells']","[1. 0. 1. 1. 0. 0. 0. 0. 1. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02414178,"22:25:treatment,27:33:treatment,37:39:treatment,46:72:treatment","Contraindications to PET, PET-CT or MR (e.g. electronic medical devices, inability to lie still for long periods) that make it unsafe for the individual to participate","['Contraindications' 'to' 'PET' ',' 'PET-CT' 'or' 'MR' '(' 'e.g' '.'
 'electronic' 'medical' 'devices' ',' 'inability' 'to' 'lie' 'still' 'for'
 'long' 'periods' ')' 'that' 'make' 'it' 'unsafe' 'for' 'the' 'individual'
 'to' 'participate']","[0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02413047,"16:26:chronic_disease,30:55:chronic_disease,63:95:chronic_disease,97:141:chronic_disease,143:164:treatment","Any identified congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, human immunodeficiency virus [HIV] infection, organ transplantation)","['Any' 'identified' 'congenital' 'or' 'acquired' 'immunodeficiency' '('
 'e.g.' ',' 'common' 'variable' 'immunodeficiency' ',' 'human'
 'immunodeficiency' 'virus' '[' 'HIV' ']' 'infection' ',' 'organ'
 'transplantation' ')']",[0. 0. 2. 0. 2. 2. 0. 0. 0. 2. 2. 2. 0. 2. 2. 2. 2. 2. 0. 0. 0. 1. 1. 0.]
NCT02412540,"1:28:chronic_disease,64:67:treatment,91:94:chronic_disease,106:139:chronic_disease,","Active psychiatric disorder that would prevent eligibility for WLS or impede adherence to CLI, including clinically significant depression (hospitalization or suicidal ideation) in past 12 months","['Active' 'psychiatric' 'disorder' 'that' 'would' 'prevent' 'eligibility'
 'for' 'WLS' 'or' 'impede' 'adherence' 'to' 'CLI' ',' 'including'
 'clinically' 'significant' 'depression' '(' 'hospitalization' 'or'
 'suicidal' 'ideation' ')' 'in' 'past' '12' 'months']","[2. 2. 2. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02411656,"13:23:cancer,36:49:cancer,58:78:cancer,82:117:cancer,130:145:cancer,177:193:treatment","Has a known malignancy (other than breast cancer) except basal cell carcinoma or squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy","['Has' 'a' 'known' 'malignancy' '(' 'other' 'than' 'breast' 'cancer' ')'
 'except' 'basal' 'cell' 'carcinoma' 'or' 'squamous' 'cell' 'carcinoma'
 'of' 'the' 'skin' ',' 'or' 'in' 'situ' 'cervical' 'cancer' 'that' 'has'
 'undergone' 'potentially' 'curative' 'therapy']","[0. 0. 0. 3. 0. 0. 0. 3. 3. 0. 0. 3. 3. 3. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0.
 0. 3. 3. 0. 0. 0. 0. 1. 1.]"
NCT02411656,"18:57:cancer,65:89:cancer,124:140:cancer,254:262:treatment,,298:307:treatment","Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate if they are stable, and have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment","['Has' 'known' 'active' 'central' 'nervous' 'system' '(' 'CNS' ')'
 'metastases' 'and/or' 'carcinomatous' 'meningitis' ';' 'subjects' 'with'
 'previously' 'treated' 'brain' 'metastases' 'may' 'participate' 'if'
 'they' 'are' 'stable' ',' 'and' 'have' 'no' 'evidence' 'of' 'new' 'or'
 'enlarging' 'brain' 'metastases' ',' 'and' 'are' 'not' 'using' 'steroids'
 'for' 'at' 'least' '7' 'days' 'prior' 'to' 'trial' 'treatment']","[0. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 1.]"
NCT02411318,"24:40:chronic_disease,46:52:cancer,54:63:chronic_disease,65:78:chronic_disease,80:85:chronic_disease,87:94:chronic_disease,96:119:chronic_disease,129:151:chronic_disease,153:167:chronic_disease,169:179:chronic_disease,181:194:chronic_disease,199:223:chronic_disease","History of significant systemic disease (eg. cancer, infection, hematological, renal, hepatic, coronary artery disease or other cardiovascular disease, endocrinologic, neurologic, rheumatologic, or gastrointestinal disease)","['History' 'of' 'significant' 'systemic' 'disease' '(' 'eg' '.' 'cancer'
 ',' 'infection' ',' 'hematological' ',' 'renal' ',' 'hepatic' ','
 'coronary' 'artery' 'disease' 'or' 'other' 'cardiovascular' 'disease' ','
 'endocrinologic' ',' 'neurologic' ',' 'rheumatologic' ',' 'or'
 'gastrointestinal' 'disease' ')']","[0. 0. 0. 2. 2. 0. 0. 0. 3. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 2. 2. 0. 0. 2.
 2. 0. 2. 0. 2. 0. 2. 0. 0. 2. 2. 0.]"
NCT02409316,"53:60:treatment,64:70:treatment,82:95:cancer,99:110:cancer,130:157:treatment,159:176:treatment","History of ER+ pathology (ER+ may be confirmed from surgery or biopsy of primary breast cancer or lymph nodes, and/or surgery or biopsy of a metastatic site, metastatic biopsy is not required)","['History' 'of' 'ER+' 'pathology' '(' 'ER+' 'may' 'be' 'confirmed' 'from'
 'surgery' 'or' 'biopsy' 'of' 'primary' 'breast' 'cancer' 'or' 'lymph'
 'nodes' ',' 'and/or' 'surgery' 'or' 'biopsy' 'of' 'a' 'metastatic' 'site'
 ',' 'metastatic' 'biopsy' 'is' 'not' 'required' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 1. 1. 0. 3. 3. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT02408861,"1:4:chronic_disease,1:16:chronic_disease,68:82:treatment,127:168:treatment","HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme linked immunosorbent assay [ELISA], test kit, and confirmed by Western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status","['HIV-1' 'infection' ',' 'as' 'documented' 'by' 'any' 'federally'
 'approved' ',' 'licensed' 'HIV' 'rapid' 'test' 'performed' 'in'
 'conjunction' 'with' 'screening' '(' 'or' 'enzyme' 'linked'
 'immunosorbent' 'assay' '[' 'ELISA' ']' ',' 'test' 'kit' ',' 'and'
 'confirmed' 'by' 'Western' 'blot' 'or' 'other' 'approved' 'test' ')' ';'
 'alternatively' ',' 'this' 'documentation' 'may' 'include' 'a' 'record'
 'demonstrating' 'that' 'another' 'physician' 'has' 'documented' 'the'
 'participant' ""'s"" 'HIV' 'status']","[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.
 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02408861,"23:37:cancer,,174:198:treatment,200:208:treatment,213:244:treatment","for participants with Kaposi sarcoma, the following apply: at least five measurable cutaneous KS lesions or any number of lesions with systemic unresectable disease with no previous local radiation, surgical, or intralesional cytotoxic therapy that would prevent response assessment","['for' 'participants' 'with' 'Kaposi' 'sarcoma' ',' 'the' 'following'
 'apply' ':' 'at' 'least' 'five' 'measurable' 'cutaneous' 'KS' 'lesions'
 'or' 'any' 'number' 'of' 'lesions' 'with' 'systemic' 'unresectable'
 'disease' 'with' 'no' 'previous' 'local' 'radiation' ',' 'surgical' ','
 'or' 'intralesional' 'cytotoxic' 'therapy' 'that' 'would' 'prevent'
 'response' 'assessment']","[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1. 1. 0. 1. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]"
NCT02407171,"5:13:cancer,27:32:cancer,55:78:treatment,108:126:treatment","For melanoma patients and NSCLC patients treated with prior anti-PD-1 therapy, patients must have received prior PD-1 therapy and have progressed (irPD) by irRC","['For' 'melanoma' 'patients' 'and' 'NSCLC' 'patients' 'treated' 'with'
 'prior' 'anti-PD-1' 'therapy' ',' 'patients' 'must' 'have' 'received'
 'prior' 'PD-1' 'therapy' 'and' 'have' 'progressed' '(' 'irPD' ')' 'by'
 'irRC']","[0. 3. 0. 0. 3. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02407171,"10:58:treatment,16:25:treatment,65:72:treatment,",have had prior treatments with Tyrosine Kinase Inhibitors (e.g. Tarceva) require only a 72-hour washout period prior to starting protocol treatment,"['have' 'had' 'prior' 'treatments' 'with' 'Tyrosine' 'Kinase' 'Inhibitors'
 '(' 'e.g' '.' 'Tarceva' ')' 'require' 'only' 'a' '72-hour' 'washout'
 'period' 'prior' 'to' 'starting' 'protocol' 'treatment']",[0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02407028,"31:58:treatment,,115:125:treatment,126:137:treatment,151:165:treatment",Ability to initiate the first hyperbaric oxygen treatment within 8 hours of admission in patients not requiring a craniotomy/craniectomy or any other major surgical procedure OR,"['Ability' 'to' 'initiate' 'the' 'first' 'hyperbaric' 'oxygen' 'treatment'
 'within' '8' 'hours' 'of' 'admission' 'in' 'patients' 'not' 'requiring'
 'a' 'craniotomy/craniectomy' 'or' 'any' 'other' 'major' 'surgical'
 'procedure' 'OR']","[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 1.
 0. 0.]"
NCT02405078,"5:17:treatment,19:31:treatment,33:46:treatment,48:56:treatment,61:84:treatment,89:98:treatment,102:110:cancer,","Any chemotherapy, radiotherapy, immunotherapy, biologic, or investigational therapy for treatment of lymphoma within 14 days prior to treatment","['Any' 'chemotherapy' ',' 'radiotherapy' ',' 'immunotherapy' ','
 'biologic' ',' 'or' 'investigational' 'therapy' 'for' 'treatment' 'of'
 'lymphoma' 'within' '14' 'days' 'prior' 'to' 'treatment']",[0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1. 0. 1. 0. 3. 0. 0. 0. 0. 0. 0.]
NCT02404870,"17:32:chronic_disease,36:57:chronic_disease,100:109:chronic_disease,126:135:treatment","Past history of eating disorder or psychiatric disorders, including severe depression, anxiety, or psychosis or presently on treatment with medications for any of these conditions","['Past' 'history' 'of' 'eating' 'disorder' 'or' 'psychiatric' 'disorders'
 ',' 'including' 'severe' 'depression' ',' 'anxiety' ',' 'or' 'psychosis'
 'or' 'presently' 'on' 'treatment' 'with' 'medications' 'for' 'any' 'of'
 'these' 'conditions']","[0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 1. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02404155,"46:54:chronic_disease,56:64:chronic_disease,66:73:chronic_disease,75:81:chronic_disease,83:97:chronic_disease","Documented nutritional deficiencies (such as Beriberi, Pellagra, Rickets, Scurvy, Keshan Disease)","['Documented' 'nutritional' 'deficiencies' '(' 'such' 'as' 'Beriberi' ','
 'Pellagra' ',' 'Rickets' ',' 'Scurvy' ',' 'Keshan' 'Disease' ')']",[0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 2. 0.]
NCT02403193,"22:38:chronic_disease,42:58:chronic_disease,146:155:treatment",Serious uncontrolled medical disorder or active infection that in the investigator's opinion would impair the patient's ability to receive study treatment,"['Serious' 'uncontrolled' 'medical' 'disorder' 'or' 'active' 'infection'
 'that' 'in' 'the' 'investigator' ""'s"" 'opinion' 'would' 'impair' 'the'
 'patient' ""'s"" 'ability' 'to' 'receive' 'study' 'treatment']",[0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02402660,"26:41:chronic_disease,211:227:treatment,,254:288:chronic_disease","Has active or historical ocular disorder in the primary study eye that, in the opinion of the investigator, may confound assessment of the retina morphologically or functionally (this could include for example cataract surgery within the past 6 months, choroidal neovascularization (CNV)","['Has' 'active' 'or' 'historical' 'ocular' 'disorder' 'in' 'the' 'primary'
 'study' 'eye' 'that' ',' 'in' 'the' 'opinion' 'of' 'the' 'investigator'
 ',' 'may' 'confound' 'assessment' 'of' 'the' 'retina' 'morphologically'
 'or' 'functionally' '(' 'this' 'could' 'include' 'for' 'example'
 'cataract' 'surgery' 'within' 'the' 'past' '6' 'months' ',' 'choroidal'
 'neovascularization' '(' 'CNV' ')']","[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0.]"
NCT02402088,"25:42:chronic_disease,51:63:chronic_disease,65:79:chronic_disease,81:90:chronic_disease,92:97:chronic_disease,99:104:chronic_disease,106:123:chronic_disease,137:148:treatment","Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, liver, thyroid pathology; subjects on medications for any medical condition","['Any' 'significant' 'current' 'medical' 'condition' 'such' 'as'
 'neurological' ',' 'cardiovascular' ',' 'endocrine' ',' 'renal' ','
 'liver' ',' 'thyroid' 'pathology' ';' 'subjects' 'on' 'medications' 'for'
 'any' 'medical' 'condition']","[0. 0. 0. 2. 2. 0. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 2. 0. 0. 0. 1. 0.
 0. 0. 0.]"
NCT02401347,"20:36:cancer,60:84:treatment,88:125:treatment,191:206:treatment,215:225:treatment,",Adequately treated brain metastases documented by baseline computed tomography (CT) or magnetic resonance imaging (MRI) scan that have not progressed since previous scans and do not require corticosteroids (except prednisone ≤ 5 mg/day or equivalent) for management of CNS symptoms,"['Adequately' 'treated' 'brain' 'metastases' 'documented' 'by' 'baseline'
 'computed' 'tomography' '(' 'CT' ')' 'or' 'magnetic' 'resonance'
 'imaging' '(' 'MRI' ')' 'scan' 'that' 'have' 'not' 'progressed' 'since'
 'previous' 'scans' 'and' 'do' 'not' 'require' 'corticosteroids' '('
 'except' 'prednisone' '≤' '5' 'mg/day' 'or' 'equivalent' ')' 'for'
 'management' 'of' 'CNS' 'symptoms']","[0. 0. 3. 3. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02401347,"30:41:treatment,45:54:treatment,,137:155:treatment","If prior platinum agent (eg, carboplatin or cisplatin) has been administered, no evidence of progression, or within 8 weeks of stopping platinum treatment","['If' 'prior' 'platinum' 'agent' '(' 'eg' ',' 'carboplatin' 'or'
 'cisplatin' ')' 'has' 'been' 'administered' ',' 'no' 'evidence' 'of'
 'progression' ',' 'or' 'within' '8' 'weeks' 'of' 'stopping' 'platinum'
 'treatment']","[0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02401074,"8:21:treatment,29:36:treatment,38:49:treatment,59:73:treatment,74:82:treatment,84:91:treatment,93:100:treatment,,135:147:treatment","Use of anti-platelet (i.e., aspirin, clopidogrel, etc) or anti-coagulant(coumadin, heparin, Xarelto®, etc) medication 5 days prior to bronchoscopy","['Use' 'of' 'anti-platelet' '(' 'i.e.' ',' 'aspirin' ',' 'clopidogrel' ','
 'etc' ')' 'or' 'anti-coagulant' '(' 'coumadin' ',' 'heparin' ','
 'Xarelto®' ',' 'etc' ')' 'medication' '5' 'days' 'prior' 'to'
 'bronchoscopy']","[0. 0. 1. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 1.]"
NCT02401035,"8:13:treatment,15:25:treatment,27:38:treatment,43:60:treatment,66:86:treatment,,118:141:treatment","Use of H2RAs, sucralfate, misoprostol, or prokinetic agents, and bismuth preparations within 1 day (24 hours) before investigational product dosing on Day 1","['Use' 'of' 'H2RAs' ',' 'sucralfate' ',' 'misoprostol' ',' 'or'
 'prokinetic' 'agents' ',' 'and' 'bismuth' 'preparations' 'within' '1'
 'day' '(' '24' 'hours' ')' 'before' 'investigational' 'product' 'dosing'
 'on' 'Day' '1']","[0. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 0. 0. 0. 0.]"
NCT02400463,"34:44:cancer,154:162:treatment,166:191:treatment",Patients with a prior history of malignancy are eligible if their malignancy has been definitely treated or is in remission and does not require ongoing adjuvant or cancer-directed therapies,"['Patients' 'with' 'a' 'prior' 'history' 'of' 'malignancy' 'are'
 'eligible' 'if' 'their' 'malignancy' 'has' 'been' 'definitely' 'treated'
 'or' 'is' 'in' 'remission' 'and' 'does' 'not' 'require' 'ongoing'
 'adjuvant' 'or' 'cancer-directed' 'therapies']","[0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 1. 1.]"
NCT02400255,"1:64:treatment,71:103:treatment,105:128:treatment,133:190:treatment","First allogeneic hematopoietic stem cell transplantation (HSCT) using myeloablative conditioning (MAC), non-myeloablative (NMA), or reduced-intensity conditioning (RIC) preparative regimens","['First' 'allogeneic' 'hematopoietic' 'stem' 'cell' 'transplantation' '('
 'HSCT' ')' 'using' 'myeloablative' 'conditioning' '(' 'MAC' ')' ','
 'non-myeloablative' '(' 'NMA' ')' ',' 'or' 'reduced-intensity'
 'conditioning' '(' 'RIC' ')' 'preparative' 'regimens']","[1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1.
 1. 1. 1. 0. 0.]"
NCT02400255,"13:28:chronic_disease,,,,79:94:chronic_disease,103:113:treatment",Significant cardiac disease (New York Heart Association classes III or IV) or unstable angina despite medication,"['Significant' 'cardiac' 'disease' '(' 'New' 'York' 'Heart' 'Association'
 'classes' 'III' 'or' 'IV' ')' 'or' 'unstable' 'angina' 'despite'
 'medication']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 1.]
NCT02398773,",61:73:treatment,78:88:cancer,,152:194:treatment",Patient must NOT have a history of > 1 line of administered chemotherapy for metastatic disease and must be off chemotherapy for a minimum of 2 weeks; prior chemotherapy in the adjuvant setting is allowed,"['Patient' 'must' 'NOT' 'have' 'a' 'history' 'of' '>' '1' 'line' 'of'
 'administered' 'chemotherapy' 'for' 'metastatic' 'disease' 'and' 'must'
 'be' 'off' 'chemotherapy' 'for' 'a' 'minimum' 'of' '2' 'weeks' ';'
 'prior' 'chemotherapy' 'in' 'the' 'adjuvant' 'setting' 'is' 'allowed']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0.]"
NCT02398240,"4:43:treatment,75:98:treatment,,114:147:cancer",No prior Hodgkin lymphoma directed therapy is allowed except for emergent mediastinal irradiation (<1000cGy) for superior vena cava (SVC) syndrome,"['No' 'prior' 'Hodgkin' 'lymphoma' 'directed' 'therapy' 'is' 'allowed'
 'except' 'for' 'emergent' 'mediastinal' 'irradiation' '(' '<' '1000cGy'
 ')' 'for' 'superior' 'vena' 'cava' '(' 'SVC' ')' 'syndrome']","[0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 0.
 0.]"
NCT02397889,"25:43:chronic_disease,54:67:chronic_disease,71:95:chronic_disease",diagnosis of a lifetime psychotic disorder including schizophrenia or schizoaffective disorder,"['diagnosis' 'of' 'a' 'lifetime' 'psychotic' 'disorder' 'including'
 'schizophrenia' 'or' 'schizoaffective' 'disorder']",[0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 2.]
NCT02397083,"21:42:chronic_disease,55:65:chronic_disease,118:128:treatment,159:169:treatment,191:207:treatment,228:236:treatment,270:292:chronic_disease,298:325:chronic_disease","Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus (e.g., inability to take oral medication or a requirement for intravenous [IV] alimentation, prior surgical procedures affecting absorption, malabsorption syndrome, and active peptic ulcer disease)","['Known' 'impairment' 'of' 'gastrointestinal' '(' 'GI' ')' 'function' 'or'
 'GI' 'disease' 'that' 'may' 'significantly' 'alter' 'the' 'absorption'
 'of' 'oral' 'everolimus' '(' 'e.g.' ',' 'inability' 'to' 'take' 'oral'
 'medication' 'or' 'a' 'requirement' 'for' 'intravenous' '[' 'IV' ']'
 'alimentation' ',' 'prior' 'surgical' 'procedures' 'affecting'
 'absorption' ',' 'malabsorption' 'syndrome' ',' 'and' 'active' 'peptic'
 'ulcer' 'disease' ')']","[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 2. 2. 0. 0.
 2. 2. 2. 2. 0.]"
NCT02397083,"81:105:chronic_disease,119:143:chronic_disease,145:166:chronic_disease,,197:207:treatment,230:248:chronic_disease,286:301:chronic_disease,,,,393:399:chronic_disease,422:451:chronic_disease,471:482:treatment,485:498:chronic_disease,507:516:chronic_disease,599:610:chronic_disease,715:732:chronic_disease,780:802:chronic_disease,,,,,971:989:chronic_disease","Patients who have any severe and/or uncontrolled medical conditions such as: a) unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction =< 6 months prior to start of everolimus, serious uncontrolled cardiac arrhythmia, or any other clinically significant cardiac disease; b) symptomatic congestive heart failure of New York Heart Association class III or IV; c) active (acute or chronic) or uncontrolled severe infection (not responding to antibiotics), liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis (i.e. quantifiable hepatitis B virus-deoxyribonucleic acid [HBV-DNA] and/or positive hepatitis B surface antigen [HbsAg], quantifiable hepatitis C virus-ribonucleic acid [HCV-RNA]); d) known severely impaired lung function (spirometry and diffusing capacity of the lung for carbon monoxide [DLCO] 50% or less of normal and oxygen [O2] saturation 88% or less at rest on room air); e) active, bleeding diathesis","['Patients' 'who' 'have' 'any' 'severe' 'and/or' 'uncontrolled' 'medical'
 'conditions' 'such' 'as' ':' 'a' ')' 'unstable' 'angina' 'pectoris' ','
 'symptomatic' 'congestive' 'heart' 'failure' ',' 'myocardial'
 'infarction' '=' '<' '6' 'months' 'prior' 'to' 'start' 'of' 'everolimus'
 ',' 'serious' 'uncontrolled' 'cardiac' 'arrhythmia' ',' 'or' 'any'
 'other' 'clinically' 'significant' 'cardiac' 'disease' ';' 'b' ')'
 'symptomatic' 'congestive' 'heart' 'failure' 'of' 'New' 'York' 'Heart'
 'Association' 'class' 'III' 'or' 'IV' ';' 'c' ')' 'active' '(' 'acute'
 'or' 'chronic' ')' 'or' 'uncontrolled' 'severe' 'infection' '(' 'not'
 'responding' 'to' 'antibiotics' ')' ',' 'liver' 'disease' 'such' 'as'
 'cirrhosis' ',' 'decompensated' 'liver' 'disease' ',' 'and' 'active'
 'and' 'chronic' 'hepatitis' '(' 'i.e' '.' 'quantifiable' 'hepatitis' 'B'
 'virus-deoxyribonucleic' 'acid' '[' 'HBV-DNA' ']' 'and/or' 'positive'
 'hepatitis' 'B' 'surface' 'antigen' '[' 'HbsAg' ']' ',' 'quantifiable'
 'hepatitis' 'C' 'virus-ribonucleic' 'acid' '[' 'HCV-RNA' ']' ')' ';' 'd'
 ')' 'known' 'severely' 'impaired' 'lung' 'function' '(' 'spirometry'
 'and' 'diffusing' 'capacity' 'of' 'the' 'lung' 'for' 'carbon' 'monoxide'
 '[' 'DLCO' ']' '50' '%' 'or' 'less' 'of' 'normal' 'and' 'oxygen' '[' 'O2'
 ']' 'saturation' '88' '%' 'or' 'less' 'at' 'rest' 'on' 'room' 'air' ')'
 ';' 'e' ')' 'active' ',' 'bleeding' 'diathesis']","[0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 2. 2. 2. 0. 2.
 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 2. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]"
NCT02394704,"5:32:treatment,34:43:treatment,45:75:treatment,86:131:treatment","Any implanted electrical device (pacemaker, vagus nerve stimulator implant, etc.) or prior treatment with a vagus nerve stimulator","['Any' 'implanted' 'electrical' 'device' '(' 'pacemaker' ',' 'vagus'
 'nerve' 'stimulator' 'implant' ',' 'etc' '.' ')' 'or' 'prior' 'treatment'
 'with' 'a' 'vagus' 'nerve' 'stimulator']",[0. 1. 1. 1. 0. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1.]
NCT02394535,"13:21:treatment,41:48:treatment,,83:95:treatment",Patients on Coumadin must be changed to Lovenox at least 1 week prior to starting capecitabine,"['Patients' 'on' 'Coumadin' 'must' 'be' 'changed' 'to' 'Lovenox' 'at'
 'least' '1' 'week' 'prior' 'to' 'starting' 'capecitabine']",[0. 0. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02394535,"1:11:treatment,35:51:treatment,75:85:treatment",ranitidine or a drug from another anti-ulcer class can be substituted for cimetidine,"['ranitidine' 'or' 'a' 'drug' 'from' 'another' 'anti-ulcer' 'class' 'can'
 'be' 'substituted' 'for' 'cimetidine']",[1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1.]
NCT02394028,"28:46:allergy_name,134:136:allergy_name,140:150:allergy_name",intolerance to one or more anti-TNF therapies are eligible to participate in the study provided they are intolerant or refractory to CS or IS therapy,"['intolerance' 'to' 'one' 'or' 'more' 'anti-TNF' 'therapies' 'are'
 'eligible' 'to' 'participate' 'in' 'the' 'study' 'provided' 'they' 'are'
 'intolerant' 'or' 'refractory' 'to' 'CS' 'or' 'IS' 'therapy']","[0. 0. 0. 0. 0. 4. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 4.
 4.]"
NCT02393885,"19:32:cancer,34:48:cancer,52:63:cancer","Has the following atrial myxoma, mural thrombus or mural tumor","['Has' 'the' 'following' 'atrial' 'myxoma' ',' 'mural' 'thrombus' 'or'
 'mural' 'tumor']",[0. 0. 0. 3. 3. 0. 3. 3. 0. 0. 0.]
NCT02393885,"37:56:chronic_disease,92:103:chronic_disease,115:139:chronic_disease,143:157:chronic_disease","Uncorrected, reversible cause(s) of atrial fibrillation, or is currently being treated for arrhythmias other than atrial fibrillation (AF) or atrial flutter","['Uncorrected' ',' 'reversible' 'cause' '(' 's' ')' 'of' 'atrial'
 'fibrillation' ',' 'or' 'is' 'currently' 'being' 'treated' 'for'
 'arrhythmias' 'other' 'than' 'atrial' 'fibrillation' '(' 'AF' ')' 'or'
 'atrial' 'flutter']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02393794,"1:18:treatment,23:32:treatment,42:60:cancer",IV bisphosphonate and denosumab for bony metastatic disease is allowed,"['IV' 'bisphosphonate' 'and' 'denosumab' 'for' 'bony' 'metastatic'
 'disease' 'is' 'allowed']",[1. 1. 0. 1. 0. 0. 3. 3. 0. 0.]
NCT02393794,"52:69:treatment,94:117:cancer,168:180:treatment,207:223:treatment","Participants who have previously been treated with endocrine therapy only, and later develop triple negative disease are eligible as long as they have had one line of chemotherapy in either the advanced or adjuvant setting","['Participants' 'who' 'have' 'previously' 'been' 'treated' 'with'
 'endocrine' 'therapy' 'only' ',' 'and' 'later' 'develop' 'triple'
 'negative' 'disease' 'are' 'eligible' 'as' 'long' 'as' 'they' 'have'
 'had' 'one' 'line' 'of' 'chemotherapy' 'in' 'either' 'the' 'advanced'
 'or' 'adjuvant' 'setting']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1. 1.]"
NCT02393794,"26:45:treatment,56:68:treatment,70:83:treatment,85:93:treatment,95:111:treatment,120:143:treatment","Subject has received any anti-cancer therapy including chemotherapy, immunotherapy, biologic, targeted therapy, or any investigational therapy","['Subject' 'has' 'received' 'any' 'anti-cancer' 'therapy' 'including'
 'chemotherapy' ',' 'immunotherapy' ',' 'biologic' ',' 'targeted'
 'therapy' ',' 'or' 'any' 'investigational' 'therapy']",[0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 1. 0. 1. 1. 0. 0. 0. 1. 1.]
NCT02393794,"43:48:cancer,52:75:cancer,77:105:cancer,129:144:cancer,154:161:cancer,162:175:cancer","with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer or prior ovarian/breast cancer in patients with BRCA associated breast cancer","['with' 'the' 'exception' 'of' 'adequately' 'treated' ',' 'basal' 'or'
 'squamous' 'cell' 'carcinoma' ',' 'non-melanomatous' 'skin' 'cancer' 'or'
 'curatively' 'resected' 'cervical' 'cancer' 'or' 'prior' 'ovarian/breast'
 'cancer' 'in' 'patients' 'with' 'BRCA' 'associated' 'breast' 'cancer']","[0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 3. 0. 3. 3. 3. 0. 0. 0. 3. 3. 0. 0. 3.
 3. 0. 0. 0. 0. 0. 0. 0.]"
NCT02393690,"19:64:treatment,66:69:treatment,74:88:treatment,117:126:treatment,173:184:allergy_name,186:214:allergy_name,223:239:allergy_name","Prior exposure to mitogen-activated protein kinase kinase (MEK), RAS, or RAF inhibitors (note: previous exposure to sorafenib is allowed) OR history of hypersensitivity to selumetinib, thyrotropin alpha (Thyrogen), or any excipient agents","['Prior' 'exposure' 'to' 'mitogen-activated' 'protein' 'kinase' 'kinase'
 '(' 'MEK' ')' ',' 'RAS' ',' 'or' 'RAF' 'inhibitors' '(' 'note' ':'
 'previous' 'exposure' 'to' 'sorafenib' 'is' 'allowed' ')' 'OR' 'history'
 'of' 'hypersensitivity' 'to' 'selumetinib' ',' 'thyrotropin' 'alpha' '('
 'Thyrogen' ')' ',' 'or' 'any' 'excipient' 'agents']","[0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 4. 0. 4. 4. 4. 0. 0. 0. 0. 0. 4. 4.]"
NCT02393690,"1:10:cancer,15:41:cancer,56:79:cancer,115:129:cancer,,206:225:cancer,227:241:cancer","medullary and anaplastic thyroid cancers are excluded; Hurthle cell carcinomas are excluded (defined as having an invasive tumor composed of > 75% oncocytic [Hurthle] cells lacking the nuclear features of papillary carcinoma, tumor necrosis, and marked mitotic activity)","['medullary' 'and' 'anaplastic' 'thyroid' 'cancers' 'are' 'excluded' ';'
 'Hurthle' 'cell' 'carcinomas' 'are' 'excluded' '(' 'defined' 'as'
 'having' 'an' 'invasive' 'tumor' 'composed' 'of' '>' '75' '%' 'oncocytic'
 '[' 'Hurthle' ']' 'cells' 'lacking' 'the' 'nuclear' 'features' 'of'
 'papillary' 'carcinoma' ',' 'tumor' 'necrosis' ',' 'and' 'marked'
 'mitotic' 'activity' ')']","[3. 0. 3. 3. 3. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02392572,"41:79:cancer,64:79:cancer,83:96:cancer","For Arm E, in addition to patients with relapsed or refractory acute leukemias or high-risk MDS, patients with untreated high-risk MDS or acute leukemias","['For' 'Arm' 'E' ',' 'in' 'addition' 'to' 'patients' 'with' 'relapsed'
 'or' 'refractory' 'acute' 'leukemias' 'or' 'high-risk' 'MDS' ','
 'patients' 'with' 'untreated' 'high-risk' 'MDS' 'or' 'acute' 'leukemias']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02392572,"4:13:treatment,19:42:treatment,74:86:treatment,91:101:treatment",No treatment with immunosuppressive drugs with the exception of low dose cyclosporine and tacrolimus,"['No' 'treatment' 'with' 'immunosuppressive' 'drugs' 'with' 'the'
 'exception' 'of' 'low' 'dose' 'cyclosporine' 'and' 'tacrolimus']",[0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 1.]
NCT02392572,"14:34:chronic_disease,65:87:chronic_disease,101:125:chronic_disease,,,,186:204:chronic_disease,209:228:chronic_disease,229:246:chronic_disease","Uncontrolled intercurrent illness including, but not limited to uncontrolled infection, symptomatic congestive heart failure (New York Heart Association class III and IV), uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' 'uncontrolled' 'infection' ',' 'symptomatic' 'congestive'
 'heart' 'failure' '(' 'New' 'York' 'Heart' 'Association' 'class' 'III'
 'and' 'IV' ')' ',' 'uncontrolled' 'cardiac' 'arrhythmia' ',' 'or'
 'psychiatric' 'illness/social' 'situations' 'that' 'would' 'limit'
 'compliance' 'with' 'study' 'requirements']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02392286,"8:21:chronic_disease,37:46:chronic_disease,55:74:chronic_disease","severe liver disease (decompensated cirrhosis, active alcoholic hepatitis)","['severe' 'liver' 'disease' '(' 'decompensated' 'cirrhosis' ',' 'active'
 'alcoholic' 'hepatitis' ')']",[0. 2. 2. 0. 0. 2. 0. 0. 2. 2. 0.]
NCT02391402,"24:35:chronic_disease,78:94:chronic_disease,99:118:chronic_disease,159:169:treatment",Individuals with other psychiatric diagnoses will not be excluded except for bipolar disorder and psychotic disorders (requirement to refrain from additional treatments might be harmful),"['Individuals' 'with' 'other' 'psychiatric' 'diagnoses' 'will' 'not' 'be'
 'excluded' 'except' 'for' 'bipolar' 'disorder' 'and' 'psychotic'
 'disorders' '(' 'requirement' 'to' 'refrain' 'from' 'additional'
 'treatments' 'might' 'be' 'harmful' ')']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 1. 0.
 0. 0. 0.]"
NCT02390752,"5:8:cancer,24:48:treatment,83:96:treatment","For NF1 PN there is no standard medical therapy, and therefore no requirement for prior therapy","['For' 'NF1' 'PN' 'there' 'is' 'no' 'standard' 'medical' 'therapy' ','
 'and' 'therefore' 'no' 'requirement' 'for' 'prior' 'therapy']",[0. 3. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02390752,",59:100:treatment,107:117:treatment,,174:187:treatment","Others: greater than or equal to 7 days from last dose of short active hematopoietic growth factors, i.e. filgrastim, greater than or equal to 14 days for long-acting, i.e. pegfilgrastim","['Others' ':' 'greater' 'than' 'or' 'equal' 'to' '7' 'days' 'from' 'last'
 'dose' 'of' 'short' 'active' 'hematopoietic' 'growth' 'factors' ',' 'i.e'
 '.' 'filgrastim' ',' 'greater' 'than' 'or' 'equal' 'to' '14' 'days' 'for'
 'long-acting' ',' 'i.e' '.' 'pegfilgrastim']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02390752,",39:60:treatment,62:84:treatment,89:107:treatment,111:121:cancer","greater than or equal to 14 days from whole brain radiation, craniospinal radiation, or targeted radiation to CNS tumors","['greater' 'than' 'or' 'equal' 'to' '14' 'days' 'from' 'whole' 'brain'
 'radiation' ',' 'craniospinal' 'radiation' ',' 'or' 'targeted'
 'radiation' 'to' 'CNS' 'tumors']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 0. 0. 1. 1. 0. 3. 3.]
NCT02389517,"12:37:chronic_disease,46:78:chronic_disease,89:123:chronic_disease","Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive","['Ongoing' 'or' 'active' 'systemic' 'infection' ',' 'active' 'hepatitis'
 'B' 'or' 'C' 'virus' 'infection' ',' 'or' 'known' 'human'
 'immunodeficiency' 'virus' '(' 'HIV' ')' 'positive']",[0. 0. 2. 2. 2. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0.]
NCT02389465,"24:46:chronic_disease,187:202:treatment,206:227:chronic_disease,,253:268:chronic_disease,270:340:chronic_disease,362:406:chronic_disease,440:464:chronic_disease,477:500:chronic_disease,502:534:chronic_disease,,,591:606:chronic_disease,626:632:chronic_disease","Clinically significant cardiovascular disease that will be assessed on a case-by-case basis. Clinically significant cardiovascular disease usually includes one or more of the following: cardiac surgery or myocardial infarction within the last 4 weeks; unstable angina; acute decompensated congestive heart failure or class IV heart failure; current significant cardiac arrhythmia or conduction disturbance, particularly those resulting in ventricular fibrillation, or causing syncope or near syncope; uncontrolled high blood pressure; QTc greater than 450msec (by history for subjects with cardiac disease); documented prior stroke","['Clinically' 'significant' 'cardiovascular' 'disease' 'that' 'will' 'be'
 'assessed' 'on' 'a' 'case-by-case' 'basis' '.' 'Clinically' 'significant'
 'cardiovascular' 'disease' 'usually' 'includes' 'one' 'or' 'more' 'of'
 'the' 'following' ':' 'cardiac' 'surgery' 'or' 'myocardial' 'infarction'
 'within' 'the' 'last' '4' 'weeks' ';' 'unstable' 'angina' ';' 'acute'
 'decompensated' 'congestive' 'heart' 'failure' 'or' 'class' 'IV' 'heart'
 'failure' ';' 'current' 'significant' 'cardiac' 'arrhythmia' 'or'
 'conduction' 'disturbance' ',' 'particularly' 'those' 'resulting' 'in'
 'ventricular' 'fibrillation' ',' 'or' 'causing' 'syncope' 'or' 'near'
 'syncope' ';' 'uncontrolled' 'high' 'blood' 'pressure' ';' 'QTc'
 'greater' 'than' '450msec' '(' 'by' 'history' 'for' 'subjects' 'with'
 'cardiac' 'disease' ')' ';' 'documented' 'prior' 'stroke']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 2. 2. 2. 2. 2.
 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 2. 2.
 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]"
NCT02389465,"76:86:allergy_name,90:102:allergy_name,114:123:allergy_name,125:132:allergy_name,143:149:allergy_name,218:230:allergy_name","Known history of relevant severe drug allergy or hypersensitivity (e.g. to Citalopram or Escitalopram, and/or to celecoxib, aspirin, or other NSAIDs only for Phase 2; known demonstration of allergic-type reactions to sulfonamides)","['Known' 'history' 'of' 'relevant' 'severe' 'drug' 'allergy' 'or'
 'hypersensitivity' '(' 'e.g' '.' 'to' 'Citalopram' 'or' 'Escitalopram'
 ',' 'and/or' 'to' 'celecoxib' ',' 'aspirin' ',' 'or' 'other' 'NSAIDs'
 'only' 'for' 'Phase' '2' ';' 'known' 'demonstration' 'of' 'allergic-type'
 'reactions' 'to' 'sulfonamides' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 0. 0. 4. 0. 4. 0. 0.
 0. 4. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0.]"
NCT02389309,"1:11:treatment,13:20:treatment,22:31:treatment,33:43:treatment","Amiodarone, sotalol, ibutilide, dofetilide","['Amiodarone' ',' 'sotalol' ',' 'ibutilide' ',' 'dofetilide']",[1. 0. 1. 0. 1. 0. 1.]
NCT02389309,"1:15:treatment,17:28:treatment,30:42:treatment,44:56:treatment,58:66:treatment","Chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide","['Chlorpromazine' ',' 'haloperidol' ',' 'mesoridazine' ',' 'thioridazine'
 ',' 'pimozide']",[1. 0. 1. 0. 1. 0. 1. 0. 1.]
NCT02389309,"28:52:treatment,54:65:treatment,67:89:treatment,122:130:treatment,194:207:treatment,,343:352:treatment","Inducers and Inhibitors of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4): patients required to be on any CYP3A4/5 inhibitors or inducers will be excluded (with the exception of dexamethasone, but all efforts should be made to reduce the dose of dexamethasone); patients must discontinue drug at least 7 days prior to starting dasatinib","['Inducers' 'and' 'Inhibitors' 'of' 'cytochrome' 'P450' 'family' '3' ','
 'subfamily' 'A' ',' 'polypeptide' '4' '(' 'CYP3A4' ')' ':' 'patients'
 'required' 'to' 'be' 'on' 'any' 'CYP3A4/5' 'inhibitors' 'or' 'inducers'
 'will' 'be' 'excluded' '(' 'with' 'the' 'exception' 'of' 'dexamethasone'
 ',' 'but' 'all' 'efforts' 'should' 'be' 'made' 'to' 'reduce' 'the' 'dose'
 'of' 'dexamethasone' ')' ';' 'patients' 'must' 'discontinue' 'drug' 'at'
 'least' '7' 'days' 'prior' 'to' 'starting' 'dasatinib']","[0. 0. 0. 0. 1. 1. 1. 1. 0. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02389309,"34:57:chronic_disease,,97:122:chronic_disease,135:158:chronic_disease,165:188:treatment","Patients with evidence of recent intratumoral hemorrhage (within 3 months of study enrollment), gastrointestinal bleeding, history of coronary artery disease or on anticoagulation therapy","['Patients' 'with' 'evidence' 'of' 'recent' 'intratumoral' 'hemorrhage'
 '(' 'within' '3' 'months' 'of' 'study' 'enrollment' ')' ','
 'gastrointestinal' 'bleeding' ',' 'history' 'of' 'coronary' 'artery'
 'disease' 'or' 'on' 'anticoagulation' 'therapy']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 2.
 0. 0. 1. 1.]"
NCT02389309,"1:8:treatment,,37:44:treatment,95:127:treatment",Surgery: at least 2 weeks following surgery including brain and spine provided post-operative magnetic resonance imaging (MRI) shows no active bleeding,"['Surgery' ':' 'at' 'least' '2' 'weeks' 'following' 'surgery' 'including'
 'brain' 'and' 'spine' 'provided' 'post-operative' 'magnetic' 'resonance'
 'imaging' '(' 'MRI' ')' 'shows' 'no' 'active' 'bleeding']",[1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02389309,"1:16:treatment,29:38:treatment,42:54:treatment",prior treatment with either dasatinib or temsirolimus,['prior' 'treatment' 'with' 'either' 'dasatinib' 'or' 'temsirolimus'],[1. 1. 0. 0. 1. 0. 1.]
NCT02388685,"27:30:treatment,32:50:treatment,52:65:treatment,67:102:treatment,104:115:treatment,119:136:treatment,138:152:chronic_disease","Known contraindication to MRI (intracardiac pacer, defibrillator, certain intracranial aneurysm clips, intraocular or cochlear implants, claustrophobia, etc.)","['Known' 'contraindication' 'to' 'MRI' '(' 'intracardiac' 'pacer' ','
 'defibrillator' ',' 'certain' 'intracranial' 'aneurysm' 'clips' ','
 'intraocular' 'or' 'cochlear' 'implants' ',' 'claustrophobia' ',' 'etc'
 '.' ')']","[0. 0. 0. 1. 0. 1. 1. 0. 1. 0. 1. 1. 1. 1. 0. 1. 0. 1. 1. 0. 2. 0. 0. 0.
 0.]"
NCT02387216,"73:87:cancer,112:130:cancer,,,192:199:treatment","Patients with a diagnosis of cytologically or histologically documented adenocarcinoma of the lung with either metastatic disease (stage IV), Stage IIIB or Stage IIIC disease not amenable to surgery with curative intent","['Patients' 'with' 'a' 'diagnosis' 'of' 'cytologically' 'or'
 'histologically' 'documented' 'adenocarcinoma' 'of' 'the' 'lung' 'with'
 'either' 'metastatic' 'disease' '(' 'stage' 'IV' ')' ',' 'Stage' 'IIIB'
 'or' 'Stage' 'IIIC' 'disease' 'not' 'amenable' 'to' 'surgery' 'with'
 'curative' 'intent']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]"
NCT02384954,"69:78:treatment,102:111:treatment,,301:308:treatment","Anti-CD20 mAb-sensitive disease is defined by a response to a prior rituximab-containing (or another treatment of an anti-CD20 monoclonal antibody) regimen, and relapse more than 6 months from the last administration of rituximab-containing (or another treatment of an anti-CD20 antibody-containing) therapy","['Anti-CD20' 'mAb-sensitive' 'disease' 'is' 'defined' 'by' 'a' 'response'
 'to' 'a' 'prior' 'rituximab-containing' '(' 'or' 'another' 'treatment'
 'of' 'an' 'anti-CD20' 'monoclonal' 'antibody' ')' 'regimen' ',' 'and'
 'relapse' 'more' 'than' '6' 'months' 'from' 'the' 'last' 'administration'
 'of' 'rituximab-containing' '(' 'or' 'another' 'treatment' 'of' 'an'
 'anti-CD20' 'antibody-containing' ')' 'therapy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02382549,"1:17:treatment,25:32:treatment,34:42:treatment,44:53:treatment,74:97:treatment","Inhaled steroids (e.g.: Advair®, Flovent®, Azmacort®) are not permitted. Topical corticosteroids are acceptable","['Inhaled' 'steroids' '(' 'e.g' '.' ':' 'Advair®' ',' 'Flovent®' ','
 'Azmacort®' ')' 'are' 'not' 'permitted' '.' 'Topical' 'corticosteroids'
 'are' 'acceptable']",[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.]
NCT02382549,"27:36:cancer,38:43:cancer,45:69:cancer,77:101:cancer","participants may have had cutaneous, uveal, mucosal primary melanoma, or an unknown primary melanoma","['participants' 'may' 'have' 'had' 'cutaneous' ',' 'uveal' ',' 'mucosal'
 'primary' 'melanoma' ',' 'or' 'an' 'unknown' 'primary' 'melanoma']",[0. 0. 0. 0. 3. 0. 3. 0. 3. 3. 3. 0. 0. 0. 3. 3. 3.]
NCT02382419,"1:75:cancer,90:120:chronic_disease,206:229:treatment","Normal Pap or Atypical Squamous Cells of Undetermined Significance (ASCUS) Pap test with HPV deoxyribonucleic acid (DNA) negative by reflex testing via Hybrid Capture 2 (Digene Corp., Gaithersburg, MD), a standard clinical assay within clinically acceptable screening guidelines (American Cancer Society [ACS]/American Society for Colposcopy and Cervical Pathology [ASCCP] 2012 Screening Guidelines)","['Normal' 'Pap' 'or' 'Atypical' 'Squamous' 'Cells' 'of' 'Undetermined'
 'Significance' '(' 'ASCUS' ')' 'Pap' 'test' 'with' 'HPV'
 'deoxyribonucleic' 'acid' '(' 'DNA' ')' 'negative' 'by' 'reflex'
 'testing' 'via' 'Hybrid' 'Capture' '2' '(' 'Digene' 'Corp.' ','
 'Gaithersburg' ',' 'MD' ')' ',' 'a' 'standard' 'clinical' 'assay'
 'within' 'clinically' 'acceptable' 'screening' 'guidelines' '('
 'American' 'Cancer' 'Society' '[' 'ACS' ']' '/American' 'Society' 'for'
 'Colposcopy' 'and' 'Cervical' 'Pathology' '[' 'ASCCP' ']' '2012'
 'Screening' 'Guidelines' ')']","[3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02379520,"16:22:cancer,61:64:chronic_disease,95:101:treatment",Diagnosis of a cancer for which the presence of a high risk HPV type has been documented in a biopsy sample,"['Diagnosis' 'of' 'a' 'cancer' 'for' 'which' 'the' 'presence' 'of' 'a'
 'high' 'risk' 'HPV' 'type' 'has' 'been' 'documented' 'in' 'a' 'biopsy'
 'sample']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 1. 0.]
NCT02378428,"18:65:treatment,58:65:treatment,,,106:123:treatment,106:115:treatment","Patients for who CEM (carboplatin, etoposide, melphalan) therapy is administered within 30 days prior to 131I-MIBG therapy or for whom this therapy is planned within 30 days following administration of 131I-MIBG","['Patients' 'for' 'who' 'CEM' '(' 'carboplatin' ',' 'etoposide' ','
 'melphalan' ')' 'therapy' 'is' 'administered' 'within' '30' 'days'
 'prior' 'to' '131I-MIBG' 'therapy' 'or' 'for' 'whom' 'this' 'therapy'
 'is' 'planned' 'within' '30' 'days' 'following' 'administration' 'of'
 '131I-MIBG']","[0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02376205,"39:67:treatment,72:86:treatment,91:104:chronic_disease,108:118:chronic_disease",Patients undergoing one- or two-level anterior cervical discectomy and fusion surgery for radiculopathy or myelopathy symptoms,"['Patients' 'undergoing' 'one-' 'or' 'two-level' 'anterior' 'cervical'
 'discectomy' 'and' 'fusion' 'surgery' 'for' 'radiculopathy' 'or'
 'myelopathy' 'symptoms']",[0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 0. 2. 0. 2. 0.]
NCT02374333,"1:13:chronic_disease,37:44:treatment,110:122:chronic_disease","CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity","['CNS3' 'disease' 'that' 'is' 'progressive' 'on' 'therapy' ',' 'or' 'with'
 'CNS' 'parenchymal' 'lesions' 'that' 'might' 'increase' 'the' 'risk' 'of'
 'CNS' 'toxicity']",[2. 2. 0. 0. 0. 0. 1. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02374021,",,,55:76:treatment,78:87:treatment,89:116:treatment,118:151:treatment","2 or more high dose radiation scans in the past year (CT scan with contrast, angiogram, SPECT nuclear medicine scan, myocardial/cardiac perfusion scan)","['2' 'or' 'more' 'high' 'dose' 'radiation' 'scans' 'in' 'the' 'past'
 'year' '(' 'CT' 'scan' 'with' 'contrast' ',' 'angiogram' ',' 'SPECT'
 'nuclear' 'medicine' 'scan' ',' 'myocardial/cardiac' 'perfusion' 'scan'
 ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 1. 0. 1. 1. 1. 1. 0.
 1. 1. 1. 0.]"
NCT02374021,"7:51:chronic_disease,58:84:chronic_disease,86:97:chronic_disease","other autoimmune and chronic inflammatory diseases (i.e. inflammatory bowel disease, sarcoidosis)","['other' 'autoimmune' 'and' 'chronic' 'inflammatory' 'diseases' '(' 'i.e'
 '.' 'inflammatory' 'bowel' 'disease' ',' 'sarcoidosis' ')']",[0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT02372006,"29:36:chronic_disease,39:46:chronic_disease,48:53:chronic_disease,55:78:chronic_disease,80:83:chronic_disease,85:94:chronic_disease","known pre-existing relevant cardiac , hepatic, renal, bone marrow dysfunction, ILD, keratitis","['known' 'pre-existing' 'relevant' 'cardiac' ',' 'hepatic' ',' 'renal' ','
 'bone' 'marrow' 'dysfunction' ',' 'ILD' ',' 'keratitis']",[0. 0. 0. 2. 0. 2. 0. 2. 0. 2. 2. 2. 0. 2. 0. 2.]
NCT02369900,"13:24:treatment,26:34:treatment,36:46:treatment,50:59:treatment","Infusion of epinephrine, dopamine, dobutamine or milrinone at time of enrollment","['Infusion' 'of' 'epinephrine' ',' 'dopamine' ',' 'dobutamine' 'or'
 'milrinone' 'at' 'time' 'of' 'enrollment']",[0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0.]
NCT02369653,"18:29:cancer,31:54:cancer,59:89:cancer","New diagnosis of de novo ALL, lymphomas (T or B cell), or mixed-phenotype acute leukemia","['New' 'diagnosis' 'of' 'de' 'novo' 'ALL' ',' 'lymphomas' '(' 'T' 'or' 'B'
 'cell' ')' ',' 'or' 'mixed-phenotype' 'acute' 'leukemia']",[0. 0. 0. 3. 3. 3. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 3. 3. 3.]
NCT02369458,"14:24:cancer,47:57:cancer,61:96:cancer,143:174:cancer","Other active malignancy with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only, carcinoma in situ of the cervix, or synchronous H&N primaries","['Other' 'active' 'malignancy' 'with' 'the' 'exception' 'of' 'basal'
 'cell' 'or' 'squamous' 'cell' 'carcinoma' 'of' 'the' 'skin' 'which'
 'were' 'treated' 'with' 'local' 'resection' 'only' ',' 'carcinoma' 'in'
 'situ' 'of' 'the' 'cervix' ',' 'or' 'synchronous' 'H' '&' 'N' 'primaries']","[0. 0. 3. 0. 0. 0. 0. 3. 3. 0. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02367196,"35:47:cancer,41:46:cancer,53:75:cancer,77:93:cancer,95:108:cancer","High grade, rapidly proliferative solid tumors (eg, small cell lung cancer, germ cell tumors, neuroblastoma) with extensive tumor burden","['High' 'grade' ',' 'rapidly' 'proliferative' 'solid' 'tumors' '(' 'eg'
 ',' 'small' 'cell' 'lung' 'cancer' ',' 'germ' 'cell' 'tumors' ','
 'neuroblastoma' ')' 'with' 'extensive' 'tumor' 'burden']","[0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 3. 3. 3. 3. 0. 3. 3. 3. 0. 3. 0. 0. 0. 3.
 0.]"
NCT02367040,"1:28:cancer,29:58:cancer,60:63:cancer,64:66:cancer",Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM),"['Lymphoplasmacytoid' 'lymphoma/Waldenström' 'macroglobulinemia' '('
 'LPL/WM' ')']",[3. 3. 3. 0. 3. 0.]
NCT02366871,"20:54:treatment,56:62:treatment,64:68:treatment","Concomitant use of dual strong inhibitors or inducers (CYP3A4, P-gp)","['Concomitant' 'use' 'of' 'dual' 'strong' 'inhibitors' 'or' 'inducers' '('
 'CYP3A4' ',' 'P-gp' ')']",[0. 0. 0. 1. 1. 1. 1. 1. 0. 1. 0. 1. 0.]
NCT02366871,"16:23:chronic_disease,24:29:chronic_disease,30:49:chronic_disease",no significant cardiac/renal/hepatic dysfunction,['no' 'significant' 'cardiac/renal/hepatic' 'dysfunction'],[0. 0. 2. 2.]
NCT02366819,"17:27:treatment,29:39:treatment,44:71:treatment,73:81:treatment,83:94:treatment,96:118:treatment","Patients taking substrates, inhibitors, or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) should be encouraged to switch to alternative drugs whenever possible, given the potential for drug-drug interactions with irinotecan","['Patients' 'taking' 'substrates' ',' 'inhibitors' ',' 'or' 'inducers'
 'of' 'cytochrome' 'P450' ',' 'family' '3' ',' 'subfamily' 'A' ','
 'polypeptide' '4' '(' 'CYP3A4' ')' 'should' 'be' 'encouraged' 'to'
 'switch' 'to' 'alternative' 'drugs' 'whenever' 'possible' ',' 'given'
 'the' 'potential' 'for' 'drug-drug' 'interactions' 'with' 'irinotecan']","[0. 0. 1. 0. 1. 0. 0. 1. 1. 1. 1. 0. 1. 1. 0. 1. 1. 0. 1. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02366754,"6:33:treatment,37:50:treatment,52:68:treatment,72:88:treatment","Have implanted cardiac pacemaker or defibrillator, cochlear implant or nerve stimulator","['Have' 'implanted' 'cardiac' 'pacemaker' 'or' 'defibrillator' ','
 'cochlear' 'implant' 'or' 'nerve' 'stimulator']",[0. 1. 1. 1. 0. 1. 0. 1. 1. 0. 1. 1.]
NCT02366611,",,,33:57:cancer,72:100:treatment,104:121:treatment",Patients with AJCC stage III-IV head and neck malignancy scheduled for definitive radiation therapy or chemoradiotherapy,"['Patients' 'with' 'AJCC' 'stage' 'III-IV' 'head' 'and' 'neck'
 'malignancy' 'scheduled' 'for' 'definitive' 'radiation' 'therapy' 'or'
 'chemoradiotherapy']",[0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 1. 1. 1. 0. 1.]
NCT02365766,"14:54:treatment,63:68:treatment,72:78:treatment,",Has received therapy with hematopoietic growth factor such as G-CSF or GM-CSF in the 14 days prior to registration,"['Has' 'received' 'therapy' 'with' 'hematopoietic' 'growth' 'factor'
 'such' 'as' 'G-CSF' 'or' 'GM-CSF' 'in' 'the' '14' 'days' 'prior' 'to'
 'registration']",[0. 0. 1. 1. 1. 1. 1. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02365467,"13:36:chronic_disease,42:57:chronic_disease,83:92:treatment",Subject has coronary artery disease with unstable angina and who has not received treatment,"['Subject' 'has' 'coronary' 'artery' 'disease' 'with' 'unstable' 'angina'
 'and' 'who' 'has' 'not' 'received' 'treatment']",[0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 1.]
NCT02365090,"1:14:chronic_disease,32:43:chronic_disease,37:43:chronic_disease,54:77:chronic_disease","Anisometropic (with or without microtropia) or fully accommodative esotropia (no tropia present with glasses),","['Anisometropic' '(' 'with' 'or' 'without' 'microtropia' ')' 'or' 'fully'
 'accommodative' 'esotropia' '(' 'no' 'tropia' 'present' 'with' 'glasses'
 ')' ',']",[2. 0. 0. 0. 0. 2. 0. 0. 0. 2. 2. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02362997,"39:62:treatment,74:86:treatment,88:100:treatment,104:117:treatment,125:129:treatment","Participants cannot have received any anti-neoplastic therapy (including radiotherapy, chemotherapy or immunotherapy) after ASCT","['Participants' 'can' 'not' 'have' 'received' 'any' 'anti-neoplastic'
 'therapy' '(' 'including' 'radiotherapy' ',' 'chemotherapy' 'or'
 'immunotherapy' ')' 'after' 'ASCT']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 0. 1. 0. 1. 0. 0. 1.]
NCT02362308,"20:58:allergy_name,65:75:allergy_name,77:95:allergy_name,97:104:allergy_name,113:140:allergy_name","Prior allergies to medications used in the study protocol (e.g. L-arginine, potassium chloride, insulin), or to drugs within the same class","['Prior' 'allergies' 'to' 'medications' 'used' 'in' 'the' 'study'
 'protocol' '(' 'e.g' '.' 'L-arginine' ',' 'potassium' 'chloride' ','
 'insulin' ')' ',' 'or' 'to' 'drugs' 'within' 'the' 'same' 'class']","[0. 0. 0. 4. 4. 4. 4. 4. 4. 0. 0. 0. 4. 0. 4. 4. 0. 4. 0. 0. 0. 0. 4. 4.
 4. 4. 4.]"
NCT02361554,"34:53:treatment,69:78:treatment,,,169:183:treatment,",Adequate trials of two different antipsychotic drugs (not including clozapine) belonging to different classes of at least 12 weeks equivalent to at least 500 mg/day of chlorpromazine within the previous 5 years,"['Adequate' 'trials' 'of' 'two' 'different' 'antipsychotic' 'drugs' '('
 'not' 'including' 'clozapine' ')' 'belonging' 'to' 'different' 'classes'
 'of' 'at' 'least' '12' 'weeks' 'equivalent' 'to' 'at' 'least' '500'
 'mg/day' 'of' 'chlorpromazine' 'within' 'the' 'previous' '5' 'years']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]"
NCT02360579,"1:18:treatment,26:46:treatment,52:64:treatment","Antibiotics (ABX) of the aminoglycoside group (ie, streptomycin, gentamicin); except those who are skin-test negative for gentamicin hypersensitivity","['Antibiotics' '(' 'ABX' ')' 'of' 'the' 'aminoglycoside' 'group' '(' 'ie'
 ',' 'streptomycin' ',' 'gentamicin' ')' ';' 'except' 'those' 'who' 'are'
 'skin-test' 'negative' 'for' 'gentamicin' 'hypersensitivity']","[1. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02360579,"1:29:treatment,74:81:cancer,101:104:cancer,112:140:cancer,,","Palliative radiation therapy is permitted so long as it does not involve lesions being selected for TIL, or as target or non-target lesions. Washout is not required if all related toxicities have resolved to ≤ Grade 1 as per CTCAE v4.03","['Palliative' 'radiation' 'therapy' 'is' 'permitted' 'so' 'long' 'as' 'it'
 'does' 'not' 'involve' 'lesions' 'being' 'selected' 'for' 'TIL' ',' 'or'
 'as' 'target' 'or' 'non-target' 'lesions' '.' 'Washout' 'is' 'not'
 'required' 'if' 'all' 'related' 'toxicities' 'have' 'resolved' 'to' '≤'
 'Grade' '1' 'as' 'per' 'CTCAE' 'v4.03']","[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 3. 0. 0. 0. 3. 3. 3. 3.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02360579,"39:55:chronic_disease,65:112:chronic_disease,117:158:chronic_disease",Patients who have any form of primary immunodeficiency (such as severe combined immunodeficiency disease [SCID] and acquired immunodeficiency syndrome [AIDS]),"['Patients' 'who' 'have' 'any' 'form' 'of' 'primary' 'immunodeficiency'
 '(' 'such' 'as' 'severe' 'combined' 'immunodeficiency' 'disease' '['
 'SCID' ']' 'and' 'acquired' 'immunodeficiency' 'syndrome' '[' 'AIDS' ']'
 ')']","[0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0.
 0. 0.]"
NCT02360579,"1:17:treatment,19:27:treatment,37:51:treatment",Targeted therapy: MEK/BRAF or other targeted agent,['Targeted' 'therapy' ':' 'MEK/BRAF' 'or' 'other' 'targeted' 'agent'],[1. 1. 0. 1. 0. 0. 1. 1.]
NCT02359253,"24:30:cancer,32:40:cancer,44:55:cancer","First focal unilateral lesion, ischemic or hemorrhagic","['First' 'focal' 'unilateral' 'lesion' ',' 'ischemic' 'or' 'hemorrhagic']",[0. 0. 0. 3. 0. 3. 0. 3.]
NCT02358850,"23:42:chronic_disease,44:51:chronic_disease,53:64:chronic_disease","Surgical indications: Chronic tonsillitis, Snoring, Sleep apnea","['Surgical' 'indications' ':' 'Chronic' 'tonsillitis' ',' 'Snoring' ','
 'Sleep' 'apnea']",[0. 0. 0. 2. 2. 0. 2. 0. 2. 2.]
NCT02358187,",57:88:treatment,92:127:treatment,,170:207:treatment",Patients must be at least 3 weeks from the last dose of standard cytotoxic chemotherapy or myelosuppressive biological therapy and at least 1 week from the last dose of non-myelosuppressive biologic therapy,"['Patients' 'must' 'be' 'at' 'least' '3' 'weeks' 'from' 'the' 'last'
 'dose' 'of' 'standard' 'cytotoxic' 'chemotherapy' 'or' 'myelosuppressive'
 'biological' 'therapy' 'and' 'at' 'least' '1' 'week' 'from' 'the' 'last'
 'dose' 'of' 'non-myelosuppressive' 'biologic' 'therapy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 1.]"
NCT02356861,"15:40:chronic_disease,49:84:chronic_disease,86:97:chronic_disease,99:107:chronic_disease","Presence of a neurodegenerative disease such as Amyotrophic Lateral Sclerosis (ALS), Parkinson's, Dementia","['Presence' 'of' 'a' 'neurodegenerative' 'disease' 'such' 'as'
 'Amyotrophic' 'Lateral' 'Sclerosis' '(' 'ALS' ')' ',' 'Parkinson' ""'s""
 ',' 'Dementia']",[2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.]
NCT02355535,"23:34:cancer,38:60:cancer,73:81:cancer,123:139:treatment",Diagnosis of advanced solid tumor or hematologic malignancy (limited to lymphoma) that has failed or become intolerant to standard therapy,"['Diagnosis' 'of' 'advanced' 'solid' 'tumor' 'or' 'hematologic'
 'malignancy' '(' 'limited' 'to' 'lymphoma' ')' 'that' 'has' 'failed' 'or'
 'become' 'intolerant' 'to' 'standard' 'therapy']",[0. 0. 0. 3. 3. 0. 3. 3. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02355535,"23:45:treatment,33:45:treatment,47:65:treatment,67:94:treatment,114:130:treatment,,159:170:treatment,,210:219:treatment","May not have received cytotoxic chemotherapy, targeted therapies, biologic response modifiers, chemotherapy, and hormonal therapy within the last 3 weeks, or nitrosureas within the last 6 weeks prior to study treatment","['May' 'not' 'have' 'received' 'cytotoxic' 'chemotherapy' ',' 'targeted'
 'therapies' ',' 'biologic' 'response' 'modifiers' ',' 'chemotherapy' ','
 'and' 'hormonal' 'therapy' 'within' 'the' 'last' '3' 'weeks' ',' 'or'
 'nitrosureas' 'within' 'the' 'last' '6' 'weeks' 'prior' 'to' 'study'
 'treatment']","[0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02355002,"22:36:chronic_disease,45:61:chronic_disease,63:73:chronic_disease,75:86:chronic_disease","Diagnosis of primary sleep disorder such as primary insomnia, narcolepsy, sleep apnea, shift work sleep disorder and others","['Diagnosis' 'of' 'primary' 'sleep' 'disorder' 'such' 'as' 'primary'
 'insomnia' ',' 'narcolepsy' ',' 'sleep' 'apnea' ',' 'shift' 'work'
 'sleep' 'disorder' 'and' 'others']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02354703,"51:58:treatment,60:67:treatment,69:81:treatment,83:95:treatment,100:115:treatment,174:184:treatment","At the Screen Visit, the subject's urine contains opiates, cocaine, amphetamines, barbiturates, or benzodiazepines that cannot be explained by appropriate use of prescribed medication","['At' 'the' 'Screen' 'Visit' ',' 'the' 'subject' ""'s"" 'urine' 'contains'
 'opiates' ',' 'cocaine' ',' 'amphetamines' ',' 'barbiturates' ',' 'or'
 'benzodiazepines' 'that' 'can' 'not' 'be' 'explained' 'by' 'appropriate'
 'use' 'of' 'prescribed' 'medication']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1.]"
NCT02354703,"40:53:chronic_disease,55:71:chronic_disease,82:100:chronic_disease,139:164:chronic_disease,166:196:chronic_disease,198:212:chronic_disease,214:229:chronic_disease","The subject has a current diagnosis of schizophrenia, bipolar disorder, or other psychotic disorder, or a non-psychotic diagnosis such as major depressive disorder, post-traumatic stress disorder, panic disorder, eating disorder, or substance use disorder","['The' 'subject' 'has' 'a' 'current' 'diagnosis' 'of' 'schizophrenia' ','
 'bipolar' 'disorder' ',' 'or' 'other' 'psychotic' 'disorder' ',' 'or' 'a'
 'non-psychotic' 'diagnosis' 'such' 'as' 'major' 'depressive' 'disorder'
 ',' 'post-traumatic' 'stress' 'disorder' ',' 'panic' 'disorder' ','
 'eating' 'disorder' ',' 'or' 'substance' 'use' 'disorder']","[0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0.]"
NCT02353819,"60:83:treatment,87:111:treatment,114:128:treatment,133:143:treatment,","Clinically negative lymph nodes as established by imaging (abdominal and pelvic CT or abdominal and pelvic MRI), nodal sampling, or dissection within 90 days prior to registration","['Clinically' 'negative' 'lymph' 'nodes' 'as' 'established' 'by' 'imaging'
 '(' 'abdominal' 'and' 'pelvic' 'CT' 'or' 'abdominal' 'and' 'pelvic' 'MRI'
 ')' ',' 'nodal' 'sampling' ',' 'or' 'dissection' 'within' '90' 'days'
 'prior' 'to' 'registration']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 1. 0. 0. 0. 0. 0. 0.]"
NCT02353819,"8:33:treatment,,72:81:treatment,85:100:cancer",Use of previous hormonal therapy for up to 9 months is allowed for the treatment of prostate cancer as well as for prostate volume reduction,"['Use' 'of' 'previous' 'hormonal' 'therapy' 'for' 'up' 'to' '9' 'months'
 'is' 'allowed' 'for' 'the' 'treatment' 'of' 'prostate' 'cancer' 'as'
 'well' 'as' 'for' 'prostate' 'volume' 'reduction']","[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 3. 3. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02353728,"1:26:chronic_disease,32:45:chronic_disease,46:65:chronic_disease",Right bundle branch block plus left anterior/posterior hemiblock,"['Right' 'bundle' 'branch' 'block' 'plus' 'left' 'anterior/posterior'
 'hemiblock']",[2. 2. 2. 2. 0. 2. 2. 2.]
NCT02352025,"63:81:chronic_disease,83:102:chronic_disease,106:122:chronic_disease","As judged by the investigator, severe uncontrolled concurrent medical conditions, psychiatric illness or social condition that would limit compliance with study requirements","['As' 'judged' 'by' 'the' 'investigator' ',' 'severe' 'uncontrolled'
 'concurrent' 'medical' 'conditions' ',' 'psychiatric' 'illness' 'or'
 'social' 'condition' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02351544,"67:89:treatment,107:124:chronic_disease,115:124:chronic_disease","Those patients are included because there is no consensus whether surgical decompression is effective for chronic migraines only, or for chronic and episodic migraines. One of the goals of this trial is to determine this","['Those' 'patients' 'are' 'included' 'because' 'there' 'is' 'no'
 'consensus' 'whether' 'surgical' 'decompression' 'is' 'effective' 'for'
 'chronic' 'migraines' 'only' ',' 'or' 'for' 'chronic' 'and' 'episodic'
 'migraines' '.' 'One' 'of' 'the' 'goals' 'of' 'this' 'trial' 'is' 'to'
 'determine' 'this']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02350764,"35:63:treatment,84:93:treatment,98:122:treatment",Patients may not have intervening systemic anti-cancer therapy between the time of resection and treatment with nivolumab,"['Patients' 'may' 'not' 'have' 'intervening' 'systemic' 'anti-cancer'
 'therapy' 'between' 'the' 'time' 'of' 'resection' 'and' 'treatment'
 'with' 'nivolumab']",[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 1. 0. 1. 1. 1.]
NCT02350764,"20:71:treatment,,85:95:treatment,,139:149:treatment",no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration,"['no' 'requirement' 'for' 'immunosuppressive' 'doses' 'of' 'systemic'
 'corticosteroids' '(' '>' '10' 'mg/day' 'prednisone' 'equivalents' ')'
 'for' 'at' 'least' '2' 'weeks' 'prior' 'to' 'study' 'drug'
 'administration']","[0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 0.]"
NCT02349958,",61:66:treatment,73:106:treatment,111:123:treatment,158:162:treatment","These patients would ordinarily choose to have 12 cycles of Taxol given after standard first-line surgery and chemotherapy, and instead choose one course of IPHC as their CC","['These' 'patients' 'would' 'ordinarily' 'choose' 'to' 'have' '12'
 'cycles' 'of' 'Taxol' 'given' 'after' 'standard' 'first-line' 'surgery'
 'and' 'chemotherapy' ',' 'and' 'instead' 'choose' 'one' 'course' 'of'
 'IPHC' 'as' 'their' 'CC']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 0. 0.]"
NCT02349867,"14:23:treatment,36:46:cancer,,99:117:treatment,121:141:cancer,145:180:cancer,189:204:cancer,218:233:cancer,240:256:treatment","Diagnosis or treatment for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, any in situ malignancy, or low-risk prostate cancer after curative therapy","['Diagnosis' 'or' 'treatment' 'for' 'another' 'malignancy' 'within' '3'
 'years' 'of' 'enrollment' ',' 'with' 'the' 'exception' 'of' 'complete'
 'resection' 'of' 'basal' 'cell' 'carcinoma' 'or' 'squamous' 'cell'
 'carcinoma' 'of' 'the' 'skin' ',' 'any' 'in' 'situ' 'malignancy' ',' 'or'
 'low-risk' 'prostate' 'cancer' 'after' 'curative' 'therapy']","[0. 0. 1. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 3. 3. 3. 0. 3.
 3. 3. 3. 3. 3. 0. 0. 0. 3. 3. 0. 0. 0. 3. 3. 0. 1. 1.]"
NCT02349867,"1:8:chronic_disease,10:23:chronic_disease,28:45:chronic_disease","Medical, psychological, or social conditions","['Medical' ',' 'psychological' ',' 'or' 'social' 'conditions']",[2. 0. 2. 0. 0. 2. 2.]
NCT02349867,"26:47:chronic_disease,51:75:chronic_disease,87:113:chronic_disease,126:140:treatment,158:167:treatment",embolic events such as a myocardial infarction or cerebrovascular accident (including transient ischemic attacks) within the 6 months prior to initiation of treatment,"['embolic' 'events' 'such' 'as' 'a' 'myocardial' 'infarction' 'or'
 'cerebrovascular' 'accident' '(' 'including' 'transient' 'ischemic'
 'attacks' ')' 'within' 'the' '6' 'months' 'prior' 'to' 'initiation' 'of'
 'treatment']","[0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 1. 1. 1. 0. 0. 0.
 1.]"
NCT02347891,"8:41:treatment,43:57:treatment,59:69:treatment,71:83:treatment,88:109:treatment,","Use of parenteral (IV or IM) antibiotics (antibacterials, antivirals, anti-fungals, or anti parasitic agents) within 60 days of Day","['Use' 'of' 'parenteral' '(' 'IV' 'or' 'IM' ')' 'antibiotics' '('
 'antibacterials' ',' 'antivirals' ',' 'anti-fungals' ',' 'or' 'anti'
 'parasitic' 'agents' ')' 'within' '60' 'days' 'of' 'Day']","[0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02346526,"29:33:cancer,,48:67:cancer,71:80:treatment,89:93:cancer,95:100:cancer,109:125:cancer,127:148:cancer","Bone-predominant metastatic CRPC: at least two skeletal metastases on bone scan with no lung, liver, and/or brain metastasis (lymph node metastasis is allowed)","['Bone-predominant' 'metastatic' 'CRPC' ':' 'at' 'least' 'two' 'skeletal'
 'metastases' 'on' 'bone' 'scan' 'with' 'no' 'lung' ',' 'liver' ','
 'and/or' 'brain' 'metastasis' '(' 'lymph' 'node' 'metastasis' 'is'
 'allowed' ')']","[0. 0. 3. 0. 0. 0. 0. 3. 3. 0. 1. 1. 0. 0. 3. 0. 3. 0. 0. 3. 3. 0. 3. 3.
 3. 0. 0. 0.]"
NCT02346253,"12:33:treatment,35:68:treatment,73:75:treatment,80:95:cancer","History of radical prostatectomy, external beam radiotherapy (EBRT), or BT for prostate cancer","['History' 'of' 'radical' 'prostatectomy' ',' 'external' 'beam'
 'radiotherapy' '(' 'EBRT' ')' ',' 'or' 'BT' 'for' 'prostate' 'cancer']",[0. 0. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 1. 0. 3. 3.]
NCT02346201,"8:17:treatment,,,28:37:treatment,,,234:249:treatment,","Use of trazodone > 50mg or lorazepam > 0.5mg or for indications other than sleeping difficulties within the 30 days preceding randomization or a period of time equal to 5 half-lives of drug, whichever period of time is longer. Other benzodiazepines are prohibited in the past 30 days or within 5 half-lives, whichever period of time is longer","['Use' 'of' 'trazodone' '>' '50mg' 'or' 'lorazepam' '>' '0.5mg' 'or' 'for'
 'indications' 'other' 'than' 'sleeping' 'difficulties' 'within' 'the'
 '30' 'days' 'preceding' 'randomization' 'or' 'a' 'period' 'of' 'time'
 'equal' 'to' '5' 'half-lives' 'of' 'drug' ',' 'whichever' 'period' 'of'
 'time' 'is' 'longer' '.' 'Other' 'benzodiazepines' 'are' 'prohibited'
 'in' 'the' 'past' '30' 'days' 'or' 'within' '5' 'half-lives' ','
 'whichever' 'period' 'of' 'time' 'is' 'longer']","[0. 0. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02344355,"1:8:treatment,,36:43:treatment,47:53:treatment",Therapy must begin ≤ 5 weeks after surgery or biopsy,['Therapy' 'must' 'begin' '≤' '5' 'weeks' 'after' 'surgery' 'or' 'biopsy'],[1. 0. 0. 0. 0. 0. 0. 1. 0. 1.]
NCT02343549,"41:53:allergy_name,90:94:allergy_name,98:106:allergy_name",History of hypersensitivity reaction to temozolomide or a history of hypersensitivity to DTIC or hydrogel,"['History' 'of' 'hypersensitivity' 'reaction' 'to' 'temozolomide' 'or' 'a'
 'history' 'of' 'hypersensitivity' 'to' 'DTIC' 'or' 'hydrogel']",[0. 0. 0. 0. 0. 4. 0. 0. 0. 0. 0. 0. 4. 0. 4.]
NCT02343042,"24:26:chronic_disease,,,78:97:treatment,105:116:cancer","Documented evidence of PD after achieving at least SD for ≥ 1 cycle during a previous MM regimen (i.e., relapsed MM)","['Documented' 'evidence' 'of' 'PD' 'after' 'achieving' 'at' 'least' 'SD'
 'for' '≥' '1' 'cycle' 'during' 'a' 'previous' 'MM' 'regimen' '(' 'i.e.'
 ',' 'relapsed' 'MM' ')']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 3. 3. 0.]
NCT02343042,"20:55:treatment,67:87:treatment,89:100:treatment,102:147:treatment,149:205:treatment,211:231:treatment,239:250:treatment,254:265:treatment","Patients receiving hematopoietic growth factor support, including erythropoietin (EPO), darbepoetin, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophagecolony stimulating factor (GM-CSF), and platelet stimulators (e.g., eltrombopag or romiplostim) may continue to do so","['Patients' 'receiving' 'hematopoietic' 'growth' 'factor' 'support' ','
 'including' 'erythropoietin' '(' 'EPO' ')' ',' 'darbepoetin' ','
 'granulocyte-colony' 'stimulating' 'factor' '(' 'G-CSF' ')' ','
 'granulocyte' 'macrophagecolony' 'stimulating' 'factor' '(' 'GM-CSF' ')'
 ',' 'and' 'platelet' 'stimulators' '(' 'e.g.' ',' 'eltrombopag' 'or'
 'romiplostim' ')' 'may' 'continue' 'to' 'do' 'so']","[0. 0. 1. 1. 1. 1. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0.]"
NCT02343042,"14:30:chronic_disease,41:63:treatment,65:75:treatment,80:91:treatment,","Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose","['Uncontrolled' 'active' 'infection' 'requiring' 'parenteral'
 'antibiotics' ',' 'antivirals' ',' 'or' 'antifungals' 'within' 'one'
 'week' 'prior' 'to' 'first' 'dose']",[0. 2. 2. 0. 1. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02342782,"1:24:chronic_disease,25:40:chronic_disease,44:71:chronic_disease",Active hepatitis B or C viral infection or hepatitis B surface antigen positive,"['Active' 'hepatitis' 'B' 'or' 'C' 'viral' 'infection' 'or' 'hepatitis'
 'B' 'surface' 'antigen' 'positive']",[2. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02342782,"1:22:treatment,10:22:treatment,26:35:treatment,,87:91:treatment,100:124:treatment,148:177:treatment","Systemic chemotherapy or radiation cannot have been given within 4 weeks prior to the Y-90 dose of radioimmunotherapy (RIT), with the exception of single agent cyclophosphamide priming chemotherapy administered for mobilization","['Systemic' 'chemotherapy' 'or' 'radiation' 'can' 'not' 'have' 'been'
 'given' 'within' '4' 'weeks' 'prior' 'to' 'the' 'Y-90' 'dose' 'of'
 'radioimmunotherapy' '(' 'RIT' ')' ',' 'with' 'the' 'exception' 'of'
 'single' 'agent' 'cyclophosphamide' 'priming' 'chemotherapy'
 'administered' 'for' 'mobilization']","[1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]"
NCT02341963,"25:64:treatment,66:97:treatment,99:130:treatment,132:159:treatment,161:193:treatment,195:209:treatment","Due to undergo elective major amputation of the lower extremity (above the knee amputation (AKA), below the knee amputation (BKA), total knee amputation (TKA), transmetatarsal amputation (TMA), toe amputation) from all causes","['Due' 'to' 'undergo' 'elective' 'major' 'amputation' 'of' 'the' 'lower'
 'extremity' '(' 'above' 'the' 'knee' 'amputation' '(' 'AKA' ')' ','
 'below' 'the' 'knee' 'amputation' '(' 'BKA' ')' ',' 'total' 'knee'
 'amputation' '(' 'TKA' ')' ',' 'transmetatarsal' 'amputation' '(' 'TMA'
 ')' ',' 'toe' 'amputation' ')' 'from' 'all' 'causes']","[0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 1.
 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0.]"
NCT02340156,"22:31:chronic_disease,43:60:chronic_disease,72:88:treatment","Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy","['Active' ',' 'uncontrolled' 'bacterial' ',' 'viral' ',' 'or' 'fungal'
 'infections' ',' 'requiring' 'systemic' 'therapy']",[0. 0. 0. 2. 0. 0. 0. 0. 2. 2. 0. 0. 1. 1.]
NCT02339922,"31:49:chronic_disease,64:75:chronic_disease,79:80:chronic_disease,81:96:chronic_disease,107:141:chronic_disease","Known ongoing or known active systemic infection, known active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive","['Known' 'ongoing' 'or' 'known' 'active' 'systemic' 'infection' ','
 'known' 'active' 'hepatitis' 'B' 'or' 'C' 'virus' 'infection' ',' 'or'
 'known' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'positive']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0.
 0. 0.]"
NCT02339922,"1:21:treatment,23:35:treatment,37:47:treatment,49:58:treatment,61:73:treatment,75:95:treatment,97:118:treatment,120:130:treatment,132:143:treatment,146:172:treatment,174:183:treatment,185:198:treatment,200:210:treatment,213:224:treatment,226:241:treatment,297:302:cancer","anti-CD20 antibodies (obinutuzumab, ofatumumab, rituximab); lenalidomide; ibritumomab tiuxetan; proteasome inhibitors (bortezomib, carfilzomib); tyrosine kinase inhibitors (ibrutinib, acalabrutinib, idelalisib); alemtuzumab; corticosteroids unless given for an indication other than treating the B-NHL","['anti-CD20' 'antibodies' '(' 'obinutuzumab' ',' 'ofatumumab' ','
 'rituximab' ')' ';' 'lenalidomide' ';' 'ibritumomab' 'tiuxetan' ';'
 'proteasome' 'inhibitors' '(' 'bortezomib' ',' 'carfilzomib' ')' ';'
 'tyrosine' 'kinase' 'inhibitors' '(' 'ibrutinib' ',' 'acalabrutinib' ','
 'idelalisib' ')' ';' 'alemtuzumab' ';' 'corticosteroids' 'unless' 'given'
 'for' 'an' 'indication' 'other' 'than' 'treating' 'the' 'B-NHL']","[1. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 0. 1. 1. 0. 1. 1. 0. 1. 0. 1. 0. 0. 1.
 1. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]"
NCT02339233,"1:15:chronic_disease,17:28:chronic_disease,30:37:chronic_disease,41:54:chronic_disease","cardiovascular, respiratory, bladder or renal disease unrelated to SCI","['cardiovascular' ',' 'respiratory' ',' 'bladder' 'or' 'renal' 'disease'
 'unrelated' 'to' 'SCI']",[2. 0. 2. 0. 2. 0. 2. 2. 0. 0. 0.]
NCT02338999,"23:36:chronic_disease,38:51:chronic_disease,53:56:chronic_disease,60:62:chronic_disease,,","Patients with current heart failure (NYHA class II, III or IV) and/or a left ventricular ejection fraction of <45% by echocardiogram at screening","['Patients' 'with' 'current' 'heart' 'failure' '(' 'NYHA' 'class' 'II' ','
 'III' 'or' 'IV' ')' 'and/or' 'a' 'left' 'ventricular' 'ejection'
 'fraction' 'of' '<' '45' '%' 'by' 'echocardiogram' 'at' 'screening']","[0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02338999,"1:11:cancer,15:50:cancer,29:38:cancer",basal cell or squamous cell carcinoma of the skin with complete excision and clear borders or adequately treated in situ carcinoma of the cervix,"['basal' 'cell' 'or' 'squamous' 'cell' 'carcinoma' 'of' 'the' 'skin'
 'with' 'complete' 'excision' 'and' 'clear' 'borders' 'or' 'adequately'
 'treated' 'in' 'situ' 'carcinoma' 'of' 'the' 'cervix']",[3. 3. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02338232,"21:34:chronic_disease,45:61:chronic_disease,72:97:treatment,102:115:chronic_disease","Subjects with known heart failure, advanced renal impairment requiring renal replacement therapy, or liver failure","['Subjects' 'with' 'known' 'heart' 'failure' ',' 'advanced' 'renal'
 'impairment' 'requiring' 'renal' 'replacement' 'therapy' ',' 'or' 'liver'
 'failure']",[0. 0. 0. 2. 2. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 2. 2.]
NCT02336451,"13:38:chronic_disease,42:52:chronic_disease,100:109:treatment,117:136:chronic_disease,182:204:chronic_disease","Patient has impairment of GI function or GI disease that may significantly alter the absorption of ceritinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome)","['Patient' 'has' 'impairment' 'of' 'GI' 'function' 'or' 'GI' 'disease'
 'that' 'may' 'significantly' 'alter' 'the' 'absorption' 'of' 'ceritinib'
 '(' 'e.g.' ',' 'ulcerative' 'diseases' ',' 'uncontrolled' 'nausea' ','
 'vomiting' ',' 'diarrhea' ',' 'or' 'malabsorption' 'syndrome' ')']","[0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 2. 2. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.]"
NCT02336451,"27:43:cancer,49:54:cancer,69:92:treatment,113:142:cancer","Patients must have active brain metastases from NSCLC, confirmed by Gadolinium-enhanced MRI without concomitant leptomeningeal carcinomatosis","['Patients' 'must' 'have' 'active' 'brain' 'metastases' 'from' 'NSCLC' ','
 'confirmed' 'by' 'Gadolinium-enhanced' 'MRI' 'without' 'concomitant'
 'leptomeningeal' 'carcinomatosis']",[0. 0. 0. 0. 3. 3. 0. 3. 0. 0. 0. 1. 1. 0. 0. 3. 3.]
NCT02335905,",,25:38:chronic_disease,75:91:treatment,97:107:treatment,154:172:treatment",One to three site(s) of osteomyelitis with expectation that transition to oral antibiotics from IV therapy will be likely prior to discharge to complete antibiotic therapy,"['One' 'to' 'three' 'site' '(' 's' ')' 'of' 'osteomyelitis' 'with'
 'expectation' 'that' 'transition' 'to' 'oral' 'antibiotics' 'from' 'IV'
 'therapy' 'will' 'be' 'likely' 'prior' 'to' 'discharge' 'to' 'complete'
 'antibiotic' 'therapy']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1.]"
NCT02335242,"17:20:treatment,53:75:cancer,,,161:171:treatment","Have a required MRI examination to confirm that the lymphatic malformation is present and is greater than 3 cm in diameter in order for the subjects to receive medication, which happens during the initial screening evaluation portion of the trial","['Have' 'a' 'required' 'MRI' 'examination' 'to' 'confirm' 'that' 'the'
 'lymphatic' 'malformation' 'is' 'present' 'and' 'is' 'greater' 'than' '3'
 'cm' 'in' 'diameter' 'in' 'order' 'for' 'the' 'subjects' 'to' 'receive'
 'medication' ',' 'which' 'happens' 'during' 'the' 'initial' 'screening'
 'evaluation' 'portion' 'of' 'the' 'trial']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02335242,"202:258:chronic_disease,299:307:chronic_disease,309:321:chronic_disease,323:346:chronic_disease,351:365:chronic_disease,384:397:chronic_disease,399:414:chronic_disease,419:434:chronic_disease","any significant cardiovascular risk factors and any condition which requires participants to use nitric oxide donors or nitrates in any form, underlying anatomic or vascular risk factor for developing non-arteritic anterior ischemic optic neuropathy (NAION) including low ocular cup to disc ratio, diabetes, hypertension, coronary artery disease, or hyperlipidemia Participants with Down syndrome, Turner syndrome and Noonan syndrome will be considered on a case-by-case basis","['any' 'significant' 'cardiovascular' 'risk' 'factors' 'and' 'any'
 'condition' 'which' 'requires' 'participants' 'to' 'use' 'nitric' 'oxide'
 'donors' 'or' 'nitrates' 'in' 'any' 'form' ',' 'underlying' 'anatomic'
 'or' 'vascular' 'risk' 'factor' 'for' 'developing' 'non-arteritic'
 'anterior' 'ischemic' 'optic' 'neuropathy' '(' 'NAION' ')' 'including'
 'low' 'ocular' 'cup' 'to' 'disc' 'ratio' ',' 'diabetes' ','
 'hypertension' ',' 'coronary' 'artery' 'disease' ',' 'or'
 'hyperlipidemia' 'Participants' 'with' 'Down' 'syndrome' ',' 'Turner'
 'syndrome' 'and' 'Noonan' 'syndrome' 'will' 'be' 'considered' 'on' 'a'
 'case-by-case' 'basis']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0.
 2. 0. 2. 2. 2. 0. 0. 2. 0. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02334865,"27:38:allergy_name,40:52:allergy_name,54:85:allergy_name,90:147:allergy_name","Known hypersensitivity to thalidomide, lenalidomide, Keyhole Limpet Hemocyanin (KLH), or granulocyte colony-macrophage stimulating factor (GM-CSF)","['Known' 'hypersensitivity' 'to' 'thalidomide' ',' 'lenalidomide' ','
 'Keyhole' 'Limpet' 'Hemocyanin' '(' 'KLH' ')' ',' 'or' 'granulocyte'
 'colony-macrophage' 'stimulating' 'factor' '(' 'GM-CSF' ')']",[0. 0. 0. 4. 0. 4. 0. 4. 4. 4. 4. 0. 0. 0. 0. 4. 4. 4. 4. 4. 0. 0.]
NCT02333162,"1:29:cancer,44:74:cancer,93:137:treatment",acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS) undergoing second allogeneic (allo)-stem cell transplant (SCT) using the same donor or different donor for disease relapse,"['acute' 'myeloid' 'leukemia' '(' 'AML' ')' 'and' 'high' 'risk'
 'myelodysplastic' 'syndrome' '(' 'MDS' ')' 'undergoing' 'second'
 'allogeneic' '(' 'allo' ')' '-stem' 'cell' 'transplant' '(' 'SCT' ')'
 'using' 'the' 'same' 'donor' 'or' 'different' 'donor' 'for' 'disease'
 'relapse']","[3. 3. 3. 3. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02332850,"14:16:cancer,38:60:treatment,66:86:treatment",Diagnosis of MM and documentation of treatment with an IMiD® and proteasome inhibitor,"['Diagnosis' 'of' 'MM' 'and' 'documentation' 'of' 'treatment' 'with' 'an'
 'IMiD®' 'and' 'proteasome' 'inhibitor']",[0. 0. 3. 0. 0. 0. 1. 1. 1. 1. 0. 1. 1.]
NCT02332668,"10:18:cancer,71:82:cancer,86:94:cancer","Advanced melanoma or PD-L1-positive advanced, relapsed, or refractory solid tumor or lymphoma","['Advanced' 'melanoma' 'or' 'PD-L1-positive' 'advanced' ',' 'relapsed' ','
 'or' 'refractory' 'solid' 'tumor' 'or' 'lymphoma']",[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 3.]
NCT02332668,"1:20:treatment,30:39:treatment,41:48:treatment,53:99:treatment,104:111:chronic_disease,115:138:chronic_disease","replacement therapy (such as thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is acceptable","['replacement' 'therapy' '(' 'such' 'as' 'thyroxine' ',' 'insulin' ','
 'or' 'physiologic' 'corticosteroid' 'replacement' 'therapy' 'for'
 'adrenal' 'or' 'pituitary' 'insufficiency' ')' 'is' 'acceptable']",[1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 1. 1. 1. 1. 0. 2. 0. 2. 2. 0. 0. 0.]
NCT02331095,"89:91:chronic_disease,141:159:treatment,161:170:treatment,188:207:treatment,209:219:treatment,221:247:treatment","A diagnosis of proximal DVT (proximal to and including popliteal vein), with or without PE, confirmed by objective imaging studies, such as Doppler ultrasound, venograms (for DVT) and/or computer tomography, angiograms, ventilation-perfusion scan (for PE)","['A' 'diagnosis' 'of' 'proximal' 'DVT' '(' 'proximal' 'to' 'and'
 'including' 'popliteal' 'vein' ')' ',' 'with' 'or' 'without' 'PE' ','
 'confirmed' 'by' 'objective' 'imaging' 'studies' ',' 'such' 'as'
 'Doppler' 'ultrasound' ',' 'venograms' '(' 'for' 'DVT' ')' 'and/or'
 'computer' 'tomography' ',' 'angiograms' ',' 'ventilation-perfusion'
 'scan' '(' 'for' 'PE' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 1. 0. 0. 0. 0.]"
NCT02329327,"1:23:chronic_disease,25:46:chronic_disease,48:92:chronic_disease,122:147:chronic_disease,149:173:chronic_disease,200:227:chronic_disease,","venous thromboembolism, myocardial infarction, disseminated intravascular coagulation (DIC), cerebral vascular accident, transient ischemic attack, unstable angina pectoris hospitalization or severe peripheral vascular disease within 2 weeks prior to screening","['venous' 'thromboembolism' ',' 'myocardial' 'infarction' ','
 'disseminated' 'intravascular' 'coagulation' '(' 'DIC' ')' ',' 'cerebral'
 'vascular' 'accident' ',' 'transient' 'ischemic' 'attack' ',' 'unstable'
 'angina' 'pectoris' 'hospitalization' 'or' 'severe' 'peripheral'
 'vascular' 'disease' 'within' '2' 'weeks' 'prior' 'to' 'screening']","[2. 2. 0. 2. 2. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 2. 2. 2.
 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0.]"
NCT02324582,",19:38:treatment,40:43:treatment,48:73:treatment","Less than 14 days post bladder biopsy, TUR, or traumatic catheterization","['Less' 'than' '14' 'days' 'post' 'bladder' 'biopsy' ',' 'TUR' ',' 'or'
 'traumatic' 'catheterization']",[0. 0. 0. 0. 1. 1. 1. 0. 1. 0. 0. 1. 1.]
NCT02324439,"1:9:treatment,66:79:chronic_disease,81:116:chronic_disease,118:127:chronic_disease,129:143:chronic_disease,147:152:chronic_disease,154:183:chronic_disease","Flaxseed supplementation may be contraindicated in patients with acute abdomen, esophageal stricture or perforation, dysphagia, GI obstruction or ileus, acute intestinal inflammation or unexplained abdominal pain. Patients with any of these conditions will be excluded from this trial as the high fiber content of flaxseed may make these conditions worse","['Flaxseed' 'supplementation' 'may' 'be' 'contraindicated' 'in' 'patients'
 'with' 'acute' 'abdomen' ',' 'esophageal' 'stricture' 'or' 'perforation'
 ',' 'dysphagia' ',' 'GI' 'obstruction' 'or' 'ileus' ',' 'acute'
 'intestinal' 'inflammation' 'or' 'unexplained' 'abdominal' 'pain' '.'
 'Patients' 'with' 'any' 'of' 'these' 'conditions' 'will' 'be' 'excluded'
 'from' 'this' 'trial' 'as' 'the' 'high' 'fiber' 'content' 'of' 'flaxseed'
 'may' 'make' 'these' 'conditions' 'worse']","[1. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 2. 0. 2. 0. 2. 2. 0. 2. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02324439,"44:68:chronic_disease,78:96:chronic_disease,181:195:treatment",Patients with a diagnosis of/problems with von Willebrand's disease or other bleeding disorders (as flaxseed may slow blood clotting; the risk of bruising or bleeding in people on anticoagulants or with bleeding disorders may be a concern),"['Patients' 'with' 'a' 'diagnosis' 'of/problems' 'with' 'von' 'Willebrand'
 ""'s"" 'disease' 'or' 'other' 'bleeding' 'disorders' '(' 'as' 'flaxseed'
 'may' 'slow' 'blood' 'clotting' ';' 'the' 'risk' 'of' 'bruising' 'or'
 'bleeding' 'in' 'people' 'on' 'anticoagulants' 'or' 'with' 'bleeding'
 'disorders' 'may' 'be' 'a' 'concern' ')']","[0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02323880,"1:16:treatment,69:82:treatment,,132:146:treatment","Corticosteroids: If used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid","['Corticosteroids' ':' 'If' 'used' 'to' 'modify' 'immune' 'adverse'
 'events' 'related' 'to' 'prior' 'therapy' ',' '>' '=' '14' 'days' 'must'
 'have' 'elapsed' 'since' 'last' 'dose' 'of' 'corticosteroid']","[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1.]"
NCT02323880,"21:51:cancer,122:134:treatment,195:216:treatment",Patients with known bone marrow metastatic disease will be eligible for study if they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions),"['Patients' 'with' 'known' 'bone' 'marrow' 'metastatic' 'disease' 'will'
 'be' 'eligible' 'for' 'study' 'if' 'they' 'meet' 'the' 'blood' 'counts'
 '(' 'may' 'receive' 'transfusions' 'provided' 'they' 'are' 'not' 'known'
 'to' 'be' 'refractory' 'to' 'red' 'cell' 'or' 'platelet' 'transfusions'
 ')']","[0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]"
NCT02323880,"51:61:cancer,129:146:cancer,140:145:cancer,148:169:cancer,188:201:cancer","patients must have had histologic verification of malignancy at original diagnosis or relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG)","['patients' 'must' 'have' 'had' 'histologic' 'verification' 'of'
 'malignancy' 'at' 'original' 'diagnosis' 'or' 'relapse' 'except' 'in'
 'patients' 'with' 'intrinsic' 'brain' 'stem' 'tumors' ',' 'optic'
 'pathway' 'gliomas' ',' 'or' 'patients' 'with' 'pineal' 'tumors' 'and'
 'elevations' 'of' 'cerebrospinal' 'fluid' '(' 'CSF' ')' 'or' 'serum'
 'tumor' 'markers' 'including' 'alpha-fetoprotein' 'or' 'beta-human'
 'chorionic' 'gonadotropin' '(' 'HCG' ')']","[0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 3. 3.
 3. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02323581,"20:45:chronic_disease,53:59:chronic_disease,63:84:chronic_disease","Known degenerative connective tissue disease, e.g., Marfan or Ehler-Danlos Syndrome","['Known' 'degenerative' 'connective' 'tissue' 'disease' ',' 'e.g.' ','
 'Marfan' 'or' 'Ehler-Danlos' 'Syndrome']",[0. 0. 2. 2. 2. 0. 0. 0. 2. 0. 2. 2.]
NCT02323191,"39:59:chronic_disease,161:183:chronic_disease,193:251:chronic_disease,253:274:chronic_disease,,310:321:chronic_disease,326:341:chronic_disease,346:363:chronic_disease,375:404:chronic_disease,432:444:chronic_disease","Evidence of significant, uncontrolled concomitant diseases, which could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina) or pulmonary disease (including obstructive pulmonary disease and history of symptomatic bronchospasm)","['Evidence' 'of' 'significant' ',' 'uncontrolled' 'concomitant' 'diseases'
 ',' 'which' 'could' 'affect' 'compliance' 'with' 'the' 'protocol' 'or'
 'interpretation' 'of' 'results' ',' 'including' 'significant'
 'cardiovascular' 'disease' '(' 'such' 'as' 'New' 'York' 'Heart'
 'Association' 'Class' 'III' 'or' 'IV' 'cardiac' 'disease' ','
 'myocardial' 'infarction' 'within' 'the' 'last' '6' 'months' ','
 'unstable' 'arrhythmias' ',' 'or' 'unstable' 'angina' ')' 'or'
 'pulmonary' 'disease' '(' 'including' 'obstructive' 'pulmonary' 'disease'
 'and' 'history' 'of' 'symptomatic' 'bronchospasm' ')']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.
 0. 0. 0. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2.
 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 2. 0.]"
NCT02323191,"23:35:treatment,37:49:treatment,61:82:treatment,94:107:treatment,","Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy that have not regressed to Grade <=1 severity (Common Terminology Criteria for Adverse Events [CTCAE] v4.03, or later versions)","['Prior' 'toxicities' 'from' 'chemotherapy' ',' 'radiotherapy' ',' 'and'
 'other' 'anti-cancer' 'therapies' ',' 'including' 'immunotherapy' 'that'
 'have' 'not' 'regressed' 'to' 'Grade' '<' '=1' 'severity' '(' 'Common'
 'Terminology' 'Criteria' 'for' 'Adverse' 'Events' '[' 'CTCAE' ']' 'v4.03'
 ',' 'or' 'later' 'versions' ')']","[0. 0. 0. 1. 0. 1. 0. 0. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02323126,"25:42:treatment,59:69:treatment,,129:145:treatment,153:165:treatment","require emergent use of systemic steroids, chronic use of prednisone (greater than 10mg or an equivalent steroid dose daily) or emergent surgery and/or radiotherapy","['require' 'emergent' 'use' 'of' 'systemic' 'steroids' ',' 'chronic' 'use'
 'of' 'prednisone' '(' 'greater' 'than' '10mg' 'or' 'an' 'equivalent'
 'steroid' 'dose' 'daily' ')' 'or' 'emergent' 'surgery' 'and/or'
 'radiotherapy']","[0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1.]"
NCT02323100,"16:36:treatment,38:58:treatment,81:115:treatment,","Current use of ivacaftor (Kalydeco), lumacaftor/ivacaftor combination, or other corrector or potentiator (Symdeko) less than 30 days from Screening","['Current' 'use' 'of' 'ivacaftor' '(' 'Kalydeco' ')' ','
 'lumacaftor/ivacaftor' 'combination' ',' 'or' 'other' 'corrector' 'or'
 'potentiator' '(' 'Symdeko' ')' 'less' 'than' '30' 'days' 'from'
 'Screening']","[0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02321501,"14:19:cancer,47:86:cancer,158:166:treatment,",ALK-positive NSCLC patients with asymptomatic central nervous system (CNS) metastases who are neurologically stable or have not required increasing doses of steroids within the 2 week prior to study entry to manage CNS symptoms,"['ALK-positive' 'NSCLC' 'patients' 'with' 'asymptomatic' 'central'
 'nervous' 'system' '(' 'CNS' ')' 'metastases' 'who' 'are'
 'neurologically' 'stable' 'or' 'have' 'not' 'required' 'increasing'
 'doses' 'of' 'steroids' 'within' 'the' '2' 'week' 'prior' 'to' 'study'
 'entry' 'to' 'manage' 'CNS' 'symptoms']","[0. 3. 0. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02321501,"1:23:cancer,38:52:cancer,87:94:treatment,",Non-ALK-positive NSCLC patients with CNS metastasis should have completed a course of therapy would be eligible for the study provided they are clinically stable for 1 month,"['Non-ALK-positive' 'NSCLC' 'patients' 'with' 'CNS' 'metastasis' 'should'
 'have' 'completed' 'a' 'course' 'of' 'therapy' 'would' 'be' 'eligible'
 'for' 'the' 'study' 'provided' 'they' 'are' 'clinically' 'stable' 'for'
 '1' 'month']","[3. 3. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02321501,"95:115:treatment,,131:146:treatment,155:169:treatment",Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing (except ALK inhibitors),"['Patients' 'who' 'are' 'currently' 'part' 'of' 'or' 'have' 'participated'
 'in' 'any' 'clinical' 'investigation' 'with' 'an' 'investigational'
 'drug' 'within' '1' 'month' 'prior' 'to' 'dosing' '(' 'except' 'ALK'
 'inhibitors' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 1. 0.
 0. 1. 1. 0.]"
NCT02321501,"14:31:chronic_disease,,,90:97:treatment,132:156:chronic_disease,160:182:chronic_disease,226:248:treatment","Uncontrolled diabetes mellitus as defined by hemoglobin A1c (HbA1c) >8% despite adequate therapy. Patients with a known history of impaired fasting glucose or diabetes mellitus (DM) may be included, however blood glucose and antidiabetic treatment must be monitored closely throughout the trial and adjusted as necessary","['Uncontrolled' 'diabetes' 'mellitus' 'as' 'defined' 'by' 'hemoglobin'
 'A1c' '(' 'HbA1c' ')' '>' '8' '%' 'despite' 'adequate' 'therapy' '.'
 'Patients' 'with' 'a' 'known' 'history' 'of' 'impaired' 'fasting'
 'glucose' 'or' 'diabetes' 'mellitus' '(' 'DM' ')' 'may' 'be' 'included'
 ',' 'however' 'blood' 'glucose' 'and' 'antidiabetic' 'treatment' 'must'
 'be' 'monitored' 'closely' 'throughout' 'the' 'trial' 'and' 'adjusted'
 'as' 'necessary']","[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02320292,"14:24:cancer,35:44:treatment,106:114:cancer",Active other malignancy requiring treatment that would interfere with the assessments of response of the lymphoma to protocol treatment and would interfere with follow-up assessments through year 5,"['Active' 'other' 'malignancy' 'requiring' 'treatment' 'that' 'would'
 'interfere' 'with' 'the' 'assessments' 'of' 'response' 'of' 'the'
 'lymphoma' 'to' 'protocol' 'treatment' 'and' 'would' 'interfere' 'with'
 'follow-up' 'assessments' 'through' 'year' '5']","[0. 0. 3. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02320292,"18:23:chronic_disease,34:42:treatment,60:68:treatment","Subjects who are HBsAg negative, anti-HBs positive, and/or anti-HBc positive, but viral DNA negative are eligible","['Subjects' 'who' 'are' 'HBsAg' 'negative' ',' 'anti-HBs' 'positive' ','
 'and/or' 'anti-HBc' 'positive' ',' 'but' 'viral' 'DNA' 'negative' 'are'
 'eligible']",[0. 0. 0. 2. 0. 0. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02319369,"93:99:chronic_disease,104:112:chronic_disease,114:127:chronic_disease,156:171:treatment,180:212:chronic_disease","Has any condition that would preclude adequate absorption of DS-3032b, including refractory nausea and vomiting, malabsorption, biliary shunt, significant bowel resection, and/or graft-versus-host disease (GVHD) affecting the gut","['Has' 'any' 'condition' 'that' 'would' 'preclude' 'adequate' 'absorption'
 'of' 'DS-3032b' ',' 'including' 'refractory' 'nausea' 'and' 'vomiting'
 ',' 'malabsorption' ',' 'biliary' 'shunt' ',' 'significant' 'bowel'
 'resection' ',' 'and/or' 'graft-versus-host' 'disease' '(' 'GVHD' ')'
 'affecting' 'the' 'gut']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 0. 0. 0. 0. 1.
 1. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0.]"
NCT02319369,"14:23:treatment,42:52:cancer,,109:120:treatment,,191:200:treatment","received any therapies intended to treat malignancy within 14 days of first receipt of DS-3032b [except for hydroxyurea, which must be discontinued at least 48 hours (Day -2) prior to study treatment]","['received' 'any' 'therapies' 'intended' 'to' 'treat' 'malignancy'
 'within' '14' 'days' 'of' 'first' 'receipt' 'of' 'DS-3032b' '[' 'except'
 'for' 'hydroxyurea' ',' 'which' 'must' 'be' 'discontinued' 'at' 'least'
 '48' 'hours' '(' 'Day' '-2' ')' 'prior' 'to' 'study' 'treatment' ']']","[0. 0. 1. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]"
NCT02317991,"108:117:treatment,160:191:chronic_disease,193:209:chronic_disease,211:234:chronic_disease,242:264:chronic_disease,304:317:chronic_disease,321:334:chronic_disease","Patients with other concurrent severe and/or uncontrolled medical disease which could compromise safety of treatment as so judged by treating physician (i.e., severely impaired lung function, severe infection, ventricular arrhythmias active ischemic heart disease, known active vasculitis of any cause, chronic liver or renal disease)","['Patients' 'with' 'other' 'concurrent' 'severe' 'and/or' 'uncontrolled'
 'medical' 'disease' 'which' 'could' 'compromise' 'safety' 'of'
 'treatment' 'as' 'so' 'judged' 'by' 'treating' 'physician' '(' 'i.e.' ','
 'severely' 'impaired' 'lung' 'function' ',' 'severe' 'infection' ','
 'ventricular' 'arrhythmias' 'active' 'ischemic' 'heart' 'disease' ','
 'known' 'active' 'vasculitis' 'of' 'any' 'cause' ',' 'chronic' 'liver'
 'or' 'renal' 'disease' ')']","[0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 2. 2. 2. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.
 0. 2. 2. 0.]"
NCT02315612,"5:22:treatment,24:41:treatment,,115:128:treatment,","For radiation therapy: Radiation therapy must have been completed at least 3 weeks prior to enrollment (including CNS radiation), with the exception that there is no time restriction if the volume of bone marrow treated is less than 10% and also the subject has measurable/evaluable disease outside the radiation port","['For' 'radiation' 'therapy' ':' 'Radiation' 'therapy' 'must' 'have'
 'been' 'completed' 'at' 'least' '3' 'weeks' 'prior' 'to' 'enrollment' '('
 'including' 'CNS' 'radiation' ')' ',' 'with' 'the' 'exception' 'that'
 'there' 'is' 'no' 'time' 'restriction' 'if' 'the' 'volume' 'of' 'bone'
 'marrow' 'treated' 'is' 'less' 'than' '10' '%' 'and' 'also' 'the'
 'subject' 'has' 'measurable/evaluable' 'disease' 'outside' 'the'
 'radiation' 'port']","[0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02315612,"46:58:cancer,46:49:chronic_disease,60:86:cancer,75:86:chronic_disease,158:174:treatment","Subjects with radiologically-detected active CNS lymphoma, leptomeningeal CNS disease or isolated CNS disease which are eligible for definitive CNS directed radiationtherapy","['Subjects' 'with' 'radiologically-detected' 'active' 'CNS' 'lymphoma' ','
 'leptomeningeal' 'CNS' 'disease' 'or' 'isolated' 'CNS' 'disease' 'which'
 'are' 'eligible' 'for' 'definitive' 'CNS' 'directed' 'radiationtherapy']",[0. 0. 0. 0. 2. 2. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02315196,"1:20:treatment,56:62:treatment,,149:167:cancer","Computed tomography of the chest, abdomen, and pelvis (CT CAP) and bone scan performed within 30 days prior to study entry and does not demonstrate metastatic disease","['Computed' 'tomography' 'of' 'the' 'chest' ',' 'abdomen' ',' 'and'
 'pelvis' '(' 'CT' 'CAP' ')' 'and' 'bone' 'scan' 'performed' 'within' '30'
 'days' 'prior' 'to' 'study' 'entry' 'and' 'does' 'not' 'demonstrate'
 'metastatic' 'disease']","[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 3. 3.]"
NCT02315196,"1:24:chronic_disease,26:38:chronic_disease,40:67:chronic_disease,72:101:chronic_disease,","Nervous system disorder (paresthesias, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2, per the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)","['Nervous' 'system' 'disorder' '(' 'paresthesias' ',' 'peripheral' 'motor'
 'neuropathy' ',' 'or' 'peripheral' 'sensory' 'neuropathy' ')' '>' '='
 'grade' '2' ',' 'per' 'the' 'Common' 'Terminology' 'Criteria' 'for'
 'Adverse' 'Events' 'version' '4.0' '(' 'CTCAE' 'v4.0' ')']","[2. 2. 2. 0. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02315196,"1:26:cancer,16:26:cancer,39:53:cancer,60:91:cancer,112:150:cancer,","Second primary malignancy except most situ carcinoma (e.g. in situ carcinoma of the cervix, adequately treated non-melanomatous carcinoma of the skin) or other malignancy treated at least 5 years previously with no evidence of recurrence","['Second' 'primary' 'malignancy' 'except' 'most' 'situ' 'carcinoma' '('
 'e.g' '.' 'in' 'situ' 'carcinoma' 'of' 'the' 'cervix' ',' 'adequately'
 'treated' 'non-melanomatous' 'carcinoma' 'of' 'the' 'skin' ')' 'or'
 'other' 'malignancy' 'treated' 'at' 'least' '5' 'years' 'previously'
 'with' 'no' 'evidence' 'of' 'recurrence']","[3. 3. 3. 0. 0. 3. 3. 0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 3. 3. 3. 3. 3.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02315196,"28:47:treatment,49:61:treatment,66:82:treatment","patients who have received corneal transplants, cadaver skin, or bone transplants are eligible","['patients' 'who' 'have' 'received' 'corneal' 'transplants' ',' 'cadaver'
 'skin' ',' 'or' 'bone' 'transplants' 'are' 'eligible']",[0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 1. 1. 0. 0.]
NCT02314377,"24:35:treatment,45:69:treatment,81:118:treatment,,143:154:treatment","Patients must not have core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to bevacizumab","['Patients' 'must' 'not' 'have' 'core' 'biopsy' 'or' 'other' 'minor'
 'surgical' 'procedure' ',' 'excluding' 'placement' 'of' 'a' 'vascular'
 'access' 'device' ',' 'within' '7' 'days' 'prior' 'to' 'bevacizumab']","[0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 1. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.
 0. 1.]"
NCT02312596,"1:6:chronic_disease,39:60:treatment,68:72:treatment","Ulcer expected to be treated with any advanced therapeutics (e.g., HBOT)","['Ulcer' 'expected' 'to' 'be' 'treated' 'with' 'any' 'advanced'
 'therapeutics' '(' 'e.g.' ',' 'HBOT' ')']",[2. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0.]
NCT02312570,"1:24:chronic_disease,25:30:chronic_disease,25:31:chronic_disease,164:172:chronic_disease,174:184:chronic_disease,186:195:treatment,197:207:chronic_disease,209:234:chronic_disease,236:242:chronic_disease,247:264:chronic_disease","Stage I pressure ulcers Ulcers that are unstageable or of deep tissue morphology that have yet to become an open wound Ulcer not of PU pathophysiology (e.g., pure diabetic, vasculitic, radiation, rheumatoid, collagen vascular disease, venous, or arterial etiology)","['Stage' 'I' 'pressure' 'ulcers' 'Ulcers' 'that' 'are' 'unstageable' 'or'
 'of' 'deep' 'tissue' 'morphology' 'that' 'have' 'yet' 'to' 'become' 'an'
 'open' 'wound' 'Ulcer' 'not' 'of' 'PU' 'pathophysiology' '(' 'e.g.' ','
 'pure' 'diabetic' ',' 'vasculitic' ',' 'radiation' ',' 'rheumatoid' ','
 'collagen' 'vascular' 'disease' ',' 'venous' ',' 'or' 'arterial'
 'etiology' ')']","[2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0.
 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 1. 0. 2. 0. 2. 2. 2. 0. 2. 0. 0. 2. 2. 0.]"
NCT02312518,"88:106:treatment,124:129:chronic_disease,162:196:treatment","Subject requires or is anticipated to require interventions directed at improvement of arterial perfusion to affected area Ulcer expected to be treated with any advanced therapeutics (e.g., HBOT)","['Subject' 'requires' 'or' 'is' 'anticipated' 'to' 'require'
 'interventions' 'directed' 'at' 'improvement' 'of' 'arterial' 'perfusion'
 'to' 'affected' 'area' 'Ulcer' 'expected' 'to' 'be' 'treated' 'with'
 'any' 'advanced' 'therapeutics' '(' 'e.g.' ',' 'HBOT' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0.
 1. 1. 1. 1. 0. 0. 0.]"
NCT02312245,"1:19:cancer,23:41:cancer,43:61:cancer,65:86:cancer","Platinum resistant or refractory ovarian, primary peritoneal or fallopian tube cancer of any subtype","['Platinum' 'resistant' 'or' 'refractory' 'ovarian' ',' 'primary'
 'peritoneal' 'or' 'fallopian' 'tube' 'cancer' 'of' 'any' 'subtype']",[3. 3. 0. 3. 3. 0. 3. 3. 0. 3. 3. 3. 0. 0. 0.]
NCT02311361,"22:48:chronic_disease,50:57:chronic_disease,59:66:chronic_disease,69:92:chronic_disease,94:108:chronic_disease,137:153:chronic_disease","Active or history of inflammatory bowel disease (colitis, Crohn s), irritable bowel disease, celiac disease, or other serious, chronic, gastrointestinal conditions associated with diarrhea","['Active' 'or' 'history' 'of' 'inflammatory' 'bowel' 'disease' '('
 'colitis' ',' 'Crohn' 's' ')' ',' 'irritable' 'bowel' 'disease' ','
 'celiac' 'disease' ',' 'or' 'other' 'serious' ',' 'chronic' ','
 'gastrointestinal' 'conditions' 'associated' 'with' 'diarrhea']","[0. 0. 0. 0. 2. 2. 2. 0. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0.
 0. 0. 0. 2. 0. 0. 0. 0.]"
NCT02311361,"1:11:treatment,13:20:treatment,26:42:treatment","Intranasal, inhaled, and topical steroids","['Intranasal' ',' 'inhaled' ',' 'and' 'topical' 'steroids']",[1. 0. 1. 0. 0. 1. 1.]
NCT02310464,"56:63:cancer,65:69:cancer,71:81:cancer,85:98:cancer","Histologically or cytologically confirmed diagnosis of gastric, lung, colorectal or breast cancer on file","['Histologically' 'or' 'cytologically' 'confirmed' 'diagnosis' 'of'
 'gastric' ',' 'lung' ',' 'colorectal' 'or' 'breast' 'cancer' 'on' 'file']",[0. 0. 0. 0. 0. 0. 3. 0. 3. 0. 3. 0. 3. 3. 0. 0.]
NCT02310464,"32:53:treatment,55:83:treatment,105:131:cancer","Patients who have not received standard chemotherapy, hormonal or targeted therapy for their underlying advanced/metastatic cancer","['Patients' 'who' 'have' 'not' 'received' 'standard' 'chemotherapy' ','
 'hormonal' 'or' 'targeted' 'therapy' 'for' 'their' 'underlying'
 'advanced/metastatic' 'cancer']",[0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 3. 3.]
NCT02310464,"15:32:chronic_disease,40:47:chronic_disease,56:66:cancer,78:90:chronic_disease,","Subjects with pleural effusions and/or ascites, due to malignancy, requiring paracentesis every 2 weeks or more frequently","['Subjects' 'with' 'pleural' 'effusions' 'and/or' 'ascites' ',' 'due' 'to'
 'malignancy' ',' 'requiring' 'paracentesis' 'every' '2' 'weeks' 'or'
 'more' 'frequently']",[0. 0. 2. 2. 0. 2. 0. 0. 0. 3. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02310399,"27:46:chronic_disease,48:61:chronic_disease,63:76:chronic_disease","Patients with evidence of Chiari malformation, hydrocephalus, spina bifid a","['Patients' 'with' 'evidence' 'of' 'Chiari' 'malformation' ','
 'hydrocephalus' ',' 'spina' 'bifid' 'a']",[0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 2. 2.]
NCT02309580,"42:64:chronic_disease,87:97:chronic_disease,,,114:138:chronic_disease,","Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification","['Currently' 'active' ',' 'clinically' 'significant' 'cardiovascular'
 'disease' ',' 'such' 'as' 'uncontrolled' 'arrhythmia' 'or' 'class' '3'
 'or' '4' 'congestive' 'heart' 'failure' 'as' 'defined' 'by' 'the' 'New'
 'York' 'Heart' 'Association' 'Functional' 'Classification']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02309580,"8:17:chronic_disease,40:64:treatment,,118:128:treatment",Recent infection requiring intravenous anti-infective treatment that was completed ≤14 days before the first dose of study drug,"['Recent' 'infection' 'requiring' 'intravenous' 'anti-infective'
 'treatment' 'that' 'was' 'completed' '≤14' 'days' 'before' 'the' 'first'
 'dose' 'of' 'study' 'drug']",[0. 2. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02308904,"25:30:treatment,32:35:treatment,39:51:treatment,","Liver iron evaluated by SQUID, MRI or liver biopsy within 12 months prior to enrollment in the study","['Liver' 'iron' 'evaluated' 'by' 'SQUID' ',' 'MRI' 'or' 'liver' 'biopsy'
 'within' '12' 'months' 'prior' 'to' 'enrollment' 'in' 'the' 'study']",[0. 0. 0. 0. 1. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02308202,"66:80:treatment,82:92:treatment,94:99:treatment,101:108:treatment,113:138:treatment","Have evidence of untreated or unstable medical illness including neuroendocrine, autoimmune, renal, hepatic, or active infectious disease","['Have' 'evidence' 'of' 'untreated' 'or' 'unstable' 'medical' 'illness'
 'including' 'neuroendocrine' ',' 'autoimmune' ',' 'renal' ',' 'hepatic'
 ',' 'or' 'active' 'infectious' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1. 1.]
NCT02304458,"1:64:treatment,73:151:treatment,83:91:treatment,,196:228:chronic_disease,252:269:treatment","Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: >= 100 days after infusion, no evidence of graft versus host disease (GVHD) and no requirement for immunosuppression","['Allogeneic' '(' 'non-autologous' ')' 'bone' 'marrow' 'or' 'stem' 'cell'
 'transplant' ',' 'or' 'any' 'stem' 'cell' 'infusion' 'including' 'donor'
 'lymphocyte' 'infusion' '(' 'DLI' ')' 'or' 'boost' 'infusion' ':' '>' '='
 '100' 'days' 'after' 'infusion' ',' 'no' 'evidence' 'of' 'graft' 'versus'
 'host' 'disease' '(' 'GVHD' ')' 'and' 'no' 'requirement' 'for'
 'immunosuppression']","[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.
 1.]"
NCT02304458,"1:13:treatment,15:25:treatment,15:26:treatment,31:40:treatment,,119:131:treatment","Interleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)","['Interleukins' ',' 'interferons' 'and' 'cytokines' '(' 'other' 'than'
 'hematopoietic' 'growth' 'factors' ')' ':' '>' '=' '21' 'days' 'after'
 'the' 'completion' 'of' 'interleukins' ',' 'interferon' 'or' 'cytokines'
 '(' 'other' 'than' 'hematopoietic' 'growth' 'factors' ')']","[1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02304458,"28:58:chronic_disease,96:118:chronic_disease,134:151:treatment",Patients with a history of congestive heart failure (CHF) or are at risk because of underlying cardiovascular disease or exposure to cardiotoxic drugs must have adequate cardiac function as clinically indicated,"['Patients' 'with' 'a' 'history' 'of' 'congestive' 'heart' 'failure' '('
 'CHF' ')' 'or' 'are' 'at' 'risk' 'because' 'of' 'underlying'
 'cardiovascular' 'disease' 'or' 'exposure' 'to' 'cardiotoxic' 'drugs'
 'must' 'have' 'adequate' 'cardiac' 'function' 'as' 'clinically'
 'indicated']","[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02303977,"1:11:cancer,38:52:cancer,53:79:cancer",Histologic or cytologic diagnosis of adenocarcinoma non-small cell lung cancer,"['Histologic' 'or' 'cytologic' 'diagnosis' 'of' 'adenocarcinoma'
 'non-small' 'cell' 'lung' 'cancer']",[3. 0. 0. 0. 0. 3. 3. 3. 3. 3.]
NCT02302235,"96:103:chronic_disease,114:123:chronic_disease,127:149:chronic_disease,151:156:chronic_disease,160:173:chronic_disease,191:204:chronic_disease,206:219:chronic_disease,221:234:chronic_disease,236:257:chronic_disease,265:298:chronic_disease,300:309:chronic_disease,311:331:chronic_disease,336:348:chronic_disease","Any systemic illness or unstable medical condition that might pose additional risk, including: cardiac, unstable metabolic or endocrine disturbances, renal or liver disease, past history of renal calculi, hyperuricemia, hypercalcemia, mitochondrial disease, known disorder of fatty acid metabolism, porphyria, carnitine deficiency and pancreatitis","['Any' 'systemic' 'illness' 'or' 'unstable' 'medical' 'condition' 'that'
 'might' 'pose' 'additional' 'risk' ',' 'including' ':' 'cardiac' ','
 'unstable' 'metabolic' 'or' 'endocrine' 'disturbances' ',' 'renal' 'or'
 'liver' 'disease' ',' 'past' 'history' 'of' 'renal' 'calculi' ','
 'hyperuricemia' ',' 'hypercalcemia' ',' 'mitochondrial' 'disease' ','
 'known' 'disorder' 'of' 'fatty' 'acid' 'metabolism' ',' 'porphyria' ','
 'carnitine' 'deficiency' 'and' 'pancreatitis']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 2. 0. 2. 2. 0. 2.
 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 2. 0. 0. 2. 2. 2. 2. 2. 0.
 2. 0. 2. 2. 0. 2.]"
NCT02301611,"13:29:cancer,36:43:treatment,52:70:treatment",Evidence of residual disease after surgery and SoC adjuvant therapies,"['Evidence' 'of' 'residual' 'disease' 'after' 'surgery' 'and' 'SoC'
 'adjuvant' 'therapies']",[0. 0. 3. 3. 0. 1. 0. 0. 1. 1.]
NCT02301546,"1:17:chronic_disease,68:84:chronic_disease,86:108:chronic_disease","systemic illness that are thought to be affecting cognition (e.g., seizure disorder, demyelinating disorder, etc.)","['systemic' 'illness' 'that' 'are' 'thought' 'to' 'be' 'affecting'
 'cognition' '(' 'e.g.' ',' 'seizure' 'disorder' ',' 'demyelinating'
 'disorder' ',' 'etc' '.' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0.]
NCT02299414,"21:30:treatment,34:44:treatment,56:72:allergy_name",Contraindication to labetalol or nifedipine (e.g. know hypersensitivity),"['Contraindication' 'to' 'labetalol' 'or' 'nifedipine' '(' 'e.g' '.'
 'know' 'hypersensitivity' ')']",[0. 0. 1. 0. 1. 0. 0. 0. 0. 4. 0.]
NCT02296684,"13:26:treatment,75:82:treatment,84:89:treatment,91:98:treatment,100:109:treatment,110:130:treatment,132:144:treatment,146:152:treatment,154:184:treatment,190:205:treatment","Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine","['Examples' 'of' 'live' 'vaccines' 'include' ',' 'but' 'are' 'not'
 'limited' 'to' ',' 'the' 'following' ':' 'measles' ',' 'mumps' ','
 'rubella' ',' 'varicella/zoster' '(' 'chicken' 'pox' ')' ',' 'yellow'
 'fever' ',' 'rabies' ',' 'Bacillus' 'Calmette-Guérin' '(' 'BCG' ')' ','
 'and' 'typhoid' 'vaccine']","[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 1. 1.
 0. 0. 0. 1. 1. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 1. 1.]"
NCT02296684,"1:70:treatment,75:141:treatment,153:163:treatment","Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)","['Prior' 'treatment' 'with' 'an' 'anti-PD-1' ',' 'anti-PD-L1' ','
 'anti-PD-L2' ',' 'anti-CD137' ',' 'or' 'anti-cytotoxic'
 'T-lymphocyte-associated' 'antigen-4' '(' 'CTLA-4' ')' 'antibody' '('
 'including' 'ipilimumab' 'or' 'any' 'other' 'antibody' 'or' 'drug'
 'specifically' 'targeting' 'T-cell' 'co-stimulation' 'or' 'checkpoint'
 'pathways' ')']","[1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02296684,"24:30:cancer,47:54:treatment,56:66:cancer,70:105:cancer,155:186:cancer","previous head and neck cancer treated only by surgery, basal cell or squamous cell carcinoma of the skin which were treated with local resection only, or carcinoma in situ of the cervix","['previous' 'head' 'and' 'neck' 'cancer' 'treated' 'only' 'by' 'surgery'
 ',' 'basal' 'cell' 'or' 'squamous' 'cell' 'carcinoma' 'of' 'the' 'skin'
 'which' 'were' 'treated' 'with' 'local' 'resection' 'only' ',' 'or'
 'carcinoma' 'in' 'situ' 'of' 'the' 'cervix']","[0. 0. 0. 0. 3. 0. 0. 0. 1. 0. 3. 3. 0. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02291978,"1:21:treatment,36:61:treatment,66:95:treatment,108:124:treatment,134:141:treatment,143:150:treatment,152:164:treatment,170:193:treatment","Conservative therapy is defined as systemic pain medications and anti-inflammatory medications, as well as physical therapy, such as massage, heating, hydrotherapy, and strengthening exercises","['Conservative' 'therapy' 'is' 'defined' 'as' 'systemic' 'pain'
 'medications' 'and' 'anti-inflammatory' 'medications' ',' 'as' 'well'
 'as' 'physical' 'therapy' ',' 'such' 'as' 'massage' ',' 'heating' ','
 'hydrotherapy' ',' 'and' 'strengthening' 'exercises']","[1. 1. 0. 0. 0. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0.
 1. 0. 0. 1. 1.]"
NCT02291978,"27:52:chronic_disease,56:59:treatment,97:115:chronic_disease,124:142:chronic_disease","Patients with evidence of lumbosacral radiculopathy on MRI or physical exam findings, including radicular leg pain, or any neurologic deficit at or below the segmental level of the highest facet to be treated, including subjects with impaired sphincter control","['Patients' 'with' 'evidence' 'of' 'lumbosacral' 'radiculopathy' 'on'
 'MRI' 'or' 'physical' 'exam' 'findings' ',' 'including' 'radicular' 'leg'
 'pain' ',' 'or' 'any' 'neurologic' 'deficit' 'at' 'or' 'below' 'the'
 'segmental' 'level' 'of' 'the' 'highest' 'facet' 'to' 'be' 'treated' ','
 'including' 'subjects' 'with' 'impaired' 'sphincter' 'control']","[0. 0. 0. 0. 2. 2. 0. 1. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 2. 2. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02291848,"28:38:treatment,42:55:treatment,,78:93:treatment",If patient has received an autologous or syngeneic SCT they must be >90 days post-transplant (Group A),"['If' 'patient' 'has' 'received' 'an' 'autologous' 'or' 'syngeneic' 'SCT'
 'they' 'must' 'be' '>' '90' 'days' 'post-transplant' '(' 'Group' 'A' ')']",[0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02291523,"12:22:chronic_disease,36:58:treatment,68:85:chronic_disease,87:96:chronic_disease","Concurrent infections that require anti-microbial therapy (such as abdominal abscess, pneumonia, etc…","['Concurrent' 'infections' 'that' 'require' 'anti-microbial' 'therapy' '('
 'such' 'as' 'abdominal' 'abscess' ',' 'pneumonia' ',' 'etc…']",[0. 2. 0. 0. 1. 1. 0. 0. 0. 2. 2. 0. 2. 0. 0.]
NCT02290951,"1:4:cancer,28:43:treatment,52:78:treatment",NHL patients must have had prior treatment with an anti-CD20 antibody therapy,"['NHL' 'patients' 'must' 'have' 'had' 'prior' 'treatment' 'with' 'an'
 'anti-CD20' 'antibody' 'therapy']",[3. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 1.]
NCT02287558,"26:47:chronic_disease,54:64:chronic_disease,75:88:chronic_disease","Inherited or significant acquired coagulopathy (i.e. hemophilia, advanced liver disease)","['Inherited' 'or' 'significant' 'acquired' 'coagulopathy' '(' 'i.e' '.'
 'hemophilia' ',' 'advanced' 'liver' 'disease' ')']",[0. 0. 0. 2. 2. 0. 0. 0. 2. 0. 0. 2. 2. 0.]
NCT02286687,"109:120:treatment,122:134:treatment,136:152:chronic_disease,154:167:chronic_disease","Any medical condition or diagnosis that would likely impair absorption of an orally administered drug (e.g. gastrectomy, ileal bypass, chronic diarrhea, gastroparesis)","['Any' 'medical' 'condition' 'or' 'diagnosis' 'that' 'would' 'likely'
 'impair' 'absorption' 'of' 'an' 'orally' 'administered' 'drug' '(' 'e.g'
 '.' 'gastrectomy' ',' 'ileal' 'bypass' ',' 'chronic' 'diarrhea' ','
 'gastroparesis' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 2.
 2. 0. 2. 0.]"
NCT02286687,"12:42:chronic_disease,44:65:chronic_disease,69:84:chronic_disease,,130:137:treatment","History of cerebrovascular accident (CVA), myocardial infarction or unstable angina within the previous 6 months before starting therapy","['History' 'of' 'cerebrovascular' 'accident' '(' 'CVA' ')' ','
 'myocardial' 'infarction' 'or' 'unstable' 'angina' 'within' 'the'
 'previous' '6' 'months' 'before' 'starting' 'therapy']",[0. 0. 2. 2. 2. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02286687,"192:206:chronic_disease,316:322:cancer,326:340:cancer","Patients must have one of the following: somatic mutations or deletions in BRCA1 or BRCA2; genomic alterations in other BRCA pathway genes (subcohorts: a. ATM, b. PALB2, c. other genes, e.g. Fanconi Anemia genes, ARID1A, MER11, RAD50, NBS1, ATR; amplification of EMSY); or germline mutation in BRCA1 or BRCA 2 (not breast or ovarian cancer)","['Patients' 'must' 'have' 'one' 'of' 'the' 'following' ':' 'somatic'
 'mutations' 'or' 'deletions' 'in' 'BRCA1' 'or' 'BRCA2' ';' 'genomic'
 'alterations' 'in' 'other' 'BRCA' 'pathway' 'genes' '(' 'subcohorts' ':'
 'a.' 'ATM' ',' 'b.' 'PALB2' ',' 'c.' 'other' 'genes' ',' 'e.g' '.'
 'Fanconi' 'Anemia' 'genes' ',' 'ARID1A' ',' 'MER11' ',' 'RAD50' ','
 'NBS1' ',' 'ATR' ';' 'amplification' 'of' 'EMSY' ')' ';' 'or' 'germline'
 'mutation' 'in' 'BRCA1' 'or' 'BRCA' '2' '(' 'not' 'breast' 'or' 'ovarian'
 'cancer' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3.
 0.]"
NCT02285101,"11:24:chronic_disease,51:58:chronic_disease,60:77:chronic_disease,82:96:chronic_disease","Advancing liver failure indicated by uncontrolled ascites, pleural effusions, or encephalopathy","['Advancing' 'liver' 'failure' 'indicated' 'by' 'uncontrolled' 'ascites'
 ',' 'pleural' 'effusions' ',' 'or' 'encephalopathy']",[0. 2. 2. 0. 0. 0. 2. 0. 2. 2. 0. 0. 2.]
NCT02285101,"13:20:chronic_disease,22:27:chronic_disease,31:54:chronic_disease","Significant hepatic, renal or bone marrow dysfunction indicated by","['Significant' 'hepatic' ',' 'renal' 'or' 'bone' 'marrow' 'dysfunction'
 'indicated' 'by']",[0. 2. 0. 2. 0. 2. 2. 2. 0. 0.]
NCT02281409,"53:59:cancer,67:92:chronic_disease,94:111:chronic_disease,","Any concomitant serious physical illness other than cancer (i.e., immune deficiency disease, bleeding disorder, etc.) within 1 year prior to dosing","['Any' 'concomitant' 'serious' 'physical' 'illness' 'other' 'than'
 'cancer' '(' 'i.e.' ',' 'immune' 'deficiency' 'disease' ',' 'bleeding'
 'disorder' ',' 'etc' '.' ')' 'within' '1' 'year' 'prior' 'to' 'dosing']","[0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02278315,"1:18:treatment,20:32:treatment,34:47:treatment,49:72:treatment,76:90:treatment,,143:161:treatment","Radiation therapy, chemotherapy, immunotherapy, investigational therapy or corticosteroid use within 2 weeks of or after eligibility-defining bone marrow biopsy","['Radiation' 'therapy' ',' 'chemotherapy' ',' 'immunotherapy' ','
 'investigational' 'therapy' 'or' 'corticosteroid' 'use' 'within' '2'
 'weeks' 'of' 'or' 'after' 'eligibility-defining' 'bone' 'marrow' 'biopsy']",[1. 1. 0. 1. 0. 1. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02278250,"84:95:cancer,110:126:treatment,,232:258:treatment,300:311:treatment,327:338:treatment,357:366:treatment","Participants with one histologically or cytologically confirmed malignant advanced solid tumor, for which no standard therapy is available which may convey clinical benefit and/or participants must have progressed after at least 1 prior chemotherapy regimen in the metastatic setting, and for which carboplatin (for Part B1), gemcitabine (for Part B2), or cisplatin (for Part B3) would be considered standard of care","['Participants' 'with' 'one' 'histologically' 'or' 'cytologically'
 'confirmed' 'malignant' 'advanced' 'solid' 'tumor' ',' 'for' 'which' 'no'
 'standard' 'therapy' 'is' 'available' 'which' 'may' 'convey' 'clinical'
 'benefit' 'and/or' 'participants' 'must' 'have' 'progressed' 'after' 'at'
 'least' '1' 'prior' 'chemotherapy' 'regimen' 'in' 'the' 'metastatic'
 'setting' ',' 'and' 'for' 'which' 'carboplatin' '(' 'for' 'Part' 'B1' ')'
 ',' 'gemcitabine' '(' 'for' 'Part' 'B2' ')' ',' 'or' 'cisplatin' '('
 'for' 'Part' 'B3' ')' 'would' 'be' 'considered' 'standard' 'of' 'care']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02277548,"56:72:treatment,74:84:treatment,89:99:treatment","Has another painful condition requiring chronic use of opioid analgesic, gabapentin, or pregabalin","['Has' 'another' 'painful' 'condition' 'requiring' 'chronic' 'use' 'of'
 'opioid' 'analgesic' ',' 'gabapentin' ',' 'or' 'pregabalin']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 1.]
NCT02276716,"17:31:treatment,41:49:treatment,51:58:treatment,60:67:treatment,69:83:treatment,85:96:treatment,100:111:treatment","Patients taking anticoagulants, such as warfarin, heparin, aspirin, pentoxifylline, clopidogrel or ticlopidine","['Patients' 'taking' 'anticoagulants' ',' 'such' 'as' 'warfarin' ','
 'heparin' ',' 'aspirin' ',' 'pentoxifylline' ',' 'clopidogrel' 'or'
 'ticlopidine']",[0. 0. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1.]
NCT02276443,"27:39:treatment,45:51:treatment,59:72:treatment",Patients not eligible for chemotherapy with taxane and/or anthracycline based chemotherapy regimens,"['Patients' 'not' 'eligible' 'for' 'chemotherapy' 'with' 'taxane' 'and/or'
 'anthracycline' 'based' 'chemotherapy' 'regimens']",[0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0.]
NCT02276443,"21:27:treatment,31:38:treatment,52:57:cancer,96:109:cancer,,,",patient can undergo biopsy or surgery of a primary tumor site for suspected or proven invasive breast cancer of clinical stage I to III,"['patient' 'can' 'undergo' 'biopsy' 'or' 'surgery' 'of' 'a' 'primary'
 'tumor' 'site' 'for' 'suspected' 'or' 'proven' 'invasive' 'breast'
 'cancer' 'of' 'clinical' 'stage' 'I' 'to' 'III']",[0. 0. 0. 1. 0. 1. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0.]
NCT02273375,"12:21:treatment,33:54:treatment,58:77:treatment",Concurrent treatment with other investigational drugs or anti-cancer therapy,"['Concurrent' 'treatment' 'with' 'other' 'investigational' 'drugs' 'or'
 'anti-cancer' 'therapy']",[0. 1. 0. 0. 1. 1. 0. 1. 1.]
NCT02273375,"23:40:chronic_disease,71:96:treatment,113:119:chronic_disease",Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RA,"['Patients' 'positive' 'for' 'hepatitis' 'C' '(' 'HCV' ')' 'antibody'
 'are' 'eligible' 'only' 'if' 'polymerase' 'chain' 'reaction' 'is'
 'negative' 'for' 'HCV' 'RA']",[0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02273375,"7:19:cancer,,102:111:treatment,223:233:cancer","other malignancies curatively treated with no evidence of disease for ≥ 5 years following the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy","['other' 'malignancies' 'curatively' 'treated' 'with' 'no' 'evidence' 'of'
 'disease' 'for' '≥' '5' 'years' 'following' 'the' 'end' 'of' 'treatment'
 'and' 'which' ',' 'in' 'the' 'opinion' 'of' 'the' 'treating' 'physician'
 ',' 'do' 'not' 'have' 'a' 'substantial' 'risk' 'of' 'recurrence' 'of'
 'the' 'prior' 'malignancy']","[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.]"
NCT02273362,"1:9:treatment,34:46:treatment,50:69:treatment",Surgical cohort (cohort A only): percutaneous or transjugular biopsy incomplete or not performed,"['Surgical' 'cohort' '(' 'cohort' 'A' 'only' ')' ':' 'percutaneous' 'or'
 'transjugular' 'biopsy' 'incomplete' 'or' 'not' 'performed']",[1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0.]
NCT02272998,"81:103:cancer,115:139:cancer,161:189:treatment",Patients with histologically or cytologically confirmed diagnosis of refractory metastatic solid tumor or chronic hematological malignancy who are eligible for investigational drug therapy,"['Patients' 'with' 'histologically' 'or' 'cytologically' 'confirmed'
 'diagnosis' 'of' 'refractory' 'metastatic' 'solid' 'tumor' 'or' 'chronic'
 'hematological' 'malignancy' 'who' 'are' 'eligible' 'for'
 'investigational' 'drug' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 3. 3. 0. 0. 0. 0. 1. 1. 1.]
NCT02272998,"31:57:chronic_disease,59:65:chronic_disease,67:98:chronic_disease,100:115:chronic_disease,119:146:chronic_disease","any patient with a history of myocardial infarction (MI), stroke, transient ischemic attack (TIA), unstable angina or peripheral vascular disease will not be eligible","['any' 'patient' 'with' 'a' 'history' 'of' 'myocardial' 'infarction' '('
 'MI' ')' ',' 'stroke' ',' 'transient' 'ischemic' 'attack' '(' 'TIA' ')'
 ',' 'unstable' 'angina' 'or' 'peripheral' 'vascular' 'disease' 'will'
 'not' 'be' 'eligible']","[0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 2. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0.
 2. 2. 2. 0. 0. 0. 0.]"
NCT02272218,"38:49:treatment,50:66:treatment,103:110:treatment,115:130:treatment","has not yet tried to treat pain with oral NSAIDs/COX-2 inhibitors (unless medical contraindications), Tylenol, or topical therapy","['has' 'not' 'yet' 'tried' 'to' 'treat' 'pain' 'with' 'oral'
 'NSAIDs/COX-2' 'inhibitors' '(' 'unless' 'medical' 'contraindications'
 ')' ',' 'Tylenol' ',' 'or' 'topical' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1.]
NCT02271919,",28:50:chronic_disease,52:74:chronic_disease,76:82:chronic_disease,84:90:chronic_disease,92:104:chronic_disease","History (last 3 months) of abnormal heart rhythms, cardiovascular disease (stroke, angina, heart attack) may result in ineligibility; these conditions will be evaluated on a case by case basis by the study physician","['History' '(' 'last' '3' 'months' ')' 'of' 'abnormal' 'heart' 'rhythms'
 ',' 'cardiovascular' 'disease' '(' 'stroke' ',' 'angina' ',' 'heart'
 'attack' ')' 'may' 'result' 'in' 'ineligibility' ';' 'these' 'conditions'
 'will' 'be' 'evaluated' 'on' 'a' 'case' 'by' 'case' 'basis' 'by' 'the'
 'study' 'physician']","[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 2. 2. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02271919,"9:20:treatment,30:40:chronic_disease,,62:98:treatment,103:125:treatment","certain medications to treat depression (last 14 days), i.e. monoamine oxidase inhibitors (MAOIs) and Elavil (Amitriptyline)","['certain' 'medications' 'to' 'treat' 'depression' '(' 'last' '14' 'days'
 ')' ',' 'i.e' '.' 'monoamine' 'oxidase' 'inhibitors' '(' 'MAOIs' ')'
 'and' 'Elavil' '(' 'Amitriptyline' ')']",[0. 1. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 1. 1. 0. 0.]
NCT02270970,"5:31:treatment,73:90:treatment,81:90:treatment",any immune suppressive therapy being taken despite option for immediate steroid treatment and later treatment rescues as needed,"['any' 'immune' 'suppressive' 'therapy' 'being' 'taken' 'despite' 'option'
 'for' 'immediate' 'steroid' 'treatment' 'and' 'later' 'treatment'
 'rescues' 'as' 'needed']",[0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT02270450,"33:50:chronic_disease,54:67:chronic_disease,96:114:treatment,118:129:chronic_disease,",Patients must not have signs of bowel perforation or acute abdomen as evidenced by free air on radiologic imaging or peritonitis on physical exam within 2 days prior to registration,"['Patients' 'must' 'not' 'have' 'signs' 'of' 'bowel' 'perforation' 'or'
 'acute' 'abdomen' 'as' 'evidenced' 'by' 'free' 'air' 'on' 'radiologic'
 'imaging' 'or' 'peritonitis' 'on' 'physical' 'exam' 'within' '2' 'days'
 'prior' 'to' 'registration']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 1. 1. 0. 2. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02269293,",41:54:treatment,62:72:treatment,74:85:treatment,87:98:treatment,100:127:treatment,138:153:treatment","At least 4 weeks must have lapsed since major surgery (e.g., laparotomy, laparoscopy, thoracotomy, video assisted thoracoscopy) prior to study treatment initiation","['At' 'least' '4' 'weeks' 'must' 'have' 'lapsed' 'since' 'major' 'surgery'
 '(' 'e.g.' ',' 'laparotomy' ',' 'laparoscopy' ',' 'thoracotomy' ','
 'video' 'assisted' 'thoracoscopy' ')' 'prior' 'to' 'study' 'treatment'
 'initiation']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 1. 1. 0. 0.
 0. 1. 1. 0.]"
NCT02269293,"64:75:chronic_disease,87:106:cancer,108:116:chronic_disease,147:163:chronic_disease,171:187:chronic_disease,203:227:chronic_disease,229:232:chronic_disease,234:240:chronic_disease,","Patients with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures which are not controlled, any brain metastases and/or epidural disease, or history of cerebrovascular accident (CVA, stroke) within six months prior to the first date of study treatment","['Patients' 'with' 'history' 'or' 'evidence' 'upon' 'physical'
 'examination' 'of' 'CNS' 'disease' ',' 'including' 'primary' 'brain'
 'tumor' ',' 'seizures' 'which' 'are' 'not' 'controlled' ',' 'any' 'brain'
 'metastases' 'and/or' 'epidural' 'disease' ',' 'or' 'history' 'of'
 'cerebrovascular' 'accident' '(' 'CVA' ',' 'stroke' ')' 'within' 'six'
 'months' 'prior' 'to' 'the' 'first' 'date' 'of' 'study' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 3. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 2. 2. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02268448,"16:40:treatment,52:59:treatment,61:76:treatment,81:101:treatment","Current use of chronic pain medications (including opioids, antidepressants and anti-epileptic drugs)","['Current' 'use' 'of' 'chronic' 'pain' 'medications' '(' 'including'
 'opioids' ',' 'antidepressants' 'and' 'anti-epileptic' 'drugs' ')']",[0. 0. 0. 1. 1. 1. 0. 0. 1. 0. 1. 0. 1. 1. 0.]
NCT02268253,",64:85:treatment,143:151:chronic_disease,153:159:chronic_disease,165:172:chronic_disease","has persistent clinically significant toxicities Grade ≥2 from previous chemotherapy not readily controlled by supportive measures (excluding alopecia, nausea, and fatigue)","['has' 'persistent' 'clinically' 'significant' 'toxicities' 'Grade' '≥2'
 'from' 'previous' 'chemotherapy' 'not' 'readily' 'controlled' 'by'
 'supportive' 'measures' '(' 'excluding' 'alopecia' ',' 'nausea' ',' 'and'
 'fatigue' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 2.
 0.]"
NCT02268253,"14:26:chronic_disease,53:64:chronic_disease,83:93:treatment",uncontrolled hypertension or clinically significant arrhythmias not controlled by medication),"['uncontrolled' 'hypertension' 'or' 'clinically' 'significant'
 'arrhythmias' 'not' 'controlled' 'by' 'medication' ')']",[0. 2. 0. 0. 0. 2. 0. 0. 0. 1. 0.]
NCT02267772,"22:35:allergy_name,102:118:chronic_disease,120:140:chronic_disease,154:174:chronic_disease,182:194:chronic_disease,196:206:chronic_disease,,","contraindications to acetaminophen including reported elevated liver function tests, hepatic injury, hepatic disorder, active liver disease, alcoholism, chronic malnutrition, known coagulapathy, hemorrhage, creatinine > 1.0, or known allergy or hypersensitivity to acetaminophen","['contraindications' 'to' 'acetaminophen' 'including' 'reported'
 'elevated' 'liver' 'function' 'tests' ',' 'hepatic' 'injury' ','
 'hepatic' 'disorder' ',' 'active' 'liver' 'disease' ',' 'alcoholism' ','
 'chronic' 'malnutrition' ',' 'known' 'coagulapathy' ',' 'hemorrhage' ','
 'creatinine' '>' '1.0' ',' 'or' 'known' 'allergy' 'or' 'hypersensitivity'
 'to' 'acetaminophen']","[0. 0. 4. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 2. 2.
 0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02266745,"14:38:chronic_disease,,,,99:120:chronic_disease,122:146:chronic_disease,148:195:treatment,197:222:chronic_disease,227:245:chronic_disease,,285:295:treatment","Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to initiation of study drug","['Uncontrolled' 'congestive' 'heart' 'failure' '(' 'New' 'York' 'Heart'
 'Association' 'Classification' '3' 'or' '4' ')' ',' 'angina' ','
 'myocardial' 'infarction' ',' 'cerebrovascular' 'accident' ','
 'coronary/peripheral' 'artery' 'bypass' 'graft' 'surgery' ',' 'transient'
 'ischemic' 'attack' ',' 'or' 'pulmonary' 'embolism' 'within' '3' 'months'
 'prior' 'to' 'initiation' 'of' 'study' 'drug']","[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 1.
 1. 1. 1. 1. 0. 2. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02266719,"1:11:chronic_disease,15:29:chronic_disease,,,44:77:chronic_disease,",Juxtarenal or suprarenal AAA and type I-IV thoracoabdominal aortic aneurysms with diameter ≥5.0 cm in diameter or 2 times the normal aortic diameter,"['Juxtarenal' 'or' 'suprarenal' 'AAA' 'and' 'type' 'I-IV'
 'thoracoabdominal' 'aortic' 'aneurysms' 'with' 'diameter' '≥5.0' 'cm'
 'in' 'diameter' 'or' '2' 'times' 'the' 'normal' 'aortic' 'diameter']",[2. 0. 2. 2. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02266719,"1:26:chronic_disease,99:137:treatment,141:160:treatment","Thoracic aortic aneurysms that extend into the arch, with the exception of those patients who had prior open surgical aortic replacement or endovascular repair, where a surgical graft or an endograft has been extended proximal and/or near the celiac artery (functional type IV) that would serve as landing zone for the investigational endograft","['Thoracic' 'aortic' 'aneurysms' 'that' 'extend' 'into' 'the' 'arch' ','
 'with' 'the' 'exception' 'of' 'those' 'patients' 'who' 'had' 'prior'
 'open' 'surgical' 'aortic' 'replacement' 'or' 'endovascular' 'repair' ','
 'where' 'a' 'surgical' 'graft' 'or' 'an' 'endograft' 'has' 'been'
 'extended' 'proximal' 'and/or' 'near' 'the' 'celiac' 'artery' '('
 'functional' 'type' 'IV' ')' 'that' 'would' 'serve' 'as' 'landing' 'zone'
 'for' 'the' 'investigational' 'endograft']","[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02266329,"8:29:treatment,39:50:treatment,54:71:treatment,83:94:treatment,",Use of prescribed stimulants (such as amphetamine or dextroamphetamine containing medications) within 2 weeks of beginning the preliminary screening period through the end of study involvement,"['Use' 'of' 'prescribed' 'stimulants' '(' 'such' 'as' 'amphetamine' 'or'
 'dextroamphetamine' 'containing' 'medications' ')' 'within' '2' 'weeks'
 'of' 'beginning' 'the' 'preliminary' 'screening' 'period' 'through' 'the'
 'end' 'of' 'study' 'involvement']","[0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02265874,"38:56:chronic_disease,69:80:treatment,84:107:treatment",patients with extensive irreversible pulmonary fibrosis (based upon lung biopsy or high resolution CT scan criterion),"['patients' 'with' 'extensive' 'irreversible' 'pulmonary' 'fibrosis' '('
 'based' 'upon' 'lung' 'biopsy' 'or' 'high' 'resolution' 'CT' 'scan'
 'criterion' ')']",[0. 0. 0. 0. 2. 2. 0. 0. 0. 1. 1. 0. 1. 1. 1. 1. 0. 0.]
NCT02264236,"34:56:chronic_disease,58:81:chronic_disease,85:101:cancer","Existing diagnosis or history of leptomeningeal disease, spinal cord compression or brain metastases unless","['Existing' 'diagnosis' 'or' 'history' 'of' 'leptomeningeal' 'disease' ','
 'spinal' 'cord' 'compression' 'or' 'brain' 'metastases' 'unless']",[0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 3. 3. 0.]
NCT02263729,"6:23:chronic_disease,25:39:chronic_disease,41:46:chronic_disease,50:57:chronic_disease","Have diabetes mellitus, cardiovascular, renal or hepatic co-morbidities","['Have' 'diabetes' 'mellitus' ',' 'cardiovascular' ',' 'renal' 'or'
 'hepatic' 'co-morbidities']",[0. 2. 2. 0. 2. 0. 2. 0. 2. 0.]
NCT02262806,"7:20:chronic_disease,7:10:chronic_disease,39:52:chronic_disease",Known HIV infection or HIV-associated lipodystrophy,['Known' 'HIV' 'infection' 'or' 'HIV-associated' 'lipodystrophy'],[0. 2. 2. 0. 0. 2.]
NCT02261519,"40:53:chronic_disease,,196:209:chronic_disease,214:233:chronic_disease","Physician confirmed DSM-V diagnosis of schizophrenia for the past 2 years based on subject's history and confirmed by psychiatric evaluation and MINI International Neuropsychiatric Interview For Schizophrenia and Psychotic Disorders, version 7.0 (MINI, Version 7.0)","['Physician' 'confirmed' 'DSM-V' 'diagnosis' 'of' 'schizophrenia' 'for'
 'the' 'past' '2' 'years' 'based' 'on' 'subject' ""'s"" 'history' 'and'
 'confirmed' 'by' 'psychiatric' 'evaluation' 'and' 'MINI' 'International'
 'Neuropsychiatric' 'Interview' 'For' 'Schizophrenia' 'and' 'Psychotic'
 'Disorders' ',' 'version' '7.0' '(' 'MINI' ',' 'Version' '7.0' ')']","[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02259621,"1:28:treatment,33:58:treatment,,73:83:treatment,135:153:chronic_disease",Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease,"['Inhaled' 'or' 'topical' 'steroids' 'and' 'adrenal' 'replacement' 'doses'
 '>' '10' 'mg' 'daily' 'prednisone' 'equivalents' 'are' 'permitted' 'in'
 'the' 'absence' 'of' 'active' 'autoimmune' 'disease']",[1. 1. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT02259504,"27:50:treatment,58:67:treatment,82:90:chronic_disease",Use (current or prior) of liquid embolic material in the treatment of the target aneurysm,"['Use' '(' 'current' 'or' 'prior' ')' 'of' 'liquid' 'embolic' 'material'
 'in' 'the' 'treatment' 'of' 'the' 'target' 'aneurysm']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 1. 0. 0. 0. 2.]
NCT02257424,"165:185:treatment,,,,,,,278:299:treatment,306:314:treatment,339:356:treatment,379:394:treatment,403:439:treatment,441:448:treatment,454:464:treatment","Current use of a prohibited medication as described in Section 6.3.8 of the protocol for Potential for Drug-Drug Interaction: apply moisturizing creams frequently, topical keratolytics (e.g. urea 20-40 % cream, salicylic acid 6%, tazarotene 0.1% cream, fluorouracil 5% cream), clobetasol propionate 0.05% ointment for erythematous areas, topical lidocaine 2%, and / or systemic pain medication such as nonsteroidal anti-inflammatory drugs, codeine, and pregabalin for pain","['Current' 'use' 'of' 'a' 'prohibited' 'medication' 'as' 'described' 'in'
 'Section' '6.3.8' 'of' 'the' 'protocol' 'for' 'Potential' 'for'
 'Drug-Drug' 'Interaction' ':' 'apply' 'moisturizing' 'creams'
 'frequently' ',' 'topical' 'keratolytics' '(' 'e.g' '.' 'urea' '20-40'
 '%' 'cream' ',' 'salicylic' 'acid' '6' '%' ',' 'tazarotene' '0.1' '%'
 'cream' ',' 'fluorouracil' '5' '%' 'cream' ')' ',' 'clobetasol'
 'propionate' '0.05' '%' 'ointment' 'for' 'erythematous' 'areas' ','
 'topical' 'lidocaine' '2' '%' ',' 'and' '/' 'or' 'systemic' 'pain'
 'medication' 'such' 'as' 'nonsteroidal' 'anti-inflammatory' 'drugs' ','
 'codeine' ',' 'and' 'pregabalin' 'for' 'pain']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.
 0. 1. 1. 1. 0. 1. 0. 0. 1. 0. 0.]"
NCT02257424,"20:80:treatment,87:96:treatment,98:111:treatment,113:126:treatment,128:137:treatment,141:154:treatment,,197:206:treatment","Patients receiving cytochrome P450 enzyme-inducing anticonvulsant drugs (EIADs) (i.e. phenytoin, carbamazepine, Phenobarbital, primidone or oxcarbazepine) within 4 weeks of the start of the study treatment","['Patients' 'receiving' 'cytochrome' 'P450' 'enzyme-inducing'
 'anticonvulsant' 'drugs' '(' 'EIADs' ')' '(' 'i.e' '.' 'phenytoin' ','
 'carbamazepine' ',' 'Phenobarbital' ',' 'primidone' 'or' 'oxcarbazepine'
 ')' 'within' '4' 'weeks' 'of' 'the' 'start' 'of' 'the' 'study'
 'treatment']","[0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02257138,"16:33:chronic_disease,203:218:chronic_disease,229:246:chronic_disease","Any coexisting medical condition that in the judgment of the treating physician is likely to interfere with study procedures or results including uncontrolled severe infections, as well as uncontrolled cardiac disease, or other organ dysfunction","['Any' 'coexisting' 'medical' 'condition' 'that' 'in' 'the' 'judgment'
 'of' 'the' 'treating' 'physician' 'is' 'likely' 'to' 'interfere' 'with'
 'study' 'procedures' 'or' 'results' 'including' 'uncontrolled' 'severe'
 'infections' ',' 'as' 'well' 'as' 'uncontrolled' 'cardiac' 'disease' ','
 'or' 'other' 'organ' 'dysfunction']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2.]"
NCT02256631,"21:40:treatment,,117:122:treatment,124:131:treatment,136:141:treatment,142:147:treatment","Any requirement for supplemental oxygen beyond 24 hours of life or requiring supplemental oxygen at the time of the VRC01, VRC01LS, or VRC07-523LS dose","['Any' 'requirement' 'for' 'supplemental' 'oxygen' 'beyond' '24' 'hours'
 'of' 'life' 'or' 'requiring' 'supplemental' 'oxygen' 'at' 'the' 'time'
 'of' 'the' 'VRC01' ',' 'VRC01LS' ',' 'or' 'VRC07-523LS' 'dose']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0.
 1. 0.]"
NCT02255383,"1:21:chronic_disease,23:37:chronic_disease,39:58:chronic_disease,60:73:chronic_disease","rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis","['rheumatoid' 'arthritis' ',' 'osteoarthritis' ',' 'traumatic' 'arthritis'
 ',' 'polyarthritis']",[2. 2. 0. 2. 0. 2. 2. 0. 2.]
NCT02254863,"22:34:treatment,36:65:treatment,70:92:treatment","receiving concurrent radiotherapy, immunosuppressive medications, or cytotoxic chemotherapy","['receiving' 'concurrent' 'radiotherapy' ',' 'immunosuppressive'
 'medications' ',' 'or' 'cytotoxic' 'chemotherapy']",[0. 0. 1. 0. 1. 1. 0. 0. 1. 1.]
NCT02253316,"1:10:chronic_disease,21:48:treatment,66:75:chronic_disease,,115:124:treatment",Infection requiring systemic antibiotic therapy or other serious infection within 14 days prior to start of study treatment,"['Infection' 'requiring' 'systemic' 'antibiotic' 'therapy' 'or' 'other'
 'serious' 'infection' 'within' '14' 'days' 'prior' 'to' 'start' 'of'
 'study' 'treatment']",[2. 0. 1. 1. 1. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02253316,",37:44:treatment,56:72:treatment,77:93:cancer,,,142:157:treatment",Received at least two cycles of any regimen as initial systemic therapy for multiple myeloma and are within 2-16 months of the first dose of initial therapy,"['Received' 'at' 'least' 'two' 'cycles' 'of' 'any' 'regimen' 'as'
 'initial' 'systemic' 'therapy' 'for' 'multiple' 'myeloma' 'and' 'are'
 'within' '2-16' 'months' 'of' 'the' 'first' 'dose' 'of' 'initial'
 'therapy']","[0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02252432,"47:62:treatment,64:73:treatment,75:87:treatment,89:101:treatment,104:129:treatment,131:138:treatment,140:150:treatment,152:161:treatment,163:173:treatment,176:187:treatment,189:201:treatment,203:219:treatment,221:244:treatment,246:271:treatment","Drugs known to cause prolonged qT: class (IA) antiarrhythmics (quinidine, procainamide, disopyramide), class III antiarrhythmics (sotalol, dofetilide, ibutilide, amiodarone), haloperidol, thioridazine, arsenic trioxide, HIV protease inhibitors, tricyclic antidepressants","['Drugs' 'known' 'to' 'cause' 'prolonged' 'qT' ':' 'class' '(' 'IA' ')'
 'antiarrhythmics' '(' 'quinidine' ',' 'procainamide' ',' 'disopyramide'
 ')' ',' 'class' 'III' 'antiarrhythmics' '(' 'sotalol' ',' 'dofetilide'
 ',' 'ibutilide' ',' 'amiodarone' ')' ',' 'haloperidol' ',' 'thioridazine'
 ',' 'arsenic' 'trioxide' ',' 'HIV' 'protease' 'inhibitors' ','
 'tricyclic' 'antidepressants']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0.
 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 0. 1. 0. 1. 1. 0. 1. 1. 1. 0. 1. 1.]"
NCT02252432,"1:25:chronic_disease,27:45:chronic_disease,47:64:chronic_disease","Restrictive lung disease (pulmonary fibrosis, myasthenia gravis)","['Restrictive' 'lung' 'disease' '(' 'pulmonary' 'fibrosis' ','
 'myasthenia' 'gravis' ')']",[2. 2. 2. 0. 2. 2. 0. 2. 2. 0.]
NCT02252081,"12:21:treatment,33:51:treatment,72:81:treatment,85:103:chronic_disease,",History of metformin use or any insulin sensitizer or any drug for the treatment of metabolic syndrome over the last one year,"['History' 'of' 'metformin' 'use' 'or' 'any' 'insulin' 'sensitizer' 'or'
 'any' 'drug' 'for' 'the' 'treatment' 'of' 'metabolic' 'syndrome' 'over'
 'the' 'last' 'one' 'year']",[0. 0. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT02250664,"11:31:treatment,33:42:treatment,52:69:treatment","Have used nicotine replacement, bupropion or other pharmacotherapies as cessation aids in the past month","['Have' 'used' 'nicotine' 'replacement' ',' 'bupropion' 'or' 'other'
 'pharmacotherapies' 'as' 'cessation' 'aids' 'in' 'the' 'past' 'month']",[0. 0. 1. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02250157,"27:37:allergy_name,41:62:allergy_name,78:106:allergy_name","Allergy or sensitivity to irinotecan or cranberry-grape juice, or any of the irinotecan tablet excipients","['Allergy' 'or' 'sensitivity' 'to' 'irinotecan' 'or' 'cranberry-grape'
 'juice' ',' 'or' 'any' 'of' 'the' 'irinotecan' 'tablet' 'excipients']",[0. 0. 0. 0. 4. 4. 4. 4. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02250157,"77:93:chronic_disease,107:131:chronic_disease,133:154:chronic_disease,,181:205:chronic_disease,207:225:chronic_disease,227:252:chronic_disease,277:295:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease requiring oxygen, known bleeding disorders, or any concomitant illness or social situation that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'myocardial' 'infarction' 'within'
 'the' 'last' '6' 'months' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'chronic' 'pulmonary' 'disease' 'requiring'
 'oxygen' ',' 'known' 'bleeding' 'disorders' ',' 'or' 'any' 'concomitant'
 'illness' 'or' 'social' 'situation' 'that' 'would' 'limit' 'compliance'
 'with' 'study' 'requirements']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0.
 0. 0. 0. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02244814,"1:13:chronic_disease,15:28:chronic_disease,30:44:chronic_disease,46:67:chronic_disease,69:81:chronic_disease,83:90:treatment,107:119:chronic_disease,121:139:chronic_disease,144:175:chronic_disease","hypertension, renal disease, thrombophilias, rheumatologic disease, preeclampsia, steroid use, history of pancreatitis, infectious disease, or intrauterine growth restriction","['hypertension' ',' 'renal' 'disease' ',' 'thrombophilias' ','
 'rheumatologic' 'disease' ',' 'preeclampsia' ',' 'steroid' 'use' ','
 'history' 'of' 'pancreatitis' ',' 'infectious' 'disease' ',' 'or'
 'intrauterine' 'growth' 'restriction']","[2. 0. 2. 2. 0. 2. 0. 2. 2. 0. 2. 0. 1. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 2.
 2. 2.]"
NCT02243813,"45:58:chronic_disease,60:78:chronic_disease,140:164:chronic_disease","Have a first or second-degree relative with Schizophrenia, Psychotic Disorder (unless substance induced or due to a medical condition), or Bipolar I or II Disorder","['Have' 'a' 'first' 'or' 'second-degree' 'relative' 'with' 'Schizophrenia'
 ',' 'Psychotic' 'Disorder' '(' 'unless' 'substance' 'induced' 'or' 'due'
 'to' 'a' 'medical' 'condition' ')' ',' 'or' 'Bipolar' 'I' 'or' 'II'
 'Disorder']","[0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 2. 2. 2. 2. 2.]"
NCT02240498,"63:74:chronic_disease,76:87:chronic_disease,102:114:chronic_disease","All patients with clinical symptoms (ex: fever, chills, pain, tachycardia, hypotension), laboratory (leukocytosis) and radiologic findings (thick walled, rim-enhancing collection with gas bubbles or air-fluid levels) compatible with an abscess that requires image-guided percutaneous drainage","['All' 'patients' 'with' 'clinical' 'symptoms' '(' 'ex' ':' 'fever' ','
 'chills' ',' 'pain' ',' 'tachycardia' ',' 'hypotension' ')' ','
 'laboratory' '(' 'leukocytosis' ')' 'and' 'radiologic' 'findings' '('
 'thick' 'walled' ',' 'rim-enhancing' 'collection' 'with' 'gas' 'bubbles'
 'or' 'air-fluid' 'levels' ')' 'compatible' 'with' 'an' 'abscess' 'that'
 'requires' 'image-guided' 'percutaneous' 'drainage']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 0. 0. 2. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02237183,"17:28:chronic_disease,44:56:treatment,60:88:treatment,,","Due to risk for hypotension in patients on vasodilators or antihypertensive medications, participants must not have blood pressure < 95 mm Hg systolic","['Due' 'to' 'risk' 'for' 'hypotension' 'in' 'patients' 'on' 'vasodilators'
 'or' 'antihypertensive' 'medications' ',' 'participants' 'must' 'not'
 'have' 'blood' 'pressure' '<' '95' 'mm' 'Hg' 'systolic']",[0. 0. 0. 0. 2. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02236013,"1:20:treatment,25:42:chronic_disease,48:59:treatment,",Emergency treatment for hyperleukocytosis with hydroxyurea for ≤ 10 days,"['Emergency' 'treatment' 'for' 'hyperleukocytosis' 'with' 'hydroxyurea'
 'for' '≤' '10' 'days']",[1. 1. 0. 2. 0. 1. 0. 0. 0. 0.]
NCT02236000,"15:45:treatment,,96:114:treatment,137:153:treatment",Chronic daily treatment with corticosteroids with a dose of greater than or equal to 10 mg/day methylprednisolone equivalent (excluding inhaled steroids),"['Chronic' 'daily' 'treatment' 'with' 'corticosteroids' 'with' 'a' 'dose'
 'of' 'greater' 'than' 'or' 'equal' 'to' '10' 'mg/day'
 'methylprednisolone' 'equivalent' '(' 'excluding' 'inhaled' 'steroids'
 ')']",[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 1. 0.]
NCT02235857,"1:20:chronic_disease,42:53:chronic_disease,55:70:chronic_disease,72:110:chronic_disease,115:131:chronic_disease","Cardiac impairments such as uncontrolled arrhyth¬mia, unstable angina, decompensated congestive heart failure, or valvular disease","['Cardiac' 'impairments' 'such' 'as' 'uncontrolled' 'arrhyth¬mia' ','
 'unstable' 'angina' ',' 'decompensated' 'congestive' 'heart' 'failure'
 ',' 'or' 'valvular' 'disease']",[2. 2. 0. 0. 0. 2. 0. 2. 2. 0. 2. 2. 2. 2. 0. 0. 2. 2.]
NCT02235857,"21:36:allergy_name,38:45:allergy_name,50:64:allergy_name","Hypersensitivity to dextran sulfate, heparin, or ethylene oxide","['Hypersensitivity' 'to' 'dextran' 'sulfate' ',' 'heparin' ',' 'or'
 'ethylene' 'oxide']",[0. 0. 4. 4. 0. 4. 0. 0. 4. 4.]
NCT02234934,"8:23:chronic_disease,56:80:chronic_disease,82:90:chronic_disease,92:103:chronic_disease","Active cardiac disease, including clinical evidence of congestive heart failure, cyanosis, hypotension","['Active' 'cardiac' 'disease' ',' 'including' 'clinical' 'evidence' 'of'
 'congestive' 'heart' 'failure' ',' 'cyanosis' ',' 'hypotension']",[0. 2. 2. 0. 0. 0. 0. 0. 2. 2. 2. 0. 2. 0. 2.]
NCT02234934,"22:56:chronic_disease,60:71:chronic_disease,98:109:chronic_disease,136:139:chronic_disease,141:151:chronic_disease,153:168:chronic_disease,172:185:chronic_disease","No co-infection with Human Immunodeficiency Virus (HIV) or hepatitis B virus (HBsAg positive) or hepatitis C virus (HCV RNA positive), CMV, adenovirus, parvovirus B 19 or toxoplasmosis","['No' 'co-infection' 'with' 'Human' 'Immunodeficiency' 'Virus' '(' 'HIV'
 ')' 'or' 'hepatitis' 'B' 'virus' '(' 'HBsAg' 'positive' ')' 'or'
 'hepatitis' 'C' 'virus' '(' 'HCV' 'RNA' 'positive' ')' ',' 'CMV' ','
 'adenovirus' ',' 'parvovirus' 'B' '19' 'or' 'toxoplasmosis']","[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 2. 0. 2. 0. 2. 2. 2. 0. 2.]"
NCT02234557,",28:36:chronic_disease,38:52:chronic_disease,54:76:chronic_disease,78:95:chronic_disease","neurologic disorder (e.g., epilepsy, cerebral palsy, traumatic brain injury, Tourette Syndrome)","['neurologic' 'disorder' '(' 'e.g.' ',' 'epilepsy' ',' 'cerebral' 'palsy'
 ',' 'traumatic' 'brain' 'injury' ',' 'Tourette' 'Syndrome' ')']",[0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0.]
NCT02233868,"48:68:chronic_disease,159:174:treatment,192:221:treatment,","Current or past DSM-IV or DSM-5 diagnosis of a psychiatric disorder (other than alcohol in AD participants and nicotine/caffeine use disorders) that required hospitalization (any length), or chronic medication management (more than 4 weeks) and that could impact brain function at the time of the study as determined by history and clinical exam","['Current' 'or' 'past' 'DSM-IV' 'or' 'DSM-5' 'diagnosis' 'of' 'a'
 'psychiatric' 'disorder' '(' 'other' 'than' 'alcohol' 'in' 'AD'
 'participants' 'and' 'nicotine/caffeine' 'use' 'disorders' ')' 'that'
 'required' 'hospitalization' '(' 'any' 'length' ')' ',' 'or' 'chronic'
 'medication' 'management' '(' 'more' 'than' '4' 'weeks' ')' 'and' 'that'
 'could' 'impact' 'brain' 'function' 'at' 'the' 'time' 'of' 'the' 'study'
 'as' 'determined' 'by' 'history' 'and' 'clinical' 'exam']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02233868,"1:25:treatment,14:24:treatment,77:87:treatment,104:115:treatment,,187:213:treatment,215:238:treatment,240:264:treatment,284:297:treatment,299:322:treatment","psychoactive medications or medication that may affect study results (e.g., analgesics [non narcotic], antibiotics (must finish course at least 24 hours prior to a scheduled procedure), antidiarrheal preparations, anti-inflammatory drugs (systemic corticosteroids are exclusionary), antinauseants, cough/cold preparations) (self-report, medical history)","['psychoactive' 'medications' 'or' 'medication' 'that' 'may' 'affect'
 'study' 'results' '(' 'e.g.' ',' 'analgesics' '[' 'non' 'narcotic' ']'
 ',' 'antibiotics' '(' 'must' 'finish' 'course' 'at' 'least' '24' 'hours'
 'prior' 'to' 'a' 'scheduled' 'procedure' ')' ',' 'antidiarrheal'
 'preparations' ',' 'anti-inflammatory' 'drugs' '(' 'systemic'
 'corticosteroids' 'are' 'exclusionary' ')' ',' 'antinauseants' ','
 'cough/cold' 'preparations' ')' '(' 'self-report' ',' 'medical' 'history'
 ')']","[1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 1. 0.
 1. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT02232516,"33:55:treatment,48:55:treatment,60:64:cancer,77:92:treatment,","Patients must not have received prior systemic therapy for PTCL (except for corticosteroids for 10 or fewer days at any dose, no washout period required as long as they discontinue prior to starting study therapy)","['Patients' 'must' 'not' 'have' 'received' 'prior' 'systemic' 'therapy'
 'for' 'PTCL' '(' 'except' 'for' 'corticosteroids' 'for' '10' 'or' 'fewer'
 'days' 'at' 'any' 'dose' ',' 'no' 'washout' 'period' 'required' 'as'
 'long' 'as' 'they' 'discontinue' 'prior' 'to' 'starting' 'study'
 'therapy' ')']","[0. 0. 0. 0. 0. 1. 1. 1. 0. 3. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02232165,"10:17:chronic_disease,19:28:chronic_disease,30:37:chronic_disease,41:54:chronic_disease","Advanced cardiac, pulmonary, hepatic or liver disease","['Advanced' 'cardiac' ',' 'pulmonary' ',' 'hepatic' 'or' 'liver' 'disease']",[0. 2. 0. 2. 0. 2. 0. 2. 2.]
NCT02231073,"32:43:chronic_disease,45:62:chronic_disease,68:88:chronic_disease,102:108:chronic_disease,110:120:chronic_disease,122:132:chronic_disease,136:162:chronic_disease","at least one of the following: rest tremor, muscular rigidity, and postural instability not cause by visual, vestibular, cerebellar or proprioceptive dysfunction","['at' 'least' 'one' 'of' 'the' 'following' ':' 'rest' 'tremor' ','
 'muscular' 'rigidity' ',' 'and' 'postural' 'instability' 'not' 'cause'
 'by' 'visual' ',' 'vestibular' ',' 'cerebellar' 'or' 'proprioceptive'
 'dysfunction']","[0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 2. 0. 2. 0. 2.
 0. 2. 2.]"
NCT02227199,"111:135:treatment,137:169:treatment,171:189:treatment,213:224:treatment,,,,,,419:458:treatment,,","Patients must have measurable disease defined as lesions that can be accurately measured in two dimensions by computed tomography (CT), magnetic resonance imaging (MRI), medical photograph (skin or oral lesion), plain x-ray, or other conventional technique and a greatest transverse diameter of 1 cm or greater; or palpable lesions with both diameters >= 2 cm; further, at least 1 of these lesions must be positive by positron emission tomography (PET) scan (i.e., Deauville score of 4 or more)","['Patients' 'must' 'have' 'measurable' 'disease' 'defined' 'as' 'lesions'
 'that' 'can' 'be' 'accurately' 'measured' 'in' 'two' 'dimensions' 'by'
 'computed' 'tomography' '(' 'CT' ')' ',' 'magnetic' 'resonance' 'imaging'
 '(' 'MRI' ')' ',' 'medical' 'photograph' '(' 'skin' 'or' 'oral' 'lesion'
 ')' ',' 'plain' 'x-ray' ',' 'or' 'other' 'conventional' 'technique' 'and'
 'a' 'greatest' 'transverse' 'diameter' 'of' '1' 'cm' 'or' 'greater' ';'
 'or' 'palpable' 'lesions' 'with' 'both' 'diameters' '>' '=' '2' 'cm' ';'
 'further' ',' 'at' 'least' '1' 'of' 'these' 'lesions' 'must' 'be'
 'positive' 'by' 'positron' 'emission' 'tomography' '(' 'PET' ')' 'scan'
 '(' 'i.e.' ',' 'Deauville' 'score' 'of' '4' 'or' 'more' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1.
 1. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02226159,"73:76:treatment,77:79:treatment,92:110:chronic_disease",Deemed to be good operative candidates by spine surgeons (patients with MRI/CT findings of neural compression with concordant symptoms) and had agreed to possible operative intervention,"['Deemed' 'to' 'be' 'good' 'operative' 'candidates' 'by' 'spine'
 'surgeons' '(' 'patients' 'with' 'MRI/CT' 'findings' 'of' 'neural'
 'compression' 'with' 'concordant' 'symptoms' ')' 'and' 'had' 'agreed'
 'to' 'possible' 'operative' 'intervention']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02225548,"27:48:chronic_disease,50:56:chronic_disease,77:87:chronic_disease,","Subject with a history of myocardial infarction, stroke or life-threatening arrhythmia within 6 months prior to screening","['Subject' 'with' 'a' 'history' 'of' 'myocardial' 'infarction' ','
 'stroke' 'or' 'life-threatening' 'arrhythmia' 'within' '6' 'months'
 'prior' 'to' 'screening']",[0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT02225548,"37:66:chronic_disease,87:95:chronic_disease,104:122:chronic_disease,124:140:cancer,146:154:cancer","Subject with clinically significant chronic hematological disease which could lead to priapism such as sickle cell anemia, multiple myeloma, and leukemia","['Subject' 'with' 'clinically' 'significant' 'chronic' 'hematological'
 'disease' 'which' 'could' 'lead' 'to' 'priapism' 'such' 'as' 'sickle'
 'cell' 'anemia' ',' 'multiple' 'myeloma' ',' 'and' 'leukemia']",[0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 2. 0. 0. 2. 2. 2. 0. 3. 3. 0. 0. 3.]
NCT02222545,"29:33:chronic_disease,46:50:treatment,62:65:chronic_disease,69:72:chronic_disease","Have a diagnosis of primary aHUS, persistent HSCT-associated TMA or TTP","['Have' 'a' 'diagnosis' 'of' 'primary' 'aHUS' ',' 'persistent'
 'HSCT-associated' 'TMA' 'or' 'TTP']",[0. 0. 0. 0. 0. 2. 0. 0. 1. 2. 0. 2.]
NCT02217709,"24:29:chronic_disease,33:58:chronic_disease,60:73:chronic_disease,75:91:chronic_disease,100:116:chronic_disease,127:142:treatment","Known prior history of mania or major psychiatric illness (schizophrenia, bipolar disorder, severe major depression requiring hospitalization, etc.)","['Known' 'prior' 'history' 'of' 'mania' 'or' 'major' 'psychiatric'
 'illness' '(' 'schizophrenia' ',' 'bipolar' 'disorder' ',' 'severe'
 'major' 'depression' 'requiring' 'hospitalization' ',' 'etc' '.' ')']",[0. 0. 0. 0. 2. 0. 2. 2. 2. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02216227,"9:28:treatment,32:50:treatment,71:83:treatment,87:98:treatment",Undergo cardiac transplants or cardiac procedures performed using the percutaneous or thoracotomy approach,"['Undergo' 'cardiac' 'transplants' 'or' 'cardiac' 'procedures' 'performed'
 'using' 'the' 'percutaneous' 'or' 'thoracotomy' 'approach']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0.]
NCT02215096,"36:53:chronic_disease,87:98:chronic_disease,100:107:chronic_disease,109:114:chronic_disease,118:133:chronic_disease","Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal or cardiac disease)","['Evidence' 'of' 'severe' 'or' 'uncontrolled' 'systemic' 'diseases' '('
 'e.g.' ',' 'unstable' 'or' 'uncompensated' 'respiratory' ',' 'hepatic'
 ',' 'renal' 'or' 'cardiac' 'disease' ')']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 2. 2. 0.]
NCT02215096,"1:21:cancer,16:21:cancer,65:71:treatment",PTEN deficient tumor as documented from archival or fresh (from biopsy) tumor tissue analyzed by GlaxoSmithKline selected laboratory,"['PTEN' 'deficient' 'tumor' 'as' 'documented' 'from' 'archival' 'or'
 'fresh' '(' 'from' 'biopsy' ')' 'tumor' 'tissue' 'analyzed' 'by'
 'GlaxoSmithKline' 'selected' 'laboratory']",[3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02215096,"12:33:chronic_disease,35:59:chronic_disease,71:86:chronic_disease,89:109:treatment,111:119:treatment,124:139:treatment,,185:214:chronic_disease,,,","history of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, stenting, or bypass grafting within the past 6 months prior to enrolment, Class III or IV heart failure as defined by the New York Heart Association functional classification system, LVEF below 50%","['history' 'of' 'myocardial' 'infarction' ',' 'acute' 'coronary'
 'syndromes' '(' 'including' 'unstable' 'angina' ')' ',' 'coronary'
 'angioplasty' ',' 'stenting' ',' 'or' 'bypass' 'grafting' 'within' 'the'
 'past' '6' 'months' 'prior' 'to' 'enrolment' ',' 'Class' 'III' 'or' 'IV'
 'heart' 'failure' 'as' 'defined' 'by' 'the' 'New' 'York' 'Heart'
 'Association' 'functional' 'classification' 'system' ',' 'LVEF' 'below'
 '50' '%']","[0. 0. 2. 2. 0. 2. 1. 1. 0. 0. 2. 2. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02213913,"1:16:cancer,22:62:treatment,36:56:treatment,209:213:cancer,216:219:cancer,245:257:treatment","B-cell lymphoma with comprehensive immunohistochemistry (IHC) panel establishing lineage (CD20, CD3) and cell of origin (CD10, BCL6 and MUM1) in addition to proliferative/prognostic markers (Ki-67, C-myc and BCL2). DHL will be identified using cytogenetics and/or immunohistochemistry","['B-cell' 'lymphoma' 'with' 'comprehensive' 'immunohistochemistry' '('
 'IHC' ')' 'panel' 'establishing' 'lineage' '(' 'CD20' ',' 'CD3' ')' 'and'
 'cell' 'of' 'origin' '(' 'CD10' ',' 'BCL6' 'and' 'MUM1' ')' 'in'
 'addition' 'to' 'proliferative/prognostic' 'markers' '(' 'Ki-67' ','
 'C-myc' 'and' 'BCL2' ')' '.' 'DHL' 'will' 'be' 'identified' 'using'
 'cytogenetics' 'and/or' 'immunohistochemistry']","[3. 3. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 3. 0. 0. 0. 0. 1. 0. 0.]"
NCT02213497,"52:63:chronic_disease,65:70:chronic_disease,72:79:chronic_disease,84:102:chronic_disease","Patients must be surgical candidates with adequate hematologic, renal, hepatic and pulmonary function","['Patients' 'must' 'be' 'surgical' 'candidates' 'with' 'adequate'
 'hematologic' ',' 'renal' ',' 'hepatic' 'and' 'pulmonary' 'function']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 2. 2.]
NCT02213289,",,,68:82:treatment,84:93:treatment,98:109:treatment","Cardiac Ejection Fraction >50% (for HER2+ patients) as assessed by echocardiogram, MUGA scan, or cardiac MRI","['Cardiac' 'Ejection' 'Fraction' '>' '50' '%' '(' 'for' 'HER2+' 'patients'
 ')' 'as' 'assessed' 'by' 'echocardiogram' ',' 'MUGA' 'scan' ',' 'or'
 'cardiac' 'MRI']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 1. 1.]
NCT02213289,"27:54:treatment,47:54:treatment,59:70:treatment,75:96:cancer,",Patients who have started first line mFOLFOX6 therapy (+/-trastuzumab for HER2 amplified tumors) may be considered for trial participation if they have received no more than 4 doses of therapy at the time of consent and screening,"['Patients' 'who' 'have' 'started' 'first' 'line' 'mFOLFOX6' 'therapy' '('
 '+/-trastuzumab' 'for' 'HER2' 'amplified' 'tumors' ')' 'may' 'be'
 'considered' 'for' 'trial' 'participation' 'if' 'they' 'have' 'received'
 'no' 'more' 'than' '4' 'doses' 'of' 'therapy' 'at' 'the' 'time' 'of'
 'consent' 'and' 'screening']","[0. 0. 0. 0. 1. 1. 1. 1. 0. 1. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02209636,"12:23:treatment,99:109:treatment,125:138:treatment","Not taking medications that interact with agents administered during experimental sessions (e.g., sildenafil interacts with nitroglycerin)","['Not' 'taking' 'medications' 'that' 'interact' 'with' 'agents'
 'administered' 'during' 'experimental' 'sessions' '(' 'e.g.' ','
 'sildenafil' 'interacts' 'with' 'nitroglycerin' ')']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0.]
NCT02208362,"74:90:chronic_disease,132:143:chronic_disease,147:148:chronic_disease,239:253:treatment","Research participants with any uncontrolled illness including ongoing or active infection; research participants with known active hepatitis B or C infection; research participants with any signs or symptoms of active infection, positive blood cultures or radiological evidence of infections","['Research' 'participants' 'with' 'any' 'uncontrolled' 'illness'
 'including' 'ongoing' 'or' 'active' 'infection' ';' 'research'
 'participants' 'with' 'known' 'active' 'hepatitis' 'B' 'or' 'C'
 'infection' ';' 'research' 'participants' 'with' 'any' 'signs' 'or'
 'symptoms' 'of' 'active' 'infection' ',' 'positive' 'blood' 'cultures'
 'or' 'radiological' 'evidence' 'of' 'infections']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]"
NCT02207439,"1:16:treatment,1:17:treatment,19:32:treatment,34:47:treatment,65:74:treatment,76:94:treatment,95:104:treatment,106:121:treatment,123:133:treatment,135:145:treatment,147:156:treatment,158:165:treatment,167:187:treatment,189:201:treatment,203:215:treatment,217:236:treatment,238:250:treatment,251:261:treatment,263:272:treatment,274:292:treatment,294:303:treatment,305:323:treatment,324:341:treatment,343:363:treatment,364:376:treatment,378:411:treatment,413:427:treatment,429:438:treatment","Anti-Convulsants: carbamazepine, Phenobarbital, Anti-Convulsant:phenytoin, Anti-Mycobacterial:rifabutin, PDE5 Inhibitors: sildenafil, vardenafil, tadalafil, HMG-CoA: Reductase Inhibitors: atorvastatin, rosuvastatin, Immuno-suppressants: cyclosporine,tacrolimus, sirolimus, Narcotic Analgesic: methadone, Oral Contraceptive:ethinyl estradiol, Macrolide Antibiotic:azithromycin, Inhaled/nasal steroid fluticasone, Antidepressant: trazodone","['Anti-Convulsants' ':' 'carbamazepine' ',' 'Phenobarbital' ','
 'Anti-Convulsant' ':' 'phenytoin' ',' 'Anti-Mycobacterial' ':'
 'rifabutin' ',' 'PDE5' 'Inhibitors' ':' 'sildenafil' ',' 'vardenafil' ','
 'tadalafil' ',' 'HMG-CoA' ':' 'Reductase' 'Inhibitors' ':' 'atorvastatin'
 ',' 'rosuvastatin' ',' 'Immuno-suppressants' ':' 'cyclosporine' ','
 'tacrolimus' ',' 'sirolimus' ',' 'Narcotic' 'Analgesic' ':' 'methadone'
 ',' 'Oral' 'Contraceptive' ':' 'ethinyl' 'estradiol' ',' 'Macrolide'
 'Antibiotic' ':' 'azithromycin' ',' 'Inhaled/nasal' 'steroid'
 'fluticasone' ',' 'Antidepressant' ':' 'trazodone']","[1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 1. 0. 1. 0. 1. 0. 1. 0. 1.
 0. 1. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 1. 0. 1. 0. 1. 1. 0.
 1. 1. 0. 1. 1. 0. 1. 0. 1. 1. 1. 0. 1. 0. 1.]"
NCT02204098,"20:49:treatment,74:84:treatment,96:129:treatment,131:148:treatment,153:175:treatment","Current use of any electronic stimulation device, such as cardiac demand pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep brain stimulators","['Current' 'use' 'of' 'any' 'electronic' 'stimulation' 'device' ',' 'such'
 'as' 'cardiac' 'demand' 'pacemakers' ',' 'automatic' 'implantable'
 'cardiac' 'defibrillator' ',' 'nerve' 'stimulators' ',' 'or' 'deep'
 'brain' 'stimulators']","[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 1. 0. 1. 1. 0. 0. 1.
 1. 1.]"
NCT02203903,"20:28:cancer,32:48:cancer,52:66:treatment","Evidence of active leukemia or lymphoma disease by flow cytometry, morphology, or cytogenetic evaluation within the marrow or extramedullary sites","['Evidence' 'of' 'active' 'leukemia' 'or' 'lymphoma' 'disease' 'by' 'flow'
 'cytometry' ',' 'morphology' ',' 'or' 'cytogenetic' 'evaluation' 'within'
 'the' 'marrow' 'or' 'extramedullary' 'sites']",[0. 0. 0. 3. 0. 3. 3. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02203695,"25:38:treatment,40:60:treatment,65:88:treatment","Concurrent use of other antiandrogens, estrogen-like agents, or 5a-reductase inhibitors","['Concurrent' 'use' 'of' 'other' 'antiandrogens' ',' 'estrogen-like'
 'agents' ',' 'or' '5a-reductase' 'inhibitors']",[0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 1. 1.]
NCT02203552,"25:57:treatment,58:73:treatment,103:122:treatment,136:145:treatment,157:171:chronic_disease","Any contraindication to magnetic resonance imaging (MRI)/PET examination including but not limited to ferromagnetic metal in the body, pacemaker, or severe claustrophobia","['Any' 'contraindication' 'to' 'magnetic' 'resonance' 'imaging' '(' 'MRI'
 ')' '/PET' 'examination' 'including' 'but' 'not' 'limited' 'to'
 'ferromagnetic' 'metal' 'in' 'the' 'body' ',' 'pacemaker' ',' 'or'
 'severe' 'claustrophobia']","[0. 0. 0. 1. 1. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 0.
 0. 0. 2.]"
NCT02203552,"23:39:chronic_disease,43:59:chronic_disease,69:87:cancer",Reported diagnosis of major depression or anxiety disorder prior to breast cancer (BC) diagnosis,"['Reported' 'diagnosis' 'of' 'major' 'depression' 'or' 'anxiety'
 'disorder' 'prior' 'to' 'breast' 'cancer' '(' 'BC' ')' 'diagnosis']",[0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 3. 3. 3. 0. 0. 0.]
NCT02203513,"46:52:cancer,60:70:cancer,74:101:cancer,103:128:cancer,137:158:cancer","For Cohorts 1-3, 5 and 6: patients must have breast and/or epithelial or endometrioid ovarian cancer, primary peritoneal cancer, and/or fallopian tube cancer histologically or cytologically confirmed at the NCI that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective","['For' 'Cohorts' '1-3' ',' '5' 'and' '6' ':' 'patients' 'must' 'have'
 'breast' 'and/or' 'epithelial' 'or' 'endometrioid' 'ovarian' 'cancer' ','
 'primary' 'peritoneal' 'cancer' ',' 'and/or' 'fallopian' 'tube' 'cancer'
 'histologically' 'or' 'cytologically' 'confirmed' 'at' 'the' 'NCI' 'that'
 'is' 'metastatic' 'or' 'unresectable' 'and' 'for' 'which' 'standard'
 'curative' 'measures' 'do' 'not' 'exist' 'or' 'are' 'no' 'longer'
 'effective']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 0. 3. 3. 3. 0. 3. 3. 3. 0. 0.
 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02203513,",40:56:treatment,58:70:treatment,72:88:treatment,94:111:treatment,116:138:treatment,,152:163:treatment","Patients must be at least 4 weeks from previous therapy (chemotherapy, hormonal therapy, and radiation therapy, or investigational agents; 6 weeks for mitomycin C)","['Patients' 'must' 'be' 'at' 'least' '4' 'weeks' 'from' 'previous'
 'therapy' '(' 'chemotherapy' ',' 'hormonal' 'therapy' ',' 'and'
 'radiation' 'therapy' ',' 'or' 'investigational' 'agents' ';' '6' 'weeks'
 'for' 'mitomycin' 'C' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 1. 0. 0. 1. 1. 0. 0. 1. 1. 0.
 0. 0. 0. 1. 1. 0.]"
NCT02203513,"14:34:chronic_disease,78:102:chronic_disease,113:128:chronic_disease,138:148:chronic_disease,173:184:chronic_disease,188:198:chronic_disease,,250:269:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, clinically significant GI bleeding or hemoptysis within 28 days prior to the start of the study, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'symptomatic' 'congestive' 'heart' 'failure' ','
 'unstable' 'angina' 'pectoris' ',' 'cardiac' 'arrhythmia' ','
 'clinically' 'significant' 'GI' 'bleeding' 'or' 'hemoptysis' 'within'
 '28' 'days' 'prior' 'to' 'the' 'start' 'of' 'the' 'study' ',' 'or'
 'psychiatric' 'illness/social' 'situations' 'that' 'would' 'limit'
 'compliance' 'with' 'study' 'requirements']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 2. 2. 0. 0. 2. 0. 0. 0.
 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02201992,"34:61:treatment,65:82:treatment,,,120:129:treatment,134:146:treatment",Patients must have completed any prior adjuvant chemotherapy or radiation therapy 2 or more weeks (6 or more weeks for mitomycin and nitrosoureas) prior to randomization and be adequately recovered at the time of randomization,"['Patients' 'must' 'have' 'completed' 'any' 'prior' 'adjuvant'
 'chemotherapy' 'or' 'radiation' 'therapy' '2' 'or' 'more' 'weeks' '(' '6'
 'or' 'more' 'weeks' 'for' 'mitomycin' 'and' 'nitrosoureas' ')' 'prior'
 'to' 'randomization' 'and' 'be' 'adequately' 'recovered' 'at' 'the'
 'time' 'of' 'randomization']","[0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02200445,",59:79:treatment,154:174:treatment,176:199:treatment,201:213:treatment,221:237:treatment,244:282:treatment","Failure to tolerate or failure to respond to at least one conventional therapy with the intention of inducing or maintaining remission (examples include oral corticosteroids, oral 5-aminosalicylates, azathioprine and/or 6-mercaptopurine, or a tumor necrosis factor (TNF) antagonist","['Failure' 'to' 'tolerate' 'or' 'failure' 'to' 'respond' 'to' 'at' 'least'
 'one' 'conventional' 'therapy' 'with' 'the' 'intention' 'of' 'inducing'
 'or' 'maintaining' 'remission' '(' 'examples' 'include' 'oral'
 'corticosteroids' ',' 'oral' '5-aminosalicylates' ',' 'azathioprine'
 'and/or' '6-mercaptopurine' ',' 'or' 'a' 'tumor' 'necrosis' 'factor' '('
 'TNF' ')' 'antagonist']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0.]"
NCT02200445,"27:35:treatment,37:47:treatment,51:63:treatment,81:96:chronic_disease,98:116:chronic_disease,118:129:chronic_disease,131:137:chronic_disease,142:177:chronic_disease","Requirement for immediate surgical, endoscopic or radiological intervention for toxic megacolon, massive hemorrhage, perforation, sepsis, or intra-abdominal or perianal abscess","['Requirement' 'for' 'immediate' 'surgical' ',' 'endoscopic' 'or'
 'radiological' 'intervention' 'for' 'toxic' 'megacolon' ',' 'massive'
 'hemorrhage' ',' 'perforation' ',' 'sepsis' ',' 'or' 'intra-abdominal'
 'or' 'perianal' 'abscess']","[0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 2. 2. 0. 2. 2. 0. 2. 0. 2. 0. 0. 2. 2. 2.
 2.]"
NCT02195232,"22:28:treatment,32:45:treatment,63:78:chronic_disease",Known intolerance of niacin or ascorbic acid (including known G6PD deficiency),"['Known' 'intolerance' 'of' 'niacin' 'or' 'ascorbic' 'acid' '('
 'including' 'known' 'G6PD' 'deficiency' ')']",[0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 2. 2. 0.]
NCT02194738,"31:50:treatment,52:57:treatment,62:75:treatment,86:97:cancer",No patients who have received neoadjuvant therapy (chemo- or radio-therapy) for this lung cancer,"['No' 'patients' 'who' 'have' 'received' 'neoadjuvant' 'therapy' '('
 'chemo-' 'or' 'radio-therapy' ')' 'for' 'this' 'lung' 'cancer']",[0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 0. 3. 3.]
NCT02193373,"5:27:treatment,,86:120:treatment,122:129:treatment,133:144:treatment","Any manipulative therapies within the previous 7 days (including but not limited to: osteopathic manipulative treatment, massage or acupuncture)","['Any' 'manipulative' 'therapies' 'within' 'the' 'previous' '7' 'days' '('
 'including' 'but' 'not' 'limited' 'to' ':' 'osteopathic' 'manipulative'
 'treatment' ',' 'massage' 'or' 'acupuncture' ')']",[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 0. 1. 0.]
NCT02193191,"15:33:chronic_disease,35:46:chronic_disease,51:64:chronic_disease","Patients with active hepatitis B, hepatitis C, or HIV infection","['Patients' 'with' 'active' 'hepatitis' 'B' ',' 'hepatitis' 'C' ',' 'or'
 'HIV' 'infection']",[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2.]
NCT02192398,"31:53:chronic_disease,60:70:chronic_disease,,,105:128:chronic_disease,145:151:chronic_disease,154:181:chronic_disease,183:196:chronic_disease,198:217:chronic_disease,233:240:chronic_disease","Has known pre-existing severe cardiovascular disease (i.e. arrhythmia - prolonged QT interval > 440ms), cerebrovascular disease/accident (i.e., stroke), hepatic or renal impairment, CNS condition, metabolic condition, or history of syncope","['Has' 'known' 'pre-existing' 'severe' 'cardiovascular' 'disease' '('
 'i.e' '.' 'arrhythmia' '-' 'prolonged' 'QT' 'interval' '>' '440ms' ')'
 ',' 'cerebrovascular' 'disease/accident' '(' 'i.e.' ',' 'stroke' ')' ','
 'hepatic' 'or' 'renal' 'impairment' ',' 'CNS' 'condition' ',' 'metabolic'
 'condition' ',' 'or' 'history' 'of' 'syncope']","[0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2.
 0. 0. 2. 2. 2. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 2.]"
NCT02192359,",,57:63:cancer,75:87:cancer,89:111:cancer,113:124:cancer,126:154:cancer,159:186:cancer,246:261:cancer,314:331:cancer","Histologically-confirmed diagnosis of a grade III or IV glioma (including glioblastoma, anaplastic astrocytoma, gliosarcoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma), or has a prior, histologically-confirmed, diagnosis of a grade II glioma and now has radiographic findings consistent with a high-grade glioma (grade III or IV)","['Histologically-confirmed' 'diagnosis' 'of' 'a' 'grade' 'III' 'or' 'IV'
 'glioma' '(' 'including' 'glioblastoma' ',' 'anaplastic' 'astrocytoma'
 ',' 'gliosarcoma' ',' 'anaplastic' 'oligodendroglioma' ',' 'or'
 'anaplastic' 'oligoastrocytoma' ')' ',' 'or' 'has' 'a' 'prior' ','
 'histologically-confirmed' ',' 'diagnosis' 'of' 'a' 'grade' 'II' 'glioma'
 'and' 'now' 'has' 'radiographic' 'findings' 'consistent' 'with' 'a'
 'high-grade' 'glioma' '(' 'grade' 'III' 'or' 'IV' ')']","[0. 0. 0. 0. 3. 3. 3. 0. 3. 0. 0. 3. 0. 3. 3. 0. 3. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.
 3. 0. 0. 0. 0. 0. 0.]"
NCT02192359,"31:37:treatment,47:55:treatment,57:68:treatment,70:79:treatment,84:96:treatment,,131:146:treatment","Use of drugs known to inhibit UGT1A1, such as atazanir, gemfibrozil, indinavir, or ketoconazole, within 2 weeks prior to start of study treatment","['Use' 'of' 'drugs' 'known' 'to' 'inhibit' 'UGT1A1' ',' 'such' 'as'
 'atazanir' ',' 'gemfibrozil' ',' 'indinavir' ',' 'or' 'ketoconazole' ','
 'within' '2' 'weeks' 'prior' 'to' 'start' 'of' 'study' 'treatment']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1.]"
NCT02191488,"61:78:cancer,72:78:cancer,104:114:cancer,119:129:cancer","Preoperative diagnosis of either presumed first-time low or high grade glioma, or recurrent glioma, or metastasis, or meningioma","['Preoperative' 'diagnosis' 'of' 'either' 'presumed' 'first-time' 'low'
 'or' 'high' 'grade' 'glioma' ',' 'or' 'recurrent' 'glioma' ',' 'or'
 'metastasis' ',' 'or' 'meningioma']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 3. 0. 0. 3.]
NCT02191098,",,,51:64:chronic_disease,81:109:chronic_disease,86:108:chronic_disease,186:205:chronic_disease","NYHA (New York Heart Association) Class III or IV heart failure, uncontrollable supraventricular arrhythmias, any history of a ventricular arrhythmia, or other clinical signs of severe cardiac dysfunction","['NYHA' '(' 'New' 'York' 'Heart' 'Association' ')' 'Class' 'III' 'or' 'IV'
 'heart' 'failure' ',' 'uncontrollable' 'supraventricular' 'arrhythmias'
 ',' 'any' 'history' 'of' 'a' 'ventricular' 'arrhythmia' ',' 'or' 'other'
 'clinical' 'signs' 'of' 'severe' 'cardiac' 'dysfunction']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 2. 2.
 0. 0. 0. 0. 0. 0. 0. 2. 2.]"
NCT02189889,"1:16:chronic_disease,44:47:treatment,67:75:chronic_disease",unstable angina (defined by chest pain and EKG changes indicating ischemia at rest),"['unstable' 'angina' '(' 'defined' 'by' 'chest' 'pain' 'and' 'EKG'
 'changes' 'indicating' 'ischemia' 'at' 'rest' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 1. 0. 0. 2. 0. 0. 0.]
NCT02188745,"38:51:treatment,60:68:treatment,73:89:treatment,116:129:treatment,131:141:treatment,156:171:treatment,208:224:treatment","Combination regimens that include an anti-estrogen and any biologic, or targeted therapy, are permitted (e.g., any CDK inhibitor, everolimus, or any other novel biologics), and are considered to be a single hormonal therapy based regimen","['Combination' 'regimens' 'that' 'include' 'an' 'anti-estrogen' 'and'
 'any' 'biologic' ',' 'or' 'targeted' 'therapy' ',' 'are' 'permitted' '('
 'e.g.' ',' 'any' 'CDK' 'inhibitor' ',' 'everolimus' ',' 'or' 'any'
 'other' 'novel' 'biologics' ')' ',' 'and' 'are' 'considered' 'to' 'be'
 'a' 'single' 'hormonal' 'therapy' 'based' 'regimen']","[0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1.
 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.]"
NCT02188745,"15:43:cancer,,,,72:85:cancer,104:115:treatment","Patients with bone-only metastatic disease with a history of ER+/HER2- breast cancer are eligible, and bone biopsy is not required, providing their primary cancer is consistent with the above-described ER and HER2 criteria","['Patients' 'with' 'bone-only' 'metastatic' 'disease' 'with' 'a' 'history'
 'of' 'ER+/HER2-' 'breast' 'cancer' 'are' 'eligible' ',' 'and' 'bone'
 'biopsy' 'is' 'not' 'required' ',' 'providing' 'their' 'primary' 'cancer'
 'is' 'consistent' 'with' 'the' 'above-described' 'ER' 'and' 'HER2'
 'criteria']","[0. 0. 1. 1. 3. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02188121,"18:42:treatment,72:78:treatment,82:85:treatment,","Receiving active cardiovascular treatment, defined as receiving both a statin or ARB in the past three months","['Receiving' 'active' 'cardiovascular' 'treatment' ',' 'defined' 'as'
 'receiving' 'both' 'a' 'statin' 'or' 'ARB' 'in' 'the' 'past' 'three'
 'months']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0.]
NCT02188121,"1:14:chronic_disease,16:40:chronic_disease,42:58:chronic_disease,60:85:chronic_disease,90:99:chronic_disease","schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, or psychosis NOS (chart diagnosis)","['schizophrenia' ',' 'schizoaffective' 'disorder' ',' 'bipolar' 'disorder'
 ',' 'major' 'depressive' 'disorder' ',' 'or' 'psychosis' 'NOS' '('
 'chart' 'diagnosis' ')']",[2. 0. 2. 2. 0. 2. 2. 0. 2. 2. 2. 0. 0. 2. 0. 0. 0. 0. 0.]
NCT02187848,"1:30:treatment,32:35:treatment,39:67:treatment",Prior maytansinoid treatments (DM1 or DM4 antibody drug conjugates),"['Prior' 'maytansinoid' 'treatments' '(' 'DM1' 'or' 'DM4' 'antibody'
 'drug' 'conjugates' ')']",[1. 1. 1. 0. 1. 0. 1. 1. 1. 1. 0.]
NCT02187198,"44:55:chronic_disease,65:76:chronic_disease,84:98:chronic_disease,100:105:chronic_disease,107:116:chronic_disease,121:138:chronic_disease,149:172:treatment","serious unstable medical illness including bradycardia or other arrhythmias, major cardiovascular, renal, endocrine, or hepatic disorders for which buprenorphine treatment is contraindicated or which at the determination of the MD is medically dangerous","['serious' 'unstable' 'medical' 'illness' 'including' 'bradycardia' 'or'
 'other' 'arrhythmias' ',' 'major' 'cardiovascular' ',' 'renal' ','
 'endocrine' ',' 'or' 'hepatic' 'disorders' 'for' 'which' 'buprenorphine'
 'treatment' 'is' 'contraindicated' 'or' 'which' 'at' 'the'
 'determination' 'of' 'the' 'MD' 'is' 'medically' 'dangerous']","[0. 0. 0. 0. 0. 2. 0. 0. 2. 0. 0. 2. 0. 2. 0. 2. 0. 0. 2. 2. 0. 0. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02186418,"21:41:treatment,55:61:chronic_disease,67:92:chronic_disease,228:251:treatment","Patients who are on chronic transfusions for clinical stroke with MRA cerebral vasculopathy will be excluded since patients in the SWITCH study who were randomized to the hydroxyurea arm had recurrent stroke, while none in the chronic transfusion arm","['Patients' 'who' 'are' 'on' 'chronic' 'transfusions' 'for' 'clinical'
 'stroke' 'with' 'MRA' 'cerebral' 'vasculopathy' 'will' 'be' 'excluded'
 'since' 'patients' 'in' 'the' 'SWITCH' 'study' 'who' 'were' 'randomized'
 'to' 'the' 'hydroxyurea' 'arm' 'had' 'recurrent' 'stroke' ',' 'while'
 'none' 'in' 'the' 'chronic' 'transfusion' 'arm']","[0. 0. 0. 0. 1. 1. 1. 0. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02186418,"34:56:chronic_disease,58:61:chronic_disease,72:95:treatment","Patients with medical history of pulmonary hypertension, PHT proved by cardiac catheterization","['Patients' 'with' 'medical' 'history' 'of' 'pulmonary' 'hypertension' ','
 'PHT' 'proved' 'by' 'cardiac' 'catheterization']",[0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 0. 1. 1.]
NCT02184520,"21:43:treatment,47:67:treatment,,86:93:treatment",Participation in an investigational device or drug clinical trials within 30 days of surgery,"['Participation' 'in' 'an' 'investigational' 'device' 'or' 'drug'
 'clinical' 'trials' 'within' '30' 'days' 'of' 'surgery']",[0. 0. 0. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 1.]
NCT02181478,"1:32:cancer,34:56:cancer,58:80:cancer,190:196:treatment","Myelodysplastic syndromes (MDS), Intermediate-1 (INT-1), intermediate-2 (INT-2) or high Revised International Prognostic Scoring System (IPSS-R) score that has failed at least 1 first line therap","['Myelodysplastic' 'syndromes' '(' 'MDS' ')' ',' 'Intermediate-1' '('
 'INT-1' ')' ',' 'intermediate-2' '(' 'INT-2' ')' 'or' 'high' 'Revised'
 'International' 'Prognostic' 'Scoring' 'System' '(' 'IPSS-R' ')' 'score'
 'that' 'has' 'failed' 'at' 'least' '1' 'first' 'line' 'therap']","[3. 3. 3. 0. 0. 0. 3. 3. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02181257,",81:122:chronic_disease,161:164:chronic_disease,173:182:chronic_disease,184:197:chronic_disease","Patients whose decline in lung function (FEV1) is related to either Restrictive Chronic Lung Allograft Dysfunction (CLAD) or other causes that do not represent BOS such as pneumonia, heart failure, etc","['Patients' 'whose' 'decline' 'in' 'lung' 'function' '(' 'FEV1' ')' 'is'
 'related' 'to' 'either' 'Restrictive' 'Chronic' 'Lung' 'Allograft'
 'Dysfunction' '(' 'CLAD' ')' 'or' 'other' 'causes' 'that' 'do' 'not'
 'represent' 'BOS' 'such' 'as' 'pneumonia' ',' 'heart' 'failure' ',' 'etc']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 2. 0. 0. 2. 0. 2. 2. 0. 0.]"
NCT02180412,"9:24:chronic_disease,128:137:treatment,151:163:treatment","Type of acute porphyria confirmed by additional testing (in addition to increased PBG), which may be completed before or after treatment begins using pretreatment samples","['Type' 'of' 'acute' 'porphyria' 'confirmed' 'by' 'additional' 'testing'
 '(' 'in' 'addition' 'to' 'increased' 'PBG' ')' ',' 'which' 'may' 'be'
 'completed' 'before' 'or' 'after' 'treatment' 'begins' 'using'
 'pretreatment' 'samples']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0. 0. 1. 0.]"
NCT02178709,"21:24:allergy_name,26:37:allergy_name,48:63:allergy_name,66:76:allergy_name,90:100:allergy_name","Hypersensitivity to 5FU, oxaliplatin (or other platinum agents), irinotecan (or to their excipients)","['Hypersensitivity' 'to' '5FU' ',' 'oxaliplatin' '(' 'or' 'other'
 'platinum' 'agents' ')' ',' 'irinotecan' '(' 'or' 'to' 'their'
 'excipients' ')']",[0. 0. 4. 0. 4. 0. 0. 0. 4. 4. 0. 0. 4. 0. 0. 0. 0. 4. 0.]
NCT02178709,"20:28:cancer,32:56:cancer,66:76:cancer,80:110:cancer,112:138:cancer,155:200:cancer,215:230:cancer","adequately treated cervical or vulvar carcinoma in situ, treated basal cell or squamous carcinoma of the skin, superficial bladder tumors (Ta, Tis & T1), ductal carcinoma in situ (DCIS) of the breast and low grade prostate cancer","['adequately' 'treated' 'cervical' 'or' 'vulvar' 'carcinoma' 'in' 'situ'
 ',' 'treated' 'basal' 'cell' 'or' 'squamous' 'carcinoma' 'of' 'the'
 'skin' ',' 'superficial' 'bladder' 'tumors' '(' 'Ta' ',' 'Tis' '&' 'T1'
 ')' ',' 'ductal' 'carcinoma' 'in' 'situ' '(' 'DCIS' ')' 'of' 'the'
 'breast' 'and' 'low' 'grade' 'prostate' 'cancer']","[0. 0. 3. 0. 3. 3. 3. 3. 0. 0. 3. 3. 0. 3. 3. 3. 3. 3. 0. 3. 3. 3. 0. 0.
 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 3. 3.]"
NCT02177838,"32:48:treatment,59:76:cancer,88:100:treatment,102:119:treatment,124:131:treatment","Patients may not have received previous therapy for their head and neck SCC, including chemotherapy, radiation therapy, or surgery beyond biopsy","['Patients' 'may' 'not' 'have' 'received' 'previous' 'therapy' 'for'
 'their' 'head' 'and' 'neck' 'SCC' ',' 'including' 'chemotherapy' ','
 'radiation' 'therapy' ',' 'or' 'surgery' 'beyond' 'biopsy']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 3. 3. 3. 3. 0. 0. 1. 0. 1. 1. 0. 0. 1. 0. 0.]
NCT02177695,"20:59:cancer,53:59:cancer,61:84:cancer,105:125:cancer,","adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years","['adequately' 'treated' 'basal' 'cell' 'or' 'squamous' 'cell' 'skin'
 'cancer' ',' 'in' 'situ' 'cervical' 'cancer' ',' 'adequately' 'treated'
 'Stage' 'I' 'or' 'II' 'cancer' 'from' 'which' 'the' 'patient' 'is'
 'currently' 'in' 'complete' 'remission' ',' 'or' 'any' 'other' 'cancer'
 'from' 'which' 'the' 'patient' 'has' 'been' 'disease' 'free' 'for' 'five'
 'years']","[0. 0. 3. 3. 3. 3. 3. 3. 3. 0. 3. 3. 3. 3. 0. 0. 0. 3. 3. 3. 3. 3. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02176967,"48:64:cancer,80:93:cancer,249:269:cancer",Patients must have newly diagnosed v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) non-amplified neuroblastoma (International Classification of Diseases for Oncology [ICD-O] morphology 9500/3) or MYCN non-amplified ganglioneuroblastoma verified by histology,"['Patients' 'must' 'have' 'newly' 'diagnosed' 'v-myc' 'avian'
 'myelocytomatosis' 'viral' 'oncogene' 'neuroblastoma' 'derived' 'homolog'
 '(' 'MYCN' ')' 'non-amplified' 'neuroblastoma' '(' 'International'
 'Classification' 'of' 'Diseases' 'for' 'Oncology' '[' 'ICD-O' ']'
 'morphology' '9500/3' ')' 'or' 'MYCN' 'non-amplified'
 'ganglioneuroblastoma' 'verified' 'by' 'histology']","[0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0.]"
NCT02176161,"35:53:chronic_disease,83:104:chronic_disease,106:129:treatment,131:146:chronic_disease,148:167:chronic_disease,188:212:chronic_disease,217:241:chronic_disease,","any unstable, serious co-existing medical conditions including but not limited to myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within 6 months prior to screening","['any' 'unstable' ',' 'serious' 'co-existing' 'medical' 'conditions'
 'including' 'but' 'not' 'limited' 'to' 'myocardial' 'infarction' ','
 'coronary' 'bypass' 'surgery' ',' 'unstable' 'angina' ',' 'cardiac'
 'arrhythmias' ',' 'clinically' 'evident' 'congestive' 'heart' 'failure'
 ',' 'or' 'cerebrovascular' 'accident' 'within' '6' 'months' 'prior' 'to'
 'screening']","[0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 2. 2. 0. 1. 1. 1. 0. 0. 0. 0. 2. 2.
 0. 0. 0. 2. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]"
NCT02174549,"1:22:treatment,31:49:treatment,51:74:treatment,79:96:treatment,120:125:cancer,146:161:treatment,204:207:treatment,213:226:treatment,","Prior local therapies such as surgical resection, radiofrequency ablation, or alcohol injection are allowed as long as tumor progresses from the prior treatment and the patients are still candidates for TAE. All prior therapy must be at least 4 weeks prior to enrollment and free from treatment-related toxicity","['Prior' 'local' 'therapies' 'such' 'as' 'surgical' 'resection' ','
 'radiofrequency' 'ablation' ',' 'or' 'alcohol' 'injection' 'are'
 'allowed' 'as' 'long' 'as' 'tumor' 'progresses' 'from' 'the' 'prior'
 'treatment' 'and' 'the' 'patients' 'are' 'still' 'candidates' 'for' 'TAE'
 '.' 'All' 'prior' 'therapy' 'must' 'be' 'at' 'least' '4' 'weeks' 'prior'
 'to' 'enrollment' 'and' 'free' 'from' 'treatment-related' 'toxicity']","[1. 1. 1. 0. 0. 1. 1. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 3. 0. 0. 0. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02172651,"25:44:treatment,56:75:treatment,77:92:treatment,94:111:treatment,113:126:treatment,131:153:treatment","Concurrent use of other anti-cancer therapy, including chemotherapy agents, targeted agents, biological agents, immunotherapy, or investigational agents not otherwise specified in this protocol","['Concurrent' 'use' 'of' 'other' 'anti-cancer' 'therapy' ',' 'including'
 'chemotherapy' 'agents' ',' 'targeted' 'agents' ',' 'biological' 'agents'
 ',' 'immunotherapy' ',' 'or' 'investigational' 'agents' 'not' 'otherwise'
 'specified' 'in' 'this' 'protocol']","[0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 0. 1. 1. 0. 1. 1. 0. 1. 0. 0. 1. 1. 0. 0.
 0. 0. 0. 0.]"
NCT02172651,"4:27:treatment,31:49:treatment,98:105:cancer,107:109:cancer,114:130:cancer","No prior radiation therapy or systemic treatment is allowed for patients undergoing resection of stage I, II, or III colon cancer","['No' 'prior' 'radiation' 'therapy' 'or' 'systemic' 'treatment' 'is'
 'allowed' 'for' 'patients' 'undergoing' 'resection' 'of' 'stage' 'I' ','
 'II' ',' 'or' 'III' 'colon' 'cancer']",[0. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 3. 0. 0. 3. 3. 3.]
NCT02172651,"25:35:chronic_disease,168:179:chronic_disease,183:184:chronic_disease,205:220:treatment","Participants with these infections are ineligible because they are at increased risk of significant complications in the perioperative period, particularly for active hepatitis B or C patients undergoing liver resection","['Participants' 'with' 'these' 'infections' 'are' 'ineligible' 'because'
 'they' 'are' 'at' 'increased' 'risk' 'of' 'significant' 'complications'
 'in' 'the' 'perioperative' 'period' ',' 'particularly' 'for' 'active'
 'hepatitis' 'B' 'or' 'C' 'patients' 'undergoing' 'liver' 'resection']","[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 0. 2. 0. 0. 1. 1.]"
NCT02172651,"16:34:treatment,42:61:treatment,82:95:chronic_disease,171:194:chronic_disease","Regular use of thiazide diuretics (i.e., hydrochlorothiazide), which can lead to hypercalcemia, and unwillingness or inability to discontinue or switch to an alternative anti-hypertensive agent","['Regular' 'use' 'of' 'thiazide' 'diuretics' '(' 'i.e.' ','
 'hydrochlorothiazide' ')' ',' 'which' 'can' 'lead' 'to' 'hypercalcemia'
 ',' 'and' 'unwillingness' 'or' 'inability' 'to' 'discontinue' 'or'
 'switch' 'to' 'an' 'alternative' 'anti-hypertensive' 'agent']","[0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 2. 2.]"
NCT02171429,"22:31:chronic_disease,42:51:treatment,57:85:treatment,,123:139:treatment,",Any major episode of infection requiring treatment with intravenous (IV) antibiotics within 8 weeks prior to screening or oral antibiotics within 4 weeks prior to screening,"['Any' 'major' 'episode' 'of' 'infection' 'requiring' 'treatment' 'with'
 'intravenous' '(' 'IV' ')' 'antibiotics' 'within' '8' 'weeks' 'prior'
 'to' 'screening' 'or' 'oral' 'antibiotics' 'within' '4' 'weeks' 'prior'
 'to' 'screening']","[0. 0. 0. 0. 2. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 0. 0.]"
NCT02169830,"1:11:treatment,13:42:treatment,44:51:treatment","Topiramate: acetazolamide (kidney stones), digoxin","['Topiramate' ':' 'acetazolamide' '(' 'kidney' 'stones' ')' ',' 'digoxin']",[1. 0. 1. 1. 1. 0. 0. 0. 1.]
NCT02169739,"10:23:chronic_disease,41:56:treatment,75:82:treatment",No major cardioembolic source requiring anticoagulation or other specific therapy,"['No' 'major' 'cardioembolic' 'source' 'requiring' 'anticoagulation' 'or'
 'other' 'specific' 'therapy']",[0. 0. 2. 0. 0. 1. 0. 0. 0. 1.]
NCT02169089,"1:24:chronic_disease,26:51:chronic_disease,53:56:chronic_disease,60:82:chronic_disease,,111:148:treatment,","Acute coronary syndrome, Transient ischemic attack, CVA or critical limb ischemia during the last 6 months or coronary/peripheral revascularization within the last 3 months","['Acute' 'coronary' 'syndrome' ',' 'Transient' 'ischemic' 'attack' ','
 'CVA' 'or' 'critical' 'limb' 'ischemia' 'during' 'the' 'last' '6'
 'months' 'or' 'coronary/peripheral' 'revascularization' 'within' 'the'
 'last' '3' 'months']","[2. 2. 2. 0. 2. 2. 2. 0. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 0.]"
NCT02169089,"19:26:treatment,32:39:treatment,41:49:treatment,51:64:treatment,66:70:treatment,72:81:treatment,83:93:treatment","Initiation of new therapy with statins, ACEI/ARB, anti-oxidants, CCBs, diuretics, β blockers","['Initiation' 'of' 'new' 'therapy' 'with' 'statins' ',' 'ACEI/ARB' ','
 'anti-oxidants' ',' 'CCBs' ',' 'diuretics' ',' 'β' 'blockers']",[0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 1.]
NCT02169037,"1:23:chronic_disease,50:58:treatment,80:105:chronic_disease,111:132:chronic_disease","acquired heart disease that may increase risk of ablation, such as significant ventricular septal defect post myocardial infarction","['acquired' 'heart' 'disease' 'that' 'may' 'increase' 'risk' 'of'
 'ablation' ',' 'such' 'as' 'significant' 'ventricular' 'septal' 'defect'
 'post' 'myocardial' 'infarction']",[2. 2. 2. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 2. 2. 2. 0. 2. 2.]
NCT02169037,"24:52:chronic_disease,54:70:chronic_disease,74:95:chronic_disease","history of significant blood clotting abnormalities, systemic thrombi or systemic embolization","['history' 'of' 'significant' 'blood' 'clotting' 'abnormalities' ','
 'systemic' 'thrombi' 'or' 'systemic' 'embolization']",[0. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0.]
NCT02167958,"25:42:treatment,83:113:cancer,145:151:cancer,158:166:cancer",Greater than 1 cycle of induction therapy required to achieve remission Preceding myelodysplastic syndrome (MDS) Presence of Flt3 abnormalities FAB M6 or M7 leukemia,"['Greater' 'than' '1' 'cycle' 'of' 'induction' 'therapy' 'required' 'to'
 'achieve' 'remission' 'Preceding' 'myelodysplastic' 'syndrome' '(' 'MDS'
 ')' 'Presence' 'of' 'Flt3' 'abnormalities' 'FAB' 'M6' 'or' 'M7'
 'leukemia']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 3. 3. 0.
 0. 3.]"
NCT02167009,"12:33:treatment,35:49:treatment,54:71:treatment","History of open prostate surgery, radiofrequency, or microwave therapy","['History' 'of' 'open' 'prostate' 'surgery' ',' 'radiofrequency' ',' 'or'
 'microwave' 'therapy']",[0. 0. 1. 1. 1. 0. 1. 0. 0. 1. 1.]
NCT02166905,"13:31:treatment,91:106:treatment,108:122:treatment,126:163:treatment,169:201:treatment","Concomitant systemic treatment with chronic use (based on the investigator's judgment) of corticosteroids, anti-histamine or non-steroidal anti-inflammatory drugs, and other platelet inhibitory agents","['Concomitant' 'systemic' 'treatment' 'with' 'chronic' 'use' '(' 'based'
 'on' 'the' 'investigator' ""'s"" 'judgment' ')' 'of' 'corticosteroids' ','
 'anti-histamine' 'or' 'non-steroidal' 'anti-inflammatory' 'drugs' ','
 'and' 'other' 'platelet' 'inhibitory' 'agents']","[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 1. 1. 0. 0.
 1. 1. 1. 1.]"
NCT02166905,"28:61:treatment,54:61:treatment,97:107:treatment,111:122:treatment,,219:225:treatment,",Patients may have received previous NY-ESO-1 vaccine therapy; patients who received maintenance paclitaxel or bevacizumab are eligible for enrollment provided they have discontinued therapy (at least 4 weeks for prior taxane or prior bevacizumab) prior to randomization and recovered from toxicities to less than grade 2,"['Patients' 'may' 'have' 'received' 'previous' 'NY-ESO-1' 'vaccine'
 'therapy' ';' 'patients' 'who' 'received' 'maintenance' 'paclitaxel' 'or'
 'bevacizumab' 'are' 'eligible' 'for' 'enrollment' 'provided' 'they'
 'have' 'discontinued' 'therapy' '(' 'at' 'least' '4' 'weeks' 'for'
 'prior' 'taxane' 'or' 'prior' 'bevacizumab' ')' 'prior' 'to'
 'randomization' 'and' 'recovered' 'from' 'toxicities' 'to' 'less' 'than'
 'grade' '2']","[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02166190,"1:18:cancer,22:40:cancer,56:74:treatment",Pancreatic cancer or cholangiocarcinoma unsuitable for surgical resection,"['Pancreatic' 'cancer' 'or' 'cholangiocarcinoma' 'unsuitable' 'for'
 'surgical' 'resection']",[3. 3. 0. 3. 0. 0. 1. 1.]
NCT02164422,"1:4:treatment,94:105:chronic_disease,129:139:treatment,147:160:treatment,173:181:chronic_disease,183:199:chronic_disease,201:239:chronic_disease,244:258:chronic_disease,","EKG evidence at baseline screening of any clinically significant conduction abnormalities or arrhythmias; known intolerance for guanfacine or any alpha blocker; history of fainting, syncopal attacks, heart failure or myocardial infarction, or impaired liver as indicated by aspartate aminotransferase (AST)","['EKG' 'evidence' 'at' 'baseline' 'screening' 'of' 'any' 'clinically'
 'significant' 'conduction' 'abnormalities' 'or' 'arrhythmias' ';' 'known'
 'intolerance' 'for' 'guanfacine' 'or' 'any' 'alpha' 'blocker' ';'
 'history' 'of' 'fainting' ',' 'syncopal' 'attacks' ',' 'heart' 'failure'
 'or' 'myocardial' 'infarction' ',' 'or' 'impaired' 'liver' 'as'
 'indicated' 'by' 'aspartate' 'aminotransferase' '(' 'AST' ')']","[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 1. 0. 0. 1. 1. 0. 0.
 0. 2. 0. 2. 2. 0. 2. 2. 2. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02163434,"117:134:chronic_disease,136:148:chronic_disease,150:163:chronic_disease,168:188:chronic_disease","Felt by the patient's obstetrician or emergency room attending physician not to have other medical problems such as bowel obstruction, pancreatitis, biliary colic, or peptic ulcer disease that could be contributing to the patient's symptoms","['Felt' 'by' 'the' 'patient' ""'s"" 'obstetrician' 'or' 'emergency' 'room'
 'attending' 'physician' 'not' 'to' 'have' 'other' 'medical' 'problems'
 'such' 'as' 'bowel' 'obstruction' ',' 'pancreatitis' ',' 'biliary'
 'colic' ',' 'or' 'peptic' 'ulcer' 'disease' 'that' 'could' 'be'
 'contributing' 'to' 'the' 'patient' ""'s"" 'symptoms']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0.
 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02162810,"31:39:treatment,55:62:treatment,,127:140:allergy_name",All patients currently taking steroids at the time of surgery or during the six-week recovery period as well as patients with betamethasone hypersensitivity,"['All' 'patients' 'currently' 'taking' 'steroids' 'at' 'the' 'time' 'of'
 'surgery' 'or' 'during' 'the' 'six-week' 'recovery' 'period' 'as' 'well'
 'as' 'patients' 'with' 'betamethasone' 'hypersensitivity']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0.]
NCT02162420,"17:22:treatment,26:32:treatment,36:50:treatment",requirement for G-CSF or GM-CSF or erythropoietin,['requirement' 'for' 'G-CSF' 'or' 'GM-CSF' 'or' 'erythropoietin'],[0. 0. 1. 0. 1. 0. 1.]
NCT02159703,"13:15:chronic_disease,19:29:chronic_disease,33:48:treatment",Presence of N0 or N1 disease in neck dissection,['Presence' 'of' 'N0' 'or' 'N1' 'disease' 'in' 'neck' 'dissection'],[0. 0. 2. 0. 2. 2. 0. 1. 1.]
NCT02159495,"99:123:treatment,131:154:treatment,,,306:321:treatment",Research participant with central nervous system (CNS) leukemic involvement that is refractory to intrathecal chemotherapy and/or cranio-spinal radiation but effectively treated to completion remission (< 5 white blood cell[WBC]/mm^3 and no blast in cerebrospinal fluid [CSF]) is eligible to proceed with lymphodepletion,"['Research' 'participant' 'with' 'central' 'nervous' 'system' '(' 'CNS'
 ')' 'leukemic' 'involvement' 'that' 'is' 'refractory' 'to' 'intrathecal'
 'chemotherapy' 'and/or' 'cranio-spinal' 'radiation' 'but' 'effectively'
 'treated' 'to' 'completion' 'remission' '(' '<' '5' 'white' 'blood'
 'cell' '[' 'WBC' ']' '/mm^3' 'and' 'no' 'blast' 'in' 'cerebrospinal'
 'fluid' '[' 'CSF' ']' ')' 'is' 'eligible' 'to' 'proceed' 'with'
 'lymphodepletion']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1.]"
NCT02159495,"27:47:treatment,60:83:chronic_disease,90:121:treatment","in the case of a positive hepatitis C antibody result, the hepatitis C virus (HCV) viral polymerase chain reaction (PCR) will have to be performed and the results should be negative","['in' 'the' 'case' 'of' 'a' 'positive' 'hepatitis' 'C' 'antibody' 'result'
 ',' 'the' 'hepatitis' 'C' 'virus' '(' 'HCV' ')' 'viral' 'polymerase'
 'chain' 'reaction' '(' 'PCR' ')' 'will' 'have' 'to' 'be' 'performed'
 'and' 'the' 'results' 'should' 'be' 'negative']","[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02159027,"33:44:chronic_disease,60:81:chronic_disease,85:103:chronic_disease,116:139:chronic_disease,166:169:chronic_disease,251:277:chronic_disease","Learning disability, history of head injury with prolonged loss of consciousness or cognitive sequelae, history of opportunistic infection of the brain or other non-HIV etiologies that, in the judgment of the investigator, can explain the subjects's mild to moderate cognitive performance","['Learning' 'disability' ',' 'history' 'of' 'head' 'injury' 'with'
 'prolonged' 'loss' 'of' 'consciousness' 'or' 'cognitive' 'sequelae' ','
 'history' 'of' 'opportunistic' 'infection' 'of' 'the' 'brain' 'or'
 'other' 'non-HIV' 'etiologies' 'that' ',' 'in' 'the' 'judgment' 'of'
 'the' 'investigator' ',' 'can' 'explain' 'the' 'subjects' ""'s"" 'mild'
 'to' 'moderate' 'cognitive' 'performance']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0.
 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0.]"
NCT02157974,"10:24:chronic_disease,28:37:chronic_disease,49:53:chronic_disease",Cause of oligomenorrhea or hirsutism other than PCOS,['Cause' 'of' 'oligomenorrhea' 'or' 'hirsutism' 'other' 'than' 'PCOS'],[0. 0. 2. 0. 2. 0. 0. 2.]
NCT02153229,"15:24:chronic_disease,48:57:allergy_name,61:85:allergy_name",Patients with porphyria or hypersensitivity to porphyrin or porphyrin-like compounds,"['Patients' 'with' 'porphyria' 'or' 'hypersensitivity' 'to' 'porphyrin'
 'or' 'porphyrin-like' 'compounds']",[0. 0. 2. 0. 0. 0. 4. 0. 4. 4.]
NCT02152995,"126:140:cancer,134:139:cancer,142:155:cancer,177:187:cancer,196:209:cancer,267:274:cancer","COHORT A: Confirmation in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) has an neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) or Kirsten rat sarcoma viral oncogene homolog (KRAS) or Harvey rat sarcoma viral oncogene homolog (HRAS) mutation at G12, G13, or Q61; this group of patients will also be referred to as RAS MUT","['COHORT' 'A' ':' 'Confirmation' 'in' 'a' 'Clinical' 'Laboratory'
 'Improvement' 'Amendments' '(' 'CLIA' ')' 'certified' 'laboratory' 'that'
 'one' 'of' 'the' 'patient' ""'s"" 'thyroid' 'tumors' '(' 'primary' 'tumor'
 ',' 'recurrent' 'tumor' ',' 'or' 'metastasis' ')' 'has' 'an'
 'neuroblastoma' 'RAS' 'viral' '(' 'v-ras' ')' 'oncogene' 'homolog' '('
 'NRAS' ')' 'or' 'Kirsten' 'rat' 'sarcoma' 'viral' 'oncogene' 'homolog'
 '(' 'KRAS' ')' 'or' 'Harvey' 'rat' 'sarcoma' 'viral' 'oncogene' 'homolog'
 '(' 'HRAS' ')' 'mutation' 'at' 'G12' ',' 'G13' ',' 'or' 'Q61' ';' 'this'
 'group' 'of' 'patients' 'will' 'also' 'be' 'referred' 'to' 'as' 'RAS'
 'MUT']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0.
 3. 3. 0. 0. 0. 0. 0. 3. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02152995,",,235:258:treatment,,279:293:treatment,295:327:treatment,332:340:treatment","Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral CT scan, magnetic resonance imaging (MRI), or calipers by clinical exam","['Patients' 'must' 'have' 'measurable' 'disease' ',' 'defined' 'as' 'at'
 'least' 'one' 'lesion' 'that' 'can' 'be' 'accurately' 'measured' 'in'
 'at' 'least' 'one' 'dimension' '(' 'longest' 'diameter' 'to' 'be'
 'recorded' 'for' 'non-nodal' 'lesions' 'and' 'short' 'axis' 'for' 'nodal'
 'lesions' ')' 'as' '>' '=' '20' 'mm' 'with' 'conventional' 'techniques'
 'or' 'as' '>' '=' '10' 'mm' 'with' 'spiral' 'CT' 'scan' ',' 'magnetic'
 'resonance' 'imaging' '(' 'MRI' ')' ',' 'or' 'calipers' 'by' 'clinical'
 'exam']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0.]"
NCT02152956,"25:37:treatment,39:61:treatment,66:90:treatment,","Previous treatment with radiotherapy, cytotoxic chemotherapy, or immunotherapeutic agents in the 4 weeks prior to study drug administration (Cycle 1 Day 1)","['Previous' 'treatment' 'with' 'radiotherapy' ',' 'cytotoxic'
 'chemotherapy' ',' 'or' 'immunotherapeutic' 'agents' 'in' 'the' '4'
 'weeks' 'prior' 'to' 'study' 'drug' 'administration' '(' 'Cycle' '1'
 'Day' '1' ')']","[0. 0. 0. 1. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02152254,"28:34:chronic_disease,39:47:chronic_disease,59:84:chronic_disease,92:118:chronic_disease","The patient has refractory nausea and vomiting or chronic gastrointestinal diseases (e.g., inflammatory bowel disease)","['The' 'patient' 'has' 'refractory' 'nausea' 'and' 'vomiting' 'or'
 'chronic' 'gastrointestinal' 'diseases' '(' 'e.g.' ',' 'inflammatory'
 'bowel' 'disease' ')']",[0. 0. 0. 0. 2. 0. 2. 0. 0. 2. 2. 0. 0. 0. 2. 2. 2. 0.]
NCT02151175,"19:27:chronic_disease,57:74:chronic_disease,90:110:chronic_disease","Subjects who have seizures secondary to drugs, alcohol, metabolic illness or progressive degenerative disease","['Subjects' 'who' 'have' 'seizures' 'secondary' 'to' 'drugs' ',' 'alcohol'
 ',' 'metabolic' 'illness' 'or' 'progressive' 'degenerative' 'disease']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2.]
NCT02148796,"44:80:chronic_disease,95:105:treatment,110:132:treatment",Participants may not have a history of any life-threatening respiratory illness that required intubation and mechanical ventilation,"['Participants' 'may' 'not' 'have' 'a' 'history' 'of' 'any'
 'life-threatening' 'respiratory' 'illness' 'that' 'required' 'intubation'
 'and' 'mechanical' 'ventilation']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 1. 0. 1. 1.]
NCT02146924,"32:48:treatment,50:61:treatment,63:72:treatment,74:83:treatment,87:98:treatment","Any known contraindications to cyclophosphamide, fludarabine, etoposide, cetuximab or tocilizumab","['Any' 'known' 'contraindications' 'to' 'cyclophosphamide' ','
 'fludarabine' ',' 'etoposide' ',' 'cetuximab' 'or' 'tocilizumab']",[0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1.]
NCT02146924,"39:52:treatment,70:88:treatment,90:103:treatment,107:116:treatment,","If research participant is undergoing leukapheresis the last dose of prior chemotherapy, immunotherapy or radiation must be at least 2 weeks before the leukapheresis procedure","['If' 'research' 'participant' 'is' 'undergoing' 'leukapheresis' 'the'
 'last' 'dose' 'of' 'prior' 'chemotherapy' ',' 'immunotherapy' 'or'
 'radiation' 'must' 'be' 'at' 'least' '2' 'weeks' 'before' 'the'
 'leukapheresis' 'procedure']","[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02146924,"45:52:chronic_disease,74:90:chronic_disease,104:128:chronic_disease,130:154:chronic_disease,156:174:chronic_disease,194:211:chronic_disease,215:234:chronic_disease,235:252:chronic_disease","Research participants with any uncontrolled illness including ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, poorly controlled pulmonary disease or psychiatric illness/social situations that would limit compliance with study requirements","['Research' 'participants' 'with' 'any' 'uncontrolled' 'illness'
 'including' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'poorly' 'controlled' 'pulmonary' 'disease'
 'or' 'psychiatric' 'illness/social' 'situations' 'that' 'would' 'limit'
 'compliance' 'with' 'study' 'requirements']","[0. 0. 0. 0. 0. 2. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0.
 0. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02145351,"1:39:treatment,55:57:chronic_disease,69:92:chronic_disease,96:112:treatment,,,,,,,,,239:254:treatment,259:266:chronic_disease,,,","Chronic treatment with a loop diuretic for control of HF symptoms + left atrial enlargement on echocardiography or E/e' ratio (≥14 average, ≥15 septal ) on echocardiography, Resting PCWP >15 mm Hg or LV end-diastolic pressure >18 mmHg at catheterization for dyspnea and/or exercise PCWP/LV end-diastolic pressure >25 mmHg, or Elevated NT-proBNP level (≥300 pg/ml )","['Chronic' 'treatment' 'with' 'a' 'loop' 'diuretic' 'for' 'control' 'of'
 'HF' 'symptoms' '+' 'left' 'atrial' 'enlargement' 'on' 'echocardiography'
 'or' 'E/e' ""'"" 'ratio' '(' '≥14' 'average' ',' '≥15' 'septal' ')' 'on'
 'echocardiography' ',' 'Resting' 'PCWP' '>' '15' 'mm' 'Hg' 'or' 'LV'
 'end-diastolic' 'pressure' '>' '18' 'mmHg' 'at' 'catheterization' 'for'
 'dyspnea' 'and/or' 'exercise' 'PCWP/LV' 'end-diastolic' 'pressure' '>'
 '25' 'mmHg' ',' 'or' 'Elevated' 'NT-proBNP' 'level' '(' '≥300' 'pg/ml'
 ')']","[1. 1. 1. 1. 1. 1. 0. 0. 0. 2. 0. 0. 2. 2. 2. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 2.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02143726,"13:37:treatment,43:61:cancer,65:107:treatment,,",Presence of fluorodeoxyglucose (FDG) avid metastatic lesions on positron emission tomography (PET)/CT scan (standardized uptake values [SUV]max > 5 of any single lesion),"['Presence' 'of' 'fluorodeoxyglucose' '(' 'FDG' ')' 'avid' 'metastatic'
 'lesions' 'on' 'positron' 'emission' 'tomography' '(' 'PET' ')' '/CT'
 'scan' '(' 'standardized' 'uptake' 'values' '[' 'SUV' ']' 'max' '>' '5'
 'of' 'any' 'single' 'lesion' ')']","[0. 0. 1. 1. 0. 0. 0. 3. 3. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02141919,"36:64:treatment,80:83:treatment,87:99:treatment",Subjects may not have received any treatment for the renal mass before such as RFA or cryoablation,"['Subjects' 'may' 'not' 'have' 'received' 'any' 'treatment' 'for' 'the'
 'renal' 'mass' 'before' 'such' 'as' 'RFA' 'or' 'cryoablation']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 1. 0. 1.]
NCT02140554,"37:45:treatment,60:78:treatment,99:125:treatment","any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including hypersensitivity to the active substances or to any of the excipients","['any' 'contraindications' 'to' 'the' 'use' 'of' 'busulfan' 'and' 'any'
 'other' 'medicinal' 'products' 'required' 'during' 'the' 'myeloablative'
 'conditioning' ',' 'including' 'hypersensitivity' 'to' 'the' 'active'
 'substances' 'or' 'to' 'any' 'of' 'the' 'excipients']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02139280,"1:31:treatment,33:54:treatment,56:89:treatment","immunomodulatory drugs (IMiDs), proteasome inhibitors, monoclonal antibodies or steroids","['immunomodulatory' 'drugs' '(' 'IMiDs' ')' ',' 'proteasome' 'inhibitors'
 ',' 'monoclonal' 'antibodies' 'or' 'steroids']",[1. 1. 1. 0. 0. 0. 1. 1. 0. 1. 1. 1. 1.]
NCT02138617,"1:16:treatment,22:32:treatment,40:51:treatment",Prior treatment with irinotecan and/or bevacizumab,['Prior' 'treatment' 'with' 'irinotecan' 'and/or' 'bevacizumab'],[1. 1. 0. 1. 0. 1.]
NCT02138214,"1:29:chronic_disease,76:94:chronic_disease,98:115:chronic_disease","Chronic neurologic condition which affects voice or swallow (for instance, multiple sclerosis or Parkinson disease)","['Chronic' 'neurologic' 'condition' 'which' 'affects' 'voice' 'or'
 'swallow' '(' 'for' 'instance' ',' 'multiple' 'sclerosis' 'or'
 'Parkinson' 'disease' ')']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0.]
NCT02134392,"100:115:chronic_disease,117:129:chronic_disease,130:165:chronic_disease,167:196:treatment,223:239:chronic_disease","Considerations for Increased Risk of Adverse Events Should Be Given to patients with decompensated liver cirrhosis, advanced HIV/acquired immune deficiency syndrome, recent bone marrow transplant, or other cause of severe immunodeficiency","['Considerations' 'for' 'Increased' 'Risk' 'of' 'Adverse' 'Events'
 'Should' 'Be' 'Given' 'to' 'patients' 'with' 'decompensated' 'liver'
 'cirrhosis' ',' 'advanced' 'HIV/acquired' 'immune' 'deficiency'
 'syndrome' ',' 'recent' 'bone' 'marrow' 'transplant' ',' 'or' 'other'
 'cause' 'of' 'severe' 'immunodeficiency']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 2. 2. 0. 1.
 1. 1. 1. 0. 0. 0. 0. 0. 0. 2.]"
NCT02134392,"7:29:chronic_disease,36:60:chronic_disease,62:74:chronic_disease","other chronic pain syndromes (e.g. chronic fatigue syndrome, fibromyalgia)","['other' 'chronic' 'pain' 'syndromes' '(' 'e.g' '.' 'chronic' 'fatigue'
 'syndrome' ',' 'fibromyalgia' ')']",[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT02133196,"12:33:cancer,50:76:cancer,107:130:cancer,132:155:cancer,160:175:cancer,","Measurable metastatic (stage IV) or unresectable non-small cell lung cancer (including but not limited to squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinomas) with at least one lesion that is resectable for TIL generation","['Measurable' 'metastatic' '(' 'stage' 'IV' ')' 'or' 'unresectable'
 'non-small' 'cell' 'lung' 'cancer' '(' 'including' 'but' 'not' 'limited'
 'to' 'squamous' 'cell' 'carcinoma' ',' 'adenosquamous' 'carcinoma' ','
 'or' 'adenocarcinomas' ')' 'with' 'at' 'least' 'one' 'lesion' 'that' 'is'
 'resectable' 'for' 'TIL' 'generation']","[0. 3. 3. 3. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 3. 3.
 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02132598,"11:17:cancer,43:99:treatment,101:132:treatment,138:170:treatment","Patients' tumors must undergo testing for Epidermal Growth Factor Receptor (EGFR) exon 19 deletion, EGFR exon 21 L858R substitution, and anaplastic lymphoma kinase (ALK) rearrangements","['Patients' ""'"" 'tumors' 'must' 'undergo' 'testing' 'for' 'Epidermal'
 'Growth' 'Factor' 'Receptor' '(' 'EGFR' ')' 'exon' '19' 'deletion' ','
 'EGFR' 'exon' '21' 'L858R' 'substitution' ',' 'and' 'anaplastic'
 'lymphoma' 'kinase' '(' 'ALK' ')' 'rearrangements']","[0. 0. 3. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 1. 1. 0. 0. 0.]"
NCT02132598,"35:74:chronic_disease,85:88:treatment,92:125:treatment",The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or computerized tomography (CT) scan,"['The' 'subject' 'has' 'evidence' 'of' 'acute' 'intracranial' 'or'
 'intratumoral' 'hemorrhage' 'either' 'by' 'MRI' 'or' 'computerized'
 'tomography' '(' 'CT' ')' 'scan']",[0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 1. 0. 1. 1. 1. 1. 0. 0.]
NCT02132598,"26:48:treatment,60:98:treatment,103:118:treatment,126:135:treatment,139:149:treatment,161:192:treatment,,213:225:treatment,227:238:treatment,,285:294:treatment","The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies; including investigational biologic agents) within 3 weeks, or nitrosoureas/ mitomycin C within 6 weeks before the first dose of study treatment","['The' 'subject' 'has' 'received' 'cytotoxic' 'chemotherapy' '('
 'including' 'investigational' 'cytotoxic' 'chemotherapy' ')' 'or'
 'biologic' 'agents' '(' 'e.g.' ',' 'cytokines' 'or' 'antibodies' ';'
 'including' 'investigational' 'biologic' 'agents' ')' 'within' '3'
 'weeks' ',' 'or' 'nitrosoureas/' 'mitomycin' 'C' 'within' '6' 'weeks'
 'before' 'the' 'first' 'dose' 'of' 'study' 'treatment']","[0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 1. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02132598,"40:43:treatment,40:48:treatment,52:71:treatment,,148:160:treatment",The subject must have a baseline brain MRI scan or CT scan of the head (in patients unable to obtain an MRI) within 14 days prior to first dose of cabozantinib,"['The' 'subject' 'must' 'have' 'a' 'baseline' 'brain' 'MRI' 'scan' 'or'
 'CT' 'scan' 'of' 'the' 'head' '(' 'in' 'patients' 'unable' 'to' 'obtain'
 'an' 'MRI' ')' 'within' '14' 'days' 'prior' 'to' 'first' 'dose' 'of'
 'cabozantinib']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02131805,"1:4:cancer,5:8:cancer,26:32:chronic_disease","BCC/SCC in area prone to trauma (including, but not limited to the skin overlying the tibia, dorsum of hands and elbow)","['BCC/SCC' 'in' 'area' 'prone' 'to' 'trauma' '(' 'including' ',' 'but'
 'not' 'limited' 'to' 'the' 'skin' 'overlying' 'the' 'tibia' ',' 'dorsum'
 'of' 'hands' 'and' 'elbow' ')']","[3. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02131597,"5:17:treatment,10:17:treatment,,134:153:chronic_disease","Off chemotherapy for 2 weeks prior to entering this study with no toxic effects of that therapy, unless there is evidence of rapidly progressive disease","['Off' 'chemotherapy' 'for' '2' 'weeks' 'prior' 'to' 'entering' 'this'
 'study' 'with' 'no' 'toxic' 'effects' 'of' 'that' 'therapy' ',' 'unless'
 'there' 'is' 'evidence' 'of' 'rapidly' 'progressive' 'disease']","[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 2. 2.]"
NCT02131597,"1:16:chronic_disease,18:27:chronic_disease,29:34:chronic_disease,45:54:chronic_disease,186:197:treatment,207:216:treatment","systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)","['systemic' 'fungal' ',' 'bacterial' ',' 'viral' ',' 'or' 'other'
 'infection' 'not' 'controlled' '(' 'defined' 'as' 'exhibiting' 'ongoing'
 'signs/symptoms' 'related' 'to' 'the' 'infection' 'and' 'without'
 'improvement' ',' 'despite' 'appropriate' 'antibiotics' 'or' 'other'
 'treatment' ')']","[2. 2. 0. 2. 0. 2. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0. 0. 1. 0.]"
NCT02131389,"1:27:chronic_disease,40:54:chronic_disease,58:82:chronic_disease","Degenerative joint disease, (including osteoarthritis or post-traumatic arthritis)","['Degenerative' 'joint' 'disease' ',' '(' 'including' 'osteoarthritis'
 'or' 'post-traumatic' 'arthritis' ')']",[2. 2. 2. 0. 0. 0. 2. 0. 2. 2. 0.]
NCT02131389,"19:41:chronic_disease,48:68:chronic_disease,70:99:chronic_disease,101:120:chronic_disease,122:150:chronic_disease","Is suffering from inflammatory arthritis (e.g. rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, etc.)","['Is' 'suffering' 'from' 'inflammatory' 'arthritis' '(' 'e.g' '.'
 'rheumatoid' 'arthritis' ',' 'juvenile' 'rheumatoid' 'arthritis' ','
 'psoriatic' 'arthritis' ',' 'systemic' 'lupus' 'erythematosus' ',' 'etc'
 '.' ')']","[0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0.
 0.]"
NCT02129348,"31:44:chronic_disease,46:70:chronic_disease,78:87:chronic_disease,92:110:chronic_disease","Current clinical diagnosis of schizophrenia, schizoaffective disorder, other psychosis, or bipolar 1 disorder (DSM-IV TR criteria)","['Current' 'clinical' 'diagnosis' 'of' 'schizophrenia' ','
 'schizoaffective' 'disorder' ',' 'other' 'psychosis' ',' 'or' 'bipolar'
 '1' 'disorder' '(' 'DSM-IV' 'TR' 'criteria' ')']",[0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02128906,"19:32:treatment,95:100:cancer,108:121:cancer","Diagnostic simple tonsillectomy is permitted, provided patient has RECIST-measurable residual tumor and/or nodal disease","['Diagnostic' 'simple' 'tonsillectomy' 'is' 'permitted' ',' 'provided'
 'patient' 'has' 'RECIST-measurable' 'residual' 'tumor' 'and/or' 'nodal'
 'disease']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3.]
NCT02128906,"28:40:treatment,44:53:treatment,89:109:cancer","Patients may have received chemotherapy or radiation for a previous, curatively treated non-HNSCC malignancy","['Patients' 'may' 'have' 'received' 'chemotherapy' 'or' 'radiation' 'for'
 'a' 'previous' ',' 'curatively' 'treated' 'non-HNSCC' 'malignancy']",[0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT02128230,"19:31:chronic_disease,33:50:chronic_disease,88:107:chronic_disease,164:173:treatment","Poorly controlled hypertension, diabetes mellitus, or other serious medical illness or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol","['Poorly' 'controlled' 'hypertension' ',' 'diabetes' 'mellitus' ',' 'or'
 'other' 'serious' 'medical' 'illness' 'or' 'psychiatric' 'illness' 'that'
 'could' 'potentially' 'interfere' 'with' 'the' 'completion' 'of'
 'treatment' 'according' 'to' 'this' 'protocol']","[0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 0. 0. 0. 0.]"
NCT02124902,"14:34:chronic_disease,66:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:201:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic'
 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ','
 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social'
 'situations' 'that' 'would' 'limit' 'compliance' 'with' 'study'
 'requirements']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0.
 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02124772,"1:14:treatment,44:50:cancer,52:83:cancer,89:116:cancer","Prior therapy: The subject's disease (i.e. cancer, neurofibromatosis type 1 [NF-1] with plexiform neurofibroma [PN]","['Prior' 'therapy' ':' 'The' 'subject' ""'s"" 'disease' '(' 'i.e' '.'
 'cancer' ',' 'neurofibromatosis' 'type' '1' '[' 'NF-1' ']' 'with'
 'plexiform' 'neurofibroma' '[' 'PN' ']']",[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 3. 3. 0. 0. 0. 3. 3. 3. 0. 0.]
NCT02124772,",,61:75:treatment,120:138:chronic_disease,139:147:chronic_disease","abnormal cardiac valve morphology (>=grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis]","['abnormal' 'cardiac' 'valve' 'morphology' '(' '>' '=grade' '2' ')'
 'documented' 'by' 'echocardiogram' '(' 'subjects' 'with' 'grade' '1'
 'abnormalities' '[' 'i.e.' ',' 'mild' 'regurgitation/stenosis' ']']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.]
NCT02122185,"19:43:treatment,65:86:treatment,108:134:treatment,144:152:treatment,161:175:cancer,179:192:treatment,196:224:treatment",Subjects for whom neoadjuvant chemotherapy followed by interval cytoreductive surgery is planned must have fine needle aspirate (FNA) or other cytology showing adenocarcinoma OR core biopsies OR surgically directed biopsies showing adenocarcinoma,"['Subjects' 'for' 'whom' 'neoadjuvant' 'chemotherapy' 'followed' 'by'
 'interval' 'cytoreductive' 'surgery' 'is' 'planned' 'must' 'have' 'fine'
 'needle' 'aspirate' '(' 'FNA' ')' 'or' 'other' 'cytology' 'showing'
 'adenocarcinoma' 'OR' 'core' 'biopsies' 'OR' 'surgically' 'directed'
 'biopsies' 'showing' 'adenocarcinoma']","[0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 1. 0.
 3. 0. 1. 1. 0. 1. 1. 1. 0. 0.]"
NCT02122185,"20:44:treatment,37:44:treatment,54:80:treatment",subjects receiving neoadjuvant chemotherapy for whom interval debulking surgery (assuming adequate response to therapy) is not planned,"['subjects' 'receiving' 'neoadjuvant' 'chemotherapy' 'for' 'whom'
 'interval' 'debulking' 'surgery' '(' 'assuming' 'adequate' 'response'
 'to' 'therapy' ')' 'is' 'not' 'planned']",[0. 0. 1. 1. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT02122185,"20:45:treatment,38:45:treatment,,,133:154:treatment,156:163:treatment,168:183:treatment","ubjects undergoing primary debulking surgery must have stage III or IV disease and have undergone surgery to include, at a minimum, removal of the uterus, ovaries and fallopian tubes","['ubjects' 'undergoing' 'primary' 'debulking' 'surgery' 'must' 'have'
 'stage' 'III' 'or' 'IV' 'disease' 'and' 'have' 'undergone' 'surgery' 'to'
 'include' ',' 'at' 'a' 'minimum' ',' 'removal' 'of' 'the' 'uterus' ','
 'ovaries' 'and' 'fallopian' 'tubes']","[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 1. 1. 0. 1. 0. 1. 1.]"
NCT02122081,"24:33:treatment,43:46:cancer,48:51:cancer,55:58:cancer,68:83:treatment","For patients receiving treatment of their AML, MDS or ALL prior to transplantation","['For' 'patients' 'receiving' 'treatment' 'of' 'their' 'AML' ',' 'MDS'
 'or' 'ALL' 'prior' 'to' 'transplantation']",[0. 0. 0. 1. 0. 0. 3. 0. 3. 0. 3. 0. 0. 1.]
NCT02121158,"24:39:chronic_disease,46:52:cancer,54:60:chronic_disease,62:75:chronic_disease,","Any disease other than cardiac disease (e.g. cancer, uremia, liver failure), associated with a likelihood of survival less than 1 year","['Any' 'disease' 'other' 'than' 'cardiac' 'disease' '(' 'e.g' '.' 'cancer'
 ',' 'uremia' ',' 'liver' 'failure' ')' ',' 'associated' 'with' 'a'
 'likelihood' 'of' 'survival' 'less' 'than' '1' 'year']","[0. 0. 0. 0. 2. 2. 0. 0. 0. 3. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02120222,"3:7:treatment,15:28:treatment,33:38:cancer,,,85:95:cancer",a BRAF and/or MEK inhibitor (if tumor contains the V600E or V600K mutation) for 628 metastatic disease,"['a' 'BRAF' 'and/or' 'MEK' 'inhibitor' '(' 'if' 'tumor' 'contains' 'the'
 'V600E' 'or' 'V600K' 'mutation' ')' 'for' '628' 'metastatic' 'disease']",[0. 1. 0. 1. 1. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0.]
NCT02115295,"55:81:cancer,83:111:cancer,115:118:cancer","For Salvage cohort: Patients with previously treated, relapsed or refractory AML, Acute Biphenotypic Leukemia, or CML in Myeloid Blast Phase are eligible","['For' 'Salvage' 'cohort' ':' 'Patients' 'with' 'previously' 'treated' ','
 'relapsed' 'or' 'refractory' 'AML' ',' 'Acute' 'Biphenotypic' 'Leukemia'
 ',' 'or' 'CML' 'in' 'Myeloid' 'Blast' 'Phase' 'are' 'eligible']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 3. 3. 3. 0. 0. 3. 0. 0. 0. 0.
 0. 0.]"
NCT02114229,"22:30:treatment,34:48:treatment,83:96:treatment",Intermittent uses of antacids or H2 antagonists are allowed while patients are on dexamethasone,"['Intermittent' 'uses' 'of' 'antacids' 'or' 'H2' 'antagonists' 'are'
 'allowed' 'while' 'patients' 'are' 'on' 'dexamethasone']",[0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1.]
NCT02114229,"4:31:treatment,33:50:treatment,54:66:treatment,90:105:treatment",No previous anticancer therapy (radiation therapy or chemotherapy) other than the use of corticosteroids,"['No' 'previous' 'anticancer' 'therapy' '(' 'radiation' 'therapy' 'or'
 'chemotherapy' ')' 'other' 'than' 'the' 'use' 'of' 'corticosteroids']",[0. 1. 1. 1. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 1.]
NCT02114229,"44:65:treatment,67:80:treatment,85:103:treatment","Requirement for constant administration of proton-pump inhibitor, H2 antagonist, or pancreatic enzymes","['Requirement' 'for' 'constant' 'administration' 'of' 'proton-pump'
 'inhibitor' ',' 'H2' 'antagonist' ',' 'or' 'pancreatic' 'enzymes']",[0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 1. 1.]
NCT02112617,"32:44:treatment,,99:116:treatment,197:222:treatment",Patients will be ineligible if chemotherapy was completed ≥ 1 year from the planned start date of radiation therapy or if the patient is referred for radiation therapy after a relapse following a regimen with chemotherapy alone,"['Patients' 'will' 'be' 'ineligible' 'if' 'chemotherapy' 'was' 'completed'
 '≥' '1' 'year' 'from' 'the' 'planned' 'start' 'date' 'of' 'radiation'
 'therapy' 'or' 'if' 'the' 'patient' 'is' 'referred' 'for' 'radiation'
 'therapy' 'after' 'a' 'relapse' 'following' 'a' 'regimen' 'with'
 'chemotherapy' 'alone']","[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0.]"
NCT02111850,"24:30:chronic_disease,38:61:chronic_disease,92:111:chronic_disease,113:136:chronic_disease,161:172:chronic_disease,194:216:chronic_disease","Clinically significant atrial and or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second or third degree heart block or have a history of ischemic heart disease, or chest pain","['Clinically' 'significant' 'atrial' 'and' 'or' 'ventricular'
 'arrhythmias' 'including' 'but' 'not' 'limited' 'to' ':' 'atrial'
 'fibrillation' ',' 'ventricular' 'tachycardia' ',' 'second' 'or' 'third'
 'degree' 'heart' 'block' 'or' 'have' 'a' 'history' 'of' 'ischemic'
 'heart' 'disease' ',' 'or' 'chest' 'pain']","[0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0.]"
NCT02111850,"39:49:treatment,70:81:chronic_disease,101:112:treatment,125:141:treatment",Patients who have previously received ipilimumab and have documented GI toxicity must have a normal colonoscopy with normal colonic biopsies,"['Patients' 'who' 'have' 'previously' 'received' 'ipilimumab' 'and' 'have'
 'documented' 'GI' 'toxicity' 'must' 'have' 'a' 'normal' 'colonoscopy'
 'with' 'normal' 'colonic' 'biopsies']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 2. 2. 0. 0. 0. 0. 1. 0. 0. 1. 1.]
NCT02109627,"1:11:treatment,15:36:treatment,41:44:cancer,50:72:treatment,,116:141:treatment,147:151:chronic_disease,",Allogeneic or autologous transplant for AML with infusion of stem cells within 90 days of study entry or on active immunosuppressive therapy for (GVHD) within 2 weeks before study entry,"['Allogeneic' 'or' 'autologous' 'transplant' 'for' 'AML' 'with' 'infusion'
 'of' 'stem' 'cells' 'within' '90' 'days' 'of' 'study' 'entry' 'or' 'on'
 'active' 'immunosuppressive' 'therapy' 'for' '(' 'GVHD' ')' 'within' '2'
 'weeks' 'before' 'study' 'entry']","[1. 0. 1. 1. 0. 3. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT02109627,"14:17:chronic_disease,19:30:chronic_disease,34:35:chronic_disease,39:48:chronic_disease","Known active HIV, hepatitis B or C or infection","['Known' 'active' 'HIV' ',' 'hepatitis' 'B' 'or' 'C' 'or' 'infection']",[0. 0. 2. 0. 2. 2. 0. 2. 0. 2.]
NCT02109627,"23:44:treatment,48:58:treatment,60:68:treatment,72:98:treatment,","Prior exposure to the investigational agent or anti-c-Met, anti-HGF or anti-VEGF directed therapy within six months prior to study entry","['Prior' 'exposure' 'to' 'the' 'investigational' 'agent' 'or' 'anti-c-Met'
 ',' 'anti-HGF' 'or' 'anti-VEGF' 'directed' 'therapy' 'within' 'six'
 'months' 'prior' 'to' 'study' 'entry']",[0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02108860,"36:71:treatment,73:76:treatment,78:81:treatment,83:85:treatment,","Initiation or dose increase of the maintenance immunosuppressive agent (MTX, AZA, MA) within 3 months prior to screening","['Initiation' 'or' 'dose' 'increase' 'of' 'the' 'maintenance'
 'immunosuppressive' 'agent' '(' 'MTX' ',' 'AZA' ',' 'MA' ')' 'within' '3'
 'months' 'prior' 'to' 'screening']",[0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02108860,"26:38:chronic_disease,68:87:chronic_disease,171:181:treatment,253:256:treatment,266:273:treatment,","Subjects with a positive tuberculosis screening test indicative of latent tuberculosis will be eligible for the study if they have no evidence of current tuberculosis on chest xray at screening and they are actively being treated for tuberculosis with INH or other therapy for latent tuberculosis given according to local health authority guidelines (e.g., CDC) that has been given for at least 4 weeks prior to randomization (Day 1)","['Subjects' 'with' 'a' 'positive' 'tuberculosis' 'screening' 'test'
 'indicative' 'of' 'latent' 'tuberculosis' 'will' 'be' 'eligible' 'for'
 'the' 'study' 'if' 'they' 'have' 'no' 'evidence' 'of' 'current'
 'tuberculosis' 'on' 'chest' 'xray' 'at' 'screening' 'and' 'they' 'are'
 'actively' 'being' 'treated' 'for' 'tuberculosis' 'with' 'INH' 'or'
 'other' 'therapy' 'for' 'latent' 'tuberculosis' 'given' 'according' 'to'
 'local' 'health' 'authority' 'guidelines' '(' 'e.g.' ',' 'CDC' ')' 'that'
 'has' 'been' 'given' 'for' 'at' 'least' '4' 'weeks' 'prior' 'to'
 'randomization' '(' 'Day' '1' ')']","[0. 0. 0. 0. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT02107703,"13:22:chronic_disease,26:42:chronic_disease,58:73:chronic_disease","Have active bacterial or fungal infection, or detectable viral infection","['Have' 'active' 'bacterial' 'or' 'fungal' 'infection' ',' 'or'
 'detectable' 'viral' 'infection']",[0. 0. 2. 0. 2. 2. 0. 0. 0. 2. 2.]
NCT02107703,"15:48:treatment,61:72:treatment,74:95:treatment,98:109:treatment,111:121:treatment,130:146:treatment,207:249:treatment","Have received prior treatment with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant, everolimus, or any CDK4/6 inhibitor. For the endocrine naïve cohort: In addition, have received treatment with any prior endocrine therapy","['Have' 'received' 'prior' 'treatment' 'with' 'chemotherapy' '(' 'except'
 'for' 'neoadjuvant/' 'adjuvant' 'chemotherapy' ')' ',' 'fulvestrant' ','
 'everolimus' ',' 'or' 'any' 'CDK4/6' 'inhibitor' '.' 'For' 'the'
 'endocrine' 'naïve' 'cohort' ':' 'In' 'addition' ',' 'have' 'received'
 'treatment' 'with' 'any' 'prior' 'endocrine' 'therapy']","[0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 1. 0. 1. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02107703,"24:42:cancer,117:126:treatment,142:154:treatment,161:180:treatment,184:212:treatment",presented de novo with metastatic disease and then relapsed with radiologic evidence of progression after receiving treatment with either an antiestrogen or an aromatase inhibitor as first line endocrine therapy for metastatic disease,"['presented' 'de' 'novo' 'with' 'metastatic' 'disease' 'and' 'then'
 'relapsed' 'with' 'radiologic' 'evidence' 'of' 'progression' 'after'
 'receiving' 'treatment' 'with' 'either' 'an' 'antiestrogen' 'or' 'an'
 'aromatase' 'inhibitor' 'as' 'first' 'line' 'endocrine' 'therapy' 'for'
 'metastatic' 'disease']","[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 0. 1.
 1. 0. 1. 1. 1. 1. 0. 0. 0.]"
NCT02106988,"51:63:treatment,65:75:treatment,81:88:treatment","willingness to accept supportive measures such as transfusions, filgrastim, and Epoetin","['willingness' 'to' 'accept' 'supportive' 'measures' 'such' 'as'
 'transfusions' ',' 'filgrastim' ',' 'and' 'Epoetin']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1.]
NCT02106650,"16:42:cancer,53:57:chronic_disease,62:66:cancer,88:97:treatment",diagnosed with hematological malignancies including PTCL and CTCL and are eligible for treatment with a dose of 30 mg/m^2,"['diagnosed' 'with' 'hematological' 'malignancies' 'including' 'PTCL'
 'and' 'CTCL' 'and' 'are' 'eligible' 'for' 'treatment' 'with' 'a' 'dose'
 'of' '30' 'mg/m^2']",[0. 0. 3. 3. 0. 2. 0. 3. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02106598,"49:54:cancer,66:83:cancer,88:105:cancer","Residual clinically or radiographically evident tumor, including primary cutaneous and mucosal melanomas","['Residual' 'clinically' 'or' 'radiographically' 'evident' 'tumor' ','
 'including' 'primary' 'cutaneous' 'and' 'mucosal' 'melanomas']",[0. 0. 0. 0. 0. 3. 0. 0. 3. 3. 0. 3. 3.]
NCT02105766,"16:34:treatment,143:167:chronic_disease,171:186:chronic_disease,206:212:chronic_disease","Fit to receive filgrastim (G-CSF) and to give peripheral blood stem cells (blood counts and blood pressure within DTM standards no history of congestive heart failure or unstable angina, and no history of stroke)","['Fit' 'to' 'receive' 'filgrastim' '(' 'G-CSF' ')' 'and' 'to' 'give'
 'peripheral' 'blood' 'stem' 'cells' '(' 'blood' 'counts' 'and' 'blood'
 'pressure' 'within' 'DTM' 'standards' 'no' 'history' 'of' 'congestive'
 'heart' 'failure' 'or' 'unstable' 'angina' ',' 'and' 'no' 'history' 'of'
 'stroke' ')']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 2. 0.]"
NCT02104349,"28:41:treatment,53:79:treatment,81:118:treatment,120:141:treatment","Patients that will undergo spine surgery including: single level lumbar fusion, posterior cervical laminectomy fusion, cervical laminaplasty","['Patients' 'that' 'will' 'undergo' 'spine' 'surgery' 'including' ':'
 'single' 'level' 'lumbar' 'fusion' ',' 'posterior' 'cervical'
 'laminectomy' 'fusion' ',' 'cervical' 'laminaplasty']",[0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0.]
NCT02101944,"1:22:chronic_disease,28:42:chronic_disease,44:56:chronic_disease,58:72:chronic_disease,74:104:chronic_disease,110:139:chronic_disease","Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein), and skin changes (POEMS) syndrome","['Plasma' 'cell' 'dyscrasia' 'with' 'polyneuropathy' ',' 'organomegaly'
 ',' 'endocrinopathy' ',' 'monoclonal' 'protein' '(' 'M-protein' ')' ','
 'and' 'skin' 'changes' '(' 'POEMS' ')' 'syndrome']",[2. 2. 2. 0. 2. 0. 2. 0. 2. 0. 2. 2. 2. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0.]
NCT02101853,"45:74:chronic_disease,76:89:chronic_disease,91:105:chronic_disease,107:128:chronic_disease,130:144:chronic_disease,146:163:chronic_disease,165:183:chronic_disease,203:231:chronic_disease","Patients known to have one of the following concomitant genetic syndromes: Down syndrome, Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome","['Patients' 'known' 'to' 'have' 'one' 'of' 'the' 'following' 'concomitant'
 'genetic' 'syndromes' ':' 'Down' 'syndrome' ',' 'Bloom' 'syndrome' ','
 'ataxia-telangiectasia' ',' 'Fanconi' 'anemia' ',' 'Kostmann' 'syndrome'
 ',' 'Shwachman' 'syndrome' 'or' 'any' 'other' 'known' 'bone' 'marrow'
 'failure' 'syndrome']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 0. 2. 0. 2. 2. 0. 2.
 2. 0. 2. 2. 0. 0. 0. 0. 2. 2. 2. 2.]"
NCT02101853,"32:44:allergy_name,46:56:allergy_name,61:111:allergy_name","Patients with known allergy to mitoxantrone, cytarabine, or both etoposide and etoposide phosphate (Etopophos)","['Patients' 'with' 'known' 'allergy' 'to' 'mitoxantrone' ',' 'cytarabine'
 ',' 'or' 'both' 'etoposide' 'and' 'etoposide' 'phosphate' '(' 'Etopophos'
 ')']",[0. 0. 0. 0. 0. 4. 0. 4. 0. 0. 4. 4. 4. 4. 4. 4. 0. 0.]
NCT02101736,"8:20:chronic_disease,57:66:treatment,72:84:treatment,88:105:treatment",Active optic glioma or other low-grade glioma requiring treatment with chemotherapy or radiation therapy,"['Active' 'optic' 'glioma' 'or' 'other' 'low-grade' 'glioma' 'requiring'
 'treatment' 'with' 'chemotherapy' 'or' 'radiation' 'therapy']",[0. 2. 2. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 1.]
NCT02101736,"39:54:chronic_disease,111:132:chronic_disease,147:159:chronic_disease,168:177:chronic_disease,179:198:chronic_disease,200:230:chronic_disease,239:264:chronic_disease","Concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (e.g. uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, chronic liver or renal disease, active upper GI tract ulceration)","['Concurrent' 'severe' 'and/or' 'uncontrolled' 'medical' 'disease' 'which'
 'could' 'compromise' 'participation' 'in' 'the' 'study' '(' 'e.g' '.'
 'uncontrolled' 'diabetes' ',' 'uncontrolled' 'hypertension' ',' 'severe'
 'infection' ',' 'severe' 'malnutrition' ',' 'chronic' 'liver' 'or'
 'renal' 'disease' ',' 'active' 'upper' 'GI' 'tract' 'ulceration' ')']","[0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 2.
 0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 2. 2. 2. 2. 0.]"
NCT02101736,"1:17:cancer,19:58:cancer,69:79:cancer,90:99:treatment,","Malignant glioma, malignant peripheral nerve sheath tumor, or other malignancy requiring treatment in the last 12 months","['Malignant' 'glioma' ',' 'malignant' 'peripheral' 'nerve' 'sheath'
 'tumor' ',' 'or' 'other' 'malignancy' 'requiring' 'treatment' 'in' 'the'
 'last' '12' 'months']",[3. 3. 0. 3. 3. 3. 3. 3. 0. 0. 0. 3. 0. 1. 0. 0. 0. 0. 0.]
NCT02101034,"24:27:chronic_disease,36:41:cancer,54:59:cancer",Arm 3: disease must be HPV-related SCCHN (defined as OPSCC or unknown primary presenting with a neck mass that is either p16 positive or HPV ISH or PCR positive),"['Arm' '3' ':' 'disease' 'must' 'be' 'HPV-related' 'SCCHN' '(' 'defined'
 'as' 'OPSCC' 'or' 'unknown' 'primary' 'presenting' 'with' 'a' 'neck'
 'mass' 'that' 'is' 'either' 'p16' 'positive' 'or' 'HPV' 'ISH' 'or' 'PCR'
 'positive' ')']","[0. 0. 0. 0. 0. 0. 2. 3. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02101034,"27:40:treatment,45:63:cancer,86:95:treatment","Phase I only: any (or no) prior therapy for metastatic disease is allowed, including cetuximab","['Phase' 'I' 'only' ':' 'any' '(' 'or' 'no' ')' 'prior' 'therapy' 'for'
 'metastatic' 'disease' 'is' 'allowed' ',' 'including' 'cetuximab']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 3. 3. 0. 0. 0. 0. 1.]
NCT02101034,"15:28:chronic_disease,33:55:treatment,90:105:treatment","patients with HIV infection and antiretroviral therapy are not excluded, as there are no pharmacokinetic tests being performed","['patients' 'with' 'HIV' 'infection' 'and' 'antiretroviral' 'therapy'
 'are' 'not' 'excluded' ',' 'as' 'there' 'are' 'no' 'pharmacokinetic'
 'tests' 'being' 'performed']",[0. 0. 2. 2. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02100891,"11:33:cancer,29:32:cancer,105:110:cancer,173:180:treatment,196:225:treatment,227:238:treatment,244:264:treatment,272:279:treatment,283:295:treatment","High-Risk Rhabdomyosarcoma (RMS) or Intermediate Risk Alveolar RMS recurring as more than loco-regional tumor: Must have progressed on or recurred after standard frontline therapy which includes chemotherapy with vincristine, actinomycin, and cyclophosphamide AND either surgery or radiotherapy","['High-Risk' 'Rhabdomyosarcoma' '(' 'RMS' ')' 'or' 'Intermediate' 'Risk'
 'Alveolar' 'RMS' 'recurring' 'as' 'more' 'than' 'loco-regional' 'tumor'
 ':' 'Must' 'have' 'progressed' 'on' 'or' 'recurred' 'after' 'standard'
 'frontline' 'therapy' 'which' 'includes' 'chemotherapy' 'with'
 'vincristine' ',' 'actinomycin' ',' 'and' 'cyclophosphamide' 'AND'
 'either' 'surgery' 'or' 'radiotherapy']","[0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 0. 0. 1. 1. 1. 0. 1. 0. 0. 1. 1. 0. 1. 0. 1.]"
NCT02099591,"22:33:chronic_disease,37:53:chronic_disease,68:76:chronic_disease",History of prolonged neutropenia or thrombocytopenia with clinical sequelae,"['History' 'of' 'prolonged' 'neutropenia' 'or' 'thrombocytopenia' 'with'
 'clinical' 'sequelae']",[0. 0. 0. 2. 0. 2. 0. 0. 2.]
NCT02099058,"22:40:treatment,51:63:treatment,65:82:treatment,84:97:treatment,99:107:treatment,116:139:treatment,,170:184:treatment,,226:234:treatment","Subject has received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within a period of 21 days or herbal therapy within 7 days prior to the first dose of ABBV-399","['Subject' 'has' 'received' 'anticancer' 'therapy' 'including'
 'chemotherapy' ',' 'radiation' 'therapy' ',' 'immunotherapy' ','
 'biologic' ',' 'or' 'any' 'investigational' 'therapy' 'within' 'a'
 'period' 'of' '21' 'days' 'or' 'herbal' 'therapy' 'within' '7' 'days'
 'prior' 'to' 'the' 'first' 'dose' 'of' 'ABBV-399']","[0. 0. 0. 1. 1. 0. 1. 0. 1. 1. 0. 1. 0. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02099058,"17:49:treatment,78:87:treatment,92:101:treatment","Subjects in the combination therapy arms A and D must be eligible to receive erlotinib, or nivolumab per most current prescribing information, or at the discretion of the Investigator","['Subjects' 'in' 'the' 'combination' 'therapy' 'arms' 'A' 'and' 'D' 'must'
 'be' 'eligible' 'to' 'receive' 'erlotinib' ',' 'or' 'nivolumab' 'per'
 'most' 'current' 'prescribing' 'information' ',' 'or' 'at' 'the'
 'discretion' 'of' 'the' 'Investigator']","[0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT02098876,"80:90:allergy_name,92:103:allergy_name,105:111:allergy_name,113:121:allergy_name,123:129:allergy_name,131:139:allergy_name,141:149:allergy_name,151:158:allergy_name,163:178:allergy_name","hypersensitivity or contraindication to device materials and their degradants, everolimus, zotarolimus, cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers","['hypersensitivity' 'or' 'contraindication' 'to' 'device' 'materials'
 'and' 'their' 'degradants' ',' 'everolimus' ',' 'zotarolimus' ','
 'cobalt' ',' 'chromium' ',' 'nickel' ',' 'platinum' ',' 'tungsten' ','
 'acrylic' 'and' 'fluoro' 'polymers']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 4. 0. 4. 0. 4. 0. 4. 0. 4. 0.
 4. 0. 4. 4.]"
NCT02098161,"38:120:treatment,38:47:treatment,96:120:treatment,122:133:treatment,135:161:treatment,152:157:treatment,238:249:treatment,251:284:treatment","Patients who are currently receiving treatment with agents that are metabolized solely through cytochrome P450 family 3, subfamily A, polypeptide 4/5 (CYP3A4/5) and have a narrow therapeutic index or are strong cytochrome P450 family 3, subfamily C, polypeptide 8 (CYP2C8) inhibitors; or are receiving treatment with agents that carry a risk for QT prolongation and are CYP3A substrates","['Patients' 'who' 'are' 'currently' 'receiving' 'treatment' 'with'
 'agents' 'that' 'are' 'metabolized' 'solely' 'through' 'cytochrome'
 'P450' 'family' '3' ',' 'subfamily' 'A' ',' 'polypeptide' '4/5' '('
 'CYP3A4/5' ')' 'and' 'have' 'a' 'narrow' 'therapeutic' 'index' 'or' 'are'
 'strong' 'cytochrome' 'P450' 'family' '3' ',' 'subfamily' 'C' ','
 'polypeptide' '8' '(' 'CYP2C8' ')' 'inhibitors' ';' 'or' 'are'
 'receiving' 'treatment' 'with' 'agents' 'that' 'carry' 'a' 'risk' 'for'
 'QT' 'prolongation' 'and' 'are' 'CYP3A' 'substrates']","[0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 1. 1. 0. 1. 1. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.]"
NCT02095184,"23:32:treatment,36:46:treatment,82:95:cancer,156:165:treatment,,203:215:treatment",Patients who received tamoxifen or raloxifene or another agent for prevention of breast cancer may be included as long as the patient has discontinued the treatment at least one month prior to baseline study biopsy,"['Patients' 'who' 'received' 'tamoxifen' 'or' 'raloxifene' 'or' 'another'
 'agent' 'for' 'prevention' 'of' 'breast' 'cancer' 'may' 'be' 'included'
 'as' 'long' 'as' 'the' 'patient' 'has' 'discontinued' 'the' 'treatment'
 'at' 'least' 'one' 'month' 'prior' 'to' 'baseline' 'study' 'biopsy']","[0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02094625,"50:57:treatment,172:181:treatment,200:209:treatment,213:240:treatment,246:286:treatment","Are anticipated to be able to comply with end-of-therapy audiology assessment (note that hearing assessments are performed per routine clinical care in children receiving cisplatin and consist of an audiogram or auditory brainstem response, and distortion-product otoacoustic emissions","['Are' 'anticipated' 'to' 'be' 'able' 'to' 'comply' 'with'
 'end-of-therapy' 'audiology' 'assessment' '(' 'note' 'that' 'hearing'
 'assessments' 'are' 'performed' 'per' 'routine' 'clinical' 'care' 'in'
 'children' 'receiving' 'cisplatin' 'and' 'consist' 'of' 'an' 'audiogram'
 'or' 'auditory' 'brainstem' 'response' ',' 'and' 'distortion-product'
 'otoacoustic' 'emissions']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 0. 0. 0. 1. 0. 1. 1. 1. 0. 0. 1. 1. 1.]"
NCT02094625,"52:66:cancer,68:83:cancer,85:97:cancer","Most common but not exclusive diagnoses consist of hepatoblastoma, medulloblastoma, osteosarcoma","['Most' 'common' 'but' 'not' 'exclusive' 'diagnoses' 'consist' 'of'
 'hepatoblastoma' ',' 'medulloblastoma' ',' 'osteosarcoma']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 0. 3.]
NCT02092324,"34:68:chronic_disease,72:98:chronic_disease,102:103:chronic_disease",Subjects with known diagnosis of human immunodeficiency virus (HIV) or chronic active Hepatitis B or C,"['Subjects' 'with' 'known' 'diagnosis' 'of' 'human' 'immunodeficiency'
 'virus' '(' 'HIV' ')' 'or' 'chronic' 'active' 'Hepatitis' 'B' 'or' 'C']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0. 2.]
NCT02091999,"21:53:treatment,58:74:chronic_disease,76:81:chronic_disease,83:92:chronic_disease,97:103:chronic_disease,134:152:treatment","Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of first dose of enfortumab vedotin","['Currently' 'receiving' 'systemic' 'antimicrobial' 'treatment' 'for'
 'active' 'infection' '(' 'viral' ',' 'bacterial' ',' 'or' 'fungal' ')'
 'at' 'the' 'time' 'of' 'first' 'dose' 'of' 'enfortumab' 'vedotin']","[0. 0. 1. 1. 1. 0. 2. 2. 0. 2. 0. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1.]"
NCT02091999,"26:78:cancer,86:107:cancer,109:121:cancer,123:129:cancer,134:141:cancer","Histologically confirmed Transitional Cell Carcinoma of the Urothelium (TCCU) (i.e., cancer of the bladder, renal pelvis, ureter, or urethra","['Histologically' 'confirmed' 'Transitional' 'Cell' 'Carcinoma' 'of' 'the'
 'Urothelium' '(' 'TCCU' ')' '(' 'i.e.' ',' 'cancer' 'of' 'the' 'bladder'
 ',' 'renal' 'pelvis' ',' 'ureter' ',' 'or' 'urethra']","[0. 0. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 3. 3. 0. 3. 0.
 0. 3.]"
NCT02091999,"104:129:cancer,131:152:cancer,157:185:cancer,,268:295:treatment","Subjects with recurrent disease or histologically or cytologically confirmed Stage III/IV diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma who have previously progressed while receiving or within 6 months of completing a platinum-containing regimen","['Subjects' 'with' 'recurrent' 'disease' 'or' 'histologically' 'or'
 'cytologically' 'confirmed' 'Stage' 'III/IV' 'diagnosis' 'of'
 'epithelial' 'ovarian' 'cancer' ',' 'fallopian' 'tube' 'cancer' ',' 'or'
 'primary' 'peritoneal' 'carcinoma' 'who' 'have' 'previously' 'progressed'
 'while' 'receiving' 'or' 'within' '6' 'months' 'of' 'completing' 'a'
 'platinum-containing' 'regimen']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 3. 3. 3. 0. 0. 3. 3.
 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02091999,"4:18:treatment,22:43:treatment,,92:110:treatment",no red blood cell or platelet transfusions are allowed within 14 days of the first dose of enfortumab vedotin,"['no' 'red' 'blood' 'cell' 'or' 'platelet' 'transfusions' 'are' 'allowed'
 'within' '14' 'days' 'of' 'the' 'first' 'dose' 'of' 'enfortumab'
 'vedotin']",[0. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02091141,"53:71:treatment,64:71:treatment,73:80:treatment,85:97:treatment,,","All non-hematological adverse events related to any prior chemotherapy, surgery, or radiotherapy must have resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade less than or equal to (≤) 2 prior to starting therapy","['All' 'non-hematological' 'adverse' 'events' 'related' 'to' 'any' 'prior'
 'chemotherapy' ',' 'surgery' ',' 'or' 'radiotherapy' 'must' 'have'
 'resolved' 'to' 'National' 'Cancer' 'Institute' 'Common' 'Terminology'
 'Criteria' 'for' 'Adverse' 'Events' '(' 'NCI' 'CTCAE' ')' 'Grade' 'less'
 'than' 'or' 'equal' 'to' '(' '≤' ')' '2' 'prior' 'to' 'starting'
 'therapy']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02091141,"31:47:treatment,,,102:117:treatment,108:117:treatment","For patients enrolling in the atezolizumab arm, ECOG score must be documented within 7 days prior to first treatment and confirmation of ECOG PS must be entered into the interactive web response system [IWRS] prior to initiation of treatment","['For' 'patients' 'enrolling' 'in' 'the' 'atezolizumab' 'arm' ',' 'ECOG'
 'score' 'must' 'be' 'documented' 'within' '7' 'days' 'prior' 'to' 'first'
 'treatment' 'and' 'confirmation' 'of' 'ECOG' 'PS' 'must' 'be' 'entered'
 'into' 'the' 'interactive' 'web' 'response' 'system' '[' 'IWRS' ']'
 'prior' 'to' 'initiation' 'of' 'treatment']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02091141,"1:25:treatment,,95:104:treatment,136:160:treatment","Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the course of the study","['Major' 'surgical' 'procedure' 'other' 'than' 'for' 'diagnosis' 'within'
 '4' 'weeks' 'prior' 'to' 'initiation' 'of' 'study' 'treatment' ',' 'or'
 'anticipation' 'of' 'need' 'for' 'a' 'major' 'surgical' 'procedure'
 'during' 'the' 'course' 'of' 'the' 'study']","[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 1. 0. 0. 0. 0. 0. 0.]"
NCT02091141,"10:44:chronic_disease,58:81:chronic_disease,93:123:chronic_disease,144:156:chronic_disease","Positive human immunodeficiency virus (HIV) test, active hepatitis B virus (HBV) infection, active hepatitis C virus (HCV) infection or active tuberculosis","['Positive' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'test' ','
 'active' 'hepatitis' 'B' 'virus' '(' 'HBV' ')' 'infection' ',' 'active'
 'hepatitis' 'C' 'virus' '(' 'HCV' ')' 'infection' 'or' 'active'
 'tuberculosis']","[0. 2. 2. 2. 2. 0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 2.]"
NCT02091141,"1:14:chronic_disease,16:24:chronic_disease,26:38:chronic_disease","Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol","['Psychological' ',' 'familial' ',' 'sociological' ',' 'or' 'geographical'
 'conditions' 'that' 'do' 'not' 'permit' 'compliance' 'with' 'the'
 'protocol']",[2. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02091141,"33:46:chronic_disease,87:102:treatment,137:147:treatment","Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of vismodegib","['Refractory' 'nausea' 'and' 'vomiting' ',' 'malabsorption' ',' 'external'
 'biliary' 'shunt' ',' 'or' 'significant' 'bowel' 'resection' 'that'
 'would' 'preclude' 'absorption' 'of' 'vismodegib']",[0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1.]
NCT02089607,"18:25:treatment,74:80:chronic_disease,85:113:chronic_disease,130:179:treatment,183:206:treatment","Examples include therapy directed to reduce rates of spinal cord injury, stroke and contrast-induced nephropathy associated with implantation of fenestrated-branched stent-grafts or advanced imaging trials designed to reduce radiation exposure during repair","['Examples' 'include' 'therapy' 'directed' 'to' 'reduce' 'rates' 'of'
 'spinal' 'cord' 'injury' ',' 'stroke' 'and' 'contrast-induced'
 'nephropathy' 'associated' 'with' 'implantation' 'of'
 'fenestrated-branched' 'stent-grafts' 'or' 'advanced' 'imaging' 'trials'
 'designed' 'to' 'reduce' 'radiation' 'exposure' 'during' 'repair']","[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 1. 1. 1. 1. 0. 1.
 1. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT02089607,"26:66:treatment,115:155:treatment,166:191:treatment,217:232:treatment,254:269:treatment,317:357:treatment,378:395:chronic_disease,397:425:chronic_disease","Participation in another investigational clinical or device trial, with the exception of participation in another investigational endovascular stent-graft protocol, percutaneous aortic valve protocol, or concomitant clinical trials designed to evaluate medical therapy strategies to reduce perioperative risk during fenestrated-branched endovascular repair, including risks of renal dysfunction, contrast-induced nephropathy, neurologic, spinal cord or cardiac complications, and/or use of advanced imaging to reduce radiation exposure during implantation of these devices","['Participation' 'in' 'another' 'investigational' 'clinical' 'or' 'device'
 'trial' ',' 'with' 'the' 'exception' 'of' 'participation' 'in' 'another'
 'investigational' 'endovascular' 'stent-graft' 'protocol' ','
 'percutaneous' 'aortic' 'valve' 'protocol' ',' 'or' 'concomitant'
 'clinical' 'trials' 'designed' 'to' 'evaluate' 'medical' 'therapy'
 'strategies' 'to' 'reduce' 'perioperative' 'risk' 'during'
 'fenestrated-branched' 'endovascular' 'repair' ',' 'including' 'risks'
 'of' 'renal' 'dysfunction' ',' 'contrast-induced' 'nephropathy' ','
 'neurologic' ',' 'spinal' 'cord' 'or' 'cardiac' 'complications' ','
 'and/or' 'use' 'of' 'advanced' 'imaging' 'to' 'reduce' 'radiation'
 'exposure' 'during' 'implantation' 'of' 'these' 'devices']","[0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0.
 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT02088554,"31:57:chronic_disease,79:108:chronic_disease,124:140:treatment",Patient has greater than mild mitral valve regurgitation or greater than mild tricuspid valve regurgitation as assessed by echocardiography,"['Patient' 'has' 'greater' 'than' 'mild' 'mitral' 'valve' 'regurgitation'
 'or' 'greater' 'than' 'mild' 'tricuspid' 'valve' 'regurgitation' 'as'
 'assessed' 'by' 'echocardiography']",[0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 1.]
NCT02087826,"31:44:chronic_disease,56:70:chronic_disease,101:123:treatment","Conditions causing intestinal malabsorption, including celiac disease or a history of intestinal or gastric bypass surgery","['Conditions' 'causing' 'intestinal' 'malabsorption' ',' 'including'
 'celiac' 'disease' 'or' 'a' 'history' 'of' 'intestinal' 'or' 'gastric'
 'bypass' 'surgery']",[0. 0. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT02085941,"23:27:cancer,29:33:cancer,37:58:cancer","must have an advanced head, neck or spine malignant tumor that would potentially benefit from a minimally invasive procedure","['must' 'have' 'an' 'advanced' 'head' ',' 'neck' 'or' 'spine' 'malignant'
 'tumor' 'that' 'would' 'potentially' 'benefit' 'from' 'a' 'minimally'
 'invasive' 'procedure']",[0. 0. 0. 0. 3. 0. 3. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02080221,"30:40:cancer,73:82:treatment,,134:147:cancer,164:179:cancer","patients with an early stage malignancy that is not expected to require treatment in the next 2 years (such as early stage, resected breast cancer or asymptomatic prostate cancer)","['patients' 'with' 'an' 'early' 'stage' 'malignancy' 'that' 'is' 'not'
 'expected' 'to' 'require' 'treatment' 'in' 'the' 'next' '2' 'years' '('
 'such' 'as' 'early' 'stage' ',' 'resected' 'breast' 'cancer' 'or'
 'asymptomatic' 'prostate' 'cancer' ')']","[0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 3. 3. 0. 0. 3. 3. 0.]"
NCT02076906,"10:29:treatment,31:43:treatment,45:63:treatment,65:82:treatment,104:118:treatment,109:118:treatment","No other anti-cancer therapy (chemotherapy, biological therapy, radiation therapy) is permitted during HIFU treatment and post treatment follow up for tolerability","['No' 'other' 'anti-cancer' 'therapy' '(' 'chemotherapy' ',' 'biological'
 'therapy' ',' 'radiation' 'therapy' ')' 'is' 'permitted' 'during' 'HIFU'
 'treatment' 'and' 'post' 'treatment' 'follow' 'up' 'for' 'tolerability']","[0. 0. 1. 1. 0. 1. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.
 0.]"
NCT02076906,"15:21:cancer,90:97:treatment,147:156:treatment",The patient's cancer must have relapsed after or failed to respond to frontline curative therapy and there must not be other potentially curative treatment options available,"['The' 'patient' ""'s"" 'cancer' 'must' 'have' 'relapsed' 'after' 'or'
 'failed' 'to' 'respond' 'to' 'frontline' 'curative' 'therapy' 'and'
 'there' 'must' 'not' 'be' 'other' 'potentially' 'curative' 'treatment'
 'options' 'available']","[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 0.]"
NCT02074631,"1:41:treatment,46:68:cancer,75:83:cancer,85:93:cancer,104:107:cancer,109:112:cancer,114:117:cancer,119:122:cancer,120:122:cancer,151:175:cancer,184:193:cancer,201:207:cancer,261:300:chronic_disease","Allogeneic hematopoietic cell transplant for hematologic malignancy (i.e. leukemia, lymphoma including ALL, AML, CML, NHL, HL) in complete remission; myelodysplastic syndrome (active dysplasia and/or blasts are permitted, but must not have active leukemia) or idiopathic severe aplastic anemia (SAA)","['Allogeneic' 'hematopoietic' 'cell' 'transplant' 'for' 'hematologic'
 'malignancy' '(' 'i.e' '.' 'leukemia' ',' 'lymphoma' 'including' 'ALL'
 ',' 'AML' ',' 'CML' ',' 'NHL' ',' 'HL' ')' 'in' 'complete' 'remission'
 ';' 'myelodysplastic' 'syndrome' '(' 'active' 'dysplasia' 'and/or'
 'blasts' 'are' 'permitted' ',' 'but' 'must' 'not' 'have' 'active'
 'leukemia' ')' 'or' 'idiopathic' 'severe' 'aplastic' 'anemia' '(' 'SAA'
 ')']","[1. 1. 1. 1. 0. 3. 3. 0. 0. 0. 3. 0. 3. 0. 3. 0. 3. 0. 3. 0. 3. 0. 3. 0.
 0. 0. 0. 0. 3. 3. 0. 0. 3. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.
 2. 2. 2. 0. 0.]"
NCT02074631,"38:52:chronic_disease,78:106:chronic_disease,108:126:chronic_disease,128:144:chronic_disease,149:166:chronic_disease","Other indications for HCT, including Fanconi anemia, other form of inherited bone marrow failure diseases, metabolic disorder, hemoglobinopathy, or immune deficiency","['Other' 'indications' 'for' 'HCT' ',' 'including' 'Fanconi' 'anemia' ','
 'other' 'form' 'of' 'inherited' 'bone' 'marrow' 'failure' 'diseases' ','
 'metabolic' 'disorder' ',' 'hemoglobinopathy' ',' 'or' 'immune'
 'deficiency']","[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 2. 2. 0. 2. 0. 0.
 2. 2.]"
NCT02074436,"1:23:chronic_disease,41:67:cancer,107:150:treatment,178:192:chronic_disease,",Acute thrombocytopenia in patients with hematological malignancies who are in remission and are receiving myelosuppressive consolidation chemotherapy that is expected to induce marrow aplasia for at least 2 weeks,"['Acute' 'thrombocytopenia' 'in' 'patients' 'with' 'hematological'
 'malignancies' 'who' 'are' 'in' 'remission' 'and' 'are' 'receiving'
 'myelosuppressive' 'consolidation' 'chemotherapy' 'that' 'is' 'expected'
 'to' 'induce' 'marrow' 'aplasia' 'for' 'at' 'least' '2' 'weeks']","[2. 2. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 2. 2.
 0. 0. 0. 0. 0.]"
NCT02074436,"49:54:treatment,56:78:treatment,82:113:treatment,","Subjects receiving procoagulant agent including DDAVP, recombinant factor VII or prothrombin complex concentrate within 24 hours of enrollment","['Subjects' 'receiving' 'procoagulant' 'agent' 'including' 'DDAVP' ','
 'recombinant' 'factor' 'VII' 'or' 'prothrombin' 'complex' 'concentrate'
 'within' '24' 'hours' 'of' 'enrollment']",[0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0.]
NCT02073097,"7:19:cancer,,74:97:cancer,101:106:cancer,110:146:cancer,160:175:cancer,182:198:treatment","Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin, or low-risk prostate cancer after curative therapy","['Other' 'malignancies' 'within' 'the' 'past' '3' 'years' 'except' 'for'
 'adequately' 'treated' 'carcinoma' 'of' 'the' 'cervix' 'or' 'basal' 'or'
 'squamous' 'cell' 'carcinomas' 'of' 'the' 'skin' ',' 'or' 'low-risk'
 'prostate' 'cancer' 'after' 'curative' 'therapy']","[0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 3. 0. 3. 3. 3. 3. 3. 3.
 0. 0. 0. 3. 3. 0. 1. 1.]"
NCT02072356,"14:37:cancer,67:70:cancer,235:241:cancer,254:259:cancer,276:299:treatment","Diagnosis of intrahepatic malignancy including but not limited to HCC; the histopathology confirmation criterion may be waived in patients with a radiographically identifiable liver mass, known laboratory or clinical risk factors for cancer or elevated tumor markers such as alpha-fetoprotein (AFP) and clinical findings","['Diagnosis' 'of' 'intrahepatic' 'malignancy' 'including' 'but' 'not'
 'limited' 'to' 'HCC' ';' 'the' 'histopathology' 'confirmation'
 'criterion' 'may' 'be' 'waived' 'in' 'patients' 'with' 'a'
 'radiographically' 'identifiable' 'liver' 'mass' ',' 'known' 'laboratory'
 'or' 'clinical' 'risk' 'factors' 'for' 'cancer' 'or' 'elevated' 'tumor'
 'markers' 'such' 'as' 'alpha-fetoprotein' '(' 'AFP' ')' 'and' 'clinical'
 'findings']","[0. 0. 3. 3. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 3. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]"
NCT02072148,"24:34:chronic_disease,38:59:chronic_disease,70:78:chronic_disease,82:90:chronic_disease",History of significant neurologic or psychiatric disorders including dementia or seizures,"['History' 'of' 'significant' 'neurologic' 'or' 'psychiatric' 'disorders'
 'including' 'dementia' 'or' 'seizures']",[0. 0. 0. 2. 0. 2. 2. 0. 2. 0. 2.]
NCT02072148,"10:25:chronic_disease,34:43:treatment,45:66:chronic_disease","Unstable cardiac disease despite treatment, myocardial infarction with months prior to study entry","['Unstable' 'cardiac' 'disease' 'despite' 'treatment' ',' 'myocardial'
 'infarction' 'with' 'months' 'prior' 'to' 'study' 'entry']",[0. 2. 2. 0. 1. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02070549,"1:42:treatment,12:21:treatment,27:42:treatment,121:134:treatment,192:204:chronic_disease,251:263:chronic_disease","Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis","['Concurrent' 'treatment' 'with' 'bisphosphonates' 'is' 'permitted' ';'
 'however' ',' 'treatment' 'must' 'be' 'initiated' 'prior' 'to' 'the'
 'first' 'dose' 'of' 'study' 'therapy' ';' 'prophylactic' 'use' 'of'
 'bisphosphonates' 'in' 'patients' 'without' 'bone' 'disease' 'is' 'not'
 'permitted' ',' 'except' 'for' 'the' 'treatment' 'of' 'osteoporosis']","[1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.]"
NCT02070549,"64:80:cancer,89:99:cancer,126:168:treatment",Patients must have a histologically or cytologically confirmed solid malignancy that is metastatic or unresectable for which standard curative or palliative treatments do not exist or are no longer effective,"['Patients' 'must' 'have' 'a' 'histologically' 'or' 'cytologically'
 'confirmed' 'solid' 'malignancy' 'that' 'is' 'metastatic' 'or'
 'unresectable' 'for' 'which' 'standard' 'curative' 'or' 'palliative'
 'treatments' 'do' 'not' 'exist' 'or' 'are' 'no' 'longer' 'effective']","[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 3. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02070549,"14:35:treatment,,,,168:178:treatment,234:260:treatment,268:317:treatment","Use of other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of trametinib and during the study; patients previously treated with v-raf murine sarcoma (RAF) and/or mitogen-activated protein kinase (MEK) inhibitors","['Use' 'of' 'other' 'investigational' 'drugs' 'within' '28' 'days' '('
 'or' 'five' 'half-lives' ',' 'whichever' 'is' 'shorter' ';' 'with' 'a'
 'minimum' 'of' '14' 'days' 'from' 'the' 'last' 'dose' ')' 'preceding'
 'the' 'first' 'dose' 'of' 'trametinib' 'and' 'during' 'the' 'study' ';'
 'patients' 'previously' 'treated' 'with' 'v-raf' 'murine' 'sarcoma' '('
 'RAF' ')' 'and/or' 'mitogen-activated' 'protein' 'kinase' '(' 'MEK' ')'
 'inhibitors']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0.
 0. 0. 1. 1. 1. 1. 1. 0. 0.]"
NCT02068092,"14:46:cancer,48:63:treatment,68:87:cancer","Diagnosis of lobular carcinoma in situ (LCIS), atypical ductal, or lobular hyperplasia","['Diagnosis' 'of' 'lobular' 'carcinoma' 'in' 'situ' '(' 'LCIS' ')' ','
 'atypical' 'ductal' ',' 'or' 'lobular' 'hyperplasia']",[0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 1. 1. 0. 0. 0. 0.]
NCT02068092,"1:28:treatment,21:28:treatment,,93:119:treatment",Prior anticoagulant therapy use is allowed provided therapy is discontinued at least 7 days prior to the breast biopsy in order to reduce the risk of bleeding,"['Prior' 'anticoagulant' 'therapy' 'use' 'is' 'allowed' 'provided'
 'therapy' 'is' 'discontinued' 'at' 'least' '7' 'days' 'prior' 'to' 'the'
 'breast' 'biopsy' 'in' 'order' 'to' 'reduce' 'the' 'risk' 'of' 'bleeding']","[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT02067975,"15:37:chronic_disease,39:57:chronic_disease,102:111:treatment","History of an organic brain disorder; mental retardation; or a medical condition, whose pathology or treatment could alter cognition","['History' 'of' 'an' 'organic' 'brain' 'disorder' ';' 'mental'
 'retardation' ';' 'or' 'a' 'medical' 'condition' ',' 'whose' 'pathology'
 'or' 'treatment' 'could' 'alter' 'cognition']",[0. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT02064673,"1:4:cancer,8:10:cancer,14:35:cancer",T3b or T4 or node positive disease,['T3b' 'or' 'T4' 'or' 'node' 'positive' 'disease'],[3. 0. 3. 0. 3. 3. 3.]
NCT02064296,"22:27:treatment,29:33:treatment,38:52:treatment","Contraindications to fcMRI, fMRI, or 1H-MRS methods","['Contraindications' 'to' 'fcMRI' ',' 'fMRI' ',' 'or' '1H-MRS' 'methods']",[0. 0. 1. 0. 1. 0. 0. 1. 1.]
NCT02064296,"1:29:chronic_disease,39:52:chronic_disease,60:70:chronic_disease,76:93:chronic_disease,","Severe psychiatric illnesses (current schizophrenia, major depression with suicidal ideation, substance abuse within two years)","['Severe' 'psychiatric' 'illnesses' '(' 'current' 'schizophrenia' ','
 'major' 'depression' 'with' 'suicidal' 'ideation' ',' 'substance' 'abuse'
 'within' 'two' 'years' ')']",[2. 2. 2. 0. 0. 2. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02064296,"46:57:treatment,61:70:treatment,97:99:chronic_disease",Willing to limit the introduction of any new medications or treatment modalities for control of FM symptoms during the study,"['Willing' 'to' 'limit' 'the' 'introduction' 'of' 'any' 'new'
 'medications' 'or' 'treatment' 'modalities' 'for' 'control' 'of' 'FM'
 'symptoms' 'during' 'the' 'study']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT02064036,"1:25:treatment,27:40:treatment,45:56:treatment,61:75:cancer",Previous radical surgery (prostatectomy) or cryosurgery for prostate cance,"['Previous' 'radical' 'surgery' '(' 'prostatectomy' ')' 'or' 'cryosurgery'
 'for' 'prostate' 'cance']",[1. 1. 1. 0. 1. 0. 0. 1. 0. 3. 3.]
NCT02064036,"8:19:treatment,35:45:treatment,47:52:treatment,",Use of dutasteride or dutasteride/tamsulosin (Jalyn) within 90 days prior to registration,"['Use' 'of' 'dutasteride' 'or' 'dutasteride/tamsulosin' '(' 'Jalyn' ')'
 'within' '90' 'days' 'prior' 'to' 'registration']",[0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02061553,"9:32:chronic_disease,49:66:chronic_disease,68:75:chronic_disease,,,","Current psychiatric instability, including very severe depression/ anxiety as indicated by PHQ-9 or GAD-7 ≥20","['Current' 'psychiatric' 'instability' ',' 'including' 'very' 'severe'
 'depression/' 'anxiety' 'as' 'indicated' 'by' 'PHQ-9' 'or' 'GAD-7' '≥20']",[0. 2. 2. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]
NCT02061293,"1:8:treatment,10:25:treatment,27:33:treatment,38:46:treatment,","Cocaine, psychostimulant, opioid, or cannabis dependence (past 12 months)","['Cocaine' ',' 'psychostimulant' ',' 'opioid' ',' 'or' 'cannabis'
 'dependence' '(' 'past' '12' 'months' ')']",[1. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02061293,"14:24:treatment,69:86:treatment,94:109:treatment,111:125:treatment,127:143:treatment,145:155:treatment,178:190:treatment,194:213:treatment,215:222:treatment,224:239:treatment","Need to take medication with significant potential to interact with study medications (e.g., antidepressants, antipsychotics, psychostimulants, treatments for addictions, other dopaminergic or serotonergic agents, lithium, anticonvulsants)","['Need' 'to' 'take' 'medication' 'with' 'significant' 'potential' 'to'
 'interact' 'with' 'study' 'medications' '(' 'e.g.' ',' 'antidepressants'
 ',' 'antipsychotics' ',' 'psychostimulants' ',' 'treatments' 'for'
 'addictions' ',' 'other' 'dopaminergic' 'or' 'serotonergic' 'agents' ','
 'lithium' ',' 'anticonvulsants' ')']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0.
 0. 0. 1. 0. 1. 1. 0. 1. 0. 1. 0.]"
NCT02058095,"13:28:treatment,33:53:chronic_disease,86:96:treatment",Patients on PDEV inhibition for erectile dysfunction who are not willing to stop the medication for the duration of the study,"['Patients' 'on' 'PDEV' 'inhibition' 'for' 'erectile' 'dysfunction' 'who'
 'are' 'not' 'willing' 'to' 'stop' 'the' 'medication' 'for' 'the'
 'duration' 'of' 'the' 'study']",[0. 0. 1. 1. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02057133,"13:22:treatment,25:34:treatment,56:78:treatment,119:151:treatment,156:174:chronic_disease","For Part A (LY2835219 + letrozole): Except for ongoing therapy with letrozole, the participant must not have received prior systemic endocrine therapy for metastatic disease","['For' 'Part' 'A' '(' 'LY2835219' '+' 'letrozole' ')' ':' 'Except' 'for'
 'ongoing' 'therapy' 'with' 'letrozole' ',' 'the' 'participant' 'must'
 'not' 'have' 'received' 'prior' 'systemic' 'endocrine' 'therapy' 'for'
 'metastatic' 'disease']","[0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 1. 1. 0. 2. 2.]"
NCT02057133,"25:35:treatment,38:48:treatment,86:118:treatment,111:118:treatment,,137:169:treatment,171:182:treatment,184:193:treatment,199:217:cancer","For Part E (LY2835219 + exemestane + everolimus): The participant must have received prior systemic endocrine therapy with at least one nonsteroidal aromatase inhibitor (anastrozole, letrozole) for metastatic disease and may be receiving ongoing therapy with either exemestane or exemestane + everolimus","['For' 'Part' 'E' '(' 'LY2835219' '+' 'exemestane' '+' 'everolimus' ')'
 ':' 'The' 'participant' 'must' 'have' 'received' 'prior' 'systemic'
 'endocrine' 'therapy' 'with' 'at' 'least' 'one' 'nonsteroidal'
 'aromatase' 'inhibitor' '(' 'anastrozole' ',' 'letrozole' ')' 'for'
 'metastatic' 'disease' 'and' 'may' 'be' 'receiving' 'ongoing' 'therapy'
 'with' 'either' 'exemestane' 'or' 'exemestane' '+' 'everolimus']","[0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0.
 1. 1. 1. 0. 1. 0. 1. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02057133,"14:25:treatment,28:39:treatment,42:52:treatment,,101:121:treatment,126:144:cancer",For Part H: (abemaciclib + trastuzumab + pertuzumab): The participant must have received at least 1 chemotherapy regimen for metastatic disease,"['For' 'Part' 'H' ':' '(' 'abemaciclib' '+' 'trastuzumab' '+' 'pertuzumab'
 ')' ':' 'The' 'participant' 'must' 'have' 'received' 'at' 'least' '1'
 'chemotherapy' 'regimen' 'for' 'metastatic' 'disease']","[0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 3.
 3.]"
NCT02057133,"6:45:cancer,58:70:treatment,,144:153:treatment",Have central nervous system (CNS) metastasis with either radiotherapy or development of neurological changes ≤14 days prior to receiving study treatment,"['Have' 'central' 'nervous' 'system' '(' 'CNS' ')' 'metastasis' 'with'
 'either' 'radiotherapy' 'or' 'development' 'of' 'neurological' 'changes'
 '≤14' 'days' 'prior' 'to' 'receiving' 'study' 'treatment']",[0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT02056873,"50:53:treatment,57:79:cancer,120:140:treatment","Any previous neurological intervention including DBS or ablative brain lesions, any metal in the head, and any type of implanted stimulator","['Any' 'previous' 'neurological' 'intervention' 'including' 'DBS' 'or'
 'ablative' 'brain' 'lesions' ',' 'any' 'metal' 'in' 'the' 'head' ','
 'and' 'any' 'type' 'of' 'implanted' 'stimulator']",[0. 0. 0. 0. 0. 1. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02056873,"39:62:chronic_disease,64:77:chronic_disease,79:93:chronic_disease,103:123:chronic_disease,125:146:chronic_disease,192:199:treatment","Severe medical co-morbidity including cardiovascular disorder, lung disorder, kidney disease, chronic neurological disease, hematological disease, or frailty that impacts tolerability of the surgery as judged by the screening physicians","['Severe' 'medical' 'co-morbidity' 'including' 'cardiovascular' 'disorder'
 ',' 'lung' 'disorder' ',' 'kidney' 'disease' ',' 'chronic' 'neurological'
 'disease' ',' 'hematological' 'disease' ',' 'or' 'frailty' 'that'
 'impacts' 'tolerability' 'of' 'the' 'surgery' 'as' 'judged' 'by' 'the'
 'screening' 'physicians']","[0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]"
NCT02056470,"95:113:chronic_disease,115:120:chronic_disease,122:140:chronic_disease","Other significant disabling problems from the muscular-skeletal system than in the knees (i.e muscular dystrophy, polio, nueropathic joints)","['Other' 'significant' 'disabling' 'problems' 'from' 'the'
 'muscular-skeletal' 'system' 'than' 'in' 'the' 'knees' '(' 'i.e'
 'muscular' 'dystrophy' ',' 'polio' ',' 'nueropathic' 'joints' ')']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0.]
NCT02053246,"11:13:chronic_disease,33:46:chronic_disease,57:82:chronic_disease,84:103:chronic_disease,108:119:chronic_disease","Causes of PH other than that of heart failure, such as: chronic thromboembolic PH, sickle-cell disease, or sarcoidosis","['Causes' 'of' 'PH' 'other' 'than' 'that' 'of' 'heart' 'failure' ','
 'such' 'as' ':' 'chronic' 'thromboembolic' 'PH' ',' 'sickle-cell'
 'disease' ',' 'or' 'sarcoidosis']",[0. 0. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 2. 2. 2. 0. 2. 2. 0. 0. 2.]
NCT02050347,"18:33:treatment,,50:60:treatment,80:87:treatment,91:95:chronic_disease",Currently taking corticosteroids (>0.5 mg/kg/day prednisone or equivalent) for therapy of GVHD,"['Currently' 'taking' 'corticosteroids' '(' '>' '0.5' 'mg/kg/day'
 'prednisone' 'or' 'equivalent' ')' 'for' 'therapy' 'of' 'GVHD']",[0. 0. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 2.]
NCT02050113,"1:7:chronic_disease,11:30:chronic_disease,,,101:116:treatment","Aortic or aortoiliac aneurysm with a history of growth ≥1.0 cm per year, or clinical indication for aneurysm repair based on symptoms","['Aortic' 'or' 'aortoiliac' 'aneurysm' 'with' 'a' 'history' 'of' 'growth'
 '≥1.0' 'cm' 'per' 'year' ',' 'or' 'clinical' 'indication' 'for'
 'aneurysm' 'repair' 'based' 'on' 'symptoms']",[2. 0. 2. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02050113,"10:31:chronic_disease,33:56:chronic_disease,61:82:chronic_disease","Previous myocardial infarction, coronary artery disease, or coronary artery stent","['Previous' 'myocardial' 'infarction' ',' 'coronary' 'artery' 'disease'
 ',' 'or' 'coronary' 'artery' 'stent']",[0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT02048852,"10:26:chronic_disease,68:91:chronic_disease,100:120:chronic_disease,122:128:chronic_disease,132:146:chronic_disease,148:164:chronic_disease,325:341:chronic_disease","unstable medical problems which may include but are not limited to immune system disorders, severe respiratory diseases, kidney or liver diseases, thyroid problems, substance abuse or dependence that would limit patients ability to follow experimental protocol (based on history and drug and alcohol questionaires) or other heart conditions","['unstable' 'medical' 'problems' 'which' 'may' 'include' 'but' 'are' 'not'
 'limited' 'to' 'immune' 'system' 'disorders' ',' 'severe' 'respiratory'
 'diseases' ',' 'kidney' 'or' 'liver' 'diseases' ',' 'thyroid' 'problems'
 ',' 'substance' 'abuse' 'or' 'dependence' 'that' 'would' 'limit'
 'patients' 'ability' 'to' 'follow' 'experimental' 'protocol' '(' 'based'
 'on' 'history' 'and' 'drug' 'and' 'alcohol' 'questionaires' ')' 'or'
 'other' 'heart' 'conditions']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 2. 2. 0. 2. 0. 2. 2. 0.
 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 2. 2.]"
NCT02048722,"20:43:cancer,53:73:cancer,78:103:cancer","Exceptions include cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor","['Exceptions' 'include' 'cervical' 'cancer' 'in-situ' ',' 'treated'
 'basal' 'cell' 'carcinoma' ',' 'or' 'superficial' 'bladder' 'tumor']",[0. 0. 3. 3. 3. 0. 0. 3. 3. 3. 0. 0. 3. 3. 3.]
NCT02048722,"1:20:chronic_disease,32:50:treatment,75:85:treatment",Progressive disease under last palliative therapy with a history of prior ifosfamide,"['Progressive' 'disease' 'under' 'last' 'palliative' 'therapy' 'with' 'a'
 'history' 'of' 'prior' 'ifosfamide']",[2. 2. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1.]
NCT02048722,"1:12:treatment,16:30:treatment,35:47:cancer",doxorubicin or taxane therapy for angiosarcoma,['doxorubicin' 'or' 'taxane' 'therapy' 'for' 'angiosarcoma'],[1. 0. 1. 1. 0. 3.]
NCT02048371,",14:44:treatment,53:60:cancer,72:83:treatment,75:83:treatment","At least one prior line of systemic therapy for the sarcoma diagnosis (neoadjuvant, adjuvant or metastatic disease)","['At' 'least' 'one' 'prior' 'line' 'of' 'systemic' 'therapy' 'for' 'the'
 'sarcoma' 'diagnosis' '(' 'neoadjuvant' ',' 'adjuvant' 'or' 'metastatic'
 'disease' ')']",[0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 3. 0. 0. 1. 0. 1. 0. 0. 0. 0.]
NCT02048371,"39:51:treatment,44:51:treatment,,,,138:162:treatment,",Patients who have received wide field radiotherapy ≤ 28 days (defined as > 50% of volume of pelvis bones or equivalent) or limited field radiation for palliation < 14 days prior to study registration or those patients who have not recovered adequately from side effects of such therapy,"['Patients' 'who' 'have' 'received' 'wide' 'field' 'radiotherapy' '≤' '28'
 'days' '(' 'defined' 'as' '>' '50' '%' 'of' 'volume' 'of' 'pelvis'
 'bones' 'or' 'equivalent' ')' 'or' 'limited' 'field' 'radiation' 'for'
 'palliation' '<' '14' 'days' 'prior' 'to' 'study' 'registration' 'or'
 'those' 'patients' 'who' 'have' 'not' 'recovered' 'adequately' 'from'
 'side' 'effects' 'of' 'such' 'therapy']","[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1.]"
NCT02048371,"72:96:chronic_disease,108:134:chronic_disease,136:156:chronic_disease,160:178:chronic_disease,,207:222:treatment","Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatment","['Subjects' 'with' 'thrombotic' ',' 'embolic' ',' 'venous' ',' 'or'
 'arterial' 'events' ',' 'such' 'as' 'cerebrovascular' 'accident' '('
 'including' 'transient' 'ischemic' 'attacks' ')' 'deep' 'vein'
 'thrombosis' 'or' 'pulmonary' 'embolism' 'within' '6' 'months' 'of'
 'start' 'of' 'study' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2.
 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT02047474,"16:21:cancer,264:288:treatment,285:287:treatment,295:314:treatment,319:351:treatment,391:394:treatment","No evidence of tumor extension to superior mesenteric artery, hepatic artery, celiac axis, aorta, or inferior vena cava, and no evidence of occlusion or encasement of the superior mesenteric vein or superior mesenteric vein/portal vein confluence, as assessed by computed tomography (CT) using pancreatic protocol (or magnetic resonance imaging [MRI] in patients who cannot undergo CT) and EUS","['No' 'evidence' 'of' 'tumor' 'extension' 'to' 'superior' 'mesenteric'
 'artery' ',' 'hepatic' 'artery' ',' 'celiac' 'axis' ',' 'aorta' ',' 'or'
 'inferior' 'vena' 'cava' ',' 'and' 'no' 'evidence' 'of' 'occlusion' 'or'
 'encasement' 'of' 'the' 'superior' 'mesenteric' 'vein' 'or' 'superior'
 'mesenteric' 'vein/portal' 'vein' 'confluence' ',' 'as' 'assessed' 'by'
 'computed' 'tomography' '(' 'CT' ')' 'using' 'pancreatic' 'protocol' '('
 'or' 'magnetic' 'resonance' 'imaging' '[' 'MRI' ']' 'in' 'patients' 'who'
 'can' 'not' 'undergo' 'CT' ')' 'and' 'EUS']","[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.
 1. 0. 0. 1. 1. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02047474,"23:35:treatment,,54:66:cancer,78:95:cancer",Patients who received chemotherapy > 5 years ago for malignancies other than pancreatic cancer are eligible,"['Patients' 'who' 'received' 'chemotherapy' '>' '5' 'years' 'ago' 'for'
 'malignancies' 'other' 'than' 'pancreatic' 'cancer' 'are' 'eligible']",[0. 0. 0. 1. 0. 0. 0. 0. 0. 3. 0. 0. 3. 3. 0. 0.]
NCT02046330,",128:142:treatment,,201:208:treatment,210:212:treatment,214:224:treatment,226:238:treatment,240:255:treatment,257:266:treatment,273:302:treatment","adequate trials ( equal>4 weeks at the usually recommended or maximum tolerated dose) of augmentation/combination of a primary antidepressant using at least 2 different augmenting/combination agents (lithium, T3, stimulants, neuroleptics, anticonvulsants, buspirone, or a second primary antidepressant)","['adequate' 'trials' '(' 'equal' '>' '4' 'weeks' 'at' 'the' 'usually'
 'recommended' 'or' 'maximum' 'tolerated' 'dose' ')' 'of'
 'augmentation/combination' 'of' 'a' 'primary' 'antidepressant' 'using'
 'at' 'least' '2' 'different' 'augmenting/combination' 'agents' '('
 'lithium' ',' 'T3' ',' 'stimulants' ',' 'neuroleptics' ','
 'anticonvulsants' ',' 'buspirone' ',' 'or' 'a' 'second' 'primary'
 'antidepressant' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 1. 1. 1. 0.]"
NCT02044120,"44:75:treatment,,126:137:treatment,139:155:treatment,157:167:treatment,169:178:treatment","Patients must have received as a minimum a first line chemotherapy regimen consisting of at least 2 of the following agents: doxorubicin, cyclophosphamide, ifosfamide, etoposide","['Patients' 'must' 'have' 'received' 'as' 'a' 'minimum' 'a' 'first' 'line'
 'chemotherapy' 'regimen' 'consisting' 'of' 'at' 'least' '2' 'of' 'the'
 'following' 'agents' ':' 'doxorubicin' ',' 'cyclophosphamide' ','
 'ifosfamide' ',' 'etoposide']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 1. 0. 1. 0. 1.]"
NCT02043548,",21:32:treatment,34:38:treatment,42:58:treatment","3 month washout for leflunomide, IVIg or cyclophosphamide","['3' 'month' 'washout' 'for' 'leflunomide' ',' 'IVIg' 'or'
 'cyclophosphamide']",[0. 0. 0. 0. 1. 0. 1. 0. 1.]
NCT02043548,"20:37:cancer,39:51:cancer,,101:127:cancer,132:144:cancer,153:158:cancer,163:186:cancer,202:233:cancer,","Evidence of active malignant disease, malignancies diagnosed within the previous 5 years (including hematological malignancies and solid tumors, except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured), or breast cancer diagnosed within the previous 10 years unless related to primary disease under investigation","['Evidence' 'of' 'active' 'malignant' 'disease' ',' 'malignancies'
 'diagnosed' 'within' 'the' 'previous' '5' 'years' '(' 'including'
 'hematological' 'malignancies' 'and' 'solid' 'tumors' ',' 'except'
 'basal' 'and' 'squamous' 'cell' 'carcinoma' 'of' 'the' 'skin' 'or'
 'carcinoma' 'in' 'situ' 'of' 'the' 'cervix' 'uteri' 'that' 'has' 'been'
 'excised' 'and' 'cured' ')' ',' 'or' 'breast' 'cancer' 'diagnosed'
 'within' 'the' 'previous' '10' 'years' 'unless' 'related' 'to' 'primary'
 'disease' 'under' 'investigation']","[0. 0. 0. 3. 3. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 3. 3. 0. 0. 3. 0.
 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02043548,"1:14:treatment,26:39:treatment,,86:99:treatment,",Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization,"['Major' 'surgery' '(' 'including' 'joint' 'surgery' ')' 'within' '8'
 'weeks' 'prior' 'to' 'screening' 'or' 'planned' 'major' 'surgery'
 'within' '6' 'months' 'following' 'randomization']",[1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT02043548,"51:53:chronic_disease,55:65:chronic_disease,67:79:chronic_disease,83:98:chronic_disease,120:154:treatment,161:176:treatment,178:186:treatment,188:197:treatment,199:210:treatment,204:206:chronic_disease,212:223:treatment","Subjects must either have the classic rash(es) of DM (heliotrope, Gottron sign or Gottron papules), possess one of the myositis-associated autoantibodies (e.g. anti-synthetase, anti-SRP, anti-Mi-2, anti-PM-Scl, anti TIF1-γ etc.), or have the diagnosis of PM agreed upon by a 3-member Adjudication Committee consisting of a rheumatologist, neurologist and neuromuscular pathologist","['Subjects' 'must' 'either' 'have' 'the' 'classic' 'rash' '(' 'es' ')'
 'of' 'DM' '(' 'heliotrope' ',' 'Gottron' 'sign' 'or' 'Gottron' 'papules'
 ')' ',' 'possess' 'one' 'of' 'the' 'myositis-associated' 'autoantibodies'
 '(' 'e.g' '.' 'anti-synthetase' ',' 'anti-SRP' ',' 'anti-Mi-2' ','
 'anti-PM-Scl' ',' 'anti' 'TIF1-γ' 'etc' '.' ')' ',' 'or' 'have' 'the'
 'diagnosis' 'of' 'PM' 'agreed' 'upon' 'by' 'a' '3-member' 'Adjudication'
 'Committee' 'consisting' 'of' 'a' 'rheumatologist' ',' 'neurologist'
 'and' 'neuromuscular' 'pathologist']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 0. 0. 0. 1. 1. 1. 0. 1. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02041936,"19:31:treatment,36:52:treatment,,89:98:treatment,108:124:treatment",Inability to stop antiplatelet and coumadin therapy for 7 days prior to and 7 days post treatment with the NanoKnife System,"['Inability' 'to' 'stop' 'antiplatelet' 'and' 'coumadin' 'therapy' 'for'
 '7' 'days' 'prior' 'to' 'and' '7' 'days' 'post' 'treatment' 'with' 'the'
 'NanoKnife' 'System']",[0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1.]
NCT02040610,"7:23:treatment,25:37:treatment,43:58:cancer",Prior systemic therapy (chemotherapy) for prostate cancer,"['Prior' 'systemic' 'therapy' '(' 'chemotherapy' ')' 'for' 'prostate'
 'cancer']",[0. 1. 1. 0. 1. 0. 0. 3. 3.]
NCT02037048,"46:60:cancer,62:85:cancer,87:107:cancer,109:128:cancer,130:138:cancer,140:147:cancer","Patients with any other diagnosis except for adenocarcinoma (squamous cell carcinoma, small cell carcinoma, mixed adenosquamous, lymphoma, sarcoma, etc.) will be ineligible","['Patients' 'with' 'any' 'other' 'diagnosis' 'except' 'for'
 'adenocarcinoma' '(' 'squamous' 'cell' 'carcinoma' ',' 'small' 'cell'
 'carcinoma' ',' 'mixed' 'adenosquamous' ',' 'lymphoma' ',' 'sarcoma' ','
 'etc' '.' ')' 'will' 'be' 'ineligible']","[0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 3. 0. 3. 3. 3. 0. 3. 3. 0. 3. 0. 3. 0.
 0. 0. 0. 0. 0. 0.]"
NCT02036268,"22:29:treatment,104:113:treatment,117:126:treatment,133:160:cancer",Scheduled to undergo surgery at IU Health North Hospital that will results in a temporary or permanent colostomy or ileostomy for a benign or malignant disease process,"['Scheduled' 'to' 'undergo' 'surgery' 'at' 'IU' 'Health' 'North'
 'Hospital' 'that' 'will' 'results' 'in' 'a' 'temporary' 'or' 'permanent'
 'colostomy' 'or' 'ileostomy' 'for' 'a' 'benign' 'or' 'malignant'
 'disease' 'process']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 3. 3.
 3. 3. 0.]"
NCT02033941,"1:21:chronic_disease,32:51:chronic_disease,53:69:chronic_disease,74:98:chronic_disease,","Major mental illness including psychotic disorders, bipolar disorder, or major depressive episode that is not in remission for less than 12 months","['Major' 'mental' 'illness' 'including' 'psychotic' 'disorders' ','
 'bipolar' 'disorder' ',' 'or' 'major' 'depressive' 'episode' 'that' 'is'
 'not' 'in' 'remission' 'for' 'less' 'than' '12' 'months']",[2. 2. 2. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT02033616,"53:126:cancer,128:142:cancer,155:172:cancer,189:207:treatment,250:271:treatment,291:307:treatment,315:330:treatment","Patients must previously have been staged as having stage III [intraperitoneal (IP)] or Stage IV (distant metastatic) ovarian, fallopian tube, or primary peritoneal cancer, have undergone surgical debulking, and have initiated or completed standard adjuvant chemotherapy, which may include intravenous (IV) and/or IP chemotherapy using standard regimens","['Patients' 'must' 'previously' 'have' 'been' 'staged' 'as' 'having'
 'stage' 'III' '[' 'intraperitoneal' '(' 'IP' ')' ']' 'or' 'Stage' 'IV'
 '(' 'distant' 'metastatic' ')' 'ovarian' ',' 'fallopian' 'tube' ',' 'or'
 'primary' 'peritoneal' 'cancer' ',' 'have' 'undergone' 'surgical'
 'debulking' ',' 'and' 'have' 'initiated' 'or' 'completed' 'standard'
 'adjuvant' 'chemotherapy' ',' 'which' 'may' 'include' 'intravenous' '('
 'IV' ')' 'and/or' 'IP' 'chemotherapy' 'using' 'standard' 'regimens']","[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 1. 1. 3. 3. 3. 0. 0. 0. 0. 0. 0.
 0. 3. 3. 0. 0. 0. 3. 3. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02031250,"30:40:cancer,48:50:cancer,52:73:cancer,83:111:chronic_disease",Locally/regionally advanced (stage T3‐4 and/or N3) nasopharyngeal cancer which is EBV (‐) (Epstein‐Barr Virus),"['Locally/regionally' 'advanced' '(' 'stage' 'T3‐4' 'and/or' 'N3' ')'
 'nasopharyngeal' 'cancer' 'which' 'is' 'EBV' '(' '‐' ')' '('
 'Epstein‐Barr' 'Virus' ')']",[0. 0. 0. 3. 3. 0. 3. 0. 3. 3. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0.]
NCT02027948,"37:49:treatment,71:88:treatment,,,,124:134:cancer,138:170:cancer",Patients who will receive induction chemotherapy followed by combined chemoradiotherapy at MSKCC for localized stage I-III esophageal or gastroesophageal junction cancer,"['Patients' 'who' 'will' 'receive' 'induction' 'chemotherapy' 'followed'
 'by' 'combined' 'chemoradiotherapy' 'at' 'MSKCC' 'for' 'localized'
 'stage' 'I-III' 'esophageal' 'or' 'gastroesophageal' 'junction' 'cancer']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 3.]
NCT02025023,"1:9:chronic_disease,,58:67:treatment,71:79:treatment,84:93:treatment",Chalazia present for less than one month and no previous injection or incision and curettage,"['Chalazia' 'present' 'for' 'less' 'than' 'one' 'month' 'and' 'no'
 'previous' 'injection' 'or' 'incision' 'and' 'curettage']",[2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1.]
NCT02021279,"24:49:chronic_disease,57:68:chronic_disease,70:103:chronic_disease,105:121:chronic_disease,123:137:chronic_disease,139:151:chronic_disease,153:165:chronic_disease,169:191:chronic_disease","Subject has a systemic connective tissue disease (e.g., scleroderma, systemic lupus erythematous (SLE), Marfans syndrome, Ehlers Danhlos, collagenosis, polymyositis or polymyalgia rheumatica)","['Subject' 'has' 'a' 'systemic' 'connective' 'tissue' 'disease' '(' 'e.g.'
 ',' 'scleroderma' ',' 'systemic' 'lupus' 'erythematous' '(' 'SLE' ')' ','
 'Marfans' 'syndrome' ',' 'Ehlers' 'Danhlos' ',' 'collagenosis' ','
 'polymyositis' 'or' 'polymyalgia' 'rheumatica' ')']","[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2.
 0. 2. 0. 2. 0. 2. 2. 0.]"
NCT02021279,"19:36:treatment,62:79:treatment,83:109:treatment,","Subject has taken systemic steroids (within the last month), immunosuppressive or immunomodulatory treatment (within the last 3 months)","['Subject' 'has' 'taken' 'systemic' 'steroids' '(' 'within' 'the' 'last'
 'month' ')' ',' 'immunosuppressive' 'or' 'immunomodulatory' 'treatment'
 '(' 'within' 'the' 'last' '3' 'months' ')']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02020707,"5:23:cancer,49:68:chronic_disease,,111:121:treatment,125:139:treatment",For gynecologic cancer cohort only recurrent or progressive disease within 30 days of the last dose of weekly paclitaxel or nab-paclitaxel,"['For' 'gynecologic' 'cancer' 'cohort' 'only' 'recurrent' 'or'
 'progressive' 'disease' 'within' '30' 'days' 'of' 'the' 'last' 'dose'
 'of' 'weekly' 'paclitaxel' 'or' 'nab-paclitaxel']",[0. 3. 3. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.]
NCT02020707,"12:25:chronic_disease,34:43:chronic_disease,45:69:chronic_disease,71:99:chronic_disease,103:119:chronic_disease","History of liver disease such as cirrhosis, chronic active hepatitis, chronic persistent hepatitis or hepatitis B or C","['History' 'of' 'liver' 'disease' 'such' 'as' 'cirrhosis' ',' 'chronic'
 'active' 'hepatitis' ',' 'chronic' 'persistent' 'hepatitis' 'or'
 'hepatitis' 'B' 'or' 'C']",[0. 0. 2. 2. 0. 0. 2. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT02020707,"27:45:cancer,54:66:cancer,68:74:cancer,76:86:cancer,88:96:cancer,98:106:cancer,108:125:cancer,127:143:cancer,145:150:cancer,156:170:cancer,215:231:cancer","allowable histologies for endometrial cancer include endometrioid, serous, clear cell, mucinous, squamous, transitional cell, undifferentiated, mixed, and carcinosarcoma (this is considered a poorly differentiated epithelial tumor)","['allowable' 'histologies' 'for' 'endometrial' 'cancer' 'include'
 'endometrioid' ',' 'serous' ',' 'clear' 'cell' ',' 'mucinous' ','
 'squamous' ',' 'transitional' 'cell' ',' 'undifferentiated' ',' 'mixed'
 ',' 'and' 'carcinosarcoma' '(' 'this' 'is' 'considered' 'a' 'poorly'
 'differentiated' 'epithelial' 'tumor' ')']","[0. 0. 0. 3. 3. 0. 3. 0. 3. 0. 3. 3. 0. 3. 0. 3. 0. 3. 3. 0. 3. 0. 3. 0.
 0. 3. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0.]"
NCT02020564,"24:43:chronic_disease,58:74:chronic_disease,76:89:chronic_disease,94:103:chronic_disease,131:156:chronic_disease,158:171:chronic_disease,173:181:chronic_disease,183:199:chronic_disease","history of significant pyschiatric illness (for example, bipolar disorder, schizophrenia, or pyschosis) or a current diagnosis of Major Depressive Disorder, Schizophrenia, Epilepsy, Bipolar Disorder","['history' 'of' 'significant' 'pyschiatric' 'illness' '(' 'for' 'example'
 ',' 'bipolar' 'disorder' ',' 'schizophrenia' ',' 'or' 'pyschosis' ')'
 'or' 'a' 'current' 'diagnosis' 'of' 'Major' 'Depressive' 'Disorder' ','
 'Schizophrenia' ',' 'Epilepsy' ',' 'Bipolar' 'Disorder']","[0. 0. 0. 2. 2. 0. 0. 0. 0. 2. 2. 0. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 2. 2.
 2. 0. 2. 0. 2. 0. 2. 2.]"
NCT02019641,"124:133:chronic_disease,135:149:chronic_disease,151:163:chronic_disease,165:180:chronic_disease","Other medical conditions that would impair aerobic capacity or the ability to engage in physical activity, including other pulmonary, cardiovascular, neurological, musculoskeletal or metabolic conditions","['Other' 'medical' 'conditions' 'that' 'would' 'impair' 'aerobic'
 'capacity' 'or' 'the' 'ability' 'to' 'engage' 'in' 'physical' 'activity'
 ',' 'including' 'other' 'pulmonary' ',' 'cardiovascular' ','
 'neurological' ',' 'musculoskeletal' 'or' 'metabolic' 'conditions']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2.
 0. 2. 0. 0. 0.]"
NCT02016781,"1:7:cancer,21:37:treatment,46:58:treatment,59:76:treatment,",Cancer treated with curative surgery without chemotherapy/radiation therapy > 5 years previously will be allowed,"['Cancer' 'treated' 'with' 'curative' 'surgery' 'without'
 'chemotherapy/radiation' 'therapy' '>' '5' 'years' 'previously' 'will'
 'be' 'allowed']",[3. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02016430,"18:38:treatment,42:51:treatment,60:75:treatment,79:85:treatment",Having undergone bariatric procedures or surgeries such as gastric banding or bypass,"['Having' 'undergone' 'bariatric' 'procedures' 'or' 'surgeries' 'such'
 'as' 'gastric' 'banding' 'or' 'bypass']",[0. 0. 1. 1. 0. 1. 0. 0. 1. 1. 0. 1.]
NCT02016235,"54:88:chronic_disease,110:129:chronic_disease,,,164:180:chronic_disease,199:217:treatment,219:234:treatment,239:248:treatment,","Exclusion criteria include history of symptomatic or asymptomatic kidney stone disease; primary or secondary hyperparathyroidism; estimated GFR <40 ml/min/1.73m2, chronic diarrhea states; intake of thiazide diuretics, glucocorticoids, or estrogens within one month of the study","['Exclusion' 'criteria' 'include' 'history' 'of' 'symptomatic' 'or'
 'asymptomatic' 'kidney' 'stone' 'disease' ';' 'primary' 'or' 'secondary'
 'hyperparathyroidism' ';' 'estimated' 'GFR' '<' '40' 'ml/min/1.73m2' ','
 'chronic' 'diarrhea' 'states' ';' 'intake' 'of' 'thiazide' 'diuretics'
 ',' 'glucocorticoids' ',' 'or' 'estrogens' 'within' 'one' 'month' 'of'
 'the' 'study']","[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0.]"
NCT02013492,",36:61:cancer,,,179:207:treatment,211:243:treatment,262:271:chronic_disease,275:299:chronic_disease","At least one solid liver lesion or vascular tumor thrombosis (involving portal vein, IVC and/or hepatic vein) > 1 cm with arterial enhancement and delayed washout on multiphasic computerized tomography (CT) or magnetic resonance imaging (MRI) in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis","['At' 'least' 'one' 'solid' 'liver' 'lesion' 'or' 'vascular' 'tumor'
 'thrombosis' '(' 'involving' 'portal' 'vein' ',' 'IVC' 'and/or' 'hepatic'
 'vein' ')' '>' '1' 'cm' 'with' 'arterial' 'enhancement' 'and' 'delayed'
 'washout' 'on' 'multiphasic' 'computerized' 'tomography' '(' 'CT' ')'
 'or' 'magnetic' 'resonance' 'imaging' '(' 'MRI' ')' 'in' 'the' 'setting'
 'of' 'cirrhosis' 'or' 'chronic' 'hepatitis' 'B' 'or' 'C' 'without'
 'cirrhosis']","[0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 2.
 0. 2. 2. 2. 2. 2. 0. 0.]"
NCT02013336,"43:56:cancer,58:74:cancer,76:89:cancer,94:106:cancer","Histologically or cytologically-confirmed Ewing sarcoma, rhabdomyosarcoma, neuroblastoma, or osteosarcoma","['Histologically' 'or' 'cytologically-confirmed' 'Ewing' 'sarcoma' ','
 'rhabdomyosarcoma' ',' 'neuroblastoma' ',' 'or' 'osteosarcoma']",[0. 0. 0. 3. 3. 0. 3. 0. 3. 0. 0. 3.]
NCT02013154,"31:49:chronic_disease,82:90:chronic_disease,92:109:chronic_disease,114:123:chronic_disease,138:156:treatment","History of known or suspected autoimmune disease with the specific exceptions of vitiligo, atopic dermatitis, or psoriasis not requiring systemic treatment","['History' 'of' 'known' 'or' 'suspected' 'autoimmune' 'disease' 'with'
 'the' 'specific' 'exceptions' 'of' 'vitiligo' ',' 'atopic' 'dermatitis'
 ',' 'or' 'psoriasis' 'not' 'requiring' 'systemic' 'treatment']",[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 0. 2. 0. 0. 1. 1.]
NCT02013154,"1:48:treatment,50:100:treatment,217:230:treatment,327:333:treatment","Prior treatment anti- programmed death-1 (PD-1)/ anti-PD-ligand 1 (PD-L1) monoclonal antibody (mAb) is permitted in patients provided the patient's disease is primary refractory, and the patient is not intolerant of pembrolizumab. Patients who are not eligible to receive pembrolizumab will be allowed to receive single agent DKN-01","['Prior' 'treatment' 'anti-' 'programmed' 'death-1' '(' 'PD-1' ')' '/'
 'anti-PD-ligand' '1' '(' 'PD-L1' ')' 'monoclonal' 'antibody' '(' 'mAb'
 ')' 'is' 'permitted' 'in' 'patients' 'provided' 'the' 'patient' ""'s""
 'disease' 'is' 'primary' 'refractory' ',' 'and' 'the' 'patient' 'is'
 'not' 'intolerant' 'of' 'pembrolizumab' '.' 'Patients' 'who' 'are' 'not'
 'eligible' 'to' 'receive' 'pembrolizumab' 'will' 'be' 'allowed' 'to'
 'receive' 'single' 'agent' 'DKN-01']","[1. 1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1.]"
NCT02013154,"1:10:treatment,16:37:treatment,54:63:treatment,",Treatment with low dose chemotherapy concurrent with radiation within 14 days prior to study entry,"['Treatment' 'with' 'low' 'dose' 'chemotherapy' 'concurrent' 'with'
 'radiation' 'within' '14' 'days' 'prior' 'to' 'study' 'entry']",[1. 0. 1. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT02012296,"1:42:treatment,58:82:treatment,84:95:treatment,97:119:treatment,123:147:treatment,149:160:treatment,162:184:treatment","Concurrent therapy with strong inhibitors or inducers of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) or cytochrome P450 family 2, subfamily C, polypeptide 8 (CYP2C8) due to concerning possible drug-drug interactions","['Concurrent' 'therapy' 'with' 'strong' 'inhibitors' 'or' 'inducers' 'of'
 'cytochrome' 'P450' 'family' '3' ',' 'subfamily' 'A' ',' 'polypeptide'
 '4' '(' 'CYP3A4' ')' 'or' 'cytochrome' 'P450' 'family' '2' ','
 'subfamily' 'C' ',' 'polypeptide' '8' '(' 'CYP2C8' ')' 'due' 'to'
 'concerning' 'possible' 'drug-drug' 'interactions']","[1. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02011971,"1:22:chronic_disease,30:38:chronic_disease,40:48:chronic_disease,50:63:chronic_disease,65:78:cancer,80:90:chronic_disease","Major medical disease (e.g., epilepsy, diabetes, heart disease, active cancer, depression)","['Major' 'medical' 'disease' '(' 'e.g.' ',' 'epilepsy' ',' 'diabetes' ','
 'heart' 'disease' ',' 'active' 'cancer' ',' 'depression' ')']",[2. 2. 2. 0. 0. 0. 2. 0. 2. 0. 2. 2. 0. 3. 3. 0. 2. 0.]
NCT02008656,"10:32:treatment,44:56:treatment,58:67:treatment,69:87:treatment,78:87:treatment,89:105:treatment,107:120:treatment,122:134:treatment,136:151:treatment,153:176:treatment,178:211:treatment,213:224:treatment,226:261:treatment,271:289:treatment","No other experimental therapies (including chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, matrix metalloprotease inhibitors, thalidomide, anti-VEGF/Flk-1 monoclonal antibody or other experimental drugs) of any kind are permitted while the patient is receiving study treatment","['No' 'other' 'experimental' 'therapies' '(' 'including' 'chemotherapy'
 ',' 'radiation' ',' 'hormonal' 'treatment' ',' 'antibody' 'therapy' ','
 'immunotherapy' ',' 'gene' 'therapy' ',' 'vaccine' 'therapy' ','
 'angiogenesis' 'inhibitors' ',' 'matrix' 'metalloprotease' 'inhibitors'
 ',' 'thalidomide' ',' 'anti-VEGF/Flk-1' 'monoclonal' 'antibody' 'or'
 'other' 'experimental' 'drugs' ')' 'of' 'any' 'kind' 'are' 'permitted'
 'while' 'the' 'patient' 'is' 'receiving' 'study' 'treatment']","[0. 0. 1. 1. 0. 0. 1. 0. 1. 0. 1. 1. 0. 1. 1. 0. 1. 0. 1. 1. 0. 1. 1. 0.
 1. 1. 0. 1. 1. 1. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT02008656,"18:32:treatment,37:56:chronic_disease,131:152:treatment","patients who are anticoagulated for atrial fibrillation or other conditions may participate, provided they are on stable doses of anticoagulant therapy","['patients' 'who' 'are' 'anticoagulated' 'for' 'atrial' 'fibrillation'
 'or' 'other' 'conditions' 'may' 'participate' ',' 'provided' 'they' 'are'
 'on' 'stable' 'doses' 'of' 'anticoagulant' 'therapy']",[0. 0. 0. 1. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02007239,"1:20:treatment,,54:62:treatment,,77:87:treatment,116:127:treatment,129:143:treatment,145:154:treatment,159:170:treatment","Vasoactive infusion for at least 12 hours, including dopamine ≥5mcg/kg/min, dobutamine≥5mcg/kg/min, or any dose of epinephrine, norepinephrine, milrinone, or vasopressin","['Vasoactive' 'infusion' 'for' 'at' 'least' '12' 'hours' ',' 'including'
 'dopamine' '≥5mcg/kg/min' ',' 'dobutamine≥5mcg/kg/min' ',' 'or' 'any'
 'dose' 'of' 'epinephrine' ',' 'norepinephrine' ',' 'milrinone' ',' 'or'
 'vasopressin']","[1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0.
 0. 1.]"
NCT02004275,"24:59:treatment,47:59:treatment,61:71:treatment,76:89:treatment,175:201:treatment,,320:328:treatment","A patient who receives induction therapy with lenalidomide, bortezomib and dexamethasone and achieves a PR or better but subsequently progresses on continued lenalidomide or lenalidomide-dexamethasone would be eligible provided the progression occurs 60 days or more after discontinuation of the bortezomib; similarly, ixazomib exposure is allowed provided they meet the definition of proteasome inhibitor sensitive disease","['A' 'patient' 'who' 'receives' 'induction' 'therapy' 'with'
 'lenalidomide' ',' 'bortezomib' 'and' 'dexamethasone' 'and' 'achieves'
 'a' 'PR' 'or' 'better' 'but' 'subsequently' 'progresses' 'on' 'continued'
 'lenalidomide' 'or' 'lenalidomide-dexamethasone' 'would' 'be' 'eligible'
 'provided' 'the' 'progression' 'occurs' '60' 'days' 'or' 'more' 'after'
 'discontinuation' 'of' 'the' 'bortezomib' ';' 'similarly' ',' 'ixazomib'
 'exposure' 'is' 'allowed' 'provided' 'they' 'meet' 'the' 'definition'
 'of' 'proteasome' 'inhibitor' 'sensitive' 'disease']","[0. 0. 0. 0. 1. 1. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02004275,"1:13:treatment,14:32:cancer,,122:150:treatment",Lenalidomide-refractory disease is defined as disease progression on or progression within 60 days of the last dose of a lenalidomide-based treatment,"['Lenalidomide-refractory' 'disease' 'is' 'defined' 'as' 'disease'
 'progression' 'on' 'or' 'progression' 'within' '60' 'days' 'of' 'the'
 'last' 'dose' 'of' 'a' 'lenalidomide-based' 'treatment']",[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT02004275,"18:37:chronic_disease,43:54:treatment,58:80:treatment",Prior history of erythema multiforme with thalidomide or lenalidomide treatment,"['Prior' 'history' 'of' 'erythema' 'multiforme' 'with' 'thalidomide' 'or'
 'lenalidomide' 'treatment']",[0. 0. 0. 2. 2. 0. 1. 0. 1. 1.]
NCT02004275,"21:28:cancer,62:75:treatment,77:79:treatment",relapsed disease is myeloma that has previously responded to prior therapy (MR or better) and subsequently progressed,"['relapsed' 'disease' 'is' 'myeloma' 'that' 'has' 'previously' 'responded'
 'to' 'prior' 'therapy' '(' 'MR' 'or' 'better' ')' 'and' 'subsequently'
 'progressed']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT02004028,"27:39:treatment,43:55:treatment,118:130:cancer",Participants who have had chemotherapy or radiotherapy any time prior to entering the study or at any prior time for mesothelioma. Patients receiving chemotherapy type drugs for benign conditions can participate in this trial,"['Participants' 'who' 'have' 'had' 'chemotherapy' 'or' 'radiotherapy'
 'any' 'time' 'prior' 'to' 'entering' 'the' 'study' 'or' 'at' 'any'
 'prior' 'time' 'for' 'mesothelioma' '.' 'Patients' 'receiving'
 'chemotherapy' 'type' 'drugs' 'for' 'benign' 'conditions' 'can'
 'participate' 'in' 'this' 'trial']","[0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02004028,"24:46:chronic_disease,58:76:chronic_disease,80:95:chronic_disease,,127:136:treatment,,,192:216:chronic_disease,226:237:chronic_disease,248:272:treatment,297:316:chronic_disease,321:340:chronic_disease","Uncontrolled or severe cardiovascular disease, including myocardial infarct or unstable angina within 6 months prior to study treatment, New York Heart Association (NYHA) Class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease, or cardiac amyloidosis","['Uncontrolled' 'or' 'severe' 'cardiovascular' 'disease' ',' 'including'
 'myocardial' 'infarct' 'or' 'unstable' 'angina' 'within' '6' 'months'
 'prior' 'to' 'study' 'treatment' ',' 'New' 'York' 'Heart' 'Association'
 '(' 'NYHA' ')' 'Class' 'II' 'or' 'greater' 'congestive' 'heart' 'failure'
 ',' 'serious' 'arrhythmias' 'requiring' 'medication' 'for' 'treatment'
 ',' 'clinically' 'significant' 'pericardial' 'disease' ',' 'or' 'cardiac'
 'amyloidosis']","[0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 2. 0. 1. 1. 1. 0. 0. 0. 2. 2. 0. 0.
 2. 2.]"
NCT02003222,"15:57:chronic_disease,,,,139:196:treatment,255:263:cancer",No history of acquired immune deficiency syndrome (AIDS)-related complications other than a history of low CD4+ T-cell count (< 200/mm^3) prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low,"['No' 'history' 'of' 'acquired' 'immune' 'deficiency' 'syndrome' '('
 'AIDS' ')' '-related' 'complications' 'other' 'than' 'a' 'history' 'of'
 'low' 'CD4+' 'T-cell' 'count' '(' '<' '200/mm^3' ')' 'prior' 'to'
 'initiation' 'of' 'combination' 'antiretroviral' 'therapy' ';' 'on'
 'study' 'CD4+' 'T-cell' 'count' 'may' 'not' 'be' 'informative' 'due' 'to'
 'leukemia' 'and' 'should' 'not' 'be' 'used' 'as' 'an' 'exclusion'
 'criterion' 'if' 'low']","[0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT02000115,"49:56:allergy_name,58:65:allergy_name,67:87:allergy_name,92:112:allergy_name,132:146:allergy_name","A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine (Ticlid), or clopidogrel (Plavix), or sensitivity to contrast media which cannot be adequately premedicated","['A' 'known' 'hypersensitivity' 'or' 'contraindication' 'to' 'aspirin' ','
 'heparin' ',' 'ticlopidine' '(' 'Ticlid' ')' ',' 'or' 'clopidogrel' '('
 'Plavix' ')' ',' 'or' 'sensitivity' 'to' 'contrast' 'media' 'which' 'can'
 'not' 'be' 'adequately' 'premedicated']","[0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 4. 4. 0. 0. 0. 0. 4. 4. 0. 0. 0. 0. 0. 0.
 4. 4. 0. 0. 0. 0. 0. 0.]"
NCT02000115,"31:48:cancer,50:58:chronic_disease,62:72:chronic_disease","Echocardiographic evidence of intracardiac mass, thrombus or vegetation","['Echocardiographic' 'evidence' 'of' 'intracardiac' 'mass' ',' 'thrombus'
 'or' 'vegetation']",[0. 0. 0. 3. 3. 0. 2. 0. 2.]
NCT02000115,"1:20:chronic_disease,,,53:76:chronic_disease,95:103:treatment",Renal insufficiency (creatinine > 3.0 mg/dL) and/or end stage renal disease requiring chronic dialysis,"['Renal' 'insufficiency' '(' 'creatinine' '>' '3.0' 'mg/dL' ')' 'and/or'
 'end' 'stage' 'renal' 'disease' 'requiring' 'chronic' 'dialysis']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 1.]
NCT01999179,"1:23:cancer,13:23:cancer,35:47:treatment,49:56:treatment,58:67:treatment,71:87:treatment","solid tumor malignancy undergoing chemotherapy, surgery, radiation or hormonal therapy for malignancy","['solid' 'tumor' 'malignancy' 'undergoing' 'chemotherapy' ',' 'surgery'
 ',' 'radiation' 'or' 'hormonal' 'therapy' 'for' 'malignancy']",[3. 3. 3. 0. 1. 0. 1. 0. 1. 0. 1. 1. 0. 0.]
NCT01996865,"17:32:treatment,,62:71:treatment,,132:142:treatment","Subjects taking corticosteroids during the last 1 week prior treatment, unless administered at a dose equivalent to < 20 mg/day of prednisone","['Subjects' 'taking' 'corticosteroids' 'during' 'the' 'last' '1' 'week'
 'prior' 'treatment' ',' 'unless' 'administered' 'at' 'a' 'dose'
 'equivalent' 'to' '<' '20' 'mg/day' 'of' 'prednisone']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01994538,"52:55:chronic_disease,73:89:chronic_disease,91:121:chronic_disease","Symptoms thought more likely to be caused by a non-UTI diagnosis (e.g., urinary calculus, sexually transmitted infection, etc.)","['Symptoms' 'thought' 'more' 'likely' 'to' 'be' 'caused' 'by' 'a'
 'non-UTI' 'diagnosis' '(' 'e.g.' ',' 'urinary' 'calculus' ',' 'sexually'
 'transmitted' 'infection' ',' 'etc' '.' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0.]
NCT01994382,"32:35:chronic_disease,36:46:chronic_disease,48:55:chronic_disease,70:77:chronic_disease",Known carrier or infection for HIV/Hep B or C. HCV ab+ must be PCR-. HBV ab+ must be HBsAg- or undetectable DNA,"['Known' 'carrier' 'or' 'infection' 'for' 'HIV/Hep' 'B' 'or' 'C.' 'HCV'
 'ab+' 'must' 'be' 'PCR-' '.' 'HBV' 'ab+' 'must' 'be' 'HBsAg-' 'or'
 'undetectable' 'DNA']",[0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.]
NCT01994382,",,70:73:cancer,74:77:cancer,81:108:cancer,110:115:cancer,117:119:cancer,121:124:cancer,126:129:cancer,131:157:cancer","Specific Patient at least 18yrs of age with histologically confirmed CLL/SLL or B-cell Non-Hodgkin lymphoma (DLBCL, FL, MCL, MZL, lymphoplasmacytic lymphoma)","['Specific' 'Patient' 'at' 'least' '18yrs' 'of' 'age' 'with'
 'histologically' 'confirmed' 'CLL/SLL' 'or' 'B-cell' 'Non-Hodgkin'
 'lymphoma' '(' 'DLBCL' ',' 'FL' ',' 'MCL' ',' 'MZL' ','
 'lymphoplasmacytic' 'lymphoma' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 3. 0. 3. 0. 3. 0. 3. 0. 3. 0.
 3. 3. 0.]"
NCT01993810,"1:27:treatment,28:62:treatment,63:92:treatment,",Fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/computed tomography (CT) scan for staging within 60 days prior to registration,"['Fludeoxyglucose' 'F' '18' '(' 'FDG' ')' '-positron' 'emission'
 'tomography' '(' 'PET' ')' '/computed' 'tomography' '(' 'CT' ')' 'scan'
 'for' 'staging' 'within' '60' 'days' 'prior' 'to' 'registration']","[1. 1. 1. 1. 0. 0. 1. 1. 1. 1. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01993810,"1:28:treatment,43:49:cancer,,76:98:treatment,,124:140:treatment","Prior systemic chemotherapy for the study cancer, if more than 4 cycles of induction chemotherapy or more than 6 months of targeted therapy","['Prior' 'systemic' 'chemotherapy' 'for' 'the' 'study' 'cancer' ',' 'if'
 'more' 'than' '4' 'cycles' 'of' 'induction' 'chemotherapy' 'or' 'more'
 'than' '6' 'months' 'of' 'targeted' 'therapy']",[1. 1. 1. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01993719,"18:21:chronic_disease,50:59:treatment,146:162:chronic_disease",Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus are less responsive to the experimental treatment and more susceptible to its toxicities.),"['Seronegative' 'for' 'HIV' 'antibody' '.' '(' 'The' 'experimental'
 'treatment' 'being' 'evaluated' 'in' 'this' 'protocol' 'depends' 'on'
 'an' 'intact' 'immune' 'system' '.' 'Patients' 'who' 'are' 'HIV'
 'seropositive' 'can' 'have' 'decreased' 'immune-competence' 'and' 'thus'
 'are' 'less' 'responsive' 'to' 'the' 'experimental' 'treatment' 'and'
 'more' 'susceptible' 'to' 'its' 'toxicities' '.' ')']","[0. 0. 2. 2. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01992861,"36:53:treatment,70:98:treatment,103:118:cancer",Patients who will undergo standard radiation therapy with concurrent cisplatin-based chemotherapy for cervical cancer,"['Patients' 'who' 'will' 'undergo' 'standard' 'radiation' 'therapy' 'with'
 'concurrent' 'cisplatin-based' 'chemotherapy' 'for' 'cervical' 'cancer']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 0. 3. 3.]
NCT01990209,",,,217:226:treatment,,274:284:treatment,332:367:treatment,","Female patients who are not of child-bearing potential and female patients of child-bearing potential who agree to use adequate contraceptive measures or abstain from heterosexual intercourse during the entire study treatment period and for 4 months after the last dose of study drug, who are not breastfeeding, and who have had a negative serum/urine pregnancy test ≤7 days prior to dosing","['Female' 'patients' 'who' 'are' 'not' 'of' 'child-bearing' 'potential'
 'and' 'female' 'patients' 'of' 'child-bearing' 'potential' 'who' 'agree'
 'to' 'use' 'adequate' 'contraceptive' 'measures' 'or' 'abstain' 'from'
 'heterosexual' 'intercourse' 'during' 'the' 'entire' 'study' 'treatment'
 'period' 'and' 'for' '4' 'months' 'after' 'the' 'last' 'dose' 'of'
 'study' 'drug' ',' 'who' 'are' 'not' 'breastfeeding' ',' 'and' 'who'
 'have' 'had' 'a' 'negative' 'serum/urine' 'pregnancy' 'test' '≤7' 'days'
 'prior' 'to' 'dosing']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0.]"
NCT01990209,"1:26:treatment,,55:64:treatment,68:93:treatment,",Major surgical procedures ≤28 days of beginning study treatment or minor surgical procedures ≤7 days,"['Major' 'surgical' 'procedures' '≤28' 'days' 'of' 'beginning' 'study'
 'treatment' 'or' 'minor' 'surgical' 'procedures' '≤7' 'days']",[1. 1. 1. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 0. 0.]
NCT01990209,"20:36:cancer,58:65:cancer,,116:128:treatment,132:177:treatment",Previously treated brain metastases are allowed provided lesions are stable for at least 3 months as documented by head CT scan or magnetic resonance imaging (MRI) of the brain,"['Previously' 'treated' 'brain' 'metastases' 'are' 'allowed' 'provided'
 'lesions' 'are' 'stable' 'for' 'at' 'least' '3' 'months' 'as'
 'documented' 'by' 'head' 'CT' 'scan' 'or' 'magnetic' 'resonance'
 'imaging' '(' 'MRI' ')' 'of' 'the' 'brain']","[0. 0. 3. 3. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1.
 1. 1. 1. 1. 1. 0. 0.]"
NCT01989585,",,62:76:treatment,126:139:chronic_disease,140:148:chronic_disease","Abnormal cardiac valve morphology (>= grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study); subjects with moderate valvular thickening should not be entered on study","['Abnormal' 'cardiac' 'valve' 'morphology' '(' '>' '=' 'grade' '2' ')'
 'documented' 'by' 'echocardiogram' '(' 'subjects' 'with' 'grade' '1'
 'abnormalities' '[' 'i.e.' ',' 'mild' 'regurgitation/stenosis' ']' 'can'
 'be' 'entered' 'on' 'study' ')' ';' 'subjects' 'with' 'moderate'
 'valvular' 'thickening' 'should' 'not' 'be' 'entered' 'on' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01989585,"1:16:treatment,18:31:treatment,33:46:treatment,48:61:treatment,63:72:treatment,76:87:treatment","Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin, s-mephenytoin","['Anticonvulsants' ':' 'carbamazepine' ',' 'oxcarbazepine' ','
 'phenobarbital' ',' 'phenytoin' ',' 's-mephenytoin']",[1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1.]
NCT01989585,"29:39:treatment,55:66:treatment,70:88:treatment",Current use of a prohibited medication; the following medications or non-drug therapies are prohibited,"['Current' 'use' 'of' 'a' 'prohibited' 'medication' ';' 'the' 'following'
 'medications' 'or' 'non-drug' 'therapies' 'are' 'prohibited']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 1. 1. 0. 0.]
NCT01989585,"102:112:allergy_name,114:124:allergy_name,129:139:allergy_name,161:186:allergy_name","History of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax, dabrafenib, or trametinib, or excipients or to dimethyl sulfoxide (DMSO)","['History' 'of' 'allergic' 'reactions' 'attributed' 'to' 'compounds' 'of'
 'similar' 'chemical' 'or' 'biologic' 'composition' 'to' 'navitoclax' ','
 'dabrafenib' ',' 'or' 'trametinib' ',' 'or' 'excipients' 'or' 'to'
 'dimethyl' 'sulfoxide' '(' 'DMSO' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 0. 4. 0. 0. 0. 0.
 0. 4. 4. 4. 0. 0.]"
NCT01989585,"7:26:treatment,42:51:treatment,60:78:treatment",Other anti-cancer therapy while on study treatment; (note: megestrol [Megace] if used as an appetite stimulant is allowed),"['Other' 'anti-cancer' 'therapy' 'while' 'on' 'study' 'treatment' ';' '('
 'note' ':' 'megestrol' '[' 'Megace' ']' 'if' 'used' 'as' 'an' 'appetite'
 'stimulant' 'is' 'allowed' ')']",[0. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01989585,"23:36:treatment,38:50:treatment,54:66:treatment,,109:119:treatment,124:158:treatment,196:223:treatment,240:256:treatment,261:276:treatment,,325:335:treatment,343:353:treatment,355:376:treatment,,460:469:treatment,471:480:treatment,","Patients who have had immunotherapy, chemotherapy or radiotherapy within 14 days prior to the first dose of navitoclax, or prior systemic anti-cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or vaccine therapy) within the last 3 weeks prior to first dose of dabrafenib and/or trametinib; chemotherapy regimens without delayed toxicity within the last 2 weeks preceding the first dose of study treatment; biologics will not be allowed within 30 days prior to, or during, navitoclax administration","['Patients' 'who' 'have' 'had' 'immunotherapy' ',' 'chemotherapy' 'or'
 'radiotherapy' 'within' '14' 'days' 'prior' 'to' 'the' 'first' 'dose'
 'of' 'navitoclax' ',' 'or' 'prior' 'systemic' 'anti-cancer' 'therapy' '('
 'chemotherapy' 'with' 'delayed' 'toxicity' ',' 'extensive' 'radiation'
 'therapy' ',' 'immunotherapy' ',' 'biologic' 'therapy' ',' 'or' 'vaccine'
 'therapy' ')' 'within' 'the' 'last' '3' 'weeks' 'prior' 'to' 'first'
 'dose' 'of' 'dabrafenib' 'and/or' 'trametinib' ';' 'chemotherapy'
 'regimens' 'without' 'delayed' 'toxicity' 'within' 'the' 'last' '2'
 'weeks' 'preceding' 'the' 'first' 'dose' 'of' 'study' 'treatment' ';'
 'biologics' 'will' 'not' 'be' 'allowed' 'within' '30' 'days' 'prior' 'to'
 ',' 'or' 'during' ',' 'navitoclax' 'administration']","[0. 0. 0. 0. 1. 0. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01989585,"1:14:treatment,7:14:treatment,160:181:treatment,189:202:treatment,204:220:treatment,210:220:treatment,","Prior therapy is allowed; for patients enrolled in the Phase I portion of the study, patients may have received any number of prior lines of therapy including treatment with a BRAF and/or MEK inhibitor; prior navitoclax use will not be allowed, unless the patient received < 7 days of navitoclax lead-in on this or another study and had to stop for reasons other than toxicity or disease progression","['Prior' 'therapy' 'is' 'allowed' ';' 'for' 'patients' 'enrolled' 'in'
 'the' 'Phase' 'I' 'portion' 'of' 'the' 'study' ',' 'patients' 'may'
 'have' 'received' 'any' 'number' 'of' 'prior' 'lines' 'of' 'therapy'
 'including' 'treatment' 'with' 'a' 'BRAF' 'and/or' 'MEK' 'inhibitor' ';'
 'prior' 'navitoclax' 'use' 'will' 'not' 'be' 'allowed' ',' 'unless' 'the'
 'patient' 'received' '<' '7' 'days' 'of' 'navitoclax' 'lead-in' 'on'
 'this' 'or' 'another' 'study' 'and' 'had' 'to' 'stop' 'for' 'reasons'
 'other' 'than' 'toxicity' 'or' 'disease' 'progression']","[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01989585,",152:180:treatment,189:197:chronic_disease,234:247:treatment,254:265:chronic_disease,266:280:chronic_disease,282:303:chronic_disease,305:317:chronic_disease,329:348:treatment","Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v. 5.0) grade 2 or higher from previous anti-cancer therapy, except alopecia or an endocrine toxicity related to immunotherapy (e.g. thyroiditis/hypothyroidism, adrenal insufficiency, hypophysitis) requiring replacement therapy, at the time of randomization","['Unresolved' 'toxicity' 'of' 'National' 'Cancer' 'Institute' 'Common'
 'Terminology' 'Criteria' 'for' 'Adverse' 'Events' ',' 'version' '5.0' '('
 'NCI' 'CTCAE' 'v.' '5.0' ')' 'grade' '2' 'or' 'higher' 'from' 'previous'
 'anti-cancer' 'therapy' ',' 'except' 'alopecia' 'or' 'an' 'endocrine'
 'toxicity' 'related' 'to' 'immunotherapy' '(' 'e.g' '.'
 'thyroiditis/hypothyroidism' ',' 'adrenal' 'insufficiency' ','
 'hypophysitis' ')' 'requiring' 'replacement' 'therapy' ',' 'at' 'the'
 'time' 'of' 'randomization']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 1. 0. 0. 2. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 2. 0. 2. 2. 0. 2.
 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]"
NCT01989507,"7:18:treatment,46:56:treatment,58:71:treatment,73:84:treatment,86:110:treatment,112:122:treatment","other medications that could affect smoking (naltrexone, buprenorphine, acamprosate, anti-seizure medications, disulfiram)","['other' 'medications' 'that' 'could' 'affect' 'smoking' '(' 'naltrexone'
 ',' 'buprenorphine' ',' 'acamprosate' ',' 'anti-seizure' 'medications'
 ',' 'disulfiram' ')']",[0. 1. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 1. 0. 1. 0.]
NCT01988246,"54:87:treatment,95:109:treatment,111:129:treatment","Planned multiple procedures for study eye during the cataract/IOL implantation surgery (e.g., trabeculectomy, corneal transplant)","['Planned' 'multiple' 'procedures' 'for' 'study' 'eye' 'during' 'the'
 'cataract/IOL' 'implantation' 'surgery' '(' 'e.g.' ',' 'trabeculectomy'
 ',' 'corneal' 'transplant' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 0. 1. 1. 0.]
NCT01988246,"8:25:treatment,27:33:treatment,35:72:treatment,75:91:treatment,,115:122:treatment,160:167:treatment,","Use of systemic steroids, NSAIDS (non-steroidal anti-inflammatory drugs), anti-VEGF agents within 7 days prior to surgery (through study exit). Daily doses of aspirin, up to 325 mg, will be permitted","['Use' 'of' 'systemic' 'steroids' ',' 'NSAIDS' '(' 'non-steroidal'
 'anti-inflammatory' 'drugs' ')' ',' 'anti-VEGF' 'agents' 'within' '7'
 'days' 'prior' 'to' 'surgery' '(' 'through' 'study' 'exit' ')' '.'
 'Daily' 'doses' 'of' 'aspirin' ',' 'up' 'to' '325' 'mg' ',' 'will' 'be'
 'permitted']","[0. 0. 1. 1. 0. 1. 0. 1. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01986205,",161:169:chronic_disease,281:291:chronic_disease,293:300:chronic_disease,302:323:chronic_disease","At least 3 of the following persistent symptoms from the injury: headaches, dizziness or balance problems, blurred vision, tiredness/fatigue or sleep problems, seizures, remembering things or solving problems, managing stress or emotional upsets, controlling temper/irritability, depression, anxiety, post-traumatic stress, or ringing in the ears","['At' 'least' '3' 'of' 'the' 'following' 'persistent' 'symptoms' 'from'
 'the' 'injury' ':' 'headaches' ',' 'dizziness' 'or' 'balance' 'problems'
 ',' 'blurred' 'vision' ',' 'tiredness/fatigue' 'or' 'sleep' 'problems'
 ',' 'seizures' ',' 'remembering' 'things' 'or' 'solving' 'problems' ','
 'managing' 'stress' 'or' 'emotional' 'upsets' ',' 'controlling'
 'temper/irritability' ',' 'depression' ',' 'anxiety' ',' 'post-traumatic'
 'stress' ',' 'or' 'ringing' 'in' 'the' 'ears']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0.
 2. 2. 0. 0. 0. 0. 0. 0.]"
NCT01986205,"7:27:chronic_disease,31:58:chronic_disease,68:86:chronic_disease",Major psychiatric disorder or degenerative mental disease (such as multiple sclerosis),"['Major' 'psychiatric' 'disorder' 'or' 'degenerative' 'mental' 'disease'
 '(' 'such' 'as' 'multiple' 'sclerosis' ')']",[0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 2. 2. 0.]
NCT01986075,"1:28:chronic_disease,78:103:chronic_disease,105:120:chronic_disease,122:143:chronic_disease","Unstable physical disorders which might make participation hazardous such as uncontrolled hypertension, acute hepatitis, uncontrolled diabetes","['Unstable' 'physical' 'disorders' 'which' 'might' 'make' 'participation'
 'hazardous' 'such' 'as' 'uncontrolled' 'hypertension' ',' 'acute'
 'hepatitis' ',' 'uncontrolled' 'diabetes']",[2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0.]
NCT01983475,"45:59:treatment,45:60:treatment,,71:81:treatment,,250:259:chronic_disease","Any patient receiving moderate or high dose corticosteroids (>40 mg/d prednisone or an equivalent dose of other corticosteroid) for longer than one week, not including drug administered in an attempt to preserve neurological function at the time of acute SCI","['Any' 'patient' 'receiving' 'moderate' 'or' 'high' 'dose'
 'corticosteroids' '(' '>' '40' 'mg/d' 'prednisone' 'or' 'an' 'equivalent'
 'dose' 'of' 'other' 'corticosteroid' ')' 'for' 'longer' 'than' 'one'
 'week' ',' 'not' 'including' 'drug' 'administered' 'in' 'an' 'attempt'
 'to' 'preserve' 'neurological' 'function' 'at' 'the' 'time' 'of' 'acute'
 'SCI']","[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]"
NCT01983462,"12:26:chronic_disease,28:46:chronic_disease,48:57:chronic_disease,66:104:chronic_disease,109:127:chronic_disease","History of gastric ulcers, bleeding disorders, dyspepsia, severe gastroesophageal reflux disease (GERD), or metabolic acidosis","['History' 'of' 'gastric' 'ulcers' ',' 'bleeding' 'disorders' ','
 'dyspepsia' ',' 'severe' 'gastroesophageal' 'reflux' 'disease' '(' 'GERD'
 ')' ',' 'or' 'metabolic' 'acidosis']",[0. 0. 2. 2. 0. 2. 2. 0. 2. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 2. 2.]
NCT01983462,"24:33:treatment,,185:197:treatment,232:246:treatment,251:270:treatment","If currently receiving treatment with or taking any of the following supplements, be willing and able to discontinue taking them for 2 weeks prior and throughout the treatment period: Vitamin C, E or other multivitamins containing vitamin C or E; or omega-3 fatty acids","['If' 'currently' 'receiving' 'treatment' 'with' 'or' 'taking' 'any' 'of'
 'the' 'following' 'supplements' ',' 'be' 'willing' 'and' 'able' 'to'
 'discontinue' 'taking' 'them' 'for' '2' 'weeks' 'prior' 'and'
 'throughout' 'the' 'treatment' 'period' ':' 'Vitamin' 'C' ',' 'E' 'or'
 'other' 'multivitamins' 'containing' 'vitamin' 'C' 'or' 'E' ';' 'or'
 'omega-3' 'fatty' 'acids']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 1. 1. 1.]"
NCT01983462,"8:44:treatment,52:59:treatment,61:68:treatment,70:78:treatment,83:91:treatment,94:110:treatment,118:128:treatment,130:139:treatment,144:155:treatment,158:165:treatment","Taking Phosphodiesterase (PDE) 5 inhibitors (e.g., Viagra®, Cialis®, Levitra®, or Revatio®); PDE 3 inhibitors (e.g., cilostazol, milrinone, or vesnarinone); lithium","['Taking' 'Phosphodiesterase' '(' 'PDE' ')' '5' 'inhibitors' '(' 'e.g.'
 ',' 'Viagra®' ',' 'Cialis®' ',' 'Levitra®' ',' 'or' 'Revatio®' ')' ';'
 'PDE' '3' 'inhibitors' '(' 'e.g.' ',' 'cilostazol' ',' 'milrinone' ','
 'or' 'vesnarinone' ')' ';' 'lithium']","[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.]"
NCT01983462,"30:39:treatment,41:50:treatment,52:59:treatment,68:86:treatment,88:95:treatment,97:104:treatment,106:111:treatment","Taking diabetic medications (Metformin, glyburide, insulin, etc.), thiazolidinediones (Avandia, Rezulin, Actos)","['Taking' 'diabetic' 'medications' '(' 'Metformin' ',' 'glyburide' ','
 'insulin' ',' 'etc' '.' ')' ',' 'thiazolidinediones' '(' 'Avandia' ','
 'Rezulin' ',' 'Actos' ')']",[0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0.]
NCT01983462,"12:35:treatment,39:69:treatment,,128:149:treatment","Use of any investigational product or investigational medical device within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments","['Use' 'of' 'any' 'investigational' 'product' 'or' 'investigational'
 'medical' 'device' 'within' '30' 'days' 'prior' 'to' 'screening' ',' 'or'
 'requirement' 'for' 'any' 'investigational' 'agent' 'prior' 'to'
 'completion' 'of' 'all' 'scheduled' 'study' 'assessments']","[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01980823,"56:70:treatment,72:75:chronic_disease,76:95:treatment,101:113:treatment,150:162:treatment","Strong Cytochrome P450 3A4 (abbreviated CYP3A4) (e.g., clarithromycin, HIV protease inhibitors, and itraconazole), given potential interactions with atorvastatin","['Strong' 'Cytochrome' 'P450' '3A4' '(' 'abbreviated' 'CYP3A4' ')' '('
 'e.g.' ',' 'clarithromycin' ',' 'HIV' 'protease' 'inhibitors' ',' 'and'
 'itraconazole' ')' ',' 'given' 'potential' 'interactions' 'with'
 'atorvastatin']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 2. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 1.]"
NCT01976585,"1:11:cancer,47:82:cancer,90:132:cancer","basal cell or completely excised non-invasive squamous cell carcinoma of the skin, or in situ squamous cell carcinoma of the cervix","['basal' 'cell' 'or' 'completely' 'excised' 'non-invasive' 'squamous'
 'cell' 'carcinoma' 'of' 'the' 'skin' ',' 'or' 'in' 'situ' 'squamous'
 'cell' 'carcinoma' 'of' 'the' 'cervix']",[3. 3. 0. 0. 0. 0. 3. 3. 3. 3. 3. 3. 0. 0. 0. 3. 3. 3. 3. 3. 3. 3.]
NCT01976169,"1:6:cancer,15:19:cancer,33:35:treatment",Tumor must be HER2-positive and RB-proficient,['Tumor' 'must' 'be' 'HER2-positive' 'and' 'RB-proficient'],[3. 0. 0. 3. 0. 1.]
NCT01974609,"93:103:chronic_disease,105:137:chronic_disease,139:164:chronic_disease,166:179:chronic_disease,181:194:chronic_disease","those with a history or symptoms of any significant medical problem in the last year (i.e., arrhythmia, impaired cardiovascular function, gastrointestinal bleeding, liver disease, renal disease)","['those' 'with' 'a' 'history' 'or' 'symptoms' 'of' 'any' 'significant'
 'medical' 'problem' 'in' 'the' 'last' 'year' '(' 'i.e.' ',' 'arrhythmia'
 ',' 'impaired' 'cardiovascular' 'function' ',' 'gastrointestinal'
 'bleeding' ',' 'liver' 'disease' ',' 'renal' 'disease' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 2. 0.
 2. 2. 0. 2. 2. 0. 2. 2. 0.]"
NCT01973270,"20:31:treatment,33:48:treatment,67:76:treatment","Being treated with benztropine, diphenhydramine, or high doses of clozapine","['Being' 'treated' 'with' 'benztropine' ',' 'diphenhydramine' ',' 'or'
 'high' 'doses' 'of' 'clozapine']",[0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 1.]
NCT01970345,"19:38:treatment,19:29:treatment,,143:148:treatment","Must be on stable medication regimens for at least three months prior to enrollment, assuming the concomitant medication is safe for use with IGF-1","['Must' 'be' 'on' 'stable' 'medication' 'regimens' 'for' 'at' 'least'
 'three' 'months' 'prior' 'to' 'enrollment' ',' 'assuming' 'the'
 'concomitant' 'medication' 'is' 'safe' 'for' 'use' 'with' 'IGF-1']","[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1.]"
NCT01970176,"15:35:chronic_disease,71:87:chronic_disease,99:124:chronic_disease","Patients with retinitis pigmentosa, previous diagnosis of nonischemic optic neuropathy, untreated proliferative retinopathy or unexplained visual disturbance","['Patients' 'with' 'retinitis' 'pigmentosa' ',' 'previous' 'diagnosis'
 'of' 'nonischemic' 'optic' 'neuropathy' ',' 'untreated' 'proliferative'
 'retinopathy' 'or' 'unexplained' 'visual' 'disturbance']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0.]
NCT01968109,"1:44:cancer,48:60:cancer,66:80:cancer",Primary central nervous system (CNS) tumors or solid tumors with CNS metastases as the only site of active disease,"['Primary' 'central' 'nervous' 'system' '(' 'CNS' ')' 'tumors' 'or'
 'solid' 'tumors' 'with' 'CNS' 'metastases' 'as' 'the' 'only' 'site' 'of'
 'active' 'disease']",[3. 3. 3. 3. 3. 3. 3. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01967823,"12:29:treatment,47:57:cancer,93:102:treatment","Definitive radiation therapy for unresectable meningioma, or for recurrent meningioma after resection","['Definitive' 'radiation' 'therapy' 'for' 'unresectable' 'meningioma' ','
 'or' 'for' 'recurrent' 'meningioma' 'after' 'resection']",[0. 1. 1. 0. 0. 3. 0. 0. 0. 0. 0. 0. 1.]
NCT01967823,"39:49:treatment,101:112:treatment,125:141:treatment",Patients who have previously received ipilimumab and have documented GI toxicity must have a normal colonoscopy with normal colonic biopsies,"['Patients' 'who' 'have' 'previously' 'received' 'ipilimumab' 'and' 'have'
 'documented' 'GI' 'toxicity' 'must' 'have' 'a' 'normal' 'colonoscopy'
 'with' 'normal' 'colonic' 'biopsies']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1.]
NCT01967238,"100:108:chronic_disease,110:133:chronic_disease,135:156:chronic_disease,158:168:cancer","Any clinically significant acute or chronic medical condition requiring care of a physician (e.g., diabetes, coronary artery disease, rheumatologic illness, malignancy, substance abuse) that, in the opinion of the investigator, would preclude participation","['Any' 'clinically' 'significant' 'acute' 'or' 'chronic' 'medical'
 'condition' 'requiring' 'care' 'of' 'a' 'physician' '(' 'e.g.' ','
 'diabetes' ',' 'coronary' 'artery' 'disease' ',' 'rheumatologic'
 'illness' ',' 'malignancy' ',' 'substance' 'abuse' ')' 'that' ',' 'in'
 'the' 'opinion' 'of' 'the' 'investigator' ',' 'would' 'preclude'
 'participation']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 2. 0. 2. 2.
 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01967238,"14:31:treatment,,74:86:treatment,91:112:treatment,",Received the influenza vaccine less than 1 month ago and/or received the pneumococcal and meningococcal vaccine less than 4 years ago,"['Received' 'the' 'influenza' 'vaccine' 'less' 'than' '1' 'month' 'ago'
 'and/or' 'received' 'the' 'pneumococcal' 'and' 'meningococcal' 'vaccine'
 'less' 'than' '4' 'years' 'ago']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01964859,"16:29:chronic_disease,55:61:chronic_disease,63:72:chronic_disease,74:87:chronic_disease","Having current skin diseases (i.e. extreme and active eczema, psoriasis, lichen planus) that the investigator feels is not safe for study participation","['Having' 'current' 'skin' 'diseases' '(' 'i.e' '.' 'extreme' 'and'
 'active' 'eczema' ',' 'psoriasis' ',' 'lichen' 'planus' ')' 'that' 'the'
 'investigator' 'feels' 'is' 'not' 'safe' 'for' 'study' 'participation']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01964261,"1:18:chronic_disease,30:50:chronic_disease,68:78:chronic_disease","Psychotic illness or chronic psychiatric disorder, including major depression if untreated","['Psychotic' 'illness' 'or' 'chronic' 'psychiatric' 'disorder' ','
 'including' 'major' 'depression' 'if' 'untreated']",[2. 2. 0. 0. 2. 2. 0. 0. 0. 2. 0. 0.]
NCT01959698,"1:36:chronic_disease,47:80:chronic_disease,91:127:chronic_disease","Hepatitis B surface antigen (HBsAg) negative, hepatitis B core antibody (HBcAb) negative, hepatitis B surface antibody (HBsAb) positive patients","['Hepatitis' 'B' 'surface' 'antigen' '(' 'HBsAg' ')' 'negative' ','
 'hepatitis' 'B' 'core' 'antibody' '(' 'HBcAb' ')' 'negative' ','
 'hepatitis' 'B' 'surface' 'antibody' '(' 'HBsAb' ')' 'positive'
 'patients']","[2. 2. 2. 2. 2. 0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01959698,",,55:68:chronic_disease,70:89:chronic_disease,111:134:chronic_disease,159:178:chronic_disease,183:203:treatment,222:230:chronic_disease","New York Heart Association (NYHA) class II or greater heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically significant pericardial disease, or electrocardiographic evidence of acute ischemia","['New' 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'class' 'II' 'or'
 'greater' 'heart' 'failure' ',' 'uncontrolled' 'angina' ',' 'severe'
 'uncontrolled' 'ventricular' 'arrhythmias' ',' 'clinically' 'significant'
 'pericardial' 'disease' ',' 'or' 'electrocardiographic' 'evidence' 'of'
 'acute' 'ischemia']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0.
 2. 2. 0. 0. 1. 0. 0. 0. 2.]"
NCT01959698,"15:20:treatment,35:40:treatment,65:70:treatment,93:116:chronic_disease,117:144:treatment","Patients with HBsAg negative, but HBcAb positive (regardless of HBsAb status) should have a hepatitis B virus (HBV) deoxyribonucleic acid (DNA) testing done and protocol","['Patients' 'with' 'HBsAg' 'negative' ',' 'but' 'HBcAb' 'positive' '('
 'regardless' 'of' 'HBsAb' 'status' ')' 'should' 'have' 'a' 'hepatitis'
 'B' 'virus' '(' 'HBV' ')' 'deoxyribonucleic' 'acid' '(' 'DNA' ')'
 'testing' 'done' 'and' 'protocol']","[0. 0. 1. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 1.
 1. 1. 0. 0. 0. 0. 0. 0.]"
NCT01959425,"5:20:treatment,,59:94:treatment,114:128:treatment,130:139:treatment,145:157:treatment,161:207:treatment","Any cardiac surgery within the past 60 days (2 months) or valvular cardiac surgical procedure at any time (i.e., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve)","['Any' 'cardiac' 'surgery' 'within' 'the' 'past' '60' 'days' '(' '2'
 'months' ')' 'or' 'valvular' 'cardiac' 'surgical' 'procedure' 'at' 'any'
 'time' '(' 'i.e.' ',' 'ventriculotomy' ',' 'atriotomy' ',' 'and' 'valve'
 'repair' 'or' 'replacement' 'and' 'presence' 'of' 'a' 'prosthetic'
 'valve' ')']","[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1.
 0. 1. 0. 0. 1. 1. 0. 1. 1. 1. 1. 1. 1. 1. 0.]"
NCT01959425,"1:18:chronic_disease,27:56:chronic_disease,58:70:chronic_disease,74:78:chronic_disease","pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or COPD) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms","['pulmonary' 'disease' ',' '(' 'e.g.' ',' 'restrictive' 'pulmonary'
 'disease' ',' 'constrictive' 'or' 'COPD' ')' 'or' 'any' 'other' 'disease'
 'or' 'malfunction' 'of' 'the' 'lungs' 'or' 'respiratory' 'system' 'that'
 'produces' 'chronic' 'symptoms']","[2. 2. 0. 0. 0. 0. 2. 2. 2. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01959204,"80:94:chronic_disease,96:107:chronic_disease,109:114:chronic_disease,116:132:chronic_disease,134:145:chronic_disease,147:158:chronic_disease,160:169:chronic_disease,174:194:chronic_disease,198:217:chronic_disease","Has the presence or history of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (except for the condition for which the procedure is being performed) as determined by the clinical investigator","['Has' 'the' 'presence' 'or' 'history' 'of' 'a' 'clinically' 'significant'
 'disorder' 'involving' 'the' 'cardiovascular' ',' 'respiratory' ','
 'renal' ',' 'gastrointestinal' ',' 'immunologic' ',' 'hematologic' ','
 'endocrine' ',' 'or' 'neurologic' 'system' '(' 's' ')' 'or' 'psychiatric'
 'disease' '(' 'except' 'for' 'the' 'condition' 'for' 'which' 'the'
 'procedure' 'is' 'being' 'performed' ')' 'as' 'determined' 'by' 'the'
 'clinical' 'investigator']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 0. 2. 0.
 2. 0. 0. 2. 2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01954576,"11:21:cancer,43:55:treatment,,189:199:cancer,203:238:cancer,288:319:cancer","Any other malignancy that required active chemotherapy within the previous 12 months prior to registration and the disease is not currently progressing and/or metastatic. The exception is basal cell or squamous cell carcinoma of the skin, which were treated with local resection only or carcinoma in situ of the cervix","['Any' 'other' 'malignancy' 'that' 'required' 'active' 'chemotherapy'
 'within' 'the' 'previous' '12' 'months' 'prior' 'to' 'registration' 'and'
 'the' 'disease' 'is' 'not' 'currently' 'progressing' 'and/or'
 'metastatic' '.' 'The' 'exception' 'is' 'basal' 'cell' 'or' 'squamous'
 'cell' 'carcinoma' 'of' 'the' 'skin' ',' 'which' 'were' 'treated' 'with'
 'local' 'resection' 'only' 'or' 'carcinoma' 'in' 'situ' 'of' 'the'
 'cervix']","[0. 0. 3. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 3. 3. 0. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01954576,"26:44:cancer,26:29:cancer,70:81:cancer,83:97:cancer,99:113:cancer,115:141:cancer,152:165:cancer,245:261:cancer","Histologically confirmed GBM (WHO grade IV); rare GBM variants (e.g. gliosarcoma, giant cell GBM, small cell GBM, GBM with oligodendroglioma features, GBM with PNET features) are allowed. Patients will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of GBM is made","['Histologically' 'confirmed' 'GBM' '(' 'WHO' 'grade' 'IV' ')' ';' 'rare'
 'GBM' 'variants' '(' 'e.g' '.' 'gliosarcoma' ',' 'giant' 'cell' 'GBM' ','
 'small' 'cell' 'GBM' ',' 'GBM' 'with' 'oligodendroglioma' 'features' ','
 'GBM' 'with' 'PNET' 'features' ')' 'are' 'allowed' '.' 'Patients' 'will'
 'be' 'eligible' 'if' 'the' 'original' 'histology' 'was' 'low-grade'
 'glioma' 'and' 'a' 'subsequent' 'histological' 'diagnosis' 'of' 'GBM'
 'is' 'made']","[0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 3. 0. 3. 3. 3.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.
 3. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01954576,"10:22:treatment,,38:40:treatment,45:70:treatment,82:91:treatment",Received radiotherapy of at least 45 Gy and temozolomide chemotherapy as initial treatment for GBM,"['Received' 'radiotherapy' 'of' 'at' 'least' '45' 'Gy' 'and'
 'temozolomide' 'chemotherapy' 'as' 'initial' 'treatment' 'for' 'GBM']",[0. 1. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 1. 0. 0.]
NCT01954316,"15:27:treatment,29:41:treatment,43:61:treatment,65:90:treatment,,127:138:treatment,142:153:treatment,184:194:treatment,248:264:treatment","Have received radiotherapy, chemotherapy, biological therapy or investigational treatment less than four weeks (six weeks for nitrosourea or mitomycin C) prior to first dose of study medication or have not recovered from all acute toxicities from prior treatments","['Have' 'received' 'radiotherapy' ',' 'chemotherapy' ',' 'biological'
 'therapy' 'or' 'investigational' 'treatment' 'less' 'than' 'four' 'weeks'
 '(' 'six' 'weeks' 'for' 'nitrosourea' 'or' 'mitomycin' 'C' ')' 'prior'
 'to' 'first' 'dose' 'of' 'study' 'medication' 'or' 'have' 'not'
 'recovered' 'from' 'all' 'acute' 'toxicities' 'from' 'prior' 'treatments']","[0. 0. 1. 0. 1. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0.
 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01953588,"38:56:cancer,58:75:treatment,130:156:chronic_disease","Clinical or radiographic evidence of metastatic disease. Metastatic workup is not required, but is recommended for patients with clinical stage III disease","['Clinical' 'or' 'radiographic' 'evidence' 'of' 'metastatic' 'disease' '.'
 'Metastatic' 'workup' 'is' 'not' 'required' ',' 'but' 'is' 'recommended'
 'for' 'patients' 'with' 'clinical' 'stage' 'III' 'disease']",[0. 0. 0. 0. 0. 3. 3. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2.]
NCT01953575,"15:18:chronic_disease,31:40:chronic_disease,,134:151:treatment,,192:221:treatment","Patients with EoE, defined as dysphagia with histologic finding of greater than or equal to 15 eosinophils per high powered field on esophageal biopsy despite at least 6 weeks of twice daily proton pump inhibitor therapy","['Patients' 'with' 'EoE' ',' 'defined' 'as' 'dysphagia' 'with'
 'histologic' 'finding' 'of' 'greater' 'than' 'or' 'equal' 'to' '15'
 'eosinophils' 'per' 'high' 'powered' 'field' 'on' 'esophageal' 'biopsy'
 'despite' 'at' 'least' '6' 'weeks' 'of' 'twice' 'daily' 'proton' 'pump'
 'inhibitor' 'therapy']","[0. 0. 2. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]"
NCT01953263,"24:43:chronic_disease,55:73:chronic_disease,75:93:chronic_disease,98:122:chronic_disease,124:139:chronic_disease,141:162:chronic_disease,164:178:chronic_disease,180:194:cancer,196:210:chronic_disease,218:234:chronic_disease","Patients with abnormal urologic conditions, including post-void residual, urethral stricture and bladder neck contracture, spastic bladder, vesicoureteral reflux, bladder stones, bladder tumors, hydronephrosis, other renal impairment","['Patients' 'with' 'abnormal' 'urologic' 'conditions' ',' 'including'
 'post-void' 'residual' ',' 'urethral' 'stricture' 'and' 'bladder' 'neck'
 'contracture' ',' 'spastic' 'bladder' ',' 'vesicoureteral' 'reflux' ','
 'bladder' 'stones' ',' 'bladder' 'tumors' ',' 'hydronephrosis' ','
 'other' 'renal' 'impairment']","[0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 2. 2. 0. 3. 3. 2. 0. 2. 2. 0. 2. 2. 0. 0.
 0. 0. 0. 0. 0. 2. 0. 0. 2. 2.]"
NCT01951885,"27:34:chronic_disease,49:68:chronic_disease,156:163:treatment","Patients with any medical illness or concurrent psychiatric illness which, in the investigators' opinion, cannot be adequately controlled with appropriate therapy","['Patients' 'with' 'any' 'medical' 'illness' 'or' 'concurrent'
 'psychiatric' 'illness' 'which' ',' 'in' 'the' 'investigators' ""'""
 'opinion' ',' 'can' 'not' 'be' 'adequately' 'controlled' 'with'
 'appropriate' 'therapy']","[0. 0. 0. 0. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1.]"
NCT01950351,"1:38:chronic_disease,61:80:chronic_disease,121:134:treatment",chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration,"['chronic' 'obstructive' 'pulmonary' 'disease' 'exacerbation' 'or' 'other'
 'respiratory' 'illness' 'requiring' 'hospitalization' 'or' 'precluding'
 'study' 'therapy' 'at' 'the' 'time' 'of' 'registration']",[2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01950234,"1:22:treatment,11:22:treatment,44:59:treatment,61:70:treatment,72:83:treatment,85:95:treatment,99:116:treatment","Stimulant medications for fatigue (such as methylphenidate, modafinil, armodafinil, amantadine or dextroamphetamine) will be permitted, but subjects will be asked to not take these medications on study visit days until all study procedures/assessments are completed","['Stimulant' 'medications' 'for' 'fatigue' '(' 'such' 'as'
 'methylphenidate' ',' 'modafinil' ',' 'armodafinil' ',' 'amantadine' 'or'
 'dextroamphetamine' ')' 'will' 'be' 'permitted' ',' 'but' 'subjects'
 'will' 'be' 'asked' 'to' 'not' 'take' 'these' 'medications' 'on' 'study'
 'visit' 'days' 'until' 'all' 'study' 'procedures/assessments' 'are'
 'completed']","[1. 1. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01950234,"1:54:treatment,97:112:treatment,114:118:treatment,120:132:treatment,134:155:treatment,157:169:treatment,173:184:treatment,,211:224:treatment","Treatment with non-cytotoxic immunosuppressive agents (including but not necessarily limited to corticosteroids, ACTH, azathioprine, mycophenolate mofetil, methotrexate or natalizumab) within 3 months prior to randomization","['Treatment' 'with' 'non-cytotoxic' 'immunosuppressive' 'agents' '('
 'including' 'but' 'not' 'necessarily' 'limited' 'to' 'corticosteroids'
 ',' 'ACTH' ',' 'azathioprine' ',' 'mycophenolate' 'mofetil' ','
 'methotrexate' 'or' 'natalizumab' ')' 'within' '3' 'months' 'prior' 'to'
 'randomization']","[1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 1. 0. 1. 0. 1.
 0. 0. 0. 0. 0. 0. 1.]"
NCT01947140,"13:25:treatment,29:41:treatment,,70:81:treatment,85:96:treatment",Exposure to chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier,"['Exposure' 'to' 'chemotherapy' 'or' 'radiotherapy' 'within' '2' 'weeks'
 '(' '6' 'weeks' 'for' 'nitrosureas' 'or' 'mitomycin' 'C' ')' 'prior' 'to'
 'entering' 'the' 'study' 'or' 'those' 'who' 'have' 'not' 'recovered'
 'from' 'adverse' 'events' 'due' 'to' 'agents' 'administered' 'more'
 'than' '2' 'weeks' 'earlier']","[0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01946074,"17:36:treatment,64:72:treatment,77:94:treatment","Subjects in the combination therapy cohorts who are to receive ABBV-181, an anti-PD1 antibody, must also meet other criteria described in the Protocol","['Subjects' 'in' 'the' 'combination' 'therapy' 'cohorts' 'who' 'are' 'to'
 'receive' 'ABBV-181' ',' 'an' 'anti-PD1' 'antibody' ',' 'must' 'also'
 'meet' 'other' 'criteria' 'described' 'in' 'the' 'Protocol']","[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT01943851,"104:134:chronic_disease,150:160:chronic_disease,169:191:chronic_disease,195:210:treatment",Able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels,"['Able' 'to' 'swallow' 'and' 'retain' 'orally' 'administered' 'medication'
 'and' 'does' 'not' 'have' 'any' 'clinically' 'significant'
 'gastrointestinal' 'abnormalities' 'that' 'may' 'alter' 'absorption'
 'such' 'as' 'malabsorption' 'syndrome' 'or' 'major' 'resection' 'of'
 'the' 'stomach' 'or' 'bowels']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 0. 0. 2.
 2. 0. 1. 1. 0. 0. 0. 0. 0.]"
NCT01943851,"36:53:chronic_disease,87:98:chronic_disease,100:107:chronic_disease,109:114:chronic_disease,116:131:chronic_disease,159:176:chronic_disease","Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal, cardiac disease, or clinically significant bleeding episodes)","['Evidence' 'of' 'severe' 'or' 'uncontrolled' 'systemic' 'diseases' '('
 'e.g.' ',' 'unstable' 'or' 'uncompensated' 'respiratory' ',' 'hepatic'
 ',' 'renal' ',' 'cardiac' 'disease' ',' 'or' 'clinically' 'significant'
 'bleeding' 'episodes' ')']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 2. 0. 2. 2. 0. 0. 0.
 0. 2. 2. 0.]"
NCT01943851,"43:46:cancer,48:50:cancer,55:58:cancer","In Part 1 and, Part 2, subjects must have AML, MM, or NHL","['In' 'Part' '1' 'and' ',' 'Part' '2' ',' 'subjects' 'must' 'have' 'AML'
 ',' 'MM' ',' 'or' 'NHL']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 0. 0. 3.]
NCT01943851,"8:22:treatment,30:38:treatment,40:47:treatment,,","Use of anticoagulants (e.g., warfarin, heparin) at therapeutic levels within 7 days prior to the first dose of GSK525762","['Use' 'of' 'anticoagulants' '(' 'e.g.' ',' 'warfarin' ',' 'heparin' ')'
 'at' 'therapeutic' 'levels' 'within' '7' 'days' 'prior' 'to' 'the'
 'first' 'dose' 'of' 'GSK525762']",[0. 0. 1. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01941316,"21:37:chronic_disease,48:57:treatment,59:79:treatment,81:91:treatment,96:107:treatment,","Must not have acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to enrollment","['Must' 'not' 'have' 'acute' 'active' 'infection' 'requiring' 'treatment'
 '(' 'systemic' 'antibiotics' ',' 'antivirals' ',' 'or' 'antifungals' ')'
 'within' '14' 'days' 'prior' 'to' 'enrollment']",[0. 0. 0. 0. 2. 2. 0. 1. 0. 1. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT01941316,"21:37:cancer,87:103:cancer,128:137:treatment,153:155:treatment,159:175:treatment,,227:249:treatment","Patients with known brain metastases are eligible only if he/she has been treated for brain metastasis, are asymptomatic after treatment, have a stable CT or MRI of the brain within 28 days of enrollment and are not receiving corticosteroid therapy to control symptoms from brain metastasis","['Patients' 'with' 'known' 'brain' 'metastases' 'are' 'eligible' 'only'
 'if' 'he/she' 'has' 'been' 'treated' 'for' 'brain' 'metastasis' ',' 'are'
 'asymptomatic' 'after' 'treatment' ',' 'have' 'a' 'stable' 'CT' 'or'
 'MRI' 'of' 'the' 'brain' 'within' '28' 'days' 'of' 'enrollment' 'and'
 'are' 'not' 'receiving' 'corticosteroid' 'therapy' 'to' 'control'
 'symptoms' 'from' 'brain' 'metastasis']","[0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 0. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]"
NCT01940094,"74:84:treatment,,121:165:chronic_disease,167:173:chronic_disease,175:196:chronic_disease","Comorbid condition that has moderate likelihood of requiring a course of prednisone within one year of enrollment (e.g. chronic obstructive pulmonary disease (COPD), asthma, adrenal insufficiency)","['Comorbid' 'condition' 'that' 'has' 'moderate' 'likelihood' 'of'
 'requiring' 'a' 'course' 'of' 'prednisone' 'within' 'one' 'year' 'of'
 'enrollment' '(' 'e.g' '.' 'chronic' 'obstructive' 'pulmonary' 'disease'
 '(' 'COPD' ')' ',' 'asthma' ',' 'adrenal' 'insufficiency' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2.
 2. 0. 0. 0. 2. 0. 2. 2. 0.]"
NCT01931202,"12:21:chronic_disease,23:41:chronic_disease,43:48:chronic_disease,53:69:chronic_disease","History of psychosis, psychotic disorder, mania, or bipolar disorder","['History' 'of' 'psychosis' ',' 'psychotic' 'disorder' ',' 'mania' ','
 'or' 'bipolar' 'disorder']",[0. 0. 2. 0. 2. 2. 0. 2. 0. 0. 2. 2.]
NCT01928589,"38:75:treatment,77:85:treatment,87:125:treatment,127:161:treatment,176:215:treatment,255:267:treatment,269:285:treatment,289:300:treatment,460:486:treatment,,,546:561:treatment,,,,,721:737:treatment,,839:856:treatment","Recommended regimens are as follows: Cyclophosphamide and Doxorubicin (AC); Taxotere, Doxorubicin and Cyclophosphamide (TAC); Taxotere and Cyclophosphamide (TC); or Taxotere, Carboplatin and Trastuzamab (TCH) prior to registration. The use of additional chemotherapy, hormonal therapy or Trastuzumab after the initial regimen is at the discretion of the Medical Oncologist. Other primary regimens are possible but the PI must be notified prior to enrollment. Partial breast irradiation must be scheduled to begin less than 71 days from the last breast surgical procedure. ECOG performance status ≤ 1. Women of child-bearing potential must have a negative (urine or blood) pregnancy test within 6 weeks prior to start of protocol therapy. Women of childbearing potential must also use effective non-hormonal contraception while undergoing radiation therapy. Ability to understand and the willingness to sign a written informed consent document","['Recommended' 'regimens' 'are' 'as' 'follows' ':' 'Cyclophosphamide'
 'and' 'Doxorubicin' '(' 'AC' ')' ';' 'Taxotere' ',' 'Doxorubicin' 'and'
 'Cyclophosphamide' '(' 'TAC' ')' ';' 'Taxotere' 'and' 'Cyclophosphamide'
 '(' 'TC' ')' ';' 'or' 'Taxotere' ',' 'Carboplatin' 'and' 'Trastuzamab'
 '(' 'TCH' ')' 'prior' 'to' 'registration' '.' 'The' 'use' 'of'
 'additional' 'chemotherapy' ',' 'hormonal' 'therapy' 'or' 'Trastuzumab'
 'after' 'the' 'initial' 'regimen' 'is' 'at' 'the' 'discretion' 'of' 'the'
 'Medical' 'Oncologist' '.' 'Other' 'primary' 'regimens' 'are' 'possible'
 'but' 'the' 'PI' 'must' 'be' 'notified' 'prior' 'to' 'enrollment' '.'
 'Partial' 'breast' 'irradiation' 'must' 'be' 'scheduled' 'to' 'begin'
 'less' 'than' '71' 'days' 'from' 'the' 'last' 'breast' 'surgical'
 'procedure' '.' 'ECOG' 'performance' 'status' '≤' '1' '.' 'Women' 'of'
 'child-bearing' 'potential' 'must' 'have' 'a' 'negative' '(' 'urine' 'or'
 'blood' ')' 'pregnancy' 'test' 'within' '6' 'weeks' 'prior' 'to' 'start'
 'of' 'protocol' 'therapy' '.' 'Women' 'of' 'childbearing' 'potential'
 'must' 'also' 'use' 'effective' 'non-hormonal' 'contraception' 'while'
 'undergoing' 'radiation' 'therapy' '.' 'Ability' 'to' 'understand' 'and'
 'the' 'willingness' 'to' 'sign' 'a' 'written' 'informed' 'consent'
 'document']","[0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01928576,"39:59:treatment,68:86:treatment,115:134:treatment","Patients must be willing to undergo a pre-treatment biopsy, either core needle biopsy or equivalent amount or via excisional specimen","['Patients' 'must' 'be' 'willing' 'to' 'undergo' 'a' 'pre-treatment'
 'biopsy' ',' 'either' 'core' 'needle' 'biopsy' 'or' 'equivalent' 'amount'
 'or' 'via' 'excisional' 'specimen']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1.]
NCT01928576,"23:76:treatment,69:76:treatment,78:91:treatment,99:116:treatment,145:163:cancer,,223:259:treatment",Patients who received adjuvant or neoadjuvant platinum-doublet chemotherapy (after surgery and/or radiation therapy) and developed recurrent or metastatic disease within 6 months of completing therapy are eligible and the adjuvant or neoadjuvant chemotherapy will count as a line of therapy as above,"['Patients' 'who' 'received' 'adjuvant' 'or' 'neoadjuvant'
 'platinum-doublet' 'chemotherapy' '(' 'after' 'surgery' 'and/or'
 'radiation' 'therapy' ')' 'and' 'developed' 'recurrent' 'or' 'metastatic'
 'disease' 'within' '6' 'months' 'of' 'completing' 'therapy' 'are'
 'eligible' 'and' 'the' 'adjuvant' 'or' 'neoadjuvant' 'chemotherapy'
 'will' 'count' 'as' 'a' 'line' 'of' 'therapy' 'as' 'above']","[0. 0. 0. 1. 1. 1. 1. 1. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01928576,"1:29:treatment,31:41:treatment,43:53:treatment,55:65:treatment,67:97:treatment,195:224:treatment,228:250:treatment","Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody therapies, any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, DNA methyltransferase therapy or HDAC inhibitor therapy","['Prior' 'therapy' 'with' 'anti-PD-1' ',' 'anti-PD-L1' ',' 'anti-PD-L2'
 ',' 'anti-CD137' ',' 'anti-CTLA-4' 'antibody' 'therapies' ',' 'any'
 'other' 'antibody' 'or' 'drug' 'specifically' 'targeting' 'T-cell'
 'co-stimulation' 'or' 'checkpoint' 'pathways' ',' 'DNA'
 'methyltransferase' 'therapy' 'or' 'HDAC' 'inhibitor' 'therapy']","[1. 1. 1. 1. 0. 1. 0. 1. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 1.]"
NCT01928576,"24:49:treatment,69:97:treatment,90:97:treatment,104:137:treatment","subject who received a tyrosine kinase inhibitor after failure of a prior platinum-based therapy, that tyrosine kinase inhibitor therapy would count as an additional line of therapy","['subject' 'who' 'received' 'a' 'tyrosine' 'kinase' 'inhibitor' 'after'
 'failure' 'of' 'a' 'prior' 'platinum-based' 'therapy' ',' 'that'
 'tyrosine' 'kinase' 'inhibitor' 'therapy' 'would' 'count' 'as' 'an'
 'additional' 'line' 'of' 'therapy']","[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01925573,"23:37:treatment,45:53:treatment,57:68:treatment","Patients on full-dose anticoagulants (e.g., warfarin or LMW heparin)","['Patients' 'on' 'full-dose' 'anticoagulants' '(' 'e.g.' ',' 'warfarin'
 'or' 'LMW' 'heparin' ')']",[0. 0. 0. 1. 0. 0. 0. 1. 0. 1. 1. 0.]
NCT01925573,"12:31:chronic_disease,35:62:chronic_disease,64:70:chronic_disease,72:75:chronic_disease,89:116:chronic_disease","history of hypertensive crisis or hypertensive encephalopathy, stroke, TIA, symptomatic peripheral vascular disease","['history' 'of' 'hypertensive' 'crisis' 'or' 'hypertensive'
 'encephalopathy' ',' 'stroke' ',' 'TIA' ',' 'symptomatic' 'peripheral'
 'vascular' 'disease']",[0. 0. 2. 2. 0. 0. 0. 0. 2. 0. 2. 0. 0. 2. 2. 2.]
NCT01925378,"23:40:chronic_disease,65:68:chronic_disease,108:123:cancer",Patients with a known immunocompromised condition or a positive HIV test. Patients with a prior history of cervical cancer,"['Patients' 'with' 'a' 'known' 'immunocompromised' 'condition' 'or' 'a'
 'positive' 'HIV' 'test' '.' 'Patients' 'with' 'a' 'prior' 'history' 'of'
 'cervical' 'cancer']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT01925131,"63:66:cancer,91:100:treatment,,178:204:treatment",Patients known to have Philadelphia chromosome positive (Ph+) ALL must have either failed treatment or been intolerant to treatment with at least two second or third generation tyrosine kinase inhibitors,"['Patients' 'known' 'to' 'have' 'Philadelphia' 'chromosome' 'positive' '('
 'Ph+' ')' 'ALL' 'must' 'have' 'either' 'failed' 'treatment' 'or' 'been'
 'intolerant' 'to' 'treatment' 'with' 'at' 'least' 'two' 'second' 'or'
 'third' 'generation' 'tyrosine' 'kinase' 'inhibitors']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 1.]"
NCT01925131,"37:49:treatment,51:73:treatment,88:101:treatment,","Patients must not have received any chemotherapy, investigational agents, or undergone major surgery within 14 days prior to registration","['Patients' 'must' 'not' 'have' 'received' 'any' 'chemotherapy' ','
 'investigational' 'agents' ',' 'or' 'undergone' 'major' 'surgery'
 'within' '14' 'days' 'prior' 'to' 'registration']",[0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT01925131,"111:118:treatment,,,210:222:treatment,224:246:treatment,250:274:treatment","in addition to routine contraceptive methods, effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation","['in' 'addition' 'to' 'routine' 'contraceptive' 'methods' ',' 'effective'
 'contraception' 'also' 'includes' 'heterosexual' 'celibacy' 'and'
 'surgery' 'intended' 'to' 'prevent' 'pregnancy' '(' 'or' 'with' 'a'
 'side-effect' 'of' 'pregnancy' 'prevention' ')' 'defined' 'as' 'a'
 'hysterectomy' ',' 'bilateral' 'oophorectomy' 'or' 'bilateral' 'tubal'
 'ligation']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 1. 0. 0. 0.]"
NCT01920737,"24:39:chronic_disease,90:109:chronic_disease,114:131:chronic_disease","Clinically significant cardiac disease (NY Heart Association Class III or IV), including chronic arrhythmias, or pulmonary disease","['Clinically' 'significant' 'cardiac' 'disease' '(' 'NY' 'Heart'
 'Association' 'Class' 'III' 'or' 'IV' ')' ',' 'including' 'chronic'
 'arrhythmias' ',' 'or' 'pulmonary' 'disease']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2.]
NCT01920737,"15:49:chronic_disease,53:56:cancer,86:107:treatment,113:130:treatment,138:162:treatment",Patients with central nervous system involvement by ALL are eligible and may receive concomitant treatment with radiation therapy and/or intrathecal chemotherapy in accordance with standard medical practice,"['Patients' 'with' 'central' 'nervous' 'system' 'involvement' 'by' 'ALL'
 'are' 'eligible' 'and' 'may' 'receive' 'concomitant' 'treatment' 'with'
 'radiation' 'therapy' 'and/or' 'intrathecal' 'chemotherapy' 'in'
 'accordance' 'with' 'standard' 'medical' 'practice']","[0. 0. 2. 2. 2. 2. 0. 3. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 1. 1. 0. 0. 0.
 0. 0. 0.]"
NCT01920061,"15:19:cancer,44:64:treatment,72:82:cancer",Patients with TNBC with no prior cytotoxic chemotherapy therapy in the metastatic setting,"['Patients' 'with' 'TNBC' 'with' 'no' 'prior' 'cytotoxic' 'chemotherapy'
 'therapy' 'in' 'the' 'metastatic' 'setting']",[0. 0. 3. 0. 0. 0. 0. 1. 1. 0. 0. 3. 0.]
NCT01919619,"1:12:chronic_disease,8:12:chronic_disease,,49:59:treatment",Active GVHD or recent GVHD and still on > 10 mg prednisone (or equivalent),"['Active' 'GVHD' 'or' 'recent' 'GVHD' 'and' 'still' 'on' '>' '10' 'mg'
 'prednisone' '(' 'or' 'equivalent' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT01918683,"1:32:treatment,34:37:treatment,42:58:treatment","Prior TACE to the target lesion, RFA, or liver transplant","['Prior' 'TACE' 'to' 'the' 'target' 'lesion' ',' 'RFA' ',' 'or' 'liver'
 'transplant']",[1. 1. 1. 1. 1. 1. 0. 1. 0. 0. 1. 1.]
NCT01918644,"23:32:cancer,34:41:cancer,45:60:cancer","Patients with primary ampullary, biliary or duodenal cancer","['Patients' 'with' 'primary' 'ampullary' ',' 'biliary' 'or' 'duodenal'
 'cancer']",[0. 0. 0. 3. 0. 3. 0. 3. 3.]
NCT01913106,"15:31:chronic_disease,33:38:chronic_disease,40:49:chronic_disease,54:71:chronic_disease,82:89:treatment","Patients with acute infections (viral, bacterial, or fungal infections requiring therapy)","['Patients' 'with' 'acute' 'infections' '(' 'viral' ',' 'bacterial' ','
 'or' 'fungal' 'infections' 'requiring' 'therapy' ')']",[0. 0. 2. 2. 0. 2. 0. 2. 0. 0. 2. 2. 0. 1. 0.]
NCT01912612,"18:22:treatment,24:28:treatment,33:44:treatment,56:66:treatment,72:81:treatment,85:110:chronic_disease,114:142:chronic_disease,241:252:treatment","Currently taking SSRI, SNRI, or TCA regimen (including Wellbutrin) for treatment of major depressive disorder or generalized anxiety disorder (without approval and involvement of the patient's treating psychiatrist to taper cases off these medications prior to study treatment)","['Currently' 'taking' 'SSRI' ',' 'SNRI' ',' 'or' 'TCA' 'regimen' '('
 'including' 'Wellbutrin' ')' 'for' 'treatment' 'of' 'major' 'depressive'
 'disorder' 'or' 'generalized' 'anxiety' 'disorder' '(' 'without'
 'approval' 'and' 'involvement' 'of' 'the' 'patient' ""'s"" 'treating'
 'psychiatrist' 'to' 'taper' 'cases' 'off' 'these' 'medications' 'prior'
 'to' 'study' 'treatment' ')']","[0. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 1. 0. 0. 1. 0. 2. 2. 2. 0. 2. 2. 2. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]"
NCT01910818,"8:22:chronic_disease,26:32:chronic_disease,,125:140:chronic_disease",Active Herpes Simplex or Zoster at the time of treatment or having experienced more than three episodes of Herpes Simplex / Zoster eruption within a year of study enrollment,"['Active' 'Herpes' 'Simplex' 'or' 'Zoster' 'at' 'the' 'time' 'of'
 'treatment' 'or' 'having' 'experienced' 'more' 'than' 'three' 'episodes'
 'of' 'Herpes' 'Simplex' '/' 'Zoster' 'eruption' 'within' 'a' 'year' 'of'
 'study' 'enrollment']","[0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT01910818,"6:32:chronic_disease,24:32:chronic_disease,37:51:chronic_disease,",with radiation-induced fibrosis and depigmentation. The fibrosis must have occurred at least 1 year prior to the date of enrollment,"['with' 'radiation-induced' 'fibrosis' 'and' 'depigmentation' '.' 'The'
 'fibrosis' 'must' 'have' 'occurred' 'at' 'least' '1' 'year' 'prior' 'to'
 'the' 'date' 'of' 'enrollment']",[0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01908777,"19:22:treatment,47:94:chronic_disease,96:115:chronic_disease,120:131:chronic_disease,,","Other significant ECG abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min)","['Other' 'significant' 'ECG' 'abnormalities' 'including' '2nd' 'degree'
 'atrio-ventricular' '(' 'AV' ')' 'block' 'type' 'II' ',' '3rd' 'degree'
 'AV' 'block' ',' 'or' 'bradycardia' '(' 'ventricular' 'rate' 'less'
 'than' '50' 'beats/min' ')']","[0. 0. 1. 0. 0. 2. 2. 2. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2. 0. 0. 2. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01906385,"37:109:treatment,122:145:treatment,151:162:treatment,202:224:treatment","Progression following both standard combined modality treatment with radiation and temozolomide chemotherapy, as well as anti-angiogenic therapy (ie, bevacizumab; patients not eligible for or refusing antiangiogenic therapy will also be allowed)","['Progression' 'following' 'both' 'standard' 'combined' 'modality'
 'treatment' 'with' 'radiation' 'and' 'temozolomide' 'chemotherapy' ','
 'as' 'well' 'as' 'anti-angiogenic' 'therapy' '(' 'ie' ',' 'bevacizumab'
 ';' 'patients' 'not' 'eligible' 'for' 'or' 'refusing' 'antiangiogenic'
 'therapy' 'will' 'also' 'be' 'allowed' ')']","[0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 0.
 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]"
NCT01904136,"1:31:cancer,110:119:treatment,,136:162:treatment","Chronic myeloid leukemia (CML): a. failed to achieve cytogenetic remission or have cytogenetic relapse after treatment with at least 2 tyrosine kinase inhibitors, or b. accelerated phase or blast phase at any time","['Chronic' 'myeloid' 'leukemia' '(' 'CML' ')' ':' 'a.' 'failed' 'to'
 'achieve' 'cytogenetic' 'remission' 'or' 'have' 'cytogenetic' 'relapse'
 'after' 'treatment' 'with' 'at' 'least' '2' 'tyrosine' 'kinase'
 'inhibitors' ',' 'or' 'b.' 'accelerated' 'phase' 'or' 'blast' 'phase'
 'at' 'any' 'time']","[3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1.
 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01903330,"1:17:chronic_disease,28:37:treatment,45:70:chronic_disease,79:107:chronic_disease,116:121:chronic_disease,134:168:treatment","Active infection requiring treatment, known immunosuppressive disease, active systemic autoimmune diseases such as lupus, receipt of systemic immunosuppressive therapy","['Active' 'infection' 'requiring' 'treatment' ',' 'known'
 'immunosuppressive' 'disease' ',' 'active' 'systemic' 'autoimmune'
 'diseases' 'such' 'as' 'lupus' ',' 'receipt' 'of' 'systemic'
 'immunosuppressive' 'therapy']",[2. 2. 0. 1. 0. 0. 2. 2. 0. 0. 1. 1. 1. 0. 0. 2. 0. 0. 0. 0. 0. 0.]
NCT01903330,"86:112:cancer,114:137:cancer,142:153:cancer",Patients must have histologically confirmed diagnosis of a recurrent/progressive WHO grade IV malignant gliomas (glioblastoma multiforme and gliosarcoma),"['Patients' 'must' 'have' 'histologically' 'confirmed' 'diagnosis' 'of'
 'a' 'recurrent/progressive' 'WHO' 'grade' 'IV' 'malignant' 'gliomas' '('
 'glioblastoma' 'multiforme' 'and' 'gliosarcoma' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 3. 3. 0. 3. 0.]
NCT01903330,"19:31:treatment,35:44:treatment,,101:109:chronic_disease","Resolution of all chemotherapy or radiation-related toxicities ≤ CTCAE Grade 1 severity, except for alopecia and hematologic toxicity","['Resolution' 'of' 'all' 'chemotherapy' 'or' 'radiation-related'
 'toxicities' '≤' 'CTCAE' 'Grade' '1' 'severity' ',' 'except' 'for'
 'alopecia' 'and' 'hematologic' 'toxicity']",[0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0.]
NCT01902810,"1:11:cancer,33:42:treatment,57:73:treatment,",Malignancy currently undergoing treatment or history of cancer treatment within 5 years,"['Malignancy' 'currently' 'undergoing' 'treatment' 'or' 'history' 'of'
 'cancer' 'treatment' 'within' '5' 'years']",[3. 0. 0. 1. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT01900301,"57:72:treatment,74:84:treatment,86:106:treatment,108:118:treatment,120:129:treatment,131:139:treatment,141:155:treatment,157:168:treatment,170:179:treatment,181:192:treatment,194:203:treatment,205:214:treatment,216:225:treatment,227:242:treatment,244:251:treatment,253:265:treatment,267:283:treatment,285:292:treatment,294:306:treatment,308:317:treatment,319:333:treatment,335:343:treatment,345:355:treatment,357:372:treatment,374:386:treatment,388:402:treatment,404:419:treatment,421:430:treatment,432:452:treatment,454:464:treatment,466:491:treatment,493:505:treatment,507:519:treatment,525:534:treatment","Other drugs that will be reasons for exclusion include: antimuscarinics, nifedipine, parasympathomimetics, amantadine, amoxapine, antacids, antidiarrheals, anxiolytics, hypnotics, atomexetine, bupropion, cisapride, clozapine, cyclobenzaprine, digoxin, disopyramide, dronabinol (THC), ethanol, maprotilline, memantine, metoclopramide, nabilone, olanzapine, opiate agonists, orphenadrine, phenothiazines, potassium salts, quinidine, sedating H1-blockers, topiramate, tricyclic antidepressants, erthyromycin, ketoconazole, and tegaserod","['Other' 'drugs' 'that' 'will' 'be' 'reasons' 'for' 'exclusion' 'include'
 ':' 'antimuscarinics' ',' 'nifedipine' ',' 'parasympathomimetics' ','
 'amantadine' ',' 'amoxapine' ',' 'antacids' ',' 'antidiarrheals' ','
 'anxiolytics' ',' 'hypnotics' ',' 'atomexetine' ',' 'bupropion' ','
 'cisapride' ',' 'clozapine' ',' 'cyclobenzaprine' ',' 'digoxin' ','
 'disopyramide' ',' 'dronabinol' '(' 'THC' ')' ',' 'ethanol' ','
 'maprotilline' ',' 'memantine' ',' 'metoclopramide' ',' 'nabilone' ','
 'olanzapine' ',' 'opiate' 'agonists' ',' 'orphenadrine' ','
 'phenothiazines' ',' 'potassium' 'salts' ',' 'quinidine' ',' 'sedating'
 'H1-blockers' ',' 'topiramate' ',' 'tricyclic' 'antidepressants' ','
 'erthyromycin' ',' 'ketoconazole' ',' 'and' 'tegaserod']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0.
 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 1. 0. 0. 0. 1.
 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 1. 0. 1. 0. 1. 0. 1. 1. 0. 1. 0. 1.
 1. 0. 1. 0. 1. 1. 0. 1. 0. 1. 0. 0. 1.]"
NCT01898793,"16:31:treatment,46:76:treatment,,152:165:treatment",Able to be off corticosteroids and any other immune suppressive medications beginning on Day -3 and continuing until 30 days after the infusion of the CIML NK cells,"['Able' 'to' 'be' 'off' 'corticosteroids' 'and' 'any' 'other' 'immune'
 'suppressive' 'medications' 'beginning' 'on' 'Day' '-3' 'and'
 'continuing' 'until' '30' 'days' 'after' 'the' 'infusion' 'of' 'the'
 'CIML' 'NK' 'cells']","[0. 0. 0. 0. 1. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 1.]"
NCT01898793,",25:45:treatment,79:82:cancer,99:102:cancer",More than one course of salvage chemotherapy for primary induction failure or AML relapsing after CR1 (phase II only),"['More' 'than' 'one' 'course' 'of' 'salvage' 'chemotherapy' 'for'
 'primary' 'induction' 'failure' 'or' 'AML' 'relapsing' 'after' 'CR1' '('
 'phase' 'II' 'only' ')']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 3. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT01898793,"4:34:cancer,30:33:cancer,,,64:83:chronic_disease,116:144:treatment,,298:309:treatment,328:338:treatment,498:518:treatment,523:549:treatment","OR Myelodysplastic syndrome (MDS) with excess blasts (>5%) and progressive disease at any time after initiation of DNA hypomethylator treatment during the past 2 years, OR failure to achieve complete or partial response or hematological improvement (see section 12.4) after at least six cycles of azacytidine or four cycles of decitabine administered during the past 2 years, OR intolerance to azacytidine or decitabine. MDS patients with isolated 5q- abnormalities that meet these criteria after lenalidomide therapy and DNA hypomethylator therapy are also eligible","['OR' 'Myelodysplastic' 'syndrome' '(' 'MDS' ')' 'with' 'excess' 'blasts'
 '(' '>' '5' '%' ')' 'and' 'progressive' 'disease' 'at' 'any' 'time'
 'after' 'initiation' 'of' 'DNA' 'hypomethylator' 'treatment' 'during'
 'the' 'past' '2' 'years' ',' 'OR' 'failure' 'to' 'achieve' 'complete'
 'or' 'partial' 'response' 'or' 'hematological' 'improvement' '(' 'see'
 'section' '12.4' ')' 'after' 'at' 'least' 'six' 'cycles' 'of'
 'azacytidine' 'or' 'four' 'cycles' 'of' 'decitabine' 'administered'
 'during' 'the' 'past' '2' 'years' ',' 'OR' 'intolerance' 'to'
 'azacytidine' 'or' 'decitabine' '.' 'MDS' 'patients' 'with' 'isolated'
 '5q-' 'abnormalities' 'that' 'meet' 'these' 'criteria' 'after'
 'lenalidomide' 'therapy' 'and' 'DNA' 'hypomethylator' 'therapy' 'are'
 'also' 'eligible']","[0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 1.
 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT01897259,"39:48:treatment,87:102:treatment,113:129:treatment,","pain over the lateral epicondyle (via palpation over the lateral epicondyle, resisted wrist extension, resisted finger extension of the middle finger) for less than six-months duration prior to enrollment","['pain' 'over' 'the' 'lateral' 'epicondyle' '(' 'via' 'palpation' 'over'
 'the' 'lateral' 'epicondyle' ',' 'resisted' 'wrist' 'extension' ','
 'resisted' 'finger' 'extension' 'of' 'the' 'middle' 'finger' ')' 'for'
 'less' 'than' 'six-months' 'duration' 'prior' 'to' 'enrollment']","[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01896999,",,,74:87:chronic_disease,102:108:chronic_disease,130:153:chronic_disease,158:178:treatment,197:205:chronic_disease","Patients must not have New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia","['Patients' 'must' 'not' 'have' 'New' 'York' 'Heart' 'Association' '('
 'NYHA' ')' 'class' 'III' 'or' 'IV' 'heart' 'failure' ',' 'uncontrolled'
 'angina' ',' 'severe' 'uncontrolled' 'ventricular' 'arrhythmias' ',' 'or'
 'electrocardiographic' 'evidence' 'of' 'acute' 'ischemia']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 0. 0. 0. 2.
 2. 0. 0. 1. 0. 0. 0. 2.]"
NCT01896999,"58:82:treatment,119:134:treatment,229:248:treatment",for the purposes of this study monoclonal antibodies and antibody drug conjugates are not considered to be activating immunotherapies and there are no additional time restrictions on prior exposure to these agents (except prior brentuximab vedotin),"['for' 'the' 'purposes' 'of' 'this' 'study' 'monoclonal' 'antibodies'
 'and' 'antibody' 'drug' 'conjugates' 'are' 'not' 'considered' 'to' 'be'
 'activating' 'immunotherapies' 'and' 'there' 'are' 'no' 'additional'
 'time' 'restrictions' 'on' 'prior' 'exposure' 'to' 'these' 'agents' '('
 'except' 'prior' 'brentuximab' 'vedotin' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]"
NCT01896921,"1:17:treatment,27:39:treatment,41:53:treatment,55:69:treatment,71:81:treatment,87:100:treatment","CYP3A inhibitors (such as ketoconazole, itraconazole, clarithromycin, nefazodone, and telithromycin)","['CYP3A' 'inhibitors' '(' 'such' 'as' 'ketoconazole' ',' 'itraconazole'
 ',' 'clarithromycin' ',' 'nefazodone' ',' 'and' 'telithromycin' ')']",[1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 0.]
NCT01895881,",34:64:chronic_disease,78:98:treatment,100:130:treatment,134:165:treatment","At least one documented saccular intracranial cerebral aneurysm detected via catheter angiography, magnetic resonance angiography or computed tomography angiography","['At' 'least' 'one' 'documented' 'saccular' 'intracranial' 'cerebral'
 'aneurysm' 'detected' 'via' 'catheter' 'angiography' ',' 'magnetic'
 'resonance' 'angiography' 'or' 'computed' 'tomography' 'angiography']",[0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 1. 1. 0. 1. 1. 1. 0. 1. 1. 1.]
NCT01895777,"1:31:treatment,56:63:treatment,113:131:chronic_disease",unwarranted radiation exposure as a result of a repeat CT scan at day 84 for a patient with an isolated case of pulmonary embolism evaluated at baseline solely by a CT scan,"['unwarranted' 'radiation' 'exposure' 'as' 'a' 'result' 'of' 'a' 'repeat'
 'CT' 'scan' 'at' 'day' '84' 'for' 'a' 'patient' 'with' 'an' 'isolated'
 'case' 'of' 'pulmonary' 'embolism' 'evaluated' 'at' 'baseline' 'solely'
 'by' 'a' 'CT' 'scan']","[1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01894061,"34:44:cancer,71:76:cancer,80:115:cancer,119:161:cancer,,,196:202:cancer,232:250:treatment","Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix and breast, adequately treated stage I or II cancer from which the patient is in complete remission","['Patients' 'must' 'have' 'no' 'concurrent' 'malignancy' 'except'
 'curatively' 'treated' 'basal' 'or' 'squamous' 'cell' 'carcinoma' 'of'
 'the' 'skin' 'or' 'carcinoma' 'in' 'situ' 'of' 'the' 'cervix' 'and'
 'breast' ',' 'adequately' 'treated' 'stage' 'I' 'or' 'II' 'cancer' 'from'
 'which' 'the' 'patient' 'is' 'in' 'complete' 'remission']","[0. 0. 0. 0. 0. 3. 0. 0. 0. 3. 0. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 1. 1.]"
NCT01893554,"14:24:treatment,14:34:treatment,,84:104:treatment",Has received salicylate (aspirin) or salicylate-containing products within 28 days prior to inoculation,"['Has' 'received' 'salicylate' '(' 'aspirin' ')' 'or'
 'salicylate-containing' 'products' 'within' '28' 'days' 'prior' 'to'
 'inoculation']",[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]
NCT01893554,"1:5:chronic_disease,9:22:chronic_disease,56:79:chronic_disease","Lung or heart disease, including any wheezing event or reactive airway disease","['Lung' 'or' 'heart' 'disease' ',' 'including' 'any' 'wheezing' 'event'
 'or' 'reactive' 'airway' 'disease']",[2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 2.]
NCT01893554,"20:43:treatment,47:67:treatment,,100:127:treatment",Receipt of another investigational vaccine or investigational drug 28 days prior to receiving this investigational RSV vaccine,"['Receipt' 'of' 'another' 'investigational' 'vaccine' 'or'
 'investigational' 'drug' '28' 'days' 'prior' 'to' 'receiving' 'this'
 'investigational' 'RSV' 'vaccine']",[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01891812,",,132:158:treatment,165:174:treatment,176:184:treatment,189:195:treatment","Present to the pediatric emergency department with VOC and whose pain scores remain greater than or equal to 7/10 on the NRS after initial standard treatment (i.e. IV fluids, morphine and NSAIDs)","['Present' 'to' 'the' 'pediatric' 'emergency' 'department' 'with' 'VOC'
 'and' 'whose' 'pain' 'scores' 'remain' 'greater' 'than' 'or' 'equal' 'to'
 '7/10' 'on' 'the' 'NRS' 'after' 'initial' 'standard' 'treatment' '('
 'i.e' '.' 'IV' 'fluids' ',' 'morphine' 'and' 'NSAIDs' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 1. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0.]"
NCT01890395,"29:48:treatment,66:82:treatment,98:102:treatment,104:114:treatment,116:122:treatment,132:158:treatment,160:187:treatment,196:212:treatment,214:230:treatment,244:263:treatment,323:352:chronic_disease","Patients @ USAMC undergoing surgical operations expected to have microcirculatory changes, i.e., CABG, open heart, aortic or other revascularizing operations, general surgical operations such as colon resections, bowel resections or any other surgical procedures in which the subject could be expected to or might develop multiple system organ failure","['Patients' '@' 'USAMC' 'undergoing' 'surgical' 'operations' 'expected'
 'to' 'have' 'microcirculatory' 'changes' ',' 'i.e.' ',' 'CABG' ',' 'open'
 'heart' ',' 'aortic' 'or' 'other' 'revascularizing' 'operations' ','
 'general' 'surgical' 'operations' 'such' 'as' 'colon' 'resections' ','
 'bowel' 'resections' 'or' 'any' 'other' 'surgical' 'procedures' 'in'
 'which' 'the' 'subject' 'could' 'be' 'expected' 'to' 'or' 'might'
 'develop' 'multiple' 'system' 'organ' 'failure']","[0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 1. 1. 0. 1. 0. 0. 1. 1.
 0. 1. 1. 1. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 2. 2. 2. 2.]"
NCT01884740,"10:19:treatment,25:32:treatment,37:46:treatment",Previous treatment with Avastin and Cetuximab,['Previous' 'treatment' 'with' 'Avastin' 'and' 'Cetuximab'],[0. 1. 0. 1. 0. 1.]
NCT01883258,"25:48:chronic_disease,50:71:chronic_disease,73:88:chronic_disease,101:131:treatment,135:146:treatment,148:172:chronic_disease,177:187:chronic_disease","History of any relevant cardiovascular diseases (myocardial infarction, angina pectoris, history of coronary artery bypass surgery or angioplasty, congestive heart failure, or arrhythmia)","['History' 'of' 'any' 'relevant' 'cardiovascular' 'diseases' '('
 'myocardial' 'infarction' ',' 'angina' 'pectoris' ',' 'history' 'of'
 'coronary' 'artery' 'bypass' 'surgery' 'or' 'angioplasty' ','
 'congestive' 'heart' 'failure' ',' 'or' 'arrhythmia' ')']","[0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0. 1. 1. 1. 1. 0. 1. 0. 2. 2.
 2. 0. 0. 2. 0.]"
NCT01880567,"17:20:chronic_disease,28:31:chronic_disease,64:75:chronic_disease",Newly diagnosed MCL: Known HIV infection; patients with active hepatitis B infection,"['Newly' 'diagnosed' 'MCL' ':' 'Known' 'HIV' 'infection' ';' 'patients'
 'with' 'active' 'hepatitis' 'B' 'infection']",[0. 0. 2. 0. 0. 2. 0. 0. 0. 0. 0. 2. 2. 0.]
NCT01880567,"17:20:chronic_disease,28:37:treatment,43:52:treatment",Newly diagnosed MCL: Prior treatment with ibrutinib,['Newly' 'diagnosed' 'MCL' ':' 'Prior' 'treatment' 'with' 'ibrutinib'],[0. 0. 2. 0. 0. 1. 0. 1.]
NCT01880567,"21:24:cancer,26:48:chronic_disease,155:173:chronic_disease,175:213:chronic_disease,229:255:chronic_disease","Relapsed/refractory MCL: Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction","['Relapsed/refractory' 'MCL' ':' 'Malabsorption' 'syndrome' ',' 'disease'
 'significantly' 'affecting' 'gastrointestinal' 'function' ',' 'or'
 'resection' 'of' 'the' 'stomach' 'or' 'small' 'bowel' 'or' 'ulcerative'
 'colitis' ',' 'symptomatic' 'inflammatory' 'bowel' 'disease' ',' 'or'
 'partial' 'or' 'complete' 'bowel' 'obstruction']","[0. 3. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0.
 2. 2. 2. 2. 0. 0. 0. 0. 2. 2. 2.]"
NCT01880567,"21:24:cancer,35:72:treatment,74:82:treatment,84:95:treatment,97:134:treatment","Relapsed/refractory MCL: Requires treatment with strong cytochrome P450, family 3, subfamily A, polypeptide 4/5 (CYP3A4/5) inhibitors","['Relapsed/refractory' 'MCL' ':' 'Requires' 'treatment' 'with' 'strong'
 'cytochrome' 'P450' ',' 'family' '3' ',' 'subfamily' 'A' ','
 'polypeptide' '4/5' '(' 'CYP3A4/5' ')' 'inhibitors']",[0. 3. 0. 0. 1. 1. 1. 1. 1. 0. 1. 1. 0. 1. 1. 0. 1. 1. 1. 1. 0. 0.]
NCT01880567,"14:26:chronic_disease,41:58:chronic_disease,79:102:chronic_disease,104:120:chronic_disease,122:139:chronic_disease,144:163:chronic_disease","uncontrolled hypertension, uncontrolled diabetes mellitus, active/symptomatic coronary artery disease, active infection, active hemorrhage, or psychiatric illness","['uncontrolled' 'hypertension' ',' 'uncontrolled' 'diabetes' 'mellitus'
 ',' 'active/symptomatic' 'coronary' 'artery' 'disease' ',' 'active'
 'infection' ',' 'active' 'hemorrhage' ',' 'or' 'psychiatric' 'illness']",[0. 2. 0. 0. 2. 2. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01878617,"13:25:treatment,18:25:treatment,27:39:treatment,49:60:cancer,89:111:treatment,116:123:treatment","No previous radiotherapy, chemotherapy or other brain tumor directed therapy other than corticosteroid therapy and surgery","['No' 'previous' 'radiotherapy' ',' 'chemotherapy' 'or' 'other' 'brain'
 'tumor' 'directed' 'therapy' 'other' 'than' 'corticosteroid' 'therapy'
 'and' 'surgery']",[0. 0. 1. 0. 1. 0. 0. 3. 3. 0. 1. 0. 0. 1. 1. 0. 1.]
NCT01877382,"59:70:cancer,74:82:cancer,126:144:treatment",Has a histologically or cytologically documented advanced solid tumor or lymphoma that has relapsed from or is refractory to standard treatment,"['Has' 'a' 'histologically' 'or' 'cytologically' 'documented' 'advanced'
 'solid' 'tumor' 'or' 'lymphoma' 'that' 'has' 'relapsed' 'from' 'or' 'is'
 'refractory' 'to' 'standard' 'treatment']",[0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01876511,"31:50:treatment,52:72:treatment,74:84:treatment,105:127:treatment,129:153:treatment,161:186:treatment,205:229:treatment,","received any of the following concomitant therapy: Interleukin-2 (IL-2), interferon, or other non-study immunotherapy regimens, immunosuppressive agents, other investigational therapies or chronic use of systemic corticosteroids within one week prior to first dose of study drug","['received' 'any' 'of' 'the' 'following' 'concomitant' 'therapy' ':'
 'Interleukin-2' '(' 'IL-2' ')' ',' 'interferon' ',' 'or' 'other'
 'non-study' 'immunotherapy' 'regimens' ',' 'immunosuppressive' 'agents'
 ',' 'other' 'investigational' 'therapies' 'or' 'chronic' 'use' 'of'
 'systemic' 'corticosteroids' 'within' 'one' 'week' 'prior' 'to' 'first'
 'dose' 'of' 'study' 'drug']","[0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0.
 0. 1. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01872975,"44:50:cancer,67:89:cancer,105:109:cancer,123:140:treatment","Any prior history, not including the index cancer, of ipsilateral invasive breast cancer or ipsilateral DCIS treated with radiation therapy","['Any' 'prior' 'history' ',' 'not' 'including' 'the' 'index' 'cancer' ','
 'of' 'ipsilateral' 'invasive' 'breast' 'cancer' 'or' 'ipsilateral' 'DCIS'
 'treated' 'with' 'radiation' 'therapy']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 3. 3. 3. 0. 0. 3. 0. 0. 1. 1.]
NCT01872975,"1:3:cancer,7:17:cancer,44:51:treatment",N2 or N3 disease detected clinically or by imaging,['N2' 'or' 'N3' 'disease' 'detected' 'clinically' 'or' 'by' 'imaging'],[3. 0. 3. 3. 0. 0. 0. 0. 1.]
NCT01872975,"54:74:cancer,75:106:treatment,223:236:cancer",Patients must have had HER2 testing performed on the primary breast tumor before neoadjuvant chemotherapy according to the current ASCO/CAP guideline recommendations for human epidermal growth factor receptor 2 testing in Breast Cancer (http://www.asco.org),"['Patients' 'must' 'have' 'had' 'HER2' 'testing' 'performed' 'on' 'the'
 'primary' 'breast' 'tumor' 'before' 'neoadjuvant' 'chemotherapy'
 'according' 'to' 'the' 'current' 'ASCO/CAP' 'guideline' 'recommendations'
 'for' 'human' 'epidermal' 'growth' 'factor' 'receptor' '2' 'testing' 'in'
 'Breast' 'Cancer' '(' 'http' ':' '//www.asco.org' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0.]"
NCT01871766,"12:21:cancer,23:31:cancer,33:45:cancer,47:55:cancer,57:73:cancer,78:92:cancer,98:116:cancer","High-risk: Embryonal, botryoid, spindle cell, alveolar, undifferentiated, or anaplastic RMS with metastatic disease at diagnosis (stage 4)","['High-risk' ':' 'Embryonal' ',' 'botryoid' ',' 'spindle' 'cell' ','
 'alveolar' ',' 'undifferentiated' ',' 'or' 'anaplastic' 'RMS' 'with'
 'metastatic' 'disease' 'at' 'diagnosis' '(' 'stage' '4' ')']","[0. 0. 3. 0. 3. 0. 3. 3. 0. 3. 0. 3. 0. 0. 3. 3. 0. 3. 3. 0. 0. 0. 0. 0.
 0.]"
NCT01871727,"8:18:cancer,31:35:cancer,58:102:cancer,108:125:cancer,108:139:cancer,","Active malignancy (except for CTCL, definitively treated basal or squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix) within the past 24 months","['Active' 'malignancy' '(' 'except' 'for' 'CTCL' ',' 'definitively'
 'treated' 'basal' 'or' 'squamous' 'cell' 'carcinoma' 'of' 'the' 'skin'
 ',' 'and' 'carcinoma' 'in-situ' 'of' 'the' 'cervix' ')' 'within' 'the'
 'past' '24' 'months']","[0. 3. 0. 0. 0. 3. 0. 0. 0. 3. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01871727,"7:51:chronic_disease,66:77:chronic_disease,81:102:chronic_disease",Known human immunodeficiency virus (HIV) infection; known active hepatitis B or hepatitis C infection,"['Known' 'human' 'immunodeficiency' 'virus' '(' 'HIV' ')' 'infection' ';'
 'known' 'active' 'hepatitis' 'B' 'or' 'hepatitis' 'C' 'infection']",[0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0.]
NCT01871454,"71:81:cancer,87:99:treatment,101:122:treatment","A reasonable attempt should be made to make a pathologic diagnosis of malignancy (ie. bronchoscopy, CT guided lung biopsy)","['A' 'reasonable' 'attempt' 'should' 'be' 'made' 'to' 'make' 'a'
 'pathologic' 'diagnosis' 'of' 'malignancy' '(' 'ie' '.' 'bronchoscopy'
 ',' 'CT' 'guided' 'lung' 'biopsy' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 1. 0. 1. 1. 1. 1. 0.]
NCT01869114,"33:44:treatment,48:58:treatment,96:99:chronic_disease",Patient may have previously had azacitidine or decitabine will be eligible to enroll on Arm A (MDS),"['Patient' 'may' 'have' 'previously' 'had' 'azacitidine' 'or' 'decitabine'
 'will' 'be' 'eligible' 'to' 'enroll' 'on' 'Arm' 'A' '(' 'MDS' ')']",[0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT01869114,"1:11:treatment,18:25:treatment,39:55:treatment,105:114:treatment",Tacrolimus (e.g. Prograf) - May cause liver transplant rejection or serious side effects in patients on sirolimus,"['Tacrolimus' '(' 'e.g' '.' 'Prograf' ')' '-' 'May' 'cause' 'liver'
 'transplant' 'rejection' 'or' 'serious' 'side' 'effects' 'in' 'patients'
 'on' 'sirolimus']",[1. 0. 0. 0. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01865162,"44:72:treatment,74:83:treatment,88:113:treatment","Documented recurrence or progression after surgical resection/debulking, radiation and temozolamide chemotherapy","['Documented' 'recurrence' 'or' 'progression' 'after' 'surgical'
 'resection/debulking' ',' 'radiation' 'and' 'temozolamide' 'chemotherapy']",[0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 1.]
NCT01864265,"34:44:treatment,48:62:treatment,66:76:treatment,105:114:treatment,118:120:chronic_disease",Patients treated before with any biological or small molecule or medication under investigation for the treatment of RA,"['Patients' 'treated' 'before' 'with' 'any' 'biological' 'or' 'small'
 'molecule' 'or' 'medication' 'under' 'investigation' 'for' 'the'
 'treatment' 'of' 'RA']",[0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 1. 0. 0. 0. 0. 1. 0. 2.]
NCT01861106,"25:35:treatment,79:84:cancer,106:121:treatment",The risk/benefit of the transplant and the possibility of transmitting viable tumor cells at the time of transplantation will be discussed with the patient,"['The' 'risk/benefit' 'of' 'the' 'transplant' 'and' 'the' 'possibility'
 'of' 'transmitting' 'viable' 'tumor' 'cells' 'at' 'the' 'time' 'of'
 'transplantation' 'will' 'be' 'discussed' 'with' 'the' 'patient']",[0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01859819,"16:32:cancer,,49:57:cancer,58:66:cancer",ewly diagnosed mature B-lineage (CD20 positive) Leukemia/Lymphoma,"['ewly' 'diagnosed' 'mature' 'B-lineage' '(' 'CD20' 'positive' ')'
 'Leukemia/Lymphoma']",[0. 0. 3. 3. 0. 0. 0. 0. 3.]
NCT01858168,"15:36:treatment,38:50:treatment,,133:142:treatment","Receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), within 2 weeks from the last dose prior to study treatment","['Receiving' 'any' 'systemic' 'chemotherapy' ',' 'radiotherapy' '('
 'except' 'for' 'palliative' 'reasons' ')' ',' 'within' '2' 'weeks' 'from'
 'the' 'last' 'dose' 'prior' 'to' 'study' 'treatment']",[0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01851369,"34:46:treatment,48:65:treatment,70:86:treatment,,,,201:213:treatment,217:228:treatment,,317:327:treatment,,402:430:treatment,522:552:treatment","Patients must have completed any chemotherapy, radiation therapy, or biologic therapy greater than or equal to 4 weeks (or 5 half-lives, whichever is shorter) prior to entering the study (6 weeks for nitrosoureas or mitomycin C). Patients must be greater than or equal to 2 weeks since any prior administration of a study drug in a Phase 0 or equivalent study and greater than or equal to 1 week from palliative radiation therapy. Patients must have recovered to eligibility levels from prior toxicity or adverse events. Treatment with bisphosphonates is permitted","['Patients' 'must' 'have' 'completed' 'any' 'chemotherapy' ',' 'radiation'
 'therapy' ',' 'or' 'biologic' 'therapy' 'greater' 'than' 'or' 'equal'
 'to' '4' 'weeks' '(' 'or' '5' 'half-lives' ',' 'whichever' 'is' 'shorter'
 ')' 'prior' 'to' 'entering' 'the' 'study' '(' '6' 'weeks' 'for'
 'nitrosoureas' 'or' 'mitomycin' 'C' ')' '.' 'Patients' 'must' 'be'
 'greater' 'than' 'or' 'equal' 'to' '2' 'weeks' 'since' 'any' 'prior'
 'administration' 'of' 'a' 'study' 'drug' 'in' 'a' 'Phase' '0' 'or'
 'equivalent' 'study' 'and' 'greater' 'than' 'or' 'equal' 'to' '1' 'week'
 'from' 'palliative' 'radiation' 'therapy' '.' 'Patients' 'must' 'have'
 'recovered' 'to' 'eligibility' 'levels' 'from' 'prior' 'toxicity' 'or'
 'adverse' 'events' '.' 'Treatment' 'with' 'bisphosphonates' 'is'
 'permitted']","[0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 1. 1. 0. 0.]"
NCT01851369,"36:61:cancer,,89:96:treatment,98:103:cancer,143:172:cancer,","Phase II: histologically confirmed colorectal adenocarcinoma post at least two lines of therapy, NSCLC post at least two lines of therapy, or granulosa cell ovarian cancer post at least one line of therapy. Patients must have measurable disease","['Phase' 'II' ':' 'histologically' 'confirmed' 'colorectal'
 'adenocarcinoma' 'post' 'at' 'least' 'two' 'lines' 'of' 'therapy' ','
 'NSCLC' 'post' 'at' 'least' 'two' 'lines' 'of' 'therapy' ',' 'or'
 'granulosa' 'cell' 'ovarian' 'cancer' 'post' 'at' 'least' 'one' 'line'
 'of' 'therapy' '.' 'Patients' 'must' 'have' 'measurable' 'disease']","[0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 1. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01850758,"92:114:treatment,121:127:treatment,149:165:treatment,,","Pain, swelling, or functional disability in the affected knee with activity, having failed conservative treatment (e.g. NSAIDs, physician initiated physical therapy) for at least 3 months or unable to return to normal day to day activities by 6 weeks","['Pain' ',' 'swelling' ',' 'or' 'functional' 'disability' 'in' 'the'
 'affected' 'knee' 'with' 'activity' ',' 'having' 'failed' 'conservative'
 'treatment' '(' 'e.g' '.' 'NSAIDs' ',' 'physician' 'initiated' 'physical'
 'therapy' ')' 'for' 'at' 'least' '3' 'months' 'or' 'unable' 'to' 'return'
 'to' 'normal' 'day' 'to' 'day' 'activities' 'by' '6' 'weeks']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 0.
 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01849146,"1:35:chronic_disease,57:91:treatment,136:164:treatment",Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with AZD1775 (MK-1775),"['Human' 'immunodeficiency' 'virus' '(' 'HIV' ')' '-positive' 'patients'
 'on' 'combination' 'antiretroviral' 'therapy' 'are' 'ineligible'
 'because' 'of' 'the' 'potential' 'for' 'pharmacokinetic' 'interactions'
 'with' 'AZD1775' '(' 'MK-1775' ')']","[2. 2. 2. 2. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 0.]"
NCT01849146,"34:46:cancer,90:107:treatment,112:124:treatment",have prior histologically proven glioblastoma that is progressive or recurrent following radiation therapy +/- chemotherapy,"['have' 'prior' 'histologically' 'proven' 'glioblastoma' 'that' 'is'
 'progressive' 'or' 'recurrent' 'following' 'radiation' 'therapy' '+/-'
 'chemotherapy']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1.]
NCT01849146,"13:18:cancer,87:96:treatment,113:125:cancer",must have a tumor tissue form indicating availability of archived tissue from initial resection at diagnosis of glioblastoma completed and signed by a pathologist,"['must' 'have' 'a' 'tumor' 'tissue' 'form' 'indicating' 'availability'
 'of' 'archived' 'tissue' 'from' 'initial' 'resection' 'at' 'diagnosis'
 'of' 'glioblastoma' 'completed' 'and' 'signed' 'by' 'a' 'pathologist']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0.]
NCT01842399,"28:41:treatment,43:50:treatment,54:60:treatment,110:123:treatment","Taking supplements such as Ginkgo biloba, Ginseng or Ginger due to their increased risk of bleeding with the muscle biopsy","['Taking' 'supplements' 'such' 'as' 'Ginkgo' 'biloba' ',' 'Ginseng' 'or'
 'Ginger' 'due' 'to' 'their' 'increased' 'risk' 'of' 'bleeding' 'with'
 'the' 'muscle' 'biopsy']",[0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1.]
NCT01841333,"28:32:treatment,61:85:cancer,101:115:treatment","High risk of relapse after HSCT, defined as the presence of minimal residual disease as measured by flow cytometry in the absence of evidence of morphologic disease on a bone marrow biopsy prior to HSCT","['High' 'risk' 'of' 'relapse' 'after' 'HSCT' ',' 'defined' 'as' 'the'
 'presence' 'of' 'minimal' 'residual' 'disease' 'as' 'measured' 'by'
 'flow' 'cytometry' 'in' 'the' 'absence' 'of' 'evidence' 'of'
 'morphologic' 'disease' 'on' 'a' 'bone' 'marrow' 'biopsy' 'prior' 'to'
 'HSCT']","[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 1. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01835626,"1:4:chronic_disease,38:60:treatment,125:135:treatment","HIV-positive patients on combination antiretroviral therapy, because of the potential for pharmacokinetic interactions with vismodegib","['HIV-positive' 'patients' 'on' 'combination' 'antiretroviral' 'therapy'
 ',' 'because' 'of' 'the' 'potential' 'for' 'pharmacokinetic'
 'interactions' 'with' 'vismodegib']",[2. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01835626,"1:24:treatment,7:16:treatment,123:142:treatment","Prior radiation therapy is acceptable but there cannot be major overlap of the previously irradiated tissues with the new radiation treatment volumes anticipated to be delivered for the purposes of this protocol, in such a way that curative intent with radiation cannot be met","['Prior' 'radiation' 'therapy' 'is' 'acceptable' 'but' 'there' 'can' 'not'
 'be' 'major' 'overlap' 'of' 'the' 'previously' 'irradiated' 'tissues'
 'with' 'the' 'new' 'radiation' 'treatment' 'volumes' 'anticipated' 'to'
 'be' 'delivered' 'for' 'the' 'purposes' 'of' 'this' 'protocol' ',' 'in'
 'such' 'a' 'way' 'that' 'curative' 'intent' 'with' 'radiation' 'can'
 'not' 'be' 'met']","[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01829958,"18:27:treatment,52:58:treatment,60:67:treatment,71:77:treatment,128:146:treatment","Intended initial treatment to include ≥2 cycles of R-CHOP, R-EPOCH or R-CEPP using standard doses and schedule.(68, 69) R-CHOP chemoimmunotherapy may be given every 14 days or every 21 days","['Intended' 'initial' 'treatment' 'to' 'include' '≥2' 'cycles' 'of'
 'R-CHOP' ',' 'R-EPOCH' 'or' 'R-CEPP' 'using' 'standard' 'doses' 'and'
 'schedule' '.' '(' '68' ',' '69' ')' 'R-CHOP' 'chemoimmunotherapy' 'may'
 'be' 'given' 'every' '14' 'days' 'or' 'every' '21' 'days']","[0. 0. 1. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01829360,"50:53:chronic_disease,61:67:chronic_disease,69:93:chronic_disease,95:111:chronic_disease","other disorder that would exclude a diagnosis of SLI (e.g., autism, developmental disability, seizure disorder)","['other' 'disorder' 'that' 'would' 'exclude' 'a' 'diagnosis' 'of' 'SLI'
 '(' 'e.g.' ',' 'autism' ',' 'developmental' 'disability' ',' 'seizure'
 'disorder' ')']",[0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 2. 0. 2. 2. 0. 2. 2. 0.]
NCT01827384,"15:30:cancer,34:47:chronic_disease,51:87:treatment,89:98:treatment","Patients with bone metastases or hypercalcemia on intravenous bisphosphonate treatment, denosumab, or similar agents","['Patients' 'with' 'bone' 'metastases' 'or' 'hypercalcemia' 'on'
 'intravenous' 'bisphosphonate' 'treatment' ',' 'denosumab' ',' 'or'
 'similar' 'agents']",[0. 0. 3. 3. 0. 2. 0. 1. 1. 1. 0. 1. 0. 0. 0. 0.]
NCT01827384,"41:53:cancer,,114:130:treatment,153:162:treatment",Patients with histologically documented solid tumors whose disease has progressed following at least one line of standard therapy and/or no standard of treatment exists that has been shown to prolong survival,"['Patients' 'with' 'histologically' 'documented' 'solid' 'tumors' 'whose'
 'disease' 'has' 'progressed' 'following' 'at' 'least' 'one' 'line' 'of'
 'standard' 'therapy' 'and/or' 'no' 'standard' 'of' 'treatment' 'exists'
 'that' 'has' 'been' 'shown' 'to' 'prolong' 'survival']","[0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT01827384,"79:98:chronic_disease,182:206:chronic_disease,208:232:chronic_disease,234:252:chronic_disease,254:275:chronic_disease,,298:324:chronic_disease,329:335:chronic_disease,371:387:chronic_disease,389:402:chronic_disease,411:420:chronic_disease,422:449:chronic_disease,466:483:chronic_disease","Patients with uncontrolled intercurrent illness including, but not limited to psychiatric illness/social situations that would limit compliance with study requirements, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, myocardial infarction in the past 6 months, invasive fungal infections, or active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis (i.e., quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA)","['Patients' 'with' 'uncontrolled' 'intercurrent' 'illness' 'including' ','
 'but' 'not' 'limited' 'to' 'psychiatric' 'illness/social' 'situations'
 'that' 'would' 'limit' 'compliance' 'with' 'study' 'requirements' ','
 'symptomatic' 'congestive' 'heart' 'failure' ',' 'unstable' 'angina'
 'pectoris' ',' 'cardiac' 'arrhythmia' ',' 'myocardial' 'infarction' 'in'
 'the' 'past' '6' 'months' ',' 'invasive' 'fungal' 'infections' ',' 'or'
 'active' '(' 'acute' 'or' 'chronic' ')' 'or' 'uncontrolled' 'severe'
 'infection' ',' 'liver' 'disease' 'such' 'as' 'cirrhosis' ','
 'decompensated' 'liver' 'disease' ',' 'and' 'active' 'and' 'chronic'
 'hepatitis' '(' 'i.e.' ',' 'quantifiable' 'HBV-DNA' 'and/or' 'positive'
 'HbsAg' ',' 'quantifiable' 'HCV-RNA' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 2.
 0. 0. 0. 2. 2. 0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01824836,"42:55:treatment,60:81:treatment,86:99:cancer",Patients must have completed recommended local therapy and adjuvant chemotherapy for breast cancer,"['Patients' 'must' 'have' 'completed' 'recommended' 'local' 'therapy'
 'and' 'adjuvant' 'chemotherapy' 'for' 'breast' 'cancer']",[0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 3. 3.]
NCT01822522,"1:17:chronic_disease,28:46:treatment,37:46:treatment,",Active infection requiring systemic treatment within 28 days before the first dose of study treatment,"['Active' 'infection' 'requiring' 'systemic' 'treatment' 'within' '28'
 'days' 'before' 'the' 'first' 'dose' 'of' 'study' 'treatment']",[2. 2. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01822522,"16:28:treatment,151:169:treatment,205:216:treatment,,,","The effects of cabozantinib on the developing human fetus are unknown; for this reason and because tyrosine kinase inhibitors agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation","['The' 'effects' 'of' 'cabozantinib' 'on' 'the' 'developing' 'human'
 'fetus' 'are' 'unknown' ';' 'for' 'this' 'reason' 'and' 'because'
 'tyrosine' 'kinase' 'inhibitors' 'agents' 'as' 'well' 'as' 'other'
 'therapeutic' 'agents' 'used' 'in' 'this' 'trial' 'are' 'known' 'to' 'be'
 'teratogenic' ',' 'women' 'of' 'child-bearing' 'potential' 'and' 'men'
 'must' 'agree' 'to' 'use' 'adequate' 'contraception' 'prior' 'to' 'study'
 'entry' 'and' 'for' 'the' 'duration' 'of' 'study' 'participation']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01822522,"10:23:treatment,29:71:treatment,75:113:treatment,142:158:cancer",baseline brain imaging with contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) scans for participants with known brain metastases is required to confirm eligibility,"['baseline' 'brain' 'imaging' 'with' 'contrast-enhanced' 'computed'
 'tomography' '(' 'CT' ')' 'or' 'magnetic' 'resonance' 'imaging' '(' 'MRI'
 ')' 'scans' 'for' 'participants' 'with' 'known' 'brain' 'metastases' 'is'
 'required' 'to' 'confirm' 'eligibility']","[0. 3. 3. 0. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT01822522,"15:45:treatment,49:68:treatment,70:79:treatment,81:90:treatment,92:111:treatment,113:123:treatment,125:135:treatment,179:189:treatment,239:273:treatment,325:342:treatment","use of any of anti-retrovirals (delavirdine) or protease inhibitors (ritonavir, indinavir, lopinavir/ritonavir, saquinavir, nelfinavir) is permitted; specifically, ritonavir and cobicistat is permitted for participants considered for the CYP3A4-inhibitor based ART regimen arm (Stratum A) of the trial; because the lists of CYP3A4 inhibitors are constantly changing, it is important to regularly consult a frequently-updated list; medical reference texts such as the physicians' desk reference may also provide this information; as part of the enrollment/informed consent procedures","['use' 'of' 'any' 'of' 'anti-retrovirals' '(' 'delavirdine' ')' 'or'
 'protease' 'inhibitors' '(' 'ritonavir' ',' 'indinavir' ','
 'lopinavir/ritonavir' ',' 'saquinavir' ',' 'nelfinavir' ')' 'is'
 'permitted' ';' 'specifically' ',' 'ritonavir' 'and' 'cobicistat' 'is'
 'permitted' 'for' 'participants' 'considered' 'for' 'the'
 'CYP3A4-inhibitor' 'based' 'ART' 'regimen' 'arm' '(' 'Stratum' 'A' ')'
 'of' 'the' 'trial' ';' 'because' 'the' 'lists' 'of' 'CYP3A4' 'inhibitors'
 'are' 'constantly' 'changing' ',' 'it' 'is' 'important' 'to' 'regularly'
 'consult' 'a' 'frequently-updated' 'list' ';' 'medical' 'reference'
 'texts' 'such' 'as' 'the' 'physicians' ""'"" 'desk' 'reference' 'may'
 'also' 'provide' 'this' 'information' ';' 'as' 'part' 'of' 'the'
 'enrollment/informed' 'consent' 'procedures']","[0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01817751,"24:39:chronic_disease,57:76:chronic_disease,86:105:chronic_disease,116:140:chronic_disease,,","Clinically significant cardiac disease, including major cardiac dysfunction, such as uncontrolled angina, clinical congestive heart failure with New York Heart Association (NYHA) class III or higher","['Clinically' 'significant' 'cardiac' 'disease' ',' 'including' 'major'
 'cardiac' 'dysfunction' ',' 'such' 'as' 'uncontrolled' 'angina' ','
 'clinical' 'congestive' 'heart' 'failure' 'with' 'New' 'York' 'Heart'
 'Association' '(' 'NYHA' ')' 'class' 'III' 'or' 'higher']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT01817751,"61:79:treatment,102:115:treatment,119:128:treatment",efforts may be made by the treating physician to change the antiepileptic drug from another agent to valproic acid or non-EIAED prior to excluding the patient from study,"['efforts' 'may' 'be' 'made' 'by' 'the' 'treating' 'physician' 'to'
 'change' 'the' 'antiepileptic' 'drug' 'from' 'another' 'agent' 'to'
 'valproic' 'acid' 'or' 'non-EIAED' 'prior' 'to' 'excluding' 'the'
 'patient' 'from' 'study']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01815359,"21:32:allergy_name,34:44:allergy_name,49:58:allergy_name","Patients with known floxuridine, leucovorin ,or mitomycin allergy","['Patients' 'with' 'known' 'floxuridine' ',' 'leucovorin' ',' 'or'
 'mitomycin' 'allergy']",[0. 0. 0. 4. 0. 4. 0. 0. 4. 0.]
NCT01807897,"18:42:treatment,18:49:treatment,112:138:treatment,143:170:treatment",Current use of a positive airway pressure device (including continuous or bi-level positive airway pressure or adaptive servo-ventilation) or supplemental oxygen therapy,"['Current' 'use' 'of' 'a' 'positive' 'airway' 'pressure' 'device' '('
 'including' 'continuous' 'or' 'bi-level' 'positive' 'airway' 'pressure'
 'or' 'adaptive' 'servo-ventilation' ')' 'or' 'supplemental' 'oxygen'
 'therapy']",[0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 1.]
NCT01807091,"48:59:chronic_disease,63:78:chronic_disease,82:106:chronic_disease",no ongoing cardiac issues such as uncontrolled arrhythmias or unstable angina or congestive heart failure,"['no' 'ongoing' 'cardiac' 'issues' 'such' 'as' 'uncontrolled'
 'arrhythmias' 'or' 'unstable' 'angina' 'or' 'congestive' 'heart'
 'failure']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 2. 2. 2.]
NCT01804634,"15:37:treatment,43:55:treatment,59:80:treatment",Refractory to induction chemotherapy with COG ANBL0532 or standard chemotherapy,"['Refractory' 'to' 'induction' 'chemotherapy' 'with' 'COG' 'ANBL0532' 'or'
 'standard' 'chemotherapy']",[0. 0. 1. 1. 0. 1. 1. 0. 1. 1.]
NCT01804465,"7:24:treatment,142:151:treatment,153:160:treatment","If no prior orchiectomy has been performed, patients must remain on luteinizing hormone-releasing hormone (LHRH) agonist or antagonist (e.g. degarelix) therapy","['If' 'no' 'prior' 'orchiectomy' 'has' 'been' 'performed' ',' 'patients'
 'must' 'remain' 'on' 'luteinizing' 'hormone-releasing' 'hormone' '('
 'LHRH' ')' 'agonist' 'or' 'antagonist' '(' 'e.g' '.' 'degarelix' ')'
 'therapy']","[0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1. 0. 1.]"
NCT01802346,"26:39:cancer,50:70:treatment,72:83:treatment,89:105:treatment,178:201:cancer",Histologically confirmed breast cancer for which chemotherapy with AC (doxorubicin plus cyclophosphamide) is being utilized in the neoadjuvant or adjuvant setting OR metastatic prostate adenocarcinoma for which Docetaxel will be administered,"['Histologically' 'confirmed' 'breast' 'cancer' 'for' 'which'
 'chemotherapy' 'with' 'AC' '(' 'doxorubicin' 'plus' 'cyclophosphamide'
 ')' 'is' 'being' 'utilized' 'in' 'the' 'neoadjuvant' 'or' 'adjuvant'
 'setting' 'OR' 'metastatic' 'prostate' 'adenocarcinoma' 'for' 'which'
 'Docetaxel' 'will' 'be' 'administered']","[0. 0. 3. 3. 0. 0. 1. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 3. 3. 0. 0. 0. 0. 0. 0.]"
NCT01801072,"63:69:treatment,71:79:treatment,81:89:treatment,91:99:treatment,101:108:treatment","Currently prescribed medication with anti-epileptic activity (keppra, dilantin, tegretol, lamictal, topamax, etc.)","['Currently' 'prescribed' 'medication' 'with' 'anti-epileptic' 'activity'
 '(' 'keppra' ',' 'dilantin' ',' 'tegretol' ',' 'lamictal' ',' 'topamax'
 ',' 'etc' '.' ')']",[0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0.]
NCT01799538,"47:68:cancer,70:87:cancer,89:109:chronic_disease","evidence of lung and other organ involvement (renal angiomyolipomas, chylous effusions, lymphangioleiomyomas)","['evidence' 'of' 'lung' 'and' 'other' 'organ' 'involvement' '(' 'renal'
 'angiomyolipomas' ',' 'chylous' 'effusions' ',' 'lymphangioleiomyomas'
 ')']",[0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 3. 3. 0. 2. 0.]
NCT01795573,"1:4:chronic_disease,17:22:treatment,26:82:treatment,75:81:treatment","HIV negative by ELISA or reverse transcription polymerase chain reaction (RT-PCR) [if ELISA is positive and RT-PCR is negative, the ELISA is considered false positive]","['HIV' 'negative' 'by' 'ELISA' 'or' 'reverse' 'transcription' 'polymerase'
 'chain' 'reaction' '(' 'RT-PCR' ')' '[' 'if' 'ELISA' 'is' 'positive'
 'and' 'RT-PCR' 'is' 'negative' ',' 'the' 'ELISA' 'is' 'considered'
 'false' 'positive' ']']","[2. 0. 0. 1. 0. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01795573,"1:4:cancer,91:104:treatment,112:123:treatment",MDS: Low/intermediate-1 IPSS risk category patients are eligible only if they have failed prior therapy or are transfusion-dependent,"['MDS' ':' 'Low/intermediate-1' 'IPSS' 'risk' 'category' 'patients' 'are'
 'eligible' 'only' 'if' 'they' 'have' 'failed' 'prior' 'therapy' 'or'
 'are' 'transfusion-dependent']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1.]
NCT01795313,"24:33:treatment,,80:90:treatment,97:106:treatment,165:173:treatment,175:183:treatment,185:194:treatment,197:209:treatment,216:226:treatment","must be off concurrent treatment or medications for at least 1 week including: Interferon (e.g. Intron-A®), allergy desensitization injetions, growth factors (e.g. Pricrut®, Aranesp®, Neulasta®), interleukins (e.g. Proleukin®), and any investigational therapeutic medication","['must' 'be' 'off' 'concurrent' 'treatment' 'or' 'medications' 'for' 'at'
 'least' '1' 'week' 'including' ':' 'Interferon' '(' 'e.g' '.' 'Intron-A®'
 ')' ',' 'allergy' 'desensitization' 'injetions' ',' 'growth' 'factors'
 '(' 'e.g' '.' 'Pricrut®' ',' 'Aranesp®' ',' 'Neulasta®' ')' ','
 'interleukins' '(' 'e.g' '.' 'Proleukin®' ')' ',' 'and' 'any'
 'investigational' 'therapeutic' 'medication']","[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
 1.]"
NCT01794559,"17:28:treatment,,63:76:treatment,94:97:treatment,",ble to stop all medications (wash out) for 5 half-lves of all medication(s) which affect the EEG. Outpatient subjects are eligible if they can be washed out of their medications in 14 days or less,"['ble' 'to' 'stop' 'all' 'medications' '(' 'wash' 'out' ')' 'for' '5'
 'half-lves' 'of' 'all' 'medication' '(' 's' ')' 'which' 'affect' 'the'
 'EEG' '.' 'Outpatient' 'subjects' 'are' 'eligible' 'if' 'they' 'can' 'be'
 'washed' 'out' 'of' 'their' 'medications' 'in' '14' 'days' 'or' 'less']","[1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.]"
NCT01793519,"14:22:treatment,24:33:treatment,38:49:treatment,","Treated with anakinra, abatacept, or tocilizumab in the last 6 months","['Treated' 'with' 'anakinra' ',' 'abatacept' ',' 'or' 'tocilizumab' 'in'
 'the' 'last' '6' 'months']",[0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT01791543,"8:32:treatment,70:80:chronic_disease,93:97:chronic_disease",Failed prior VT or PVC ablation due to spontaneous recurrence of the arrhythmia or frequent PVCs,"['Failed' 'prior' 'VT' 'or' 'PVC' 'ablation' 'due' 'to' 'spontaneous'
 'recurrence' 'of' 'the' 'arrhythmia' 'or' 'frequent' 'PVCs']",[0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 2. 0. 0. 2.]
NCT01787682,"22:40:chronic_disease,51:58:chronic_disease,62:76:chronic_disease",History of untreated metabolic diseases including hepatic or renal disorder,"['History' 'of' 'untreated' 'metabolic' 'diseases' 'including' 'hepatic'
 'or' 'renal' 'disorder']",[0. 0. 0. 2. 2. 0. 2. 0. 2. 2.]
NCT01787487,"22:32:cancer,134:144:cancer,146:181:cancer,186:227:cancer","Patients with active malignancy of other type than required for this study, are not eligible with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast","['Patients' 'with' 'active' 'malignancy' 'of' 'other' 'type' 'than'
 'required' 'for' 'this' 'study' ',' 'are' 'not' 'eligible' 'with' 'the'
 'exception' 'of' 'currently' 'treated' 'basal' 'cell' ',' 'squamous'
 'cell' 'carcinoma' 'of' 'the' 'skin' ',' 'or' 'carcinoma' 'in' 'situ'
 'of' 'the' 'cervix' 'or' 'breast']","[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3.
 0. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0.]"
NCT01787409,"15:30:cancer,83:112:cancer,117:133:cancer,137:158:cancer","patients with B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma or post-transplant DLBCL are also eligible","['patients' 'with' 'B' 'cell' 'lymphoma' ',' 'unclassifiable' ',' 'with'
 'features' 'intermediate' 'between' 'diffuse' 'large' 'B' 'cell'
 'lymphoma' 'and' 'Burkitt' 'lymphoma' 'or' 'post-transplant' 'DLBCL'
 'are' 'also' 'eligible']","[0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 0. 3. 3. 0. 3. 3. 0.
 0. 0.]"
NCT01781611,"21:28:allergy_name,32:44:allergy_name,84:95:chronic_disease,,,,,","Contraindication to aspirin or dipyridamole, including history of recent or severe GI bleeding, hemoglobin <9 mg/dL, platelet count of <30,000 /mm3 or unstable platelet coun","['Contraindication' 'to' 'aspirin' 'or' 'dipyridamole' ',' 'including'
 'history' 'of' 'recent' 'or' 'severe' 'GI' 'bleeding' ',' 'hemoglobin'
 '<' '9' 'mg/dL' ',' 'platelet' 'count' 'of' '<' '30,000' '/mm3' 'or'
 'unstable' 'platelet' 'coun']","[0. 0. 4. 0. 4. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01774019,"23:40:cancer,49:90:cancer,101:122:cancer","Diagnosis of probable pancreatic cancer, distal common bile duct (CBD) cholangiocarcinoma and other periampullary cancers (histology not required)","['Diagnosis' 'of' 'probable' 'pancreatic' 'cancer' ',' 'distal' 'common'
 'bile' 'duct' '(' 'CBD' ')' 'cholangiocarcinoma' 'and' 'other'
 'periampullary' 'cancers' '(' 'histology' 'not' 'required' ')']",[0. 0. 0. 3. 3. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT01773694,"25:43:treatment,47:53:cancer,58:75:cancer",patients undergoing any surgical treatment of benign and malignant lesions by any physician in the Dermatology department,"['patients' 'undergoing' 'any' 'surgical' 'treatment' 'of' 'benign' 'and'
 'malignant' 'lesions' 'by' 'any' 'physician' 'in' 'the' 'Dermatology'
 'department']",[0. 0. 0. 1. 1. 0. 3. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT01766297,"23:32:treatment,,52:59:treatment,,90:102:treatment",Must be able to start treatment within 12 weeks of surgery or 8 weeks of finalization of chemotherapy,"['Must' 'be' 'able' 'to' 'start' 'treatment' 'within' '12' 'weeks' 'of'
 'surgery' 'or' '8' 'weeks' 'of' 'finalization' 'of' 'chemotherapy']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1.]
NCT01760863,"17:50:chronic_disease,92:115:treatment,97:115:treatment","Patients with a fungal prosthetic joint infection, unable to tolerate or refuse to undergo oral antibiotic therapy, unable to follow-up at the specified intervals, allergic to the therapy of preference, or have an organism that is not amenable to oral antibiotic therapy","['Patients' 'with' 'a' 'fungal' 'prosthetic' 'joint' 'infection' ','
 'unable' 'to' 'tolerate' 'or' 'refuse' 'to' 'undergo' 'oral' 'antibiotic'
 'therapy' ',' 'unable' 'to' 'follow-up' 'at' 'the' 'specified'
 'intervals' ',' 'allergic' 'to' 'the' 'therapy' 'of' 'preference' ','
 'or' 'have' 'an' 'organism' 'that' 'is' 'not' 'amenable' 'to' 'oral'
 'antibiotic' 'therapy']","[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01760655,"1:14:cancer,16:29:treatment,33:55:cancer",Secondary AML (prior therapy or hematologic malignancy),"['Secondary' 'AML' '(' 'prior' 'therapy' 'or' 'hematologic' 'malignancy'
 ')']",[3. 3. 0. 1. 1. 0. 3. 3. 0.]
NCT01758042,"21:28:treatment,83:90:allergy_name,94:113:allergy_name","Contraindication to therapy with any one of the proposed agents (e.g., history of allergy to rabbit serum in ATG)","['Contraindication' 'to' 'therapy' 'with' 'any' 'one' 'of' 'the'
 'proposed' 'agents' '(' 'e.g.' ',' 'history' 'of' 'allergy' 'to' 'rabbit'
 'serum' 'in' 'ATG' ')']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 4. 4. 4. 4. 0.]
NCT01757418,"11:17:chronic_disease,38:58:treatment,62:88:treatment",Increased stroke risk as assessed by transcranial Doppler or magnetic resonance imaging (all subjects undergo testing),"['Increased' 'stroke' 'risk' 'as' 'assessed' 'by' 'transcranial' 'Doppler'
 'or' 'magnetic' 'resonance' 'imaging' '(' 'all' 'subjects' 'undergo'
 'testing' ')']",[0. 2. 0. 0. 0. 0. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.]
NCT01754857,"28:39:chronic_disease,96:105:allergy_name,115:142:allergy_name",Severe or life-threatening anaphylaxis or hypersensitivity reaction when previously exposed to rituximab or other monoclonal antibody therapy,"['Severe' 'or' 'life-threatening' 'anaphylaxis' 'or' 'hypersensitivity'
 'reaction' 'when' 'previously' 'exposed' 'to' 'rituximab' 'or' 'other'
 'monoclonal' 'antibody' 'therapy']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 4. 0. 0. 4. 4. 4.]
NCT01750567,",63:74:treatment,76:88:treatment,90:97:treatment,99:106:treatment,108:120:treatment,125:146:treatment","Patients who relapse after receiving a one or more courses of fludarabine, bendamustine, cytoxan, rituxan, chlorambucil, or campath based therapy","['Patients' 'who' 'relapse' 'after' 'receiving' 'a' 'one' 'or' 'more'
 'courses' 'of' 'fludarabine' ',' 'bendamustine' ',' 'cytoxan' ','
 'rituxan' ',' 'chlorambucil' ',' 'or' 'campath' 'based' 'therapy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 1.
 1.]"
NCT01742338,"36:43:chronic_disease,45:61:chronic_disease,65:70:chronic_disease","Alternative diagnosis for cause of dyspnea, increased sputum or cough","['Alternative' 'diagnosis' 'for' 'cause' 'of' 'dyspnea' ',' 'increased'
 'sputum' 'or' 'cough']",[0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 2.]
NCT01742299,"74:82:treatment,131:141:treatment,173:192:treatment",Patient has participated in a Novartis sponsored combination trial where imatinib was dispensed in combination with another study medication and patient is still receiving combination therapy,"['Patient' 'has' 'participated' 'in' 'a' 'Novartis' 'sponsored'
 'combination' 'trial' 'where' 'imatinib' 'was' 'dispensed' 'in'
 'combination' 'with' 'another' 'study' 'medication' 'and' 'patient' 'is'
 'still' 'receiving' 'combination' 'therapy']","[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01737502,"1:14:treatment,22:32:treatment,35:46:treatment,63:79:chronic_disease,,114:127:treatment,,177:199:treatment,218:240:treatment","Major surgery (i.e., laparotomy), open biopsy, or significant traumatic injury =< 4 weeks prior to registration; minor surgery =< 2 weeks prior to registration; insertion of a vascular access device is not considered major or minor surgery in this regard","['Major' 'surgery' '(' 'i.e.' ',' 'laparotomy' ')' ',' 'open' 'biopsy' ','
 'or' 'significant' 'traumatic' 'injury' '=' '<' '4' 'weeks' 'prior' 'to'
 'registration' ';' 'minor' 'surgery' '=' '<' '2' 'weeks' 'prior' 'to'
 'registration' ';' 'insertion' 'of' 'a' 'vascular' 'access' 'device' 'is'
 'not' 'considered' 'major' 'or' 'minor' 'surgery' 'in' 'this' 'regard']","[1. 1. 0. 0. 0. 1. 0. 0. 1. 1. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 0.
 0.]"
NCT01734512,"44:68:chronic_disease,116:126:treatment,134:152:chronic_disease,167:173:chronic_disease,175:183:chronic_disease,185:193:chronic_disease,195:217:chronic_disease,221:242:treatment","Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection","['Impairment' 'of' 'gastrointestinal' 'function' 'or' 'gastrointestinal'
 'disease' 'that' 'may' 'significantly' 'alter' 'the' 'absorption' 'of'
 'everolimus' '(' 'e.g.' ',' 'ulcerative' 'disease' ',' 'uncontrolled'
 'nausea' ',' 'vomiting' ',' 'diarrhea' ',' 'malabsorption' 'syndrome'
 'or' 'small' 'bowel' 'resection']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 2. 2. 0. 0. 2. 0.
 2. 0. 2. 0. 2. 2. 0. 1. 1. 1.]"
NCT01730937,",14:32:cancer,36:61:cancer,,188:229:treatment,233:265:treatment,284:293:chronic_disease,297:321:chronic_disease","At least one solid liver lesion or vascular tumor thrombosis (involving portal vein, inferior vena cava [IVC] and/or hepatic vein) > 1 cm with arterial enhancement and delayed washout on multi-phasic computerized tomography (CT) or magnetic resonance imaging (MRI) in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis","['At' 'least' 'one' 'solid' 'liver' 'lesion' 'or' 'vascular' 'tumor'
 'thrombosis' '(' 'involving' 'portal' 'vein' ',' 'inferior' 'vena' 'cava'
 '[' 'IVC' ']' 'and/or' 'hepatic' 'vein' ')' '>' '1' 'cm' 'with'
 'arterial' 'enhancement' 'and' 'delayed' 'washout' 'on' 'multi-phasic'
 'computerized' 'tomography' '(' 'CT' ')' 'or' 'magnetic' 'resonance'
 'imaging' '(' 'MRI' ')' 'in' 'the' 'setting' 'of' 'cirrhosis' 'or'
 'chronic' 'hepatitis' 'B' 'or' 'C' 'without' 'cirrhosis']","[0. 0. 0. 3. 3. 3. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 0.
 0. 0. 0. 0. 2. 0. 2. 2. 2. 2. 2. 0. 0.]"
NCT01730937,"13:28:treatment,57:62:cancer,222:224:treatment,228:231:treatment,","Measureable hepatic disease and/or presence of vascular tumor thrombosis (involving portal vein, IVC and/or hepatic vein) which may not be measureable as per Response Evaluation Criteria in Solid Tumors (RECIST) on liver CT or MRI, within 28 days of registration","['Measureable' 'hepatic' 'disease' 'and/or' 'presence' 'of' 'vascular'
 'tumor' 'thrombosis' '(' 'involving' 'portal' 'vein' ',' 'IVC' 'and/or'
 'hepatic' 'vein' ')' 'which' 'may' 'not' 'be' 'measureable' 'as' 'per'
 'Response' 'Evaluation' 'Criteria' 'in' 'Solid' 'Tumors' '(' 'RECIST' ')'
 'on' 'liver' 'CT' 'or' 'MRI' ',' 'within' '28' 'days' 'of' 'registration']","[0. 1. 1. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0.]"
NCT01730937,"1:19:treatment,24:27:cancer,43:49:cancer",prior chemotherapy for HCC or a different cancer,['prior' 'chemotherapy' 'for' 'HCC' 'or' 'a' 'different' 'cancer'],[1. 1. 0. 3. 0. 0. 0. 3.]
NCT01730118,"24:43:chronic_disease,,95:101:chronic_disease,103:127:chronic_disease,129:150:chronic_disease,152:163:chronic_disease,197:206:treatment,229:241:treatment","Clinically significant cardiac dysfunction defined as a history of >= NYHA Class II symptoms, angina, congestive heart failure, myocardial infarction, arrhythmias or cardiac dysfunction requiring treatment or discontinuation of chemotherapy","['Clinically' 'significant' 'cardiac' 'dysfunction' 'defined' 'as' 'a'
 'history' 'of' '>' '=' 'NYHA' 'Class' 'II' 'symptoms' ',' 'angina' ','
 'congestive' 'heart' 'failure' ',' 'myocardial' 'infarction' ','
 'arrhythmias' 'or' 'cardiac' 'dysfunction' 'requiring' 'treatment' 'or'
 'discontinuation' 'of' 'chemotherapy']","[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 2. 0. 2. 2.
 0. 2. 0. 0. 0. 0. 1. 0. 0. 0. 1.]"
NCT01730118,"10:18:treatment,23:40:chronic_disease,78:95:treatment,105:114:chronic_disease",Negative serology for hepatitis B and C unless the result is consistent with prior vaccination or prior infection with full recovery,"['Negative' 'serology' 'for' 'hepatitis' 'B' 'and' 'C' 'unless' 'the'
 'result' 'is' 'consistent' 'with' 'prior' 'vaccination' 'or' 'prior'
 'infection' 'with' 'full' 'recovery']",[0. 1. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 2. 0. 0. 0.]
NCT01730118,"15:22:cancer,24:32:cancer,34:39:cancer,41:48:cancer,49:74:cancer,76:95:cancer,97:107:cancer,109:116:cancer,118:139:cancer,144:170:cancer,180:192:cancer,,,","Patients with ovarian, cervical, colon, gastric/gastroesophageal junction, non-small cell lung, renal cell, bladder, malignant soft tissue and bone tumor prostate cancer or other solid tumors that is known to be HER2 1+, 2+ or 3+ by IHC OR have a Vysis FISH result greater than or equal to 1.8","['Patients' 'with' 'ovarian' ',' 'cervical' ',' 'colon' ','
 'gastric/gastroesophageal' 'junction' ',' 'non-small' 'cell' 'lung' ','
 'renal' 'cell' ',' 'bladder' ',' 'malignant' 'soft' 'tissue' 'and' 'bone'
 'tumor' 'prostate' 'cancer' 'or' 'other' 'solid' 'tumors' 'that' 'is'
 'known' 'to' 'be' 'HER2' '1+' ',' '2+' 'or' '3+' 'by' 'IHC' 'OR' 'have'
 'a' 'Vysis' 'FISH' 'result' 'greater' 'than' 'or' 'equal' 'to' '1.8']","[0. 0. 3. 0. 3. 0. 3. 0. 3. 3. 0. 3. 3. 3. 0. 3. 3. 0. 3. 0. 3. 3. 3. 0.
 3. 3. 3. 3. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01730118,"1:6:cancer,7:16:cancer,18:21:cancer,23:26:cancer,28:31:cancer,76:81:cancer","Tumor stage T3a, T3b, T4a, T4b and any node positive disease regardless of tumor stage","['Tumor' 'stage' 'T3a' ',' 'T3b' ',' 'T4a' ',' 'T4b' 'and' 'any' 'node'
 'positive' 'disease' 'regardless' 'of' 'tumor' 'stage']",[3. 3. 3. 0. 3. 0. 3. 0. 3. 0. 0. 0. 0. 0. 0. 0. 3. 0.]
NCT01720836,"1:3:cancer,5:9:cancer,12:14:cancer,17:21:cancer,","IB (T2NO), II & IIIA (N2 negative)","['IB' '(' 'T2NO' ')' ',' 'II' '&' 'IIIA' '(' 'N2' 'negative' ')']",[3. 0. 3. 0. 0. 3. 0. 3. 0. 0. 0. 0.]
NCT01720147,"20:32:treatment,36:51:treatment,88:97:treatment",Patients receiving cyclosporine or digoxin therapy or are unable to discontinue either treatment due to medical reasons,"['Patients' 'receiving' 'cyclosporine' 'or' 'digoxin' 'therapy' 'or' 'are'
 'unable' 'to' 'discontinue' 'either' 'treatment' 'due' 'to' 'medical'
 'reasons']",[0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.]
NCT01715220,",,,,,135:144:treatment,150:174:treatment,178:185:treatment",Patients with right upper quadrant abdominal pain of less than 24 hours' duration between ages 18 and 60 years of age will be offered treatment with sublingual nitroglycerin or placebo,"['Patients' 'with' 'right' 'upper' 'quadrant' 'abdominal' 'pain' 'of'
 'less' 'than' '24' 'hours' ""'"" 'duration' 'between' 'ages' '18' 'and'
 '60' 'years' 'of' 'age' 'will' 'be' 'offered' 'treatment' 'with'
 'sublingual' 'nitroglycerin' 'or' 'placebo']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 1. 1. 0. 1.]"
NCT01712308,"13:37:chronic_disease,39:54:chronic_disease,68:86:chronic_disease","Symptomatic congestive heart failure, unstable angina, or unstable cardiac arrhythmia","['Symptomatic' 'congestive' 'heart' 'failure' ',' 'unstable' 'angina' ','
 'or' 'unstable' 'cardiac' 'arrhythmia']",[0. 2. 2. 2. 0. 2. 2. 0. 0. 0. 2. 2.]
NCT01703949,"19:34:cancer,35:46:treatment,47:54:treatment,,",Resolution of all non-hematologic brentuximab vedotin-related adverse events (AEs) to < grade 2,"['Resolution' 'of' 'all' 'non-hematologic' 'brentuximab' 'vedotin-related'
 'adverse' 'events' '(' 'AEs' ')' 'to' '<' 'grade' '2']",[0. 0. 0. 3. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01701986,"1:19:chronic_disease,44:85:chronic_disease,92:99:chronic_disease,101:124:chronic_disease,,,","Active hepatitis B, either active carrier (hepatitis B virus surface antigen [HBsAg] +) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] >= 10,000 copies/mL, or >= 2,000 IU/mL)","['Active' 'hepatitis' 'B' ',' 'either' 'active' 'carrier' '(' 'hepatitis'
 'B' 'virus' 'surface' 'antigen' '[' 'HBsAg' ']' '+' ')' 'or' 'viremic'
 '(' 'hepatitis' 'B' 'virus' '[' 'HBV' ']' 'deoxyribonucleic' 'acid' '['
 'DNA' ']' '>' '=' '10,000' 'copies/mL' ',' 'or' '>' '=' '2,000' 'IU/mL'
 ')']","[2. 2. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01697865,"1:21:chronic_disease,51:58:treatment,60:78:chronic_disease","Chronic rotator cuff tear with severe retraction, atrophy, fatty infiltration","['Chronic' 'rotator' 'cuff' 'tear' 'with' 'severe' 'retraction' ','
 'atrophy' ',' 'fatty' 'infiltration']",[2. 2. 2. 0. 0. 0. 0. 0. 1. 0. 2. 2.]
NCT01697371,"18:31:cancer,48:58:cancer,107:126:cancer",New radiographic liver lesions consistent with metastases in patients with known pathologically confirmed non-lymphoma cancer,"['New' 'radiographic' 'liver' 'lesions' 'consistent' 'with' 'metastases'
 'in' 'patients' 'with' 'known' 'pathologically' 'confirmed'
 'non-lymphoma' 'cancer']",[0. 0. 3. 3. 0. 0. 3. 0. 0. 0. 0. 0. 0. 3. 3.]
NCT01697293,"10:22:treatment,24:35:treatment,51:70:treatment,78:88:treatment,92:102:treatment,106:125:treatment,136:146:cancer","No prior chemotherapy, irradiation, or definitive therapeutic surgery (e.g., mastectomy or lumpectomy or axillary dissection) for this malignancy","['No' 'prior' 'chemotherapy' ',' 'irradiation' ',' 'or' 'definitive'
 'therapeutic' 'surgery' '(' 'e.g.' ',' 'mastectomy' 'or' 'lumpectomy'
 'or' 'axillary' 'dissection' ')' 'for' 'this' 'malignancy']",[0. 0. 1. 0. 1. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0. 1. 0. 1. 1. 0. 0. 0. 3.]
NCT01697293,"1:26:cancer,28:66:cancer,71:100:cancer,108:122:cancer,131:158:treatment,172:189:cancer","lobular carcinoma in situ, contralateral ductal carcinoma in situ, or contralateral invasive ductal and/or lobular cancer (and no prior adjuvant chemotherapy for previous breast malignancy)","['lobular' 'carcinoma' 'in' 'situ' ',' 'contralateral' 'ductal'
 'carcinoma' 'in' 'situ' ',' 'or' 'contralateral' 'invasive' 'ductal'
 'and/or' 'lobular' 'cancer' '(' 'and' 'no' 'prior' 'adjuvant'
 'chemotherapy' 'for' 'previous' 'breast' 'malignancy' ')']","[3. 3. 3. 3. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.
 0. 0. 3. 3. 0.]"
NCT01697293,"13:37:chronic_disease,48:63:chronic_disease,65:83:chronic_disease,88:107:chronic_disease","symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['symptomatic' 'congestive' 'heart' 'failure' ',' 'unstable' 'angina'
 'pectoris' ',' 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric'
 'illness/social' 'situations' 'that' 'would' 'limit' 'compliance' 'with'
 'study' 'requirements']",[0. 2. 2. 2. 0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01696734,"1:9:chronic_disease,11:19:chronic_disease,24:47:chronic_disease","valvular, ischemic, or pulmonary heart disease","['valvular' ',' 'ischemic' ',' 'or' 'pulmonary' 'heart' 'disease']",[2. 0. 2. 0. 0. 2. 2. 2.]
NCT01688388,"1:33:chronic_disease,39:64:chronic_disease,66:91:chronic_disease,93:107:chronic_disease","Mixed connective tissue diseases e.g. rheumatoid poly arthritis, thromboangitis obliterans, systemic lupus","['Mixed' 'connective' 'tissue' 'diseases' 'e.g' '.' 'rheumatoid' 'poly'
 'arthritis' ',' 'thromboangitis' 'obliterans' ',' 'systemic' 'lupus']",[2. 2. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 0. 2. 2.]
NCT01684904,"1:16:treatment,21:38:cancer,42:66:treatment",Prior radiation for esophageal cancer or prior chest radiotherapy,"['Prior' 'radiation' 'for' 'esophageal' 'cancer' 'or' 'prior' 'chest'
 'radiotherapy']",[1. 1. 0. 3. 3. 0. 1. 1. 1.]
NCT01684397,"1:21:cancer,25:48:cancer,89:98:treatment","basal cell carcinoma or squamous cell carcinoma, of skin which were completely cured by resection","['basal' 'cell' 'carcinoma' 'or' 'squamous' 'cell' 'carcinoma' ',' 'of'
 'skin' 'which' 'were' 'completely' 'cured' 'by' 'resection']",[3. 3. 3. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01681589,"12:23:treatment,25:41:chronic_disease,46:53:chronic_disease,82:85:chronic_disease","History of craniectomy, active infection, or seizure activity beyond 1 week post-TBI","['History' 'of' 'craniectomy' ',' 'active' 'infection' ',' 'or' 'seizure'
 'activity' 'beyond' '1' 'week' 'post-TBI']",[0. 0. 1. 0. 2. 2. 0. 0. 2. 0. 0. 0. 0. 2.]
NCT01681264,"24:46:chronic_disease,53:63:chronic_disease,,,98:121:chronic_disease,123:130:chronic_disease,134:150:chronic_disease,152:165:chronic_disease,167:186:chronic_disease,202:209:chronic_disease","Has known pre-existing cardiovascular disease (i.e. arrhythmia - prolonged QT interval > 440ms), cerebrovascular disease, hepatic or renal impairment, CNS condition, metabolic condition, or history of syncope","['Has' 'known' 'pre-existing' 'cardiovascular' 'disease' '(' 'i.e' '.'
 'arrhythmia' '-' 'prolonged' 'QT' 'interval' '>' '440ms' ')' ','
 'cerebrovascular' 'disease' ',' 'hepatic' 'or' 'renal' 'impairment' ','
 'CNS' 'condition' ',' 'metabolic' 'condition' ',' 'or' 'history' 'of'
 'syncope']","[0. 0. 0. 2. 2. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 2.
 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 2.]"
NCT01681264,"30:37:treatment,39:52:treatment,54:63:treatment,68:88:treatment","Tests positive for non-study opioids, illicit drugs, marijuana, or non-prescribed drugs","['Tests' 'positive' 'for' 'non-study' 'opioids' ',' 'illicit' 'drugs' ','
 'marijuana' ',' 'or' 'non-prescribed' 'drugs']",[0. 0. 0. 0. 1. 0. 1. 1. 0. 1. 0. 0. 1. 1.]
NCT01676753,"24:39:chronic_disease,41:53:chronic_disease,94:102:allergy_name,106:126:allergy_name,136:174:allergy_name,184:211:allergy_name","Patient has history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or prior allogeneic bone marrow transplantation or prior solid organ transplantation","['Patient' 'has' 'history' 'of' 'severe' 'allergic' ',' 'anaphylactic' ','
 'or' 'other' 'hypersensitivity' 'reactions' 'to' 'chimeric' 'or'
 'humanized' 'antibodies' 'or' 'prior' 'allogeneic' 'bone' 'marrow'
 'transplantation' 'or' 'prior' 'solid' 'organ' 'transplantation']","[0. 0. 0. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 4. 0. 4. 4. 0. 0. 4. 4. 4. 4.
 0. 0. 4. 4. 4.]"
NCT01676259,"1:7:chronic_disease,9:31:chronic_disease,33:38:chronic_disease,43:60:chronic_disease,72:88:treatment","Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy","['Active' ',' 'uncontrolled' 'bacterial' ',' 'viral' ',' 'or' 'fungal'
 'infections' ',' 'requiring' 'systemic' 'therapy']",[2. 0. 2. 2. 0. 2. 0. 0. 2. 2. 0. 0. 1. 1.]
NCT01676259,"8:27:chronic_disease,37:54:chronic_disease,60:69:chronic_disease,,,157:171:treatment","Severe chronic obstructive or other pulmonary disease with hypoxemia (requires supplementary oxygen, symptoms due to hypoxemia or oxygen saturation <90% by pulse oximetry after a 2 minute walk) or in the opinion of the investigator any physiological state likely to cause systemic or regional hypoxemia","['Severe' 'chronic' 'obstructive' 'or' 'other' 'pulmonary' 'disease'
 'with' 'hypoxemia' '(' 'requires' 'supplementary' 'oxygen' ',' 'symptoms'
 'due' 'to' 'hypoxemia' 'or' 'oxygen' 'saturation' '<' '90' '%' 'by'
 'pulse' 'oximetry' 'after' 'a' '2' 'minute' 'walk' ')' 'or' 'in' 'the'
 'opinion' 'of' 'the' 'investigator' 'any' 'physiological' 'state'
 'likely' 'to' 'cause' 'systemic' 'or' 'regional' 'hypoxemia']","[0. 2. 2. 0. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT01670877,"24:39:chronic_disease,41:61:chronic_disease,79:90:chronic_disease","History of significant cardiac disease, cardiac risk factors, or uncontrolled arrhythmias","['History' 'of' 'significant' 'cardiac' 'disease' ',' 'cardiac' 'risk'
 'factors' ',' 'or' 'uncontrolled' 'arrhythmias']",[0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 2.]
NCT01670877,"14:34:chronic_disease,77:93:chronic_disease,95:119:chronic_disease,121:139:chronic_disease,144:181:chronic_disease","Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'intercurrent' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' ',' 'ongoing' 'or' 'active' 'infection' ',' 'unstable'
 'angina' 'pectoris' ',' 'cardiac' 'arrhythmia' ',' 'or' 'psychiatric'
 'illness/social' 'situations' 'that' 'would' 'limit' 'compliance' 'with'
 'study' 'requirements']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 2. 0. 2. 2. 0. 0. 2.
 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT01668082,"1:31:treatment,48:59:cancer,54:59:cancer,63:84:treatment,104:110:treatment,",Pre-operative brain MR imaging suggestive of a brain tumor or pre-operative imaging showing a tumor or biopsy of a tumor mass prior to planned resection of the mass,"['Pre-operative' 'brain' 'MR' 'imaging' 'suggestive' 'of' 'a' 'brain'
 'tumor' 'or' 'pre-operative' 'imaging' 'showing' 'a' 'tumor' 'or'
 'biopsy' 'of' 'a' 'tumor' 'mass' 'prior' 'to' 'planned' 'resection' 'of'
 'the' 'mass']","[1. 3. 3. 1. 0. 0. 0. 0. 3. 0. 1. 1. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01660607,"21:30:chronic_disease,32:37:chronic_disease,41:57:chronic_disease,87:108:treatment","Active uncontrolled bacterial, viral or fungal infection, defined as currently taking antimicrobial therapy and progression of clinical symptoms","['Active' 'uncontrolled' 'bacterial' ',' 'viral' 'or' 'fungal' 'infection'
 ',' 'defined' 'as' 'currently' 'taking' 'antimicrobial' 'therapy' 'and'
 'progression' 'of' 'clinical' 'symptoms']",[0. 0. 2. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01659541,"1:10:chronic_disease,12:32:chronic_disease,37:51:chronic_disease","Scoliosis, chest wall deformity, or marked obesity","['Scoliosis' ',' 'chest' 'wall' 'deformity' ',' 'or' 'marked' 'obesity']",[2. 0. 2. 2. 2. 0. 0. 2. 2.]
NCT01653080,"1:24:chronic_disease,36:57:chronic_disease,68:103:treatment",Acute renal dysfunction due to the hepato-renal syndrome or in the perioperative liver transplantation period,"['Acute' 'renal' 'dysfunction' 'due' 'to' 'the' 'hepato-renal' 'syndrome'
 'or' 'in' 'the' 'perioperative' 'liver' 'transplantation' 'period']",[2. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 1. 1. 1. 0.]
NCT01648751,"87:92:chronic_disease,94:114:chronic_disease,116:127:chronic_disease,129:146:chronic_disease,148:163:chronic_disease,169:191:chronic_disease","Connective tissue diseases known to affect collagen or elastin remodeling (including: Lupus, Rheumatoid Arthritis, Scleroderma, Sjogrens syndrome, Marfan syndrome, and Ehlers-Danlos syndrome)","['Connective' 'tissue' 'diseases' 'known' 'to' 'affect' 'collagen' 'or'
 'elastin' 'remodeling' '(' 'including' ':' 'Lupus' ',' 'Rheumatoid'
 'Arthritis' ',' 'Scleroderma' ',' 'Sjogrens' 'syndrome' ',' 'Marfan'
 'syndrome' ',' 'and' 'Ehlers-Danlos' 'syndrome' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 2. 0. 2. 0. 2. 2. 0. 2.
 2. 0. 0. 2. 2. 0.]"
NCT01648023,"12:26:allergy_name,55:68:treatment,75:83:treatment",Allergy to contrast media that cannot be managed with standard care (e.g. steroids),"['Allergy' 'to' 'contrast' 'media' 'that' 'can' 'not' 'be' 'managed'
 'with' 'standard' 'care' '(' 'e.g' '.' 'steroids' ')']",[0. 0. 4. 4. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 0.]
NCT01648023,"54:64:allergy_name,66:77:allergy_name,82:91:allergy_name","Patients with prior contraindications for the use of irinotecan, gemcitabine, or cisplatin","['Patients' 'with' 'prior' 'contraindications' 'for' 'the' 'use' 'of'
 'irinotecan' ',' 'gemcitabine' ',' 'or' 'cisplatin']",[0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 0. 4.]
NCT01639508,"13:38:treatment,,99:114:treatment,,186:190:treatment,194:207:treatment","Any type of systemic anticancer agent (including investigational) within 3 weeks of first dose of study treatment, or within 5 half-lives of the agent whichever is shorter. Subjects on LHRH or GnRH agonists may be maintained on these agents","['Any' 'type' 'of' 'systemic' 'anticancer' 'agent' '(' 'including'
 'investigational' ')' 'within' '3' 'weeks' 'of' 'first' 'dose' 'of'
 'study' 'treatment' ',' 'or' 'within' '5' 'half-lives' 'of' 'the' 'agent'
 'whichever' 'is' 'shorter' '.' 'Subjects' 'on' 'LHRH' 'or' 'GnRH'
 'agonists' 'may' 'be' 'maintained' 'on' 'these' 'agents']","[0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0.]"
NCT01639508,"36:48:cancer,52:71:cancer,,112:124:treatment",The subject has any evidence of an endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib,"['The' 'subject' 'has' 'any' 'evidence' 'of' 'an' 'endotracheal' 'or'
 'endobronchial' 'tumor' 'within' '28' 'days' 'before' 'the' 'first'
 'dose' 'of' 'cabozantinib']",[0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT01639508,"1:7:chronic_disease,19:22:chronic_disease,33:41:chronic_disease,49:70:chronic_disease","stroke (including TIA, or other ischemic event) myocardial infarction","['stroke' '(' 'including' 'TIA' ',' 'or' 'other' 'ischemic' 'event' ')'
 'myocardial' 'infarction']",[2. 0. 0. 2. 0. 0. 0. 2. 0. 0. 2. 2.]
NCT01631617,"46:56:treatment,57:82:treatment,84:105:treatment,110:137:treatment","Subjects receiving or planning to receive an IND agent, ultraviolet light therapy, monoclonal antibodies, or systemic immunosuppressants","['Subjects' 'receiving' 'or' 'planning' 'to' 'receive' 'an' 'IND' 'agent'
 ',' 'ultraviolet' 'light' 'therapy' ',' 'monoclonal' 'antibodies' ','
 'or' 'systemic' 'immunosuppressants']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 1. 0. 1. 1. 0. 0. 1. 1.]
NCT01631617,"8:15:treatment,19:34:treatment,,67:76:treatment",Use of topical or oral CAM agents within 4 weeks of initiation of treatment,"['Use' 'of' 'topical' 'or' 'oral' 'CAM' 'agents' 'within' '4' 'weeks' 'of'
 'initiation' 'of' 'treatment']",[0. 0. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1.]
NCT01627301,"1:10:treatment,16:27:treatment,76:85:treatment,87:100:treatment,102:116:treatment","treatment with medications known to affect the sympathetic nervous system (clonidine, beta blockers, ACE inhibitors)","['treatment' 'with' 'medications' 'known' 'to' 'affect' 'the'
 'sympathetic' 'nervous' 'system' '(' 'clonidine' ',' 'beta' 'blockers'
 ',' 'ACE' 'inhibitors' ')']",[1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 1. 1. 0.]
NCT01626079,"1:45:chronic_disease,72:86:treatment,109:121:treatment",Chronic Obstructive Pulmonary Disease (COPD) requiring continuous home oxygen therapy or chronic outpatient oral steroid use,"['Chronic' 'Obstructive' 'Pulmonary' 'Disease' '(' 'COPD' ')' 'requiring'
 'continuous' 'home' 'oxygen' 'therapy' 'or' 'chronic' 'outpatient' 'oral'
 'steroid' 'use']",[2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1. 0.]
NCT01626079,"1:28:chronic_disease,30:56:chronic_disease,58:83:chronic_disease,98:122:chronic_disease,131:144:chronic_disease,156:178:chronic_disease,189:197:chronic_disease,201:213:chronic_disease","Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non ischemic etiology","['Hypertrophic' 'cardiomyopathy' ',' 'restrictive' 'cardiomyopathy' ','
 'constrictive' 'pericarditis' ',' 'or' 'any' 'other' 'structural' 'heart'
 'disease' 'causing' 'heart' 'failure' 'other' 'than' 'dilated'
 'cardiomyopathy' 'of' 'either' 'ischemic' 'or' 'non' 'ischemic'
 'etiology']","[2. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 0. 0.
 2. 0. 2. 2. 0.]"
NCT01626079,"36:58:treatment,36:45:treatment,132:134:treatment","Leaflet anatomy which may preclude MitraClip implantation, proper MitraClip positioning on the leaflets or sufficient reduction in MR by the MitraClip","['Leaflet' 'anatomy' 'which' 'may' 'preclude' 'MitraClip' 'implantation'
 ',' 'proper' 'MitraClip' 'positioning' 'on' 'the' 'leaflets' 'or'
 'sufficient' 'reduction' 'in' 'MR' 'by' 'the' 'MitraClip']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT01626079,"1:28:treatment,33:52:treatment,89:109:treatment",Transseptal catheterization and femoral vein access is determined to be feasible by the MitraClip implanting investigator,"['Transseptal' 'catheterization' 'and' 'femoral' 'vein' 'access' 'is'
 'determined' 'to' 'be' 'feasible' 'by' 'the' 'MitraClip' 'implanting'
 'investigator']",[1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.]
NCT01625923,"62:72:treatment,83:91:treatment,93:102:treatment,104:111:treatment,113:126:treatment,128:139:treatment,156:166:treatment,183:199:treatment,201:209:treatment,214:230:treatment,277:284:treatment,288:297:treatment","Subjects who are taking drugs that potentially interact with olanzapine including diazepam, lorazepam, alcohol, carbamazepine, fluvoxamine, olanzapine and fluoxetine in combination, CNS acting drugs, levodopa and dopamine agonist, and olanzapine when used in combination with lithium or valproate","['Subjects' 'who' 'are' 'taking' 'drugs' 'that' 'potentially' 'interact'
 'with' 'olanzapine' 'including' 'diazepam' ',' 'lorazepam' ',' 'alcohol'
 ',' 'carbamazepine' ',' 'fluvoxamine' ',' 'olanzapine' 'and' 'fluoxetine'
 'in' 'combination' ',' 'CNS' 'acting' 'drugs' ',' 'levodopa' 'and'
 'dopamine' 'agonist' ',' 'and' 'olanzapine' 'when' 'used' 'in'
 'combination' 'with' 'lithium' 'or' 'valproate']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 1.
 0. 0. 0. 1. 1. 1. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.]"
NCT01625234,"17:30:treatment,58:68:treatment,94:102:treatment",Patients may be ALK TKI-naive or may have received prior crizotinib and/or second generation ALK TKIs,"['Patients' 'may' 'be' 'ALK' 'TKI-naive' 'or' 'may' 'have' 'received'
 'prior' 'crizotinib' 'and/or' 'second' 'generation' 'ALK' 'TKIs']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.]
NCT01624090,"1:8:treatment,12:42:treatment,71:81:chronic_disease","Aspirin or salicylate-containing products, which may increase risk of hemorrhage","['Aspirin' 'or' 'salicylate-containing' 'products' ',' 'which' 'may'
 'increase' 'risk' 'of' 'hemorrhage']",[1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 2.]
NCT01624090,"38:55:treatment,48:55:treatment,96:108:treatment,","Patients may have received localized radiation therapy to non-target lesions provided that the radiotherapy is completed 14 days prior to commencing therapy, and the patient has recovered from any toxicity","['Patients' 'may' 'have' 'received' 'localized' 'radiation' 'therapy' 'to'
 'non-target' 'lesions' 'provided' 'that' 'the' 'radiotherapy' 'is'
 'completed' '14' 'days' 'prior' 'to' 'commencing' 'therapy' ',' 'and'
 'the' 'patient' 'has' 'recovered' 'from' 'any' 'toxicity']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0.]"
NCT01624090,"63:75:cancer,80:101:cancer,103:119:cancer,121:137:cancer,139:170:cancer,174:193:cancer","Patients with measurable inoperable, histologically confirmed primary lung and esophageal carcinomas, thymic neoplasms, germ cell tumors, malignant pleural mesotheliomas or chest wall sarcomas","['Patients' 'with' 'measurable' 'inoperable' ',' 'histologically'
 'confirmed' 'primary' 'lung' 'and' 'esophageal' 'carcinomas' ',' 'thymic'
 'neoplasms' ',' 'germ' 'cell' 'tumors' ',' 'malignant' 'pleural'
 'mesotheliomas' 'or' 'chest' 'wall' 'sarcomas']","[0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 3. 3. 0. 3. 3. 0. 3. 3. 3. 0. 3. 3. 3. 0.
 3. 3. 3.]"
NCT01623167,"27:36:chronic_disease,85:97:treatment,102:113:treatment,,",Subjects with known liver cirrhosis in severity that would preclude tolerability of cyclosporine and eltrombopag as evidenced by albumin < 35g/L,"['Subjects' 'with' 'known' 'liver' 'cirrhosis' 'in' 'severity' 'that'
 'would' 'preclude' 'tolerability' 'of' 'cyclosporine' 'and' 'eltrombopag'
 'as' 'evidenced' 'by' 'albumin' '<' '35g/L']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01622868,"1:29:treatment,7:24:treatment,57:66:treatment,",Prior radiation therapy (RT) (any site) with concurrent lapatinib defined as 1 or more days on which the patient received both radiation therapy and lapatinib on the same day,"['Prior' 'radiation' 'therapy' '(' 'RT' ')' '(' 'any' 'site' ')' 'with'
 'concurrent' 'lapatinib' 'defined' 'as' '1' 'or' 'more' 'days' 'on'
 'which' 'the' 'patient' 'received' 'both' 'radiation' 'therapy' 'and'
 'lapatinib' 'on' 'the' 'same' 'day']","[1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01620216,"5:36:cancer,38:53:treatment,58:73:treatment,86:94:treatment,99:107:treatment,111:120:treatment,124:133:treatment","for Philadelphia positive (Ph+) ALL, initial therapy and salvage therapy may include steroids and imatinib or dasatinib or nilotinib","['for' 'Philadelphia' 'positive' '(' 'Ph+' ')' 'ALL' ',' 'initial'
 'therapy' 'and' 'salvage' 'therapy' 'may' 'include' 'steroids' 'and'
 'imatinib' 'or' 'dasatinib' 'or' 'nilotinib']",[0. 3. 3. 3. 3. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 1. 0. 1. 0. 1. 0. 1.]
NCT01619761,"1:35:cancer,78:87:treatment,113:122:treatment,145:152:treatment","Acute lymphoblastic leukemia (ALL): induction failure, primary refractory to treatment (do not achieve complete remission after first course of therapy) or are beyond first remission including second or greater remission or active disease","['Acute' 'lymphoblastic' 'leukemia' '(' 'ALL' ')' ':' 'induction'
 'failure' ',' 'primary' 'refractory' 'to' 'treatment' '(' 'do' 'not'
 'achieve' 'complete' 'remission' 'after' 'first' 'course' 'of' 'therapy'
 ')' 'or' 'are' 'beyond' 'first' 'remission' 'including' 'second' 'or'
 'greater' 'remission' 'or' 'active' 'disease']","[3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01619761,"41:65:cancer,67:99:cancer,85:93:cancer,209:245:treatment,283:307:chronic_disease,352:370:treatment,391:415:cancer","Patients must have one of the following hematologic malignancies: acute myelogenous leukemia (AML), induction failure, high-risk for relapse first remission (with intermediate-risk or high-risk cytogenetics, fms-related tyrosine kinase 3 [FLT3] mutation positive and/or evidence of minimal residual disease by flow cytometry), secondary leukemia from prior chemotherapy and/or arising from myelodysplastic syndrome, any disease beyond first remission","['Patients' 'must' 'have' 'one' 'of' 'the' 'following' 'hematologic'
 'malignancies' ':' 'acute' 'myelogenous' 'leukemia' '(' 'AML' ')' ','
 'induction' 'failure' ',' 'high-risk' 'for' 'relapse' 'first' 'remission'
 '(' 'with' 'intermediate-risk' 'or' 'high-risk' 'cytogenetics' ','
 'fms-related' 'tyrosine' 'kinase' '3' '[' 'FLT3' ']' 'mutation'
 'positive' 'and/or' 'evidence' 'of' 'minimal' 'residual' 'disease' 'by'
 'flow' 'cytometry' ')' ',' 'secondary' 'leukemia' 'from' 'prior'
 'chemotherapy' 'and/or' 'arising' 'from' 'myelodysplastic' 'syndrome' ','
 'any' 'disease' 'beyond' 'first' 'remission']","[0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0.
 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0.]"
NCT01618357,"1:16:treatment,18:46:treatment,52:63:treatment","Bisphosphonates, hormone modification therapy, and trastuzumab are permitted without restriction","['Bisphosphonates' ',' 'hormone' 'modification' 'therapy' ',' 'and'
 'trastuzumab' 'are' 'permitted' 'without' 'restriction']",[1. 0. 1. 1. 1. 0. 0. 1. 0. 0. 0. 0.]
NCT01618357,"16:26:cancer,68:78:chronic_disease,82:107:cancer,101:107:cancer,109:132:cancer,","No other prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for 5 years","['No' 'other' 'prior' 'malignancy' 'is' 'allowed' 'except' 'for'
 'adequately' 'treated' 'basal' 'cell' 'or' 'squamous' 'cell' 'skin'
 'cancer' ',' 'in' 'situ' 'cervical' 'cancer' ',' 'or' 'any' 'other'
 'cancer' 'from' 'which' 'the' 'patient' 'has' 'been' 'disease-free' 'for'
 '5' 'years']","[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 2. 2. 0. 3. 3. 3. 3. 0. 3. 3. 3. 3. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01618357,"1:37:chronic_disease,39:63:chronic_disease,68:86:chronic_disease","Symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia","['Symptomatic' 'congestive' 'heart' 'failure' ',' 'unstable' 'angina'
 'pectoris' ',' 'or' 'cardiac' 'arrhythmia']",[2. 2. 2. 2. 0. 2. 2. 2. 0. 0. 2. 2.]
NCT01617161,"22:26:chronic_disease,,,74:77:chronic_disease,98:111:treatment",Individuals who have AIDS (CD4 < 200 or an AIDS-defining illness) or are HIV positive and not on HAART therapy,"['Individuals' 'who' 'have' 'AIDS' '(' 'CD4' '<' '200' 'or' 'an'
 'AIDS-defining' 'illness' ')' 'or' 'are' 'HIV' 'positive' 'and' 'not'
 'on' 'HAART' 'therapy']",[0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 1. 1.]
NCT01614990,"10:19:treatment,21:35:treatment,37:53:treatment,55:72:treatment,64:72:treatment,74:87:treatment,89:101:treatment","having a pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, or other implants","['having' 'a' 'pacemaker' ',' 'aneurysm' 'clips' ',' 'neurostimulators'
 ',' 'cochlear' 'implants' ',' 'metal' 'in' 'eyes' ',' 'steel' 'worker'
 ',' 'or' 'other' 'implants']",[0. 0. 1. 0. 1. 1. 0. 1. 0. 1. 1. 0. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0.]
NCT01614197,"1:19:treatment,82:89:treatment,97:115:treatment,117:134:treatment,138:151:treatment","Anti-cancer Agents: Patients who are currently receiving or may receive while on therapy, other anti-cancer agents, radiation therapy or immunotherapy are not eligible","['Anti-cancer' 'Agents' ':' 'Patients' 'who' 'are' 'currently' 'receiving'
 'or' 'may' 'receive' 'while' 'on' 'therapy' ',' 'other' 'anti-cancer'
 'agents' ',' 'radiation' 'therapy' 'or' 'immunotherapy' 'are' 'not'
 'eligible']","[1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 0. 1. 1. 0. 1. 0.
 0. 0.]"
NCT01614197,"1:29:treatment,,73:98:treatment,105:113:treatment,,129:155:treatment",Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor,"['Hematopoietic' 'growth' 'factors' ':' 'At' 'least' '14' 'days' 'after'
 'the' 'last' 'dose' 'of' 'a' 'long-acting' 'growth' 'factor' '(' 'e.g'
 '.' 'Neulasta' ')' 'or' '7' 'days' 'for' 'short-acting' 'growth' 'factor']","[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 0. 0. 0.
 0. 0. 1. 1. 1.]"
NCT01614197,"1:19:treatment,53:65:chronic_disease,,111:121:treatment,125:143:treatment",Stem Cell Infusion: No evidence of active graft vs. host disease and at least 84 days must have elapsed after transplant or stem cell infusion,"['Stem' 'Cell' 'Infusion' ':' 'No' 'evidence' 'of' 'active' 'graft' 'vs.'
 'host' 'disease' 'and' 'at' 'least' '84' 'days' 'must' 'have' 'elapsed'
 'after' 'transplant' 'or' 'stem' 'cell' 'infusion']","[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.
 1. 1.]"
NCT01608438,"1:9:chronic_disease,11:20:chronic_disease,22:29:chronic_disease,31:41:chronic_disease,46:75:chronic_disease,101:108:chronic_disease,122:147:treatment","Vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, even without history of seizure, and without anticonvulsant medication","['Vascular' ',' 'traumatic' ',' 'tumoral' ',' 'infectious' ',' 'or'
 'metabolic' 'lesion' 'of' 'the' 'brain' ',' 'even' 'without' 'history'
 'of' 'seizure' ',' 'and' 'without' 'anticonvulsant' 'medication']","[2. 0. 2. 0. 2. 0. 2. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 2. 0. 0. 0. 1.
 1.]"
NCT01604512,"53:61:cancer,96:102:cancer,118:128:cancer,143:153:cancer,173:196:treatment","Pathological or clinical/radiological diagnosis of aneoplasm , either primary (e.g., malignant glioma) or secondary (metastasis from systemic malignancy) with a history of brain radiation therapy","['Pathological' 'or' 'clinical/radiological' 'diagnosis' 'of' 'aneoplasm'
 ',' 'either' 'primary' '(' 'e.g.' ',' 'malignant' 'glioma' ')' 'or'
 'secondary' '(' 'metastasis' 'from' 'systemic' 'malignancy' ')' 'with'
 'a' 'history' 'of' 'brain' 'radiation' 'therapy']","[3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3.
 3. 3. 3. 1. 1. 1.]"
NCT01599559,"1:19:chronic_disease,46:54:cancer,114:129:chronic_disease",Cardiac impairment due to local extension of lymphoma will not be an exclusion criterion in the absence of other cardiac disease,"['Cardiac' 'impairment' 'due' 'to' 'local' 'extension' 'of' 'lymphoma'
 'will' 'not' 'be' 'an' 'exclusion' 'criterion' 'in' 'the' 'absence' 'of'
 'other' 'cardiac' 'disease']",[2. 2. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]
NCT01595529,"16:34:chronic_disease,52:55:chronic_disease,57:67:cancer,69:91:treatment,119:134:treatment,144:168:treatment","Presence of an immunocompromising condition (e.g., HIV, malignancy, solid-organ transplant recipients, use of chronic corticosteroids or other immunosuppressive agents)","['Presence' 'of' 'an' 'immunocompromising' 'condition' '(' 'e.g.' ','
 'HIV' ',' 'malignancy' ',' 'solid-organ' 'transplant' 'recipients' ','
 'use' 'of' 'chronic' 'corticosteroids' 'or' 'other' 'immunosuppressive'
 'agents' ')']","[0. 0. 0. 2. 0. 0. 0. 0. 2. 0. 3. 0. 1. 1. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1.
 0.]"
NCT01591356,"45:106:allergy_name,108:117:allergy_name,122:146:allergy_name","History of allergic reactions attributed to compounds of similar chemical or biologic composition to DOPC, Magnevist, or fluorodeoxyglucose (FDG)","['History' 'of' 'allergic' 'reactions' 'attributed' 'to' 'compounds' 'of'
 'similar' 'chemical' 'or' 'biologic' 'composition' 'to' 'DOPC' ','
 'Magnevist' ',' 'or' 'fluorodeoxyglucose' '(' 'FDG' ')']",[0. 0. 0. 0. 0. 0. 4. 4. 4. 4. 4. 4. 4. 4. 4. 0. 4. 0. 0. 4. 4. 0. 0.]
NCT01591356,"38:60:chronic_disease,90:102:chronic_disease,126:147:chronic_disease,151:166:chronic_disease,,,252:284:chronic_disease,294:312:chronic_disease,347:382:chronic_disease,409:446:chronic_disease,465:477:chronic_disease","Patients with clinically significant cardiovascular disease; this includes: uncontrolled hypertension (greater than 140/90); myocardial infarction or unstable angina within 6 months prior to registration; New York Heart Association (NYHA) grade II or greater congestive heart failure; serious cardiac arrhythmia requiring medication; grade II or greater peripheral vascular disease; patients with clinically significant peripheral artery disease, e.g., those with claudication, within 6 months of first date of treatment on this study","['Patients' 'with' 'clinically' 'significant' 'cardiovascular' 'disease'
 ';' 'this' 'includes' ':' 'uncontrolled' 'hypertension' '(' 'greater'
 'than' '140/90' ')' ';' 'myocardial' 'infarction' 'or' 'unstable'
 'angina' 'within' '6' 'months' 'prior' 'to' 'registration' ';' 'New'
 'York' 'Heart' 'Association' '(' 'NYHA' ')' 'grade' 'II' 'or' 'greater'
 'congestive' 'heart' 'failure' ';' 'serious' 'cardiac' 'arrhythmia'
 'requiring' 'medication' ';' 'grade' 'II' 'or' 'greater' 'peripheral'
 'vascular' 'disease' ';' 'patients' 'with' 'clinically' 'significant'
 'peripheral' 'artery' 'disease' ',' 'e.g.' ',' 'those' 'with'
 'claudication' ',' 'within' '6' 'months' 'of' 'first' 'date' 'of'
 'treatment' 'on' 'this' 'study']","[0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 2. 0. 2. 2. 2. 2. 0. 2. 2. 0. 2. 2. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01591356,"19:22:treatment,60:62:treatment,,,,,354:365:treatment","when imaging (DCE-MRI, DW-MRI and PET-computed tomography [CT] imaging) is being performed for secondary objectives (dose level III [or when the dose reaches at least 1,500 ug/m^2] and during the expansion phase) at least one lesion (>= 2 cm) not adjacent to the diaphragm will be required when measured by conventional techniques, including palpation, plain x-ray, CT, and MRI","['when' 'imaging' '(' 'DCE-MRI' ',' 'DW-MRI' 'and' 'PET-computed'
 'tomography' '[' 'CT' ']' 'imaging' ')' 'is' 'being' 'performed' 'for'
 'secondary' 'objectives' '(' 'dose' 'level' 'III' '[' 'or' 'when' 'the'
 'dose' 'reaches' 'at' 'least' '1,500' 'ug/m^2' ']' 'and' 'during' 'the'
 'expansion' 'phase' ')' 'at' 'least' 'one' 'lesion' '(' '>' '=' '2' 'cm'
 ')' 'not' 'adjacent' 'to' 'the' 'diaphragm' 'will' 'be' 'required' 'when'
 'measured' 'by' 'conventional' 'techniques' ',' 'including' 'palpation'
 ',' 'plain' 'x-ray' ',' 'CT' ',' 'and' 'MRI']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 0.]"
NCT01589263,"1:23:chronic_disease,25:35:chronic_disease,37:75:chronic_disease,80:98:chronic_disease","Eaton-Lambert syndrome, hemophilia, hereditary clotting factors deficiency, or bleeding diathesis","['Eaton-Lambert' 'syndrome' ',' 'hemophilia' ',' 'hereditary' 'clotting'
 'factors' 'deficiency' ',' 'or' 'bleeding' 'diathesis']",[2. 2. 0. 2. 0. 2. 2. 2. 2. 0. 0. 2. 2.]
NCT01589263,"32:57:cancer,61:68:cancer,70:86:treatment,90:97:treatment,99:117:chronic_disease,122:146:treatment","History or current evidence of carcinoma of the prostate or bladder, pelvic radiation or surgery, urethral stricture, or bladder neck obstruction","['History' 'or' 'current' 'evidence' 'of' 'carcinoma' 'of' 'the'
 'prostate' 'or' 'bladder' ',' 'pelvic' 'radiation' 'or' 'surgery' ','
 'urethral' 'stricture' ',' 'or' 'bladder' 'neck' 'obstruction']",[0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 1. 1. 1. 1. 0. 1. 0. 2. 2. 0. 0. 0. 0. 0.]
NCT01584076,"16:26:treatment,35:44:treatment,48:52:chronic_disease,56:79:chronic_disease",Current use of medication for the treatment of ADHD or psychological disorders,"['Current' 'use' 'of' 'medication' 'for' 'the' 'treatment' 'of' 'ADHD'
 'or' 'psychological' 'disorders']",[0. 0. 0. 1. 0. 0. 1. 0. 2. 0. 2. 2.]
NCT01582191,",57:79:treatment,,185:201:treatment,277:294:treatment,296:330:treatment,415:424:treatment","Patients must be at least 3 weeks beyond their previous cytotoxic chemotherapy; patient must be at least 5 half-lives or 3 weeks, whichever is shorter, from their previous targeted or biologic therapy; in addition, patients must be at least 3 weeks beyond the last session of radiation therapy; local palliative radiation therapy that is not delivered to all target lesions is allowed immediately before or during treatment","['Patients' 'must' 'be' 'at' 'least' '3' 'weeks' 'beyond' 'their'
 'previous' 'cytotoxic' 'chemotherapy' ';' 'patient' 'must' 'be' 'at'
 'least' '5' 'half-lives' 'or' '3' 'weeks' ',' 'whichever' 'is' 'shorter'
 ',' 'from' 'their' 'previous' 'targeted' 'or' 'biologic' 'therapy' ';'
 'in' 'addition' ',' 'patients' 'must' 'be' 'at' 'least' '3' 'weeks'
 'beyond' 'the' 'last' 'session' 'of' 'radiation' 'therapy' ';' 'local'
 'palliative' 'radiation' 'therapy' 'that' 'is' 'not' 'delivered' 'to'
 'all' 'target' 'lesions' 'is' 'allowed' 'immediately' 'before' 'or'
 'during' 'treatment']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 1.]"
NCT01581580,"36:59:treatment,,,103:105:chronic_disease,113:119:treatment","History of appropriate response to dopaminergic medication, with at least a 30% improvement in motor UPDRS with L-DOPA by history or in-clinic testing, for the PD patients","['History' 'of' 'appropriate' 'response' 'to' 'dopaminergic' 'medication'
 ',' 'with' 'at' 'least' 'a' '30' '%' 'improvement' 'in' 'motor' 'UPDRS'
 'with' 'L-DOPA' 'by' 'history' 'or' 'in-clinic' 'testing' ',' 'for' 'the'
 'PD' 'patients']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 2. 0.]"
NCT01576575,"8:52:treatment,54:61:treatment,65:70:treatment,149:168:treatment","Use of prescription or non-prescription medications, herbals or foods known to be metabolized by or affect CYP3A activity (this includes the use of oral contraceptives)","['Use' 'of' 'prescription' 'or' 'non-prescription' 'medications' ','
 'herbals' 'or' 'foods' 'known' 'to' 'be' 'metabolized' 'by' 'or' 'affect'
 'CYP3A' 'activity' '(' 'this' 'includes' 'the' 'use' 'of' 'oral'
 'contraceptives' ')']","[0. 0. 1. 1. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 0.]"
NCT01572480,"16:26:chronic_disease,60:86:chronic_disease,91:106:treatment","Has refractory GI disease with refractory nausea/vomiting, inflammatory bowel disease, or bowel resection that would prevent absorption","['Has' 'refractory' 'GI' 'disease' 'with' 'refractory' 'nausea/vomiting'
 ',' 'inflammatory' 'bowel' 'disease' ',' 'or' 'bowel' 'resection' 'that'
 'would' 'prevent' 'absorption']",[0. 0. 2. 2. 0. 0. 0. 0. 2. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01570998,"21:47:treatment,38:47:treatment,49:57:treatment,61:73:treatment,122:127:cancer",Patients undergoing primary systemic treatment (hormones or chemotherapy) as initial treatment with neoadjuvant reducing tumor size,"['Patients' 'undergoing' 'primary' 'systemic' 'treatment' '(' 'hormones'
 'or' 'chemotherapy' ')' 'as' 'initial' 'treatment' 'with' 'neoadjuvant'
 'reducing' 'tumor' 'size']",[0. 0. 1. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 3. 0.]
NCT01568177,"21:30:treatment,41:47:chronic_disease,49:60:chronic_disease,91:109:chronic_disease,123:127:chronic_disease,,","Contraindication to Adenosine including asthma, heart block (second and third degree) and sinus node disease, significant COPD/asthma, or systemic hypotension (<90mmHg)","['Contraindication' 'to' 'Adenosine' 'including' 'asthma' ',' 'heart'
 'block' '(' 'second' 'and' 'third' 'degree' ')' 'and' 'sinus' 'node'
 'disease' ',' 'significant' 'COPD/asthma' ',' 'or' 'systemic'
 'hypotension' '(' '<' '90mmHg' ')']","[0. 0. 1. 0. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 2. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT01562626,",104:109:cancer,150:167:treatment,202:204:treatment,208:218:treatment,226:244:treatment","Patients enrolled at Dose Level 6 or higher in the phase I portion of the trial must have at least one tumor mass suitable and easily accessible for excisional biopsy, or alternatively, accessible for CT or ultrasound guided core needle biopsy","['Patients' 'enrolled' 'at' 'Dose' 'Level' '6' 'or' 'higher' 'in' 'the'
 'phase' 'I' 'portion' 'of' 'the' 'trial' 'must' 'have' 'at' 'least' 'one'
 'tumor' 'mass' 'suitable' 'and' 'easily' 'accessible' 'for' 'excisional'
 'biopsy' ',' 'or' 'alternatively' ',' 'accessible' 'for' 'CT' 'or'
 'ultrasound' 'guided' 'core' 'needle' 'biopsy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0.
 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 1. 1.]"
NCT01562626,"14:22:chronic_disease,31:39:chronic_disease,43:49:chronic_disease,79:82:chronic_disease,94:104:treatment,106:111:treatment,113:118:treatment,129:157:treatment,165:181:chronic_disease","any existing thrombus (either arterial or venous) as well as known history of DVT, permanent pacemakers, AICDs, LVADs, or other intravascular cardiac device, known AV malformations","['any' 'existing' 'thrombus' '(' 'either' 'arterial' 'or' 'venous' ')'
 'as' 'well' 'as' 'known' 'history' 'of' 'DVT' ',' 'permanent'
 'pacemakers' ',' 'AICDs' ',' 'LVADs' ',' 'or' 'other' 'intravascular'
 'cardiac' 'device' ',' 'known' 'AV' 'malformations']","[0. 0. 2. 0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 1. 0. 1. 0. 1. 0.
 0. 0. 1. 1. 1. 0. 0. 2. 2.]"
NCT01554371,"1:25:chronic_disease,50:68:chronic_disease,103:124:chronic_disease,,168:179:treatment,245:260:chronic_disease","Congestive heart failure, Clinically significant cardiac arrhythmia, history or current evidence of a myocardial infarction during the last 6 months, and/or a current ECG tracing that is abnormal in the opinion of the treating Investigator, or unstable angina","['Congestive' 'heart' 'failure' ',' 'Clinically' 'significant' 'cardiac'
 'arrhythmia' ',' 'history' 'or' 'current' 'evidence' 'of' 'a'
 'myocardial' 'infarction' 'during' 'the' 'last' '6' 'months' ',' 'and/or'
 'a' 'current' 'ECG' 'tracing' 'that' 'is' 'abnormal' 'in' 'the' 'opinion'
 'of' 'the' 'treating' 'Investigator' ',' 'or' 'unstable' 'angina']","[2. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]"
NCT01553942,"27:35:allergy_name,37:46:allergy_name,51:61:allergy_name","Known hypersensitivity to afatinib, cisplatin, or pemetrexed","['Known' 'hypersensitivity' 'to' 'afatinib' ',' 'cisplatin' ',' 'or'
 'pemetrexed']",[0. 0. 0. 4. 0. 4. 0. 0. 4.]
NCT01553071,"62:72:cancer,131:139:treatment,143:162:treatment",Patients must have histologically or cytologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective,"['Patients' 'must' 'have' 'histologically' 'or' 'cytologically'
 'confirmed' 'malignancy' 'that' 'is' 'metastatic' 'or' 'unresectable'
 'and' 'for' 'which' 'standard' 'curative' 'or' 'palliative' 'measures'
 'do' 'not' 'exist' 'or' 'are' 'no' 'longer' 'effective']","[0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT01553071,"1:18:treatment,20:32:treatment,,,94:105:treatment,109:120:treatment,140:151:treatment,154:162:treatment","Radiation therapy, chemotherapy, and other investigational agents within 3weeks (6 weeks for nitrosourea or mitomycin C) prior to starting fenretinide + safingol","['Radiation' 'therapy' ',' 'chemotherapy' ',' 'and' 'other'
 'investigational' 'agents' 'within' '3weeks' '(' '6' 'weeks' 'for'
 'nitrosourea' 'or' 'mitomycin' 'C' ')' 'prior' 'to' 'starting'
 'fenretinide' '+' 'safingol']","[1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 1.
 0. 1.]"
NCT01553071,"35:42:treatment,44:53:treatment,84:100:cancer,124:146:treatment,,178:194:treatment","patients with previously treated (surgery, radiation or both), clinically inactive brain metastases, who have not received corticosteroid therapy within three weeks of starting protocol therapy","['patients' 'with' 'previously' 'treated' '(' 'surgery' ',' 'radiation'
 'or' 'both' ')' ',' 'clinically' 'inactive' 'brain' 'metastases' ','
 'who' 'have' 'not' 'received' 'corticosteroid' 'therapy' 'within' 'three'
 'weeks' 'of' 'starting' 'protocol' 'therapy']","[0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 1. 1. 0.
 0. 0. 0. 0. 1. 1.]"
NCT01543490,"15:31:chronic_disease,33:42:chronic_disease,44:49:chronic_disease,53:59:chronic_disease,71:90:chronic_disease,102:113:chronic_disease","Have an acute ocular infection (bacterial, viral or fungal) or active ocular inflammation other than blepharitis in the study eye","['Have' 'an' 'acute' 'ocular' 'infection' '(' 'bacterial' ',' 'viral' 'or'
 'fungal' ')' 'or' 'active' 'ocular' 'inflammation' 'other' 'than'
 'blepharitis' 'in' 'the' 'study' 'eye']",[0. 0. 0. 2. 2. 0. 2. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0.]
NCT01539109,"1:16:treatment,18:24:treatment,29:45:treatment","Implanted pumps, shunts, or neurostimulators","['Implanted' 'pumps' ',' 'shunts' ',' 'or' 'neurostimulators']",[1. 1. 0. 1. 0. 0. 1.]
NCT01538966,"31:41:chronic_disease,59:66:treatment,70:85:treatment",Newly diagnosed patients with acromegaly who have not had surgery or medical therapy,"['Newly' 'diagnosed' 'patients' 'with' 'acromegaly' 'who' 'have' 'not'
 'had' 'surgery' 'or' 'medical' 'therapy']",[0. 0. 0. 0. 2. 0. 0. 0. 0. 1. 0. 1. 1.]
NCT01532687,"1:13:treatment,15:28:treatment,30:46:treatment,48:71:treatment,75:91:treatment","Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy","['Chemotherapy' ',' 'immunotherapy' ',' 'biologic' 'therapy' ','
 'investigational' 'therapy' 'or' 'hormonal' 'therapy']",[1. 0. 1. 0. 1. 1. 0. 1. 1. 0. 1. 1.]
NCT01532687,"17:34:chronic_disease,36:44:chronic_disease,49:54:chronic_disease,75:93:treatment","presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major","['presence' 'of' 'any' 'non-healing' 'wound' ',' 'fracture' ',' 'or'
 'ulcer' '(' 'procedures' 'such' 'as' 'catheter' 'placement' 'not'
 'considered' 'to' 'be' 'major']",[0. 0. 0. 2. 2. 0. 2. 0. 0. 2. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.]
NCT01522768,"51:57:treatment,123:131:treatment,139:155:cancer,180:189:treatment,209:218:treatment,225:227:treatment",All patients with disease technically amenable to biopsy will be asked to undergo a biopsy. Patient must agree to allow 2 biopsies of any malignant lesion that can be accessed by endoscopy or with the aid or radiology (i.e. CT guided),"['All' 'patients' 'with' 'disease' 'technically' 'amenable' 'to' 'biopsy'
 'will' 'be' 'asked' 'to' 'undergo' 'a' 'biopsy' '.' 'Patient' 'must'
 'agree' 'to' 'allow' '2' 'biopsies' 'of' 'any' 'malignant' 'lesion'
 'that' 'can' 'be' 'accessed' 'by' 'endoscopy' 'or' 'with' 'the' 'aid'
 'or' 'radiology' '(' 'i.e' '.' 'CT' 'guided' ')']","[0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 0. 3. 3. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 0.]"
NCT01522768,"1:24:treatment,69:78:treatment,190:197:chronic_disease","Concurrent radiotherapy is not permitted for disease progression on treatment on protocol (except in the context specified in section 9.0), but might be allowed for pre-existing non-target lesions","['Concurrent' 'radiotherapy' 'is' 'not' 'permitted' 'for' 'disease'
 'progression' 'on' 'treatment' 'on' 'protocol' '(' 'except' 'in' 'the'
 'context' 'specified' 'in' 'section' '9.0' ')' ',' 'but' 'might' 'be'
 'allowed' 'for' 'pre-existing' 'non-target' 'lesions']","[1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 2.]"
NCT01522768,"21:32:treatment,78:88:cancer,126:141:treatment,167:183:treatment",Previously received trastuzumab as part of a regimen in the perioperative or metastatic setting with evidence of progression 9Zr-trastuzumab use as imaging agent for 89Zr-trastuzumab PET permitted,"['Previously' 'received' 'trastuzumab' 'as' 'part' 'of' 'a' 'regimen' 'in'
 'the' 'perioperative' 'or' 'metastatic' 'setting' 'with' 'evidence' 'of'
 'progression' '9Zr-trastuzumab' 'use' 'as' 'imaging' 'agent' 'for'
 '89Zr-trastuzumab' 'PET' 'permitted']","[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0.
 1. 0. 0.]"
NCT01516788,"34:63:chronic_disease,68:83:chronic_disease,96:111:chronic_disease,123:150:chronic_disease","Participants with a diagnosis of Erythropoietic Protoporphyria and Solar Urticaria, or another photodermatoses other than Polymorphous light eruption","['Participants' 'with' 'a' 'diagnosis' 'of' 'Erythropoietic'
 'Protoporphyria' 'and' 'Solar' 'Urticaria' ',' 'or' 'another'
 'photodermatoses' 'other' 'than' 'Polymorphous' 'light' 'eruption']",[0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 2. 0. 0. 2. 2. 2.]
NCT01508390,"1:8:cancer,38:40:treatment,48:51:treatment,57:66:treatment","M-stage determined by physical exam, CT and/or MRI, and bone scan","['M-stage' 'determined' 'by' 'physical' 'exam' ',' 'CT' 'and/or' 'MRI' ','
 'and' 'bone' 'scan']",[3. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 1.]
NCT01505569,",,51:69:treatment,122:132:cancer,164:173:treatment","Children less than 8 months of age at the time of definitive surgery (for histopathologic diagnosis), any histology, any metastatic state, with total or sub-total resection","['Children' 'less' 'than' '8' 'months' 'of' 'age' 'at' 'the' 'time' 'of'
 'definitive' 'surgery' '(' 'for' 'histopathologic' 'diagnosis' ')' ','
 'any' 'histology' ',' 'any' 'metastatic' 'state' ',' 'with' 'total' 'or'
 'sub-total' 'resection']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3.
 0. 0. 0. 0. 0. 0. 1.]"
NCT01505569,"1:14:cancer,44:64:cancer,141:152:cancer,182:215:treatment",Neuroblastoma (ICD-O morphology 9500/3) or ganglioneuroblastoma (nodular or intermixed) verified by histology or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamine metabolites,"['Neuroblastoma' '(' 'ICD-O' 'morphology' '9500/3' ')' 'or'
 'ganglioneuroblastoma' '(' 'nodular' 'or' 'intermixed' ')' 'verified'
 'by' 'histology' 'or' 'demonstration' 'of' 'clumps' 'of' 'tumor' 'cells'
 'in' 'bone' 'marrow' 'with' 'elevated' 'urinary' 'catecholamine'
 'metabolites']","[3. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0.
 0. 0. 0. 0. 1. 1. 1.]"
NCT01505569,"74:77:cancer,79:89:cancer,91:101:cancer,103:118:cancer,122:138:cancer,,,,,215:225:cancer","This would require a clinical situation consistent with the diagnosis of GCT (testicular, peritoneal, retroperitoneal or mediastinal mass, elevated tumor marker levels {HCG ≥ 500; AFP ≥ 500} and typical pattern of metastases)","['This' 'would' 'require' 'a' 'clinical' 'situation' 'consistent' 'with'
 'the' 'diagnosis' 'of' 'GCT' '(' 'testicular' ',' 'peritoneal' ','
 'retroperitoneal' 'or' 'mediastinal' 'mass' ',' 'elevated' 'tumor'
 'marker' 'levels' '{' 'HCG' '≥' '500' ';' 'AFP' '≥' '500' '}' 'and'
 'typical' 'pattern' 'of' 'metastases' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 0. 3. 0. 3. 0. 3. 3. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0.]"
NCT01505062,"39:60:treatment,75:98:treatment,,130:137:treatment",Current or anticipated treatment with anticoagulant therapy or the use of anticoagulation therapy within the four weeks prior to surgery,"['Current' 'or' 'anticipated' 'treatment' 'with' 'anticoagulant' 'therapy'
 'or' 'the' 'use' 'of' 'anticoagulation' 'therapy' 'within' 'the' 'four'
 'weeks' 'prior' 'to' 'surgery']",[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1.]
NCT01500551,"37:71:chronic_disease,73:84:chronic_disease,88:105:chronic_disease","A subject known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus","['A' 'subject' 'known' 'to' 'be' 'infected' 'with' 'human'
 'immunodeficiency' 'virus' '(' 'HIV' ')' ',' 'hepatitis' 'B' 'or'
 'hepatitis' 'C' 'virus']",[0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 2. 0. 0. 0.]
NCT01495637,"1:28:chronic_disease,30:55:cancer,,124:130:allergy_name","Autoimmune thrombocytopenia, myelodysplastic syndromes with > 20% marrow blast cells, or known allergy/hypersensitivity to GM-CSF","['Autoimmune' 'thrombocytopenia' ',' 'myelodysplastic' 'syndromes' 'with'
 '>' '20' '%' 'marrow' 'blast' 'cells' ',' 'or' 'known'
 'allergy/hypersensitivity' 'to' 'GM-CSF']",[2. 2. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4.]
NCT01494662,",33:50:treatment,56:78:treatment,80:89:treatment,97:105:treatment,109:125:treatment,130:147:treatment","At least 2 weeks washout period post chemotherapy, any prior protocol therapy, lapatinib, other targeted or biologic therapy, or radiation therapy is required prior to study entry","['At' 'least' '2' 'weeks' 'washout' 'period' 'post' 'chemotherapy' ','
 'any' 'prior' 'protocol' 'therapy' ',' 'lapatinib' ',' 'other' 'targeted'
 'or' 'biologic' 'therapy' ',' 'or' 'radiation' 'therapy' 'is' 'required'
 'prior' 'to' 'study' 'entry']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 1. 0. 1. 0. 0. 1. 0. 1. 1. 0. 0. 1.
 1. 0. 0. 0. 0. 0. 0.]"
NCT01494662,"127:136:allergy_name,141:146:allergy_name,183:227:allergy_name,239:248:allergy_name,250:263:allergy_name,265:278:allergy_name,280:292:allergy_name,294:307:allergy_name,309:322:allergy_name,327:336:allergy_name","History of severe allergic reactions or intolerability attributed to compounds of similar chemical or biologic composition to neratinib and T-DM1 for Cohorts 4A-4C Concurrent use of enzyme-inducing antiepileptic drugs (EIAEDs), including phenytoin, carbamazepine, oxcarbazepine, fosphenytoin, phenobarbital, pentobarbital, or primidone","['History' 'of' 'severe' 'allergic' 'reactions' 'or' 'intolerability'
 'attributed' 'to' 'compounds' 'of' 'similar' 'chemical' 'or' 'biologic'
 'composition' 'to' 'neratinib' 'and' 'T-DM1' 'for' 'Cohorts' '4A-4C'
 'Concurrent' 'use' 'of' 'enzyme-inducing' 'antiepileptic' 'drugs' '('
 'EIAEDs' ')' ',' 'including' 'phenytoin' ',' 'carbamazepine' ','
 'oxcarbazepine' ',' 'fosphenytoin' ',' 'phenobarbital' ','
 'pentobarbital' ',' 'or' 'primidone']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 4. 0. 4. 0. 0. 0. 0.
 0. 0. 4. 4. 4. 4. 0. 0. 0. 0. 4. 0. 4. 0. 4. 0. 4. 0. 4. 0. 4. 0. 0. 4.]"
NCT01494662,"27:39:treatment,43:55:treatment,67:89:treatment,,",Participants who have had chemotherapy or radiotherapy (including investigational agents) within 2 weeks prior to entering the study or those who have not recovered adequately from adverse events due to agents administered more than 4 weeks earlier,"['Participants' 'who' 'have' 'had' 'chemotherapy' 'or' 'radiotherapy' '('
 'including' 'investigational' 'agents' ')' 'within' '2' 'weeks' 'prior'
 'to' 'entering' 'the' 'study' 'or' 'those' 'who' 'have' 'not' 'recovered'
 'adequately' 'from' 'adverse' 'events' 'due' 'to' 'agents' 'administered'
 'more' 'than' '4' 'weeks' 'earlier']","[0. 0. 0. 0. 1. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01494662,"41:44:treatment,62:71:treatment,73:81:treatment","Patients with known contraindication to MRI, such as cardiac pacemaker, shrapnel, or ocular foreign body","['Patients' 'with' 'known' 'contraindication' 'to' 'MRI' ',' 'such' 'as'
 'cardiac' 'pacemaker' ',' 'shrapnel' ',' 'or' 'ocular' 'foreign' 'body']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0.]
NCT01481974,"58:70:treatment,122:149:treatment,173:194:treatment","Be receiving any investigational drug (a drug other than Treprostinil administered under an IND) or participating in any other investigational study, with the exception of alemtuzumab (Campath)","['Be' 'receiving' 'any' 'investigational' 'drug' '(' 'a' 'drug' 'other'
 'than' 'Treprostinil' 'administered' 'under' 'an' 'IND' ')' 'or'
 'participating' 'in' 'any' 'other' 'investigational' 'study' ',' 'with'
 'the' 'exception' 'of' 'alemtuzumab' '(' 'Campath' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1. 0. 0.]"
NCT01474889,"16:45:treatment,68:94:treatment,107:133:treatment,137:184:treatment,,,273:308:treatment,,","Involvement in intensive diabetes management defined as the use of basal-bolus insulin analog delivery by multi-dose injection (MDI) or continuous subcutaneous insulin infusion (CSII) together with self-monitoring of blood glucose values four or more times daily, without continuous glucose monitoring (CGM), under the direction of an endocrinologist, diabetologist, or diabetes nurse practitioner with at least 3 clinical evaluations during the previous 12 months","['Involvement' 'in' 'intensive' 'diabetes' 'management' 'defined' 'as'
 'the' 'use' 'of' 'basal-bolus' 'insulin' 'analog' 'delivery' 'by'
 'multi-dose' 'injection' '(' 'MDI' ')' 'or' 'continuous' 'subcutaneous'
 'insulin' 'infusion' '(' 'CSII' ')' 'together' 'with' 'self-monitoring'
 'of' 'blood' 'glucose' 'values' 'four' 'or' 'more' 'times' 'daily' ','
 'without' 'continuous' 'glucose' 'monitoring' '(' 'CGM' ')' ',' 'under'
 'the' 'direction' 'of' 'an' 'endocrinologist' ',' 'diabetologist' ','
 'or' 'diabetes' 'nurse' 'practitioner' 'with' 'at' 'least' '3' 'clinical'
 'evaluations' 'during' 'the' 'previous' '12' 'months']","[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 1.
 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT01464034,"2:16:chronic_disease,18:30:chronic_disease,32:46:chronic_disease","(polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)","['(' 'polyneuropathy' ',' 'organomegaly' ',' 'endocrinopathy' ','
 'monoclonal' 'protein' ',' 'and' 'skin' 'changes' ')']",[0. 2. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01464034,"24:46:treatment,90:108:chronic_disease,144:152:treatment,,,,193:221:treatment,238:266:chronic_disease,267:290:chronic_disease","Pts must agree to take enteric-coated aspirin 81 mg orally daily, or if history of prior thrombotic disease, must be fully anticoagulated with warfarin (INR 2-3) or be treated with full-dose, low molecular weight heparin, as if to treat deep venous thrombosis (DVT)/pulmonary embolism (PE)at the investigator's discretion","['Pts' 'must' 'agree' 'to' 'take' 'enteric-coated' 'aspirin' '81' 'mg'
 'orally' 'daily' ',' 'or' 'if' 'history' 'of' 'prior' 'thrombotic'
 'disease' ',' 'must' 'be' 'fully' 'anticoagulated' 'with' 'warfarin' '('
 'INR' '2-3' ')' 'or' 'be' 'treated' 'with' 'full-dose' ',' 'low'
 'molecular' 'weight' 'heparin' ',' 'as' 'if' 'to' 'treat' 'deep' 'venous'
 'thrombosis' '(' 'DVT' ')' '/pulmonary' 'embolism' '(' 'PE' ')' 'at'
 'the' 'investigator' ""'s"" 'discretion']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0.
 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 2. 2. 2.
 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT01459107,"58:79:chronic_disease,84:95:chronic_disease,131:161:chronic_disease,167:180:chronic_disease",Conditions that may impact functional outcomes including Lipopolysaccharidosis and amyloidosis (may impact nerve regeneration) or rare disorders of bone healing like osteopetrosis,"['Conditions' 'that' 'may' 'impact' 'functional' 'outcomes' 'including'
 'Lipopolysaccharidosis' 'and' 'amyloidosis' '(' 'may' 'impact' 'nerve'
 'regeneration' ')' 'or' 'rare' 'disorders' 'of' 'bone' 'healing' 'like'
 'osteopetrosis']",[0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 0. 2.]
NCT01459107,"119:137:treatment,244:253:treatment,356:387:treatment","No co-existing medical condition which, in the opinion of the study team, could affect the immunomodulatory protocol, surgical procedure, or functional results (see Donor and Recipient Exclusion Criteria below. If the condition is amenable to treatment, the study team must agree that said condition should not significantly enhance the surgical risks of upper extremity transplantation.)","['No' 'co-existing' 'medical' 'condition' 'which' ',' 'in' 'the' 'opinion'
 'of' 'the' 'study' 'team' ',' 'could' 'affect' 'the' 'immunomodulatory'
 'protocol' ',' 'surgical' 'procedure' ',' 'or' 'functional' 'results' '('
 'see' 'Donor' 'and' 'Recipient' 'Exclusion' 'Criteria' 'below' '.' 'If'
 'the' 'condition' 'is' 'amenable' 'to' 'treatment' ',' 'the' 'study'
 'team' 'must' 'agree' 'that' 'said' 'condition' 'should' 'not'
 'significantly' 'enhance' 'the' 'surgical' 'risks' 'of' 'upper'
 'extremity' 'transplantation' '.' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 0.]"
NCT01445821,"4:15:treatment,87:128:treatment,141:152:chronic_disease,161:199:treatment","On cardiac MRI, a diastolic septal bounce or diastolic septal flattering (D-sign), or diffuse myocardial gadolinium enhancement, or diffuse hypokinesis (patchy late gadolinium myocardial enhancement are not exclusion criteria)","['On' 'cardiac' 'MRI' ',' 'a' 'diastolic' 'septal' 'bounce' 'or'
 'diastolic' 'septal' 'flattering' '(' 'D-sign' ')' ',' 'or' 'diffuse'
 'myocardial' 'gadolinium' 'enhancement' ',' 'or' 'diffuse' 'hypokinesis'
 '(' 'patchy' 'late' 'gadolinium' 'myocardial' 'enhancement' 'are' 'not'
 'exclusion' 'criteria' ')']","[0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0.
 2. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0.]"
NCT01444209,"28:33:cancer,54:57:treatment,61:63:treatment",Patients must have visible tumor on imaging studies (MRI or CT),"['Patients' 'must' 'have' 'visible' 'tumor' 'on' 'imaging' 'studies' '('
 'MRI' 'or' 'CT' ')']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 1. 0. 1. 0.]
NCT01436968,"1:16:treatment,21:36:cancer,45:49:treatment,53:56:treatment","Prior treatment for prostate cancer, except TURP or ADT","['Prior' 'treatment' 'for' 'prostate' 'cancer' ',' 'except' 'TURP' 'or'
 'ADT']",[1. 1. 0. 3. 3. 0. 0. 1. 0. 1.]
NCT01434472,"71:86:cancer,88:125:cancer,127:148:cancer,,213:244:treatment","Patients must have a histologically confirmed diagnosis of aggressive B-cell lymphoma (diffuse large B-cell lymphoma [DLBCL], Burkitt lymphoma [BL], etc.) expressing the CD20 antigen and have failed at least one prior standard systemic therapy","['Patients' 'must' 'have' 'a' 'histologically' 'confirmed' 'diagnosis'
 'of' 'aggressive' 'B-cell' 'lymphoma' '(' 'diffuse' 'large' 'B-cell'
 'lymphoma' '[' 'DLBCL' ']' ',' 'Burkitt' 'lymphoma' '[' 'BL' ']' ','
 'etc' '.' ')' 'expressing' 'the' 'CD20' 'antigen' 'and' 'have' 'failed'
 'at' 'least' 'one' 'prior' 'standard' 'systemic' 'therapy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 3. 3. 3. 3. 3. 0. 0. 0. 3. 3. 3. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1.]"
NCT01434316,"37:56:treatment,58:67:treatment,69:77:treatment,79:88:treatment,93:101:treatment,,161:172:treatment,197:212:treatment,266:283:treatment,285:300:treatment,330:339:treatment,344:359:cancer,,433:471:treatment,473:507:treatment","Patients must not receive any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) while on this study except for medications that are prescribed for supportive care but may potentially have an anti-cancer effect (i.e. megestrol acetate, bisphosphonates); in addition, men receiving treatment for prostate cancer will be maintained at castrate levels of testosterone by continuation of luteinizing-releasing hormone agonists; palliative radiation therapy (XRT) can be administered on study after documented discussion with the principal investigator; for patients in expansion cohorts, this must not involve target lesions","['Patients' 'must' 'not' 'receive' 'any' 'other' 'anti-cancer' 'therapy'
 '(' 'cytotoxic' ',' 'biologic' ',' 'radiation' ',' 'or' 'hormonal'
 'other' 'than' 'for' 'replacement' ')' 'while' 'on' 'this' 'study'
 'except' 'for' 'medications' 'that' 'are' 'prescribed' 'for' 'supportive'
 'care' 'but' 'may' 'potentially' 'have' 'an' 'anti-cancer' 'effect' '('
 'i.e' '.' 'megestrol' 'acetate' ',' 'bisphosphonates' ')' ';' 'in'
 'addition' ',' 'men' 'receiving' 'treatment' 'for' 'prostate' 'cancer'
 'will' 'be' 'maintained' 'at' 'castrate' 'levels' 'of' 'testosterone'
 'by' 'continuation' 'of' 'luteinizing-releasing' 'hormone' 'agonists' ';'
 'palliative' 'radiation' 'therapy' '(' 'XRT' ')' 'can' 'be'
 'administered' 'on' 'study' 'after' 'documented' 'discussion' 'with'
 'the' 'principal' 'investigator' ';' 'for' 'patients' 'in' 'expansion'
 'cohorts' ',' 'this' 'must' 'not' 'involve' 'target' 'lesions']","[0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 1. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01434316,"33:61:cancer,57:60:cancer,63:68:cancer,70:100:cancer,96:99:cancer",Subjects with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS) or with features suggestive of AML/MDS,"['Subjects' 'with' 'treatment-related' 'acute' 'myeloid' 'leukemia' '('
 'AML' ')' '(' 't-AML' ')' '/myelodysplastic' 'syndrome' '(' 'MDS' ')'
 'or' 'with' 'features' 'suggestive' 'of' 'AML/MDS']",[0. 0. 0. 3. 3. 3. 3. 3. 0. 0. 3. 0. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0.]
NCT01434316,"28:67:cancer,,163:172:treatment,181:198:treatment","patients with a history of central nervous system (CNS) metastases that have been treated must be stable with no symptoms for > 3 months after completion of that treatment and off steroid treatment, with image documentation required prior to study enrollment","['patients' 'with' 'a' 'history' 'of' 'central' 'nervous' 'system' '('
 'CNS' ')' 'metastases' 'that' 'have' 'been' 'treated' 'must' 'be'
 'stable' 'with' 'no' 'symptoms' 'for' '>' '3' 'months' 'after'
 'completion' 'of' 'that' 'treatment' 'and' 'off' 'steroid' 'treatment'
 ',' 'with' 'image' 'documentation' 'required' 'prior' 'to' 'study'
 'enrollment']","[0. 0. 0. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01433315,"61:75:treatment,77:87:treatment,89:101:treatment,103:116:treatment,118:128:treatment","On no prescription medications other than second generation antihistamines (Cetirizine, Fexofenadine, Desloratadine, Loratadine, etc), oral contraceptive pills, or intrauterine devices","['On' 'no' 'prescription' 'medications' 'other' 'than' 'second'
 'generation' 'antihistamines' '(' 'Cetirizine' ',' 'Fexofenadine' ','
 'Desloratadine' ',' 'Loratadine' ',' 'etc' ')' ',' 'oral' 'contraceptive'
 'pills' ',' 'or' 'intrauterine' 'devices']","[0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01430390,"41:53:cancer,60:80:cancer,98:113:treatment,137:171:treatment",History of relapsed or refractory CD19+ malignancies (e.g. Non Hodgkin Lymphoma) who have failed prior treatment and require autologous hematopoietic stem cell transplant,"['History' 'of' 'relapsed' 'or' 'refractory' 'CD19+' 'malignancies' '('
 'e.g' '.' 'Non' 'Hodgkin' 'Lymphoma' ')' 'who' 'have' 'failed' 'prior'
 'treatment' 'and' 'require' 'autologous' 'hematopoietic' 'stem' 'cell'
 'transplant']","[0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 1. 1. 0. 0. 0. 1. 1.
 1. 1.]"
NCT01430390,"8:21:treatment,23:46:treatment,,74:82:treatment",Recent prior therapy: Systematic chemotherapy less than 2 weeks prior to infusion,"['Recent' 'prior' 'therapy' ':' 'Systematic' 'chemotherapy' 'less' 'than'
 '2' 'weeks' 'prior' 'to' 'infusion']",[0. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1.]
NCT01430390,"15:19:treatment,100:113:treatment,165:177:treatment,","The patient's HSCT donor, or if HSCT donor is not available a third party donor, must consent to a leukapheresis or whole blood donation(s) obtained at one or more phlebotomies which, in aggregate, will total approximately 250 ml for adults and no more than 5ml/kg per draw from pediatric donors","['The' 'patient' ""'s"" 'HSCT' 'donor' ',' 'or' 'if' 'HSCT' 'donor' 'is'
 'not' 'available' 'a' 'third' 'party' 'donor' ',' 'must' 'consent' 'to'
 'a' 'leukapheresis' 'or' 'whole' 'blood' 'donation' '(' 's' ')'
 'obtained' 'at' 'one' 'or' 'more' 'phlebotomies' 'which' ',' 'in'
 'aggregate' ',' 'will' 'total' 'approximately' '250' 'ml' 'for' 'adults'
 'and' 'no' 'more' 'than' '5ml/kg' 'per' 'draw' 'from' 'pediatric'
 'donors']","[0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01422746,"4:15:treatment,152:176:treatment,178:188:treatment,190:199:treatment,201:216:treatment,222:235:treatment","No medications known to affect the reproductive system or glucose metabolism can be taken in the 3 months prior to the study. Such medications include oral contraceptive pills, progestins, metformin, glucocorticoids, and psychotropics","['No' 'medications' 'known' 'to' 'affect' 'the' 'reproductive' 'system'
 'or' 'glucose' 'metabolism' 'can' 'be' 'taken' 'in' 'the' '3' 'months'
 'prior' 'to' 'the' 'study' '.' 'Such' 'medications' 'include' 'oral'
 'contraceptive' 'pills' ',' 'progestins' ',' 'metformin' ','
 'glucocorticoids' ',' 'and' 'psychotropics']","[0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 1. 0. 1. 0. 1. 0. 1. 0. 0. 1.]"
NCT01421810,"1:8:chronic_disease,37:53:chronic_disease,60:81:chronic_disease",Obesity associated with a diagnosed genetic syndrome (e.g. Prader-Willi syndrome),"['Obesity' 'associated' 'with' 'a' 'diagnosed' 'genetic' 'syndrome' '('
 'e.g' '.' 'Prader-Willi' 'syndrome' ')']",[2. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0.]
NCT01420887,"16:39:chronic_disease,43:51:chronic_disease,86:100:chronic_disease","Progressive or recalcitrant neuropathy or neuritis, except for isolated intermittent ulnar neuritis","['Progressive' 'or' 'recalcitrant' 'neuropathy' 'or' 'neuritis' ','
 'except' 'for' 'isolated' 'intermittent' 'ulnar' 'neuritis']",[0. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 2. 2.]
NCT01419561,"1:6:chronic_disease,8:15:chronic_disease,17:39:chronic_disease,44:62:chronic_disease","Cough, dyspnea, airway hyperreactivity, or nasal inflammation","['Cough' ',' 'dyspnea' ',' 'airway' 'hyperreactivity' ',' 'or' 'nasal'
 'inflammation']",[2. 0. 2. 0. 2. 2. 0. 0. 2. 2.]
NCT01415882,"11:26:treatment,28:51:treatment,53:64:treatment,68:80:treatment,","High dose corticosteroids, immune modulatory drugs (thalidomide or lenalidomide) =< 7 days prior to registration","['High' 'dose' 'corticosteroids' ',' 'immune' 'modulatory' 'drugs' '('
 'thalidomide' 'or' 'lenalidomide' ')' '=' '<' '7' 'days' 'prior' 'to'
 'registration']",[0. 0. 1. 0. 1. 1. 1. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01415882,"1:14:treatment,24:44:treatment,56:66:treatment,70:81:treatment",Prior therapy with any proteasome inhibitor other than bortezomib or carfilzomib,"['Prior' 'therapy' 'with' 'any' 'proteasome' 'inhibitor' 'other' 'than'
 'bortezomib' 'or' 'carfilzomib']",[1. 1. 0. 0. 1. 1. 0. 0. 1. 0. 1.]
NCT01415752,"25:36:treatment,41:78:chronic_disease,86:93:treatment,,,","Must be willing to take prophylaxis for Pneumocystis jiroveci pneumonia (PCP) during therapy and until at least 2 months following the completion of therapy or until the CD4 cells recover to over 250 cells/mm³, whichever occurs later","['Must' 'be' 'willing' 'to' 'take' 'prophylaxis' 'for' 'Pneumocystis'
 'jiroveci' 'pneumonia' '(' 'PCP' ')' 'during' 'therapy' 'and' 'until'
 'at' 'least' '2' 'months' 'following' 'the' 'completion' 'of' 'therapy'
 'or' 'until' 'the' 'CD4' 'cells' 'recover' 'to' 'over' '250' 'cells/mm³'
 ',' 'whichever' 'occurs' 'later']","[0. 0. 0. 0. 0. 1. 0. 2. 2. 2. 2. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01415752,"49:69:chronic_disease,99:106:treatment,,,129:144:treatment",Patients on Arms G and H without a history of a thromboembolic event are required to take a daily aspirin (81 mg or 325 mg) for DVT prophylaxis,"['Patients' 'on' 'Arms' 'G' 'and' 'H' 'without' 'a' 'history' 'of' 'a'
 'thromboembolic' 'event' 'are' 'required' 'to' 'take' 'a' 'daily'
 'aspirin' '(' '81' 'mg' 'or' '325' 'mg' ')' 'for' 'DVT' 'prophylaxis']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1.]"
NCT01409161,",,,101:109:cancer,139:148:chronic_disease,162:169:chronic_disease",Patients with creatinine > 2.5 times upper limit of normal unless felt to be related the underlying leukemia by the treating physician or hemolysis or Gilbert's disease,"['Patients' 'with' 'creatinine' '>' '2.5' 'times' 'upper' 'limit' 'of'
 'normal' 'unless' 'felt' 'to' 'be' 'related' 'the' 'underlying'
 'leukemia' 'by' 'the' 'treating' 'physician' 'or' 'hemolysis' 'or'
 'Gilbert' ""'s"" 'disease']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 2.
 0. 0. 0. 2.]"
NCT01407809,"6:26:chronic_disease,,,,,,,258:267:treatment,275:285:treatment","Mild visual function loss, defined as grades 0,1 or 2 on the Humphrey Visual Field Analyzer SITA Standard 24-2 Test grading scale (Table 4) at presentation and a worsening to moderate or greater visual function loss, defined as grades 3-5, after 1 month of treatment and/or medication intolerance","['Mild' 'visual' 'function' 'loss' ',' 'defined' 'as' 'grades' '0,1' 'or'
 '2' 'on' 'the' 'Humphrey' 'Visual' 'Field' 'Analyzer' 'SITA' 'Standard'
 '24-2' 'Test' 'grading' 'scale' '(' 'Table' '4' ')' 'at' 'presentation'
 'and' 'a' 'worsening' 'to' 'moderate' 'or' 'greater' 'visual' 'function'
 'loss' ',' 'defined' 'as' 'grades' '3-5' ',' 'after' '1' 'month' 'of'
 'treatment' 'and/or' 'medication' 'intolerance']","[0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 0. 1. 0.]"
NCT01389024,"7:27:chronic_disease,60:68:treatment,69:79:treatment",Known airway abnormalities that would increase the risk of sedation/anesthesia,"['Known' 'airway' 'abnormalities' 'that' 'would' 'increase' 'the' 'risk'
 'of' 'sedation/anesthesia']",[0. 2. 2. 0. 0. 0. 0. 0. 0. 1.]
NCT01389024,"1:35:treatment,39:50:treatment,,82:91:treatment",Treatment with anti-sickling drugs or hydroxyurea within 3 months or anticipated treatment during the course of the study,"['Treatment' 'with' 'anti-sickling' 'drugs' 'or' 'hydroxyurea' 'within'
 '3' 'months' 'or' 'anticipated' 'treatment' 'during' 'the' 'course' 'of'
 'the' 'study']",[1. 1. 1. 1. 0. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01384513,"1:31:cancer,54:76:chronic_disease,80:129:chronic_disease","MDS (myelodysplastic syndrome), specific subtypes of RA (refractory anemia) or RARS (refractory anemia with ringed sideroblasts) subtypes","['MDS' '(' 'myelodysplastic' 'syndrome' ')' ',' 'specific' 'subtypes' 'of'
 'RA' '(' 'refractory' 'anemia' ')' 'or' 'RARS' '(' 'refractory' 'anemia'
 'with' 'ringed' 'sideroblasts' ')' 'subtypes']",[3. 3. 3. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 2. 2. 2. 2. 2. 2. 0. 0. 0.]
NCT01379573,"39:56:chronic_disease,65:68:chronic_disease,72:74:chronic_disease,158:161:chronic_disease","Mother may be asymptomatic, or have a rheumatic disease such as SLE or SS. Maternal health status has not been considered an influence on the development of CHB","['Mother' 'may' 'be' 'asymptomatic' ',' 'or' 'have' 'a' 'rheumatic'
 'disease' 'such' 'as' 'SLE' 'or' 'SS' '.' 'Maternal' 'health' 'status'
 'has' 'not' 'been' 'considered' 'an' 'influence' 'on' 'the' 'development'
 'of' 'CHB']","[0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 2.]"
NCT01367444,"1:16:treatment,51:68:treatment,70:82:treatment","Laboratory test abnormalities or abnormalities in electrocardiogram, chest X-rays that in the opinion of the Principal Investigator would make the patient unsuitable for participation in the study","['Laboratory' 'test' 'abnormalities' 'or' 'abnormalities' 'in'
 'electrocardiogram' ',' 'chest' 'X-rays' 'that' 'in' 'the' 'opinion' 'of'
 'the' 'Principal' 'Investigator' 'would' 'make' 'the' 'patient'
 'unsuitable' 'for' 'participation' 'in' 'the' 'study']","[1. 1. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT01366612,"19:30:chronic_disease,35:60:chronic_disease,75:84:treatment",Recovery from all hematologic and non-hematology toxicities from previous therapies,"['Recovery' 'from' 'all' 'hematologic' 'and' 'non-hematology' 'toxicities'
 'from' 'previous' 'therapies']",[0. 0. 0. 2. 0. 2. 2. 0. 0. 1.]
NCT01365169,"35:42:cancer,44:68:cancer,70:84:cancer,86:100:cancer,111:131:chronic_disease,133:153:cancer","Diagnosis of any of the following cancers: stage 1-4b oropharyngeal, hypopharyngeal, nasopharyngeal, salivary gland or oral cavity; stage 3-4b laryngeal","['Diagnosis' 'of' 'any' 'of' 'the' 'following' 'cancers' ':' 'stage'
 '1-4b' 'oropharyngeal' ',' 'hypopharyngeal' ',' 'nasopharyngeal' ','
 'salivary' 'gland' 'or' 'oral' 'cavity' ';' 'stage' '3-4b' 'laryngeal']","[0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 3. 0. 3. 0. 3. 0. 0. 2. 2. 2. 2. 0. 0. 0.
 0.]"
NCT01365169,"21:28:chronic_disease,32:49:chronic_disease,65:80:chronic_disease,82:135:chronic_disease,138:141:chronic_disease",Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease (New York Heart Association functional class III or IV) (PCS study),"['Underlying' 'unstable' 'cardiac' 'or' 'pulmonary' 'disease' 'or'
 'symptomatic' 'cardiac' 'disease' '(' 'New' 'York' 'Heart' 'Association'
 'functional' 'class' 'III' 'or' 'IV' ')' '(' 'PCS' 'study' ')']","[0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 2. 2. 2. 2. 2. 2. 2. 2. 2. 0. 0. 2. 0.
 0.]"
NCT01360606,"14:35:chronic_disease,77:93:chronic_disease,,,206:230:chronic_disease,,,285:314:chronic_disease,316:335:chronic_disease,346:369:treatment,381:394:treatment,398:405:treatment,408:433:chronic_disease","Uncontrolled inter-current illness including, but not limited to ongoing or active infection (> grade 2 National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version 4.0), congestive heart failure (> New York Heart Association (NYHA) class 2), active coronary artery disease (CAD), cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin), uncontrolled hypertension and any condition which could jeopardize the safety of the patient and his/her compliance in the study","['Uncontrolled' 'inter-current' 'illness' 'including' ',' 'but' 'not'
 'limited' 'to' 'ongoing' 'or' 'active' 'infection' '(' '>' 'grade' '2'
 'National' 'Cancer' 'Institute' '[' 'NCI' ']' '-Common' 'Terminology'
 'Criteria' 'for' 'Adverse' 'Events' '[' 'CTCAE' ']' 'version' '4.0' ')'
 ',' 'congestive' 'heart' 'failure' '(' '>' 'New' 'York' 'Heart'
 'Association' '(' 'NYHA' ')' 'class' '2' ')' ',' 'active' 'coronary'
 'artery' 'disease' '(' 'CAD' ')' ',' 'cardiac' 'arrhythmias' 'requiring'
 'anti-arrhythmic' 'therapy' 'other' 'than' 'beta' 'blockers' 'or'
 'digoxin' ')' ',' 'uncontrolled' 'hypertension' 'and' 'any' 'condition'
 'which' 'could' 'jeopardize' 'the' 'safety' 'of' 'the' 'patient' 'and'
 'his/her' 'compliance' 'in' 'the' 'study']","[0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 2. 2. 2. 2. 0. 0. 0. 2. 2. 0. 1. 1. 0. 0. 1. 1. 0. 1. 0.
 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01351103,"1:40:chronic_disease,44:68:chronic_disease,116:127:treatment,169:175:chronic_disease,177:185:chronic_disease,187:195:chronic_disease,197:219:chronic_disease,221:242:treatment","Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of oral LGK974 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection)","['Impairment' 'of' 'gastrointestinal' 'function' 'or' 'gastrointestinal'
 'disease' 'that' 'may' 'significantly' 'alter' 'the' 'absorption' 'of'
 'oral' 'LGK974' '(' 'e.g.' ',' 'ulcerative' 'diseases' ',' 'uncontrolled'
 'nausea' ',' 'vomiting' ',' 'diarrhea' ',' 'malabsorption' 'syndrome' ','
 'small' 'bowel' 'resection' ')']","[2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 2.
 0. 2. 0. 2. 0. 2. 2. 0. 1. 1. 1. 0.]"
NCT01349101,"19:21:chronic_disease,,33:44:chronic_disease,66:76:treatment,89:98:treatment",For patients with RA or RARS or isolated 5q- they can proceed to transplant without any treatment,"['For' 'patients' 'with' 'RA' 'or' 'RARS' 'or' 'isolated' '5q-' 'they'
 'can' 'proceed' 'to' 'transplant' 'without' 'any' 'treatment']",[0. 0. 0. 2. 0. 0. 0. 2. 2. 0. 0. 0. 0. 1. 0. 0. 1.]
NCT01345344,"20:36:treatment,83:94:treatment,110:124:treatment",on stable doses of medication prior to entering the study and agree not to change medications or dosages (or CAM treatments) during the trial,"['on' 'stable' 'doses' 'of' 'medication' 'prior' 'to' 'entering' 'the'
 'study' 'and' 'agree' 'not' 'to' 'change' 'medications' 'or' 'dosages'
 '(' 'or' 'CAM' 'treatments' ')' 'during' 'the' 'trial']","[0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 0.]"
NCT01341080,"34:54:chronic_disease,56:86:treatment,95:110:chronic_disease,112:130:chronic_disease,135:154:chronic_disease","Subjects with a history of major psychiatric disorder, deep brain stimulation surgery, recent cerebral trauma, cardiac arrhythmia, or renal insufficiency","['Subjects' 'with' 'a' 'history' 'of' 'major' 'psychiatric' 'disorder' ','
 'deep' 'brain' 'stimulation' 'surgery' ',' 'recent' 'cerebral' 'trauma'
 ',' 'cardiac' 'arrhythmia' ',' 'or' 'renal' 'insufficiency']",[0. 0. 0. 0. 0. 0. 2. 2. 0. 1. 1. 1. 1. 0. 0. 2. 2. 0. 2. 2. 0. 0. 2. 2.]
NCT01333046,"5:13:cancer,26:36:cancer,44:74:cancer,100:107:treatment",the lymphoma is a second malignancy e.g. a Richters transformation of CLL after failing front line therapy,"['the' 'lymphoma' 'is' 'a' 'second' 'malignancy' 'e.g' '.' 'a' 'Richters'
 'transformation' 'of' 'CLL' 'after' 'failing' 'front' 'line' 'therapy']",[0. 3. 0. 0. 0. 3. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0. 1.]
NCT01313533,"12:42:treatment,43:78:treatment,83:124:treatment,129:165:treatment","First time coronary artery bypass surgery,redo coronary artery bypass surgery and combined valve repair/replacement surgery and coronary artery bypass graft surgery are eligible to participate in study","['First' 'time' 'coronary' 'artery' 'bypass' 'surgery' ',' 'redo'
 'coronary' 'artery' 'bypass' 'surgery' 'and' 'combined' 'valve'
 'repair/replacement' 'surgery' 'and' 'coronary' 'artery' 'bypass' 'graft'
 'surgery' 'are' 'eligible' 'to' 'participate' 'in' 'study']","[0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT01312857,"1:17:chronic_disease,19:26:chronic_disease,28:50:chronic_disease","Active infection, ascites, hepatic encephalopathy","['Active' 'infection' ',' 'ascites' ',' 'hepatic' 'encephalopathy']",[2. 2. 0. 2. 0. 2. 2.]
NCT01312857,"35:46:chronic_disease,48:49:chronic_disease,51:52:chronic_disease,58:74:chronic_disease","Patients with current evidence of hepatitis A, B, C (ie, active hepatitis)","['Patients' 'with' 'current' 'evidence' 'of' 'hepatitis' 'A' ',' 'B' ','
 'C' '(' 'ie' ',' 'active' 'hepatitis' ')']",[0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 2. 0. 0. 0. 2. 2. 0.]
NCT01306045,"20:38:chronic_disease,65:71:treatment,76:95:treatment",Patients must have biopsiable disease and be willing to undergo biopsy for molecular profiling,"['Patients' 'must' 'have' 'biopsiable' 'disease' 'and' 'be' 'willing' 'to'
 'undergo' 'biopsy' 'for' 'molecular' 'profiling']",[0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 1. 0. 1. 1.]
NCT01306045,"36:47:treatment,57:86:treatment,203:232:treatment,,381:424:treatment,479:506:cancer,522:559:treatment,673:682:treatment","The eligibility of patients taking medications that are potent inducers or inhibitors of that enzyme will be determined following a review of their case by the Principal Investigator. (A list of potent CYP3A4 inducers or inhibitors can be found in Appendix F). Every effort should be made to switch patients taking such agents or substances to other medications before they begin treatment with one of the experimental drug included in this protocol, particularly patients with gliomas or brain metastases who are taking enzyme-inducing anticonvulsant agents. A comprehensive list of medications and substances known or with the potential to alter the pharmacokinetics of sunitinib through CYP3A4","['The' 'eligibility' 'of' 'patients' 'taking' 'medications' 'that' 'are'
 'potent' 'inducers' 'or' 'inhibitors' 'of' 'that' 'enzyme' 'will' 'be'
 'determined' 'following' 'a' 'review' 'of' 'their' 'case' 'by' 'the'
 'Principal' 'Investigator' '.' '(' 'A' 'list' 'of' 'potent' 'CYP3A4'
 'inducers' 'or' 'inhibitors' 'can' 'be' 'found' 'in' 'Appendix' 'F' ')'
 '.' 'Every' 'effort' 'should' 'be' 'made' 'to' 'switch' 'patients'
 'taking' 'such' 'agents' 'or' 'substances' 'to' 'other' 'medications'
 'before' 'they' 'begin' 'treatment' 'with' 'one' 'of' 'the'
 'experimental' 'drug' 'included' 'in' 'this' 'protocol' ','
 'particularly' 'patients' 'with' 'gliomas' 'or' 'brain' 'metastases'
 'who' 'are' 'taking' 'enzyme-inducing' 'anticonvulsant' 'agents' '.' 'A'
 'comprehensive' 'list' 'of' 'medications' 'and' 'substances' 'known' 'or'
 'with' 'the' 'potential' 'to' 'alter' 'the' 'pharmacokinetics' 'of'
 'sunitinib' 'through' 'CYP3A4']","[0. 0. 0. 0. 0. 1. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.]"
NCT01306019,"1:26:chronic_disease,41:47:chronic_disease,51:70:chronic_disease,74:106:chronic_disease,110:133:chronic_disease",Mucocutaneous candidiasis (chronic oral thrush or candida esophagitis or candida intertriginous infection or candida nail infections; must be culture positive to satisfy this criterion),"['Mucocutaneous' 'candidiasis' '(' 'chronic' 'oral' 'thrush' 'or'
 'candida' 'esophagitis' 'or' 'candida' 'intertriginous' 'infection' 'or'
 'candida' 'nail' 'infections' ';' 'must' 'be' 'culture' 'positive' 'to'
 'satisfy' 'this' 'criterion' ')']","[2. 2. 0. 0. 0. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01280994,"1:20:chronic_disease,26:35:chronic_disease,39:53:chronic_disease,,72:75:treatment",Respiratory illness of a bacterial or viral etiology within 30 days of MRI,"['Respiratory' 'illness' 'of' 'a' 'bacterial' 'or' 'viral' 'etiology'
 'within' '30' 'days' 'of' 'MRI']",[2. 2. 0. 0. 2. 0. 2. 2. 0. 0. 0. 0. 1.]
NCT01280669,"1:21:treatment,25:47:treatment,51:59:treatment,",Posterior subtenon's or intravitreal injection of steroids 90 days prior to Baseline,"['Posterior' 'subtenon' ""'s"" 'or' 'intravitreal' 'injection' 'of'
 'steroids' '90' 'days' 'prior' 'to' 'Baseline']",[1. 1. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0.]
NCT01270724,"37:46:cancer,51:56:cancer,68:90:cancer,92:106:cancer,109:128:cancer,130:145:cancer,150:171:cancer","Patients with histologically proven germinoma and MMGCT, including endodermal sinus tumor (yolk sac tumor), embryonal carcinoma, choriocarcinoma and mixed germ cell tumor","['Patients' 'with' 'histologically' 'proven' 'germinoma' 'and' 'MMGCT' ','
 'including' 'endodermal' 'sinus' 'tumor' '(' 'yolk' 'sac' 'tumor' ')' ','
 'embryonal' 'carcinoma' ',' 'choriocarcinoma' 'and' 'mixed' 'germ' 'cell'
 'tumor']","[0. 0. 0. 0. 3. 0. 3. 0. 0. 3. 3. 3. 0. 3. 3. 3. 0. 0. 3. 3. 0. 3. 0. 3.
 3. 3. 3.]"
NCT01261728,"1:15:chronic_disease,32:37:cancer,41:47:treatment",Hydronephrosis associated with tumor on biopsy will be considered invasive by definition,"['Hydronephrosis' 'associated' 'with' 'tumor' 'on' 'biopsy' 'will' 'be'
 'considered' 'invasive' 'by' 'definition']",[2. 0. 0. 3. 0. 1. 0. 0. 0. 0. 0. 0.]
NCT01261728,"10:18:treatment,,83:90:treatment,95:121:treatment",low dose warfarin up to 2 mg po daily or use of subcutaneous low molecular weight heparin for thromboembolic prophylaxis,"['low' 'dose' 'warfarin' 'up' 'to' '2' 'mg' 'po' 'daily' 'or' 'use' 'of'
 'subcutaneous' 'low' 'molecular' 'weight' 'heparin' 'for'
 'thromboembolic' 'prophylaxis']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1.]
NCT01245712,"34:39:cancer,48:79:cancer,92:120:cancer","On histological examination, the tumor must be ductal carcinoma in situ (DCIS) or invasive adenocarcinoma of the breast","['On' 'histological' 'examination' ',' 'the' 'tumor' 'must' 'be' 'ductal'
 'carcinoma' 'in' 'situ' '(' 'DCIS' ')' 'or' 'invasive' 'adenocarcinoma'
 'of' 'the' 'breast']",[0. 0. 0. 0. 0. 3. 0. 0. 3. 3. 3. 3. 3. 0. 0. 0. 0. 3. 3. 3. 3.]
NCT01245712,"1:31:cancer,107:116:treatment,120:137:treatment,146:154:treatment","Suspicious microcalcifications, or densities (in the ipsilateral or contralateral breast as documented on mammogram or breast ultrasound) unless biopsied and found to be benign","['Suspicious' 'microcalcifications' ',' 'or' 'densities' '(' 'in' 'the'
 'ipsilateral' 'or' 'contralateral' 'breast' 'as' 'documented' 'on'
 'mammogram' 'or' 'breast' 'ultrasound' ')' 'unless' 'biopsied' 'and'
 'found' 'to' 'be' 'benign']","[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 0. 1. 0. 0.
 0. 0. 0.]"
NCT01241708,"1:13:treatment,17:29:treatment,,58:67:treatment",Chemotherapy or radiotherapy within 8 days of initiating treatment in this study,"['Chemotherapy' 'or' 'radiotherapy' 'within' '8' 'days' 'of' 'initiating'
 'treatment' 'in' 'this' 'study']",[1. 0. 1. 0. 0. 0. 0. 0. 1. 0. 0. 0.]
NCT01220583,"15:43:treatment,51:56:treatment,60:73:treatment,82:94:treatment","No concurrent hematopoietic growth factors (e.g., G-CSF or pegfilgrastim) during radiotherapy","['No' 'concurrent' 'hematopoietic' 'growth' 'factors' '(' 'e.g.' ','
 'G-CSF' 'or' 'pegfilgrastim' ')' 'during' 'radiotherapy']",[0. 0. 1. 1. 1. 0. 0. 0. 1. 0. 1. 0. 0. 1.]
NCT01220583,"4:31:treatment,35:52:treatment,57:82:cancer,84:102:treatment,119:125:cancer",No prior systemic chemotherapy or radiation therapy for salivary gland malignancy (prior chemotherapy for a different cancer is allowable),"['No' 'prior' 'systemic' 'chemotherapy' 'or' 'radiation' 'therapy' 'for'
 'salivary' 'gland' 'malignancy' '(' 'prior' 'chemotherapy' 'for' 'a'
 'different' 'cancer' 'is' 'allowable' ')']",[0. 1. 1. 1. 0. 1. 1. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0.]
NCT01200940,",73:82:treatment,108:130:treatment,158:172:treatment","Recent (past 2 months) use of drugs that alter glucose metabolism (e.g. metformin), alter gastric pH (e.g. proton pump inhibitors) or gastric emptying (e.g. metoclopramide)","['Recent' '(' 'past' '2' 'months' ')' 'use' 'of' 'drugs' 'that' 'alter'
 'glucose' 'metabolism' '(' 'e.g' '.' 'metformin' ')' ',' 'alter'
 'gastric' 'pH' '(' 'e.g' '.' 'proton' 'pump' 'inhibitors' ')' 'or'
 'gastric' 'emptying' '(' 'e.g' '.' 'metoclopramide' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.
 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 1. 0.]"
NCT01185132,"13:16:treatment,85:95:treatment,134:144:treatment",Findings on MRI scanning revealing relevant suspicion of disease outside of planned lumpectomy volume should be further evaluated by ultrasound,"['Findings' 'on' 'MRI' 'scanning' 'revealing' 'relevant' 'suspicion' 'of'
 'disease' 'outside' 'of' 'planned' 'lumpectomy' 'volume' 'should' 'be'
 'further' 'evaluated' 'by' 'ultrasound']",[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 1.]
NCT01184547,"14:20:chronic_disease,24:41:chronic_disease,48:57:chronic_disease,59:63:chronic_disease","Uncontrolled asthma or pulmonary disease (e.g. emphysema, COPD)","['Uncontrolled' 'asthma' 'or' 'pulmonary' 'disease' '(' 'e.g' '.'
 'emphysema' ',' 'COPD' ')']",[0. 2. 0. 2. 2. 0. 0. 0. 2. 0. 2. 0.]
NCT01174121,"15:27:cancer,56:63:treatment,65:82:treatment,88:100:treatment,111:125:cancer,119:125:cancer,138:147:treatment","Patients with glioblastoma must have received standard surgery, radiation therapy, and chemotherapy for their primary tumors and require resection of their tumors for palliative or other clinical indication","['Patients' 'with' 'glioblastoma' 'must' 'have' 'received' 'standard'
 'surgery' ',' 'radiation' 'therapy' ',' 'and' 'chemotherapy' 'for'
 'their' 'primary' 'tumors' 'and' 'require' 'resection' 'of' 'their'
 'tumors' 'for' 'palliative' 'or' 'other' 'clinical' 'indication']","[0. 0. 3. 0. 0. 0. 0. 1. 0. 1. 1. 0. 0. 1. 0. 0. 3. 3. 0. 0. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT01174108,"1:26:chronic_disease,30:43:chronic_disease,76:91:treatment",Major anticipated illness or organ failure incompatible with survival from PBSC transplant,"['Major' 'anticipated' 'illness' 'or' 'organ' 'failure' 'incompatible'
 'with' 'survival' 'from' 'PBSC' 'transplant']",[2. 2. 2. 0. 2. 2. 0. 0. 0. 0. 1. 1.]
NCT01130077,"30:48:cancer,50:77:cancer,81:92:cancer","Eligible histologies include glioblastoma (GBM), anaplastic astrocytoma (AA) or gliosarcoma","['Eligible' 'histologies' 'include' 'glioblastoma' '(' 'GBM' ')' ','
 'anaplastic' 'astrocytoma' '(' 'AA' ')' 'or' 'gliosarcoma']",[0. 0. 0. 3. 3. 0. 0. 0. 3. 3. 3. 0. 0. 0. 3.]
NCT01130077,"17:35:cancer,40:58:cancer,72:84:treatment,92:109:treatment",Newly diagnosed high-grade gliomas* or brain stem gliomas who received chemotherapy during radiation therapy. Patients may not have received chemotherapy after radiation therapy was completed,"['Newly' 'diagnosed' 'high-grade' 'gliomas' '*' 'or' 'brain' 'stem'
 'gliomas' 'who' 'received' 'chemotherapy' 'during' 'radiation' 'therapy'
 '.' 'Patients' 'may' 'not' 'have' 'received' 'chemotherapy' 'after'
 'radiation' 'therapy' 'was' 'completed']","[0. 0. 3. 3. 0. 0. 3. 3. 3. 0. 0. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0.]"
NCT01130077,"74:87:treatment,,128:159:treatment,163:198:treatment,,241:278:treatment",Patients on Strata C and D must have recovered from the toxic effects of prior therapy: at least 3 weeks form the last dose of standard cytotoxic chemotherapy or myelosuppressive biological therapy and at least 1 week from the last dose of non-myelosuppressive biologic therapy,"['Patients' 'on' 'Strata' 'C' 'and' 'D' 'must' 'have' 'recovered' 'from'
 'the' 'toxic' 'effects' 'of' 'prior' 'therapy' ':' 'at' 'least' '3'
 'weeks' 'form' 'the' 'last' 'dose' 'of' 'standard' 'cytotoxic'
 'chemotherapy' 'or' 'myelosuppressive' 'biological' 'therapy' 'and' 'at'
 'least' '1' 'week' 'from' 'the' 'last' 'dose' 'of' 'non-myelosuppressive'
 'biologic' 'therapy']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 1. 1. 1. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]"
NCT01128816,"16:19:treatment,23:27:treatment,31:60:treatment,65:74:treatment,78:89:chronic_disease,110:133:treatment,,178:187:treatment",Current use of ASV or CPAP or mandibular advancement device for treatment of sleep apnea or treated with any investigational therapy during the last 4 weeks (including approved therapies being used in unapproved indications),"['Current' 'use' 'of' 'ASV' 'or' 'CPAP' 'or' 'mandibular' 'advancement'
 'device' 'for' 'treatment' 'of' 'sleep' 'apnea' 'or' 'treated' 'with'
 'any' 'investigational' 'therapy' 'during' 'the' 'last' '4' 'weeks' '('
 'including' 'approved' 'therapies' 'being' 'used' 'in' 'unapproved'
 'indications' ')']","[0. 0. 0. 1. 0. 1. 0. 1. 1. 1. 0. 1. 0. 2. 2. 0. 0. 0. 0. 1. 1. 0. 0. 0.
 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.]"
NCT01101451,"15:28:cancer,60:69:treatment,73:85:treatment",Patients with cervix cancer who have received any previous radiation or chemotherapy,"['Patients' 'with' 'cervix' 'cancer' 'who' 'have' 'received' 'any'
 'previous' 'radiation' 'or' 'chemotherapy']",[0. 0. 3. 3. 0. 0. 0. 0. 0. 1. 0. 1.]
NCT01099644,"5:11:cancer,5:10:cancer,23:28:cancer,139:155:treatment,","For tumors other than DSRCT, patients must have a history of tumor progression or recurrence or failure to achieve complete response with standard therapy or <20% chance of long term disease-free survival","['For' 'tumors' 'other' 'than' 'DSRCT' ',' 'patients' 'must' 'have' 'a'
 'history' 'of' 'tumor' 'progression' 'or' 'recurrence' 'or' 'failure'
 'to' 'achieve' 'complete' 'response' 'with' 'standard' 'therapy' 'or' '<'
 '20' '%' 'chance' 'of' 'long' 'term' 'disease-free' 'survival']","[0. 3. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.
 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01096368,"4:19:treatment,31:52:treatment,57:72:treatment,,132:141:treatment",No prior treatment other than surgical intervention and corticosteroids; patients are allowed to have had more than one attempt at resection prior to enrollment,"['No' 'prior' 'treatment' 'other' 'than' 'surgical' 'intervention' 'and'
 'corticosteroids' ';' 'patients' 'are' 'allowed' 'to' 'have' 'had' 'more'
 'than' 'one' 'attempt' 'at' 'resection' 'prior' 'to' 'enrollment']","[0. 1. 1. 0. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0.
 0.]"
NCT01087294,"1:25:treatment,32:40:treatment,,,53:62:chronic_disease","Donor T cell engraftment after alloHSCT (>50% donor chimerism of the T cell compartment and a peripheral blood T cell number from the NIH, CC clinical lab of at least 50 CD3+ cells/uL)","['Donor' 'T' 'cell' 'engraftment' 'after' 'alloHSCT' '(' '>' '50' '%'
 'donor' 'chimerism' 'of' 'the' 'T' 'cell' 'compartment' 'and' 'a'
 'peripheral' 'blood' 'T' 'cell' 'number' 'from' 'the' 'NIH' ',' 'CC'
 'clinical' 'lab' 'of' 'at' 'least' '50' 'CD3+' 'cells/uL' ')']","[1. 1. 1. 1. 0. 1. 0. 0. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01087294,"1:16:treatment,69:72:cancer,74:89:cancer,111:120:cancer,125:154:cancer","Prior (DCI) DLI is not an eligibility requirement for patients with ALL, Burkitt lyphoma, ALL like high-grade lymphomas, or diffuse large B-cell lymphoma","['Prior' '(' 'DCI' ')' 'DLI' 'is' 'not' 'an' 'eligibility' 'requirement'
 'for' 'patients' 'with' 'ALL' ',' 'Burkitt' 'lyphoma' ',' 'ALL' 'like'
 'high-grade' 'lymphomas' ',' 'or' 'diffuse' 'large' 'B-cell' 'lymphoma']","[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 3. 3. 0. 0. 0. 0. 3. 0. 0.
 3. 3. 3. 3.]"
NCT01061515,"1:26:chronic_disease,83:100:chronic_disease,102:120:chronic_disease","Gastrointestinal ailments that may alter the absorption of oral medications (i.e. bowel obstruction, short-gut syndrome)","['Gastrointestinal' 'ailments' 'that' 'may' 'alter' 'the' 'absorption'
 'of' 'oral' 'medications' '(' 'i.e' '.' 'bowel' 'obstruction' ','
 'short-gut' 'syndrome' ')']",[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 2. 0.]
NCT01061515,"20:42:treatment,43:90:treatment,95:98:chronic_disease",Patients receiving antiretroviral therapy Highly Active Anti Retroviral Treatment (HAART) for HIV infection are excluded from the study because of possible pharmacokinetic interactions,"['Patients' 'receiving' 'antiretroviral' 'therapy' 'Highly' 'Active'
 'Anti' 'Retroviral' 'Treatment' '(' 'HAART' ')' 'for' 'HIV' 'infection'
 'are' 'excluded' 'from' 'the' 'study' 'because' 'of' 'possible'
 'pharmacokinetic' 'interactions']","[0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0.]"
NCT01059786,",46:64:cancer,100:104:treatment,112:117:treatment","Patients with flow cytometry consistent with HCL variant (HCLv) are eligible, including those with CD25 and/or CD103 negative disease","['Patients' 'with' 'flow' 'cytometry' 'consistent' 'with' 'HCL' 'variant'
 '(' 'HCLv' ')' 'are' 'eligible' ',' 'including' 'those' 'with' 'CD25'
 'and/or' 'CD103' 'negative' 'disease']",[0. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0.]
NCT01059786,"1:10:treatment,,,159:175:treatment,213:228:treatment","Treatment indicated based on demonstration of at least one of the following no more than 4 weeks from the time of enrollment, and no less than 6 months after prior cladribine and no less than 4 weeks after other prior treatment","['Treatment' 'indicated' 'based' 'on' 'demonstration' 'of' 'at' 'least'
 'one' 'of' 'the' 'following' 'no' 'more' 'than' '4' 'weeks' 'from' 'the'
 'time' 'of' 'enrollment' ',' 'and' 'no' 'less' 'than' '6' 'months'
 'after' 'prior' 'cladribine' 'and' 'no' 'less' 'than' '4' 'weeks' 'after'
 'other' 'prior' 'treatment']","[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT01054196,"1:21:chronic_disease,64:80:chronic_disease,94:118:chronic_disease,120:144:chronic_disease,146:164:chronic_disease,169:206:chronic_disease","Uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements","['Uncontrolled' 'illness' 'including' ',' 'but' 'not' 'limited' 'to' ','
 'ongoing' 'or' 'active' 'infection' ',' 'symptomatic' 'congestive'
 'heart' 'failure' ',' 'unstable' 'angina' 'pectoris' ',' 'cardiac'
 'arrhythmia' ',' 'or' 'psychiatric' 'illness/social' 'situations' 'that'
 'would' 'limit' 'compliance' 'with' 'study' 'requirements']","[2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 2. 2. 2. 0. 2. 2. 2. 0. 2.
 2. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0.]"
NCT01045148,"1:16:treatment,21:46:cancer,48:70:treatment,72:93:treatment","Radical surgery for carcinoma of the prostate, prior pelvic radiation, pelvic surgical clips or other metallic foreign bodies","['Radical' 'surgery' 'for' 'carcinoma' 'of' 'the' 'prostate' ',' 'prior'
 'pelvic' 'radiation' ',' 'pelvic' 'surgical' 'clips' 'or' 'other'
 'metallic' 'foreign' 'bodies']",[1. 1. 0. 3. 3. 3. 3. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT01042522,"34:55:cancer,79:103:cancer,152:162:cancer,","Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years","['Patients' 'with' 'a' 'history' 'of' 'other' 'invasive' 'malignancies'
 ',' 'with' 'the' 'exception' 'of' 'non-melanoma' 'skin' 'cancer' ','
 'are' 'excluded' 'if' 'there' 'is' 'any' 'evidence' 'of' 'other'
 'malignancy' 'being' 'present' 'within' 'the' 'last' 'five' 'years']","[0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 3. 0. 0. 0. 0. 0. 0. 0.]"
NCT01037790,"1:29:cancer,47:51:cancer,55:68:cancer",Metastatic colorectal cancer that harbors the Kras or BRAF mutation (15-30 enrollment slots),"['Metastatic' 'colorectal' 'cancer' 'that' 'harbors' 'the' 'Kras' 'or'
 'BRAF' 'mutation' '(' '15-30' 'enrollment' 'slots' ')']",[3. 3. 3. 0. 0. 0. 3. 0. 3. 3. 0. 0. 0. 0. 0.]
NCT01028846,"28:50:chronic_disease,62:72:treatment,74:130:treatment,132:146:treatment,151:159:treatment","Medications for medical or psychiatric conditions including: dofetilide, fosphenytoin/phenytoin trichlormethiazide (any thiazide), chlorpromazine and warfarin","['Medications' 'for' 'medical' 'or' 'psychiatric' 'conditions' 'including'
 ':' 'dofetilide' ',' 'fosphenytoin/phenytoin' 'trichlormethiazide' '('
 'any' 'thiazide' ')' ',' 'chlorpromazine' 'and' 'warfarin']",[0. 0. 0. 0. 2. 2. 0. 0. 1. 0. 1. 1. 1. 1. 0. 0. 0. 1. 0. 1.]
NCT01011777,"38:59:treatment,61:79:treatment,81:100:treatment,102:127:treatment,129:184:treatment,186:200:treatment","Negative Study Donor Virology Panel (Hep B surface antigen, HIV 1 / 2 antibody, Hep B core antibody, Rapid Plasma Reagin (RPR), Human T-cell Lymphotrophic Virus (HTLV) I / II antibody, Hep C antibody)","['Negative' 'Study' 'Donor' 'Virology' 'Panel' '(' 'Hep' 'B' 'surface'
 'antigen' ',' 'HIV' '1' '/' '2' 'antibody' ',' 'Hep' 'B' 'core'
 'antibody' ',' 'Rapid' 'Plasma' 'Reagin' '(' 'RPR' ')' ',' 'Human'
 'T-cell' 'Lymphotrophic' 'Virus' '(' 'HTLV' ')' 'I' '/' 'II' 'antibody'
 ',' 'Hep' 'C' 'antibody' ')']","[0. 0. 0. 0. 0. 0. 1. 1. 1. 1. 0. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 1.
 1. 1. 0. 0. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT00977977,"1:34:chronic_disease,45:66:treatment,78:93:chronic_disease,95:98:chronic_disease,100:116:chronic_disease,118:132:chronic_disease,134:156:chronic_disease,158:168:chronic_disease","Active acute or chronic infection requiring antimicrobial therapy or serious viral infection (HIV, hepatitis B or C, herpes simplex, varicella zoster virus, parvovirus)","['Active' 'acute' 'or' 'chronic' 'infection' 'requiring' 'antimicrobial'
 'therapy' 'or' 'serious' 'viral' 'infection' '(' 'HIV' ',' 'hepatitis'
 'B' 'or' 'C' ',' 'herpes' 'simplex' ',' 'varicella' 'zoster' 'virus' ','
 'parvovirus' ')']","[2. 2. 2. 2. 2. 0. 1. 1. 0. 0. 2. 2. 0. 2. 0. 2. 2. 2. 2. 0. 2. 2. 0. 2.
 2. 2. 0. 2. 0.]"
NCT00977977,",,69:99:treatment,101:114:treatment,118:121:treatment,",Nephrotic range proteinuria (>3.5 g/24 hours) that persists despite angiotensin antagonist therapy (ACE inhibitor or ARB) for at least 2 months unless intolerant,"['Nephrotic' 'range' 'proteinuria' '(' '>' '3.5' 'g/24' 'hours' ')' 'that'
 'persists' 'despite' 'angiotensin' 'antagonist' 'therapy' '(' 'ACE'
 'inhibitor' 'or' 'ARB' ')' 'for' 'at' 'least' '2' 'months' 'unless'
 'intolerant']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 0. 1. 0. 0. 0. 0.
 0. 0. 0. 0.]"
NCT00975520,"51:68:treatment,77:94:treatment,116:133:chronic_disease",Intercurrent illness that will interfere with the radiation therapy such as immunosuppression due to medication or medical condition,"['Intercurrent' 'illness' 'that' 'will' 'interfere' 'with' 'the'
 'radiation' 'therapy' 'such' 'as' 'immunosuppression' 'due' 'to'
 'medication' 'or' 'medical' 'condition']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 0. 0. 0. 0. 2. 2.]
NCT00975520,"1:56:treatment,68:97:treatment,101:114:cancer,118:138:cancer,179:185:cancer","Previous radical radiation therapy to the head and neck, excluding superficial radiation therapy to cutaneous SCC or basal cell carcinoma, which is not within or overlapping the tumour bed","['Previous' 'radical' 'radiation' 'therapy' 'to' 'the' 'head' 'and' 'neck'
 ',' 'excluding' 'superficial' 'radiation' 'therapy' 'to' 'cutaneous'
 'SCC' 'or' 'basal' 'cell' 'carcinoma' ',' 'which' 'is' 'not' 'within'
 'or' 'overlapping' 'the' 'tumour' 'bed']","[1. 1. 1. 1. 1. 1. 1. 1. 1. 0. 0. 1. 1. 1. 0. 3. 3. 0. 3. 3. 3. 0. 0. 0.
 0. 0. 0. 0. 0. 3. 0.]"
NCT00969111,"8:20:treatment,24:36:treatment,91:100:treatment",Taking Saw Palmetto or methotrexate and unable or unwilling to discontinue its use during radiation,"['Taking' 'Saw' 'Palmetto' 'or' 'methotrexate' 'and' 'unable' 'or'
 'unwilling' 'to' 'discontinue' 'its' 'use' 'during' 'radiation']",[0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT00967577,"1:30:treatment,32:43:treatment,,74:83:treatment",Prior investigational therapy (medications or devices) within 6 weeks of treatment,"['Prior' 'investigational' 'therapy' '(' 'medications' 'or' 'devices' ')'
 'within' '6' 'weeks' 'of' 'treatment']",[1. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0. 1.]
NCT00967577,"56:77:cancer,79:89:cancer,91:104:cancer,106:112:cancer,114:133:cancer,135:145:cancer,147:155:cancer,157:162:cancer,164:173:cancer,178:185:cancer","This will include, but is not limited to patients with cancers of the kidney, urothelium, head and neck, breast, non-small cell lung, colorectal, pancreas, ovary, esophagus and gliomas","['This' 'will' 'include' ',' 'but' 'is' 'not' 'limited' 'to' 'patients'
 'with' 'cancers' 'of' 'the' 'kidney' ',' 'urothelium' ',' 'head' 'and'
 'neck' ',' 'breast' ',' 'non-small' 'cell' 'lung' ',' 'colorectal' ','
 'pancreas' ',' 'ovary' ',' 'esophagus' 'and' 'gliomas']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 3. 0. 3. 3. 3. 0. 3. 0.
 3. 3. 3. 0. 3. 0. 3. 0. 3. 0. 3. 0. 3.]"
NCT00959140,"1:4:cancer,5:8:cancer,15:28:cancer",AML/ALL: with Bi-phenotypic features,['AML/ALL' ':' 'with' 'Bi-phenotypic' 'features'],[3. 0. 0. 3. 0.]
NCT00929006,"23:29:cancer,31:38:cancer,43:61:cancer","A personal history of breast, ovarian, or endometrial cancer","['A' 'personal' 'history' 'of' 'breast' ',' 'ovarian' ',' 'or'
 'endometrial' 'cancer']",[0. 0. 0. 0. 3. 0. 3. 0. 0. 3. 3.]
NCT00929006,"53:82:chronic_disease,102:121:chronic_disease,144:167:chronic_disease","History and/or physical exam findings suggestive of hypogonadotropic hypogonadism (e.g., symptoms of estrogen deficiency) including functional hypothalamic amenorrhea (which may be suggested by a constellation of symptoms including restrictive eating patterns, excessive exercise, psychological stress, etc.)","['History' 'and/or' 'physical' 'exam' 'findings' 'suggestive' 'of'
 'hypogonadotropic' 'hypogonadism' '(' 'e.g.' ',' 'symptoms' 'of'
 'estrogen' 'deficiency' ')' 'including' 'functional' 'hypothalamic'
 'amenorrhea' '(' 'which' 'may' 'be' 'suggested' 'by' 'a' 'constellation'
 'of' 'symptoms' 'including' 'restrictive' 'eating' 'patterns' ','
 'excessive' 'exercise' ',' 'psychological' 'stress' ',' 'etc' '.' ')']","[0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT00929006,"35:56:chronic_disease,83:107:chronic_disease,109:115:chronic_disease,139:163:treatment","Significant history of cardiac or pulmonary dysfunction (e.g., known or suspected congestive heart failure, asthma requiring intermittent systemic corticosteroids, etc.)","['Significant' 'history' 'of' 'cardiac' 'or' 'pulmonary' 'dysfunction' '('
 'e.g.' ',' 'known' 'or' 'suspected' 'congestive' 'heart' 'failure' ','
 'asthma' 'requiring' 'intermittent' 'systemic' 'corticosteroids' ','
 'etc' '.' ')']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 2. 2. 2. 0. 2. 0. 0. 1. 1. 0. 0.
 0. 0.]"
NCT00924027,"16:21:cancer,58:71:treatment,146:163:treatment",Any patient or tumor/anatomical factors that may prevent brachytherapy apparatus from being properly and safely inserted and positioned and from radiation therapy being administered per ABS guidelines,"['Any' 'patient' 'or' 'tumor/anatomical' 'factors' 'that' 'may' 'prevent'
 'brachytherapy' 'apparatus' 'from' 'being' 'properly' 'and' 'safely'
 'inserted' 'and' 'positioned' 'and' 'from' 'radiation' 'therapy' 'being'
 'administered' 'per' 'ABS' 'guidelines']","[0. 0. 0. 3. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 0.]"
NCT00924027,"36:43:treatment,58:67:treatment,94:112:cancer",Patients who are unable to undergo surgery and must have treatment for an inoperable primary endometrial cancer,"['Patients' 'who' 'are' 'unable' 'to' 'undergo' 'surgery' 'and' 'must'
 'have' 'treatment' 'for' 'an' 'inoperable' 'primary' 'endometrial'
 'cancer']",[0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 0. 0. 0. 3. 3.]
NCT00919503,"33:50:treatment,54:71:treatment,76:89:treatment",DONOR: Deemed unable to undergo marrow harvesting or PBSC mobilization and leukapheresis,"['DONOR' ':' 'Deemed' 'unable' 'to' 'undergo' 'marrow' 'harvesting' 'or'
 'PBSC' 'mobilization' 'and' 'leukapheresis']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 1.]
NCT00911560,"1:13:cancer,,,85:98:treatment,105:122:treatment","High-risk NB (as defined above) and in 1) first CR at 6 ≥ months from initiation of immunotherapy using anti-GD2 antibody, or 2) second or subsequent remission","['High-risk' 'NB' '(' 'as' 'defined' 'above' ')' 'and' 'in' '1' ')'
 'first' 'CR' 'at' '6' '≥' 'months' 'from' 'initiation' 'of'
 'immunotherapy' 'using' 'anti-GD2' 'antibody' ',' 'or' '2' ')' 'second'
 'or' 'subsequent' 'remission']","[3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 1.
 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT00909909,"1:13:treatment,,102:114:treatment,139:171:treatment,175:197:treatment","Chemotherapy is not administered for ≥ 21 days before, during, and for ≥ 21 days after completion of radiotherapy (for patients receiving external beam radiotherapy boost or chest wall irradiation)","['Chemotherapy' 'is' 'not' 'administered' 'for' '≥' '21' 'days' 'before'
 ',' 'during' ',' 'and' 'for' '≥' '21' 'days' 'after' 'completion' 'of'
 'radiotherapy' '(' 'for' 'patients' 'receiving' 'external' 'beam'
 'radiotherapy' 'boost' 'or' 'chest' 'wall' 'irradiation' ')']","[1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 0. 1. 1. 1. 1. 0. 1. 1. 1. 0.]"
NCT00909909,"4:29:chronic_disease,44:72:chronic_disease,74:85:chronic_disease,90:105:chronic_disease","No collagen vascular disease, specifically systemic lupus erythematosus, scleroderma, or dermatomyositis","['No' 'collagen' 'vascular' 'disease' ',' 'specifically' 'systemic'
 'lupus' 'erythematosus' ',' 'scleroderma' ',' 'or' 'dermatomyositis']",[0. 2. 2. 2. 0. 0. 2. 2. 2. 0. 2. 0. 0. 2.]
NCT00906984,"106:116:cancer,164:170:cancer,183:188:cancer","The histopathology confirmation criterion may be waived in patients with a radiographically identifiable liver mass, known laboratory or clinical risk factors for cancer or elevated tumor markers such as Alpha-fetoprotein assay (AFP) (clinical diagnosis)","['The' 'histopathology' 'confirmation' 'criterion' 'may' 'be' 'waived'
 'in' 'patients' 'with' 'a' 'radiographically' 'identifiable' 'liver'
 'mass' ',' 'known' 'laboratory' 'or' 'clinical' 'risk' 'factors' 'for'
 'cancer' 'or' 'elevated' 'tumor' 'markers' 'such' 'as'
 'Alpha-fetoprotein' 'assay' '(' 'AFP' ')' '(' 'clinical' 'diagnosis' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 3.
 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT00887146,"21:42:treatment,73:82:treatment,99:107:chronic_disease",Receiving any other investigational agent that would be considered as a treatment for the primary neoplasm,"['Receiving' 'any' 'other' 'investigational' 'agent' 'that' 'would' 'be'
 'considered' 'as' 'a' 'treatment' 'for' 'the' 'primary' 'neoplasm']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 2.]
NCT00887146,"20:44:treatment,,68:84:cancer,126:141:treatment,145:163:treatment","if they have had a prior surgical procedure > 3 months earlier for low grade glioma, as long as the patient has not received prior radiation or prior chemotherapy","['if' 'they' 'have' 'had' 'a' 'prior' 'surgical' 'procedure' '>' '3'
 'months' 'earlier' 'for' 'low' 'grade' 'glioma' ',' 'as' 'long' 'as'
 'the' 'patient' 'has' 'not' 'received' 'prior' 'radiation' 'or' 'prior'
 'chemotherapy']","[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0.]"
NCT00887146,"25:43:treatment,47:64:treatment,73:79:cancer",who have never received prior chemotherapy or radiation therapy for the glioma,"['who' 'have' 'never' 'received' 'prior' 'chemotherapy' 'or' 'radiation'
 'therapy' 'for' 'the' 'glioma']",[0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 3.]
NCT00871260,"1:19:treatment,33:36:treatment,38:47:treatment,49:62:treatment","Contra-indications to MRI (i.e. ICD, pacemaker, aneurysm clip, etc)","['Contra-indications' 'to' 'MRI' '(' 'i.e' '.' 'ICD' ',' 'pacemaker' ','
 'aneurysm' 'clip' ',' 'etc' ')']",[1. 0. 0. 0. 0. 0. 1. 0. 1. 0. 1. 1. 0. 0. 0.]
NCT00862433,"12:22:treatment,34:41:treatment,54:78:treatment,80:103:treatment,108:119:treatment","No regular medication other than aspirin (other than oral hypoglycemic agents, hormonal contraceptives and medications taken only on an as-needed basis)","['No' 'regular' 'medication' 'other' 'than' 'aspirin' '(' 'other' 'than'
 'oral' 'hypoglycemic' 'agents' ',' 'hormonal' 'contraceptives' 'and'
 'medications' 'taken' 'only' 'on' 'an' 'as-needed' 'basis' ')']",[0. 0. 1. 0. 0. 1. 0. 0. 0. 1. 1. 1. 0. 1. 1. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT00862433,"77:102:chronic_disease,,,133:155:chronic_disease,157:181:chronic_disease,183:210:chronic_disease,215:236:chronic_disease","with no known target organ damage (End organ damage includes the following: proliferative retinopathy, serum creatinine < 1.8 m/dl, ischemic heart disease, congestive heart failure, peripheral vascular disease and peripheral neuropathy)","['with' 'no' 'known' 'target' 'organ' 'damage' '(' 'End' 'organ' 'damage'
 'includes' 'the' 'following' ':' 'proliferative' 'retinopathy' ','
 'serum' 'creatinine' '<' '1.8' 'm/dl' ',' 'ischemic' 'heart' 'disease'
 ',' 'congestive' 'heart' 'failure' ',' 'peripheral' 'vascular' 'disease'
 'and' 'peripheral' 'neuropathy' ')']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 2.
 2. 2. 0. 2. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0.]"
NCT00819208,"10:22:treatment,41:50:treatment,55:68:cancer",No prior radiotherapy as a component of treatment for primary tumor,"['No' 'prior' 'radiotherapy' 'as' 'a' 'component' 'of' 'treatment' 'for'
 'primary' 'tumor']",[0. 0. 1. 0. 0. 0. 0. 1. 0. 3. 3.]
NCT00801489,"20:43:treatment,26:43:treatment,222:244:treatment","Up to one cycle of prior induction therapy will be permitted to include patients in whom presence of good-risk cytogenetics was initially missed; if the patient is in remission from induction therapy, he/she will receive post-remission therapy; if the patient is not in remission then he/she will receive induction therapy","['Up' 'to' 'one' 'cycle' 'of' 'prior' 'induction' 'therapy' 'will' 'be'
 'permitted' 'to' 'include' 'patients' 'in' 'whom' 'presence' 'of'
 'good-risk' 'cytogenetics' 'was' 'initially' 'missed' ';' 'if' 'the'
 'patient' 'is' 'in' 'remission' 'from' 'induction' 'therapy' ',' 'he/she'
 'will' 'receive' 'post-remission' 'therapy' ';' 'if' 'the' 'patient' 'is'
 'not' 'in' 'remission' 'then' 'he/she' 'will' 'receive' 'induction'
 'therapy']","[0. 0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT00788164,"4:32:treatment,40:55:treatment,65:105:treatment,113:125:treatment,","No immunosuppressive medication (i.e., steroid therapy or other immunosuppressive/immunomodulating drugs [e.g., cyclosporine]) within the past 2 months","['No' 'immunosuppressive' 'medication' '(' 'i.e.' ',' 'steroid' 'therapy'
 'or' 'other' 'immunosuppressive/immunomodulating' 'drugs' '[' 'e.g.' ','
 'cyclosporine' ']' ')' 'within' 'the' 'past' '2' 'months']",[0. 1. 1. 0. 0. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0.]
NCT00739362,"1:28:chronic_disease,40:77:chronic_disease,154:186:chronic_disease","Chronic pulmonary disorders, including chronic obstructive pulmonary disease that would limit ability to follow the protocol (investigator judgment) and obstructive sleep apnea syndrome","['Chronic' 'pulmonary' 'disorders' ',' 'including' 'chronic' 'obstructive'
 'pulmonary' 'disease' 'that' 'would' 'limit' 'ability' 'to' 'follow'
 'the' 'protocol' '(' 'investigator' 'judgment' ')' 'and' 'obstructive'
 'sleep' 'apnea' 'syndrome']","[2. 2. 2. 0. 0. 2. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0.]"
NCT00739362,"1:14:chronic_disease,16:25:chronic_disease,34:50:chronic_disease,,,","Liver disease (cirrhosis, active hepatitis B or C, and AST or ALT greater than or equal to 1.5 times normal)","['Liver' 'disease' '(' 'cirrhosis' ',' 'active' 'hepatitis' 'B' 'or' 'C'
 ',' 'and' 'AST' 'or' 'ALT' 'greater' 'than' 'or' 'equal' 'to' '1.5'
 'times' 'normal' ')']",[2. 2. 0. 2. 0. 0. 2. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00737893,"30:43:chronic_disease,47:67:treatment,71:82:treatment",The patient has a history of spinal trauma or surgery to the brain or spinal cord,"['The' 'patient' 'has' 'a' 'history' 'of' 'spinal' 'trauma' 'or' 'surgery'
 'to' 'the' 'brain' 'or' 'spinal' 'cord']",[0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 1. 1. 0. 0. 0.]
NCT00720785,",34:50:treatment,62:84:treatment,110:120:cancer",At least 4 weeks since any prior systemic therapy (excluding corticosteroid therapy) to treat the underlying malignancy (standard or investigational),"['At' 'least' '4' 'weeks' 'since' 'any' 'prior' 'systemic' 'therapy' '('
 'excluding' 'corticosteroid' 'therapy' ')' 'to' 'treat' 'the'
 'underlying' 'malignancy' '(' 'standard' 'or' 'investigational' ')']",[0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0.]
NCT00720785,"1:8:cancer,78:87:treatment,93:103:treatment",Myeloma patients are required to have disease which has progressed following treatment with bortezomib,"['Myeloma' 'patients' 'are' 'required' 'to' 'have' 'disease' 'which' 'has'
 'progressed' 'following' 'treatment' 'with' 'bortezomib']",[3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1.]
NCT00720785,"25:35:cancer,63:80:treatment,84:105:treatment",disease confirmed to be metastatic and unresectable for which standard curative or beneficial treatments are no longer effective,"['disease' 'confirmed' 'to' 'be' 'metastatic' 'and' 'unresectable' 'for'
 'which' 'standard' 'curative' 'or' 'beneficial' 'treatments' 'are' 'no'
 'longer' 'effective']",[0. 0. 0. 0. 3. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 0. 0.]
NCT00719888,"1:29:cancer,31:57:cancer,59:62:cancer,63:66:cancer,69:98:cancer,100:126:cancer,130:149:cancer,,200:215:treatment","Chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, lymphoplasmacytic lymphoma or follicular lymphoma that have progressed after at least two different prior therapies","['Chronic' 'lymphocytic' 'leukemia' '/small' 'lymphocytic' 'lymphoma' '('
 'CLL/SLL' ')' ',' 'marginal' 'zone' 'B-cell' 'lymphoma' ','
 'lymphoplasmacytic' 'lymphoma' 'or' 'follicular' 'lymphoma' 'that' 'have'
 'progressed' 'after' 'at' 'least' 'two' 'different' 'prior' 'therapies']","[3. 3. 3. 3. 3. 3. 0. 3. 0. 0. 3. 3. 3. 3. 0. 3. 3. 0. 3. 3. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 1.]"
NCT00719888,"14:37:chronic_disease,39:48:chronic_disease,66:85:chronic_disease,98:106:chronic_disease,108:127:chronic_disease,129:147:chronic_disease,191:213:chronic_disease,230:259:chronic_disease,293:309:treatment,311:318:chronic_disease,351:360:chronic_disease,364:378:chronic_disease,380:399:chronic_disease,401:424:chronic_disease,,,479:494:chronic_disease","atients with fulminant liver failure, cirrhosis with evidence of portal hypertension or bridging fibrosis, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, or correctable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3 mg/dL, and symptomatic biliary disease will be excluded","['atients' 'with' 'fulminant' 'liver' 'failure' ',' 'cirrhosis' 'with'
 'evidence' 'of' 'portal' 'hypertension' 'or' 'bridging' 'fibrosis' ','
 'alcoholic' 'hepatitis' ',' 'esophageal' 'varices' ',' 'a' 'history' 'of'
 'bleeding' 'esophageal' 'varices' ',' 'hepatic' 'encephalopathy' ',' 'or'
 'correctable' 'hepatic' 'synthetic' 'dysfunction' 'evidenced' 'by'
 'prolongation' 'of' 'the' 'prothrombin' 'time' ',' 'ascites' 'related'
 'to' 'portal' 'hypertension' ',' 'bacterial' 'or' 'fungal' 'abscess' ','
 'biliary' 'obstruction' ',' 'chronic' 'viral' 'hepatitis' 'with' 'total'
 'serum' 'bilirubin' '>' '3' 'mg/dL' ',' 'and' 'symptomatic' 'biliary'
 'disease' 'will' 'be' 'excluded']","[0. 0. 2. 2. 2. 0. 2. 0. 0. 0. 2. 2. 0. 0. 2. 0. 2. 2. 0. 2. 2. 0. 0. 0.
 0. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 2. 0. 0.
 0. 0. 0. 2. 0. 2. 2. 0. 2. 2. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT00716066,"1:33:chronic_disease,35:51:chronic_disease,53:68:chronic_disease,70:78:chronic_disease,80:96:chronic_disease,98:112:chronic_disease","Autoimmune peripheral neuropathy (anti-Hu [Anna-1], anti-GM1 [GD1b], anti-MAG, anti-ganglioside, anti-sulfatide)","['Autoimmune' 'peripheral' 'neuropathy' '(' 'anti-Hu' '[' 'Anna-1' ']' ','
 'anti-GM1' '[' 'GD1b' ']' ',' 'anti-MAG' ',' 'anti-ganglioside' ','
 'anti-sulfatide' ')']",[2. 2. 2. 0. 2. 2. 0. 0. 0. 2. 2. 0. 0. 0. 2. 0. 2. 0. 2. 0.]
NCT00715611,"18:34:chronic_disease,48:68:treatment,70:79:treatment,84:105:treatment","Patients with an active infection that require systemic antibiotics, antiviral, or antifungal treatments","['Patients' 'with' 'an' 'active' 'infection' 'that' 'require' 'systemic'
 'antibiotics' ',' 'antiviral' ',' 'or' 'antifungal' 'treatments']",[0. 0. 0. 2. 2. 0. 0. 1. 1. 0. 1. 0. 0. 1. 1.]
NCT00711373,"1:25:chronic_disease,39:46:chronic_disease,47:54:chronic_disease,55:63:chronic_disease",Congenital Abnormalities: co-existent absence/atrophy/agenesis of any tissue may affect post transplant results,"['Congenital' 'Abnormalities' ':' 'co-existent' 'absence/atrophy/agenesis'
 'of' 'any' 'tissue' 'may' 'affect' 'post' 'transplant' 'results']",[2. 2. 0. 0. 2. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00703105,"33:44:treatment,,88:93:cancer,193:215:treatment",Patients must not have received irradiation for the four weeks prior to removal of the tumor and no previously irradiated tumor deposits may be used for tumor lysate in the development of the dendritic cell vaccine,"['Patients' 'must' 'not' 'have' 'received' 'irradiation' 'for' 'the'
 'four' 'weeks' 'prior' 'to' 'removal' 'of' 'the' 'tumor' 'and' 'no'
 'previously' 'irradiated' 'tumor' 'deposits' 'may' 'be' 'used' 'for'
 'tumor' 'lysate' 'in' 'the' 'development' 'of' 'the' 'dendritic' 'cell'
 'vaccine']","[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 1.]"
NCT00695214,"34:42:treatment,56:72:treatment,76:92:treatment",Other contraindication to use of propofol (decision of anesthesiologist or otolaryngologist.),"['Other' 'contraindication' 'to' 'use' 'of' 'propofol' '(' 'decision' 'of'
 'anesthesiologist' 'or' 'otolaryngologist' '.' ')']",[0. 0. 0. 0. 0. 1. 0. 0. 0. 1. 0. 1. 0. 0.]
NCT00670358,"28:64:treatment,81:88:treatment,121:132:treatment,140:148:treatment,152:180:treatment","Able to receive concurrent prophylactic anticoagulation therapy (e.g., low-dose aspirin [81 mg] daily or an alternative prophylaxis [e.g., warfarin or low molecular weight heparin])","['Able' 'to' 'receive' 'concurrent' 'prophylactic' 'anticoagulation'
 'therapy' '(' 'e.g.' ',' 'low-dose' 'aspirin' '[' '81' 'mg' ']' 'daily'
 'or' 'an' 'alternative' 'prophylaxis' '[' 'e.g.' ',' 'warfarin' 'or'
 'low' 'molecular' 'weight' 'heparin' ']' ')']","[0. 0. 0. 0. 1. 1. 1. 0. 0. 0. 1. 1. 1. 1. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0.
 1. 0. 0. 0. 0. 0. 0. 0.]"
NCT00670358,"15:27:treatment,29:41:treatment,46:59:treatment,79:89:cancer","No concurrent radiotherapy, chemotherapy, or immunotherapy for another active malignancy","['No' 'concurrent' 'radiotherapy' ',' 'chemotherapy' ',' 'or'
 'immunotherapy' 'for' 'another' 'active' 'malignancy']",[0. 0. 1. 0. 1. 0. 0. 1. 0. 0. 0. 3.]
NCT00632853,"79:109:cancer,121:138:cancer,140:181:cancer,187:226:cancer","Limited-stage disease patients with disease restricted to one hemithorax with regional lymph node metastases, including ipsilateral hilar, ipsilateral and contralateral mediastinal, and ipsilateral supraclavicular lymph nodes","['Limited-stage' 'disease' 'patients' 'with' 'disease' 'restricted' 'to'
 'one' 'hemithorax' 'with' 'regional' 'lymph' 'node' 'metastases' ','
 'including' 'ipsilateral' 'hilar' ',' 'ipsilateral' 'and' 'contralateral'
 'mediastinal' ',' 'and' 'ipsilateral' 'supraclavicular' 'lymph' 'nodes']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 3. 3. 3. 0. 0. 3. 3. 3. 3. 0. 0. 0. 0.
 0. 0. 0. 0. 0.]"
NCT00630565,"15:40:chronic_disease,75:82:cancer,84:92:cancer,127:142:treatment","Patients with cytogenetic abnormalities suggesting an improved prognosis [t(8:21), t(15;17) and inv(16)] will be eligible for transplantation in first remission","['Patients' 'with' 'cytogenetic' 'abnormalities' 'suggesting' 'an'
 'improved' 'prognosis' '[' 't' '(' '8:21' ')' ',' 't' '(' '15' ';' '17'
 ')' 'and' 'inv' '(' '16' ')' ']' 'will' 'be' 'eligible' 'for'
 'transplantation' 'in' 'first' 'remission']","[3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3.
 3. 3. 3. 3. 3. 3. 1. 3. 3. 3.]"
NCT00630253,"15:17:chronic_disease,46:66:chronic_disease,74:104:cancer,143:168:chronic_disease","Patients with FA must have moderately severe aplastic anemia (AA), early myelodysplastic syndrome (MDS) with no excess blasts with or without chromosomal abnormalities","['Patients' 'with' 'FA' 'must' 'have' 'moderately' 'severe' 'aplastic'
 'anemia' '(' 'AA' ')' ',' 'early' 'myelodysplastic' 'syndrome' '(' 'MDS'
 ')' 'with' 'no' 'excess' 'blasts' 'with' 'or' 'without' 'chromosomal'
 'abnormalities']","[0. 0. 2. 0. 0. 0. 0. 2. 2. 2. 0. 0. 0. 0. 3. 3. 3. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 2. 2.]"
NCT00594217,",12:16:chronic_disease,62:78:chronic_disease,84:98:chronic_disease,131:147:chronic_disease","women with PCOS (defined as clinical/biochemical evidence of hyperandrogenism plus oligomenorrhea, but with no evidence for other endocrinopathies)","['women' 'with' 'PCOS' '(' 'defined' 'as' 'clinical/biochemical'
 'evidence' 'of' 'hyperandrogenism' 'plus' 'oligomenorrhea' ',' 'but'
 'with' 'no' 'evidence' 'for' 'other' 'endocrinopathies' ')']",[0. 0. 2. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0. 0. 0. 0. 0. 0. 0. 2. 0.]
NCT00584649,"26:34:treatment,73:90:chronic_disease,154:176:treatment,204:210:treatment,212:226:treatment,231:242:treatment","who are scheduled for an ablation procedure for suspected inappropriate sinus tachycardia, with symptomatic palpitations during periods where documented electrogram recordings suggest sinus tachycardia (holter, event recorder, or 12 lead ECG)","['who' 'are' 'scheduled' 'for' 'an' 'ablation' 'procedure' 'for'
 'suspected' 'inappropriate' 'sinus' 'tachycardia' ',' 'with'
 'symptomatic' 'palpitations' 'during' 'periods' 'where' 'documented'
 'electrogram' 'recordings' 'suggest' 'sinus' 'tachycardia' '(' 'holter'
 ',' 'event' 'recorder' ',' 'or' '12' 'lead' 'ECG' ')']","[0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0.
 0. 0. 1. 0. 1. 1. 0. 0. 1. 1. 1. 0.]"
NCT00573027,"16:39:chronic_disease,,,86:105:chronic_disease,,142:153:treatment",No obstructive coronary artery disease performed within the previous 24 months (<50% luminal obstruction in one or more coronary arteries on angiography),"['No' 'obstructive' 'coronary' 'artery' 'disease' 'performed' 'within'
 'the' 'previous' '24' 'months' '(' '<' '50' '%' 'luminal' 'obstruction'
 'in' 'one' 'or' 'more' 'coronary' 'arteries' 'on' 'angiography' ')']","[0. 0. 2. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0.
 1. 0.]"
NCT00542373,"15:34:cancer,99:110:chronic_disease,114:127:chronic_disease","Subjects with premalignant lesion, or potentially premalignant lesion, of the oral cavity mucosa (leukoplakia or erythroplakia)","['Subjects' 'with' 'premalignant' 'lesion' ',' 'or' 'potentially'
 'premalignant' 'lesion' ',' 'of' 'the' 'oral' 'cavity' 'mucosa' '('
 'leukoplakia' 'or' 'erythroplakia' ')']",[0. 0. 3. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 0. 2. 0.]
NCT00492778,"28:49:treatment,42:49:treatment,57:78:treatment,",Patients may have received prior hormone therapy and/or systemic chemotherapy; such therapy must have been completed at least 6 months prior to study entry and the patient has clear evidence of disease subsequent to such therapy,"['Patients' 'may' 'have' 'received' 'prior' 'hormone' 'therapy' 'and/or'
 'systemic' 'chemotherapy' ';' 'such' 'therapy' 'must' 'have' 'been'
 'completed' 'at' 'least' '6' 'months' 'prior' 'to' 'study' 'entry' 'and'
 'the' 'patient' 'has' 'clear' 'evidence' 'of' 'disease' 'subsequent' 'to'
 'such' 'therapy']","[0. 0. 0. 0. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT00492778,"38:56:treatment,47:56:treatment,74:79:cancer,149:151:treatment,155:166:treatment","Patients who have undergone complete surgical resection of the recurrent tumor and have no evidence of residual disease evaluable clinically and by CT or MRI imaging, following resection","['Patients' 'who' 'have' 'undergone' 'complete' 'surgical' 'resection'
 'of' 'the' 'recurrent' 'tumor' 'and' 'have' 'no' 'evidence' 'of'
 'residual' 'disease' 'evaluable' 'clinically' 'and' 'by' 'CT' 'or' 'MRI'
 'imaging' ',' 'following' 'resection']","[0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0.
 1. 1. 0. 0. 0.]"
NCT00483249,"18:25:allergy_name,27:42:allergy_name,47:56:allergy_name","Known allergy to Nitinol, stainless steel, or polyester","['Known' 'allergy' 'to' 'Nitinol' ',' 'stainless' 'steel' ',' 'or'
 'polyester']",[0. 0. 0. 4. 0. 4. 4. 0. 0. 4.]
NCT00432094,"26:31:cancer,74:93:chronic_disease,112:122:treatment",Patients with increasing tumor markers only (i.e. no imaging evidence of progressive disease) are eligible for transplant,"['Patients' 'with' 'increasing' 'tumor' 'markers' 'only' '(' 'i.e' '.'
 'no' 'imaging' 'evidence' 'of' 'progressive' 'disease' ')' 'are'
 'eligible' 'for' 'transplant']",[0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 1.]
NCT00383656,",32:61:chronic_disease,85:97:cancer,101:116:cancer,130:137:treatment,167:179:treatment,196:220:treatment,224:242:treatment,247:255:cancer,259:281:cancer",Women and minors with acquired hypogonadotropic hypogonadism will have a history of hypothalamic or pituitary tumor treated with surgery alone or in combination with radiotherapy or a history of hypothalamic irradiation as adjunctive therapy for leukemia or craniofacial neoplasms,"['Women' 'and' 'minors' 'with' 'acquired' 'hypogonadotropic'
 'hypogonadism' 'will' 'have' 'a' 'history' 'of' 'hypothalamic' 'or'
 'pituitary' 'tumor' 'treated' 'with' 'surgery' 'alone' 'or' 'in'
 'combination' 'with' 'radiotherapy' 'or' 'a' 'history' 'of'
 'hypothalamic' 'irradiation' 'as' 'adjunctive' 'therapy' 'for' 'leukemia'
 'or' 'craniofacial' 'neoplasms']","[0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 1. 1. 3. 3. 0. 0. 1. 0. 0. 0. 0. 0.
 1. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 3. 0. 3. 3.]"
NCT00368355,"25:28:cancer,,,75:78:cancer,107:133:chronic_disease,137:162:chronic_disease",Patients with high risk ALL in CR1 or ALL or high grade (stage III or IV) NHL after first relapse or with primary refractory disease or minimal residual diseases,"['Patients' 'with' 'high' 'risk' 'ALL' 'in' 'CR1' 'or' 'ALL' 'or' 'high'
 'grade' '(' 'stage' 'III' 'or' 'IV' ')' 'NHL' 'after' 'first' 'relapse'
 'or' 'with' 'primary' 'refractory' 'disease' 'or' 'minimal' 'residual'
 'diseases']","[0. 0. 0. 0. 3. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0. 0.
 2. 2. 2. 0. 2. 2. 2.]"
NCT00358657,"63:76:chronic_disease,78:87:chronic_disease,118:137:chronic_disease,158:177:chronic_disease,179:197:chronic_disease,241:263:chronic_disease,435:454:chronic_disease","patients will be excluded if they are found to have fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, bridging fibrosis, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction","['patients' 'will' 'be' 'excluded' 'if' 'they' 'are' 'found' 'to' 'have'
 'fulminant' 'liver' 'failure' ',' 'cirrhosis' 'of' 'the' 'liver' 'with'
 'evidence' 'of' 'portal' 'hypertension' ',' 'bridging' 'fibrosis' ','
 'alcoholic' 'hepatitis' ',' 'esophageal' 'varices' ',' 'a' 'history' 'of'
 'bleeding' 'esophageal' 'varices' ',' 'hepatic' 'encephalopathy' ','
 'uncorrectable' 'hepatic' 'synthetic' 'dysfunction' 'evidenced' 'by'
 'prolongation' 'of' 'the' 'prothrombin' 'time' ',' 'ascites' 'related'
 'to' 'portal' 'hypertension' ',' 'bacterial' 'or' 'fungal' 'liver'
 'abscess' ',' 'biliary' 'obstruction']","[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 2. 0. 0. 0. 0. 0. 0. 2. 2. 0.
 0. 0. 0. 2. 2. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 2. 2.]"
NCT00338377,"3:22:treatment,24:39:treatment,41:52:treatment,54:79:treatment,120:136:chronic_disease,,157:172:treatment,190:216:treatment","A stress cardiac test (stress thallium, stress MUGA, dobutamine echocardiogram or other stress test that will rule out cardiac ischemia) within 6 months of lymphodepletion. (Turnstile II - Chemotherapy/Cell Infusion-Inclusion Criteria)","['A' 'stress' 'cardiac' 'test' '(' 'stress' 'thallium' ',' 'stress' 'MUGA'
 ',' 'dobutamine' 'echocardiogram' 'or' 'other' 'stress' 'test' 'that'
 'will' 'rule' 'out' 'cardiac' 'ischemia' ')' 'within' '6' 'months' 'of'
 'lymphodepletion' '.' '(' 'Turnstile' 'II' '-' 'Chemotherapy/Cell'
 'Infusion-Inclusion' 'Criteria' ')']","[0. 1. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 1. 1. 0. 0.]"
NCT00338377,"18:33:treatment,61:73:treatment,74:87:treatment",Is not receiving B-RAF treatment (Cohort C) (Turnstile II - Chemotherapy/Cell Infusion Exclusion Criteria),"['Is' 'not' 'receiving' 'B-RAF' 'treatment' '(' 'Cohort' 'C' ')' '('
 'Turnstile' 'II' '-' 'Chemotherapy/Cell' 'Infusion' 'Exclusion'
 'Criteria' ')']",[0. 0. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0.]
NCT00338377,"20:39:cancer,41:55:cancer,59:79:cancer,83:105:chronic_disease","Patients must have metastatic melanoma, uveal melanoma or stage III in-transit or regional nodal disease. (Turnstile I)","['Patients' 'must' 'have' 'metastatic' 'melanoma' ',' 'uveal' 'melanoma'
 'or' 'stage' 'III' 'in-transit' 'or' 'regional' 'nodal' 'disease' '.' '('
 'Turnstile' 'I' ')']",[0. 0. 0. 3. 3. 0. 3. 3. 0. 3. 3. 3. 0. 2. 2. 2. 0. 0. 0. 0. 0.]
NCT00338377,"15:24:treatment,97:111:treatment,,165:180:treatment,192:213:treatment,217:242:treatment,,292:307:treatment,,376:379:cancer","Patients with VP shunts must have VP shunts with on/off valves and must be expected to tolerate VP shunt valve off for more than 6 hours Patients who have received CNS irradiation, including whole brain radiation or stereotactic radiosurgery, are eligible, if they are at least 1 weeks post CNS-irradiation (Cohort D)Patients who are currently being treated with IT IL-2 for LMD are eligible. No wash out period is required. (Cohort D)","['Patients' 'with' 'VP' 'shunts' 'must' 'have' 'VP' 'shunts' 'with'
 'on/off' 'valves' 'and' 'must' 'be' 'expected' 'to' 'tolerate' 'VP'
 'shunt' 'valve' 'off' 'for' 'more' 'than' '6' 'hours' 'Patients' 'who'
 'have' 'received' 'CNS' 'irradiation' ',' 'including' 'whole' 'brain'
 'radiation' 'or' 'stereotactic' 'radiosurgery' ',' 'are' 'eligible' ','
 'if' 'they' 'are' 'at' 'least' '1' 'weeks' 'post' 'CNS-irradiation' '('
 'Cohort' 'D' ')' 'Patients' 'who' 'are' 'currently' 'being' 'treated'
 'with' 'IT' 'IL-2' 'for' 'LMD' 'are' 'eligible' '.' 'No' 'wash' 'out'
 'period' 'is' 'required' '.' '(' 'Cohort' 'D' ')']","[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 1. 1. 1. 0. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 3. 0. 0. 0. 0.
 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]"
NCT00285935,"11:30:treatment,88:95:treatment,99:110:treatment,138:157:treatment,161:169:treatment",Taking no medication or drugs likely to interfere with the study objectives (including statins or medications that affect hormones [e.g. birth control pills or steroids]),"['Taking' 'no' 'medication' 'or' 'drugs' 'likely' 'to' 'interfere' 'with'
 'the' 'study' 'objectives' '(' 'including' 'statins' 'or' 'medications'
 'that' 'affect' 'hormones' '[' 'e.g' '.' 'birth' 'control' 'pills' 'or'
 'steroids' ']' ')']","[0. 0. 1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 1. 0. 0. 0. 0. 0. 0. 1.
 1. 1. 0. 1. 0. 0.]"
NCT00169806,"70:91:treatment,96:111:chronic_disease,121:137:chronic_disease","Patients of Methodist Urology in Indianapolis, IN who are undergoing endoscopic procedures for nephrolithiasis or other urologic disease","['Patients' 'of' 'Methodist' 'Urology' 'in' 'Indianapolis' ',' 'IN' 'who'
 'are' 'undergoing' 'endoscopic' 'procedures' 'for' 'nephrolithiasis' 'or'
 'other' 'urologic' 'disease']",[0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 2. 0. 0. 2. 2.]
NCT00147056,"8:15:treatment,,,91:106:treatment,,127:136:treatment",Use of Avastin in the preceding two weeks or planned use in the forthcoming two weeks and VEGF inhibitors within + 30 days of treatment,"['Use' 'of' 'Avastin' 'in' 'the' 'preceding' 'two' 'weeks' 'or' 'planned'
 'use' 'in' 'the' 'forthcoming' 'two' 'weeks' 'and' 'VEGF' 'inhibitors'
 'within' '+' '30' 'days' 'of' 'treatment']","[0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 0. 0. 0. 0.
 1.]"
NCT00107289,"1:5:treatment,21:24:treatment,50:59:treatment",MIBG-avid malignant CCT and evaluable disease on MIBG scan at time of enrollment on protocol,"['MIBG-avid' 'malignant' 'CCT' 'and' 'evaluable' 'disease' 'on' 'MIBG'
 'scan' 'at' 'time' 'of' 'enrollment' 'on' 'protocol']",[1. 1. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.]
NCT00092222,"21:31:cancer,50:59:treatment,108:118:treatment,168:171:chronic_disease",Presence of another malignancy requiring current treatment that would preclude the use of all of the study treatments or the ability to monitor the natural history of MCD untreated,"['Presence' 'of' 'another' 'malignancy' 'requiring' 'current' 'treatment'
 'that' 'would' 'preclude' 'the' 'use' 'of' 'all' 'of' 'the' 'study'
 'treatments' 'or' 'the' 'ability' 'to' 'monitor' 'the' 'natural'
 'history' 'of' 'MCD' 'untreated']","[0. 0. 0. 3. 0. 0. 1. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 1. 0. 0. 0. 0. 0. 0.
 0. 0. 0. 2. 0.]"
NCT00075387,"14:31:chronic_disease,61:74:treatment,76:87:treatment,92:110:treatment","diagnosis of high-grade glioma will be made on the basis of needle biopsy, open biopsy, or surgical resection","['diagnosis' 'of' 'high-grade' 'glioma' 'will' 'be' 'made' 'on' 'the'
 'basis' 'of' 'needle' 'biopsy' ',' 'open' 'biopsy' ',' 'or' 'surgical'
 'resection']",[0. 0. 2. 2. 0. 0. 0. 0. 0. 0. 0. 1. 1. 0. 1. 1. 0. 0. 1. 1.]
